PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	LIN, K; KURLAND, IJ; LI, L; LEE, YH; OKAR, D; MARECEK, JF; PILKIS, SJ				LIN, K; KURLAND, IJ; LI, L; LEE, YH; OKAR, D; MARECEK, JF; PILKIS, SJ			EVIDENCE FOR NH2-TERMINAL AND COOH-TERMINAL INTERACTIONS IN RAT 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; DEPENDENT PROTEIN-KINASE; AMINO-ACID-SEQUENCE; FRUCTOSE 2,6-BISPHOSPHATE; ESCHERICHIA-COLI; PHOSPHO GROUP; LIVER; EXPRESSION; DOMAIN; FRUCTOSE-6-PHOSPHATE	The pH kinetic behavior of several rat fructose-2,6-bisphosphatase forms was analyzed. The bisphosphatase maximal velocity of the hepatic 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase optimal at pH 5, but decreased to 12% of the optimal value in the pH range 7.0-7.5. This decrease depended on deprotonation of a group with a pK of 5.7. In contrast, the separate bisphosphatase domain, a 30-amino acid COOH-terminal truncated form (CT30) of the liver enzyme, and the skeletal muscle bifunctional enzyme exhibited pH-insensitive maximal velocities which were 5-10-fold higher than that of the bisphosphatase of the liver bifunctional enzyme at pH 7.0-7.5. The pK values of the C-2 and C-6 phosphoryl groups were 6.0 and 5.75, respectively, as determined by P-31 NMR. Analysis of log k(cat)/K-m versus pH profiles revealed two pK values, one at 6.1, which probably is a substrate pK, and the other at 8.4, which represents an enzyme group. Protein kinase-catalyzed phosphorylation of the liver isoform activated the bisphosphatase, and the pK of the group seen in the k(cat) profile was increased from 5.7 to 6.4. However, phosphorylation of the CT30 mutant had no effect on the bisphosphatase. The data indicate that NH2- and COOH-terminal interactions in the liver bifunctional enzyme affect the pH dependence of the fructose-2,6-bisphosphatase and its activation by phosphorylation.	SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT CHEM,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038354, R01DK038354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; Cleland W W, 1979, Methods Enzymol, V63, P103; COLOSIA AD, 1988, J BIOL CHEM, V263, P18669; CREPIN KM, 1989, EUR J BIOCHEM, V183, P443; DARVILLE MI, 1989, P NATL ACAD SCI USA, V86, P6543, DOI 10.1073/pnas.86.17.6543; ELMAGHRABI MR, 1982, J BIOL CHEM, V257, P7603; ELMAGHRABI MR, 1984, BIOCHEM BIOPH RES CO, V123, P749; ELMAGHRABI MR, 1982, P NATL ACAD SCI-BIOL, V79, P315, DOI 10.1073/pnas.79.2.315; ELMAGHRABI MR, 1990, FRUCTOSE 2 6 BISPHOS, P87; Fersht A., 1985, ENZYME STRUCTURE MEC; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURLAND IJ, 1992, J BIOL CHEM, V267, P4416; KURLAND IJ, 1993, J BIOL CHEM, V268, P14056; LANGE AJ, 1991, ARCH BIOCHEM BIOPHYS, V290, P258, DOI 10.1016/0003-9861(91)90617-R; LANGE AJ, 1990, NUCLEIC ACIDS RES, V18, P3652, DOI 10.1093/nar/18.12.3652; LANGE AJ, 1992, J BIOL CHEM, V267, P15673; LANGE AJ, 1989, BIOCHEM BIOPH RES CO, V169, P406; LEE YH, 1994, J MOL BIOL, V235, P1147, DOI 10.1006/jmbi.1994.1065; LI L, 1992, J BIOL CHEM, V267, P21588; LI L, 1992, J BIOL CHEM, V267, P16669; LIN K, 1992, J BIOL CHEM, V267, P19163; LIN K, 1992, J BIOL CHEM, V267, P6556; Lin K, 1990, Protein Expr Purif, V1, P169, DOI 10.1016/1046-5928(90)90012-N; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURRAY KJ, 1984, J BIOL CHEM, V259, P7673; OSTANIN K, 1992, J BIOL CHEM, V267, P22830; PILKIS SJ, 1987, ENZYMES, V28, P3; SAKATA J, 1991, J BIOL CHEM, V266, P15764; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEWART HB, 1985, J BIOL CHEM, V260, P2935; STEWART HB, 1986, J BIOL CHEM, V261, P8793; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAULER A, 1988, P NATL ACAD SCI USA, V85, P6642, DOI 10.1073/pnas.85.18.6642; TAULER A, 1990, J BIOL CHEM, V265, P15617; TOMINAGA N, 1993, J BIOL CHEM, V268, P15951; VANETTEN RL, 1982, ANN NY ACAD SCI, V390, P27; VANSCHAFTINGEN E, 1981, BIOCHEM BIOPH RES CO, V103, P362, DOI 10.1016/0006-291X(81)91701-0; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143; VANWAZER JR, 1958, PHOSPHORUS ITS COMPO, V1, P583; VENTURA F, 1992, J BIOL CHEM, V267, P17939	42	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16953	16960						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207019				2022-12-27	WOS:A1994NR29600066
J	NUNEZ, E; ARAGON, C				NUNEZ, E; ARAGON, C			STRUCTURAL-ANALYSIS AND FUNCTIONAL-ROLE OF THE CARBOHYDRATE COMPONENT OF GLYCINE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ GLUCOSE COTRANSPORTER; BRUSH-BORDER MEMBRANE; RAT-BRAIN; LINKED OLIGOSACCHARIDES; DOPAMINE TRANSPORTER; N-GLYCOSYLATION; SPINAL-CORD; EXPRESSION; CLONING; GLYCOPROTEINS	The sodium- and chloride-coupled glycine transporter from pig brain stem has been shown to be a 100-kDa glycoprotein (Lopez-Corcuera, B., Vazquez, J., and Aragon, C. (1991) J. Biol. Chem. 266, 24809-24814). To structurally identify the carbohydrate components of glycine transporter, the purified and radioiodinated protein was subjected to specific glycosidase treatments. When the glycine transporter was treated with peptide-N-glycosidase F (PNGaseF) to remove N-linked oligosaccharides, a significant reduction of the apparent molecular mass of the protein was observed. However, incubations with endoglycosidase F and O-glycanase did not affect the electrophoretic mobility of the protein, and neuraminidase produced a slight reduction of its apparent mass. The effect of PNGaseF indicates that sugar chains represent about 30% of the mass of this heavily glycosylated transporter. The deglycosylated form is recognized by previously characterized anti-100-kDa protein antiserum (Lopez-Corcuera, B., Alcantara, R., Vazquez, J., and Aragon, C. (1993) J. Biol. Chem. 268, 2239-2243), suggesting that the epitopes are in the peptidic part of the glycoprotein. These and other results suggest that glycine transporter-linked carbohydrates are predominantly tri- or tetra- antennary complex N-linked oligosaccharides containing sialic acid residues. To investigate the functional role of the carbohydrate moiety, liposomes reconstituted with purified glycine transporter were subjected to PNGaseF and neuraminidase treatments, and the effect on specific glycine transport activity was tested. Whereas neuraminidase did not affect the activity of the transporter, PNGaseF treatment produced a drastic reduction of transport activity. This treatment produced two different deglycosylated glycine transporter species, suggesting that two N-glycosylation sites would be occupied in the native protein. These studies arise as a first evidence supporting the notion that N-linked carbohydrates play a relevant role in glycine transporter functionality.	UNIV AUTONOMA MADRID,FAC CIENCIAS,CTR BIOL MOLEC SEVERO OCHOA,DEPT BIOL MOLEC,E-28049 MADRID,SPAIN	Autonomous University of Madrid			Aragon, Carmen/K-9783-2014	Aragon, Carmen/0000-0001-8287-9386				AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; ASANO T, 1991, J BIOL CHEM, V266, P24632; ASANO T, 1993, FEBS LETT, V324, P258, DOI 10.1016/0014-5793(93)80129-I; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; FEUGEAS JP, 1990, BIOCHIM BIOPHYS ACTA, V1030, P60, DOI 10.1016/0005-2736(90)90238-J; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; HASELBECK A, 1990, GLYCOCONJUGATE J, V7, P63, DOI 10.1007/BF01050403; HEDIGER MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P360, DOI 10.1016/0005-2736(91)90323-Z; HIRAYAMA BA, 1992, BIOCHIM BIOPHYS ACTA, V1103, P37, DOI 10.1016/0005-2736(92)90054-P; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kyshe-Andersen J, 1984, J BIOCHEM BIOPH METH, V10, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEW R, 1991, BRAIN RES, V539, P239, DOI 10.1016/0006-8993(91)91627-D; LIU QR, 1993, J BIOL CHEM, V268, P22802; LIU QR, 1992, P NATL ACAD SCI USA, V89, P6639, DOI 10.1073/pnas.89.14.6639; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; LOPEZCORCUERA B, 1991, J BIOL CHEM, V266, P24809; LOPEZCORCUERA B, 1993, J BIOL CHEM, V268, P2239; LOPEZCORCUERA B, 1989, EUR J BIOCHEM, V181, P519, DOI 10.1111/j.1432-1033.1989.tb14754.x; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; MESSNER DJ, 1985, J BIOL CHEM, V260, P597; MONSIGNY M, 1980, EUR J BIOCHEM, V104, P147, DOI 10.1111/j.1432-1033.1980.tb04410.x; OTT RJ, 1992, J BIOL CHEM, V267, P133; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; RADIAN R, 1986, J BIOL CHEM, V261, P5437; Rasmussen JR., 1992, CURR OPIN STRUC BIOL, V2, P682; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4655; YUSUFI ANK, 1988, J BIOL CHEM, V263, P13683	35	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16920	16924						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207014				2022-12-27	WOS:A1994NR29600061
J	CHEN, J; ISHII, M; WANG, L; ISHII, K; COUGHLIN, SR				CHEN, J; ISHII, M; WANG, L; ISHII, K; COUGHLIN, SR			THROMBIN RECEPTOR ACTIVATION - CONFIRMATION OF THE INTRAMOLECULAR TETHERED LIGANDING HYPOTHESIS AND DISCOVERY OF AN ALTERNATIVE INTERMOLECULAR LIGANDING MODE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; EXTRACELLULAR DOMAIN; TERNARY COMPLEX; RHODOPSIN; MUTATIONS; CHIMERAS; CLONING; BINDING; MUTANTS; STATE	Cleavage of the thrombin receptor's amino-terminal exodomain at the Arg(41)Ser(42) peptide bond within the sequence...LDPR(41)/S(42)FLLRN... is necessary and sufficient for receptor activation by proteases. The synthetic peptide SFLLRN activates the receptor independent of proteolysis. We proposed that the SPLLRN sequence is a tethered peptide ligand; receptor cleavage unmasks this agonist which then binds intramolecularly to effect receptor activation. The alternative hypothesis that receptor cleavage or exogenous SFLLRN effect receptor activation by disrupting tonic inhibitory interactions exerted by the receptor's amino-terminal exodomain has not been excluded. We report that Delta AMINO, a mutant thrombin receptor lacking the amino-terminal exodomain, was not constitutively active and responded to SFLLRN but not thrombin when expressed in Xenopus oocytes or mammalian cells. Thrombin signaling was restored when Delta AMINO was co-expressed with ATE-CD8 which encoded the receptor's amino-terminal exodomain fused to the transmembrane domain of CD8. Co expression of a thrombin receptor lacking a functional tethered ligand domain (''F43A'') with a non-signaling receptor mutant bearing an intact tethered ligand domain (''YYY'') also reconstituted thrombin signaling. However, the EC(50) for thrombin activation of cells co-expressing F43A and YYY was > 1000-fold that for cells expressing comparable levels of wild type receptor, while EC(50)s for activation by SFLLRN were similar. These and other data refute the release hom inhibition hypothesis and suggest that while intermolecular liganding between two thrombin receptor molecules can occur, the intramolecular tethered liganding mechanism is the predominant mode of thrombin receptor activation.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821, R01HL044907] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44907, HL43821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CONKLIN BR, 1994, NATURE, V367, P22, DOI 10.1038/367022a0; COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; ISHII K, 1993, J BIOL CHEM, V268, P9780; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; MOYLE WR, 1991, J BIOL CHEM, V266, P10807; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0	26	177	182	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16041	16045						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206902				2022-12-27	WOS:A1994NQ72900017
J	FORMISANO, P; DENOVELLIS, G; MIELE, C; TRIPODI, F; CARUSO, M; PALUMBO, G; BEGUINOT, L; BEGUINOT, F				FORMISANO, P; DENOVELLIS, G; MIELE, C; TRIPODI, F; CARUSO, M; PALUMBO, G; BEGUINOT, L; BEGUINOT, F			INTERNALIZATION OF THE CONSTITUTIVELY ACTIVE ARGININE-1152-]GLUTAMINE INSULIN-RECEPTOR OCCURS INDEPENDENTLY OF INSULIN AT AN ACCELERATED RATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUXTAMEMBRANE REGION; KINASE-ACTIVITY; BETA-SUBUNIT; ENDOCYTOSIS; AUTOPHOSPHORYLATION; FIBROBLASTS; ADIPOCYTES; REQUIRES; PATHWAYS; MUTATION	Signals controlling the insulin receptor endocytotic pathway have been investigated using the R1152Q insulin receptor mutant (M). This mutant receptor exhibits high levels of insulin-independent kinase activity, im paired autophosphorylation, and lack of an insulin stimulatory effect on both auto- and substrate phosphorylation. NIH-3T3 fibroblasts expressing M receptors displayed a 2.5-fold higher I-125-insulin internalization rate than wild type (WT) but lacked insulin-induced receptor internalization and down-regulation. Cell surface recycling of internalized receptors also occurred at a higher rate in M cells and was unaffected by insulin. Cell preincubation with 35 mM Tris, which inhibits the insulin receptor degradative route, elicited no effect on M receptor recycling but inhibited that of WT by 40%. In contrast, the energy depleter 2,4-dinitrophenol, which inhibits normal insulin receptor retroendocytosis, impaired M receptor recycling 4-fold more effectively than that of WT. The release of internalized intact I-125-insulin was 6-fold greater in M than in WT fibroblasts and was almost completely inhibited by dinitrophenol, whereas insulin degradation by M cells was 4-fold decreased as compared with WT. Thus, internalization and recycling of the constitutively active Gln(1152) receptor kinase occur in the absence of autophosphorylation. However, tyrosine phosphorylation appears to be required for proper sorting of endocytosed insulin receptors.	UNIV NAPLES,FAC MED,SCH MED,CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; HOSP SAN RAFFAELE,DIBIT,MOLEC ONCOL LAB,I-20132 MILAN,ITALY; HOSP SAN RAFFAELE,CNR,CTR NEUROSCI & BIOIMMAGINI,I-20132 MILAN,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			Formisano, Pietro/J-4237-2018; Palumbo, Giuseppe/N-3136-2016	Formisano, Pietro/0000-0001-7020-6870; Palumbo, Giuseppe/0000-0001-9380-8436				BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1990, J BIOL CHEM, V265, P16450; CARPENTIER JL, 1989, DIABETOLOGIA, V32, P627; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; FORMISANO P, 1993, J BIOL CHEM, V268, P5241; GEIGER D, 1989, EXP CELL RES, V185, P33, DOI 10.1016/0014-4827(89)90034-7; GRAKO KA, 1992, ENDOCRINOLOGY, V130, P3441, DOI 10.1210/en.130.6.3441; HARI J, 1987, J BIOL CHEM, V262, P15341; LUND KA, 1990, J BIOL CHEM, V265, P15713; MARSHALL S, 1981, J BIOL CHEM, V256, P1464; MARSHALL S, 1987, J BIOL CHEM, V262, P12005; MARSHALL S, 1985, J BIOL CHEM, V260, P3517; MARSHALL S, 1985, J BIOL CHEM, V260, P3524; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCLAIN DA, 1988, DIABETES, V37, P806, DOI 10.2337/diabetes.37.6.806; MCCLAIN DA, 1992, AM J MED SCI, V304, P192, DOI 10.1097/00000441-199209000-00009; PETRUZZIELLO A, 1993, J CLIN ENDOCR METAB, V77, P409, DOI 10.1210/jc.77.2.409; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; RUSSELL DS, 1987, J BIOL CHEM, V262, P11830; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; THIES RS, 1990, J BIOL CHEM, V265, P10132; VANOBBERGHEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1052; YAMAMOTOHONDA R, 1990, J BIOL CHEM, V265, P14777	24	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16242	16246						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206928				2022-12-27	WOS:A1994NQ72900046
J	MOFFAT, GJ; MCLAREN, AW; WOLF, CR				MOFFAT, GJ; MCLAREN, AW; WOLF, CR			INVOLVEMENT OF JUN AND FOS PROTEINS IN REGULATING TRANSCRIPTIONAL ACTIVATION OF THE HUMAN PI CLASS GLUTATHIONE-S-TRANSFERASE GENE IN MULTIDRUG-RESISTANT MCF7 BREAST-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFERS RESISTANCE; EXPRESSION; RNA; DNA; ELEMENTS; SEQUENCES; ACID	Elevated levels of the human pi class glutathione S-transferase (GSTP1-1) have been implicated in the development of antineoplastic drug resistance. Using GSTP1 promoter deletion constructs we have shown that enhanced GSTP1 transcription (up to 18-fold) is the predominant mechanism responsible for increased GSTP1-1 levels in a multidrug resistant derivative (VCREMS) of the human mammary carcinoma cell line MCF7. Furthermore, disruption of a putative AP-1 response element within the GSTP1 promoter (nucleotides -69 to -63) abrogated GSTP1 transcription in both cell lines. In addition, band shift assays demonstrated binding of a VCREMS nuclear complex to the promoter region C1 (-73 to -54) which could be competed for by a DNA fragment containing a known AP-1 binding site from the human collagenase promoter. However, no such competition was observed for the major MCF7 C1 complex. The role of a Fos-Jun like complex in regulating GSTP1 transcription in VCREMS cells was further emphasized by the introduction of point mutations within the C1 region which were known to inhibit AP-1 binding and the interaction of antisera raised against human c-Jun and c-Fos with the major C1 complex in VCREMS cells. These studies therefore highlight cell-specific differences in the binding pattern of Jun and Fos proteins to the GSTP1 promoter which are likely to play an important role in regulating transcriptional activation of the GSTP1 gene in drug-resistant breast cancer cells.			MOFFAT, GJ (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, BIOMED RES CTR, IMPERIAL CANC RES FUND, MOLEC PHARMACOL UNIT, DUNDEE DD1 9SY, SCOTLAND.							ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BATIST G, 1986, J BIOL CHEM, V261, P5544; BLACK SM, 1990, BIOCHEM J, V268, P309, DOI 10.1042/bj2680309; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DICCIANNI MB, 1992, NUCLEIC ACIDS RES, V20, P5153, DOI 10.1093/nar/20.19.5153; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIXON KH, 1989, BIOCHEM BIOPH RES CO, V163, P815, DOI 10.1016/0006-291X(89)92295-X; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GORMAN C, 1986, DNA CLONING PRACTICA, V3; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; KANO T, 1987, CANCER RES, V47, P5626; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MORROW CS, 1992, J BIOL CHEM, V267, P10544; MORROW CS, 1990, GENE, V88, P215, DOI 10.1016/0378-1119(90)90034-O; MOSCOW JA, 1989, MOL PHARMACOL, V36, P22; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; OKUDA A, 1989, J BIOL CHEM, V264, P16919; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1989, ADV CANCER RES, V52, P205; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WHELAN RDH, 1992, INT J CANCER, V52, P241, DOI 10.1002/ijc.2910520215; XIA CL, 1991, BIOCHEM BIOPH RES CO, V176, P233, DOI 10.1016/0006-291X(91)90914-S; XIA CL, 1993, BIOCHEM J, V292, P845, DOI 10.1042/bj2920845	36	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16397	16402						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206948				2022-12-27	WOS:A1994NQ72900067
J	RANDELL, EW; PARKES, JG; OLIVIERI, NF; TEMPLETON, DM				RANDELL, EW; PARKES, JG; OLIVIERI, NF; TEMPLETON, DM			UPTAKE OF NON-TRANSFERRIN-BOUND IRON BY BOTH REDUCTIVE AND NONREDUCTIVE PROCESSES IS MODULATED BY INTRACELLULAR IRON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVILLOUS MEMBRANE-VESICLES; PLASMA-MEMBRANE; FERRIC IRON; SACCHAROMYCES-CEREVISIAE; RAT-LIVER; DIFERRIC TRANSFERRIN; TRANSPORT-SYSTEM; CELLS; SULFATE; MOUSE	Non-transferrin-bound iron (NTBI) uptake occurs in a variety of cells by a saturable, specific and temperature-sensitive process. Our previous studies indicated that NTBI uptake by cardiac myocytes and Hep G2 cells was reversibly up regulated by iron deposition, In the present work we have characterized this up-regulation and examined its mechanism by comparing the uptake of oxidized (Fe3+) and ascorbate-reduced (Fe2+) forms of iron. Iron loading markedly enhanced the uptake of iron both in the presence and absence of ascorbate, but the increment was greater when ascorbate was absent. This up-regulation is partially inhibited by actinomycin D and cycloheximide, indicating a requirement for protein synthesis. Uptake by the iron-loaded cells was less sensitive to thiol-alkylating agents and competing metal ions, but was more sensitive to proteolysis. Iron loading causes an increase in both K-m and V-max for uptake of both Fe2+ and Fe3+, although the values differ, suggesting dis tinct rate-limiting steps for uptake of Fe2+ and Fe3+. Consistent with this idea, uptake of the two ions showed differential sensitivity to thiol reagents, competing metal ions and monensin. The Fe2+-specific chelators bathophenanthroline disulfonate and ferrozine markedly inhibited iron uptake whether ascorbate was present or not, indicating that Fe3+ uptake is dependent on reduction to the ferrous state. This requirement for reduction was independent of the iron status of the cells, demonstrating that the process of up-regulation is not due to the appearance of a new mechanism for translocation of Fe3+ without reduction. Taken together, the evidence favors a model of NTBI transport where an obligate and rate-determining reduction of Fe3+ occurs prior to or during uptake, followed by translocation through an Fe2+ carrier. The distinct translocation mechanisms of uptake in the presence and absence of ascorbate suggest that exogenous Fe2+ does not access the carrier available to the nascent ferrous ion derived from the reductase and is consistent with close coupling between the reduction and the translocation processes. In iron-loaded cells with increased rates of NTBI transport, a similar mechanism prevails.	UNIV TORONTO, DEPT CLIN BIOCHEM, TORONTO M5G 1L5, ON, CANADA; HOSP SICK CHILDREN, DIV HEMATOL ONCOL, TORONTO M5G 1X8, ON, CANADA; HOSP SICK CHILDREN, DEPT BIOCHEM, TORONTO M5G 1X8, ON, CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Olivieri, Nancy/AAI-2250-2020	Templeton, Douglas/0000-0003-0693-662X				ALREFAIE FN, 1992, BRIT J HAEMATOL, V82, P431, DOI 10.1111/j.1365-2141.1992.tb06441.x; ANDERSON GJ, 1992, J INORG BIOCHEM, V47, P249, DOI 10.1016/0162-0134(92)84070-4; Baes C.F., 1986, HYDROLYSIS METAL CAT; BASSET P, 1986, CANCER RES, V46, P1644; BLAZKA ME, 1991, TOXICOL APPL PHARM, V110, P355, DOI 10.1016/S0041-008X(05)80018-3; BRUGGEMANN W, 1993, PLANTA, V190, P151, DOI 10.1007/BF00196606; CONRAD ME, 1993, AM J HEMATOL, V42, P67, DOI 10.1002/ajh.2830420114; COWART RE, 1993, ANAL BIOCHEM, V211, P151, DOI 10.1006/abio.1993.1246; CRAVEN CM, 1987, P NATL ACAD SCI USA, V84, P3457, DOI 10.1073/pnas.84.10.3457; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DENEER HG, 1993, CAN J MICROBIOL, V39, P480, DOI 10.1139/m93-068; DJEHA A, 1992, BIOCHIM BIOPHYS ACTA, V1133, P147, DOI 10.1016/0167-4889(92)90062-G; EIDE D, 1992, J BIOL CHEM, V267, P20774; GRANT D, 1992, BIOCHEM J, V282, P601, DOI 10.1042/bj2820601; GROOTVELD M, 1989, J BIOL CHEM, V264, P4417; HERSHKO C, 1987, BRIT J HAEMATOL, V66, P149, DOI 10.1111/j.1365-2141.1987.tb01291.x; HERSHKO C, 1988, CRC CR REV CL LAB SC, V26, P303, DOI 10.3109/10408368809105894; INMAN RS, 1993, J BIOL CHEM, V268, P8521; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOJIMA S, 1983, EUR J NUCL MED, V8, P52, DOI 10.1007/BF00252556; LESUISSE E, 1991, BIOCHEM J, V280, P545, DOI 10.1042/bj2800545; LINK G, 1985, J LAB CLIN MED, V106, P147; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDA H, 1991, J EXP MED, V174, P7, DOI 10.1084/jem.174.1.7; MORGAN EH, 1988, BIOCHIM BIOPHYS ACTA, V943, P428, DOI 10.1016/0005-2736(88)90374-4; NILSEN T, 1991, BIOCHIM BIOPHYS ACTA, V1095, P39, DOI 10.1016/0167-4889(91)90042-V; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; OSHIRO S, 1993, J BIOL CHEM, V268, P21586; PARKES JG, 1993, J LAB CLIN MED, V122, P36; RAJA KB, 1992, BIOCHIM BIOPHYS ACTA, V1135, P141, DOI 10.1016/0167-4889(92)90129-Y; RICHARDSON DR, 1992, J BIOL CHEM, V267, P21384; RICHARDSON DR, 1992, BIOCHIM BIOPHYS ACTA, V1103, P275, DOI 10.1016/0005-2736(92)90097-6; RICHARDSON DR, 1990, BIOCHIM BIOPHYS ACTA, V1053, P1, DOI 10.1016/0167-4889(90)90018-9; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; SCHEIBER B, 1993, ARCH BIOCHEM BIOPHYS, V305, P225, DOI 10.1006/abbi.1993.1415; SCHNEIDER W, 1988, CHIMIA, V42, P9; STOJKOVSKI S, 1992, BIOCHIM BIOPHYS ACTA, V1137, P155, DOI 10.1016/0167-4889(92)90197-J; STREMMEL W, 1987, EUR J CLIN INVEST, V17, P136, DOI 10.1111/j.1365-2362.1987.tb02393.x; STURROCK A, 1990, J BIOL CHEM, V265, P3139; SUN IL, 1987, J BIOL CHEM, V262, P15915; TEICHMANN R, 1990, J CLIN INVEST, V86, P2145, DOI 10.1172/JCI114953; THORSTENSEN K, 1988, J BIOL CHEM, V263, P8844; THORSTENSEN K, 1990, BIOCHIM BIOPHYS ACTA, V1052, P29, DOI 10.1016/0167-4889(90)90053-G; WEI L, 1992, ARTERIOSCLER THROMB, V12, P503, DOI 10.1161/01.ATV.12.4.503; WEISS P, 1989, J BIOL CHEM, V264, P11572; WELCH RM, 1993, PLANTA, V190, P555, DOI 10.1007/BF00224795; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WRIGHT TL, 1986, J BIOL CHEM, V261, P909; YANG CY, 1986, J INORG BIOCHEM, V28, P393, DOI 10.1016/0162-0134(86)80025-3	50	116	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16046	16053						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206903				2022-12-27	WOS:A1994NQ72900018
J	CHEN, WY; CHEN, NY; YUN, J; WAGNER, TE; KOPCHICK, JJ				CHEN, WY; CHEN, NY; YUN, J; WAGNER, TE; KOPCHICK, JJ			IN-VITRO AND IN-VIVO STUDIES OF ANTAGONISTIC EFFECTS OF HUMAN GROWTH-HORMONE ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; TRANSGENIC MICE; SCANNING MUTAGENESIS; EXTRACELLULAR DOMAIN; BINDING-PROTEIN; INSULIN-LIKE; GH ANALOG; RECEPTOR; EXPRESSION; GENE	A bovine growth hormone (bGH) analog, bGH-G119R, has been shown to act as a functional antagonist of GH activity both in vitro and in vivo. In the present study, human (h) GH analogs with alterations in the third alpha-helix (G120A, G120R) and N terminus (I4A) were generated. These two regions have been reported to form binding site 2 in hGH, which is involved in in vitro dimerization of the GH receptor (GHR). The biological activities of these hGH analogs were tested in vitro by a radioreceptor assay and an assay to test the ability of the molecules to induce tyrosine phosphorylation of a 93-kDa protein in a human lymphocyte line, IM-9. The growth rate of transgenic mice that express different hGH analogs was used as an in vivo test of the activity of the molecules. The results demonstrated that G120R is a potent hGH antagonist both in vitro and in vivo. Transgenic mice expressing G120R demonstrated a growth-suppressed phenotype. However, I4A, which has been demonstrated to be a potent inhibitor of in vitro GHR dimerization, exhibited full growth promoting activity in transgenic mice. Thus, the ability of hGH analogs to induce GHR dimerization in vitro and the ability to promote growth in vivo are not directly correlated.	OHIO UNIV,DEPT BIOL SCI,PROGRAM MOLEC & CELLULAR BIOL,ATHENS,OH 45701; OHIO UNIV,EDISON BIOTECHNOL INST,ATHENS,OH 45701	University System of Ohio; Ohio University; University System of Ohio; Ohio University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042137] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42137-01A2] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CHEN WY, 1991, J BIOL CHEM, V266, P2252; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; CHEN WY, 1990, P NATL ACAD SCI USA, V87, P5061, DOI 10.1073/pnas.87.13.5061; CHEN WY, 1991, ENDOCRINOLOGY, V129, P1402, DOI 10.1210/endo-129-3-1402; CLEVENGER CV, 1990, ENDOCRINOLOGY, V127, P3151, DOI 10.1210/endo-127-6-3151; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FERNANDEZ E, 1990, ANAL BIOCHEM, V191, P268, DOI 10.1016/0003-2697(90)90218-X; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GORIN E, 1990, ENDOCRINOLOGY, V126, P2973; KOPCHICK JJ, 1985, DNA-J MOLEC CELL BIO, V4, P23, DOI 10.1089/dna.1985.4.23; KORNBERG LJ, 1992, BIOCHEM INT, V28, P873; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOBIE PE, 1991, J BIOL CHEM, V266, P22645; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; OKADA S, 1992, ENDOCRINOLOGY, V130, P2284, DOI 10.1210/en.130.4.2284; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; ROBERTS JM, 1982, CELL, V29, P109, DOI 10.1016/0092-8674(82)90095-2; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; SONNENBERG, 1992, FASEB J, V6, P288; STEWART TA, 1992, ENDOCRINOLOGY, V130, P405, DOI 10.1210/en.130.1.405; STRED SE, 1990, ENDOCRINOLOGY, V127, P2506, DOI 10.1210/endo-127-5-2506; STRED SE, 1992, ENDOCRINOLOGY, V130, P1626, DOI 10.1210/en.130.3.1626; STUBBART JR, 1991, ENDOCRINOLOGY, V129, P1659, DOI 10.1210/endo-129-3-1659; TOLLET P, 1991, MOL ENDOCRINOL, V5, P1351; WAGNER TE, 1981, P NATL ACAD SCI-BIOL, V78, P6376, DOI 10.1073/pnas.78.10.6376; WANG XZ, 1994, P NATL ACAD SCI USA, V91, P1391, DOI 10.1073/pnas.91.4.1391; WATAHIKI M, 1989, J BIOL CHEM, V264, P312	35	114	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15892	15897						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195244				2022-12-27	WOS:A1994NP51300076
J	CROSSLEY, M; TSANG, AP; BIEKER, JJ; ORKIN, SH				CROSSLEY, M; TSANG, AP; BIEKER, JJ; ORKIN, SH			REGULATION OF THE ERYTHROID KRUPPEL-LIKE FACTOR (EKLF) GENE PROMOTER BY THE ERYTHROID TRANSCRIPTION FACTOR GATA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; DNA-BINDING; GLOBIN GENE; POSITIVE REGULATOR; MAMMALIAN-CELLS; CACCC ELEMENT; EXPRESSION; FAMILY; MOUSE; DIFFERENTIATION	Erythroid Kruppel-like factor (EKLF) is an erythroid-specific transcription factor that binds a CACCC motif found in the human beta-globin gene promoter. We have studied the promoter of the EKLF gene and identified binding sites for the transcription factors GATA-1 and CCAAT-binding Protein 1 (CP1). We show that both types of binding sites are required for full activity, and that the GATA motif at -60 is essential. The EKLF promoter can be directly activated in nonerythroid cells in col transfection experiments by forced expression of GATA-1. These results suggest that EKLF is dependent on GATA-1 for its expression and lies downsteam of, or coincident with, GATA-1 in a regulatory hierarchy in erythroid development.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT,DIV HEMATOL ONCOL,BOSTON,MA 02115; HOWARD HUGHES MED INST,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Crossley, Merlin/D-7888-2011	Crossley, Merlin/0000-0003-2057-3642				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DAYLOT N, 1993, NUCLEIC ACIDS RES, V21, P4031; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FENG WC, 1994, J BIOL CHEM, V269, P1492; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; MACLEOD K, 1991, MOL CELL BIOL, V11, P4324, DOI 10.1128/MCB.11.9.4324; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; Maxam A M, 1980, Methods Enzymol, V65, P499; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; NISHIOKA Y, 1979, CELL, V18, P875, DOI 10.1016/0092-8674(79)90139-9; ORKIN SH, 1992, BLOOD, V80, P575; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHEN SH, 1981, CELL, V26, P191, DOI 10.1016/0092-8674(81)90302-0; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WATT P, 1990, NUCLEIC ACIDS RES, V18, P1339, DOI 10.1093/nar/18.6.1339; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	30	101	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15440	15444						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195185				2022-12-27	WOS:A1994NP51300010
J	DMELLO, NP; CHILDRESS, AM; FRANKLIN, DS; KALE, SP; PINSWASDI, C; JAZWINSKI, SM				DMELLO, NP; CHILDRESS, AM; FRANKLIN, DS; KALE, SP; PINSWASDI, C; JAZWINSKI, SM			CLONING AND CHARACTERIZATION OF LAG1, A LONGEVITY-ASSURANCE GENE IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; SACCHAROMYCES-CEREVISIAE; LIFE-SPAN; DROSOPHILA-MELANOGASTER; MESSENGER-RNAS; PLASMID DNA; CELL-CYCLE; SENESCENCE; PROTEINS; MEMBRANE	The yeast Saccharomyces cerevisiae has a finite life span that is measured by the number of times the individual cell divides. The gene coding for one of several transcripts that are differentially expressed during the replicative life span has been cloned. The nucleotide sequence revealed an open reading frame capable of encoding a transmembrane protein of 411 amino acids that displays no significant similarities to any known proteins. Nevertheless, sequences similar to this gene were found in several mammals, including humans. The transcript levels decreased with replicative age of yeast cells. A gene deletion in haploid eels resulted in a pronounced increase (approximately 50%) in mean and in maximum life span. These results indicate that this gene, which we call LAG1, plays a role in determining yeast longevity.	LOUISIANA STATE UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,CTR AGING,NEW ORLEANS,LA 70112	Louisiana State University System; Louisiana State University System								ANDREWS BJ, 1992, NATURE, V355, P393, DOI 10.1038/355393a0; ARCANGIOLI B, 1985, EMBO J, V4, P2627, DOI 10.1002/j.1460-2075.1985.tb03980.x; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3997; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3926; CHEN JB, 1990, MOL MICROBIOL, V4, P2081, DOI 10.1111/j.1365-2958.1990.tb00568.x; EGILMEZ NK, 1989, J BACTERIOL, V171, P37, DOI 10.1128/jb.171.1.37-42.1989; EGILMEZ NK, 1990, J GERONTOL, V45, pB9, DOI 10.1093/geronj/45.1.B9; EGILMEZ NK, 1989, J BIOL CHEM, V264, P14312; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Finch CE, 1990, LONGEVITY SENESCENCE; FRIEDMAN DB, 1988, GENETICS, V118, P75; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; Guthrie C, 1991, GUIDE YEAST GENETICS; HAMILTON R, 1987, NUCLEIC ACIDS RES, V15, P3581, DOI 10.1093/nar/15.8.3581; HINNEBUSCH AG, 1983, P NATL ACAD SCI-BIOL, V80, P5374, DOI 10.1073/pnas.80.17.5374; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAZWINSKI SM, 1990, MOL MICROBIOL, V4, P337, DOI 10.1111/j.1365-2958.1990.tb00601.x; JAZWINSKI SM, 1982, P NATL ACAD SCI-BIOL, V79, P3428, DOI 10.1073/pnas.79.11.3428; JOHNSON TE, 1987, P NATL ACAD SCI USA, V84, P3777, DOI 10.1073/pnas.84.11.3777; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUCKINBILL LS, 1984, EVOLUTION, V38, P996, DOI 10.1111/j.1558-5646.1984.tb00369.x; LUMPKIN CK, 1986, SCIENCE, V232, P393, DOI 10.1126/science.2421407; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MULLER I, 1980, MECH AGEING DEV, V12, P47, DOI 10.1016/0047-6374(80)90028-7; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSE MR, 1984, EVOLUTION, V38, P1004, DOI 10.1111/j.1558-5646.1984.tb00370.x; Sacher G. A., 1978, The genetics of aging., P151; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P9; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8578; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	41	187	195	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15451	15459						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195187				2022-12-27	WOS:A1994NP51300012
J	REDDY, ST; HERSCHMAN, HR				REDDY, ST; HERSCHMAN, HR			LIGAND-INDUCED PROSTAGLANDIN SYNTHESIS REQUIRES EXPRESSION OF THE TIS10/PGS-2 PROSTAGLANDIN SYNTHASE GENE IN MURINE FIBROBLASTS AND MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; MITOGEN-INDUCIBLE CYCLOOXYGENASE; ENDOPEROXIDE SYNTHASE; 5-LIPOXYGENASE-ACTIVATING PROTEIN; LEUKOTRIENE SYNTHESIS; ARACHIDONIC-ACID; DEXAMETHASONE; RELEASE; TIS10	Phospholipase activation has been considered rate-limiting for ligand-stimulated prostaglandin (PG) synthesis. Constitutive prostaglandin synthase EC 1.14.99.1 (PGS-1) has been thought to convert arachidonate released following ligand stimulation to PGH(2). However, a second prostaglandin synthase, TIS10/PGS-2, is inducible in many cell types, including fibroblasts and macrophages. We have used antisense oligonucleotide inhibition of TIS10/PGS-2 induction to investigate the role of this enzyme in ligand-induced prostaglandin production in fibroblasts and macrophages. Antisense TIS10/ PGS-2 oligonucleotides block mitogen-induced prostaglandin production and TIS10/PGS-2 protein synthesis in both Swiss 3T3 cells and murine embryo fibroblast cultures, without inhibiting either constitutive PGS-1 activity or mitogen stimulated arachidonic acid release. TIS10/PGS-2 antisense oligonucleotides also block production of PGE(2) from endogenous arachidonate following endotoxin stimulation of both RAW 264.7 macrophage cells and murine peritoneal macrophages. In contrast, the constitutive prostaglandin synthase present in macrophages is unable to convert arachidonate released following endotoxin stimulation into prostaglandin. TIS10/PGS-2 expression is necessary for both mitogen-induced prostaglandin production in murine fibroblasts and endotoxin-induced prostaglandin synthesis in macrophages. PGS-1 present in these cells cannot utilize arachidonic acid released in response to mitogen or endotoxin stimulation.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,STRUCT BIOL & MOLEC MED LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024797] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24797] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBOUR SE, 1993, J BIOL CHEM, V268, P21862; BENAV P, 1989, FEBS LETT, V259, P64, DOI 10.1016/0014-5793(89)81495-4; BUTLERGRALLA E, 1983, BIOCHEM BIOPH RES CO, V111, P194, DOI 10.1016/S0006-291X(83)80135-1; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FREEMAN CP, 1966, J LIPID RES, V7, P324; GILBERT RS, 1994, J CELL PHYSIOL, V159, P67, DOI 10.1002/jcp.1041590110; HABENICHT AJR, 1985, ADV PROSTAG THROMB L, V13, P37; HABIB A, 1993, J BIOL CHEM, V268, P23448; HAMASAKI Y, 1993, ARCH BIOCHEM BIOPHYS, V304, P226, DOI 10.1006/abbi.1993.1343; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LEE SH, 1992, J BIOL CHEM, V267, P25934; MASFERRER JL, 1990, J CLIN INVEST, V86, P1375, DOI 10.1172/JCI114850; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; OBANNION MK, 1991, J BIOL CHEM, V267, P23261; REDDY ST, 1994, J LEUKOCYTE BIOL, V55, P192, DOI 10.1002/jlb.55.2.192; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; REID GK, 1990, J BIOL CHEM, V265, P19818; Rudnicki M.A., 1987, TERATOCARCINOMAS EMB; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P433; SIROIS J, 1992, J BIOL CHEM, V267, P6382; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	26	249	251	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15473	15480						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195190				2022-12-27	WOS:A1994NP51300015
J	SANTOS, C; BALLESTA, JPG				SANTOS, C; BALLESTA, JPG			RIBOSOMAL-PROTEIN P0, CONTRARY TO PHOSPHOPROTEINS P1 AND P2, IS REQUIRED FOR RIBOSOME ACTIVITY AND SACCHAROMYCES-CEREVISIAE VIABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; ESCHERICHIA-COLI; ACIDIC PROTEINS; ANTIGENIC DETERMINANT; MONOCLONAL-ANTIBODIES; GTPASE DOMAIN; LARGE SUBUNIT; YEAST; GENE; RNA	Protein P0 in Saccharomyces cerevisiae is found only in the ribosomes and not free in a cytoplasmic pool like the structurally related acidic P1 and P2 proteins. Analogously, P0 stays bound to the particles in conditions that release the other P proteins. Attempts to obtain yeast strains carrying an interrupted P0 gene by direct gene disruption techniques of different yeast strains always resulted in haploid cells carrying one disrupted and one intact copy of the gene. Disruption of the unique P0 genomic copy seems to induce a duplication and occasionally a chromosomal transposition of the gene. Conditional null mutants of P0 were then constructed carrying the P0 gene under the control of the inducible GAL1 promoter. A 2-3-fold excess of P0 mRNA is found in the conditional mutant when grown in galactose; however, only a small increase of the P0 protein is detected in total cell extracts. No P0 protein is detected in the cell supernatant, indicating that, like the standard ribosomal proteins and opposite to the other P proteins, the protein not bound to the ribosomes is degraded. Transfer of the mutants to the restrictive conditions causes, after some generations, a growth stop that finally leads to cell death. The growth decline is paralleled by a reduction in the polysome number and the appearance of half mer particles as well as by an accumulation of 60 S particles deficient in P0 and in the acidic proteins P1 and P2. These results indicate that P0 is required for the interaction of the acidic P1 and P2 proteins with the ribosomes, and in its absence, deficient 60 S ribosomes are assembled which are inactive in protein synthesis resulting in cell lethality.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Santos, Cruz/ABG-3054-2020	Santos, Cruz/0000-0001-5164-5050				ABOVICH N, 1985, MOL CELL BIOL, V5, P3429, DOI 10.1128/MCB.5.12.3429; ALKSNE LE, 1993, J BIOL CHEM, V268, P10813; BALLESTA JPG, 1993, PROTEIN SYNTHESIS TA, P67; BEAUCLERK AAD, 1984, J BIOL CHEM, V259, P6559; BERMEJO B, 1994, J BIOL CHEM, V269, P3968; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; CAMPOS F, 1990, BIOCHIM BIOPHYS ACTA, V1087, P142, DOI 10.1016/0167-4781(90)90198-B; DABBS ER, 1991, BIOCHIMIE, V73, P639, DOI 10.1016/0300-9084(91)90043-Z; DESHMUKH M, 1993, MOL CELL BIOL, V13, P2835, DOI 10.1128/MCB.13.5.2835; EGEBJERG J, 1990, J MOL BIOL, V213, P275, DOI 10.1016/S0022-2836(05)80190-1; ELBARADI TTAL, 1987, J MOL BIOL, V195, P909, DOI 10.1016/0022-2836(87)90494-3; ELKON K, 1986, P NATL ACAD SCI USA, V83, P7419, DOI 10.1073/pnas.83.19.7419; FRIED HM, 1985, MOL CELL BIOL, V5, P99, DOI 10.1128/MCB.5.1.99; GUNTHER R, 1991, J BIOL CHEM, V266, P24557; HAMEL E, 1972, J BIOL CHEM, V247, P6810; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HIGHLAND JH, 1975, J BIOL CHEM, V250, P831; INFANTE AA, 1971, BIOCHIM BIOPHYS ACTA, V246, P81, DOI 10.1016/0005-2787(71)90074-8; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JUANVIDALES F, 1983, EUR J BIOCHEM, V136, P275, DOI 10.1111/j.1432-1033.1983.tb07738.x; KOREN E, 1992, J CLIN INVEST, V89, P1236, DOI 10.1172/JCI115707; KRUSE C, 1985, P NATL ACAD SCI USA, V82, P7515, DOI 10.1073/pnas.82.22.7515; LUCIOLI A, 1988, MOL CELL BIOL, V8, P4792, DOI 10.1128/MCB.8.11.4792; MARQUIS DM, 1981, J MOL BIOL, V150, P121, DOI 10.1016/0022-2836(81)90327-2; MESRI EA, 1990, J CLIN MICROBIOL, V28, P1219, DOI 10.1128/JCM.28.6.1219-1224.1990; MITSUI K, 1988, J BIOCHEM-TOKYO, V104, P908, DOI 10.1093/oxfordjournals.jbchem.a122581; MITSUI K, 1988, NUCLEIC ACIDS RES, V16, P3573, DOI 10.1093/nar/16.8.3573; MITSUI K, 1989, J BIOCHEM-TOKYO, V106, P223, DOI 10.1093/oxfordjournals.jbchem.a122836; NARANDA T, 1993, J BIOL CHEM, V268, P2451; NARANDA T, 1991, P NATL ACAD SCI USA, V88, P10563, DOI 10.1073/pnas.88.23.10563; NEWTON CH, 1990, J BACTERIOL, V172, P579, DOI 10.1128/jb.172.2.579-588.1990; REMACHA M, 1990, MOL CELL BIOL, V10, P2182, DOI 10.1128/MCB.10.5.2182; REMACHA M, 1992, J BIOL CHEM, V267, P12061; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; ROTENBERG MO, 1988, GENE DEV, V2, P160, DOI 10.1101/gad.2.2.160; SAENZROBLES MT, 1990, BIOCHIM BIOPHYS ACTA, V1050, P51, DOI 10.1016/0167-4781(90)90140-W; SAENZROBLES MT, 1988, EUR J BIOCHEM, V177, P531, DOI 10.1111/j.1432-1033.1988.tb14405.x; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZMADRID F, 1979, EUR J BIOCHEM, V98, P409, DOI 10.1111/j.1432-1033.1979.tb13200.x; SANCHEZMADRID F, 1981, EUR J BIOCHEM, V114, P609, DOI 10.1111/j.1432-1033.1981.tb05187.x; SCHIJMAN AG, 1992, IMMUNOL LETT, V33, P15, DOI 10.1016/0165-2478(92)90087-5; Sherman F., 1983, METHODS YEAST GENETI; SHIMMIN LC, 1989, J MOL EVOL, V29, P448, DOI 10.1007/BF02602915; SOTO M, 1993, J BIOL CHEM, V268, P21835; STRYCHARZ WA, 1978, J MOL BIOL, V126, P123, DOI 10.1016/0022-2836(78)90355-8; SYNETOS D, 1992, J BIOL CHEM, V267, P3008; TOWBIN H, 1982, J BIOL CHEM, V257, P2709; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSURUGI K, 1985, J BIOCHEM-TOKYO, V98, P1427, DOI 10.1093/oxfordjournals.jbchem.a135410; UCHIUMI T, 1992, J BIOL CHEM, V267, P19179; UCHIUMI T, 1987, P NATL ACAD SCI USA, V84, P5580, DOI 10.1073/pnas.84.16.5580; VANAGTHOVEN AJ, 1977, BIOCHEM BIOPH RES CO, V77, P989, DOI 10.1016/S0006-291X(77)80075-2; VILELLA MD, 1991, EUR J BIOCHEM, V196, P407, DOI 10.1111/j.1432-1033.1991.tb15831.x; WARNER JR, 1977, CELL, V11, P201, DOI 10.1016/0092-8674(77)90331-2; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; ZINKER S, 1980, BIOCHIM BIOPHYS ACTA, V606, P76, DOI 10.1016/0005-2787(80)90099-4; ZINKER S, 1976, J BIOL CHEM, V251, P1799	57	104	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15689	15696						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195220				2022-12-27	WOS:A1994NP51300048
J	RAPAPORT, D; SHAI, Y				RAPAPORT, D; SHAI, Y			INTERACTION OF FLUORESCENTLY LABELED ANALOGS OF THE AMINO-TERMINAL FUSION PEPTIDE OF SENDAI VIRUS WITH PHOSPHOLIPID-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTIFICIAL LIPID-MEMBRANES; INFLUENZA-VIRUS; ENERGY-TRANSFER; DEPENDENT FUSION; PARDAXIN ANALOGS; N-TERMINUS; PROTEIN; HEMAGGLUTININ; VESICLES; GLYCOPROTEIN	A peptide representing the NH2-terminal (33 amino acid residues) of the fusion protein (F) of Sendai virus, as well as its Gly(12) --> Ala(12) mutant, were synthesized, fluorescently labeled, and spectroscopically and functionally characterized. Peptide-induced vesicle fusion was demonstrated by a combination of increased visible absorbance, lipid mixing assay, and electron microscopy. Both peptides, with the mutant peptide being significantly more potent, were shown to induce membrane fusion and bilayer perturbation of negatively charged phospholipid vesicles. These results are consistent with a previous study that showed that a similar mutation in the homologous NH2-terminal segment of simian virus 5 greatly enhanced syncytium formation (Horvath, C. M., and Lamb, R. A. (1992) J. Virol. 66, 2443-2455). Circular dichroism spectroscopy revealed similar high alpha-helical contents of both peptides in methanol and in trifluoroethanol. Using fluorescently labeled peptide analogues we found that (i) the peptides' membrane partition coefficients are in the range of 10(5) M(-1); (ii) the NH2 terminus of the wild-type peptide is located within the lipid bilayer, whereas that of the variant peptide lies on the surface; and (iii) both peptides tend to self-associate in their membrane-bound state. The results support a model in which an alpha-helical secondary structure and self-aggregation of peptides are necessary conditions for membrane fusion. The observed differences in the peptides' fusogenic abilities are hypothesized to result from differences in the peptides' degree of penetration into the membrane, induction of membrane destabilization, and ability to cause vesicles to aggregate. The data support Sendai virus-cell fusion models in which the fusion peptide plays a crucial role in fusion induction by destabilizing the bilayer and by triggering the association of viral fusion protein molecules.	WEIZMANN INST SCI, DEPT MEMBRANE RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BESCHIASCHVILI G, 1990, BIOCHEMISTRY-US, V29, P52, DOI 10.1021/bi00453a007; BLUMBERG BM, 1985, J GEN VIROL, V66, P317, DOI 10.1099/0022-1317-66-2-317; BLUMENTHAL R, 1987, CURR TOP MEMBR TRANS, V29, P203; BOSCH ML, 1989, SCIENCE, V244, P694, DOI 10.1126/science.2541505; BURGER KNJ, 1991, BIOCHIM BIOPHYS ACTA, V1065, P121, DOI 10.1016/0005-2736(91)90221-S; CHOPPIN PW, 1980, REV INFECT DIS, V2, P40; CRANE SE, 1991, VIROLOGY, V185, P488, DOI 10.1016/0042-6822(91)90805-L; DUZGUNES N, 1992, J MEMBRANE BIOL, V128, P71, DOI 10.1007/BF00231872; FREED EO, 1990, P NATL ACAD SCI USA, V87, P4650, DOI 10.1073/pnas.87.12.4650; FREED EO, 1992, P NATL ACAD SCI USA, V89, P70, DOI 10.1073/pnas.89.1.70; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P12363, DOI 10.1021/bi00097a013; GETHING MJ, 1978, P NATL ACAD SCI USA, V75, P2737, DOI 10.1073/pnas.75.6.2737; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; GLUSHAKOVA SE, 1992, BIOCHIM BIOPHYS ACTA, V1110, P202, DOI 10.1016/0005-2736(92)90360-X; HOEKSTRA D, 1990, J BIOENERG BIOMEMBR, V22, P121, DOI 10.1007/BF00762943; HORVATH CM, 1992, J VIROL, V66, P2443, DOI 10.1128/JVI.66.4.2443-2455.1992; HSU MC, 1981, J BIOL CHEM, V256, P3557; LEAR JD, 1987, J BIOL CHEM, V262, P6500; LEE S, 1992, BIOCHIM BIOPHYS ACTA, V1103, P157, DOI 10.1016/0005-2736(92)90069-X; LELKES PI, 1984, LIPOSOME TECHNOLOGY, V1, P37; LI SC, 1992, INT J PEPT PROT RES, V40, P243; LOEW LM, 1983, BIOCHEMISTRY-US, V22, P837, DOI 10.1021/bi00273a020; LUCY JA, 1982, BIOL MEMBR, V4, P367; MARTIN I, 1991, BIOCHEM BIOPH RES CO, V175, P872, DOI 10.1016/0006-291X(91)91646-T; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MURATA M, 1991, BIOCHEM BIOPH RES CO, V179, P1050, DOI 10.1016/0006-291X(91)91925-3; MURATA M, 1987, BIOCHEMISTRY-US, V26, P4056, DOI 10.1021/bi00387a047; NIR S, 1980, BIOCHEMISTRY-US, V19, P6030, DOI 10.1021/bi00567a013; NOVICK SL, 1988, P NATL ACAD SCI USA, V85, P7433, DOI 10.1073/pnas.85.20.7433; PARENTE RA, 1988, J BIOL CHEM, V263, P4724; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; RAFALSKI M, 1991, BIOCHEMISTRY-US, V30, P10211, DOI 10.1021/bi00106a020; RAJARATHNAM K, 1989, BIOCHEMISTRY-US, V28, P3168, DOI 10.1021/bi00434a009; RAPAPORT D, 1991, J BIOL CHEM, V266, P23769; RAPAPORT D, 1992, BIOCHEMISTRY-US, V31, P8868, DOI 10.1021/bi00152a025; RAPAPORT D, 1993, BIOCHEMISTRY-US, V32, P3291, DOI 10.1021/bi00064a011; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; RIZZO V, 1987, BIOCHEMISTRY-US, V26, P2751, DOI 10.1021/bi00384a015; SCHWARZ G, 1986, BIOCHIM BIOPHYS ACTA, V861, P141, DOI 10.1016/0005-2736(86)90412-8; SERRANO L, 1992, NATURE, V356, P453, DOI 10.1038/356453a0; SHAI Y, 1990, J BIOL CHEM, V265, P20202; SHAI Y, 1991, J BIOL CHEM, V266, P22346; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; SLEPUSHKIN VA, 1990, BIOCHEM BIOPH RES CO, V172, P952, DOI 10.1016/0006-291X(90)90768-I; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; TAYLOR JW, 1987, METHOD ENZYMOL, V154, P473; WHARTON SA, 1988, J GEN VIROL, V69, P1847, DOI 10.1099/0022-1317-69-8-1847; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WOLBER PK, 1979, BIOPHYS J, V28, P197, DOI 10.1016/S0006-3495(79)85171-1; YEAGLE PL, 1991, BIOCHIM BIOPHYS ACTA, V1065, P49, DOI 10.1016/0005-2736(91)90009-W; Yeagle PL, 1993, VIRAL FUSION MECHANI, P313; ZHONG LX, 1992, P NATL ACAD SCI USA, V89, P4462, DOI 10.1073/pnas.89.10.4462; ZIMMERBERG J, 1993, ANNU REV BIOPH BIOM, V22, P433, DOI 10.1146/annurev.bb.22.060193.002245	57	71	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15124	15131						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195149				2022-12-27	WOS:A1994NP73800043
J	GUARDIOLADIAZ, HM; BOSWELL, C; SEASHOLTZ, AF				GUARDIOLADIAZ, HM; BOSWELL, C; SEASHOLTZ, AF			THE CAMP-RESPONSIVE ELEMENT IN THE CORTICOTROPIN-RELEASING HORMONE GENE MEDIATES TRANSCRIPTIONAL REGULATION BY DEPOLARIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE; RAT HYPOTHALAMUS INVITRO; DEPENDENT PROTEIN-KINASE; IMMEDIATE EARLY GENES; NERVE GROWTH-FACTOR; CYCLIC-AMP; MEMBRANE DEPOLARIZATION; MESSENGER-RNA; CELL-LINE; PREINITIATION COMPLEX	Membrane depolarization is a critical element of neuronal signaling, In this study, the biochemical and molecular mechanisms involved in transcriptional regulation of the corticotropin-releasing hormone (CRH) gene by depolarization were investigated. In PC-12 cells, potassium-induced membrane depolarization increased expression of a CRH-reporter construct in a cAMP-dependent manner. This synergistic activation was mediated via calcium influx, predominantly via L-type calcium channels, and calmodulin. RNase protection assays demonstrated increased levels of CRH-reporter transcripts in stably transfected cells after treatment with cAMP and potassium, with the induced transcripts initiating at the major transcription initiation site of the human CRH gene. At the genomic level, the CRH cAMP-responsive element conferred both positive cAMP and synergistic cAMP/depolarization regulation to a heterologous promoter. Additionally, DNase I protection assays demonstrated similar nuclear protein/DNA binding profiles across the cAMP-responsive element after treatment of PC-12 cells with potassium or potassium/cAMP. These results support a model in which the protein(s) binding to the cAMP-responsive element integrates signals initiated by multiple pathways (cAMP and calcium) and transmits that integrated signal to the basal transcription machinery, resulting in increased levels of gene expression.	UNIV MICHIGAN, MENTAL HLTH RES INST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007544] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29 DK42730] Funding Source: Medline; NIGMS NIH HHS [T32-GM07544] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER GK, 1988, J BIOL CHEM, V263, P5846; ADLER GK, 1990, MOL CELL ENDOCRINOL, V70, P165, DOI 10.1016/0303-7207(90)90156-3; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MJO, 1987, NEUROENDOCRINOLOGY, V46, P147, DOI 10.1159/000124812; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DORIN RI, 1989, MOL ENDOCRINOL, V3, P1537, DOI 10.1210/mend-3-10-1537; EMANUEL RL, 1990, ENDOCRINOLOGY, V126, P3016, DOI 10.1210/endo-126-6-3016; FRIM DM, 1988, J CLIN INVEST, V82, P287, DOI 10.1172/JCI113585; FUJIMOTO M, 1991, NEUROSCI LETT, V122, P9, DOI 10.1016/0304-3940(91)90180-2; Ginty D D, 1992, Curr Opin Neurobiol, V2, P312, DOI 10.1016/0959-4388(92)90121-Z; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Guardiola-Diaz H., 1992, Society for Neuroscience Abstracts, V18, P753; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KILBOURNE EJ, 1990, MOL BRAIN RES, V8, P121, DOI 10.1016/0169-328X(90)90056-J; KONGSAMUT S, 1986, P NATL ACAD SCI USA, V83, P2243, DOI 10.1073/pnas.83.7.2243; LIU F, 1993, J BIOL CHEM, V268, P6714; MAJZOUB J, 1988, INT CONGR SER, V798, P231; Maxam A M, 1980, Methods Enzymol, V65, P499; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; OWENS MJ, 1991, PHARMACOL REV, V43, P425; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RITCHIE AK, 1979, J PHYSIOL-LONDON, V286, P541, DOI 10.1113/jphysiol.1979.sp012636; ROBINSON BG, 1989, MOL CELL ENDOCRINOL, V61, P175, DOI 10.1016/0303-7207(89)90128-7; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; SEASHOLTZ AF, 1988, MOL ENDOCRINOL, V2, P1311, DOI 10.1210/mend-2-12-1311; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHIBAHARA S, 1983, EMBO J, V2, P775, DOI 10.1002/j.1460-2075.1983.tb01499.x; SMITH MA, 1986, ENDOCRINOLOGY, V118, P1997, DOI 10.1210/endo-118-5-1997; SPENGLER D, 1992, MOL ENDOCRINOL, V6, P1931, DOI 10.1210/me.6.11.1931; SUDA T, 1985, LIFE SCI, V37, P1499, DOI 10.1016/0024-3205(85)90181-X; TSAGARAKIS S, 1991, J MOL ENDOCRINOL, V7, P71, DOI 10.1677/jme.0.0070071; TSAGARAKIS S, 1988, ENDOCRINOLOGY, V123, P1962, DOI 10.1210/endo-123-4-1962; USOWICZ MM, 1990, J PHYSIOL-LONDON, V426, P95, DOI 10.1113/jphysiol.1990.sp018128; VANNGUYEN T, 1990, J NEUROSCI, V10, P2825; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T	46	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14784	14791						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182084				2022-12-27	WOS:A1994NM06500074
J	KISHIDA, S; SHIRATAKI, H; SASAKI, T; KATO, M; KAIBUCHI, K; TAKAI, Y				KISHIDA, S; SHIRATAKI, H; SASAKI, T; KATO, M; KAIBUCHI, K; TAKAI, Y			RAB3A GTPASE-ACTIVATING PROTEIN-INHIBITING ACTIVITY OF RABPHILIN-3A, A PUTATIVE RAB3A TARGET PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GDP DISSOCIATION INHIBITOR; GDP/GTP EXCHANGE PROTEIN; BINDING PROTEIN; SMG P25A; REGULATORY PROTEIN; SYNAPTIC VESICLES; KINASE-C; RAS; SMG-P25A; TISSUE	Rabphilin-3A is a putative target protein for Rab3A, a member of the small G protein superfamily that is implicated in regulated secretion, particularly in neuro-transmitter release. Rabphilin-3A contains at least two functionally different domains: the N-terminal Rab3A-binding domain and the C-terminal C2 domain, which interacts with both Ca2+ and phospholipid. Because Rabphilin-3A interacts preferentially with GTP-Rab3A rather than with GDP-Rab3A, we have examined here whether Rabphilin-3A affects the GTPase activity of Rab3A. Rabphilin-3A and its N-terminal fragment, but not its C-terminal fragment, very weakly stimulated the basal GTPase activity of Rab3A. However, Rabphilin-3A and its N-terminal fragment strongly inhibited the Rab3A GAp-stimulated GTPase activity of Rab3A. Ca2+ and phospholipid showed no effect on these activities of Rabphilin-3A. The physiological significance of the GAP activity of Rabphilin-3A is obscure, but it is likely that Rabphilin-3A inhibits Rab3A GAP activity and keeps Rab3A in the GTP-bound active form during its action as a target molecule for Rab3A.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Kobe University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)				kishida, shosei/0000-0003-0405-851X				ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN E, 1989, MOL CELL BIOL, V9, P4807, DOI 10.1128/MCB.9.11.4807; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MIZOGUCHI A, 1992, BIOCHEM BIOPH RES CO, V186, P1345, DOI 10.1016/S0006-291X(05)81554-2; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; MORII M, 1991, J BIOL CHEM, V12, P7646; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLOFSSON B, 1988, ONCOGENE, V3, P231; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SANO K, 1989, BIOCHEM BIOPH RES CO, V158, P377, DOI 10.1016/S0006-291X(89)80058-0; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988	27	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22259	22261						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226731				2022-12-27	WOS:A1993MD34800012
J	WOJTKOWIAK, D; GEORGOPOULOS, C; ZYLICZ, M				WOJTKOWIAK, D; GEORGOPOULOS, C; ZYLICZ, M			ISOLATION AND CHARACTERIZATION OF CLPX, A NEW ATP-DEPENDENT SPECIFICITY COMPONENT OF THE CLP PROTEASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA-DNA REPLICATION; HEAT-SHOCK PROTEIN; SPECIALIZED NUCLEOPROTEIN STRUCTURES; BACTERIOPHAGE-LAMBDA; O-PROTEIN; REGULATORY SUBUNIT; LON PROTEASE; DEGRADATION; PROTEOLYSIS; INITIATION	We have used C-14-labeled bacteriophage lambdaO-DNA replication protein as a probe to identify and purify Escherichia coli proteases capable of its degradation. In this manner, five different proteases (termed Lop) have been identified capable of degrading lambdaO protein to acid-soluble fragments in an ATP-dependent fashion. One of these activities was purified to homogeneity and shown to be composed of two different polypeptides. The 23,000-Da component (LopP) was identified as the previously characterized ClpAP protein, known to complex with ClpA to form the ClpAP, an ATP-dependent protease, capable of degrading casein. The second 46,000-Da component was identified as ClpX (LopC), coded by a gene located in the same operon, but promoter distal to that coding for ClpP (Gottesman, S., Clark, W. P., de Crecy-Lagard, V., and Maurizi, M. R. (1993) J. Biol. Chem. 268, 22618-22626). This identification was based on the determination of the sequence of the first 24 amino acid residues of the purified ClpX protein and its identity with that predicted by the DNA sequence. The ClpXP protease is substrate specific, since it degrades casein (known to be degraded by ClpAP), lambdaP, or DnaK proteins slowly or not at all. These results suggest that ClpX protein directs ClpP protease to specific substrates. It is estimated that 50% of all lambdaO-specific protease activity present in crude E. coli extracts is due to the ClpXP protease. We propose that transient inhibition of lambdaO degradation observed in vivo during the later stages of lambda-DNA replication in vivo is responsible for the switch from bidirectional to unidirectional replication. One round unidirectional replication will lead to strand separation resulting in a switch from early (theta) to late (sigma) mode of lambda-DNA replication.	UNIV GDANSK,DEPT MOLEC BIOL,DIV BIOPHYS,KLADKI 24,PL-80952 GDANSK,POLAND; UNIV GENEVA,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND	Fahrenheit Universities; University of Gdansk; University of Geneva								BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; CRAIG NL, 1980, NATURE, V283, P26, DOI 10.1038/283026a0; DERBYSHIRE KM, 1990, P NATL ACAD SCI USA, V87, P4048, DOI 10.1073/pnas.87.11.4048; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; Furth M., 1983, LAMBDA 2, P145; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; GOTTESMAN S, 1981, CELL, V24, P225, DOI 10.1016/0092-8674(81)90518-3; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG BJ, 1987, P NATL ACAD SCI USA, V84, P5550, DOI 10.1073/pnas.84.16.5550; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KELLER JA, 1988, MOL MICROBIOL, V2, P31, DOI 10.1111/j.1365-2958.1988.tb00004.x; KITAGAWA M, 1991, J BACTERIOL, V173, P4247, DOI 10.1128/JB.173.14.4247-4253.1991; KROH HE, 1990, J BACTERIOL, V172, P6026, DOI 10.1128/jb.172.10.6026-6034.1990; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIPINSKA B, 1980, BIOCHEM BIOPH RES CO, V92, P120, DOI 10.1016/0006-291X(80)91528-4; LIPINSKA B, 1990, J BACTERIOL, V172, P1791, DOI 10.1128/jb.172.4.1791-1797.1990; MAURIZI MR, 1987, J BIOL CHEM, V262, P2696; MAURIZI MR, 1990, J BIOL CHEM, V265, P12536; MCMACKEN R, 1983, MECHANISMS DNA REPLI, P819; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; MILLER CG, 1987, ESCHERICHIA COLI SAL, P680; MIZUSAWA S, 1983, P NATL ACAD SCI-BIOL, V80, P358, DOI 10.1073/pnas.80.2.358; PHILLIPS TA, 1984, J BACTERIOL, V159, P283, DOI 10.1128/JB.159.1.283-287.1984; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROBERTS JD, 1983, NUCLEIC ACIDS RES, V11, P7435, DOI 10.1093/nar/11.21.7435; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SCHOULAKERSCHWARZ R, 1991, P NATL ACAD SCI USA, V88, P4996, DOI 10.1073/pnas.88.11.4996; SHERMAN MY, 1992, EMBO J, V11, P71; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; TILLY K, 1989, J BACTERIOL, V171, P1585, DOI 10.1128/jb.171.3.1585-1589.1989; TORRESCABASSA AS, 1987, J BACTERIOL, V169, P981, DOI 10.1128/jb.169.3.981-989.1987; TREMPY JE, 1989, J BACTERIOL, V171, P3348, DOI 10.1128/jb.171.6.3348-3353.1989; TSURIMOTO T, 1982, MOL GEN GENET, V187, P79, DOI 10.1007/BF00384387; VOELLMY RW, 1981, NATURE, V290, P419, DOI 10.1038/290419a0; WOLD MS, 1982, P NATL ACAD SCI-BIOL, V79, P6176, DOI 10.1073/pnas.79.20.6176; WOO KM, 1989, J BIOL CHEM, V264, P2088; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	48	215	217	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22609	22617						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226769				2022-12-27	WOS:A1993MD34800064
J	WONG, SH; HONG, WJ				WONG, SH; HONG, WJ			THE SXYQRL SEQUENCE IN THE CYTOPLASMIC DOMAIN OF TGN38 PLAYS A MAJOR ROLE IN TRANS-GOLGI NETWORK LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; 2 INTERNALIZATION SIGNALS; INTEGRAL MEMBRANE-PROTEIN; HUMAN GLYCOPHORIN-A; BREFELDIN-A; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; MDCK CELLS; ORGANELLE STRUCTURE; SECRETORY PATHWAY	The trans-Golgi network (TGN) plays a central role in protein sorting/targeting. TGN38 is an integral membrane protein confined mainly to the TGN. When the cytoplasmic 32-residue sequence of TGN38 was fused to the ecto- and transmembrane domains of glycophorin A (a surface protein), the resulting chimeric protein was localized to the TGN. Detailed mutagenesis of the 32-residue sequence revealed that the Ser, Tyr, and Leu residues at positions 23, 25, and 28, respectively, are essential for TGN localization. Further studies demonstrate that the sequence SXYQRL can by itself confer significant TGN localization.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,MEMBRANE BIOL LAB,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			HONG, Wanjin/E-9927-2010					AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BURKE J, 1992, J BIOL CHEM, V267, P24433; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; HONG WJ, 1993, BIOESSAYS, V15, P231, DOI 10.1002/bies.950150403; HSU VW, 1992, CELL, V69, P625, DOI 10.1016/0092-8674(92)90226-3; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LADINSKY MS, 1992, EUR J CELL BIOL, V59, P92; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LOW SH, 1991, J BIOL CHEM, V266, P19710; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MORROW B, 1987, J BIOL CHEM, V262, P13812; MORROW K, 1992, J CELL BIOL, V116, P577; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; REMALEY AT, 1991, J BIOL CHEM, V266, P24176; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; SIEBERT PD, 1986, P NATL ACAD SCI USA, V83, P1665, DOI 10.1073/pnas.83.6.1665; SPIESS M, 1985, J BIOL CHEM, V260, P1979; SWIFT AM, 1991, J CELL BIOL, V115, P9; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; TANG BL, 1992, J BIOL CHEM, V267, P10122; TANG BL, 1992, EUR J CELL BIOL, V59, P228; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	56	121	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22853	22862						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226795				2022-12-27	WOS:A1993MD34800098
J	DAWSON, KM; COOK, A; DEVINE, JM; EDWARDS, RM; HUNTER, MG; RAPER, RH; ROBERTS, G				DAWSON, KM; COOK, A; DEVINE, JM; EDWARDS, RM; HUNTER, MG; RAPER, RH; ROBERTS, G			PLASMINOGEN MUTANTS ACTIVATED BY THROMBIN - POTENTIAL THROMBUS-SELECTIVE THROMBOLYTIC AGENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULAR-CLONING; BLOOD-COAGULATION; FACTOR-XI; FIBRIN; PLASMA; SITE; CELLS	Plasmin, the enzyme responsible for degradation of fibrin in blood clots and thus thrombolysis, is normally formed when its zymogen plasminogen is activated by cleavage of the Arg(561)-Val(562) bond by specific plasminogen activators. We have altered the activation characteristics of plasminogen by substituting the P3, P2, and P1' cleavage site residues with sequences from thrombin-cleavable proteins to produce a novel thrombolytic agent which instead is activated by the blood clotting system. Plasminogen variants with thrombin cleavage sites from fibrinogen, the thrombin receptor, factor XIII, and factor XI were cleaved by thrombin with times to 50% cleavage of 28 h, 2.5 h, 5.7 min, and 3 min, respectively. In vitro clot lysis studies have shown that a variant in which the P3-P1' residues of plasminogen were substituted by the P7-P1' residues (Thr(363)-Ile(370)) from factor XI (T51) was sufficiently rapidly cleaved by thrombin to be activated by the endogenous thrombin produced by the coagulation cascade, resulting in rapid clot dissolution. Thrombin activatable plasminogen therefore has the capacity to short circuit the physiological hemostatic mechanisms and produce fibrinolytic activity localized to the site of thrombin formation, that is, at the thrombus itself. The novel activation mechanism combined with the natural long circulating half-life of plasminogen gives this type of thrombolytic agent the potential for thrombus-selective plasmin generation and an extended duration of action.			DAWSON, KM (corresponding author), BRITISH BIOTECHNOL LTD, WATLINGTON RD, OXFORD OX4 5LY, ENGLAND.							APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BEGUIN S, 1992, THROMB HAEMOSTASIS, V67, P33; BLOMBACK B, 1967, NATURE, V215, P1445, DOI 10.1038/2151445a0; BLOMBACK B, 1977, CHEM BIOL THROMBIN, P275; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; CASTELLINO FJ, 1981, CHEM REV, V81, P431, DOI 10.1021/cr00045a001; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; COLLEN D, 1993, LANCET, V342, P34, DOI 10.1016/0140-6736(93)91888-S; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DAWSON KM, 1991, Patent No. 9118; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; FENTON JW, 1988, ADV CLIN ENZYMOL, V6, P186; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIJNEN HR, 1990, BIOTECHNOL THER, V1, P273; Machovich R, 1990, Blood Coagul Fibrinolysis, V1, P79, DOI 10.1097/00001721-199003000-00011; NAITO K, 1991, J BIOL CHEM, V266, P7353; NASKI MC, 1991, BIOCHEMISTRY-US, V30, P934, DOI 10.1021/bi00218a008; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; SHERRY S, 1987, AM J CARDIOL, V59, P984, DOI 10.1016/0002-9149(87)91139-8; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; SUENSON E, 1981, BIOCHEM J, V197, P619, DOI 10.1042/bj1970619; SUTTIE JW, 1977, PHYSIOL REV, V57, P1, DOI 10.1152/physrev.1977.57.1.1; TAKAGI T, 1974, BIOCHEMISTRY-US, V13, P750, DOI 10.1021/bi00701a018; THORSEN S, 1981, BIOCHIM BIOPHYS ACTA, V668, P377, DOI 10.1016/0005-2795(81)90171-9; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0	31	23	25	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15989	15992						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206894				2022-12-27	WOS:A1994NQ72900009
J	YEH, YC; LIU, HF; ELLIS, CA; LU, AL				YEH, YC; LIU, HF; ELLIS, CA; LU, AL			MAMMALIAN TOPOISOMERASE-I HAS BASE MISMATCH NICKING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; DNA TOPOISOMERASES; HUMAN-CELLS; NUCLEOTIDE-SEQUENCE; NUCLEAR EXTRACTS; PAIR MISMATCHES; ANTITUMOR DRUGS; CAMPTOTHECIN	The all-type nicking enzyme (ATE) from human HeLa cells or calf thymus can nick DNA at the first phosphodiester bond 5' to all 8 possible mismatched bases. The strand disparity of this nicking is influenced by the neighboring nucleotide sequences. After nicking, the ATE covalently binds to the 3' end of the DNA product to form a cleavable complex, whose formation is insensitive to camptothecin, a specific inhibitor of eukaryotic topoisomerase I (Topo-I). During the purification of ATE from calf thymus, a Mg2+-independent relaxation activity, characteristic of eukaryotic Topo-I, copurifies with the mismatch-nicking activity. The ATE from calf thymus may be a breakdown product of Topo-I. N-terminal amino acid analysis indicates that one of the polypeptides with ATE activity contains the C-terminal portion of Topo-I. Moreover, active human Topo-I, expressed as a fusion protein in Escherichia coli, is also capable of nicking all 8 base mispairs in the absence of Mg2+. This mismatch-specific nicking activity may be a novel property of the mammalian Topo-I.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035132] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35132] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; DARPA P, 1990, CANCER RES, V50, P6919; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; DELBINO G, 1991, EXP CELL RES, V193, P27, DOI 10.1016/0014-4827(91)90534-2; ENG WK, 1988, MOL PHARMACOL, V34, P755; FUJII H, 1989, J BIOL CHEM, V264, P10057; HABER LT, 1988, J BACTERIOL, V170, P197, DOI 10.1128/jb.170.1.197-202.1988; HONG YR, 1993, VIROLOGY, V194, P481, DOI 10.1006/viro.1993.1287; HORWITZ MS, 1971, BIOCHEM BIOPH RES CO, V45, P723; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; JAVAHERIAN K, 1982, NUCLEIC ACIDS RES, V10, P6945, DOI 10.1093/nar/10.21.6945; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KOIWAI O, 1993, GENE, V125, P211, DOI 10.1016/0378-1119(93)90331-V; KUDINOV AR, 1992, FEBS LETT, V314, P267, DOI 10.1016/0014-5793(92)81486-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN NA, 1993, GENETICS, V133, P799; LI LH, 1972, CANCER RES, V32, P2643; LIEB M, 1986, GENETICS, V114, P1041; LIEB M, 1983, MOL GEN GENET, V191, P118, DOI 10.1007/BF00330898; LIM M, 1986, CELL BIOL TOXICOL, V2, P485, DOI 10.1007/BF00117850; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LIU LF, 1989, DNA TOPOLOGY ITS BIO, P371; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; LU AL, 1988, GENETICS, V118, P593; MARTIN SR, 1983, METHOD ENZYMOL, V100, P137; Maxam A M, 1980, Methods Enzymol, V65, P499; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; NASH HA, 1987, P NATL ACAD SCI USA, V84, P4049, DOI 10.1073/pnas.84.12.4049; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; SCHMITT B, 1984, EUR J BIOCHEM, V144, P127, DOI 10.1111/j.1432-1033.1984.tb08440.x; SHEN CC, 1990, J MOL BIOL, V212, P67, DOI 10.1016/0022-2836(90)90305-6; Speicher D.W., 1989, TECHNIQUES PROTEIN C, P24; STEPHENSON C, 1989, J BIOL CHEM, V264, P21177; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU SS, 1988, J BIOL CHEM, V263, P6829; TOBEY RA, 1972, CANCER RES, V32, P2720; TRASK DK, 1983, NUCLEIC ACIDS RES, V11, P2779, DOI 10.1093/nar/11.9.2779; TRICOLI JV, 1983, BIOCHEMISTRY-US, V22, P2025, DOI 10.1021/bi00277a045; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; TSAIWU JYYJ, 1991, J BACTERIOL, V173, P1902, DOI 10.1128/jb.173.6.1902-1910.1991; TSAO YP, 1992, CANCER RES, V52, P1823; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; Yanagida M, 1990, DNA TOPOLOGY ITS BIO, P299; YEH YC, 1991, J BIOL CHEM, V266, P6480; ZHANG H, 1990, CANCER CELL-MON REV, V2, P23	57	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15498	15504						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195193				2022-12-27	WOS:A1994NP51300019
J	MA, D; COOK, DN; PON, NG; HEARST, JE				MA, D; COOK, DN; PON, NG; HEARST, JE			EFFICIENT ANCHORING OF RNA-POLYMERASE IN ESCHERICHIA-COLI DURING COUPLED TRANSCRIPTION-TRANSLATION OF GENES ENCODING INTEGRAL INNER MEMBRANE POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-I MUTANTS; CYTOPLASMIC MEMBRANE; DNA; PROTEINS; DOMAINS; INVIVO; TRANSLOCATION; RESISTANCE; PROMOTER; TEMPLATE	While it has been known that supercoliing of the DNA template can be induced by transcription, the mechanism and the efficiency of this process in vivo is not fully understood. We report here that transcription of genes encoding 16 S rRNA, a stable RNA species, or cytoplasmic polypeptides leads to very little or no detectable DNA supercoliing even under the optimum conditions in Escherichia coli. This indicates that hydrodynamic drag on the transcription complex (including RNA polymrase, nascent RNA, ribosomes, and nascent polypeptides) is not sufficient to anchor RNA polymerase during coupled transcription-translation. On the other hand, transcription of membrane-associated genes encoding integral inner membrane or exported periplasmic polypeptides leads to apparent DNA supercoliing. Transcription of genes encoding integral inner membrane polypeptides leads to significantly greater anchoring of RNA polymerase than does transcription of genes encoding periplasmic polypeptides. This may reflect differences in the coupling of transcription-translation with membrane association during expression of these two classes of polypeptides. Evidence is further presented to suggest that the anchoring of RNA polymerase is probably achieved through the interaction of nascent polypeptides with the cytoplasmic surface of the inner membrane during coupled transcription-translation. Moreover, transcription of a membrane-associated gene can, under certain circumstances, induce topological anchoring of an RNA polymerase transcribing a neighboring gene that ordinarily is not membrane-associated Finally, the potential biological consequences of our findings are discussed.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV STRUCT BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley				/0000-0002-6129-2938	NIGMS NIH HHS [R1 GM 41911A-03-NF-03/92] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041911] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUJARD H, 1987, METHOD ENZYMOL, V155, P416; COOK DN, 1992, P NATL ACAD SCI USA, V89, P10603, DOI 10.1073/pnas.89.22.10603; COOK DN, 1994, NUCLEIC ACIDS MOL BI, V8; DEUSCHLE U, 1986, EMBO J, V5, P2987, DOI 10.1002/j.1460-2075.1986.tb04596.x; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; LEE C, 1986, ANNU REV CELL BIOL, V2, P315, DOI 10.1146/annurev.cellbio.2.1.315; LILLEY DMJ, 1991, MOL MICROBIOL, V5, P779, DOI 10.1111/j.1365-2958.1991.tb00749.x; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LODGE JK, 1989, J BACTERIOL, V171, P2181, DOI 10.1128/jb.171.4.2181-2187.1989; LYNCH AS, 1993, J BACTERIOL, V175, P1645, DOI 10.1128/JB.175.6.1645-1655.1993; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; OKAZAKI R, 1974, METHOD MOL BIOL, V7, P1; PRUSS GJ, 1986, P NATL ACAD SCI USA, V83, P8952, DOI 10.1073/pnas.83.23.8952; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; Sambrook J, 1989, MOL CLONING LABORATO; TRUCKSIS M, 1991, J BACTERIOL, V173, P5854, DOI 10.1128/jb.173.18.5854-5860.1991; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	21	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15362	15370						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195175				2022-12-27	WOS:A1994NP73800076
J	RICHO, GR; CONNER, GE				RICHO, GR; CONNER, GE			STRUCTURAL REQUIREMENTS OF PROCATHEPSIN-D ACTIVATION AND MATURATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CATHEPSIN-D; INTRAMOLECULAR ACTIVATION; DIRECTED MUTAGENESIS; PORCINE PEPSINOGEN; HUMAN-FIBROBLASTS; ACTIVE-SITE; ENZYME; CELLS; PROTEINASE; SEQUENCE	Cathepsin D biosynthesis involves several proteolytic events; however, the enzymology and sequence of these events are not known. Procathepsin D undergoes a pH-dependent, intramolecular proteolysis in vitro which removes 26 residues yielding an active form that is intermediate in size between procathepsin D and single-chain cathepsin D. This form, designated pseudocathepsin D, has not been shown to be an in vivo intermediate. The N-terminal sequence of the light chain of cathepsin D, isolated from human placenta, showed that 42 residues were removed as compared with 44 residues predicted by comparison with porcine cathepsin D. Site-directed mutations were generated at both processing sites within the propeptide of procathepsin D. Mutation at the autocatalytic site prevented in vitro autoactivation, but, after transfection of mouse Ltk(-) cells, the mutant procathepsin D was transported to the lysosome and processed normally to the mature enzyme despite its inability to autoactivate in vitro. Mutation at the mature N terminus of cathepsin D prevented in vivo formation of the single-chain form of the enzyme; however, the protein was still processed to the two-chain form of human cathepsin D. This change at the mature N terminus did not prevent in vitro autoactivation. Procathepsin D with mutations at both cleavage sites was processed to the two-chain form despite the inability to undergo removal of the propeptide. These results indicated that stepwise autoactivation and propeptide removal were not necessary for later processing or delivery of human cathepsin D to the lysosome. The results also suggested that pseudocathepsin D was not a normal intermediate of procathepsin D processing in vivo.	UNIV MIAMI, SCH MED, DEPT CELL BIOL & ANAT, MIAMI, FL 33101 USA	University of Miami			Conner, Gregory/AAI-1285-2021	Conner, Gregory/0000-0003-2217-2252	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035812] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35812] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALJANABI J, 1972, J BIOL CHEM, V247, P4628; BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; BUSTIN M, 1971, J BIOL CHEM, V246, P615; CONNER GE, 1990, DNA CELL BIOL, V9, P1, DOI 10.1089/dna.1990.9.1; CONNER GE, 1989, BIOCHEMISTRY-US, V28, P3530, DOI 10.1021/bi00434a057; CONNER GE, 1992, BIOCHEMISTRY-US, V31, P1142, DOI 10.1021/bi00119a024; CONNER GE, 1989, BIOCHEM J, V263, P601, DOI 10.1042/bj2630601; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; DYKES CW, 1976, BIOCHEM J, V153, P141, DOI 10.1042/bj1530141; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FISHER PA, 1982, J CELL BIOL, V92, P674, DOI 10.1083/jcb.92.3.674; FRUTON JS, 1970, ADV ENZYMOL REL S BI, V33, P401; GIESELMANN V, 1985, J BIOL CHEM, V260, P3215; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HASILIK A, 1982, EUR J BIOCHEM, V125, P317, DOI 10.1111/j.1432-1033.1982.tb06685.x; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HUANG JS, 1979, J BIOL CHEM, V254, P1405; JUPP RA, 1991, ADV EXP MED BIOL, V306, P461; KAGEYAMA T, 1982, BIOCHEM BIOPH RES CO, V107, P1117, DOI 10.1016/0006-291X(82)90637-4; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; MARCINISZYN J, 1976, J BIOL CHEM, V251, P7095; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCAMAN MT, 1986, J BIOL CHEM, V261, P5345; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MCPHIE P, 1972, J BIOL CHEM, V247, P4277; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PEDERSEN VB, 1979, EUR J BIOCHEM, V94, P573, DOI 10.1111/j.1432-1033.1979.tb12927.x; POHL J, 1988, BIOCHEMISTRY-US, V27, P4827, DOI 10.1021/bi00413a037; POWERS JC, 1977, ACID PROTEASES STRUC, P141, DOI DOI 10.1007/978-1-4757-0719-9_9; RICHARDS AD, 1990, J BIOL CHEM, V265, P7733; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; SAMAREL AM, 1989, AM J PHYSIOL, V257, pC1069, DOI 10.1152/ajpcell.1989.257.6.C1069; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCARBOROUGH PE, 1991, ADV EXP MED BIOL, V306, P343; SCARBOROUGH PE, 1993, PROTEIN SCI, V2, P264; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Takahashi K., 1985, ASPARTIC PROTEINASES, P265; TAKAHASHI T, 1983, J BIOL CHEM, V258, P6435; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; VANDENHAZEL HB, 1992, EUR J BIOCHEM, V207, P277; WOOLFORD CA, 1993, J BIOL CHEM, V268, P8990; YONEZAWA S, 1988, J BIOL CHEM, V263, P16504; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	47	82	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14806	14812						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182087				2022-12-27	WOS:A1994NM06500077
J	HOSTEN, CM; SULLIVAN, AM; PALANIAPPAN, V; FITZGERALD, MM; TERNER, J				HOSTEN, CM; SULLIVAN, AM; PALANIAPPAN, V; FITZGERALD, MM; TERNER, J			RESONANCE RAMAN-SPECTROSCOPY OF THE CATALYTIC INTERMEDIATES AND DERIVATIVES OF CHLOROPEROXIDASE FROM CALDARIOMYCES-FUMAGO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PI-CATION RADICALS; ELECTRON-PARAMAGNETIC RESONANCE; HORSERADISH-PEROXIDASE COMPOUND; PORPHYRIN FORCE-FIELD; NUCLEAR MAGNETIC-RESONANCE; CYTOCHROME-C PEROXIDASE; HEME-LINKED IONIZATION; THIOLATE LIGATION; ACTIVE-SITE; NICKEL OCTAETHYLPORPHYRIN	Near-ultraviolet resonance Raman spectra of chloroperoxidase derivatives and high valent intermediates show frequencies that can be systematically assigned. In accord with previous observations of low nu(4) frequencies for the ferric enzyme, and quite low nu(4) frequencies for the ferrous enzyme, low nu(4) frequencies are observed for ferryl compound II and several ferric derivatives. Resonance Raman spectra of chloroperoxidase compound I feature upshifted nu(2), nu(11), and nu(37) frequencies and other characteristics that argue for a (2)A(1u) in preference to a (2)A(2u) ground state for the porphyrin pi-cation radical. A moderately intense anomalously polarized band is observed at a frequency typical for octaethylporphyrin pi-cation radicals, which have been previously assigned as the (2)A(1u) radical type. Similar resonance Raman spectral attributes are observed for horseradish peroxidase compound I, supporting a (2)A(1u) symmetry state assignment for this species also. A (2)A(1u) symmetry state assignment for chloroperoxidase and horseradish peroxidase compounds I is consistent with the beta pyrrole substituent pattern of the protoporphyrin hemes found in these enzymes.	VIRGINIA COMMONWEALTH UNIV,DEPT CHEM,RICHMOND,VA 23284	Virginia Commonwealth University					NIGMS NIH HHS [GM34443-06S1A1, GM48758] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S15GM048758, R01GM034443] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE M, 1978, J CHEM PHYS, V69, P4526, DOI 10.1063/1.436450; Anderson LA, 1990, STRUCT BOND, V74, P1; ANZENBACHER P, 1989, INORG CHEM, V28, P4491, DOI 10.1021/ic00324a013; Ballou D. P., 1971, THESIS U MICHIGAN; BANGCHAROENPAURPONG O, 1986, BIOCHEMISTRY-US, V25, P2374, DOI 10.1021/bi00357a011; BILL E, 1990, HYPERFINE INTERACT, V58, P2343, DOI 10.1007/BF02398341; BILL E, 1990, EUR J BIOCHEM, V188, P665, DOI 10.1111/j.1432-1033.1990.tb15448.x; BLANKE SR, 1989, BIOTECHNOL LETT, V11, P769, DOI 10.1007/BF01026094; BLANKE SR, 1989, THESIS U MICHIGAN AN; BORG DC, 1970, P NATL ACAD SCI USA, V67, P813, DOI 10.1073/pnas.67.2.813; BOSO B, 1983, J CHEM PHYS, V79, P1122, DOI 10.1063/1.445913; BOSSHARD HR, 1991, PEROXIDASES CHEM BIO, V2, P51; CHAMPION PM, 1976, BIOCHIM BIOPHYS ACTA, V446, P486, DOI 10.1016/0005-2795(76)90015-5; CHAMPION PM, 1978, J AM CHEM SOC, V100, P3743, DOI 10.1021/ja00480a015; CHAMPION PM, 1973, BIOCHEMISTRY-US, V12, P426, DOI 10.1021/bi00727a011; CHAMPION PM, 1975, BIOCHEMISTRY-US, V14, P4159, DOI 10.1021/bi00690a002; CHAMPION PM, 1988, BIOL APPLICATIONS RA, V3, P249; CHOI S, 1982, J AM CHEM SOC, V104, P4337, DOI 10.1021/ja00380a005; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; CHOI SH, 1983, J AM CHEM SOC, V105, P3683, DOI 10.1021/ja00349a056; CHUANG WJ, 1992, J BIOL CHEM, V267, P13293; CRAMER SP, 1978, J AM CHEM SOC, V100, P7282, DOI 10.1021/ja00491a027; CZERNUSZEWICZ RS, 1989, J AM CHEM SOC, V111, P3860, DOI 10.1021/ja00193a017; DAWSON JH, 1992, NEW J CHEM, V16, P577; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DAWSON JH, 1976, J AM CHEM SOC, V98, P3709, DOI 10.1021/ja00428a055; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; DEMONTELLANO PRO, 1987, J BIOL CHEM, V262, P11641; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; DINELLO RK, 1981, J BIOL CHEM, V256, P6903; DINELLO RK, 1979, BIOCHEM BIOPH RES CO, V86, P190, DOI 10.1016/0006-291X(79)90399-1; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; DOLPHIN D, 1973, ANN NY ACAD SCI, V206, P177, DOI 10.1111/j.1749-6632.1973.tb43211.x; DOLPHIN D, 1974, ACCOUNTS CHEM RES, V7, P26, DOI 10.1021/ar50073a005; DUGAD LB, 1992, BIOCHEMISTRY-US, V31, P1651, DOI 10.1021/bi00121a011; Dunford H. B., 1982, BIOL CHEM IRON, P337; EGAWA T, 1992, FEBS LETT, V305, P206, DOI 10.1016/0014-5793(92)80668-7; FELTON RH, 1976, BIOCHIM BIOPHYS ACTA, V434, P82, DOI 10.1016/0005-2795(76)90037-4; FUHROP JH, 1969, J AM CHEM SOC, V91, P4174, DOI 10.1021/ja01043a027; FUJII H, 1993, J AM CHEM SOC, V115, P4641, DOI 10.1021/ja00064a027; FUJITA E, 1985, J AM CHEM SOC, V107, P7665, DOI 10.1021/ja00311a073; FUJITA I, 1983, J AM CHEM SOC, V105, P3296, DOI 10.1021/ja00348a056; GANS P, 1986, J AM CHEM SOC, V108, P1223, DOI 10.1021/ja00266a017; GODZIELA GM, 1986, J AM CHEM SOC, V108, P2237, DOI 10.1021/ja00269a019; GRIFFIN BW, 1991, PEROXIDASES CHEM BIO, V2, P85; HAGER LP, 1972, J AM CHEM SOC, V94, P4364, DOI 10.1021/ja00767a068; HANSON LK, 1981, J AM CHEM SOC, V103, P663, DOI 10.1021/ja00393a028; HASHIMOTO S, 1991, J AM CHEM SOC, V113, P6542, DOI 10.1021/ja00017a027; HASHIMOTO S, 1986, J BIOL CHEM, V261, P1110; HOLLENBERG PF, 1973, J BIOL CHEM, V248, P2630; HOLLENBERG PF, 1980, J BIOL CHEM, V255, P4801; HU SZ, 1993, J BIOL CHEM, V268, P6189; KASHIWAGI H, 1981, INT J QUANTUM CHEM, V20, P843, DOI 10.1002/qua.560200408; KITAGAWA T, 1976, J AM CHEM SOC, V98, P5169, DOI 10.1021/ja00433a019; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; LAMAR GN, 1989, J BIOL CHEM, V264, P5428; LI XY, 1990, J PHYS CHEM-US, V94, P47, DOI 10.1021/j100364a008; LI XY, 1989, J AM CHEM SOC, V111, P7012, DOI 10.1021/ja00200a018; LI XY, 1990, J PHYS CHEM-US, V94, P31, DOI 10.1021/j100364a007; MACOR KA, 1990, INORG CHEM, V29, P1996, DOI 10.1021/ic00335a044; MANDON D, 1992, INORG CHEM, V31, P4404, DOI 10.1021/ic00047a031; Marnett L.J., 1986, CYTOCHROME P 450 STR, P29; McMurry T. J., 1986, CYTOCHROME P450 STRU, P1; MORISHIMA I, 1984, J AM CHEM SOC, V106, P7666, DOI 10.1021/ja00337a002; NAKASHIMA S, 1990, INORG CHEM, V29, P5207, DOI 10.1021/ic00351a014; Neidleman S.L., 1986, BIOHALOGENATION PRIN; OERTLING WA, 1988, BIOCHEMISTRY-US, V27, P3331, DOI 10.1021/bi00409a032; OERTLING WA, 1987, J PHYS CHEM-US, V91, P5887, DOI 10.1021/j100307a016; OERTLING WA, 1989, J PHYS CHEM-US, V93, P1311, DOI 10.1021/j100341a028; OZAKI Y, 1976, J BIOCHEM-TOKYO, V80, P1447, DOI 10.1093/oxfordjournals.jbchem.a131420; PAENG KJ, 1988, J AM CHEM SOC, V110, P7913, DOI 10.1021/ja00231a073; PALANIAPPAN V, 1989, J BIOL CHEM, V264, P16046; PALANIAPPAN V, 1992, SPRINGER P PHYSICS, V68, P32; PALANIAPPAN V, 1991, SPECTROSCOPY BIOL MO, P419; PALCIC MM, 1980, BIOCHEM BIOPH RES CO, V94, P1123, DOI 10.1016/0006-291X(80)90535-5; PALMER G, 1983, IRON PORPHYRINS 2, P43; PARTHASARATHI N, 1987, J AM CHEM SOC, V109, P3865, DOI 10.1021/ja00247a009; PICKARD MA, 1981, CAN J MICROBIOL, V27, P1298, DOI 10.1139/m81-199; PRENDERGAST K, 1991, J PHYS CHEM-US, V95, P9728, DOI 10.1021/j100177a025; RAKHIT G, 1976, BIOCHEM BIOPH RES CO, V71, P803, DOI 10.1016/0006-291X(76)90902-5; RECZEK CM, 1989, J MOL STRUCT, V214, P27, DOI 10.1016/0022-2860(89)80004-3; REMBA RD, 1979, BIOCHEMISTRY-US, V18, P2280, DOI 10.1021/bi00578a023; ROBERTS JE, 1981, J AM CHEM SOC, V103, P7654, DOI 10.1021/ja00415a044; ROBERTS JE, 1981, J BIOL CHEM, V256, P2118; RUTTER R, 1983, BIOCHEMISTRY-US, V22, P4769, DOI 10.1021/bi00289a024; RUTTER R, 1984, BIOCHEMISTRY-US, V23, P6809, DOI 10.1021/bi00321a082; RUTTER R, 1982, J BIOL CHEM, V257, P7958; SAGE JT, 1991, BIOCHEMISTRY-US, V30, P1227, DOI 10.1021/bi00219a010; SAMOKYSZYN VM, 1991, BIOCHEMISTRY-US, V30, P11646, DOI 10.1021/bi00114a006; SANDUSKY PO, 1991, J PHYS CHEM-US, V95, P4300, DOI 10.1021/j100164a024; SANDUSKY PO, 1989, J AM CHEM SOC, V111, P6437, DOI 10.1021/ja00198a074; SCHULZ CE, 1984, BIOCHEMISTRY-US, V23, P4743, DOI 10.1021/bi00315a033; SCHULZ CE, 1979, FEBS LETT, V103, P102, DOI 10.1016/0014-5793(79)81259-4; SITTER AJ, 1988, J BIOL CHEM, V263, P13032; SITTER AJ, 1985, J BIOL CHEM, V260, P7515; SKILLMAN AG, 1992, J AM CHEM SOC, V114, P9538, DOI 10.1021/ja00050a037; SONO M, 1991, BIOCHIM BIOPHYS ACTA, V1078, P351, DOI 10.1016/0167-4838(91)90156-T; SPELLANE PJ, 1980, INORG CHEM, V19, P386, DOI 10.1021/ic50204a021; Spiro T.G., 1983, IRON PORPHYRINS P2, P89; SPIRO TG, 1976, J AM CHEM SOC, V98, P5482, DOI 10.1021/ja00434a013; SPIRO TG, 1985, ADV PROTEIN CHEM, V37, P111, DOI 10.1016/S0065-3233(08)60064-9; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; TERNER J, 1984, BIOCHIM BIOPHYS ACTA, V789, P80, DOI 10.1016/0167-4838(84)90064-5; THOMAS JA, 1970, J BIOL CHEM, V245, P3129; WOLBERG A, 1970, J AM CHEM SOC, V92, P2982, DOI 10.1021/ja00713a010	105	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13966	13978						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188677				2022-12-27	WOS:A1994NL60600040
J	LI, S; ROSEN, JM				LI, S; ROSEN, JM			DISTAL REGULATORY ELEMENTS REQUIRED FOR RAT WHEY ACIDIC PROTEIN GENE-EXPRESSION IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; HIGH-LEVEL EXPRESSION; DNA-BINDING PROTEINS; TISSUE-SPECIFIC EXPRESSION; HUMAN CYTOMEGALO-VIRUS; HYPERSENSITIVE SITES; MAMMARY-GLAND; CASEIN GENE; MYC GENE; PROMOTER	Previous studies have demonstrated that a 3.0-kilobase, rat whey acidic protein (WAP) transgene containing 949 base pairs (bp) 5' and 70 bp 3'-flanking DNA is expressed specifically in the mammary gland of transgenic mice in a copy number dependent, position-independent manner (1). In order to localize the critical regulatory elements important for tissue-specific, high level WAP gene expression, DNase I hypersensitivity mapping studies of WAP transgenes were performed in nuclei isolated from mammary gland and liver. Two regions of DNase I hypersensitivity located at approximately -150 and -800 bp from the site of transcription initiation, respectively, were detected only in nuclei isolated from the lactating mammary gland. Within the distal hypersensitive region several binding sites for members of the CTF/NFI family of transcription factors were identified using in vitro DNase I and dimethyl sulfate interference footprinting and electrophoretic mobility shift assays. Genomic footprinting established that such protein-DNA interactions occur preferentially in the lactating mammary gland. The analysis of several 5' deletion constructs identified the region between -853 and -729 bp as essential for WAP transgene expression. These results suggest that the distal DNase I hypersensitive region contains binding sites for CTF/NFI and plays a critical role in the regulation of WAP gene expression in transgenic mice.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine					NATIONAL CANCER INSTITUTE [R01CA016303, R37CA016303] Funding Source: NIH RePORTER; NCI NIH HHS [CA16303] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; ALSHAWI R, 1990, MOL CELL BIOL, V10, P1192, DOI 10.1128/MCB.10.3.1192; AUSUBEL FM, 1987, CURRENT PROTOCALS MO, V1; BAYNA EM, 1990, NUCLEIC ACIDS RES, V18, P2977, DOI 10.1093/nar/18.10.2977; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; BOYER BB, 1991, MOL CELL BIOL, V11, P4147, DOI 10.1128/MCB.11.8.4147; BUETTI E, 1986, J MOL BIOL, V190, P379, DOI 10.1016/0022-2836(86)90009-4; BURDON T, 1991, J BIOL CHEM, V266, P6909; CHAMBERLAIN JW, 1991, MOL CELL BIOL, V11, P3564, DOI 10.1128/MCB.11.7.3564; CHEN LH, 1989, CELL REGUL, V1, P45, DOI 10.1091/mbc.1.1.45; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DALE TC, 1992, MOL CELL BIOL, V12, P905, DOI 10.1128/MCB.12.3.905; DENTE L, 1988, GENE DEV, V2, P259, DOI 10.1101/gad.2.2.259; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; DOPPLER W, 1991, MOL ENDOCRINOL, V5, P1624, DOI 10.1210/mend-5-11-1624; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GREWAL T, 1992, MOL CELL BIOL, V12, P2339, DOI 10.1128/MCB.12.5.2339; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P964, DOI 10.1128/MCB.5.5.964; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUNZBURG WH, 1991, MOL ENDOCRINOL, V5, P123, DOI 10.1210/mend-5-1-123; HENNIGHAUSEN L, 1985, NATURE, V314, P289, DOI 10.1038/314289a0; HENNIGHAUSEN L, 1986, EMBO J, V5, P1367, DOI 10.1002/j.1460-2075.1986.tb04368.x; HENNIGHAUSEN L, 1990, Protein Expression and Purification, V1, P3, DOI 10.1016/1046-5928(90)90037-Y; HOBBS AA, 1982, J BIOL CHEM, V257, P3598; IVANOV V I, 1990, Molekulyarnaya Biologiya (Moscow), V24, P1605; JEANG KT, 1987, J VIROL, V61, P1559, DOI 10.1128/JVI.61.5.1559-1570.1987; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; LEE KF, 1988, NUCLEIC ACIDS RES, V16, P1027, DOI 10.1093/nar/16.3.1027; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LUBON H, 1987, NUCLEIC ACIDS RES, V15, P2103, DOI 10.1093/nar/15.5.2103; LUO XN, 1991, J BIOL CHEM, V266, P21004; MCKENZIE RM, 1978, J DAIRY SCI, V61, P723, DOI 10.3168/jds.S0022-0302(78)83639-X; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NITSCH D, 1990, MOL CELL BIOL, V10, P3334, DOI 10.1128/MCB.10.7.3334; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SHAUL Y, 1986, EMBO J, V5, P1967, DOI 10.1002/j.1460-2075.1986.tb04451.x; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823; WATSON CJ, 1991, NUCLEIC ACIDS RES, V19, P6603, DOI 10.1093/nar/19.23.6603; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096	58	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14235	14243						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188706				2022-12-27	WOS:A1994NL60600077
J	CHEN, SRW; AIREY, JA; MACLENNAN, DH				CHEN, SRW; AIREY, JA; MACLENNAN, DH			POSITIONING OF MAJOR TRYPTIC FRAGMENTS IN THE CA2+ RELEASE CHANNEL (RYANODINE RECEPTOR) RESULTING FROM PARTIAL DIGESTION OF RABBIT SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALIGNANT HYPERTHERMIA; CALCIUM-RELEASE; FUNCTIONAL EXPRESSION; H-3 RYANODINE; IDENTIFICATION; PURIFICATION; BINDING; COMPLEX; VESICLES; MUTATION	Site-specific antibodies against different regions of the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum (ryanodine receptor) were developed and used as probes for immunoblotting of the major tryptic fragments resulting from partial digestion of the ryanodine receptor in sarcoplasmic reticulum membranes. Five major tryptic fragments, some of which migrated as doublets, with apparent masses of 150/140, 110/100, 55, 170/160, and 76 kDa were ordered so that they covered the bulk of the protein from the NH2 to the COOH terminus. Tryptic subfragments of 53, 63, and 115/95 kDa were also derived from the 150/140-, 110/100-, and 170/160-kDa fragments, respectively. All of these fragments and subfragments were detected only in the insoluble membrane fraction of the trypsinized sarcoplasmic reticulum. Upon Na2CO3 extraction, the 150/140-, 110/100-, and 55-kDa fragments could be solubilized, suggesting their origin in the cytoplasmic domain of the ryanodine receptor. The 170/160- and 76-kDa fragments and the 115/195-kDa subfragment remained insoluble, suggesting their origin in the transmembrane region of the ryanodine receptor. The 150/140-,110/100-,170/160-, and 76-kDa fragments and the 115/95 subfragment co-migrated near the bottom of a sucrose density gradient after CHAPS solubilization, suggesting that they were associated in an oligomeric complex. By contrast, the 53- and 63-kDa subfragments and the 55-kDa fragment were detected near the top of the sucrose gradient after CHAPS solubilization, suggesting that they were not involved in the formation of the core of the oligomeric complex. These studies identify 7 sites that are exposed to trypsin in the ryanodine receptor in sarcoplasmic reticulum, 3 of which are novel and 4 of which are in the same location as proteolytic cleavage sites identified previously (Marks, A. R., Fleischer, S., and Tempst, P. (1990) J. Biol. Chem. 265, 13143-13149).	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA; UNIV NEVADA,SCH MED,DEPT PHARMACOL,RENO,NV 89557	University of Toronto; Nevada System of Higher Education (NSHE); University of Nevada Reno					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL027470] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL27470] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIREY JA, 1990, J BIOL CHEM, V265, P14187; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CAMPBELL KP, 1981, J BIOL CHEM, V256, P4626; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; CHU A, 1988, BIOCHEMISTRY-US, V27, P2827, DOI 10.1021/bi00408a025; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWKES MJ, 1992, J BIOL CHEM, V267, P6702; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; INUI M, 1987, J BIOL CHEM, V262, P1740; LAI FA, 1987, BIOCHEM BIOPH RES CO, V143, P704, DOI 10.1016/0006-291X(87)91411-2; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MEISSNER G, 1989, J BIOL CHEM, V264, P1715; MICKELSON JR, 1988, J BIOL CHEM, V263, P9310; MICKELSON JR, 1992, FEBS LETT, V301, P49, DOI 10.1016/0014-5793(92)80208-X; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; RARDON DP, 1990, CIRC RES, V67, P84, DOI 10.1161/01.RES.67.1.84; Sambrook J, 1989, MOL CLONING LABORATO; SHOSHANBARMATZ V, 1988, J BIOL CHEM, V263, P16772; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; ZHANG Y, 1993, NAT GENET, V5, P61; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	36	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22642	22649						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226772				2022-12-27	WOS:A1993MD34800068
J	MICHAELY, P; BENNETT, V				MICHAELY, P; BENNETT, V			THE MEMBRANE-BINDING DOMAIN OF ANKYRIN CONTAINS 4 INDEPENDENTLY FOLDED SUBDOMAINS, EACH COMPRISED OF 6 ANKYRIN REPEATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CANDIDATE PROTOONCOGENE BCL-3; HUMAN ERYTHROCYTE ANKYRIN; CELL-CYCLE CONTROL; ANION-EXCHANGER; TRANSCRIPTION FACTORS; CYTOPLASMIC DOMAIN; TAU-PROTEIN; SUBUNIT; REL	Ankyrin repeats are a 33-amino acid motif present in a number of proteins of diverse functions including transcription factors, cell differentiation molecules, and structural proteins. This motif has been shown to mediate protein interactions in the case of ankyrin as well as several other repeat-bearing proteins. In ankyrin, 24 tandemly arrayed repeats are arranged to form a globular, membrane-binding domain. This report provides evidence that the repeats in this domain fold into four independently folded subdomains of six repeats each. Limited proteolytic digestions of defined regions of the membrane-binding domain identified protease-sensitive sites, which divided this domain into subdomains of approximately six repeats each. Hydro-dynamic measurements and circular dichroism spectroscopy of expressed subdomains confirmed that these six-repeat regions exist as folded, globular structures. The requirement of a complete set of six repeats for proper folding was determined using a series of protein constructs, which sequentially deleted repeats from the last subdomain. Deletion of even one repeat resulted in a 40% loss of alpha-helicity. Deletions removing three or more repeats abolished the helical signal completely. The spherical shapes of the intact domain and of the subdomains (inferred from hydrodynamic values) suggest that the four subdomains are organized in either a tetrahedral or square planar configuration. Two six-repeat subdomains were found to be required for high affinity association with the anion exchanger, suggesting that at least some of the protein interactions mediated by ankyrin repeats involve multiple subdomains.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University	MICHAELY, P (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029808, R01DK029808] Funding Source: NIH RePORTER; NIDDK NIH HHS [537DK29808] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BOGUSKI MS, 1986, J BIOL CHEM, V261, P6398; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DAVIS JQ, 1990, J BIOL CHEM, V265, P17252; DAVIS JQ, 1993, J CELL BIOL, V121, P121, DOI 10.1083/jcb.121.1.121; DAVIS JQ, 1984, J BIOL CHEM, V259, P3550; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIYATKIN NI, 1990, FEBS LETT, V270, P127, DOI 10.1016/0014-5793(90)81250-R; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MARTIN RG, 1960, J BIOL CHEM, V236, P1372; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; SRINIVASAN Y, 1992, J BIOL CHEM, V267, P7483; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TSE W, 1990, THESIS YALE U, P101; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0	35	93	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22703	22709						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226780				2022-12-27	WOS:A1993MD34800076
J	ROSA, JL; VENTURA, F; TAULER, A; BARTRONS, R				ROSA, JL; VENTURA, F; TAULER, A; BARTRONS, R			REGULATION OF HEPATIC 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE 2,6-BISPHOSPHATASE GENE-EXPRESSION BY GLUCAGON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; RAT-LIVER; MULTIHORMONAL REGULATION; HORMONAL-CONTROL; BINDING-PROTEIN; FRUCTOSE-2,6-BISPHOSPHATASE; INSULIN; TRANSCRIPTION; HEPATOCYTES	The control of hepatic 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase gene expression by glucagon was studied. Intraperitoneal administration of glucagon rapidly decreased the fructose 2,6-bisphosphate content by phosphorylation of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase and diminution of its V(max). Immunologic studies using a specific liver antibody showed that the amount of enzyme rapidly decreased. Northern blot analysis showed that the isozyme expressed is the adult liver form. The 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase mRNA content decreased, whereas that of phosphoenolpyruvate carboxykinase increased, and that of albumin did not change. Run-on transcription assays with isolated nuclei showed inhibition in the relative transcription rate of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase gene and a stimulation of phosphoenolpyruvate carboxykinase gene. The regulation of mRNA stability of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase by glucagon was also studied. The half-life of mRNA decreased in the presence of glucagon, suggesting that proteins modulated by a glucagon-dependent process are regulating its stability. The time course of mRNA levels correlated with the transcription inhibition of gene and destabilization of mRNA, indicating that glucagon modulates 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase gene expression at both transcriptional and posttranscriptional levels.	UNIV BARCELONA,DEPT CIENCIES FISIOL HUMANES & NUTR,UNITAT BIOQUIM,CAMPUS BELLVITGE,E-08907 LHOSPITALET LLOBR,SPAIN	University of Barcelona			Rosa, Jose Luis/K-6685-2014; Ventura, Francesc/ABG-2285-2020; Ventura, Francesc/K-9700-2014; Tauler, Albert/D-5183-2014	Rosa, Jose Luis/0000-0002-6161-5688; Ventura, Francesc/0000-0001-9673-9405; Ventura, Francesc/0000-0001-9673-9405; Tauler, Albert/0000-0003-0193-0667; Bartrons, Ramon/0000-0001-9349-5847				ATWATER JA, 1990, ANNU REV GENET, V24, P519; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARTRONS R, 1983, BIOCHEM J, V214, P829, DOI 10.1042/bj2140829; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHRIST B, 1988, EUR J BIOCHEM, V178, P373, DOI 10.1111/j.1432-1033.1988.tb14460.x; CIFUENTES ME, 1991, J BIOL CHEM, V266, P1557; CLAYTON DF, 1985, MOL CELL BIOL, V5, P2623, DOI 10.1128/MCB.5.10.2623; COLOSIA AD, 1988, J BIOL CHEM, V263, P18669; CREPIN KM, 1989, BIOCHEM J, V264, P151, DOI 10.1042/bj2640151; DARVILLE MI, 1987, FEBS LETT, V224, P317, DOI 10.1016/0014-5793(87)80476-3; GIL J, 1986, BIOCHEM BIOPH RES CO, V136, P498, DOI 10.1016/0006-291X(86)90468-7; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; HOD Y, 1988, J BIOL CHEM, V263, P7747; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; IYNEDJIAN PB, 1977, J BIOL CHEM, V252, P655; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; JOHNSON TR, 1991, P NATL ACAD SCI USA, V88, P5287, DOI 10.1073/pnas.88.12.5287; KUMMEL L, 1990, BIOCHEM BIOPH RES CO, V169, P406, DOI 10.1016/0006-291X(90)90346-O; LAITINEN J, 1990, J CELL BIOL, V111, P9, DOI 10.1083/jcb.111.1.9; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LANGE AJ, 1989, BIOCHEM BIOPH RES CO, V162, P753, DOI 10.1016/0006-291X(89)92374-7; LANGE AJ, 1992, J BIOL CHEM, V267, P15673; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MARKER AJ, 1989, J BIOL CHEM, V264, P7000; MIRALPEIX M, 1992, DIABETOLOGIA, V35, P243, DOI 10.1007/BF00400924; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; PILKIS SJ, 1990, DIABETES CARE, V13, P582, DOI 10.2337/diacare.13.6.582; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; ROSA JL, 1990, BIOCHEM J, V270, P645, DOI 10.1042/bj2700645; ROSA JL, 1992, BIOCHEM J, V287, P113, DOI 10.1042/bj2870113; ROSA JL, 1992, P NATL ACAD SCI USA, V89, P3746, DOI 10.1073/pnas.89.9.3746; Sambrook J, 1989, MOL CLONING LABORATO; SARGENT TD, 1979, P NATL ACAD SCI USA, V76, P3256, DOI 10.1073/pnas.76.7.3256; SASAKI K, 1984, J BIOL CHEM, V259, P5242; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VENTURA F, 1991, BIOCHEM J, V276, P455, DOI 10.1042/bj2760455; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	49	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22540	22545						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226764				2022-12-27	WOS:A1993MD34800055
J	MOROZOV, VE; FALZON, M; ANDERSON, CW; KUFF, EL				MOROZOV, VE; FALZON, M; ANDERSON, CW; KUFF, EL			DNA-DEPENDENT PROTEIN-KINASE IS ACTIVATED BY NICKS AND LARGER SINGLE-STRANDED GAPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TERMINAL TRANSACTIVATION DOMAIN; VIRUS-40 T-ANTIGEN; KU PROTEIN; CELL-CYCLE; HUMAN P53; PHOSPHORYLATION; BINDING; AUTOANTIGEN; EBP-80	DNA-PK is a DNA-activated serine/threonine protein kinase capable of phosphorylating a number of nuclear DNA-binding proteins. Purified human DNA-PK has two subunits, a 350-kDa polypeptide, Prkdc, which binds ATP and is presumed to contain the catalytic site, and the Ku autoantigen which mediates DNA binding and activation. Previous studies have shown that DNA-PK is activated in vitro by linear double-stranded DNA fragments; however, the Ku subunit binds a broader range of DNA structures. Here we show that EBP-80, a protein originally isolated as a transcription factor for a retroviral long terminal repeat element and subsequently found to be similar to if not identical with Ku, also mediates kinase activation. The EBP-80-Prkdc complex is activated by nanomolar concentrations of DNA constructs containing single-to-double strand transitions, including a closed stem-loop structure and single strand gaps of 0 (nick), 6, and 30 nucleotides. Kinase activation parallels the ability of EBP-80 to bind these and other constructs. Our results extend the range of DNA configurations known to activate DNA-PK and are consistent with the participation of this enzyme complex in several nuclear functions.	NCI,BIOCHEM LAB,BETHESDA,MD 20892; UNIV TEXAS,DEPT PHARMACOL & TOXICOL,GALVESTON,TX 77555; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Medical Branch Galveston; United States Department of Energy (DOE); Brookhaven National Laboratory								Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BRILL SJS, 1990, GENE DEV, V4, P968; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; CAO QP, 1994, IN PRESS BIOCHEMISTR; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CARTER TH, 1991, PROG MOL SUBCELL BIO, V12, P37; CHEN YR, 1991, J VIROL, V65, P5131, DOI 10.1128/JVI.65.10.5131-5140.1991; COLLINS JM, 1977, J BIOL CHEM, V252, P141; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; DVIR A, 1993, J BIOL CHEM, V268, P10440; FALZON M, 1991, MOL CELL BIOL, V11, P117, DOI 10.1128/MCB.11.1.117; FALZON M, 1990, J BIOL CHEM, V265, P13084; FALZON M, 1993, J BIOL CHEM, V268, P10546; FANG F, 1993, J CELL SCI, V106, P983; FISCELLA M, 1993, ONCOGENE, V8, P1519; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LIU SH, 1993, J BIOL CHEM, V268, P21147; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1986, J BIOL CHEM, V261, P375; MIMORI T, 1981, J CLIN INVEST, V68, P661; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; REEVES WH, 1992, RHEUM DIS CLIN N AM, V18, P391; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; VISHWANATHA JK, 1990, BIOCHEMISTRY-US, V29, P8753, DOI 10.1021/bi00489a036	34	132	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16684	16688						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206988				2022-12-27	WOS:A1994NR29600028
J	THOMASON, PA; JAMES, SR; CASEY, PJ; DOWNES, CP				THOMASON, PA; JAMES, SR; CASEY, PJ; DOWNES, CP			A G-PROTEIN BETA-GAMMA-SUBUNIT-RESPONSIVE PHOSPHOINOSITIDE 3-KINASE ACTIVITY IN HUMAN PLATELET CYTOSOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							THROMBIN-STIMULATED PLATELETS; NUCLEOTIDE-BINDING PROTEIN; RECEPTOR TYROSINE KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; ADENYLYL CYCLASE; ALPHA-SUBUNITS; ADP-RIBOSYLATION; PERTUSSIS TOXIN; SH2 DOMAINS; ACTIVATION	Thrombin activates phosphoinositide 3-kinase (PI 3-kinase) in platelets via a mechanism involving G-proteins, possibly of both the heterotrimeric and the low molecular weight families. We have investigated the regulation of PI 3-kinase present in platelet cytosol, and we show that this activity can be stimulated by a mixed preparation of G-protein beta gamma-subunits. This stimulation is reversed by preincubation of the beta gamma-subunits with GDP-liganded alpha-subunits. The beta gamma-stimulated activity is inhibited by wortmannin, a recently identified inhibitor of PI 3-kinase in other systems. In addition, the activity associates with PDGF receptor phosphotyrosyl peptide and monoclonal antibody designed to interact with the p85 subunit of PI 3-kinase. We suggest that this beta gamma-sensitive activity is related to previously identified forms of PI 3-kinase.	DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University	THOMASON, PA (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND.			Thomason, Peter/0000-0003-3104-8392; Casey, Patrick/0000-0002-7366-9309				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BRASS LF, 1986, J BIOL CHEM, V261, P6838; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARTER AN, 1994, IN PRESS BIOCH J; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FRY M J, 1992, Current Biology, V2, P78, DOI 10.1016/0960-9822(92)90207-Q; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KING WG, 1991, BIOCHEM J, V278, P475, DOI 10.1042/bj2780475; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; Low M. G, 1990, METHODS INOSITIDE RE, P145; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHANG J, 1993, J BIOL CHEM, V268, P22251	39	158	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16525	16528						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206965				2022-12-27	WOS:A1994NR29600002
J	NAKAMURA, S; SUZUKI, H; KANAZAWA, T				NAKAMURA, S; SUZUKI, H; KANAZAWA, T			THE ATP-INDUCED CHANGE OF TRYPTOPHAN FLUORESCENCE REFLECTS A CONFORMATIONAL CHANGE UPON FORMATION OF ADP-SENSITIVE PHOSPHOENZYME IN THE SARCOPLASMIC-RETICULUM CA2+-ATPASE - STOPPED-FLOW SPECTROFLUOROMETRY AND CONTINUOUS-FLOW RAPID QUENCHING METHOD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR LINKED FUNCTIONS; NUCLEOTIDE-BINDING DOMAIN; ADENOSINE-TRIPHOSPHATASE; REACTION-MECHANISM; CATALYTIC SITE; CA-2+-TRANSPORTING ATPASE; INTRINSIC FLUORESCENCE; TRANSPORT ATPASE; TIGHT-BINDING; CA-2+ ATPASE	The ATP-induced change in the tryptophan fluorescence of the Ca2+-ATPase was determined with sarcoplasmic reticulum vesicles at pH 7.0 in the presence of Ca2+ under various conditions by steady-state measurements and stopped-flow spectrofluorometry, Formation of the phosphoenzyme intermediate was also determined by the continuous flow-rapid quenching method. The steady-state fluorescence at 0 degrees C decreased by 1.1% on addition of ATP, whereas no fluorescence change was induced by adenosine 5'-(beta,gamma-methylene)triphosphate (a nonhydrolyzable ATP analog incapable of phosphorylating the enzyme). The time course of the ATP-induced fluorescence drop agreed well with that of the phosphoenzyme formation under all of the conditions tested, and the phosphoenzyme formed was largely sensitive to ADP. When phosphoenzyme isomerization from the ADP-sensitive form to the ADP-insensitive form was almost completely prevented by N-ethylmaleimide treatment, the time course of the ATP induced fluorescence drop again agreed with that of the phosphoenzyme formation. These results show that the ATP-induced fluorescence drop occurs upon formation of the ADP-sensitive phosphoenzyme. The results further indicate that the tryptophan fluorescence of this enzyme is insensitive to the conformational change which was previously shown (Suzuki, H., Obara, M., Kuwayama, H., and Kanazawa, T. (1987) J. Biol. Chem. 262, 15448-15456) to occur upon formation of the calcium enzyme-substrate complex. Thus, we conclude that the ATP-induced drop in the tryptophan fluorescence reflects a conformational change occurring upon formation of the ADP-sensitive phosphoenzyme.	ASAHIKAWA MED COLL, DEPT BIOCHEM, ASAHIKAWA 078, JAPAN; ASAHIKAWA MED COLL, DEPT DERMATOL, ASAHIKAWA 078, HOKKAIDO, JAPAN	Asahikawa Medical College; Asahikawa Medical College								ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BASTIDE F, 1973, Journal of Biological Chemistry, V248, P8385; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CHAMPEIL P, 1986, FEBS LETT, V206, P93, DOI 10.1016/0014-5793(86)81347-3; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; DAIHO T, 1993, BIOCHEMISTRY-US, V32, P10021, DOI 10.1021/bi00089a018; DEFORESTA B, 1990, EUR J BIOCHEM, V194, P383; DEGANI C, 1973, J BIOL CHEM, V248, P8222; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; DUPONT Y, 1978, NATURE, V273, P396, DOI 10.1038/273396a0; DUPONT Y, 1985, STRUCTURE FUNCTION S, P225; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; HARA H, 1986, J BIOL CHEM, V261, P6584; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; INESI G, 1992, ANN NY ACAD SCI, V671, P32, DOI 10.1111/j.1749-6632.1992.tb43782.x; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; KANAZAWA T, 1970, J BIOCHEM-TOKYO, V68, P593, DOI 10.1093/oxfordjournals.jbchem.a129392; KAWAKITA M, 1980, J BIOCHEM, V87, P609, DOI 10.1093/oxfordjournals.jbchem.a132785; KUBO K, 1990, BIOCHIM BIOPHYS ACTA, V1040, P251, DOI 10.1016/0167-4838(90)90084-S; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LACAPERE JJ, 1990, J BIOL CHEM, V265, P8583; LACAPERE JJ, 1993, BIOCHEMISTRY-US, V32, P3414, DOI 10.1021/bi00064a027; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKINOSE M, 1967, PFLUG ARCH GES PHYS, V294, pR82; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; OBARA M, 1988, J BIOL CHEM, V263, P3690; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; STEFANOVA HI, 1993, BIOCHEMISTRY-US, V32, P356, DOI 10.1021/bi00052a044; SUZUKI H, 1987, J BIOL CHEM, V262, P15448; TAKAKUWA Y, 1979, BIOCHEM BIOPH RES CO, V88, P1209, DOI 10.1016/0006-291X(79)91108-2; TAKISAWA H, 1981, NATURE, V290, P271, DOI 10.1038/290271a0; VIANNA AL, 1975, BIOCHIM BIOPHYS ACTA, V410, P389, DOI 10.1016/0005-2744(75)90241-7; YAMADA S, 1980, J BIOL CHEM, V255, P3108; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; YAMAMOTO H, 1988, J BIOCHEM-TOKYO, V103, P452, DOI 10.1093/oxfordjournals.jbchem.a122291; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706; YAMASAKI K, 1994, J BIOL CHEM, V269, P4129	48	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16015	16019						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206898				2022-12-27	WOS:A1994NQ72900013
J	WU, YY; LOCKYER, JM; SUGIYAMA, E; PAVLOVA, NV; LI, YT; LI, SC				WU, YY; LOCKYER, JM; SUGIYAMA, E; PAVLOVA, NV; LI, YT; LI, SC			EXPRESSION AND SPECIFICITY OF HUMAN G(M2) ACTIVATOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-HEXOSAMINIDASE-A; ENZYMIC-HYDROLYSIS; GM2 GANGLIOSIDOSIS; SULFATIDE ACTIVATOR; CERAMIDE GLYCANASE; ESCHERICHIA-COLI; HUMAN-BRAIN; DEGRADATION; SAP-1; GENE	The cDNA encoding G(M2) activator was expressed in the Escherichia coli/pT7-7 system. The yield of the G(M2) activator with greater than 99% purity was about 3 mg per liter culture. The recombinant G(M2) activator was found to be as active as that isolated from human kidney. The availability of the recombinant G(M2) activator enabled us to critically examine the specificity of this activator protein. Our results show that the specificity of G(M2) activator is not as strict as that reported previously. Although G(M2) activator stimulates most efficiently the degradation of G(M2) carried out by beta-N-acetylhexosaminidase A (Hex A), this activator also stimulates the following reactions: (a) conversion of G(M2) to G(A2) by clostridial sialidase; (b) hydrolysis of GalNAc from dipalmitoylphosphatidylethanolamine-II(3)NeuAcGgOse(3) by Hex A; and (c) liberation of Gal from G(M1) by beta-galactosidase at a high activator concentration. Thus, this activator does not differentiate between G(M2) and dipalmitoylphosphatidylethanolamine-II(3)NeuAcGgOse(3) or between Hex A and clostridial sialidase. The micellar forms of G(D2) and GalNAc-G(D1a) were found to be more readily hydrolyzed by Hex A than G(M2) in the absence of G(M2) activator. Our results also show that saposin B can enhance the stimulatory activity of G(M2) activator, but it cannot promote the stimulatory activity of sodium taurodeoxycholate. Taken together, our results suggest that the mechanism of action of G(M2) activator is different from saposin B, and the action of G(M2) activator is more than to solubilize lipid substrates. The effectiveness of G(M2) activator in stimulating the hydrolysis of G(M2) may be due to its abil ity to recognize the specific trisaccharide structure of the G(M2) epitope, GalNAc beta 1 --> 4(NeuAc alpha 2 --> 3)Gal-, and to modify the GalNAc-NeuAc interaction in this structure.	TULANE UNIV,SCH MED,DEPT BIOCHEM,NEW ORLEANS,LA 70112; TULANE UNIV,SCH MED,DEPT MED,NEW ORLEANS,LA 70112	Tulane University; Tulane University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 09626] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO S, 1989, J BIOL CHEM, V264, P3478; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BURG J, 1985, ANN HUM GENET, V49, P41, DOI 10.1111/j.1469-1809.1985.tb01674.x; CONZELMANN E, 1978, P NATL ACAD SCI USA, V75, P3979, DOI 10.1073/pnas.75.8.3979; CONZELMANN E, 1979, H-S Z PHYSIOL CHEM, V360, P1837, DOI 10.1515/bchm2.1979.360.2.1837; CONZELMANN E, 1982, EUR J BIOCHEM, V123, P455, DOI 10.1111/j.1432-1033.1982.tb19789.x; FUJIBAYASHI S, 1985, AM J HUM GENET, V37, P741; FURST W, 1988, BIOL CHEM H-S, V369, P317, DOI 10.1515/bchm3.1988.369.1.317; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; HARRIS G, 1954, CHEM IND-LONDON, P249; HECHTMAN P, 1982, PEDIATR RES, V16, P217, DOI 10.1203/00006450-198203000-00011; HIRABAYASHI Y, 1983, J NEUROCHEM, V40, P168, DOI 10.1111/j.1471-4159.1983.tb12667.x; INUI K, 1985, HUM GENET, V69, P197, DOI 10.1007/BF00293023; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KLIMA H, 1993, BIOCHEM J, V292, P571, DOI 10.1042/bj2920571; KOERNER TAW, 1983, BIOCHEMISTRY-US, V22, P2676, DOI 10.1021/bi00280a014; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVERY SB, 1991, GLYCOCONJUGATE J, V8, P484, DOI 10.1007/BF00769848; LI SC, 1970, J BIOL CHEM, V245, P5153; LI SC, 1988, J BIOL CHEM, V263, P6588; LI SC, 1982, METHOD ENZYMOL, V83, P588; LI SC, 1981, J BIOL CHEM, V256, P6234; LI SC, 1976, J BIOL CHEM, V251, P1159; LI YT, 1991, J BIOL CHEM, V266, P10723; LI YT, 1973, J BIOL CHEM, V248, P7512; LI YT, 1984, LYSOSOM BIOL PATHOL, P99; MARSTON FAO, 1984, BIO-TECHNOL, V2, P800, DOI 10.1038/nbt0984-800; MEIER EM, 1991, J BIOL CHEM, V266, P1879; MURAYAMA JI, 1979, ANAL BIOCHEM, V73, P535; NAGARAJAN S, 1992, BIOCHEM J, V282, P807, DOI 10.1042/bj2820807; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; PASCHER I, 1977, CHEM PHYS LIPIDS, V20, P175, DOI 10.1016/0009-3084(77)90033-0; RADIN NS, 1972, METHOD ENZYMOL, V28, P300; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARSDALE JN, 1990, BIOCHEMISTRY-US, V29, P9843, DOI 10.1021/bi00494a014; SCHRODER M, 1989, FEBS LETT, V251, P197, DOI 10.1016/0014-5793(89)81454-1; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; SVENNERHOLM L, 1972, METHODS CARBOHYD CHE, V6, P464; TANG PW, 1985, BIOCHEM BIOPH RES CO, V132, P474, DOI 10.1016/0006-291X(85)91158-1; UDA Y, 1977, J BIOL CHEM, V252, P5194; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; WU YY, 1993, T AM SOC NEUROCHEM, V24, P187; WYNN CH, 1986, BIOCHEM J, V240, P921, DOI 10.1042/bj2400921; XIE B, 1991, BIOCHEM BIOPH RES CO, V177, P1217, DOI 10.1016/0006-291X(91)90671-S; ZHOU B, 1989, J BIOL CHEM, V264, P12272	46	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16276	16283						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206933				2022-12-27	WOS:A1994NQ72900051
J	KANEIISHII, C; YASUKAWA, T; MORIMOTO, RI; ISHII, S				KANEIISHII, C; YASUKAWA, T; MORIMOTO, RI; ISHII, S			C-MYB-INDUCED TRANSACTIVATION MEDIATED BY HEAT-SHOCK ELEMENTS WITHOUT SEQUENCE-SPECIFIC DNA-BINDING OF C-MYB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HSP70 PROMOTER; TRANSCRIPTION FACTOR; LEUCINE-ZIPPER; V-MYB; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; ONCOGENE PRODUCT; PROTO-ONCOGENE; GENE; EXPRESSION	The c-myb proto-oncogene product (c-Myb) can transactivate the human hsp70 promoter in a transient cotransfection assay. The present studies have demonstrated that the heat shock element (HSE) in the hsp7O promoter mediates trans-activation by c-Myb. Mutagenesis of the DNA sequence in HSE indicated that the NGAAN motif is necessary for not only the heat shock response but also the c-Myb-induced trans-activation. The HSE in the hsp70 promoter does not contain a c-Myb-binding site, implying that the sequence-specific DNA binding of c-Myb is not required for the HSE-dependent trans-activation by c-Myb. We had demonstrated that a disruption of the leucine zipper motif in the central portion of the c-Myb molecule increased the degree of c-Myb-induced trans-activation of the promoter containing c-Myb-binding sites, suggesting that a putative inhibitor binds to c-Myb through this leucine zipper (Kanie-Ishii, C., MacMillan, E. M., Nomura, T., Sarai, A., Ramsay, R. G., Aimoto, S., Ishii, S., and Gonda, T J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 3088-3092). However, disruption of the leucine zipper in c-Myb abolished the HSE-dependent trans-activation by c-Myb, whereas deletion of the transcriptional activation domain containing acidic amino acids in c-Myb did not abolish the HSE-dependent trans-activation by c-Myb. These results suggest that c-Myb can activate transcription of the gene containing HSEs by interacting with unidentified trans-acting factor(s) but not by a direct binding to the promoter through its DNA-binding domain.	UNIV TSUKUBA, INST BASIC MED SCI, TSUKUBA, IBARAKI 305, JAPAN; NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA	University of Tsukuba; Northwestern University	KANEIISHII, C (corresponding author), INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOLEC GENET LAB, TSUKUBA, IBARAKI 305, JAPAN.		Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FOOS G, 1993, ONCOGENE, V8, P1775; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GODENBERG CJ, 1988, J BIOL CHEM, V263, P19734; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HIGUCHI R, 1990, PCR TECHNOLOGY PRINC, P61; HU YL, 1991, ONCOGENE, V6, P1549; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA T, 1993, J BIOL CHEM, V268, P21914; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WILLIAMS GT, 1990, MOL CELL BIOL, V10, P3125, DOI 10.1128/MCB.10.6.3125; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608	54	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15768	15775						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195231				2022-12-27	WOS:A1994NP51300059
J	STRUM, JC; SMALL, GW; PAUIG, SB; DANIEL, LW				STRUM, JC; SMALL, GW; PAUIG, SB; DANIEL, LW			1-BETA-D-ARABINOFURANOSYLCYTOSINE STIMULATES CERAMIDE AND DIGLYCERIDE FORMATION IN HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; PROTEIN-KINASE-C; MYELOID-LEUKEMIA CELLS; SIGNAL-TRANSDUCTION; SPHINGOMYELIN TURNOVER; DIPHOSPHATE CHOLINE; GENE-EXPRESSION; FACTOR-ALPHA; FREE SYSTEM	The effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on phospholipid metabolism was investigated in HL-60 cells. Treatment of cells with ara-C resulted in a time- and dose-dependent increase in the mass of ceramide and diglyceride. When cells were treated with 10 mu M ara-C, an increase in the mass of ceramide and diglyceride was detectable at 5 min and reached a plateau at 30 min with a 2-fold increase compared to control cells. Treatment of cells with 10 mu M ara-C resulted in the activation of neutral sphingomyelinase with a peak at 30 min that represented a S-fold increase in specific activity. ara-C also increased expression of the transcription factor NF-B-kappa which is related to the control of monocyte differentiation. These findings suggest that ara C activates phospholipid hydrolytic pathways to generate second messengers that control gene expression and differentiation in the HL-60 cell line,	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center				, George/0000-0002-7585-7258	NCI NIH HHS [CA-12197, CA-43297, CA-48995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043297, R01CA048995, P30CA012197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AANEN C, 1985, SEMIN ONCOL, V12, P120; ARIMA N, 1992, J IMMUNOL, V149, P83; AUSUBEL FM, 1989, SHORT PORTOCOLS MOL; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRACH MA, 1992, MOL PHARMACOL, V41, P60; CAPIZZI RL, 1988, YALE J BIOL MED, V61, P11; CHEDID M, 1991, J IMMUNOL, V147, P867; DALY PF, 1990, CANCER RES, V50, P552; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5045; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FREI E, 1969, CANCER RES, V29, P1325; FURTH JJ, 1968, CANCER RES, V28, P2061; GALE RP, 1979, NEW ENGL J MED, V300, P1189, DOI 10.1056/NEJM197905243002105; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRIFFIN J, 1982, EXP HEMATOL, V10, P774; HOHMANN HP, 1991, MOL CELL BIOL, V11, P259, DOI 10.1128/MCB.11.1.259; KALEN A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P90, DOI 10.1016/0005-2760(92)90160-W; KAUFMAN PA, 1992, J CLIN INVEST, V90, P121, DOI 10.1172/JCI115824; KHARBANDA S, 1991, BIOCHEMISTRY-US, V30, P7947, DOI 10.1021/bi00246a011; KIM MY, 1991, J BIOL CHEM, V266, P484; KUCERA GL, 1992, CANCER RES, V52, P3886; KUFE DW, 1980, J BIOL CHEM, V255, P8997; LAUZON GJ, 1978, CANCER RES, V38, P1723; LAUZON GJ, 1978, CANCER RES, V38, P1730; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MICHALEWICZ R, 1984, LEUKEMIA RES, V8, P783, DOI 10.1016/0145-2126(84)90099-7; NICULESCU F, 1993, J IMMUNOL, V150, P214; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; PINTO A, 1988, MED ONCOL TUMOR PHAR, V5, P91; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAO BG, 1976, J LIPID RES, V17, P506; SCHRECKER AW, 1970, CANCER RES, V30, P632; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; YANG JL, 1986, ACTA PHARMACOL SINIC, V4, P368; YANG ZH, 1993, J BIOL CHEM, V268, P20520	41	154	168	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15493	15497						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195192				2022-12-27	WOS:A1994NP51300018
J	THOMAS, DC; ROTH, MG				THOMAS, DC; ROTH, MG			THE BASOLATERAL TARGETING SIGNAL IN THE CYTOPLASMIC DOMAIN OF GLYCOPROTEIN-G FROM VESICULAR STOMATITIS-VIRUS RESEMBLES A VARIETY OF INTRACELLULAR TARGETING MOTIFS RELATED BY PRIMARY SEQUENCE BUT HAVING DIVERSE TARGETING ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRANSFERRIN RECEPTOR; POLYMERIC IMMUNOGLOBULIN RECEPTOR; POLARIZED EPITHELIAL-CELLS; LYSOSOMAL ACID-PHOSPHATASE; TRANS-GOLGI NETWORK; DENSITY-LIPOPROTEIN RECEPTOR; 2 INTERNALIZATION SIGNALS; SITE-SPECIFIC MUTAGENESIS; TYROSINE-CONTAINING MOTIF; FACTOR-II RECEPTOR	Using systematic site-directed mutagenesis, the basolateral targeting signal in the cytoplasmic domain of glycoprotein G from vesicular stomatitis virus (VSV G) has been localized to an 11-amino acid sequence, which contains two essential residues and a third that makes a minor contribution. A tyrosine at position 19 of the 29-residue carboxyl-terminal cytoplasmic tail is the most important residue and cannot be replaced by other aromatic amino acids, while an isoleucine at position 22, 3 residues carboxyl-terminal to this tyrosine, is also critical but can be replaced by other aliphatic residues. Additionally, an arginine at position 16 makes a minor contribution. Therefore the crucial elements of this targeting signal can be represented by the sequence Y-X-X-aliphatic. While earlier investigation has suggested similarity between basolateral targeting and internalization signals, alignment of this sequence with other cytoplasmic targeting signal suggests the existence of a broad class of homologous targeting motifs that direct protein delivery to a variety of cellular locations. This in turn suggests the existence of a family of homologous receptors, distributed throughout the cell, which differ in their affinity for subsets of these targeting sequences.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Roth, Michael/0000-0002-9056-332X	NIGMS NIH HHS [T32GM08203, GM37547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037547, T32GM008203] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIGORENA S, 1992, NATURE, V358, P337, DOI 10.1038/358337a0; AREOTI B, 1994, J CELL BIOL, V123, P1149; BARBER LD, 1993, ANNU REV CELL BIOL, V9, P163; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CAPLAN M, 1989, FUNCTIONAL EPITHELIA, P71; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COMPTON T, 1989, P NATL ACAD SCI USA, V86, P4112, DOI 10.1073/pnas.86.11.4112; DARGEMONT C, 1993, EMBO J, V12, P1713, DOI 10.1002/j.1460-2075.1993.tb05816.x; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; FULLER SD, 1985, EMBO J, V4, P297, DOI 10.1002/j.1460-2075.1985.tb03629.x; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GIRONES N, 1991, J BIOL CHEM, V266, P19006; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOTTARDI CJ, 1993, SCIENCE, V260, P552, DOI 10.1126/science.8386395; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; GRUENBERG J, 1987, P NATL ACAD SCI USA, V84, P5738; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAZAROVITS J, 1990, J BIOL CHEM, V265, P4760; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LEZAROVITS J, 1988, CELL, V53, P743; MALLABIABARRENA A, 1992, NATURE, V357, P593, DOI 10.1038/357593a0; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MCQUEEN NL, 1987, J BIOL CHEM, V262, P16233; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; NABI IR, 1993, MOL BIOL CELL, V4, P627, DOI 10.1091/mbc.4.6.627; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NEAME SJ, 1993, J CELL BIOL, V121, P1299, DOI 10.1083/jcb.121.6.1299; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; OZAKI K, 1993, J BIOCHEM-TOKYO, V113, P271, DOI 10.1093/oxfordjournals.jbchem.a124038; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PESONEN M, 1984, J CELL BIOL, V99, P796, DOI 10.1083/jcb.99.3.796; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; PUDDINGTON L, 1987, P NATL ACAD SCI USA, V84, P2756; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; ROTH MG, 1993, CELL BIOL BIOTECHNOL, P137; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; STAPPERT J, 1992, NUCLEIC ACIDS RES, V20, P624, DOI 10.1093/nar/20.3.624; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WONG SH, 1993, J BIOL CHEM, V268, P22853; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	70	112	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15732	15739						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195226				2022-12-27	WOS:A1994NP51300054
J	VANHELLEMOND, JJ; SLOT, JW; GEELEN, MJH; VANGOLDE, LMG; VERMEULEN, PS				VANHELLEMOND, JJ; SLOT, JW; GEELEN, MJH; VANGOLDE, LMG; VERMEULEN, PS			ULTRASTRUCTURAL-LOCALIZATION OF CTP-PHOSPHOETHANOLAMINE CYTIDYLYLTRANSFERASE IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CULTURED GLIOMA-CELLS; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; PHOSPHATE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLETHANOLAMINE; ETHANOLAMINE; HEPATOCYTES; ENZYMES	CTP:phosphoethanolamine cytidylyltransferase (EC 2.7.7.14) (ethanolamine-phosphate cytidylyltransferase, ET) was recently purified to homogeneity from a post-microsomal supernatant of rat liver and subsequently used to raise a polyclonal antibody against the enzyme in rabbits (Vermeulen, P. S., Tijburg, L. B. M., Geelen, M. J. H., and van Golde, L. M. G. (1993) J. Biol. Chem 268, 7458-7464). In the present study, we used the affinity-purified antibody against ET for ultrastructural immunogold labeling studies on rat liver cryosections. Single-label experiments clearly demonstrated that ET label was not randomly distributed in hepatocytes. The ET label was concentrated in areas that contained cisternae of the rough endoplasmic reticulum, whereas other cellular organelles (nuclei, mitochondria, and peroxisomes) were only marginally labeled for ET. Double-label experiments for ET and established markers for either soluble or integral endoplasmic reticulum proteins suggested a bimodal distribution of ET between the RER cisternae and the cytosolic space. Complementary single-label studies for ET and the soluble marker protein showed that the fraction of ET label that was present on RER cisternae was significantly greater than that of the soluble marker, supporting the idea of an uneven distribution. These immunoelectron microscopy studies strongly suggest that the cellular organization of ET differs considerably from that reported recently for the corresponding enzyme in the CDP-choline pathway, CTP:phosphocholine cytidylyltransferase (Wang, Y., Sweiter T. D., Weinhold, P. A., and Kent, C. (1993) J. Biol. Chem. 268, 5899-5904).	UNIV UTRECHT,SCH VET MED,VET BIOCHEM LAB,3508 TD UTRECHT,NETHERLANDS; UNIV UTRECHT,CTR ELECTRON MICROSCOPY,SCH MED,3508 TD UTRECHT,NETHERLANDS	Utrecht University; Utrecht University			van Hellemond, Jaap/T-7555-2019	van Hellemond, Jaap/0000-0003-4862-7796				FELDMAN DA, 1993, J BIOL CHEM, V268, P3127; GEORGE TP, 1989, BIOCHIM BIOPHYS ACTA, V1004, P283, DOI 10.1016/0005-2760(89)90075-1; GEORGE TP, 1991, BIOCHIM BIOPHYS ACTA, V1084, P185, DOI 10.1016/0005-2760(91)90219-8; JAMIL H, 1993, BIOCHEM J, V291, P419, DOI 10.1042/bj2910419; JELSEMA CL, 1978, J BIOL CHEM, V253, P7960; KAPRELYANTS AS, 1988, TRENDS BIOCHEM SCI, V13, P43, DOI 10.1016/0968-0004(88)90024-2; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KHOLODENKO BN, 1993, FEBS LETT, V320, P71, DOI 10.1016/0014-5793(93)81660-R; SCHNEIDER WC, 1966, ANAL BIOCHEM, V14, P121, DOI 10.1016/0003-2697(66)90064-9; SLOT JW, 1986, LAB INVEST, V55, P363; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; SUNDLER R, 1973, BIOCHIM BIOPHYS ACTA, V306, P218, DOI 10.1016/0005-2760(73)90227-0; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; TIJBURG LBM, 1992, METHOD ENZYMOL, V209, P258; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P225; VERMEULEN PS, 1993, J BIOL CHEM, V268, P7458; WANG YL, 1993, J BIOL CHEM, V268, P5899	20	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15415	15418						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195180				2022-12-27	WOS:A1994NP51300005
J	ZHAO, LJ; MUKHERJEE, S; NARAYAN, O				ZHAO, LJ; MUKHERJEE, S; NARAYAN, O			BIOCHEMICAL-MECHANISM OF HIV-I VPR FUNCTION - SPECIFIC INTERACTION WITH A CELLULAR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VIRION-ASSOCIATED PROTEIN; PRODUCTIVE INFECTION; HUMAN MACROPHAGES; MOLECULAR CLONE; TYPE-1; GENE; DNA; LOCALIZATION; LYMPHOCYTES	vpr is an accessory gene of human immunodeficiency virus I (HIV-I). Although unnecessary for viral replication in T cell lines, growing evidence suggests that it is essential for virus replication in monocytes/macrophages and for replication in vivo. We expressed HIV-I vpr in Escherichia coli and purified Vpr by affinity chromatography. In a coprecipitation assay, the purified Vpr interacted specifically with a cellular protein designated as Vpr-interacting protein, or RIP, Mutational analysis suggested that this interaction required a domain rich in leucine/isoleucine residues and highly conserved between HIV-I and SIVmac Vprs. During transient expression in mammalian cells, HIV-I Vpr was localized in the nucleus. However, mutational analysis failed to identify in Vpr a typical nuclear localization signal rich in basic amino acid residues. Instead, Vpr nuclear localization seemed to correlate with Vpr interaction with RIP. Mutations in the C-terminal 20-amino acid region containing a cryptic nuclear localization signal did not abolish Vpr nuclear localization or interaction with RIP, whereas point mutations in the leucine/isoleucine-rich domain abolished Vpr interaction with RTP and rendered Vpr unstable during transient expression. These results suggest that RIP may be involved in Vpr function.			ZHAO, LJ (corresponding author), UNIV KANSAS,MED CTR,DEPT MICROBIOL MOLEC GENET & IMMUNOL,MARION MERRELL DOW FDN,KANSAS CITY,KS 66160, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029382] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032203] Funding Source: NIH RePORTER; NCRR NIH HHS [RR06753] Funding Source: Medline; NIAID NIH HHS [AI29382] Funding Source: Medline; NINDS NIH HHS [NS32203] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATCHISON ML, 1987, CELL, V48, P212; BALOTTA C, 1993, J VIROL, V67, P4409, DOI 10.1128/JVI.67.7.4409-4414.1993; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; HATTORI N, 1990, P NATL ACAD SCI USA, V87, P8080, DOI 10.1073/pnas.87.20.8080; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LORI F, 1992, J VIROL, V66, P5553, DOI 10.1128/JVI.66.9.5553-5560.1992; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; REGIER DA, 1990, AIDS RES HUM RETROV, V6, P1221, DOI 10.1089/aid.1990.6.1221; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; WESTERVELT P, 1992, J VIROL, V66, P3925, DOI 10.1128/JVI.66.6.3925-3931.1992; WONGSTAAL F, 1987, AIDS RES HUM RETROV, V3, P33, DOI 10.1089/aid.1987.3.33; YU XF, 1990, J VIROL, V64, P5688, DOI 10.1128/JVI.64.11.5688-5693.1990; YUAN X, 1990, AIDS RES HUM RETROV, V6, P1265, DOI 10.1089/aid.1990.6.1265; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445; ZHAO LJ, 1993, GENE, V137, P345, DOI 10.1016/0378-1119(93)90032-X; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	30	117	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15577	15582						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195203				2022-12-27	WOS:A1994NP51300031
J	GUO, XD; WATTANAPERMPOOL, J; PALMITER, KA; MURPHY, AM; SOLARO, RJ				GUO, XD; WATTANAPERMPOOL, J; PALMITER, KA; MURPHY, AM; SOLARO, RJ			MUTAGENESIS OF CARDIAC TROPONIN-I - ROLE OF THE UNIQUE NH2-TERMINAL PEPTIDE IN MYOFILAMENT ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; 2 ADJACENT PHOSPHOSERINES; SKELETAL-MUSCLE; RAT-HEART; BIOLOGICAL-ACTIVITY; ISOFORM EXPRESSION; RABBIT; BINDING; BOVINE; PHOSPHORYLATION	Phosphorylation of Ser residues in the NH2-terminal extension unique to cardiac troponin I (cTnI) is known to occur through protein kinase A and to alter myofilament Ca2+ activation (Robertson, S. P., Johnson, J. D., Holroyde, M. J., Kranias, E. G., Potter, J. D., and Solaro, R. J. (1982) J. Biol. Chem. 257, 260-263). Yet, how the NH2-terminal extension may itself affect thin filament Ca2+ signaling is unknown. To approach this question we have used molecular cloning, mutagenesis, and bacterial synthesis of a full-length cTnI: and a truncated mutant (cTnI/NH2) missing the 32 amino acids. Using reconstituted preparations we could show no differences between cTnI and cTnI/NH2 either in inhibition of actomyosin ATPase activity, in Ca2+-reversible inhibitory activity, or in the relation between pCa and Ca2+ binding to the regulatory site of cTnC at either pH 7.0 or 6.5. There were also no significant differences at either pH in the pCa-MgATPase activity relation of myofibrils into which the various species of TnI had been exchanged. Our results indicate: 1) that phosphorylation most likely induces a new state of TnI activity rather than altering an intrinsic effect of the NH2-terminal peptide on Ca2+ activation; and 2) that domains outside the NH2-terminal extension are important with regard to differences in effects of acidic pH on Ca2+ activation on cardiac and skeletal myofilaments.	UNIV ILLINOIS, COLL MED, DEPT PHYSIOL & BIOPHYS, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022231, R29HL050184, T32HL007692] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29-HL-50184, T32 HL-07692, R01-HL-22231] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER SG, 1982, J BIOCHEM BIOPH METH, V7, P7, DOI 10.1016/0165-022X(82)90031-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELSALEH SC, 1988, J BIOL CHEM, V263, P3274; ENDOH M, 1988, CIRC RES, V62, P247, DOI 10.1161/01.RES.62.2.247; GRAND RJA, 1976, BIOCHEM J, V159, P633, DOI 10.1042/bj1590633; HASTINGS KEM, 1991, J BIOL CHEM, V266, P19659; HATAKENAKA M, 1992, EUR J BIOCHEM, V205, P985, DOI 10.1111/j.1432-1033.1992.tb16865.x; HOLROYDE MJ, 1979, BIOCHIM BIOPHYS ACTA, V586, P63, DOI 10.1016/0304-4165(79)90405-7; HUNKELER NM, 1991, CIRC RES, V69, P1409, DOI 10.1161/01.RES.69.5.1409; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVIS PC, 1987, CRIT REV BIOCH, V16, P233; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P2821, DOI 10.1021/bi00408a024; LIAO R, 1990, THESIS U ALABAMA BIR; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MARTIN AF, 1991, CIRC RES, V69, P1244, DOI 10.1161/01.RES.69.5.1244; MITTMANN K, 1990, FEBS LETT, V273, P41, DOI 10.1016/0014-5793(90)81046-Q; MURPHY AM, 1991, BIOCHEMISTRY-US, V30, P707, DOI 10.1021/bi00217a018; PAGANI ED, 1983, AM J PHYSIOL, V245, pH713, DOI 10.1152/ajpheart.1983.245.5.H713; PAN BS, 1987, J BIOL CHEM, V262, P7839; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; SABRY MA, 1989, J MUSCLE RES CELL M, V10, P85, DOI 10.1007/BF01739858; SAGGIN L, 1989, J BIOL CHEM, V264, P16299; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENG Z, 1993, BIOPHYS J, V64, pA136; SOLARO RJ, 1976, NATURE, V262, P615, DOI 10.1038/262615a0; SOLARO RJ, 1986, CIRC RES, V58, P721, DOI 10.1161/01.RES.58.5.721; SOLARO RJ, 1993, MODULATION CARDIAC C, P160; SOLARO RJ, 1988, PHYSL PATHOPHYSIOLOG, P291; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWIDEREK K, 1988, EUR J BIOCHEM, V176, P335, DOI 10.1111/j.1432-1033.1988.tb14286.x; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1981, J BIOL CHEM, V256, P2374; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	40	85	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15210	15216						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195157				2022-12-27	WOS:A1994NP73800054
J	TAOUIS, M; LEVYTOLEDANO, R; ROACH, P; TAYLOR, SI; GORDEN, P				TAOUIS, M; LEVYTOLEDANO, R; ROACH, P; TAYLOR, SI; GORDEN, P			STRUCTURAL BASIS BY WHICH A RECESSIVE MUTATION IN THE ALPHA-SUBUNIT OF THE INSULIN-RECEPTOR AFFECTS INSULIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; HIGH-AFFINITY; BETA-SUBUNIT; PLASMA-MEMBRANE; LIGAND-BINDING; KINASE; CELLS; AUTOPHOSPHORYLATION; RESISTANCE; ANTIBODIES	Recently, a mutation substituting Leu for Ser(323) in the alpha-subunit of the human insulin receptor has been identified in an insulin-resistant patient. The Leu(323) mutation leads to a severe impairment in insulin binding without significantly altering the processing or cell surface expression of the receptor. In order to study how alpha beta half-receptors interact to form the insulin-binding site, we cotransfected NIH-3T3 cells with two insulin receptor cDNA constructs: a truncated insulin receptor lacking the C-terminal 43 amino acids (Delta 43) and the full-length Leu(323) mutant receptor. A clonal cell line from cotransfected cells expresses a hybrid receptor consisting of a Leu(323) half-receptor and a Delta 43 half-receptor. We demonstrate that the Leu(323)-Delta 43 hybrid receptor binds insulin with high affinity. Furthermore, by cross-linking I-125-insulin to immobilized hybrid receptors, we show that only the alpha beta(Delta) half of the hybrid receptor binds insulin. Since the isolated half-insulin receptor has low affinity for insulin, this suggests that the addition of even a non-binding alpha-subunit can result in high affinity binding to the holoreceptor (alpha alpha(mut)beta(Delta)beta). Both beta and beta(Delta)-subunits of the Leu(323)-Delta 43 hybrid receptor are phosphorylated in vivo and in vitro in an insulin-dependent manner, suggesting an intramolecular transphosphorylation mechanism and that the presence of the Leu(323) mutant receptor that lacks an intrinsic high affinity binding site does not prevent the associated beta-subunit from functioning either as a tyrosine kinase or as a phosphate acceptor in the hybrid insulin receptor molecule (alpha alpha(mut)beta(Delta)beta). Furthermore, we show that the hybrid receptor can phosphorylate insulin receptor substrate-1 (IRS-1) in response to insulin and can be coimmunoprecipitated together with IRS-1 by anti-IRS-1 antibody.	NIDDK,DIABET BRANCH,BETHESDA,MD 20892; INRA,RECH AVICOLES STN,F-37380 NOUZILLY,FRANCE	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); INRAE			Taouis, Mohammed/CAA-1797-2022	Taouis, Mohammed/0000-0002-4101-691X				ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; CAMA A, 1988, DIABETES, V37, P982, DOI 10.2337/diabetes.37.7.982; CAMA A, 1992, J BIOL CHEM, V267, P8383; CAMA A, 1991, J CLIN ENDOCR METAB, V73, P894, DOI 10.1210/jcem-73-4-894; DEMEYTS P, 1973, BIOCHEM BIOPH RES CO, V55, P154, DOI 10.1016/S0006-291X(73)80072-5; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FRATTALI AL, 1993, J BIOL CHEM, V268, P7393; FRATTALI AL, 1992, J BIOL CHEM, V267, P19521; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; LEE JS, 1993, J BIOL CHEM, V268, P4092; LEVYTOLEDANO R, 1994, EMBO J, V13, P835, DOI 10.1002/j.1460-2075.1994.tb06326.x; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MYERS MG, 1991, J BIOL CHEM, V266, P10616; PANG DT, 1983, J BIOL CHEM, V258, P2514; PANG DT, 1984, J BIOL CHEM, V259, P8589; PILCH PF, 1979, J BIOL CHEM, V254, P3375; SHOELSON SE, 1993, J BIOL CHEM, V268, P4085; SOOS MA, 1993, BIOCHEM J, V290, P419, DOI 10.1042/bj2900419; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; TAOUIS M, 1993, MOL CELL ENDOCRINOL, V96, P113, DOI 10.1016/0303-7207(93)90101-O; TAYLOR SI, 1984, J CLIN ENDOCR METAB, V58, P182, DOI 10.1210/jcem-58-1-182; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; YIP CC, 1992, J BIOL CHEM, V267, P13131; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858	28	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14912	14918						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195122				2022-12-27	WOS:A1994NP73800013
J	HORWITZ, EM; MALONEY, KA; LEY, TJ				HORWITZ, EM; MALONEY, KA; LEY, TJ			A HUMAN PROTEIN CONTAINING A COLD SHOCK DOMAIN BINDS SPECIFICALLY TO H-DNA UPSTREAM FROM THE HUMAN GAMMA-GLOBIN GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA+ HEREDITARY PERSISTENCE; STAGE-SPECIFIC EXPRESSION; POINT MUTATION 5'; FETAL HEMOGLOBIN; TRANSGENIC MICE; Y-BOX; CHROMOSOMAL LOCALIZATION; FUNCTIONAL-ANALYSIS; PROMOTER ELEMENT; ESCHERICHIA-COLI	We previously determined that a region between positions -228 and -189 upstream from the human gamma-globin genes can form an intramolecular tripler (H-DNA) in supercoiled plasmids. To identify proteins that might interact with this DNA structure, we performed expression cloning using an adult bone marrow cDNA library and the single-stranded region of the H-DNA structure as a probe. We cloned molecules very similar to two previously identified cDNAs, dbpA and dbpB. The dbpB-like protein (called BP-8 in this study) interacts specifically (R(D) similar to 4 nM) with two homopyrimidine ''half-sites'' in the single-stranded gamma-228 to -189 probe, but binds to double-stranded DNA containing the same sequence with 100-fold less affinity. We have also shown that supercoiled plasmids containing the gamma-228 to -189 region contain a high affinity binding site for BP-8 that is stabilized by factors that stabilize H-DNA; two HPFH point mutations (-202 C --> G or C --> T) that destabilize the secondary DNA structure abolish the high affinity binding site. Collectively, these data show that dbpB/BP-8 binds specifically to homopyrimidine half-sites in single-stranded DNA, and that it also binds to H-DNA structures that contain homopyrimidine tracts in the single-stranded and triple-stranded regions.	ST LOUIS CHILDRENS HOSP,DEPT PEDIAT,DIV BONE MARROW TRANSPLANTAT & STEM CELL BIOL,ST LOUIS,MO 63110; ST LOUIS CHILDRENS HOSP,DEPT MED,ST LOUIS,MO 63110; ST LOUIS CHILDRENS HOSP,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,ST LOUIS,MO 63110	St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)					NCI NIH HHS [CA-49712, CA-01704] Funding Source: Medline; NIDDK NIH HHS [DK-38682] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712, K12CA001704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038682, R01DK038682] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CATALA F, 1989, NUCLEIC ACIDS RES, V17, P3811, DOI 10.1093/nar/17.10.3811; CHADA K, 1986, NATURE, V319, P685, DOI 10.1038/319685a0; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; COLLINS FS, 1984, BLOOD, V64, P1292; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; FIRULLI AB, 1992, BIOCHEM BIOPH RES CO, V185, P264, DOI 10.1016/S0006-291X(05)80985-4; FISCHER KD, 1990, NUCLEIC ACIDS RES, V18, P5685, DOI 10.1093/nar/18.19.5685; GAI XX, 1992, NUCLEIC ACIDS RES, V20, P601, DOI 10.1093/nar/20.3.601; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; GRAY WJ, 1985, BLOOD, V66, pA71; GUMUCIO DL, 1991, BLOOD, V78, P1853; GUMUCIO DL, 1988, MOL CELL BIOL, V8, P5310, DOI 10.1128/MCB.8.12.5310; GUMUCIO DL, 1991, REGULATION HEMOGLOBI, P277; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; JANE SM, 1993, MOL CELL BIOL, V13, P3272, DOI 10.1128/MCB.13.6.3272; KANG S, 1992, J BIOL CHEM, V267, P20887; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOLLIAS G, 1986, CELL, V46, P89, DOI 10.1016/0092-8674(86)90862-7; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KOLLURI R, 1991, NUCLEIC ACIDS RES, V19, P4771, DOI 10.1093/nar/19.17.4771; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; LEY TJ, 1991, BLOOD, V77, P1146; LLOYD JA, 1992, MOL CELL BIOL, V12, P1561, DOI 10.1128/MCB.12.4.1561; LLOYD JA, 1989, NUCLEIC ACIDS RES, V17, P4339, DOI 10.1093/nar/17.11.4339; Lohman TM., 1990, BIOL NONSPECIFIC DNA, P131; LYAMICHEV VI, 1985, J BIOMOL STRUCT DYN, V3, P327, DOI 10.1080/07391102.1985.10508420; MCDONAGH KT, 1991, J BIOL CHEM, V266, P11965; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; ONEILL D, 1990, NUCLEIC ACIDS RES, V18, P1977, DOI 10.1093/nar/18.8.1977; OZER J, 1990, J BIOL CHEM, V265, P22143; PEREZSTABLE C, 1990, MOL CELL BIOL, V10, P1116, DOI 10.1128/MCB.10.3.1116; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; SAKURA H, 1988, GENE, V73, P499; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHINDELIN H, 1992, PROTEINS, V14, P120, DOI 10.1002/prot.340140113; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; SHAUGHNESSY M, 1992, CURR EYE RES, V11, P1992; SHIMIZU M, 1989, J BIOL CHEM, V264, P5944; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; SPITKOVSKY DD, 1992, NUCLEIC ACIDS RES, V20, P797, DOI 10.1093/nar/20.4.797; SRIVASTAVA M, 1990, J BIOL CHEM, V265, P14922; STAMATOYANNOPOULOS G, 1991, SCIENCE, V252, P383, DOI 10.1126/science.2017679; STAMATOYANNOPOULOS G, 1993, MOL CELL BIOL, V13, P7636, DOI 10.1128/MCB.13.12.7636; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SYKES K, 1990, MOL CELL BIOL, V10, P95, DOI 10.1128/MCB.10.1.95; TAFURI SR, 1993, J BIOL CHEM, V268, P12213; TAFURI SR, 1992, NEW BIOL, V4, P349; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TRUDEL M, 1987, MOL CELL BIOL, V7, P4024, DOI 10.1128/MCB.7.11.4024; ULRICH MJ, 1990, BLOOD, V75, P990; ULRICH MJ, 1992, J BIOL CHEM, V267, P18649; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WABER PG, 1986, BLOOD, V67, P551; WOLFFE AP, 1992, NEW BIOL, V4, P290	59	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14130	14139						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188694				2022-12-27	WOS:A1994NL60600062
J	LEBRUN, JJ; ALI, S; SOFER, L; ULLRICH, A; KELLY, PA				LEBRUN, JJ; ALI, S; SOFER, L; ULLRICH, A; KELLY, PA			PROLACTIN-INDUCED PROLIFERATION OF NB2 CELLS INVOLVES TYROSINE PHOSPHORYLATION OF THE PROLACTIN RECEPTOR AND ITS ASSOCIATED TYROSINE KINASE JAK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTORS; RAT LYMPHOMA-CELLS; ERYTHROPOIETIN RECEPTOR; EXPRESSION; PROTEIN; STIMULATION; ACTIVATION; FAMILY; FORMS	The interaction of prolactin with its receptor in the Nb2 cell line has been shown to induce the phosphorylation of cell associated proteins and mitogenesis. It has been reported previously that one of these proteins, phosphorylated upon prolactin stimulation, was a tyrosine kinase. We have identified this kinase as JAK2, and demonstrate its association with the prolactin receptor. In addition, we show that the prolactin receptor itself becomes tyrosine phosphorylated upon ligand stimulation in Nb2 cells. These actions are time-dependent and occur rapidly after prolactin stimulation, with first the kinase being activated within 5 min and then the receptor being phosphorylated maximally at 20 min. Moreover, phosphorylation of both JAK2 and the receptor as well as Nb2 cell proliferation are dependent on the concentration of lactogenic hormone, resulting in a bell-shaped response curve similar to that observed in the two site model of hGH action. This indicates that early events in signal transduction as well as later events like mitogenesis and proliferation involve prolactin receptor dimerization. Together these data indicate that the prolactin receptor in Nb2 cells is associated to JAK2 and that upon ligand stimulation, and receptor dimerization, the kinase and the receptor are tyrosine-phosphorylated, which represents the first event in the process of prolactin receptor signal transduction in Nb2 cells.	FAC MED NECKER ENFANTS MALAD, INSERM, U344, UNITE ENDOCRINOL MOLEC, F-75730 PARIS, FRANCE; MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, W-8033 MARTINSRIED, GERMANY	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Max Planck Society			Kelly, Paul/A-7951-2008; Lebrun, Jean-Jacques/GNP-5222-2022	sofer, luc/0000-0001-9999-9667				ALI S, 1991, J BIOL CHEM, V266, P20110; ALI S, 1992, MOL ENDOCRINOL, V6, P1242, DOI 10.1210/me.6.8.1242; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; COMSA J, 1981, REV PHYSIOL BIOCH P, V92, P115; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ELBERG G, 1990, J BIOL CHEM, V265, P14770; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GOUT PW, 1980, CANCER RES, V40, P2433; KELLY PA, 1993, RECENT PROG HORM RES, V48; LESUEUR L, 1991, P NATL ACAD SCI USA, V88, P824, DOI 10.1073/pnas.88.3.824; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NOBLE RL, 1975, CANCER RES, V35, P766; PELLEGRINI I, 1992, MOL ENDOCRINOL, V6, P1023, DOI 10.1210/me.6.7.1023; RICHARDS JF, 1982, MOL CELL ENDOCRINOL, V26, P41, DOI 10.1016/0303-7207(82)90005-3; RILLEMA JA, 1992, ENDOCRINOLOGY, V131, P973, DOI 10.1210/en.131.2.973; RUI H, 1992, J BIOL CHEM, V267, P24076; RUSSELL DH, 1984, BIOCHEM BIOPH RES CO, V121, P899, DOI 10.1016/0006-291X(84)90762-9; SABHARWAL P, 1992, P NATL ACAD SCI USA, V89, P7713, DOI 10.1073/pnas.89.16.7713; SHACKELFORD DA, 1991, CELL REGUL, V2, P73, DOI 10.1091/mbc.2.1.73; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG XY, 1993, J BIOL CHEM, V268, P3573; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	34	191	191	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14021	14026						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188682				2022-12-27	WOS:A1994NL60600047
J	LILIE, H; MCLAUGHLIN, S; FREEDMAN, R; BUCHNER, J				LILIE, H; MCLAUGHLIN, S; FREEDMAN, R; BUCHNER, J			INFLUENCE OF PROTEIN DISULFIDE-ISOMERASE (PDI) ON ANTIBODY FOLDING IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN LIGHT CHAIN; ENDOPLASMIC-RETICULUM; CONSTANT FRAGMENT; PEPTIDE-BINDING; HEAVY-CHAIN; BIP; BIOSYNTHESIS; RENATURATION; COMPONENT; REDUCTION	The role of eucaryotic protein disulfide isomerase (PDI) in the folding and reoxidation of proteins in vitro was investigated using an antibody Fab fragment as a model substrate, since PDI is known to participate in the disulfide bond formation of immunoglobulins in vivo. PDI has no effect on the folding of the Fab fragment with intact disulfide bonds, suggesting that, at least in this system, PDI is not able to influence the folding process in a chaperone-like manner. Instead, the role of PDI is limited to disulfide bond formation as demonstrated for the folding of the denatured and reduced Fab fragment. Here, PDI influences the yield of reactivation enormously with a maximum effect at about stoichiometric amounts of PDI and Fab. Furthermore, PDI changes the redox dependence of the reaction. In the presence of PDI, formation of the correct disulfide bonds is possible at higher oxidizing conditions compared to the spontaneous reaction. The requirements both for stoichiometric amounts of PDI and for the presence of PDI during the first seconds of refolding suggest that there is a kinetic competition between rapid structure formation of the antibody domains and interaction of PDI with cysteine residues in the folding protein.	UNIV REGENSBURG, INST BIOPHYS & PHYS BIOCHEM, D-93053 REGENSBURG, GERMANY; UNIV KENT, BIOL LAB, CANTERBURY CT2 7NJ, KENT, ENGLAND	University of Regensburg; University of Kent			Buchner, Johannes/A-2651-2010	McLaughlin, Stephen/0000-0001-9135-6253				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKWAY BE, 1980, BIOCHEM J, V191, P873, DOI 10.1042/bj1910873; BUCHNER J, 1991, CURR OPIN BIOTECH, V2, P532, DOI 10.1016/0958-1669(91)90077-I; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; BUCHNER J, 1990, DECHEMA BIOTECHNOLOG, V3, P1035; BUCKEL P, 1987, GENE, V51, P13, DOI 10.1016/0378-1119(87)90469-0; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; DELAMETTE F, 1975, CELL IMMUNOL, V19, P262, DOI 10.1016/0008-8749(75)90208-7; DELLACOR.E, 1973, BIOCHEM J, V136, P597; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEDMAN RB, 1991, CONFORMATIONS FORCES, P204; Freedman Robert B., 1992, P455; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOTO Y, 1981, J MOL BIOL, V146, P321, DOI 10.1016/0022-2836(81)90391-0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAENICKE R, 1993, CHEMTRACTS BIOCH MOL, V4, P1; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; JOHNSTONE A, 1987, IMMUNOCHEMISTRY PRAC, P55; KAWATA Y, 1991, BIOCHEMISTRY-US, V30, P4367, DOI 10.1021/bi00232a001; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3061, DOI 10.1021/bi00464a024; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; KIKUCHI H, 1986, BIOCHEMISTRY-US, V25, P2009, DOI 10.1021/bi00356a026; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LILIE H, 1993, PROTEIN SCI, V2, P1490, DOI 10.1002/pro.5560020913; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MILLS ENC, 1983, BIOCHEM J, V213, P245, DOI 10.1042/bj2130245; MYLLYLA R, 1983, EUR J BIOCHEM, V134, P7, DOI 10.1111/j.1432-1033.1983.tb07523.x; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PAVER JL, 1989, FEBS LETT, V242, P352; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; ROTH RA, 1981, BIOCHEMISTRY-US, V20, P6594, DOI 10.1021/bi00526a012; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; RUDOLPH R, 1990, MODERN METHOD IN PROTEIN- AND NUCLEIC ACID RESEARCH, P149; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WILDE CE, 1978, BIOCHEMISTRY-US, V17, P3209, DOI 10.1021/bi00609a006	52	85	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14290	14296						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188714				2022-12-27	WOS:A1994NL60600085
J	ROESLER, WJ; SIMARD, J; GRAHAM, JG; MCFIE, PJ				ROESLER, WJ; SIMARD, J; GRAHAM, JG; MCFIE, PJ			CHARACTERIZATION OF THE LIVER-SPECIFIC COMPONENT OF THE CAMP RESPONSE UNIT IN THE PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP) GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; C/EBP-RELATED PROTEINS; CYCLIC-AMP; TRANSCRIPTION FACTOR; GLUCOCORTICOID RECEPTOR; REGULATORY ELEMENTS; HEPATOMA-CELLS; ALBUMIN GENE; EXPRESSION; INDUCTION	The cAMP response unit of the phosphoenolpyruvate carboxykinase (GTP) (EC 4.1.1.32) gene promoter consists of two independently weak components; the typical cAMP response element and a region of the promoter that contains three binding sites for CCAAT/enhancer-binding proteins. Previous work from our laboratory indicated that all three binding sites were required for the full response to cAMP. However, in the present study, we demonstrate that the activity of this latter component cannot be mimicked by multiple copies of other well characterized CCAAT/enhancer-binding protein binding sites. Re examination of the promoter region containing the three C/EBP binding sites revealed the presence of an additional cis-element, which is required to mediate the activation by cAMP. This DNA sequence binds a protein in HepG2 nuclear extracts that is distinct from CCAAT/enhancer-binding protein and cAMP response element-binding protein, and evidence is presented which suggests that its identity is activator protein-1. Thus, the robust response of the phosphoenolpyruvate carboxykinase gene promoter to cAMP in liver requires the involvement of three different transcription factors. Utilization of multiple transcription factors to mediate the activation by cAMP likely allows for a tissue-specific response to this signal, a mechanism whereby to fine-tune the extent of the response, and a mechanism whereby to integrate signals from separate signaling pathways into a coordinated response.			ROESLER, WJ (corresponding author), UNIV SASKATCHEWAN,COLL MED,DEPT BIOCHEM,SASKATOON S7N 0W0,SK,CANADA.							AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIU JS, 1991, J BIOL CHEM, V266, P19095; MEISNER H, 1985, BIOCHEMISTRY-US, V24, P421, DOI 10.1021/bi00323a027; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PEERS B, 1991, J BIOL CHEM, V266, P18127; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROESLER WJ, 1990, TRENDS ENDOCRIN MET, V1, P347, DOI 10.1016/1043-2760(90)90082-E; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Sambrook J, 1989, MOL CLONING LABORATO; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z	42	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14276	14283						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188712				2022-12-27	WOS:A1994NL60600083
J	BHATTACHARYYA, DK; BANDYOPADHYAY, U; BANERJEE, RK				BHATTACHARYYA, DK; BANDYOPADHYAY, U; BANERJEE, RK			CHEMICAL AND KINETIC EVIDENCE FOR AN ESSENTIAL HISTIDINE RESIDUE IN THE ELECTRON-TRANSFER FROM AROMATIC DONOR TO HORSERADISH-PEROXIDASE COMPOUND-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; HORSE RADISH PEROXIDASE; PROSTHETIC HEME; TRANSFER COMPLEX; PARA CRESOL; RESONANCE; MECHANISM; OXIDATION; DIETHYLPYROCARBONATE; SPECTROSCOPY	Horseradish peroxidase, when incubated with diethyl pyrocarbonate (DEPC), a histidine-specific reagent, shows time-dependent inactivation to oxidize aromatic electron donor, guaiacol. The inactivation follows pseudo-first order kinetics with a second order rate constant of 0.67 min-1 M-1. The pH dependence of inactivation shows an inflection point at 6.02, indicating histidine derivatization by DEPC. A difference spectrum of modified versus native enzyme shows a peak at 244 nm for N-carbethoxyhistidine that is diminished by hydroxylamine. Stoichiometric studies indicate that out of 2 histidine residues modified, one is responsible for inactivation. A plot of log reciprocal half-time of inactivation against log DEPC concentration suggests that only 1 histidine is essential. From the computer-stimulated structure of horseradish peroxidase, we tentatively suggest that this critical histidine is most likely distal histidine 42. Binding studies show that this histidine is not involved in guaiacol binding. Modified enzyme forms compound I with H2O2 but not compound II, suggesting a block of electron transfer process. Modified compound I cannot oxidize guaiacol as evidenced by the absence of donor-induced spectral shift from 408 nm, suggesting a block of electron transfer from bound donor to compound I. We suggest that this tentatively identified distal histidine controls aromatic donor oxidation by regulating electron transport without affecting donor binding or compound I formation.	INDIAN INST CHEM BIOL, DEPT PHYSIOL, 4 RAJA SC MULLICK RD, CALCUTTA 700032, W BENGAL, INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)								AIBARA S, 1982, J BIOCHEM-TOKYO, V92, P531, DOI 10.1093/oxfordjournals.jbchem.a133961; ATOR MA, 1987, J BIOL CHEM, V262, P14954; ATOR MA, 1987, J BIOL CHEM, V262, P1542; BAEK HK, 1989, BIOCHEMISTRY-US, V28, P5714, DOI 10.1021/bi00440a003; BHATTACHARYYA DK, 1992, J BIOL CHEM, V267, P9800; BJORKSTEN F, 1970, BIOCHIM BIOPHYS ACTA, V212, P396, DOI 10.1016/0005-2744(70)90245-7; BLANKE SR, 1990, J BIOL CHEM, V265, P12454; BOSSHARD HR, 1984, J BIOL CHEM, V259, P5683; BURNS PS, 1975, J CHEM SOC CHEM COMM, P795, DOI 10.1039/c39750000795; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; CHANCE B, 1949, ARCH BIOCHEM, V21, P416; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V41, P416, DOI 10.1016/0003-9861(52)90470-0; CHURCH FC, 1985, J BIOL CHEM, V260, P4936; CRITCHLOW JE, 1972, J BIOL CHEM, V247, P3703; CRITCHLOW JE, 1972, J BIOL CHEM, V247, P3714; DE SK, 1986, EUR J BIOCHEM, V160, P319, DOI 10.1111/j.1432-1033.1986.tb09974.x; DEMONTELLANO PRO, 1987, ACCOUNTS CHEM RES, V20, P289; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; DUNFORD HB, 1982, ADV INORG BIOCHEM, V4, P41; DUNFORD HB, 1979, BIOCHEM BIOPH RES CO, V89, P764, DOI 10.1016/0006-291X(79)90695-8; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FISHEL LA, 1987, BIOCHEMISTRY-US, V26, P351, DOI 10.1021/bi00376a004; Frew J. E., 1984, ADV INORG BIOINORG M, V3, P175; GEORGE P, 1952, NATURE, V169, P612, DOI 10.1038/169612a0; GOMI T, 1983, BIOCHEMISTRY-US, V22, P137, DOI 10.1021/bi00270a020; HOSOYA T, 1960, J BIOCHEM-TOKYO, V47, P794, DOI 10.1093/oxfordjournals.jbchem.a127127; HOSOYA T, 1989, BIOCHEMISTRY-US, V28, P2639, DOI 10.1021/bi00432a042; KEILIN D, 1951, BIOCHEM J, V49, P88, DOI 10.1042/bj0490088; LEIGH JS, 1975, FEBS LETT, V51, P304, DOI 10.1016/0014-5793(75)80913-6; LEVY HM, 1963, J BIOL CHEM, V238, P3654; Lundblad R.L, 1984, CHEM REAGENTS PROTEI, VI; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; MORISHIMA I, 1978, BIOCHEMISTRY-US, V17, P4384, DOI 10.1021/bi00614a005; MORRISON M, 1976, ANNU REV BIOCHEM, V45, P861, DOI 10.1146/annurev.bi.45.070176.004241; OERTLING WA, 1988, BIOCHEMISTRY-US, V27, P3331, DOI 10.1021/bi00409a032; OVADI J, 1967, ACTA BIOCHIM BIOPHYS, V2, P445; PAUL KG, 1978, ACTA CHEM SCAND B, V32, P395, DOI 10.3891/acta.chem.scand.32b-0395; PENNERHAHN JE, 1986, J AM CHEM SOC, V108, P7819, DOI 10.1021/ja00284a054; POULOS TL, 1980, J BIOL CHEM, V255, P322; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; POULOS TL, 1982, ELECTRON TRANSPORT O, V2, P217; RICARD J, 1974, EUR J BIOCHEM, V44, P359, DOI 10.1111/j.1432-1033.1974.tb03493.x; SAKURADA J, 1986, J BIOL CHEM, V261, P9657; SAMS CF, 1988, BIOCHEMISTRY-US, V27, P2277, DOI 10.1021/bi00407a005; SANTIMONE M, 1975, CAN J BIOCHEM CELL B, V53, P649, DOI 10.1139/o75-090; SAUNDERS BC, 1964, PEROXIDASE; SCHEJTER A, 1976, ARCH BIOCHEM BIOPHYS, V174, P36, DOI 10.1016/0003-9861(76)90321-0; SCHONBAUM GR, 1973, J BIOL CHEM, V248, P502; SCHONBAUM GR, 1971, PROBES STRUCTURE FUN, V2, P533; SHIGA T, 1975, ARCH BIOCHEM BIOPHYS, V167, P469, DOI 10.1016/0003-9861(75)90489-0; SHOEMAKER KR, 1988, PEPTIDES CHEM BIOL, P15; SMULEVICH G, 1991, BIOCHEMISTRY-US, V30, P9546, DOI 10.1021/bi00103a023; STRICKLAND EH, 1968, J BIOL CHEM, V243, P3560; TAKEUCHI M, 1986, J BIOCHEM-TOKYO, V99, P1571, DOI 10.1093/oxfordjournals.jbchem.a135630; Tien M, 1987, NATURE, V326, P520, DOI 10.1038/326520a0; WELINDER KG, 1979, EUR J BIOCHEM, V96, P483, DOI 10.1111/j.1432-1033.1979.tb13061.x; YAMAZAKI I, 1981, MOL CELL BIOCHEM, V40, P143; YAMAZAKI I, 1960, J BIOL CHEM, V235, P2444	60	33	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22292	22298						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226738				2022-12-27	WOS:A1993MD34800019
J	HOOPER, KP; PADMANABHAN, R; EBNER, KE				HOOPER, KP; PADMANABHAN, R; EBNER, KE			EXPRESSION OF THE EXTRACELLULAR DOMAIN OF THE RAT-LIVER PROLACTIN RECEPTOR AND ITS INTERACTION WITH OVINE PROLACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; ESCHERICHIA-COLI; MOLECULAR-CLONING; CELL-LINE; IDENTIFICATION; PURIFICATION; SEQUENCE; NECROSIS; FORMS	A clone of the extracellular domain of the rat liver prolactin receptor was generated by the RNA-based polymerase chain reaction, and the NH2-terminal 210 amino acids were expressed in HeLa cells using a vaccinia virus/T7 hybrid expression system. The protein was isolated from serum-free culture medium directly by chromatography on an ovine prolactin affinity column and yielded approximately 1.5 mg of protein/liter of suspension culture. The extracellular domain of the rat prolactin receptor inhibited the ovine prolactin-dependent mitogenesis of rat lymphoma Nb2 cells with an IC50 of 7.1 pM and bound I-125-labeled ovine prolactin with a K(d) of 1.21 +/- 0.19 nM. In contrast, the binding of the I-125-labeled extracellular domain to ovine prolactin exhibited positive cooperativity with a Hill coefficient of 1.73. High pressure gel filtration chromatography was used to demonstrate the formation of a complex consisting of one molecule of ovine prolactin and two molecules of the extracellular domain of the rat prolactin receptor. Complex formation occurred with human growth hormone, but not with ovine growth hormone, a non-lactogen.	UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, 3901 RAINBOW BLVD, KANSAS CITY, KS 66160 USA	University of Kansas; University of Kansas Medical Center					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018584] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 18584] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALI S, 1991, J BIOL CHEM, V266, P20110; ANDREWS GK, 1987, DEVELOPMENT, V100, P463; BAJPAI A, 1991, BIOCHEM BIOPH RES CO, V180, P1312, DOI 10.1016/S0006-291X(05)81338-5; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; COOKE NE, 1989, ENDOCRINOLOGY, V1, P384; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUAN DSR, 1991, J BIOL CHEM, V266, P413; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; ELROYSTEIN O, 1992, CURRENT PROTOCOLS MO; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P13268; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1990, J BIOL CHEM, V265, P3111; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GOUT PW, 1980, CANCER RES, V40, P2433; GRAY PW, 1990, P NATL ACAD SCI USA, V87, P7380, DOI 10.1073/pnas.87.19.7380; HARRIS KW, 1992, J BIOL CHEM, V267, P15205; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAX I, 1991, J BIOL CHEM, V266, P13828; MALISZEWSKI CR, 1990, J IMMUNOL, V144, P3028; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NECESSARY PC, 1984, J BIOL CHEM, V259, P6942; NECESSARY PC, 1985, MOL CELL ENDOCRINOL, V39, P247, DOI 10.1016/0303-7207(85)90068-1; NIALL HD, 1971, P NATL ACAD SCI USA, V68, P866, DOI 10.1073/pnas.68.4.866; PAUL JI, 1990, J BIOL CHEM, V265, P13074; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; POSTELVINAY MC, 1991, P NATL ACAD SCI USA, V88, P6687, DOI 10.1073/pnas.88.15.6687; PRASAD R, 1980, J BIOL CHEM, V255, P5834; ROZAKISADCOCK M, 1991, J BIOL CHEM, V266, P16472; ROZAKISADCOCK M, 1992, J BIOL CHEM, V267, P7428; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOTT P, 1992, MOL CELL ENDOCRINOL, V89, P47, DOI 10.1016/0303-7207(92)90210-W; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SHIU RPC, 1983, ENDOCRINOLOGY, V113, P159, DOI 10.1210/endo-113-1-159; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; TANAKA M, 1992, BIOCHEM BIOPH RES CO, V188, P490, DOI 10.1016/0006-291X(92)91082-2; VISSAVAJJHALA P, 1990, J BIOL CHEM, V265, P4746; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; WERENSKIOLD AK, 1992, EUR J BIOCHEM, V204, P1041, DOI 10.1111/j.1432-1033.1992.tb16726.x	52	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22347	22352						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226744				2022-12-27	WOS:A1993MD34800026
J	PRASAD, R; KUMAR, A; WIDEN, SG; CASASFINET, JR; WILSON, SH				PRASAD, R; KUMAR, A; WIDEN, SG; CASASFINET, JR; WILSON, SH			IDENTIFICATION OF RESIDUES IN THE SINGLE-STRANDED DNA-BINDING SITE OF THE 8-KDA DOMAIN OF RAT DNA POLYMERASE-BETA BY UV CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; VIRUS REVERSE-TRANSCRIPTASE; ESCHERICHIA-COLI; PRIMER BINDING; DIRECTED MUTAGENESIS; HUMAN-CELLS; PROTEIN; LOCALIZATION; ENZYME; REGION	Rat DNA polymerase beta (beta-pol) is a 39-kDa monomeric protein, organized in two structurally and functionally distinct domains. The 8-kDa NH-2-terminal domain binds single-stranded (ss) DNA, whereas the 31-kDa COOH-terminal domain does not. To facilitate studies on ssDNA binding structure-function relationships of beta-pol, we overexpressed the 8-kDa domain in Escherichia coli, and purified the recombinant protein to homogeneity. Single-stranded nucleic acid binding of the recombinant 8-kDa domain was found to be similar to that previously reported for the 8-kDa fragment prepared by proteolysis of intact beta-pol (Kumar, A., Widen, S. G., Williams, K. R., Kedar, P., Karpel, R. L., and Wilson, S. H. (1990b) J. Biol. Chem. 265, 2124-2131; Casas-Finet, J. R., Kumar, A., Morris, G., Wilson, S. H., and Karpel, R. L. (1991) J. Biol. Chem. 266, 19618-19625). Residues in or near the DNA-binding pocket of the recombinant 8-kDa domain were examined by photochemical cross-linking to [P-32] p(dT)16. Cross-linking was localized to a tryptic fragment spanning residues 28 through 35 and a V8 protease fragment spanning residues 27 through 58. Sequence analysis of the various [P-32]p(dT)16-labeled proteins indicated that Ser30 and His34 were modified by cross-linking to p(dT)16. Therefore, these residues of the ssDNA-binding domain of beta-pol appear to be in close contact with this nucleic acid probe.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,1023 PROFESSIONAL BLDG,H-51,GALVESTON,TX 77555; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC,STRUCT BIOCHEM LAB,FREDERICK,MD 21702	University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293				ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P907, DOI 10.1021/bi00676a006; ANDERSON RS, 1987, GENE, V60, P163, DOI 10.1016/0378-1119(87)90224-1; BARUN F, 1975, BIOCHEMISTRY-US, V14, P558; BASU A, 1992, BIOCHEMISTRY-US, V31, P616, DOI 10.1021/bi00117a045; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAYER GD, 1983, J MOL BIOL, V169, P565, DOI 10.1016/S0022-2836(83)80065-5; CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; CASASFINET JR, 1992, BIOCHEMISTRY-US, V31, P10272, DOI 10.1021/bi00157a014; CLEGHON V, 1992, J BIOL CHEM, V267, P17872; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; COLEMAN JE, 1978, BIOCHEMISTRY-US, V17, P5038, DOI 10.1021/bi00616a028; COLEMAN JE, 1976, BIOCHEMISTRY-US, V15, P5419, DOI 10.1021/bi00670a001; DATE T, 1990, BIOCHEMISTRY-US, V29, P5027, DOI 10.1021/bi00473a005; FARRAR YJK, 1991, BIOCHEMISTRY-US, V30, P3075, DOI 10.1021/bi00226a014; FRY M, 1986, ANIMAL CELL DNA POLY; HARVON A, 1977, BIOCHEMISTRY-US, V16, P5631; HOCKENSMITH JW, 1991, METHOD ENZYMOL, V208, P211; KIM SJ, 1993, IN PRESS J MOL BIOL; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALY P, 1980, BIOCHEMISTRY-US, V19, P4179, DOI 10.1021/bi00559a007; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MERRILL BM, 1984, J BIOL CHEM, V259, P850; MILLER MR, 1982, J BIOL CHEM, V257, P204; PRIGODICH RV, 1986, BIOCHEMISTRY-US, V25, P3666, DOI 10.1021/bi00360a029; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; Sambrook J, 1989, MOL CLONING LABORATO; Shetlar M.D., 1980, PHOTOCHEMICAL AND PHOTOBIOLOGICAL REVIEWS, V5, P105; SMITH CA, 1984, BIOCHEMISTRY-US, V23, P1383, DOI 10.1021/bi00302a008; SOBOL RW, 1991, BIOCHEMISTRY-US, V30, P10623, DOI 10.1021/bi00108a004; TIRUMALAI RS, 1991, BIOCHEMISTRY-US, V30, P6436, DOI 10.1021/bi00240a014; WILLIAMS KR, 1991, METHOD ENZYMOL, V208, P516; WILLIAMS KR, 1987, PROTEIN-STRUCT FUNCT, P45; WILSON S, 1988, BIOCHIM BIOPHYS ACTA, V949, P149, DOI 10.1016/0167-4781(88)90078-4; WILSON SH, 1991, CANCER BIOL BIOSYNTH, P55; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199	40	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22746	22755						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226785				2022-12-27	WOS:A1993MD34800082
J	SUCHER, NJ; BROSE, N; DEITCHER, DL; AWOBULUYI, M; GASIC, GP; BADING, H; CEPKO, CL; GREENBERG, ME; JAHN, R; HEINEMANN, SF; LIPTON, SA				SUCHER, NJ; BROSE, N; DEITCHER, DL; AWOBULUYI, M; GASIC, GP; BADING, H; CEPKO, CL; GREENBERG, ME; JAHN, R; HEINEMANN, SF; LIPTON, SA			EXPRESSION OF ENDOGENOUS NMDAR1 TRANSCRIPTS WITHOUT RECEPTOR PROTEIN SUGGESTS POST-TRANSCRIPTION CONTROL IN PC12-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEOCHROMOCYTOMA PC12 CELLS; RETINAL GANGLION-CELLS; EXCITATORY AMINO-ACIDS; NERVE GROWTH-FACTOR; MESSENGER-RNA; RAT-BRAIN; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; PURKINJE-CELLS; IONIC CURRENTS	Expression of RNA for the NMDAR1 subunit of the N-methyl-D-aspartate receptor was detected by Northern hybridization in both nerve growth factor-differentiated and undifferentiated rat pheochromocytoma (PC12) cells. The NMDA receptor type 1 (NMDAR1) message in PC12 cells was similar in size to that expressed in hippocampal neurons. PC12 cell cDNAs that were amplified by polymerase chain reaction with primers flanking the coding region of NMDAR1 corresponded to the NMDAR1 splice variant NMDA receptor type 1 isoform C (NMDAR1C). Using calcium imaging or patch-clamp recording, no functional NMDA-gated ion channels were found in PC12 cells. A monoclonal antibody against NMDAR1 was developed in order to investigate whether or not NMDAR1 protein was present in PC12 cells. Only trace amounts of NMDAR1 protein were found in native PC 12 cells. However, expression of NMDAR1 protein was detected in PC12 cells that were transfected with an expression vector containing an NMDAR1C clone under control of a cytomegalovirus promoter. These findings suggest that the expression of NMDAR1 protein in PC12 cells may be controlled by post-transcriptional mechanisms. The PC12 cell line may serve as a model system for the study of the transcriptional, post-transcriptional, and translational regulation of NMDAR1. Furthermore, the presence of NMDAR1 RNA in a particular cell type may not necessarily indicate expression of NMDAR1 protein.	HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02215; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02215; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02114; SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,LA JOLLA,CA 92037; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Salk Institute; Howard Hughes Medical Institute; Yale University	SUCHER, NJ (corresponding author), HARVARD UNIV,CHILDRENS HOSP,DEPT NEUROL,CELLULAR & MOLEC NEUROSCI LAB,BOSTON,MA 02115, USA.		Deitcher, David/K-6538-2019	Lipton, Stuart/0000-0002-3490-1259; Sucher, Nikolaus/0000-0001-6233-1612; Jahn, Reinhard/0000-0003-1542-3498; Deitcher, David/0000-0002-8512-8868	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD029587] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [T32EY007110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023021] Funding Source: NIH RePORTER; NEI NIH HHS [T32 EY07110] Funding Source: Medline; NICHD NIH HHS [P01 HD29587] Funding Source: Medline; NINDS NIH HHS [R01 NS23021] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIZENMAN E, 1988, J PHYSIOL-LONDON, V396, P75, DOI 10.1113/jphysiol.1988.sp016951; AUDINAT E, 1990, J PHYSIOL-LONDON, V430, P297, DOI 10.1113/jphysiol.1990.sp018292; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BAEV KV, 1992, NEUROSCIENCE, V46, P925, DOI 10.1016/0306-4522(92)90194-7; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BROSE N, 1990, J BIOL CHEM, V265, P10604; CHAZOT PL, 1992, J NEUROCHEM, V59, P1176, DOI 10.1111/j.1471-4159.1992.tb08364.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUJITA K, 1989, ENVIRON HEALTH PERSP, V80, P127, DOI 10.2307/3430738; GARTHWAITE G, 1987, DEV BRAIN RES, V36, P288, DOI 10.1016/0165-3806(87)90034-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HELLEWELL SB, 1990, BRAIN RES, V527, P244, DOI 10.1016/0006-8993(90)91143-5; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUG MS, 1987, METHOD ENZYMOL, V152, P316; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KUMAR KN, 1991, NATURE, V354, P70, DOI 10.1038/354070a0; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDOUARIN NM, 1981, ANNU REV PHYSIOL, V43, P653, DOI 10.1146/annurev.ph.43.030181.003253; LIEBHABER SA, 1992, J MOL BIOL, V226, P609, DOI 10.1016/0022-2836(92)90619-U; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; LOVINGER DM, 1988, NEUROSCI LETT, V94, P314, DOI 10.1016/0304-3940(88)90037-7; MANDEL G, 1988, P NATL ACAD SCI USA, V85, P924, DOI 10.1073/pnas.85.3.924; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; ROGERS SW, 1991, J NEUROSCI, V11, P2713; ROSEMUND C, 1992, J NEUROPHYSIOL, V68, P1901, DOI 10.1152/jn.1992.68.5.1901; Sambrook J, 1989, MOL CLONING LABORATO; SCHUBERT D, 1992, P NATL ACAD SCI USA, V89, P8264, DOI 10.1073/pnas.89.17.8264; SHIGEMOTO R, 1992, NEUROSCI LETT, V144, P229, DOI 10.1016/0304-3940(92)90756-W; SUCHER NJ, 1991, J NEUROSCI RES, V30, P582, DOI 10.1002/jnr.490300316; SUCHER NJ, 1991, NEUROSCIENCE, V43, P135, DOI 10.1016/0306-4522(91)90423-L; SUCHER NJ, 1990, BRAIN RES, V533, P248, DOI 10.1016/0006-8993(90)91346-I; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; USOWICZ MM, 1989, NATURE, V339, P380, DOI 10.1038/339380a0; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A	59	146	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22299	22304						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226739				2022-12-27	WOS:A1993MD34800020
J	YU, X; HAO, LN; INESI, G				YU, X; HAO, LN; INESI, G			A PK CHANGE OF ACIDIC RESIDUES CONTRIBUTES TO CATION COUNTERTRANSPORT IN THE CA-ATPASE OF SARCOPLASMIC-RETICULUM - ROLE OF H+ IN CA2+-ATPASE COUNTERTRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECONSTITUTED PROTEOLIPOSOMES; CALCIUM-TRANSPORT; PUMP CURRENT; CA-2+-ATPASE; VESICLES; CA-2+; ELECTROGENICITY; BINDING; PERMEABILITY; MEMBRANES	Proteoliposomal vesicles reconstituted with sarcoplasmic reticulum ATPase and exogenous lipids sustain ATP-dependent Ca2+ uptake and H+ ejection, as well as net charge displacement by Ca2+. We have studied the effect of lumenal (inner) and medium (extravesicular) pH variations on the countertransport ratios of H+ and Ca2+. We find that the Ca2+/H+ molar ratio is approximately 1 when the lumenal and medium pH is near neutrality, but changes with a specific pattern when the medium pH is varied in the presence of a constant lumenal pH and when the lumenal pH is varied in the presence of a constant medium pH. Empirical analysis of the experimental data shows that the apparent pK of the residue(s) releasing H+ into the medium is approximately 6.1, whereas the apparent pK of the residue(s) binding lumenal H+ is approximately 7.7. Assuming that the same acidic residues are involved in H+ and Ca2+ countertransport, our findings suggest a lower affinity for H+ in their outward orientation (prevalent in the ground state of the enzyme) and a higher affinity for H+ in lumenal orientation (prevalent in the phosphorylated state of the enzyme). Cyclic pK changes, coupled to ATP utilization, promote cation exchange, Ca2+ uptake, and H+ ejection by the vesicles. The stoichiometry of countertransport and net charge displacement is matched by a corresponding electrogenic behavior. A calculation of voltage development related to initial rates of charge transfer (dV/dt = (dQ/dt)/C-m) is given as a corrective replacement of a previous steady state calculation.			YU, X (corresponding author), UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201, USA.							AKERMAN KEO, 1979, FEBS LETT, V100, P291, DOI 10.1016/0014-5793(79)80354-3; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CORNELIUS F, 1991, FEBS LETT, V284, P46, DOI 10.1016/0014-5793(91)80758-U; DEMEIS L, 1982, J BIOL CHEM, V257, P1289; EISENRAUCH A, 1990, FEBS LETT, V268, P152, DOI 10.1016/0014-5793(90)80996-V; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; GARRET C, 1981, FEBS LETT, V136, P216, DOI 10.1016/0014-5793(81)80621-7; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1990, J MEMBRANE BIOL, V116, P1, DOI 10.1007/BF01871666; INESI G, 1994, CELL PHYSIOL BIOCHEM, V4, P135, DOI 10.1159/000154717; LEVY D, 1990, J BIOL CHEM, V265, P19524; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADEIRA VMC, 1978, ARCH BIOCHEM BIOPHYS, V185, P316, DOI 10.1016/0003-9861(78)90173-X; MEISSNER G, 1980, J BIOL CHEM, V255, P6814; MEISSNER G, 1981, J BIOL CHEM, V256, P636; MORIMOTO T, 1986, J BIOCHEM-TOKYO, V99, P1071, DOI 10.1093/oxfordjournals.jbchem.a135571; MURPHY AJ, 1992, J BIOL CHEM, V267, P16990; NISHIE I, 1990, J BIOL CHEM, V265, P2488; POSSMEYER EF, 1994, J BIOL CHEM, V269, P1896; RIGAUD JL, 1983, BIOCHEM BIOPH RES CO, V111, P373, DOI 10.1016/0006-291X(83)90316-9; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; SUMBILLA C, 1991, J BIOL CHEM, V266, P12682; UENO T, 1981, J BIOCHEM-TOKYO, V89, P1247; YAMAGUCHI M, 1985, J BIOL CHEM, V260, P4896; YU X, 1993, BIOPHYS J, V64, P1232, DOI 10.1016/S0006-3495(93)81489-9; ZIMNIAK P, 1978, J BIOL CHEM, V253, P4631	29	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16656	16661						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206985				2022-12-27	WOS:A1994NR29600024
J	CHIU, MH; TAMURA, T; WADHWA, MS; RICE, KG				CHIU, MH; TAMURA, T; WADHWA, MS; RICE, KG			IN-VIVO TARGETING FUNCTION OF N-LINKED OLIGOSACCHARIDES WITH TERMINATING GALACTOSE AND N-ACETYLGALACTOSAMINE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASIALOGLYCOPROTEIN RECEPTOR; TRIANTENNARY GLYCOPEPTIDE; BOVINE FETUIN; RAT-LIVER; BINDING; GLYCOPROTEINS; HEPATOCYTES; RABBIT; RECOGNITION; LECTIN	N-Linked biantennary, triantennary, and core fucosylated biantennary oligosaccharides were isolated from animal glycoproteins and derivatized at their reducing end with Boc-tyrosine. The terminal Gal residues were enzymatically removed and replaced with GalNAc. Tyrosinamide-oligosaccharides were radioiodinated and administered intravenously to mice. Pharmacokinetic and biodistribution studies revealed structure depend ent differences in the steady-state volume of distribution, total body clearance rate, and targeting efficiency. Tyrosinamide-oligosaccharides were found to resist metabolism relative to a natural triantennary glycopeptide which was rapidly degraded in vivo. Triantennary oligosaccharides containing terminal Gal or GalNAc targeted the liver efficiently whereas biantennary oligosaccharides containing terminal Gal residues and differing only in their core fucosylation avoided recognition by the asialoglycoprotein receptor and were cleared unmetabolized by renal filtration. In contrast, biantennary oligosaccharides containing terminal GalNAc residues targeted the liver with much greater efficiency than Gal-terminated triantennary oligosaccharide. Core fucosylation reduced the metabolism rate of tyrosinamide-biantennary in the liver. The results establish the utility of tyrosinamide-oligosaccharides as probes to analyze the ligand specificity of mammalian lectins in vivo and demonstrate that a GalNAc-termi nated biantennary is a potent ligand for the asialoglycoprotein receptor.	OHIO STATE UNIV, DIV PHARMACEUT & PHARMACEUT CHEM, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University					NIDDK NIH HHS [DK45742] Funding Source: Medline; NIGMS NIH HHS [GM48048] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045742] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BAENZIGER JU, 1980, CELL, V22, P611, DOI 10.1016/0092-8674(80)90371-2; BENET LZ, 1979, J PHARM SCI, V68, P1071, DOI 10.1002/jps.2600680845; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; GROSS V, 1987, EUR J BIOCHEM, V162, P83, DOI 10.1111/j.1432-1033.1987.tb10545.x; HUDGIN RL, 1974, J BIOL CHEM, V249, P5536; KEMMENOE BH, 1987, CANCER RES, V47, P1135; KOJIMA S, 1990, BIOL CHEM H-S, V371, P331, DOI 10.1515/bchm3.1990.371.1.331; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; LEE RT, 1987, GLYCOCONJUGATE J, V4, P317, DOI 10.1007/BF01048365; LEE YC, 1983, J BIOL CHEM, V258, P199; LEE YC, 1989, CIBA F S, V145, P80; LIN YC, 1992, J AM CHEM SOC, V114, P5452, DOI 10.1021/ja00039a082; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; PALCIC M M, 1991, Glycobiology, V1, P205, DOI 10.1093/glycob/1.2.205; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; REGOECZI E, 1980, ARCH BIOCHEM BIOPHYS, V205, P76, DOI 10.1016/0003-9861(80)90085-5; RICE KG, 1990, J BIOL CHEM, V265, P18429; RICE KG, 1990, ANAL BIOCHEM, V184, P249, DOI 10.1016/0003-2697(90)90676-Z; RICE KG, 1990, J BIOL CHEM, V265, P18423; RIEGELMAN S, 1980, J PHARMACOKINET BIOP, V8, P509, DOI 10.1007/BF01059549; SILVA M, 1994, ARCH BIOCHEM BIOPHYS, V312, P151; SMITH PL, 1993, J BIOL CHEM, V268, P795; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; TAMURA T, 1994, ANAL BIOCHEM, V216, P335, DOI 10.1006/abio.1994.1050; TOMIYA N, 1993, J BIOL CHEM, V268, P113; TOWNSEND RR, 1986, BIOCHEMISTRY-US, V25, P5716, DOI 10.1021/bi00367a055; VANLENTEN L, 1972, J BIOL CHEM, V247, P4633; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WAGNER J. G., 1975, FUNDAMENTALS CLIN PH, Vfirst, P57	31	75	84	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16195	16202						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206921				2022-12-27	WOS:A1994NQ72900039
J	MORRIS, TW; REED, KE; CRONAN, JE				MORRIS, TW; REED, KE; CRONAN, JE			IDENTIFICATION OF THE GENE ENCODING LIPOATE-PROTEIN LIGASE-A OF ESCHERICHIA-COLI - MOLECULAR-CLONING AND CHARACTERIZATION OF THE LPLA GENE AND GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 DNA-POLYMERASE; PYRUVATE-DEHYDROGENASE COMPLEX; GLYCINE CLEAVAGE SYSTEM; LIPOIC ACID METABOLISM; BIOTIN BIOSYNTHESIS; BINDING DOMAINS; RNA-POLYMERASE; EXPRESSION; SEQUENCE; LIPOYLATION	R(+)-Lipoic acid is a cofactor required for function of the alpha-keto acid dehydrogenase and glycine cleavage enzyme complexes. The naturally occurring form of lipoate is attached by amide linkage to the epsilon-amino group of a specific lysine residue within conserved lipoate-accepting protein domains. Lipoate-protein ligase(s) catalyze the formation of this amide bond between lipoyl groups and specific apoproteins. We report the isolation of the lplA gene which encodes an Escherichia coli lipoate-protein ligase. Strains with lplA null mutations transport lipoic acid normally but have severe defects in the incorporation and utilization of exogenously supplied lipoic acid and lipoic acid analogs. These strains are also highly resistant to selenolipoate (a growth-inhibiting lipoate analog) and contain no detectable lipoate-protein Ligase activity in cell extracts. The lplA gene has been cloned, sequenced, and physically mapped to min 99.6 (4657 kilobases) of the E. coli chromosome. Upon over expression, the 38-kDa lplA gene product was purified to homogeneity and shown to have a mass, N-terminal sequence and amino acid composition consistent with the deduced 337 residue primary sequence. Enzyme assays show that purified LplA catalyzes the ATP-dependent attachment of [S-35]lipoic acid to apoprotein, thus confirming that lplA encodes lipoate-protein ligase A. Analysis of lplA null mutants also indicates the existence of a second (lplA-independent) lipoyl-ligase enzyme in E. coli, This is the first identification of a lipoate ligase gene and the first analysis of a purified lipoate ligase enzyme.	UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			Cronan, John/V-6626-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015650, R01AI015650] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15650] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTT J, 1993, BIOCHEMISTRY-US, V32, P9649, DOI 10.1021/bi00088a017; ALI ST, 1990, MOL MICROBIOL, V4, P943, DOI 10.1111/j.1365-2958.1990.tb00667.x; BARKER DF, 1980, J BACTERIOL, V143, P789, DOI 10.1128/JB.143.2.789-800.1980; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BROOKFIELD DE, 1991, FEBS LETT, V295, P13, DOI 10.1016/0014-5793(91)81373-G; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CARAFA YD, 1990, J MOL BIOL, V216, P835, DOI 10.1016/S0022-2836(99)80005-9; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; CRONAN JE, 1989, CELL, V58, P427, DOI 10.1016/0092-8674(89)90421-2; Davis R., 1980, ADV BACTERIAL GENETI; DAVIS TN, 1982, VIROLOGY, V120, P287, DOI 10.1016/0042-6822(82)90031-9; DUPRE S, 1980, ARCH BIOCHEM BIOPHYS, V202, P361, DOI 10.1016/0003-9861(80)90438-5; FUJIWARA K, 1992, J BIOL CHEM, V267, P20011; GRANA D, 1988, GENETICS, V120, P319; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; GUEST JR, 1985, J MOL BIOL, V185, P743, DOI 10.1016/0022-2836(85)90059-2; HAYDEN MA, 1993, BIOCHEMISTRY-US, V32, P3778, DOI 10.1021/bi00065a033; HERBERT AA, 1975, ARCH MICROBIOL, V106, P259, DOI 10.1007/BF00446532; HIPPS DS, 1992, BIOCHEM J, V283, P665, DOI 10.1042/bj2830665; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; ITZHAKI RF, 1964, ANAL BIOCHEM, V9, P401, DOI 10.1016/0003-2697(64)90200-3; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; Miller J.H., 1972, EXPT MOL GENETICS; MITRA SK, 1965, J BIOL CHEM, V240, P4072; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; NEUWALD AF, 1985, NUCLEIC ACIDS RES, V13, P7025, DOI 10.1093/nar/13.19.7025; NEUWALD AF, 1989, GENE, V82, P219, DOI 10.1016/0378-1119(89)90047-4; NOLL KM, 1988, J BACTERIOL, V170, P4315, DOI 10.1128/jb.170.9.4315-4321.1988; OH YK, 1969, CAN J MICROBIOL, V15, P183, DOI 10.1139/m69-030; PACKMAN LC, 1991, BIOCHEM J, V277, P153, DOI 10.1042/bj2770153; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; RAWLINGS M, 1988, FASEB J, V2, pA1559; REED KE, 1994, P NATL ACAD SCI USA, V91, P3720, DOI 10.1073/pnas.91.9.3720; REED KE, 1993, J BACTERIOL, V175, P1325, DOI 10.1128/JB.175.5.1325-1336.1993; REED LJ, 1958, J BIOL CHEM, V232, P123; ROEDER W, 1979, MOL GEN GENET, V176, P361, DOI 10.1007/BF00333098; Sambrook J, 1989, MOL CLONING LABORATO; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TSUNODA JN, 1967, ARCH BIOCHEM BIOPHYS, V118, P395, DOI 10.1016/0003-9861(67)90366-9; VANDENBOOM T, 1990, VIROLOGY, V177, P11; VANDENBOOM TJ, 1991, J BACTERIOL, V173, P6411, DOI 10.1128/jb.173.20.6411-6420.1991; Watson J. D., 1987, MOL BIOL GENE; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; WILSON K, 1987, CURRENT PROTOCOLS MO, V1; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257	50	143	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16091	16100						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206909				2022-12-27	WOS:A1994NQ72900024
J	ABDELLATIF, M; MACLELLAN, WR; SCHNEIDER, MD				ABDELLATIF, M; MACLELLAN, WR; SCHNEIDER, MD			P21 RAS AS A GOVERNOR OF GLOBAL GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CARDIAC-MUSCLE; GROWTH-FACTORS; SIGNAL TRANSDUCTION; BETA-GALACTOSIDASE; BINDING PROTEIN; MAMMALIAN-CELLS; TRANSCRIPTION; P53; INDUCTION; RECEPTOR	The molecular mechanisms for signaling by receptor serine/threonine kinases are incompletely understood. To test the potential involvement of p21 H-Ras proteins in signal transduction for type beta transforming growth factors (TGF beta), TGF beta-responsive and constitutive reporter genes were cotransfected into cardiac myocytes and mink lung epithelial cells, with dominant inhibitory (Asn-17) or activated (Arg-12) Ras expression vectors. Asn-17 Ras inhibited both TGF beta-dependent and basal expression of inducible promoters (skeletal alpha-actin and plasminogen activator inhibitor-1), with equivalent dose-response relations. All seven reporter constructs were comparably sensitive to down-regulation by Asn-17 Ras, including those driven by nominally constitutive viral control regions or a TATA-less initiator element. Ah constructs were up-regulated by Arg-12 Ras more variably. Wild-type Ras had intermediate effects and could rescue a minimal thymidine kinase promoter from inhibition by dominant negative Ras. Thus, a Ras-dependent event is required for efficient expression of an unexpectedly global or inclusive set of genes.	BAYLOR COLL MED,DEPT MED,MOLEC CARDIOL UNIT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007706, R01HL039141, R01HL047567] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL39141, T32 HL07706, R01 HL47567] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOGUSKI MS, 1993, NATURE, V366, P943; BRAND T, 1993, J BIOL CHEM, V268, P11500; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; HAN M, 1991, GENE DEV, V5, P2188, DOI 10.1101/gad.5.12a.2188; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SPANDIDOS DA, 1985, BIOSCIENCE REP, V5, P1035, DOI 10.1007/BF01119624; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; THORBURN A, 1993, J BIOL CHEM, V268, P2244; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WOOD KV, 1991, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P11; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	36	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15423	15426						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195182				2022-12-27	WOS:A1994NP51300007
J	KRISHNAN, V; WANG, XH; SAFE, S				KRISHNAN, V; WANG, XH; SAFE, S			ESTROGEN RECEPTOR-SP1 COMPLEXES MEDIATE ESTROGEN-INDUCED CATHEPSIN-D GENE-EXPRESSION IN MCF-7 HUMAN BREAST-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; EXTRACELLULAR-MATRIX; RESPONSIVE ELEMENT; FLANKING REGION; REGULATED RNAS; GROWTH-FACTORS; MESSENGER-RNA; TAMOXIFEN; MECHANISM; 52-KILODALTON	Cathepsin D is an estrogen (17 beta-estradiol, E(2))-inducible lysosomal protease. A putative estrogen receptor (ER)-Sp1-like sequence (GGGCGG(n)(23)ACGGG) has been identified in the non-coding strand of the cathepsin D promoter (-199 to -165), and electromobility shift assays of nuclear extracts from MCF-7 and HeLa cells confirm that both the ER and Sp1 protein bind to P-32-labeled ER/Sp1 oligo. For example, nuclear extracts from MCF-7 cells bind to the P-32-labeled ER/Sp1 oligo; however, ER/ Sp1 binding can be decreased by selective competition with excess unlabeled estrogen responsive element and Sp1 oligos, immunodepletion with ER or Sp1 antibodies, and by treating cells with ICI 164,384, an antiestrogen which inhibits formation of ER homodimer. Moreover, E(2)-induced chloramphenicol acetyltransferase (CAT) activity in MCF-7 cells cotransfected with a human estrogen receptor expression plasmid and a plasmid containing an ER/Sp1 sequence cloned upstream to a thymidine kinase promoter and a CAT reporter. In cotreatment studies, ICI 164,384 inhibited E(2)-induced CAT activity. In contrast, E(2) did not induce CAT activity in MCF-7 cells transfected with plasmids containing mutations in the ER or Sp1 segments of the ER/Sp1 oligo, thus confirming that both cognate binding sites are required for estrogen responsiveness.	TEXAS A&M UNIV, DEPT VET PHYSIOL & PHARMACOL, COLLEGE STN, TX 77843 USA	Texas A&M University System; Texas A&M University College Station					NIEHS NIH HHS [ES04176] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004176] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIOZZO P, 1988, CANCER RES, V48, P3688; CAVAILLES V, 1988, NUCLEIC ACIDS RES, V16, P1903, DOI 10.1093/nar/16.5.1903; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CAVAILLES V, 1991, BIOCHEM BIOPH RES CO, V174, P816, DOI 10.1016/0006-291X(91)91491-T; CAVAILLES V, 1993, P NATL ACAD SCI USA, V90, P203, DOI 10.1073/pnas.90.1.203; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; DENISON MS, 1990, MOL CELL ENDOCRINOL, V69, P51, DOI 10.1016/0303-7207(90)90088-P; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; DICKSON RB, 1986, CANCER SURV, V5, P617; DUBIK D, 1992, ONCOGENE, V7, P1587; JOHNSON MD, 1993, CANCER RES, V53, P873; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUTE TE, 1992, CANCER RES, V52, P5198; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; LYKKESFELDT AE, 1992, ACTA ONCOL, V31, P131, DOI 10.3109/02841869209088892; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MAY FEB, 1987, J BIOL CHEM, V262, P15894; MONTCOURRIER P, 1990, CANCER RES, V50, P6045; MORISSET M, 1986, ENDOCRINOLOGY, V119, P2773, DOI 10.1210/endo-119-6-2773; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDECKER B, 1991, DNA CELL BIOL, V10, P423, DOI 10.1089/dna.1991.10.423; ROCHEFORT H, 1990, BREAST CANCER RES TR, V16, P3, DOI 10.1007/BF01806570; ROCHEFORT H, 1992, EUR J CANCER, V28A, P1780, DOI 10.1016/0959-8049(92)90003-K; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SPYRATOS F, 1989, LANCET, V2, P1115; TANDON AK, 1990, NEW ENGL J MED, V322, P297, DOI 10.1056/NEJM199002013220504; THORPE SM, 1989, CANCER RES, V49, P6008; WAKELING AE, 1991, REGULATORY MECHANISM, P239; WANG X, 1993, MOL CELL ENDOCRINOL, V96, P159, DOI 10.1016/0303-7207(93)90106-T; WESTLEY B, 1980, CELL, V20, P353, DOI 10.1016/0092-8674(80)90621-2; WESTLEY B, 1984, J BIOL CHEM, V259, P30; WESTLEY BR, 1989, J STEROID BIOCHEM, V32, P365, DOI 10.1016/0022-4731(89)90208-2; WESTLEY BR, 1987, NUCLEIC ACIDS RES, V15, P3773, DOI 10.1093/nar/15.9.3773; WUPENG XS, 1992, MOL ENDOCRINOL, V6, P231, DOI 10.1210/me.6.2.231	37	204	211	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15912	15917						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195246				2022-12-27	WOS:A1994NP51300079
J	MARTENS, JA; BRANDL, CJ				MARTENS, JA; BRANDL, CJ			GCN4P ACTIVATION OF THE YEAST TRP3 GENE IS ENHANCED BY ABF1P AND USES A SUBOPTIMAL TATA ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN GENES; DNA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; CONSTITUTIVE TRANSCRIPTION; SATURATION MUTAGENESIS; RESPONSIVE ELEMENTS; NUCLEOTIDE-SEQUENCE; HIS4 TRANSCRIPTION; UPSTREAM; SITE	Transcription of the TRP3 gene of Saccharomyces cerevisiae is regulated by GCN4p from a position proximal to the transcriptional initiation sites. The promoter's apparent lack of a conventional TATA element sequence has led it to be used as a model for TATA-less promoters. Through mutational analysis of the TRP3 promoter, we have identified two additional regulatory elements required for expression. The first, located 57 base pairs (bp) upstream of the GCN4p binding site, binds ABF1p in vitro. The ABF1p binding site was required for maximal levels of GCN4p-activated transcription in vivo; however, the -fold activation by GCN4p was not altered by ABF1p. The second element, positioned 23 bp downstream of the GCN4p binding site, contained the TATAlike sequence, TATTAA. This element was required for both basal and activated expression and almost certainly functions as a TATA-binding protein interaction site. Mutations that improved its TATA character for native or an altered specificity mutant of TATA-binding protein correspondingly improved its function. Interestingly, basal expression induced by ABF1p was virtually unchanged in the presence of point mutations in the TATTAA element. Furthermore, unlike the case for HIS3 where only a limited subset of TATA-like sequences can activate transcription in conjunction with GCN4p, many divergent TATA-like sequences allowed GCN4p activation of TRP3. We suggest that the apparent promoter specific use of these TATA elements by GCN4p results from ABF1p amplifying the GCN4p-induced expression to a detectable level.	UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5C1,ON,CANADA	Western University (University of Western Ontario)								AEBI M, 1984, CURR GENET, V8, P165, DOI 10.1007/BF00417812; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; BRAM RJ, 1987, MOL CELL BIOL, V7, P403, DOI 10.1128/MCB.7.1.403; BRANDL CJ, 1990, MOL CELL BIOL, V10, P4256, DOI 10.1128/MCB.10.8.4256; BRANDL CJ, 1992, J BIOL CHEM, V267, P20943; BRAUS GH, 1991, MICROBIOL REV, V55, P349, DOI 10.1128/MMBR.55.3.349-370.1991; BRINDLE PK, 1990, MOL CELL BIOL, V10, P4872, DOI 10.1128/MCB.10.9.4872; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHAMBERS A, 1990, NUCLEIC ACIDS RES, V18, P5393, DOI 10.1093/nar/18.18.5393; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CHEN W, 1989, EMBO J, V8, P261, DOI 10.1002/j.1460-2075.1989.tb03372.x; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHEN W, 1985, EMBO J, V4, P3273, DOI 10.1002/j.1460-2075.1985.tb04077.x; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DELLASETA F, 1990, MOL CELL BIOL, V10, P2437, DOI 10.1128/MCB.10.5.2437; DEVLIN C, 1991, MOL CELL BIOL, V11, P3642, DOI 10.1128/MCB.11.7.3642; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DORSMAN JC, 1989, NUCLEIC ACIDS RES, V17, P4917, DOI 10.1093/nar/17.13.4917; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FURTERGRAVES EM, 1990, MOL GEN GENET, V223, P407, DOI 10.1007/BF00264447; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HALFTER H, 1989, EMBO J, V8, P4265, DOI 10.1002/j.1460-2075.1989.tb08612.x; HAMIL KG, 1988, MOL CELL BIOL, V8, P4328, DOI 10.1128/MCB.8.10.4328; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; KIM S, 1986, MOL CELL BIOL, V6, P4251, DOI 10.1128/MCB.6.12.4251; KLOPOTOW.T, 1965, ARCH BIOCHEM BIOPHYS, V112, P562, DOI 10.1016/0003-9861(65)90096-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MAHADEVAN S, 1990, MOL CELL BIOL, V10, P4447, DOI 10.1128/MCB.10.9.4447; MIOZZARI G, 1978, J BACTERIOL, V134, P48, DOI 10.1128/JB.134.1.48-59.1978; MORROW BE, 1989, J BIOL CHEM, V264, P9061; MOSCH HU, 1990, EMBO J, V9, P2951, DOI 10.1002/j.1460-2075.1990.tb07487.x; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; NISHIZAWA M, 1989, MOL CELL BIOL, V9, P442, DOI 10.1128/MCB.9.2.442; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; REMACLE JE, 1992, MOL CELL BIOL, V12, P5516, DOI 10.1128/MCB.12.12.5516; Sambrook J, 1989, MOL CLONING LABORATO; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SCOTT EW, 1990, NUCLEIC ACIDS RES, V18, P7099, DOI 10.1093/nar/18.23.7099; SCOTT EW, 1993, MOL CELL BIOL, V13, P543, DOI 10.1128/MCB.13.1.543; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SILVE S, 1992, MOL CELL BIOL, V12, P4197, DOI 10.1128/MCB.12.9.4197; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; STRUHL K, 1982, NATURE, V300, P284, DOI 10.1038/300284a0; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TRAWICK JD, 1992, MOL CELL BIOL, V12, P2302, DOI 10.1128/MCB.12.5.2302; TSCHUMPER G, 1980, GENE, V10, P157, DOI 10.1016/0378-1119(80)90133-X; VIGNAIS ML, 1987, EMBO J, V6, P1451, DOI 10.1002/j.1460-2075.1987.tb02386.x; WALKER SS, 1989, MOL CELL BIOL, V9, P2914, DOI 10.1128/MCB.9.7.2914; WANG HM, 1990, MOL CELL BIOL, V10, P1743, DOI 10.1128/MCB.10.4.1743; WILLETT CE, 1993, MOL CELL BIOL, V13, P2623, DOI 10.1128/MCB.13.4.2623; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WU AL, 1993, J BIOL CHEM, V268, P18850; ZALKIN H, 1984, J BIOL CHEM, V259, P3985	62	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15661	15667						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195216				2022-12-27	WOS:A1994NP51300044
J	MARCHAND, P; TANG, J; BOND, JS				MARCHAND, P; TANG, J; BOND, JS			MEMBRANE ASSOCIATION AND OLIGOMERIC ORGANIZATION OF THE ALPHA-SUBUNIT AND BETA-SUBUNIT OF MOUSE MEPRIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL LOCALIZATION; COS-1 CELLS; EXPRESSION; KIDNEY; HYDROLASE; PROTEINS; CLONING; RECEPTORS; RELEASE; ENZYME	Meprins are oligomeric cell surface metalloproteinases of the ''astacin family.'' They consist of two types of subunits (alpha and beta), which are evolutionarily related and whose cDNA sequences predict a similar domain structure. The present work shows that reducing agents solubilized meprin alpha subunits (approximately 90%), but not beta subunits, from mouse kidney brush border membranes. In addition, immunoblotting of membranes or purified meprins with an antibody raised to the alpha subunit epidermal growth factor like domain, predicted to be near the COOH terminus from the cDNA-deduced amino acid sequence, indicated that this domain is not present in the mature alpha subunit. By contrast, an epitope predicted to be near the COOH terminus of the beta subunit was present in the mature form of beta. When meprins were solubilized from brush border membranes by papain, the size of the alpha subunit (approximately 90 kDa) did not change, while the beta subunit decreased from 110 to 90 kDa with concomitant loss of the COOH-terminal epitope. These data indicate that beta is a type I transmembrane protein, while alpha does not transverse the membrane and its association is dependent on disulfide bonds. The oligomeric organization of purified meprin A (EC 3.4.24.18), examined by sedimentation equilibrium analysis and native gradient gel electrophoresis, is that of disulfide-bridged dimers which aggregate noncovalently to form higher molecular weight complexes, predominantly tetramers. Western blotting of ICR kidney brush border membrane proteins identified alpha(2) homodimers and alpha beta heterodimers. Treatment of mouse or rat kidney brush border membranes with 7 M urea solubilized alpha(2), but not alpha beta dimers. Thus, the mature alpha subunit exists in alpha(2) and alpha beta disulfide linked dimers which form tetramers, and the alpha(2) homodimers associate with the membrane through noncovalent interactions with alpha beta.	PENN STATE UNIV,COLL MED,DEPT BIOCHEM & MOLEC BIOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NIDDK NIH HHS [DK 19691] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019691, R37DK019691, R56DK019691] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITHAL HN, 1988, J IMMUNOL METHODS, V112, P62; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BELDENT V, 1993, J BIOL CHEM, V268, P26428; BUTLER PE, 1988, J BIOL CHEM, V263, P13419; BUTLER PE, 1989, PROTEOLYTIC ENZYMES, P193; CORBEIL D, 1993, FEBS LETT, V335, P361, DOI 10.1016/0014-5793(93)80420-Y; COTTON RGH, 1978, EUR J BIOCHEM, V83, P319, DOI 10.1111/j.1432-1033.1978.tb12097.x; DUMERMUTH E, 1993, FEBS LETT, V335, P367, DOI 10.1016/0014-5793(93)80421-P; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; GORBEA CM, 1993, J BIOL CHEM, V268, P21035; GORBEA CM, 1991, ARCH BIOCHEM BIOPHYS, V290, P549, DOI 10.1016/0003-9861(91)90580-C; GORBEA CM, IN PRESS MAMMALIAN B; GRUNBERG J, 1993, FEBS LETT, V335, P376, DOI 10.1016/0014-5793(93)80422-Q; HALL JL, 1993, ARCH BIOCHEM BIOPHYS, V307, P73, DOI 10.1006/abbi.1993.1562; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; JIANG WP, 1993, J BIOL CHEM, V268, P10380; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JOHNSON GD, 1994, J BIOL CHEM, V269, P7682; JOHNSON GD, 1992, J BIOL CHEM, V267, P13505; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; NYKJAER A, 1994, J IMMUNOL, V152, P505; SIM RB, 1993, METHOD ENZYMOL, V223, P13; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; SOJAR HT, 1987, METHOD ENZYMOL, V138, P341; STERCHI EE, 1988, ARCH BIOCHEM BIOPHYS, V265, P105, DOI 10.1016/0003-9861(88)90376-1; SUZUKI S, 1986, P NATL ACAD SCI USA, V83, P8614, DOI 10.1073/pnas.83.22.8614; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115	29	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15388	15393						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195177				2022-12-27	WOS:A1994NP73800079
J	OHNUMA, S; SUZUKI, M; NISHINO, T				OHNUMA, S; SUZUKI, M; NISHINO, T			ARCHAEBACTERIAL ETHER-LINKED LIPID BIOSYNTHETIC GENE - EXPRESSION CLONING, SEQUENCING, AND CHARACTERIZATION OF GERANYLGERANYL-DIPHOSPHATE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SUBUNITS CONTAIN; C-TERMINAL CYSTEINE; SULFOLOBUS-ACIDOCALDARIUS; ESCHERICHIA-COLI; PYROPHOSPHATE SYNTHETASE; HALOBACTERIAL GLYCOSAMINOGLYCAN; SACCHAROMYCES-CEREVISIAE; ISOPRENOID MODIFICATION; NUCLEOTIDE-SEQUENCE; METHYL-ESTER	Archaebacterial Sulfolobus acidocaldarius geranylgeranyl-diphosphate (GGPP) synthase (EC 2.5.1.29) catalyzes consecutive condensations of isopentenyl diphosphate with allylic diphosphates to produce GGPP which is the important precursor of archaebacterial ether-linked lipids. We developed an expression screening method for cloning the GGPP synthase gene, which utilizes the carotenoid biosynthesis genes of Erwinia uredovora to visualize a clone expressing GGPP synthase, and then screened a genomic DNA library from S. acidocaldarius for the GGPP synthase gene by using this method. Positive clones were shown to contain GGPP synthase gene by the use of an in vitro assay. Extracts from Escherichia coli transformants catalyzed the condensation of isopentenyl diphosphate with farnesyl diphosphate (FPP) to produce (all-E)-GGPP. The nucleotide sequence of the 2.3-kilobase HindIII fragment of the cloned fragment was determined. This sequence specifies two open reading frames, ORF-1 and ORF-2. ORF-1 encodes GGPP synthase with the expected molecular weight of 36,873, and ORF-2 encodes a protein with homology for UDP-N-acetylglucosamine-dolichyl phosphate N-acetylglucosaminephosphotransferase. The cloned GGPP synthase was partially purified with several chromatographies after heat treatment of cell free extract. This enzyme is extremely thermostable and has an optimal pH at 5.8. Dimethylallyl diphosphate, geranyl diphosphate, and (all-E)-FPP are, in decreasing order of activity, acceptable as allylic substrates to produce (all-E)-GGPP. When dimethylallyl diphosphate or geranyl diphosphate are the allylic substrates, a significant amount of mixture of the products is shorter than GGPP. (2Z,6E)-FPP is not a substrate. This enzyme recognizes the E-configuration of allylic substrate.	TOHOKU UNIV, DEPT BIOCHEM & ENGN, AOBA KU, SENDAI, MIYAGI 980, JAPAN	Tohoku University				Ohnuma, Shin-ichi/0000-0002-3305-5126				ADAMSON P, 1992, J BIOL CHEM, V267, P20033; ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BECKLER GS, 1986, MOL GEN GENET, V204, P133, DOI 10.1007/BF00330200; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CUE D, 1985, P NATL ACAD SCI USA, V82, P4207, DOI 10.1073/pnas.82.12.4207; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; INATOMI K, 1983, CHEM LETT, P1191, DOI 10.1246/cl.1983.1191; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KONISHI J, 1987, J BIOCHEM, V102, P1379, DOI 10.1093/oxfordjournals.jbchem.a122184; KOYAMA T, 1985, J BIOCHEM, V98, P449, DOI 10.1093/oxfordjournals.jbchem.a135299; KUNTZ M, 1992, PLANT J, V2, P25; LECHNER J, 1985, J BIOL CHEM, V260, P860; LIN XL, 1990, J BIOL CHEM, V265, P1490; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MESCHER MF, 1976, P NATL ACAD SCI USA, V73, P2687, DOI 10.1073/pnas.73.8.2687; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PAUL G, 1987, J BIOL CHEM, V262, P9587; PAUL G, 1986, J BIOL CHEM, V261, P1020; POULTER CD, 1988, J AM CHEM SOC, V110, P2620, DOI 10.1021/ja00216a041; PUHLER G, 1989, NUCLEIC ACIDS RES, V17, P4517, DOI 10.1093/nar/17.12.4517; REITER WD, 1990, P NATL ACAD SCI USA, V87, P9509, DOI 10.1073/pnas.87.24.9509; ROSA MD, 1977, PHYTOCHEMISTRY, V16, P1909; ROSA MD, 1982, PHYTOCHEMISTRY, V21, P595; ROSA MD, 1988, PROG LIPID RES, V27, P153; SAGAMI H, 1989, BIOCHIM BIOPHYS ACTA, V1002, P218, DOI 10.1016/0005-2760(89)90290-7; Sambrook J, 1989, MOL CLONING LABORATO; TAKAHASHI I, 1982, J BIOCHEM-TOKYO, V92, P1527, DOI 10.1093/oxfordjournals.jbchem.a134077; TAYLOR DP, 1983, J BACTERIOL, V154, P580, DOI 10.1128/JB.154.2.580-590.1983; WOOD AG, 1983, J BACTERIOL, V156, P19, DOI 10.1128/JB.156.1.19-29.1983; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; ZHANG DL, 1990, J AM CHEM SOC, V112, P1264, DOI 10.1021/ja00159a067	40	96	105	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14792	14797						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182085				2022-12-27	WOS:A1994NM06500075
J	BRANCACCIO, A; CUTRUZZOLA, F; ALLOCATELLI, CT; BRUNORI, M; SMERDON, SJ; WILKINSON, AJ; DOU, Y; KEENAN, D; IKEDASAITO, M; BRANTLEY, RE; OLSON, JS				BRANCACCIO, A; CUTRUZZOLA, F; ALLOCATELLI, CT; BRUNORI, M; SMERDON, SJ; WILKINSON, AJ; DOU, Y; KEENAN, D; IKEDASAITO, M; BRANTLEY, RE; OLSON, JS			STRUCTURAL FACTORS GOVERNING AZIDE AND CYANIDE BINDING TO MAMMALIAN METMYOGLOBINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; SITE-DIRECTED MUTAGENESIS; FERRIC APLYSIA MYOGLOBIN; DISTAL HISTIDINE; LIGAND-BINDING; X-RAY; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; ANIONIC LIGANDS; CARBON-MONOXIDE	The structural factors governing azide and cyanide binding have been examined by measuring the effects of 46 mutations at key topological positions in the distal pocket in sperm whale, pig, and human myoglobin. Replacement of His(64)(E7) with smaller amino acids results in dramatic increases in the association rate constant for azide binding primarily due to relief of steric hindrance imposed by the imidazole side chain. Gln(64) and His(64) (native) metmyoglobins have abnormally low rate constants for azide dissociation (0.1-0.3 s(-1)) due to direct hydrogen bonding between the N-epsilon atoms of these residues and the bound ligand. Mutations at positions 67(E10) and 68(E11) produce large but complex changes in the azide binding parameters as a result of both steric and electrostatic effects, which alter water coordination, influence the rate of anion movement into the distal pocket, and affect the stability of the Fe-N-3 bond. Replacement of Phe(46) with Leu or Val and substitution of Arg(Lys)45 with Glu and Ser cause disorder in the position of the distal histidine side chain and result in 4-700-fold increases in both k'(N3) and k(N3) but produce little ohange in overall azide affinity. All of these results suggest strongly that azide enters the distal pocket of native myoglobin through a polar channel that is regulated by a His(64) ''gate.'' In contrast to azide binding, the rate constant for cyanide association decreases 4-300-fold when the distal histidine is replaced with apolar residues. His(64), Gln(64), and distal pocket water molecules appear to facilitate deprotonation of HCN, which is the major kinetic barrier to cyanide binding at neutral pH.	UNIV ROMA LA SAPIENZA,CNR,CTR BIOL MOLEC,I-00185 ROME,ITALY; UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251; RICE UNIV,WM KECK CTR COMPUTAT BIOL,HOUSTON,TX 77251	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of York - UK; Case Western Reserve University; Rice University; Rice University	BRANCACCIO, A (corresponding author), UNIV ROMA LA SAPIENZA,DEPT BIOCHEM SCI A ROSSI FANELLI,I-00185 ROME,ITALY.		Brancaccio, Andrea/C-5876-2009; Cutruzzola', Francesca/G-4052-2011	Brancaccio, Andrea/0000-0003-4690-8826; Cutruzzola', Francesca/0000-0002-4621-2135; Smerdon, Stephen/0000-0001-5688-8465; Brunori, Maurizio/0000-0002-7795-1635; Olson, John/0000-0002-0760-5403; Wilkinson, Anthony/0000-0003-4577-9479	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039492, T32GM008280, R01GM035649] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35649, GM-08280, GM-39492] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLOCATELLI CT, 1993, BIOCHEMISTRY-US, V32, P6041; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BOLOGNESI M, 1989, J MOL BIOL, V205, P529, DOI 10.1016/0022-2836(89)90224-6; BOLOGNESI M, 1990, J MOL BIOL, V213, P621, DOI 10.1016/S0022-2836(05)80249-9; BOLOGNESI M, 1982, J MOL BIOL, V158, P305, DOI 10.1016/0022-2836(82)90435-1; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CARVER TE, 1991, BIOCHEMISTRY-US, V30, P4697, DOI 10.1021/bi00233a009; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CUTRUZZOLA F, 1991, FEBS LETT, V282, P281, DOI 10.1016/0014-5793(91)80495-O; CZERMINSKI R, 1991, PROTEINS, V10, P70, DOI 10.1002/prot.340100107; DODSON G, 1988, PROTEIN ENG, V2, P233, DOI 10.1093/protein/2.3.233; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; Eigen M., 1974, TECHNIQUES CHEMIST 2, VVI, P63; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; GIACOMETTI GM, 1981, J MOL BIOL, V151, P315, DOI 10.1016/0022-2836(81)90518-0; GIACOMETTI GM, 1975, BIOCHEMISTRY-US, V14, P1584, DOI 10.1021/bi00679a006; GIACOMETTI GM, 1981, J MOL BIOL, V146, P363, DOI 10.1016/0022-2836(81)90393-4; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; JOHNSON KA, 1989, J MOL BIOL, V207, P459, DOI 10.1016/0022-2836(89)90269-6; KOTTALAM J, 1988, J AM CHEM SOC, V110, P7690, DOI 10.1021/ja00231a018; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; Mattevi A, 1991, J Mol Recognit, V4, P1, DOI 10.1002/jmr.300040102; MINTOROVITCH J, 1989, BIOCHEMISTRY-US, V28, P6099, DOI 10.1021/bi00440a055; MINTOROVITCH J, 1988, BIOCHEMISTRY-US, V27, P8045, DOI 10.1021/bi00421a011; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; OLDFIELD TJ, 1992, BIOCHEMISTRY-US, V31, P8732, DOI 10.1021/bi00152a008; Olson J S, 1981, Methods Enzymol, V76, P631; OLSON JS, 1988, NATURE, V336, P265, DOI 10.1038/336265a0; PERUTZ MF, 1966, J MOL BIOL, V21, P199, DOI 10.1016/0022-2836(66)90088-X; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; Pifat G, 1973, Biophys Chem, V1, P112, DOI 10.1016/0301-4622(73)80007-9; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; RIZZI M, 1991, STRUCTURE SPERM WHAL; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; STFYER L, 1964, J MOL BIOL, V8, P309; Stitt F, 1939, J AM CHEM SOC, V61, P1263, DOI 10.1021/ja01874a075; TENTORI L, 1973, INT J PEPT PROT RES, V5, P187; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; VARADARAJAN R, 1985, P NATL ACAD SCI USA, V82, P6504; VERPLOEG DA, 1971, J BIOL CHEM, V246, P2725; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012	51	109	109	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13843	13853						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188662				2022-12-27	WOS:A1994NL60600022
J	SEVERINOV, K; KASHLEV, M; SEVERINOVA, E; BASS, I; MCWILLIAM, K; KUTTER, E; NIKIFOROV, V; SNYDER, L; GOLDFARB, A				SEVERINOV, K; KASHLEV, M; SEVERINOVA, E; BASS, I; MCWILLIAM, K; KUTTER, E; NIKIFOROV, V; SNYDER, L; GOLDFARB, A			A NONESSENTIAL DOMAIN OF ESCHERICHIA-COLI RNA-POLYMERASE REQUIRED FOR THE ACTION OF THE TERMINATION FACTOR ALC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; RIFAMPICIN RESISTANCE; RPOB GENE; MUTATION; SEQUENCE; PURIFICATION; POLYPEPTIDE; EXPRESSION; SITES	An evolutionarily nonconserved region of similar to 250 amino acids can be deleted from the amino-terminal part of the beta subunit of Escherichia coli RNA polymerase without effect on the enzyme's basic function. The non-essential segment is located between two highly conserved motifs and is flanked by sequences participating in the rifampicin binding site. The results define the second non-essential domain in the beta subunit, in addition to the more distal dispensable segment identified previously. The Alc protein of bacteriophage T4 participates in the host transcription shutoff after infection by causing premature termination of transcription on E. coli DNA. Point mutations which prevent Ale action in vivo change amino acids in the non essential NH2-terminal domain of the beta subunit. These point mutations as well as deletions which remove the non-essential region also prevent Alc action. Thus, in the RNA polymerase molecule, the proximal non-essential domain of beta may function as an acceptor of Alc or other regulatory factors.	RUSSIAN ACAD SCI, INST MOLEC GENET, MOSCOW, RUSSIA; PUBL HLTH RES INST CITY NEW YORK INC, NEW YORK, NY 10016 USA; MICHIGAN STATE UNIV, DEPT MICROBIOL, E LANSING, MI 48824 USA; EVERGREEN STATE COLL, OLYMPIA, WA 98505 USA	Russian Academy of Sciences; Michigan State University			Severinov, Konstantin/C-8545-2016		NIGMS NIH HHS [GM-30717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030717] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRY G, 1979, P NATL ACAD SCI USA, V76, P4922, DOI 10.1073/pnas.76.10.4922; BAUTZ EKF, 1976, RNA POLYMERASE, P273; BORODIN AM, 1988, DOKL AKAD NAUK SSSR+, V302, P1261; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CLARK MA, 1992, CURR MICROBIOL, V25, P283, DOI 10.1007/BF01575863; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; JAMES P, 1991, J BIOL CHEM, V266, P5616; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; KAO C, 1987, J BACTERIOL, V169, P1232, DOI 10.1128/jb.169.3.1232-1238.1987; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KASHLEV M, 1993, CELL, V75, P147, DOI 10.1016/S0092-8674(05)80091-1; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; LIAO DQ, 1992, J BIOL CHEM, V267, P22787; LISITSYN N, 1988, EUR J BIOCHEM, V117, P363; LISITSYN NA, 1984, MOL GEN GENET, V196, P173, DOI 10.1007/BF00334112; MALIK S, 1984, J BIOL CHEM, V259, P3292; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; OHME M, 1986, FEBS LETT, V200, P87, DOI 10.1016/0014-5793(86)80516-6; OVCHINNIKOV YA, 1981, EUR J BIOCHEM, V116, P621, DOI 10.1111/j.1432-1033.1981.tb05381.x; SAGITOV V, 1992, J BIOL CHEM, V268, P2195; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SNYDER L, 1988, GENETICS, V118, P173; SNYDER L, 1976, P NATL ACAD SCI USA, V69, P603; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	28	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14254	14259						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188709				2022-12-27	WOS:A1994NL60600080
J	YAMANO, A; TEETER, MM				YAMANO, A; TEETER, MM			CORRELATED DISORDER OF THE PURE PRO(22)/LEU(25) FORM OF CRAMBIN AT 150-K REFINED TO 1.05-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CRAMBIN; CRYSTALS; MOVEMENTS	The high resolution crystal structure of crambin has been based on the crystals containing two sequence forms (the mixed form). Here, we report the crystal structure of the sequence isomer having Pro and Leu at residues 22 and 25 (the PL form), This elimination of the sequence heterogeneity resulted in a simpler structure which permits a more accurate modeling of protein disorder. In the observed disorder, the PL form structure and the mixed form structure have significant differences: 1) the disorder caused by the sequence heterogeneity (pro(2)/Ser(22), Leu/Ile(25), Tyr(29)) is absent in the PL form; 2) Phe(13) and Glu(23) disordered in the mixed form have only one conformation in the PL form; and 3) Asn(12) has multiple conformations in the PL form. During the study of disorder in the PL form structure, we found that conformational correlation can be inferred from a structure determined with Bragg's reflections by introducing fundamental stereochemical information, van der Waals contact (Gursky, O., Badger, J., Li, Y., and Caspar, D. L. D. (1992) Biophys. J. 63, 1210-1220), although an x-ray structure is an image averaged over a large number of copies and the period of data collection and does not carry direct evidence about correlations. The correlations among Thr(2), Arg(10), and Ile(34) present the dearest example. The dimension of this correlation is comparable with the short-range (4-8 Angstrom) correlations in the atomic displacements concluded from the x-ray diffuse scattering experiments (Caspar, D. L. D., Clarage, J. B., Salunke, D. M., and Clarage, M. S. (1988) Nature 322, 659-662; Clarage, J. B., Clarage, M. S., Phillips, W. C., Sweet, R. M., and Caspar, D. L. D. (1992) Proteins 12, 145-157).	BOSTON COLL,MERKERT CHEM CTR,DEPT CHEM,CHESTNUT HILL,MA 02167	Boston College								BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P79; CANTOR CR, 1980, BIOPHYSICAL CHEM 1, P259; CASPAR DLD, 1988, NATURE, V332, P659, DOI 10.1038/332659a0; CLARAGE JB, 1992, PROTEINS, V12, P145, DOI 10.1002/prot.340120208; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HENDRICKSON WA, 1981, NATURE, V290, P109; HOPE H, 1988, ACTA CRYSTALLOGR B, V44, P22, DOI 10.1107/S0108768187008632; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KURIYAN J, 1991, PROTEINS, V10, P340, DOI 10.1002/prot.340100407; MCPHERSON A, 1989, PREPARATION ANAL PRO, P94; PETERS D, 1981, J MOL STRUCT, V85, P107; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SMITH JL, 1986, BIOCHEMISTRY-US, V25, P5018, DOI 10.1021/bi00366a008; TEETER MM, 1993, J MOL BIOL, V230, P292, DOI 10.1006/jmbi.1993.1143; TEETER MM, 1981, BIOCHEMISTRY-US, V20, P5437, DOI 10.1021/bi00522a013; TEETER MM, 1979, J MOL BIOL, V127, P219, DOI 10.1016/0022-2836(79)90242-0; TEETER MM, 1986, ANN NY ACAD SCI, V482, P163; Van ETTEN C. H., 1965, PHYTOCHEMETRY, V4, P467, DOI 10.1016/S0031-9422(00)86198-1; VERMEULEN JAWH, 1987, FEBS LETT, V219, P426, DOI 10.1016/0014-5793(87)80265-X	19	28	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13956	13965						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188676				2022-12-27	WOS:A1994NL60600039
J	YOUNG, CL; FEIERSTEIN, A; SOUTHWICK, FS				YOUNG, CL; FEIERSTEIN, A; SOUTHWICK, FS			CALCIUM REGULATION OF ACTIN FILAMENT CAPPING AND MONOMER BINDING BY MACROPHAGE CAPPING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE CALCIUM; PLASMA GELSOLIN; VILLIN; SITES; PHAGOCYTOSIS; NUCLEATION; DOMAIN; POLYMERIZATION; CYTOSKELETON; PURIFICATION	Macrophage capping protein (MCP) is a unique member of the gelsolin-villin family of calcium-activated barbed end capping proteins which in micromolar Ca2+ also binds actin monomers and nucleates actin assembly. Unlike gelsolin, MCP cannot sever actin filaments, and its Ca2+ dependent interaction with actin is completely reversible. The Ca2+ binding properties of MCP and its Ca2+-dependent functions were studied quantitatively. MCP undergoes a Ca2+-induced conformational change as evidenced by different chymotryptic digest patterns in 0.2 mM CaCl2 compared with 2 mM EGTA. MCP has a single low affinity Ca2+ binding site (K-D = 37 mu M). Binding of MCP to actin monomers requires a similar Ca2+ concentration ([Ca2+](0.5) = 62 mu M) suggesting that MCP.Ca2+ complex formation promotes monomer binding. In contrast, filament capping by MCP requires 1/60th of the Ca2+ concentration required for monomer binding, half-maximal capping occurring at 1 mu M Ca2+. The marked difference in the Ca2+ sensitivity of these two functions indicate the MCP's primary actin regulatory role in the macrophage is likely to be capping of the barbed ends of actin filaments.	UNIV FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida	YOUNG, CL (corresponding author), UNIV FLORIDA, COLL MED, DEPT MED, DIV INFECT DIS, GAINESVILLE, FL 32610 USA.				NIAID NIH HHS [R01 AI023262, AI 23262] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023262] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON AC, 1971, NATURE-NEW BIOL, V232, P153; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BRENNER SL, 1980, J BIOL CHEM, V255, P1670; BRYAN J, 1984, J BIOL CHEM, V259, P7480; BRYAN J, 1986, J CELL BIOL, V102, P1439, DOI 10.1083/jcb.102.4.1439; CANO ML, 1991, J CELL BIOL, V115, P677, DOI 10.1083/jcb.115.3.677; CASELLA JF, 1986, J BIOL CHEM, V261, P915; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; DABIRI GA, 1992, J BIOL CHEM, V267, P16545; ESTES JE, 1987, J BIOL CHEM, V262, P4952; FRIEDEN C, 1988, BIOCHEMISTRY-US, V27, P3812, DOI 10.1021/bi00410a044; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; HARTWIG JH, 1986, J CELL BIOL, V103, P1007, DOI 10.1083/jcb.103.3.1007; HESTERBERG LK, 1983, J BIOL CHEM, V258, P365; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; KIM E, 1992, INFECT IMMUN, V60, P1244, DOI 10.1128/IAI.60.3.1244-1248.1992; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; KRUSKAL BA, 1987, J CELL BIOL, V105, P2685, DOI 10.1083/jcb.105.6.2685; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LIN DC, 1978, J BIOL CHEM, V253, P1415; MARTELL AE, 1980, CRITICAL STABILITY C, V5, P144; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; NORTHROP J, 1986, J BIOL CHEM, V261, P9274; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; PINDER JC, 1986, J MOL BIOL, V191, P461, DOI 10.1016/0022-2836(86)90141-5; POTTER JD, 1983, METHOD ENZYMOL, V102, P135; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; RUPLEY JA, 1967, METHOD ENZYMOL, V11, P905; SOUTHWICK FS, 1986, J BIOL CHEM, V261, P14191; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TROTTER JA, 1981, EXP CELL RES, V132, P235, DOI 10.1016/0014-4827(81)90099-9; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; WEEDS AG, 1986, EUR J BIOCHEM, V161, P69, DOI 10.1111/j.1432-1033.1986.tb10125.x; WERNESS P, 1985, J UROLOGY, V104, P1; YIN HL, 1980, J BIOL CHEM, V255, P9494; YIN HL, 1980, J BIOL CHEM, V255, P9490; YOUNG CL, 1990, BIOCHEMISTRY-US, V29, P2232, DOI 10.1021/bi00461a005; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; ZIMMERLE CT, 1987, BIOCHEMISTRY-US, V26, P6545, DOI 10.1021/bi00394a039	42	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13997	14002						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188679				2022-12-27	WOS:A1994NL60600043
J	KIJIMA, M; YOSHIDA, M; SUGITA, K; HORINOUCHI, S; BEPPU, T				KIJIMA, M; YOSHIDA, M; SUGITA, K; HORINOUCHI, S; BEPPU, T			TRAPOXIN, AN ANTITUMOR CYCLIC TETRAPEPTIDE, IS AN IRREVERSIBLE INHIBITOR OF MAMMALIAN HISTONE DEACETYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMED NIH3T3 CELLS; RAT 3Y1 FIBROBLASTS; SODIUM-BUTYRATE; TRICHOSTATIN-A; ERYTHROLEUKEMIA-CELLS; DIFFERENTIATION; ACETYLATION; CHROMATIN; ACTIVATION; REPRESSION	Trapoxin (cyclo-(L-phenylalanyl-L-phenylalanyl-D-pipecolinyl-L-2-amino-8-oxo-9, 10-epoxy-decanoyl)) is a fungal product that induces morphological reversion from transformed to normal in sis-transformed NIH3T3 fibroblasts. Trapoxin was found to cause accumulation of highly acetylated core histones in a variety of mammalian cell lines. In vitro experiments using partially purified mouse histone deacetylase showed that a low concentration of trapoxin irreversibly inhibited deacetylation of acetylated histone molecules. Chemical reduction of an epoxide group in trapoxin completely abolished the inhibitory activity, suggesting that trapoxin binds covalently to the histone deacetylase via the epoxide. In contrast, inhibition by trichostatin A, a known potent inhibitor of histone deacetylase, was reversible. Despite the different mode of inhibition, trapoxin and trichostatin A induced almost the same biological effects on the cell cycle and differentiation. These results strongly suggest that the in vivo effects commonly induced by these agents can be attributed to histone hyperacetylation resulting from the inhibition of histone deacetylase.	UNIV TOKYO, FAC AGR, DEPT AGR CHEM, YAYOI 1-1-1, BUNKYO KU, TOKYO 113, JAPAN; SHIONOGI & CO LTD, SHIONOGI RES LABS,DEPT MICROBIOL,DIV ONCOL, FUKUSHIMA KU, OSAKA 553, JAPAN	University of Tokyo; Shionogi & Company Limited			Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674				ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; COUSENS LS, 1979, J BIOL CHEM, V254, P1716; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HOSHIKAWA Y, 1991, AGR BIOL CHEM TOKYO, V55, P1491, DOI 10.1080/00021369.1991.10870799; INOUE A, 1970, BIOCHIM BIOPHYS ACTA, V220, P307, DOI 10.1016/0005-2744(70)90015-X; ITAZAKI H, 1990, J ANTIBIOT, V43, P1524, DOI 10.7164/antibiotics.43.1524; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KLEHR D, 1992, BIOCHEMISTRY-US, V31, P3222, DOI 10.1021/bi00127a025; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; LEDER A, 1975, CELL, V5, P319, DOI 10.1016/0092-8674(75)90107-5; MCKNIGHT GS, 1980, CELL, V22, P469; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NISHIMUNE Y, 1983, EXP CELL RES, V146, P439, DOI 10.1016/0014-4827(83)90147-7; NOGUCHI PD, 1978, J HISTOCHEM CYTOCHEM, V26, P761, DOI 10.1177/26.9.361885; PRASAD KN, 1976, IN VITRO CELL DEV B, V12, P125; RIDSDALE JA, 1987, NUCLEIC ACIDS RES, V15, P1081, DOI 10.1093/nar/15.3.1081; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; SUGITA K, 1992, CANCER RES, V52, P168; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; TSUJI N, 1976, J ANTIBIOT, V29, P1, DOI 10.7164/antibiotics.29.1; VIDALI G, 1972, J BIOL CHEM, V247, P7365; YAMADA K, 1985, J CELL PHYSIOL, V122, P59, DOI 10.1002/jcp.1041220110; YOSHIDA H, 1992, JPN J CANCER RES, V83, P324, DOI 10.1111/j.1349-7006.1992.tb00109.x; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1987, CANCER RES, V47, P3688; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	33	483	552	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22429	22435						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226751				2022-12-27	WOS:A1993MD34800039
J	LAI, KH; DAVE, KI; WILD, JR				LAI, KH; DAVE, KI; WILD, JR			BIMETALLIC BINDING MOTIFS IN ORGANOPHOSPHORUS HYDROLASE ARE IMPORTANT FOR CATALYSIS AND STRUCTURAL ORGANIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-DIMINUTA; ESCHERICHIA-COLI; BACTERIAL PHOSPHOTRIESTERASE; ZINC ENZYMES; GENE; SITE; HYDROLYSIS; HISTIDINE; EXPRESSION; PROTEIN	Organophosphorus hydrolase is a broad spectrum phosphoric acid hydrolase (EC 3.1.8.1) which appears to contain a binuclear metal center with two metals interactively involved in catalysis and/or structural functions. Site-directed mutagenesis has been employed to evaluate the participation of the various histidine and cysteine residues in metal coordination. The kinetic characteristics and metal binding stoichiometries of the purified site-directed substitutions of each of the histidine and cysteine residues in the catalytic domain of the protein to asparagine and serine residues, respectively, were determined. These data support the hypothesis that the histidines at positions 55, 57, and 201 are coordinated to a metal ion (M(1)) at the active center of the enzyme and that His(254) and His(257) are involved in the formation of a second structural metal center (M(2)). These and other unidentified amino acids may participate in a co-catalytic center. Although previous solution chemical studies concluded that cysteines are not involved in metal coordination, serine substitutions for Cys(59) and Cys(227) do affect metal content and catalytic activity. In contrast, substitution of asparagine for His(230) does not affect the metal stoichiometry, but does reduce the k(cat) by 10(-4), indicating that it may be directly involved in the reaction chemistry. The H201N substitution eliminates activity but maintains one molar equivalent of metal and may function as a bridging ligand.	TEXAS A&M UNIV,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station								ASHANI Y, 1991, LIFE SCI, V49, P367, DOI 10.1016/0024-3205(91)90444-G; AULD DS, 1988, METHOD ENZYMOL, V158, P13, DOI 10.1016/0076-6879(88)58043-6; AULD DS, 1988, METHOD ENZYMOL, V158, P71, DOI 10.1016/0076-6879(88)58048-5; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7438, DOI 10.1021/bi00244a010; DAVE KI, 1993, CHEM-BIOL INTERACT, V87, P55, DOI 10.1016/0009-2797(93)90025-T; DONARSKI WJ, 1989, BIOCHEMISTRY-US, V28, P4650, DOI 10.1021/bi00437a021; DUMAS DP, 1989, BIOTECHNOL APPL BIOC, V11, P235; DUMAS DP, 1989, J BIOL CHEM, V264, P19659; DUMAS DP, 1990, ARCH BIOCHEM BIOPHYS, V277, P155, DOI 10.1016/0003-9861(90)90564-F; DUMAS DP, 1990, J BIOL CHEM, V265, P21498; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; EHRIG T, 1991, BIOCHEMISTRY-US, V30, P1062, DOI 10.1021/bi00218a026; FALCHUK KH, 1988, METHOD ENZYMOL, V158, P422, DOI 10.1016/0076-6879(88)58073-4; HOLMQUIST B, 1988, METHOD ENZYMOL, V158, P6, DOI 10.1016/0076-6879(88)58042-4; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; LAMBEIR AM, 1992, BIOCHEMISTRY-US, V31, P5459, DOI 10.1021/bi00139a006; MCDANIEL CS, 1988, J BACTERIOL, V70, P2306; MILLER CE, 1992, STRUCTURE FUNCTION S; MILLER WT, 1991, BIOCHEMISTRY-US, V30, P6970, DOI 10.1021/bi00242a023; MULBRY WW, 1989, J BACTERIOL, V171, P6740, DOI 10.1128/jb.171.12.6740-6746.1989; MULBRY WW, 1986, APPL ENVIRON MICROB, V51, P926, DOI 10.1128/AEM.51.5.926-930.1986; OMBURO GA, 1992, J BIOL CHEM, V267, P13278; OMBURO GA, 1993, BIOCHEMISTRY-US, V32, P9148, DOI 10.1021/bi00086a021; RIORDAN JF, 1988, METHOD ENZYMOL, V158, P3, DOI 10.1016/0076-6879(88)58041-2; Sambrook J, 1989, MOL CLONING LABORATO; SERDAR CM, 1989, BIO-TECHNOL, V7, P1151; SHAPIRO R, 1988, METHOD ENZYMOL, V158, P344, DOI 10.1016/0076-6879(88)58065-5; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P54; TONEY MD, 1993, BIOCHEMISTRY-US, V32, P1471, DOI 10.1021/bi00057a010; UHLEN M, 1990, METHOD ENZYMOL, V185, P129; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; VALLEE BL, 1993, P NATL ACAD SCI USA, V90, P2715, DOI 10.1073/pnas.90.7.2715; VALLEE BL, 1993, BIOCHEMISTRY-US, V32, P6493, DOI 10.1021/bi00077a001	34	87	88	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16579	16584						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206975				2022-12-27	WOS:A1994NR29600012
J	MUNZER, JS; DALY, SE; JEWELLMOTZ, EA; LINGREL, JB; BLOSTEIN, R				MUNZER, JS; DALY, SE; JEWELLMOTZ, EA; LINGREL, JB; BLOSTEIN, R			TISSUE-SPECIFIC AND ISOFORM-SPECIFIC KINETIC-BEHAVIOR OF THE NA,K-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; RED-BLOOD-CELLS; INFECTED INSECT CELLS; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; ENZYMATIC-PROPERTIES; RAT NA,K-ATPASE; XENOPUS OOCYTES; NA+/K+-ATPASE; SODIUM-PUMP	The objective of this study has been to delineate the side-specific effects of Na+ and K+ on the transport kinetics of tissue-specific Na/K pumps. Two experimental systems have been used. In one, Na/K pumps of exogenous microsomal membrane sources (rat axolemma, kidney) were delivered by membrane fusion into dog erythrocytes, and in the other, the three isoforms of the catalytic subunit of the rat enzyme were individually transfected into HeLa cells as in previous studies (Jewell, E. A., and Lingrel, J.B (1991) J. Biol. Chem. 266, 16925-16930), with the alpha(2) and alpha(3) isoforms rendered relatively resistant to ouabain by site-directed mutagenesis. Whereas the kidney microsomes comprise the alpha(1) catalytic isoform, the axolemma microsomes were predominantly alpha(3) (approximate to 60%) with lesser amounts of alpha(2) (approximate to 25%) and alpha(1) (approximate to 15%) as measured by the ouabain-sensitive profile of phosphoenzyme as well as by immunoblotting with isoform-specific antibodies using membranes of known specific activity as standards (alpha(1) of kidney, alpha(1) and alpha(2) of muscle). Both systems were analyzed with respect to the effects of varying concentrations of cytoplasmic Na+ and extracellular K+ on pump-mediated Rb-86(+)(K+) influx. With the individual isoform-transfected HeLa cells and monensin added to vary and control the intracellular Na+ concentration, differences in apparent affinities of the alpha(3) isoform compared with the alpha(1) and alpha(2) isoforms were observed, i.e. a approximate to 3-fold higher affinity for extracellular K+ and approximate to 4-fold lower affinity for cytoplasmic Na+. Thus, in the presence of 10 mM extracellular Na+, apparent K-0.5 values for extracellular K+ activation of K+(Rb+) influxes were 0.22 +/- 0.02 mM for alpha(1), 0.20 +/- 0.02 mM for alpha(2), and 0.09 +/- 0.01 mM for alpha(3). At high intracellular K+ (greater than or equal to 100 mM) and saturating extracellular K+ concentrations, apparent K-0.5 values for cytoplasmic Na+ activation were 17.6 +/- 1.1 mM for alpha(1), 19.7 +/- 1.0 mM for alpha(2), and 63.5 +/- 9.1 mM for alpha(3). The functional differences observed with the individual isoform-transfected cells were completely consistent with the kinetic differences observed with the axolemma and kidney pumps fused into erythrocytes. Axolemma pumps had a approximate to 3-fold lower K-0.5 for extracellular K+ and a approximate to 2-fold higher K-0.5 for cytoplasmic Na+. In the HeLa transfectants, differences in affinities for cytoplasmic Na+ were associated with differences in the steady-state intracellular Na+ concentration, i.e. 27.5 mM in alpha(3)-transfected cells compared with 15.7 and 19.7 mM in alpha(1)- and alpha(2)-transfected cells, respectively.	MCGILL UNIV, DEPT MED, MONTREAL H3G 1A4, PQ, CANADA; UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	McGill University; University of Cincinnati					PHS HHS [R0HIL28573] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERREBIBERTRAND I, 1990, BIOCHIM BIOPHYS ACTA, V1021, P148, DOI 10.1016/0005-2736(90)90027-L; BLANCO G, 1993, P NATL ACAD SCI USA, V90, P1824, DOI 10.1073/pnas.90.5.1824; BLANCO G, 1990, BIOCHIM BIOPHYS ACTA, V1027, P1, DOI 10.1016/0005-2736(90)90039-Q; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; BLOSTEIN R, 1988, METHOD ENZYMOL, V156, P171; BRINES ML, 1992, BRAIN RES, V591, P94, DOI 10.1016/0006-8993(92)90982-F; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; DHIR R, 1990, BIOCHIM BIOPHYS ACTA, V1026, P141, DOI 10.1016/0005-2736(90)90056-T; FORBUSH B, 1983, ANAL BIOCHEM, V128, P159, DOI 10.1016/0003-2697(83)90356-1; GARAY RP, 1973, J PHYSIOL-LONDON, V231, P297, DOI 10.1113/jphysiol.1973.sp010234; GARRAHAN PJ, 1967, J PHYSIOL-LONDON, V192, P175, DOI 10.1113/jphysiol.1967.sp008295; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GRISAR T, 1979, BRAIN RES, V165, P87, DOI 10.1016/0006-8993(79)90047-7; HABER RS, 1987, AM J PHYSIOL, V253, pF26, DOI 10.1152/ajprenal.1987.253.1.F26; HARINDER HS, 1992, J BIOL CHEM, V267, P5040; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; INABA M, 1986, J BIOL CHEM, V261, P6099; INOUE N, 1974, SODIUM PUMP RECENT D, V46, P597; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1971, BIOCHIM BIOPHYS ACTA, V233, P366, DOI 10.1016/0005-2736(71)90334-8; KIMELBERG HK, 1978, BRAIN RES, V141, P305, DOI 10.1016/0006-8993(78)90200-7; KRNJEVIC K, 1975, CAN J PHYSIOL PHARM, V53, P923, DOI 10.1139/y75-126; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES GJ, 1991, BRAIN RES REV, V16, P283, DOI 10.1016/0165-0173(91)90011-V; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LYTTON J, 1985, J BIOL CHEM, V260, P75; MAIRBAURL H, 1992, J GEN PHYSIOL, V99, P721, DOI 10.1085/jgp.99.5.721; Markwell M A, 1981, Methods Enzymol, V72, P296; MCGILL DL, 1991, J BIOL CHEM, V266, P15824; MUNZER JS, 1992, J BIOL CHEM, V267, P5202; MUNZER JS, 1993, 7TH P INT C SOD PUMP; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; OBRIEN WJ, 1994, ARCH BIOCHEM BIOPHYS, V310, P32, DOI 10.1006/abbi.1994.1136; PARKER JC, 1983, AM J PHYSIOL, V244, pC324, DOI 10.1152/ajpcell.1983.244.5.C324; POLLACK LR, 1981, J CELL PHYSIOL, V106, P85, DOI 10.1002/jcp.1041060110; REICHENBACH A, 1992, CAN J PHYSIOL PHARM, V70, pS239, DOI 10.1139/y92-267; SCHWARZ W, 1988, BIOCHIM BIOPHYS ACTA, V945, P167, DOI 10.1016/0005-2736(88)90479-8; SHYJAN AW, 1990, J BIOL CHEM, V265, P5166; SHYJAN AW, 1990, P NATL ACAD SCI USA, V87, P1178, DOI 10.1073/pnas.87.3.1178; SKOU JC, 1962, BIOCHIM BIOPHYS ACTA, V58, P314, DOI 10.1016/0006-3002(62)91015-6; STIMERS JR, 1990, J GEN PHYSIOL, V95, P77, DOI 10.1085/jgp.95.1.77; Strehler B. L., 1974, METHOD ENZYMAT AN, P2112, DOI [10.1016/b978-0-12-091304-6.50065-3, DOI 10.1016/B978-0-12-091304-6.50065-3]; SWEADNER KJ, 1992, CAN J PHYSIOL PHARM, V70, pS255, DOI 10.1139/y92-269; SWEADNER KJ, 1985, J BIOL CHEM, V260, P1508; SWEADNER KJ, 1988, METHOD ENZYMOL, V156, P65; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; SYKOVA E, 1983, PROG BIOPHYS MOL BIO, V42, P135, DOI 10.1016/0079-6107(83)90006-8; URAYAMA O, 1988, BIOCHEM BIOPH RES CO, V156, P796, DOI 10.1016/S0006-291X(88)80914-8; URAYAMA O, 1979, J BIOCHEM, V86, P1371, DOI 10.1093/oxfordjournals.jbchem.a132654; WATTS AG, 1991, P NATL ACAD SCI USA, V88, P7425, DOI 10.1073/pnas.88.16.7425	56	177	177	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16668	16676						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206986				2022-12-27	WOS:A1994NR29600026
J	QI, XY; LEONOVA, T; GRABOWSKI, GA				QI, XY; LEONOVA, T; GRABOWSKI, GA			FUNCTIONAL HUMAN SAPOSINS EXPRESSED IN ESCHERICHIA-COLI - EVIDENCE FOR BINDING AND ACTIVATION PROPERTIES OF SAPOSINS-C WITH ACID BETA-GLUCOSIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAUCHER DISEASE; CATALYTIC ACTIVITY; LYSOSOMAL STORAGE; PROTEIN-2 SAP-2; GLUCOCEREBROSIDASE; MECHANISM; GENE; IDENTIFICATION; BIOSYNTHESIS; FIBROBLASTS	Small (80-amino acid) glycoproteins or saposins are important for the in vivo function of several lysosomal hydrolases. Four saposins, A, B, C, and D, are encoded by a single locus termed prosaposin. Saposins C and A are thought to function in vivo as activators of acid beta-glucosidase. The physiologic role of saposin C has been confirmed, whereas that of saposin A role has not. To investigate the effects of saposins C and A on acid beta-glucosidase activity, the coding sequence for the individual saposins was expressed in Escherichia coli and the recombinant proteins purified to homogeneity. Recombinant and natural saposins A and C activated acid beta-glucosidase similarly only in micromolar amounts. Saposin C had specific activation of acid beta-glucosidase activity at <200 nM. A second phase of activation was achieved at >1 mu M. In comparison, saposin A consistently activated acid beta-glucosidase only at >1 mu M. Two mutant saposins C (Cys(382) --> Phe and Cys(382) --> Gly) were created and shown to compete with saposin C for a site on acid beta-glucosidase. The mutant saposins did not activate the enzyme. Recombinant saposin A (<200 nM) competed with saposin C for a site on the enzyme but without activating effects. These studies show that saposin A is not an in vitro activator of acid beta-glucosidase at physiologic concentrations, although binding occurs without activating acid beta-glucosidase. The studies with mutant saposins C indicate that the binding and activation effects of saposins C are distinct events. These results indicate that the saposin C-induced conformational change in the enzyme occurs via highly specific, probably multivalent, interactions between acid beta-glucosidase and saposin C.	CHILDRENS HOSP RES FDN, DIV HUMAN GENET, CINCINNATI, OH 45229 USA; UNIV CINCINNATI, COLL MED, DEPT PEDIAT, CINCINNATI, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036729] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36729] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERENT SL, 1981, BIOCHIM BIOPHYS ACTA, V664, P572, DOI 10.1016/0005-2760(81)90134-X; BURG J, 1985, ANN HUM GENET, V49, P41, DOI 10.1111/j.1469-1809.1985.tb01674.x; COLLARD MW, 1988, BIOCHEMISTRY-US, V27, P4557, DOI 10.1021/bi00412a050; CONZELMANN E, 1984, DEV NEUROSCI-BASEL, V6, P58, DOI 10.1159/000112332; CREIGHTON TE, 1974, J MOL BIOL, V87, P563, DOI 10.1016/0022-2836(74)90104-1; FABBRO D, 1991, J BIOL CHEM, V266, P15021; FUJIBAYASHI S, 1985, AM J HUM GENET, V37, P741; FUJIBAYASHI S, 1986, BIOCHIM BIOPHYS ACTA, V875, P554; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GAVRIELIRORMAN E, 1989, GENOMICS, V5, P486; GAVRIELIRORMAN E, 1992, GENOMICS, V13, P312; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; GRABOWSKI GA, 1989, ENZYME, V41, P131, DOI 10.1159/000469068; GRACE ME, 1990, BIOCHEM BIOPH RES CO, V168, P771, DOI 10.1016/0006-291X(90)92388-G; GRACE ME, 1990, J BIOL CHEM, V265, P6827; GREENBERG P, 1990, BIOCHIM BIOPHYS ACTA, V1039, P12, DOI 10.1016/0167-4838(90)90220-A; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V304, P110, DOI 10.1006/abbi.1993.1328; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; HO MW, 1971, P NATL ACAD SCI USA, V68, P2810, DOI 10.1073/pnas.68.11.2810; HOLTSCHMIDT H, 1991, FEBS LETT, V280, P267, DOI 10.1016/0014-5793(91)80308-P; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; LEINEKUGEL P, 1992, HUM GENET, V88, P513, DOI 10.1007/BF00219337; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORIMOTO S, 1988, BIOCHEM BIOPH RES CO, V156, P403, DOI 10.1016/S0006-291X(88)80855-6; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; MORIMOTO S, 1990, J BIOL CHEM, V265, P1933; MORIMOTO S, 1990, P NATL ACAD SCI USA, V87, P3493, DOI 10.1073/pnas.87.9.3493; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; PRENCE E, 1985, ARCH BIOCHEM BIOPHYS, V236, P98, DOI 10.1016/0003-9861(85)90609-5; RAFI MA, 1993, SOMAT CELL MOLEC GEN, V19, P1, DOI 10.1007/BF01233949; SANO A, 1988, J BIOL CHEM, V263, P19597; SCHNABEL D, 1991, FEBS LETT, V284, P57, DOI 10.1016/0014-5793(91)80760-Z; SIBILLE A, 1993, AM J HUM GENET, V52, P1094; TSUJI S, 1988, P NATL ACAD SCI USA, V85, P2349, DOI 10.1073/pnas.85.7.2349; TSUJI S, 1987, NEW ENGL J MED, V316, P570, DOI 10.1056/NEJM198703053161002; WEILER S, 1993, J MOL NEUROSCI, V4, P161, DOI 10.1007/BF02782499; ZHANG XL, 1991, HUM GENET, V87, P211, DOI 10.1007/BF00204185; ZIMRAN A, 1989, LANCET, V2, P349	40	81	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16746	16753						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206997				2022-12-27	WOS:A1994NR29600038
J	QUIRK, K; GILLARD, NP; RAGAN, CI; WHITING, PJ; MCKERNAN, RM				QUIRK, K; GILLARD, NP; RAGAN, CI; WHITING, PJ; MCKERNAN, RM			MODEL OF SUBUNIT COMPOSITION OF GAMMA-AMINOBUTYRIC-ACID A RECEPTOR SUBTYPES EXPRESSED IN RAT CEREBELLUM WITH RESPECT TO THEIR ALPHA-SUBUNIT AND GAMMA/DELTA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A RECEPTOR; BENZODIAZEPINE RECEPTORS; MESSENGER-RNAS; ALCOHOL ANTAGONIST; MOLECULAR-BIOLOGY; ISO-OLIGOMERS; DELTA-SUBUNIT; GRANULE CELLS; BRAIN; ANTIBODIES	Antibodies specific for subunits of the gamma aminobutyric acid A (GABA(A)) receptor have been used to immunoprecipitate [H-3]muscimol, [H-3]Ro 15-4513, and [H-3]Ro 15-1788 binding sites from deoxycholate-solubilized preparations of rat cerebellum. Of the antisera raised against alpha subunits, those specific for alpha(6) immunoprecipitated the largest proportion of receptors. Two populations of alpha(6)-containing GABA(A) receptors were identified. The first was labeled with [H-3]Ro 15-4513 and exhibited a pharmacological profile consistent with that observed for alpha(6) beta(2) gamma(2) in transfected cells (Luddens, H., Pritchett, D. B., Kohler, M., Killisch, I., Keinanen, K., Monyer, H., Sprengel, R., and Seeberg, P.H. (1990) Nature 346, 648-651). The second population was labeled only with [H-3]muscimol and was deduced, from quantitative inmunoprecipitation studies using combinations of antibodies, to contain both alpha(6) and delta subunits. The alpha(6) subunit was not observed to be present in combination with other alpha subunits or the gamma(1) subunit. Each of the other alpha subunits was found to be present in only one population of receptors in the cerebellum. Some subunits (alpha(4), alpha(5), and gamma(3)) were not detectable. By combining information from quantitative immunoprecipitation experiments and Western blot analysis, a model describing the composition of all GABA(A) receptors in the cerebellum was constructed that defined the following alpha and gamma/delta combinations (percentage of cerebellar GABA(A) receptors): alpha(6) gamma(2) (36%), alpha(6) delta (23%), alpha(1) gamma(2) (28%), alpha(2) gamma(1) (8%), and alpha(3) gamma(2) (5%).	MERCK SHARP & DOHME LTD,RES LABS,NEUROSCI RES CTR,DEPT BIOCHEM,HARLOW CM20 2QR,ESSEX,ENGLAND	Merck & Company				Whiting, Paul/0000-0002-4121-1379				BAUDE A, 1992, NEUROSCIENCE, V51, P739, DOI 10.1016/0306-4522(92)90513-2; BENKE D, 1991, FEBS LETT, V283, P145, DOI 10.1016/0014-5793(91)80573-L; BORMANN J, 1988, P NATL ACAD SCI USA, V85, P9336, DOI 10.1073/pnas.85.23.9336; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; DUGGAN MJ, 1992, J NEUROCHEM, V58, P72, DOI 10.1111/j.1471-4159.1992.tb09278.x; DUGGAN MJ, 1990, J BIOL CHEM, V265, P3831; ENDO S, 1993, J NEUROCHEM, V60, P1388, DOI 10.1111/j.1471-4159.1993.tb03300.x; FRITSCHY JM, 1992, P NATL ACAD SCI USA, V89, P6726, DOI 10.1073/pnas.89.15.6726; HARLOW E, 1988, ANTIBODIES LABORATOR, P309; HERB A, 1992, P NATL ACAD SCI USA, V89, P1433, DOI 10.1073/pnas.89.4.1433; KATO K, 1990, J MOL BIOL, V214, P619, DOI 10.1016/0022-2836(90)90276-R; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; LUDDENS H, 1991, J RECEPTOR RES, V11, P535, DOI 10.3109/10799899109066426; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MALHERBE P, 1990, FEBS LETT, V260, P261, DOI 10.1016/0014-5793(90)80118-3; MCKERNAN RM, 1991, NEURON, V7, P667, DOI 10.1016/0896-6273(91)90379-E; MERTENS S, 1993, J BIOL CHEM, V268, P5965; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; POLLARD S, 1993, J BIOL CHEM, V268, P3753; PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SEEBURG PH, 1990, COLD SPRING HARBOR S; SEQUIER JM, 1988, P NATL ACAD SCI USA, V85, P7815, DOI 10.1073/pnas.85.20.7815; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SIEGHART W, 1989, TRENDS PHARMACOL SCI, V10, P407, DOI 10.1016/0165-6147(89)90189-2; SIEGHART W, 1987, J NEUROCHEM, V48, P46, DOI 10.1111/j.1471-4159.1987.tb13125.x; SOMOGYI P, 1989, J NEUROSCI, V9, P2197; THOMPSON CL, 1992, NEUROSCI LETT, V144, P53, DOI 10.1016/0304-3940(92)90714-I; TURNER DM, 1991, J PHARMACOL EXP THER, V257, P1236; VONBLANKENFELD G, 1990, NEUROSCI LETT, V115, P269, DOI 10.1016/0304-3940(90)90467-N; WILCOX AS, 1992, P NATL ACAD SCI USA, V89, P5857, DOI 10.1073/pnas.89.13.5857; WILSONSHAW D, 1991, FEBS LETT, V284, P211, DOI 10.1016/0014-5793(91)80687-X; WISDEN W, 1989, NEUROSCI LETT, V106, P7, DOI 10.1016/0304-3940(89)90193-6; WISDEN W, 1991, FEBS LETT, V289, P227, DOI 10.1016/0014-5793(91)81076-K; WISDEN W, 1988, NEURON, V1, P937, DOI 10.1016/0896-6273(88)90151-1; YMER S, 1990, EMBO J, V9, P3261, DOI 10.1002/j.1460-2075.1990.tb07525.x; YMER S, 1989, FEBS LETT, V258, P119, DOI 10.1016/0014-5793(89)81630-8; ZEZULA J, 1991, FEBS LETT, V284, P15, DOI 10.1016/0014-5793(91)80750-W; ZIMPRICH F, 1991, NEUROSCI LETT, V127, P125, DOI 10.1016/0304-3940(91)90910-L	43	121	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16020	16028						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206899				2022-12-27	WOS:A1994NQ72900014
J	BANNO, Y; OKANO, Y; NOZAWA, Y				BANNO, Y; OKANO, Y; NOZAWA, Y			THROMBIN-MEDIATED PHOSPHOINOSITIDE HYDROLYSIS IN CHINESE-HAMSTER OVARY CELLS OVEREXPRESSING PHOSPHOLIPASE C-DELTA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSENSITIVE G-PROTEIN; BETA-GAMMA-SUBUNITS; C ISOZYMES; ALPHA-SUBUNITS; SACCHAROMYCES-CEREVISIAE; INOSITOL TRISPHOSPHATE; PC12 CELLS; KINASE-C; ACTIVATION; RECEPTOR	The regulatory mechanism(s) of a phosphoinositide-specific phospholipase C, PLC-delta 1, was investigated using a clone of stably overexpressed PLC-delta 1 (PLC delta 30 cells) in Chinese hamster ovary cells. Thrombin stimulation of PLC delta 30 cells exhibited 6.5-fold increase in total inositol phosphates (InsP), which was significantly higher than that in the vector-transfected (V1) cells (2.0-fold). AIF-(4) increased InsP accumulation in both V1 and PLC delta 30 cells, and pertussis toxin partially blocked InsP accumulation in thrombin-stimulated PLC delta 30 cells. Guanosine thiotriphosphate (GTP gamma S) markedly potentiated thrombin-stimulated InsP generation in permeabilized PLC delta 30 cells compared with V1 cells, suggesting possible involvement of a G-protein (s) in the activation of PLC-delta 1, In PLC delta 30 cells, ionomycin-induced significant InsP generation and thrombin-stimulated InsP generation were completely inhibited by addition of EGTA. Furthermore, the stimulatory effects of thrombin plus GTP gamma S in PLC delta 30 cells were more sensitive to change in free calcium concentration than in V1 cells. Suppression by 12-O-tetradecanoylphorbol 13-acetate of thrombin-stimulated InsP accumulation was not affected by increasing Ca2+ concentration. These results indicate that thrombin-induced PLC-delta 1 activation is regulated via both G-protein(s) and calcium.	GIFU UNIV, SCH MED, DEPT BIOCHEM, GIFU 500, JAPAN	Gifu University								BAIROCH A, 1990, FEBS LETT, V269, P454, DOI 10.1016/0014-5793(90)81214-9; BANNO Y, 1993, BIOCHEM J, V292, P401, DOI 10.1042/bj2920401; BANNO Y, 1992, J BIOL CHEM, V267, P6488; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BRASS LF, 1992, J BIOL CHEM, V267, P6044; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHO YS, 1993, FEBS LETT, V334, P257, DOI 10.1016/0014-5793(93)80689-R; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; DOWNES P, 1982, CELL CALCIUM, V3, P467, DOI 10.1016/0143-4160(82)90031-8; EBERHARD DA, 1988, TRENDS NEUROSCI, V11, P517, DOI 10.1016/0166-2236(88)90174-9; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; FU T, 1992, FEBS LETT, V307, P301, DOI 10.1016/0014-5793(92)80700-Q; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HUNG DT, 1992, J BIOL CHEM, V267, P20831; KANOH H, 1992, J NEUROCHEM, V59, P1786, DOI 10.1111/j.1471-4159.1992.tb11011.x; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KIM MJ, 1993, BIOCHEM BIOPH RES CO, V194, P706, DOI 10.1006/bbrc.1993.1879; KRIZ R, 1990, CIBA F SYMP, V150, P112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CW, 1993, J BIOL CHEM, V268, P21318; LEONIS MA, 1993, J BIOL CHEM, V268, P9416; MARTIN TFJ, 1991, BIOCHEM J, V280, P753, DOI 10.1042/bj2800753; MEADE CJ, 1986, BIOCHEM J, V238, P425, DOI 10.1042/bj2380425; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MITCHELL FM, 1993, BIOCHEM J, V293, P495, DOI 10.1042/bj2930495; NEYLON CB, 1992, J BIOL CHEM, V267, P7295; OZAWA K, 1993, J BIOL CHEM, V268, P2280; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PALMER S, 1986, BIOCHEM J, V238, P491, DOI 10.1042/bj2380491; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARK DJ, 1992, J BIOL CHEM, V267, P1496; RATH HM, 1990, J BIOL CHEM, V265, P3080; RHEE SG, 1991, BIOCHEM SOC T, V19, P337, DOI 10.1042/bst0190337; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RYU SH, 1990, J BIOL CHEM, V265, P17941; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; TAKASHIMA A, 1989, J BIOL CHEM, V264, P10654; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WU DQ, 1993, J BIOL CHEM, V268, P3704; WU DQ, 1992, J BIOL CHEM, V267, P1811; YOKOO T, 1993, P NATL ACAD SCI USA, V90, P1804, DOI 10.1073/pnas.90.5.1804	51	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15846	15852						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195239				2022-12-27	WOS:A1994NP51300070
J	LEE, YC; PARK, CS; STROTT, CA				LEE, YC; PARK, CS; STROTT, CA			MOLECULAR-CLONING OF A CHIRAL-SPECIFIC 3-ALPHA-HYDROXYSTEROID SULFOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER DEHYDROEPIANDROSTERONE SULFOTRANSFERASE; PREGNENOLONE-BINDING PROTEIN; SULFATES BILE-ACIDS; PIG ADRENAL-CORTEX; ESTROGEN SULFOTRANSFERASE; RAT-LIVER; SEQUENCE-ANALYSIS; EXPRESSION; CDNA; PURIFICATION	A novel stereoselective hydroxysteroid sulfotransferase (HST) that acts on neutral steroids having the 3-hydroxyl group in the a orientation but not on steroids where the 3-hydroxyl group is oriented in the beta position has been cloned and expressed. Primary screening of a guinea pig adrenal cDNA library was performed by colony hybridization using an oligonucleotide probe based on a highly homologous region among known steroid sulfotransferases. Selected clones consisted of overlapping sequences but were incomplete. The rapid amplification of cDNA ends procedure was used to construct a full-length guinea pig HST cDNA. The guinea pig HST cDNA transiently transfected into Chinese hamster ovary K1 cells expressed a protein identical in size to that of purified guinea pig HST specific for 3 alpha-hydroxylated neutral steroids that was recently reported (Driscoll, W. J., Martin, B. M., Chen, H.-C., and Strott, C. A. (1993) J. Biol. Chem. 268, 23496-23503). The expressed HST likewise exhibited sulfotransferase activity that was directed specifically toward steroid substrates containing a 3-hydroxyl group in the alpha orientation; on the other hand, steroids with a 3 beta-hydroxyl group were not sulfonated by the expressed HST. Thus, the cloned HST cDNA clearly coded for a steroid sulfotransferase with chiral specificity for 3 alpha-hydroxylated neutral steroids and was, therefore, given the designation of guinea pig 3 alpha-hydroxysteroid sulfotransferase (gp3 alpha-HST). The full-length gp3 alpha-HST cDNA consisted of 1182 base pairs and coded for a protein containing 287 amino acids. The deduced amino acid sequence of the protein shares 65/79, 65/80, and 62/76% identity/similarity with rat, mouse, and human HST, respectively. Northern blot analysis of guinea pig tissues revealed no apparent gender differences in either mRNA species or distribution; a single 1.4-kilobase HST mRNA species was present in adrenal and liver tissue. Interestingly, the adrenal mRNA content was considerably more abundant than that found in the liver. Evidence for 3 alpha-HST mRNA was not detected in kidney, heart, lung, muscle, spleen, or uterus.	NICHHD,ENDOCRINOL & REPROD RES BRANCH,STEROIE REGULAT SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ADAMS JB, 1988, MOL CELL ENDOCRINOL, V58, P231, DOI 10.1016/0303-7207(88)90159-1; BARNES S, 1989, J LIPID RES, V30, P529; Bernstein S., 1970, CHEM BIOL ASPECTS ST; BROOKS SC, 1978, J TOXICOL ENV HEALTH, V4, P283, DOI 10.1080/15287397809529662; BURTON RM, 1974, FUNDAMENTALS LIPID C, P408; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMER KA, 1993, BIOCHEM J, V289, P233, DOI 10.1042/bj2890233; DAVIS LG, 1986, BASIC METHODS MOL BI, P72; DEMYAN WF, 1992, MOL ENDOCRINOL, V6, P589, DOI 10.1210/me.6.4.589; DRISCOLL WJ, 1993, J BIOL CHEM, V268, P23496; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HOMMA H, 1991, CHEM PHARM BULL, V39, P1499; Huxtable RJ, 1986, BIOCH SULFUR, P293; KOMATSU K, 1993, BIOCHEM BIOPH RES CO, V194, P1297, DOI 10.1006/bbrc.1993.1965; KONG ANT, 1992, BIOCHEM BIOPH RES CO, V187, P448, DOI 10.1016/S0006-291X(05)81514-1; KONG ANT, 1993, PHARMACEUT RES, V10, P627, DOI 10.1023/A:1018926825475; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE YC, 1990, P NATL ACAD SCI USA, V87, P2003, DOI 10.1073/pnas.87.5.2003; MULDER GJ, 1990, CONJUGATION REACTION, P197; NASH AR, 1988, AUST J BIOL SCI, V41, P507; OEDA T, 1992, MOL ENDOCRINOL, V6, P1216, DOI 10.1210/me.6.8.1216; OGURA K, 1989, BIOCHEM BIOPH RES CO, V165, P168, DOI 10.1016/0006-291X(89)91050-4; OHL VS, 1977, ARCH BIOCHEM BIOPHYS, V180, P186, DOI 10.1016/0003-9861(77)90024-8; OTTERNESS DM, 1992, MOL PHARMACOL, V41, P865; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; RADOMINSKA A, 1990, BIOCHEM J, V272, P597, DOI 10.1042/bj2720597; Roy A.B., 1981, SULFATION DRUGS RELA, P83; Roy AB, 1970, CHEM BIOL ASPECTS ST, P74; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STROTT CA, 1983, J STEROID BIOCHEM, V18, P489, DOI 10.1016/0022-4731(83)90070-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHITNALL MH, 1993, ENDOCRINOLOGY, V133, P2284, DOI 10.1210/en.133.5.2284; ZHU XY, 1993, BIOCHEM BIOPH RES CO, V192, P671, DOI 10.1006/bbrc.1993.1467; 1992, ENZYME NOMENCLATURE, P299	37	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15838	15845						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195238				2022-12-27	WOS:A1994NP51300069
J	MURATALIEV, MB; BOYER, PD				MURATALIEV, MB; BOYER, PD			INTERACTION OF MITOCHONDRIAL F-1-ATPASE WITH TRINITROPHENYL DERIVATIVES OF ATP AND ADP - PARTICIPATION OF 3RD CATALYTIC SITE AND ROLE OF MG2+ IN ENZYME INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-SITES; ESCHERICHIA-COLI F(1)-ATPASE; STEADY-STATE KINETICS; ISOLATED BETA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; CHLOROPLAST ATPASE; SINGLE SITE; F1-ATPASE; MECHANISM; HYDROLYSIS	Relatively high ATP concentrations show an unexpected lack of inhibition of the hydrolysis of low concentrations of trinitrophenyl ATP (TNP-ATP) by mitochondrial F-1-ATPase. In striking contrast low TNP-ATP concentrations markedly inhibit the hydrolysis of much higher ATP concentrations. The three catalytic sites undergoing sequential conformational changes have different conformations at any instant of catalysis, and only two need to be filled for rapid, steady-state ATP hydrolysis. The remaining site has low affinity for ATP (K-d 2 mM) but about 10(4) greater affinity for TNP-ATP (K-m and K-d about 0.2 mu M). Thus 500 mu M ATP does not prevent binding of less than 1 mu M TNP-ATP. As the site binding the TNP-ATP undergoes sequential conformational changes the TNP-ATP is hydrolyzed and products are released. The results give strong support to the view that all three catalytic sites proceed equivalently in ATP as well as TNP-ATP hydrolysis. The conformation that has the lowest affinity for ATP has over a 10-fold greater affinity for ADP (K-d 150 mu M) and may be akin to the conformation to which ADP binds during net ATP synthesis by the ATP synthase. The recognition of these features was made possible by new information obtained from detailed studies of the interactions of Mg2+, TNP-ADP, TNP-ATP, ATP, and noncatalytic sites on initial and steady-state hydrolysis rates.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA	Scripps Research Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIDDK NIH HHS [DK08126] Funding Source: Medline; NIGMS NIH HHS [GM11094] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK008126, R01DK008126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011094] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIDWAI AP, 1989, J BIOL CHEM, V264, P11790; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BULYGIN VV, 1991, BIOCHEM J, V276, P149, DOI 10.1042/bj2760149; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; EBEL RE, 1975, J BIOL CHEM, V250, P191; FALLER LD, 1990, BIOCHEMISTRY-US, V29, P3179, DOI 10.1021/bi00465a004; FELDMAN RI, 1985, J BIOL CHEM, V260, P3088; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; HIRATSUKA T, 1975, J BIOCHEM-TOKYO, V78, P1135, DOI 10.1093/oxfordjournals.jbchem.a131009; HISABORI T, 1992, J BIOL CHEM, V267, P4551; HUTTON RL, 1979, J BIOL CHEM, V254, P9990; JAULT JM, 1993, J BIOL CHEM, V268, P1558; KALASHNIKOVA TY, 1988, EUR J BIOCHEM, V177, P213, DOI 10.1111/j.1432-1033.1988.tb14364.x; KIRONDE FAS, 1986, J BIOL CHEM, V261, P2544; KNOWLES AF, 1972, J BIOL CHEM, V247, P6624; KORMER ZS, 1982, EUR J BIOCHEM, V121, P451, DOI 10.1111/j.1432-1033.1982.tb05808.x; KOZLOV IA, 1985, FEBS LETT, V182, P425, DOI 10.1016/0014-5793(85)80347-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILGROM YM, 1993, J BIOL CHEM, V268, P23179; MILLS DA, 1991, J BIOL CHEM, V266, P7440; MURATALIEV MB, 1991, BIOCHEMISTRY-US, V30, P8305, DOI 10.1021/bi00098a004; MURATALIEV MB, 1992, BIOCHEMISTRY-US, V31, P12885, DOI 10.1021/bi00166a025; MURATALIEV MB, 1992, EUR J BIOCHEM, V209, P681, DOI 10.1111/j.1432-1033.1992.tb17336.x; MUSIER KM, 1988, BIOCHEMISTRY-US, V27, P7015, DOI 10.1021/bi00418a052; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RAO R, 1988, J BIOL CHEM, V263, P5569; SHAPIRO AB, 1991, J BIOL CHEM, V266, P17276; SINES JJ, 1986, BIOCHEMISTRY-US, V25, P6144, DOI 10.1021/bi00368a047; TIEDGE H, 1986, BIOL CHEM H-S, V367, P689, DOI 10.1515/bchm3.1986.367.2.689; TURINA P, 1993, J BIOL CHEM, V268, P6978; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; VULFSON EN, 1986, BIOL MEMBRANY, V3, P339; WAGNER R, 1986, EUR J BIOCHEM, V161, P205, DOI 10.1111/j.1432-1033.1986.tb10143.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WATANABE T, 1982, J BIOL CHEM, V257, P1510; WEBER J, 1993, J BIOL CHEM, V268, P20126; ZOU JM, 1993, J BIOL CHEM, V268, P1531	45	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15431	15439						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195184				2022-12-27	WOS:A1994NP51300009
J	OHTA, Y; SAKAKI, T; YABUSAKI, Y; OHKAWA, H; KAWATO, S				OHTA, Y; SAKAKI, T; YABUSAKI, Y; OHKAWA, H; KAWATO, S			ROTATION AND MEMBRANE TOPOLOGY OF GENETICALLY EXPRESSED METHYLCHOLANTHRENE-INDUCIBLE CYTOCHROME P-450IA1 LACKING THE N-TERMINAL HYDROPHOBIC SEGMENT IN YEAST MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CYTOCHROME-P-450; PROTEIN ROTATION; NADPH-CYTOCHROME-P450 REDUCTASE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; ADRENOCORTICAL MITOCHONDRIA; PHOSPHOLIPID-VESICLES; INNER MEMBRANE; FUSED ENZYME; PROTEOLIPOSOMES	A modified rat liver cytochrome P-450IA1, lacking amino acids 2-30, a proposed membrane anchor for cytochrome P-450, was expressed genetically in yeast microsomal membranes. This truncated cytochrome is practically active in the deethylation of 7-ethoxycoumarin. A full-length cytochrome P-450IA1 was also expressed in yeast microsomes. Rotational diffusion of P-450IA1 was examined by observing the flash-induced absorption anisotropy r(t) of the P-450.CO complex. The anisotropy decayed to a time-independent value within a 2-ms time range. Since the decay curve has the characteristics of a slow rotation of membrane-embedded cytochrome, the theoretical analysis of r(t) was performed based on a ''rotation-about-membrane normal'' model. 41% of the shortened P-450IA1 was rotating with the rotational relaxation time phi of 1020 mu s, whereas 27% of the full length P-450IA1 was mobile with phi = 1101 mu s. The high salt treatment did not remove the shortened cytochrome from the membrane and also did not drastically weaken the interactions of the cytochrome with the membrane, as judged from the slow rotation characteristics (phi = 830 mu s). These results demonstrate that the N-terminal shortened P-450IA1 is incorporated properly into the yeast microsomal membrane and that the N-terminal hydrophobic segment is not solely responsible for attachment to the membrane, providing evidence that additional segments of P-450IA1 are involved in the membrane binding	UNIV TOKYO,COLL ARTS & SCI,INST PHYS,MEGURO KU,TOKYO 153,JAPAN; SUMITOMO CHEM CO LTD,TAKARAZUKA RES CTR,BIOTECHNOL LAB,TAKARAZUKA,HYOGO 665,JAPAN	University of Tokyo; Sumitomo Chem Co Ltd			Ohta, Yoshihiro/C-8741-2013	Ohta, Yoshihiro/0000-0001-7416-0507				BROWN CA, 1989, J BIOL CHEM, V264, P4442; Cherry R J, 1978, Methods Enzymol, V54, P47; DELEMOSCHIARANDINI C, 1987, J CELL BIOL, V104, P209, DOI 10.1083/jcb.104.2.209; EDWARDS RJ, 1991, BIOCHEMISTRY-US, V30, P71, DOI 10.1021/bi00215a011; ESTABROOK RW, 1979, ACS SYM SER, V97, P149; ETTER HU, 1991, J BIOL CHEM, V266, P18600; Gotoh O., 1989, FRONTIERS BIOTRANSFO, V1, P195; GUENGERICH FP, 1987, MAMMALIAN CYTOCHROME, V2; GUT J, 1982, J BIOL CHEM, V257, P7030; GUT J, 1985, BIOCHIM BIOPHYS ACTA, V817, P217, DOI 10.1016/0005-2736(85)90023-9; GUT J, 1983, J BIOL CHEM, V258, P8588; HARADA N, 1981, J BIOCHEM-TOKYO, V89, P237, DOI 10.1093/oxfordjournals.jbchem.a133187; IWASE T, 1991, BIOCHEMISTRY-US, V30, P8347, DOI 10.1021/bi00098a010; KAWATO S, 1982, J BIOL CHEM, V257, P7023; KAWATO S, 1991, J BIOCHEM-TOKYO, V109, P587, DOI 10.1093/oxfordjournals.jbchem.a123424; KAWATO S, 1981, BIOPHYS J, V36, P277, DOI 10.1016/S0006-3495(81)84728-5; KAWATO S, 1988, J BIOCHEM-TOKYO, V104, P188, DOI 10.1093/oxfordjournals.jbchem.a122439; KAWATO S, 1981, J BIOL CHEM, V256, P7518; LARSON JR, 1991, J BIOL CHEM, V266, P7321; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; MURAKAMI H, 1987, DNA-J MOLEC CELL BIO, V6, P189, DOI 10.1089/dna.1987.6.189; MURAKAMI H, 1990, J BIOCHEM, V108, P859, DOI 10.1093/oxfordjournals.jbchem.a123293; NELSON DR, 1988, J BIOL CHEM, V263, P6038; OEDA K, 1985, DNA CELL BIOL, V4, P204; OHTA Y, 1992, BIOCHEMISTRY-US, V31, P12680, DOI 10.1021/bi00165a019; OHTA Y, 1991, J BIOCHEM-TOKYO, V109, P594, DOI 10.1093/oxfordjournals.jbchem.a123425; OHTA Y, 1990, J BIOCHEM-TOKYO, V107, P97, DOI 10.1093/oxfordjournals.jbchem.a123020; OMURA T, 1964, J BIOL CHEM, V239, P2370; SAKAKI T, 1987, DNA-J MOLEC CELL BIO, V6, P31, DOI 10.1089/dna.1987.6.31; SAKAKI T, 1985, J BIOCHEM-TOKYO, V98, P167, DOI 10.1093/oxfordjournals.jbchem.a135255; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; VERGERES G, 1989, BIOCHEMISTRY-US, V28, P3650, DOI 10.1021/bi00435a005; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701	34	20	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15597	15600						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195206				2022-12-27	WOS:A1994NP51300034
J	ROSALES, R; HARRIS, N; AHN, BY; MOSS, B				ROSALES, R; HARRIS, N; AHN, BY; MOSS, B			PURIFICATION AND IDENTIFICATION OF A VACCINIA VIRUS-ENCODED INTERMEDIATE STAGE PROMOTER-SPECIFIC TRANSCRIPTION FACTOR THAT HAS HOMOLOGY TO EUKARYOTIC TRANSCRIPTION FACTOR SII (TFIIS) AND AN ADDITIONAL ROLE AS A VIRAL-RNA POLYMERASE SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MUTATIONAL ANALYSIS; POLY(A) POLYMERASE; ELONGATION-FACTOR; DNA-REPLICATION; EARLY GENES; VIRIONS; GUANYLYLTRANSFERASE; EXPRESSION; TEMPLATE	Enzymes and factors, required for in vitro transcription of templates regulated by vaccinia virus intermediate stage promoters, are present in HeLa cells infected with vaccinia virus in the presence of an inhibitor of DNA replication. Previous studies indicated that in vitro transcription could be reconstituted by adding a partially purified transcription factor to the viral RNA polymerase and capping enzyme. By using an independent purification procedure, we isolated two vaccinia virus intermediate transcription factors VITF-1 and VITF-2 that were necessary for transcription of several different intermediate stage promoter templates but not for early or late stage promoter templates. VITF-1 was purified to homogeneity, and the sequences of two tryptic peptides were mapped to the fourth open reading frame within the HindIII E fragment (E4L) of the vaccinia virus genome, which had previously been shown to encode an RNA polymerase subunit of 30 kDa (RPO30) with homology to eukaryotic transcription elongation factor SII. Co-chromatography of VITF-1 with the E4L-derived protein was demonstrated using specific antiserum. In addition, transcriptionally active recombinant VITF-1 was made by expressing the E4L open reading frame in Escherichia coli. Thus, E4L encodes a multifunctional protein, serving as a RNA polymerase subunit and a stage-specific transcription factor. The stepwise binding of capping enzyme, VITF-1, and VITF-2 to a DNA/viral RNA polymerase complex was demonstrated.	NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Moss, Bernard/0000-0002-2154-8564				AHN BY, 1992, P NATL ACAD SCI USA, V89, P3536, DOI 10.1073/pnas.89.8.3536; AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; AHN BY, 1994, J BIOL CHEM, V269, P7552; BALDICK CJ, 1993, J VIROL, V67, P3515, DOI 10.1128/JVI.67.6.3515-3527.1993; BALDICK CJ, 1992, J VIROL, V66, P4710, DOI 10.1128/JVI.66.8.4710-4719.1992; BAROUDY BM, 1980, J BIOL CHEM, V255, P4372; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1990, J VIROL, V64, P5376, DOI 10.1128/JVI.64.11.5376-5382.1990; BROYLES SS, 1990, J VIROL, V64, P1523, DOI 10.1128/JVI.64.4.1523-1529.1990; DAVISON AJ, 1989, J MOL BIOL, V210, P749, DOI 10.1016/0022-2836(89)90107-1; DAVISON AJ, 1989, J MOL BIOL, V210, P771, DOI 10.1016/0022-2836(89)90108-3; GERSHON PD, 1991, CELL, V66, P1269, DOI 10.1016/0092-8674(91)90048-4; GERSHON PD, 1990, P NATL ACAD SCI USA, V87, P4401, DOI 10.1073/pnas.87.11.4401; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HARRIS N, 1993, P NATL ACAD SCI USA, V90, P2860, DOI 10.1073/pnas.90.7.2860; HIRSCHMANN P, 1990, J VIROL, V64, P6063, DOI 10.1128/JVI.64.12.6063-6069.1990; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KATES J, 1970, J MOL BIOL, V50, P19, DOI 10.1016/0022-2836(70)90101-4; KATES JR, 1967, P NATL ACAD SCI USA, V58, P134, DOI 10.1073/pnas.58.1.134; KECK JG, 1990, CELL, V61, P801, DOI 10.1016/0092-8674(90)90190-P; KECK JG, 1993, J VIROL, V67, P5740, DOI 10.1128/JVI.67.10.5740-5748.1993; MANLEY JL, 1987, TRANSCRIPTION TRANSL, P72; MARTIN SA, 1975, J BIOL CHEM, V250, P9330; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; MUNYON W, 1967, P NATL ACAD SCI USA, V58, P2280, DOI 10.1073/pnas.58.6.2280; ROHRMANN G, 1985, J VIROL, V56, P349, DOI 10.1128/JVI.56.2.349-355.1985; ROSALES R, 1994, P NATL ACAD SCI US, V91; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1990, METHOD ENZYMOL, V181, P170; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; VOS JC, 1991, CELL, V65, P105, DOI 10.1016/0092-8674(91)90412-R; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x; VOS JC, 1988, EMBO J, V7, P3487, DOI 10.1002/j.1460-2075.1988.tb03224.x; WEI CM, 1975, P NATL ACAD SCI USA, V72, P318, DOI 10.1073/pnas.72.1.318; WRIGHT CF, 1991, J VIROL, V65, P3715, DOI 10.1128/JVI.65.7.3715-3720.1991; ZHANG YF, 1994, J VIROL, V68, P1360, DOI 10.1128/JVI.68.3.1360-1370.1994; [No title captured]	41	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14260	14267						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188710				2022-12-27	WOS:A1994NL60600081
J	TAGLIALATELA, M; CHAMPAGNE, MS; DREWE, JA; BROWN, AM				TAGLIALATELA, M; CHAMPAGNE, MS; DREWE, JA; BROWN, AM			COMPARISON OF H-5, S-6, AND H-5-S-6 EXCHANGES ON PORE PROPERTIES OF VOLTAGE-DEPENDENT K+ CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; SODIUM-CHANNEL; TEA BLOCKADE; RAT-BRAIN; TETRAETHYLAMMONIUM; SHAKER; MUTATIONS; REGION; INACTIVATION; PERMEATION	Evidence is now substantial that membrane segments besides H-5 contribute to the pore of K+ channels. We found that substitution of the H-5 region of Shaker B (ShB) with the corresponding sequence of NGK2 expressed channels which retained the single channel K+ conductance (g(K+)) of the host ShB channel. A reverse chimera with ShB H-5 region transplanted into NGK2 also retained the g(K+) of the host NGK2. Point mutations V443L+T449Y in ShB H-5 converted internal tetraethylammonium (TEA) affinity to NGK2 values, and T449Y converted external TEA affinity and Rb+ conductance (g(Rb+)) to NGK2 values. In ShB, exchanging a short stretch of 9 amino acids located just past the transmembrane segment referred to as S-6, post-S-6, produced a large increase in g(K+) with no effect on internal or external TEA blockade. Within S-6, 3 important residues for internal TEA blockade were identified. Thus, H-5 determines external TEA blockade and both H-5 and S-6 may determine internal TEA blockade, but neither H-5 nor S-6 alone restored the donor g(K+). However, chimeric channels in which H-5, S-6, and post-S-6 were exchanged transferred g(K+) of NGK2 to ShB or the g(K+) of ShB to NGK2. Thus, contributions from H-5, S-6, and its cytoplasmic extension post-S-6 make the pore of voltage-dependent Shaker K+ channels a polysegmental mosaic structure.			TAGLIALATELA, M (corresponding author), BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030, USA.		Taglialatela, Maurizio/ABH-4262-2020; Taglialatela, Maurizio/AAB-8621-2022; Taglialatela, Maurizio/A-2062-2019; Taglialatela, Maurizio/K-1840-2013	Taglialatela, Maurizio/0000-0002-8202-0560; Taglialatela, Maurizio/0000-0002-8202-0560	NHLBI NIH HHS [HL36930] Funding Source: Medline; NINDS NIH HHS [NS23877] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUMANN A, 1987, EMBO J, V6, P3419, DOI 10.1002/j.1460-2075.1987.tb02665.x; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; DEBIASI M, 1993, PFLUG ARCH EUR J PHY, V422, P354, DOI 10.1007/BF00374291; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GOULDING EH, 1993, NATURE, V364, P61, DOI 10.1038/364061a0; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hille B., 1992, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISAKOFF EY, 1991, NATURE, V353, P86; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KIRSCH GE, 1993, NEURON, V11, P503, DOI 10.1016/0896-6273(93)90154-J; KIRSCH GE, 1992, BIOPHYS J, V62, P136, DOI 10.1016/S0006-3495(92)81800-3; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; NEWLAND CF, 1992, NEURON, V8, P975, DOI 10.1016/0896-6273(92)90212-V; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; Sambrook J, 1989, MOL CLONING LABORATO; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; TAGLIALATELA M, 1993, PFLUG ARCH EUR J PHY, V423, P104, DOI 10.1007/BF00374967; TAGLIALATELA M, 1991, MOL PHARMACOL, V40, P299; TANG SQ, 1993, J BIOL CHEM, V268, P13026; WITTKA R, 1991, FEBS LETT, V286, P193, DOI 10.1016/0014-5793(91)80972-6; YELLEN G, 1987, ANNU REV BIOPHYS BIO, V16, P227; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	33	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13867	13873						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188663				2022-12-27	WOS:A1994NL60600025
J	PAN, GH; SADOWSKI, PD				PAN, GH; SADOWSKI, PD			IDENTIFICATION OF THE FUNCTIONAL DOMAINS OF THE FLP RECOMBINASE - SEPARATION OF THE NONSPECIFIC AND SPECIFIC DNA-BINDING, CLEAVAGE, AND LIGATION DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; 2-MU-M CIRCLE PLASMID; SACCHAROMYCES-CEREVISIAE; TARGET SITE; COPY NUMBER; PROTEIN; YEAST; SEQUENCES; TYROSINE; MUTANTS	The FLP recombinase of the 2-mum plasmid of Saccharomyces cerevisiae binds to its recognition target (FRT) site, induces a bend in the DNA, and promotes DNA cleavage and strand ligation. We have subjected this protein to limited proteolysis and have purified three polypeptides: P13 (13 kDa), P21 (21 kDa), and P32 (32 kDa). These peptides are derived from the following regions of FLP: P13, amino acids 2-123; P21, amino acids 148-346; P32, amino acids 124-423. In this report, we show that P13 binds to DNA nonspecifically and P32, like P21, binds to the FRT site specifically. A single molecule of P32 is able to induce a bend in the DNA of 55-degrees, similar to that induced by intact FLP (63-degrees). P13 enhances the binding of P21 or P32 to the FRT site. Both P32 and P21 can catalyze DNA ligation in combination with P13. P32 can cleave and covalently attach to the FRT site in combination with P13, whereas P21 cannot. These results suggest that FLP contains two DNA-binding domains. A nonspecific DNA-binding region is located in the NH-2-terminal 123 amino acids, whereas the region that imparts specific DNA-binding resides in amino acids 148-346. Only the regions in P13 and P21 are needed for ligation activity, but those in P13 and P32 are required for cleavage.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A8, ONTARIO, CANADA	University of Toronto								AMIN AA, 1990, J MOL BIOL, V214, P55, DOI 10.1016/0022-2836(90)90146-D; ANDREWS BJ, 1987, J MOL BIOL, V193, P345, DOI 10.1016/0022-2836(87)90223-3; ANDREWS BJ, 1985, CELL, V40, P795, DOI 10.1016/0092-8674(85)90339-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCKNER RC, 1986, J BIOL CHEM, V261, P1798; CHEN JW, 1991, P NATL ACAD SCI USA, V88, P5944, DOI 10.1073/pnas.88.14.5944; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; EVANS BR, 1990, J BIOL CHEM, V265, P18504; FRIESEN H, 1992, J MOL BIOL, V225, P313, DOI 10.1016/0022-2836(92)90924-9; FUTCHER AB, 1984, J BACTERIOL, V157, P283, DOI 10.1128/JB.157.1.283-290.1984; FUTCHER AB, 1983, J BACTERIOL, V154, P612, DOI 10.1128/JB.154.2.612-622.1983; FUTCHER AB, 1986, J THEOR BIOL, V119, P197, DOI 10.1016/S0022-5193(86)80074-1; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P2320; HOESS R, 1990, J MOL BIOL, V216, P873, DOI 10.1016/S0022-2836(99)80007-2; JAYARAM M, 1988, P NATL ACAD SCI USA, V85, P7902, DOI 10.1073/pnas.85.21.7902; KULPA J, 1993, J BIOL CHEM, V268, P1101; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBRETON B, 1988, GENETICS, V118, P393; MEYERLEON L, 1990, MOL CELL BIOL, V10, P235, DOI 10.1128/MCB.10.1.235; MEYERLEON L, 1988, MOL CELL BIOL, V8, P3784, DOI 10.1128/MCB.8.9.3784; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; PAN GH, 1992, J BIOL CHEM, V267, P12397; PAN GH, 1993, J BIOL CHEM, V268, P3683; PAN H, 1991, J BIOL CHEM, V266, P11347; PROTEAU G, 1986, NUCLEIC ACIDS RES, V14, P4787, DOI 10.1093/nar/14.12.4787; SCHWARTZ CJE, 1989, J MOL BIOL, V205, P647, DOI 10.1016/0022-2836(89)90310-0; SCHWARTZ CJE, 1990, J MOL BIOL, V216, P289, DOI 10.1016/S0022-2836(05)80320-1; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030	29	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22546	22551						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226765				2022-12-27	WOS:A1993MD34800056
J	WILKS, A; DEMONTELLANO, PRO				WILKS, A; DEMONTELLANO, PRO			RAT-LIVER HEME OXYGENASE - HIGH-LEVEL EXPRESSION OF A TRUNCATED SOLUBLE FORM AND NATURE OF THE MESO-HYDROXYLATING SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CHICK LIVER; IX-ALPHA; PURIFICATION; MICROSOMES; DEGRADATION; CDNA; METALLOPORPHYRINS; OXIDATION; REDUCTASE	A rat heme oxygenase (HO-1) gene without the sequence coding for the last 23 amino acids has been constructed and expressed behind the pho A promoter in Escherichia coli. The enzyme is expressed at high levels as a soluble catalytically active protein that causes the bacterial cells to accumulate biliverdin. The purified truncated heme-heme oxygenase complex is spectroscopically indistinguishable from the complex with the native enzyme and converts heme to biliverdin when reconstituted with rat liver cytochrome P450 reductase. Reaction of the recombinant heme-heme oxygenase complex with H2O2 produces a species with the spectroscopic properties of verdoheme. Unidentified products are obtained when this intermediate is directly extracted from the protein, but biliverdin is obtained if the verdoheme-protein complex is exposed to cytochrome P450 reductase and NADPH before the extraction step. In contrast, reaction of the heme-heme oxygenase complex with meta-chloroperbenzoic acid (mCPBA), tert-butylhydroperoxide, or cumene hydroperoxide yields a ferryl (Fe(IV)=O) complex. Reaction of the heme-heme oxygenase complex with mCPBA also produces an EPR-detectable protein radical. In accord with formation of a ferryl intermediate, recombinant heme oxygenase catalyzes the mCPBA- and alkylhydroperoxide-dependent peroxidation of 2-methoxyphenol (guaiacol). Guaiacol oxidation is not observed during turnover of the enzyme by cytochrome P450 reductase/NADPH or H2O2. Conversely, biliverdin is not formed with tert-butylhydroperoxide or mCPBA. H2O2 thus supports the first step of the normal catalytic oxidation of heme by heme oxygenase, but alkyl and acyl hydroperoxides do not. These results suggest that the alpha-meso-hydroxylation required for biliverdin formation is mediated by the distal of the two oxygens in the iron-dioxygen intermediate (Fe-O-O) engendered by reaction with either cytochrome P450 reductase/NADPH or H2O2.	UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CTR LIVER, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIDDK NIH HHS [DK30297, 5 P30 DK26743] Funding Source: Medline; NIGMS NIH HHS [GM32488] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743, R01DK030297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEK HK, 1992, J AM CHEM SOC, V114, P718, DOI 10.1021/ja00028a046; BONKOVSKY HL, 1990, EUR J BIOCHEM, V189, P155, DOI 10.1111/j.1432-1033.1990.tb15472.x; BONNETT R, 1972, J CHEM SOC PERK T 1, P2540, DOI 10.1039/p19720002540; CRAIG SP, 1991, P NATL ACAD SCI USA, V88, P2500, DOI 10.1073/pnas.88.6.2500; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; DOCHERTY JC, 1984, J BIOL CHEM, V259, P3066; EVANS CO, 1991, BIOCHEM J, V273, P659, DOI 10.1042/bj2730659; GUENGERICH FP, 1978, BIOCHEMISTRY-US, V17, P3633, DOI 10.1021/bi00610a033; HEWSON WD, 1979, PORPHYRINS, V7, P295; ISHIKAWA K, 1991, EUR J BIOCHEM, V202, P161, DOI 10.1111/j.1432-1033.1991.tb16357.x; JACKSON AH, 1968, J CHEM SOC C, P302, DOI 10.1039/j39680000302; JACKSON AH, 1978, TETRAHEDRON LETT, P5135; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; KING NK, 1963, J BIOL CHEM, V238, P1520; KONDO T, 1971, BIOCHEM J, V121, P601, DOI 10.1042/bj1210601; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1986, J BIOL CHEM, V261, P411; MEUNIER B, 1992, CHEM REV, V92, P1411, DOI 10.1021/cr00014a008; OCARRA P, 1969, FEBS LETT, V5, P295; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; Sambrook J, 1989, MOL CLONING LABORATO; SANO S, 1986, P NATL ACAD SCI USA, V83, P531, DOI 10.1073/pnas.83.3.531; SCHAEFER WH, 1985, BIOCHEMISTRY-US, V24, P3254, DOI 10.1021/bi00334a027; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; TATSUMI K, 1981, INORG CHEM, V20, P3771, DOI 10.1021/ic50225a040; TENHUNEN R, 1972, BIOCHEMISTRY-US, V11, P1716, DOI 10.1021/bi00759a029; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; WILKS A, 1992, J BIOL CHEM, V267, P8827; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YONETANI T, 1967, J BIOL CHEM, V242, P1974; YOSHIDA T, 1991, EUR J BIOCHEM, V199, P729, DOI 10.1111/j.1432-1033.1991.tb16177.x; YOSHIDA T, 1984, J BIOCHEM-TOKYO, V96, P563, DOI 10.1093/oxfordjournals.jbchem.a134868; YOSHIDA T, 1980, J BIOL CHEM, V255, P4418; YOSHIDA T, 1989, BIOCHEM BIOPH RES CO, V163, P1086, DOI 10.1016/0006-291X(89)92332-2; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHIDA T, 1979, J BIOL CHEM, V254, P4487; YOSHIDA T, 1982, J BIOL CHEM, V257, P9345; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x; YOSHIDA T, 1980, J BIOCHEM-TOKYO, V88, P557, DOI 10.1093/oxfordjournals.jbchem.a133003; YOSHINAGA T, 1990, BIOCHEM J, V270, P659, DOI 10.1042/bj2700659; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7778	42	233	237	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22357	22362						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226746				2022-12-27	WOS:A1993MD34800028
J	CSERJESI, P; LILLY, B; HINKLEY, C; PERRY, M; OLSON, EN				CSERJESI, P; LILLY, B; HINKLEY, C; PERRY, M; OLSON, EN			HOMEODOMAIN PROTEIN MHOX AND MADS PROTEIN MYOCYTE ENHANCER-BINDING FACTOR-II CONVERGE ON A COMMON ELEMENT IN THE MUSCLE CREATINE-KINASE ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; TRANSCRIPTION FACTORS; REGULATORY ELEMENTS; CARDIAC-MUSCLE; NUCLEAR FACTOR; FACTOR-II; GENE; EXPRESSION; PROMOTER; BRAIN	MHox is a mesoderm-specific homeodomain protein that binds an A/T-rich element that is essential for activity of the muscle creatine kinase (MCK) enhancer. The MHox binding site also binds the ubiquitous homeodomain protein Oct-1 as well as myocyte enhancer-binding factor-2 (MEF2), which belongs to the MADS superfamily of transactivators. To determine which of these proteins activates MCK transcription through the A/T element, we mutated this sequence such that it would selectively bind MHox, MEF2, or Oct-1 and tested the activities of the mutant enhancers in skeletal muscle cells. These mutant enhancers revealed that only MEF2 is able to activate the MCK enhancer through the A/T element. The convergence of homeodomain and MADS proteins on the A/T element in the MCK enhancer provides a mechanism through which a single DNA sequence can mediate positive and negative regulation of gene transcription and is reminiscent of the roles of these two classes of transcription factors in the control of other cell-specific genes.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			LILLY, BRENDA/N-6867-2015	LILLY, BRENDA/0000-0002-3125-7496				AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; ANDRES V, 1992, DEVELOPMENT, V116, P321; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P17; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HINKLEY C, 1991, MOL CELL BIOL, V11, P641, DOI 10.1128/MCB.11.2.641; HOBSON GM, 1988, NUCLEIC ACIDS RES, V16, P8925, DOI 10.1093/nar/16.18.8925; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KERN MJ, 1992, NUCLEIC ACIDS RES, V20, P5189, DOI 10.1093/nar/20.19.5189; KOMURO I, 1993, EMBO J, V12, P1387, DOI 10.1002/j.1460-2075.1993.tb05783.x; KORNBERG TB, 1993, J BIOL CHEM, V268, P26813; KURATANI S, 1994, DEV BIOL, V161, P357, DOI 10.1006/dbio.1994.1037; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; NOHNO T, 1993, DEV BIOL, V158, P254, DOI 10.1006/dbio.1993.1184; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	38	60	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16740	16745						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206996				2022-12-27	WOS:A1994NR29600037
J	PANAGIOTIDIS, CA; BURKHOLDER, WF; GAITANARIS, GA; GRAGEROV, A; GOTTESMAN, ME; SILVERSTEIN, SJ				PANAGIOTIDIS, CA; BURKHOLDER, WF; GAITANARIS, GA; GRAGEROV, A; GOTTESMAN, ME; SILVERSTEIN, SJ			INHIBITION OF DNAK AUTOPHOSPHORYLATION BY HEAT-SHOCK PROTEINS AND POLYPEPTIDE SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAK; GLUCOSE-REGULATED PROTEIN; PEPTIDE BINDING DOMAIN; MOLECULAR CHAPERONES; STRESS PROTEINS; ATPASE ACTIVITY; HSP70 HOMOLOG; REPLICATION; GENE; PHOSPHORYLATION	DnaK, the Hsp70 of Escherichia coli, autophosphorylates in vitro. Of the two heat shock proteins that interact with DnaK, GrpE inhibits DnaK phosphorylation, whereas DnaJ has no effect on the reaction. Three synthetic peptides are shown to inhibit DnaK phosphorylation. The potency of a given peptide correlates with its affinity for the DnaK protein. A truncated DnaK that lacks the carboxyl-terminal peptide-binding domain autophosphorylates; this reaction is resistant to the inhibitory peptides. Phosphorylation of the truncated DnaK is still inhibited by GrpE, indicating that the GrpE-binding site resides in the DnaK amino-terminal domain. Thus, DnaK phosphorylation is regulated in vitro, and possibly in vivo, by physiologically relevant substrates and cofactors.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT MICROBIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, INST CANC RES, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, INTEGRATED PROGRAM CELLULAR MOLEC & BIOPHYS STUDI, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University				Panagiotidis, Christos/0000-0001-9683-7320	NCI NIH HHS [CA23767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIRSHAPIRA D, 1990, P NATL ACAD SCI USA, V87, P1749, DOI 10.1073/pnas.87.5.1749; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; CEGIELSKA A, 1989, BIOCHIMIE, V71, P1071, DOI 10.1016/0300-9084(89)90113-2; CEGIELSKA A, 1989, J BIOL CHEM, V264, P21122; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; EZAKI B, 1989, MOL GEN GENET, V218, P183, DOI 10.1007/BF00331267; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREIDENPJ, 1992, EMBO J, V11, P63; FRIEDMAN DI, 1984, MICROBIOL REV, V48, P299, DOI 10.1128/MMBR.48.4.299-325.1984; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10342; GROSS CA, 1990, STRESS PROTEINS BIOL, P167; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HWANG DS, 1990, J BIOL CHEM, V265, P19244; KELLER JA, 1988, MOL MICROBIOL, V2, P31, DOI 10.1111/j.1365-2958.1988.tb00004.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAUX PG, 1978, CELL, V13, P427, DOI 10.1016/0092-8674(78)90317-3; LEUSTEK T, 1991, ARCH BIOCHEM BIOPHYS, V289, P256, DOI 10.1016/0003-9861(91)90469-Y; LEUSTEK T, 1989, P NATL ACAD SCI USA, V86, P7805, DOI 10.1073/pnas.86.20.7805; LEUSTEK T, 1992, CELL MOL BIOL, V38, P1; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOOMIS WF, 1982, MOL CELL BIOL, V2, P484, DOI 10.1128/MCB.2.5.484; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MIZZEN LA, 1991, CELL REGUL, V2, P165, DOI 10.1091/mbc.2.2.165; Morimoto RI, 1990, STRESS PROTEINS BIOL; Neidhardt FC, 1987, HEAT SHOCK RESPONSE, P1334; PAEK KH, 1987, J BACTERIOL, V169, P283, DOI 10.1128/jb.169.1.283-290.1987; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PELHAM HRB, 1990, STRESS PROTEINS BIOL, P287; RIEUL C, 1987, EUR J BIOCHEM, V168, P621, DOI 10.1111/j.1432-1033.1987.tb13461.x; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; SAKAKIBARA Y, 1988, J BACTERIOL, V170, P972, DOI 10.1128/jb.170.2.972-979.1988; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schlesinger M. J., 1982, HEAT SHOCK BACTERIA; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHERMAN MY, 1992, NATURE, V357, P167, DOI 10.1038/357167a0; SHERMAN MY, 1991, J BACTERIOL, V173, P7249, DOI 10.1128/jb.173.22.7249-7256.1991; SHERMAN MY, 1993, P NATL ACAD SCI USA, V90, P8648, DOI 10.1073/pnas.90.18.8648; SHI WY, 1992, J BACTERIOL, V174, P6256, DOI 10.1128/JB.174.19.6256-6263.1992; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; TILLY K, 1989, J BACTERIOL, V171, P1585, DOI 10.1128/jb.171.3.1585-1589.1989; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG TF, 1993, J BIOL CHEM, V268, P26049; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	60	17	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16643	16647						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206983				2022-12-27	WOS:A1994NR29600022
J	QUADRONI, M; JAMES, P; CARAFOLI, E				QUADRONI, M; JAMES, P; CARAFOLI, E			ISOLATION OF PHOSPHORYLATED CALMODULIN FROM RAT-LIVER AND IDENTIFICATION OF THE IN-VIVO PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; NUCLEOTIDE PHOSPHODIESTERASE; PEPTIDE COMPLEX; ENZYME; BRAIN; STIMULATION; RECOGNITION; POLYLYSINE; MEMBRANE; CELLS	A procedure is described for the isolation of calmodulin (CaM) from rat liver which produces a fraction containing non phosphorylated, mono-, di-, and triphosphocalmodulin as determined by mass spectrometric analysis. The distribution of CaM between the various phospho-species varies from preparation to preparation even though the isolation procedure is rigidly defined, suggesting that CaM phosphorylation may be a very labile phenomenon dependent on the state of the liver as it is removed from the animal. Approximately 15% of CaM in the cell is phosphorylated. The in vivo phosphorylation sites were determined by mass spectrometric analysis of a combined CNBr and trypsin digestion of the phosphocalmodulin (phospho-CaM)-containing fractions. Phosphorylated peptides were sequenced using two mass scanning devices linked together for collisionally activated fragmentation studies to determine peptide sequences, and the phosphorylation sites were determined as Thr-79, Ser-81, and Ser-101. These correspond to three of the four in vitro target sites of calmodulin phosphorylation by casein kinase II, which indicates that this may be the enzyme responsible for the phosphorylation in vivo. A preliminary study on the modulatory activity of phosphorylated calmodulin using a sample extensively phosphorylated in vitro with casein kinase II confirmed that phospho-CaM has an altered biological activity, i.e. reduced activation of the erythrocyte plasma membrane Ca2+ pump.	ETH ZURICH,INST BIOCHEM,CH-8092 ZURICH,SWITZERLAND; ETH ZURICH,DEPT BIOL,PROT CHEM LAB,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094; Quadroni, Manfredo/0000-0002-2720-4084				AGOSTINIS P, 1992, J BIOL CHEM, V267, P9732; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BROOKS JC, 1973, J BIOL CHEM, V248, P4189; FUKAMI Y, 1986, P NATL ACAD SCI USA, V83, P4190, DOI 10.1073/pnas.83.12.4190; GUERINI D, 1984, J BIOL CHEM, V259, P5172; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P6247, DOI 10.1021/bi00239a024; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; MCCLOSKEY JA, 1990, METHODS ENZYMOL, V193; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1987, FEBS LETT, V215, P241, DOI 10.1016/0014-5793(87)80154-0; NAKAJO S, 1986, BIOCHEM INT, V13, P687; NIGGLI V, 1981, J BIOL CHEM, V256, P395; NIGGLI V, 1981, J BIOL CHEM, V256, P359; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PLANCKE YD, 1983, MOL CELL BIOL, V3, P1412, DOI 10.1128/MCB.3.8.1412; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SACKS DB, 1992, BIOCHEM J, V283, P21, DOI 10.1042/bj2830021; SACKS DB, 1992, BIOCHEM J, V286, P211, DOI 10.1042/bj2860211; SARNO S, 1993, BIOCHEM BIOPH RES CO, V194, P83, DOI 10.1006/bbrc.1993.1788; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501; WOLFF DJ, 1972, J BIOL CHEM, V247, P4180; WOLFF DJ, 1974, ARCH BIOCHEM BIOPHYS, V163, P349, DOI 10.1016/0003-9861(74)90486-X	26	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16116	16122						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206911				2022-12-27	WOS:A1994NQ72900027
J	DEMORAIS, SMF; WILKINSON, GR; BLAISDELL, J; NAKAMURA, K; MEYER, UA; GOLDSTEIN, JA				DEMORAIS, SMF; WILKINSON, GR; BLAISDELL, J; NAKAMURA, K; MEYER, UA; GOLDSTEIN, JA			THE MAJOR GENETIC-DEFECT RESPONSIBLE FOR THE POLYMORPHISM OF S-MEPHENYTOIN METABOLISM IN HUMANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HYDROXYLATION POLYMORPHISM; OXIDATION POLYMORPHISM; LIVER-MICROSOMES; DEBRISOQUIN; DEFICIENCY; PHENOTYPE; JAPANESE	The metabolism of the anticonvulsant drug mephenytoin exhibits a genetic polymorphism in humans, with the poor metabolizer trait being inherited in an autosomal recessive fashion. There are large interracial differences in the frequency of the poor metabolizer phenotype, with Oriental populations having a 5-fold greater frequency compared to Caucasians. Impaired metabolism of mephenytoin and a number of other currently used drugs results from a defect in a cytochrome P450 enzyme recently identified as CYP2C19. Attempts over the past decade to define the molecular genetic basis of the polymorphism have, however, been unsuccessful. We now report that the principal defect in poor metabolizers is a single base pair (G --> A) mutation in exon 5 of CYP2C19, which creates an aberrant splice site. This change alters the reading frame of the mRNA starting with amino acid 215 and produces a premature stop codon 20 amino acids downstream, which results in a truncated, non-functional protein. We further demonstrate that 7/10 Caucasian and 10/17 Japanese poor metabolizers are homozygous for this defect, indicating that this is the major defect responsible for the poor metabolizer phenotype. Finally, the familial inheritance of the deficient allele was found to be concordant with that of the phenotypic trait.	NIEHS,RES TRIANGLE PK,NC 27709; VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232; MED COLL OITA,DEPT CLIN PHARMACOL & THERAPEUT,OITA 87955,JAPAN; UNIV BASEL,BIOZENTRUM,DEPT PHARMACOL,CH-4056 BASEL,SWITZERLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Vanderbilt University; Oita University; University of Basel			Goldstein, Joyce/A-6681-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031304] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31304] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEDOYIN A, 1994, PHARMACOGENETICS, V4, P27; ANDERSSON T, 1992, PHARMACOGENETICS, V2, P25, DOI 10.1097/00008571-199202000-00005; ARNS PA, 1990, PHARMACOLOGIST, V32, P140; BAUMANN P, 1986, INT CLIN PSYCHOPHARM, V1, P102, DOI 10.1097/00004850-198604000-00002; BERTILSSON L, 1989, CLIN PHARMACOL THER, V45, P348, DOI 10.1038/clpt.1989.40; BROLY F, 1991, DNA CELL BIOL, V10, P545, DOI 10.1089/dna.1991.10.545; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALY AK, 1993, PHARMACOL THERAPEUT, V57, P129, DOI 10.1016/0163-7258(93)90053-G; DEMORAIS SMF, 1993, BIOCHEM BIOPH RES CO, V194, P194, DOI 10.1006/bbrc.1993.1803; ESTES PA, 1992, J BIOL CHEM, V267, P14902; GOLDSTEIN JA, 1994, BIOCHEMISTRY-US, V33, P1743, DOI 10.1021/bi00173a017; GONZALEZ FJ, 1991, CLIN PHARMACOL THER, V50, P233, DOI 10.1038/clpt.1991.131; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; INABA T, 1986, AM J HUM GENET, V38, P768; KUPFER A, 1985, CLIN PHARMACOL THER, V38, P414; KUPFER A, 1984, EUR J CLIN PHARMACOL, V26, P753, DOI 10.1007/BF00541938; MEIER UT, 1985, CLIN PHARMACOL THER, V38, P488, DOI 10.1038/clpt.1985.213; MEIER UT, 1985, ANAL BIOCHEM, V151, P286, DOI 10.1016/0003-2697(85)90177-0; NAKAMURA K, 1985, CLIN PHARMACOL THER, V38, P402, DOI 10.1038/clpt.1985.194; NIELSON KK, 1991, ACTA PHYSL SCAN S, V14, P172; ROMKES M, 1991, BIOCHEMISTRY-US, V30, P3247, DOI 10.1021/bi00227a012; Sambrook J, 1989, MOL CLONING LABORATO; SINDRUP SH, 1993, THER DRUG MONIT, V15, P11, DOI 10.1097/00007691-199302000-00002; SKJELBO E, 1991, CLIN PHARMACOL THER, V49, P18, DOI 10.1038/clpt.1991.4; WARD SA, 1991, BRIT J CLIN PHARMACO, V31, P689, DOI 10.1111/j.1365-2125.1991.tb05594.x; WARD SA, 1987, CLIN PHARMACOL THER, V42, P96, DOI 10.1038/clpt.1987.114; WARD SA, 1989, CLIN PHARMACOL THER, V45, P72, DOI 10.1038/clpt.1989.11; WEDLUND PJ, 1984, CLIN PHARMACOL THER, V36, P773, DOI 10.1038/clpt.1984.256; WILKINSON GR, 1989, PHARMACOL THERAPEUT, V43, P53, DOI 10.1016/0163-7258(89)90047-8; WRIGHTONSA, 1993, ARCH BIOCH, V306, P240	30	836	879	3	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15419	15422						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195181				2022-12-27	WOS:A1994NP51300006
J	NAKANISHI, H; KAIBUCHI, K; ORITA, S; UENO, N; TAKAI, Y				NAKANISHI, H; KAIBUCHI, K; ORITA, S; UENO, N; TAKAI, Y			DIFFERENT FUNCTIONS OF SMG GDP DISSOCIATION STIMULATOR AND MAMMALIAN COUNTERPART OF YEAST CDC25	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-RELEASING FACTOR; GTP-BINDING PROTEINS; GDP/GTP EXCHANGE PROTEIN; RAS P21; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; CYCLASE PATHWAY; TYROSINE KINASE; TERMINAL REGION; GRB2	We have previously shown that both Smg GDP dissociation stimulator (GDS) and mammalian Cdc25 (mCdc25) stimulate the GDP/GTP exchange reaction of Ki-Ras and that Smg GDS is active only on the posttranslationally lipid-modified form of Ki-Ras, whereas mCdc25 is active on both the lipid modified and unmodified forms but is more active on the lipid-modified form. In the present study, we compared more detailed kinetic properties of Smg GDS and mCdc25 by use of the lipid-modified form of Ki-Ras as a common substrate. Both Smg GDS and mCdc25 stimulated the dissociation of GDP from Ki-Ras and formed the stable binary complex with Ki-Ras. In the presence of guanosine 5'-(3-O-thio) triphosphate (GTP gamma S), the stable ternary complex of Smg GDS GTP gamma S-Ki-Ras was produced, whereas GTP gamma S induced the dissociation of mCdc25 from mCdc25-Ki-Ras complex, yielding GTP gamma S-Ki-Ras. mCdc25 stimulated the dissociation of GDP from both the membrane bound and soluble forms of Ki-Ras, whereas Sng GDS was far less active on the membrane-bound form than on the soluble form. Moreover, Smg GDS translocated the GTP gamma S-bound form of membrane bound Ki-Ras to the soluble fraction as the stable ternary complex of Smg GDS-GTP gamma S-Ki-Ras, whereas mCdc25 did not show this activity. These results suggest that Smg GDS and mCdc25 play different roles in the regulation of Ki-Ras.	OSAKA UNIV,SCH MED,DEPT MOLEC BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN; KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI 444,AICHI,JAPAN; SHIONOGI INST MED SCI,SETTSU 566,JAPAN	Osaka University; Kobe University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Shionogi & Company Limited				Nakanishi, Hiroyuki/0000-0002-9765-0266				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; ITOH T, 1993, J BIOL CHEM, V268, P3025; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KAWAMURA M, 1993, BIOCHEM BIOPH RES CO, V190, P832, DOI 10.1006/bbrc.1993.1124; KAWAMURA S, 1991, BIOCHEM BIOPH RES CO, V174, P1095, DOI 10.1016/0006-291X(91)91533-I; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; ORITA S, 1993, J BIOL CHEM, V268, P25542; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; Steck T L, 1974, Methods Enzymol, V31, P172; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YOSHIDA K, 1988, CANCER RES, V48, P5503; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	36	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15085	15091						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195145				2022-12-27	WOS:A1994NP73800038
J	PERREGAUX, D; GABEL, CA				PERREGAUX, D; GABEL, CA			INTERLEUKIN-1-BETA MATURATION AND RELEASE IN RESPONSE TO ATP AND NIGERICIN - EVIDENCE THAT POTASSIUM-DEPLETION MEDIATED BY THESE AGENTS IS A NECESSARY AND COMMON FEATURE OF THEIR ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ATP; MOUSE MACROPHAGES; PRECURSOR INTERLEUKIN-1-BETA; SACCHAROMYCES-CEREVISIAE; BIOLOGICAL-ACTIVITY; PLASMA-MEMBRANES; LEADER PEPTIDE; IL-1-BETA; SECRETION; MONOCYTES	Lipopolysaccharide (LPS)-stimulated mouse peritoneal macrophages produce large quantities of interleukin (IL)-1 beta but in the absence of a secondary stimulus little of this cytokine is proteolytically processed to its mature biologically active state and externalized. The potassium-proton ionophore nigericin and ATP are known to promote the maturation and release of IL-1 beta from LPS-stimulated cells. We investigated the mechanisms by which these agents act in an attempt to understand requirements of the post-translational processing. Like nigericin, the ionophores A204 and lasalocid induced the release and maturation of IL-1 beta. The electrogenic potassium ionophore valinomycin, however, did not stimulate these post-translational events. Addition of nigericin or lasalocid to LPS-stimulated cells produced a rapid intracellular acidification; A204, however, did not alter pH, indicating that an acidification was not necessary for activation of IL-1 beta maturation. Macrophages treated with ATP became rounded and swollen, and after 30 min of treatment their appearance was comparable with cells treated with nigericin. Post-translational maturation and release of IL-1 beta began immediately after ATP addition. The majority of the 17-kDa mature IL-1 beta produced within the first 30 min of treatment was recovered extracellularly; in contrast, during this same time period the 35-kDa IL-1 beta precursor and the cytoplasmic marker enzyme lactate dehydrogenase and the lysosomal enzyme beta-N-acetylglucosaminidase remained cell-associated. ATP, therefore, promoted both the proteolytic maturation of IL-1 beta and the release of the biologically active species in the absence of cell lysis. Longer incubations with ATP caused cytolysis as judged by the release of the cytoplasmic enzymes. ADP was less active than ATP at initiating the post-translational maturation and release of IL-1 beta and AMP, GTP, and UTP were totally inactive. ATP, nigericin, A204, and lasalocid promoted a rapid and complete loss of the potassium analog Rb-86(+) from cells,that were preloaded with this cation; valinomycin-treated cells released only a portion of the radiolabeled cation. Agents that promoted the maturation and release of IL-1 beta from LPS-stimulated macrophages, therefore, shared an ability to mobilize intracellular potassium. Macrophages treated with ATP or nigericin in medium that contained KCl rather than NaCl failed to proteolytically activate and to release IL-1 beta. These data suggest that ATP and nigericin induce a net decrease in intracellular levels of K+ which is necessary for activation of the post-translational maturation of IL-1 beta.	PFIZER INC, DIV CENT RES, DEPT IMMUNOL & INFECT DIS, GROTON, CT 06340 USA	Pfizer								AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BALDARI C, 1987, EMBO J, V6, P229, DOI 10.1002/j.1460-2075.1987.tb04743.x; BALDARI CT, 1989, J IMMUNOL, V142, P785; BEUSCHER HU, 1990, J IMMUNOL, V144, P2179; BEYER EC, 1991, J BIOL CHEM, V266, P7971; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHIN J, 1993, J IMMUNOL, V151, P5574; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; ELMOATASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31, DOI 10.1016/0167-4889(92)90025-7; GIRI JG, 1985, J IMMUNOL, V134, P343; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GRAY PW, 1986, J IMMUNOL, V137, P3644; GRINSTEIN S, 1989, METHOD ENZYMOL, V173, P777; Hall C W, 1978, Methods Enzymol, V50, P439; HARA N, 1990, COMP BIOCHEM PHYS A, V97, P417, DOI 10.1016/0300-9629(90)90633-4; HARA N, 1990, FEBS LETT, V267, P281, DOI 10.1016/0014-5793(90)80945-F; HAZUDA DJ, 1991, J BIOL CHEM, V266, P7081; HAZUDA DJ, 1990, J BIOL CHEM, V265, P6318; HOGQUIST KA, 1991, J IMMUNOL, V147, P2181; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HOWARD AD, 1991, J IMMUNOL, V147, P2964; JOBLING SA, 1988, J BIOL CHEM, V263, P16372; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; LIVI GP, 1991, J BIOL CHEM, V266, P15348; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MATSUSHIMA K, 1986, J IMMUNOL, V136, P2883; MIZUTANI H, 1991, J EXP MED, V174, P821, DOI 10.1084/jem.174.4.821; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; Reed P W, 1979, Methods Enzymol, V55, P435; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SIDERS WM, 1993, J BIOL CHEM, V268, P22170; SINGER II, 1988, J EXP MED, V167, P389, DOI 10.1084/jem.167.2.389; SOUTHWICK FS, 1982, BIOCHEMISTRY-US, V21, P6321, DOI 10.1021/bi00267a043; STEINBERG TH, 1987, J BIOL CHEM, V262, P3118; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; SUNG SSJ, 1985, J BIOL CHEM, V260, P3442; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; YOUNG PR, 1988, J CELL BIOL, V107, P447, DOI 10.1083/jcb.107.2.447	45	583	592	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15195	15203						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195155				2022-12-27	WOS:A1994NP73800052
J	SHIROTANI, K; TAYLORPAPADIMITRIOU, J; GENDLER, SJ; IRIMURA, T				SHIROTANI, K; TAYLORPAPADIMITRIOU, J; GENDLER, SJ; IRIMURA, T			TRANSCRIPTIONAL REGULATION OF THE MUC1 MUCIN GENE IN COLON-CARCINOMA CELLS BY A SOLUBLE FACTOR - IDENTIFICATION OF A REGULATORY ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; BREAST-CANCER; CORE PROTEIN; EXPRESSION; GLYCOPROTEINS; TISSUES; ANTIGEN	We have investigated a mechanism of the regulation of mucin core polypeptide (MUC1) gene expression, which is induced by a soluble stimulatory factor, in KM12C human colon carcinoma cells. Conditioned media from normal human colon tissues elevated the level of expression of MUC1 mRNA. Transcriptional activation of the MUC1 gene was analyzed by transient expression of MUC1-CAT reporter plasmids containing the 5'-flanking sequence of the MUC1 gene fused to the bacterial chloramphenicol acetyltransferase (CAT) gene. A region between base pairs -531 and -520 of the 5'-flanking sequence of the MUC1 gene was sufficient for the induction of CAT activity by normal colon conditioned medium (NCCM). Mutagenesis of 3 base pairs within the region corresponding to sequence -531 to -517 from ACAGGGAGCGGTTAG to ACAGGGAGATTTTAG substantially decreased the induction of CAT activity by NCCM. Nuclear extracts from untreated or NCCM-treated KM12C cells were tested for their interaction with P-32-labeled oligonucleotides corresponding to this sequence. A specifically retarded band was identified after electrophoretic analysis. The quantity or mobility of this band was not changed by NCCM treatment. When an oligonucleotide with the three point mutations was used as a competitor, the retarded band remained at the same position. This element (positions -531 to -520), which we call the responsive mucin element, does not contain any sequence that corresponds to previously described cis-acting elements. A protein component complexed with this sequence was identified with a molecular mass of similar to 70 kDa by SDS-polyacrylamide gel electrophoresis.	UNIV TOKYO, FAC PHARMACEUT SCI, DIV CHEM TOXICOL & IMMUNOCHEM, BUNKYO KU, TOKYO 113, JAPAN; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; MAYO CLIN SCOTTSDALE, SCOTTSDALE, AZ 85259 USA	University of Tokyo; Cancer Research UK; Mayo Clinic; Mayo Clinic Phoenix								ABE M, 1993, P NATL ACAD SCI USA, V90, P282, DOI 10.1073/pnas.90.1.282; ABE M, 1990, J CELL PHYSIOL, V143, P226, DOI 10.1002/jcp.1041430205; BAECKSTROM D, 1993, CANCER RES, V53, P755; BURCHELL J, 1983, J IMMUNOL, V131, P508; BURCHELL J, 1987, CANCER RES, V47, P5476; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOHI DF, 1993, J BIOL CHEM, V268, P10133; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; HO SB, 1993, CANCER RES, V53, P641; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IRIMURA T, 1990, CANCER RES, V50, P3331; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; LANDCASTER CA, 1990, BIOCHEM BIOPH RES CO, V173, P1019; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; NAKAMORI S, 1994, GASTROENTEROLOGY, V106, P353, DOI 10.1016/0016-5085(94)90592-4; PEAT N, 1992, CANCER RES, V52, P1954; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOJAR HT, 1987, METHOD ENZYMOL, V138, P341; ZARETSKY JZ, 1990, FEBS LETT, V265, P46, DOI 10.1016/0014-5793(90)80880-R; ZOTTER S, 1987, LAB INVEST, V57, P193	22	28	28	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15030	15035						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195140				2022-12-27	WOS:A1994NP73800031
J	ZWOLLO, P; DESIDERIO, S				ZWOLLO, P; DESIDERIO, S			SPECIFIC RECOGNITION OF THE BLK PROMOTER BY THE B-LYMPHOID TRANSCRIPTION FACTOR B-CELL-SPECIFIC ACTIVATOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR COMPLEX; TYROSINE KINASE GENE; IG-BETA COMPONENTS; LYMPHOCYTES-B; MEMBRANE IMMUNOGLOBULIN; MOLECULAR-COMPONENTS; WAARDENBURG SYNDROME; PAIRED DOMAIN; FACTOR BSAP; ASSOCIATION	Several genes of the src family encode protein-tyrosine kinases that associate with the B-cell antigen receptor complex and are activated upon receptor cross-linking, including blk, lyn, and fyn. The blk gene is the only member of this family whose expression is restricted to B-lymphhoid cells. In the B lineage, blk is developmentally regulated: blk transcripts are first detected in pro-B-cells and persist until the differentiation of mature B-cells to plasma cells. We have found that the blk promoter is a target for a specific DNA-binding protein whose activity in B-lymphoid cell lines is positively correlated with blk expression. By three criteria, we have identified this DNA-binding protein as the transcription factor B-cell-specific activator protein (BSAP): 1) oligonucleotides containing known BSAP recognition sites were found to compete specifically with blk for binding to the protein detected in B-lymphoid extracts; 2) authentic BSAP was shown to bind the same site within the blk promoter as the protein identified in B-lymphoid extracts; and 3) the specific DNA-protein complex formed in B-lymphoid extracts was shown to react with an anti-BSAP antiserum. BSAP has been implicated previously in the transcriptional regulation of CD19, whose pattern of expression in B-cell development coincides with that of blk. These observations, and the correlation between expression of BSAP and expression of blk, suggest that BSAP is a positive regulator of blk transcription.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University					NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NCI NIH HHS [CA16519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ALESSANDRINI A, 1991, MOL CELL BIOL, V11, P2096, DOI 10.1128/MCB.11.4.2096; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; FELDHAUS AL, 1992, MOL CELL BIOL, V12, P1126, DOI 10.1128/MCB.12.3.1126; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HAGMAN J, 1991, EMBO J, V10, P3409, DOI 10.1002/j.1460-2075.1991.tb04905.x; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; Hill Robert E., 1992, Current Opinion in Cell Biology, V4, P967, DOI 10.1016/0955-0674(92)90126-W; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; KASHIWAMURA SI, 1990, J IMMUNOL, V145, P337; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LIAO F, 1992, J IMMUNOL, V148, P2909; NEL AE, 1984, BIOCHEM BIOPH RES CO, V125, P859, DOI 10.1016/0006-291X(84)91362-7; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TEDDER TF, 1989, J IMMUNOL, V143, P712; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	46	64	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15310	15317						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195169				2022-12-27	WOS:A1994NP73800068
J	SMITH, DL; TAO, T; MAGUIRE, ME				SMITH, DL; TAO, T; MAGUIRE, ME			MEMBRANE TOPOLOGY OF A P-TYPE ATPASE - THE MGTB MAGNESIUM TRANSPORT PROTEIN OF SALMONELLA-TYPHIMURIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SARCOPLASMIC-RETICULUM MEMBRANE; POSITIVELY CHARGED RESIDUES; X-RAY-DIFFRACTION; ESCHERICHIA-COLI; H+-ATPASE; NEUROSPORA-CRASSA; TRANSMEMBRANE SEGMENTS; CYTOPLASMIC LOCATION; COMPLEMENTARY-DNA	P-type ATPases are a family of cation transport enzymes present in all species from bacteria to mammals whose members mediate membrane flux of all common biologically relevant cations. More than 50 members of this family of transporters have been sequenced; extensive structural data are available, and several members have been analyzed by site-directed mutagenesis. Nonetheless, there is no current consensus regarding their membrane topology. In this work, the Salmonella typhimurium Mg2+ transporting P-type ATPase encoded by the MgtB locus has been used as a model for P-type ATPases. Unlike other prokaryotic P-type ATPases, the MgtB protein is similar in length, amino acid sequence, and hydropathy profile to known eukaryotic P-type ATPases. The membrane topology of MgtB was analyzed by several epitope insertions in MgtB and from the activity of 35 protein fusions between MgtB and the reporter enzymes BlaM (beta-lactamase) and LacZ (beta-galactosidase). The epitope insertions within MgtB all retained function as assessed by cation uptake assays and were regulated normally by the level of Mg2+ within the growth medium. The epitope insertion and fusion protein data are completely incompatible with the numerous previously proposed models for P-type ATPases predicting 7, 8, 9, or 12 transmembrane segments. Rather, they indicate that MgtB contains 10 transmembrane segments with both amino and carboxyl termini residing within the cytosol. By extension, we suggest that all eukaryotic P-type ATPases contain 10 transmembrane segments with both termini within the cytosol.			SMITH, DL (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, CLEVELAND, OH 44106 USA.				NHLBI NIH HHS [HL18708] Funding Source: Medline; NIGMS NIH HHS [GM39447] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039447] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1986, J BIOL CHEM, V261, P4896; ANDERSSON H, 1992, J BIOL CHEM, V267, P1491; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; ASTURIAS FJ, 1991, BIOPHYS J, V59, P488, DOI 10.1016/S0006-3495(91)82242-1; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BROOMESMITH JK, 1986, GENE, V49, P341, DOI 10.1016/0378-1119(86)90370-7; BROOMESMITH JK, 1990, MOL MICROBIOL, V4, P1637, DOI 10.1111/j.1365-2958.1990.tb00540.x; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; COLYER J, 1989, BIOCHEM J, V262, P439, DOI 10.1042/bj2620439; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; EPSTEIN W, 1990, BACTERIA, V12, P87; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GREEN NM, 1992, ANN NY ACAD SCI, V671, P104, DOI 10.1111/j.1749-6632.1992.tb43788.x; GRUBBS RD, 1989, METHOD ENZYMOL, V173, P546; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENNESSEY JP, 1990, J BIOL CHEM, V265, P532; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; HMIEL SP, 1989, J BACTERIOL, V171, P4742, DOI 10.1128/jb.171.9.4742-4751.1989; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JI, 1992, J BIOL CHEM, V267, P938; LEWIS MJ, 1990, J BIOL CHEM, V265, P10541; LLOYD AD, 1990, J BACTERIOL, V172, P1688, DOI 10.1128/jb.172.4.1688-1693.1990; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAGUIRE ME, 1992, J BIOENERG BIOMEMBR, V24, P319; MANDALA SM, 1989, J BIOL CHEM, V264, P16276; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1988, TRENDS GENET, V4, P223, DOI 10.1016/0168-9525(88)90154-0; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; MATTHEWS I, 1989, BIOCHEM BIOPH RES CO, V161, P683, DOI 10.1016/0006-291X(89)92653-3; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAKAMOTO RK, 1989, ANN NY ACAD SCI, V574, P165; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PASCOLINI D, 1988, BIOPHYS J, V54, P679, DOI 10.1016/S0006-3495(88)83003-0; PASCOLINI D, 1988, BIOPHYS J, V54, P669, DOI 10.1016/S0006-3495(88)83002-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; RAO US, 1991, J BIOL CHEM, V266, P14740; RICHARDSON JS, 1989, TRENDS BIOCHEM SCI, V14, P304, DOI 10.1016/0968-0004(89)90070-4; SACHS G, 1992, J BIOENERG BIOMEMBR, V24, P301; SACHS G, 1992, ANN NY ACAD SCI, V671, P204; SANMILLAN JL, 1989, J BACTERIOL, V171, P5536, DOI 10.1128/jb.171.10.5536-5541.1989; SCARBOROUGH GA, 1990, J BIOL CHEM, V265, P16145; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SMITH RL, 1993, J BIOL CHEM, V268, P14071; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; SNAVELY MD, 1989, J BACTERIOL, V171, P4761, DOI 10.1128/jb.171.9.4761-4766.1989; SNAVELY MD, 1991, J BIOL CHEM, V266, P824; SOLIOZ M, 1987, J BIOL CHEM, V262, P7358; SWEADNER KJ, 1992, ANN NY ACAD SCI, V671, P217, DOI 10.1111/j.1749-6632.1992.tb43798.x; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; TUNWELL REA, 1991, BIOCHIM BIOPHYS ACTA, V1073, P585, DOI 10.1016/0304-4165(91)90234-8; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1990, PROTEIN ENG, V4, P109, DOI 10.1093/protein/4.2.109; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WU JH, 1992, J BIOL CHEM, V267, P12570; YUN CH, 1991, J BIOL CHEM, V266, P10967	72	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22469	22479						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226755				2022-12-27	WOS:A1993MD34800045
J	ALLENBY, G; JANOCHA, R; KAZMER, S; SPECK, J; GRIPPO, JF; LEVIN, AA				ALLENBY, G; JANOCHA, R; KAZMER, S; SPECK, J; GRIPPO, JF; LEVIN, AA			BINDING OF 9-CIS-RETINOIC ACID AND ALL-TRANS-RETINOIC ACID TO RETINOIC ACID RECEPTOR-ALPHA, RECEPTOR-BETA, AND RECEPTOR-GAMMA - RETINOIC ACID RECEPTOR-GAMMA BINDS ALL-TRANS-RETINOIC ACID PREFERENTIALLY OVER 9-CIS-RETINOIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL EXPRESSION; NUCLEAR RECEPTORS; VITAMIN-A; IDENTIFICATION; MOUSE; TRANSCRIPTION; PROTEINS; ANALOGS; PATTERN; LIGAND	Both 9-cis-retinoic acid (RA) and all-trans-RA (t-RA) compete for [H-3]9-cis-RA binding to RA receptors (RAR alpha, beta, and gamma) in nucleosol fractions from transiently transfected COS-1 cells with IC50 values of approximately 12 and 5 nM, respectively. Curiously, 9-cis-RA competes for [H-3]t-RA binding to mouse RAR alpha, beta, and gamma with IC50 values of 31, 8, and 60 nM, respectively, while t-RA itself does not exhibit such differential competition (IC50 values for RARs, 5 nM). A similar pattern is observed with human retinoic acid receptors (RARs). Differential binding of 9-cis-RA to the RAR beta and gamma receptors is also found following in vitro transcription and translation of these receptors. Displacement assays demonstrate that t-RA exhibits similar off-rates for RAR alpha, beta, and gamma. However, 9-cis-RA is 6-fold more rapidly displaced from RAR gamma than from RAR beta. When RAR-transfected COS-1 cells are incubated with [H-3]t-RA, [H-3]-9-cis-RA or various mixtures of these two radioligands, high performance liquid chromatography analysis demonstrates that the ligands bound in nucleosol fractions from RAR beta-transfected cells reflect the isomer content of the media. However, in identical whole cell assays, nucleosol fractions from RAR gamma-transfected cells preferentially bind t-RA over 9-cis-RA, consistent with the in vitro data. These binding kinetics in vitro and in whole cells suggest that there could be differences in the interactions of the receptor subtypes with the endogenous retinoic acids under physiologic conditions.	HOFFMANN LA ROCHE INC,DEPT TOXICOL & PATHOL,NUTLEY,NJ 07110	Roche Holding								ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; ASTROM A, 1990, BIOCHEM BIOPH RES CO, V173, P339, DOI 10.1016/S0006-291X(05)81062-9; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRIPPO JF, 1987, J BIOL CHEM, V262, P4492; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCCLEAN SW, 1982, CLIN CHEM, V28, P693; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROBERTS AB, 1984, RETINOIDS, V2, P209; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, DEVELOPMENT, V111, P45; RUBERTE E, 1993, DEVELOPMENT, V118, P267; RUBERTE E, 1992, RETINOIDS NORMAL DEV, P99; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHROOT B, 1993, RETINOIDS PROGR RES, P261; SMITH SM, 1991, DEVELOPMENT, V111, P245; SMITH SM, 1987, J NUTR, V117, P857, DOI 10.1093/jn/117.5.857; TATE BF, 1994, MOL CELL BIOL, V14, P2323, DOI 10.1128/MCB.14.4.2323; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THOMPSON JN, 1964, PROC R SOC SER B-BIO, V159, P510, DOI 10.1098/rspb.1964.0017; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	45	111	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16689	16695						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206989				2022-12-27	WOS:A1994NR29600029
J	GRIMSLEY, JK; TJALKENS, RB; STRAUCH, MA; BIRD, TH; SPIEGELMAN, GB; HOSTOMSKY, Z; WHITELEY, JM; HOCH, JA				GRIMSLEY, JK; TJALKENS, RB; STRAUCH, MA; BIRD, TH; SPIEGELMAN, GB; HOSTOMSKY, Z; WHITELEY, JM; HOCH, JA			SUBUNIT COMPOSITION AND DOMAIN-STRUCTURE OF THE SPO0A SPORULATION TRANSCRIPTION FACTOR OF BACILLUS-SUBTILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE; PROTEIN; PHOSPHORELAY; INITIATION; REGULATOR; BINDING; ABRB; GENE; PHOSPHORYLATION; NTRC	The Spo0A transcription factor is responsible for the initiation of sporulation and is active in transcription only after phosphorylation by a specific signal transduction pathway, the phosphorelay. The effect of phosphorylation on the physical properties of Spo0A was determined. Spo0A and Spo0A similar to P both behaved as monomers during Sephacryl chromatography and gel electrophoresis, suggesting that phosphorylation did not modify the oligomerization state of the protein. Trypsin digested Spo0A at a single cleavage site between residues 142 and 143 within a hinge connecting two tightly folded domains. The amino domain retains ability to be phosphorylated by the phosphorelay. The carboxyl domain is active as a DNA-binding protein and retains the sequence specificity of the intact molecule for 0A boxes on the abrB promoter as revealed by footprinting studies. The carboxyl domain stimulated in vitro transcription from the spoIIG promoter 5-fold greater than an equal amount of Spo0A and about half as well as equivalent amounts of Spo0A similar to P. Thus, the unphosphorylated amino domain inhibits the transcription stimulation activity of the carboxyl domain. We suggest that phosphorylation activates transcription regulation functions of Spo0A by modifying the spatial relationships of the amino and carboxyl domains.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV CELL BIOL, LA JOLLA, CA 92037 USA; UNIV BRITISH COLUMBIA, DEPT MICROBIOL, VANCOUVER V6T 1Z3, BC, CANADA; AGOURON PHARMACEUT INC, LA JOLLA, CA 92037 USA	Scripps Research Institute; University of British Columbia; Pfizer					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019416, R01GM045727, R01GM019416] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45727, GM19416] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; BIRD TH, 1993, MOL MICROBIOL, V9, P741, DOI 10.1111/j.1365-2958.1993.tb01734.x; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; DRUMMOND M, 1986, EMBO J, V5, P441, DOI 10.1002/j.1460-2075.1986.tb04230.x; FERRARI FA, 1985, P NATL ACAD SCI USA, V82, P2647, DOI 10.1073/pnas.82.9.2647; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; KAHN D, 1991, MOL MICROBIOL, V5, P987, DOI 10.1111/j.1365-2958.1991.tb00774.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRICK MJ, 1983, EMBO J, V2, P39, DOI 10.1002/j.1460-2075.1983.tb01377.x; OHLSEN KL, 1994, P NATL ACAD SCI USA, V91, P1756, DOI 10.1073/pnas.91.5.1756; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEREGO M, 1988, MOL MICROBIOL, V2, P689, DOI 10.1111/j.1365-2958.1988.tb00079.x; SATOLA SW, 1992, J BACTERIOL, V174, P1448, DOI 10.1128/jb.174.5.1448-1453.1992; SIMMS SA, 1985, J BIOL CHEM, V260, P161; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STRAUCH M, 1990, P NATL ACAD SCI USA, V87, P1801, DOI 10.1073/pnas.87.5.1801; STRAUCH MA, 1989, EMBO J, V8, P1615, DOI 10.1002/j.1460-2075.1989.tb03546.x; TRACH K, 1991, RES MICROBIOL, V142, P815, DOI 10.1016/0923-2508(91)90060-N; YORK K, 1992, J BACTERIOL, V174, P2648, DOI 10.1128/jb.174.8.2648-2658.1992	20	56	57	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16977	16982						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207022				2022-12-27	WOS:A1994NR29600069
J	MACLELLAN, WR; LEE, TC; SCHWARTZ, RJ; SCHNEIDER, MD				MACLELLAN, WR; LEE, TC; SCHWARTZ, RJ; SCHNEIDER, MD			TRANSFORMING GROWTH-FACTOR-BETA RESPONSE ELEMENTS OF THE SKELETAL ALPHA-ACTIN GENE - COMBINATORIAL ACTION OF SERUM RESPONSE FACTOR, YY1, AND THE SV40 ENHANCER-BINDING PROTEIN, TEF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC EXPRESSION; LOOP-HELIX PROTEINS; ZINC FINGER PROTEIN; HEAVY-CHAIN GENE; NUCLEAR FACTOR-I; C-MYC PROMOTER; TRANSCRIPTION FACTOR; DNA-BINDING; CARDIAC-MUSCLE; XENOPUS EMBRYOS	Skeletal alpha-actin (SkA) is representative of the cardiac genes that are expressed at high levels in embryonic myocardium, down-regulated after birth, and reactivated by trophic signals including type beta-transforming growth factors (TGF beta). To investigate the molecular basis for cardiac-restricted and TGF beta-induced SkA transcription, we have undertaken a mutational analysis of the SkA promoter in ventricular myocytes, with emphasis on the role of three nominal serum response elements. Serum response factor (SRF) and the bifunctional factor YY1 are the predominant cardiac proteins contacting the proximal SRE (SRE1). Mutations of SRE1 that prevent recognition by SRF and YY1, or SRF alone, virtually abolish SkA transcription in both TGF beta- and vehicle-treated cells; mutation of distal SREs was ineffective. A mutation which selectively abrogates YY1 binding increases both basal and TGF beta-dependent expression, substantiating the predicted role of YY1 as an inhibitor of SRF effects. However, efficient SkA transcription requires combinatorial action of SRE1 with consensus sites for Sp1 and the SV40 enhancer-binding protein, TEF-1. As isolated motifs, either SRE1- or TEF-1-binding sites function as TGF beta response elements. Induction of the SkA promoter by TGF beta required SRF and TEF-1 in concert, unlike other pathways for TGF beta dependent gene expression.	BAYLOR COLL MED,DEPT MED,MOLEC CARDIOL UNIT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NHLBI NIH HHS [R01 HL47567, R01 HL39141, T32 HL07706] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047567, T32HL007706, R01HL039141] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BRAND T, 1993, J BIOL CHEM, V268, P11500; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FLINK IL, 1992, J BIOL CHEM, V267, P9917; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GUSTAFSON TA, 1988, MOL CELL BIOL, V8, P4110, DOI 10.1128/MCB.8.10.4110; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JARVIS EE, 1989, GENE DEV, V3, P936, DOI 10.1101/gad.3.7.936; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; LEE TC, 1992, NUCLEIC ACIDS RES, V20, P140, DOI 10.1093/nar/20.1.140; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LIN YCA, 1992, J IMMUNOL, V149, P2914; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MOHUN TJ, 1991, EMBO J, V10, P933, DOI 10.1002/j.1460-2075.1991.tb08027.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SANTORO IM, 1991, MOL CELL BIOL, V11, P6296, DOI 10.1128/MCB.11.12.6296; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; STRUTHERS RS, 1992, P NATL ACAD SCI USA, V89, P11451, DOI 10.1073/pnas.89.23.11451; TAYLOR M, 1989, DEVELOPMENT, V106, P67; TAYLOR MV, 1991, NUCLEIC ACIDS RES, V19, P2669, DOI 10.1093/nar/19.10.2669; Thompson NL, 1988, GROWTH FACTORS, V1, P91, DOI 10.3109/08977198809000251; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TUIL D, 1990, J MOL BIOL, V213, P677, DOI 10.1016/S0022-2836(05)80255-4; VILLARREAL FJ, 1992, AM J PHYSIOL, V262, pH1861, DOI 10.1152/ajpheart.1992.262.6.H1861; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	58	150	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16754	16760						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206998				2022-12-27	WOS:A1994NR29600039
J	CLARKLEWIS, I; DEWALD, B; LOETSCHER, M; MOSER, B; BAGGIOLINI, M				CLARKLEWIS, I; DEWALD, B; LOETSCHER, M; MOSER, B; BAGGIOLINI, M			STRUCTURAL REQUIREMENTS FOR INTERLEUKIN-8 FUNCTION IDENTIFIED BY DESIGN OF ANALOGS AND CXC CHEMOKINE HYBRIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PEPTIDE-2; PLATELET FACTOR-IV; BETA-THROMBOGLOBULIN; RECEPTOR-BINDING; 3-DIMENSIONAL STRUCTURE; TERMINAL SEQUENCE; GRO-ALPHA; CYTOKINE; PROTEIN; SPECTROSCOPY	Structure-activity relationships of human interleukin-8 (IL-8) were probed using chemically synthesized analogs with single or double amino acid substitutions, as well. as hybrids derived by substituting IL-8 regions into IP10, a related protein that lacks IL-8 activity. The analogs were tested for functional activity by measuring induction of elastase release from human neutrophils and competition for binding of radiolabeled IL-8. The hybrid studies indicated that Gly(31) and Pro(32), as well as the NH2-terminal region from IL-8 are required to convert IP10 into a fully functional protein, suggesting that these elements are critical for IL-8 activity. Both disulfide bridges, linking residue 7 to 34 and residue 9 to 50, were critical for function, as shown by substituting the cysteine pairs with alpha-aminobutyric acid. Single conservative substitutions were generally accepted into the 10-22 region of IL-8, which contrasts with the ELR motif (residues 4-6), previously shown to be essential for activity. The importance of residues within the 10-15 region and the 17-22 region was demonstrated with hybrids. In addition, some of the 4-22 residues have structural roles that may be important; for example, Tyr(13), Phe(17), and Phe(21) are involved in aromatic interactions in the IL-8 structure, and are also moderately sensitive to modification. Except for Cys(50), the results argue against a role for the 36-72 region, including the COOH-terminal alpha-helix, in receptor binding. We conclude that the disulfide bridges and 30-35 turn provide a structural scaffold for the NH2-terminal region which includes the primary receptor-binding site (the ELR motif) and secondary binding and conformational determinants between residues 10 and 22.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BERN,THEODOR KOCHER INST,CH-3000 BERN,SWITZERLAND	University of British Columbia; University of Bern	CLARKLEWIS, I (corresponding author), UNIV BRITISH COLUMBIA,BIOMED RES CTR,2222 HLTH SCI MALL,VANCOUVER V6T 1Z3,BC,CANADA.			Moser, Bernhard/0000-0002-4354-4572	NIGMS NIH HHS [R01 GM-50969-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050969] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; CLARKLEWIS I, 1988, P NATL ACAD SCI USA, V85, P7897, DOI 10.1073/pnas.85.21.7897; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CLARKLEWIS I, 1989, USE HPLC RECEPTOR BI, P43; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1991, J MOL BIOL, V217, P611, DOI 10.1016/0022-2836(91)90518-B; DEWALD B, 1992, IMMUNOL LETT, V32, P81, DOI 10.1016/0165-2478(92)90203-Z; FAIRBROTHER WJ, 1993, FEBS LETT, V330, P302, DOI 10.1016/0014-5793(93)80893-Y; GEISER T, 1993, J BIOL CHEM, V268, P15419; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HOLT JC, 1986, BIOCHEMISTRY-US, V25, P1988, DOI 10.1021/bi00356a023; LINDLEY I, 1988, P NATL ACAD SCI USA, V85, P9199, DOI 10.1073/pnas.85.23.9199; LUSTER AD, 1993, J EXP MED, V178, P1057, DOI 10.1084/jem.178.3.1057; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MAYO KH, 1989, BIOCHEMISTRY-US, V28, P9469, DOI 10.1021/bi00450a034; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MOSER B, 1991, J BIOL CHEM, V266, P10666; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; PROOST P, 1993, BIOCHEMISTRY-US, V32, P10170, DOI 10.1021/bi00089a037; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; VANDAMME J, 1989, EUR J BIOCHEM, V181, P337; WALZ A, 1989, BIOCHEM BIOPH RES CO, V159, P969, DOI 10.1016/0006-291X(89)92203-1; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; YOSHIMURA T, 1989, MOL IMMUNOL, V26, P87; ZUCKER MB, 1991, P SOC EXP BIOL MED, V198, P693	36	165	222	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16075	16081						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206907				2022-12-27	WOS:A1994NQ72900022
J	MATTHEWS, JB; SMITH, JA; TALLY, KJ; AWTREY, CS; NGUYEN, HV; RICH, J; MADARA, JL				MATTHEWS, JB; SMITH, JA; TALLY, KJ; AWTREY, CS; NGUYEN, HV; RICH, J; MADARA, JL			NA-K-2CL COTRANSPORT IN INTESTINAL EPITHELIAL-CELLS - INFLUENCE OF CHLORIDE EFFLUX AND F-ACTIN ON REGULATION OF COTRANSPORTER ACTIVITY AND BUMETANIDE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORT; SHARK RECTAL GLAND; SMOOTH-MUSCLE CELLS; NA+/K+/CL COTRANSPORT; ADENOCARCINOMA CELLS; ACTIVATION; CAMP; CYTOSKELETON; PROTEIN; CHANNEL	Although cAMP-dependent epithelial chloride secretion is largely regulated via apical membrane chloride channels, cAMP also remodels basolateral F-actin and activates basolateral Na-K-2Cl cotransport. Whether activation of cotransport is a primary event or secondary to activation of chloride efflux is not established, and the basis for the cytoskeletal dependence is unknown. We studied cotransport in the intestinal line HT29 (which lacks cAMP-regulated chloride efflux) and in its subclone Cl.19A (in which this pathway is present). Cotransporter activity was enhanced by forskolin in both lines but to a considerably greater extent in subclone Cl.19A, in which the number of bumetanide binding sites was also observed to increase. The F-actin stabilizer phalloidin markedly attenuated cAMP-stimulated cotransport in Cl.19A monolayers, but the increase in bumetanide binding was preserved. These studies identify two mechanisms for activation of Na-K-2Cl cotransport by cAMP: components independent and dependent of cAMP elicited chloride efflux. Additional Na-K-2Cl cotransporters become accessible to the cell surface coincident with the salt efflux-dependent activation of cotransport. While F-actin rearrangements influence salt efflux-dependent up-regulation of the cotransporter, this influence occurs independently of increases in bumetanide-accessible cotransporters.	BRIGHAM & WOMENS HOSP, DEPT PATHOL, DIV GASTROINTESTINAL PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, CTR DIGEST DIS, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University	MATTHEWS, JB (corresponding author), BETH ISRAEL HOSP, DEPT SURG, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK048010, R37DK035932, R01DK035932, P01DK033506] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33506, DK-35932, R29 DK48010-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGERON C, 1984, CANCER RES, V44, P3961; BREITWIESER GE, 1990, AM J PHYSIOL, V258, pC749, DOI 10.1152/ajpcell.1990.258.4.C749; CANTIELLO H F, 1991, Journal of Cell Biology, V115, p353A; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; CANTIELLO HF, 1993, J BIOL CHEM, V268, P4596; DING G, 1991, AM J PHYSIOL, V260, pC9, DOI 10.1152/ajpcell.1991.260.1.C9; FORBUSH B, 1992, AM J PHYSIOL, V262, pC1000, DOI 10.1152/ajpcell.1992.262.4.C1000; FRANKI N, 1992, AM J PHYSIOL, V263, pC995, DOI 10.1152/ajpcell.1992.263.5.C995; FRANKLIN CC, 1989, J BIOL CHEM, V264, P6667; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; GAO Y, 1992, AM J PHYSIOL, V263, pC908, DOI 10.1152/ajpcell.1992.263.4.C908; HAAS M, 1986, J BIOL CHEM, V261, P8434; HAAS M, 1993, AM J PHYSIOL, V264, pC189, DOI 10.1152/ajpcell.1993.264.1.C189; HAAS M, 1990, AM J PHYSIOL, V259, pC557, DOI 10.1152/ajpcell.1990.259.4.C557; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HALM DR, 1990, TXB SECRETORY DIARRH, P47; HECHT G, 1988, J CLIN INVEST, V82, P1516, DOI 10.1172/JCI113760; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; JESSEN F, 1992, BIOCHIM BIOPHYS ACTA, V1110, P199, DOI 10.1016/0005-2736(92)90359-T; KIM HD, 1988, BIOCHIM BIOPHYS ACTA, V946, P397, DOI 10.1016/0005-2736(88)90415-4; KLEIN JD, 1993, J GEN PHYSIOL, V102, pA18; LYTLE C, 1992, AM J PHYSIOL, V262, pC1009, DOI 10.1152/ajpcell.1992.262.4.C1009; LYTLE C, 1992, J BIOL CHEM, V267, P25438; MATTHEWS JB, 1992, J CLIN INVEST, V90, P1608, DOI 10.1172/JCI116030; MATTHEWS JB, 1993, AM J PHYSIOL, V265, pG371, DOI 10.1152/ajpgi.1993.265.2.G370; MOLITORIS BA, 1991, AM J PHYSIOL, V260, pF769; MORRIS AP, 1992, J BIOL CHEM, V267, P5575; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; ODONNELL ME, 1986, P NATL ACAD SCI USA, V83, P6132, DOI 10.1073/pnas.83.16.6132; ODONNELL ME, 1989, J BIOL CHEM, V264, P20326; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; OWEN NE, 1985, J CELL BIOL, V101, P454, DOI 10.1083/jcb.101.2.454; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; SHAPIRO M, 1991, J CLIN INVEST, V87, P1903, DOI 10.1172/JCI115215; SINGH AK, 1991, AM J PHYSIOL, V261, pC51, DOI 10.1152/ajpcell.1991.261.1.C51; SLOTKI IN, 1993, AM J PHYSIOL, V264, pC857, DOI 10.1152/ajpcell.1993.264.4.C857; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; TURNER JT, 1990, AM J PHYSIOL, V258, pC266, DOI 10.1152/ajpcell.1990.258.2.C266; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; WADE JB, 1988, AM J PHYSIOL, V255, pC526, DOI 10.1152/ajpcell.1988.255.4.C526; ZIYADEH FN, 1992, AM J PHYSIOL, V262, pF468, DOI 10.1152/ajprenal.1992.262.3.F468; Zweibaum A., 1991, HDB PHYSL GASTROINTE, P223	42	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15703	15709						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195222				2022-12-27	WOS:A1994NP51300050
J	DEQUARDCHABLAT, M; SELLEM, CH				DEQUARDCHABLAT, M; SELLEM, CH			THE S12 RIBOSOMAL-PROTEIN OF PODOSPORA-ANSERINA BELONGS TO THE S19 BACTERIAL FAMILY AND CONTROLS THE MITOCHONDRIAL GENOME INTEGRITY THROUGH CYTOPLASMIC TRANSLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GENE-EXPRESSION; TRANSFER-RNA; YEAST; DNA; TRANSFORMATION; SEQUENCES; RIG; IDENTIFICATION	In the filamentous fungus Podospora anserina, two nuclear genes are involved in the premature death syndrome associated with a site-specific deletion of the mitochondrial DNA: a mutant allele of the AS1 gene, encoding the cytoplasmic ribosomal protein S12, and an uncharacterized gene closely linked to the mating-type locus. We describe here the cloning and the sequencing of the wild-type and two mutant alleles of the AS1 gene. The P. anserina S12 protein belongs to the bacterial S19 ribosomal protein family and shows 72% identity with the S15 human ribosomal protein. Transformation experiments have shown that the AS1-4 mutation itself is responsible for the premature death phenotype and that it corresponds to a Gly to Asp change in the highly conserved COOH-terminal part of the protein. Use of antibodies directed against S12 did not permit detection of the mutant ribosomal protein inside the mitochondria. However, cross-reactions were observed with at least one mitochondrial ribosomal protein displaying a higher molecular weight than S12. The mitochondrial protein does not seem to be a by-product of the AS1 gene but is more likely the mitochondrial homologue of S12. These results strongly suggest that the mutant S12 protein acts indirectly to promote the mitochondrial deletion, via the cytoplasmic translation.	CNRS,CTR GENET MOLEC,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	DEQUARDCHABLAT, M (corresponding author), UNIV PARIS 11,INST MICROBIOL & GENET,CNRS,URA 1354,BAT 400,F-91405 ORSAY,FRANCE.							BALLANCE DJ, 1986, YEAST, V2, P229, DOI 10.1002/yea.320020404; BELCOUR L, 1991, P NATL ACAD SCI USA, V88, P3579, DOI 10.1073/pnas.88.9.3579; BERGES T, 1989, J GEN MICROBIOL, V135, P601; BONEN L, 1993, FASEB J, V7, P40, DOI 10.1096/fasebj.7.1.8422973; BRYGOO Y, 1985, MOL GEN GENET, V200, P128, DOI 10.1007/BF00383325; CAMONIS JH, 1990, GENE, V86, P263, DOI 10.1016/0378-1119(90)90288-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONKLIN PL, 1991, NUCLEIC ACIDS RES, V19, P2701, DOI 10.1093/nar/19.10.2701; COPPINRAYNAL E, 1989, MOL GEN GENET, V219, P270, DOI 10.1007/BF00261187; DEBUCHY R, 1993, MOL GEN GENET, V241, P667, DOI 10.1007/BF00279909; DEQUARDCHABLAT M, 1986, J MOL BIOL, V190, P167, DOI 10.1016/0022-2836(86)90290-1; DEQUARDCHABLAT M, 1991, TRENDS GENET, V7, P240; DEQUARDCHABLAT M, 1987, THESIS U PARIS ORSAY; DIJK J, 1977, FEBS LETT, V77, P295, DOI 10.1016/0014-5793(77)80255-X; Dujon B., 1989, MOBILE DNA, P861; Esser K, 1974, HDB GENETICS, V1, P531; GOYON C, 1988, GENE, V63, P297, DOI 10.1016/0378-1119(88)90533-1; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KITAGAWA M, 1991, FEBS LETT, V283, P210, DOI 10.1016/0014-5793(91)80590-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECELLIER G, 1994, CURR GENET, V25, P122, DOI 10.1007/BF00309536; LEFEBVRE O, 1992, P NATL ACAD SCI USA, V89, P10512, DOI 10.1073/pnas.89.21.10512; LIN FL, 1984, J MOL BIOL, V172, P77, DOI 10.1016/0022-2836(84)90415-7; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; Marcou D., 1961, ANN SCI NAT BOT BIOL, V12, P653; MATHESON AT, 1990, RIBOSOME, P617; MORAES CT, 1991, AM J HUM GENET, V48, P492; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; NEUPERT W, 1979, METHOD ENZYMOL, V61, P79; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PICARD M, 1991, GENETICS, V128, P539; PICARDBENNOUN M, 1985, FEBS LETT, V184, P1, DOI 10.1016/0014-5793(85)80640-2; PICARDBENNOUN M, 1976, MOL GEN GENET, V147, P299, DOI 10.1007/BF00582881; POHL T, 1988, J BIOL CHEM, V263, P4293; PON CL, 1982, FEBS LETT, V137, P163, DOI 10.1016/0014-5793(82)80339-6; RIZET G, 1953, CR HEBD ACAD SCI, V237, P838; RIZET G, 1953, CR HEBD ACAD SCI, V237, P1106; Rogers SO, 1988, PLANT MOL BIOL MAN A, VA6, P1, DOI DOI 10.1007/978-94-017-5294-7_; SELLEM CH, 1990, MOL GEN GENET, V224, P232, DOI 10.1007/BF00271556; SHIGA K, 1990, P NATL ACAD SCI USA, V87, P3594, DOI 10.1073/pnas.87.9.3594; STAPPERT J, 1992, NUCLEIC ACIDS RES, V20, P624, DOI 10.1093/nar/20.3.624; SUDARICKOV AB, 1986, MOL GEN GENET, V203, P316, DOI 10.1007/BF00333973; TAKASAWA S, 1992, FEBS LETT, V307, P318, DOI 10.1016/0014-5793(92)80704-K; TAKEMURA M, 1992, NUCLEIC ACIDS RES, V20, P3199, DOI 10.1093/nar/20.12.3199; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; VIGNAIS ML, 1990, J BIOL CHEM, V265, P14669; WADA KN, 1990, NUCLEIC ACIDS RES, V18, P2367, DOI 10.1093/nar/18.suppl.2367; WITTMANNLIEBOLD B, 1990, RIBOSOME, P598; WOOL IG, 1990, RIBOSOME, P203; WOOLFORD JL, 1991, ADV GENET, V29, P63, DOI 10.1016/S0065-2660(08)60107-8; WU M, 1987, J BIOL CHEM, V262, P12275; YAGUCHI M, 1978, FEBS LETT, V88, P227, DOI 10.1016/0014-5793(78)80180-X; ZEVIANI M, 1990, AM J HUM GENET, V47, P904	55	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14951	14956						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195128				2022-12-27	WOS:A1994NP73800019
J	KADOWAKI, H; GRANT, MA				KADOWAKI, H; GRANT, MA			MECHANISM OF G(M3) GANGLIOSIDE SYNTHESIS - KINETIC-STUDY OF RAT-LIVER CMP-N-NEURAMINATE-LACTOSYLCERAMIDE ALPHA-2,3-SIALYLTRANSFERASE EMPLOYING 19 MOLECULAR-SPECIES OF LACTOSYLCERAMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; ACETYLNEURAMINIC ACID; GOLGI-APPARATUS; NEUTRAL GLYCOSPHINGOLIPIDS; ENZYMATIC CHARACTERIZATION; CERAMIDE COMPOSITION; MOUSE-LIVER; SIALIC-ACID; SIALYLTRANSFERASE; MEMBRANE	The apparent K-m and V-max of CMP-N-acetylneuraminate:lactosylceramide alpha 2,3-sialyltransferase (LacCer alpha 2,3-ST) for lactosylceramide and CMP-N-acetylneuraminic acid were determined using 19 molecular species of lactosylceramide. The K-m for lactosylceramide varied 6-fold among these molecular species of lactosylceramide, but there was a poor correlation between the K-m for a particular molecular species and the activity of LacCer alpha 2,3-ST for that molecular species. The K-m for CMP-N-acetylneuraminic acid also varied depending on the molecular species of lactosylceramide used as substrate, and there was a good correlation between the K-m of LacCer alpha 2,3-ST for CMP-N-acetylneuraminic acid and the activity of the enzyme. Kinetic studies indicate that the reaction mechanism of LacCer alpha 2,3-ST is a sequential, Ordered Bi Bi system. From considerations of the effects of the structure of the lactosylceramide molecular species on the V-max and K-m for CMP-N-acetylneuraminic acid, it is likely that LacCer alpha 2,3-ST first binds lactosylceramide and then CMP-N-acetylneuraminic acid and that the rate-limiting step in the reaction is the release of the product G(M3).	BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118	Boston University	KADOWAKI, H (corresponding author), VET ADM MED CTR JAMAICA PLAIN,DIV LIPID METAB,RES BLDG,RM B-8,150 S HUNTINGTON AVE,BOSTON,MA 02130, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023354] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-23354] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BENDIAK B, 1982, EUR J BIOCHEM, V128, P355; BLOJ B, 1981, J BIOL CHEM, V256, P5988; BOSMANN HB, 1972, BIOCHIM BIOPHYS ACTA, V279, P456, DOI 10.1016/0304-4165(72)90167-5; BOUHOURS JF, 1993, ADV LIPID RES, V26, P353; BREIMER ME, 1974, BIOCHIM BIOPHYS ACTA, V348, P232, DOI 10.1016/0005-2760(74)90234-3; BURCZAK JD, 1984, BIOCHIM BIOPHYS ACTA, V804, P442, DOI 10.1016/0167-4889(84)90072-7; BUSAM K, 1986, EUR J BIOCHEM, V160, P23, DOI 10.1111/j.1432-1033.1986.tb09934.x; CAPASSO JM, 1984, P NATL ACAD SCI-BIOL, V81, P7051, DOI 10.1073/pnas.81.22.7051; CAREY DJ, 1980, CELL, V19, P597, DOI 10.1016/S0092-8674(80)80036-5; COATES SW, 1980, J BIOL CHEM, V255, P9225; CRAIN RC, 1980, BIOCHEMISTRY-US, V19, P1433, DOI 10.1021/bi00548a026; CREEK KE, 1981, BIOCHIM BIOPHYS ACTA, V643, P292, DOI 10.1016/0005-2736(81)90075-4; FELGNER PL, 1983, BIOCHEMISTRY-US, V22, P1670, DOI 10.1021/bi00276a023; FOLCH J, 1957, J BIOL CHEM, V226, P497; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; IBER H, 1991, EUR J BIOCHEM, V195, P115, DOI 10.1111/j.1432-1033.1991.tb15683.x; IWAMORI M, 1978, J BIOCHEM-TOKYO, V84, P1609, DOI 10.1093/oxfordjournals.jbchem.a132287; IWAMORI M, 1984, J BIOCHEM-TOKYO, V95, P761, DOI 10.1093/oxfordjournals.jbchem.a134667; KADOWAKI H, 1988, J LIPID RES, V29, P52; KADOWAKI H, 1989, J LIPID RES, V30, P1789; KADOWAKI H, 1989, J LIPID RES, V30, P616; KADOWAKI H, 1984, J LIPID RES, V25, P1132; KADOWAKI H, 1993, J LIPID RES, V34, P905; KANNAGI R, 1982, P NATL ACAD SCI-BIOL, V79, P3470, DOI 10.1073/pnas.79.11.3470; KANNAGI R, 1983, CANCER RES, V43, P4997; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KELETI T, 1984, BIOCHEM J, V223, P299, DOI 10.1042/bj2230299; LADISCH S, 1992, BIOCHIM BIOPHYS ACTA, V1125, P180, DOI 10.1016/0005-2760(92)90043-U; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANSSON JE, 1978, J NEUROCHEM, V30, P273, DOI 10.1111/j.1471-4159.1978.tb07064.x; MANTEL CR, 1993, BIOCHEM J, V289, P815, DOI 10.1042/bj2890815; MASSEY JB, 1982, BIOCHEMISTRY-US, V21, P3630, DOI 10.1021/bi00258a016; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; MELKERSONWATSON LJ, 1991, J BIOL CHEM, V266, P19865; MELKERSONWATSON LJ, 1991, J BIOL CHEM, V266, P4448; NEUENHOFER S, 1985, BIOCHEMISTRY-US, V24, P525, DOI 10.1021/bi00323a042; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RADIN NS, 1974, LIPIDS, V9, P358, DOI 10.1007/BF02533114; REARICK JI, 1979, J BIOL CHEM, V254, P4444; RICHARDSON CL, 1977, BIOCHIM BIOPHYS ACTA, V488, P88, DOI 10.1016/0005-2760(77)90125-4; ROSEMAN MA, 1980, BIOCHEMISTRY-US, V19, P439, DOI 10.1021/bi00544a006; ROSENBERG A, 1966, J LIPID RES, V7, P122; SADLER JE, 1979, J BIOL CHEM, V254, P5934; SCHACHTE.H, 1970, J BIOL CHEM, V245, P1090; Segel I. H., 1975, ENZYME KINETICS, P560; STEWART RJ, 1993, BIOCHEMISTRY-US, V32, P10666, DOI 10.1021/bi00091a017; ULLMAN MD, 1977, J LIPID RES, V18, P371; WELCH GR, 1988, J THEOR BIOL, V130, P407, DOI 10.1016/S0022-5193(88)80206-6	52	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14931	14938						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195125				2022-12-27	WOS:A1994NP73800016
J	MURAKAMI, S; CHEONG, J; KANEKO, S				MURAKAMI, S; CHEONG, J; KANEKO, S			HUMAN HEPATITIS-VIRUS X-GENE ENCODES A REGULATORY DOMAIN THAT REPRESSES TRANSACTIVATION OF X-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; B VIRUS; TRANS-ACTIVATION; STRUCTURAL PROTEINS; BINDING PROTEIN; VIRAL ENHANCERS; EXPRESSION; SEQUENCES; ELEMENTS	The human hepatitis B virus (HBV) X gene seems to be essential for establishment of viral infection, and the X gene product, HBx, transactivates virus and host genes through a wide variety of cis elements, whereas regulation of HBx has not been fully understood. We found that transactivation-negative HBx mutants truncated at the C-terminal portion specifically repressed the HBx transactivation in trans. The ability to trans repress the HBx transactivation is confined to the N-terminal third of HBx. Transactivation-positive constructs of HBx were divided into two groups by their sensitivity to transrepression due to the presence of the N-terminal third. Thus the regulatory domain, the N-terminal third, is separated from the transacting domain and responsible for the negative regulations, the trans-repression and sensitivity to X trans-repression. A possible direct association between the HBx regulatory domains was tested by far-Western blotting using purified fused forms of HBx proteins. The regulatory domain was found to associate preferentially with the full HBx or the regulatory domain, but not with the transacting domain. Taken together, it is possible that HBx has a self-regulatory mechanism that avoids excessive HBx transactivation and is important for regulation of X gene expression.	KANAZAWA UNIV, SCH MED, INST MED 1, KANAZAWA 920, ISHIKAWA, JAPAN	Kanazawa University	MURAKAMI, S (corresponding author), KANAZAWA UNIV, CANC RES INST, DEPT BIOPHYS, KANAZAWA 920, JAPAN.							AVANTAGGIATI ML, 1992, ARCH VIROL, P57; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; DIAMANTIS ID, 1992, J HEPATOL, V15, P400, DOI 10.1016/0168-8278(92)90077-3; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P3683, DOI 10.1128/MCB.10.7.3683; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; FAKTOR O, 1990, ONCOGENE, V5, P867; GREENE WC, 1991, NEW ENGL J MED, V324, P308, DOI 10.1056/NEJM199101313240506; GUO WT, 1991, J VIROL, V65, P6686, DOI 10.1128/JVI.65.12.6686-6692.1991; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HUAN BF, 1992, P NATL ACAD SCI USA, V89, P9059, DOI 10.1073/pnas.89.19.9059; HUGH FM, 1991, SCIENCE, V252, P842; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KANEKO S, 1988, J VIROL, V62, P3979, DOI 10.1128/JVI.62.11.3979-3984.1988; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KODAMA K, 1985, J VIROL, V56, P978, DOI 10.1128/JVI.56.3.978-986.1985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBER B, 1991, VIROLOGY, V184, P808, DOI 10.1016/0042-6822(91)90458-N; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MURAKAMI S, 1994, VIROLOGY, V199, P243, DOI 10.1006/viro.1994.1119; MURAKAMI S, 1990, GASTROENTEROL JPN, V2, P11; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; TAKADA S, 1990, JPN J CANCER RES, V81, P1191, DOI 10.1111/j.1349-7006.1990.tb02675.x; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TWU JS, 1989, P NATL ACAD SCI USA, V86, P2046, DOI 10.1073/pnas.86.6.2046; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; WU HL, 1991, VIROLOGY, V185, P644, DOI 10.1016/0042-6822(91)90535-J; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; ZHANG P, 1992, VIROLOGY, V191, P31, DOI 10.1016/0042-6822(92)90163-J	40	106	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15118	15123						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195148				2022-12-27	WOS:A1994NP73800042
J	OCONNELL, JP; WILLENBROCK, F; DOCHERTY, AJP; EATON, D; MURPHY, G				OCONNELL, JP; WILLENBROCK, F; DOCHERTY, AJP; EATON, D; MURPHY, G			ANALYSIS OF THE ROLE OF THE COOH-TERMINAL DOMAIN IN THE ACTIVATION, PROTEOLYTIC ACTIVITY, AND TISSUE INHIBITOR OF METALLOPROTEINASE INTERACTIONS OF GELATINASE-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							72 KDA PROGELATINASE; IV COLLAGENASE; MATRIX METALLOPROTEINASE-9; MEDIATED INDUCTION; FIBROSARCOMA CELLS; COMPLEX-FORMATION; PURIFICATION; STROMELYSIN; PHENOTYPE; PLASMINOGEN	Recombinant human progelatinase B and a COOH terminally truncated version, pro-Delta(426-688) gelatinase B have been prepared from a myeloma cell expression system. Both proenzymes could be processed to active forms by stromelysin-1 to give an NH2 terminus of Phe(88), or by treatment with 4-aminophenylmercuric acetate resulting in an NH2-terminal Met(75). The kinetics of activation using either treatment was not affected by removal of the enzyme COOH-terminal domain. The specific activities of both gelatinase B and Delta(426-688) gelatinase B, activated using either method, were found to be similar using either a quenched fluorescent peptide or gelatin as the substrate. Fibroblast monolayers were shown to mediate processing of both progelatinases at similar rates in the presence of either plasminogen or prostromelysin-1. Active wild-ty pe gelatinase B was inhibited by tissue inhibitor of metalloproteinase (TIMP)-1 at a much faster rate than TIMP-2. COOH-terminal truncation of either enzyme or inhibitor gave a marked reduction in the rate constant for TIMP-1 inhibition but had no effect on the rate of TIMP-2 binding. It can be concluded that the COOH-terminal domain of progelatinase B is not involved in autolytic or cellular activation and does not affect the catalytic activity of the enzyme. However, COOH terminal domain interactions between active gelatinase B and TIMP-1 significantly enhance the rate of complex formation.	STRANGEWAYS RES LAB,CAMBRIDGE CB1 4RN,ENGLAND; CELLTECH LTD,DEPT BIOCHEM,SLOUGH SL1 4EN,BERKS,ENGLAND	Celltech Group Ltd								BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; CRABBE T, 1992, BIOCHEMISTRY-US, V31, P8500, DOI 10.1021/bi00151a017; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; GAVRILOVIC J, 1989, CELL BIOL INT REP, V13, P367, DOI 10.1016/0309-1651(89)90163-X; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hunt L T, 1987, Protein Seq Data Anal, V1, P21; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KUBOTA S, 1991, BIOCHEM BIOPH RES CO, V181, P1539, DOI 10.1016/0006-291X(91)92114-Y; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; Murphy G, 1992, Matrix Suppl, V1, P224; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1981, BIOCHEM J, V199, P807, DOI 10.1042/bj1990807; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1986, J BIOL CHEM, V261, P14245; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STACK MS, 1989, J BIOL CHEM, V264, P4277; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TRIEBEL S, 1992, FEBS LETT, V298, P280, DOI 10.1016/0014-5793(92)80077-T; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; YAMAGATA S, 1989, BIOCHEM BIOPH RES CO, V158, P228, DOI 10.1016/S0006-291X(89)80202-5	39	134	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14967	14973						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195131				2022-12-27	WOS:A1994NP73800022
J	TAKAHAGI, M; IWASAKI, H; SHINAGAWA, H				TAKAHAGI, M; IWASAKI, H; SHINAGAWA, H			STRUCTURAL REQUIREMENTS OF SUBSTRATE DNA FOR BINDING TO AND CLEAVAGE BY RUVC, A HOLLIDAY JUNCTION RESOLVASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RUVA; T4 ENDONUCLEASE-VII; SACCHAROMYCES-CEREVISIAE; CRUCIFORM DNA; CONJUGATIONAL RECOMBINATION; GENE-3 ENDONUCLEASE; BRANCH MIGRATION; SUPERCOILED DNA; 4-WAY JUNCTION; RESOLUTION	To elucidate the molecular mechanism of the resolution of Holliday junctions by Escherichia coli RuvC protein, we studied biochemical properties of the protein using various synthetic DNA junctions as model substrates. RuvC cleaves not only a four-way junction but also three-way junctions efficiently. The central core of homology in the junction is essential for the substrates to be cleavable by RuvC. Although the divalent cations are essential for the endonuclease activity, RuvC efficiently forms specific complexes with four-way junctions in the absence of the cations, irrespective of the presence of homologous core sequences. By using T7 endonuclease I as a probe, we studied the topology of the substrate junctions used in our study. The results suggest that RuvC cleaves the three-way junctions with homology core when they become four-way conformers. From the present studies, we propose that RuvC initially binds mostly nonproductively to four-way junctions, which does not require divalent metals, and subsequently cleaves the junctions by a mechanism dependent on a divalent cation and a particular topological conformer that is induced by the sequences at the mobile junctions.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT EXPTL CHEMOTHERAPY,SUITA,OSAKA 565,JAPAN	Osaka University			Iwasaki, Hiroshi/Y-7946-2018	Iwasaki, Hiroshi/0000-0002-0153-6873				BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BHATTACHARYYA A, 1991, J MOL BIOL, V221, P1191, DOI 10.1016/0022-2836(91)90928-Y; BHATTACHARYYA A, 1989, NUCLEIC ACIDS RES, V17, P6821, DOI 10.1093/nar/17.17.6821; CHEN JH, 1988, BIOCHEMISTRY-US, V27, P6032, DOI 10.1021/bi00416a031; CHURCHILL MEA, 1988, P NATL ACAD SCI USA, V85, P4653, DOI 10.1073/pnas.85.13.4653; COOPER JP, 1987, J MOL BIOL, V198, P711, DOI 10.1016/0022-2836(87)90212-9; COOPER JP, 1989, P NATL ACAD SCI USA, V86, P7336, DOI 10.1073/pnas.86.19.7336; DEMASSY B, 1987, J MOL BIOL, V193, P359, DOI 10.1016/0022-2836(87)90224-5; DEMASSY B, 1984, COLD SPRING HARB SYM, V49, P715, DOI 10.1101/SQB.1984.049.01.081; DICKIE P, 1987, J BIOL CHEM, V262, P14826; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; ELBOROUGH KM, 1990, EMBO J, V9, P2931, DOI 10.1002/j.1460-2075.1990.tb07484.x; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HSIEH CH, 1989, P NATL ACAD SCI USA, V86, P4833, DOI 10.1073/pnas.86.13.4833; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1989, MOL GEN GENET, V219, P328, DOI 10.1007/BF00261196; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; JENSCH F, 1989, EMBO J, V8, P4325, DOI 10.1002/j.1460-2075.1989.tb08619.x; KEMPER B, 1984, COLD SPRING HARB SYM, V49, P815, DOI 10.1101/SQB.1984.049.01.092; LILLEY DMJ, 1984, CELL, V36, P413, DOI 10.1016/0092-8674(84)90234-4; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1987, J GEN MICROBIOL, V133, P2531; LU M, 1991, J BIOL CHEM, V266, P2531; LU M, 1990, J BIOL CHEM, V265, P16778; MIZUUCHI K, 1982, CELL, V29, P357, DOI 10.1016/0092-8674(82)90152-0; MUELLER JE, 1988, P NATL ACAD SCI USA, V85, P9441, DOI 10.1073/pnas.85.24.9441; MUELLER JE, 1990, J BIOL CHEM, V265, P13918; MURCHIE AIH, 1991, EMBO J, V10, P713, DOI 10.1002/j.1460-2075.1991.tb08001.x; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; PARSONS CA, 1990, NUCLEIC ACIDS RES, V18, P4377, DOI 10.1093/nar/18.15.4377; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; PICKSLEY SM, 1990, J MOL BIOL, V212, P723, DOI 10.1016/0022-2836(90)90233-C; POTTMEYER S, 1992, J MOL BIOL, V223, P607, DOI 10.1016/0022-2836(92)90977-R; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHIBA T, 1993, MOL GEN GENET, V237, P395, DOI 10.1007/BF00279443; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SHINAGAWA H, 1991, BIOCHIMIE, V73, P505, DOI 10.1016/0300-9084(91)90120-P; SYMINGTON LS, 1985, P NATL ACAD SCI USA, V82, P7247, DOI 10.1073/pnas.82.21.7247; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; VONKITZING E, 1990, NUCLEIC ACIDS RES, V18, P2671, DOI 10.1093/nar/18.9.2671; WEST SC, 1985, P NATL ACAD SCI USA, V82, P6445, DOI 10.1073/pnas.82.19.6445; WILLIAMSON JR, 1990, NUCLEIC ACIDS RES, V18, P379, DOI 10.1093/nar/18.2.379	50	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15132	15139						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195150				2022-12-27	WOS:A1994NP73800044
J	TURK, E; MARTIN, MG; WRIGHT, EM				TURK, E; MARTIN, MG; WRIGHT, EM			STRUCTURE OF THE HUMAN NA+/GLUCOSE COTRANSPORTER GENE SGLT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTESTINAL NA+/GLUCOSE; GLUCOSE TRANSPORTERS; EXPRESSION CLONING; FUNCTIONAL EXPRESSION; HUMAN-CHROMOSOMES; ORGANIZATION; CDNA; ASSIGNMENT; SEQUENCE; PROTEIN	Intestinal uptake of dietary glucose and galactose is mediated by the SGLT1 Na+/glucose cotransporter of the brush border. An SGLT1 missense mutation underlies hereditary glucose/galactose malabsorption, characterized by potentially fatal diarrhea; conversely, oral rehydration therapy exploits normal transport to alleviate life-threatening diarrhea of infectious origin. We have mapped the entire human SGLT1 Na+/glucose cotransporter gene from cosmid and lambda phage clones representing a genomic region of 112 kilobases. Transcription initiation occurred from a site 27 base pairs 3' of a TATAA sequence. All exon-flanking regions were sequenced, and the entire 112-kilobase region mapped with four restriction enzymes. SGLT1 is comprised of 15 exons (spanning 72 kilobases); a possible evolutionary origin from a six-membrane-span ancestral precursor via a gene duplication event is suggested from comparison of exons against protein secondary structure and from sequence considerations. A new missense mutation in exon 1 causing glucose/galactose malabsorption is also described. This is the first Na+-dependent cotransporter gene structure reported. These data facilitate the search for new glucose/galactose malabsorption-related mutations in this important gene and provide a basis for future evolutionary comparisons with other Na+-dependent cotransporters.	UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Martín, María/HDL-9512-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301, R01DK019567, R01DK044582] Funding Source: NIH RePORTER; NIDDK NIH HHS [NIDDK CURE-UCLA DK-41301, NIDDK DK-44582, NIDDK DK-19567] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1988, MOL REPROD DEV; BALDINI A, 1991, GENOMICS, V9, P770, DOI 10.1016/0888-7543(91)90374-N; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BIRREN BW, 1989, ANAL BIOCHEM, V177, P282, DOI 10.1016/0003-2697(89)90052-3; CARLE GF, 1986, SCIENCE, V232, P65, DOI 10.1126/science.3952500; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EVANS GA, 1987, METHOD ENZYMOL, V152, P604; GRAHAM MY, NUCLEIC ACIDS RES, V15, p443P7; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1989, GENOMICS, V4, P297, DOI 10.1016/0888-7543(89)90333-9; Hirayama Bruce A., 1992, Journal of General Physiology, V100, p19A; HIRSCHHORN N, 1991, SCI AM, V264, P50, DOI 10.1038/scientificamerican0591-50; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KIMMICH GA, 1981, PHYSL GASTROINTESTIN, P1035; KONG CT, 1993, J BIOL CHEM, V268, P1509; KOPITO RR, 1987, J BIOL CHEM, V262, P8035; KORENBERG JR, 1978, HUM GENET, V43, P13, DOI 10.1007/BF00396473; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Krainer AR, 1988, TRANSCRIPTION SPLICI, P131; KWON HM, 1992, J BIOL CHEM, V267, P6297; LESCALEMATYS L, 1993, BIOCHEM J, V291, P435, DOI 10.1042/bj2910435; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MCCLATCHEY AI, 1992, HUM MOL GENET, V1, P521; NEF P, 1984, P NATL ACAD SCI-BIOL, V81, P7975, DOI 10.1073/pnas.81.24.7975; OHTA T, 1990, MOL CELL BIOL, V10, P6491, DOI 10.1128/MCB.10.12.6491; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; SHIRAZIBEECHEY SP, 1991, J PHYSIOL-LONDON, V437, P699, DOI 10.1113/jphysiol.1991.sp018620; TURK E, 1993, GENOMICS, V17, P752, DOI 10.1006/geno.1993.1399; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; WELLS RG, 1992, AM J PHYSIOL, V263, P459; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WRIGHT E M, 1992, Current Opinion in Cell Biology, V4, P696, DOI 10.1016/0955-0674(92)90091-P; WRIGHT EM, 1993, SOC GEN PHY, V48, P229; WRIGHT EM, 1994, IN PRESS PHYSL GASTR	42	91	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15204	15209						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195156				2022-12-27	WOS:A1994NP73800053
J	DENG, L; SHUMAN, S				DENG, L; SHUMAN, S			A ROLE FOR THE H4 SUBUNIT OF VACCINIA RNA-POLYMERASE IN TRANSCRIPTION INITIATION AT A VIRAL EARLY PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS EARLY TRANSCRIPTION; MESSENGER-RNA; CAPPING ENZYME; ESCHERICHIA-COLI; EUKARYOTIC TRANSCRIPTION; GENE; IDENTIFICATION; PURIFICATION; TERMINATION; ELONGATION	The vaccinia virus H4 gene encodes an essential subunit of the DNA-dependent RNA polymerase holoenzyme encapsidated within virus particles (Ahn, B., and Moss, B. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 3536-3540; Kane, E. M., and Shuman, S. (1992) J. Virol. 66, 5752-5762). The role of this protein in transcription of viral early genes was revealed by the effects of affinity-purified anti-H4 antibody on discrete phases of the early transcription reaction in vitro. Anti-H4 specifically prevented the synthesis of a 21-nucleotide nascent RNA chain but had no impact on elongation of the 21-mer RNA by preassembled ternary complexes. Inhibition of initiation but not elongation was also observed with affinity-purified anti-D6 antibody directed against the 70-kDa subunit of the vaccinia early transcription initiation factor (ETF). Native gel mobility-shift assays showed that anti-H4 prevented the NTP-dependent recruitment of RNA polymerase to the preinitiation complex of ETF bound at the early promoter. Two species of ternary complexes could be resolved by native gel electrophoresis. Addition of anti-H4 to preformed complexes elicited a supershift of both ternary species but not of the preinitiation complex. Supershift by anti-D6 revealed that the more rapidly migrating species of ternary complex did not contain immunoreactive ETF. Loss of ETF from the ternary complex was time-dependent. Thus, whereas the H4 protein was a stable constituent of the elongation complex, ETF was dissociable. We suggest that H4 functions as a molecular bridge to ETF and thereby allows specific recognition of early promoters by the core RNA polymerase. H4 is unlike bacterial sigma factor in that it remains bound to polymerase after the elongation complex is established.			DENG, L (corresponding author), SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42498] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1992, P NATL ACAD SCI USA, V89, P3536, DOI 10.1073/pnas.89.8.3536; AHN BY, 1990, J VIROL, V64, P3019, DOI 10.1128/JVI.64.6.3019-3024.1990; AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; AHN BY, 1992, J VIROL, V66, P971, DOI 10.1128/JVI.66.2.971-982.1992; AMEGADZIE BY, 1991, J BIOL CHEM, V266, P13712; AMEGADZIE BY, 1992, J VIROL, V66, P3003, DOI 10.1128/JVI.66.5.3003-3010.1992; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1991, J BIOL CHEM, V266, P15539; BROYLES SS, 1990, J VIROL, V64, P5376, DOI 10.1128/JVI.64.11.5376-5382.1990; BROYLES SS, 1986, P NATL ACAD SCI USA, V83, P3141, DOI 10.1073/pnas.83.10.3141; CONG PJ, 1992, J BIOL CHEM, V267, P16424; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HAGLER J, 1992, J VIROL, V66, P2982, DOI 10.1128/JVI.66.5.2982-2989.1992; HAGLER J, 1992, J BIOL CHEM, V267, P7644; HAGLER J, 1992, P NATL ACAD SCI USA, V89, P10009; HARRIS N, 1993, P NATL ACAD SCI USA, V90, P2860, DOI 10.1073/pnas.90.7.2860; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; KANE EM, 1992, J VIROL, V66, P5752, DOI 10.1128/JVI.66.10.5752-5762.1992; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LI J, 1993, J BIOL CHEM, V268, P20016; LI J, 1993, J BIOL CHEM, V268, P2773; LUO Y, 1991, J BIOL CHEM, V266, P13303; MOSS B, 1991, J BIOL CHEM, V266, P1355; PATEL DD, 1989, J VIROL, V63, P1076, DOI 10.1128/JVI.63.3.1076-1086.1989; QUICK SD, 1990, VIROLOGY, V178, P603, DOI 10.1016/0042-6822(90)90362-U; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1989, J BIOL CHEM, V264, P21356; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x	34	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14323	14328						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188718				2022-12-27	WOS:A1994NL60600090
J	SACHS, A; WAHLE, E				SACHS, A; WAHLE, E			POLY(A) TAIL METABOLISM AND FUNCTION IN EUKARYOTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MESSENGER-RNA PRECURSORS; TRANSLATION INITIATION; POLYADENYLATION; POLYMERASE; PROTEIN; DEADENYLATION; PURIFICATION; EXPRESSION; CLEAVAGE; REQUIRES		UNIV BASEL,BIOCTR,ZELLBIOL ABT,CH-4056 BASEL,SWITZERLAND	University of Basel	SACHS, A (corresponding author), UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.			Wahle, Elmar/0000-0003-2504-0677				ASTROM J, 1992, J BIOL CHEM, V267, P15184; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BIENROTH S, 1992, EMBO J, V12, P585; BRAWERMAN G, 1981, CRC CR REV BIOCH MOL, V10, P1, DOI 10.3109/10409238109114634; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; FOX CA, 1992, EMBO J, V11, P5021, DOI 10.1002/j.1460-2075.1992.tb05609.x; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KELLER W, 1991, EMBO J, V10, P4241, DOI 10.1002/j.1460-2075.1991.tb05002.x; LOWELL JE, 1992, GENE DEV, V6, P2088, DOI 10.1101/gad.6.11.2088; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; Sachs A, 1990, CURR OPIN CELL BIOL, V2, P1092, DOI 10.1016/0955-0674(90)90161-7; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WAHLE E, 1992, J BIOL CHEM, V268, P2937; WEISS EA, 1991, EMBO J, V10, P215, DOI 10.1002/j.1460-2075.1991.tb07938.x; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WILUSZ J, 1990, MOL CELL BIOL, V10, P1244, DOI 10.1128/MCB.10.3.1244; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8	28	185	188	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					22955	22958						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226806				2022-12-27	WOS:A1993MF51500001
J	ANTONSSON, B; MONTESSUIT, S; FRIEDLI, L; PAYTON, MA; PARAVICINI, G				ANTONSSON, B; MONTESSUIT, S; FRIEDLI, L; PAYTON, MA; PARAVICINI, G			PROTEIN-KINASE-C IN YEAST - CHARACTERISTICS OF THE SACCHAROMYCES-CEREVISIAE PKC1 GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN KINASE; PHORBOL ESTER; RAT-BRAIN; INOSITOL TRISPHOSPHATE; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; REGULATORY DOMAIN; BINDING ACTIVITY; 2ND MESSENGERS; FISSION YEAST	The Saccharomyces cerevisiae PKC1 gene encodes a homolog of mammalian protein kinase C (Levin, D. E., Fields, F. O., Kunisawa, R., Bishop, J. M., and Thorner, J. (1990) Cell 62, 213-224). A protein of 150 kDa is recognized by a polyclonal antiserum raised against a trpE-Pkc1 fusion protein. In subcellular fractionations, Pkc1p associates with the 100,000 x g particulate fraction. This association is resistant to extraction with high salt concentrations, alkali buffer, or nonionic detergents, suggesting that Pkc1p may be associated with a large protein complex. Pkc1p modified at its COOH terminus with two repeats of the Staphylococcus aureus protein A IgG-binding fragment (ZZ sequence tag) was able to fully restore the growth defects of a pkc1(ts) strain at restrictive temperature, ZZ-tagged Pkc1p was partially purified by chromatography on DEAE-Sepharose, followed by IgG-Sepharose. In vitro, Pkc1p phosphorylates the pseudosubstrate peptide and myelin basic protein, but not histones. Replacing an isoleucine with an arginine 2 amino acids COOH-terminal of the acceptor serine in the substrate peptide resulted in a 10-fold decrease of K-m. Pkc1p activity was independent of cofactors such as phospholipids, diacylglycerol, and Ca2+, known to activate several mammalian protein kinase C isoenzymes, making it a rather distantly related member of the protein kinase C superfamily.	GLAXO INST MOLEC BIOL SA, CH-1228 PLAN LES OUATES, SWITZERLAND	GlaxoSmithKline								AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; FARLEY J, 1986, NATURE, V319, P220, DOI 10.1038/319220a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; HOUSE C, 1987, J BIOL CHEM, V262, P772; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; IWAI T, 1992, J BIOCHEM, V112, P7, DOI 10.1093/oxfordjournals.jbchem.a123868; KARIN M, 1991, MOL ASPECTS CELLULAR, V6, P235; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KOHRER K, 1993, J BIOL CHEM, V268, P559; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LUO JH, 1993, J BIOL CHEM, V268, P3715; MADISON DV, 1986, NATURE, V321, P695, DOI 10.1038/321695a0; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; MAZZEI GJ, 1993, J BIOL CHEM, V268, P7401; MEISENHELDER J, 1991, METHOD ENZYMOL, V197, P288; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OGITA K, 1990, P NATL ACAD SCI USA, V87, P5011, DOI 10.1073/pnas.87.13.5011; OHMURA E, 1985, ENDOCRINOLOGY, V116, P728, DOI 10.1210/endo-116-2-728; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PARAVICINI G, 1992, MOL BIOL CELL, V3, P415, DOI 10.1091/mbc.3.4.415; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; PEARS C, 1992, BIOCHEM J, V283, P515, DOI 10.1042/bj2830515; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; RAVID S, 1992, P NATL ACAD SCI USA, V89, P5877, DOI 10.1073/pnas.89.13.5877; RAVID S, 1989, J BIOL CHEM, V264, P15144; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; Sherman F, 1979, METHODS YEAST GENETI; SIMON AJ, 1991, P ROY SOC B-BIOL SCI, V243, P165, DOI 10.1098/rspb.1991.0027; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; TODA T, 1993, EMBO J, V12, P1987, DOI 10.1002/j.1460-2075.1993.tb05848.x; VIDA TA, 1990, J CELL BIOL, V111, P2871, DOI 10.1083/jcb.111.6.2871; WATANABE M, 1994, J BIOL CHEM, V269, P16829; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WEINSTEIN IB, 1991, ORIGINS OF HUMAN CANCER, P113; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; Woodgett JR., 1987, CELL MEMBRANES, P215, DOI [10.1007/978-1-4613-1915-3_6, DOI 10.1007/978-1-4613-1915-3_6]; ZALEWSKI PD, 1990, FEBS LETT, V273, P131, DOI 10.1016/0014-5793(90)81067-X	70	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16821	16828						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207004				2022-12-27	WOS:A1994NR29600049
J	DING, JB; LU, DJ; PEREZSALA, D; MA, YT; MADDOX, JF; GILBERT, BA; BADWEY, JA; RANDO, RR				DING, JB; LU, DJ; PEREZSALA, D; MA, YT; MADDOX, JF; GILBERT, BA; BADWEY, JA; RANDO, RR			FARNESYL-L-CYSTEINE ANALOGS CAN INHIBIT OR INITIATE SUPEROXIDE RELEASE BY HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; CARBOXYL-METHYLATION; NADPH OXIDASE; CHEMOATTRACTANT RECEPTORS; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-D; PHORBOL ESTERS; KINASE-C	A series of farnesylcysteine analogs was studied with respect to their abilities to interfere with fMet-Leu-Phe (fMLP)-stimulated superoxide (O-2(radical-anion)) release by human neutrophils. Simple acyl derivatives of farnesyl-L-cysteine, such as the N-acetyl (L-AFC) and N-isobutyryl derivatives (L-iBFC), which are substrates for the isoprenylated protein methyltransferase, can block O-2(radical-anion) release. The N-butyryl analog (L-BFC), which is an isomer of L-iBFC and also a substrate for the methyltransferase, does not inhibit O-2(radical-anion) release but actually stimulates it in the absence of fMLP. Other analogs, including the N-pivaloyl derivative, which has been found to be neither a substrate nor an inhibitor of methyltransferase, also stimulate very large quantities of O-2(radical-anion) production. The stimulatory effects of these derivatives are saturable and exquisitively sensitive to small structural changes in the analogs. The signal transduction pathway(s) utilized by pivaloyl derivatives for triggering O-2(radical-anion) generation is very similar to that employed by fMLP. These data make it clear that farnesyl-L-cysteine analogs do not produce their pharmacological effects in neutrophils via methyltransferase blockade. This could be further demonstrated by showing that sinefungin and S-adenosylhomocysteine, both powerful and general methyltransferase inhibitors which bind at the S-adenosylmethionine site, had no effect in preventing the increased oxygen consumption associated with O-2(radical-anion) production in permeabilized neutrophils. These studies reveal that farnesyl-L-cysteine analogs interact with a hitherto undefined target in neutrophils that may be exploited for inhibiting or stimulating the inflammatory or antimicrobial responses of these cells.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; BOSTON BIOMED RES INST, BOSTON, MA 02114 USA; CSIC, MADRID, SPAIN	Harvard University; Harvard Medical School; Boston Biomedical Research Institute; Consejo Superior de Investigaciones Cientificas (CSIC)			Perez-Sala, Dolores/L-5969-2014	Perez-Sala, Dolores/0000-0003-0600-665X	NHLBI NIH HHS [HL-34346] Funding Source: Medline; NIAID NIH HHS [AI-23323, AI-28342] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034346] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028342, R01AI023323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ACKERMAN GA, 1968, LAB INVEST, V19, P290; Akbar Huzoor, 1993, P NATL ACAD SCI USA, V90, P868; ALI H, 1993, J BIOL CHEM, V268, P24247; BABIOR BM, 1991, AM J HEMATOL, V37, P263, DOI 10.1002/ajh.2830370410; BADWEY JA, 1989, BIOCHEM BIOPH RES CO, V158, P1029, DOI 10.1016/0006-291X(89)92825-8; BADWEY JA, 1989, J BIOL CHEM, V264, P14947; BADWEY JA, 1982, BIOCHEM BIOPH RES CO, V106, P170, DOI 10.1016/0006-291X(82)92073-3; BARBER JR, 1984, J BIOL CHEM, V259, P7115; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; CHALLISS RAJ, 1988, BIOCHEM BIOPH RES CO, V157, P684, DOI 10.1016/S0006-291X(88)80304-8; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; CURNUTTE JT, 1993, CLIN IMMUNOL IMMUNOP, V67, pS2, DOI 10.1006/clin.1993.1078; CURNUTTE JT, 1987, ADV HUM GENET, V16, P229; DIETRICH A, 1994, EUR J BIOCHEM, V219, P171, DOI 10.1111/j.1432-1033.1994.tb19927.x; DING JB, 1992, J BIOL CHEM, V267, P6442; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; GILBERT BA, 1992, J AM CHEM SOC, V114, P3966, DOI 10.1021/ja00036a052; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HEITHIER H, 1992, EUR J BIOCHEM, V204, P1169, DOI 10.1111/j.1432-1033.1992.tb16744.x; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; KRECK ML, 1994, J BIOL CHEM, V269, P4161; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LU DJ, 1990, J BIOL CHEM, V265, P13721; LUSCINSKAS FW, 1990, BIOCHEM PHARMACOL, V39, P355, DOI 10.1016/0006-2952(90)90035-J; METZ SA, 1993, BIOCHEM J, V295, P31, DOI 10.1042/bj2950031; MITSUYAMA T, 1993, FEBS LETT, V328, P67, DOI 10.1016/0014-5793(93)80967-Y; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; NACCACHE PH, 1979, SCIENCE, V203, P461, DOI 10.1126/science.760200; OHTA H, 1985, J BIOL CHEM, V260, P5771; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PEREZSALA D, 1991, P NATL ACAD SCI USA, V88, P3043, DOI 10.1073/pnas.88.8.3043; PEREZSALA D, 1992, BIOCHEM J, V284, P835, DOI 10.1042/bj2840835; PERRY DK, 1992, J IMMUNOL, V149, P2749; PHILIPS MR, 1991, J BIOL CHEM, V266, P1289; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PILLINGER MH, 1994, J BIOL CHEM, V269, P1486; PUGH CSG, 1978, J BIOL CHEM, V253, P4075; QUINN MT, 1993, J BIOL CHEM, V268, P20983; ROBINSON JM, 1987, J CELL BIOL, V105, P417, DOI 10.1083/jcb.105.1.417; ROBINSON JM, 1985, J CELL BIOL, V101, P1052, DOI 10.1083/jcb.101.3.1052; SCHEER A, 1993, FEBS LETT, V319, P110, DOI 10.1016/0014-5793(93)80047-X; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SHI YQ, 1992, J BIOL CHEM, V267, P9547; SHIRATAKI H, 1991, J BIOL CHEM, V266, P20672; SNYDERMAN R, 1984, ANNU REV IMMUNOL, V2, P257, DOI 10.1146/annurev.immunol.2.1.257; TAN EW, 1991, J AM CHEM SOC, V113, P6299, DOI 10.1021/ja00016a072; TAN EW, 1991, J BIOL CHEM, V266, P10719; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WILDE MW, 1989, J BIOL CHEM, V264, P190	57	42	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16837	16844						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207006				2022-12-27	WOS:A1994NR29600051
J	FAKLER, B; HERLITZE, S; AMTHOR, B; ZENNER, HP; RUPPERSBERG, JP				FAKLER, B; HERLITZE, S; AMTHOR, B; ZENNER, HP; RUPPERSBERG, JP			SHORT ANTISENSE OLIGONUCLEOTIDE-MEDIATED INHIBITION IS STRONGLY DEPENDENT ON OLIGO LENGTH AND CONCENTRATION BUT ALMOST INDEPENDENT OF LOCATION OF THE TARGET SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPA RECEPTOR CHANNELS; MESSENGER-RNA; XENOPUS-OOCYTES; COMPLEMENTARY-DNA; DIRECTED CLEAVAGE; HYBRID ARREST; OLIGODEOXYNUCLEOTIDES; TRANSLATION; OLIGODEOXYRIBONUCLEOTIDES; DEGRADATION	The inhibitory effect of short antisense oligodeoxynucleotides (aODNs) on cRNA expression in Xenopus oocytes was measured using an electrophysiological assay based on subunit-specific block of cloned alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptors. The effect of both phosphorothioate modified (PS) and phosphodiester (PO) aODNs was strongly length dependent with a half-maximal inhibition calculated for an oligo length of 7.6 nucleotides (nt) and 9.9 nt, respectively. More than 95% inhibition was mediated by a PS aODN of 12 nt and by PO aODNs greater than or equal to 15 nt. At a given length PS and PO aODNs showed differential dependence of their inhibitory effect on the injected aODN concentration (half-maximal inhibition at 18 ng/mu l for a PO 12-mer and at 0.19 ng mu/l for a PS 12-mer) and differential saturation behavior. The inhibitory effect of aODNs, even as short as 8 nt for PS oligomers, was highly sequence specific, but almost independent of the position of the respective target site on the cRNA (for PS 8-mers, greater than or equal to 70% expression inhibition throughout the tested target sites from the translation initiation to the 3'-untranslated region). Thus, short PS aODNs can be reliably used in order to specifically inhibit protein expression in experiments addressing physiological, molecular biological, and perhaps even therapeutical issues.	UNIV TUBINGEN,HALS NASEN OHREN KLIN,SEKT SENSOR BIOPHYS,D-72076 TUBINGEN,GERMANY; MAX PLANCK INST MED RES,ZELLPHYSIOL ABT,D-69120 HEIDELBERG,GERMANY	Eberhard Karls University of Tubingen; Max Planck Society								AGRAWAL S, 1990, P NATL ACAD SCI USA, V87, P1401, DOI 10.1073/pnas.87.4.1401; BAKER C, 1990, NUCLEIC ACIDS RES, V18, P3537, DOI 10.1093/nar/18.12.3537; BOIZIAU C, 1992, P NATL ACAD SCI USA, V89, P768, DOI 10.1073/pnas.89.2.768; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CAZENAVE C, 1987, NUCLEIC ACIDS RES, V15, P4717, DOI 10.1093/nar/15.12.4717; CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; COSSTICK R, 1985, BIOCHEMISTRY-US, V24, P3630, DOI 10.1021/bi00335a035; DAGLE JM, 1990, NUCLEIC ACIDS RES, V18, P4751, DOI 10.1093/nar/18.16.4751; DASH P, 1987, P NATL ACAD SCI USA, V84, P7896, DOI 10.1073/pnas.84.22.7896; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; DRAGUHN A, 1991, NEUROSCI LETT, V132, P187, DOI 10.1016/0304-3940(91)90298-8; ELBARADI T, 1991, EMBO J, V10, P1407, DOI 10.1002/j.1460-2075.1991.tb07661.x; GAO WY, 1992, MOL PHARMACOL, V41, P223; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; HERLITZE S, 1993, NEURON, V10, P1131, DOI 10.1016/0896-6273(93)90061-U; KAWASAKI ES, 1985, NUCLEIC ACIDS RES, V13, P4991, DOI 10.1093/nar/13.13.4991; KITAJIAMA J, 1992, J BIOL CHEM, V267, P25881; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LALLIER T, 1993, SCIENCE, V259, P692, DOI 10.1126/science.8430321; LAPLANCHE LA, 1986, NUCLEIC ACIDS RES, V14, P9081, DOI 10.1093/nar/14.22.9081; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; LOTAN I, 1988, NEURON, V1, P963, DOI 10.1016/0896-6273(88)90153-5; MAHER LJ, 1988, NUCLEIC ACIDS RES, V16, P3341, DOI 10.1093/nar/16.8.3341; MINSHULL J, 1986, NUCLEIC ACIDS RES, V14, P6433, DOI 10.1093/nar/14.16.6433; MONIA BP, 1992, J BIOL CHEM, V267, P19954; SAISONBEHMOARAS T, 1991, EMBO J, V10, P1111, DOI 10.1002/j.1460-2075.1991.tb08051.x; SHAW JP, 1991, NUCLEIC ACIDS RES, V19, P747, DOI 10.1093/nar/19.4.747; SHUTTLEWORTH J, 1988, EMBO J, V7, P427, DOI 10.1002/j.1460-2075.1988.tb02830.x; SHUTTLEWORTH J, 1988, GENE, V72, P267, DOI 10.1016/0378-1119(88)90152-7; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SOMMER B, 1990, SCIENCE, V252, P1715; SPITZER S, 1988, NUCLEIC ACIDS RES, V16, P11691, DOI 10.1093/nar/16.24.11691; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STULL RA, 1992, NUCLEIC ACIDS RES, V20, P3501, DOI 10.1093/nar/20.13.3501; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WOOLF TM, 1990, NUCLEIC ACIDS RES, V18, P1763, DOI 10.1093/nar/18.7.1763; WOOLF TM, 1992, P NATL ACAD SCI USA, V89, P7305, DOI 10.1073/pnas.89.16.7305; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280	45	39	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16187	16194						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206920				2022-12-27	WOS:A1994NQ72900038
J	HUANG, TG; SUHAN, J; HACKNEY, DD				HUANG, TG; SUHAN, J; HACKNEY, DD			DROSOPHILA KINESIN MOTOR DOMAIN EXTENDING TO AMINO-ACID POSITION-392 IS DIMERIC WHEN EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN; SURFACE LATTICE; CYTOPLASMIC MICROTUBULES; SEQUENCE; TUBULIN; DECORATION; PROTEINS; FAMILY	A truncated domain of the a-subunit of Drosophila kinasin was obtained by expression in Escherichia coli and purified to homogeneity in the presence of MgATP. This domain (designated DKH392) extends to amino acid 392 and contains the complete N-terminal region of kinesin which is highly conserved between species. The DKH392 construct includes an additional 52 amino acids beyond the minimal motor domain of 340 amino acid residues which has been previously characterized as DKH340 (Huang, T.-G., and Hackney, D, D. (1994) J. Biol. Chem. 269, 16493-16501). The s(20,w) values for DKH340 and DKH392 are 3.3 and 5.2 S and the D-20,D-w values are 7.7 x 10(-7) and 4.9 x 10(-7) cm(3) s(-1), respectively. These results indicate that DKH340 is a monomer in solution, but DKH392 is a dimer. In the presence of adenosine 5-(beta,gamma-imido)triphosphate, DKH392 binds to microtubules with a stoichiometry of two head domains (one DKH392 dimer) per tubulin heterodimer in contrast to the tight binding of one DKH340 per tubulin heterodimer. Electron microscopy indicates that both DKH340 monomers and DKM392 dimers decorate microtubules with a periodicity of 8 nm.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213	Carnegie Mellon University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028562] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28562] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERS GK, 1967, J BIOL CHEM, V242, P3237; AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENDOW SA, 1991, TRENDS BIOCHEM SCI, V16, P221, DOI 10.1016/0968-0004(91)90089-E; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HISANAGA S, 1989, CELL MOTIL CYTOSKEL, V12, P264, DOI 10.1002/cm.970120407; HOLLEY LH, 1989, P NATL ACAD SCI USA, V86, P152, DOI 10.1073/pnas.86.1.152; HUANG TG, 1994, J BIOL CHEM, V269, P16493; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; MANDELKOW EM, 1986, J CELL BIOL, V102, P1067, DOI 10.1083/jcb.102.3.1067; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; SCHULTHEISS R, 1983, J MOL BIOL, V170, P471, DOI 10.1016/S0022-2836(83)80158-2; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	22	95	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16502	16507						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206960				2022-12-27	WOS:A1994NQ72900081
J	LUNDELL, D; LUNN, CA; SENIOR, MM; ZAVODNY, PJ; NARULA, SK				LUNDELL, D; LUNN, CA; SENIOR, MM; ZAVODNY, PJ; NARULA, SK			IMPORTANCE OF THE LOOP CONNECTING A-HELIX AND B-HELIX OF HUMAN INTERFERON-GAMMA IN RECOGNITION BY INTERFERON-GAMMA RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; MOLECULAR-CLONING; POINT MUTATION; CDNA; EXPRESSION; SEQUENCE; ASSIGNMENTS	Characterization of murine human hybrid interferon-gamma (IFN-gamma) molecules suggests that substitution of the peptide connecting the A and B helices in human IFN-gamma with the murine sequence significantly blocks the protein's binding to the human interferon-gamma receptor. Mutagenesis showed that this effect is localized to the central part of this A-B loop peptide, particularly Ser(20), Asp(21), Val(22), and Ala(23). One mutant, IFN-gamma/A23E,D24E,N25K, was examined by NMR. This ''EEK'' mutation does not significantly alter the conformation of interferon-gamma, suggesting that the effects of these mutations are not the result of global conformational changes. The A-B loop is near histidine 111, a residue previously shown to be important in receptor-ligand interaction (Lunn, C.A., Fossetta, J., Dalgarno, D., Murgolo, N., Windsor, W., Zavodny, P.J., Narula, S.K., and Lundell, D. (1992) Protein Eng. 5, 253-257). We show that copper forms a complex between histidine 19 in the A-B loop and histidine 111. This metal complex lacks the ability to interact with the interferon-gamma receptor. These results suggest that the A-B loop contains important struc tural information needed for receptor-ligand binding and hence biological activity of human interferon-gamma.	SCHERING PLOUGH CORP, RES INST, RES & DEV, PHYS & ANALYT CHEM, KENILWORTH, NJ 07033 USA	Merck & Company; Schering Plough Corporation	LUNDELL, D (corresponding author), SCHERING PLOUGH CORP, RES INST, DEPT IMMUNOL, 2015 GALLOPING HILL RD, KENILWORTH, NJ 07033 USA.							ARAKAWA T, 1986, J BIOL CHEM, V261, P8534; BURTON LE, 1984, BIOL INTERFERON SYST, P403; CERRETTI DP, 1986, J IMMUNOL, V136, P4561; DIJKEMA R, 1985, EMBO J, V4, P761, DOI 10.1002/j.1460-2075.1985.tb03694.x; DIJKMANS R, 1990, LYMPHOKINE RES, V9, P345; DOBELI H, 1988, J BIOTECHNOL, V7, P199, DOI 10.1016/0168-1656(88)90052-1; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; GRAY PW, 1982, NATURE, V295, P503, DOI 10.1038/295503a0; GRAY PW, 1983, P NATL ACAD SCI-BIOL, V80, P5842, DOI 10.1073/pnas.80.19.5842; GRZESIEK S, 1992, BIOCHEMISTRY-US, V31, P8180, DOI 10.1021/bi00150a009; HEMDAN ES, 1989, P NATL ACAD SCI USA, V86, P1811, DOI 10.1073/pnas.86.6.1811; JARPE MA, 1993, J INTERFERON RES, V13, P99, DOI 10.1089/jir.1993.13.99; LUNDELL D, 1991, PROTEIN ENG, V4, P335, DOI 10.1093/protein/4.3.335; LUNN CA, 1992, PROTEIN ENG, V5, P249, DOI 10.1093/protein/5.3.249; LUNN CA, 1992, J BIOL CHEM, V267, P17920; LUNN CA, 1992, PROTEIN ENG, V5, P253, DOI 10.1093/protein/5.3.253; MCINNES CJ, 1990, NUCLEIC ACIDS RES, V18, P4012, DOI 10.1093/nar/18.13.4012; ROGER D, 1990, NUCLEIC ACIDS RES, V18, P4259, DOI 10.1093/nar/18.14.4259; RUBINSTEIN S, 1981, J VIROL, V37, P755, DOI 10.1128/JVI.37.2.755-758.1981; SAKAGUCHI M, 1988, FEBS LETT, V230, P201, DOI 10.1016/0014-5793(88)80671-9; SAKAI TT, 1993, BIOCHEMISTRY-US, V32, P5650, DOI 10.1021/bi00072a022; SAMUDZI CT, 1991, J BIOL CHEM, V266, P21791; SCHREIBER RD, 1985, J IMMUNOL, V134, P1609; ZUCKER K, 1992, J INTERFERON RES, V12, P191, DOI 10.1089/jir.1992.12.191	24	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16159	16162						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206916				2022-12-27	WOS:A1994NQ72900034
J	MCBROOM, LDB; SADOWSKI, PD				MCBROOM, LDB; SADOWSKI, PD			CONTACTS OF THE ABF1 PROTEIN OF SACCHAROMYCES-CEREVISIAE WITH A DNA-BINDING SITE AT MATA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTONOMOUSLY REPLICATING SEQUENCES; CRYSTAL-STRUCTURE; FLP RECOMBINASE; TARGET SEQUENCE; TRANSCRIPTIONAL ACTIVATOR; RNA-POLYMERASE; FACTOR-I; YEAST; GENE; EXPRESSION	The ABF1 protein of Saccharomyces cerevisiae is a multifunctional DNA-binding protein that is required for cell viability. The ABF1 protein has previously been shown to bind to a number of yeast sequences having a consensus of: 5'-A/G TC A/G C/T C/T NNNNACG-3'. A heretofore undiscovered ABF1-binding site was found in the MATa region. We have used missing contact analysis of this ABF1-binding site to show that removal of the conserved bases, as well as of some bases which are not conserved, reduces binding. We have probed contacts of ABF1 with the DNA-binding site using dimethyl sulfate and potassium permanganate and find that the protein makes extensive contacts with both the major and minor grooves. Ethylation interference studies indicate that numerous phosphate contacts are also important for ABF1 binding. Interference studies indicate that the ABF1 protein is also in close proximity to the DNA that is 5' and 3' of the conserved bases of the binding site. The extensive DNA contacts exhibited by ABF1 may play a role in the protein-induced bending of the DNA target (McBroom, L. D. B., and Sadowski, P. D. (1994) J. Biol. Chem. 169, 16461-16468).	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA	University of Toronto								Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ANDREWS BJ, 1987, J MOL BIOL, V193, P345, DOI 10.1016/0022-2836(87)90223-3; ANDREWS BJ, 1985, CELL, V40, P795, DOI 10.1016/0092-8674(85)90339-3; ASTELL CR, 1981, CELL, V27, P15, DOI 10.1016/0092-8674(81)90356-1; BEATTY LG, 1988, J MOL BIOL, V204, P283, DOI 10.1016/0022-2836(88)90576-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; DELLASETA F, 1990, MOL CELL BIOL, V10, P2437, DOI 10.1128/MCB.10.5.2437; DELLASETA F, 1990, J BIOL CHEM, V265, P15168; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; EISENBERG S, 1988, P NATL ACAD SCI USA, V85, P743, DOI 10.1073/pnas.85.3.743; GOEL A, 1988, MOL CELL BIOL, V8, P2572, DOI 10.1128/MCB.8.6.2572; HALFTER H, 1989, EMBO J, V8, P3029, DOI 10.1002/j.1460-2075.1989.tb08453.x; HALFTER H, 1989, EMBO J, V8, P4265, DOI 10.1002/j.1460-2075.1989.tb08612.x; HAMIL KG, 1988, MOL CELL BIOL, V8, P4328, DOI 10.1128/MCB.8.10.4328; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HEDGE RS, 1992, NATURE, V359, P505; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOLLAND JP, 1990, MOL CELL BIOL, V10, P4863, DOI 10.1128/MCB.10.9.4863; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; JONES EW, 1977, GENETICS, V85, P23; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCBROOM LDB, 1994, J BIOL CHEM, V269, P16461; MCBROOM LDB, 1993, THESIS U TORONTO; PANIGRAHI GB, 1992, NUCLEIC ACIDS RES, V20, P5927, DOI 10.1093/nar/20.22.5927; RHODE PR, 1989, GENE DEV, V3, P1926, DOI 10.1101/gad.3.12a.1926; RHODE PR, 1992, MOL CELL BIOL, V12, P1064, DOI 10.1128/MCB.12.3.1064; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SILVE S, 1992, MOL CELL BIOL, V12, P4197, DOI 10.1128/MCB.12.9.4197; TAYLOR MJ, 1985, J BIOL CHEM, V260, P4531; TRAWICK JD, 1992, MOL CELL BIOL, V12, P2302, DOI 10.1128/MCB.12.5.2302; TSCHUMPER G, 1980, GENE, V10, P157, DOI 10.1016/0378-1119(80)90133-X; WALKER SS, 1989, MOL CELL BIOL, V9, P2914, DOI 10.1128/MCB.9.7.2914; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	45	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16455	16460						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206954				2022-12-27	WOS:A1994NQ72900075
J	VANVEEN, HW; ABEE, T; KORTSTEE, GJJ; KONINGS, WN; ZEHNDER, AJB				VANVEEN, HW; ABEE, T; KORTSTEE, GJJ; KONINGS, WN; ZEHNDER, AJB			SUBSTRATE-SPECIFICITY OF THE 2 PHOSPHATE-TRANSPORT SYSTEMS OF ACINETOBACTER-JOHNSONII-210A IN RELATION TO PHOSPHATE SPECIATION IN ITS AQUATIC ENVIRONMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECTONEMA-BORYANUM CYANOPHYCEAE; ELEMENTAL COMPOSITION; POLYPHOSPHATE BODIES; STRAIN 210A; ACCUMULATION; MECHANISM; MANGANESE	In natural waters and domestic waste waters in which divalent metal ions are present in excess of P-i, H2PO4-, HPO42-, and MeHPO(4) prevail at pH values physiological for Acinetobacter johnsonii 210A (pH 5.5-8.0). In view of the ability of this organism to extensively accumulate P-i and divalent cations in cytoplasmic polyphosphate granules, the substrate specificity of its two P-i transport systems was studied. The constitutive, proton motive force-driven P-i carrier, previously shown to be dependent on divalent cations, plays a major role in the divalent cation and P-i flux by translocating MeHPO(4) rather than P-i. This notion is confirmed by the observation that divalent cations are cotransported with P-i in a 1:1 stoichiometry in proteoliposomes containing reconstituted P-i carrier protein. In contrast, the P-i repressible, periplasmic binding protein-dependent P-i transport system mediates the uptake of H2PO4- and HPO42- P-i uptake, but not MeHPO(4) uptake, was stimulated in cells under P-i limitation, and the periplasmic P-i-binding protein has affinity for H2PO4- and HPO42-, but not for MeHPO(4). When operating in concert, both systems enable A. johnsonii 210A to efficiently acquire P-i from its habitat through uptake of the predominant P-i species.	AGR UNIV WAGENINGEN,DEPT MICROBIOL,6703 CT WAGENINGEN,NETHERLANDS; AGR UNIV WAGENINGEN,DEPT FOOD SCI,6703 HD WAGENINGEN,NETHERLANDS; UNIV GRONINGEN,DEPT MICROBIOL,9751 NN HAREN,NETHERLANDS	Wageningen University & Research; Wageningen University & Research; University of Groningen			Konings, Wilhelmus N./C-7063-2013; Van Veen, Hendrik W./A-4162-2008	Van Veen, Hendrik W./0000-0002-9658-8077				AMES GFL, 1990, J BACTERIOL, V172, P4133, DOI 10.1128/jb.172.8.4133-4137.1990; ARCHIBALD FS, 1984, J BACTERIOL, V158, P1; BAXTER M, 1980, PROTOPLASMA, V104, P81, DOI 10.1007/BF01279371; BONTING CFC, 1993, ARCH MICROBIOL, V159, P428, DOI 10.1007/BF00288589; BONTING CFC, 1991, J BACTERIOL, V173, P6484, DOI 10.1128/jb.173.20.6484-6488.1991; BONTING CFC, 1992, ARCH MICROBIOL, V158, P139, DOI 10.1007/BF00245217; DEINEMA MH, 1980, FEMS MICROBIOL LETT, V9, P275; DEINEMA MH, 1985, WATER SCI TECHNOL, V17, P119, DOI 10.2166/wst.1985.0226; DRIESSEN AJM, 1985, P NATL ACAD SCI USA, V82, P7555, DOI 10.1073/pnas.82.22.7555; FRIEDBERG I, 1968, J BACTERIOL, V96, P544, DOI 10.1128/JB.96.2.544-553.1968; Fuhs GW, 1975, MICROB ECOL, V2, P119, DOI 10.1007/BF02010434; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; JENSEN TE, 1982, ENVIRON POLLUT A, V27, P119, DOI 10.1016/0143-1471(82)90104-0; KJELDSTAD B, 1991, CAN J MICROBIOL, V37, P562, DOI 10.1139/m91-094; KUBENA BD, 1986, J BIOL CHEM, V261, P7995; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; Martell A. E., 1976, CRITICAL STABILITY C, VIV; MEDVECZKY N, 1969, BIOCHIM BIOPHYS ACTA, V192, P369, DOI 10.1016/0304-4165(69)90382-1; MEDVECZKY N, 1970, BIOCHIM BIOPHYS ACTA, V211, P158, DOI 10.1016/0005-2736(70)90090-8; Morel F.M.M., 1983, PRINCIPLES AQUATIC C; MURPHY M, 1986, APPL MICROBIOL BIOT, V24, P512, DOI 10.1007/BF00250333; RENSINK JH, 1991, WATER SCI TECHNOL, V23, P651, DOI 10.2166/wst.1991.0515; SILLEN LG, 1964, STABILITY CONSTANTS, P180; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Snoeyink VL., 1980, WATER CHEM; Stumm W., 1981, AQUATIC CHEM; van Groenestijn J.W., 1988, THESIS AGR U WAGENIN; VANGROENESTIJN JW, 1988, APPL ENVIRON MICROB, V54, P2894, DOI 10.1128/AEM.54.12.2894-2901.1988; VANGROENESTIJN JW, 1989, A VAN LEEUW J MICROB, V55, P67, DOI 10.1007/BF02309620; VANGROENESTIJN JW, 1987, ARCH MICROBIOL, V148, P14, DOI 10.1007/BF00429640; VANVEEN HW, 1993, J BACTERIOL, V175, P200, DOI 10.1128/JB.175.1.200-206.1993; VANVEEN HW, 1993, J BIOL CHEM, V268, P19377; WEBSTER JA, 1984, J BACTERIOL, V158, P441, DOI 10.1128/JB.158.2.441-446.1984; ZEHNDER AJB, 1990, NOVEL BIODEGRADABLE, P235	35	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16212	16216						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206923				2022-12-27	WOS:A1994NQ72900041
J	UEKI, K; MATSUDA, S; TOBE, K; GOTOH, Y; TAMEMOTO, H; YACHI, M; AKANUMA, Y; YAZAKI, Y; NISHIDA, E; KADOWAKI, T				UEKI, K; MATSUDA, S; TOBE, K; GOTOH, Y; TAMEMOTO, H; YACHI, M; AKANUMA, Y; YAZAKI, Y; NISHIDA, E; KADOWAKI, T			FEEDBACK-REGULATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE KINASE-ACTIVITY OF C-RAF-1 BY INSULIN AND PHORBOL ESTER STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; THREONINE PHOSPHORYLATION; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; NUCLEOTIDE EXCHANGE; RAF-1 KINASE; RAS; RECEPTOR; SERINE; GRB2	Recently, it has been reported that Raf-1 kinase (Raf-1) has mitogen-activated protein kinase kinase kinase (MAPKKK) activity in various cells, although Raf-1 and MAP kinase kinase (MAPKK) can be phosphorylated by MAP kinase (MAPK) in vitro. Here we show that the maximal hyperphosphorylation of Raf-1 and MAPKK (10 min) was substantially achieved after the maximal activation of MAPKKK of Raf-1, MAPKK (2-5 min), and MAPK in Chinese hamster ovary cells overexpressing human insulin receptor (CHO-HIR cells) treated with insulin or 12-O-tetradecanoylphorbol-13-acetate (TPA). Moreover, we show that overexpression of MAPK in CHO-HIR cells resulted in enhanced hyperphosphorylation of Raf-1, MAPKK, and mammalian homolog of son of sevenless (mSos) after insulin or TPA stimulation as compared with parental cells. Furthermore, the maximal hyperphosphorylation of Raf-1 appears to be accompanied by a significant decrease in MAPKKK activity. These results suggest that 1) signals initiated by insulin and TPA converge on Raf-1 and activate its MAPKKK activity and 2) Raf-1, MAPKK, and mSos not only lie upstream of MAPK but also are phosphorylated by MAPK, directly or indirectly, and at least Raf-1 kinase activity might be down-regulated by this feedback mechanism.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; ASAHI LIFE FDN,INST DIABET CARE & RES,CHIYODA KU,TOKYO 100,JAPAN	University of Tokyo; University of Tokyo; Asahi Life Foundation								AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BOTWELL D, 1992, P NATL ACAD SCI USA, V89, P6511; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; IZUMI T, 1991, J BIOL CHEM, V266, P7933; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEVERE E, 1992, EMBO J, V11, P4815; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STURGILL TW, 1988, NATURE, V344, P7150; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOBE K, 1992, J BIOL CHEM, V267, P21089; TOBE K, 1991, J BIOL CHEM, V266, P24793; TOBE K, 1993, J BIOL CHEM, V268, P11167; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	45	81	83	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15756	15761						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195229				2022-12-27	WOS:A1994NP51300057
J	FONG, TM; YU, H; CASCIERI, MA; UNDERWOOD, D; SWAIN, CJ; STRADER, CD				FONG, TM; YU, H; CASCIERI, MA; UNDERWOOD, D; SWAIN, CJ; STRADER, CD			INTERACTION OF GLUTAMINE-165 IN THE 4TH TRANSMEMBRANE SEGMENT OF THE HUMAN NEUROKININ-1 RECEPTOR WITH QUINUCLIDINE ANTAGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-P ANTAGONIST; NONPEPTIDE ANTAGONIST; NK1 RECEPTOR; POTENT; BINDING; RHODOPSIN; PEPTIDES	Substance P binds to and activates the neurokinin-1 receptor with high affinity, thereby modulating several neuronal pathways including pain transmission and neurogenic inflammation. Several high affinity non-peptide antagonists have recently been described. To elucidate the molecular interactions specific for binding to the neurokinin-1 receptor, site-directed mutagenesis has been utilized to identify amino acid residues that interact directly with antagonists. Glutamine 165 in the fourth transmembrane segment was shown to be critical for the binding of CP-96,345 but not SR140333. Analysis of quinuclidine analogs suggests that glutamine 165 interacts with the C-3 heteroatom in this class of antagonists, probably through a hydrogen bond. Glutamine 165 also plays a minor role in the binding of peptides and RP67580. In contrast, serine 169 was determined to be critical for the binding of RP67580. These data indicate that residues 165 and 169 in the fourth transmembrane segment, along with residues in the fifth, sixth, and seventh transmembrane segments as demonstrated previously, form the non-peptide antagonist binding site in the neurokinin-l receptor. Furthermore, the antagonist binding site overlaps with the binding site for peptide agonists in the fourth and seventh transmembrane segments.	MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOLEC SYST,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,RES LABS,HARLOW CM20 2PT,ESSEX,ENGLAND	Merck & Company; Merck & Company	FONG, TM (corresponding author), MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOLEC PHARMACOL & BIOCHEM,BLDG 80M-213,RAHWAY,NJ 07065, USA.							ANDREWS PR, 1986, TRENDS PHARMACOL SCI, P148; ATTWOOD TK, 1991, GENE, V98, P153, DOI 10.1016/0378-1119(91)90168-B; CASCIERI MA, 1992, MOL PHARMACOL, V42, P458; FONG TM, 1994, J BIOL CHEM, V269, P2728; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FONG TM, 1993, NATURE, V362, P350; GARRET C, 1991, P NATL ACAD SCI USA, V88, P10208, DOI 10.1073/pnas.88.22.10208; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; HELKE CJ, 1990, FASEB J, V4, P1606, DOI 10.1096/fasebj.4.6.1969374; HENRY JL, 1993, REGUL PEPTIDES, V46, P138, DOI 10.1016/0167-0115(93)90024-3; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; IVERSEN LL, 1987, TOP MED CHEM, V65, P1; Lefevre I. A., 1993, Society for Neuroscience Abstracts, V19, P722; LOWE JA, 1992, J MED CHEM, V35, P2591, DOI 10.1021/jm00092a009; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; PEYRONEL JF, 1992, BIOORG MED CHEM LETT, V2, P37, DOI 10.1016/S0960-894X(00)80650-2; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; REGOLI D, 1989, PHARMACOLOGY, V38, P1, DOI 10.1159/000138512; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHMIDT AW, 1992, EUR J PHARMACOL, V215, P351, DOI 10.1016/0014-2999(92)90057-B; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; SWAIN CJ, 1993, BIOORG MED CHEM LETT, V3, P1703, DOI 10.1016/S0960-894X(00)80046-3; THOMAS DD, 1982, J MOL BIOL, V154, P145, DOI 10.1016/0022-2836(82)90422-3; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x	28	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14957	14961						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195129				2022-12-27	WOS:A1994NP73800020
J	JUANG, SH; HUANG, JQ; LI, YQ; SALAS, PJI; FREGIEN, N; CARRAWAY, CAC; CARRAWAY, KL				JUANG, SH; HUANG, JQ; LI, YQ; SALAS, PJI; FREGIEN, N; CARRAWAY, CAC; CARRAWAY, KL			MOLECULAR-CLONING AND SEQUENCING OF A 58-KDA MEMBRANE-ASSOCIATED AND MICROFILAMENT-ASSOCIATED PROTEIN FROM ASCITES TUMOR-CELL MICROVILLI WITH SEQUENCE SIMILARITIES TO RETROVIRAL GAG PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MAMMARY ADENOCARCINOMA; MURINE LEUKEMIA-VIRUS; SIGNAL TRANSDUCTION; GLYCOPROTEIN COMPLEX; SARCOMA-VIRUS; CYTOSKELETON; ACTIN; IDENTIFICATION; SUBLINES; ACID	The MAT-C1 subline of the 13762 rat mammary adenocarcinoma has highly stable, branched microvilli and immobile cell surface receptors. A membrane- and microfilament-associated 58-kDa protein (p58) in the MAT-C1 microvilli has been implicated in the stabilization of the microvilli and microfilament-membrane interactions. This protein is associated with a high M(r) glycoprotein complex containing the (proto)oncogene p185(neu) and other signal transduction components in a putative microfilament-associated signal transduction particle. Amino acid sequences were obtained from two trypsin peptides of p58. Screening a MAT-C1 cDNA library with a degenerate oligonucleotide derived from the larger peptide and polymerase chain reaction amplification of cDNA ends permitted the isolation of overlapping cDNAs encoding the 427-amino acid open reading frame of p58. In vitro transcription and translation using a full-length cDNA gave a protein of approximately 55 kDa, which reacts with anti-p58 antiserum and reconstitutes into a complex with actin and glycoproteins from the membrane-microfilament interaction site. When COS-7 cells were transfected with the full-length cDNA, p58 was localized in a punctate distribution. In addition, the transfected cells exhibited fewer microfilament cables than untransfected neighboring cells. The amino acid sequence showed a surprising similarity to mammalian retroviral Gag proteins and included regions corresponding to p15, p12 and the N-terminal 80% of p30. Comparisons of p58 and the corresponding regions of the Gag proteins for Moloney murine leukemia virus indicated that about 60% of their amino acid residues were identical. These studies suggest that p58 is the product of an endogenous retroviral gene whose expression as a cellular protein alters the properties of the tumor cell to provide a selective advantage for tumor growth in the animal.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT R124,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101	University of Miami; University of Miami			Salas, Pedro J./AAS-9455-2021	Salas, Pedro/0000-0002-7411-1366	NATIONAL CANCER INSTITUTE [P30CA014395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033795] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14395] Funding Source: Medline; NIGMS NIH HHS [GM 33795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; BOLOGNESI DP, 1978, SCIENCE, V199, P183, DOI 10.1126/science.202022; BURRIDGE K, 1986, Cancer Reviews, V4, P18; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARRAWAY CAC, 1983, P NATL ACAD SCI-BIOL, V80, P430, DOI 10.1073/pnas.80.2.430; CARRAWAY CAC, 1985, EXP CELL RES, V161, P150, DOI 10.1016/0014-4827(85)90499-9; CARRAWAY CAC, 1982, BIOCHIM BIOPHYS ACTA, V719, P126; CARRAWAY CAC, 1991, J BIOL CHEM, V266, P16238; CARRAWAY CAC, 1985, EXP CELL RES, V157, P71, DOI 10.1016/0014-4827(85)90153-3; CARRAWAY CAC, 1993, J BIOL CHEM, V268, P5582; CARRAWAY CAC, 1983, CELL MOTIL CYTOSKEL, V3, P491, DOI 10.1002/cm.970030516; CARRAWAY KL, 1980, NATURE, V285, P508, DOI 10.1038/285508a0; CARRAWAY KL, 1982, J CELL BIOL, V94, P624, DOI 10.1083/jcb.94.3.624; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CARRAWAY KL, 1979, J CELL BIOL, V83, P529, DOI 10.1083/jcb.83.3.529; COUDRIER E, 1983, EMBO J, V2, P469, DOI 10.1002/j.1460-2075.1983.tb01446.x; DAMSKY CH, 1977, J CELL BIOL, V75, P593, DOI 10.1083/jcb.75.2.593; EDBAUER CA, 1983, VIROLOGY, V130, P415, DOI 10.1016/0042-6822(83)90096-X; EDBAUER CA, 1984, VIROLOGY, V134, P389, DOI 10.1016/0042-6822(84)90306-4; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Geiger B, 1989, CURR OPIN CELL BIOL, V1, P103, DOI 10.1016/S0955-0674(89)80045-6; GIUFFRE RM, 1982, J VIROL, V42, P963, DOI 10.1128/JVI.42.3.963-968.1982; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; HOWARD SC, 1982, JNCI-J NATL CANCER I, V69, P33; HUGGINS JW, 1980, EXP CELL RES, V127, P27; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LIU YC, 1989, J BIOL CHEM, V264, P1208; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; PALMITER RD, 1978, VIROLOGY, V91, P423, DOI 10.1016/0042-6822(78)90388-4; PRYWES R, 1985, J VIROL, V54, P123, DOI 10.1128/JVI.54.1.123-132.1985; RASHEED S, 1983, SCIENCE, V221, P155, DOI 10.1126/science.6344220; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; SCHULTZ AM, 1983, J VIROL, V46, P355, DOI 10.1128/JVI.46.2.355-361.1983; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, EXP CELL RES, V126, P417, DOI 10.1016/0014-4827(80)90281-5; STONE JC, 1984, CELL, V37, P549, DOI 10.1016/0092-8674(84)90385-4; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG Y-L, 1992, P1; WEISS R, 1985, RNA TUMOR VIRUSES MO, P999; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	47	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15067	15075						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195143				2022-12-27	WOS:A1994NP73800036
J	MOTEJLEK, K; HAUSELMANN, R; LEITGEB, S; LUSCHER, B				MOTEJLEK, K; HAUSELMANN, R; LEITGEB, S; LUSCHER, B			BSF1, A NOVEL BRAIN-SPECIFIC DNA-BINDING PROTEIN RECOGNIZING A TANDEMLY REPEATED PURINE DNA ELEMENT IN THE GABA(A) RECEPTOR DELTA-SUBUNIT GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTORS INTERACT; MESSENGER-RNAS; RAT-BRAIN; TRANSCRIPTION FACTOR; A-RECEPTORS; MOLECULAR-BIOLOGY; ALPHA-SUBUNIT; NGFI-C; EXPRESSION; PROMOTER	The rat GABA(A) receptor delta subunit gene has been isolated and its promoter mapped to facilitate studies of neuron-specific gene transcription. The gene is transcribed from a single promoter with several clustered transcriptional initiation sites. The major start site maps to a prototype initiator sequence located in the center of a TATA-less CpG-rich island, Analysis of the 5'-flanking region of the GABA(A) receptor delta subunit gene revealed a novel tandemly repeated purine sequence element. Furthermore, gel retardation assays identified several tissue-specific and ubiquitous proteins that bind to this sequence. One of these factors, brain specific factor (BSF) 1, was only observed in extracts from brain and was distinct from BETA and PAL, two DNA-binding proteins with similar purine rich recognition sequences. The distribution of BSF1 in brain closely matched the expression pattern previously determined for the delta subunit mRNA, and its binding activity appeared simultaneously with GABA(A) receptor delta subunit mRNA during differentiation of cerebellar granule cells in vitro. Our data therefore suggest that BSF1 is a novel brain-specific and neuronal cell type-enriched factor possibly involved in differential transcription of the GABA(A) receptor delta subunit gene.	UNIV ZURICH,INST PHARMACOL,ZURICH,SWITZERLAND	University of Zurich			Luscher, Bernhard/C-3528-2009	Luscher, Bernhard/0000-0003-1375-1906				BENKE D, 1991, J BIOL CHEM, V266, P4478; BIANCHI A, 1990, J BIOL CHEM, V265, P21789; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOVOLIN P, 1992, J NEUROCHEM, V59, P62, DOI 10.1111/j.1471-4159.1992.tb08876.x; BOVOLIN P, 1992, P NATL ACAD SCI USA, V89, P9344, DOI 10.1073/pnas.89.19.9344; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; CROSBY SD, 1992, P NATL ACAD SCI USA, V89, P4739, DOI 10.1073/pnas.89.10.4739; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; CUTTING GR, 1992, GENOMICS, V12, P801, DOI 10.1016/0888-7543(92)90312-G; ELDER GA, 1992, MOL BRAIN RES, V15, P99, DOI 10.1016/0169-328X(92)90156-6; ELDER GA, 1992, MOL BRAIN RES, V15, P85, DOI 10.1016/0169-328X(92)90155-5; FISCHER G, 1982, EXP CELL RES, V139, P285, DOI 10.1016/0014-4827(82)90253-1; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FRITSCHY JM, 1992, P NATL ACAD SCI USA, V89, P6726, DOI 10.1073/pnas.89.15.6726; GAMBARANA C, 1991, NEUROSCIENCE, V45, P423, DOI 10.1016/0306-4522(91)90238-J; HAAS S, 1993, MOL CELL BIOL, V13, P3103, DOI 10.1128/MCB.13.5.3103; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KIRKNESS EF, 1993, J BIOL CHEM, V268, P4420; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAURIE DJ, 1992, J NEUROSCI, V12, P4151; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; LEONARD JP, 1991, MOL NEUROBIOLOGY PRA, P161; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MALHERBE P, 1990, MOL BRAIN RES, V8, P199, DOI 10.1016/0169-328X(90)90017-8; MATHIS JM, 1992, EMBO J, V11, P2551, DOI 10.1002/j.1460-2075.1992.tb05320.x; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIURA M, 1990, J NEUROCHEM, V55, P1180, DOI 10.1111/j.1471-4159.1990.tb03123.x; MOHLER H, 1990, NEUROCHEM RES, V15, P199, DOI 10.1007/BF00972210; MULLER T, 1994, IN PRESS J NEUROSCI; NEDIVI E, 1992, J NEUROSCI, V12, P691; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PECORINO LT, 1991, MOL CELL BIOL, V11, P3139, DOI 10.1128/MCB.11.6.3139; PIANI D, 1992, EUR J IMMUNOL, V22, P2429, DOI 10.1002/eji.1830220936; POULTER MO, 1992, J NEUROSCI, V12, P2888, DOI 10.1523/JNEUROSCI.12-08-02888.1992; RIPPE K, 1992, METHOD ENZYMOL, V211, P199; RIPPE K, 1992, EMBO J, V11, P3777, DOI 10.1002/j.1460-2075.1992.tb05463.x; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHNITZER J, 1981, J NEUROIMMUNOL, V1, P429, DOI 10.1016/0165-5728(81)90022-9; SCHOFIELD PR, 1990, TRENDS NEUROSCI, V13, P8, DOI 10.1016/0166-2236(90)90052-C; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOMMER B, 1990, DNA CELL BIOL, V9, P561, DOI 10.1089/dna.1990.9.561; STOYKOVA AS, 1992, NEURON, V8, P541, DOI 10.1016/0896-6273(92)90282-I; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y; WISDEN W, 1992, J NEUROSCI, V12, P1040	61	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15265	15273						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195163				2022-12-27	WOS:A1994NP73800062
J	MCCLOSKEY, MA; QIAN, YX				MCCLOSKEY, MA; QIAN, YX			SELECTIVE EXPRESSION OF POTASSIUM CHANNELS DURING CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; MUCOSAL MAST-CELLS; INDUCED HISTAMINE-RELEASE; ANTI-ALLERGIC COMPOUNDS; CALCIUM INFLUX; INTRACELLULAR CALCIUM; PATCH-CLAMP; IGE BINDING; RAT; RECEPTORS	In rodents, mast cell progenitors differentiate into distinct mucosal and serosal phenotypes which differ markedly in their functional responses to antigenic and peptidergic stimulation. Although the molecular basis of mast cell differentiation or functional specialization is unknown, it is possible that regulation of calcium entry contributes to one or both processes. The prolonged secretory response of mucosal mast cells (MMC) and the antigen-elicited synthesis of interleukin-3 by immature MMC both require a rise of cytoplasmic calcium sustained by Ca2+ influx across the plasma membrane. This Ca2+ entry is highly sensitive to membrane potential, affording a possible site for regulation of mast cell function by receptor-linked ion channels. We found that rat interleukin-3-dependent bone marrow-derived mast cells of the mucosal phenotype expressed two K+ conductances, neither of which is present in the prototype serosal mast cell from rat peritoneum. An inwardly rectifying K+ conductance was constitutively active and a latent outwardly rectifying K+ conductance was elicited rapidly upon ligation of cell surface adenosine or P-2 purinergic receptors linked to G proteins of the G(i) family. Stimulation of P2( )receptors dramatically potentiated antigen-triggered secretion in a pertussis toxin-sensitive manner, suggesting that activation of the outwardly rectifying K+ channel may regulate antigen-dependent functions of MMC.			MCCLOSKEY, MA (corresponding author), IOWA STATE UNIV SCI & TECHNOL,DEPT ZOOL & GENET,AMES,IA 50011, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048144] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48144] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI H, 1990, J BIOL CHEM, V265, P745; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BEFUS AD, 1982, J IMMUNOL, V128, P2475; COCKCROFT S, 1979, NATURE, V279, P541, DOI 10.1038/279541a0; COHEN DR, 1986, NUCLEIC ACIDS RES, V14, P3641, DOI 10.1093/nar/14.9.3641; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; FEWTRELL C, 1987, BIOCHEMISTRY-US, V26, P6995, DOI 10.1021/bi00396a021; FROESE A, 1982, IMMUNOLOGY, V46, P117; GHILDYAL N, 1993, J IMMUNOL, V151, P3206; HAIG DM, 1988, IMMUNOLOGY, V65, P205; HAIG DM, 1982, NATURE, V300, P188, DOI 10.1038/300188a0; HAIG DM, 1988, LYMPHOKINES, V15, P65; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIDE M, 1991, J BIOL CHEM, V266, P15221; KANNER BI, 1983, P NATL ACAD SCI-BIOL, V80, P5744, DOI 10.1073/pnas.80.18.5744; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; LEE TDG, 1985, IMMUNOLOGY, V55, P721; LINDAU M, 1986, J GEN PHYSIOL, V88, P349, DOI 10.1085/jgp.88.3.349; LIU FT, 1980, J IMMUNOL, V124, P2728; MACDONALD AJ, 1989, IMMUNOLOGY, V67, P414; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; MCCLOSKEY MA, 1984, J CELL BIOL, V99, P778, DOI 10.1083/jcb.99.3.778; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; MEYER C, 1983, J IMMUNOL, V131, P911; Miller H. R. P., 1992, Allergy and immunity to helminths: common mechanisms or divergent pathways., P228; MOHR FC, 1987, J CELL BIOL, V104, P783, DOI 10.1083/jcb.104.3.783; MOHR FC, 1987, J BIOL CHEM, V262, P10638; MOHR FC, 1987, J IMMUNOL, V138, P1564; MUKAI M, 1992, AM J PHYSIOL, V262, pC84, DOI 10.1152/ajpcell.1992.262.1.C84; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PEARCE FL, 1982, J IMMUNOL, V128, P2481; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; QIAN YX, 1993, P NATL ACAD SCI USA, V90, P7844, DOI 10.1073/pnas.90.16.7844; QIAN YX, 1993, J IMMUNOL, V150, pA145; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; RANDRIAMAMPITA C, 1991, CELL CALCIUM, V12, P313, DOI 10.1016/0143-4160(91)90005-Y; SAGIEISENBERG R, 1983, J MEMBRANE BIOL, V75, P97, DOI 10.1007/BF01995629; SELDIN DC, 1985, P NATL ACAD SCI USA, V82, P3871, DOI 10.1073/pnas.82.11.3871; SHANAHAN F, 1985, J IMMUNOL, V135, P1331; SHANAHAN F, 1986, INT ARCH ALLER A IMM, V80, P424, DOI 10.1159/000234092; VLODAVSKY I, 1980, CELL, V19, P607, DOI 10.1016/S0092-8674(80)80037-7; WILGENBUS KK, 1992, INT J CANCER, V51, P522, DOI 10.1002/ijc.2910510404; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; WOODBURY RG, 1984, NATURE, V312, P450, DOI 10.1038/312450a0	49	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14813	14819						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182088				2022-12-27	WOS:A1994NM06500078
J	SANDIG, M; RAO, Y; SIU, CH				SANDIG, M; RAO, Y; SIU, CH			THE HOMOPHILIC BINDING-SITE OF THE NEURAL CELL-ADHESION MOLECULE NCAM IS DIRECTLY INVOLVED IN PROMOTING NEURITE OUTGROWTH FROM CULTURED NEURAL RETINAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-CAM; INTERCELLULAR-ADHESION; MEMBRANE ATTACHMENT; HOMOPHILIC BINDING; CHICK-EMBRYO; NEURONS; ANTIBODIES; CADHERIN; DOMAINS; GROWTH	The neural cell adhesion molecule NCAM mediates intercellular adhesion by hemophilic binding and its homophilic binding site has been mapped to a decapeptide sequence 243-KYSFNYDGSE-252 located within the third immunoglobulin-like domain of chick NCAM. To investigate the relationship between homophilic binding and NCAM-dependent neurite outgrowth, mutations were created in the binding site of NCAM-140 cDNA. Mutant NCAMs were expressed in L cells, and their ability to promote neurite outgrowth from chick retinal ganglion cells was assayed in coculture systems. Mutations that resulted in the loss of NCAM homophilic binding failed to promote neurite outgrowth from retinal cells. Alternatively, synthetic peptides containing the decapeptide sequence of the homophilic binding site were used to block NCAM homophilic interaction. Peptides that inhibited NCAM-NCAM binding also blocked neurite elongation. However, the peptide P5 (243-KYSFNY-DGSELIIKKVDKSDE-263), despite being an inhibitor of NCAM-NCAM binding, induced the sprouting of multiple neurites. Moreover, peptide P5 stimulated a 2-fold increase in neurite-bearing cells, suggesting that P5 is a potent inducer of neurite outgrowth. Only E4-E6 retinal cells could be induced by P5, corresponding closely to their NCAM-responsive embryonic stages. The P5 effects were inhibited by pertussis toxin, indicating the involvement of a G-protein-dependent pathway. Taken together, these results provide evidence for a direct role of the NCAM homophilic binding site in the regulation of neurite outgrowth.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO M5G 1L6, ON, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5G 1L6, ON, CANADA	University of Toronto; University of Toronto								ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BHAT TN, 1990, NATURE, V344, P371; BIXBY JL, 1987, DEV BIOL, V119, P363, DOI 10.1016/0012-1606(87)90041-8; BIXBY JL, 1987, P NATL ACAD SCI USA, V84, P2555, DOI 10.1073/pnas.84.8.2555; BLOCH RJ, 1992, J CELL BIOL, V116, P449, DOI 10.1083/jcb.116.2.449; COLE GJ, 1987, NEUROSCI LETT, V78, P227, DOI 10.1016/0304-3940(87)90638-0; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; COLE GJ, 1986, J CELL BIOL, V102, P403, DOI 10.1083/jcb.102.2.403; CROSSIN KL, 1985, P NATL ACAD SCI USA, V82, P6942, DOI 10.1073/pnas.82.20.6942; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; Doherty P, 1992, Curr Opin Neurobiol, V2, P595, DOI 10.1016/0959-4388(92)90024-F; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DOHERTY P, 1992, NATURE, V356, P791, DOI 10.1038/356791a0; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; DOHERTY P, 1989, J CELL BIOL, V109, P789, DOI 10.1083/jcb.109.2.789; DOHERTY P, 1993, J CELL BIOL, V122, P181, DOI 10.1083/jcb.122.1.181; DRAZBA J, 1990, DEV BIOL, V138, P82, DOI 10.1016/0012-1606(90)90178-L; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EDELMAN GM, 1987, P NATL ACAD SCI USA, V84, P8502, DOI 10.1073/pnas.84.23.8502; FREI T, 1992, J CELL BIOL, V118, P177, DOI 10.1083/jcb.118.1.177; GENNARINI G, 1991, NEURON, V6, P595, DOI 10.1016/0896-6273(91)90062-5; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HE HT, 1986, EMBO J, V5, P2489, DOI 10.1002/j.1460-2075.1986.tb04526.x; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P9822, DOI 10.1073/pnas.83.24.9822; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HOFFMAN S, 1986, J CELL BIOL, V103, P145, DOI 10.1083/jcb.103.1.145; HOFFMAN S, 1982, J BIOL CHEM, V257, P7720; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; JOHNSON PW, 1989, NEURON, V3, P377, DOI 10.1016/0896-6273(89)90262-6; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; MAHANTHAPPA NK, 1992, DEV BIOL, V150, P47, DOI 10.1016/0012-1606(92)90006-3; MATSUNAGA M, 1988, NATURE, V334, P62, DOI 10.1038/334062a0; MURRAY BA, 1992, J CELL BIOL, V117, P1311, DOI 10.1083/jcb.117.6.1311; NEUGEBAUER KM, 1988, J CELL BIOL, V107, P1177, DOI 10.1083/jcb.107.3.1177; PIZZEY JA, 1989, J CELL BIOL, V109, P3465, DOI 10.1083/jcb.109.6.3465; POLLERBERG GE, 1993, DEV BIOL, V156, P324, DOI 10.1006/dbio.1993.1081; RAO Y, 1993, J BIOL CHEM, V268, P20630; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; RUTISHAUSER U, 1982, P NATL ACAD SCI-BIOL, V79, P685, DOI 10.1073/pnas.79.2.685; RUTISHAUSER U, 1976, P NATL ACAD SCI USA, V73, P577, DOI 10.1073/pnas.73.2.577; RUTISHAUSER U, 1980, J CELL BIOL, V87, P370, DOI 10.1083/jcb.87.2.370; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P819, DOI 10.1152/physrev.1988.68.3.819; RUTISHAUSER U, 1983, J CELL BIOL, V97, P145, DOI 10.1083/jcb.97.1.145; RUTISHAUSER U, 1986, NEURON, V1, P3; Sambrook J, 1989, MOL CLONING LABORATO; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; Stewart JM, 1984, SOLID PHASE PEPTIDE; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; THANOS S, 1984, P NATL ACAD SCI-BIOL, V81, P1906, DOI 10.1073/pnas.81.6.1906; THIERY JP, 1977, J BIOL CHEM, V252, P6841; Walsh F. S., 1991, SEMIN NEUROSCI, V3, P271; WATANABE M, 1986, J CELL BIOL, V103, P1721, DOI 10.1083/jcb.103.5.1721; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS EJ, 1992, J CELL BIOL, V119, P883, DOI 10.1083/jcb.119.4.883; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844; YAZAKI T, 1991, BIOMED RES-TOKYO, V12, P223, DOI 10.2220/biomedres.12.223	62	37	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14841	14848						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182092				2022-12-27	WOS:A1994NM06500082
J	ALLGEIER, A; OFFERMANNS, S; VANSANDE, J; SPICHER, K; SCHULTZ, G; DUMONT, JE				ALLGEIER, A; OFFERMANNS, S; VANSANDE, J; SPICHER, K; SCHULTZ, G; DUMONT, JE			THE HUMAN THYROTROPIN RECEPTOR ACTIVATES G-PROTEINS G(S) AND G(Q/11)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-GAMMA-SUBUNITS; CYCLIC-AMP CASCADES; 2 G-PROTEINS; PHOSPHOLIPASE-C; ADENYLYL CYCLASE; ALPHA-SUBUNITS; PHOSPHATIDYLINOSITOL HYDROLYSIS; MUSCARINIC RECEPTOR; CELLS; HORMONE	The human thyrotropin receptor leads upon activation to the stimulation of phospholipase C and adenylyl cyclase. It is presently not known whether this bifurcating signaling occurs via two different G-proteins (G(q/11) and G(s)) or via one G-protein (G(s)). Receptor-activated G(s) releases beta gamma subunits and alpha(s), which then could regulate phospholipase C and adenylyl cyclase, respectively. In order to elucidate the signaling pathways induced by the activated thyroid-stimulating hormone (TSH) receptor, we studied the coupling of the TSH receptor to G(s) and G(q/11) in human thyroid membranes. TSH concentration dependently led to the activation of two forms of G(s) (G(s short) and G(s long) ) as well as of G(q) and G(11), demonstrating that signaling pathways induced by TSH already bifurcate in the course of the receptor-G-protein interaction. These data strongly suggest the concept that phospholipase C and adenylyl cyclase activation through the TSH receptor are mediated by G(q/11) and G(s), respectively.	FREE UNIV BERLIN, INST PHARMAKOL, D-14195 BERLIN, GERMANY	Free University of Berlin	ALLGEIER, A (corresponding author), FREE UNIV BRUSSELS, INST INTERDISCIPLINARY RES, 808 ROUTE LENNIK, B-1070 BRUSSELS, BELGIUM.		Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BLANK JL, 1991, J BIOL CHEM, V266, P18206; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; COCHAUX P, 1987, EUR J BIOCHEM, V170, P435, DOI 10.1111/j.1432-1033.1987.tb13718.x; EASON MG, 1992, J BIOL CHEM, V267, P15795; FARGIN A, 1989, J BIOL CHEM, V264, P14848; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HIDAKA A, 1993, BIOCHEM BIOPH RES CO, V196, P187, DOI 10.1006/bbrc.1993.2233; HUNG DT, 1992, J BIOL CHEM, V267, P20831; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LARSON E, 1986, ANAL BIOCHEM, V155, P243, DOI 10.1016/0003-2697(86)90432-X; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; LAURENT E, 1991, J CLIN INVEST, V87, P1634, DOI 10.1172/JCI115178; LAURENT E, 1987, MOL CELL ENDOCRINOL, V52, P273, DOI 10.1016/0303-7207(87)90055-4; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; ODA K, 1992, FEBS LETT, V299, P187, DOI 10.1016/0014-5793(92)80244-B; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OFFERMANNS S, 1992, BIOCHEM J, V282, P551, DOI 10.1042/bj2820551; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; PAULSSEN RH, 1992, EUR J BIOCHEM, V204, P413, DOI 10.1111/j.1432-1033.1992.tb16651.x; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, FEBS LETT, V286, P214, DOI 10.1016/0014-5793(91)80976-A; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; VANSANDE J, 1993, EUR J PHARM-MOLEC PH, V247, P177, DOI 10.1016/0922-4106(93)90075-K; WU DQ, 1992, J BIOL CHEM, V267, P1811	32	168	169	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13733	13735						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188646				2022-12-27	WOS:A1994NL60600003
J	FARIA, TN; BLAKESLEY, VA; KATO, H; STANNARD, B; LEROITH, D; ROBERTS, CT				FARIA, TN; BLAKESLEY, VA; KATO, H; STANNARD, B; LEROITH, D; ROBERTS, CT			ROLE OF THE CARBOXYL-TERMINAL DOMAINS OF THE INSULIN AND INSULIN-LIKE GROWTH-FACTOR-I RECEPTORS IN RECEPTOR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AUTOPHOSPHORYLATION SITES; PROTEIN KINASE-C; FAMILY; PHOSPHORYLATION; SPECIFICITY; BINDING; MITOGENESIS; REGIONS; LIGAND; GENE	The insulin and insulin-like growth factor I receptors (IR and IGF-IR, respectively) are heterotetrameric tyrosine kinases consisting of two extracellular ligand-binding alpha subunits and two transmembrane catalytic beta subunits. A number of lines of evidence have suggested that the IR and IGF-IR differ with respect to their ability to elicit mitogenic versus metabolic events upon activation by cognate ligands. To ascertain the contribution of the poorly conserved carboxyl-terminal domains to the differential functioning of the IR and IGF-IR, we have constructed receptor chimeras in which the carboxyl-terminal domain of one receptor was fused to the remainder of the heterologous receptor. The responses of a number of parameters after ligand stimulation were examined in stably transfected NIH-3T3 cells expressing the chimeric receptors or the analogous wild-type receptor sequence. Replacement of the IR carboxyl terminus with that of the IGF-IR severely affected insulin stimulated responses, whereas substitution of the carboxyl terminus of the IGF-IR with that of the IR had a minimal effect. These data suggest that the carboxyl-terminal domains of the IR and IGF-IR are not interchangeable and that the mitogenic activity of the IR can be influenced by sequences present in the carboxyl-terminal domain. The analogous functions of the IGF-IR, on the other hand, do not appear to be greatly affected by the presence of the IR carboxyl-terminal domain.	NIDDK,DIABET BRANCH,MOLEC & CELLULAR PHYSIOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772				ABBOTT AM, 1992, J BIOL CHEM, V267, P10759; ADAMO M, 1992, BIOFACTORS, V3, P151; ANDO A, 1992, J BIOL CHEM, V267, P12788; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BARON V, 1991, BIOCHEMISTRY-US, V30, P9365, DOI 10.1021/bi00102a033; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; CAMA A, 1993, J BIOL CHEM, V268, P8060; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; DICKENS M, 1992, BIOCHEM J, V287, P201, DOI 10.1042/bj2870201; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FUJITAYAMAGUCHI Y, 1989, BIOCHEM J, V263, P813, DOI 10.1042/bj2630813; GOTTSCHALK WK, 1992, BIOCHEM BIOPH RES CO, V189, P906; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOVIS JG, 1986, J BIOL CHEM, V261, P380; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KALIMAN P, 1992, J BIOL CHEM, V267, P10645; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KATO H, 1993, J BIOL CHEM, V268, P2655; KURACHI H, 1992, BIOCHEM BIOPH RES CO, V187, P934, DOI 10.1016/0006-291X(92)91287-Z; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LEVYTOLEDANO R, 1993, BIOCHIM BIOPHYS ACTA, V1220, P1, DOI 10.1016/0167-4889(93)90090-C; LEWIS RE, 1990, BIOCHEMISTRY-US, V29, P1807, DOI 10.1021/bi00459a020; LEWIS RE, 1990, J BIOL CHEM, V265, P947; LIU DL, 1993, J VIROL, V67, P6835, DOI 10.1128/JVI.67.11.6835-6840.1993; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MEYERS MG, 1991, J BIOL CHEM, V266, P10616; MORRISON BD, 1989, J BIOL CHEM, V264, P9994; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; SAHAL D, 1988, ARCH BIOCHEM BIOPHYS, V260, P416, DOI 10.1016/0003-9861(88)90465-1; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SHIER P, 1989, J BIOL CHEM, V264, P14605; TAKATA Y, 1992, J BIOL CHEM, V267, P9065; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; THIES RS, 1989, J BIOL CHEM, V264, P12820; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; YAMAMOTOHONDA R, 1993, J BIOL CHEM, V268, P16859	42	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13922	13928						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188672				2022-12-27	WOS:A1994NL60600034
J	HSIEH, M; HENSLEY, P; BRENOWITZ, M; FETROW, JS				HSIEH, M; HENSLEY, P; BRENOWITZ, M; FETROW, JS			A MOLECULAR-MODEL OF THE INDUCER BINDING DOMAIN OF THE GALACTOSE REPRESSOR OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOSE REPRESSOR; GAL REPRESSOR; LAC REPRESSOR; L-ARABINOSE; ACTIVE-TRANSPORT; 3-DIMENSIONAL STRUCTURE; CONFORMATIONAL CHANGE; TERTIARY TEMPLATES; PROTEIN STRUCTURES; GLOBULAR-PROTEINS	The C-terminal inducer binding domain of the Escherichia coli galactose repressor (GalR) is homologous to several periplasmic chemoreceptor proteins whose three-dimensional structures have been determined at high resolution (Vyas, N. K., Vyas, M. N., and Quiocho, F. A. (1991) J. Biol. Chem. 266, 5226-5237; Mowbray, S. L. and Cole, L. B. (1992) J. Mol. Biol. 225, 155-175). The protein backbone was constructed from the coordinates of glucose/galactose-binding protein using the Homology program (Biosym Technologies, San Diego). Loops were built by searching for substructures in the structure data base, and the side chains were built using a rotamer-based program. A small amount of energy minimization relieved steric strain within the model. The GalR model that has been constructed is consistent with the principles of protein structure; values obtained for the compactness and buried surface area of the model compare favorably with those determined for the chemoreceptor protein structures. The model is consistent with, and provides structural interpretations for, experimental results obtained from physical and biochemical studies. Predictions are made concerning the residues conferring the specificity of galactose induction of GalR and for self association to dimers. The model provides a first step toward correlating the structure and regulation of GalR and in determining the chemistry of its homologous and heterologous interactions that are critical to its role as a regulator of transcription initiation.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA; SUNY ALBANY, DEPT BIOL SCI, ALBANY, NY 12222 USA; SMITH KLINE & BEECHAM LABS, RES & DEV, DEPT MACROMOLEC SCI, KING OF PRUSSIA, PA 19406 USA	Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Albany; GlaxoSmithKline				Fetrow, Jacquelyn/0000-0002-0528-2049	NCI NIH HHS [2P30CA13330-22] Funding Source: Medline; NIGMS NIH HHS [GM39929, 5-F31-GM13850] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039929, F31GM013850, R29GM039929] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.genet.23.1.227; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; AULD DS, 1991, BIOCHEMISTRY-US, V30, P8684, DOI 10.1021/bi00099a028; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRENOWITZ M, 1990, BIOCHEMISTRY-US, V29, P3374, DOI 10.1021/bi00465a033; BROWN MP, 1994, J BIOL CHEM, V269, P12600; BRYANT SH, 1993, PROTEINS, V16, P92, DOI 10.1002/prot.340160110; BUTTIN G, 1963, J MOL BIOL, V7, P183, DOI 10.1016/S0022-2836(63)80045-5; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHANG WI, 1993, J BIOL CHEM, V268, P17613; CHEN J, 1992, J BIOL CHEM, V267, P13843; CHOY HE, 1992, P NATL ACAD SCI USA, V89, P11264, DOI 10.1073/pnas.89.23.11264; COHEN FE, 1991, BIOCHEMISTRY-US, V30, P11221, DOI 10.1021/bi00111a005; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DALMAWEISZHAUSZ DD, 1992, BIOCHEMISTRY-US, V31, P6980, DOI 10.1021/bi00145a016; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5479, DOI 10.1021/bi00367a020; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5468, DOI 10.1021/bi00367a018; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5474, DOI 10.1021/bi00367a019; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FETROW JS, 1993, BIO-TECHNOL, V11, P479, DOI 10.1038/nbt0493-479; GODZIK A, 1992, P NATL ACAD SCI USA, V89, P12098, DOI 10.1073/pnas.89.24.12098; GOODRICH JA, 1992, J MOL BIOL, V224, P15, DOI 10.1016/0022-2836(92)90573-3; GRAHAM HC, 1991, EUR J BIOCHEM, V196, P261, DOI 10.1111/j.1432-1033.1991.tb15813.x; GREER J, 1991, METHOD ENZYMOL, V202, P239; GREER J, 1980, P NATL ACAD SCI-BIOL, V77, P3393, DOI 10.1073/pnas.77.6.3393; HABER R, 1988, P NATL ACAD SCI USA, V85, P9683, DOI 10.1073/pnas.85.24.9683; HENSLEY P, 1975, J BIOL CHEM, V250, P952; HOGG RW, 1977, J BIOL CHEM, V252, P5135; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LAMERICHS RMJN, 1989, BIOCHEMISTRY-US, V28, P2985, DOI 10.1021/bi00433a037; LAMERICHS RMJN, 1990, EUR J BIOCHEM, V194, P629, DOI 10.1111/j.1432-1033.1990.tb15662.x; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MAJUMDAR A, 1987, J BIOL CHEM, V262, P2326; MALONEYHUSS K, 1992, J MOL BIOL, V225, P859, DOI 10.1016/0022-2836(92)90406-A; MATTHEW JB, 1985, ANNU REV BIOPHYS BIO, V14, P387; MATTHEWS KS, 1979, J BIOL CHEM, V254, P3348; MENG MH, 1991, P NATL ACAD SCI USA, V88, P4015, DOI 10.1073/pnas.88.9.4015; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; MOWBRAY SL, 1992, J MOL BIOL, V227, P418, DOI 10.1016/0022-2836(92)90898-T; MULLERHILL B, 1983, NATURE, V302, P163, DOI 10.1038/302163a0; NEWCOMER ME, 1981, J BIOL CHEM, V256, P3218; NICHOLS JC, 1993, J BIOL CHEM, V268, P17602; OVERINGTON J, 1992, PROTEIN SCI, V1, P216; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PACE HC, 1990, P NATL ACAD SCI USA, V87, P1870, DOI 10.1073/pnas.87.5.1870; PLATT T, 1973, J BIOL CHEM, V248, P110; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; QUIOCHO FA, 1984, NATURE, V310, P381, DOI 10.1038/310381a0; RASHIN AA, 1984, J MOL BIOL, V173, P515, DOI 10.1016/0022-2836(84)90394-2; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SCHUMACHER MA, 1993, J BIOL CHEM, V268, P12282; SCRIPTURE JB, 1987, J MOL BIOL, V197, P37, DOI 10.1016/0022-2836(87)90607-3; SENEAR DF, 1993, ELECTROPHORESIS, V14, P704, DOI 10.1002/elps.11501401112; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STEITZ TA, 1976, J MOL BIOL, V104, P197, DOI 10.1016/0022-2836(76)90009-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VONWILCKENBERGMANN B, 1982, P NATL ACAD SCI-BIOL, V79, P2427; VYAS MN, 1989, J BIOL CHEM, V264, P20817; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WARTELL RM, 1988, NUCLEIC ACIDS RES, V16, P11531, DOI 10.1093/nar/16.24.11531; WEICKERT MJ, 1992, J MOL BIOL, V226, P69, DOI 10.1016/0022-2836(92)90125-4; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; YANG JT, 1986, METHOD ENZYMOL, V130, P208; ZEHFUS MH, 1986, BIOCHEMISTRY-US, V25, P5759, DOI 10.1021/bi00367a062	72	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13825	13835						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188660				2022-12-27	WOS:A1994NL60600020
J	MATHUR, M; GOODWIN, L; COWIN, P				MATHUR, M; GOODWIN, L; COWIN, P			INTERACTIONS OF THE CYTOPLASMIC DOMAIN OF THE DESMOSOMAL CADHERIN DSG1 WITH PLAKOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; JUNCTIONAL PLAQUE PROTEIN; BETA-CATENIN; PEMPHIGUS-VULGARIS; ALPHA-ACTININ; FAMILY; UVOMORULIN; VINCULIN; HOMOLOG; IDENTIFICATION	Dsg1 is a 165-kDa glycoprotein component of suprabasal epidermal desmosomes and the prototype of a subset of the cadherin superfamily of cell-cell adhesion proteins known as desmogleins. The adhesive function of classical cadherins is known to be dependent upon their association with cytoplasmic components called catenins. In the case of desmogleins, a single interaction has been described with a protein called plakoglobin that is found in desmosomal plaques, adherens junctions, and the cytosol. Several proteins with homology to plakoglobin have been described that regulate junction assembly and implement morphoregulatory signals. To address the functional significance of plakoglobin-desmoglein interaction, we have mapped the sequences of Dsg1 that are crucial for this association by using blot overlay techniques. By examining the binding of plakoglobin to a deletion series of the Dsg1 cytoplasmic domain expressed as fusion proteins, we have defined a 19-amino acid sequence that is important for association. This region of Dsg1 sequence shows significant similarity to the catenin-binding domain of classical cadherins, suggesting a common mechanism for the association of plakoglobin with desmosomes and adherens junctions.	NYU, MED CTR, RONALD O PERELMAN DEPT DERMATOL, NEW YORK, NY 10016 USA; NYU, MED CTR, DEPT CELL BIOL, NEW YORK, NY 10016 USA; NYU, MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University; New York University				Cowin, Pamela/0000-0002-1827-1154	NIGMS NIH HHS [R01-GM47429] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047429] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; Buxton R S, 1992, Semin Cell Biol, V3, P157; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; COWIN P, 1985, J CELL BIOL, V101, P1442, DOI 10.1083/jcb.101.4.1442; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; COWIN P, 1993, MOL BASIS MORPHOGENE, P49; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FRANKE WW, 1987, BIOL CELL, V59, P205, DOI 10.1111/j.1768-322X.1987.tb00532.x; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; GEIGER B, 1983, DIFFERENTIATION, V23, P189; GOODWIN L, 1990, BIOCHEM BIOPH RES CO, V173, P1224, DOI 10.1016/S0006-291X(05)80917-9; GORBSKY G, 1981, J CELL BIOL, V90, P243, DOI 10.1083/jcb.90.1.243; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HIGGINS RC, 1979, ANAL BIOCHEM, V93, P257, DOI 10.1016/S0003-2697(79)80077-9; KAPPRELL HP, 1987, EUR J BIOCHEM, V166, P505, DOI 10.1111/j.1432-1033.1987.tb13543.x; KAPPRELL HP, 1988, J CELL BIOL, V106, P1679, DOI 10.1083/jcb.106.5.1679; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KOCH PJ, 1992, P NATL ACAD SCI USA, V89, P353, DOI 10.1073/pnas.89.1.353; KORMAN NJ, 1989, NEW ENGL J MED, V321, P631, DOI 10.1056/NEJM198909073211002; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NATHKE IS, 1993, MOL BIOL CELL, V4, pA473; NILLES LA, 1991, J CELL SCI, V99, P809; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PARKER AE, 1991, J BIOL CHEM, V266, P10438; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PIEPENHAGEN PA, 1993, J CELL SCI, V104, P751; PUTTAGUNTA S, 1994, J BIOL CHEM, V269, P1949; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1985, J CELL BIOL, V101, P2070, DOI 10.1083/jcb.101.6.2070; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WHEELER GN, 1991, P NATL ACAD SCI USA, V88, P4796, DOI 10.1073/pnas.88.11.4796	54	120	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14075	14080						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188687				2022-12-27	WOS:A1994NL60600054
J	REHN, M; HINTIKKA, E; PIHLAJANIEMI, T				REHN, M; HINTIKKA, E; PIHLAJANIEMI, T			PRIMARY STRUCTURE OF THE ALPHA-1 CHAIN OF MOUSE TYPE-XVIII COLLAGEN, PARTIAL STRUCTURE OF THE CORRESPONDING GENE, AND COMPARISON OF THE ALPHA-1(XVIII) CHAIN WITH ITS HOMOLOG, THE ALPHA-1(XV) COLLAGEN CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT EXONS; ORGANIZATION; DOMAIN	We have isolated cDNAs that complete the elucidation of the primary structure of the mouse alpha 1(XVIII) collagen chain, a polypeptide homologous to the alpha 1(XV) collagen chain. The 1315-residue alpha 1(XVIII) chain includes a 25-residue signal peptide, a 301-residue NH2-terminal noncollagenous domain (NC1), a 674-residue collagenous sequence with nine interruptions of 10-24 residues, and a 315-residue COOH-terminal noncollagenous domain (NC11). Seven of the collagenous domains and both flanking noncollagenous domains share homology with the alpha 1(XV) chain. The COOH terminal noncollagenous domains are unique to the alpha 1(XVIII) and alpha 1(XV) chains, and they contain a homologous beginning, a variable portion, and a highly homologous COOH-terminal half with 4 conserved cysteines. The differences in the collagenous sequences probably preclude the existence of the two chains in the same molecule, however. A 12.5-kilobase pair genomic sequence was found to contain the 12 extreme 3'-exons of the alpha 1(XVIII) gene, covering 40% of the coding sequences. Exons start with either a complete codon or a split codon for the glycines of Gly-Xaa-Yaa repeats, and seven exons completely cover the NC11 domain. Comparison of the sequences encoded by these seven exons with the corresponding region of the alpha 1(XV) gene indicated conserved exon-intron organization, suggesting that the two genes derive from a common ancestor.	UNIV OULU,DEPT MED BIOCHEM,SF-90220 OULU,FINLAND; UNIV OULU,BIOCTR,COLLAGEN RES UNIT,SF-90220 OULU,FINLAND	University of Oulu; University of Oulu				Pihlajaniemi, Taina/0000-0002-1664-9045				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; HAYMAN AR, 1990, J BIOL CHEM, V265, P9864; KERE J, 1992, GENOMICS, V14, P241, DOI 10.1016/S0888-7543(05)80212-5; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KIVIRIKKO S, 1994, J BIOL CHEM, V269, P4773; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI K, 1991, J BIOL CHEM, V266, P24064; LI KH, 1993, J BIOL CHEM, V268, P8825; LOZANO G, 1985, P NATL ACAD SCI USA, V82, P4050, DOI 10.1073/pnas.82.12.4050; Mayne R, 1993, CURR OPIN CELL BIOL, V5, P883, DOI 10.1016/0955-0674(93)90039-S; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MYERS JC, 1992, P NATL ACAD SCI USA, V89, P10144, DOI 10.1073/pnas.89.21.10144; MYERS JC, 1993, GENE, V123, P211, DOI 10.1016/0378-1119(93)90126-N; OH SP, 1994, IN PRESS P NATL ACAD; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; REHN M, 1994, IN PRESS P NATL ACAD; Sambrook J, 1989, MOL CLONING LABORATO; SANDELL LJ, 1990, EXTRACELLULAR MATRIX, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOININEN R, 1989, J BIOL CHEM, V264, P13565; TIKKA L, 1991, J BIOL CHEM, V266, P17713; VANDERREST M, 1993, CURR OPIN STRUC BIOL, V3, P430, DOI 10.1016/S0959-440X(05)80117-4; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; YOSHIOKA H, 1992, GENOMICS, V13, P884, DOI 10.1016/0888-7543(92)90176-S; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449	29	78	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13929	13935						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188673				2022-12-27	WOS:A1994NL60600035
J	TORNKVIST, A; PARPAL, S; GUSTAVSSON, J; STRALFORS, P				TORNKVIST, A; PARPAL, S; GUSTAVSSON, J; STRALFORS, P			INHIBITION OF RAF-1 KINASE EXPRESSION ABOLISHES INSULIN STIMULATION OF DNA-SYNTHESIS IN H4IIE HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASES; GROWTH-FACTOR; MITOGENIC SIGNAL; PROTEIN-KINASE; PHOSPHORYLATION; RECEPTORS; CHO-K1	The involvement of Raf-1 kinase in the insulin signal transduction chain leading to control of cell proliferation was studied in the H4IIE rat hepatoma cell line by inhibiting expression of the kinase with antisense oligodeoxyribonucleotide directed against Raf-1 mRNA, Antisense oligonucleotide was found to reduce (at 2 mu M) or completely block (at 15 mu M) the stimulation by insulin of DNA synthesis, measured as thymidine incorporation. The residual DNA synthesis seen in the absence of insulin stimulation was also inhibited by the Raf-1 kinase antisense oligonucleotide.	LINKOPING UNIV,FAC HLTH SCI,DEPT CELL BIOL,S-58185 LINKOPING,SWEDEN	Linkoping University				Stralfors, Peter/0000-0002-1196-1806				BELFRAGE P, 1986, MECHANISMS INSULIN A; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; DENT P, 1993, MOL BIOL CELL, V4, P483, DOI 10.1091/mbc.4.5.483; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DICKENS M, 1992, BIOCHEM J, V287, P201, DOI 10.1042/bj2870201; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; HOFMANN C, 1989, J BIOL CHEM, V264, P8606; IZUMI T, 1991, J BIOL CHEM, V266, P7933; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LEE RM, 1992, J BIOL CHEM, V267, P1088; MAMOUNAS M, 1991, P NATL ACAD SCI USA, V88, P3530, DOI 10.1073/pnas.88.9.3530; MAMOUNAS M, 1989, P NATL ACAD SCI USA, V86, P9294, DOI 10.1073/pnas.86.23.9294; MESSINA JL, 1990, BIOCHEM BIOPH RES CO, V172, P759, DOI 10.1016/0006-291X(90)90739-A; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; SHIMIZU Y, 1986, J BIOL CHEM, V261, P7342	20	13	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13919	13921						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188671				2022-12-27	WOS:A1994NL60600033
J	BURSTEIN, ES; BRONDYK, WH; MACARA, IG; KAIBUCHI, K; TAKAI, Y				BURSTEIN, ES; BRONDYK, WH; MACARA, IG; KAIBUCHI, K; TAKAI, Y			REGULATION OF THE GTPASE CYCLE OF THE NEURONALLY EXPRESSED RAS-LIKE GTP-BINDING PROTEIN RAB3A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GDP DISSOCIATION INHIBITOR; SMG P25A; EXCHANGE PROTEIN; MEMBRANES; TISSUE; PROTEIN-P25RAB3A; PURIFICATION; P25RAB3A; SMG-P25A; RESIDUES	The small GTP-binding protein Rab3A (identical to smg p25A) is expressed in neural/exocrine/endocrine cells, is distributed between the cytosol and secretory vesicle membranes, and may cycle between these locations to regulate exocytosis. It is proposed that the GTP/GDP state of Rab3A controls this distribution. In PC12 cells, cytosolic Rab3A is predominantly GDP-bound, whereas membrane-associated Rab3A is approximately 50% GTP-bound. Two cytosolic factors, GDP dissociation inhibitor (GDI) and guanine nucleotide releasing factor (GRF), act only on GDP.Rab3A, and preferentially with post-translationally modified Rab3A. Rab3A GTPase-activating protein (GAP) does not preferentially act on processed Rab3A, and interacts selectively with GTP.Rab3A. GDI antagonizes GRF but not GAP activity toward Rab3A. These data are consistent with the concept of an ordered Rab3A cycle controlled by factors that regulate the guanine-nucleotide binding state of Rab3A.	UNIV VERMONT, DEPT PATHOL, BURLINGTON, VT 05405 USA; KOBE UNIV, SCH MED, DEPT BIOCHEM, KOBE 650, JAPAN	University of Vermont; Kobe University	BURSTEIN, ES (corresponding author), UNIV VERMONT, DEPT PSYCHIAT, BURLINGTON, VT 05405 USA.				NATIONAL CANCER INSTITUTE [R01CA056300] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [F32EY006411] Funding Source: NIH RePORTER; NCI NIH HHS [CA56300] Funding Source: Medline; NEI NIH HHS [F32EY06411] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BURSTEIN E, 1989, MOL CELL BIOL, V9, P4807, DOI 10.1128/MCB.9.11.4807; BURSTEIN ES, 1992, BIOCHEM J, V282, P387, DOI 10.1042/bj2820387; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; KURODA S, 1992, BIOCHEM BIOPH RES CO, V185, P473, DOI 10.1016/S0006-291X(05)81009-5; MOLLARD G, 1990, NATURE, V349, P79; NONAKA H, 1991, BIOCHEM BIOPH RES CO, V174, P556, DOI 10.1016/0006-291X(91)91453-J; SANO K, 1989, BIOCHEM BIOPH RES CO, V158, P377, DOI 10.1016/S0006-291X(89)80058-0; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x	26	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22247	22250						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226729				2022-12-27	WOS:A1993MD34800009
J	GILON, P; SHEPHERD, RM; HENQUIN, JC				GILON, P; SHEPHERD, RM; HENQUIN, JC			OSCILLATIONS OF SECRETION DRIVEN BY OSCILLATIONS OF CYTOPLASMIC CA2+ AS EVIDENCED IN SINGLE PANCREATIC-ISLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INHIBIT INSULIN RELEASE; INTRACELLULAR CALCIUM; <CA2+>I OSCILLATIONS; PULSATILE SECRETION; CYTOSOLIC CALCIUM; CHROMAFFIN CELLS; B-CELL; MEMBRANE; PROLACTIN; ABILITY	It is often assumed, but has not been demonstrated, that the oscillations of cytoplasmic calcium (Ca2+i) that occur in various secretory cells induce oscillations in secretion. Here, we have used single pancreatic islets from normal mice to monitor simultaneously insulin release and Ca2+i in beta-cells for periods up to 25 min. Ca2+i and insulin secretion were found to oscillate in synchrony during stimulation by glucose. This synchrony persisted when the frequency of both events changed spontaneously or upon addition of the hypoglycaemic sulfonylurea tolbutamide, or when their relative amplitudes varied. Repolarizing the beta-cell membrane with diazoxide abolished both Ca2+i and insulin oscillations. In contrast, epinephrine suppressed insulin oscillations in spite of the persistence of Ca2+i oscillations. This study is the first direct demonstration that, in an intact organ, sustained oscillations of Ca2+i induced by a physiological stimulus entrain synchronous oscillations of the functional response, and that both events can vary simultaneously or be dissociated depending on the experimental conditions.	UNIV CATHOLIQUE LOUVAIN,FAC MED,UNITE ENDOCRINOL & METAB,UCL 55-30,AVE HIPPOCRATE 55,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain								ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BERGSTEN P, 1993, BIOCHEM BIOPH RES CO, V192, P1182, DOI 10.1006/bbrc.1993.1541; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; CHEEK TR, 1989, J CELL BIOL, V109, P1219, DOI 10.1083/jcb.109.3.1219; COOK DL, 1982, DIABETES, V31, P985, DOI 10.2337/diabetes.31.11.985; DOUGLAS WW, 1968, BRIT J PHARMACOL, V34, P451, DOI 10.1111/j.1476-5381.1968.tb08474.x; DREWS G, 1990, ENDOCRINOLOGY, V126, P1646, DOI 10.1210/endo-126-3-1646; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; GILLIS KD, 1992, PFLUGERS ARCH, V420, P131; GILON P, 1992, J BIOL CHEM, V267, P20713; HENQUIN JC, 1982, BIOCHEM PHARMACOL, V31, P1407, DOI 10.1016/0006-2952(82)90036-3; HENQUIN JC, 1992, NUTRIENT REGULATION, P173; HOLL RW, 1988, J BIOL CHEM, V263, P9682; JONES PM, 1987, FEBS LETT, V219, P139, DOI 10.1016/0014-5793(87)81206-1; LAW GJ, 1989, MOL ENDOCRINOL, V3, P539, DOI 10.1210/mend-3-3-539; LAW GJ, 1989, BIOCHEM BIOPH RES CO, V158, P811, DOI 10.1016/0006-291X(89)92794-0; LEFEBVRE PJ, 1987, DIABETOLOGIA, V30, P443, DOI 10.1007/BF00279610; LINDAU M, 1992, BIOPHYS J, V61, P19, DOI 10.1016/S0006-3495(92)81812-X; MALGAROLI A, 1991, FEBS LETT, V283, P169, DOI 10.1016/0014-5793(91)80580-V; MEISSNER HP, 1976, NATURE, V262, P502, DOI 10.1038/262502a0; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; PENNER R, 1988, J EXP BIOL, V139, P329; Rosario L M, 1986, Adv Exp Med Biol, V211, P413; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; TAMAGAWA T, 1985, BIOMED RES-TOKYO, V6, P429, DOI 10.2220/biomedres.6.429; THOMAS P, 1993, EMBO J, V12, P303, DOI 10.1002/j.1460-2075.1993.tb05657.x; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; WATERS SB, 1992, ENDOCRINOLOGY, V130, P2091, DOI 10.1210/en.130.4.2091; WEIGLE DS, 1987, DIABETES, V36, P764, DOI 10.2337/diab.36.6.764	32	305	312	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22265	22268						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226733				2022-12-27	WOS:A1993MD34800014
J	HUIBREGTSE, JM; GOOD, PD; MARCZYNSKI, GT; JAEHNING, JA; ENGELKE, DR				HUIBREGTSE, JM; GOOD, PD; MARCZYNSKI, GT; JAEHNING, JA; ENGELKE, DR			GAL4 PROTEIN-BINDING IS REQUIRED BUT NOT SUFFICIENT FOR DEREPRESSION AND INDUCTION OF GAL2 EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SACCHAROMYCES-CEREVISIAE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATOR; YEAST GENES; INVIVO; RNA; SEQUENCES; PHOSPHORYLATION; REPRESSION; COMPLEXES	The Saccharomyces cerevisiae GAL2 gene upstream activator sequence (UAS) region was examined for protein bound in vivo by chromatin footprinting at high resolution. Gal4 transcriptional activator protein binds to the two consensus UAS sites whether GAL2 expression is induced, uninduced, or repressed by growth with different carbon sources. Although wild type strains show loss of the Gal4 protein-specific footprint in repressing media containing glucose, constitutive high level expression of Gal4 protein restores the GAL2 UAS footprints without fully derepressing GAL2 transcription. Thus binding of the Gal4 activator to target sites in the DNA is required but not sufficient for GAL2 derepression and induction. Gal4-independent protein-DNA complexes were also detected in the region, including one over the previously noted centromere-binding protein (CP1) site upstream of the Gal4 complexes.	UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NCRR NIH HHS [MO1-RR00042] Funding Source: Medline; NIAID NIH HHS [R04 AI00874] Funding Source: Medline; NIGMS NIH HHS [R01 GM38101] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI000874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038101] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; AXELROD JD, 1989, NUCLEIC ACIDS RES, V17, P171, DOI 10.1093/nar/17.1.171; BAKER SM, 1987, MOL GEN GENET, V208, P127, DOI 10.1007/BF00330433; BRAM RJ, 1987, MOL CELL BIOL, V7, P403, DOI 10.1128/MCB.7.1.403; BRAM RJ, 1986, EMBO J, V5, P603, DOI 10.1002/j.1460-2075.1986.tb04253.x; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GRIGGS DW, 1991, P NATL ACAD SCI USA, V88, P8597, DOI 10.1073/pnas.88.19.8597; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HUIBREGTSE JM, 1987, MOL CELL BIOL, V7, P3212, DOI 10.1128/MCB.7.9.3212; HUIBREGTSE JM, 1989, P NATL ACAD SCI USA, V86, P65, DOI 10.1073/pnas.86.1.65; HUIBREGTSE JM, 1989, MOL CELL BIOL, V9, P3244, DOI 10.1128/MCB.9.8.3244; HULL MW, 1991, METHOD CELL BIOL, V35, P384; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; LEE JY, 1991, MOL CELL BIOL, V11, P721, DOI 10.1128/MCB.11.2.721; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; LONG RM, 1991, MOL CELL BIOL, V11, P2311, DOI 10.1128/MCB.11.4.2311; MYLIN LM, 1989, GENE DEV, V3, P1157, DOI 10.1101/gad.3.8.1157; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; NEHLIN JO, 1989, GENE, V85, P313, DOI 10.1016/0378-1119(89)90423-X; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; PARTHUN MR, 1992, MOL CELL BIOL, V12, P4981, DOI 10.1128/MCB.12.11.4981; PARTHUN MR, 1992, MOL CELL BIOL, V12, P5683, DOI 10.1128/MCB.12.12.5683; SELLECK SB, 1988, P NATL ACAD SCI USA, V85, P5399, DOI 10.1073/pnas.85.15.5399; SELLECK SB, 1987, NATURE, V325, P173, DOI 10.1038/325173a0; SELLECK SB, 1987, MOL CELL BIOL, V7, P3260, DOI 10.1128/MCB.7.9.3260; STONE G, 1993, EMBO J, V12, P1375, DOI 10.1002/j.1460-2075.1993.tb05782.x; SZKUTNICKA K, 1989, J BACTERIOL, V171, P4486, DOI 10.1128/JB.171.8.4486-4493.1989; ZAREL L, 1992, PROG NUCLEIC ACID RE, V44, P67	29	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22219	22222						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226724				2022-12-27	WOS:A1993MD34800002
J	RUTTER, GA; THELER, JM; MURGIA, M; WOLLHEIM, CB; POZZAN, T; RIZZUTO, R				RUTTER, GA; THELER, JM; MURGIA, M; WOLLHEIM, CB; POZZAN, T; RIZZUTO, R			STIMULATED CA2+ INFLUX RAISES MITOCHONDRIAL FREE CA2+ TO SUPRAMICROMOLAR LEVELS IN A PANCREATIC BETA-CELL LINE - POSSIBLE ROLE IN GLUCOSE AND AGONIST-INDUCED INSULIN-SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-HEART MITOCHONDRIA; PYRUVATE-DEHYDROGENASE; CALCIUM-TRANSPORT; EXTRACELLULAR ATP; CYTOSOLIC CA2+; RINM5F CELLS; B-CELLS; CA-2+; METABOLISM; ISLETS	The effects of stimulated Ca2+ influx on cytosolic ([Ca2+]c) or intramitochondrial free Ca2+ ([Ca2+]m) were examined in the new pancreatic beta-cell line, INS-1. [Ca2+]c was monitored by video imaging of single fura-2-loaded INS-1 cells, or in populations of cells transfected with non-targeted (cytosolic) aequorin. [Ca2+]m was measured after transfection with aequorin targeted to the mitochondria by fusion of the gene in frame with the signal peptide of cytochrome c oxidase subunit VIII. Two physiological stimuli of native beta-cells, glucose and ATP, raised [Ca2+]c in INS-1 cells largely by stimulating Ca2+ influx. Thus, glucose (20 mM) induced repetitive transient increases in [Ca2+]c (0.42 min-1, mean amplitude 229 nM above 102 nM basal). These transients were largely due to periodic stimulation of Ca2+ influx through voltage-sensitive Ca2+ channels, since they could be rapidly and reversibly blocked by chelation of external Ca2+, by addition of the hyperpolarizing agent diazoxide, or with the Ca2+ channel blocker SR 7037. ATP, by contrast, caused single transient [Ca2+]c increases, to about 300 nM above basal levels, which could be inhibited by >90% upon external Ca2+ chelation. Challenge of aequorin-transfected cells with ATP increased [Ca2+]m to 4 muM or above, an effect blocked by EGTA. Furthermore, plasma membrane depolarization with high K+, used as a glucose surrogate to mimic, in a synchronized fashion, the influx-induced Ca2+ transients observed at the single-cell level, also increased [Ca2+]m to >4 muM. Similar increases in [Ca2+]m were also measured in other aequorin-transfected insulin-secreting cells, RINm5F, during mobilization of internal Ca2+ with carbachol. In contrast, glucose-induced changes in [Ca2+]m were below the level of detection in INS-1 cell populations, consistent with the asynchrony of the [Ca2+]c transients induced by this nutrient at the single-cell level, and the consequent small average [Ca2+]c rise. These data are in line with the view that stimulated Ca2+ influx into excitable cells raises [Ca2+]m as efficiently as internal Ca2+ mobilization in nonexcitable cells. In the case of INS-1 and pancreatic beta-cells, this may be important both to enhance oxidative metabolism, hence fueling the secretory process, and also to maintain the production of metabolic signaling molecules.	UNIV PADUA, DIV BIOMED SCI, I-35121 PADUA, ITALY	University of Padua	RUTTER, GA (corresponding author), UNIV GENEVA, MED CTR, DEPT MED, DIV CLIN BIOCHEM, CH-1211 GENEVA 4, SWITZERLAND.		Rizzuto, Rosario/B-6312-2008	Rutter, Guy/0000-0001-6360-0343; Rizzuto, Rosario/0000-0001-7044-5097				AMMALA C, 1991, NATURE, V353, P849, DOI 10.1038/353849a0; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; BARTHEL F, 1992, METHODS NEUROSCI, V9, P291; BERTRAND G, 1987, BRIT J PHARMACOL, V91, P783, DOI 10.1111/j.1476-5381.1987.tb11276.x; BRUN T, 1993, J BIOL CHEM, V268, P18905; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; Cobbold PH, 1991, CELLULAR CALCIUM PRA, P55; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DAVIDSON AM, 1989, BIOCHEM J, V258, P817, DOI 10.1042/bj2580817; DEAN PM, 1973, DIABETOLOGIA, V9, P115, DOI 10.1007/BF01230690; DENTON RM, 1980, FEBS LETT, V119, P1, DOI 10.1016/0014-5793(80)80986-0; GESCHWIND JF, 1989, BIOCHIM BIOPHYS ACTA, V1012, P107, DOI 10.1016/0167-4889(89)90018-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYLFE E, 1991, CELL CALCIUM, V12, P229, DOI 10.1016/0143-4160(91)90023-8; HANSFORD RG, 1985, REV PHYSIOL BIOCH P, V102, P1, DOI 10.1007/BFb0034084; JANJIC D, 1992, DIABETOLOGIA, V35, P482, DOI 10.1007/BF02342448; JANJIC D, 1992, EUR J BIOCHEM, V210, P297, DOI 10.1111/j.1432-1033.1992.tb17421.x; KRAUSE E-G, 1988, Journal of Molecular and Cellular Cardiology, V20, pS54; LI GD, 1991, J BIOL CHEM, V266, P3449; LONGO EA, 1991, J BIOL CHEM, V266, P9314; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MARIE S, 1993, IN PRESS J BIOL CHEM, V268; MCCORMACK JG, 1990, BIOCHEM J, V267, P527, DOI 10.1042/bj2670527; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; PANTEN U, 1987, ISI ATLAS-PHARMACOL, V1, P307; PRALONG WF, 1992, P NATL ACAD SCI USA, V89, P132, DOI 10.1073/pnas.89.1.132; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; RORSMAN P, 1992, EMBO J, V11, P2877, DOI 10.1002/j.1460-2075.1992.tb05356.x; ROSSIER JR, 1989, J BIOL CHEM, V264, P16598; RUTTER GA, 1988, BIOCHEM J, V252, P181, DOI 10.1042/bj2520181; RUTTER GA, 1989, BIOCHIM BIOPHYS ACTA, V1014, P263, DOI 10.1016/0167-4889(89)90222-X; RUTTER GA, 1992, BIOCHIM BIOPHYS ACTA, V1175, P107, DOI 10.1016/0167-4889(92)90016-5; RUTTER GA, 1990, INT J BIOCHEM, V22, P1081, DOI 10.1016/0020-711X(90)90105-C; RUTTER GA, 1990, BIOCHEM J, V271, P627, DOI 10.1042/bj2710627; SENER A, 1990, BIOCHIM BIOPHYS ACTA, V1019, P42, DOI 10.1016/0005-2728(90)90122-K; TANAHASHI H, 1990, GENE, V96, P249, DOI 10.1016/0378-1119(90)90260-X; THELER JM, 1992, J BIOL CHEM, V267, P18110; WENDTGALLITELLI MF, 1991, J PHYSIOL-LONDON, V435, P349, DOI 10.1113/jphysiol.1991.sp018514; WOLLHEIM CB, 1986, ANN NY ACAD SCI, V488, P317; WOLLHEIM CB, 1986, J BIOL CHEM, V261, P8314	45	172	174	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22385	22390						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226749				2022-12-27	WOS:A1993MD34800032
J	BROSE, N; HUNTLEY, GW; STERNBACH, Y; SHARMA, G; MORRISON, JH; HEINEMANN, SF				BROSE, N; HUNTLEY, GW; STERNBACH, Y; SHARMA, G; MORRISON, JH; HEINEMANN, SF			DIFFERENTIAL ASSEMBLY OF COEXPRESSED GLUTAMATE-RECEPTOR SUBUNITS IN NEURONS OF RAT CEREBRAL-CORTEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ASPARTATE RECEPTORS; NMDA RECEPTOR; FUNCTIONAL EXPRESSION; IMMUNOCYTOCHEMICAL LOCALIZATION; MOLECULAR-CLONING; AFFINITY KAINATE; NERVOUS-SYSTEM; CLONED CDNAS; BRAIN; CHANNEL	In the rat, subunits of the glutamate receptor family fall into three pharmacologically distinct groups: alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid preferring receptors (Glu R1-4), kainate preferring receptors (Glu R5-7, KA 1, KA 2), and N-methyl-D-aspartate preferring receptors (NMDA R1, NMDA R2A-2D). In the present study, we demonstrate immunocytochemically that the majority of neurons in rat cerebral cortex coexpress members of all three groups of glutamate receptor subunits, Glu R2/3, Glu R5/6/7, and NMDA R1. Using immunoaffinity purified or immunoprecipitated alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid, kainate and N-methyl-D-aspartate receptors, we show that alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors containing Glu R1-4, kainate receptors containing Glu R6, Glu R7, and KA 2 and N-methyl-D-aspartate receptors containing NMDA R1 each form distinct protein complexes that do not share subunits. Our data indicate that a mechanism exists which allows for the specific assembly of selected glutamate receptor subunits into functionally and structurally distinct heteromeric receptors.	SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,LA JOLLA,CA 92037; CUNY MT SINAI SCH MED,FISHBERG RES CTR NEUROBIOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT GERIATR & ADULT DEV,NEW YORK,NY 10029	Salk Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Morrison, John/F-9229-2012	Huntley, George W./0000-0003-3645-6192	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006647, R37AG006647] Funding Source: NIH RePORTER; NIA NIH HHS [AG 06647] Funding Source: Medline; NINDS NIH HHS [NS 28706, NS 11549] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BETTLER B, 1992, NEURON, V8, P257, DOI 10.1016/0896-6273(92)90292-L; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BLACKSTONE CD, 1992, ANN NEUROL, V31, P680, DOI 10.1002/ana.410310620; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BRACKLEY PTH, 1993, J PHARMACOL EXP THER, V265, P910; BROSE N, 1993, J BIOL CHEM, V268, P22663; HENLEY JM, 1992, P NATL ACAD SCI USA, V89, P4806, DOI 10.1073/pnas.89.11.4806; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUNTLEY GW, 1993, J NEUROSCI, V13, P2965; IKEDA K, 1992, FEBS LETT, V313, P34, DOI 10.1016/0014-5793(92)81178-O; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMELI H, 1992, FEBS LETT, V307, P139, DOI 10.1016/0014-5793(92)80753-4; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; NAKANISHI S, 1992, SCIENCE, V258, P579; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; Puchalski R. B., 1993, Society for Neuroscience Abstracts, V19, P71; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROGERS SW, 1991, J NEUROSCI, V11, P2713; SAKIMURA K, 1992, NEURON, V8, P267, DOI 10.1016/0896-6273(92)90293-M; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SIEGEL SJ, 1994, P NATL ACAD SCI USA, V91, P564, DOI 10.1073/pnas.91.2.564; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WENTHOLD RJ, 1994, J BIOL CHEM, V269, P1332; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N	38	99	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16780	16784						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207001				2022-12-27	WOS:A1994NR29600043
J	NGUYEN, M; BRANTON, PE; WALTON, PA; OLTVAI, ZN; KORSMEYER, SJ; SHORE, GC				NGUYEN, M; BRANTON, PE; WALTON, PA; OLTVAI, ZN; KORSMEYER, SJ; SHORE, GC			ROLE OF MEMBRANE ANCHOR DOMAIN OF BCL-2 IN SUPPRESSION OF APOPTOSIS CAUSED BY E1B-DEFECTIVE ADENOVIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MITOCHONDRIAL OUTER-MEMBRANE; PROGRAMMED CELL-DEATH; 19-KILODALTON PROTEIN; MONOCLONAL-ANTIBODIES; E1A PROTEINS; TRANSFORMATION; ONCOPROTEIN; GENERATION; SEQUENCE; MUTANTS	Bcl-2 is an integral membrane protein that functions as a suppressor of programmed cell death. It contains a COOH-terminal signal anchor sequence that is selective for import and insertion of Bcl-2 into the mitochondrial outer membrane and, by a different mechanism, can also direct the protein to other membrane sites. Deletion of the signal anchor sequence rendered Bcl-2 cytosolic and impaired its ability to prevent apoptotic death of human KB cells infected with a mutant form of adenovirus type 5 that does not make E1B 19-kDa protein. When the predicted transmembrane domain of the Bcl-2 signal anchor was replaced with that of the signal anchor of the yeast outer mitochondrial membrane protein, Mas70p, the Bcl-2/Mas70p hybrid was found to be very similar to Bcl-2 in its distribution within transfected KB cells, in its ability to heterodimerize with Bax, and in its ability to suppress apoptosis. These results are consistent with a model in which the transmembrane segment contributes to the function of Bcl-2 by targeting and anchoring the protein to strategic membrane locations in the cell. Concentration of Bcl-2 at these sites may contribute to its proposed role as a regulator, or component, of an antioxidant pathway.	MCGILL UNIV, DEPT ANAT & CELL BIOL, MONTREAL H3G 1Y6, PQ, CANADA; WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT PATHOL, ST LOUIS, MO 63110 USA	McGill University; Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	NGUYEN, M (corresponding author), MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1Y6, PQ, CANADA.							BILLETT EE, 1984, BIOCHEM J, V221, P765, DOI 10.1042/bj2210765; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; FORMAN HJ, 1982, FREE RADICAL BIO MED, V5, P65; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HINES V, 1990, EMBO J, V9, P3171; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KORSMEYER SJ, 1992, BLOOD, V80, P879; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; MAK I, 1983, J VIROL, V45, P1107, DOI 10.1128/JVI.45.3.1107-1117.1983; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; MCLORIE W, 1991, J GEN VIROL, V72, P1467, DOI 10.1099/0022-1317-72-6-1467; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; TANAKA S, 1993, J BIOL CHEM, V268, P10920; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZHANG S, 1992, J VIROL, V66, P2302, DOI 10.1128/JVI.66.4.2302-2309.1992	31	164	174	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16521	16524						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206964				2022-12-27	WOS:A1994NR29600001
J	REARDON, JE; CROUCH, RC; STJOHNWILLIAMS, L				REARDON, JE; CROUCH, RC; STJOHNWILLIAMS, L			REDUCTION OF 3'-AZIDO-3'-DEOXYTHYMIDINE (AZT) AND AZT NUCLEOTIDES BY THIOLS - KINETICS AND PRODUCT IDENTIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CELLULAR DNA-POLYMERASES; PLACEBO-CONTROLLED TRIAL; AIDS-RELATED COMPLEX; BONE-MARROW CELLS; REVERSE-TRANSCRIPTASE; AZIDOTHYMIDINE AZT; NMR-SPECTROSCOPY; LIVER-MICROSOMES; TOXIC CATABOLITE	3'-Azido-3'-deoxythymidine (AZT), AZT 5'-monophosphate, and AZT 5'-triphosphate (AZTTP) were reduced by dithiothreitol with second-order rate constants of 2.30 x 10(-3), 1.50 x 10(-3), and 7.46 x 10(-4) M(-1) s(-1), respectively. Handlon and Oppenheimer reported that AZT is quantitatively reduced by thiols to 3'-amino-3'-deoxythymidine (Handlon, A. L., and Oppenheimer, N. J. (1988) Pharm. Res. (N. Y.) 5, 297-299). In the present report, multiple products of this reaction were identified by the techniques of UV spectroscopy, phosphate analysis, coelution with authentic standards from reversed-phase high pressure liquid chromatography, two-dimensional NMR spectroscopy, and mass spectrometry. The product mixture from reduction of AZT 5'-monophosphate at pH 7.1 and 25 degrees C was composed of 2,3'-anhydro-beta-D-threo-thymidine 5'-monophosphate (6.4%), 3'-amino-3'-deoxythymidine 5'-monophosphate (19.6%), beta-D-threo-thymidine 5'-monophosphate (6.8%), thymine and 3-amino-2,3-dideoxyribal 5-monophosphate (8.9%), beta-D-threo-thymidine 3',5'-cyclic monophosphate (9.1%), 3'-deoxy-2',3'-didehydrothymidine 5'-monophosphate (31.5%), and 3',5'-anhydro-beta-D-threo- hymidine (17.8%). Thymine and 3',5'-anhydro-beta-D-threo-thymidine were also products of reduction of AZT and AZTTP. Furthermore, the nucleosides of the above monophosphates were products of reduction of AZT, and the corresponding triphosphates were products of reduction of AZTTP. The product ratios were dependent on the level of phosphorylation of AZT and on the pH of the reaction. Mechanisms for formation of these products are proposed.	WELLCOME RES LABS,DIV ORGAN CHEM,RES TRIANGLE PK,NC 27709	Wellcome Research Laboratories	REARDON, JE (corresponding author), WELLCOME RES LABS,DIV EXPTL THERAPY,RES TRIANGLE PK,NC 27709, USA.							Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BAX A, 1981, J MAGN RESON, V42, P164, DOI 10.1016/0022-2364(81)90022-6; CHEN CH, 1991, MOL PHARMACOL, V39, P625; CHENG YC, 1990, ANN NY ACAD SCI, V616, P217; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; CRETTON EM, 1991, MOL PHARMACOL, V39, P258; CRETTON EM, 1991, ANTIMICROB AGENTS CH, V35, P801, DOI 10.1128/AAC.35.5.801; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; FRICK LW, 1988, BIOCHEM BIOPH RES CO, V154, P124, DOI 10.1016/0006-291X(88)90659-6; FRIDLAND A, 1990, MOL PHARMACOL, V37, P665; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HANDLON AL, 1988, PHARMACEUT RES, V5, P297, DOI 10.1023/A:1015926720740; HART GJ, 1992, ANTIMICROB AGENTS CH, V36, P1688, DOI 10.1128/AAC.36.8.1688; HORWITZ J, 1968, SYNTHETIC PROCEDURES, V1, P344; IZUTA S, 1991, BIOCHEM BIOPH RES CO, V179, P776, DOI 10.1016/0006-291X(91)91884-F; KAWCZYNSKI W, 1991, J ELECTROANAL CHEM, V321, P441; KEILBAUGH SA, 1991, BIOCHEM PHARMACOL, V42, pR5, DOI 10.1016/0006-2952(91)90672-R; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LABBE G, 1969, CHEM REV, V69, P345, DOI 10.1021/cr60259a004; LACEY SF, 1992, J BIOL CHEM, V267, P15789; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MANJI H, 1993, J NEUROL, V240, P479, DOI 10.1007/BF00874117; MANSURI MM, 1989, J MED CHEM, V32, P461, DOI 10.1021/jm00122a029; MARTIN JL, 1994, 7 INT C ANT RES, P67; NICKEL W, 1992, J BIOL CHEM, V267, P848; ONO K, 1989, MOL PHARMACOL, V35, P578; PLACIDI L, 1993, CLIN PHARMACOL THER, V54, P168, DOI 10.1038/clpt.1993.128; RAJAONARISON JF, 1993, THERAPIE, V48, P341; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; SIMPSON DM, 1993, NEUROLOGY, V43, P971, DOI 10.1212/WNL.43.5.971; STAGG MP, 1992, CLIN PHARMACOL THER, V51, P668, DOI 10.1038/clpt.1992.79; VOLHERDING PA, 1990, NEW ENGL J MED, V322, P941; ZHU Z, 1991, MOL PHARMACOL, V40, P838	40	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15999	16008						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206896				2022-12-27	WOS:A1994NQ72900011
J	MIRISOLA, MG; SEIDITA, G; VERROTTI, AC; DIBLASI, F; FASANO, O				MIRISOLA, MG; SEIDITA, G; VERROTTI, AC; DIBLASI, F; FASANO, O			MUTAGENIC ALTERATION OF THE DISTAL SWITCH-II REGION OF RAS BLOCKS CDC25-DEPENDENT SIGNALING FUNCTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE CDC25; SENSITIVE ADENYLATE-CYCLASE; SDC25 C-DOMAIN; CELL-CYCLE; NUCLEOTIDE EXCHANGE; GUANINE-NUCLEOTIDES; NIH3T3 CELLS; WILD-TYPE; YEAST; GENE	We have explored the role of the distal switch II region of the yeast RAS2 protein in determining the response to the nucleotide exchange factor CDC25. We first constructed yeast tester strains in which the deletion of the chromosomal CDC25, RAS1, and RAS2 genes, in combination with the chromosomal suppressor CRI4, resulted in detectable phenotypes in vivo and in vitro. Phenotypes included impaired growth at 37 degrees C, defective glucose-induced cyclic AMP signaling, and low adenylyl cyclase activity of membrane preparations. Tester strains were subsequently used for the reintroduction of various combinations of wild-type and mutated RAS2 and CDC25 genes by genetic techniques, as well as for in vitro reconstitution assays with the corresponding proteins. CDC25 restored both growth and glucose-induced cyclic AMP signaling in the presence, but not in the absence of wild-type RAS2. A gene encoding a RAS2 protein with a mutationally altered switch II region was expressed but was ineffective in reintegrating exchange factor-dependent responses in vivo. Wild-type, but not mutagenically altered, RAS2 proteins were stimulated by exchange factors in vitro. We conclude that the conserved distal switch II region is required for CDC25-dependent activation of RAS.	DIPARTIMENTO BIOL CELLULARE & SVILUPPO, I-90123 PALERMO, ITALY; CNR, IST BIOL SVILUPPO, I-90123 PALERMO, ITALY; CTR ONCOBIOL SPERIMENTALE, I-90123 PALERMO, ITALY	Consiglio Nazionale delle Ricerche (CNR)			mirisola, mario/GZK-2599-2022	mirisola, mario/0000-0003-2555-2226; Di Blasi, Francesco/0000-0001-8085-7538				BARLAT I, 1993, ONCOGENE, V8, P215; BARONI MD, 1989, MOL CELL BIOL, V9, P2715, DOI 10.1128/MCB.9.6.2715; BARONI MD, 1992, BIOCHEM BIOPH RES CO, V186, P467, DOI 10.1016/S0006-291X(05)80831-9; BOUTELET F, 1985, EMBO J, V4, P2635, DOI 10.1002/j.1460-2075.1985.tb03981.x; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; Broach J. R., 1983, EXPT MANIPULATION GE, P83; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CASPERSON GF, 1983, J BIOL CHEM, V258, P7911; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHEVALLIERMULTON MC, 1993, J BIOL CHEM, V268, P11113; CRECHET JB, 1990, J BIOL CHEM, V265, P1563; CRECHET JB, 1993, J BIOL CHEM, V268, P14836; DAMAK F, 1991, MOL CELL BIOL, V11, P202, DOI 10.1128/MCB.11.1.202; DEVENDITTIS E, 1986, EMBO J, V5, P3657, DOI 10.1002/j.1460-2075.1986.tb04696.x; DEVENDITTIS E, 1986, EUR J BIOCHEM, V161, P473; FASANO O, 1988, EMBO J, V7, P3375, DOI 10.1002/j.1460-2075.1988.tb03210.x; FEGER G, 1991, EMBO J, V10, P349, DOI 10.1002/j.1460-2075.1991.tb07956.x; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FRASCOTTI G, 1991, BIOCHIM BIOPHYS ACTA, V1089, P206, DOI 10.1016/0167-4781(91)90009-B; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HORTSCH M, 1985, J BIOL CHEM, V260, P9137; HOWE LR, 1993, ONCOGENE, V8, P2583; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KAVOUNIS C, 1991, FEBS LETT, V281, P235, DOI 10.1016/0014-5793(91)80401-N; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; MARTEGANI E, 1984, EUR J BIOCHEM, V144, P205, DOI 10.1111/j.1432-1033.1984.tb08450.x; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATSUMOTO K, 1984, J BACTERIOL, V157, P277, DOI 10.1128/JB.157.1.277-282.1984; MILLER AF, 1992, BIOCHEMISTRY-US, V31, P10208, DOI 10.1021/bi00157a007; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MORTIMER RK, 1981, MOL BIOL YEAST SACCH, P11; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; Pai EF, 1991, CURR OPIN STRUC BIOL, V1, P941, DOI 10.1016/0959-440X(91)90089-C; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; RATZKIN B, 1977, P NATL ACAD SCI USA, V74, P487, DOI 10.1073/pnas.74.2.487; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHERMAN F, 1986, LABORATORY COURSE MA; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STOUTEN PFW, 1993, FEBS LETT, V320, P1, DOI 10.1016/0014-5793(93)81644-F; STRUHL K, 1980, J MOL BIOL, V136, P309, DOI 10.1016/0022-2836(80)90376-9; TAMANOI F, 1988, BIOCHIM BIOPHYS ACTA, V948, P1, DOI 10.1016/0304-419X(88)90002-9; THEVELEIN JM, 1991, MOL MICROBIOL, V5, P1301, DOI 10.1111/j.1365-2958.1991.tb00776.x; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026	59	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15740	15748						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195227				2022-12-27	WOS:A1994NP51300055
J	BASSING, CH; HOWE, DJ; SEGARINI, PR; DONAHOE, PK; WANG, XF				BASSING, CH; HOWE, DJ; SEGARINI, PR; DONAHOE, PK; WANG, XF			A SINGLE HETEROMERIC RECEPTOR COMPLEX IS SUFFICIENT TO MEDIATE BIOLOGICAL EFFECTS OF TRANSFORMING GROWTH-FACTOR-BETA LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SERINE THREONINE KINASE; II RECEPTOR; CELL-PROLIFERATION; ACTIVIN; CLONING; EXPRESSION; FAMILY	Transforming growth factor beta (TGF-beta), a multifunctional cytokine that regulates a variety of biological functions, signals through a heteromeric receptor complex of the type I and type II TGF-beta receptors. The type II receptor, a transmembrane serine-threonine kinase, was cloned based on its ability to directly bind TGF-beta. Recently, a number of candidate type I TGF-beta receptors have been isolated. Although only one of these transmembrane kinases (R4) has been shown to mediate TGF-beta-dependent gene activation, others bind TGF-beta when overexpressed in COS cells. Consequently, it has been postulated that the diversity of TGF-beta responses is generated through the association of distinct type I receptors with the type II TGF-beta receptor, thus creating receptor complexes of differential signaling capacities. In contrast to this model, we demonstrate that stable expression of only the R4 type I TGF-beta receptor in a mutant cell line lacking endogenous type I TGF-beta receptor was able to complex with the endogenous type II TGF-beta receptor and restore the effects of TGF-beta on inhibition of cell proliferation and activation of specific genes, regardless of which of the three mammalian isoforms of TGF-beta was used as the ligand. Therefore, R4 acts as a fully functional type I TGF-beta receptor and the differential effects of TGF-beta are likely mediated by a single receptor complex consisting of R4 and the type II receptor.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; CELTRIX PHARMACEUT, SANTA CLARA, CA 95054 USA; MASSACHUSETTS GEN HOSP, PEDIAT SURG RES LAB, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT SURG, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA	Duke University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045746] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45746] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BOURNE HR, 1989, ONCOGENES MOL ORIGIN, P97; BOYD FT, 1989, J BIOL CHEM, V264, P2272; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUZAKI K, 1993, J BIOL CHEM, V268, P12719; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1993, ONCOGENE, V8, P2879; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMAZAKI Y, 1993, DNA SEQUENCE, V3, P297	20	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14861	14864						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195115				2022-12-27	WOS:A1994NP73800004
J	ITABE, H; TAKESHIMA, E; IWASAKI, H; KIMURA, J; YOSHIDA, Y; IMANAKA, T; TAKANO, T				ITABE, H; TAKESHIMA, E; IWASAKI, H; KIMURA, J; YOSHIDA, Y; IMANAKA, T; TAKANO, T			A MONOCLONAL-ANTIBODY AGAINST OXIDIZED LIPOPROTEIN RECOGNIZES FOAM CELLS IN ATHEROSCLEROTIC LESIONS - COMPLEX-FORMATION OF OXIDIZED PHOSPHATIDYLCHOLINES AND POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ACTIVATING FACTOR ACETYLHYDROLASE; CHOLESTERYL ESTER ACCUMULATION; MACROPHAGE SCAVENGER RECEPTOR; ENDOTHELIAL-CELLS; LIPID-PEROXIDATION; APOLIPOPROTEIN-B; ARACHIDONIC-ACID; LINOLEIC-ACID; OXIDATION	In this study we have used homogenates of human atheromatous plaque as immunogen to establish a murine monoclonal antibody which recognizes oxidized low density lipoprotein (LDL). This monoclonal antibody, FOH1a/DLH3, reacted with oxidized LDL, but enzyme-linked immunosorbent assay showed that it had no reaction with native, acetylated, or malonaldehydetreated LDL. The antibody cross reacted with oxidized high density lipoprotein, suggesting that specific sequences of the apolipoprotein B are not essential for antigen recognition by the antibody. Immunohistochemical analysis of thin paraffin sections from human coronary arteries showed that foam cells derived from macrophages in atherosclerotic lesions were heavily stained by this antibody. Several other structures in the lesions, including swollen collagen fibers, cellular debris in necrotic cores, and endothelial cells, were moderately stained. The epitope of this antibody was characterized by a model antigen generating system using ferrous ion-induced peroxidation of lipids. When the total lipid fraction extracted from LDL was treated with the ferrous ion-induced peroxidation system, the reaction mixture was recognized by the antibody. Antigenic product(s) was produced only when phosphatidylcholine (PC) was treated with the ferrous ion-induced peroxidation, other lipids failed to react to the antibody. To investigate the possible formation of a complex of antigenic product with a polypeptide, a synthetic peptide and a rabbit antiserum against the peptide were used. Reaction mixture of ferrous ion-induced peroxidation of PC in the presence of the peptide was added to a microtiter well precoated with the monoclonal antibody FOH1a/DLH3. After washing, the peptide remaining in the well was detected with rabbit antiserum against the peptide, whereas no reactivity was observed when peptide alone was added to the well. Binding of the antigenic complex to the precoated monoclonal antibody was competed by oxidized PC produced in the absence of any polypeptide. We conclude that oxidized phospholipid product(s) is the epitope of the monoclonal antibody and that the oxidized phospholipid forms complexes with polypeptides. The antigenic materials are detected in foam cells in atherosclerotic lesions.	VESSEL RES LAB INC,KANAGAWA 25901,JAPAN; YAMANASHI MED UNIV,DEPT PATHOL,YAMANASHI 40938,JAPAN	University of Yamanashi	ITABE, H (corresponding author), TEIKYO UNIV,FAC PHARMACEUT SCI,DEPT MICROBIOL & MOLEC PATHOL,SAGAMIKO,KANAGAWA 19901,JAPAN.		板部板部, 洋之/ABC-7746-2020	Imanaka, Tsuneo/0000-0003-4677-1356				BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BHADRA S, 1991, BIOCHEM BIOPH RES CO, V176, P431, DOI 10.1016/0006-291X(91)90942-Z; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYD HC, 1989, AM J PATHOL, V135, P815; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Buege J A, 1978, Methods Enzymol, V52, P302; CARPENTER KLH, 1993, BIOCHIM BIOPHYS ACTA, V1167, P121, DOI 10.1016/0005-2760(93)90151-X; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; GALIS ZS, 1992, LAB INVEST, V66, P624; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GONEN B, 1987, ATHEROSCLEROSIS, V65, P265, DOI 10.1016/0021-9150(87)90042-6; GRAHAM A, 1993, FEBS LETT, V330, P181, DOI 10.1016/0014-5793(93)80269-Z; HARBERLAND ME, 1988, SCIENCE, V241, P215; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; HOFF HF, 1992, J BIOL CHEM, V267, P602; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V962, P8; JESSUP W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P167, DOI 10.1016/0005-2760(92)90287-6; KAMIDO H, 1992, FEBS LETT, V304, P269, DOI 10.1016/0014-5793(92)80635-T; KIMURA J, 1986, VIRCHOWS ARCH A, V410, P159; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; LOUGHEED M, 1991, J BIOL CHEM, V266, P14519; MAHLEY RW, 1979, J CLIN INVEST, V64, P743, DOI 10.1172/JCI109518; MANGIN EL, 1993, CIRC RES, V72, P161, DOI 10.1161/01.RES.72.1.161; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MOWRI H, 1988, BIOCHIM BIOPHYS ACTA, V963, P208, DOI 10.1016/0005-2760(88)90282-2; OBRIEN PJ, 1969, CAN J BIOCHEM CELL B, V47, P485, DOI 10.1139/o69-076; PLAINSKI W, 1990, ARTERIOSCLEROSIS, V10, P325; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; ROMA P, 1992, J LIPID RES, V33, P819; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SATTLER W, 1991, BIOCHIM BIOPHYS ACTA, V1081, P65, DOI 10.1016/0005-2760(91)90251-C; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEINBRECHER UP, 1989, J LIPID RES, V30, P305; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; TANAKA T, 1993, BIOCHIM BIOPHYS ACTA, V1166, P264, DOI 10.1016/0005-2760(93)90107-K; TOKUMURA A, 1988, BIOCHEM BIOPH RES CO, V155, P863, DOI 10.1016/S0006-291X(88)80575-8; TRAKHT IN, 1986, ATHEROSCLER REV, V17, P51; VIJAYAGOPAL P, 1985, BIOCHIM BIOPHYS ACTA, V837, P251, DOI 10.1016/0005-2760(85)90048-7; WANG T, 1991, BIOCHIM BIOPHYS ACTA, V1084, P129, DOI 10.1016/0005-2760(91)90211-Y; WANG T, 1992, J LIPID RES, V33, P525; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZHOU X, 1992, J LIPID RES, V33, P1233	47	265	273	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15274	15279						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195164				2022-12-27	WOS:A1994NP73800063
J	MATRINGE, M; CAMADRO, JM; JOYARD, J; DOUCE, R				MATRINGE, M; CAMADRO, JM; JOYARD, J; DOUCE, R			LOCALIZATION OF FERROCHELATASE ACTIVITY WITHIN MATURE PEA-CHLOROPLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPING CUCUMBER CHLOROPLASTS; HORDEUM-VULGARE-L; PROTOPORPHYRINOGEN OXIDASE; PROTOCHLOROPHYLLIDE OXIDOREDUCTASE; SPINACH-CHLOROPLASTS; MOLECULAR-CLONING; ETIOLATED BARLEY; HERBICIDES; GENE; ETIOPLASTS	Precise localization within the chloroplast of the membrane-bound enzymes involved in heme and chlorophyll biosynthetic pathways is of central importance for better understanding the regulation of the carbon flow into these two pathways. In this study we examine the localization of ferrochelatase activity within mature pea chloroplasts. Our results provide evidence that chloroplast ferrochelatase is associated only with thylakoid membranes. The presence of ferrochelatase in chloroplast thylakoids emphasizes the role of this membrane system in chloroplast protoheme biosynthesis. Furthermore, these results raise the possibility that heme and chlorophyll biosynthesis are compartmentalized in two distinct membrane systems within mature chloroplasts.	CEN,DEPT BIOL MOLEC & STRUCT,PHYSIOL CELLULAIRE VEGETALE LAB,CNRS,URA 576,F-38041 GRENOBLE,FRANCE; UNIV GRENOBLE 1,F-38041 GRENOBLE,FRANCE; UNIV PARIS 07,INST JACQUES MONOD,BIOCHIM PORRPHYRINES LAB,CNRS,F-75251 PARIS,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite				Camadro, Jean-Michel/0000-0002-8549-2707				[Anonymous], METHODS CHLOROPLAST; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Beale S. I., 1990, BIOSYNTHESIS HEME CH, P287; BLOCK MA, 1980, BIOCHIM BIOPHYS ACTA, V631, P210, DOI 10.1016/0304-4165(80)90069-0; BROWN SB, 1984, BIOCHEM J, V220, P861, DOI 10.1042/bj2200861; CAMADRO JM, 1984, J BIOL CHEM, V259, P5678; CAMADRO JM, 1981, BIOCHIMIE, V63, P463, DOI 10.1016/S0300-9084(81)80022-3; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DEHESH K, 1986, PLANTA, V169, P172, DOI 10.1007/BF00392311; DEMATTEIS F, 1980, BIOCHEM J, V187, P285, DOI 10.1042/bj1870285; DORNE AJ, 1990, P NATL ACAD SCI USA, V87, P71, DOI 10.1073/pnas.87.1.71; Douce R., 1979, Advances in Botanical Research, V7, P1, DOI 10.1016/S0065-2296(08)60087-7; FRUSTACI JM, 1992, J BACTERIOL, V174, P4223, DOI 10.1128/JB.174.13.4223-4229.1992; FUESLER TP, 1984, PLANT PHYSIOL, V75, P662, DOI 10.1104/pp.75.3.662; FUHRHOP JH, 1975, PORPHYRINS METALLOPO, P806; HANSSON M, 1992, J BACTERIOL, V174, P8081, DOI 10.1128/JB.174.24.8081-8093.1992; JACOBS JM, 1991, PLANT PHYSIOL, V97, P197, DOI 10.1104/pp.97.1.197; JONES MS, 1970, BIOCHEM J, V119, P453, DOI 10.1042/bj1190453; JONES OTG, 1968, BIOCHEM J, V107, P113, DOI 10.1042/bj1070113; JONES OTG, 1967, BIOCHEM BIOPH RES CO, V28, P671, DOI 10.1016/0006-291X(67)90367-1; JOYARD J, 1990, J BIOL CHEM, V265, P21820; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; LABBEBOIS R, 1993, METAL IONS FUNGI; LEE HJ, 1993, PLANT PHYSIOL, V102, P881, DOI 10.1104/pp.102.3.881; LITTLE HN, 1976, BIOCHEM J, V156, P309, DOI 10.1042/bj1560309; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATRINGE M, 1992, J BIOL CHEM, V267, P4646; MATRINGE M, 1992, EUR J BIOCHEM, V209, P861, DOI 10.1111/j.1432-1033.1992.tb17358.x; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; PORRA RJ, 1968, BIOCHEM J, V108, P343, DOI 10.1042/bj1080343; PORRA RJ, 1963, BIOCHEM J, V87, P181, DOI 10.1042/bj0870181; SATO N, 1993, EMBO J, V12, P555, DOI 10.1002/j.1460-2075.1993.tb05687.x; SCALLA R, 1993, REV WEED SCI, V6, P103; SHAW P, 1985, EUR J CELL BIOL, V39, P50; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; WALKER CJ, 1991, PLANT PHYSIOL, V95, P1189, DOI 10.1104/pp.95.4.1189	37	29	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15010	15015						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195137				2022-12-27	WOS:A1994NP73800028
J	PENN, RB; BENOVIC, JL				PENN, RB; BENOVIC, JL			STRUCTURE OF THE HUMAN GENE ENCODING THE BETA-ADRENERGIC-RECEPTOR KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-ADRENERGIC RECEPTOR; CHROMOSOMAL LOCALIZATION; MOLECULAR-CLONING; RHODOPSIN KINASE; PROTEIN; FAMILY; EXPRESSION; TRANSCRIPTION; TRANSLOCATION; MEMBER	The beta-adrenergic receptor kinase (beta ARK) specifically phosphorylates the agonist-occupied forms of the beta(2)-adrenergic receptor and related G protein-coupled receptors. beta ARK is one of the best characterized members of a growing family of G protein-coupled receptor kinases. In this article we report the isolation and structural organization of the human beta ARK gene. The gene spans approximately 23 kilobases and is composed of 21 exons interrupted by 20 introns. Exon sizes range from 52 bases (exon 7) to over 1200 bases (exon 21), intron sizes from 68 bases (intron L) to 10.8 kilobases (intron A). The splice sites for donor and acceptor were in agreement with the canonical GT/AG rule. Functional regions of beta ARK are described with respect to their location within the exon-intron organization of the gene. Primer extension and RNase protection assays suggest a major transcription start site approximately 246 bases upstream of the start ATG. Sequence analysis of the 5'-flanking/promoter region reveals many features characteristic of mammalian housekeeping genes, i.e. the lack of a TATA box, an absent or nonstandard positioned CAAT box, high GC content, and the presence of Sp1-binding sites. The extraordinarily high GC content of the 5'-flanking region (>80%) helps define this region as a CpG island that may be a principal regulator of beta ARK expression.	THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA	Jefferson University								Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1991, FEBS LETT, V283, P122, DOI 10.1016/0014-5793(91)80568-N; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CAWLEY KC, 1993, J BIOL CHEM, V268, P1194; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MAYOR F, 1987, J BIOL CHEM, V262, P6468; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PALCZEWSKI K, 1992, J BIOL CHEM, V267, P18991; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; Vega Laso Maria R., 1993, Journal of Biological Chemistry, V268, P6453	47	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14924	14930						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195124				2022-12-27	WOS:A1994NP73800015
J	BENNETT, BD; WANG, ZY; KUANG, WJ; WANG, AL; GROOPMAN, JE; GOEDDEL, DV; SCADDEN, DT				BENNETT, BD; WANG, ZY; KUANG, WJ; WANG, AL; GROOPMAN, JE; GOEDDEL, DV; SCADDEN, DT			CLONING AND CHARACTERIZATION OF HTK, A NOVEL TRANSMEMBRANE TYROSINE KINASE OF THE EPH SUBFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CONSERVED FEATURES; RECEPTOR; GENE; FAMILY; IDENTIFICATION; SEQUENCE; MOUSE; PHOSPHORYLATION; CLASSIFICATION	Using a polymerase chain reaction based strategy, we identified a novel transmembrane tyrosine kinase in CD34+ human bone marrow cells and a human hepatocellular carcinoma cell line, Hep3B. This protein, hepatoma transmembrane kinase or Htk, shares amino acid similarity with the EPH subfamily of tyrosine kinases. The HTK gene is located on human chromosome 7. The predicted 987-amino acid sequence of Htk includes a transmembrane region and signal sequence. In the predicted extracellular domain, a cysteine-rich region and tandem fibronectin type III repeats are present while a single uninterrupted catalytic domain is present in the intracellular domain. These features are consistent with other members of the Eph subfamily. Antibodies raised against Htk extracellular domain immunoprecipitated a 120-kDa protein from either in vitro translated HTK or Hep3B cells which localized primarily to the Hep3B membrane subcellular fraction. Purified in vitro translated Htk was enzymatically active and autophosphorylated on tyrosine in kinase assays. Furthermore, antibodies against Htk ECD were agonistic, inducing Htk tyrosine phosphorylation in transfected NIH3T3 cells. Northern blot analysis demonstrated a single HTK transcript abundantly present in placenta and in a range of primary tissues and malignant cell lines. HTK appears to be expressed in fetal but not adult brain and in primitive and myeloid but not lymphoid hematopoietic cells. The novel transmembrane protein, Htk, may function as a receptor with an expression pattern suggesting a role in events mediating differentiation and development.	HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA; GENENTECH INC, San Francisco, CA 94080 USA	Harvard University; Harvard Medical School; Roche Holding; Genentech								BAER M R, 1992, Current Opinion in Oncology, V4, P24, DOI 10.1097/00001622-199202000-00005; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BOHME B, 1993, ONCOGENE, V8, P2857; COOPER JA, 1984, J BIOL CHEM, V259, P7835; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; HUNTER T, 1982, J BIOL CHEM, V257, P4843; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARU Y, 1990, MOL CELL BIOL, V10, P435; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NIETO MA, 1992, DEVELOPMENT, V116, P1137; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; SMITH MW, 1988, J MOL EVOL, V27, P45, DOI 10.1007/BF02099729; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	75	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14211	14218						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188704				2022-12-27	WOS:A1994NL60600074
J	REMMERS, AE; POSNER, R; NEUBIG, RR				REMMERS, AE; POSNER, R; NEUBIG, RR			FLUORESCENT GUANINE-NUCLEOTIDE ANALOGS AND G-PROTEIN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; INTRINSIC FLUORESCENCE; ALPHA-SUBUNIT; CONFORMATIONAL CHANGE; CRYSTAL-STRUCTURE; MOLECULAR SWITCH; HIGH-AFFINITY; RAS PROTEIN; GTP; RECEPTOR	The N-methyl-3'-O-anthranoyl (MANT) guanine nucleotide analogs are useful environmentally sensitive fluorescent probes for studying G protein mechanisms. Both MANT-GTF gamma S (mGTP gamma S) and MANT-GTP (mGTP) displayed a magnesium-dependent increase in fluorescence upon binding to bovine brain G(o). A much greater increase in MANT-guanine nucleotide fluorescence was observed with excitation at 280 nm compared with 350 nm, due to energy transfer from tryptophan in G(o). G(o)- bound mGTP gamma S displays a blue-shift in its emission spectrum indicating a nonpolar environment for the G(o)- bound MANT For the hydrolyzable analog, mGTP, the increase in fluorescence is followed by a decrease as it is hydrolyzed to mGDP. Unexpectedly, dissociation of mGDP was fast (t(1/2) 1.7 s) by comparison with GDP itself (t(1/2) 120 s). Binding of mGTP gamma S to G(o) was slow, but mastoparan increased the rate approximately 4-fold. For mGTP, mastoparan increased both the rate of binding and the peak fluorescence, even at saturating mGTP concentrations. Modeling the mGTP fluorescence kinetics in the presence and absence of mastoparan results in two novel conclusions. First, mGTP does not fully activate the G protein, even when bound. Second, mastoparan appears to increase the rate of the G protein conformational activation step, in addition to its known effect on GDP release.	UNIV MICHIGAN, SCH MED, DEPT PHARMACOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; NO ARIZONA UNIV, DEPT CHEM, FLAGSTAFF, AZ 86011 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Northern Arizona University				Neubig, Richard/0000-0003-0501-0008; Remmers, Ann/0000-0002-2465-7651	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014654] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00042] Funding Source: Medline; NIGMS NIH HHS [GM 39561, GM 14654] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT N, 1985, J BIOL CHEM, V260, P4156; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; ECCLESTON JF, 1991, BIOCHEM SOC T, V19, P432, DOI 10.1042/bst0190432; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; HAZLETT TL, 1990, BIOPHYS J, V57, P289; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HIGASHIJIMA T, 1991, METHOD ENZYMOL, V195, P321; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOLBROOK SR, 1989, P NATL ACAD SCI USA, V86, P1751, DOI 10.1073/pnas.86.6.1751; KATADA T, 1987, FEBS LETT, V213, P353, DOI 10.1016/0014-5793(87)81521-1; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KIM MH, 1987, BIOCHEMISTRY-US, V26, P3664, DOI 10.1021/bi00386a061; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MAZZONI MR, 1993, J PROTEIN CHEM, V12, P215, DOI 10.1007/BF01026043; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLS JS, 1991, BIOPHYS J, V59, P348; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P	38	61	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13771	13778						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188654				2022-12-27	WOS:A1994NL60600012
J	SOMERS, CE; MOSHER, DF				SOMERS, CE; MOSHER, DF			PROTEIN-KINASE-C MODULATION OF FIBRONECTIN MATRIX ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMA FIBRONECTIN; HUMAN-FIBROBLASTS; BINDING; DEGRADATION; DOMAIN; SITES	Fibroblasts have cell surface sites that mediate the assembly of fibronectin (Fn) into the extracellular matrix. Treatment of fibroblasts with kinase inhibitors (ML-7, H7, HA1004, calphostin C, and staurosporine) resulted in the rapid decrease in the binding of I-125-labeled plasma Fn and iodinated amino-terminal fragments of Fn. The dose responses of the four inhibitors suggest that the target kinase is protein kinase C (PKC) rather than the cyclic AMP- or cyclic GMP-dependent kinases. Three different fibroblastic cells were similarly affected. The inhibition was rapid and reversible and could not be overcome by increasing concentrations of Fn. Treatment of fibroblasts with phorbol esters and other agents that activate PKC resulted in increased amounts of I-125-labeled Fn binding to the cell surface. These results imply that Fn matrix assembly is modulated by PKC-mediated phosphorylation.	UNIV WISCONSIN,DEPT BIOMOLEC CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	SOMERS, CE (corresponding author), UNIV WISCONSIN,DEPT MED,MADISON,WI 53706, USA.				NHLBI NIH HHS [HL21644] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; ALLENHOFFMANN BL, 1987, J BIOL CHEM, V262, P14361; ALLENHOFFMANN BL, 1988, MOL CELL BIOL, V8, P4234, DOI 10.1128/MCB.8.10.4234; ASANO T, 1984, J PHARMACOL EXP THER, V231, P141; CHECOVICH WJ, 1992, ARTERIOSCLER THROMB, V12, P1122, DOI 10.1161/01.ATV.12.10.1122; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; FOGERTY FJ, 1990, CELL DIFFER DEV, V32, P439, DOI 10.1016/0922-3371(90)90061-Z; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; ITO M, 1986, BIOCHEMISTRY-US, V25, P4179, DOI 10.1021/bi00363a002; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCKEOWNLONGO PJ, 1984, J CELL BIOL, V98, P22, DOI 10.1083/jcb.98.1.22; MCKEOWNLONGO PJ, 1989, FIBRONECTIN, P163; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; RENNARD SI, 1981, ARCH BIOCHEM BIOPHYS, V206, P205, DOI 10.1016/0003-9861(81)90082-5; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAITOH M, 1986, BIOCHEM BIOPH RES CO, V140, P280, DOI 10.1016/0006-291X(86)91087-9; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; WOODS A, 1992, J CELL SCI, V101, P277; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	28	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22277	22280						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226736				2022-12-27	WOS:A1993MD34800017
J	STAGSTED, J; OLSSON, L; HOLMAN, GD; CUSHMAN, SW; SATOH, S				STAGSTED, J; OLSSON, L; HOLMAN, GD; CUSHMAN, SW; SATOH, S			INHIBITION OF INTERNALIZATION OF GLUCOSE TRANSPORTERS AND IGF-II RECEPTORS - MECHANISM OF ACTION OF MHC CLASS-I-DERIVED PEPTIDES WHICH AUGMENT THE INSULIN-RESPONSE IN RAT ADIPOSE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; HISTOCOMPATIBILITY ANTIGENS; STIMULATED TRANSLOCATION; POTENTIAL MECHANISM; INTRACELLULAR POOL; 3T3-L1 ADIPOCYTES; ASSOCIATION; BINDING; SURFACE; SYSTEMS	Peptides from the alpha1 domain of the major histocompatibility complex class I antigen (MHC class I), e.g. D(k)-(61-85) and D(k)-(62-85), have been shown previously to augment glucose uptake in insulin-stimulated cells and to inhibit insulin receptor internalization (Stagsted, J., Reaven, G. M., Hansen, T., Goldstein, A., and Olsson, L. (1990) Cell 62, 297-307). We now report that these peptides inhibit by 80-100% the internalization of glucose transporters (GLUT4) and insulin-like growth factor II (IGF-II) receptors in insulin-stimulated cells and correspondingly double insulin-stimulated glucose transport activity and the number of GLUT4 and IGF-II receptors on the cell surface. In addition, the peptides enhance the apparent affinity about 3-fold of IGF-II binding to its receptor. It is concluded that the effects of the peptides on glucose transport and IGF-II binding are a consequence of the peptide-mediated inhibition of internalization of GLUT4 and IGF-II receptor. The active peptides are derived from the alpha1 domain of a MHC class I molecule, suggesting that the latter is involved in regulation of internalization of cell surface integral membrane proteins such as the GLUT4 and IGF-II and insulin receptors.	RECEPTRON INC,CONCORD,CA 94520; UNIV BATH,DEPT BIOCHEM,BATH BA2 7AY,AVON,ENGLAND; NIDDKD,DIABET BRANCH,EXPTL DIABET METAB & NUTR SECT,BETHESDA,MD 20892	University of Bath; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Holman, Geoffrey/0000-0001-7045-1358				APPELL KC, 1988, J BIOL CHEM, V263, P10824; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DUE C, 1986, P NATL ACAD SCI USA, V83, P6007, DOI 10.1073/pnas.83.16.6007; EDIDIN M, 1990, MOL IMMUNOL, V27, P1313, DOI 10.1016/0161-5890(90)90036-Y; EDIDIN M, 1988, IMMUNOL TODAY, V9, P218, DOI 10.1016/0167-5699(88)91218-2; FEHLMANN M, 1985, P NATL ACAD SCI USA, V82, P8634, DOI 10.1073/pnas.82.24.8634; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; LIEGLER T, 1991, P NATL ACAD SCI USA, V88, P6755, DOI 10.1073/pnas.88.15.6755; MATTHAEI S, 1991, DIABETES, V40, P850, DOI 10.2337/diabetes.40.7.850; OKA Y, 1984, P NATL ACAD SCI-BIOL, V81, P4028, DOI 10.1073/pnas.81.13.4028; OKA Y, 1988, J BIOL CHEM, V263, P13432; PHILLIPS ML, 1986, P NATL ACAD SCI USA, V83, P3474, DOI 10.1073/pnas.83.10.3474; SATOH S, 1993, J BIOL CHEM, V268, P17820; SCHREIBER AB, 1984, J CELL BIOL, V98, P725, DOI 10.1083/jcb.98.2.725; SHARON M, 1988, J IMMUNOL, V141, P3512; SIMONSEN M, 1983, ANN INST PASTEUR IMM, VD134, P85, DOI 10.1016/S0769-2625(83)80059-2; SIMONSEN M, 1985, PROG ALLERGY, V36, P151; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SOLANO AR, 1988, P NATL ACAD SCI USA, V85, P5087, DOI 10.1073/pnas.85.14.5087; STAGSTED J, 1990, CELL, V62, P297, DOI 10.1016/0092-8674(90)90367-N; STAGSTED J, 1993, J BIOL CHEM, V268, P1770; STAGSTED J, 1993, P NATL ACAD SCI USA, V90, P7686, DOI 10.1073/pnas.90.16.7686; STAGSTED J, 1991, J BIOL CHEM, V266, P12844; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; VERLAND S, 1989, J IMMUNOL, V143, P945; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378; YANG J, 1993, J BIOL CHEM, V268, P4600; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	34	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22809	22813						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226791				2022-12-27	WOS:A1993MD34800091
J	YAN, PF; LI, SL; LIANG, SJ; GIANNINI, S; FUJITAYAMAGUCHI, Y				YAN, PF; LI, SL; LIANG, SJ; GIANNINI, S; FUJITAYAMAGUCHI, Y			THE ROLE OF COOH-TERMINAL AND ACIDIC DOMAINS IN THE ACTIVITY AND STABILITY OF HUMAN INSULIN-RECEPTOR PROTEIN-TYROSINE KINASE STUDIED BY PURIFIED DELETION MUTANTS OF THE BETA-SUBUNIT DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; BACULOVIRUS EXPRESSION SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; BASIC POLYCATIONS; PURIFICATION; AUTOPHOSPHORYLATION; ASSOCIATION; SPECIFICITY; MITOGENESIS	We have previously expressed the human insulin receptor beta subunit domain containing transmembrane and cytoplasmic domains (IRTMTPK) in insect cells, and showed that the purified IRTMTPK was highly active (Li, S. L., Yan, P.-F., Pax, I. B., and Fujita-Yamaguchi, Y. (1992) Biochemistry 31, 12455-12462). To investigate the role of COOH-terminal and acidic domains of the insulin receptor kinase, we have expressed deletion mutants IRTMTPKDELTACT (DELTA76 amino acids) and IRTMTPKDELTAAcid (DELTA19 amino acids). Both enzymes were purified by a one-step method using the same immunoaffinity column as used for IRTMTPK. While K(m) and V(max) for prephosphorylated IRTMTPK and DELTAAcid mutant enzyme determined using poly(Glu, Tyr) (4:1) were similar, catalytic efficiency of the DELTACT mutant enzyme was significantly lower than those of IRTMTPK and DELTAAcid mutant enzyme as judged by K(m) and V(max). Experiments for thermostability and susceptibility to proteases revealed that T(m) of DELTACT mutant enzyme was 3.5-degrees-C lower than that of IRTMTPK enzyme (=33.3-degrees-C) and that DELTACT mutant enzyme was digested by either trypsin or Lys-C into a 28,000 core domain much faster than IRTMTPK. Activation of DELTACT mutant enzyme by polylysine was less significant than that of IRTMTPK and DELTAAcid mutant enzyme, approximately 4-versus approximately 17-fold. These studies suggested that the COOH-terminal domain plays important roles in both catalytic efficiency and stability of the insulin receptor kinase, and that the acidic domain by itself is not responsible for kinase activation by polylysine.	CITY HOPE NATL MED CTR,BECKMAN RES INT,DEPT MOLEC GENET,1450 E DUARTE RD,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NATIONAL CANCER INSTITUTE [P30CA033572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034427] Funding Source: NIH RePORTER; NCI NIH HHS [CA33572] Funding Source: Medline; NIDDK NIH HHS [DK34427] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDO A, 1992, J BIOL CHEM, V267, P12788; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BIENER Y, 1990, EUR J BIOCHEM, V194, P243, DOI 10.1111/j.1432-1033.1990.tb19449.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FUJITAYAMAGUCHI Y, 1989, BIOCHEM J, V263, P813, DOI 10.1042/bj2630813; FUJITAYAMAGUCHI Y, 1983, J BIOL CHEM, V258, P5045; FUJITAYAMAGUCHI Y, 1985, CANCER CELL, V3, P123; FUNG MC, 1988, J VIROL METHODS, V19, P33, DOI 10.1016/0166-0934(88)90005-5; KATHURIA S, 1986, P NATL ACAD SCI USA, V83, P8570, DOI 10.1073/pnas.83.22.8570; KOCK CA, 1991, SCIENCE, V252, P668; KOHANSKI RA, 1989, J BIOL CHEM, V264, P20984; LI SL, 1992, BIOCHEMISTRY-US, V31, P12455, DOI 10.1021/bi00164a023; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MORRISON BD, 1989, J BIOL CHEM, V264, P9994; MYERS MG, 1991, J BIOL CHEM, V266, P10616; ROSEN OM, 1988, FEBS LETT, V231, P397, DOI 10.1016/0014-5793(88)80858-5; SAHAL D, 1988, ARCH BIOCHEM BIOPHYS, V260, P416, DOI 10.1016/0003-9861(88)90465-1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; THIES RS, 1989, J BIOL CHEM, V264, P12820; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; XU ZY, 1991, BIOCHEMISTRY-US, V30, P11811; YAMAMOTO K, 1992, ENDOCRINOLOGY, V130, P1490, DOI 10.1210/en.130.3.1490; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; ZICK Y, 1983, J BIOL CHEM, V258, P3431	27	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22444	22449						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226752				2022-12-27	WOS:A1993MD34800041
J	DEMPSEY, PJ; COFFEY, RJ				DEMPSEY, PJ; COFFEY, RJ			BASOLATERAL TARGETING AND EFFICIENT CONSUMPTION OF TRANSFORMING GROWTH FACTOR-ALPHA WHEN EXPRESSED IN MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; TGF-ALPHA; CYTOPLASMIC DOMAIN; TRANSGENIC MICE; IMMUNOCYTOCHEMICAL LOCALIZATION; MEMBRANE-PROTEINS; KINASE-ACTIVITY; SORTING SIGNAL; MAMMARY-GLAND	To investigate the trafficking of transforming growth factor-alpha precursor (pro-TGF-alpha) in polarized epithelial cells, wild type and membrane-fixed human pro-TGF-alpha were introduced into Madin-Darby canine kidney (MDCK) cells. We show that wild type pro-TGF-alpha was synthesized and processed normally to release mature 5.6-KDa TGF-alpha into the basal medium while membrane-fixed pro-TGF-alpha remained cell-associated. Antibody (mAb-528) receptor blockade experiments demonstrated the efficient consumption of basally released TGF-alpha by basolateral epidermal growth factor receptors, indicating that TGF-alpha can act in an autocrine manner in these polarized epithelial cells. Biochemical analysis showed pro-TGF-alpha was expressed on the basolateral surface as either a 17- or 30-kDa species; the 17-kDa forms of both pro-TGF-alpha constructs had basolateral/apical ratios of >20:1. By confocal microscopy, membrane-fixed pro-TGF-alpha was immunolocalized to lateral membrane surfaces. In pulse-chase experiments combined with cell surface immunoprecipitation, we demonstrated that newly synthesized wild type and membrane-fixed pro-TGF-alpha are delivered directly to the basolateral surface with 94 and 96% efficiency, respectively. These results also provide direct evidence for sequential cleavage of pro-TGF-alpha at the basolateral membrane surface. Thus, pro-TGF-alpha is sorted intracellularly and vectorially targeted to the basolateral membrane domain in these polarized epithelial cells. The MDCK cell line provides an ideal in vitro model to examine the molecular basis for trafficking of pro-TGF-alpha and other epidermal growth factor-like growth factors in polarized epithelial cells and their potential interactions with basolateral epidermal growth factor receptors.	VANDERBILT UNIV,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232	Vanderbilt University	DEMPSEY, PJ (corresponding author), VANDERBILT UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,C-2104 MED CTR N,NASHVILLE,TN 37232, USA.				NCI NIH HHS [CA46413, CA09592-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009592, R01CA046413] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; Bosenberg MW, 1993, CURR OPIN CELL BIOL, V5, P832, DOI 10.1016/0955-0674(93)90032-L; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRANDLI AW, 1991, J BIOL CHEM, V266, P8560; BREWER CB, 1991, J CELL BIOL, V114, P314; BURWEN SJ, 1984, J CELL BIOL, V99, P1259, DOI 10.1083/jcb.99.4.1259; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; COFFEY RJ, 1992, CELL GROWTH DIFFER, V3, P347; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DUNN WA, 1984, J CELL BIOL, V98, P2148, DOI 10.1083/jcb.98.6.2148; FULLER SD, 1986, J CELL BIOL, V103, P1767, DOI 10.1083/jcb.103.5.1767; GILL GN, 1984, J BIOL CHEM, V259, P7755; GOTTARDI CJ, 1993, SCIENCE, V260, P552, DOI 10.1126/science.8386395; GRAEVE L, 1989, J CELL BIOL, V109, P2809, DOI 10.1083/jcb.109.6.2809; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALTER SA, 1992, AM J PATHOL, V140, P1131; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; JU WD, 1991, NEW BIOL, V3, P380; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MARATOSFLIER E, 1987, J CELL BIOL, V105, P1595, DOI 10.1083/jcb.105.4.1595; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MASUI H, 1993, J CELL BIOL, V120, P85, DOI 10.1083/jcb.120.1.85; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MULLIN JM, 1988, CANCER RES, V48, P4886; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; OJAKIAN GK, 1988, J CELL BIOL, V107, P2377, DOI 10.1083/jcb.107.6.2377; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SALIDO EC, 1986, J ULTRA MOL STRUCT R, V96, P105, DOI 10.1016/0889-1605(86)90011-X; SALIDO EC, 1986, J HISTOCHEM CYTOCHEM, V34, P1155, DOI 10.1177/34.9.2426343; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHEVING LA, 1989, J BIOL CHEM, V264, P1735; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SIEMERS KA, 1993, SCIENCE, V260, P554, DOI 10.1126/science.260.5107.554; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; STHILAIRE RJ, 1983, P NATL ACAD SCI-BIOL, V80, P3797; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; VAUGHAN TJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P322, DOI 10.1016/0167-4781(92)90170-5; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WOLNER DA, 1992, J CELL BIOL, V116, P889; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZURZOLO C, 1993, SCIENCE, V260, P550, DOI 10.1126/science.8386394	64	84	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16878	16889						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207010				2022-12-27	WOS:A1994NR29600056
J	FREIJE, JMP; DIEZITZA, I; BALBIN, M; SANCHEZ, LM; BLASCO, R; TOLIVIA, J; LOPEZOTIN, C				FREIJE, JMP; DIEZITZA, I; BALBIN, M; SANCHEZ, LM; BLASCO, R; TOLIVIA, J; LOPEZOTIN, C			MOLECULAR-CLONING AND EXPRESSION OF COLLAGENASE-3, A NOVEL HUMAN MATRIX METALLOPROTEINASE PRODUCED BY BREAST CARCINOMAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL COLLAGENASE; HUMAN FIBROBLAST COLLAGENASE; RAT OSTEOBLASTIC CELLS; SUBSTRATE-SPECIFICITY; SYNOVIAL FIBROBLASTS; SEQUENCE-ANALYSIS; CYSTEINE SWITCH; GENE FAMILY; PROTEIN; STROMELYSIN-3	A cDNA coding for a new human matrix metalloproteinase (MMP) has been cloned from a cDNA library derived from a breast tumor. The isolated cDNA contains an open reading frame coding for a polypeptide of 471 amino acids. The predicted protein sequence displays extensive similarity to the previously known MMPs and presents all the structural features characteristic of the members of this protein family, including the well conserved PRCGXPD motif, involved in the latency of the enzyme and the zinc-binding domain (HEXGHXXXXXHS). In addition, this novel human MMP contains in its amino acid sequence several residues specific to the collagenase subfamily (Tyr-214, Asp-235, and Gly-237) and lacks the 9-residue insertion present in the stromelysins. According to these structural characteristics, the MMP described herein has been tentatively called collagenase-3, since it represents the third member of this subfamily, composed at present of fibroblast and neutrophil collagenases. The collagenase-3 cDNA was expressed in a vaccinia virus system, and the recombinant protein was able to degrade fibrillar collagens, providing support to the hypothesis that the isolated cDNA codes for an authentic collagenase. Northern blot analysis of RNA from normal and pathological tissues demonstrated the existence in breast tumors of three different mRNA species, which seem to be the result of the utilization of different polyadenylation sites present in the 3'-noncoding region of the gene. By contrast, no collagenase-3 mRNA was detected either by Northern blot or RNA polymerase chain reaction analysis with RNA from other human tissues, including normal breast, mammary fibroadenomas, liver, placenta, ovary, uterus, prostate, and parotid gland. On the basis of the increased expression of collagenase-3 in breast carcinomas and the absence of detectable expression in normal tissues, a possible role for this metalloproteinase in the tumoral process is proposed.	UNIV OVIEDO,DEPT BIOL FUNC,E-33006 OVIEDO,SPAIN; UNIV OVIEDO,DEPT MORFOL & BIOL CELULAR,E-33006 OVIEDO,SPAIN; INIA MAPA,CTR INVEST SANIDAD ANIM,E-28130 MADRID,SPAIN	University of Oviedo; University of Oviedo			Tolivia, Jorge/A-6950-2008; Freije, José M.P./A-6535-2008; Blasco, Rafael/B-5829-2016; Diez-Itza, Irene/AAA-6858-2019; López-Otín, Carlos/AAB-2106-2020; Balbín, Milagros/I-4206-2015; Tolivia, Jorge/D-2248-2010	Freije, José M.P./0000-0002-4688-8266; López-Otín, Carlos/0000-0001-6964-1904; Balbín, Milagros/0000-0001-5325-0407; Tolivia, Jorge/0000-0001-8984-8849; Blasco, Rafael/0000-0002-8819-5767; DIEZ ITZA, IRENE/0000-0002-8077-6655				ABRAHAMSON M, 1990, BIOCHEM J, V268, P287, DOI 10.1042/bj2680287; BASSET P, 1993, BREAST CANCER RES TR, V24, P185, DOI 10.1007/BF01833259; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BLASCO R, 1991, J VIROL, V65, P5910, DOI 10.1128/JVI.65.11.5910-5920.1991; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOHISY JC, 1992, MOL ENDOCRINOL, V6, P1834, DOI 10.1210/me.6.11.1834; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIEZITZA I, 1993, BRIT J CANCER, V68, P637, DOI 10.1038/bjc.1993.399; FESSLER LI, 1984, J BIOL CHEM, V259, P9783; FREIJE JP, 1991, J BIOL CHEM, V266, P20538; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HASTY KA, 1987, J BIOL CHEM, V262, P10048; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HENRIET P, 1992, FEBS LETT, V310, P175, DOI 10.1016/0014-5793(92)81323-E; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KLEINE T, 1993, BIOCHEMISTRY-US, V32, P14125, DOI 10.1021/bi00214a008; LEVY A, 1992, GENOMICS, V13, P881, DOI 10.1016/0888-7543(92)90175-R; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Maniatis T., 1982, MOL CLONING; MASUI Y, 1977, BIOCHEM MED METAB B, V17, P215, DOI 10.1016/0006-2944(77)90026-6; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1993, J BIOL CHEM, V268, P15435; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; MURPHY GJP, 1991, FEBS LETT, V289, P4, DOI 10.1016/0014-5793(91)80895-A; NAGASE H, 1991, BIOCHEM SOC T, V19, P715, DOI 10.1042/bst0190715; OKADA Y, 1986, J BIOL CHEM, V261, P14245; QIAN F, 1989, CANCER RES, V49, P4870; QIAN F, 1991, ANTICANCER RES, V11, P1445; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; QUINN CO, 1990, J BIOL CHEM, V265, P22342; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SANCHEZ LM, 1992, J BIOL CHEM, V267, P24725; SANCHEZ LM, 1992, CANCER RES, V52, P95; SANCHEZ LM, 1993, BRIT J CANCER, V67, P1076, DOI 10.1038/bjc.1993.197; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT DK, 1992, MOL ENDOCRINOL, V6, P2153, DOI 10.1210/me.6.12.2153; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; Sloane B F, 1990, Semin Cancer Biol, V1, P137; SNCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; TOLIVIA J, 1985, J NEUROSCI METH, V13, P305, DOI 10.1016/0165-0270(85)90078-0; URIA JA, 1994, CANCER RES, V54, P2091; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	59	664	707	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16766	16773						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207000				2022-12-27	WOS:A1994NR29600041
J	BENDER, CJ; ROSENZWEIG, AC; LIPPARD, SJ; PEISACH, J				BENDER, CJ; ROSENZWEIG, AC; LIPPARD, SJ; PEISACH, J			NUCLEAR HYPERFINE COUPLING OF NITROGEN IN THE COORDINATION SPHERE OF THE DIIRON CENTER OF METHANE MONOOXYGENASE HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-ECHO; METHYLOCOCCUS-CAPSULATUS-BATH; METHYLOSINUS-TRICHOSPORIUM OB3B; IRON-SULFUR PROTEINS; PARAMAGNETIC RESONANCE; MONO-OXYGENASE; HEME COMPOUNDS; COMPONENT; MODULATION; COMPLEXES	Electron spin echo envelope modulation spectroscopy identified two ligand N-14 interactions with the mixed-valence, Fe(II/III) diiron center of methane monooxygenase hydroxylase from Methylococcus capsulatus (Bath). Characteristic features of the spectra obtained at 9 and 10 GHz were analyzed and fit by simulation. One of the nitrogens possessed superhyperfine parameters (A(iso) = 0.8 MHz, r(eff) = 3.2 Angstrom, e(2)Qq = 1.8 MHz, eta = 0.35) consistent with a non-coordinating amino nitrogen of a histidine imidazole ligand to a Fe(III). The second, more strongly interacting nitrogen (A(iso) = 5.0 MHz, r(eff) = 2.2 Angstrom e(2)Qq = 3.0 MHz, eta = 0.3) corresponds to the N-delta directly bound to the effective Fe(II). These findings extend the previous electron nuclear double resonance results on the Methylosinus trichosporium hydroxylase (Hendrich, M. P., Fox, B. G., Andersson, K. K,, Debrunner, P. G., and Lipscomb, J. D. (1992) J. Biol. Chem. 267, 261-269), which identified the N-delta-Fe(II) interaction but failed to quantify its magnitude. Measurement of the linear electric field g shift of this mixed-valence species indicated that the site is charge-polarized on to one of the iron atoms, and its symmetry suggests that either charge is shifted away from the Fe-Fe axis (if g(max) is defined by the Fe-Fe axis) or that g(mid) and g(max) are perpendicular to the Fe-Fe axis (charge strongly localized at Fe(III) and axis taken as g(min)).	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	BENDER, CJ (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.				NCRR NIH HHS [RR-02583] Funding Source: Medline; NIGMS NIH HHS [GM-40168, GM-32134] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032134, R01GM032134, R01GM040168, R37GM040168] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTANAITIS BC, 1985, J BIOL CHEM, V260, P4572; ANTHONY C, 1982, BIOCH METHYLOTROPHS, P296; ASHBY CIH, 1978, J AM CHEM SOC, V100, P6057, DOI 10.1021/ja00487a014; BLUMBERG WE, 1974, ARCH BIOCHEM BIOPHYS, V162, P502, DOI 10.1016/0003-9861(74)90210-0; CAMMACK R, 1988, BIOCHIM BIOPHYS ACTA, V956, P307, DOI 10.1016/0167-4838(88)90148-3; COLBY J, 1978, BIOCHEM J, V171, P461, DOI 10.1042/bj1710461; COLBY J, 1977, BIOCHEM J, V165, P395, DOI 10.1042/bj1650395; CORNELIUS JB, 1990, J PHYS CHEM-US, V94, P6977, DOI 10.1021/j100381a013; DEROSE VJ, 1993, J AM CHEM SOC, V115, P6440, DOI 10.1021/ja00067a081; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; ERICSON A, 1988, J AM CHEM SOC, V110, P2330, DOI 10.1021/ja00215a070; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; FOX BG, 1989, J BIOL CHEM, V264, P10023; FOX BG, 1993, J AM CHEM SOC, V115, P3688, DOI 10.1021/ja00062a039; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V30, P1892; HENDRICH MP, 1992, J BIOL CHEM, V267, P261; KOSMAN DJ, 1980, BIOCHEMISTRY-US, V19, P1304, DOI 10.1021/bi00548a007; LOBRUTTO R, 1987, ADV MEMBRANE BIOCH B, P449; MAGLIOZZO RS, 1993, BIOCHEMISTRY-US, V32, P8446, DOI 10.1021/bi00084a009; MCCRACKEN J, 1987, J AM CHEM SOC, V109, P4064, DOI 10.1021/ja00247a037; MIMS WB, 1984, J MAGN RESON, V59, P291, DOI 10.1016/0022-2364(84)90174-4; MIMS WB, 1974, REV SCI INSTRUM, V45, P1583, DOI 10.1063/1.1686567; MIMS WB, 1972, PHYS REV B-SOLID ST, V5, P2409, DOI 10.1103/PhysRevB.5.2409; MIMS WB, 1976, J CHEM PHYS, V64, P1074, DOI 10.1063/1.432294; MIMS WB, 1974, BIOCHEMISTRY-US, V13, P3346, DOI 10.1021/bi00713a026; MIMS WB, 1978, J CHEM PHYS, V69, P4921, DOI 10.1063/1.436479; MIMS WB, 1976, LINEAR ELECTRIC FIEL; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; Ortiz de Montellano P.R., 2015, CYTOCHROME P450 STRU, P912; PEISACH J, 1977, J BIOL CHEM, V252, P5643; PEISACH J, 1979, J BIOL CHEM, V254, P2379; RIST GH, 1970, J CHEM PHYS, V52, P4633, DOI 10.1063/1.1673696; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; STENKAMP RE, 1984, J AM CHEM SOC, V106, P618, DOI 10.1021/ja00315a027; THOMANN H, 1993, J AM CHEM SOC, V115, P8881, DOI 10.1021/ja00072a068; WILKINS RG, 1992, CHEM SOC REV, V21, P171, DOI 10.1039/cs9922100171; WOODLAND MP, 1986, BIOCHIM BIOPHYS ACTA, V873, P237, DOI 10.1016/0167-4838(86)90050-6; WOODLAND MP, 1984, J BIOL CHEM, V259, P53	39	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15993	15998						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206895				2022-12-27	WOS:A1994NQ72900010
J	KNOLL, LJ; JOHNSON, DR; GORDON, JI				KNOLL, LJ; JOHNSON, DR; GORDON, JI			BIOCHEMICAL-STUDIES OF 3 SACCHAROMYCES-CEREVISIAE ACYL-COA SYNTHETASES, FAA1P, FAA2P, AND FAA3P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN N-MYRISTOYLTRANSFERASE; MYRISTIC ACID AUXOTROPHY; X-LINKED ADRENOLEUKODYSTROPHY; IMMUNODEFICIENCY VIRUS-I; ADP-RIBOSYLATION FACTOR; EXOGENOUS FATTY-ACIDS; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; ANTIBIOTIC CERULENIN; LIGASE DEFICIENCY	The efficiency and specificity of protein N-myristoylation appear to be influenced by the availability of myristoyl CoA and other potential acyl-CoA substrates of myristoyl-CoA:protein N-myristoyltransferase. Recent studies have revealed that Saccharomyces cerevisiae contains at least three acyl-CoA synthetase genes (FAA for fatty acid activation). We have expressed Faa1p, Faa2p, and Faa3p in a strain of Escherichia coli that lacks its own endogenous acyl-CoA synthetase (FadD). Each S. cerevisiae acyl CoA synthetase contained a carboxyl-terminal His tag so that it could be purified to homogeneity in a single step using nickel chelate affinity chromatography. In vitro assays of C3:0-C24:0 fatty acids indicate that Faa1p prefers C12:0-C16:0, with myristic and pentadecanoic acid (C15:0) having the highest activities. Faa2p can accommodate a wider range of acyl chain lengths: C9:0-C13:0 are preferred and have equivalent activities, although C7:0-C17:0 fatty acids are tolerated as substrates with no greater than a a-fold variation in specific activity. The myristoyl-CoA synthetase activities of Faa1p and Faa2p are 2 orders of magnitude greater than that of Faa3p in vitro. Faa3p has a preference for C-16 and C-18 fatty acids with a cis double bond at C-9-C-10. The temperature optimum for Faa1p is 30 degrees C, while Faa2p and Faa3p have the greatest activities at 25 degrees C. These in vitro observations were confirmed using two in vivo assays: (i) measurement of the ability of each S. cerevisiae acyl-CoA synthetase to direct the incorporation of exogenously derived tritiated myristate, palmitate, or oleate into cellular phospholipids produced in a fadD(-) strain off. coli during exponential growth at 24 or 37 degrees C and (ii) measurement of the incorporation of [H-3]myristate into a yeast N-myristoylprotein coexpressed with Nmt1p and Faa1p, Faa2p, or Faa3p in the fadD(-) strain.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NIAID NIH HHS [AI30188, AI27179] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179, U01AI030188] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AWAYA J, 1975, BIOCHIM BIOPHYS ACTA, V409, P267, DOI 10.1016/0005-2760(75)90022-3; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BARTANA J, 1973, BIOCHEM J, V135, P411, DOI 10.1042/bj1350411; BARTANA J, 1973, BIOCHEM J, V131, P199, DOI 10.1042/bj1310199; BHATNAGAR RS, 1994, J BIOL CHEM, V269, P11045; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; DEVADAS B, 1992, J BIOL CHEM, V267, P7224; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; DURONIO RJ, 1991, J CELL BIOL, V113, P1313, DOI 10.1083/jcb.113.6.1313; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; FUNABASHI H, 1989, J BIOCHEM-TOKYO, V105, P751, DOI 10.1093/oxfordjournals.jbchem.a122739; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; HASHMI M, 1986, FEBS LETT, V196, P247, DOI 10.1016/0014-5793(86)80256-3; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; HORI T, 1987, J BIOCHEM-TOKYO, V101, P949, DOI 10.1093/oxfordjournals.jbchem.a121964; HOSAKA K, 1981, J BIOCHEM, V89, P1799, DOI 10.1093/oxfordjournals.jbchem.a133380; HUNTER K, 1972, BIOCHIM BIOPHYS ACTA, V260, P639, DOI 10.1016/0005-2760(72)90013-6; ICHIHARA K, 1991, J LIPID RES, V32, P1709; JOHNSON DR, 1993, J BIOL CHEM, V268, P483; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KISHORE NS, 1993, J BIOL CHEM, V268, P4889; KNOLL LJ, 1993, J BIOL CHEM, V268, P4281; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KUMAR GB, 1993, J BIOL CHEM, V268, P15469; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGNER CA, 1992, J BIOL CHEM, V267, P17159; LAZO O, 1989, ARCH BIOCHEM BIOPHYS, V270, P722, DOI 10.1016/0003-9861(89)90555-9; LAZO O, 1988, P NATL ACAD SCI USA, V85, P7647, DOI 10.1073/pnas.85.20.7647; LODGE JK, 1994, J BIOL CHEM, V269, P2996; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU TB, 1994, J BIOL CHEM, V269, P5346; MCCAMMON MT, 1990, J BACTERIOL, V172, P5816, DOI 10.1128/jb.172.10.5816-5827.1990; MCDONOUGH VM, 1992, J BIOL CHEM, V267, P5931; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MORIKAWA M, 1978, EUR J BIOCHEM, V84, P61, DOI 10.1111/j.1432-1033.1978.tb12141.x; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; NUNN WD, 1986, J BIOL CHEM, V261, P167; OKUYAMA H, 1979, J BIOL CHEM, V254, P2281; PIETZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436; RANGWALA SH, 1991, BIO-TECHNOL, V9, P477, DOI 10.1038/nbt0591-477; ROCK CO, 1985, J BIOL CHEM, V260, P2720; RUDNICK DA, 1993, ADV ENZYMOL RAMB, V67, P375; RUDNICK DA, 1993, P NATL ACAD SCI USA, V90, P1087, DOI 10.1073/pnas.90.3.1087; RUDNICK DA, 1992, P NATL ACAD SCI USA, V89, P10507, DOI 10.1073/pnas.89.21.10507; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; RUDNICK DA, 1992, LIPID MODIFICATION P, P36; SCHLOSSMAN DM, 1978, J BACTERIOL, V133, P1368, DOI 10.1128/JB.133.3.1368-1376.1978; SIMONS RW, 1980, J BACTERIOL, V142, P621, DOI 10.1128/JB.142.2.621-632.1980; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WANDERS RJA, 1988, BIOCHEM BIOPH RES CO, V153, P618, DOI 10.1016/S0006-291X(88)81140-9; WIEGAND RC, 1992, J BIOL CHEM, V267, P8591	71	97	116	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16348	16356						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206942				2022-12-27	WOS:A1994NQ72900061
J	TSINOREMAS, NF; SCHAEFER, MR; GOLDEN, SS				TSINOREMAS, NF; SCHAEFER, MR; GOLDEN, SS			BLUE AND RED-LIGHT REVERSIBLY CONTROL PSBA EXPRESSION IN THE CYANOBACTERIUM SYNECHOCOCCUS SP STRAIN PCC-7942	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; PHOTOSYSTEM-II; GENE-EXPRESSION; HARVESTING COMPLEX; SP STRAIN-PCC-7942; HIGHER-PLANTS; TRANSCRIPTS; FAMILY; INTENSITY; PHYCOERYTHRIN	The three psbA genes encoding the photosystem II D1 protein in Synechococcus sp. strain PCC 7942 respond differentially to an increase in intensity of white light through transcriptional induction of psbAII and psbAIII and accelerated degradation of psbAI and psbAIII messages. We report that the genes exhibit a novel photoreversible response involving blue and red light that is almost indistinguishable from the high-white light response. Transfer of cells from white to low-fluence blue light caused a decrease in the level of the psbAI message and increased levels of psbAII and psbAIII messages, whereas transfer to red or far-red light had little effect. Five min of blue light was sufficient to trigger psbAII and psbAIII induction; five min of subsequent red irradiation attenuated this response, whereas subsequent green or far-red light (or darkness) had no effect. Response to both high and blue light was insensitive to inhibitors of photosynthetic electron transport. We propose that Synechococcus modulates photosystem II biosynthesis in a variable light environment through a photoreception signal pathway, which is independent of photosystem II activity and which is distinct from red/ green-reversible control of chromatically adapting cyanobacteria and the red/far-red-reversible phytochrome of plants.	TEXAS A&M UNIV, DEPT BIOL, COLLEGE STN, TX 77843 USA	Texas A&M University System; Texas A&M University College Station					NIGMS NIH HHS [R01 GM37040] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037040] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; ANDERSON SL, 1991, J BACTERIOL, V173, P2761, DOI 10.1128/JB.173.9.2761-2767.1991; Andersson B., 1991, CURRENT TOPICS BIOEN, V16, P1; AUSUBEL FM, 1987, CURR PROTOCOLS MOL B; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BLATT MR, 1983, PLANTA, V159, P267, DOI 10.1007/BF00397535; BRUSSLAN J, 1989, EMBO J, V8, P1237, DOI 10.1002/j.1460-2075.1989.tb03497.x; BRYANT DA, 1986, CAN B FISH AQUAT SCI, V214, P423; BUSTOS SA, 1991, J BACTERIOL, V173, P7525, DOI 10.1128/jb.173.23.7525-7533.1991; BUSTOS SA, 1990, J BACTERIOL, V172, P1998, DOI 10.1128/jb.172.4.1998-2004.1990; BUSTOS SA, 1992, MOL GEN GENET, V232, P221, DOI 10.1007/BF00280000; CAMPBELL D, 1993, PLANT CELL, V5, P451, DOI 10.2307/3869725; CLARKE AK, 1993, P NATL ACAD SCI USA, V90, P9973, DOI 10.1073/pnas.90.21.9973; CONLEY PB, 1985, SCIENCE, V230, P550, DOI 10.1126/science.3931221; CORROCHANO LM, 1988, PLANTA, V174, P315, DOI 10.1007/BF00959516; DEMARSAC NT, 1993, FEMS MICROBIOL LETT, V104, P119; DEMARSAC NT, 1988, METHOD ENZYMOL, V167, P318; FLUHR R, 1986, EMBO J, V5, P2063, DOI 10.1002/j.1460-2075.1986.tb04467.x; FLUHR R, 1986, P NATL ACAD SCI USA, V83, P2358, DOI 10.1073/pnas.83.8.2358; GALLAND P, 1987, P NATL ACAD SCI USA, V84, P104, DOI 10.1073/pnas.84.1.104; GAMBLE PE, 1989, EMBO J, V8, P2785, DOI 10.1002/j.1460-2075.1989.tb08424.x; GILMARTIN PM, 1992, PLANT CELL, V4, P839, DOI 10.1105/tpc.4.7.839; GOLDEN SS, 1986, EMBO J, V5, P2789, DOI 10.1002/j.1460-2075.1986.tb04569.x; GOLDEN SS, 1994, IN PRESS MOL BIOL CY; GROSSMAN AR, 1993, J BACTERIOL, V175, P575, DOI 10.1128/JB.175.3.575-582.1993; HARDING RW, 1981, PLANT PHYSIOL, V68, P745, DOI 10.1104/pp.68.3.745; HARRISON MA, 1991, FEBS LETT, V282, P295, DOI 10.1016/0014-5793(91)80499-S; JONES LW, 1965, J PHYCOL, V1, P7, DOI 10.1111/j.1529-8817.1965.tb04548.x; KALLA SR, 1988, J BACTERIOL, V170, P2961, DOI 10.1128/jb.170.7.2961-2970.1988; KAUFMAN LS, 1993, PLANT PHYSIOL, V102, P333, DOI 10.1104/pp.102.2.333; KUHLEMEIER C, 1987, ANNU REV PLANT PHYS, V38, P221; KULKARNI RD, 1994, J BACTERIOL, V176, P959, DOI 10.1128/JB.176.4.959-965.1994; KULKARNI RD, 1992, J BACTERIOL, V174, P3775, DOI 10.1128/JB.174.11.3775-3781.1992; LI RX, 1993, P NATL ACAD SCI USA, V90, P11678, DOI 10.1073/pnas.90.24.11678; LOMAX TL, 1987, J BACTERIOL, V169, P2675, DOI 10.1128/jb.169.6.2675-2684.1987; LOPEZDIAZ I, 1980, PLANTA, V150, P134, DOI 10.1007/BF00582356; MAZEL D, 1986, NUCLEIC ACIDS RES, V14, P8279, DOI 10.1093/nar/14.21.8279; MUELLER UW, 1991, IDENTIFICATION PROTE; MULLINEAUX CW, 1990, PHOTOSYNTH RES, V23, P297, DOI 10.1007/BF00034860; OELMULLER R, 1988, PLANT PHYSIOL, V88, P1084, DOI 10.1104/pp.88.4.1084; PERISIC O, 1992, PLANT CELL, V4, P831, DOI 10.1105/tpc.4.7.831; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; SCHAEFER MR, 1989, J BACTERIOL, V171, P3973, DOI 10.1128/jb.171.7.3973-3981.1989; SCHAEFER MR, 1990, CURRENT RES PHOTOSYN, P863; Senger H., 1987, BLUE LIGHT RESPONSES; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SMART LB, 1991, EMBO J, V10, P3289, DOI 10.1002/j.1460-2075.1991.tb04893.x; THOMPSON WF, 1991, ANNU REV PLANT PHYS, V42, P423, DOI 10.1146/annurev.pp.42.060191.002231; TOBIN EM, 1985, ANNU REV PLANT PHYS, V36, P569, DOI 10.1146/annurev.pp.36.060185.003033	49	61	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16143	16147						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206914				2022-12-27	WOS:A1994NQ72900031
J	CAYLA, X; VANHOOF, C; BOSCH, M; WAELKENS, E; VANDEKERCKHOVE, J; PEETERS, B; MERLEVEDE, W; GORIS, J				CAYLA, X; VANHOOF, C; BOSCH, M; WAELKENS, E; VANDEKERCKHOVE, J; PEETERS, B; MERLEVEDE, W; GORIS, J			MOLECULAR CLOTTING, EXPRESSION, AND CHARACTERIZATION OF PTPA, A PROTEIN THAT ACTIVATES THE TYROSYL PHOSPHATASE-ACTIVITY OF PROTEIN PHOSPHATASE 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; SERINE THREONINE PHOSPHATASES; RABBIT SKELETAL-MUSCLE; PHOSPHOTYROSYL-PROTEIN; REGULATORY SUBUNIT; OKADAIC ACID; ATP-BINDING; T-ANTIGEN; SEQUENCE; IDENTIFICATION	PTPA, or phosphotyrosyl phosphatase activator, is a protein that stimulates the tyrosyl phosphatase activity of protein phosphatase 2A in an ATP, Mg2+-requiring reaction (Cayla, X., Goris, J., Hermann, J., Hendrix, P., Ozon, R., and Merlevede, W (1990) Biochemistry 29, 658-667). We constructed oligonucleotide probes based on the amino acid sequences of peptides isolated from purified PTPA and used them to probe rabbit muscle and human heart cDNA libraries. A putative full-length clone was isolated from the rabbit skeletal muscle as well as from the human heart library. The nucleotide sequence of both clones contains an open reading frame of 969 nucleotides starting from an assigned initial ATG codon and encodes for a protein of 323 amino acids. The predicted rabbit and human PTPA protein sequences show an identity of 96.6%. The predicted protein matched all the peptide sequences obtained from the rabbit skeletal muscle protein. Bacterially expressed protein, as well as the in vitro reticulocyte lysate translation product, comigrated with the purified 37-kDa protein on sodium dodecyl sulfate-polyacrylamide gels. Both proteins reacted with immunopurified, anti-PTPA polyclonal antiserum. The recombinant protein was a soluble and active protein. Northern blot analysis revealed two transcripts of 2.8 and 4 kilobases, respectively, in human placenta but only one 2.8-kilobase transcript in rabbit and rat tissues. High levels of PTPA mRNA were detected in testis, which contrasted with the low levels present in skeletal muscle.	KATHOLIEKE UNIV LEUVEN,FAC GENEESKUNDE,AFDELING BIOCHEM,B-3000 LOUVAIN,BELGIUM; STATE UNIV GHENT,FYSIOL SCHEIKUNDE LAB,B-9000 GHENT,BELGIUM; UNIV PARIS 06,REPROD PHYSIOL LAB,F-75005 PARIS,FRANCE	KU Leuven; Ghent University; UDICE-French Research Universities; Sorbonne Universite								ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; ALEXANDER D, 1989, EUR J BIOCHEM, V181, P55, DOI 10.1111/j.1432-1033.1989.tb14693.x; BRAUTIGAN DL, 1993, ADV PROT PHOSPHATASE, V7, P49; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; CAYLA X, 1993, EUR J BIOCHEM, V214, P281, DOI 10.1111/j.1432-1033.1993.tb17922.x; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHERNOFF J, 1983, J BIOL CHEM, V258, P7852; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOULKES JG, 1983, J BIOL CHEM, V258, P431; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; GORIS J, 1988, BIOCHEM J, V256, P1029, DOI 10.1042/bj2561029; GUAN KL, 1991, J BIOL CHEM, V266, P17026; GUO H, 1992, P NATL ACAD SCI USA, V30, P2500; HACCARD O, 1990, EUR J BIOCHEM, V192, P633, DOI 10.1111/j.1432-1033.1990.tb19270.x; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HENDRIX P, 1993, J BIOL CHEM, V268, P7339; HENDRIX P, 1989, ADV PROTEIN PHOSPHAT, V5, P593; HERMANN J, 1988, EUR J BIOCHEM, V173, P17, DOI 10.1111/j.1432-1033.1988.tb13961.x; JAKES S, 1986, BIOCHIM BIOPHYS ACTA, V888, P135, DOI 10.1016/0167-4889(86)90079-0; JESSUS C, 1989, EUR J BIOCHEM, V180, P15, DOI 10.1111/j.1432-1033.1989.tb14609.x; JESSUS C, 1989, BIOCHEM J, V260, P45, DOI 10.1042/bj2600045; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LI HC, 1982, CURR TOP CELL REGUL, V21, P129; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611	43	76	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15668	15675						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195217				2022-12-27	WOS:A1994NP51300045
J	WANG, W; HENDRIKS, DF; SCHARPE, SS				WANG, W; HENDRIKS, DF; SCHARPE, SS			CARBOXYPEPTIDASE-U, A PLASMA CARBOXYPEPTIDASE WITH HIGH-AFFINITY FOR PLASMINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM; CATALYZED HYDROLYSIS; TERMINAL LYSINE; CREATINE-KINASE; BINDING-SITES; FIBRIN; ACTIVATOR; ANAPHYLATOXIN; PURIFICATION; MECHANISM	A novel basic carboxypeptidase clearly different from carboxypeptidase N has been isolated from human plasma. It circulates as an enzymatically inactive precursor enzyme bound to plasminogen. During fibrinolysis, it can be converted to its active form, carboxypeptidase U, through the action of plasmin. The active enzyme has an apparent molecular weight of 53,000 as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. It hydrolyzes the synthetic peptides hippuryl-L-arsnine and hippuryl-L-lysine but, in contrast to other human basic carboxypeptidases, has only a limited esterase activity. After its activation, carboxypeptidase U tends to be very unstable.	UNIV INSTELLING ANTWERP,DEPT MED BIOCHEM,B-2610 WILRIJK,BELGIUM	University of Antwerp			Hendriks, Dirk/E-3797-2017					AVILES FX, 1993, EUR J BIOCHEM, V211, P381, DOI 10.1111/j.1432-1033.1993.tb17561.x; BELEW M, 1980, BIOCHIM BIOPHYS ACTA, V621, P169, DOI 10.1016/0005-2795(80)90169-5; BOKISCH VA, 1970, J CLIN INVEST, V49, P2427, DOI 10.1172/JCI106462; CAMPBELL W, 1989, BIOCHEM BIOPH RES CO, V162, P933, DOI 10.1016/0006-291X(89)90762-6; CAMPBELL W, 1991, J LAB CLIN MED, V115, P610; CHRISTENSEN U, 1979, BIOCHIM BIOPHYS ACTA, V569, P177, DOI 10.1016/0005-2744(79)90052-4; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; EATON DL, 1991, J BIOL CHEM, V266, P21833; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; Erdos E., 1979, HDB EXPT PHARM S, VXXV, P427; ERDOS EG, 1967, BIOCHEM PHARMACOL, V16, P1287, DOI 10.1016/0006-2952(67)90159-1; GORSKI JP, 1979, P NATL ACAD SCI USA, V76, P5299, DOI 10.1073/pnas.76.10.5299; GUREWICH V, 1992, ANN NY ACAD SCI, V667, P224, DOI 10.1111/j.1749-6632.1992.tb51619.x; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HARPEL PC, 1985, J BIOL CHEM, V260, P4432; HENDRIKS D, 1985, CLIN CHEM, V31, P1936; HENDRIKS D, 1988, CLIN CHIM ACTA, V172, P253, DOI 10.1016/0009-8981(88)90331-2; HENDRIKS D, 1990, BIOCHIM BIOPHYS ACTA, V1034, P86, DOI 10.1016/0304-4165(90)90157-R; HENDRIKS D, 1989, J CLIN CHEM CLIN BIO, V27, P277; HENDRIKS D, 1989, CLIN CHEM, V35, P177; HENDRIKS D, 1987, BIOCHEM SOC T, V16, P359; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V155, P591, DOI 10.1016/S0006-291X(88)80535-7; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; LEVIN Y, 1982, P NATL ACAD SCI-BIOL, V79, P4618, DOI 10.1073/pnas.79.15.4618; PANNELL R, 1988, J CLIN INVEST, V81, P853, DOI 10.1172/JCI113394; PERRYMAN MB, 1984, CLIN CHEM, V30, P662; PLUMMER TH, 1978, J BIOL CHEM, V253, P3907; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; SKIDGEL RA, 1984, BIOCHEM PHARMACOL, V33, P3471, DOI 10.1016/0006-2952(84)90122-9; TULINSKY A, 1988, PROTEINS, V3, P85, DOI 10.1002/prot.340030203; VOGEL AJ, 1970, PRACTICAL ORGANIC CH, P584	33	177	182	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15937	15944						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195249				2022-12-27	WOS:A1994NP51300083
J	HAO, H; TYSHENKO, MG; WALKER, VK				HAO, H; TYSHENKO, MG; WALKER, VK			DIHYDROFOLATE-REDUCTASE OF DROSOPHILA - CLONING AND EXPRESSION OF A GENE WITH A RARE TRANSCRIPT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; INTRON SIZE; MELANOGASTER; CELLS; HETEROGENEITY; ORGANIZATION; REGION	Traditionally, dihydrofolate reductase (DHFR) has been isolated and the corresponding gene cloned from drug-resistant cell lines which have amplified DHFR genes after selection. A Dhfr sequence has now been obtained by nested polymerase chain reaction (PCR) from Drosophila bearing a single gene copy. Using the PCR amplified partial cDNA as a probe, Dhfr was cloned by screening a Drosophila genomic library. It consists of regulatory regions as well as a 599-nucleotide coding region with a single 50-base pair (bp) intron and encodes a protein of 182 amino acids. Previously we have shown that the enzyme has kinetic properties characteristic of both ''prokaryotic'' and ''eukaryotic'' DHFRs. Here we show that the organization of Drosophila Dhfr is strikingly different from its mammalian counterparts and most similar to that of mosquito. A 790-bp transcript was detected by Northern blot analysis, with a single transcription start site located 27 bp upstream of ATG codon. The Drosophila genome contains a single Dhfr copy at 89E and a selected cell line has not amplified the gene. Confirmation of the identity of this gene has been obtained by kinetic studies of recombinant DHFR overexpressed in Escherichia coli cells.	QUEENS UNIV,DEPT BIOL,KINGSTON K7L 3N6,ON,CANADA	Queens University - Canada								AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALT FW, 1978, J BIOL CHEM, V253, P1357; ANDREWS J, 1985, GENE, V35, P217, DOI 10.1016/0378-1119(85)90174-X; BARCLAY BJ, 1988, GENE, V63, P175, DOI 10.1016/0378-1119(88)90523-9; BEVERLEY SM, 1986, P NATL ACAD SCI USA, V83, P2584, DOI 10.1073/pnas.83.8.2584; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; CAROTHERS AM, 1983, NUCLEIC ACIDS RES, V11, P1997, DOI 10.1093/nar/11.7.1997; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; CHIA W, 1985, J MOL BIOL, V186, P689, DOI 10.1016/0022-2836(85)90389-4; CROUSE GF, 1982, J BIOL CHEM, V257, P7887; ENGELS WR, 1986, FOCUS, V8, P6; HAMLIN JL, 1990, BIOCHIM BIOPHYS ACTA, V1087, P107, DOI 10.1016/0167-4781(90)90195-8; HARLOW E, 1988, ANTIBODIES LABORATOR, P497; KUMAR AA, 1980, BIOCHEMISTRY-US, V19, P667, DOI 10.1021/bi00545a010; LAGOSKY PA, 1987, NUCLEIC ACIDS RES, V15, P10355, DOI 10.1093/nar/15.24.10355; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; MASTERS JN, 1985, MOL CELL BIOL, V5, P493, DOI 10.1128/MCB.5.3.493; MCGROGAN M, 1985, J BIOL CHEM, V260, P2307; MCPHERSON MJ, 1991, PCR PRACTICAL APPROA, P42; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P425, DOI 10.1128/MCB.6.2.425; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; NUNBERG JH, 1980, CELL, V19, P355, DOI 10.1016/0092-8674(80)90510-3; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PARDUE ML, 1986, DROSOPHILA PRACTICAL, V5, P120; PARK YJ, 1993, INSECT BIOCHEM MOLEC, V23, P255, DOI 10.1016/0965-1748(93)90006-E; RANCOURT SL, 1990, BIOCHEM CELL BIOL, V68, P1075, DOI 10.1139/o90-161; RANCOURT SL, 1990, BIOCHIM BIOPHYS ACTA, V1039, P261, DOI 10.1016/0167-4838(90)90258-H; Sambrook J, 1989, MOL CLONING LABORATO; SHOTKOSKI FA, 1991, EUR J BIOCHEM, V201, P157, DOI 10.1111/j.1432-1033.1991.tb16268.x; SMITH DR, 1980, NUCLEIC ACIDS RES, V8, P2255, DOI 10.1093/nar/8.10.2255; STONE D, 1979, J BIOL CHEM, V254, P480; YANG JK, 1984, J MOL BIOL, V176, P169, DOI 10.1016/0022-2836(84)90419-4	32	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15179	15185						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195153				2022-12-27	WOS:A1994NP73800050
J	KATO, K; GOTO, S; INAGUMA, Y; HASEGAWA, K; MORISHITA, R; ASANO, T				KATO, K; GOTO, S; INAGUMA, Y; HASEGAWA, K; MORISHITA, R; ASANO, T			PURIFICATION AND CHARACTERIZATION OF A 20-KDA PROTEIN THAT IS HIGHLY HOMOLOGOUS TO ALPHA-B-CRYSTALLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; NON-LENTICULAR TISSUES; HUMAN GLIOMA-CELLS; SENSITIVE IMMUNOASSAY; STRESS PROTEINS; BRAIN; TRANSLOCATION; LOCALIZATION; KIDNEY; HSP28	A 20-kDa protein (p20) that had internal amino acid sequences highly similar to those of alpha B crystallin was purified from rat and human skeletal muscle. p20 coeluted with alpha B crystallin and HSP27/28 during column chromatography on DEAE-Sepharose and on Bio-Gel A-5m. p20 was separated from alpha B crystallin and HSP27/28 and was resolved into two fractions, a minor first peak and a major second peak, by column chromatography on S-Sepharose in the presence of 7 M urea. During chromatography on a column of Superdex 75pg, even in the presence of 7 M urea, p20 in the second peak was eluted as aggregates near the exclusion volume of the column, whereas p20 in the first peak was eluted in fractions that corresponded to a lower molecular mass. Further chromatography on a TSK-SP-5PW column yielded pure preparations of each of the two forms of rat and human p20. The fragmentation patterns of the two forms of the respective p20 proteins generated by digestion with endoproteinase Asp-N were identical. The primary structures of rat and human p20, determined with an NH2-terminal sequenator, were highly homologous to those of alpha B crystallin and HSP27/28. p20 was present in all rat tissues examined and at high levels (>1 mu g/mg protein) in the soleus muscle, heart, and diaphragm, as are alpha B crystallin and HSP27. Centrifugation on sucrose density gradients allowed detection of the aggregated form and the small form of p20, as well as of HSP27, in extracts of rat muscle tissues. During heating at 45 degrees C of tissue in vitro, p20 in rat diaphragm was redistributed from the cytoplasm to the insoluble fraction, and dissociation of the aggregated p20 to the small form was enhanced. These results suggest that p20 is related to stress proteins.			KATO, K (corresponding author), AICHI PREFECTURAL COLONY,INST DEV RES,DEPT BIOCHEM,KASUGAI,AICHI 48003,JAPAN.							BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; CORCES V, 1980, P NATL ACAD SCI-BIOL, V77, P5390, DOI 10.1073/pnas.77.9.5390; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; ENGEL WK, 1962, NEUROLOGY, V12, P778, DOI 10.1212/WNL.12.11.778; Gros E., 1967, METHOD ENZYMOL, V11, P238; INAGUMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P844, DOI 10.1016/0006-291X(92)91809-5; INAGUMA Y, 1993, J BIOCHEM-TOKYO, V114, P378, DOI 10.1093/oxfordjournals.jbchem.a124184; IWAKI A, 1990, J BIOL CHEM, V265, P22197; IWAKI T, 1990, J HISTOCHEM CYTOCHEM, V38, P31, DOI 10.1177/38.1.2294148; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KATO K, 1983, METHOD ENZYMOL, V92, P345; KATO K, 1993, BIOCHIM BIOPHYS ACTA, V1175, P257, DOI 10.1016/0167-4889(93)90214-A; KATO K, 1993, J BIOCHEM-TOKYO, V114, P640, DOI 10.1093/oxfordjournals.jbchem.a124230; KATO K, 1976, J IMMUNOL, V116, P1554; KATO K, 1994, J BIOL CHEM, V269, P11274; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; KATO K, 1992, J BIOL CHEM, V267, P7718; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KUROBE N, 1990, BIOMED RES-TOKYO, V11, P187, DOI 10.2220/biomedres.11.187; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P113, DOI 10.1007/BF00221052; NAGINENI CN, 1989, FEBS LETT, V249, P89, DOI 10.1016/0014-5793(89)80022-5; TAKEISHI K, 1982, J BIOCHEM-TOKYO, V92, P1173, DOI 10.1093/oxfordjournals.jbchem.a134033; TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1; VINCENT M, 1982, J MOL BIOL, V162, P365, DOI 10.1016/0022-2836(82)90532-0; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	28	198	207	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15302	15309						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195168				2022-12-27	WOS:A1994NP73800067
J	YAMAZOE, M; SHIRAHIGE, K; RASHID, MB; KANEKO, Y; NAKAYAMA, T; OGASAWARA, N; YOSHIKAWA, H				YAMAZOE, M; SHIRAHIGE, K; RASHID, MB; KANEKO, Y; NAKAYAMA, T; OGASAWARA, N; YOSHIKAWA, H			A PROTEIN WHICH BINDS PREFERENTIALLY TO SINGLE-STRANDED CORE SEQUENCE OF AUTONOMOUSLY REPLICATING SEQUENCE IS ESSENTIAL FOR RESPIRATORY-FUNCTION IN MITOCHONDRIA OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-RICH STRAND; MULTIPROTEIN COMPLEX; ESCHERICHIA-COLI; SHUTTLE VECTORS; YEAST; DNA; GENE; IDENTIFICATION; PURIFICATION; ACTIVATION	From yeast nuclear extract, we have identified several DNA-protein complexes using the T-rich strand of core consensus sequence of autonomously replicating sequence by gel shift assay. One of them showed preferential binding to the T-rich sequence of the DNA. We have partially purified a protein constituent of this complex and cloned its gene. The gene has an open reading frame encoding a protein of 380 amino acids (M(r) = 42,100) which is processed to a mature protein of 371 amino acids (M(r) = 40,900). The protein has neither significant amino acid homology with any previously reported proteins nor characteristic motifs. A putative HAP2/HAP3/HAP4 binding sequence was found at about 1 kilobase upstream of the gene. Disruption of the chromosomal gene revealed that the gene was neither essential for cell viability nor involved in DNA replication, but was essential for mitochondrial respiratory function. We therefore named the gene MRF1 for mitochondrial respiratory function 1. In a mrf1 null mutant the absorption spectra of cytochromes b, a, and a(3) were undetectable, although mitochondrial DNA and protein synthesis in mitochondria were intact. Antibodies against MRF1 detected the antigen localized predominantly in the nucleus in vivo. These results suggest that MRF1 is a transcriptional regulatory protein of some genes whose products are necessary for the functional assembly of mitochondrial respiratory proteins.	NARA ADV INST SCI & TECHNOL, GRAD SCH BIOL SCI, DEPT MOLEC BIOL, IKOMA, OSAKA 63001, JAPAN; OSAKA UNIV, SCH MED, DEPT GENET, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, FAC ENGN, DEPT BIOTECHNOL, SUITA, OSAKA 565, JAPAN; MIYAZAKI MED COLL, DEPT BIOCHEM, MIYAZAKI 88916, JAPAN	Nara Institute of Science & Technology; Osaka University; Osaka University; University of Miyazaki			Ogasawara, Naotake/B-7971-2011	Shirahige, Katsuhiko/0000-0002-7862-1144				ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; DIFFLEY JFX, 1988, CANCER CELL, V6, P235; DONNINI C, 1986, J BACTERIOL, V168, P1250, DOI 10.1128/jb.168.3.1250-1253.1986; ESTES HG, 1992, P NATL ACAD SCI USA, V89, P11156, DOI 10.1073/pnas.89.23.11156; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; FOX TD, 1991, METHOD ENZYMOL, V194, P149; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GRAYHACK EJ, 1992, MOL CELL BIOL, V12, P3573, DOI 10.1128/MCB.12.8.3573; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; KENG T, 1992, MOL GEN GENET, V234, P233, DOI 10.1007/BF00283844; KUNO K, 1991, MOL GEN GENET, V230, P45, DOI 10.1007/BF00290649; KUNO K, 1990, GENE, V95, P73, DOI 10.1016/0378-1119(90)90415-N; LANNIGAN DA, 1989, P NATL ACAD SCI USA, V86, P863, DOI 10.1073/pnas.86.3.863; MARMIROLI N, 1984, MOL GEN GENET, V198, P69, DOI 10.1007/BF00328703; PARISI MA, 1993, MOL CELL BIOL, V13, P1951, DOI 10.1128/MCB.13.3.1951; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIRAHIGE K, 1993, MOL CELL BIOL, V13, P5043, DOI 10.1128/MCB.13.8.5043; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRAWICK JD, 1989, MOL CELL BIOL, V9, P5350, DOI 10.1128/MCB.9.12.5350; VERDIER JM, 1990, YEAST, V6, P271, DOI 10.1002/yea.320060402; VERMA R, 1992, J BIOL CHEM, V267, P1648; ZEIDLER R, 1993, J BIOL CHEM, V268, P20191	33	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15244	15252						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195160				2022-12-27	WOS:A1994NP73800059
J	DWIVEDI, UN; SHIRAISHI, N; CAMPBELL, WH				DWIVEDI, UN; SHIRAISHI, N; CAMPBELL, WH			IDENTIFICATION OF AN ESSENTIAL CYSTEINE OF NITRATE REDUCTASE VIA MUTAGENESIS OF ITS RECOMBINANT CYTOCHROME-B REDUCTASE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NADH-CYTOCHROME-B5 REDUCTASE; ESCHERICHIA-COLI; SQUASH NADH; BINDING; EXPRESSION; SEQUENCE; CORN; CHLORELLA; FAMILY; SITE	Five cysteine residues in the recombinant cytochrome b reductase domain of corn leaf NADH:nitrate reductase (EC 1.6.6.1) were modified by site-directed mutagenesis. At least two amino acid replacement mutants were generated for each of the 5 cysteines of this domain. Characteristics of the amino acid replacement mutants correlated well with the structural location of the cysteine residues in the preliminary three-dimensional model of the cytochrome b reductase domain: somewhat exposed cysteines could be replaced by hydrophilic amino acid residues, while more buried cysteines by hydrophobic residues. An exception was found for the invariant cysteine near the C terminus, which is found in all nitrate reductases and also in the closely related NADH: cytochrome b(5) reductase, as well as, most other members of this flavoenzyme family. No substitution for the invariant cysteine yielded highly active enzyme, although these mutants had normal visible spectra. When the in variant cysteine was mutated to serine, the cytochrome b reductase domain was resistant to inhibition by pchloromercuribenzoate, an inhibitor of nitrate reductases. Kinetic analysis suggested that the catalytic efficiency of the mutant was markedly reduced. We concluded, the invariant cysteine plays an important role in catalysis and may be essential for high catalytic efficiency of nitrate reductases.	MICHIGAN TECHNOL UNIV,PHYTOTECHNOL RES CTR,HOUGHTON,MI 49931; MICHIGAN TECHNOL UNIV,DEPT BIOL SCI,HOUGHTON,MI 49931	Michigan Technological University; Michigan Technological University			Dwivedi, Upendra/AAM-7657-2021	Dwivedi, Upendra/0000-0002-4053-2795; Campbell, Wilbur/0000-0001-6432-7537				ALIVERTI A, 1993, BIOCHEMISTRY-US, V32, P6374, DOI 10.1021/bi00076a010; ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; BARBER MJ, 1986, J BIOL CHEM, V261, P4562; CAMPBELL WH, 1990, TRENDS BIOCHEM SCI, V15, P315, DOI 10.1016/0968-0004(90)90021-3; CAMPBELL WH, 1992, PLANT PHYSIOL, V99, P693, DOI 10.1104/pp.99.2.693; CANNONS AC, 1993, J BIOL CHEM, V268, P3268; CANNONS AC, 1991, BIOCHEM J, V278, P203, DOI 10.1042/bj2780203; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; DEV IK, 1988, P NATL ACAD SCI USA, V85, P1472, DOI 10.1073/pnas.85.5.1472; EVANS HJ, 1953, PLANT PHYSIOL, V28, P233, DOI 10.1104/pp.28.2.233; GARRETT RH, 1969, J BIOL CHEM, V244, P2870; HANIU M, 1989, BIOCHEMISTRY-US, V28, P8639, DOI 10.1021/bi00447a054; HYDE GE, 1990, BIOCHEM BIOPH RES CO, V168, P1285, DOI 10.1016/0006-291X(90)91168-R; HYDE GE, 1991, J BIOL CHEM, V266, P23542; HYDE GE, 1989, PLANT MOL BIOL, V13, P233, DOI 10.1007/BF00016141; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KUBO Y, 1988, J BIOL CHEM, V263, P19684; LU GG, 1992, J MOL BIOL, V224, P277, DOI 10.1016/0022-2836(92)90592-8; NASON A, 1953, J BIOL CHEM, V202, P655; NEAME PJ, 1989, J BIOL CHEM, V264, P20894; ORIHUELIRANZO B, 1981, PHOTOSYNTHESIS, V4, P715; RAY FA, 1992, BIOTECHNIQUES, V13, P342; REDINBAUGH MG, 1985, J BIOL CHEM, V260, P3380; RELIMPIO AM, 1971, FEBS LETT, V17, P226, DOI 10.1016/0014-5793(71)80152-7; ROUZE P, 1992, SOC EXP BIOL SEMIN S, V49, P45, DOI 10.1017/CBO9780511600395.004; SHEN AL, 1991, J BIOL CHEM, V266, P19976; SHIRABE K, 1991, J BIOL CHEM, V266, P7531; SOLOMONSON LP, 1990, ANNU REV PLANT PHYS, V41, P225, DOI 10.1146/annurev.pp.41.060190.001301	29	37	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13785	13791						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188655				2022-12-27	WOS:A1994NL60600014
J	KNAB, AM; FERTALA, J; BJORNSTI, MA				KNAB, AM; FERTALA, J; BJORNSTI, MA			MECHANISMS OF CAMPTOTHECIN RESISTANCE IN YEAST DNA TOPOISOMERASE-I MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE TYROSINE; HAMSTER DC3F CELLS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; ANTITUMOR DRUGS; CLONING; GENE; SEQUENCE; BINDING; IDENTIFICATION	The anti-cancer drug camptothecin targets eukaryotic DNA topoisomerase I by trapping the covalent complex formed between the catalytically active enzyme and DNA. Saccharomyces cerevisiae cells expressing yeast DNA topoisomerase I mutant top1 vac (I725R, N726A) or top1N726L, in which the amino acid residues N terminus to the active site tyrosine Tyr-727 were changed as indicated, were found to be camptothecin-resistant even though the mutant proteins expressed in Escherichia coli were previously shown to be active. Assays of enzyme-catalyzed relaxation of supercoiled DNA in vitro and in vivo in yeast showed that the camptothecin resistance of these mutants arises by entirely different mechanisms. Top1N726L-catalyzed DNA relaxation was not detected in yeast. The Top1 vac protein was catalytically active; however, camptothecin was inefficient in trapping the covalent intermediate formed between the Top1 vac enzyme and DNA. Yeast cells expressing human mutant htop1 vac, with similar substitutions near the active site tyrosine Tyr-723, were also camptothecin-resistant. Surprisingly, in the absence of camptothecin, yeast rad52 mutants defective in the repair of double-stranded DNA breaks were nonviable when top1N726L or top1 vac was overexpressed but viable when htop1 vac was overexpressed. These results suggest differences between yeast and human enzyme function in vivo.			KNAB, AM (corresponding author), THOMAS JEFFERSON UNIV, DEPT BIOCHEM & MOLEC BIOL, PHILADELPHIA, PA 19107 USA.				NIGMS NIH HHS [GM 44810] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDOH T, 1987, P NATL ACAD SCI USA, V84, P5565, DOI 10.1073/pnas.84.16.5565; Ausubel FM, 1988, MOL REPROD DEV; BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BJORNSTI MA, 1989, CANCER RES, V49, P6318; Bjornsti MA, 1991, CURR OPIN STRUC BIOL, V1, P99, DOI 10.1016/0959-440X(91)90017-N; BOROS I, 1984, GENE, V30, P257, DOI 10.1016/0378-1119(84)90130-6; CHAMPOUX JJ, 1989, J BIOL CHEM, V264, P1010; CHANPOUX JJ, 1990, DNA TOPOLOGY ITS BIO, P217; DARPA P, 1990, CANCER RES, V50, P6919; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; DELBINO G, 1990, CANCER RES, V50, P5746; ENG WK, 1990, MOL PHARMACOL, V38, P471; ENG WK, 1988, MOL PHARMACOL, V34, P755; ENG WK, 1989, J BIOL CHEM, V264, P13373; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GOTO T, 1985, P NATL ACAD SCI USA, V82, P7178, DOI 10.1073/pnas.82.21.7178; GROMOVA II, 1993, NUCLEIC ACIDS RES, V21, P593, DOI 10.1093/nar/21.3.593; GUPTA RS, 1988, CANCER RES, V48, P6404; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; HOLM C, 1989, CANCER RES, V49, P6365; HOROWITZ MS, 1971, BIOCHEM BIOPH RES CO, V45, P723, DOI 10.1016/0006-291X(71)90476-1; HSEIH TS, 1992, NUCLEIC ACIDS RES, V20, P6177; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KJELDSEN E, 1988, J MOL BIOL, V202, P333, DOI 10.1016/0022-2836(88)90462-7; KUBOTA N, 1992, BIOCHEM BIOPH RES CO, V188, P571, DOI 10.1016/0006-291X(92)91094-7; LEVIN NA, 1993, GENETICS, V133, P799; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MADDEN KR, 1992, CANCER RES, V52, P525; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; SIKORSKI RS, 1989, GENETICS, V122, P9; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; TAMURA H, 1991, NUCLEIC ACIDS RES, V19, P69, DOI 10.1093/nar/19.1.69; TANIZAWA A, 1992, CANCER RES, V52, P1848; THRASH C, 1985, P NATL ACAD SCI USA, V82, P4374, DOI 10.1073/pnas.82.13.4374; UEMURA T, 1987, NUCLEIC ACIDS RES, V15, P9727, DOI 10.1093/nar/15.23.9727; Wang J. C., 1990, DNA TOPOLOGY ITS BIO, P321; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JC, 1987, NATL CANCER I MONOGR, V4, P3; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	50	84	96	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22322	22330						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226741				2022-12-27	WOS:A1993MD34800023
J	PUCEAT, M; HILALDANDAN, R; STRULOVICI, B; BRUNTON, LL; BROWN, JH				PUCEAT, M; HILALDANDAN, R; STRULOVICI, B; BRUNTON, LL; BROWN, JH			DIFFERENTIAL REGULATION OF PROTEIN-KINASE-C ISOFORMS IN ISOLATED NEONATAL AND ADULT-RAT CARDIOMYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CARDIAC MYOCYTES; GENE-EXPRESSION; HEART MYOCYTES; CELLS; ACTIVATION; EPSILON; ISOZYMES; ENDOTHELIN; CALCIUM	We have immunologically identified the isoforms of protein kinase C (PKC) present in neonatal and adult rat cardiomyocytes and examined their regulation by hormones and phorbol ester. Both cell types express the Ca2+-dependent alpha-PKC and the Ca2+-independent epsilon- and delta-PKC isoforms. The atypical zeta-PKC isoform is also expressed in neonatal, but only weakly in adult cells. Stimulation of the alpha(1)-adrenergic or purinergic receptor with phenylephrine or ATP, respectively, increases membrane-associated immunoreactivity of both epsilon- and delta-PKC in neonatal and adult cells; endothelin and carbachol are also effective in adult cells. In contrast, none of the agonists leads to increases in membrane-associated alpha-PKC in cardiomyocytes. PKC zeta is also unaffected by receptor stimulation. The phorbol ester phorbol 12-myristate 13-acetate causes redistribution and subsequently down-regulation of alpha-, epsilon-, and delta- but not zeta-PKC. The three isoforms are down-regulated at distinctively different rates, with alpha-PKC being the most rapid and epsilon-PKC the slowest. We used selective down-regulation of alpha-, epsilon-, and delta-PKC to investigate the role of these isoforms in PKC phosphorylation-dependent events in neonatal myocytes. Our findings suggest that epsilon-PKC is responsible for the phenylephrine-induced phosphorylation of MARCKS, an endogenous PKC-specific substrate. In contrast, agonist-induced c-fos expression is unlikely to be mediated by epsilon-PKC since the response is rapidly down-regulated and apparently Ca2+-dependent. Our finding that the PKC isoforms are differentially responsive to neurohormones suggests that they play distinct and specific roles in cardiac function.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			PUCEAT, michel/R-6140-2017	PUCEAT, michel/0000-0001-9055-7563	NHLBI NIH HHS [HL41307, HL28143, HL46345] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345, R01HL041307, R01HL028143] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; ALLEN BG, 1991, BIOCHEMISTRY-US, V30, P4334, DOI 10.1021/bi00231a032; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JH, 1992, TRENDS CARDIOVAS MED, V2, P209, DOI 10.1016/1050-1738(92)90026-O; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOSEMECI A, 1988, CIRC RES, V62, P347, DOI 10.1161/01.RES.62.2.347; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HILALDANDAN R, 1992, J BIOL CHEM, V267, P10620; IRONS CE, 1992, J BIOL CHEM, V267, P5211; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KAKU T, 1991, AM J PHYSIOL, V260, pC635, DOI 10.1152/ajpcell.1991.260.3.C635; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KOHOUT TA, 1993, AM J PHYSIOL, V264, pC1350, DOI 10.1152/ajpcell.1993.264.5.C1350; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KOSAKA Y, 1988, BIOCHEM BIOPH RES CO, V151, P973, DOI 10.1016/S0006-291X(88)80461-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASLIAH E, 1990, J NEUROSCI, V10, P2113; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; PUCEAT M, 1991, BIOCHEM J, V274, P55, DOI 10.1042/bj2740055; PUCEAT M, 1992, TRENDS PHARMACOL SCI, V13, P263, DOI 10.1016/0165-6147(92)90080-P; QU Y, 1991, MOL CELL BIOCHEM, V103, P171; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREJO J, 1991, J BIOL CHEM, V266, P7876; TRILIVAS I, 1989, J BIOL CHEM, V264, P3102; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121	37	262	264	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16938	16944						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207017				2022-12-27	WOS:A1994NR29600064
J	BASSHAM, DC; CREIGHTON, AM; KARNAUCHOV, I; HERRMANN, RG; KLOSGEN, RB; ROBINSON, C				BASSHAM, DC; CREIGHTON, AM; KARNAUCHOV, I; HERRMANN, RG; KLOSGEN, RB; ROBINSON, C			MUTATIONS AT THE STROMAL PROCESSING PEPTIDASE CLEAVAGE SITE OF A THYLAKOID LUMEN PROTEIN-PRECURSOR AFFECT THE RATE OF PROCESSING BUT NOT THE FIDELITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; CHLOROPLAST TRANSIT PEPTIDES; NUCLEOTIDE-SEQUENCE; TRANSPORT; PLASTOCYANIN; MATURATION; SPINACH; DOMAIN; IMPORT; 23-KDA	Nuclear-encoded stromal proteins are imported into the chloroplast by means of presequences, or transit peptides, which are removed after import by a stromal processing peptidase (SPP); the presequences of thylakoid lumen proteins are processed by SPP at intermediate sites prior to transport of these proteins across the thylakoid membrane. SPP has been previously shown to be a highly specific enzyme, but the basis for the reaction specificity is unclear, because the cleavage sites of different substrates display virtually no primary structure similarity. We have examined the influence of the cleavage site residues on the SPP reaction mechanism by introducing mutations at these positions (denoted -1 and +1, relative to the SPP cleavage site) within the presequence of the lumenal 33-kDa photosystem II protein. Substitution of the -1 Arg by Ala or Met leads to a 5-7-fold reduction in the rate of processing, whereas substitution by Glu almost completely blocks cleavage. The replacement of the +1 Ala by Lys likewise almost completely blocks cleavage. None of the introduced -1 mutations affect cleavage fidelity; we show that all three mutants are cleaved only at the correct site. All of the mutant precursors are efficiently imported into the thylakoid lumen of intact chloroplasts, indicating that this cleavage event is not an important element of the overall import pathway. The results indicate that the identity of the -1 residue, within the context of a given presequence, is important in terms of influencing processing efficiency, but that the site of cleavage is specified by other determinants. At least a proportion of the other determinants are likely to be in close proximity to the cleavage site, since the deletion of a 7-residue section spanning this site completely blocks processing.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND; UNIV MUNICH,INST BOT,D-80638 MUNICH,GERMANY	University of Warwick; University of Munich								ABAD MS, 1991, PLANT PHYSIOL, V96, P1220, DOI 10.1104/pp.96.4.1220; BASSHAM DC, 1991, J BIOL CHEM, V266, P23606; CLARK SE, 1991, J CELL BIOL, V114, P681, DOI 10.1083/jcb.114.4.681; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; JAMES HE, 1989, J BIOL CHEM, V264, P19573; JANSEN T, 1987, FEBS LETT, V216, P234, DOI 10.1016/0014-5793(87)80696-8; KIRWIN PM, 1988, J BIOL CHEM, V263, P18128; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; MEADOWS JW, 1991, PLANT MOL BIOL, V16, P1085, DOI 10.1007/BF00016082; MOULD RM, 1991, J BIOL CHEM, V266, P17286; MUSGROVE JE, 1989, PLANT PHYSIOL, V90, P1616, DOI 10.1104/pp.90.4.1616; OBLONG JE, 1992, EMBO J, V11, P4401, DOI 10.1002/j.1460-2075.1992.tb05540.x; PILON M, 1992, J BIOL CHEM, V267, P19907; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; THEG SM, 1992, BIOCHEMISTRY-US, V31, P5035; TYAGI A, 1987, MOL GEN GENET, V207, P288, DOI 10.1007/BF00331591; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535	20	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16062	16066						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206905				2022-12-27	WOS:A1994NQ72900020
J	POTEMPA, J; KORZUS, E; TRAVIS, J				POTEMPA, J; KORZUS, E; TRAVIS, J			THE SERPIN SUPERFAMILY OF PROTEINASE-INHIBITORS - STRUCTURE, FUNCTION, AND REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN ALPHA-1-PROTEINASE INHIBITOR; LEUKOCYTE ELASTASE INHIBITOR; SERINE PROTEASE INHIBITORS; REACTIVE SITE LOOP; PLASMINOGEN-ACTIVATOR; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; ANTITHROMBIN-III; ALPHA1-PROTEINASE INHIBITOR; LIMITED PROTEOLYSIS		UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; JAGIELLONIAN UNIV,INST MOLEC BIOL,PL-31120 KRAKOW,POLAND	University System of Georgia; University of Georgia; Jagiellonian University								ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; AULAK KS, 1993, J BIOL CHEM, V268, P18088; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BAUMANN U, 1992, J MOL BIOL, V226, P1207, DOI 10.1016/0022-2836(92)91062-T; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; BLANTON RE, 1994, MOL BIOCHEM PARASIT, V63, P1, DOI 10.1016/0166-6851(94)90003-5; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Boswell D. R., 1986, REC ADV CLIN IMMUNOL, V4, P1; BRANDT A, 1990, EUR J BIOCHEM, V194, P499, DOI 10.1111/j.1432-1033.1990.tb15644.x; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; CHAI KX, 1993, J BIOL CHEM, V268, P24498; COHEN AB, 1978, BIOCHEMISTRY-US, V17, P392, DOI 10.1021/bi00596a002; DESROCHERS PE, 1991, J CLIN INVEST, V87, P2258, DOI 10.1172/JCI115262; DOOLITTLE RF, 1983, SCIENCE, V222, P417, DOI 10.1126/science.6604942; DUBIN A, 1992, J BIOL CHEM, V267, P6576; ENGH RA, 1990, PROTEIN ENG, V3, P469, DOI 10.1093/protein/3.6.469; FLINK IL, 1986, P NATL ACAD SCI USA, V83, P7708, DOI 10.1073/pnas.83.20.7708; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; GUZDEK A, 1990, FEBS LETT, V272, P125, DOI 10.1016/0014-5793(90)80464-T; HAMMOND GL, 1987, P NATL ACAD SCI USA, V84, P5153, DOI 10.1073/pnas.84.15.5153; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HILGENFELDT U, 1990, EUR J CLIN PHARMACOL, V38, P125; HOLLAND LJ, 1992, J BIOL CHEM, V267, P7053; HOOD DB, 1991, BIOCHEMISTRY-US, V30, P9054, DOI 10.1021/bi00101a021; HOOK VYH, 1993, J BIOL CHEM, V268, P20570; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; ING NH, 1989, J BIOL CHEM, V264, P3372; JOHNSON D, 1977, BIOCHEM J, V163, P639, DOI 10.1042/bj1630639; JORDAN RE, 1987, SCIENCE, V237, P777, DOI 10.1126/science.3649921; KANOST MR, 1989, J BIOL CHEM, V264, P965; KRESS LF, 1986, J CELL BIOCHEM, V32, P51, DOI 10.1002/jcb.240320106; LOBERMANN H, 1984, J MOL BIOL, V177, P531; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1993, J BIOL CHEM, V268, P516; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MAST AE, 1991, J BIOL CHEM, V266, P15810; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MATHESON NR, 1986, J BIOL CHEM, V261, P404; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MIURA Y, 1994, J BIOL CHEM, V269, P542; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; MORIHARA K, 1984, J BIOCHEM, V95, P795, DOI 10.1093/oxfordjournals.jbchem.a134671; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MOUREY L, 1990, BIOCHIMIE, V72, P599, DOI 10.1016/0300-9084(90)90123-X; NARUMI H, 1993, EUR J BIOCHEM, V214, P181, DOI 10.1111/j.1432-1033.1993.tb17911.x; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PERKINS SJ, 1992, J MOL BIOL, V228, P1235, DOI 10.1016/0022-2836(92)90329-I; POTEMPA J, 1991, J BIOL CHEM, V266, P21482; POTEMPA J, 1986, J BIOL CHEM, V261, P14330; PRATT CW, 1993, BLOOD COAGUL FIBRIN, V4, P479, DOI 10.1097/00001721-199306000-00013; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P189; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1992, BIOCHEMISTRY-US, V31, P7560, DOI 10.1021/bi00148a017; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEELE FR, 1992, P NATL ACAD SCI USA, V90, P1526; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; SUZUKI Y, 1991, J BIOL CHEM, V266, P928; TRAVIS J, 1986, BIOL CHEM H-S, V367, P853, DOI 10.1515/bchm3.1986.367.2.853; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WAGNER SL, 1989, J BIOL CHEM, V264, P611; WANG SY, 1992, J BIOL CHEM, V267, P15362; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	74	791	823	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15957	15960						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206889				2022-12-27	WOS:A1994NQ72900001
J	SU, Y; ROSENTHAL, D; SMULSON, M; SPIEGEL, S				SU, Y; ROSENTHAL, D; SMULSON, M; SPIEGEL, S			SPHINGOSINE 1-PHOSPHATE, A NOVEL SIGNALING MOLECULE, STIMULATES DNA-BINDING ACTIVITY OF AP-1 IN QUIESCENT SWISS 3T3 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDIC-ACID LEVELS; CELLULAR PROLIFERATION; TRANSDUCTION PATHWAYS; MAP KINASES; CELLS; JUN; FOS; TRANSCRIPTION; SPHINGOSINE-1-PHOSPHATE	Sphingosine and sphingosine 1-phosphate, metabolites of sphingolipids, stimulate cell proliferation in quiescent Swiss 3T3 fibroblasts and induce transient increases in intracellular free calcium (Zhang, H., Desai, N. N., Olivera, A., Seki, T., Brooker, G., and Spiegel, S. (1991) J. Cell Biol. 114, 155-167). However, little is yet known of the nuclear events that follow the early responses induced by sphingolipid metabolites. Using a gel retardation assay, we found that specific DNA binding activity of activator protein-1 (AP-1) was markedly increased after treatment of quiescent Swiss 3T3 fibro- blasts with sphingosine 1-phosphate and sphingosine. The DNA binding specificity of AP-1 was confirmed with competing probes containing consensus sequences of AP-1, AP-2, AP-3, SP-1, and NF1/CTF. The c-fos gene product was detected in the AP-1 complex using anti-c-Fos antibody. The dose response for stimulation of DNA binding activity of AP-1 by sphingosine 1-phosphate correlated closely with its effect on DNA synthesis. Furthermore, an inhibitor of sphingosine kinase, DL-threo-dihydrosphingosine, which inhibits sphingosine-induced DNA synthesis and the formation of sphingosine 1-phosphate, also inhibited sphingosine-stimulated AP-1 DNA binding activity. This result further supports our proposal that sphingosine 1-phosphate mediates the mitogenic effect of sphingosine. Our results indicate that sphingosine 1-phosphate-induced DNA synthesis and cell division may result from activation of AP-1 protein, linking signal transduction by sphingolipid metabolites to gene expression.	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007	Georgetown University			Rosenthal, Dean S/J-2360-2014	Rosenthal, Dean/0000-0002-7624-0209	NIGMS NIH HHS [1RO1 GM43880] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; DESAI NN, 1992, J BIOL CHEM, V267, P23122; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GINSBERG D, 1990, ONCOGENE, V5, P1285; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1992, GLYCOCONJUGATE J, V9, P109; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SPIEGEL S, 1989, J BIOL CHEM, V264, P16512; SPIEGEL S, 1993, ADV LIPID RES, V25, P105; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P1311, DOI 10.1515/bchm2.1973.354.2.1311; STOFFEL W, 1970, H-S Z PHYSIOL CHEM, V351, P1041, DOI 10.1515/bchm2.1970.351.2.1041; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; VANWIJNEN AJ, 1991, J CELL BIOCHEM, V47, P337, DOI 10.1002/jcb.240470408; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WU WS, 1992, ONCOGENE, V7, P2287; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZHANG H, 1990, J BIOL CHEM, V265, P21309; [No title captured]	46	89	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16512	16517						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206962				2022-12-27	WOS:A1994NQ72900083
J	TANS, G; NICOLAES, GAF; CHRISTELLA, M; THOMASSEN, LGD; HEMKER, HC; VANZONNEVELD, AJ; PANNEKOEK, H; ROSING, J				TANS, G; NICOLAES, GAF; CHRISTELLA, M; THOMASSEN, LGD; HEMKER, HC; VANZONNEVELD, AJ; PANNEKOEK, H; ROSING, J			ACTIVATION OF HUMAN FACTOR-V BY MEIZOTHROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							THROMBIN-CATALYZED ACTIVATION; COAGULATION FACTOR-V; BOVINE FACTOR-V; FACTOR-XA; PROTHROMBIN ACTIVATION; PROTEIN-C; INTERMEDIATE; PHOSPHOLIPIDS; PURIFICATION; CONVERSION	A recombinant human prothrombin was prepared in which Arg(155) was replaced by Ala. The recombinant prothrombin was converted into a meizothrombin derivative (R155A meizothrombin) that was resistant to autocatalytic removal of the fragment 1 domain. R155A meizothrombin appeared to be a potent factor V activator in reaction mixtures that contained negatively charged phospholipid vesicles. Factor V activation by R155A meizothrombin was characterized by second-order rate constants of 0.06 x 10(6) M(-1) S-1 in the absence of phospholipid and 18 x 10(6) M(-1) S-1 in the presence of 60 mu M phospholipid vesicles composed of a 10:90 mol/mol mixture of phosphatidylserine (PS) and phosphatidylcholine (PC). The rate constant for thrombin-catalyzed activation of factor V was hardly affected by the presence of phospholipid vesicles and was 4.0 x 10(6) M(-1) S-1. The initial rate of activation of 3 nM factor V by R155A meizothrombin was a function of the concentration of PS/PC vesicles present in the reaction mixture, and the calculated rate constant reached a plateau value at greater than or equal to 50 mu M PS/PC. Gel electrophoretic analysis of factor V activation showed that R155A meizothrombin and thrombin cleaved the susceptible peptide bonds in factor V at different rates. However, both activators finally generated a factor Va molecule composed of a heavy chain with an M(r) of 104,000 and a light chain doublet with M(r) values of 74,000 and 71,000. Since meizothrombin is one of the major reaction products formed during the initial phase of prothrombin activation, these findings are indicative of a significant contribution of meizothrombin to in vivo factor V activation.	UNIV LIMBURG,CARDIOVASC RES INST,DEPT BIOCHEM,6200 MD MAASTRICHT,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM,1105 AZ AMSTERDAM,NETHERLANDS	Hasselt University; Maastricht University; University of Amsterdam; Academic Medical Center Amsterdam			van Zonneveld, Anton Jan/D-8060-2018; Nicolaes, Gerry A.F./A-8421-2016	van Zonneveld, Anton Jan/0000-0002-1676-7738; Nicolaes, Gerry A.F./0000-0002-2482-0412; Thomassen, Stella/0000-0002-9686-6364; Hemker, Coen/0000-0003-1669-2358				BOVILL EG, 1993, THROMB HAEMOSTASIS, V69, P779; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1989, J BIOL CHEM, V264, P4743; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORREVOETS AJG, 1993, J BIOL CHEM, V268, P779; KANE WH, 1981, J BIOL CHEM, V256, P1002; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KUWADA M, 1983, ANAL BIOCHEM, V131, P173, DOI 10.1016/0003-2697(83)90150-1; MANN KG, 1990, BLOOD, V76, P1; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PIETERS J, 1988, BLOOD, V72, P2048; RHEE MJ, 1982, BIOCHEMISTRY-US, V21, P3437, DOI 10.1021/bi00257a029; ROSING J, 1993, J BIOL CHEM, V268, P21130; ROSING J, 1986, J BIOL CHEM, V261, P4224; ROSING J, 1980, J BIOL CHEM, V255, P274; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TANS G, 1991, J BIOL CHEM, V266, P21864; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; WALLS JD, 1989, GENE, V81, P139, DOI 10.1016/0378-1119(89)90344-2	23	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15969	15972						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206891				2022-12-27	WOS:A1994NQ72900004
J	GAO, B; KUNOS, G				GAO, B; KUNOS, G			TRANSCRIPTION OF THE RAT ALPHA(1B) ADRENERGIC-RECEPTOR GENE IN LIVER IS CONTROLLED BY 3 PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; MESSENGER-RNAS; ALPHA-1B-ADRENERGIC RECEPTOR; DNA-SYNTHESIS; EXPRESSION; TISSUE; CELLS; DIFFERENTIATION; PURIFICATION; STIMULATION	The proximal 5'-flanking region of the rat alpha(1B) adrenergic receptor (alpha(1B)AR) gene contains discrete transcription start points (tsp) utilized in liver, located at -54, -57 (tsp1), and -443 base pairs (tsp2) upstream from the translation start codon (Gao, B., and Kunos, G. (1993) Gene (Amst.) 131, 243-247). Primer extension analyses using 5' upstream primers now identify an additional cluster of tsp between -1035 and -1340 base pairs (tsp3). Northern blots of rat liver mRNA reveal three alpha(1B)AR mRNAs of 2.3, 2.7, and 3.3 kilobases in length. Transient transfections of putative promoter/pCAT constructs document the existence of three promoters, P1 (-127, -49), P2 (-813, -432), and P3 (-1363, -1107), which direct transcription from tsp1, tsp2, and tsp3, respectively. P1 contains no recognition sequences for known transcription factors. P2 is (G + C)-rich, lacks a TATA box, and contains a cAMP response element, GC, CACC, and GCAAT boxes, and binding sites for nuclear factor I. P3 contains a putative TATATA and CCAAT box and is flanked by recognition sites for the liver-specific CCAAT/enhancer binding protein and hepatocyte nuclear factor 5. These findings indicate that heterogeneity of alpha(1B)AR mRNA in liver is related to transcription of the gene by three distinct promoters. Differential control of these promoters may underlie the well documented developmental and tissue-specific regulation of the alpha(1B)AR.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL & TOXICOL, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT MED, RICHMOND, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University								ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BURCH RM, 1986, J BIOL CHEM, V261, P1236; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; CRUISE JL, 1985, SCIENCE, V227, P749, DOI 10.1126/science.2982212; DENG CL, 1994, J RECEPTOR RES, V14, P119, DOI 10.3109/10799899409067000; DYNAN WS, 1985, NATURE, V262, P864; GAO B, 1993, GENE, V131, P243, DOI 10.1016/0378-1119(93)90300-R; GARLATTI M, 1993, J BIOL CHEM, V268, P6567; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HEIKKILA P, 1993, J BIOL CHEM, V268, P24677; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HU ZW, 1993, J BIOL CHEM, V268, P3610; ISHAC EJN, 1992, J CELL PHYSIOL, V152, P79, DOI 10.1002/jcp.1041520111; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; KOST DP, 1992, PATHOBIOLOGY, V60, P303, DOI 10.1159/000163740; KUNOS G, 1987, BIOCHEM PHARMACOL, V36, P1185, DOI 10.1016/0006-2952(87)90068-2; KUNOS G, 1984, TRENDS PHARMACOL SCI, V5, P380, DOI 10.1016/0165-6147(84)90476-0; LAZARWESLEY E, 1991, ENDOCRINOLOGY, V129, P1116, DOI 10.1210/endo-129-2-1116; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MCGEHEE RE, 1990, MOL CELL ENDOCRINOL, V74, P1, DOI 10.1016/0303-7207(90)90200-R; MCGEHEE RE, 1991, J RECEPTOR RES, V11, P773, DOI 10.3109/10799899109064679; MCGROGAN M, 1985, J BIOL CHEM, V260, P2307; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; QUINN PG, 1993, J BIOL CHEM, V268, P16999; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; REFSNES M, 1992, J CELL PHYSIOL, V151, P164, DOI 10.1002/jcp.1041510121; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Sambrook J, 1989, MOL CLONING LABORATO; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003	41	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15762	15767						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195230				2022-12-27	WOS:A1994NP51300058
J	KAVANAUGH, MP; WANG, H; ZHANG, Z; ZHANG, WB; WU, YN; DECHANT, E; NORTH, RA; KABAT, D				KAVANAUGH, MP; WANG, H; ZHANG, Z; ZHANG, WB; WU, YN; DECHANT, E; NORTH, RA; KABAT, D			CONTROL OF CATIONIC AMINO-ACID-TRANSPORT AND RETROVIRAL RECEPTOR FUNCTIONS IN A MEMBRANE-PROTEIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC MURINE RETROVIRUSES; CELL-SURFACE RECEPTOR; MAMMALIAN-CELLS; PLASMA-MEMBRANE; HOST RANGE; GENE; EXPRESSION; MOUSE; IDENTIFICATION; SUPERINFECTION	A partial cDNA sequence indicated that the T lymphocyte early-activation gene (Tea) encodes a protein related to the dual-function ecotropic retrovirus receptor/cationic amino acid transporter (ecoR/CAT1), and RNA blots suggested highest Tea expression in T lymphocytes and liver (MacLeod, C. L., Finley, K., Kakuda, D. Kozad, C. A., and Wilkinson, M. F. (1990) Mol. Cell. Biol. 7, 3663-3674). The sequence of full-length Tea cDNA from liver (3683 bases) predicts a 657-amino-acid protein (CAT2 alpha) with 12-14 transmembrane domains. A long (515 base) region with six initiation codons and termination codons precedes the translation start codon. The liver Tea cDNA is identical to Tea cDNA from T lymphocytes (encoding CAT2 beta) with the exception of an apparent alternatively spliced sequence encoding a hydrophilic loop of 43 amino acids. The liver-specific sequence contains unique consensus sites for phosphorylation by cyclic AMP dependent protein kinase and by protein kinase C. Injection of Xenopus oocytes with CAT2 alpha or CAT2 beta messenger RNA resulted in expression of Na+-independent cationic amino acid transport that was detected by current measurements under voltage-clamp. Although the amino acid sequences of the isoforms differ in only 21 of 43 residues with the majority of substitutions being conservative, the apparent affinity of CAT2 beta for arginine uptake was 70-fold higher than the CAT2 alpha isoform (K-m 38 mu M versus 2.7 mM). Neither isoform functioned as a receptor for ecotropic or amphotropic murine retroviruses. However, CAT1-CAT2 chimeric proteins that contain the first three putative extracellular loops of ecoR/CAT1 functioned as ecotropic receptors despite a diminished capacity to bind the viral envelope glycoprotein. The chimeric proteins also functioned as basic amino acid transporters with substrate affinities corresponding to the CATS isoform constituting the carboxyl-terminal portion. These results demonstrate that domains of these transporters can function in chimeric combinations to control viral receptor and transport functions.	OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	Oregon Health & Science University	KAVANAUGH, MP (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201, USA.		North, Richard/GQA-6156-2022; Zhang, Zheng/J-2388-2014	Zhang, Zheng/0000-0003-2497-0362	NCI NIH HHS [CA25810] Funding Source: Medline; NIDA NIH HHS [DA03160] Funding Source: Medline; NIGMS NIH HHS [GM48709] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA025810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA003160, R01DA003160] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALBRITTON LM, 1993, J VIROL, V67, P2091, DOI 10.1128/JVI.67.4.2091-2096.1993; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BESTWICK RK, 1988, P NATL ACAD SCI USA, V85, P5404, DOI 10.1073/pnas.85.15.5404; BOYD CAR, 1992, PFLUG ARCH EUR J PHY, V422, P87, DOI 10.1007/BF00381518; CHESEBRO B, 1985, VIROLOGY, V141, P119, DOI 10.1016/0042-6822(85)90188-6; CHRISTENSEN HN, 1984, P NATL ACAD SCI USA, V51, P337; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J VIROL, V67, P2097, DOI 10.1128/JVI.67.4.2097-2102.1993; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; CONE RD, 1984, P NATL ACAD SCI-BIOL, V81, P6349, DOI 10.1073/pnas.81.20.6349; GAZDAR AF, 1977, CELL, V11, P949, DOI 10.1016/0092-8674(77)90306-3; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; HARDLOGTEN ME, 1984, J BIOL CHEM, V259, P3519; KAVANAUGH MP, 1993, BIOCHEMISTRY-US, V32, P5781, DOI 10.1021/bi00073a009; KAWASAKI ES, 1991, PCR PROTOCOLS GUIDE, P21; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KIRK SJ, 1990, BIOCHEM BIOPH RES CO, V173, P660, DOI 10.1016/S0006-291X(05)80086-5; KOZAK CA, 1979, SCIENCE, V204, P69, DOI 10.1126/science.219475; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MILLER AD, 1985, MOL CELL BIOL, V5, P431, DOI 10.1128/MCB.5.3.431; PERLMUTTER RM, 1990, ENZYME, V44, P214, DOI 10.1159/000468759; PERRY RP, 1990, ENZYME, V44, P83, DOI 10.1159/000468749; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEIN WD, 1990, CHANNELS CARRIERS PU, P127; WANG H, 1991, J VIROL, V65, P6468, DOI 10.1128/JVI.65.12.6468-6477.1991; WANG H, 1992, J BIOL CHEM, V267, P23617; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; YAHI N, 1992, J VIROL, V66, P4848, DOI 10.1128/JVI.66.8.4848-4854.1992; YOSHIMOTO T, 1991, VIROLOGY, V185, P10, DOI 10.1016/0042-6822(91)90748-Z; YOSHIMOTO T, 1992, J VIROL, V66, P4377, DOI 10.1128/JVI.66.7.4377-4381.1992; YOSHIMOTO T, 1992, J VIROL, V67, P1310	37	73	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15445	15450						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195186				2022-12-27	WOS:A1994NP51300011
J	MORTENSEN, UH; RAASCHOUNIELSEN, M; BREDDAM, K				MORTENSEN, UH; RAASCHOUNIELSEN, M; BREDDAM, K			RECOGNITION OF C-TERMINAL AMIDE GROUPS BY (SERINE) CARBOXYPEPTIDASE-Y INVESTIGATED BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL PROTECTIVE PROTEIN; MALTED BARLEY	Serine carboxypeptidases have the ability to hydrolyze peptides as well as peptide amides. Previously, it has been demonstrated that Asn(51) and Glu(145) (in the protonated form) each donate a hydrogen bond to the alpha-carboxylate of peptide substrate. It is here demonstrated by characterization of carboxypeptidase Y derivatives, mutationally altered at positions 51 and 145, that the same groups are involved in the interaction with the C-terminal carboxyamide group of peptide amides. Asn(51) donates a hydrogen bond to the C=O group of the substrate, and Glu(145) (in the charged form) accepts one from the NH2 group of the substrate. Thus, the ionic state of Glu(145) is different when peptides are hydrolyzed as compared with when peptide amides are hydrolyzed. This explains why K-m for the hydrolysis of peptides increases with pH, whereas it remains constant for peptide amides. As a consequence, k(cat)/K-m for the hydrolysis of peptide amides is higher than for the hydrolysis of peptides at pH > 8. At physiological pH, peptides and peptide amides are hydrolyzed with rates of the same order of magnitude; this is in accordance with reports describing that serine carboxypeptidases are involved in the degradation of biologically active peptide amides.	CARLSBERG LAB, DEPT CHEM, DK-2500 VALBY, DENMARK				Mortensen, Uffe/AAQ-1150-2021					BONE R, 1991, METHOD ENZYMOL, V202, P643; BREDDAM K, 1984, CARLSBERG RES COMMUN, V49, P473, DOI 10.1007/BF02904400; BREDDAM K, 1984, CARLSBERG RES COMMUN, V49, P535, DOI 10.1007/BF02907554; BREDDAM K, 1987, CARLSBERG RES COMMUN, V52, P297, DOI 10.1007/BF02907172; BREDDAM K, 1980, CARLSBERG RES COMMUN, V45, P237, DOI 10.1007/BF02906177; BREDDAM K, 1986, CARLSBERG RES COMMUN, V51, P83, DOI 10.1007/BF02907561; CHRISTIANSON DW, 1987, J AM CHEM SOC, V109, P5536, DOI 10.1021/ja00252a046; FISHER JM, 1988, J BIOL CHEM, V263, P16515; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; GARDELL SJ, 1987, J BIOL CHEM, V262, P576; JACKMAN HL, 1992, J BIOL CHEM, V267, P2872; JACKMAN HL, 1990, J BIOL CHEM, V265, P11265; JOHANSEN JT, 1976, CARLSBERG RES COMMUN, V41, P1, DOI 10.1007/BF02908689; KANSTRUP A, 1991, ANAL BIOCHEM, V194, P41, DOI 10.1016/0003-2697(91)90148-M; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; MORTENSEN UH, 1994, BIOCHEMISTRY-US, V33, P508, DOI 10.1021/bi00168a016; MORTENSEN UH, 1994, J AM CHEM SOC, V116, P34, DOI 10.1021/ja00080a005; RIORDAN JF, 1973, BIOCHEMISTRY-US, V12, P3915, DOI 10.1021/bi00744a020; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SORENSEN SB, 1989, CARLSBERG RES COMMUN, V54, P193, DOI 10.1007/BF02904473; SORENSEN SB, 1986, CARLSBERG RES COMMUN, V51, P475, DOI 10.1007/BF02906889; SORENSEN SB, 1987, CARLSBERG RES COMMUN, V52, P285, DOI 10.1007/BF02907171; SVENDSEN I, 1993, FEBS LETT, V333, P39, DOI 10.1016/0014-5793(93)80371-Z; ZHOU XY, 1991, EMBO J, V10, P4041, DOI 10.1002/j.1460-2075.1991.tb04980.x	24	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15528	15532						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195197				2022-12-27	WOS:A1994NP51300023
J	CANTLEY, LG; CUNHA, MJ; ZHOU, XM				CANTLEY, LG; CUNHA, MJ; ZHOU, XM			OUABAIN-RESISTANT OR6 CELLS EXPRESS THE MURINE ALPHA(1)-SUBUNIT OF THE NA,K-ATPASE WITH A T-797-I-797 SUBSTITUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ALPHA-SUBUNIT; GENE; IDENTIFICATION; SENSITIVITY; REGION; CHAIN; CDNA	Introduction of the murine ''ouabain resistance gene'' (Levenson, R., Racaniello, V., Albritton, L., and Housman, D. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 1489-1493) into African Green monkey CV1 cells reportedly resulted in one cell line, OR6 cells, which was found to be resistant to >1 mM ouabain (English, L., Epstein, J., Cantley, L., Housman, D., and Levenson, R. (1985) J. Biol. Chem. 260, 1114-1119). The present analysis of the genomic sequence of the alpha(1)-subunit of the Na,K-ATPase from OR6 cells reveals copies of the gene for the murine and human alpha(1)-subunit of the Na,K-ATPase and not the monkey gene, indicating that the cells have been misidentified. The sequence of the murine alpha(1)-subunit from OR6 cells reveals a single point mutation encoding a T-797-I-797 amino acid substitution at the H-6 membrane border. Transfection of CV1 cells with a murine alpha(1) cDNA containing this point mutation resulted in cells with an IC50 for ouabain of approximately 5 mM. These data show that the super ouabain-resistant phenotype of OR6 cells is due to expression of a mutant form of the murine alpha(1)-subunit of the sodium pump (rather than the ouabain resistance gene) and further support the recent data suggesting involvement of the H-5-H-6 domain in ouabain inhibition of the sodium pump.	ARIAD PHARMACEUT, BOSTON, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Takeda Oncology	CANTLEY, LG (corresponding author), HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV NEPHROL, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NIDDK NIH HHS [DK18078] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018078] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURNS EL, 1993, J BIOL CHEM, V268, P25632; CANTLEY LG, 1992, J BIOL CHEM, V267, P17271; EMANUEL JR, 1988, J BIOL CHEM, V263, P7726; EMANUEL JR, 1989, MOL CELL BIOL, V9, P3744, DOI 10.1128/MCB.9.9.3744; ENGLISH LH, 1985, J BIOL CHEM, V260, P1114; EPSTEIN JA, 1988, AM J PHYSIOL, V254, pC847, DOI 10.1152/ajpcell.1988.254.6.C847; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KENT RB, 1987, SCIENCE, V237, P901, DOI 10.1126/science.3039660; LEVENSON R, 1984, P NATL ACAD SCI-BIOL, V81, P1489, DOI 10.1073/pnas.81.5.1489; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LUGO TG, 1985, BIOCHEM GENET, V23, P1, DOI 10.1007/BF00499108; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1990, J BIOL CHEM, V265, P6638; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SCHULZ JT, 1988, J BIOL CHEM, V263, P624; SWEADNER KJ, 1991, SOC GEN PHY, V46, P63; ZHOU XM, 1993, J BIOL CHEM, V268, P4126	18	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15358	15361						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195174				2022-12-27	WOS:A1994NP73800075
J	SUN, XM; COHEN, GM				SUN, XM; COHEN, GM			MG2+-DEPENDENT CLEAVAGE OF DNA INTO KILOBASE PAIR FRAGMENTS IS RESPONSIBLE FOR THE INITIAL DEGRADATION OF DNA IN APOPTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALCIUM-DEPENDENT ENDONUCLEASE; PROGRAMMED CELL-DEATH; INTERNUCLEOSOMAL FRAGMENTATION; ACTIVATION; THYMOCYTES; CHROMATIN; ABSENCE; IDENTIFICATION; PURIFICATION	Cleavage of DNA into oligonucleosomal fragments, recognizable as a DNA ladder on agarose gel electrophoresis, is usually considered as the biochemical hallmark of apoptosis. Recently, it has been shown that this internucleosomal cleavage is preceded by the formation of large fragments of DNA of greater than or equal to 700, 200-250, and 30-50 kilobase pairs (kbp) in length. Using isolated thymocyte nuclei, we now demonstrate that the formation of these large fragments is Mg2+- but not Ca2+-dependent. Further degradation of greater than or equal to 460- and 200-250-kbp fragments to 30-5O-kbp fragments but not oligonucleosomal cleavage is also Mg2+-dependent but is facilitated by Ca2+. In contrast, formation of oligonucleosomal fragments does not occur in the presence of either Ca2+ or Mg2+ alone but requires the presence of both cations. These results sup port the hypothesis that the formation of these large fragments and the subsequent internucleosomal cleavage are distinct steps in the degradation of DNA in apoptosis in thymocytes.	UNIV LEICESTER, MRC, TOXICOL UNIT, LEICESTER LE1 9HN, ENGLAND	University of Leicester			Cohen, Gerald M/A-1687-2008					ARENDS MJ, 1990, AM J PATHOL, V136, P593; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BELLARD M, 1989, METHOD ENZYMOL, V170, P317; BROWN DG, 1993, J BIOL CHEM, V268, P3037; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; COHEN JJ, 1984, J IMMUNOL, V132, P38; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; FILIPSKI J, 1990, EMBO J, V9, P1319, DOI 10.1002/j.1460-2075.1990.tb08241.x; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GOTTLIEB J, 1990, J BIOL CHEM, V265, P10836; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P475, DOI 10.1016/0006-291X(73)90736-5; KAWABATA H, 1993, BIOCHEM BIOPH RES CO, V191, P247, DOI 10.1006/bbrc.1993.1209; KOKILEVA L, 1981, INT J BIOCHEM, V13, P483, DOI 10.1016/0020-711X(81)90121-X; MCCONKEY DJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P284, DOI 10.1016/0003-9861(90)90261-V; NELIPOVICH PA, 1988, INT J RADIAT BIOL, V53, P749, DOI 10.1080/09553008814551111; NIKONOVA LV, 1982, BIOCHIM BIOPHYS ACTA, V699, P281, DOI 10.1016/0167-4781(82)90118-X; OBERHAMMER F, 1993, J CELL SCI, V104, P317; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; ORRENIUS S, 1992, TOXICOL LETT, V64-5, P357, DOI 10.1016/0378-4274(92)90208-2; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PRESTON RR, 1990, SCIENCE, V250, P285, DOI 10.1126/science.2218533; SOOKITOTH A, 1989, EXP CELL RES, V184, P44, DOI 10.1016/0014-4827(89)90362-5; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; TOMEI LD, 1993, P NATL ACAD SCI USA, V90, P853, DOI 10.1073/pnas.90.3.853; WALKER PR, 1986, J BIOL CHEM, V261, P7044; WALKER PR, 1991, CANCER RES, V51, P1078; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WILLIAMS G T, 1992, Trends in Cell Biology, V2, P263, DOI 10.1016/0962-8924(92)90198-V; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	33	130	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14857	14860						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195114				2022-12-27	WOS:A1994NP73800003
J	BURNETT, VL; LAWTON, MP; PHILPOT, RM				BURNETT, VL; LAWTON, MP; PHILPOT, RM			CLONING AND SEQUENCING OF FLAVIN-CONTAINING MONOOXYGENASES FMO3 AND FMO4 FROM RABBIT AND CHARACTERIZATION OF FMO3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG-LIVER-MICROSOMES; FUNCTION AMINE OXIDASE; MULTIPLE FORMS; GEL-ELECTROPHORESIS; COVALENT STRUCTURE; RIBONUCLEIC-ACID; MOUSE; PURIFICATION; LUNG; GENE	The flavin-containing monooxygenases (FMO) are a family of enzymes that contain putative FAD- and NADPH-binding domains within the first 200 residues of their N termini. The cDNAs encoding these enzymes contain an area of relatively high identity over the 5' half of the coding region. Rabbit genomic DNA was probed under low stringency conditions, with a mixture of 5' cDNA fragments encoding rabbit FMO1, FMO2, or FMO5. Bands associated specifically with FMO1, FMO2, or FMO5 were resolved by analysis at high stringency with individual probes. Several bands were detected that could not be assigned to FMO1, FMO2, or FMO5. The behavior of the 5' probes at low versus high stringency was used to facilitate the isolation of cDNAs corresponding to the unknown DNA bands. A cDNA library was constructed from rabbit liver mRNA and screened under low stringency hybridization conditions (30 degrees C, 50% formamide, 1 x SSC, 0.1% SDS) with the mixture of 5' FMO1, FMO2, and FMO5 cDNA probes. A total of 157 clones was detected. Of these, 117 clones remained under high stringency hybridization conditions (65 degrees C, 50% formamide, 0.1 x SSC, 0.1% SDS) and were identified as FMO1 (95 clones) or FMO5 (22 clones). Of the 40 remaining clones, 36 were characterized by sequence analysis as encoding FMO3, previously identified at the protein level by Ozols (Ozols, J. (1991) Arch. Biochem. Biophys. 290, 103-115) as a second rabbit liver FMO. Four clones were shown to encode an FMO not previously described for the rabbit, FMO4. No clones encoding FMO2 were isolated from the liver library. Sequence analysis revealed that FMO3 and FMO4 are 56% identical, and analysis of genomic DNA indicated that each is encoded by a single gene. Message distribution was tissue-, species-, and form-specific. The properties of FMO3 cDNA expressed in Escherichia coli were found to be more similar to those of FMO1 than FMO2, but to differ significantly from both. Rabbit genomic DNA was probed under conditions of low stringency with a mixture of 5' cDNA fragments encoding all five FMO forms and produced results consistent with the possibility of one additional FMO.	NIEHS,CELLULAR & MOLEC PHARMACOL LAB,RES TRIANGLE PK,NC 27709; N CAROLINA STATE UNIV,DEPT TOXICOL,RALEIGH,NC 27695	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; North Carolina State University								ARMSTRONG KA, 1989, YEAST GENETIC ENG, P165; ATTAASAFOADJEI E, 1993, J BIOL CHEM, V268, P9681; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AYESH R, 1990, PHARMACOL THERAPEUT, V45, P387, DOI 10.1016/0163-7258(90)90074-C; BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANNAN GA, 1982, MOL PHARMACOL, V22, P787; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVEREUX TR, 1977, CHEM-BIOL INTERACT, V18, P277, DOI 10.1016/0009-2797(77)90014-X; DIXIT A, 1984, ARCH BIOCHEM BIOPHYS, V233, P50, DOI 10.1016/0003-9861(84)90600-3; DOLPHIN C, 1991, J BIOL CHEM, V266, P12379; DOLPHIN CT, 1992, BIOCHEM J, V287, P261, DOI 10.1042/bj2870261; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GASSER R, 1990, BIOCHEMISTRY-US, V29, P119, DOI 10.1021/bi00453a014; GASSER R, 1988, MOL PHARMACOL, V32, P22; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GUAN SH, 1991, BIOCHEMISTRY-US, V30, P9892, DOI 10.1021/bi00105a012; HAJJAR NP, 1982, BIOCHEM PHARMACOL, V31, P745, DOI 10.1016/0006-2952(82)90458-0; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; ITOH K, 1993, BIOCHIM BIOPHYS ACTA, V1173, P165, DOI 10.1016/0167-4781(93)90177-F; KIMURA T, 1983, BIOCHEM BIOPH RES CO, V110, P640, DOI 10.1016/0006-291X(83)91197-X; LAWTON MP, 1994, ARCH BIOCHEM BIOPHYS, V308, P254, DOI 10.1006/abbi.1994.1035; LAWTON MP, 1993, J BIOL CHEM, V268, P5728; LAWTON MP, 1991, MOL PHARMACOL, V40, P692; LAWTON MP, 1990, J BIOL CHEM, V265, P5855; LI SSL, 1985, EUR J BIOCHEM, V149, P215, DOI 10.1111/j.1432-1033.1985.tb08914.x; LOMRI N, 1992, P NATL ACAD SCI USA, V89, P1685, DOI 10.1073/pnas.89.5.1685; MCCLELLAND M, 1982, NUCLEIC ACIDS RES, V10, P7865, DOI 10.1093/nar/10.23.7865; NIKBAKHT KN, 1992, PHARMACOGENETICS, V2, P207, DOI 10.1097/00008571-199210000-00003; OZOLS J, 1990, J BIOL CHEM, V265, P10289; OZOLS J, 1991, ARCH BIOCHEM BIOPHYS, V290, P103, DOI 10.1016/0003-9861(91)90596-B; PERNECKY SJ, 1993, P NATL ACAD SCI USA, V90, P2651, DOI 10.1073/pnas.90.7.2651; POULSEN LL, 1977, ARCH BIOCHEM BIOPHYS, V183, P563, DOI 10.1016/0003-9861(77)90391-5; SABOURIN PJ, 1984, INT J BIOCHEM, V16, P713, DOI 10.1016/0020-711X(84)90180-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUSEN PJ, 1990, J BIOL CHEM, V265, P6139; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMYSER BP, 1985, BIOCHEM PHARMACOL, V34, P1145, DOI 10.1016/0006-2952(85)90487-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TYNES RE, 1985, BIOCHEM BIOPH RES CO, V126, P1069, DOI 10.1016/0006-291X(85)90294-3; TYNES RE, 1987, MOL PHARMACOL, V31, P569; VENKATESH K, 1991, BIOCHEM PHARMACOL, V42, P1411, DOI 10.1016/0006-2952(91)90453-C; WELLS D, 1985, P NATL ACAD SCI USA, V82, P2834, DOI 10.1073/pnas.82.9.2834; WILLIAMS DE, 1984, BIOCHEM BIOPH RES CO, V125, P116, DOI 10.1016/S0006-291X(84)80342-3; YAMADA H, 1990, ARCH BIOCHEM BIOPHYS, V280, P305, DOI 10.1016/0003-9861(90)90334-U; Ziegler D. M., 1988, DRUG METAB REV, V6, P1; ZIEGLER DM, 1977, TRENDS BIOCHEM SCI, V2, P79, DOI 10.1016/0968-0004(77)90042-1; ZIEGLER DM, 1972, ARCH BIOCHEM BIOPHYS, V150, P116, DOI 10.1016/0003-9861(72)90017-3; Ziegler DM., 1980, ENZYMATIC BASIS DETO, VI, P201	50	48	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14314	14322						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188717				2022-12-27	WOS:A1994NL60600089
J	ZHUANG, P; YIN, M; HOLLAND, JC; PETERSON, CB; HOWELL, EE				ZHUANG, P; YIN, M; HOLLAND, JC; PETERSON, CB; HOWELL, EE			ARTIFICIAL DUPLICATION OF THE R67 DIHYDROFOLATE-REDUCTASE GENE TO CREATE PROTEIN ASYMMETRY - EFFECTS ON PROTEIN-ACTIVITY AND FOLDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HELICAL PROTEIN; PLASMID R67; STABILITY; PHENYLALANINE-137; DENATURATION; CONFORMATION; PEPTIDES; BINDING	R67 dihydrofolate reductase (DHFR), encoded by an R plasmid, provides resistance to the antibacterial drug trimethoprim. This enzyme does not exhibit any structural or sequence homologies with chromosomal DHFR. A recent crystal structure of tetrameric R67 DHFR (D. Matthews, X. Nguyen-huu, and N. Narayana, personal communication) shows a single pore traversing the length of the molecule. Numerous physical and kinetic experiments suggest the pore is the active site. Since the center of the pore possesses exact 222 symmetry, mutagenesis of residues designed to explore substrate binding will probably also affect cofactor binding. As a first step in breaking this inevitable symmetry in R67 DHFR, the gene has been duplicated. The protein product, R67 DHFR(double), is twice the molecular mass of native R67 DHFR and is fully active with k(cat) = 1.2 s-1, K(m(NADPH)) = 2.7 muM and K(m(dihydrofolate)) = 6.3 muM. Equilibrium unfolding studies in guanidine-HCl indicate R67 DHFR(double) is more stable than native R67 DHFR at physically reasonable protein concentrations. Microcalorimetry studies show native R67 DHFR undergoes fully reversible thermal unfolding. Unfolding can be described by a two-state process since a ratio of DELTAH(calorimetric) to DELTAH(van't Hoff) equals 0.96. In contrast, thermal unfolding of R67 DHFR(double) is not fully reversible and possesses an oligomerization component introduced by the gene duplication event.	UNIV TENNESSEE, DEPT BIOCHEM, KNOXVILLE, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville				Howell, Elizabeth/0000-0001-6157-433X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM035308, R01GM035308] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35308] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABE LM, 1992, PROTEIN SCI, V1, P1244, DOI 10.1002/pro.5560011003; BACCANARI D, 1975, BIOCHEMISTRY-US, V14, P5267, DOI 10.1021/bi00695a006; BERNASCONI CF, 1976, RELAXATION KINETICS, P11; BLAKE CCF, 1977, NATURE, V268, P115, DOI 10.1038/268115a0; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BLAKLEY RL, 1960, NATURE, V188, P231, DOI 10.1038/188231a0; BRISSON N, 1984, GENE, V28, P271, DOI 10.1016/0378-1119(84)90266-X; CHAN HS, 1989, J CHEM PHYS, V90, P492, DOI 10.1063/1.456500; CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9660, DOI 10.1073/pnas.87.24.9660; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; DILANNI C L, 1990, Journal of Biological Chemistry, V265, P17348; DUNN SMJ, 1990, BIOCHEMISTRY-US, V29, P8569, DOI 10.1021/bi00489a010; GITTELMAN MS, 1990, BIOCHEMISTRY-US, V29, P7011, DOI 10.1021/bi00482a009; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HO SP, 1987, J AM CHEM SOC, V109, P6751, DOI 10.1021/ja00256a032; HOLLAND JC, 1993, IN PRESS ADV EXPT ME; HOLTZER A, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P177; HORECKER BL, 1948, J BIOL CHEM, V175, P385; HOWELL EE, 1990, BIOCHEMISTRY-US, V29, P8561, DOI 10.1021/bi00489a009; KRAUT J, 1987, BIOL MACROMOL ASSEM, V3, P1; MATTHEWS DA, 1986, BIOCHEMISTRY-US, V25, P4194, DOI 10.1021/bi00363a005; MICHINSON C, 1989, BIOCHEMISTRY-US, V28, P4807; MORRISON JF, 1990, CHEMISTRY AND BIOLOGY OF PTERIDINES 1989, P728; NICHOLS R, 1993, BIOCHEMISTRY-US, V32, P1695, DOI 10.1021/bi00058a002; Pace C.N., 1990, PROTEIN STRUCTURE PR, P311; PACE CN, 1991, ANGEW CHEM INT EDIT, V30, P343, DOI 10.1002/anie.199103433; REECE LJ, 1991, BIOCHEMISTRY-US, V30, P10895, DOI 10.1021/bi00109a013; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SHORTLE D, 1989, J BIOL CHEM, V264, P5315; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; TAKAHASHI K, 1981, BIOCHEMISTRY-US, V20, P6185, DOI 10.1021/bi00524a042; TARTOF KD, 1987, FOCUS, V9, P12; VILLAFRANCA JE, 1987, BIOCHEMISTRY-US, V26, P2182, DOI 10.1021/bi00382a017; WARD WHJ, 1988, BIOCHEMISTRY-US, V27, P1041, DOI 10.1021/bi00403a029; YANG YR, 1980, P NATL ACAD SCI-BIOL, V77, P5187, DOI 10.1073/pnas.77.9.5187	36	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22672	22679						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226776				2022-12-27	WOS:A1993MD34800072
J	GOLDBERG, Y; TREIER, M; GHYSDAEL, J; BOHMANN, D				GOLDBERG, Y; TREIER, M; GHYSDAEL, J; BOHMANN, D			REPRESSION OF AP-1-STIMULATED TRANSCRIPTION BY C-ETS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; ETS-RELATED PROTEIN; DNA-BINDING; C-ETS; ACTIVATION DOMAINS; RESPONSE ELEMENT; ANTIGEN RECEPTOR; LEUKEMIA-VIRUS; GENE FAMILY; V-JUN	The transcriptional activities of c-Ets-1 and v-Ets and their functional interaction with the AP-1 factor c-Jun were investigated. Several recombinant Ets proteins were produced and purified either from bacteria or from insect cells. Plasmid DNAs that contained the polyoma virus enhancer Ets/AP-1 element were used as templates for in vitro transcription assays in the presence of HeLa nuclear extract and Various combinations of the Jun and Ets proteins. Under these conditions full-length c-Ets-1 on its own does not markedly influence transcription but abolishes the strong transcriptional stimulation normally elicited by Jun. This repression depends on the Ets-binding site and on specific features of c-Ets-1 structure, as both v-Ets and a natural splicing variant c-Ets-1 (Delta VII) fail to inhibit Jun activity. These findings suggest that c-Ets may act both as a transcriptional repressor or activator depending on promoter context and splicing pattern.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			GHYSDAEL, Jacques/F-3377-2013; Treier, Mathias/AAD-6388-2021	Goldberg, Yves/0000-0001-7446-8595				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BONLUKOS KE, 1989, MOL CELL BIOL, V9, P5718; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GEGONNE A, 1992, NEW BIOL, V4, P512; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HO IC, 1990, J EXP MED, V172, P1443, DOI 10.1084/jem.172.5.1443; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MIYAMOTO NG, 1984, NUCLEIC ACIDS RES, V12, P8778; MIYATAKE S, 1991, MOL CELL BIOL, V11, P5894, DOI 10.1128/MCB.11.12.5894; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PAPAVASSILIOU AG, 1992, ANAL BIOCHEM, V203, P302, DOI 10.1016/0003-2697(92)90317-Z; POGNONEC P, 1989, ONCOGENE, V4, P691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; POGNONEC P, 1990, ONCOGENE, V5, P603; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; RAO VN, 1992, ONCOGENE, V7, P65; REDDY ESP, 1988, ONCOGENE RES, V3, P239; Sambrook J, 1989, MOL CLONING LABORATO; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WERNERT N, 1992, AM J PATHOL, V140, P119; WILDEMAN AG, 1984, EMBO J, V3, P3129, DOI 10.1002/j.1460-2075.1984.tb02269.x; WISDOM R, 1992, GENE DEV, V6, P667, DOI 10.1101/gad.6.4.667; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	57	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16566	16573						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206973				2022-12-27	WOS:A1994NR29600010
J	FAVRE, B; ZOLNIEROWICZ, S; TUROWSKI, P; HEMMINGS, BA				FAVRE, B; ZOLNIEROWICZ, S; TUROWSKI, P; HEMMINGS, BA			THE CATALYTIC SUBUNIT OF PROTEIN PHOSPHATASE 2A IS CARBOXYL-METHYLATED IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; T-ANTIGEN; PHOSPHORYLASE-PHOSPHATASE; SUBSTRATE-SPECIFICITY; SIGNAL TRANSDUCTION; ESTERIFIED PROTEINS; CELLULAR-REGULATION; OKADAIC ACID; B-SUBUNIT; TYPE-2A	We have used polyclonal antibodies against an internal peptide (residues 169 to 182; Ab(169/182)) and a peptide corresponding to the carboxyl terminus (residues 299 to 309; Ab(299/309)) to look for in vivo modifications of protein phosphatase 2A catalytic (PP2Ac) subunit. Treatment of extracts from human breast cancer (MCF7) cells with either alkali or ethanol increased immunoreactivity of PP2Ac subunit severalfold on Western blots with Ab(299/309), but did not apparently change molecular weight or isoelectric point of the protein. In contrast, immunoreactivity with Ab(169/182) was unchanged by these treatments. Subsequently, we demonstrated that the increase in PP2Ac subunit recognition by Ab(299/309) coincides with the demethylation of this protein at the carboxyl-terminal leucine (Leu(309)). Methylation of PP2Ac subunit, in vitro, increases its activity toward both phosphorylase a and a phosphopeptide. The carboxyl-terminal sequence (TPDYJFL) of PP2Ac subunit is completely conserved between mammals, yeast, fruit fly, and plants which suggests that regulation of this enzyme activity by carboxyl-terminal methylation has been conserved during evolution.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; AGOSTINIS P, 1990, EUR J BIOCHEM, V189, P235, DOI 10.1111/j.1432-1033.1990.tb15482.x; ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; BINSTOCK J, 1984, METHOD ENZYMOL, V106, P310; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT H, 1974, BIOCHEM BIOPH RES CO, V61, P598, DOI 10.1016/0006-291X(74)90999-1; CHELSKY D, 1985, BIOCHEMISTRY-US, V24, P6651, DOI 10.1021/bi00344a053; CHELSKY D, 1984, ANAL BIOCHEM, V141, P143, DOI 10.1016/0003-2697(84)90437-8; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; GALINDO E, 1992, P NATL ACAD SCI USA, V89, P7398, DOI 10.1073/pnas.89.16.7398; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; GUY GR, 1993, J BIOL CHEM, V268, P2141; HARLOW E, 1988, ANTIBODIES LABORATOR; Hayashi R, 1976, Methods Enzymol, V45, P568; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KATO K, 1974, BIOCHIM BIOPHYS ACTA, V358, P299, DOI 10.1016/0005-2744(74)90460-4; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; KIM SD, 1984, METHOD ENZYMOL, V106, P295; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE J, 1993, J BIOL CHEM, V268, P19192; LUDLOW JW, 1992, ONCOGENE, V7, P1011; LUTZ MP, 1993, J BIOL CHEM, V268, P12136; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MURRAY ED, 1986, J BIOL CHEM, V261, P306; NAJBAUER J, 1991, ANAL BIOCHEM, V197, P412, DOI 10.1016/0003-2697(91)90413-N; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Rubin C S, 1974, Methods Enzymol, V38, P308; SCHLENDER KK, 1986, BIOCHIM BIOPHYS ACTA, V889, P200, DOI 10.1016/0167-4889(86)90105-9; SHACTER E, 1984, ANAL BIOCHEM, V138, P416, DOI 10.1016/0003-2697(84)90831-5; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; USUI H, 1988, J BIOL CHEM, V263, P3752; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; XIE HY, 1993, J BIOL CHEM, V268, P13364; XIE HY, 1994, J BIOL CHEM, V269, P1981; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484	54	160	171	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16311	16317						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206937				2022-12-27	WOS:A1994NQ72900056
J	GIROS, B; WANG, YM; SUTER, S; MCLESKEY, SB; PIFL, C; CARON, MG				GIROS, B; WANG, YM; SUTER, S; MCLESKEY, SB; PIFL, C; CARON, MG			DELINEATION OF DISCRETE DOMAINS FOR SUBSTRATE, COCAINE, AND TRICYCLIC ANTIDEPRESSANT INTERACTIONS USING CHIMERIC DOPAMINE-NOREPINEPHRINE TRANSPORTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CLONING; EXPRESSION	Neurotransmitter transporters determine the intensity and duration of signal transduction by controlling the rapid removal of transmitter molecules from the synaptic cleft. The importance of their function is further reflected by the medical and social implications of compounds that inhibit their activity such as the antidepressants and cocaine. Molecular characterization of these transporters has revealed that they are members of a large family of membrane proteins with 12 putative transmembrane domains. However, little information exists as to whether discrete domains of these proteins mediate the various defined functions of these transporters. In this study, we constructed a series of chimeras between two structurally related but pharmacologically distinct transporters, the dopamine and norepinephrine transporters. The properties of these chimeric transporters suggest that distinct regions of these molecules determine these individual functions. Regions from the amino-terminal through the first five transmembrane domains are likely to be involved in the uptake mechanisms and ionic dependence. Regions within transmembrane domains 6-8 determine tricyclic antidepressant binding and cocaine interactions, whereas the carboxyl-terminal region encompassing transmembrane domain 9 through the COOH-terminal tail appears to be responsible for the stereoselectivity and high affinity for substrates. The dissociation of the substrate uptake and cocaine binding properties of these transporters further raises the possibility that antagonists of cocaine action devoid of uptake blockade activity might be developed for the clinical management of cocaine addiction.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University	GIROS, B (corresponding author), DUKE UNIV,MED CTR,DEPT CELL BIOL,HOWARD HUGHES MED INST LABS,BOX 3287,DURHAM,NC 27710, USA.		GIROS, Bruno/ABD-5790-2021	GIROS, Bruno/0000-0001-5876-9822; Pifl, Christian/0000-0003-1456-4264	NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH040159, P50MH040159] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-44221, MH-40159] Funding Source: Medline; NINDS NIH HHS [NS-15976] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; CARON MG, 1993, NATURE, V366, P409, DOI 10.1038/366409a0; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GIROS B, 1992, MOL PHARMACOL, V42, P383; KANNER BI, 1983, BIOCHIM BIOPHYS ACTA, V726, P293, DOI 10.1016/0304-4173(83)90013-7; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KITAYAMA S, 1993, SYNAPSE, V15, P58, DOI 10.1002/syn.890150107; MCELVAIN JS, 1992, BIOCHEM PHARMACOL, V43, P2189, DOI 10.1016/0006-2952(92)90178-L; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PIFL C, 1993, J NEUROSCI, V13, P4246, DOI 10.1523/jneurosci.13-10-04246.1993; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; UHL GR, 1992, TRENDS PHARMACOL SCI, V13, P421, DOI 10.1016/0165-6147(92)90133-Q; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; VANDENBERG OJ, 1992, MOL BRAIN RES, V15, P161	18	255	258	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15985	15988						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206893				2022-12-27	WOS:A1994NQ72900008
J	MCKENNA, MP; HEKMATSCAFE, DS; GAINES, P; CARLSON, JR				MCKENNA, MP; HEKMATSCAFE, DS; GAINES, P; CARLSON, JR			PUTATIVE DROSOPHILA PHEROMONE-BINDING PROTEINS EXPRESSED IN A SUBREGION OF THE OLFACTORY SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOGASTER MEIGEN DIPTERA; PHENOL-CHLOROFORM EXTRACTION; SINGLE-STEP METHOD; ODORANT-BINDING; MOLECULAR-CLONING; MANDUCA-SEXTA; ANTENNAL SENSILLA; ANTHERAEA-PERNYI; GENETIC-ANALYSIS; MAXILLARY PALP	Four genes expressed in the olfactory system of Drosophila melanogaster have been identified by subtractive hybridization. Two of these genes, OS-E and OS-F, are related to genes encoding moth pheromone-binding proteins. The OS-E and OS-F genes are tightly linked and are expressed in a subregion of the antenna (the primary olfactory organ), A protein sequence analysis suggests the possibility that pheromone-binding proteins are members of a larger class of proteins, extending beyond the olfactory system. The predicted product of a third gene, OS-D, shares features common to vertebrate odorant-binding proteins, but has a primary structure unlike odorant-binding proteins. The fourth gene, OS-C, encodes a novel 13-kDa protein that contains a putative nuclear import sequence and an acid-rich region. The expression patterns of these genes differ within the antenna; their transcript distributions support the notion of specialized roles for different olfactory sensilla. The functions of the OS gene products have not been demonstrated; however, the potential identification of pheromone binding proteins in Drosophila, a species with well characterized genetics, may offer a means of analyzing the function of these molecules that is not available in other systems.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511	Yale University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036862] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC00139] Funding Source: Medline; NIGMS NIH HHS [GM 36862] Funding Source: Medline; NIMH NIH HHS [MH18397] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALCORTA E, 1991, J NEUROPHYSIOL, V65, P702, DOI 10.1152/jn.1991.65.3.702; AYER RK, 1992, J NEUROBIOL, V23, P965, DOI 10.1002/neu.480230804; AYYUB C, 1990, J NEUROGENET, V6, P243, DOI 10.3109/01677069009107114; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BENZER S, 1967, P NATL ACAD SCI USA, V58, P1112, DOI 10.1073/pnas.58.3.1112; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; BOGUSKI MS, 1992, J LIPID RES, V33, P957; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BREER H, 1990, INSECT BIOCHEM, V20, P735, DOI 10.1016/0020-1790(90)90088-C; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CHADWICK R, 1987, EMBO J, V6, P779, DOI 10.1002/j.1460-2075.1987.tb04820.x; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; DALESSIO JM, 1987, FOCUS, V9, P1; DEAR TN, 1991, BIOCHEMISTRY-US, V30, P10376, DOI 10.1021/bi00107a003; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GYORGYI TK, 1988, P NATL ACAD SCI USA, V85, P9851, DOI 10.1073/pnas.85.24.9851; HAFEN E, 1986, DROSOPHILA PRACTICAL, P139; HELFAND SL, 1989, P NATL ACAD SCI USA, V86, P2908, DOI 10.1073/pnas.86.8.2908; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HIGGINS HG, 1992, CABIOS, V8, P189; HUBER R, 1987, J MOL BIOL, V198, P499, DOI 10.1016/0022-2836(87)90296-8; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; ITOH T, 1991, INT J INSECT MORPHOL, V20, P235, DOI 10.1016/0020-7322(91)90013-Y; KAISSLING KE, 1986, ANNU REV NEUROSCI, V9, P121, DOI 10.1146/annurev.ne.09.030186.001005; KAWASAKI H, 1985, ANAL BIOCHEM, V148, P297, DOI 10.1016/0003-2697(85)90232-5; KRIEGER J, 1991, BIOCHIM BIOPHYS ACTA, V1088, P277, DOI 10.1016/0167-4781(91)90064-S; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LEE KH, 1987, SCIENCE, V235, P1053, DOI 10.1126/science.3493528; LERNER MR, 1990, CHEM SENSES, V15, P191, DOI 10.1093/chemse/15.2.191; LILLY M, 1990, GENETICS, V124, P293; MCKENNA M, 1989, P NATL ACAD SCI USA, V86, P8118, DOI 10.1073/pnas.86.20.8118; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MONACO HL, 1992, BIOPOLYMERS, V32, P457, DOI 10.1002/bip.360320425; MONTE P, 1989, BEHAV GENET, V19, P267, DOI 10.1007/BF01065910; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; PAK WL, 1978, PHYSL VISUAL FLIGHT, P553; PALAZZOLO MJ, 1987, GENE, V52, P197, DOI 10.1016/0378-1119(87)90046-1; PALAZZOLO MJ, 1989, NEURON, V3, P527, DOI 10.1016/0896-6273(89)90211-0; PELOSI P, 1990, CHEM SENSES, V15, P205, DOI 10.1093/chemse/15.2.205; PEVSNER J, 1990, CHEM SENSES, V15, P217, DOI 10.1093/chemse/15.2.217; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RAHA D, 1994, J NEUROBIOL, V25, P169, DOI 10.1002/neu.480250208; RAMING K, 1990, J COMP PHYSIOL B, V160, P503, DOI 10.1007/BF00258977; RAMING K, 1989, FEBS LETT, V256, P215, DOI 10.1016/0014-5793(89)81751-X; RIESGOESCOVAR J, 1992, J NEUROBIOL, V23, P947, DOI 10.1002/neu.480230803; RODRIGUES V, 1978, P INDIAN ACAD SCI B, V87, P147; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANES JR, 1976, DEV BIOL, V51, P282, DOI 10.1016/0012-1606(76)90144-5; SCHNEIDER D, 1992, NATURWISSENSCHAFTEN, V79, P241, DOI 10.1007/BF01175388; SINGH RN, 1985, INT J INSECT MORPHOL, V14, P291; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; SPIETH H, 1983, MATING BEHAVIOR SEXU, P223; STEINBRECHT RA, 1992, CELL TISSUE RES, V270, P287, DOI 10.1007/BF00328015; STOCKER RF, 1988, DEV BIOL, V127, P12, DOI 10.1016/0012-1606(88)90184-4; STOCKER RF, 1983, CELL TISSUE RES, V232, P237, DOI 10.1007/BF00213783; STOCKER RF, 1989, BEHAV GENET, V19, P371, DOI 10.1007/BF01066165; VENKATESH S, 1984, INT J INSECT MORPHOL, V13, P51, DOI 10.1016/0020-7322(84)90032-1; Vogt R.G., 1987, P385; VOGT RG, 1981, NATURE, V293, P161, DOI 10.1038/293161a0; VOGT RG, 1991, J NEUROBIOL, V22, P74, DOI 10.1002/neu.480220108; VOGT RG, 1991, J NEUROSCI, V11, P2972; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALKER JM, 1978, NATURE, V271, P281, DOI 10.1038/271281a0; WOODARD C, 1992, J NEUROGENET, V8, P17, DOI 10.3109/01677069209167269; WOODARD C, 1989, GENETICS, V123, P315; [No title captured]	72	282	340	2	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16340	16347						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206941				2022-12-27	WOS:A1994NQ72900060
J	VOGEL, U; JENSEN, KF				VOGEL, U; JENSEN, KF			EFFECTS OF GUANOSINE 3',5'-BISDIPHOSPHATE (PPGPP) ON RATE OF TRANSCRIPTION ELONGATION IN ISOLEUCINE-STARVED ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA OPERON; SOURCE SHIFT-DOWN; POOL SIZE; EXPRESSION; ORGANIZATION; TERMINATION; COMPONENTS; POLYMERASE; STARVATION; INVITRO	We measured the transcription elongation rate on two mRNA genes, i.e. infB and lacZ, and on a part of the rrnB gene under conditions when wild type (rel(+)) Escherichia coli and relaxed (relA) mutants were exposed to isoleucine starvation. The RNA chain growth rates were calculated from the time lag between induction of transcription and the appearance of specific hybridization to probes complementary to the 3' ends of the genes, i.e. from the transcription time. The rate of mRNA chain elongation responded differently in rel(+) and relA strains exposed to isoleucine starvation as it decreased (similar to 50%) in rel(+) strains that accumulated high concentrations of guanosine 3',5'-bisdiphosphate (ppGpp) and increased (similar to 15%) the relA mutant whose ppGpp pool decayed during starvation. These results show that ppGpp inhibits mRNA chain elongation in vivo. However, stable RNA chain elongation appeared unaffected by ppGpp pool size and was twice as fast as mRNA chain elongation in exponentially growing cells.			VOGEL, U (corresponding author), UNIV COPENHAGEN,INST MOLEC BIOL,DEPT BIOL CHEM,SOLVGADE 83,DK-1307 COPENHAGEN K,DENMARK.		Vogel, Ulla B/I-5048-2012; Vogel, Ulla/ABC-2212-2020	Vogel, Ulla B/0000-0001-6807-1524; Vogel, Ulla/0000-0001-6807-1524				ANDERSEN JT, 1991, MOL MICROBIOL, V5, P327, DOI 10.1111/j.1365-2958.1991.tb02113.x; BARACCHINI E, 1988, J BIOL CHEM, V263, P2597; BERG KL, 1989, J MOL BIOL, V209, P345, DOI 10.1016/0022-2836(89)90002-8; Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; BROSIUS J, 1981, J MOL BIOL, V148, P107, DOI 10.1016/0022-2836(81)90508-8; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; CLARK DJ, 1967, J MOL BIOL, V23, P99, DOI 10.1016/S0022-2836(67)80070-6; CONDON C, 1993, EMBO J, V12, P4305, DOI 10.1002/j.1460-2075.1993.tb06115.x; HANSEN MT, 1975, J BACTERIOL, V122, P585, DOI 10.1128/JB.122.2.585-591.1975; HERNANDEZ VJ, 1993, J BIOL CHEM, V268, P10851; HERNANDEZ VJ, 1990, J BIOL CHEM, V265, P11605; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; JOHNSEN K, 1977, J BACTERIOL, V131, P18, DOI 10.1128/JB.131.1.18-29.1977; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; LAGOSKY PA, 1981, J BIOL CHEM, V256, P1651; LEAVITT RI, 1962, J BACTERIOL, V83, P624, DOI 10.1128/JB.83.3.624-630.1962; LINN T, 1985, PLASMID, V14, P134, DOI 10.1016/0147-619X(85)90073-3; MOLIN S, 1977, J BACTERIOL, V131, P7, DOI 10.1128/JB.131.1.7-17.1977; PLUMBRIDGE JA, 1983, J MOL BIOL, V167, P227, DOI 10.1016/S0022-2836(83)80333-7; SORENSEN MA, 1989, J MOL BIOL, V207, P365, DOI 10.1016/0022-2836(89)90260-X; SQUIRES CL, 1993, P NATL ACAD SCI USA, V90, P970, DOI 10.1073/pnas.90.3.970; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TURNBOUGH CL, 1983, P NATL ACAD SCI-BIOL, V80, P368, DOI 10.1073/pnas.80.2.368; VOGEL U, 1991, J BACTERIOL, V173, P1168, DOI 10.1128/jb.173.3.1168-1174.1991; VOGEL U, 1992, MOL MICROBIOL, V6, P2191, DOI 10.1111/j.1365-2958.1992.tb01393.x	25	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16236	16241						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206927				2022-12-27	WOS:A1994NQ72900045
J	LITHGOW, T; JUNNE, T; WACHTER, C; SCHATZ, G				LITHGOW, T; JUNNE, T; WACHTER, C; SCHATZ, G			YEAST MITOCHONDRIA LACKING THE 2 IMPORT RECEPTORS MAS20P AND MAS70P CAN EFFICIENTLY AND SPECIFICALLY IMPORT PRECURSOR PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; INTERMEMBRANE SPACE; CYTOCHROME-B2; COMPLEX; CARRIER; STEPS; MOM19; ATP	Mas20p and Mas70p are integral proteins of the yeast mitochondrial outer membrane that appear to function as receptors for precursor proteins imported from the cytosol. Loss of either receptor alone does not block import or kill the cells, but deletion of Mas20p causes loss of respiration (Ramage, L., Junne, T., Hahne, K., Lithgow, T, and Schatz, G. (1993) EMBO J. 12, 4115-4123). Here we show that this respiratory deficiency is only temporary; given time to adapt, virtually all cells lacking Mas20p regain respiration without regaining Mas20p. The respiratory defect can also be suppressed (at a frequency of about 10(-6)) by a dominant mutation of a single nuclear gene. The suppressed cells, unlike the unsuppressed ones, tolerate disruption of the MAS70 gene. The resulting double disruptants lack both Mas20p and Mas70p, yet are viable and able to respire. Protein import into mitochondria isolated from these cells is efficient, specific, and highly sensitive to protease treatment. We propose that at least one additional mitochondrial surface protein can function as a protein import receptor and that the activity of this component is up-regulated by a stress response or by an extragenic suppressor.			LITHGOW, T (corresponding author), UNIV BASEL,BIOCTR,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.		Lithgow, Trevor J/H-5925-2017	Lithgow, Trevor J/0000-0002-0102-7884				DAUM G, 1982, J BIOL CHEM, V257, P3075; DAUM G, 1982, J BIOL CHEM, V257, P3028; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; HAID A, 1983, METHOD ENZYMOL, V96, P192; Hannavy K, 1993, CURR OPIN CELL BIOL, V5, P694, DOI 10.1016/0955-0674(93)90142-D; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HURT EC, 1986, EMBO J, V5, P1343, DOI 10.1002/j.1460-2075.1986.tb04365.x; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; MOCZKO M, 1993, FEBS LETT, V326, P251, DOI 10.1016/0014-5793(93)81801-6; NAKAI M, 1993, J BIOL CHEM, V268, P24262; OHASHI A, 1982, J BIOL CHEM, V257, P3042; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFANNER N, 1987, J BIOL CHEM, V262, P7528; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; RIEZMAN H, 1983, EMBO J, V2, P1113, DOI 10.1002/j.1460-2075.1983.tb01554.x; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; ZWIZINSKI C, 1984, J BIOL CHEM, V259, P7850	27	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15325	15330						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195170				2022-12-27	WOS:A1994NP73800070
J	THIEL, G; SCHOCH, S; PETERSOHN, D				THIEL, G; SCHOCH, S; PETERSOHN, D			REGULATION OF SYNAPSIN-I GENE-EXPRESSION BY THE ZINC-FINGER TRANSCRIPTION FACTOR ZIF268/EGR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; IMMEDIATE EARLY GENES; SERUM GROWTH-FACTORS; C-FOS; SILENCER ELEMENT; BINDING; PROTEIN; ACTIVATION; MOUSE; DIFFERENTIATION	zif268/egr-1 is an immediate early response gene that is involved in regulation of growth and differentiation. Its mRNA encodes a sequence-specific transcriptional activator containing three zinc fingers that act as the DNA-binding domain. Although zif268/egr-1 is expressed in the nervous system during neuronal excitation, no target gene has yet been identified. Here we report that the zif268/egr-1 protein bound in vitro to two sites in the proximal regulatory region of the human synapsin I gene. The zif268/egr-1 protein was also shown to stimulate transcription from this control region in transactivation assays. Additionally, the presence of a putative neural-restrictive silencer element next to one of the zif268/egr-1-binding sites interfered with transactivation in a tissue-independent manner. An analysis of the temporal expression pattern of zif268/egr-1 and synapsin I during neuronal differentiation of P19 embryonal carcinoma cells revealed that zif268/egr-1 mRNA was induced on day 5 and synapsin I mRNA on day 8 after retinoic acid treatment. From this data we conclude that the synapsin I gene is a target of the zif268 transcription factor; however, intermediate factors may also be involved in the activation.			THIEL, G (corresponding author), UNIV COLOGNE, INST GENET, ZULPICHERESTR 47, D-50674 COLOGNE, GERMANY.		Schoch, Susanne/F-7741-2012					ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DARLAND T, 1991, ONCOGENE, V6, P1367; DUMAN RS, 1992, J NEUROCHEM, V59, P1753, DOI 10.1111/j.1471-4159.1992.tb11007.x; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LANOIX J, 1991, CELL GROWTH DIFFER, V2, P391; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LIM RW, 1987, ONCOGENE, V1, P263; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NARANJO JR, 1991, NEURON, V6, P607, DOI 10.1016/0896-6273(91)90063-6; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; OZCELIK T, 1990, AM J HUM GENET, V47, P551; PAPAVASSILIOU AG, 1992, NUCLEIC ACIDS RES, V20, P4365, DOI 10.1093/nar/20.16.4365; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEKULOVICH RE, 1988, J VIROL, V62, P4510, DOI 10.1128/JVI.62.12.4510-4522.1988; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SIERRA F, 1990, LABORATORY GUIDE IN; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SUDHOF TC, 1990, J BIOL CHEM, V265, P7849; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; THIEL G, 1991, P NATL ACAD SCI USA, V88, P3431, DOI 10.1073/pnas.88.8.3431; THIEL G, 1993, BRAIN PATHOL, V3, P87, DOI 10.1111/j.1750-3639.1993.tb00729.x; THOMAS M, 1993, EUR J BIOCHEM, V218, P143, DOI 10.1111/j.1432-1033.1993.tb18360.x; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	49	171	176	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15294	15301						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195167				2022-12-27	WOS:A1994NP73800066
J	UCHIJIMA, M; SATO, H; FUJII, M; SEIKI, M				UCHIJIMA, M; SATO, H; FUJII, M; SEIKI, M			TAX PROTEINS OF HUMAN T-CELL LEUKEMIA-VIRUS TYPE-1 AND TYPE-2 INDUCE EXPRESSION OF THE GENE ENCODING ERYTHROID-POTENTIATING ACTIVITY (TISSUE INHIBITOR OF METALLOPROTEINASES-1, TIMP-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR TAX; CAMP-RESPONSIVE ELEMENT; HTLV-I; TRANSACTIVATOR TAX; TUMOR-CELLS; DNA-BINDING; ENHANCER; SEQUENCE; SERUM; LEUKEMOGENESIS	A growth factor-like activity for erythroid cells (erythroid-potentiating activity) is produced by the T cells infected with human T cell leukemia virus type 2 (HTLV-2) (Gasson, J. C., Golde, D, W, Kaufman, S. E., Westbrook, C. A, Hewick, R. M., Kaufmann, R. J., Wong, G. G., Temple, P.A., Leary, A. C., Brown, E. L., Orr, E. C., and Clark, S. C. (1985) Nature 315, 768-771) and is reportedly identical with tissue inhibitors of matrix metalloproteinases-l (TIMP-1) (Docherty, A. J. P., Lyons, A., Smith, B. J., Wright, E. M., Stephens, P. E., Harris, T J. R., Murphy, G., and Reynolds, J. J. (1985) Nature 318, 66-69). We found that adult T-cell leukemia cell lines infected with HTLV-1 also express high levels of a TMIP-1 transcript. A viral transactivator of HTLV-1, Taxi, in a human T-cell line (Jurkat), was sufficient to stimulate transcription of the TIMP-1 gene. Deletion and mutation analysis of the TIMP-1 gene promoter showed that the AP-1 binding site in the 38-base pair sequence conserved between the human and mouse genes was essential for activation by Taxi. The transactivator of HTLV-2 also stimulated the promoter through the same cis-element. The reported growth promoting activity of TIMP-1 against erythroid cells and potentially against HTLV-1-infected T-cells may modulate the clinical course of adult T-cell leukemia.	KANAZAWA UNIV, CANC RES INST, DEPT MOLEC ONCOL & VIROL, KANAZAWA, ISHIKAWA 920, JAPAN	Kanazawa University			Seiki, Motoharu/K-9443-2015; SATO, Hiroshi/D-8454-2015					ALEXANDRE C, 1991, ONCOGENE, V6, P1851; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; AVALOS BR, 1988, BLOOD, V71, P1720; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; CANN AJ, 1989, J VIROL, V63, P1474, DOI 10.1128/JVI.63.3.1474-1479.1989; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; FUJII M, 1991, ONCOGENE, V6, P2349; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; HIRAI H, 1992, ONCOGENE, V7, P1737; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; KATOH I, 1989, EMBO J, V8, P497, DOI 10.1002/j.1460-2075.1989.tb03403.x; KELLY K, 1992, ONCOGENE, V7, P1463; KOSSAKOWSKA AE, 1991, BLOOD, V77, P2475; MURATE T, 1993, EXP HEMATOL, V21, P169; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NEMETH JA, 1993, EXP CELL RES, V207, P376, DOI 10.1006/excr.1993.1204; SATO H, 1992, ONCOGENE, V7, P77; SATO H, 1993, ONCOGENE, V8, P395; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; TSUCHIYA Y, 1993, CANCER RES, V53, P1397; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; Weiss R A, 1992, Semin Cancer Biol, V3, P321; WOESSNER JF, 1991, J RHEUMATOL, V18, P99; YAMAGUCHI K, 1990, PATHOGENESIS ADULT T; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; YOSHIDA M, 1989, GENOME, V31, P662, DOI 10.1139/g89-121; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	41	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14946	14950						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195127				2022-12-27	WOS:A1994NP73800018
J	YOKOTE, K; MORI, S; HANSEN, K; MCGLADE, J; PAWSON, T; HELDIN, CH; CLAESSONWELSH, L				YOKOTE, K; MORI, S; HANSEN, K; MCGLADE, J; PAWSON, T; HELDIN, CH; CLAESSONWELSH, L			DIRECT INTERACTION BETWEEN SHC AND THE PLATELET-DERIVED GROWTH-FACTOR BETA-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; PROTEIN-TYROSINE KINASES; PHOSPHOLIPASE-C-GAMMA; PDGF RECEPTOR; SIGNAL TRANSDUCTION; SRC-FAMILY; PHOSPHORYLATION SITES; AUTOPHOSPHORYLATION SITES; CDNA CLONING; IDENTIFICATION	The Src homology 2 (SH2) domain-containing Shc proteins p52(shc) and p46(shc) become phosphorylated upon activation of several tyrosine kinases and are implicated in mitogenic signal transduction. Ligand stimulation of the platelet-derived growth factor (PDGF) beta-receptor leads to autophosphorylation of tyrosine residues, which is known to mediate interactions with several SH2 domain containing signaling molecules. In this study, we have characterized the interaction between the PDGF beta-receptor and Shc. PDGF beta-receptor coprecipitation in Shc immunoprecipitates was dependent on stimulation with PDGF-BB. The Shc SH2 domain expressed as a bacterial fusion protein bound the autophosphorylated PDGF beta-receptor. Moreover, the Shc SH2 domain could bind the autophosphorylated purified baculovirus-expressed PDGF beta-receptor intracellular domain, which indicates a direct association of Shc with the PDGF beta-receptor. Activation of the PDGF beta-receptor induced the preferential phosphorylation of p52(shc). Tyrosine-phosphorylated Shc, in turn, formed a complex with the signaling molecule Grb2. Synthetic peptide analysis revealed that certain autophosphorylation sites in the PDGF beta-receptor (Tyr-579, Tyr-740, Tyr-751, and Tyr-771) were able to mediate the specific binding of the Shc SH2 domain as well as intact Shc proteins. A mutant PDGF beta-receptor in which Tyr-579 was replaced with phenylalanine showed 40% impaired association of Shc in vivo, but phosphorylation of Shc proteins was not affected. We conclude that multiple autophosphorylation sites in the PDGF beta-receptor are responsible for the binding of Shc. This is in contrast to previously characterized interactions between the PDGF beta-receptor and SH2 domain-containing proteins, which generally involve one high affinity binding site in the receptor.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	YOKOTE, K (corresponding author), LUDWIG INST CANC RES, CTR BIOMED, BOX 595, S-75124 UPPSALA, SWEDEN.		Pawson, Tony J/E-4578-2013	Claesson-Welsh, Lena/0000-0003-4275-2000; Hansen, Klaus/0000-0001-9657-8816				BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEGATTO O, 1993, ONCOGENE, V8, P2105; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUMMERS MD, 1988, MANUAL METHODS BACUL; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	161	165	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15337	15343						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195171				2022-12-27	WOS:A1994NP73800072
J	HAO, LN; RIGAUD, JL; INESI, G				HAO, LN; RIGAUD, JL; INESI, G			CA2+/H+ COUNTERTRANSPORT AND ELECTROGENICITY IN PROTEOLIPOSOMES CONTAINING ERYTHROCYTE PLASMA-MEMBRANE CA-ATPASE AND EXOGENOUS LIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA-2+-ATPASE; CALCIUM-PUMP; CA-2+ PUMP; PURIFICATION; CALMODULIN; ACTIVATOR; PHOSPHODIESTERASE; RECONSTITUTION; LIPOSOMES; TRANSPORT	A reconstituted proteoliposomal system was obtained with Ca-ATPase purified from human erythrocyte membrane (plasma membrane, PM ATPase), and liposomes prepared by reverse-phase evaporation. The reconstituted PM ATPase behaved as an electrogenic Ca2(+)/H+ exchanger and, under optimal conditions, utilization of 1 mol of ATP was accompanied by uptake of one Ca2+ by the vesicles, and ejection of one H+ from the lumen of the vesicles. Ca2+ uptake was greatly (5-fold) stimulated by the addition of calmodulin, and by collapsing the H+ gradient with the ionophore carbonyl cyanide p-trifluoromethoxyphenylhydrazone. In the presence of calmodulin and p-trifluoromethoxyphenylhydrazone, the reconstituted system sustained transport rates of 1.00 +/- 0.12 mu mol of Ca2+/mg of protein min(-1) (30 degrees C), reaching asymptotic levels of 8.05 +/- 0.41 mu mol of Ca2+/mg of protein (i.e. 20 mM lumenal Ca2+). The corresponding net charge transfer produced a maximal electrical gradient of 40.5 +/- 1.8 mV at steady state. Demonstration of the electrogenic behavior of the PM ATPase, obtained for the first time with these experiments, was critically dependent on the detergent used in the reconstitution procedure. The lumenal pH rise had a much greater rate-limiting effect on the pump, than the electrical potential developed by the pump.	CENS,DEPT BIOL CELLULAIRE & MOLEC,F-91191 GIF SUR YVETTE,FRANCE	CEA	HAO, LN (corresponding author), UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201, USA.							APELL HJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P480, DOI 10.1016/0005-2736(87)90055-1; CARAFOLI E, 1991, ANNU REV PHYSIOL, V53, P531, DOI 10.1146/annurev.physiol.53.1.531; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; GASSNER B, 1988, CELL CALCIUM, V9, P95, DOI 10.1016/0143-4160(88)90029-2; GOPINATH RM, 1977, BIOCHEM BIOPH RES CO, V77, P1203, DOI 10.1016/S0006-291X(77)80107-1; HORGAN DJ, 1972, ANAL BIOCHEM, V48, P147, DOI 10.1016/0003-2697(72)90178-9; INESI G, 1989, J BIOL CHEM, V264, P5929; JARRETT HW, 1978, J BIOL CHEM, V253, P4676; JARRETT HW, 1977, BIOCHEM BIOPH RES CO, V77, P1210, DOI 10.1016/S0006-291X(77)80108-3; KOSKKOSICKA D, 1988, J BIOL CHEM, V263, P18184; KOSKOSICKA D, 1986, J BIOL CHEM, V261, P3333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY D, 1990, J BIOL CHEM, V265, P19524; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; NIGGLI V, 1982, J BIOL CHEM, V257, P2350; NIGGLI V, 1981, J BIOL CHEM, V256, P395; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; RIGAUD JL, 1983, BIOCHEM BIOPH RES CO, V111, P373, DOI 10.1016/0006-291X(83)90316-9; ROSSI JPFC, 1982, J PHYSIOL-LONDON, V327, P1; Scarpa A, 1979, Methods Enzymol, V56, P301; SCHATZMANN HJ, 1973, J PHYSIOL-LONDON, V235, P551, DOI 10.1113/jphysiol.1973.sp010403; SMALLWOOD JI, 1983, J BIOL CHEM, V258, P1092; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WAISMAN DM, 1981, J BIOL CHEM, V256, P415; YU X, 1993, BIOPHYS J, V64, P1232, DOI 10.1016/S0006-3495(93)81489-9; YU X, 1993, FEBS LETT, V328, P301, DOI 10.1016/0014-5793(93)80948-T	28	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14268	14275						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188711				2022-12-27	WOS:A1994NL60600082
J	LIU, YF; JAKOBS, KH; RASENICK, MM; ALBERT, PR				LIU, YF; JAKOBS, KH; RASENICK, MM; ALBERT, PR			G-PROTEIN SPECIFICITY IN RECEPTOR-EFFECTOR COUPLING - ANALYSIS OF THE ROLES OF G(O) AND G(I)2 IN GH4C1 PITUITARY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; BETA-GAMMA-SUBUNITS; ADENYLYL CYCLASE; SOMATOSTATIN RECEPTORS; DOPAMINE-D2 RECEPTOR; SIGNAL TRANSDUCTION; KINASE-C; INHIBITION; ALPHA; HYDROLYSIS	In rat pituitary GH4C1 cells, activation of transfected dopamine D-2 receptors (long, D-2L, or short, D-2S, form) and endogenously expressed somatostatin and muscarinic M4 receptors induced inhibition of cAMP synthesis and of Bay K 8644-induced calcium entry via pertussis toxin-sensitive G proteins. To analyze the role of alpha(o) and alpha(i)2 in relaying of these signals, alpha(o) or alpha(i)2 antisense constructs were separately and stably transfected into GH4C1 cells. Reverse transcription-polymerase chain reaction and Western blot analyses indicated specific ablation of alpha(o) or alpha(i)2 in the antisense transfectant clones. Elimination of alpha(o) selectively abolished receptor-mediated inhibition of calcium entry. Notably, the action of dopamine D-2L receptor was partially (about 30%) retained. By contrast, depletion of alpha(i)2 selectively impaired receptor-mediated inhibition of cAMP accumulation. Inhibition of basal cAMP synthesis by any of the four receptors studied was blocked in alpha(i)2-depleted clones. Additionally, dopamine D-2L, somatostatin and muscarinic M4 receptor-mediated inhibition of vasoactive intestinal peptide-stimulated cAMP formation was also abolished. Remarkably, somatostatin even potentiated (by 30%) the action of vasoactive intestinal peptide in alpha(i)2-antisense clones. In contrast, the action of dopamine D-2S receptor on stimulated cAMP synthesis remained largely unaltered. The results demonstrate that alpha(o) specifically triggers receptor-induced closure of calcium channels, whereas alpha(i)2 specifically mediates inhibition of adenylyl cyclase in GH4C1 cells. Furthermore, the data suggest that G(i) protein specificity in receptor coupling to inhibition of adenylyl cyclase depends critically on the activity state of the enzyme. Moreover, the results indicate an essential difference in coupling of dopamine D-2L and D-2S receptors to G proteins.	MCGILL UNIV,DEPT PHARMACOL & THERAPEUT,MONTREAL H3G 1Y6,PQ,CANADA; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612	McGill University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	LIU, YF (corresponding author), UNIV ESSEN GESAMTHSCH,INST PHARMAKOL,D-45122 ESSEN,GERMANY.		Albert, Paul/E-4804-2010	Albert, Paul/0000-0002-1809-3554				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ALBERT PR, 1990, J BIOL CHEM, V265, P2098; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; COTECCHIA S, 1990, J BIOL CHEM, V265, P1633; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1393; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JONES DT, 1987, J BIOL CHEM, V262, P14211; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LAW SF, 1992, MOL PHARMACOL, V42, P398; LAW SF, 1991, J BIOL CHEM, V266, P17885; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LIU YF, 1992, J NEUROCHEM, V59, P2311; LIU YF, 1991, J BIOL CHEM, V266, P23689; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; PINKASKRAMARSKI R, 1990, NEUROSCI LETT, V108, P335, DOI 10.1016/0304-3940(90)90663-T; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHONBRUNN A, 1978, J BIOL CHEM, V253, P6437; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; VALLAR L, 1990, J BIOL CHEM, V265, P10320; WANG N, 1990, J BIOL CHEM, V265, P1239; WU DQ, 1992, J BIOL CHEM, V267, P25798	40	124	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13880	13886						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188665				2022-12-27	WOS:A1994NL60600027
J	MOSIOR, M; EPAND, RM				MOSIOR, M; EPAND, RM			CHARACTERIZATION OF THE CALCIUM-BINDING SITE THAT REGULATES ASSOCIATION OF PROTEIN-KINASE-C WITH PHOSPHOLIPID-BILAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVALENT-CATIONS; LIPID VESICLES; MEMBRANES; PHOSPHATIDYLSERINE; COOPERATIVITY; ACTIVATION; DIACYLGLYCEROL; POTENTIALS; ADSORPTION; SUBSTRATE	Association of calcium-dependent isotypes of protein kinase C (PKC) with a phospholipid bilayer is regulated by a single Ca2+-binding site. The dependence of PKC association with phosphatidylserine containing mem branes on the concentration of Ca2+ is linear in the submicro- to submillimolar range. The Ca2+-regulated association of PKC with the membrane is sensitive to the factors that alter the diffuse double-layer potential produced by anionic lipids such as phosphatidylserine (PS). This indicates that the Ca2+-binding site on the membrane-bound enzyme senses a higher concentration of Ca2+ than is present in bulk solution. This is a consequence of the accumulation of Ca2+ in the layer adjacent to the plane of the membrane by the double-layer potential. Calculations based on the Gouy-Chapman-Stern theory of the diffuse double layer yielded a unique value of the Ca2+ dissociation constant for the Ca2+-PKC-bilayer complex equal to similar to 700 nM. The soluble form of the enzyme has a 3.5 order of magnitude lower affinity for Ca2+. The free energy of interaction between the Ca2+- and PS-binding sites is large (similar to 5 kcal/mol). In contrast, the interaction between the diacylglycerol-binding site and either the Ca2+- or PS-binding site appears to be weak.	MCMASTER UNIV, DEPT BIOCHEM, HAMILTON L8N 3Z5, ON, CANADA	McMaster University			, Richard/R-2316-2019	, Richard/0000-0002-9602-9558				BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7970, DOI 10.1021/bi00246a014; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; BURNS DJ, 1992, PROTEIN KINASE C CUR, P25; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; DWYER JD, 1981, BIOPOLYMERS, V20, P2323, DOI 10.1002/bip.1981.360201104; EPAND RM, 1992, EUR J BIOCHEM, V208, P327, DOI 10.1111/j.1432-1033.1992.tb17190.x; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HUANG KP, 1986, J BIOL CHEM, V261, P2134; KAIBUCHI K, 1981, J BIOL CHEM, V256, P7146; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KROLL MH, 1993, J BIOL CHEM, V268, P3520; LESTER DS, 1990, INT J BIOL MACROMOL, V12, P251, DOI 10.1016/0141-8130(90)90005-U; LUO JH, 1993, J BIOL CHEM, V268, P23580; MAURER MC, 1992, BIOCHEMISTRY-US, V31, P7714, DOI 10.1021/bi00148a036; MCLAUGHLIN A, 1978, BIOCHIM BIOPHYS ACTA, V513, P338, DOI 10.1016/0005-2736(78)90203-1; MCLAUGHLIN S, 1988, J PHYSIOL-LONDON, V396, P189, DOI 10.1113/jphysiol.1988.sp016958; MCLAUGHLIN S, 1981, J GEN PHYSIOL, V77, P445, DOI 10.1085/jgp.77.4.445; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; MCLAUGHLIN S, 1977, CURR TOP MEMBR TRANS, V9, P71; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; MOSIOR M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P185, DOI 10.1016/0005-2736(92)90178-O; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; REYNOLDS JA, 1979, BIOCHEMISTRY-US, V18, P264, DOI 10.1021/bi00569a004; SHAH J, 1992, BIOCHIM BIOPHYS ACTA, V1119, P19, DOI 10.1016/0167-4838(92)90228-6; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K	33	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13798	13805						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188656				2022-12-27	WOS:A1994NL60600016
J	MUKHERJI, S; SODERLING, TR				MUKHERJI, S; SODERLING, TR			REGULATION OF CA2+ CALMODULIN-DEPENDENT PROTEIN-KINASE-II BY INTERSUBUNIT-CATALYZED AND INTRASUBUNIT-CATALYZED AUTOPHOSPHORYLATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LONG-TERM POTENTIATION; DIRECTED MUTAGENESIS; PHOSPHORYLATION; SITE; PURIFICATION; INHIBITION; EXPRESSION; MECHANISM; SUBUNIT; BRAIN	Autophosphorylation of CaM kinase II on Thr(286) is known to occur by an intraholoenzyme mechanism, but it is not known whether this reaction is intra or intersubunit catalyzed in the native heteromeric enzyme containing 10-12 alpha/beta subunits. In this study inactive CaM kinase II beta subunit, generated by mutation of Lys(43) to Ala, and active kinase a subunit were expressed separately (homomeric kinases) or co expressed (heteromeric kinase) using the baculovirus/Sf9 cell expression system and purified on CaM-Sepharose. Ca2+/CaM-de- pendent autophosphorylation of heteromeric alpha/beta kinase, which activated the enzyme, produced rapid autophosphorylation on Thr(286) in both the active alpha and inactive beta subunits; the latter could only occur by intersubunit catalysis. Ca2+/CaM-independent autophosphorylation of nonactivated heteromeric kinase was slow, resulted in partial loss of total kinase activity, occurred only in the alpha subunit, and existed on Thr(306) but not Thr(286). This result demonstrates intrasubunit catalysis of Thr(306) autophosphorylation. These observations that regulatory autophosphorylations of Thr(286) and Thr(306) were inter- and intrasubunit-catalyzed, respectively, have important consequences for structure/function models of CaM kinase II and for involvement of CaM kinase II autophosphorylation and activation during synaptic plasticity in neural systems.			MUKHERJI, S (corresponding author), OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA.				NIGMS NIH HHS [GM 41292] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT MK, 1983, J BIOL CHEM, V258, P2735; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KURET J, 1985, J BIOL CHEM, V260, P6427; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; MEFFERT MK, 1991, ANN NY ACAD SCI, V627, P2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SODERLING TR, 1993, MOL CELL BIOCHEM, V128, P93, DOI 10.1007/BF01076760; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; TODHUNTER JA, 1977, BIOCHIM BIOPHYS ACTA, V485, P87, DOI 10.1016/0005-2744(77)90195-4	29	102	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13744	13747						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188649				2022-12-27	WOS:A1994NL60600006
J	SELVAN, RS; BUTTERFIELD, JH; KRANGEL, MS				SELVAN, RS; BUTTERFIELD, JH; KRANGEL, MS			EXPRESSION OF MULTIPLE CHEMOKINE GENES BY A HUMAN MAST-CELL LEUKEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; MONOCYTE CHEMOATTRACTANT; GLUCOCORTICOIDS INHIBIT; INFLAMMATORY CYTOKINES; INTERLEUKIN-1; FAMILY; IGE; DEXAMETHASONE	The chemokines are a large group of cytokines that are recognized to be important mediators of inflammation. In this study we show that the human mast cell leukemia line HMC-1 is a source of multiple chemokines, including I-309, monocyte chemoattractant protein 1, macrophage inflammatory protein-1 alpha, macrophage inflammatory protein-1 beta, RANTES, and interleukin-8. I-309 and MCP-1 transcripts are expressed at low levels in unstimulated HMC-1. However, phorbol ester treatment up-regulates these and other chemokine transcript levels and also up regulates chemokine protein synthesis and secretion. Induction of chemokine transcripts in HMC-1 requires de novo protein synthesis. We compared the effects of anti-inflammatory glucocorticoids on the expression of chemokine genes in HMC-1 to their effects in activated T cells. We find that methyl prednisolone reduces MCP-1 but not other chemokine transcripts in HMC-1, even though there are distinct and more general effects on chemokine transcripts in activated T-cells. These effects are attributed to inhibition of transcription rather than transcript stability. Our results suggest that human mast cells may be a source of multiple chemokines, that glucocorticoids may inhibit the expression of only a subset of these chemokines, and that mast cells and T-cell chemokine expression may occur via distinct regulatory pathways.	DUKE UNIV, MED CTR, DEPT IMMUNOL, DURHAM, NC 27710 USA; MAYO CLIN & MAYO FDN, DEPT INTERNAL MED, DIV ALLERG DIS, ROCHESTER, MN 55905 USA	Duke University; Mayo Clinic								ALIZADEH H, 1986, J IMMUNOL, V137, P2555; ARYA SK, 1984, J IMMUNOL, V133, P273; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BENYON RC, 1991, J IMMUNOL, V147, P2253; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BOCHNER BS, 1987, J IMMUNOL, V139, P2303; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; CHENSUE SW, 1991, AM J PATHOL, V138, P395; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSER P, 1980, BRIT J HAEMATOL, V45, P5, DOI 10.1111/j.1365-2141.1980.tb03805.x; DINARELLO CA, 1987, NEW ENGL J MED, V317, P940, DOI 10.1056/NEJM198710083171506; DJALDETTI R, 1990, BIOMED PHARMACOTHER, V44, P515, DOI 10.1016/0753-3322(90)90172-6; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; IRANI AMA, 1992, BLOOD, V80, P3009; JIANG YL, 1991, BIOCHEM BIOPH RES CO, V178, P1400, DOI 10.1016/0006-291X(91)91049-I; JIANG YL, 1990, J BIOL CHEM, V265, P18318; KAWAHARA RS, 1991, J BIOL CHEM, V266, P13261; KIRNBAUER R, 1991, J INVEST DERMATOL, V96, P484, DOI 10.1111/1523-1747.ep12470181; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MILLER MD, 1990, J IMMUNOL, V145, P2737; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MILLER MD, 1992, P NATL ACAD SCI USA, V89, P2950, DOI 10.1073/pnas.89.7.2950; MILLER MD, 1989, J IMMUNOL, V143, P2907; MOLLER A, 1993, J IMMUNOL, V151, P3261; MUKAIDA N, 1991, J IMMUNOL, V146, P1212; NORTHROP JP, 1992, J EXP MED, V175, P1235, DOI 10.1084/jem.175.5.1235; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; POON M, 1991, J BIOL CHEM, V266, P22375; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHULMAN ES, 1993, CRIT REV IMMUNOL, V13, P35; STOECKLE M Y, 1990, New Biologist, V2, P313; VILLIGER PM, 1992, J IMMUNOL, V149, P722; WITTE LD, 1978, CIRC RES, V42, P402, DOI 10.1161/01.RES.42.3.402; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582; ZUCKERMAN SH, 1989, EUR J IMMUNOL, V19, P301, DOI 10.1002/eji.1830190213	41	124	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13893	13898						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188667				2022-12-27	WOS:A1994NL60600029
J	ALI, MS; ROCHE, TE; PATEL, MS				ALI, MS; ROCHE, TE; PATEL, MS			IDENTIFICATION OF THE ESSENTIAL CYSTEINE RESIDUE IN THE ACTIVE-SITE OF BOVINE PYRUVATE-DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; ESCHERICHIA-COLI; BETA-SUBUNIT; COMPLEX; COMPONENT; SEQUENCE; KIDNEY; HEART; INACTIVATION; PURIFICATION	Pyruvate dehydrogenase (E1), the first catalytic component of the bovine pyruvate dehydrogenase complex, is composed of two nonidentical subunits in a tetrameric alpha2beta2 form. The sulfhydryl-specific reagent N-ethylmaleimide (NEM) was used to identify the reactivities and function of cysteinyl residues and subsequent identification of these residues in the active site of bovine E1. Treatment of E1 with 0.2 mM NEM resulted in loss (90%) of enzymatic activity; the inactivation followed bimolecular reaction kinetics. The inactivation was almost entirely prevented by thiamin pyrophosphate (TPP) and pyruvate; protection is probably due to formation of the hydroxyethylidene-TPP intermediate. To identify the reactive cysteinyl residues in the active site region, the nonessential SH groups in E1 were first modified with NEM in the presence of TPP and pyruvate. After quenching with dithiothreitol and removal of the substrate and cofactor by dialysis, the modified E1 was treated with [C-14]NEM to label the exposed cysteinyl residue(s) in or near the active site region. The data indicate that NEM reacted in the active site region of the E1 component with a stoichiometry of 2 mol of [C-14]NEM bound per mol of E1 tetramer. The initial rapid labeling of E1 with [C-14]NEM established that incorportaion was predominantly into the alpha subunit. A single radiolabeled peptide was isolated following V8 protease digestion of radiolabeled E1 by [C-14]NEM. Sequence analysis of the labeled peptide derived from bovine E1 demonstrated that the labeled cysteinyl residue was equivalent to Cys-62 in the alpha subunit (mature form) of human E1.	KANSAS STATE UNIV AGR & APPL SCI, DEPT BIOCHEM, MANHATTAN, KS 66506 USA; CASE WESTERN RESERVE UNIV, DEPT BIOCHEM, CLEVELAND, OH 44106 USA	Kansas State University; Case Western Reserve University					NIDDK NIH HHS [DK18320, DK20478] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020478, R55DK018320, R01DK018320] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRERA CR, 1972, ARCH BIOCHEM BIOPHYS, V148, P343, DOI 10.1016/0003-9861(72)90152-X; BEHAL RH, 1989, BIOCHEM BIOPH RES CO, V164, P941, DOI 10.1016/0006-291X(89)91549-0; CATE RL, 1980, J BIOL CHEM, V255, P7556; FLOURNOY DS, 1989, BIOCHEMISTRY-US, V28, P9594, DOI 10.1021/bi00451a007; FREY PA, 1989, ANN NY ACAD SCI, V573, P21, DOI 10.1111/j.1749-6632.1989.tb14984.x; HAWKINS CF, 1990, EUR J BIOCHEM, V191, P337, DOI 10.1111/j.1432-1033.1990.tb19128.x; HO L, 1989, P NATL ACAD SCI USA, V86, P5330, DOI 10.1073/pnas.86.14.5330; HO L, 1990, GENE, V86, P297, DOI 10.1016/0378-1119(90)90294-2; KHAILOVA LS, 1985, BIOCHEM INT, V10, P291; KHAILOVA LS, 1989, ANN NY ACAD SCI, V573, P36, DOI 10.1111/j.1749-6632.1989.tb14985.x; KHAILOVA LS, 1982, BIOCHEM INT, V5, P525; KHAILOVA LS, 1983, BIOCHEM INT, V7, P223; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINN TC, 1972, ARCH BIOCHEM BIOPHYS, V148, P327, DOI 10.1016/0003-9861(72)90151-8; MATUDA S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P1, DOI 10.1016/0167-4781(91)90076-X; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P2221; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; ROCHE TE, 1972, BIOCHEM BIOPH RES CO, V48, P840, DOI 10.1016/0006-291X(72)90684-5; ROCHE TE, 1977, ARCH BIOCHEM BIOPHYS, V183, P664, DOI 10.1016/0003-9861(77)90400-3; SCHWARTZ ER, 1970, J BIOL CHEM, V245, P183; STEPP LR, 1985, BIOCHEMISTRY-US, V24, P7187, DOI 10.1021/bi00346a026; TU GC, 1988, J BIOL CHEM, V263, P1212; URATA Y, 1991, J NUTR SCI VITAMINOL, V37, P257	23	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22353	22356						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226745				2022-12-27	WOS:A1993MD34800027
J	ANDERSON, GM; SHAW, AR; SHAFER, JA				ANDERSON, GM; SHAW, AR; SHAFER, JA			FUNCTIONAL-CHARACTERIZATION OF PROMOTER ELEMENTS INVOLVED IN REGULATION OF HUMAN B-BETA-FIBRINOGEN EXPRESSION - EVIDENCE FOR BINDING OF NOVEL ACTIVATOR AND REPRESSOR PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-6 RESPONSE ELEMENT; RAT ALPHA-2-MACROGLOBULIN GENE; RISK FACTOR; DNA; TRANSCRIPTION; SEQUENCES; FAMILY; C/EBP; IDENTIFICATION; DEXAMETHASONE	A high level of plasma fibrinogen has been shown to be an important risk factor for myocardial infarction and stroke. Thus, we were prompted to investigate regulation of human fibrinogen biosynthesis, a process wherein expression of the Bbeta-chain of fibrinogen appears to be rate-limiting for fibrinogen secretion. Using electrophoretic mobility shift assays with synthetic probes representing portions of the human Bbeta-fibrinogen promoter, we have defined several elements that bind distinct classes of transcription factors present in human hepatoma cell nuclear extracts. The contribution of each element to promoter activity was demonstrated in transfection experiments using promoter-chloramphenicol acetyltransferase constructs and human hepatoma cells. Our observations indicate that two distinct sequence elements are required for maximal induction of transcription by interleukin-6. One of these sequences is an IL-6-RE core element similar to that reported for the rat alpha2-macroglobulin promoter and the other is a binding site for the C/EBP family of transcription factors. We also report two additional elements, one negative- and one positive-acting, that bind novel sequence-specific factors.	MERCK SHARP & DOHME LTD,DEPT CELLULAR & MOLEC BIOL,W POINT,PA 19486	Merck & Company	ANDERSON, GM (corresponding author), MERCK SHARP & DOHME LTD,DEPT BIOL CHEM,W POINT,PA 19486, USA.							AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BIRCH HE, 1986, J BIOL CHEM, V261, P8077; BRECHNER T, 1991, MOL BIOL MED, V8, P267; CROTHERS DM, 1987, NATURE, V325, P464, DOI 10.1038/325464a0; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; Higuchi R, 1989, PCR TECHNOLOGY PRINC, P31; Higuchi R., 1989, PCR TECHNOLOGY, P61; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; HUBER P, 1987, NUCLEIC ACIDS RES, V15, P1615, DOI 10.1093/nar/15.4.1615; HUBER P, 1990, J BIOL CHEM, V265, P5695; KANELL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183; KANT JA, 1985, P NATL ACAD SCI USA, V82, P2344, DOI 10.1073/pnas.82.8.2344; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Maniatis T., 1982, MOL CLONING; MANN EA, 1991, J BIOL CHEM, V266, P16931; MARINKOVIC S, 1989, J IMMUNOL, V142, P808; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; OTTO JM, 1987, J CELL BIOL, V105, P1067, DOI 10.1083/jcb.105.3.1067; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROY SN, 1990, J BIOL CHEM, V265, P6389; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STONE MC, 1985, J ROY COLL GEN PRACT, V35, P565; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; YU S, 1983, J BIOL CHEM, V258, P3407	36	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22650	22655						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226773				2022-12-27	WOS:A1993MD34800069
J	SHIMOMURA, T; KONDO, J; OCHIAI, M; NAKA, D; MIYAZAWA, K; MORIMOTO, Y; KITAMURA, N				SHIMOMURA, T; KONDO, J; OCHIAI, M; NAKA, D; MIYAZAWA, K; MORIMOTO, Y; KITAMURA, N			ACTIVATION OF THE ZYMOGEN OF HEPATOCYTE GROWTH-FACTOR ACTIVATOR BY THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HAGEMAN-FACTOR; SINGLE CHAIN FORM; SCATTER FACTOR; BLOOD-COAGULATION; MOLECULAR-CLONING; EPITHELIAL-CELLS; HEPATOPOIETIN-A; FACTOR-XII; RAT-LIVER; PURIFICATION	Hepatocyte growth factor activator (HGF activator) is a serine protease which converts single-chain HGF to the active two-chain form. HGF activator purified from human serum has a molecular mass of 34 kDa and consists of two chains held together by a disulfide bond. The nucleotide sequence of HGF activator cDNA shows that HGF activator is derived from the COOH-terminal region of a precursor of 655 amino acids by proteolytic cleavage of the bonds between Arg372 and Val373 and between Arg407 and Ile408 and that the precursor consists of multiple domains homologous to those observed in blood coagulation factor XII. In this study, we identified the precursor of HGF activator in human plasma using an enzyme-linked immunosorbent assay system. The precursor was purified from plasma by a five-step procedure. The purified precursor did not activate single-chain HGF. The precursor was efficiently cleaved in vitro by thrombin, at the bond between Arg407 and Ile408, in the presence of negatively charged substances. The cleaved precursor activated single-chain HGF. These findings led us to conclude that HGF activator is present in plasma as an inactive zymogen and that the zymogen is activated by the cleavage of the bond between Arg407 and Ile408 by thrombin. Characteristic structural domains in the NH2-terminal region of the zymogen may be involved in the binding of the zymogen to negatively charged substances, which stimulates the activation of the zymogen by thrombin.	KANSAI MED UNIV, INST LIVER RES, MORIGUCHI, OSAKA 570, JAPAN	Kansai Medical University	SHIMOMURA, T (corresponding author), MITSUBISHI KASEI CORP, RES CTR, BIOSCI LAB, KAMOSHIDA CHO, MIDORI KU, YOKOHAMA 227, JAPAN.		Ochiai, Masanori/A-4372-2012; MIYAZAWA, KEIJI/I-9713-2014	Ochiai, Masanori/0000-0002-0022-347X; 				CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; DUNN JT, 1982, J BIOL CHEM, V257, P1779; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HERNANDEZ J, 1992, J CELL PHYSIOL, V150, P116, DOI 10.1002/jcp.1041500116; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KAPLAN AP, 1988, METHOD ENZYMOL, V163, P3; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MASUMOTO A, 1991, BIOCHEM BIOPH RES CO, V174, P90, DOI 10.1016/0006-291X(91)90489-T; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAITO K, 1991, J BIOL CHEM, V266, P7353; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; RAMADORI G, 1992, BIOCHEM BIOPH RES CO, V183, P739, DOI 10.1016/0006-291X(92)90545-V; REVAK SD, 1974, J CLIN INVEST, V54, P619, DOI 10.1172/JCI107799; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SCHIRMACHER P, 1992, HEPATOLOGY, V15, P5, DOI 10.1002/hep.1840150103; SHIMOMURA T, 1992, CYTOTECHNOLOGY, V8, P219, DOI 10.1007/BF02522039; TANS G, 1987, SEMIN THROMB HEMOST, V13, P1, DOI 10.1055/s-2007-1003471; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; ZARNEGAR R, 1989, CANCER RES, V49, P3314	30	181	190	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22927	22932						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226803				2022-12-27	WOS:A1993MD34800107
J	KUBALAK, SW; MILLERHANCE, WC; OBRIEN, TX; DYSON, E; CHIEN, KR				KUBALAK, SW; MILLERHANCE, WC; OBRIEN, TX; DYSON, E; CHIEN, KR			CHAMBER SPECIFICATION OF ATRIAL MYOSIN LIGHT CHAIN-2 EXPRESSION PRECEDES SEPTATION DURING MURINE CARDIOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MYOCARDIAL-CELLS; EMBRYONIC STEM-CELLS; GENE-EXPRESSION; HEART MORPHOGENESIS; CARDIAC-MUSCLE; PURIFICATION; INDUCTION; PATTERNS; SMOOTH; MODEL	To study the molecular mechanisms that control patterning of the heart tube during early cardiogenesis, we have used the ventricular myosin regulatory light chain (MLC-2v), which is expressed in the ventricular segment of the primitive heart tube, as a genetic marker for ventricular specification in rodents. To assess whether the atrial isoform, MLC-2a, could also serve as a chamber-specific marker, we cloned an atrial MLC-2 cDNA (554 base pairs) which displayed homology to the human MLC-2a cDNA at both the nucleotide (87%) and amino acid (95%) levels. Northern blot, reverse transcriptase-linked polymerase chain reaction, RNase protection, and Western blot analysis revealed atrial restricted expression in the adult mouse heart, very low levels in aorta, and no detectable expression in ventricle, skeletal muscle, uterus, or liver. In situ hybridization studies during mouse embryogenesis revealed cardiac specific expression throughout days 8-16 postcoitum, with atrial restricted expression from day 12 and qualitatively greater atrial expression than ventricular from day 9. Thus, a preferential pattern of expression in the atria occurs prior to septation. The MLC-2a gene was differentially regulated when compared with MLC-2v expression during embryonic stem cell cardiogenesis in vitro with MLC-2a transcript levels detectable from day 6 in suspension cultures as compared with day 9 for MLC-2v. The region-specific expression of the MLC-2a and MLC-2v genes in their respective chambers during early cardiogenesis provides genetic markers for chamber specification (atrial and ventricular) in both the in vitro and in vivo context.	UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,VET ADM MED CTR,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,AMER HEART ASSOC,BUGHER FDN CTR MOLEC BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego					NHLBI NIH HHS [HL-45069, HL-51549, HL-36139] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045069, R01HL036139, R01HL051549] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOIT R, 1984, CELL CAMBRIDGE, V39, P129; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHIEN KR, 1993, SCIENCE, V260, P916, DOI 10.1126/science.8493528; DEGROOT IJM, 1989, ANAT REC, V224, P365, DOI 10.1002/ar.1092240305; DELCARPIO JB, 1991, CIRC RES, V69, P1591, DOI 10.1161/01.RES.69.6.1591; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DONO R, 1993, DEVELOPMENT, V118, P1157; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FULLER SJ, 1993, CIRCULATION, V88, P282; GRANT JW, 1990, J CELL BIOL, V111, P1127, DOI 10.1083/jcb.111.3.1127; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAILSTONES D, 1992, J BIOL CHEM, V267, P23295; HOLTZER H, 1957, J BIOPHYS BIOCHEM CY, V3, P705, DOI 10.1083/jcb.3.5.705; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KOMURO I, 1993, CIRCULATION, V88, P5; KUMAR CC, 1989, BIOCHEMISTRY-US, V28, P4027, DOI 10.1021/bi00435a059; LEE KJ, 1992, J BIOL CHEM, V267, P15875; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LYONS GE, 1994, TRENDS CARDIOVAS MED, V4, P70, DOI 10.1016/1050-1738(94)90012-4; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MESSER NG, 1988, FEBS LETT, V135, P232; MILLERHANCE WC, 1993, J BIOL CHEM, V268, P25244; MUTHUCHAMY M, 1993, MOL CELL BIOL, V13, P3311, DOI 10.1128/MCB.13.6.3311; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; ROBBINS J, 1992, TRENDS CARDIOVAS MED, V2, P44, DOI 10.1016/1050-1738(92)90003-B; Sambrook J, 1989, MOL CLONING LABORATO; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; TAUBMAN MB, 1987, J CELL BIOL, V104, P1505, DOI 10.1083/jcb.104.6.1505; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	35	187	190	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16961	16970						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207020				2022-12-27	WOS:A1994NR29600067
J	MIRANDAVIZUETE, A; MARTINEZGALISTEO, E; ASLUND, F; LOPEZBAREA, J; PUEYO, C; HOLMGREN, A				MIRANDAVIZUETE, A; MARTINEZGALISTEO, E; ASLUND, F; LOPEZBAREA, J; PUEYO, C; HOLMGREN, A			NULL THIOREDOXIN AND GLUTAREDOXIN ESCHERICHIA-COLI K-12-MUTANTS HAVE NO ENHANCED SENSITIVITY TO MUTAGENS DUE TO A NEW GSH-DEPENDENT HYDROGEN DONOR AND HIGH INCREASES IN RIBONUCLEOTIDE REDUCTASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARABINOSE-RESISTANCE; SALMONELLA-TYPHIMURIUM; SULFATE REDUCTION; MESSENGER-RNA; DEOXYRIBONUCLEOTIDE; GLUTATHIONE; PROTEIN; PURIFICATION; CATALASE; GENES	This work investigates whether a mutator phenotype is associated to the simultaneous deficiency in thioredoxin and glutaredoxin, the two known hydrogen donors of ribonucleotide reductase. To this end, new Escherichia coli K-12 strains carrying Delta trxA and/or grx::kan null mutations were constructed to monitor mutagenesis by selecting forward mutations to L-arabinose resistance. Highly sensitive and specific enzyme-linked immunoassays were developed to confirm that trx(-)grx(-) cells lacked thioredoxin and glutaredoxin. A number of remarkable properties were observed in the newly constructed thioredoxin- and glutaredoxin-deficient bacteria compared with the wild type cells. Thus, they (i) grew on minimal medium plates, suggesting that the presence of thioredoxin and glutaredoxin may not be absolutely essential for sulfate reduction; (ii) showed normal mutagenic sensitivities toward a wide variety of DNA-damaging agents, as compared with wild type cells and trx(-) or grx(-) single mutants; (iii) displayed 14% of GSH-dependent and 30% of NADPH-dependent ribonucleotide reduction capacity with CDP as substrate in the presence or the absence of exogenous ribonucleotide reductase, respectively; and (iv) showed very high levels of ribonucleotide reductase activity, which was increased from 19- to 23-fold. The existence of a new glutathione-dependent hydrogen donor for ribonucleotide reductase and the high activity levels of this enzyme in trx(-)grx(-) defective cells could explain that thioredoxin and the first discovered glutaredoxin are not essential for deoxyribonucleotide synthesis, even under mutagenic stress.	UNIV CORDOBA,DEPT GENET,E-14071 CORDOBA,SPAIN; UNIV CORDOBA,INST BIOL BASICA & APLICADA,E-14071 CORDOBA,SPAIN; UNIV CORDOBA,DEPT BIOQUIM & BIOL MOLEC,E-14071 CORDOBA,SPAIN; KAROLINSKA INST,MED NOBEL INST BIOCHEM,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN	Universidad de Cordoba; Universidad de Cordoba; Universidad de Cordoba; Karolinska Institutet			IBIS, REDOX/J-7473-2017; Miranda-Vizuete, Antonio/D-6927-2012; Lopez-Barea, Juan/K-7258-2014; Pueyo, Carmen/B-4509-2016	Miranda-Vizuete, Antonio/0000-0002-6856-5396; Lopez-Barea, Juan/0000-0002-2280-3379; Pueyo, Carmen/0000-0002-2624-2011				ABRIL N, 1992, ENVIRON MOL MUTAGEN, V19, P288, DOI 10.1002/em.2850190405; ABRIL N, 1990, ENVIRON MOL MUTAGEN, V15, P184, DOI 10.1002/em.2850150403; ABRIL N, 1994, MOL GEN GENET, V242, P744, DOI 10.1007/BF00283431; Bjornberg O, 1991, Protein Expr Purif, V2, P287, DOI 10.1016/1046-5928(91)90085-W; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CURTISS R, 1981, MANUAL METHODS GENER, P243; DAVIS RW, 1980, MANUAL GENETIC ENG A; DORADO G, 1988, CANCER RES, V48, P907; DYSON HJ, 1989, BIOCHEMISTRY-US, V28, P7074, DOI 10.1021/bi00443a044; FILPULA D, 1977, J BACTERIOL, V130, P107, DOI 10.1128/JB.130.1.107-113.1977; FUCHS JA, 1989, GLUTATHIONE CHEM BIO, V3, P551; GIBERT I, 1990, MOL GEN GENET, V220, P400, DOI 10.1007/BF00391745; HANKE PD, 1983, J BACTERIOL, V154, P1040, DOI 10.1128/JB.154.3.1040-1045.1983; HANKE PD, 1984, MOL GEN GENET, V193, P327, DOI 10.1007/BF00330689; HAUSER J, 1992, J BACTERIOL, V174, P6844, DOI 10.1128/JB.174.21.6844-6851.1992; HERA C, 1986, MUTAGENESIS, V1, P267, DOI 10.1093/mutage/1.4.267; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1978, J BIOL CHEM, V253, P430; HOOG JO, 1983, EUR J BIOCHEM, V136, P223, DOI 10.1111/j.1432-1033.1983.tb07730.x; Kemeny DM., 1991, PRACTICAL GUIDE ELIS; KREDICH NM, 1987, ESCHERICHIA COLI SAL, V1, P419; KUNZ BA, 1991, ANNU REV GENET, V25, P339, DOI 10.1146/annurev.ge.25.120191.002011; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; PRIETOALAMO MJ, 1993, CARCINOGENESIS, V14, P237, DOI 10.1093/carcin/14.2.237; PUEYO C, 1979, MUTAT RES, V64, P249, DOI 10.1016/0165-1161(79)90094-3; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; RUIZRUBIO M, 1984, EMBO J, V3, P1435, DOI 10.1002/j.1460-2075.1984.tb01989.x; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; SEDGWICK B, 1980, MOL GEN GENET, V180, P85, DOI 10.1007/BF00267355; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TSANG MLS, 1981, J BACTERIOL, V146, P1059, DOI 10.1128/JB.146.3.1059-1066.1981; TUGGLE CK, 1986, EMBO J, V5, P1077, DOI 10.1002/j.1460-2075.1986.tb04325.x; TUGGLE CK, 1990, J BACTERIOL, V172, P1711, DOI 10.1128/jb.172.4.1711-1718.1990	37	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16631	16637						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206982				2022-12-27	WOS:A1994NR29600020
J	BRINKS, S; FLUGGE, UI; CHAUMONT, F; BOUTRY, M; EMMERMANN, M; SCHMITZ, U; BECKER, K; PFANNER, N				BRINKS, S; FLUGGE, UI; CHAUMONT, F; BOUTRY, M; EMMERMANN, M; SCHMITZ, U; BECKER, K; PFANNER, N			PREPROTEINS OF CHLOROPLAST ENVELOPE INNER MEMBRANE CONTAIN TARGETING INFORMATION FOR RECEPTOR-DEPENDENT IMPORT INTO FUNGAL MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; PHOSPHATE TRANSLOCATOR; ENDOPLASMIC-RETICULUM; PROCESSING PEPTIDASE; SPINACH-CHLOROPLASTS; INTERMEMBRANE SPACE; PLANT-MITOCHONDRIA; TRANSIT PEPTIDE	The amino-terminal transit sequences of two preproteins destined for the chloroplast inner envelope membrane show similarities to mitochondrial presequences in the prevalence of positive charges and the potential formation of an amphipathic alpha-helix. We studied if these preproteins could be imported into mitochondria and found a low, yet significant import into isolated plant mitochondria. The plant mitochondria were previously shown not to import precursors of chloroplast stromal or thylakoidal proteins. To analyze the specificity of import into mitochondria we used the established import systems of fungal mitochondria. The envelope preproteins were efficiently imported into Saccharomyces cerevisiae or Neurospora crassa mitochondria. Their import showed the characteristics of specific mitochondrial protein uptake, including a requirement for the main receptor MOM19 (mitochondrial outer membrane protein of 19 kDa) and a membrane potential across the inner membrane, and depended on the presence of the chloroplast transit sequence. We conclude that some chloroplast transit sequences contain sufficient information for specific interaction with mitochondrial import receptors (at least from fungal sources).	UNIV FREIBURG, INST BIOCHEM, D-79104 FREIBURG, GERMANY; UNIV WURZBURG, JULIUS VON SACHS INST BIOWISSENSCH, D-97082 WURZBURG, GERMANY; UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; INST GENBIOL FORSCH, D-14195 BERLIN, GERMANY; UNIV MUNICH, INST PHYSIOL CHEM, D-80336 MUNICH, GERMANY	University of Freiburg; University of Wurzburg; Universite Catholique Louvain; University of Munich			Chaumont, Francois/A-5006-2010; Pfanner, Nikolaus/AAV-7878-2021	Boutry, Marc/0000-0002-2315-6900; Brink, Susanne C./0000-0002-3272-9707				BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BOUTRY M, 1987, NATURE, V328, P340, DOI 10.1038/328340a0; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; CHAUMONT F, 1990, J BIOL CHEM, V265, P16856; CHEN WJ, 1987, CELL, V49, P651, DOI 10.1016/0092-8674(87)90541-1; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; DRESESWERRINGLOER U, 1991, EUR J BIOCHEM, V195, P361, DOI 10.1111/j.1432-1033.1991.tb15714.x; FLUGGE UI, 1989, EMBO J, V8, P39, DOI 10.1002/j.1460-2075.1989.tb03346.x; FLUGGE UI, 1986, EUR J BIOCHEM, V160, P563, DOI 10.1111/j.1432-1033.1986.tb10075.x; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HELDT HW, 1971, BIOCHIM BIOPHYS ACTA, V234, P83, DOI 10.1016/0005-2728(71)90133-2; Horwich A, 1990, CURR OPIN CELL BIOL, V2, P625, DOI 10.1016/0955-0674(90)90103-L; HUANG JT, 1990, PLANT CELL, V2, P1249, DOI 10.1105/tpc.2.12.1249; HURT EC, 1986, EMBO J, V5, P1343, DOI 10.1002/j.1460-2075.1986.tb04365.x; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; KALOUSEK F, 1992, EMBO J, V11, P2803, DOI 10.1002/j.1460-2075.1992.tb05347.x; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; LILLEY RM, 1974, BIOCHIM BIOPHYS ACTA, V368, P269, DOI 10.1016/0005-2728(74)90174-1; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MOCZKO M, 1993, FEBS LETT, V326, P251, DOI 10.1016/0014-5793(93)81801-6; MOURIOUX G, 1981, PLANT PHYSIOL, V67, P470, DOI 10.1104/pp.67.3.470; NEUBURGER M, 1982, ARCH BIOCHEM BIOPHYS, V217, P312, DOI 10.1016/0003-9861(82)90507-0; Nicholls D.G., 1992, BIOENERGETICS, V2, P22; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; RIEZMAN H, 1983, EMBO J, V2, P1113, DOI 10.1002/j.1460-2075.1983.tb01554.x; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHMITZ UK, 1989, PLANT CELL, V1, P783, DOI 10.1105/tpc.1.8.783; SEGUIREAL B, 1992, FEBS LETT, V313, P2, DOI 10.1016/0014-5793(92)81171-H; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; SOLL J, 1993, PHYSIOL PLANTARUM, V87, P433, DOI 10.1111/j.1399-3054.1993.tb01752.x; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; THEG SM, 1989, J BIOL CHEM, V264, P6730; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WHATLEY FR, 1963, METHOD ENZYMOL, V6, P308, DOI 10.1016/0076-6879(63)06177-2; WHELAN J, 1990, PLANT MOL BIOL, V14, P977, DOI 10.1007/BF00019394; WILLEY DL, 1991, PLANTA, V183, P451, DOI 10.1007/BF00197745; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; ZARA V, 1992, J BIOL CHEM, V267, P12077	60	48	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16478	16485						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206957				2022-12-27	WOS:A1994NQ72900078
J	HIASA, H; MARIANS, KJ				HIASA, H; MARIANS, KJ			TOPOISOMERASE-IV CAN SUPPORT ORIC DNA-REPLICATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; PBR322 DNA; NALIDIXIC-ACID; GYRASE; PURIFICATION; DECATENATION; ORIGIN; REQUIREMENT; NOVOBIOCIN; INITIATION	Escherichia coli has two type II topoisomerases, DNA gyrase and topoisomerase IV (Topo IV). Topo IV is required for the decatenation of the linked daughter chromosomes at the terminal stages of DNA replication, whereas gyrase, because of its ability to convert to negative supercolis the positive supercolis generated by replication fork progression in a circular chromosome, is required to support nascent chain elongation. Using an oriC DNA replication system in vitro, we show that Topo IV, which can relax positive supercolis, can also support replication fork progression. This activity is only observed at substoichiometric ratios of Topo IV to template, at higher ratios, the template becomes relaxed and initiation of DNA replication cannot occur. Topo IV was capable of supporting bidirectional DNA replication from oriC, although, unlike the case with gyrase, some templates apparently replicated unidirectionally. This suggests that either gyrase itself or a certain minimum superhelical density is required for proper initiation of DNA replication from oriC.			HIASA, H (corresponding author), MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL, 1275 YORK AVE, NEW YORK, NY 10021 USA.				NIGMS NIH HHS [GM 34558] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BOHK JJ, 1983, GENE, V24, P265; FAIRWEATHER NF, 1980, J BACTERIOL, V142, P153, DOI 10.1128/JB.142.1.153-161.1980; FILUTOWICZ M, 1980, MOL GEN GENET, V177, P301, DOI 10.1007/BF00267443; FILUTOWICZ M, 1982, MOL GEN GENET, V191, P282; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P4474, DOI 10.1073/pnas.73.12.4474; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P2093; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1992, J BIOL CHEM, V267, P25676; KEUZER KN, 1979, J BACTERIOL, V140, P424; MARIANS KJ, 1987, J BIOL CHEM, V262, P10362; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PELLETIER AJ, 1989, J BACTERIOL, V171, P1739, DOI 10.1128/jb.171.3.1739-1741.1989; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PENG H, 1993, J BIOL CHEM, V268, P24481; STAUDENBAUER WL, 1981, NUCLEIC ACIDS RES, V9, P3589, DOI 10.1093/nar/9.15.3589; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; STECK TR, 1984, J BACTERIOL, V158, P397, DOI 10.1128/JB.158.2.397-403.1984; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WU CA, 1992, J BIOL CHEM, V267, P4030	31	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16371	16375						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206945				2022-12-27	WOS:A1994NQ72900064
J	KEEFER, JR; KENNEDY, ME; LIMBIRD, LE				KEEFER, JR; KENNEDY, ME; LIMBIRD, LE			UNIQUE STRUCTURAL FEATURES IMPORTANT FOR STABILIZATION VERSUS POLARIZATION OF THE ALPHA(2A)-ADRENERGIC RECEPTOR ON THE BASOLATERAL MEMBRANE OF MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; MDCK CELLS; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS; ALPHA-2A-ADRENERGIC RECEPTOR; LIGAND-BINDING; ALPHA-2-ADRENERGIC RECEPTORS; MUTATIONAL ANALYSIS; INTRACELLULAR LOOP	The alpha(2A)-adrenergic receptor (alpha(2A)AR) is polarized to the basolateral membrane of Madin-Darby canine kidney cells via direct targeting. Examination of mutant <alpha >(2A)AR reveals that direct delivery is independent of NH,-terminal glycosylation, COOH-terminal acylation, or protein sequences within the large third cytoplasmic loop or COOH-terminal tail. Combined mutation of these structural features also does not perturb alpha(2A)AR delivery, suggesting that a three-dimensional structure imparted by non-contiguous endofacial sequences does not confer alpha(2A)AR targeting and that motifs in or near the bilayer must be involved in targeting of the alpha(2A)AR. Mutation of a conserved Asp residue in transmembrane two that alters receptor-G-protein interactions also does not impair alpha(2A)AR targeting. Finally, modification of sequences in transmembrane seven that resemble tyrosine-containing endocytosis motifs utilized for targeting by some proteins does not perturb alpha(2A)AR sorting. Interestingly, deletion of the large third cytoplasmic loop of the alpha(2A)AR decreases receptor half-life on the basolateral surface from approximately 11 to 4.5 h without altering the ability of the alpha(2A)AR to couple to G-proteins. These data suggest that although targeting of the alpha(2A)AR likely involves bilayer sequences, the third cytoplasmic loop may contain structural features that promote stabilization of the alpha(2A)AR on the basolateral surface of Madin-Darby canine kidney cells.	VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025182, R01HL043671, R37HL043671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043879] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 25182, HL 43671] Funding Source: Medline; NIDDK NIH HHS [DK 43879] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHABRE O, 1994, IN PRESS J BIOL CHEM, V269; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; GERHARDT MA, 1990, MOL PHARMACOL, V38, P214; GILLY WF, 1990, NEURON, V5, P663, DOI 10.1016/0896-6273(90)90220-A; GOTTARDI CJ, 1993, SCIENCE, V260, P552, DOI 10.1126/science.8386395; GUYER CA, 1990, J BIOL CHEM, V265, P17318; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LANIER SM, 1986, MOL PHARMACOL, V29, P219; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NEAME SJ, 1993, J CELL BIOL, V121, P1299, DOI 10.1083/jcb.121.6.1299; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; RANDS E, 1990, J BIOL CHEM, V265, P10759; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SUMMERS RJ, 1984, FED PROC, V43, P2917; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; VALET P, 1993, J CLIN INVEST, V91, P2049, DOI 10.1172/JCI116427; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; WANG CD, 1991, MOL PHARMACOL, V40, P168; WANG Z, 1993, MOL ENDOCRINOL, V7, P85, DOI 10.1210/me.7.1.85	38	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16425	16432						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206950				2022-12-27	WOS:A1994NQ72900071
J	NORDMANN, B; LEBERT, MR; ALAM, M; NITZ, S; KOLLMANNSBERGER, H; OESTERHELT, D; HAZELBAUER, GL				NORDMANN, B; LEBERT, MR; ALAM, M; NITZ, S; KOLLMANNSBERGER, H; OESTERHELT, D; HAZELBAUER, GL			IDENTIFICATION OF VOLATILE FORMS OF METHYL-GROUPS RELEASED BY HALOBACTERIUM-SALINARIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSORY RHODOPSIN-I; ACCEPTING TAXIS PROTEINS; ESCHERICHIA-COLI; SIGNAL TRANSDUCTION; BACILLUS-SUBTILIS; HALOBIUM; CHEMOTAXIS; MUTANTS; ARCHAEBACTERIA; PHOTOTAXIS	Halobacterium salinarium (formerly H. halobium) is a chemotactic and phototactic archaeon from which volatile methyl groups are released continually, a phenomenon related to its sensory system. We found that released methyl groups comprised two different chemical species, methanol and methanethiol, the sulfur analog of methanol. Radiolabeling experiments showed that the methyl groups of both compounds, as well as the sulfur of methanethiol, were derived from methionine but were donated to cellular components and subsequently cleaved to produce the respective volatile compounds. Previous work had shown that chemostimuli and photostimuli result in transient increases in the rate of release of volatile methyl groups. We found that these in creases reflected increased release of methanol but not of methanethiol. Thus, the methyl group chemistry of the H. salinarium sensory system is analogous to the well-studied chemotactic system of Escherichia coli. The reactions that result in methanethiol release are of unknown function and have unusual features. They may involve a methionine-gamma-lyase activity we detected in H. salinarium. Sulfur derived from methionine was found attached to specific proteins in reduction-sensitive disulfide linkages.	WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; TECH UNIV MUNCHEN WEIHENSTEPHAN,INST LEBENSMITTELTECHNOL & ANALYT CHEM,D-85350 FREISING,GERMANY	Washington State University; Max Planck Society; Technical University of Munich					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029963] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29963] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALAM M, 1989, EMBO J, V8, P631, DOI 10.1002/j.1460-2075.1989.tb03418.x; ALAM M, 1991, J BACTERIOL, V173, P5837, DOI 10.1128/jb.173.18.5837-5842.1991; BURROWS GG, 1989, J BIOL CHEM, V264, P17309; CHELSKY D, 1984, ANAL BIOCHEM, V141, P143, DOI 10.1016/0003-2697(84)90437-8; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; KEHRY MR, 1984, J BIOL CHEM, V259, P1828; NEISH AC, 1957, METHOD ENZYMOL, V3, P255, DOI 10.1016/S0076-6879(57)03386-8; NITZ S, 1991, J CHROMATOGR, V547, P516, DOI 10.1016/S0021-9673(01)88682-9; Oesterhelt D, 1974, Methods Enzymol, V31, P667; OESTERHELT D, 1990, BIOL CHEMOTACTIC RES, P219; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; SODA K, 1983, TRENDS BIOCHEM SCI, V8, P214, DOI 10.1016/0968-0004(83)90216-5; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; SPUDICH EN, 1989, P NATL ACAD SCI USA, V86, P7746, DOI 10.1073/pnas.86.20.7746; SPUDICH EN, 1988, J BACTERIOL, V170, P4280, DOI 10.1128/jb.170.9.4280-4285.1988; SPUDICH EN, 1982, P NATL ACAD SCI-BIOL, V79, P4308, DOI 10.1073/pnas.79.14.4308; SPUDICH JL, 1988, ANNU REV BIOPHYS BIO, V17, P193; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P931, DOI 10.1016/S0076-6879(57)03481-3; SUNDBERG SA, 1985, J BACTERIOL, V164, P282, DOI 10.1128/JB.164.1.282-287.1985; SUNDBERG SA, 1990, J BACTERIOL, V172, P2328, DOI 10.1128/jb.172.5.2328-2335.1990; THOELKE MS, 1990, J BIOL CHEM, V265, P1928; THOELKE MS, 1989, BIOCHEMISTRY-US, V28, P5585, DOI 10.1021/bi00439a037; YAO VJ, 1992, P NATL ACAD SCI USA, V89, P11915, DOI 10.1073/pnas.89.24.11915	23	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16449	16454						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206953				2022-12-27	WOS:A1994NQ72900074
J	UMAYAHARA, Y; KAWAMORI, R; WATADA, H; IMANO, E; IWAMA, N; MORISHIMA, T; YAMASAKI, Y; KAJIMOTO, Y; KAMADA, T				UMAYAHARA, Y; KAWAMORI, R; WATADA, H; IMANO, E; IWAMA, N; MORISHIMA, T; YAMASAKI, Y; KAJIMOTO, Y; KAMADA, T			ESTROGEN REGULATION OF THE INSULIN-LIKE GROWTH-FACTOR-I GENE-TRANSCRIPTION INVOLVES AN AP-1 ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; C-JUN; GLUCOCORTICOID RECEPTOR; THYROID-HORMONE; RETINOIC ACID; FOS-JUN; FUNCTIONAL ANTAGONISM; NEGATIVE REGULATION; OSTEOBLASTIC CELLS; RESPONSE ELEMENT	As a step toward elucidating the physiological role of insulin-like growth factor-I (IGF-I) in mediating estrogen action, we sought to determine the molecular basis of the phenomenon. In HepG2 cells expressing exogenous estrogen receptors (ER), a reporter gene plasmid containing 600 base pairs of the chicken IGF-I promoter enhanced expression of luciferase 8.6-fold in response to 10(-6) M 17 beta-estradiol, indicating that the IGF-I promoter is a target of estrogen regulation. Although no conventional estrogen-responsive element was identified within the promoter fragment, the AP-1 motif located therein was shown to be essential; the estrogen-responsive enhancement of the Fos-Jun binding to the AP-1 motif, which takes place by means of post-translational modification, mediates the estrogen action. A direct or indirect interaction between the estrogen-ER complex and the Fos-Jun complex seems to facilitate the Fos-Jun binding to the target DNA. Although ER binding to the target DNA was not considered to be involved in the signaling pathway, the DNA binding domain-deficient ER did not mediate the phenomenon, providing support for the existence of a unique function of the DNA binding domain of ER in facilitating some protein-protein interaction. In conclusion, our present observations demonstrate that the chicken IGF-I gene promoter is controlled by estrogen through a unique pathway involving Fos, Jun, and the DNA binding domain of ER.	OSAKA UNIV,SCH MED,DEPT MED 1,SUITA,OSAKA 565,JAPAN	Osaka University				Watada, Hirotaka/0000-0001-5961-1816				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; ERNST M, 1991, MOL ENDOCRINOL, V5, P1081, DOI 10.1210/mend-5-8-1081; ERNST M, 1989, ENDOCRINOLOGY, V125, P825, DOI 10.1210/endo-125-2-825; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRILL HJ, 1983, J CLIN CHEM CLIN BIO, V21, P175; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JENSEN DE, 1991, ONCOGENE, V6, P1219; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAJIMOTO Y, 1993, BIOCHEM BIOPH RES CO, V190, P767, DOI 10.1006/bbrc.1993.1115; KAJIMOTO Y, 1991, J BIOL CHEM, V266, P9724; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KIKUCHI K, 1992, J BIOL CHEM, V267, P21505; KIM SW, 1991, MOL ENDOCRINOL, V5, P1964, DOI 10.1210/mend-5-12-1964; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MURPHY LJ, 1990, ENDOCR REV, V11, P443, DOI 10.1210/edrv-11-3-443; MURPHY LJ, 1987, MOL ENDOCRINOL, V1, P445, DOI 10.1210/mend-1-7-445; MURPHY LJ, 1988, ENDOCRINOLOGY, V122, P325, DOI 10.1210/endo-122-1-325; MURPHY LJ, 1989, MOL CELL ENDOCRINOL, V64, P81, DOI 10.1016/0303-7207(89)90067-1; NAGAOKA I, 1990, J CLIN INVEST, V85, P448, DOI 10.1172/JCI114458; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; ROGERS SA, 1991, J CLIN INVEST, V87, P347, DOI 10.1172/JCI114992; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; Sambrook J, 1989, MOL CLONING LABORATO; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOLLET P, 1990, MOL ENDOCRINOL, V4, P1934, DOI 10.1210/mend-4-12-1934; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; WEISZ A, 1990, MOL ENDOCRINOL, V4, P1041, DOI 10.1210/mend-4-7-1041; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; WEISZ A, 1988, MOL ENDOCRINOL, V2, P816, DOI 10.1210/mend-2-9-816; WOLF M, 1989, ENDOCRINOLOGY, V125, P2905, DOI 10.1210/endo-125-6-2905; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x	57	318	323	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16433	16442						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206951				2022-12-27	WOS:A1994NQ72900072
J	CROUCH, E; CHANG, D; RUST, K; PERSSON, A; HEUSER, J				CROUCH, E; CHANG, D; RUST, K; PERSSON, A; HEUSER, J			RECOMBINANT PULMONARY SURFACTANT PROTEIN-D - POSTTRANSLATIONAL MODIFICATION AND MOLECULAR ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; CARBOHYDRATE-RECOGNITION DOMAIN; MANNOSE-BINDING PROTEIN; SP-A; STRUCTURAL SIMILARITY; EXPRESSION; COLLAGEN; CDNA; ACCUMULATION; ORGANIZATION	Pulmonary surfactant protein D (SP-D) is a member of a family of collagenous C-type lectins that includes the serum mannose binding proteins and surfactant protein A. Recent studies have shown that rat SP-D (rSP-D) molecules are assembled as tetramers of trimeric subunits (12 mers) and that dodecamers can participate in higher orders of molecular assembly involving interactions of the amino-terminal peptide domains. In order to further study the assembly of SP-D in vitro, Chinese hamster ovary K1 cells were transfected with a full-length rat SP-D cDNA, and stable transfectants with high levels of SP-D production (approximately 6 x 10(6) dodecamers/ cell/24 h) were obtained using a glutamine synthetase selection system. The secreted molecules (RrSP-D), which were purified by affinity chromatography on maltosyl-agarose, comigrated with rSP-D on SDS-polyacrylamide gel electrophoresis in the presence and absence of reduction, and coeluted with rSP-D dodecamers from 4% agarose. The major bacterial collagenase-resistant peptide showed a decreased mobility on reduction consistent with the formation of intrachain disulfide bonds. A 17-kDa pepsin-resistant fragment was isolated following overnight digestion with pepsin at 27 degrees C, confirming the formation of a triple helical domain comparable in size and thermal stability to that of natural SP-D. The expressed protein contained sialylated endoglycosidase F-sensitive carbohydrate; amino acid analysis of acid and alkaline hydrolysates demonstrated essentially normal levels of hydroxyproline, hydroxylysine, and hydroxylysine-glycosides. Electron microscopic studies showed a molecular structure indistinguishable from lung SP-D, with a similar small subpopulation of molecules showing higher orders of multimerization. Solid-phase neoglycoprotein binding assays gave the same saccharide inhibition profile as natural rat SP-D, and both proteins showed efficient saccharide-dependent agglutination of Escherichia coli. These studies demonstrate that a single genetically distinct chain type can account for the various and complex molecular assemblies of SP-D, and further verify the potential physiologic significance of the disulfide-bonded multimers and higher aggregates isolated from rat, bovine, and human lung lavage.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NHLBI NIH HHS [HL-44015] Funding Source: Medline; NIGMS NIH HHS [GM-29647] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029647] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALAKOKKO L, 1991, J BIOL CHEM, V266, P14175; ALCORN JL, 1992, AM J PHYSIOL, V262, pL437, DOI 10.1152/ajplung.1992.262.4.L437; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, pCH16; BONALDO P, 1990, MATRIX, V10, P139, DOI 10.1016/S0934-8832(11)80162-9; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; CROUCH E, 1991, AM J PATHOL, V139, P765; CROUCH E, 1993, AM J PATHOL, V142, P241; CROUCH E, 1991, AM J RESP CELL MOL, V5, P13, DOI 10.1165/ajrcmb/5.1.13; CROUCH E, 1993, J BIOL CHEM, V268, P2976; CROUCH E, 1991, AM J PHYSIOL, V260, pL247, DOI 10.1152/ajplung.1991.260.4.L247; CROUCH E, 1992, FASEB J, V6, pA1160; GREENSPAN DS, 1989, J BIOL CHEM, V264, P20683; HAAGSMAN HP, 1989, AM J PHYSIOL, V257, pL421, DOI 10.1152/ajplung.1989.257.6.L421; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; KALINA M, 1993, J HISTOCHEM CYTOCHEM, V41, P57, DOI 10.1177/41.1.8417113; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; LEE ST, 1988, J BIOL CHEM, V263, P13414; LIM BL, 1993, IMMUNOLOGY, V78, P159; LU JH, 1992, BIOCHEM J, V284, P795, DOI 10.1042/bj2840795; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; MANZKEINKE H, 1992, EUR J CELL BIOL, V57, P95; MAZZORANA M, 1993, J BIOL CHEM, V268, P3029; MCCORMACK FX, 1990, BIOCHIM BIOPHYS ACTA, V1087, P190, DOI 10.1016/0167-4781(90)90204-F; PENMAN M, 1991, J BIOL CHEM, V266, P23985; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON A, 1990, J BIOL CHEM, V265, P5755; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; PERSSON AV, 1992, BIOCHEMISTRY-US, V31, P12183, DOI 10.1021/bi00163a030; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; SASTRY K, 1993, CURR OPIN IMMUNOL, V5, P59, DOI 10.1016/0952-7915(93)90082-4; SCHWEINLE JE, 1993, J BIOL CHEM, V268, P364; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; VOSS T, 1991, AM J RESP CELL MOL, V4, P88, DOI 10.1165/ajrcmb/4.1.88; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2	35	109	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15808	15813						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195236				2022-12-27	WOS:A1994NP51300064
J	ZHANG, YJ; RUTLEDGE, BJ; ROLLINS, BJ				ZHANG, YJ; RUTLEDGE, BJ; ROLLINS, BJ			STRUCTURE/ACTIVITY ANALYSIS OF HUMAN MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) BY MUTAGENESIS - IDENTIFICATION OF A MUTATED PROTEIN THAT INHIBITS MCP-1-MEDIATED MONOCYTE CHEMOTAXIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; RECOMBINANT PROTEINS; RECEPTOR-BINDING; CYTOKINE FAMILY; JE GENE; INTERLEUKIN-8; CELLS; PURIFICATION; RESIDUES	Monocyte chemoattractant protein-1 (MCP-1) is a monocyte-specific chemoattractant and activator and is a member of the chemokine-beta family of cytokines. To identify regions of MCP-1 which are required for its biological activity, me constructed human MCP-1 mutants that were expressed in eukaryotic cells and tested for their ability to attract monocytes in vitro. Deletion of amino acids 2-8 destroyed activity, suggesting that the amino-terminal region is necessary for activity. Within the deleted region, mutation of aspartate 3 to alanine produced a protein with 9% of wild-type activity, whereas mutation of asparagine 6 to alanine produced a protein with 52.9% of wild-type activity. Mutation of amino acids within the first intercysteine loop yielded variable results. Changing tyrosine 28 to aspartate or arginine 30 to leucine each produced proteins with essentially no monocyte chemoattractant activity. The side chains of these amino acids are predicted to point into a putative receptor binding cleft, and these loss-of-function mutations are consistent with this model. Also consistent is the retention of 60% of wad-type activity after mutation of serine 27 to glutamine, since the side chain of serine 27 is predicted to point away from the binding cleft. However, mutation of arginine 24, which lies outside of this area, to phenylalanine produced a protein with only 5% of wild-type activity, suggesting more complex interactions. Truncations of the carboxyl terminus, as well as mutation of aspartate 68 to leucine, generated proteins with 10-20% of wild-type activity. (Another carboxyl-terminal insertional mutation demonstrated that O-linked carbohydrate in MCP-l alpha may be added to a threonine in the carboxyl-terminal region.) These findings are consistent with a structural model of dimeric MCP-1 which is similar to interleukin-8 in which amino acids that point into a cleft between the two carboxyl-terminal alpha-helices of the subunits are important for receptor binding. In addition, however, amino acids at the amino terminus and others outside of the interhelical cleft are also essential for activity. The carboxyl terminal alpha-helix is not required for signaling per se but is required for maximal specific activity. Finally, four mutant proteins partially inhibited the ability of wild-type MCP-1 to attract monocytes in vitro. In particular, mutant 7ND (deletion of amino acids 2-8) in hibited MCP-1 activity by 50% at a molar ratio of 75:1, displaced MCP-1 from its receptor on monocytes at a similar ratio, and bound to a single class of receptors on human monocytes with a K-d of 2.6 nM. However, 7ND bound only to 10% of the number of receptors to which MCP-1 bound, suggesting that part of its inhibitory activity may be due to binding to MCP-1 itself.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA053091] Funding Source: NIH RePORTER; NCI NIH HHS [CA53091] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BEALL CJ, 1992, J BIOL CHEM, V267, P3455; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; Clore G M, 1992, Cytokines, V4, P18; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; ERNST CA, 1994, J IMMUNOL, V152, P3541; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; GRONENBORN AM, 1991, PROTEIN ENG, V4, P263, DOI 10.1093/protein/4.3.263; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; JIANG YL, 1990, J BIOL CHEM, V265, P18318; KAUFMAN RJ, 1987, EMBO J, V6, P187, DOI 10.1002/j.1460-2075.1987.tb04737.x; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; MUNSON PJ, 1992, MACLIGAND VERSION 4; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; ROLLINS BJ, 1991, CANCER CELL-MON REV, V3, P517; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROLLINS BJ, 1991, BLOOD, V78, P1112; ROLLINS BJ, 1991, MOL CELL BIOL, V11, P3125, DOI 10.1128/MCB.11.6.3125; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHRAUFSTATTER IU, 1993, J IMMUNOL, V151, P6418; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; TANAKA S, 1988, FEBS LETT, V236, P467, DOI 10.1016/0014-5793(88)80078-4; VALENTE AJ, 1991, BIOCHEM BIOPH RES CO, V176, P309, DOI 10.1016/0006-291X(91)90925-W; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YOSHIMURA T, 1989, J IMMUNOL, V142, P1956	30	152	176	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15918	15924						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195247				2022-12-27	WOS:A1994NP51300080
J	PAVELAVRANCIC, M; PFEIFER, E; SCHRODER, W; VONDOHREN, H; KLEINKAUF, H				PAVELAVRANCIC, M; PFEIFER, E; SCHRODER, W; VONDOHREN, H; KLEINKAUF, H			IDENTIFICATION OF THE ATP BINDING-SITE IN TYROCIDINE SYNTHETASE-1 BY SELECTIVE MODIFICATION WITH FLUORESCEIN 5'-ISOTHIOCYANATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASES; METHIONYL-TRANSFER RNA; AMINO-ACID-SEQUENCE; SARCOPLASMIC-RETICULUM; ESCHERICHIA-COLI; ASPERGILLUS-NIDULANS; SIGNATURE SEQUENCE; NEUROSPORA-CRASSA; ADENYLATE KINASE; LABELED PEPTIDE	Identification of the nucleotide binding site in peptide synthetases has been approached by affinity labeling of tyrocidine synthetase 1 with fluorescein 5'-isothiocyanate. Binding was accompanied by irreversible inhibition of the ATP-dependent phenylalanine activation reaction and was prevented in the presence of MgATP(2-). The reaction obeyed pseudo first-order rate kinetics and was accelerated by Mg2+. Complete inhibition corresponded to incorporation of 2.3 mol of fluorescein 5'-isothiocyanate (FITC)/mol of protein. Upon protection by MgATP(2-), about 1 mol of FITC is still incorporated; however, this does not affect activity. The modified synthetase was extensively fragmented by tryptic digestion and the labeled fragments isolated by reverse-phase high performance liquid chromatography. Two peptides, DHQVKIR and LDKMPLTPNDKIDR, have been identified by sequencing, and the FITC conjugate of the former peptide has been detected by laser desorption mass spectrometry. The labeled residues, Lys-422 and Lys-505, are located within highly conserved segments of this new class of synthetases.	TECH UNIV BERLIN,INST BIOCHEM & MOLEK BIOL,D-10587 BERLIN,GERMANY; FREE UNIV BERLIN,INST BIOCHEM,SEQUENZIERUNGS LAB,D-14195 BERLIN,GERMANY	Technical University of Berlin; Free University of Berlin			Pavela-Vrancic, Maja/E-5424-2017	Pavela-Vrancic, Maja/0000-0002-2036-5547				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BURBAUM JJ, 1991, J BIOL CHEM, V266, P16965; CONNERTON IF, 1990, MOL MICROBIOL, V4, P451, DOI 10.1111/j.1365-2958.1990.tb00611.x; CREMO CR, 1989, J BIOL CHEM, V264, P6608; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DREUSICKE D, 1988, J MOL BIOL, V199, P649; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FILOTEO AG, 1987, J BIOL CHEM, V262, P6526; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; GABROCZI DN, 1988, J BIOL CHEM, V263, P812; HOUNTONDJI C, 1990, BIOCHEMISTRY-US, V29, P11266, DOI 10.1021/bi00503a016; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOYOZA E, 1988, EUR J BIOCHEM, V176, P661; MACCABE AP, 1991, J BIOL CHEM, V266, P12646; MARAHIEL MA, 1992, FEBS LETT, V307, P40, DOI 10.1016/0014-5793(92)80898-Q; MARAHIEL MA, 1985, MOL GEN GENET, V201, P231, DOI 10.1007/BF00425664; MECHULAM Y, 1991, J MOL BIOL, V217, P465, DOI 10.1016/0022-2836(91)90750-Z; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; ORR I, 1993, J BIOL CHEM, V268, P1376; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PARDO JP, 1988, J BIOL CHEM, V263, P18664; PAVELAVRANCIC M, 1994, EUR J BIOCHEM, V220, P535, DOI 10.1111/j.1432-1033.1994.tb18653.x; PHILLIPS NFB, 1988, BIOCHEMISTRY-US, V27, P3314, DOI 10.1021/bi00409a029; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V974, P1; TATE CA, 1991, J BIOL CHEM, V266, P16165; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; VANLIEMPT H, 1993, 50 YEARS PENICILLIN, P136; VANLIEMPT H, 1991, BIOMED BIOCHIM ACTA, V50, P256; VONDOHREN H, 1993, INDUSTRIAL MICROORGANISMS: BASIC AND APPLIED MOLECULAR GENETICS, P159; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG K, 1992, J BIOL CHEM, V267, P3577; WECKERMANN R, 1988, NUCLEIC ACIDS RES, V16, P11841, DOI 10.1093/nar/16.24.11841; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	40	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14962	14966						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195130				2022-12-27	WOS:A1994NP73800021
J	AKSOY, S; SZUMLANSKI, CL; WEINSHILBOUM, RM				AKSOY, S; SZUMLANSKI, CL; WEINSHILBOUM, RM			HUMAN LIVER NICOTINAMIDE N-METHYLTRANSFERASE CDNA CLONING, EXPRESSION, AND BIOCHEMICAL-CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; THIOPURINE METHYLTRANSFERASE; MOLECULAR-CLONING; COMPLETE NUCLEOTIDE; MESSENGER-RNAS; GENE; PHARMACOGENETICS; INHERITANCE; TRANSLATION; INITIATION	Nicotinamide N-methyltransferase (NNMT) catalyzes the N-methylation of nicotinamide and other pyridines. Human liver NNMT activity has a bimodal frequency distribution, an observation which raises the possibility that this enzyme activity might be regulated by a genetic polymorphism, a polymorphism that could have functional implications for individual differences in drug and xenobiotic toxicity. As a first step toward testing that hypothesis, we set out to clone and express a cDNA for human liver NNMT. Human liver NNMT was partially purified, photoaffinity-labeled, subjected to limited proteolysis, and partial amino acid sequence information was obtained. The polymerase chain reaction was then used to amplify a 550-nucleotide sequence with human liver cDNA as template and primers designed on the basis of the NNMT amino acid sequence. The 5'- and 3'-ends of a human liver NNMT cDNA were obtained by use of the rapid amplification of cDNA ends. The combined use of these approaches resulted in the isolation of a human liver NNMT cDNA that was 969 nucleotides in length, with a 792-nucleotide open reading frame that encoded a 264-amino acid protein with a calculated molecular mass of 29.6 kDa. The human liver NNMT cDNA was transcribed in vitro and translated with a reticulocyte lysate system to yield a protein with a molecular mass of approximately 29 kDa that comigrated during SDS-polyacrylamide gel electrophoresis with photoaffinity-labeled human liver NNMT. The NNMT cDNA was also subcloned into the eukaryotic expression vector p91023(B). COS-1 cells transfected with this construct expressed a high level of NNMT enzymatic activity, and the biochemical properties of this activity were similar to those of human liver NNMT. Human liver NNMT and transfected COS-1 cell NNMT had apparent K-m values for the two cosubstrates for the reaction, nicotinamide and S-adenosyl-L-methionine, of 0.43 and 0.38 mM and of 1.8 and 2.2 mu M, respectively. IC50 values for the inhibition of NNMT by N-1-methylnicotinamide were 60 and 30 mu M for human liver and COS-1 cell-expressed NNMT, respectively. Cloning of a cDNA for human liver NNMT will help make it possible to test the hypothesis that inheritance may play a role in the regulation of individual differences in human liver NNMT activity.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic			Aksoy, Serap/K-2244-2019	Aksoy, Serap/0000-0001-9941-143X	NIGMS NIH HHS [GM 35720, GM 28157] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028157] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAETGE EE, 1986, P NATL ACAD SCI USA, V83, P5454, DOI 10.1073/pnas.83.15.5454; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTONI GL, 1951, J BIOL CHEM, V189, P745; CANTONI GL, 1951, J BIOL CHEM, V189, P203; CLELAND WW, 1963, NATURE, V198, P463, DOI 10.1038/198463a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DSOUZA J, 1980, XENOBIOTICA, V10, P151, DOI 10.3109/00498258009033741; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HALEY TJ, 1979, CLIN TOXICOL, V14, P1; HIS W, 1884, ARCH EXP PATHOL PH, V22, P253; HONCHEL R, 1993, MOL PHARMACOL, V43, P878; JAHNEN W, 1990, BIOCHEM BIOPH RES CO, V166, P139, DOI 10.1016/0006-291X(90)91922-F; KANEDA N, 1988, J BIOL CHEM, V263, P7672; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1985, P NATL ACAD SCI USA, V82, P689, DOI 10.1073/pnas.82.3.689; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LANGSTON JW, 1985, TRENDS NEUROSCI, V8, P79; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MORITA S, 1992, MOL BRAIN RES, V13, P313, DOI 10.1016/0169-328X(92)90214-V; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PRICE RA, 1993, GENET EPIDEMIOL, V10, P123, DOI 10.1002/gepi.1370100205; PRICE RA, 1989, GENET EPIDEMIOL, V6, P651, DOI 10.1002/gepi.1370060602; RINI J, 1989, CLIN CHIM ACTA, V186, P359; SINGER TP, 1987, J NEUROCHEM, V49, P1, DOI 10.1111/j.1471-4159.1987.tb03384.x; VANLOON JA, 1990, DRUG METAB DISPOS, V18, P632; VANLOON JA, 1992, BIOCHEM PHARMACOL, V44, P775, DOI 10.1016/0006-2952(92)90416-G; WADA KN, 1990, NUCLEIC ACIDS RES, V18, P2367, DOI 10.1093/nar/18.suppl.2367; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WARNER DR, 1992, THESIS U LOUISVILLE; WEINSHILBOUM R, 1989, PHARMACOL THERAPEUT, V43, P77, DOI 10.1016/0163-7258(89)90048-X; WEINSHILBOUM RM, 1977, AM J HUM GENET, V29, P125; WEINSHILBOUM RM, 1980, AM J HUM GENET, V32, P651; WEISBERG EP, 1989, MOL BRAIN RES, V6, P159, DOI 10.1016/0169-328X(89)90050-8; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	39	221	230	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14835	14840						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182091				2022-12-27	WOS:A1994NM06500081
J	FINAN, P; SHIMIZU, Y; GOUT, I; HSUAN, J; TRUONG, O; BUTCHER, C; BENNETT, P; WATERFIELD, MD; KELLIE, S				FINAN, P; SHIMIZU, Y; GOUT, I; HSUAN, J; TRUONG, O; BUTCHER, C; BENNETT, P; WATERFIELD, MD; KELLIE, S			AN SH3 DOMAIN AND PROLINE-RICH SEQUENCE MEDIATE AN INTERACTION BETWEEN 2 COMPONENTS OF THE PHAGOCYTE NADPH OXIDASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOSOLIC COMPONENTS; ACTIVATION; MEMBRANE; PROTEIN	Neutrophils possess a multicomponent NADPH oxidase system capable of producing large quantities of superoxide in a process known as the respiratory burst (1). Upon stimulation of a phagocytic cell, two cytosolic components of the oxidase, p67(phox) and p47(phax), associate with a membrane-bound flavocytochrome b and a small GTP-binding protein to form a functional enzyme complex. Each of the Phox proteins contains two src homology 3 (SH3) domains, which are of unknown function but are potential mediators of protein-protein interactions between components of the activated oxidase. We have isolated a 47-kDa protein from lysates of differentiated HL60 cells that specifically bound to the carboxyl-terminal SH3 domain of p67(phox) and not to any other SH3 domain tested. This protein was identified as p47(phox), and the putative SH3 domain binding site was located to a carboxyl terminal proline-rich region. Proline-rich synthetic peptides based on this carboxyl-terminal region specifically inhibited the binding of p47(phox) to the carboxyl-terminal SH3 domain of p67(phox), and sequential truncation defined a unique minimal sequence, which, although similar, does not match the consensus sequence defined for other SH3-binding proteins.	LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,LONDON WC1E 6BT,ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London	FINAN, P (corresponding author), LITTLEMORE HOSP,YAMANOUCHI RES INST,OXFORD OX4 4XN,ENGLAND.		Hsuan, Justin/C-8825-2009; Kellie, Stuart/A-6036-2010	Hsuan, Justin/0000-0001-6083-7564; Kellie, Stuart/0000-0002-8163-1474				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LUI X, 1993, MOL CELL BIOL, V13, P5225; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PARK JW, 1992, J BIOL CHEM, V267, P17327; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557	23	141	142	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13752	13755						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188650				2022-12-27	WOS:A1994NL60600008
J	HANLON, DW; ORDAL, GW				HANLON, DW; ORDAL, GW			CLONING AND CHARACTERIZATION OF GENES ENCODING METHYL-ACCEPTING CHEMOTAXIS PROTEINS IN BACILLUS-SUBTILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; SENSORY TRANSDUCTION; SIGNAL TRANSDUCTION; FUNCTIONAL HOMOLOGY; RNA-POLYMERASE; GROUP TURNOVER; PHOSPHORYLATION; ADAPTATION; METHYLESTERASE	Several genes homologous to the methyl-accepting chemotaxis proteins (MCPs) of Escherichia coli have been cloned and characterized from the Gram-positive bacterium, Bacillus subtilis. Sequence analysis reveals four large open reading frames, designated mcpA, mcpB, tlpA, and tlpB, each encoding a predicted 72-kDa protein. These proteins exhibit strong homology to chemoreceptors from several organisms, although similarity is limited to the C-terminal domain. These transducer genes were mapped to a chromosomal position of 279 degrees, which is distant from previously identified fla, mot, or che loci, Each gene was inactivated by insertion of a nonpolar chloramphenicol acetyltransferase cassette in the N-terminal region. In vivo methylation of the bacterial strain deficient in mcpA revealed the loss of several methylated bands in the range of the MCP previously designated as H1, and greatly reduced methylation of the MCP designated as H2. Furthermore, this bacterial strain exhibited a chemotaxis deficiency toward glucose and alpha-methylglucoside. Inactivation of mcpB caused a reduction in methylation of the MCP designated as H3, while chemotaxis toward asparagine, aspartate, glutamine, and histidine was significantly impaired in this strain. Despite strong homology, inactivation of tlpA and tlpB did not result in an observed deficiency in chemotaxis. Most unusually, these mutant strains exhibited a striking tendency to adhere together and resisted disaggregation.	UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,URBANA,IL 61801; UNIV ILLINOIS,COLL LIBERAL ARTS & SCI,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020336] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20336] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHLGREN JA, 1983, BIOCHEM J, V213, P759, DOI 10.1042/bj2130759; ALLEY MRK, 1992, GENE DEV, V6, P825, DOI 10.1101/gad.6.5.825; AZEVEDO V, 1993, P NATL ACAD SCI USA, V90, P6047, DOI 10.1073/pnas.90.13.6047; BEDALE WA, 1988, J BACTERIOL, V170, P223, DOI 10.1128/jb.170.1.223-227.1988; BERG HC, 1972, NATURE, V239, P500, DOI 10.1038/239500a0; BISCHOFF DS, 1992, MOL MICROBIOL, V6, P23, DOI 10.1111/j.1365-2958.1992.tb00833.x; BOLLINGER J, 1984, P NATL ACAD SCI-BIOL, V81, P3287, DOI 10.1073/pnas.81.11.3287; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BOYD A, 1980, J BACTERIOL, V143, P809, DOI 10.1128/JB.143.2.809-815.1980; BOYD A, 1983, NATURE, V301, P623, DOI 10.1038/301623a0; BURGESSCASSLER A, 1982, J BIOL CHEM, V257, P2835; GOLDMAN DJ, 1982, BIOCHEMISTRY-US, V21, P915, DOI 10.1021/bi00534a016; GOLDMAN DJ, 1984, BIOCHEMISTRY-US, V23, P2600, DOI 10.1021/bi00307a010; GOY MF, 1977, P NATL ACAD SCI USA, V74, P4964, DOI 10.1073/pnas.74.11.4964; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HANLON DW, 1993, BIOCHIM BIOPHYS ACTA, V1158, P345, DOI 10.1016/0304-4165(93)90034-6; HANLON DW, 1992, J BACTERIOL, V174, P4218, DOI 10.1128/JB.174.13.4218-4222.1992; HANLON DW, 1994, IN PRESS MICROBIOLOG; HAZELBAUER GL, 1988, CAN J MICROBIOL, V34, P466, DOI 10.1139/m88-080; HAZELBAUER GL, 1983, INT REV CYTOL, V81, P33, DOI 10.1016/S0074-7696(08)62334-7; Hazelbauer GL, 1992, CURR OPIN STRUC BIOL, V2, P505; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; KEHRY MR, 1983, P NATL ACAD SCI USA, V81, P3287; KIRSCH ML, 1993, J BIOL CHEM, V268, P18610; KLEENE SJ, 1977, J BIOL CHEM, V252, P3214; KRIKOS A, 1983, CELL, V33, P615, DOI 10.1016/0092-8674(83)90442-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LIU JD, 1991, J BACTERIOL, V173, P4941, DOI 10.1128/jb.173.16.4941-4951.1991; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; Maniatis T., 1982, MOL CLONING; MARQUEZ LM, 1990, J BACTERIOL, V172, P3435, DOI 10.1128/jb.172.6.3435-3443.1990; MCCLEARY WR, 1990, J BACTERIOL, V172, P4877, DOI 10.1128/jb.172.9.4877-4887.1990; MIREL DB, 1989, J BACTERIOL, V171, P3095, DOI 10.1128/jb.171.6.3095-3101.1989; MIREL DB, 1992, J BACTERIOL, V174, P4197, DOI 10.1128/JB.174.13.4197-4204.1992; NETTLETON DO, 1989, J BACTERIOL, V171, P120, DOI 10.1128/jb.171.1.120-123.1989; NOWLIN DM, 1987, J BIOL CHEM, V262, P6039; ORDAL GW, 1976, J MOL BIOL, V100, P103, DOI 10.1016/S0022-2836(76)80037-X; ORDAL GW, 1983, J BACTERIOL, V154, P1088, DOI 10.1128/JB.154.3.1088-1097.1983; ORDAL GW, 1977, J BACTERIOL, V129, P151, DOI 10.1128/JB.129.1.151-155.1977; ORDAL GW, 1977, J BACTERIOL, V129, P156, DOI 10.1128/JB.129.1.156-165.1977; ORDAL GW, 1975, SCIENCE, V189, P802, DOI 10.1126/science.808854; ORDAL GW, 1979, J GEN MICROBIOL, V118, P471; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRINGER WR, 1977, P NATL ACAD SCI USA, V74, P533, DOI 10.1073/pnas.74.2.533; STEWART RC, 1990, J BACTERIOL, V172, P3388, DOI 10.1128/jb.172.6.3388-3399.1990; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TAYLOR BL, 1990, MEMBRANE TRANSPORT I, P69; TERWILLIGER TC, 1986, J BIOL CHEM, V261, P814; THOELKE MS, 1990, J BIOL CHEM, V265, P1928; THOELKE MS, 1988, BIOCHEMISTRY-US, V27, P8453, DOI 10.1021/bi00422a024; THOELKE MS, 1989, BIOCHEMISTRY-US, V27, P8453; ULLAH AHJ, 1981, J BACTERIOL, V145, P958, DOI 10.1128/JB.145.2.958-965.1981; VANDERWERF P, 1977, J BIOL CHEM, V252, P2793; YAO VJ, 1992, P NATL ACAD SCI USA, V89, P11915, DOI 10.1073/pnas.89.24.11915; ZUBERI AR, 1990, J BACTERIOL, V172, P1870, DOI 10.1128/jb.172.4.1870-1876.1990	60	88	96	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14038	14046						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188684				2022-12-27	WOS:A1994NL60600050
J	VASSBOTN, FS; HAVNEN, OK; HELDIN, CH; HOLMSEN, H				VASSBOTN, FS; HAVNEN, OK; HELDIN, CH; HOLMSEN, H			NEGATIVE FEEDBACK-REGULATION OF HUMAN PLATELETS VIA AUTOCRINE ACTIVATION OF THE PLATELET-DERIVED GROWTH-FACTOR ALPHA-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; TYROSINE PHOSPHORYLATION; PDGF RECEPTOR; PROTEIN-PHOSPHORYLATION; SIGNAL TRANSDUCTION; C3H FIBROBLASTS; B-CHAIN; CELLS; BINDING; IDENTIFICATION	Human platelets contain platelet-derived growth factor (PDGF) in their alpha-granules which is released during platelet exocytosis. We show by immunoprecipitation and I-125-PDGF binding experiments that human platelets have functionally active PDGF alpha-receptors, but not beta-receptors. The PDGF alpha-receptor (PDGFR-alpha) was identified as a 170-kDa glycosylated protein-tyrosine kinase as found in other cell types. Stimulation of platelets with 0.1 unit/ml thrombin resulted in a significant increase (2-5-fold) of the tyrosine phosphorylation of the PDGFR-alpha, as determined by immunoprecipitation with phosphotyrosine antiserum as well as with PDGFR-alpha antiserum. The observed thrombin-induced autophosphorylation of the PDGFR-alpha was inhibited by the addition of a neutralizing monoclonal PDGF antibody. Thus, our results suggest that the platelet PDGFR-alpha is stimulated in an autocrine manner by PDGF secreted during platelet activation. Preincubation of platelets with PDGF inhibited thrombin-induced platelet aggregation and secretion of ATP + ADP and beta-hexosaminidase. Thrombin-induced platelet aggregation was also reversed when PDGF was added 30 s after thrombin stimulation. Inhi bition of the autocrine PDGF pathway during platelet activation by the PDGF antibody led to a potentiation of thrombin-induced beta-hexosaminidase secretion. Thus, the PDGFR-alpha takes part in a negative feedback regulation during platelet activation. Our demonstration of PDGF alpha-receptors on human platelets and its inhibitory function during platelet activation identifies a new possible role of PDGF in the regulation of thrombosis.	BIOMED CTR,LUDWIG INST CANC RES,S-75123 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research	VASSBOTN, FS (corresponding author), UNIV BERGEN,DEPT BIOCHEM & MOLEC BIOL,N-5009 BERGEN,NORWAY.							AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAR RS, 1989, ENDOCRINOLOGY, V124, P1841, DOI 10.1210/endo-124-4-1841; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; Botting R, 1989, Arch Mal Coeur Vaiss, V82 Spec No 4, P11; BRYCKAERT MC, 1989, J BIOL CHEM, V264, P4336; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DANGELMAIER CA, 1980, ANAL BIOCHEM, V104, P182, DOI 10.1016/0003-2697(80)90296-1; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; EK B, 1984, J BIOL CHEM, V259, P1145; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; GERRARD JM, 1985, NOUV REV FR HEMATOL, V27, P267; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HOLMSEN H, 1989, BIOCHEM J, V260, P589, DOI 10.1042/bj2600589; Holmsen H., 1990, HEMATOLOGY, P1200; HORAK ID, 1990, ONCOGENE, V5, P597; KAPLAN DR, 1979, BLOOD, V53, P1043; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOYAMA N, 1992, J BIOL CHEM, V267, P22806; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5834; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; NAKURAMA SI, 1989, J BIOL CHEM, V264, P7089; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; RAINES EW, 1993, BIOL PLATELET DERIVE, P74; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; SMITS A, 1991, P NATL ACAD SCI USA, V88, P8159, DOI 10.1073/pnas.88.18.8159; Smits A, 1989, GROWTH FACTORS, V2, P1, DOI 10.3109/08977198909069076; STEEN VM, 1985, THROMB HAEMOSTASIS, V54, P680; TYSNES OB, 1985, THROMB RES, V40, P329, DOI 10.1016/0049-3848(85)90268-3; VASSBOTN FS, 1992, J BIOL CHEM, V267, P15635; VASSBOTN FS, 1994, J CELL PHYSIOL, V158, P381, DOI 10.1002/jcp.1041580221; VASSBOTN FS, 1990, BIOCHIM BIOPHYS ACTA, V1054, P246, DOI 10.1016/0167-4889(90)90248-C; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WITTE LD, 1978, CIRC RES, V42, P402, DOI 10.1161/01.RES.42.3.402; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZHAO YH, 1990, ONCOGENE, V5, P1629	50	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13874	13879						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188664				2022-12-27	WOS:A1994NL60600026
J	WANG, MH; GONIAS, SL; SKEEL, A; WOLF, BB; YOSHIMURA, T; LEONARD, EJ				WANG, MH; GONIAS, SL; SKEEL, A; WOLF, BB; YOSHIMURA, T; LEONARD, EJ			PROTEOLYTIC ACTIVATION OF SINGLE-CHAIN PRECURSOR MACROPHAGE-STIMULATING PROTEIN BY NERVE GROWTH FACTOR-GAMMA AND EPIDERMAL GROWTH FACTOR-BINDING PROTEIN, MEMBERS OF THE KALLIKREIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCATTER FACTOR; BIOSYNTHESIS; SEQUENCE; MICE	Promacrophage-stimulating protein (MSP) is an 80 kDa protein that acquires biological activity after cleavage at an Arg-Val bond to a disulfide-linked alpha beta heterodimer by serine proteases of the intrinsic coagulation cascade. These proteases, which include serum kallikrein, factor XIIa and factor XIa, are members of the trypsin family of serine proteases. We now report that two other members of the family, nerve growth factor -gamma (NGF-gamma) and epidermal growth factor-binding protein (EGF-BP), cleave and activate pro-MSP to the disulfide-linked alpha beta heterodimer. Cleavage of 1.5 nM pro-MSP by 1 nM NGF-gamma or EGF-BP at 37 degrees C was almost complete within 30 min. These concentrations of enzyme are about 2 orders of magnitude less than is required for cleavage by serum kalllikrein or factor XIIa. Cleavage of pro-MSP to MSP was associated with a conformational change in the protein, because the cleaved product, but not pro-MSP, was detected by a sandwich enzyme linked immunoassay. Cleavage caused the appearance of biological activity, as measured by chemotactic activity of MSP for resident peritoneal macrophages, by MSP induced macrophage shape change, and by stimulation of macrophage ingestion of C3bi-coated erythrocytes. These findings suggest the possibility of cooperative interactions between NGF-gamma or EGF-BP and pro-MSP in inflammation and wound healing.	UNIV VIRGINIA, HLTH SCI CTR, DEPT PATHOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT BIOCHEM, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia	WANG, MH (corresponding author), NCI, FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB, IMMUNOPATHOL SECT,BLDG 560, RM 12-71, FREDERICK, MD 21702 USA.							BOWCOCK AM, 1988, MOL BRAIN RES, V3, P165, DOI 10.1016/0169-328X(88)90062-9; BOYLE MDP, 1985, J IMMUNOL, V134, P564; BOYLE MDP, 1982, P NATL ACAD SCI-BIOL, V79, P2519, DOI 10.1073/pnas.79.8.2519; BRACCI-LAUDIERO L, 1992, NEUROSCI LETT, V147, P9; BRACCILAUDIERO L, 1993, NEUROREPORT, V4, P563, DOI 10.1097/00001756-199305000-00025; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BRODIE C, 1992, J IMMUNOL, V148, P3492; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; DARLING TL, 1984, CELL CULTURE METHODS, V4, P79; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRINKWATER CC, 1988, TRENDS BIOCHEM SCI, V13, P169, DOI 10.1016/0968-0004(88)90144-2; FAHNESTOCK M, 1991, CURR TOP MICROBIOL, V165, P1; HUTSON JM, 1979, NATURE, V279, P793, DOI 10.1038/279793a0; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LEONARD EJ, 1978, EXP CELL RES, V114, P117, DOI 10.1016/0014-4827(78)90043-5; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LI AKC, 1980, P NATL ACAD SCI-BIOL, V77, P4379, DOI 10.1073/pnas.77.7.4379; MAGNUSSON S, 1975, PROTEASES BIOL CONTR, P123; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; SHIMAMOTO A, 1993, FEBS LETT, V333, P61, DOI 10.1016/0014-5793(93)80375-5; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; WANG MH, 1993, J LEUKOCYTE BIOL, V54, P289, DOI 10.1002/jlb.54.4.289; WANG MH, 1994, IN PRESS J BIOL CHEM; WOLF BB, 1993, J BIOL CHEM, V268, P16327; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461; YOUNG M, 1979, BIOCHEMISTRY-US, V18, P3050, DOI 10.1021/bi00581a022	28	51	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13806	13810						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188657				2022-12-27	WOS:A1994NL60600017
J	OBERMEIER, A; LAMMERS, R; WIESMULLER, KH; JUNG, G; SCHLESSINGER, J; ULLRICH, A				OBERMEIER, A; LAMMERS, R; WIESMULLER, KH; JUNG, G; SCHLESSINGER, J; ULLRICH, A			IDENTIFICATION OF TRK BINDING-SITES FOR SHC AND PHOSPHATIDYLINOSITOL 3'-KINASE AND FORMATION OF A MULTIMERIC SIGNALING COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; PHOSPHOLIPASE-C-GAMMA; EGF RECEPTOR; PC12 CELLS; PHOSPHORYLATION; TRANSDUCTION; ASSOCIATION; ACTIVATION; PROTEINS	Phosphotyrosine-containing synthetic peptides were used to identify the binding sites for cellular polypeptides involved in nerve growth factor receptor/Trk-mediated signal transduction. In vitro association of SHC and the p85 subunit of phosphatidylinositol 3'-kinase with the Trk tyrosine kinase was prevented only by phosphorylated Y-490- and Y-751-containing peptides, respectively. In spite of the close proximity of the p85 binding site to that of phospholipase Cgamma (Y-785), both target proteins are able to interact with the same receptor molecule simultaneously.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY; UNIV TUBINGEN,INST ORGAN CHEM,W-7400 TUBINGEN 1,GERMANY; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Max Planck Society; Eberhard Karls University of Tubingen; New York University								BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HERBST R, 1992, J BIOL CHEM, V267, P13210; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KITAS EA, 1989, TETRAHEDRON LETT, V30, P6229, DOI 10.1016/S0040-4039(01)93351-9; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; THORPE GHG, 1985, CLIN CHEM, V31, P1335; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	25	271	277	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					22963	22966						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226808				2022-12-27	WOS:A1993MF51500003
J	JOSHI, AK; SMITH, S				JOSHI, AK; SMITH, S			CONSTRUCTION, EXPRESSION, AND CHARACTERIZATION OF A MUTATED ANIMAL FATTY-ACID SYNTHASE DEFICIENT IN THE DEHYDRASE FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; MOLECULAR-CLONING; ESCHERICHIA-COLI; SACCHAROPOLYSPORA-ERYTHRAEA; LIMITED TRYPSINIZATION; MULTIFUNCTIONAL ENZYME; SYNTHETASE COMPLEX; GENE; DOMAINS; ORGANIZATION	The location of the dehydrase domain in the multi-functional animal fatty acid synthase has been determined by engineering a fatty acid synthase mutant deficient in dehydrase activity. A full-length fatty acid synthase cDNA encoding a mutated histidine residue (His878 --> Ala) was constructed and expressed in insect Sf9 cells using a baculoviral vector. The mutated recombinant fatty acid synthase retained all partial activities of the multifunctional complex except the dehydrase and was unable to synthesize fatty acids. Beta-hydroxybutyryl moieties were formed by the mutant fatty acid synthase from acetyl-CoA, malonyl-CoA, and NADPH and slowly released as the CoA thioester, confirming that this protein cannot perform the dehydration reaction. This finding points to an important catalytic role for His878 in the dehydration reaction and establishes that the dehydrase domain is located immediately adjacent to the carboxyl terminus of the transferase domain. Examination of the completed domain map for the animal fatty acid synthase indicates that the catalytic domains are clustered in two groups separated by a central structural core: the ketoacyl synthase, malonyl/acetyltransferase, and dehydrase in the amino-terminal half and the enoyl reductase, ketoreductase, acyl carrier protein, and thioesterase in the carboxyl-terminal half. A model is proposed in which the two centers for acyl chain initiation, elongation and termination, are formed by the cooperation of the three amino-terminal domains of one subunit with the four carboxyl-terminal domains of the other subunit.	CHILDRENS HOSP OAKLAND,RES INST,747 52ND ST,OAKLAND,CA 94609	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland					NIDDK NIH HHS [DK-16073] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016073] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMY CM, 1992, P NATL ACAD SCI USA, V89, P1105, DOI 10.1073/pnas.89.3.1105; AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; ANNAND RR, 1993, J AM CHEM SOC, V115, P1088, DOI 10.1021/ja00056a038; BECK J, 1990, EUR J BIOCHEM, V192, P487, DOI 10.1111/j.1432-1033.1990.tb19252.x; BEVITT DJ, 1992, EUR J BIOCHEM, V204, P39, DOI 10.1111/j.1432-1033.1992.tb16603.x; CRONAN JE, 1988, J BIOL CHEM, V263, P4641; DONADIO S, 1992, GENE, V111, P51, DOI 10.1016/0378-1119(92)90602-L; FOSTER RJ, 1985, J BIOL CHEM, V260, P2826; HOLZER KP, 1989, P NATL ACAD SCI USA, V86, P4387, DOI 10.1073/pnas.86.12.4387; JOSHI AK, 1993, IN PRESS BIOCH J; KITAMOTO T, 1988, J MOL BIOL, V203, P183, DOI 10.1016/0022-2836(88)90101-5; KUMAR S, 1970, J BIOL CHEM, V245, P4732; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATHUR M, 1992, J BIOL CHEM, V267, P19388; MCCARTHY AD, 1983, EUR J BIOCHEM, V136, P501, DOI 10.1111/j.1432-1033.1983.tb07769.x; NAGGERT J, 1991, BIOCHEM J, V273, P787, DOI 10.1042/bj2730787; O'Reilly D. R., 1992, BACULOVIRUS EXPRESSI, P1; PETITHORY JR, 1993, BIOCHEM J, V292, P361, DOI 10.1042/bj2920361; RANGAN VS, 1991, J BIOL CHEM, V266, P19180; SCHWEIZER M, 1986, MOL GEN GENET, V203, P479, DOI 10.1007/BF00422073; SCHWEIZER M, 1989, NUCLEIC ACIDS RES, V17, P567, DOI 10.1093/nar/17.2.567; Smith S, 1975, Methods Enzymol, V35, P65, DOI 10.1016/0076-6879(75)35139-2; Smith S, 1981, Methods Enzymol, V71 Pt C, P181, DOI 10.1016/0076-6879(81)71026-7; SMITH S, 1976, P NATL ACAD SCI USA, V73, P1184, DOI 10.1073/pnas.73.4.1184; SMITH S, 1979, ARCH BIOCHEM BIOPHYS, V197, P379, DOI 10.1016/0003-9861(79)90259-5; STOOPS JK, 1981, J BIOL CHEM, V256, P5128; TSUKAMOTO Y, 1988, J BIOL CHEM, V263, P16225; TSUKAMOTO Y, 1983, J BIOL CHEM, V258, P5312; ULLMAN AH, 1978, ANAL BIOCHEM, V84, P85, DOI 10.1016/0003-2697(78)90486-4; WITKOWSKI A, 1991, EUR J BIOCHEM, V198, P571, DOI 10.1111/j.1432-1033.1991.tb16052.x; YUAN Z, 1986, J BIOL CHEM, V261, P3643	31	78	80	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22508	22513						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226759				2022-12-27	WOS:A1993MD34800050
J	MALEK, SN; DESIDERIO, S				MALEK, SN; DESIDERIO, S			SH2 DOMAINS OF THE PROTEIN-TYROSINE KINASES BLK, LYN, AND FYN(T) BIND DISTINCT SETS OF PHOSPHOPROTEINS FROM B-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; SRC HOMOLOGY REGION-2; GROWTH-FACTOR RECEPTOR; C-SRC; PHOSPHORYLATED PROTEINS; SIGNAL TRANSDUCTION; HIGH-AFFINITY; PHOSPHATIDYLINOSITOL 3-KINASE; MEMBRANE IMMUNOGLOBULIN; STABLE ASSOCIATION	Several members of the Src family, including Blk, Lyn, Fyn(T), and Lck, are expressed in B cells. These kinases associate with the antigen receptor complex, and the activities of Blk, Fyn(T), and Lyn increase upon receptor engagement. Differences in the amino acid sequences and patterns of expression of these kinases suggest that they serve distinct functions. In this communication it is shown that the SH2 domains from Blk, Lyn, and Fyn(T) preferentially bind distinct sets of phosphoproteins from the mature B cell line A20. These interactions were found to depend on recognition of phosphotyrosine. The Blk SH2 domain bound more than 10 distinct phosphoprotein species, most of which reacted with an antiphosphotyrosine antibody; the phosphotyrosine content of these proteins was increased if surface immunoglobulin was cross-linked before extracts were made. Phosphoproteins of 72, 76, 115, and 130 kDa bound to the SH2 domains of Blk, Lyn, and Fyn(T). Phosphoamino acid analysis of these four proteins revealed that each contained phosphoserine, phosphothreonine, and phosphotyrosine. Proteins of 90 kDa, 130 kDa, and 150 kDa were preferentially bound by the Blk SH2 domain, while the Fyn(T) SH2 domain showed preferential binding to proteins of 76 and 180 kDa. The Lyn SH2 binding profile resembled that of Blk, but differences in the binding specificities of these kinases were also observed. Thus, among proteins that exhibit increased tyrosine phosphorylation following antigen receptor cross-linking, several have been identified that bind preferentially to SH2 domains of Blk, Fyn(T), or Lyn, suggesting that these kinases serve distinct functions. In addition, chimeric Fyn(T)-Blk SH2 domains were shown to be functional in binding assays and to exhibit binding specificities intermediate between those of the parent domains, consistent with the interpretation that the differences we observe in phosphoprotein binding by Fyn(T) and Blk SH2 domains reflect differences in their native structures.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	MALEK, SN (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.							APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COOKE M P, 1989, New Biologist, V1, P66; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; DAVIDPFEUTY T, 1990, EUR J BIOCHEM, V192, P55, DOI 10.1111/j.1432-1033.1990.tb19194.x; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; KOZMA LM, 1991, METHOD ENZYMOL, V201, P28; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHAW AC, 1990, CELL, V63, P381, DOI 10.1016/0092-8674(90)90171-A; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VERDERAME MF, 1989, MOL CELL BIOL, V9, P338; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	59	36	36	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22557	22565						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226767				2022-12-27	WOS:A1993MD34800058
J	TEALE, B; KHANNA, KK; SINGH, SP; LAVIN, MF				TEALE, B; KHANNA, KK; SINGH, SP; LAVIN, MF			RADIATION-ACTIVATED DNA-BINDING PROTEIN CONSTITUTIVELY PRESENT IN ATAXIA-TELANGIECTASIA NUCLEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZING-RADIATION; HUMAN-CELLS; TRANSCRIPTION FACTOR; CHROMOSOME 11Q22-23; TOPOISOMERASE-II; KINASE-C; GENE; LOCALIZATION; IDENTIFICATION; EXPRESSION	We have recently described the appearance of a specific DNA-binding protein in nuclei from human cells exposed to ionizing radiation which was not detected in nuclear extracts from unperturbed cells (Singh, S. P., and Lavin, M. F. (1990) Mol. Cell. Biol. 10, 5279-5285). We report here a similar activity which is constitutively present in nuclei of both unirradiated and irradiated cells from patients with the human genetic disorder ataxia telangiectasia (A-T). Activity was present in unirradiated nuclear extracts from 3 A-T cell lines of different complementation groups, but was not detected or was present only at a low level in 4 controls. Active protein was detected in the cytoplasm of both cell types. Exposure to ionizing radiation did not change the amount of DNA binding activity in A-T nuclei but led to an increase in nuclei from 4 control cell lines. Purification of the binding activities from A-T nuclei and control cytoplasm was carried out by affinity chromatography, as described previously for control extracts (Teale, B., Singh, S. P., Khanna, K. K., Findik, D., and Lavin, M. F. (1992) J. Biol. Chem. 267, 10295-10301). Southwestern analysis and UV cross-linking confirmed the presence of a major DNA-binding species at 70 kDa in both cases with a minor binding activity at 47 kDa also evident. It was not possible to distinguish between the binding activities from A-T and control cells under different conditions, and phosphorylation was required for binding activity in both cases. Footprint analysis revealed that the same sequence was being recognized by the control and A-T proteins. The constitutive presence of a specific radiation-responsive DNA-binding protein in A-T cells may be indicative of a continuous state of stress in these cells.	QUEENSLAND INST MED RES,BANCROFT CTR,QUEENSLAND CANC FUND RES UNIT,PO ROYAL BRISBANE HOSP,HERSTON 4029,AUSTRALIA; CSIRO,DEPT PREVENT MED & COMMUNITY HLTH,CANBERRA,ACT 2601,AUSTRALIA	QIMR Berghofer Medical Research Institute; Commonwealth Scientific & Industrial Research Organisation (CSIRO)			Lavin, Martin F/F-5961-2014; singh, surinder/C-9528-2009	Lavin, Martin F/0000-0002-5940-4769; singh, surinder/0000-0003-4488-8147; Khanna, Kum Kum/0000-0001-8650-5381				ANGULO JF, 1991, NUCLEIC ACIDS RES, V19, P5117, DOI 10.1093/nar/19.19.5117; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BATES PR, 1989, MUTAT RES, V218, P165, DOI 10.1016/0921-8777(89)90023-2; BAXTER G, 1988, IMMUNOL CELL BIOL, V67, P57; BODER E, 1985, ATAXIA TELANGIECTASI, P1; BOOTHMAN DA, 1989, CANCER RES, V49, P2871; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DAVIES SM, 1989, NUCLEIC ACIDS RES, V17, P1337, DOI 10.1093/nar/17.4.1337; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMASHENKO AD, 1990, INT J RADIAT BIOL, V57, P315, DOI 10.1080/09553009014552431; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FOROUD T, 1991, AM J HUM GENET, V49, P1263; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; GLAZER PM, 1989, P NATL ACAD SCI USA, V86, P1163, DOI 10.1073/pnas.86.4.1163; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HANAWALT PC, 1986, TRENDS GENET, V2, P124, DOI 10.1016/0168-9525(86)90201-5; HOBSON K, 1991, ANAL BIOCHEM, V193, P220, DOI 10.1016/0003-2697(91)90012-I; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Jones N, 1990, Semin Cancer Biol, V1, P5; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAPP LN, 1992, AM J HUM GENET, V51, P45; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KINGSTON RE, 1987, MOL CELL BIOL, V7, P1530, DOI 10.1128/MCB.7.4.1530; KRAMER M, 1990, RADIAT ENVIRON BIOPH, V29, P303, DOI 10.1007/BF01210410; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVIN MF, 1988, MUTAT RES, V193, P193, DOI 10.1016/0167-8817(88)90030-2; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEYKO W, 1986, INT J RADIAT BIOL, V49, P743, DOI 10.1080/09553008514552971; MCCONVILLE CM, 1990, HUM GENET, V85, P215; MCFARLIN DE, 1972, MEDICINE, V51, P281, DOI 10.1097/00005792-197207000-00002; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; PAINTER RB, 1986, INT J RADIAT BIOL, V49, P771; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PATERSON MC, 1976, NATURE, V260, P444, DOI 10.1038/260444a0; PETERSON RD, 1964, LANCET, V9, P1189; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PIPPARD EC, 1988, CANCER RES, V48, P2929; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SINGH SP, 1988, NUCLEIC ACIDS RES, V16, P3919, DOI 10.1093/nar/16.9.3919; SINGH SP, 1990, MOL CELL BIOL, V10, P5279, DOI 10.1128/MCB.10.10.5279; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; TEALE B, 1992, J BIOL CHEM, V267, P10295	50	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22450	22455						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226753				2022-12-27	WOS:A1993MD34800042
J	ALLAIN, F; DENYS, A; SPIK, G				ALLAIN, F; DENYS, A; SPIK, G			CHARACTERIZATION OF SURFACE BINDING-SITES FOR CYCLOPHILIN-B ON A HUMAN TUMOR T-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYCLOSPORINE-A; PROTEIN CYCLOPHILIN; S-CYCLOPHILIN; SEQUENCE; CALCINEURIN; SENSITIVITY; ACTIVATION; INHIBITION; ISOMERASE; COMPLEXES	Cyclophilin B (CyPB) is a cyclosporin-binding protein, known to be located mainly within the endoplasmic reticulum vesicles. Its previous characterization in human milk implies that the protein may be released from the secretory pathway and recovered in biological fluids. In an attempt to understand the role of the extracellular CyPB, we have investigated the binding capacity of the protein to cells derived from human T- and B-lymphocytes. We present here evidence that CyPB binds to T-lymphocytes and that the binding to the Jurkat T-cell surface is specific, saturable, and reversible. The dissociation constant K-d was 12 nM, and the number of binding sites was estimated to 35,000/cell. We report that the surface-bound CyPB was internalized at 37 degrees C and subsequently degraded in the cell. We also show that the immunosuppressive drug cyclosporin A does not inhibit the surface binding of CyPB, and does not interfere with internalization of the protein. These results support the hypothesis that the selective action of the immunosuppressive drug results in part from its interaction with the extracellular form of CyPB.	UNIV SCI & TECH LILLE FLANDRES ARTOIS, CHIM BIOL LAB, CNRS, UNITE MIXTE RECH 111, F-59655 VILLENEUVE DASCQ, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille				Allain, Fabrice/0000-0002-4484-6302				ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; CACALANO NA, 1992, P NATL ACAD SCI USA, V89, P4353, DOI 10.1073/pnas.89.10.4353; CARONI P, 1991, J BIOL CHEM, V266, P10739; DAVIS TR, 1991, BIOCHIM BIOPHYS ACTA, V1095, P145, DOI 10.1016/0167-4889(91)90077-B; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FISHER G, 1989, NATURE, V337, P476; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; INOUE T, 1993, BIOCHEM BIOPH RES CO, V190, P857, DOI 10.1006/bbrc.1993.1127; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; POVLSEN JV, 1990, SCAND J IMMUNOL, V32, P45, DOI 10.1111/j.1365-3083.1990.tb02890.x; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; RYFFEL B, 1991, IMMUNOLOGY, V72, P399; SANDER B, 1986, SCAND J IMMUNOL, V23, P435; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SHERRY B, 1992, P NATL ACAD SCI USA, V89, P3511, DOI 10.1073/pnas.89.8.3511; SPIK G, 1991, J BIOL CHEM, V266, P10735; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; VAITUKAITIS J, 1971, J CLIN ENDOCR METAB, V33, P988, DOI 10.1210/jcem-33-6-988; XU Q, 1992, J BIOL CHEM, V267, P11968; YANG SY, 1986, J IMMUNOL, V137, P1097	27	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16537	16540						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206968				2022-12-27	WOS:A1994NR29600005
J	BEZOUSKA, K; VLAHAS, G; HORVATH, O; JINOCHOVA, G; FISEROVA, A; GIORDA, R; CHAMBERS, WH; FEIZI, T; POSPISIL, M				BEZOUSKA, K; VLAHAS, G; HORVATH, O; JINOCHOVA, G; FISEROVA, A; GIORDA, R; CHAMBERS, WH; FEIZI, T; POSPISIL, M			RAT NATURAL-KILLER-CELL ANTIGEN, NKR-P1, RELATED TO C-TYPE ANIMAL LECTINS IS A CARBOHYDRATE-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; ACTIVATION ANTIGEN; MONOCLONAL-ANTIBODIES; RECOGNITION DOMAINS; MOLECULAR-CLONING; ESCHERICHIA-COLI; LIGAND-BINDING; MOUSE NKR-P1; NK-CELLS; EXPRESSION	Natural killer receptor protein 1 (NKR-P1, a family of proteins), which is a dimeric transmembrane protein predominantly on rat and murine natural killer cells, contains an extracellular motif related to calcium-dependent animal lectins. The domain architecture of this protein and the finding that its cross-linking with antibody results in activation of natural killer cells make it a promising candidate for a receptor function. We have expressed a full-length NKR-P1 protein of the rat in COS cells and prepared soluble extracellular fragments by controlled proteolysis or by expression of truncated cDNA in bacteria. Dimerization of soluble NKR-P1 is predominantly dependent on the presence of an intact juxtamembrane stalk region and independent of N-glycosylation. Binding and inhibition studies using monosaccharides and neoglycoconjugates indicate that NKR-P1 is a lectin with a preference order of GalNAc > GlcNAc >> Fuc >> Gal > Man. At neutral pH, Ca2+ is tightly associated with the protein such that only a proportion can be removed by 10 mM EGTA. However, NKR-P1 can be decalcified completely at pH 10 with a total loss of carbohydrate binding. After recalcification at pH 8, carbohydrate binding is completely restored. Thus, NKR-P1 differs from other calcium-dependent animal lectins investigated so far in its pattern of monosaccharide recognition and in the tightness of Ca2+ binding.	ACAD SCI CZECH REPUBL, INST MICROBIOL, DEPT IMMUNOL & GNOTOBIOL, CR-14220 PRAGUE 4, CZECH REPUBLIC; UNIV PITTSBURGH, PITTSBURGH CANC INST, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, DEPT PATHOL, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA 15213 USA; MRC, CLIN RES CTR, GLYCOCONJUGATES SECT, HARROW HA1 3UJ, MIDDX, ENGLAND	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Medical Research Council Clinical Trials Unit	BEZOUSKA, K (corresponding author), CHARLES UNIV, INST BIOTECHNOL, HLAVOVA 8-2030, CR-12840 PRAGUE 2, CZECH REPUBLIC.		Giorda, Roberto/Q-6010-2019; Giorda, Roberto/J-1052-2014	Giorda, Roberto/0000-0001-8175-9606; Giorda, Roberto/0000-0001-8175-9606; Feizi, Ten/0000-0001-6495-0329				ANDERSON SK, 1993, P NATL ACAD SCI USA, V90, P542, DOI 10.1073/pnas.90.2.542; CHAMBERS WH, 1989, J EXP MED, V169, P1373, DOI 10.1084/jem.169.4.1373; CHAMBERS WH, 1993, GLYCOBIOLOGY, V3, P9, DOI 10.1093/glycob/3.1.9; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; DARBRE A, 1988, PRACTICAL PROTEIN CH, P517; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; DRICKAMER K, 1993, PROG NUCLEIC ACID RE, V45, P207, DOI 10.1016/S0079-6603(08)60870-3; Feizi Ten, 1993, Current Opinion in Structural Biology, V3, P701, DOI 10.1016/0959-440X(93)90053-N; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; GIORDA R, 1991, J IMMUNOL, V147, P1701; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; HAMANN J, 1993, J IMMUNOL, V150, P4920; HARLOW E, 1988, ANTIBODIES LABORATOR, P424; HARRIS DT, 1989, J IMMUNOL, V143, P727; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOFER E, 1992, IMMUNOL TODAY, V13, P429, DOI 10.1016/0167-5699(92)90067-H; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANIER LL, 1988, J EXP MED, V167, P1572, DOI 10.1084/jem.167.5.1572; LANIER LL, 1992, CURR OPIN IMMUNOL, V4, P38, DOI 10.1016/0952-7915(92)90121-T; LOEB JA, 1988, J BIOL CHEM, V263, P9752; LOPEZCABRERA M, 1993, J EXP MED, V178, P537, DOI 10.1084/jem.178.2.537; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOOREHEAD WR, 1979, CLIN CHEM, V20, P1458; ORTALDO JR, 1981, J IMMUNOL, V127, P2401; PALMITER RD, 1977, J BIOL CHEM, V252, P6386; ROSENSTEIN IJ, 1992, INFECT IMMUN, V60, P5078, DOI 10.1128/IAI.60.12.5078-5084.1992; RYAN JC, 1992, J IMMUNOL, V149, P1631; RYAN JC, 1991, J IMMUNOL, V147, P3244; Sambrook J, 1989, MOL CLONING LABORATO; SILICIANO RF, 1985, NATURE, V317, P428, DOI 10.1038/317428a0; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1992, COLD SPRING HARB SYM, V57, P281, DOI 10.1101/SQB.1992.057.01.033; YABE T, 1993, IMMUNOGENETICS, V37, P455; YOKOYAMA WM, 1991, J IMMUNOL, V147, P3229	42	90	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16945	16952						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207018				2022-12-27	WOS:A1994NR29600065
J	CROSSLEY, M; ORKIN, SH				CROSSLEY, M; ORKIN, SH			PHOSPHORYLATION OF THE ERYTHROID TRANSCRIPTION FACTOR GATA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; BETA-GLOBIN LOCUS; CASEIN KINASE-II; PROTEIN-KINASE; GENE-TRANSCRIPTION; CONTROL REGION; HYPERSENSITIVE SITE-3; REGULATORY ELEMENT; MAMMALIAN-CELLS; DISTAL ENHANCER	GATA-1 is a zinc finger DNA-binding protein thought to be involved in the expression of the vast majority of erythroid specific genes. We have examined the phosphorylation of GATA-1 in murine erythroleukemia (MEL) cells and have mapped the sites of phosphorylation by overexpression of GATA-1 in monkey kidney COS cells. We show that GATA-1 is phosphorylated on 6 serines within its amino terminus in uninduced MEL cells and that a 7th site, serine 310, becomes phosphorylated after MEL cells are induced to differentiate by exposure to dimethyl sulfoxide. This site lies near the carboxyl boundary of the DNA-binding domain in a conserved region of the protein believed to be involved in DNA bending. Detailed analyses indicate, however, that phosphorylation at this site, or the other sites identified, does not significantly influence DNA-binding affinity or specificity, DNA bending, or transcriptional transactivation by GATA-1.	CHILDRENS HOSP, DANA FARBER CANC INST, DEPT PEDIAT, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Howard Hughes Medical Institute			Crossley, Merlin/D-7888-2011	Crossley, Merlin/0000-0003-2057-3642				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANTONIOU M, 1990, GENE DEV, V4, P1007, DOI 10.1101/gad.4.6.1007; BARTON MC, 1993, GENE DEV, V7, P1796, DOI 10.1101/gad.7.9.1796; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; GALLARDA JL, 1989, GENE DEV, V3, P1845, DOI 10.1101/gad.3.12a.1845; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HIGGS DR, 1993, CURR BIOL, V3, P548, DOI 10.1016/0960-9822(93)90054-R; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LACRONIQUE V, 1992, NUCLEIC ACIDS RES, V20, P5669, DOI 10.1093/nar/20.21.5669; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; ORKIN SH, 1992, BLOOD, V80, P575; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; PILZ RB, 1992, J BIOL CHEM, V267, P16161; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; REDDY PMS, 1993, MOL CELL BIOL, V13, P1093, DOI 10.1128/MCB.13.2.1093; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ DA, 1983, J BIOL CHEM, V258, P777; SCHWARTZBAUER G, 1992, NUCLEIC ACIDS RES, V20, P4429, DOI 10.1093/nar/20.17.4429; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STEINFELDER HJ, 1992, P NATL ACAD SCI USA, V89, P5942, DOI 10.1073/pnas.89.13.5942; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; WATT P, 1990, NUCLEIC ACIDS RES, V18, P1339, DOI 10.1093/nar/18.6.1339; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10642, DOI 10.1073/pnas.88.23.10642	70	103	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16589	16596						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206977				2022-12-27	WOS:A1994NR29600014
J	KUDLICKI, W; ODOM, OW; KRAMER, G; HARDESTY, B				KUDLICKI, W; ODOM, OW; KRAMER, G; HARDESTY, B			ACTIVATION AND RELEASE OF ENZYMATICALLY INACTIVE, FULL-LENGTH RHODANESE THAT IS BOUND TO RIBOSOMES AS PEPTIDYL-TRANSFER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION TRANSLATION; PROTEIN; POLYPEPTIDES; BINDING; CHAINS; SYSTEM; GROEL; DNAJ	Synthesis of rhodanese in a cell-free coupled transcription/translation system derived from Escherichia coli leads to an accumulation of full length rhodanese protein on the ribosomes as well as to enzymatically active protein that is released from the ribosomes into the supernatant fraction. The ribosome-bound protein is enzymatically inactive but can be activated and released from the ribosomes without additional protein synthesis by subsequent incubation in the presence of the added chaperones DnaJ, DnaK, GrpE, GroEL, and GroES plus ATP. Efficient activation requires that all of the chaperones are present together during incubation which yields fully active rhodanese. Incubation in the presence of DnaJ only inhibits release whereas incubation with only GroES or DnaK promotes the release of enzymatically inactive protein. Incubation of the ribosome with puromycin leads to the release of enzymatically inactive protein whereas release and activation in the presence of all of the chaperones is blocked by sparsomycin. The effect of these antibiotics provides very strong evidence that enzymatically inactive, full-length rhodanese is bound to the ribosomes as peptidyl-tRNA and that the peptidyl transferase reaction is required for its release. Considered together, the data indicate that chaperone-mediated late stages of rhodanese folding into the enzymatically active, native conformation are intimately associated with the process of termination and release that occurs as part of the reaction cycle of protein synthesis.	UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712	University of Texas System; University of Texas Austin								ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAHR BR, 1954, J AM CHEM SOC, V76, P2838; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; Cundliffe E., 1980, RIBOSOMES STRUCTURE, P555; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; HARDESTY B, 1994, MEMBRANE PROTEIN TRA; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; JARABAK R, 1974, BIOCHEMISTRY-US, V13, P3233, DOI 10.1021/bi00713a006; KUDLICKI W, 1992, ANAL BIOCHEM, V206, P389, DOI 10.1016/0003-2697(92)90383-I; KUDLICKI W, 1994, ANAL BIOCHEM, V217, P12, DOI 10.1006/abio.1994.1077; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MILLER DM, 1991, J BIOL CHEM, V266, P4686; NATHANS D, 1963, NATURE, V197, P1076, DOI 10.1038/1971076a0; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; ODOM OW, 1992, J BIOL CHEM, V267, P19117; PICKING WD, 1992, BIOCHEMISTRY-US, V31, P2368, DOI 10.1021/bi00123a023; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; SPIRIN AS, 1988, SCIENCE, V242, P1162, DOI 10.1126/science.3055301; TATE WP, 1994, TRANSLATIONAL APPARA, P253; TSALKOVA T, 1993, BIOCHEMISTRY-US, V32, P3377, DOI 10.1021/bi00064a022; TSOU CL, 1988, BIOCHEMISTRY-US, V27, P1809, DOI 10.1021/bi00406a001	24	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16549	16553						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206970				2022-12-27	WOS:A1994NR29600007
J	VIEIRA, L; LAVAN, A; DAGGER, F; CABANTCHIK, ZI				VIEIRA, L; LAVAN, A; DAGGER, F; CABANTCHIK, ZI			THE ROLE OF ANIONS IN PH REGULATION OF LEISHMANIA-MAJOR PROMASTIGOTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; SENSITIVE NA+/H+ ANTIPORT; INTRACELLULAR PH; CYTOPLASMIC PH; CHLORIDE TRANSPORT; MEMBRANE; DONOVANI; CELLS; H+; IDENTIFICATION	The pH regulation of Leishmania major promastigotes was studied as a function of the ionic composition of the medium and in response to acid and alkali load. Intracellular pH (pH(i)) was monitored by on-line ratio fluorescence using the fluorescence dependent pH indicator 2',7'-bis-(carboxyethyl)-5,6-carboxyfluorescein (BCECF). In Cl--based medium (pH 7.4, 30 degrees C), the steady state pH(i) was maintained at 6.75 +/- 0.01. Only a minor (less than or equal to 0.07 +/- 0.02 unit) decrease in steady state pH(i) was observed when parasites were treated with H+-ATPase inhibitors such as vanadate, N-ethylmaleimide, or bafilomycin. After treatment with the impermeantanion transport blocker DIDS, or in the presence of the reduced analog H2DIDS, pH(i) decreased by greater than or equal to 0.2 unit. In gluconate-based medium, however, pH(i) gradually decreased to 6.53 +/- 0.05 and showed a swift but time dependent recovery (alkalinization) when Cl- or other halides or nitrate were restored to the medium. That recovery was also inhibited by pretreating cells with DIDS or exposing them to H2DIDS. The findings provide evidence for Cl- transport mechanisms that support a pH, regulatory process which is operative in acidic-neutral cytoplasmic milieu. Under alkali load induced by weak base treatment, parasites undergo a rapid alkalinization which was followed first by a fast but limited acidification and subsequently by a slower but more robust acidification (recovery) to reach a pH(i) of 6.85 +/- 0.05. The recovery of pH(i) was markedly reduced in the presence of H2DIDS and/or in the absence of Cl- in the medium. Based on these results and on the fact that the natural parasite environment is both alkaline and rich in HCO3-CO32- ions, we propose (Cl-)(o) (HCO3-)(i) or (Cl-)(o)-(OH-)(i) exchange as the major mechanism of regulatory cell acidification which is operative upon cell alkalinization. The possibility that similar pH regulatory mechanisms are operative in Leishmania promastigotes in both acidic and alkaline conditions is considered. The putative pH regulatory mechanisms might serve as potential targets for therapeutic intervention.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,KUVIN CTR STUDY INFECT DIS JERUSALEM,DEPT PARASITOL,IL-91904 JERUSALEM,ISRAEL; CENT UNIV VENEZUELA,FAC CIENCIAS,DEPT BIOL CELULAR,CARACAS 1041A,VENEZUELA	Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of Central Venezuela					NIAID NIH HHS [AI20342] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI020342, R01AI020342] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; BARNOY S, 1984, BIOCHIM BIOPHYS ACTA, V778, P612, DOI 10.1016/0005-2736(84)90413-9; BILLINGSLEY PF, 1990, ARCH INSECT BIOCHEM, V15, P149, DOI 10.1002/arch.940150304; BORON WF, 1985, J GEN PHYSIOL, V85, P325, DOI 10.1085/jgp.85.3.325; BORON WF, 1986, ANNU REV PHYSIOL, V48, P377; BOSIA A, 1993, J CELL PHYSIOL, V154, P527, DOI 10.1002/jcp.1041540311; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC857, DOI 10.1152/ajpcell.1988.255.6.C857; BOYER JL, 1992, ANNU REV PHYSIOL, V54, P415, DOI 10.1146/annurev.ph.54.030192.002215; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CABANTCHIK ZI, 1994, HDB BIOMEMBRANES, P297; DAGGER F, 1992, EUR J CELL BIOL, V58, P182; DOW JAT, 1992, J EXP BIOL, V172, P355; GLASER TA, 1988, P NATL ACAD SCI USA, V85, P7602, DOI 10.1073/pnas.85.20.7602; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; ILLSLEY NP, 1988, AM J PHYSIOL, V255, pC789, DOI 10.1152/ajpcell.1988.255.6.C789; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; LIVEANU V, 1991, EUR J CELL BIOL, V54, P95; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; MEADE JC, 1987, MOL CELL BIOL, V7, P3937, DOI 10.1128/MCB.7.11.3937; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; OLSNES S, 1987, J CELL PHYSIOL, V132, P192, DOI 10.1002/jcp.1041320203; PADAN E, 1981, BIOCHIM BIOPHYS ACTA, V650, P151, DOI 10.1016/0304-4157(81)90004-6; PARIS S, 1983, J BIOL CHEM, V258, P3503; REUSS L, 1984, J GEN PHYSIOL, V83, P801, DOI 10.1085/jgp.83.6.801; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; SIMON BJ, 1992, BIOCHEM J, V287, P423, DOI 10.1042/bj2870423; TETI A, 1991, AM J PHYSIOL, V260, pC1315; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TONNESSEN TI, 1990, AM J PHYSIOL, V258, pC1117, DOI 10.1152/ajpcell.1990.258.6.C1117; VANHEEL B, 1984, AM J PHYSIOL, V246, pC391, DOI 10.1152/ajpcell.1984.246.5.C391; VAZHAIKKURICHI MR, 1993, AM J PHYSIOL, V264, pG874; XIE XS, 1989, J BIOL CHEM, V264, P18870; ZILBERSTEIN D, 1989, MOL BIOCHEM PARASIT, V36, P109, DOI 10.1016/0166-6851(89)90183-7; ZILBERSTEIN D, 1988, BIOCHEM J, V256, P13, DOI 10.1042/bj2560013; ZILBERSTEIN D, 1985, P NATL ACAD SCI USA, V82, P1716, DOI 10.1073/pnas.82.6.1716	40	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16254	16259						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206930				2022-12-27	WOS:A1994NQ72900048
J	SATRE, MA; ZGOMBICKNIGHT, M; DUESTER, G				SATRE, MA; ZGOMBICKNIGHT, M; DUESTER, G			THE COMPLETE STRUCTURE OF HUMAN CLASS-IV ALCOHOL-DEHYDROGENASE (RETINOL DEHYDROGENASE) DETERMINED FROM THE ADH7 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LIVER; BETA-SUBUNIT; FORMALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASES; ENZYMATIC-PROPERTIES; MOLECULAR-CLONING; BINDING-PROTEIN; HUMAN STOMACH; CDNA; SEQUENCE	A novel human alcohol dehydrogenase (ADH) gene called ADH7 has been characterized and determined to encode class IV ADH, an ADH isozyme which is very active as a retinol dehydrogenase. A nearly full-length cDNA for ADH7 was isolated from a human stomach cDNA library, and a 5' genomic clone containing exons 1 and 2 was isolated from a human genomic library. DNA sequence analysis of the cDNA and genomic clones revealed the complete coding region of the gene and the deduced full-length amino acid sequence of human class IV ADH composed of 373 amino acids following the initiator methionine. The class IV identity of the sequence was confirmed by agreement with previously determined sequences for several human stomach class IV ADH peptides. Alignment of the full-length predicted amino acid sequence of human class IV ADH with the full-length sequences of the other four known human ADH classes revealed sequence identities of 69% (class I), 59% (class II), 61% (class III), and 60% (class V). The higher sequence identity shared with human class I AI)H suggests that the genes for ADH classes I and IV may have diverged from a common ancestor after the separation of the other classes, and may still share common physiological functions. Discussed is the possibility that one of these functions is retinol oxidation for the synthesis of retinoic acid, a hormone important for cellular differentiation.	LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute					NIAAA NIH HHS [AA07261] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007261] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; BEISSWENGER TB, 1985, P NATL ACAD SCI USA, V82, P8369, DOI 10.1073/pnas.82.24.8369; BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; BOLEDA MD, 1989, ARCH BIOCHEM BIOPHYS, V274, P74, DOI 10.1016/0003-9861(89)90416-5; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHAMBON P, 1993, GENE, V135, P223, DOI 10.1016/0378-1119(93)90069-F; CHEN CS, 1991, BIOCHEM BIOPH RES CO, V181, P743, DOI 10.1016/0006-291X(91)91253-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; DUESTER G, 1986, J BIOL CHEM, V261, P2027; DUESTER G, 1984, P NATL ACAD SCI-BIOL, V81, P4055, DOI 10.1073/pnas.81.13.4055; FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205; GIRI PR, 1989, BIOCHEM BIOPH RES CO, V164, P453, DOI 10.1016/0006-291X(89)91741-5; HARDING PP, 1992, J BIOL CHEM, V267, P14145; HEDEN LO, 1986, FEBS LETT, V194, P327, DOI 10.1016/0014-5793(86)80111-9; HENEHAN GTM, 1993, BIOCHEMISTRY-US, V32, P736, DOI 10.1021/bi00054a001; HOOG JO, 1987, BIOCHEMISTRY-US, V26, P1926, DOI 10.1021/bi00381a021; HUR MW, 1992, GENE, V121, P305, DOI 10.1016/0378-1119(92)90135-C; IKUTA T, 1986, P NATL ACAD SCI USA, V83, P634, DOI 10.1073/pnas.83.3.634; IKUTA T, 1985, P NATL ACAD SCI USA, V82, P2703, DOI 10.1073/pnas.82.9.2703; JORNVALL H, 1987, P NATL ACAD SCI USA, V84, P2580, DOI 10.1073/pnas.84.9.2580; JULIA P, 1987, EUR J BIOCHEM, V162, P179, DOI 10.1111/j.1432-1033.1987.tb10559.x; KIM CI, 1992, ARCH BIOCHEM BIOPHYS, V294, P388, DOI 10.1016/0003-9861(92)90700-7; KOIVUSALO M, 1989, FEBS LETT, V257, P105, DOI 10.1016/0014-5793(89)81797-1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREBS HA, 1970, BIOCHEM J, V118, P635, DOI 10.1042/bj1180635; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; li T K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P427; MATSUO Y, 1989, FEBS LETT, V243, P57, DOI 10.1016/0014-5793(89)81217-7; MEZEY E, 1971, EXP MOL PATHOL, V15, P148, DOI 10.1016/0014-4800(71)90095-5; MORENO A, 1991, J BIOL CHEM, V266, P1128; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PARES X, 1992, FEBS LETT, V303, P69, DOI 10.1016/0014-5793(92)80479-Z; PARES X, 1990, FEBS LETT, V277, P115, DOI 10.1016/0014-5793(90)80822-Z; PERSSON B, 1993, EUR J BIOCHEM, V216, P49, DOI 10.1111/j.1432-1033.1993.tb18115.x; PICKER Y, 1993, ADV EXP MED BIOL, V328, P411; PIETRUSZKO R, 1979, BIOCH PHARMACOLOGY E, V1, P87; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; Sambrook J, 1989, MOL CLONING LABORATO; SHARMA CP, 1989, BIOCHEM BIOPH RES CO, V164, P631, DOI 10.1016/0006-291X(89)91507-6; STEWART MJ, 1990, GENE, V90, P271, DOI 10.1016/0378-1119(90)90190-3; STONE CL, 1993, ALCOHOL CLIN EXP RES, V17, P911, DOI 10.1111/j.1530-0277.1993.tb00863.x; SUN HW, 1992, J MOL EVOL, V34, P522, DOI 10.1007/BF00160465; VONBAHRLINDSTROM H, 1986, BIOCHEMISTRY-US, V25, P2465; VONBAHRLINDSTROM H, 1991, GENE, V103, P269, DOI 10.1016/0378-1119(91)90285-J; Yang Z. N., 1993, Alcoholism Clinical and Experimental Research, V17, P496; YASUNAMI M, 1991, P NATL ACAD SCI USA, V88, P7610, DOI 10.1073/pnas.88.17.7610; YIN SJ, 1993, ALCOHOL CLIN EXP RES, V17, P376, DOI 10.1111/j.1530-0277.1993.tb00779.x; YIN SJ, 1990, BIOCHEM INT, V22, P829; ZACHMAN RD, 1961, J BIOL CHEM, V236, P2309; ZGOMBICKNIGHT M, 1994, J BIOL CHEM, V269, P6790; ZHENG YW, 1993, J BIOL CHEM, V268, P24933	53	58	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15606	15612						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195208				2022-12-27	WOS:A1994NP51300036
J	XU, J; GREEN, PC; KEMP, RG				XU, J; GREEN, PC; KEMP, RG			IDENTIFICATION OF BASIC RESIDUES INVOLVED IN SUBSTRATE-BINDING AND CATALYSIS BY PYROPHOSPHATE-DEPENDENT PHOSPHOFRUCTOKINASE FROM PROPIONIBACTERIUM-FREUDENREICHII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PHOSPHOFRUCTOKINASE; SITE-DIRECTED MUTAGENESIS; PH-DEPENDENCE; ACTIVE-SITE; PHOSPHOFRUCTO-1-KINASE; MECHANISM; ATP	Despite overall low identity of sequence between ATP- and PPi-dependent phosphofructo-1-kinases (PFK), an alignment permits the tentative identification of catalytically important residues in PP1-dependent PFK. Seven basic residues of the PPi-dependent PFK of Propionibacterium freudenreichii, Arg-310, Lys-315, Arg-326, Arg-186, Arg-78, Arg-90, and Lys-148 were chosen on the basis of this alignment for site-directed mutagenesis to neutral residues. Mutants R186A, K315A, and R326A had substantial increases of 43-, 389- and 678-fold, respectively, in K-m for fructose 6-phosphate relative to wild-type enzyme and relatively small effects on k(cat). The modest kinetic effects of mutations at Arg-78, Arg-90, and Arg-310 were not considered to indicate important roles for these residues. On the other hand, mutant K148M had a K-m for PPi that was increased by 132-fold and k(cat) lowered by a factor of 490. Cho and Cook (Cho, Y.-K., and Cook, P. F. (1988) Biochemistry 28, 4155-4160) concluded on the basis of kinetic and chemical modification data that the enzyme utilizes a proton shuttle mechanism and that two lysines are involved in substrate binding. The present data along with our previous data on mutant D151A support a double proton shuttle mechanism involving Asp-151 and Lys-148 with Lys-148, Arg-326, Lys-315, and perhaps Arg-186 being important for substrate binding.	CHICAGO MED SCH,DEPT BIOL CHEM,N CHICAGO,IL 60064	Chicago Medical School					NIDDK NIH HHS [NIDDK DK19912] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019912] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER SA, 1990, NATURE, V343, P575, DOI 10.1038/343575a0; BERGER SA, 1991, BIOCHEMISTRY-US, V30, P8477, DOI 10.1021/bi00098a027; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHO YK, 1989, BIOCHEMISTRY-US, V28, P4155, DOI 10.1021/bi00436a005; CHO YK, 1988, J BIOL CHEM, V263, P5135; DEVILLEBONNE D, 1991, BIOCHEMISTRY-US, V30, P5750, DOI 10.1021/bi00237a017; FOTHERGILLGILMORE LA, 1993, PROG BIOPHYS MOL BIO, V59, P105, DOI 10.1016/0079-6107(93)90001-Z; GREEN PC, 1993, J BIOL CHEM, V268, P5085; GREEN PC, 1992, BIOCHEMISTRY-US, V31, P4815, DOI 10.1021/bi00135a011; HELLINGA HW, 1987, NATURE, V327, P437, DOI 10.1038/327437a0; LADROR US, 1991, J BIOL CHEM, V266, P16550; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAINE R, 1992, EUR J BIOCHEM, V207, P1109, DOI 10.1111/j.1432-1033.1992.tb17148.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P983; VALDEZ BC, 1989, J BIOL CHEM, V264, P131; ZHENG RL, 1992, J BIOL CHEM, V267, P23640; ZHENG RL, 1992, FASEB J, V6, pA335	18	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15553	15557						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195200				2022-12-27	WOS:A1994NP51300027
J	HIGMAN, MA; NILES, EG				HIGMAN, MA; NILES, EG			LOCATION OF THE S-ADENOSYL-L-METHIONINE BINDING REGION OF THE VACCINIA VIRUS MESSENGER-RNA (GUANINE-7-)METHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA CAPPING ENZYME; MESSENGER-RNA; O-METHYLTRANSFERASE; ESCHERICHIA-COLI; DNA; PROTEIN; GUANYLYLTRANSFERASE; IDENTIFICATION; METHYLATION; VIRIONS	The mRNA (guanine-7-)methyltransferase activity of the heterodimeric vaccinia virus mRNA capping enzyme was previously mapped to the carboxyl terminal 396 amino acids of the large subunit, D1R. This activity is enhanced 30- to 50-fold by the association of the the small subunit, D12L (Higman, M. A., Christen, L. A., and Niles, E. G. (1994) J. Biol. Chem. 269, 14974-14981). Irradiation with ultraviolet light specifically photolinks S-[methyl-H-3]S-adenosyl-L-methionine to the large subunit of both the intact capping enzyme and a methyltransferase subdomain, which consists of the D12L subunit associated with the carboxyl-terminal 346 amino acids of the D1R subunit. The extent of linkage was shown to be dependent on the length of incubation, intensity of ultraviolet light, and the concentration of both active enzyme and substrate. The covalent modification was inhibited by S-adenosyl-L-homocysteine, a known competitive inhibitor of the mRNA (guanine-7-)methyltransferase activity, demonstrating specific photolabeling of the active site. Sequence-specific chemical cleavage of the photolinked methyltransferase domain with mild acid or cyanogen bromide revealed linkage of S-adenosyl-L-methionine to two regions of the large subunit. Analysis of the products of cyanogen bromide and hydroxylamine cleavage mapped the photolinked fragments to amino acids 499 to 579 and 806 to 844 of the D1R subunit. Photolinkage of AdoMet to D1R(498-844) was shown to be unaffected by the association of the small subunit.	SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT BIOCHEM, BUFFALO, NY 14214 USA; SUNY BUFFALO, SCH MED & BIOMED SCI, CTR ADV MOLEC BIOL & IMMUNOL, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028824] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28824] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBOSA E, 1978, J BIOL CHEM, V253, P7692; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; Bornstein P, 1977, Methods Enzymol, V47, P132; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; CONG PJ, 1993, J BIOL CHEM, V268, P7256; CONG PJ, 1992, J BIOL CHEM, V267, P16424; GREENLEN D, 1993, MOL MICROBIOL, V9, P145; Gros E., 1967, METHOD ENZYMOL, V11, P238; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HIGMAN MA, 1994, J BIOL CHEM, V269, P14974; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; HIGMAN MA, 1992, J BIOL CHEM, V269, P14930; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landon, 1977, Methods Enzymol, V47, P145; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; MARTIN SA, 1975, J BIOL CHEM, V250, P9330; MARTIN SA, 1976, J BIOL CHEM, V251, P7313; MARTIN SA, 1975, J BIOL CHEM, V250, P9322; MORGAN JR, 1984, J VIROL, V52, P283; NILES EG, 1993, J BIOL CHEM, V268, P24986; NILES EG, 1989, VIROLOGY, V172, P513, DOI 10.1016/0042-6822(89)90194-3; PAIK WK, 1989, BIOCHEM CELL BIOL, V67, P602; REICH NO, 1990, J BIOL CHEM, V265, P8929; ROTH JA, 1992, REV PHYSIOL BIOCH P, V120, P1, DOI 10.1007/BFb0036121; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; SOM S, 1990, J BIOL CHEM, V265, P4278; SUBBARAMAIAH K, 1992, J BIOL CHEM, V267, P8636; SUMNER J, 1986, J BIOL CHEM, V261, P7697; SYED SK, 1993, BIOCHEMISTRY-US, V32, P2242, DOI 10.1021/bi00060a016; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; WARD LD, 1990, CURRENT RES PROTEIN, P179; WRIGHT LS, 1993, J NEUROCHEM, V60, P1475, DOI 10.1111/j.1471-4159.1993.tb03310.x; YUAN R, 1981, ANNU REV BIOCHEM, V50, P285, DOI 10.1146/annurev.bi.50.070181.001441	38	23	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14982	14987						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195133				2022-12-27	WOS:A1994NP73800024
J	SAVAS, U; BHATTACHARYYA, KK; CHRISTOU, M; ALEXANDER, DL; JEFCOATE, CR				SAVAS, U; BHATTACHARYYA, KK; CHRISTOU, M; ALEXANDER, DL; JEFCOATE, CR			MOUSE CYTOCHROME P-450EF, REPRESENTATIVE OF A NEW 1B SUBFAMILY OF CYTOCHROME P-450S - CLONING, SEQUENCE DETERMINATION AND TISSUE EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; INDUCIBLE CYTOCHROME-P450; METABOLISM; P450; ENZYMES; CELLS; GENE; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; 7,12-DIMETHYLBENZ<A>ANTHRACENE; CARCINOGENESIS	A novel benz[a]anthracene and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-inducible cytochrome P-450 (P450EF), which is very active in polycyclic aromatic hydrocarbon metabolism, has been purified from C3H10T1/2 mouse embryo fibroblasts (Pottenger, L. H., Christou, M., and Jefcoate, C. R. (1991) Arch. Biochem. Biophys. 286, 488-497). P450EF was shown to be immunologically unrelated to the major known P-450 families. A 4.9-kilobase (kb) cDNA encoding P450EF has been isolated from a lambda ZAP cDNA expression library generated from mRNA of TCDD-induced C3H10T1/2 cells. This cDNA comprises 175-base pair (bp) 5'-noncoding, 1629-bp open reading, and about 3100-bp 3'-noncoding sequence. A SmaI fragment of the 4.9-kb cDNA hybridized to a 5.2-kb mRNA species equally induced by benz[a]anthracene (10 mu M) and TCDD (10 nM) in C3H10T1/2 cells, consistent with the involvement of the Ah receptor in this induction process. The deduced amino acid sequence (543 amino acids), the longest of any known cytochrome P-450, exhibits 41 and 38% identity to mouse CYP1A1 and CYP1A2, respectively, and less but substantial similarity (30-33% identity) to many members of the CYP2 family. There are five extended regions of greater than or equal to 50% identity to CYP1A1 as follows: (a) 51-118; (b) 199-222; (c) 326-343 (I-helix, O-2-binding threonine); (d) 357-430; and (e) 460-487 (heme-binding cysteine). These sequence relationships suggest that P450EF is a member of a new CYP1B subfamily (mouse CYP1B1). Hybridization of mRNA and immunoblot analyses of microsomes both demonstrated beta-naphthoflavone (beta-NF) inducibility of Cyp1b-1 expression in C3H mouse lung, liver, and uterus although at lower levels relative to Cyp1a-1. The mobility of the beta-NF-inducible immunoreactive liver protein was significantly higher than that of the CYP1B1 protein detected in mouse lung, uterus, and C3H10T1/2 cells, Compared with the beta-NF-induced uterus, polycyclic aromatic hydrocarbon-induced uterine fibroblasts exhibited 10-20-fold higher levels of CYP1B1, suggesting that stromal fibroblasts are a major source of the protein.	UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NCI NIH HHS [CA16265] Funding Source: Medline; NIEHS NIH HHS [T32 ES07015] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007015] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERNHARDT R, 1983, BIOCHIM BIOPHYS ACTA, V745, P140, DOI 10.1016/0167-4838(83)90042-0; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTOU M, 1990, CARCINOGENESIS, V11, P1691, DOI 10.1093/carcin/11.10.1691; CHRISTOU M, 1993, CANCER RES, V53, P968; CHRISTOU M, 1989, ARCH BIOCHEM BIOPHYS, V270, P162, DOI 10.1016/0003-9861(89)90018-0; CHRISTOU M, IN PRESS CARCINOGENE; CONNEY AH, 1982, CANCER RES, V42, P4875; EDWARDS RJ, 1989, BIOCHEMISTRY-US, V28, P3762, DOI 10.1021/bi00435a021; FEINBERG AP, 1983, ANAL BIOCHEM, V12, P6; GUENGERICH FP, 1992, FASEB J, V6, P745, DOI 10.1096/fasebj.6.2.1537465; HENIKOFF S, 1987, METHOD ENZYMOL, V28, P357; JAISWAL AK, 1985, SCIENCE, V228, P80, DOI 10.1126/science.3838385; JEFCOATE CR, 1992, FRONTIERS BIOTRANSFO, V6, P33; KOZAK M, 1983, MICROBIOL REV, V47, P1; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON DR, 1988, J BIOL CHEM, V263, P6038; OTTO S, 1992, ENDOCRINOLOGY, V131, P3067, DOI 10.1210/en.131.6.3067; OTTO S, 1991, ENDOCRINOLOGY, V129, P970, DOI 10.1210/endo-129-2-970; PELKONEN O, 1982, PHARMACOL REV, V34, P189; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POTTENGER LH, 1990, CARCINOGENESIS, V11, P321, DOI 10.1093/carcin/11.2.321; POTTENGER LH, 1991, ARCH BIOCHEM BIOPHYS, V286, P488, DOI 10.1016/0003-9861(91)90070-Y; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; POULOS TL, 1985, J BIOL CHEM, V260, P6122; PYERIN W, 1986, BIOCHEM BIOPH RES CO, V134, P461, DOI 10.1016/S0006-291X(86)80443-0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAS U, 1993, CARCINOGENESIS, V14, P2013, DOI 10.1093/carcin/14.10.2013; SHEN ZY, 1993, P NATL ACAD SCI USA, V90, P11483, DOI 10.1073/pnas.90.24.11483; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; WAXMAN DJ, 1988, BIOCHEM PHARMACOL, V37, P71, DOI 10.1016/0006-2952(88)90756-3; WHITLOCK JP, 1987, PHARMACOL REV, V39, P147; WILSON NM, 1984, CARCINOGENESIS, V5, P1475, DOI 10.1093/carcin/5.11.1475	40	208	216	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14905	14911						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195121				2022-12-27	WOS:A1994NP73800012
J	TIAN, WN; PIGNATARE, JN; STANTON, RC				TIAN, WN; PIGNATARE, JN; STANTON, RC			SIGNAL-TRANSDUCTION PROTEINS THAT ASSOCIATE WITH THE PLATELET-DERIVED GROWTH-FACTOR (PDGF) RECEPTOR MEDIATE THE (PDGF)-INDUCED RELEASE OF GLUCOSE-6-PHOSPHATE-DEHYDROGENASE FROM PERMEABILIZED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; RAT HEPATOCYTES; TYROSINE PHOSPHORYLATION; ENZYME; BINDING; INVIVO; ADULT; GAP	Permeabilized rat kidney cells rapidly released glucose 6-phosphate dehydrogenase (G6PD) following stimulation with peptide growth factors (Stanton, R. C., Seifter, J. L., Boxer, D. C., Zimmerman, E., and Cantley, L. C. (1991) J. Biol. Chem. 266, 12442-12448). To evaluate the signal transduction pathways mediating release of G6PD, two cell Lines transfected with wild type or mutant platelet-derived growth factor (PDGF) receptors (PDGFR) were studied using two permeabilization protocols. G6PD release was evaluated by enzyme activity and Western blot analysis. PDGF caused a significant increase in G6PD release in 1 min in cells transfected with wild type PDGFR. PDGF did not stimulate G6PD release in cells transfected with tyrosine kinase-deficient PDGFR. PDGF did not stimulate G6PD release in cells transfected with partially autophosphorylation-deficient PDGFR in which four known signaling proteins do not associate with the PDGFR The PDGF-stimulated release of G6PD was partially restored in PDGFR mutants in which either phosphatidylinositol-3-kinase or phospholipase C gamma 1 could associate with the PDGFR Lastly, there was no basal or PDGF-stimulated phosphorylation of G6PD. We conclude that release of G6PD: 1) requires intrinsic PDGFR tyrosine kinase activity; 2) requires PDGFR autophosphorylation; 3) is mediated by signaling proteins that associate with the PDGFR; 4) is not mediated by direct phosphorylation of G6PD.	NEW ENGLAND DEACONESS HOSP,JOSLIN DIABET CTR,DIV RENAL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School								ARORA KK, 1993, J BIOL CHEM, V268, P18259; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CONRICODE KM, 1990, J BIOL CHEM, V265, P20931; FARQUHAR JK, 1968, P SOC EXP BIOL MED, V129, P809; HARRISON ML, 1991, J BIOL CHEM, V266, P4106; HORECKER BL, 1965, J CHEM EDUC, V42, P244, DOI 10.1021/ed042p244; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LOW PS, 1987, J BIOL CHEM, V262, P4592; NAPIER MA, 1987, ARCH BIOCHEM BIOPHYS, V259, P296, DOI 10.1016/0003-9861(87)90496-6; REED BY, 1987, J BIOL CHEM, V262, P8712; SCHAFFER WT, 1985, AM J PHYSIOL, V248, pE719, DOI 10.1152/ajpendo.1985.248.6.E719; SOCHOR M, 1986, BIOCHEM J, V234, P573, DOI 10.1042/bj2340573; STANTON RC, 1988, AM J PHYSIOL, V254, pC267, DOI 10.1152/ajpcell.1988.254.2.C267; STANTON RC, 1991, J BIOL CHEM, V266, P12442; SWEZEY RR, 1986, J CELL BIOL, V103, P1509, DOI 10.1083/jcb.103.4.1509; SWEZEY RR, 1988, P NATL ACAD SCI USA, V85, P812, DOI 10.1073/pnas.85.3.812; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WEBER G, 1987, MOD LIVER CELL EXP, V43, P303; Wilson J E, 1980, Curr Top Cell Regul, V16, P1; WOOD T, 1985, PENTOSE PHOSPHATE PA, P1; YOSHIMOTO K, 1983, J BIOL CHEM, V258, P2355	25	77	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14798	14805						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182086				2022-12-27	WOS:A1994NM06500076
J	CHEN, XS; KURRE, U; JENKINS, NA; COPELAND, NG; FUNK, CD				CHEN, XS; KURRE, U; JENKINS, NA; COPELAND, NG; FUNK, CD			CDNA CLONING, EXPRESSION, MUTAGENESIS OF C-TERMINAL ISOLEUCINE, GENOMIC STRUCTURE, AND CHROMOSOMAL LOCALIZATIONS OF MURINE 12-LIPOXYGENASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC 15-LIPOXYGENASE; AMINO-ACID SEQUENCE; ARACHIDONATE 12-LIPOXYGENASE; MOLECULAR-CLONING; POLYMORPHONUCLEAR LEUKOCYTES; HUMAN 5-LIPOXYGENASE; PORCINE LEUKOCYTES; MESSENGER-RNA; LIPOXYGENASE; PLATELETS	Two types of 12-lipoxygenase that catalyze the transformation of arachidonic acid to 12(S)-hydroperoxyeicosatetraenoic acid (12-HPETE) have been previously classified into platelet-type and leukocyte-type categories. Here, we document, for the first time, a molecular characterization of both forms within the same species. The amino acid sequence of the murine platelet 12-lipoxygenase deduced from its cDNA is 58% identical to the murine spleen/leukocyte 12-lipoxygenase. Expression constructs carrying the cDNAs for the two 12-lipoxygenase forms were introduced into human embryonic kidney 293 cells. The platelet-type enzyme metabolized arachidonic acid exclusively to 12-HPETE, whereas the leukocyte-type enzyme formed both 12-HPETE and 15-hydro(pero)xyeicosatetraenoic acid in a ratio of approximate to 3:1. Linoleic acid was metabolized to a similar extent by the latter enzyme to 13-hydro(pero)xyoctadecadienoic acid but not by the platelet enzyme. Mutagenesis and deletion of the highly conserved lipoxygenase C-terminal isoleucine (Ile(663)), a residue believed to be involved in the non-heme iron atom coordination of all lipoxygenases, was performed. Deletion of Ile(663) and substitution with most amino acids abolished enzyme activity. Only a valine substitution retained significant activity. These findings would tend to indicate a stringent requirement for the proper spatial alignment and folding of the C-terminal chain back into the core of the enzyme to interact with the iron atom by analogy with the recently determined crystal structure of a soybean lipoxygenase (Boyington, J. C., Gaffney, B. J., and Amzel, L. M. (1993) Science 260, 1482-1486). The platelet-type and leukocyte-type 12-lipoxygenase genes were cloned from a murine 129 Sv genomic library. Both genes are divided into a similar 14-exon/13-intron format, with the platelet-type gene being approximately twice the size of the leukocyte-type gene (13 versus 7.5 kilobases). A segment of a third gene was also isolated and probably represents a pseudogene derivative of either of these 12-lipoxygenase genes. All three genes were mapped to the central region of mouse chromosome 11 in a region of homology with human chromosome 17. Antibodies prepared against the two forms of 12-lipoxygenase revealed the differential distribution of the two enzymes throughout the mouse.	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NCI NIH HHS [NCI N01-CO-74101] Funding Source: Medline; NHLBI NIH HHS [HL02710, HL46017] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046017] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARAKAWA T, 1992, J BIOL CHEM, V267, P12188; BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; BELLQUILLEY CP, 1993, J PHARMACOL EXP THER, V267, P676; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHBERG AM, 1989, GENETICS, V122, P153; CHANG WC, 1993, J BIOL CHEM, V268, P18734; CHEN XS, 1993, FASEB J, V7, P694, DOI 10.1096/fasebj.7.8.8500694; CHEN XS, 1993, EUR J BIOCHEM, V214, P845, DOI 10.1111/j.1432-1033.1993.tb17988.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOPRA H, 1991, INT J CANCER, V49, P774, DOI 10.1002/ijc.2910490524; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEMARZO N, 1992, AM J PHYSIOL, V262, pL198; FLEMING J, 1989, GENE, V79, P181, DOI 10.1016/0378-1119(89)90103-0; FUNK CD, 1992, P NATL ACAD SCI USA, V89, P3962, DOI 10.1073/pnas.89.9.3962; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; FUNK CD, 1991, J BIOL CHEM, V266, P12508; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; FUNK CD, 1991, PROSTAGLANDINS LEUKO, P97; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; Green EL, 1981, GENETICS PROBABILITY, P77; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HILL RJ, 1988, J LAB CLIN MED, V111, P73; HONN KV, 1989, FASEB J, V3, P2285, DOI 10.1096/fasebj.3.11.2673900; HUSSAIN H, 1994, AM J PHYSIOL, V266, pC243, DOI 10.1152/ajpcell.1994.266.1.C243; IZUMI T, 1991, EUR J BIOCHEM, V202, P1231, DOI 10.1111/j.1432-1033.1991.tb16495.x; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; MARGALIT A, 1993, P NATL ACAD SCI USA, V90, P2589, DOI 10.1073/pnas.90.7.2589; MATSUDA S, 1993, BIOCHIM BIOPHYS ACTA, V1180, P243, DOI 10.1016/0925-4439(93)90045-3; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; MINOR W, 1993, BIOCHEMISTRY-US, V32, P6320, DOI 10.1021/bi00076a003; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NADEL JA, 1991, J CLIN INVEST, V87, P1139, DOI 10.1172/JCI115110; NISHIYAMA M, 1993, J HISTOCHEM CYTOCHEM, V41, P111, DOI 10.1177/41.1.8417106; NISHIYAMA M, 1992, J NEUROCHEM, V58, P1395, DOI 10.1111/j.1471-4159.1992.tb11355.x; NUGTEREN DH, 1975, BIOCHIM BIOPHYS ACTA, V380, P299, DOI 10.1016/0005-2760(75)90016-8; OKUMA M, 1977, NEW ENGL J MED, V297, P1351; OPREY J, 1989, GENE, V84, P493, DOI 10.1016/0378-1119(89)90526-X; PEMBER SO, 1983, BLOOD, V61, P1105; Sambrook J, 1989, MOL CLONING LABORATO; SHANNON VR, 1993, AM J PHYSIOL, V264, pG104, DOI 10.1152/ajpgi.1993.264.1.G104; SHEPPARD KA, 1992, BIOCHIM BIOPHYS ACTA, V1133, P223, DOI 10.1016/0167-4889(92)90073-K; SHIBATA D, 1987, J BIOL CHEM, V262, P10080; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SINZINGER H, 1991, AM J HEMATOL, V36, P202, DOI 10.1002/ajh.2830360308; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKAHASHI Y, 1993, J BIOL CHEM, V268, P16443; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; UEDA N, 1990, J BIOL CHEM, V265, P2311; WALL NA, 1992, MECH DEVELOP, V37, P111, DOI 10.1016/0925-4773(92)90073-S; WALSTRA P, 1987, BIOCHIM BIOPHYS ACTA, V921, P312, DOI 10.1016/0005-2760(87)90032-4; WATANABE T, 1993, EUR J BIOCHEM, V212, P605, DOI 10.1111/j.1432-1033.1993.tb17699.x; WATANABE T, 1993, BIOCHEM BIOPH RES CO, V192, P1023, DOI 10.1006/bbrc.1993.1519; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; YOKOYAMA C, 1986, J BIOL CHEM, V261, P6714; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142; YOSHIMOTO T, 1992, J BIOL CHEM, V267, P24805	60	188	192	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13979	13987						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188678				2022-12-27	WOS:A1994NL60600041
J	KASLIN, E; HEYER, WD				KASLIN, E; HEYER, WD			SCHIZOSACCHAROMYCES-POMBE FATTY-ACID SYNTHASE MEDIATES DNA STRAND EXCHANGE IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RECA PROTEIN; HOMOLOGOUS RECOMBINATION; STIMULATORY FACTOR; SEQUENCE-ANALYSIS; RENATURATION; GENE; PURIFICATION; MECHANISM; BINDING	During purification of a strand exchange activity from Schizosaccharomyces pombe using the three-strand reaction of double-stranded linear and circular single-stranded DNA, we identified p190/210 as an activity that stimulated the strand exchange activity of p140(exo2) by about 10-fold. The accompanying report (Kaslin, E., and Heyer, W.-D. (1994) J. Biol. Chem. 269, 0000-0000) described the purification and characterization of p140(exo2), likely to be the S. pombe homolog of the Saccharomyces cerevisiae strand exchange protein p175(SEP1). Here, we report the purification of p190/210 from S. pombe cells and its identification as fatty acid synthase (FAS). S. pombe FAS (p190/210) binds to single-stranded and double-stranded DNA, leading to condensation of DNA into large aggregates. In addition, it is capable of renaturing complementary single-stranded DNA. Besides stimulating the strand exchange activity of p140(exo2), FAS (p190/210) itself exhibits strand exchange activity provided the double-stranded substrate has single-stranded tails. We propose a probable mechanism for the action of FAS (p190/210) during DNA strand exchange in vitro. Since FAS (p190/210) is highly unlikely to have a role in homologous recombination in vivo, we discuss the implications of our data on the interpretation of other homologous pairing and strand exchange proteins purified from eukaryotes using this or similar assays.	UNIV BERN, INST GEN MICROBIOL, CH-3012 BERN, SWITZERLAND	University of Bern								ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; BAHLER J, 1993, IN PRESS CHROMOSOMA; BEDALE WA, 1993, J BIOL CHEM, V268, P15004; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK AB, 1991, MOL CELL BIOL, V11, P2576, DOI 10.1128/MCB.11.5.2576; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYKSTRA CC, 1991, MOL CELL BIOL, V11, P2583, DOI 10.1128/MCB.11.5.2583; EGGLESTON AK, 1991, BIOCHIMIE, V73, P163, DOI 10.1016/0300-9084(91)90199-B; GRIFFITH JD, 1988, CRC CR REV BIOCH MOL, V23, pS43, DOI 10.3109/10409238809083375; HALBROOK J, 1989, J BIOL CHEM, V264, P21403; HAMATAKE RK, 1989, J BIOL CHEM, V264, P13336; HEYER WD, 1988, J BIOL CHEM, V263, P15189; HEYER WD, 1989, BIOCHEMISTRY-US, V28, P2856, DOI 10.1021/bi00433a017; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; KASLIN E, 1994, J BIOL CHEM, V269, P14094; KAWASAKI I, 1990, P NATL ACAD SCI USA, V87, P1628, DOI 10.1073/pnas.87.4.1628; KAWASAKI I, 1989, P NATL ACAD SCI USA, V86, P5281, DOI 10.1073/pnas.86.14.5281; KIM JM, 1990, GENETICS, V126, P799; KOHNE DE, 1977, BIOCHEMISTRY-US, V16, P5329, DOI 10.1021/bi00643a026; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KONFORTI BB, 1992, J MOL BIOL, V227, P38, DOI 10.1016/0022-2836(92)90680-I; KOTTIG H, 1991, MOL GEN GENET, V226, P310, DOI 10.1007/BF00273618; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; KUHN L, 1972, EUR J BIOCHEM, V24, P492, DOI 10.1111/j.1432-1033.1972.tb19711.x; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P10717, DOI 10.1021/bi00500a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LYNEN F, 1969, METHOD ENZYMOL, V14, P17; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MOORE SP, 1990, J BIOL CHEM, V265, P11108; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; NORRIS D, 1990, BIOCHEMISTRY-US, V29, P7911, DOI 10.1021/bi00486a019; NORRIS D, 1990, BIOCHEMISTRY-US, V29, P7903, DOI 10.1021/bi00486a018; PANYUTIN IG, 1993, J MOL BIOL, V230, P413, DOI 10.1006/jmbi.1993.1159; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; PONTIUS BW, 1992, J BIOL CHEM, V267, P13815; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PONTIUS BW, 1991, P NATL ACAD SCI USA, V88, P8237, DOI 10.1073/pnas.88.18.8237; SANDER M, 1991, P NATL ACAD SCI USA, V88, P6780, DOI 10.1073/pnas.88.15.6780; SCHIEDNER G, 1990, EMBO J, V9, P2937, DOI 10.1002/j.1460-2075.1990.tb07485.x; SCHWEIZER E, 1978, MOL CELL BIOCHEM, V21, P95; SCHWEIZER M, 1986, MOL GEN GENET, V203, P479, DOI 10.1007/BF00422073; SIKORAV JL, 1991, J MOL BIOL, V222, P1085, DOI 10.1016/0022-2836(91)90595-W; SMITH GR, 1988, MICROBIOL REV, V52, P1; STOOPS JK, 1978, J BIOL CHEM, V253, P4464; SZANKASI P, 1992, BIOCHEMISTRY-US, V31, P6769, DOI 10.1021/bi00144a017; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WIEDER R, 1981, BIOPOLYMERS, V20, P1537, DOI 10.1002/bip.1981.360200711; WIESNER P, 1988, EUR J BIOCHEM, V177, P69, DOI 10.1111/j.1432-1033.1988.tb14346.x	53	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14103	14110						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188691				2022-12-27	WOS:A1994NL60600058
J	SHEN, GZ; VERMAAS, WFJ				SHEN, GZ; VERMAAS, WFJ			CHLOROPHYLL IN A SYNECHOCYSTIS SP PCC-6803 MUTANT WITHOUT PHOTOSYSTEM-I AND PHOTOSYSTEM-II CORE COMPLEXES - EVIDENCE FOR PERIPHERAL ANTENNA CHLOROPHYLLS IN CYANOBACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; ANACYSTIS-NIDULANS R2; A/B PROTEIN COMPLEX; SPECTROSCOPIC PROPERTIES; SP PCC-6803; POLYPEPTIDE; ORGANIZATION; PURIFICATION; MEMBRANES; SUBUNIT	The chlorophyll protein organization has been investigated in thylakoid membranes from mutants of the cyanobacterium Synechocystis sp. PCC 6803, in which the photosystem II (PS II) genes psbB and/or psbC (coding for CP47 and CP43, respectively) were inactivated together with the psaAB operon (coding for the photosystem I (PS I) core complex) and the apcE gene (coding for the phycobilisome anchor protein). Lack of the CP43 protein led to a significant decrease of the D1, D2, and CP47 proteins and a decrease in the 77 K fluorescence emission peak at 685 nm. In the absence of the CP47 protein, no PS II reaction center assembly was detected and the 77 K fluorescence emission peak at 695 nm was lost. The psbB(-)/psbC(-)/PS I-less/apcE(-) mutant had no assembly of the D1, D2, CP47, and CP43 proteins, had lost the 77 K fluorescence emission peaks at 685 and 695 nm, but retained about 15% of the chlorophyll present in the PS I-less/apcE(-) background strain. A broad 77 K fluorescence emission band with a maximum at 678 nm was displayed in the PS II-less, PS I-less mutant upon excitation of the remaining chlorophyll. A 678 nm shoulder was observed in the 77 K fluorescence emission spectrum of thylakoids from the psbB(-)/PS I-less/apcE(-) mutant, which still contains CP43 but no PS LI reaction center. This shoulder was absent in thylakoids from the psbC(-)/PS I-less/apcE(-) mutant, which contain some PS II reaction center complexes. These results are consistent with the chlorophyll associated with the 678 nm emission to serve as peripheral antenna to PS II. The fluorescence emission characteristics of this chlorophyll are different from those of an accessory chlorophyll-binding protein expressed under iron-stress conditions in cyanobacteria. The chlorophyll remaining in the absence of PS II and PS I is indicative of a new chlorophyll binding protein in cyanobacterial thylakoids.	ARIZONA STATE UNIV,DEPT BOT,TEMPE,AZ 85287; ARIZONA STATE UNIV,CTR STUDY EARLY EVENTS PHOTOSYNTHESIS,TEMPE,AZ 85287	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe								AKABORI K, 1988, BIOCHIM BIOPHYS ACTA, V932, P345, DOI 10.1016/0005-2728(88)90170-3; ANDERSON JM, 1986, ENCY PLANT PHYSL, V19, P269; BARBATO R, 1991, FEBS LETT, V286, P86, DOI 10.1016/0014-5793(91)80947-2; BASSI R, 1987, J BIOL CHEM, V262, P13333; BASSI R, 1987, EUR J BIOCHEM, V163, P221, DOI 10.1111/j.1432-1033.1987.tb10791.x; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BOERNER RJ, 1993, J BIOL CHEM, V268, P1817; BRYANT DA, 1992, PHOTOSYSTEMS STRUCTU, P501; Bryant DA, 1991, PHOTOSYNTHETIC APP B, V7, P257; BULLERJAHN GS, 1985, BIOCHIM BIOPHYS ACTA, V810, P148, DOI 10.1016/0005-2728(85)90130-6; BURNAP RL, 1993, PLANT PHYSIOL, V103, P893, DOI 10.1104/pp.103.3.893; DEVITRY C, 1984, BIOCHIM BIOPHYS ACTA, V767, P415, DOI 10.1016/0005-2728(84)90039-2; EATONRYE JJ, 1991, PLANT MOL BIOL, V17, P1165, DOI 10.1007/BF00028733; FUJITA Y, 1988, PLANT CELL PHYSL, V29, P305; GOLBECK JH, 1988, FEBS LETT, V228, P268, DOI 10.1016/0014-5793(88)80013-9; HAWORTH P, 1983, BIOCHIM BIOPHYS ACTA, V724, P151, DOI 10.1016/0005-2728(83)90036-1; HEMELRIJK PW, 1992, BIOCHIM BIOPHYS ACTA, V1098, P159, DOI 10.1016/S0005-2728(05)80331-7; HERRIN DL, 1987, ARCH BIOCHEM BIOPHYS, V254, P397, DOI 10.1016/0003-9861(87)90117-2; HUNDAL T, 1990, BIOCHIM BIOPHYS ACTA, V1017, P235, DOI 10.1016/0005-2728(90)90190-F; IKEUCHI M, 1992, BOT MAG TOKYO, V105, P327, DOI 10.1007/BF02489425; IKEUCHI M, 1992, RES PHOTOSYNTHESIS, V2, P175; KIM S, 1992, FEBS LETT, V314, P67, DOI 10.1016/0014-5793(92)81463-V; KUANG TY, 1984, ARCH BIOCHEM BIOPHYS, V235, P618, DOI 10.1016/0003-9861(84)90236-4; KWA SLS, 1992, BIOCHIM BIOPHYS ACTA, V1101, P143, DOI 10.1016/0005-2728(92)90198-B; LAM E, 1984, PLANT PHYSIOL, V74, P650, DOI 10.1104/pp.74.3.650; LAUDENBACH DE, 1988, J BACTERIOL, V170, P5018, DOI 10.1128/jb.170.11.5018-5026.1988; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; LJUNGBERG U, 1986, EUR J BIOCHEM, V158, P477, DOI 10.1111/j.1432-1033.1986.tb09779.x; LUNDELL DJ, 1985, J BIOL CHEM, V260, P646; MacKinney G, 1941, J BIOL CHEM, V140, P315; MONTOYA G, 1991, FEBS LETT, V283, P255, DOI 10.1016/0014-5793(91)80601-X; NAKATANI HY, 1984, BIOCHIM BIOPHYS ACTA, V765, P347, DOI 10.1016/0005-2728(84)90175-0; NAKAYAMA K, 1990, PLANT CELL PHYSIOL, V31, P253; NILSSON F, 1990, PLANT MOL BIOL, V14, P1051, DOI 10.1007/BF00019402; PAKRASI HB, 1985, P NATL ACAD SCI USA, V82, P6903, DOI 10.1073/pnas.82.20.6903; PAKRASI HB, 1992, PHOTOSYSTEMS STRUCTU, P231; RIETHMAN HC, 1988, BIOCHIM BIOPHYS ACTA, V935, P141, DOI 10.1016/0005-2728(88)90211-3; RIETHMAN HC, 1988, PLANT PHYSIOL, V88, P497, DOI 10.1104/pp.88.2.497; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; ROGNER M, 1990, J BIOL CHEM, V265, P6189; SATOH K, 1979, PLANT CELL PHYSIOL, V20, P499; SATOH K, 1983, OXYGEN EVOLVING SYST, P27; SHEN GZ, 1993, PLANT CELL, V5, P1853, DOI 10.1105/tpc.5.12.1853; SHEN GZ, 1993, BIOCHEMISTRY-US, V32, P5109, DOI 10.1021/bi00070a019; TANG XS, 1984, PLANT CELL PHYSIOL, V25, P935; THORNBER JP, 1986, ENCY PLANT PHYSL, V19, P98; VANDORSSEN RJ, 1987, BIOCHIM BIOPHYS ACTA, V890, P134, DOI 10.1016/0005-2728(87)90014-4; VERMAAS W, 1990, BIOCHEMISTRY-US, V29, P5325, DOI 10.1021/bi00474a017; VERMAAS WFJ, 1988, PHOTOSYNTH RES, V17, P97, DOI 10.1007/BF00047683; VERMAAS WFJ, 1986, P NATL ACAD SCI USA, V83, P9474, DOI 10.1073/pnas.83.24.9474; VERMAAS WFJ, 1991, PHOTOSYNTHETIC APP B, V7, P25; WEDEL N, 1992, FEBS LETT, V314, P61, DOI 10.1016/0014-5793(92)81462-U; WITT HT, 1990, CURRENT RES PHOTOSYN, V2, P547; WOLLMAN FA, 1982, BIOCHIM BIOPHYS ACTA, V680, P352, DOI 10.1016/0005-2728(82)90149-9; YAMAGUCHI N, 1988, PLANT CELL PHYSIOL, V29, P123; YU JJ, 1990, PLANT CELL, V2, P315	56	53	59	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13904	13910						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188669				2022-12-27	WOS:A1994NL60600031
J	LI, SC; DEBER, CM				LI, SC; DEBER, CM			PEPTIDE ENVIRONMENT SPECIFIES CONFORMATION - HELICITY OF HYDROPHOBIC SEGMENTS COMPARED IN AQUEOUS, ORGANIC, AND MEMBRANE ENVIRONMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SECONDARY STRUCTURE; PROTEIN; GLYCINE; TRIFLUOROETHANOL; RESIDUES; CHAINS; SIGNAL	Transmembrane segments in integral membrane proteins exist characteristically as helices in lipid bilayers, yet are often rich in residues considered helix-destabilizing (Val, Ile, Gly) in soluble proteins. We propose that helicity of a transmembrane segment is likely to be affected by factors other than the ''intrinsic'' helical propensities of its component amino acids. This hypothesis is tested by comparing the conformation(s) in aqueous, organic, membrane-mimetic (micellar), and membrane (bilayer) environments of designed model peptides with systematically altered helical propensity and/or segmental hydrophobicity. Peptides of prototypic sequence NH2-(Ser-Lys)2-Ala5-Leu6-Ala7-Ala8-Leu9-Ala10-Trp11-Ala12-Leu13-Ala14-(Lys-Ser)3-OH were synthesized, which incorporate a hydrophobic core ''guest'' segment (residues 5-14) into a water-soluble hydrophilic host matrix. Related peptides featured substitution of Leu6,9,13 --> Gly, Leu6,9,13 --> Ala, and Ala7,10,14 --> Gly. Circular dichroism spectra revealed that algorithms for soluble proteins correctly predicted peptide helical proclivities in aqueous solutions, but peptide helicity in organic (trifluoroethanol) solvents, membrane-mimetic SDS micelles, and negatively charged lipid bilayer vesicles, was found to be governed almost exclusively by the segmental hydrophobicity of the peptide mid-hydrophobic core segment. In related Trp fluorescence studies, peptide-membrane association was similarly correlated with extent of hydrophobic interaction.	HOSP SICK CHILDREN, RES INST, DIV BIOCHEM RES, TORONTO M5G 1X8, ONTARIO, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A8, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BRUCH MD, 1990, J BIOL CHEM, V265, P3851; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DEBER CM, 1986, ARCH BIOCHEM BIOPHYS, V251, P68, DOI 10.1016/0003-9861(86)90052-4; EFTINK MR, 1991, METHOD BIOCHEM ANAL, V35, P127; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; ENGEL M, 1991, BIOCHEMISTRY-US, V30, P3161, DOI 10.1021/bi00227a002; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI SC, 1992, INT J PEPT PROT RES, V40, P243; LI SC, 1992, FEBS LETT, V311, P217, DOI 10.1016/0014-5793(92)81106-V; LYU PC, 1991, P NATL ACAD SCI USA, V88, P5317, DOI 10.1073/pnas.88.12.5317; MCLEAN LR, 1990, BIOCHIM BIOPHYS ACTA, V1024, P1, DOI 10.1016/0005-2736(90)90201-X; MILIK M, 1992, P NATL ACAD SCI USA, V89, P9391, DOI 10.1073/pnas.89.20.9391; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; WALLACE BA, 1986, P NATL ACAD SCI USA, V83, P9423, DOI 10.1073/pnas.83.24.9423; ZHONG LX, 1992, P NATL ACAD SCI USA, V89, P4462, DOI 10.1073/pnas.89.10.4462	20	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					22975	22978						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226811				2022-12-27	WOS:A1993MF51500006
J	MAEKAWA, M; NAKAMURA, S; HATTORI, S				MAEKAWA, M; NAKAMURA, S; HATTORI, S			PURIFICATION OF A NOVEL RAS GTPASE-ACTIVATING PROTEIN FROM RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 GENE-PRODUCT; MOLECULAR-CLONING; GROWTH-FACTOR; PC12 CELLS; BOVINE BRAIN; GAP; P21; IDENTIFICATION; BINDING; STIMULATION	GTPase-activating protein (GAP) and neurofibromin, a gene product of neurofibromatosis type I gene, have been identified as factors that stimulate GTPase activity of ras p21. We have previously suggested the presence of novel GAP activity that is immunologically distinguishable from GAP or neurofibromin in both the cytosolic and the particulate fractions of rat brain (Hattori, S., Maekawa, M., and Nakamura, S. (1992) Oncogene 7, 481-485). We have purified this novel GAP molecule from the cytosolic fraction of rat brain by more than 200,000-fold by five successive column chromatographies with a recovery of 6%. Apparent molecular mass of this molecule was estimated to be 100 kDa (p100GAP(ras)). The same p100GAP(ras) was purified from the particulate fraction after extraction with high salt. The activation of GTPase was observed with normal ras p21 but not with oncogenic ras p21, Rap1B/smg21B, or Ram25K. The dissociation constant of p100GAP(ras) toward ras p21 estimated by competitive inhibition using ras p21 in complex with nonhydrolyzable analog of GTP was two times higher than that of neurofibromin and was lower than that of GAP by 2 orders of magnitude. These results clearly indicate that p100GAP(ras) is a novel ras GAP molecule.	NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,4-1-1 OGAWAHIGASHI,KODAIRA,TOKYO 187,JAPAN	National Center for Neurology & Psychiatry - Japan								BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HATTORI S, 1992, ONCOGENE, V7, P481; HATTORI S, 1991, BIOCHEM BIOPH RES CO, V177, P83, DOI 10.1016/0006-291X(91)91951-8; HOSHINO M, 1988, MOL CELL BIOL, V8, P4169, DOI 10.1128/MCB.8.10.4169; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORII N, 1991, J BIOL CHEM, V266, P7646; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUROYA K, 1992, ONCOGENE, V7, P277; NAGATA K, 1989, J BIOL CHEM, V264, P17000; NICE EC, 1992, J BIOL CHEM, V267, P1546; NISHIO K, 1982, ANAL BIOCHEM, V126, P239, DOI 10.1016/0003-2697(82)90509-7; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	49	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22948	22952						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226805				2022-12-27	WOS:A1993MD34800110
J	MIYASAKA, H; OKABE, S; ISHIGURO, K; UCHIDA, T; HIROKAWA, N				MIYASAKA, H; OKABE, S; ISHIGURO, K; UCHIDA, T; HIROKAWA, N			INTERACTION OF THE TAIL DOMAIN OF HIGH-MOLECULAR-WEIGHT SUBUNITS OF NEUROFILAMENTS WITH THE COOH-TERMINAL REGION OF TUBULIN AND ITS REGULATION BY TAU-PROTEIN KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; HELICAL FILAMENT EPITOPE; MAMMALIAN NEUROFILAMENTS; INTERMEDIATE FILAMENTS; NEURONAL CYTOSKELETON; TRIPLET PROTEINS; AXONAL-TRANSPORT; QUICK-FREEZE; PHOSPHORYLATION; INVITRO	We previously showed that neurofilaments interact with microtubules (MTs) via their high molecular weight subunits (NF-H) after alkaline phosphatase treatment. Here we studied the effects of phosphorylation of NF-H on this interaction. Tau protein kinase II, Ser/Thr protein kinase, phosphorylated NF-H in the tail domain, decreased its electrophoretic mobility to a native level, and also restored its property to be less interactive with MTs. Phosphorylation by cAMP-dependent protein kinase caused no shift of electrophoretic mobility or dissociation from MTs. We conclude that the tail domain of NF-H directly interacts with the MT surface, and the interaction is regulated via phosphorylation of the tail domain of NF-H by Ser/Thr protein kinase like tau protein kinase II. To characterize the binding domain of NF-H on MTs, subtilisin digestion of MTs and competition analysis with the MT binding fragment of tau protein were performed. The dissociation constant of NF-H to subtilisin MTs was higher than that to intact MTs. The maximum binding of NF-H was reduced when tau fragments existed. These results revealed that the COOH-terminal region of tubulin is involved in the binding to NF-H, and the NF-H and microtubule-associated protein binding domains are closely apposed on the surface of MTs.	UNIV TOKYO,FAC MED,DEPT ANAT & CELL BIOL,BUNKYO KU,TOKYO 113,JAPAN; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN	University of Tokyo				Okabe, Shigeo/0000-0003-1216-8890				AAMODT EJ, 1984, BIOCHEMISTRY-US, V23, P6023, DOI 10.1021/bi00320a019; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; FLYNN G, 1987, J BIOL CHEM, V262, P15443; FREMISCO JR, 1980, J BIOL CHEM, V255, P4240; GARDNER EE, 1984, J NEUROSCI RES, V11, P145, DOI 10.1002/jnr.490110204; GEISLER N, 1983, EMBO J, V2, P1295, DOI 10.1002/j.1460-2075.1983.tb01584.x; GEISLER N, 1981, J MOL BIOL, V151, P565, DOI 10.1016/0022-2836(81)90011-5; GLASS DB, 1986, J BIOL CHEM, V261, P2987; GUAN RJ, 1992, J NEUROCHEM, V58, P1365, DOI 10.1111/j.1471-4159.1992.tb11351.x; HEIMANN R, 1985, J BIOL CHEM, V260, P2160; HIROKAWA N, 1988, J NEUROSCI, V8, P2769; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HIROKAWA N, 1985, J CELL BIOL, V101, P227, DOI 10.1083/jcb.101.1.227; HISANAGA S, 1989, J NEUROSCI, V9, P959; HISANAGA S, 1990, J BIOL CHEM, V265, P21852; HISANAGA S, 1991, J BIOL CHEM, V266, P21798; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; INAGAKI M, 1988, J BIOL CHEM, V263, P5970; ISHIGURO K, 1991, NEUROSCI LETT, V128, P195, DOI 10.1016/0304-3940(91)90259-V; ISHIGURO K, 1988, J BIOCHEM-TOKYO, V104, P319, DOI 10.1093/oxfordjournals.jbchem.a122465; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; JONES SM, 1982, J BIOL CHEM, V257, P9902; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; KANAI Y, 1992, EMBO J, V11, P3953, DOI 10.1002/j.1460-2075.1992.tb05489.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LETTERRIER JF, 1984, J NEUROCHEM, V43, P1385; LIEM RKH, 1978, J CELL BIOL, V79, P637, DOI 10.1083/jcb.79.3.637; MELKI R, 1991, BIOCHEMISTRY-US, V30, P11536, DOI 10.1021/bi00113a008; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MINAMI Y, 1983, J BIOCHEM-TOKYO, V94, P2023, DOI 10.1093/oxfordjournals.jbchem.a134557; MINAMI Y, 1984, J BIOCHEM-TOKYO, V96, P1481, DOI 10.1093/oxfordjournals.jbchem.a134977; NIXON R A, 1992, Current Opinion in Cell Biology, V4, P8, DOI 10.1016/0955-0674(92)90052-E; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; RODIONOV VI, 1990, J BIOL CHEM, V265, P5702; RUNGE MS, 1981, P NATL ACAD SCI USA, V78, P1385; Sambrook J, 1989, MOL CLONING LABORATO; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SIHAG RK, 1990, J BIOL CHEM, V265, P4166; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858	43	111	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22695	22702						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226779				2022-12-27	WOS:A1993MD34800075
J	SAHR, KE; COETZER, TL; MOY, LS; DERICK, LH; CHISTI, AH; JAROLIM, P; LORENZO, F; DELGIUDICE, EM; IOLASCON, A; GALLANELLO, R; CAO, A; DELAUNAY, J; LIU, SC; PALEK, J				SAHR, KE; COETZER, TL; MOY, LS; DERICK, LH; CHISTI, AH; JAROLIM, P; LORENZO, F; DELGIUDICE, EM; IOLASCON, A; GALLANELLO, R; CAO, A; DELAUNAY, J; LIU, SC; PALEK, J			SPECTRIN CAGLIARI - AN ALA -] GLY SUBSTITUTION IN HELIX-1 OF BETA-SPECTRIN REPEAT-17 THAT SEVERELY DISRUPTS THE STRUCTURE AND SELF-ASSOCIATION OF THE ERYTHROCYTE SPECTRIN HETERODIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICE SITE MUTATION; ALPHA-I DOMAIN; HEREDITARY ELLIPTOCYTOSIS; MOLECULAR DEFECT; FRAMESHIFT MUTATION; MEMBRANE SKELETONS; CHAIN VARIANT; PYROPOIKILOCYTOSIS; CDNA; GENE	The spectrin tetramer, the principal structural element of the red cell membrane skeleton, is formed by stable head-to-head self-association of two spectrin heterodimers. The self-association site appears to be formed by interactions between helices 1 and 2 of beta spectrin repeat 17 of one dimer with helix 3 of alpha spectrin repeat 1 of the other dimer to form two combined alpha-beta triple-helical segments. The head of the heterodimer appears to involve similar intradimer interactions. We describe the first example of an amino acid substitution in helix 1 of this combined alpha-beta triple-helical segment, which, although relatively minor, profoundly impairs tetramer formation. Strikingly, low angle rotary shadowing electron microscopy of isolated spectrin dimers reveals that this mutation also severely disrupts the head of the heterodimer causing it to be open. Following linkage studies which were most consistent with a beta spectrin gene mutation, a nucleotide change was identified in codon 2018, resulting in an Ala --> Gly substitution in the first helical domain of beta spectrin repeat 17. Because glycine is a strong helix breaker, this change is predicted to disrupt the conformation of this helical domain. Our results indicate that this helical domain must play direct roles in the alpha-beta interdimer interactions that form the self-association site of the tetramer and in the alpha-beta intradimer interactions at the head of the heterodimer.	UNIV WITWATERSRAND, S AFRICAN INST MED RES, JOHANNESBURG 2001, SOUTH AFRICA; FAC MED GRANGE BLANCHE, CNRS, URA 1171, F-69373 LYON 08, FRANCE; INST PASTEUR LYON, F-69365 LYON 07, FRANCE; FIRST PEDIAT CLIN, DEPT PEDIAT, I-80138 NAPLES, ITALY; UNIV CAGLIARI, INST CLIN & BIOL EVOLUT, I-09100 CAGLIARI, ITALY	University of Witwatersrand; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Cagliari	SAHR, KE (corresponding author), TUFTS UNIV, ST ELIZABETHS HOSP, SCH MED, DEPT BIOMED RES, DIV HEMATOL ONCOL, BOSTON, MA 02135 USA.		del Giudice, Emanuele Muraglia/AAC-2824-2019; Coetzer, Theresa/C-1920-2009; Iolascon, Achille/A-4461-2014		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037462, R37HL027215, R01HL027215] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-27215, HL-37462] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKLOUTI F, 1991, BRIT J HAEMATOL, V78, P108, DOI 10.1111/j.1365-2141.1991.tb04391.x; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; BENNETT V, 1977, J BIOL CHEM, V252, P2753; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; BYERS TJ, 1992, P NATL ACAD SCI USA, V89, P6187, DOI 10.1073/pnas.89.13.6187; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; COETZER T, 1990, BLOOD, V75, P2235; COETZER TL, 1986, BLOOD, V67, P919; COETZER TL, 1991, J CLIN INVEST, V88, P743, DOI 10.1172/JCI115371; DELGIUDICE EM, 1992, BLOOD S, V80, pA277; DESILVA TM, 1992, BIOCHEMISTRY-US, V31, P10872, DOI 10.1021/bi00159a030; FASMAN GD, 1976, BIOPHYS J, V16, P1201, DOI 10.1016/S0006-3495(76)85768-2; FLOYD PB, 1991, BLOOD, V78, P1364; GALLAGHER PG, 1991, J BIOL CHEM, V266, P15154; GALLAGHER PG, 1992, BLOOD S, V80, pA145; GARBARZ M, 1992, BLOOD, V80, P1066; GARBARZ M, 1991, J CLIN INVEST, V88, P76, DOI 10.1172/JCI115307; GARBARZ M, 1990, BLOOD, V75, P1691; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Goossens M, 1981, Methods Enzymol, V76, P805; HOFFMAN N, 1987, NUCLEIC ACIDS RES, V15, P4696, DOI 10.1093/nar/15.11.4696; HU RJ, 1992, J BIOL CHEM, V267, P18715; KNOWLES WJ, 1983, J CLIN INVEST, V71, P1867, DOI 10.1172/JCI110942; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOTULA L, 1993, J BIOL CHEM, V268, P14788; LAWLER J, 1984, J CLIN INVEST, V73, P1688, DOI 10.1172/JCI111376; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; LIU SC, 1990, BLOOD, V76, P198; LIU SC, 1981, J CLIN INVEST, V68, P597, DOI 10.1172/JCI110293; MORLE L, 1990, J CLIN INVEST, V86, P548, DOI 10.1172/JCI114743; MORROW JS, 1981, J CELL BIOL, V88, P463, DOI 10.1083/jcb.88.2.463; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PALEK J, 1992, BLOOD, V80, P308; PRCHAL JT, 1987, P NATL ACAD SCI USA, V84, P7468, DOI 10.1073/pnas.84.21.7468; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SERRANO L, 1992, NATURE, V356, P453, DOI 10.1038/356453a0; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1993, J BIOL CHEM, V268, P4227; SPEICHER DW, 1982, J BIOL CHEM, V257, P9093; SYKES BC, 1983, LANCET, V2, P787; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; TSE WT, 1991, BLOOD, V78, P517; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; UNGEWICKELL E, 1978, EUR J BIOCHEM, V88, P379, DOI 10.1111/j.1432-1033.1978.tb12459.x; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YOON SH, 1991, J BIOL CHEM, V266, P8490	54	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22656	22662						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226774				2022-12-27	WOS:A1993MD34800070
J	SCHULTHEIS, PJ; WALLICK, ET; LINGREL, JB				SCHULTHEIS, PJ; WALLICK, ET; LINGREL, JB			KINETIC-ANALYSIS OF OUABAIN BINDING TO NATIVE AND MUTATED FORMS OF NA,K-ATPASE AND IDENTIFICATION OF A NEW REGION INVOLVED IN CARDIAC GLYCOSIDE INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED ADENOSINE-TRIPHOSPHATASE; SITE-DIRECTED MUTAGENESIS; ALPHA-SUBUNIT; SARCOPLASMIC-RETICULUM; COMPETITION KINETICS; SODIUM; DIGITALIS; NA+,K+-ATPASE; RESIDUES; SURFACE	Cardiac glycosides inhibit the Na,K-ATPase by binding to the catalytic alpha subunit of the enzyme. Site-directed mutagenesis of the H1-H2 domain has demonstrated the importance of this region in determining cardiac glycoside affinity. In this study, random mutagenesis was used to identify an amino acid, arginine 880, in the COOH-terminal portion of the alpha subunit which influences the sensitivity of the enzyme to ouabain. This residue is predicted to reside in the H7-H8 extracellular loop. Conversion of arginine 880 to a proline causes a 10-fold increase in the dissociation rate constant and a 2-fold increase in the association rate constant for [H-3]ouabain binding. This results in an enzyme with a K(D) for ouabain 5-fold higher than the wild-type sheep alpha1 isoform. These data are compatible with arginine 880 comprising a portion of the ouabain binding site. Furthermore, if arginine 880 is at the physical binding site, then this finding lends support to models that place this amino acid extracellularly since cardiac glycosides interact with the extracellular surface of the Na,K-ATPase. The ouabain binding characteristics of substitution R880P were compared with those of several different Na,K-ATPases, each of which contains a single amino acid substitution in the H1-H2 region of the alpha subunit. The substituted enzymes, C104A, Y108A, E116Q, P118K, and Y124F, vary considerably in their rates of dissociation (1-4-fold increase in the dissociation rate constant). In addition, the rate of association of [H-3]ouabain binding to substitution P118K is 2-fold slower than that of the wild-type enzyme. These results suggest that the H1-H2 domain may participate directly in ouabain binding as well as be involved in conformational changes, both of which could affect the sensitivity of the enzyme to ouabain.	UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, 231 BETHESDA AVE, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT PHARMACOL, CINCINNATI, OH 45267 USA	University of Cincinnati; University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028573] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 28573] Funding Source: Medline; PHS HHS [HW50613] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS RJ, 1983, J CARDIOVASC PHARM, V5, P468, DOI 10.1097/00005344-198305000-00020; AKERA T, 1977, PHARMACOL REV, V29, P187; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BALL WJ, 1982, BIOCHIM BIOPHYS ACTA, V719, P413, DOI 10.1016/0304-4165(82)90228-8; BALL WJ, 1988, METHOD ENZYMOL, V156, P87; BESANCON M, 1992, ACTA PHYSIOL SCAND, V146, P77; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; DEFFO T, 1983, BIOCHEMISTRY-US, V22, P6303, DOI 10.1021/bi00295a041; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; GOELDNER MP, 1983, BIOCHEMISTRY-US, V22, P4685, DOI 10.1021/bi00289a012; HALL C, 1980, P NATL ACAD SCI-BIOL, V77, P4529, DOI 10.1073/pnas.77.8.4529; HANSEN O, 1984, PHARMACOL REV, V36, P143; HOLZINGER F, 1992, FEBS LETT, V314, P477, DOI 10.1016/0014-5793(92)81530-Y; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JARV J, 1980, J BIOL CHEM, V255, P2649; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1982, J BIOL CHEM, V257, P7435; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KIRLEY TL, 1991, J BIOL CHEM, V266, P19953; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE LK, 1973, J BIOL CHEM, V248, P7197; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LINGREL JB, 1991, SOC GEN PHY, V46, P1; LUCKIE DB, 1992, BIOPHYS J, V62, P220, DOI 10.1016/S0006-3495(92)81807-6; MACKNIGHT ADC, 1977, PHYSIOL REV, V57, P510, DOI 10.1152/physrev.1977.57.3.510; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; OBRIEN WJ, 1993, J BIOL CHEM, V268, P7707; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; ROGERS TB, 1979, BIOCHEMISTRY-US, V18, P135, DOI 10.1021/bi00568a021; ROSSI B, 1980, J BIOL CHEM, V255, P9936; RUOHO A, 1974, P NATL ACAD SCI USA, V71, P2352, DOI 10.1073/pnas.71.6.2352; SCHREIBER G, 1985, J BIOL CHEM, V260, P8789; SCHREIBER G, 1985, J BIOL CHEM, V260, P8795; SCHULTHEIS PJ, 1993, BIOCHEMISTRY-US, V32, P544, DOI 10.1021/bi00053a020; SCHWARTZ A, 1969, J PHARMACOL EXP THER, V168, P31; SCHWARTZ A, 1975, PHARMACOL REV, V27, P3; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Thomas R., 1990, ADV DRUG RES, P311; THOMAS RC, 1972, PHYSIOL REV, V52, P563, DOI 10.1152/physrev.1972.52.3.563; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH KJ, 1979, ANNU REV PHYSIOL, V41, P181, DOI 10.1146/annurev.ph.41.030179.001145; WALLICK ET, 1988, METHOD ENZYMOL, V156, P201; WALLICK ET, 1980, ARCH BIOCHEM BIOPHYS, V202, P442, DOI 10.1016/0003-9861(80)90448-8; YODA A, 1975, MOL PHARMACOL, V11, P653; YODA A, 1974, ANN NY ACAD SCI, V242, P598, DOI 10.1111/j.1749-6632.1974.tb19120.x	56	75	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22686	22694						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226778				2022-12-27	WOS:A1993MD34800074
J	MILNE, KG; FIELD, RA; MASTERSON, WJ; COTTAZ, S; BRIMACOMBE, JS; FERGUSON, MAJ				MILNE, KG; FIELD, RA; MASTERSON, WJ; COTTAZ, S; BRIMACOMBE, JS; FERGUSON, MAJ			PARTIAL-PURIFICATION AND CHARACTERIZATION OF THE N-ACETYLGLUCOSAMINYL-PHOSPHATIDYLINOSITO DE-N-ACETYLASE OF GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR BIOSYNTHESIS IN AFRICAN TRYPANOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; MEMBRANE ANCHORS; ZWITTERIONIC DETERGENT; TOXOPLASMA-GONDII; CLASS-H; BRUCEI; ETHANOLAMINE; PROTEIN; CELLS; DONOR	N-Acetylglucosaminylphosphatidylinositol (GlcNAc-PI) de-N-acetylase was solubilized from the bloodstream form of African trypanosomes using Zwittergent 3-14. The solubilized GlcNAc-PI de-N-acetylase was assayed using radiolabeled GlcNAc-PI substrates. The enzyme was partially purified about 140-fold from washed trypanosome membranes using conventional liquid chromatography. The enzyme has a K-m of 1.5 mu M. Replacement of the di-O-substituted D-myo-inositol of the natural GlcNAc-PI substrate by the L-myo-inositol isomer did not significantly alter the ability of the compound to act as a substrate for the de-N-acetylase, suggesting that the C-2 to C-5 hydroxyl groups of the myoinositol ring do not play a critical role in substrate recognition. A substrate analogue lacking fatty acids was a relatively poor substrate for the enzyme, indicating that the lipid component plays an important role in substrate recognition and/or presentation of the substrate to the enzyme in detergent micelles. Substrate analogues lacking the glycerophosphate component were not recognized by the enzyme, suggesting that this component is important in the substrate recognition process.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND; UNIV DUNDEE,DEPT CHEM,DUNDEE DD1 4HN,SCOTLAND	University of Dundee; University of Dundee			Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714; cottaz, sylvain/0000-0001-8674-0162; Field, Rob/0000-0001-8574-0275	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILYES EM, 1982, BIOCHEM J, V203, P245, DOI 10.1042/bj2030245; BAME KJ, 1991, J BIOL CHEM, V266, P12461; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BROWN DA, 1993, CURR OPIN IMMUNOL, V5, P338; CORNISHB.A, 1974, BIOCHEM J, V139, P721, DOI 10.1042/bj1390721; COTTAZ S, 1993, J CHEM SOC PERK T 1, P2945, DOI 10.1039/p19930002945; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DOERING TL, 1989, J BIOL CHEM, V264, P11168; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1991, CELL BIOL INT REP, V15, P991, DOI 10.1016/0309-1651(91)90052-K; FERGUSON MAJ, 1992, BIOCHEM J, V284, P297, DOI 10.1042/bj2840297; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; GEROLD P, 1994, J BIOL CHEM, V269, P2597; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HOLDER AA, 1983, BIOCHEM J, V209, P261, DOI 10.1042/bj2090261; INOUE N, 1993, J BIOL CHEM, V268, P6882; KAFETZOPOULOS D, 1993, P NATL ACAD SCI USA, V90, P2564, DOI 10.1073/pnas.90.7.2564; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; KAMITANI T, 1993, J BIOL CHEM, V268, P20733; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALPARTIDA F, 1980, FEBS LETT, V111, P69, DOI 10.1016/0014-5793(80)80763-0; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1991, EMBO J, V10, P2041, DOI 10.1002/j.1460-2075.1991.tb07734.x; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MENON AK, 1992, J BIOL CHEM, V267, P15277; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MILNE KG, 1992, EUR J BIOCHEM, V208, P309, DOI 10.1111/j.1432-1033.1992.tb17188.x; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; NEUGEBAUER J, 1992, GUIDE PROPERTIES USE, P25; PUOTI A, 1993, J BIOL CHEM, V268, P7215; TOMAVO S, 1992, J BIOL CHEM, V267, P21446; TOMAVO S, 1992, J BIOL CHEM, V267, P11721; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	37	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16403	16408						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206949				2022-12-27	WOS:A1994NQ72900068
J	CHADENEAU, C; LEMOULLAC, B; DENIS, MG				CHADENEAU, C; LEMOULLAC, B; DENIS, MG			A NOVEL MEMBER OF THE IMMUNOGLOBULIN GENE SUPERFAMILY EXPRESSED IN RAT CARCINOMA CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ADHESION MOLECULE; CARCINOEMBRYONIC ANTIGEN; COLON-CARCINOMA; SURFACE; ENDOTHELIUM; PROTEIN; CLONING; DOMAINS; POLIOVIRUS	Defined by monoclonal antibody E4, the pE4 antigen is a 66,000-Da glycoprotein which is expressed at the cell surface of rat colon and mammary carcinomas, but only in trace amounts in normal adult rat tissues. To determine the structure of this tumor-associated antigen and to identify its functional domains, we have cloned a cDNA coding for this protein. It encodes a 416-amino acid protein with an expected molecular weight for the core protein of similar to 42,000. The predicted amino acid sequence reveals that pE4 contains the conserved amino acids and domain structures characteristic of members of the immunoglobulin gene superfamily. Comparison of this sequence with data banks revealed a significant homology with the human and mouse receptors for poliovirus. However, pE4 is not the rat receptor for poliovirus, as different patterns were obtained by hybridization of rat genomic DNA with both probes. A major similar to 2.2-kilobase transcript of the pE4 gene was detected in all the rat tumor cell lines tested. In contrast, barely detectable levels of pE4 mRNA were found in normal adult rat tissues.	INST BIOL,INSERM,CJF 9011,DEPT MED BIOCHEM,F-44035 NANTES,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			; Denis, Marc/K-8049-2015	Chadeneau, Corinne/0000-0001-8808-1738; Denis, Marc/0000-0001-5865-3248				ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BRACKENBURY R, 1985, CANCER METAST REV, V4, P41, DOI 10.1007/BF00047736; BURGOON MP, 1991, J CELL BIOL, V112, P1017, DOI 10.1083/jcb.112.5.1017; CHADENEAU C, 1991, INT J CANCER, V47, P903, DOI 10.1002/ijc.2910470620; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DENIS MG, 1993, INT J CANCER, V55, P275, DOI 10.1002/ijc.2910550218; DENIS MG, 1992, INT J CANCER, V50, P930, DOI 10.1002/ijc.2910500619; DOUILLARD JY, 1989, CANCER RES, V49, P687; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; JOHNSON JP, 1989, P NATL ACAD SCI USA, V86, P641, DOI 10.1073/pnas.86.2.641; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; MARTINPADURA I, 1991, CANCER RES, V51, P2239; MCCAUGHAN GW, 1987, IMMUNOGENETICS, V5, P329; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; TAKAYASU T, 1981, J BIOCHEM-TOKYO, V89, P421, DOI 10.1093/oxfordjournals.jbchem.a133217; TANG DG, 1993, J BIOL CHEM, V268, P22883; TURBIDE C, 1991, J BIOL CHEM, V266, P309; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAWRYK SO, 1989, IMMUNOL REV, V108, P135, DOI 10.1111/j.1600-065X.1989.tb00016.x; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZENNADI R, 1992, INT J CANCER, V52, P934, DOI 10.1002/ijc.2910520618	30	75	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15601	15605						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195207				2022-12-27	WOS:A1994NP51300035
J	ENSLEN, H; SUN, PQ; BRICKEY, D; SODERLING, SH; KLAMO, E; SODERLING, TR				ENSLEN, H; SUN, PQ; BRICKEY, D; SODERLING, SH; KLAMO, E; SODERLING, TR			CHARACTERIZATION OF CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE-IV - ROLE IN TRANSCRIPTIONAL REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEIN; MEMBRANE DEPOLARIZATION; GENE-TRANSCRIPTION; BRAIN CALMODULIN; EXPRESSION; PHOSPHORYLATION; GR; AUTOPHOSPHORYLATION; CELLS; CREB	We have characterized Ca2+/calmodulin-dependent protein kinase IV (CaM kinase IV), expressed using the baculovirus/Sf9 cell system, to assess its potential role in Ca2+-dependent transcriptional regulation. CaM kinase IV was strongly inhibited in vitro by KN-62, a specific CaM kinase inhibitor which suppresses Ca2+-dependent transcription of several genes, so we tested whether CaM kinase IV could stimulate transcription. Co-transfection of COS-1 cells by cDNA for CaM kinase IV gave no 3-fold stimulation of a reporter gene expression, whereas co-transfection with CaM kinase II gave no transcriptional stimulation, Since this transcriptional response was mediated by phosphorylation of cAMP responsive element-binding protein (CREB), we determined the kinetics and site specificities of CaM kinases IV and II for phosphorylating CREB in vitro. CaM kinases IV and II and cAMP kinase (protein kinase A) all had similar K-m values for CREB (1-5 mu M), but the V-max of CaM kinase IV was 40-fold lower than those of CaM kinase II and protein kinase A. Although all three kinases phosphorylated Ser(133) in CREB, CaM kinase II also gave equal phosphorylation of a second site which was not Ser(98). The two CREB phosphorylation sites were separately P-32-labeled, and the abilities of protein phosphatases 1, 2A, and 2B (calcineurin) to dephosphorylate them were tested. Our results show that all three phosphatases could dephosphorylate both sites, and calcineurin was a stronger catalyst for dephosphorylating site 1 (Ser(133)) than for site 2. These results indicate that CaM kinase TV may be important in Ca2+-dependent transcriptional regulation through phosphorylation of Ser(133) in CREB. The fact that CaM kinase II phosphorylates another site in addition to Ser(333) in CREB raises the possibility that this second phosphorylation site may account for the suppressed ability of CaM kinase II to enhance transcription through the CRE/CREB system. In addition multiple protein phosphatases, including calcineurin, may exert a modulatory effect on transcription depending on which site they dephosphorylate.	OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT CELL BIOL & ANAT, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University			Enslen, Hervé/M-3400-2017	Enslen, Hervé/0000-0001-9741-5293	NIDDK NIH HHS [DK44239] Funding Source: Medline; NIGMS NIH HHS [GM41292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P1495, DOI 10.1210/me.7.11.1495; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KAMESHITA I, 1993, J BIOCHEM-TOKYO, V113, P583, DOI 10.1093/oxfordjournals.jbchem.a124087; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MIYANO O, 1992, J BIOL CHEM, V267, P1198; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; SUN PQ, 1992, MOL ENDOCRINOL, V6, P1858, DOI 10.1210/me.6.11.1858; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370	40	343	351	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15520	15527						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195196				2022-12-27	WOS:A1994NP51300022
J	FORTESDIAS, CL; LIN, Y; EWELL, J; DINIZ, CR; LIU, TY				FORTESDIAS, CL; LIN, Y; EWELL, J; DINIZ, CR; LIU, TY			A PHOSPHOLIPASE A(2) INHIBITOR FROM THE PLASMA OF THE SOUTH-AMERICAN RATTLESNAKE (CROTALUS-DURISSUS-TERRIFICUS) - PROTEIN-STRUCTURE, GENOMIC STRUCTURE, AND MECHANISM OF ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIMERESURUS-FLAVOVIRIDIS; ANTIHEMORRHAGIC FACTOR; SNAKE-VENOM; ERINACEUS-EUROPAEUS; OPOSSUM SERUM; BLOOD-PLASMA; PURIFICATION; CROTOXIN; HEDGEHOG; SEQUENCE	The lethal toxicity of the South American rattlesnake (Crotalus durissus terrificus) venom can be attributed mainly to the presence of a pre-synaptic neurotoxin, crotoxin, with phospholipase A(2) activity. Crotoxin is a heterodimer of an acidic protein (CA) and a basic phospholipase A(2) (CB). An anti-toxic protein of subunit molecular mass 23.6 kDa that neutralizes both lethal and PLA(2) activity of crotalid venom and crotoxin has been previously purified from the plasma of this snake (Fortes-Dias, C., Fonseca, B. C. B., Kochva, E., and Diniz, C. R. (1991) Toxicon 29, 997-1008). The protein has been named CNF for Crotalus neutralizing factor. In the present study, we have shown that CNF exists as an oligomeric aggregate of (CNF)(n), where n = 6-8, and when it interacts with crotoxin, it replaces the acidic protein CA of crotoxin to form a stable near stoichiometric complex of CNF.CB. The CNF.CB complex no longer exhibits PLA(2) activity and is inert in vivo, Thus, the exchange reaction between CA.CB of crotoxin and CNF to form CNF.CB and free CA is reminiscent of the interaction of crotoxin with its target receptor at the neuromuscular transmission site in the presynaptic cells. A cDNA encoding CNF has been isolated from a liver cDNA library using an appropriate nucleotide probe. The nucleotide sequence codes for a 19-residue signal peptide, followed by a 181-residue protein of which 16 are half-cystines. Calculated molecular mass is 20.06 kDa, and there is a putative N-linked carbohydrate site at Asn(157).	US FDA, CTR BIOL EVALUAT & RES, DIV ALLERGEN PROD & PARASITOL, BETHESDA, MD 20892 USA	US Food & Drug Administration (FDA)	FORTESDIAS, CL (corresponding author), FDN EZEQUIEL DIAS, CTR PESQUISA & DESENVOLVIMENTO, BELO HORIZONTE, MG, BRAZIL.		Fortes-Dias, Consuelo L/I-4896-2012; Fortes-Dias, Consuelo Latorre/U-9962-2019	Fortes-Dias, Consuelo L/0000-0002-4494-5108; Fortes-Dias, Consuelo Latorre/0000-0002-4494-5108				BON C, 1989, ACTA PHYSIOL PHARM L, V39, P439; CATANESE JJ, 1992, BIOCHEMISTRY-US, V31, P410, DOI 10.1021/bi00117a015; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DEWIT CA, 1987, TOXICON, V25, P1209, DOI 10.1016/0041-0101(87)90139-5; DOMONT GB, 1991, TOXICON, V29, P1183, DOI 10.1016/0041-0101(91)90191-S; FORTES-DIAS C L, 1990, Ciencia e Cultura (Sao Paulo), V42, P501; FORTESDIAS CL, 1991, TOXICON, V29, P997, DOI 10.1016/0041-0101(91)90082-3; FRAENKELCONRAT H, 1983, J TOXICOL-TOXIN REV, V1, P205; HABERMANN E, 1954, H-S Z PHYSIOL CHEM, V297, P179, DOI 10.1515/bchm2.1954.297.1.179; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; INOUE S, 1991, J BIOL CHEM, V266, P1001; JENG TW, 1978, P NATL ACAD SCI USA, V75, P600, DOI 10.1073/pnas.75.2.600; KIHARA H, 1976, J BIOCHEM-TOKYO, V80, P341, DOI 10.1093/oxfordjournals.jbchem.a131282; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; KOGAKI H, 1989, J BIOCHEM-TOKYO, V106, P966, DOI 10.1093/oxfordjournals.jbchem.a122983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL M, 1991, INT J BIOCHEM, V23, P287, DOI 10.1016/0020-711X(91)90108-Y; MENCHACA JM, 1981, TOXICON, V19, P623, DOI 10.1016/0041-0101(81)90100-8; MIRANDA ME, 1982, ACTA PHYSIOL LAT AM, V32, P103; OMORISAT.T, 1972, BIOCHIM BIOPHYS ACTA, V285, P414, DOI 10.1016/0005-2795(72)90328-5; OVADIA M, 1977, TOXICON, V15, P549, DOI 10.1016/0041-0101(77)90106-4; OVADIA M, 1978, TOXICON, V16, P661, DOI 10.1016/0041-0101(78)90194-0; PERALES J, 1989, BRAZ J MED BIOL RES, V22, P25; RUBSAMEN K, 1971, N-S ARCH PHARMAKOL, V270, P274; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKI C, 1980, TOXICON, V18, P235, DOI 10.1016/0041-0101(80)90002-1; Slotta KH, 1938, BER DTSCH CHEM GES, V71, P1076, DOI 10.1002/cber.19380710527; TARNG SF, 1986, TOXICON, V24, P567, DOI 10.1016/0041-0101(86)90177-7; TOMIHARA Y, 1988, TOXICON, V26, P420, DOI 10.1016/0041-0101(88)90013-X; TOMIHARA Y, 1987, TOXICON, V25, P685, DOI 10.1016/0041-0101(87)90117-6; VANDERMEERS A, 1991, EUR J BIOCHEM, V196, P537, DOI 10.1111/j.1432-1033.1991.tb15847.x; WEISSENBERG S, 1992, TOXICON, V30, P591, DOI 10.1016/0041-0101(92)90853-W	33	77	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15646	15651						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195214				2022-12-27	WOS:A1994NP51300042
J	SHA, M; BALASTA, ML; GOSS, DJ				SHA, M; BALASTA, ML; GOSS, DJ			AN INTERACTION OF WHEAT-GERM INITIATION-FACTOR 4B WITH OLIGORIBONUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; SINGLE-STRANDED-DNA; MESSENGER-RNA; CAP ANALOGS; BINDING; FLUORESCENCE; TRANSLATION; COMPLEXES	The binding of oligoribonucleotides to wheat germ protein synthesis initiation factor eIF-4B was measured by direct fluorescence techniques. An analysis of the equilibrium association constants (K-eq) indicates that eIF-4B binding is not affected by the m(7)GTP cap structure or the AUG. eIF-4B is insensitive to hairpin structures within the oligoribonucleotide. The binding site size is approximately 18 bases. The binding of oligoribonucleotide to eIF-4B as a function of pH, temperature, and ionic strength is also described. The pH dependent binding showed an increase in binding with increasing pH in contrast to the sharp pH optimum observed for cap binding protein eIF-4E (Carberry, S. E., Darzynkiewicz, E., and Goss, D. J. (1991) Biochemistry 30, 1624-1627). Assuming all tryptophan residues contribute to the observed fluorescence, iodide quenching showed that 8(+/- 1) out 9 of eIF-4B's tryptophan residues are on the surface of the eIF-4B protein. A specific anion effect of Cl- on eIF-4B binding to oligoribonucleotide was found when comparing the ionic strength effect of KC2H3O2 and KCl.	CUNY HUNTER COLL, DEPT CHEM, NEW YORK, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)								BALASTA ML, 1993, J BIOL CHEM, V268, P18599; BROWNING KS, 1989, J BIOL CHEM, V264, P8491; BROWNING KS, 1987, J BIOL CHEM, V262, P538; BUJALOWSKI W, 1988, J BIOL CHEM, V263, P4629; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P7799, DOI 10.1021/bi00372a003; CARBERRY SE, 1989, BIOCHEMISTRY-US, V28, P8078, DOI 10.1021/bi00446a017; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P1624, DOI 10.1021/bi00220a026; CARBERRY SE, 1990, BIOCHEMISTRY-US, V29, P3337, DOI 10.1021/bi00465a027; CARBERRY SE, 1992, BIOCHEMISTRY-US, V31, P1427, DOI 10.1021/bi00120a020; DRAPER DE, 1988, METHOD ENZYMOL, V164, P221; Eadie GS, 1942, J BIOL CHEM, V146, P85; EDERY I, 1983, J BIOL CHEM, V258, P1398; GILL SJ, 1976, J CHEM THERMODYN, V8, P445, DOI 10.1016/0021-9614(76)90065-3; GILL SJ, 1967, BIOCHEMISTRY-US, V6, P272, DOI 10.1021/bi00853a042; GOSS DJ, 1984, J BIOL CHEM, V259, P7374; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; LAKOWICZ JR, 1973, BIOCHEMISTRY-US, V12, P4171, DOI 10.1021/bi00745a021; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P279; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LAX SR, 1986, METHOD ENZYMOL, V118, P109; LAX SR, 1986, J BIOL CHEM, V261, P5632; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LIN TI, 1977, ANAL BIOCHEM, V77, P10, DOI 10.1016/0003-2697(77)90284-6; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PIMENTEL GC, 1971, ANNU REV PHYS CHEM, V22, P347, DOI 10.1146/annurev.pc.22.100171.002023; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; WEBER G, 1975, ADV PROTEIN CHEM, V29, P2	31	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14872	14877						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195117				2022-12-27	WOS:A1994NP73800007
J	BENOS, DJ; MCPHERSON, S; HAHN, BH; CHAIKIN, MA; BENVENISTE, EN				BENOS, DJ; MCPHERSON, S; HAHN, BH; CHAIKIN, MA; BENVENISTE, EN			CYTOKINES AND HIV ENVELOPE GLYCOPROTEIN GP120 STIMULATE NA+/H+ EXCHANGE IN ASTROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; CENTRAL-NERVOUS-SYSTEM; TRANSFORMING GROWTH FACTOR-BETA-1; FACTOR-ALPHA; INTERFERON-GAMMA; GENE-EXPRESSION; FACTOR-BETA; BRAIN; INTERLEUKIN-1	The pathogenesis of the human immunodeficiency virus (HIV)-associated cognitive/motor complex, or acquired immunodeficiency syndrome (AIDS) dementia complex, is unknown, but it afflicts over 50% of all patients infected with HIV-1. Because neurons are not directly infected with HIV-1, the causes of neuronal dysfunction are undoubtedly indirect. We investigated the role of the astrocyte in the development of AIDS dementia complex, focusing on cytokine and HIV-1 gp120 stimulation of Na+/H+ exchange (NHE) activity of primary rat astrocytes, Our results show that the cytokines tumor necrosis factor-alpha, interferon (IFN)-gamma, and interleukin (IL)-1 beta (all found to be elevated in the central nervous system of AIDS patients), can stimulate Na+/H+ exchange, but that transforming growth factor-beta, IL-2, and IL-6 do not. IFN-gamma and gp120-induced activation of Na+/H+ exchange appears to be mediated through activation of tyrosine-kinase (TK), because TK inhibitors block the action of IFN-gamma and gp120. Additionally, gp120 induces tyrosine phosphorylation of two proteins (similar to 90 and 130 kDa), which is also inhibited by TK inhibitors. The predominant NHE isoform present in rat astrocytes is NHE-1; however, other isoforms are also present. We conclude that Na+/H+ exchange of rat astrocytes can be differentially stimulated by cytokines and HIV-1 gp120. We hypothesize that the resultant increase in intracellular pH with its concomitant changes in astrocyte membrane permeability properties produces an imbalance in the K+ and glutamate microenvironment of the neurons, leading to a rise in intraneuronal Ca2+ and eventual neuronal dysfunction and/or demise.	UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,AIDS RES CTR,BIRMINGHAM,AL 35294; SMITHKLINE BEECHAM PHARMACEUT,KING OF PRUSSIA,PA 19406	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; GlaxoSmithKline	BENOS, DJ (corresponding author), UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BHSB 706,BIRMINGHAM,AL 35294, USA.			Hahn, Beatrice/0000-0002-9400-9887	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH050421] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 50421] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BENOS DJ, 1994, P NATL ACAD SCI USA, V91, P494, DOI 10.1073/pnas.91.2.494; BENVENISTE EN, 1991, J BIOL CHEM, V266, P18119; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; Boron WF, 1992, KIDNEY PHYSL PATHOPH, P219; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; GALLO P, 1989, J NEUROIMMUNOL, V23, P109, DOI 10.1016/0165-5728(89)90029-5; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GRINSTEIN S, 1988, NA PLUS H PLUS EXCHA, P359; HENRARD DR, 1992, AIDS RES HUM RETROV, V8, P47, DOI 10.1089/aid.1992.8.47; IVEYHOYLE M, 1991, P NATL ACAD SCI USA, V88, P512, DOI 10.1073/pnas.88.2.512; LASKY LA, 1986, SCIENCE, V233, P209, DOI 10.1126/science.3014647; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; MERRILL JE, 1989, J VIROL, V63, P4404, DOI 10.1128/JVI.63.10.4404-4408.1989; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; MORGANTIKOSSMANN MC, 1992, J NEUROIMMUNOL, V39, P163, DOI 10.1016/0165-5728(92)90185-N; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUNIS JR, 1990, J CLIN INVEST, V85, P591, DOI 10.1172/JCI114478; NORRIS JG, 1994, J IMMUNOL, V152, P841; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PANEK RB, 1992, P NATL ACAD SCI USA, V89, P11518, DOI 10.1073/pnas.89.23.11518; SCHLUESENER HJ, 1990, J NEUROIMMUNOL, V27, P41, DOI 10.1016/0165-5728(90)90134-9; SCHNEIDERSCHAULIES J, 1992, VIROLOGY, V191, P765, DOI 10.1016/0042-6822(92)90252-K; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SPENCER DC, 1992, ANNU REV MICROBIOL, V46, P655; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TORUDELBAUFFE D, 1990, J NEUROCHEM, V54, P1056, DOI 10.1111/j.1471-4159.1990.tb02357.x; TYOR WR, 1992, ANN NEUROL, V31, P3499; WAHL LM, 1989, P NATL ACAD SCI USA, V86, P621, DOI 10.1073/pnas.86.2.621; WAHL SM, 1991, J EXP MED, V173, P981, DOI 10.1084/jem.173.4.981; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WANG Z, 1993, J BIOL CHEM, V268, P11925; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; YONG VW, 1991, P NATL ACAD SCI USA, V88, P7016, DOI 10.1073/pnas.88.16.7016	38	95	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13811	13816						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188658				2022-12-27	WOS:A1994NL60600018
J	LANS, MS; LI, Q; LU, J; MODI, WS; NOTKINS, AL				LANS, MS; LI, Q; LU, J; MODI, WS; NOTKINS, AL			GENOMIC ORGANIZATION, 5'-UPSTREAM SEQUENCE, AND CHROMOSOMAL LOCALIZATION OF AN INSULINOMA-ASSOCIATED INTRONLESS GENE, IA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; RECEPTOR; PROMOTER; EXPRESSION; PROTEIN; REGIONS; SV40; DNA	IA-1 is a novel cDNA originally isolated from a human insulinoma subtraction library (ISL-153). It encodes a protein containing both a zinc finger DNA-binding domain and a putative prohormone domain. IA-1 transcripts have been found thus far only in tumors of neuroendocrine origin. Clinical studies have shown that IA-1 is a sensitive marker for neuroendocrine differentiation of human lung tumors. In this study, we cloned and sequenced the entire IA-1 gene and its 5'-upstream region from a human liver genomic library. In situ hybridization localized the IA-1 gene to the short arm of human chromosome 20. Sequence analysis and restriction enzyme mapping showed that the IA-1 gene is uninterrupted and appears to be intronless. Evidence that IA-1 is an intronless gene that can translate into protein was obtained from in vitro translation studies that showed that both IA-1 cDNA and IA-1 genomic DNA yielded identical protein products of approximately 61,000 daltons. Examination of the 5'-upstream region (2090 base pairs) revealed several tissue-specific regulatory elements, including glucokinase upstream promoter elements and a Pit-1 factor binding site. The presence of several different upstream regulatory elements may account for IA-1 gene expression in different neuroendocrine tumors.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS DEV PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	LANS, MS (corresponding author), NIDR,ORAL MED LAB,BLDG 30,RM 121,BETHESDA,MD 20892, USA.							ALLARD WJ, 1987, NUCLEIC ACIDS RES, V15, P10604, DOI 10.1093/nar/15.24.10604; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; DEMCHYSHYN L, 1992, P NATL ACAD SCI USA, V89, P5522, DOI 10.1073/pnas.89.12.5522; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; GOTO Y, 1992, J BIOL CHEM, V267, P15252; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JONES KA, 1984, CELL, V36, P155, DOI 10.1016/0092-8674(84)90084-9; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LAN MS, 1993, CANCER RES, V53, P4169; LAWN RM, 1981, NUCLEIC ACIDS RES, V9, P1045, DOI 10.1093/nar/9.5.1045; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; NAGATA S, 1980, NATURE, V287, P401, DOI 10.1038/287401a0; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NINOMIYA Y, 1986, J BIOL CHEM, V261, P5041; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; Sambrook J, 1989, MOL CLONING LABORATO; SHELTON NE, 1992, J MED GENET, V12, P4578; STEIN GS, 1984, HISTONE GENES STRUCT, P397; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; TEEBI AS, 1992, AM J MED GENET, V42, P35, DOI 10.1002/ajmg.1320420109; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; WHITTAKER PA, 1986, GENE, V41, P129, DOI 10.1016/0378-1119(86)90276-3; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	30	152	156	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14170	14174						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188699				2022-12-27	WOS:A1994NL60600068
J	TAN, KO; SATER, GR; MYERS, AM; ROBSON, RM; HUIATT, TW				TAN, KO; SATER, GR; MYERS, AM; ROBSON, RM; HUIATT, TW			MOLECULAR CHARACTERIZATION OF AVIAN MUSCLE TITIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; MAMMALIAN SKELETAL-MUSCLE; STRIATED-MUSCLE; IMMUNOELECTRON MICROSCOPY; MONOCLONAL-ANTIBODIES; ELASTIC PROTEIN; THICK FILAMENTS; IMMUNOGLOBULIN SUPERFAMILY; INVIVO PHOSPHORYLATION; CONNECTIN FILAMENTS	Titin is an approximately 3000-kDa polypeptide that constitutes a set of elastic filaments that connect thick filaments to the Z-line in vertebrate striated muscle myofibrils. To characterize the primary structure of titin, three over-lapping cDNA clones comprising 2.4 kilobases of avian muscle titin coding sequence were obtained from a cDNA library constructed from embryonic chick cardiac muscle RNA size-selected for large transcripts. Expression of one cDNA clone in Escherichia coli produced a fusion protein that reacted specifically with titin antibodies, and titin antiserum affinity-purified against this fusion protein reacted specifically with titin on immunoblots of chicken cardiac and skeletal muscle myofibrils. Indirect immunofluorescence localization with the fusion protein-specific antibodies demonstrated that the cDNA sequence was from the region of titin located in the myofibrillar A-band adjacent to the A/I junction. Derived amino acid sequences demonstrated a repeating pattern of fibronectin type III and immunoglobulin C2 motifs, as shown previously for a portion of rabbit skeletal muscle titin located in the central region of the A-band and for other myofibrillar proteins that bind to myosin. Differences between the rabbit and chicken titin sequences included a unique, serine-rich region in one motif, which represents a potential phosphorylation site. This is the first report of sequence information for avian titin from a previously uncharacterized portion of the titin molecule.	IOWA STATE UNIV SCI & TECHNOL, DEPT ANIM SCI, MUSCLE BIOL GRP, 3112 MOLEC BIOL BLDG, AMES, IA 50011 USA; IOWA STATE UNIV SCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, AMES, IA 50011 USA	Iowa State University; Iowa State University				Tan, Kuan/0000-0002-0947-7337				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; AYMESOUTHGATE A, 1991, P NATL ACAD SCI USA, V88, P7973, DOI 10.1073/pnas.88.18.7973; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; DEWET JR, 1984, DNA-J MOLEC CELL BIO, V3, P437, DOI 10.1089/dna.1.1984.3.437; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; EPSTEIN HF, 1991, SCIENCE, V251, P1039, DOI 10.1126/science.1998120; FULTON AB, 1991, BIOESSAYS, V13, P157, DOI 10.1002/bies.950130403; FUNATSU T, 1993, J CELL BIOL, V120, P711, DOI 10.1083/jcb.120.3.711; FURST DO, 1989, J CELL SCI, V94, P119; FURST DO, 1992, J CELL SCI, V102, P769; FURST DO, 1988, J CELL BIOL, V106, P1563, DOI 10.1083/jcb.106.5.1563; FYRBERG CC, 1992, P ROY SOC B-BIOL SCI, V249, P33, DOI 10.1098/rspb.1992.0080; GILOH H, 1982, SCIENCE, V217, P1253; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HARLOW E, 1988, ANTIBODIES LABORATOR; HILL C, 1986, J CELL BIOL, V102, P1099, DOI 10.1083/jcb.102.3.1099; HOOG C, 1986, NUCLEIC ACIDS RES, V14, P703, DOI 10.1093/nar/14.2.703; HOROWITS R, 1987, J CELL BIOL, V105, P2217, DOI 10.1083/jcb.105.5.2217; HOROWITS R, 1992, BIOPHYS J, V61, P392, DOI 10.1016/S0006-3495(92)81845-3; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ITOH Y, 1988, J BIOCHEM-TOKYO, V104, P504, DOI 10.1093/oxfordjournals.jbchem.a122499; ITOH Y, 1986, J BIOCHEM, V100, P439, DOI 10.1093/oxfordjournals.jbchem.a121732; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; KURZBAN GP, 1988, BIOCHEM BIOPH RES CO, V150, P1155, DOI 10.1016/0006-291X(88)90750-4; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASALLE F, 1983, J CELL BIOL, V97, pA258; Maniatis T., 1982, MOL CLONING; MARUYAMA K, 1985, J CELL BIOL, V101, P2167, DOI 10.1083/jcb.101.6.2167; MARUYAMA K, 1981, J BIOCHEM, V89, P701, DOI 10.1093/oxfordjournals.jbchem.a133249; MARUYAMA K, 1986, INT REV CYTOL, V104, P81, DOI 10.1016/S0074-7696(08)61924-5; MARUYAMA K, 1984, J BIOCHEM, V95, P1423, DOI 10.1093/oxfordjournals.jbchem.a134750; Mosher, 1989, FIBRONECTIN, P1; NOGUCHI J, 1992, J BIOL CHEM, V267, P20302; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PIEROBONBORMIOLI S, 1992, J MUSCLE RES CELL M, V13, P35, DOI 10.1007/BF01738425; PRICE MG, 1993, J BIOL CHEM, V268, P21800; RICHARDSON FL, 1981, EUR J CELL BIOL, V26, P91; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; RYDLANDER L, 1980, CHROMOSOMA, V81, P101, DOI 10.1007/BF00292425; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SOMERVILLE LL, 1987, BIOCHEM BIOPH RES CO, V147, P986, DOI 10.1016/S0006-291X(87)80167-5; SOMERVILLE LL, 1988, ARCH BIOCHEM BIOPHYS, V262, P118, DOI 10.1016/0003-9861(88)90174-9; TAN KO, 1992, MOL BIOL CELL, V3, P1467; TRINICK J, 1984, J MOL BIOL, V180, P331, DOI 10.1016/S0022-2836(84)80007-8; TRINICK J, 1992, FEBS LETT, V307, P44, DOI 10.1016/0014-5793(92)80899-R; Trinick J, 1991, CURR OPIN CELL BIOL, V3, P112, DOI 10.1016/0955-0674(91)90173-V; VAUGHAN KT, 1993, J BIOL CHEM, V268, P3670; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG K, 1979, P NATL ACAD SCI USA, V76, P3698, DOI 10.1073/pnas.76.8.3698; WANG K, 1991, P NATL ACAD SCI USA, V88, P7101, DOI 10.1073/pnas.88.16.7101; Wang K, 1985, Cell Muscle Motil, V6, P315; WANG K, 1982, METHOD ENZYMOL, V85, P264; WANG SM, 1988, J CELL BIOL, V107, P1075, DOI 10.1083/jcb.107.3.1075; WANG SM, 1985, J MUSCLE RES CELL M, V6, P293, DOI 10.1007/BF00713171; WHITING A, 1989, J MOL BIOL, V205, P263, DOI 10.1016/0022-2836(89)90381-1; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS CL, 1992, LAB INVEST, V66, P331; YOSHIDOMI H, 1985, BIOMED RES-TOKYO, V6, P207; 1991, PROGRAM MANUAL GCG P	64	17	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22900	22907						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226799				2022-12-27	WOS:A1993MD34800103
J	GARCIAMORALES, P; SACEDA, M; KENNEY, N; KIM, N; SALOMON, DS; GOTTARDIS, MM; SOLOMON, HB; SHOLLER, PF; JORDAN, VC; MARTIN, MB				GARCIAMORALES, P; SACEDA, M; KENNEY, N; KIM, N; SALOMON, DS; GOTTARDIS, MM; SOLOMON, HB; SHOLLER, PF; JORDAN, VC; MARTIN, MB			EFFECT OF CADMIUM ON ESTROGEN-RECEPTOR LEVELS AND ESTROGEN-INDUCED RESPONSES IN HUMAN BREAST-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; SINGLE CALCIUM CHANNELS; GROWTH FACTOR-ALPHA; MCF-7 CELLS; GENE-TRANSCRIPTION; HEAVY-METALS; RAT-BRAIN; EXPRESSION; DNA; PROTEIN	The effects of cadmium on estrogen receptor and other estrogen-regulated genes in the human breast cancer cell line MCF-7 were studied. Treatment of MCF-7 cells with 1 mu M cadmium decreased the level of estrogen receptor 58%. Cadmium induced a parallel decrease in estrogen receptor mRNA (62%). Progesterone receptor levels increased 3.2-fold after cadmium treatment. This induction was blocked by the anti-estrogen ICI-164,384. Progesterone receptor mRNA was also increased by cadmium, as well as cathepsin D mRNA. An in vitro nuclear transcription run-on assay showed that cadmium increased the transcription of the progesterone receptor and pS2 genes and decreased transcription of the estrogen receptor gene. These are not general effects of heavy metals, as zinc, 25 and 100 mu M, did not affect progesterone receptor protein and mRNA levels. Cadmium stimulated pS2 and progesterone receptor mRNAs in a clone of MDA-MB-231 cells transfected with the human estrogen receptor, but had no effect in MDA-MB-231 cells transfected with antisense estrogen receptor. Cadmium also stimulated an estrogen response element in transient transfection experiments. These data suggest that the effects of cadmium are mediated by the estrogen receptor independent of estradiol. In addition to its effect on gene expression, cadmium induced the growth of MCF-7 cells 5.6-fold.	GEORGETOWN UNIV, VINCENT T LOMBARDI CANC RES CTR, DEPT BIOCHEM & MOLEC BIOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, VINCENT T LOMBARDI CANC RES CTR, DEPT MED ONCOL, WASHINGTON, DC 20007 USA; NCI, TUMOR GROWTH FACTOR SECT, TUMOR IMMUNOL & BIOL LAB, BETHESDA, MD 20892 USA; UNIV WISCONSIN, CTR COMPREHENS CANC, DEPT HUMAN ONCOL, MADISON, WI 53792 USA	Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Wisconsin System; University of Wisconsin Madison			Saceda, Miguel/A-1581-2008; JORDAN, V.Craig/AAX-3562-2020; Jordan, V. Craig/H-4491-2011; Garcia Morales, Pilar/ABD-4362-2021	Saceda, Miguel/0000-0002-1564-3602; 				ALAM J, 1989, J BIOL CHEM, V264, P6371; BAKO G, 1982, CAN J PUBLIC HEALTH, V73, P92; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BLOCK C, 1992, J BIOL CHEM, V267, P19824; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; DENTON RR, 1992, J BIOL CHEM, V267, P7263; DUBIK D, 1992, ONCOGENE, V7, P1587; ELINDER CG, 1985, BRIT J IND MED, V42, P651; EPNER DE, 1991, J CELL PHYSIOL, V148, P68, DOI 10.1002/jcp.1041480109; FISHMAN JH, 1988, BIOCHEM BIOPH RES CO, V152, P783, DOI 10.1016/S0006-291X(88)80106-2; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; HINKLE PM, 1987, J BIOL CHEM, V262, P16333; JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KEAVENEY M, 1991, J MOL ENDOCRINOL, V6, P111, DOI 10.1677/jme.0.0060111; KIPLING MD, 1967, LANCET, V1, P730; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; LANSMAN JB, 1986, J GEN PHYSIOL, V88, P321, DOI 10.1085/jgp.88.3.321; LEMEN RA, 1976, ANN NY ACAD SCI, V271, P273, DOI 10.1111/j.1749-6632.1976.tb23122.x; MARTIN MB, 1986, J BIOL CHEM, V261, P2355; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MISRA S, 1989, BIOCHIM BIOPHYS ACTA, V1007, P325, DOI 10.1016/0167-4781(89)90155-3; MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305; NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P935, DOI 10.1210/endo-122-3-935; NELSON MT, 1986, J GEN PHYSIOL, V87, P201, DOI 10.1085/jgp.87.2.201; PEI J, 1990, J BIOL CHEM, V265, P14061; PIVA R, 1992, BIOCHEM BIOPH RES CO, V183, P996, DOI 10.1016/S0006-291X(05)80289-X; PREDKI PF, 1992, J BIOL CHEM, V267, P5842; READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263; SABBAH M, 1987, J BIOL CHEM, V262, P8631; SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157, DOI 10.1210/mend-2-12-1157; SHIBUYA I, 1992, ENDOCRINOLOGY, V131, P1936, DOI 10.1210/en.131.4.1936; SIMONS SS, 1990, J BIOL CHEM, V265, P1938; SLATER EP, 1991, MOL ENDOCRINOL, V5, P386, DOI 10.1210/mend-5-3-386; SMITH JB, 1989, J BIOL CHEM, V264, P7115; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; SUSZKIW J, 1984, BRAIN RES, V323, P31, DOI 10.1016/0006-8993(84)90262-2; TANG N, 1991, CELL BIOL TOXICOL, V7, P401, DOI 10.1007/BF00124074; THEVENOD F, 1992, BIOPHYS J, V63, P162, DOI 10.1016/S0006-3495(92)81575-8; WEISZ A, 1990, MOL ENDOCRINOL, V4, P1041, DOI 10.1210/mend-4-7-1041	44	232	238	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16896	16901						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207012				2022-12-27	WOS:A1994NR29600058
J	CHANG, PY; BENECKE, H; LEMARCHANDBRUSTEL, Y; LAWITTS, J; MOLLER, DE				CHANG, PY; BENECKE, H; LEMARCHANDBRUSTEL, Y; LAWITTS, J; MOLLER, DE			EXPRESSION OF A DOMINANT-NEGATIVE MUTANT HUMAN INSULIN-RECEPTOR IN THE MUSCLE OF TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; SIGNAL TRANSDUCTION; GLUCOSE-TRANSPORT; DIABETIC SUBJECTS; SKELETAL-MUSCLE; ADIPOSE-TISSUE; MORBIDLY OBESE; BETA-SUBUNIT; RESISTANCE; MUTATION	To examine the in vivo effects of a kinase-deficient mutant human insulin receptor, we used the muscle creatine kinase promoter to express a putative dominant-negative receptor: Ala(1134) --> Thr (Moller, D. E., Yokota, A., White, M. F., Pazianos, A G., and Flier, J. S. (1990) J. Biol. Chem. 265, 14979-14985) in transgenic mice, Two lines were generated, where receptor expression was restricted to striated muscle and was increased by 5-12-fold in skeletal muscle. Transgenic gluteal muscle insulin receptor kinase activity was reduced by approximate to 80% after maximal in vivo insulin stimulation. Glycogen content in this muscle was reduced by 45% in transgenic mice. Insulin levels were approximate to 2-fold higher, and glucose concentrations were 12% higher in transgenics fed ad libitum. Transgenic mice exhibited reduced in vivo sensitivity to low dose (0.1 milliunits/g) intravenous insulin. In isolated soleus muscles from transgenics, where mutant receptors were expressed at lower levels, insulin-stimulated receptor kinase activity was reduced by 42%, but insulin-stimulated 2-deoxyglucose uptake was unaffected. These results indicate that (i) overexpression of a kinase-deficient human insulin receptor in muscle causes dominant-negative effects at the level of receptor kinase activation, (ii) impairment of insulin-stimulated muscle receptor tyrosine kinase activity can cause decreased insulin sensitivity in vivo, (iii) kinase-defective receptor mutants may be used to create novel animal models of tissue-specific insulin resistance.	BETH ISRAEL HOSP, CHARLES A DANA RES INST, DIV ENDOCRINOL & METAB, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DEPT MED, HARVARD THORNDIKE LAB, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA; FAC MED NICE, INSERM, U145, F-06034 NICE, FRANCE	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045874] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45874] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BENECKE H, 1993, DIABETES, V42, P206, DOI 10.2337/diabetes.42.1.206; BENECKE H, 1992, J CLIN INVEST, V89, P2066, DOI 10.1172/JCI115819; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; CAMA A, 1993, J BIOL CHEM, V268, P8060; CAMA A, 1991, J CLIN ENDOCR METAB, V73, P894, DOI 10.1210/jcem-73-4-894; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DOHM GL, 1988, J CLIN INVEST, V82, P486, DOI 10.1172/JCI113622; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FREIDENBERG GR, 1991, J CLIN INVEST, V87, P2222, DOI 10.1172/JCI115257; FREIDENBERG GR, 1987, J CLIN INVEST, V79, P240, DOI 10.1172/JCI112789; GARVEY WT, 1988, J CLIN INVEST, V81, P1528, DOI 10.1172/JCI113485; GOTTSCHALK WK, 1991, J BIOL CHEM, V266, P8814; GRIGORESCU F, 1984, J BIOL CHEM, V259, P5003; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HARUTA T, 1993, DIABETES, V42, P1837, DOI 10.2337/diabetes.42.12.1837; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; HOGAN B, 1986, MANIPULATING MOUSE E; IWANISHI M, 1993, DIABETOLOGIA, V36, P414, DOI 10.1007/BF00402277; JAMES DE, 1985, AM J PHYSIOL, V248, pE567, DOI 10.1152/ajpendo.1985.248.5.E567; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KIM H, 1992, DIABETOLOGIA, V35, P261, DOI 10.1007/BF00400927; KLEIN HH, 1993, DIABETES, V42, P883, DOI 10.2337/diabetes.42.6.883; KRAEGEN EW, 1985, AM J PHYSIOL, V248, pE353; LEMARCHANDBRUSTEL Y, 1978, AM J PHYSIOL, V234, pE348, DOI 10.1152/ajpendo.1978.234.4.E348; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MARSHALL S, 1980, J CLIN INVEST, V66, P763, DOI 10.1172/JCI109914; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MOLLER DE, 1988, NEW ENGL J MED, V319, P1526, DOI 10.1056/NEJM198812083192306; MOLLER DE, 1990, J BIOL CHEM, V265, P14979; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MOLLER DE, 1994, DIABETES, V43, P247, DOI 10.2337/diabetes.43.2.247; MOLLER DE, 1990, MOL ENDOCRINOL, V4, P1183, DOI 10.1210/mend-4-8-1183; MOUNTJOY KG, 1990, BIOCHEM BIOPH RES CO, V169, P978, DOI 10.1016/0006-291X(90)91990-A; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; NOZAKI O, 1993, J CLIN ENDOCR METAB, V77, P169, DOI 10.1210/jc.77.1.169; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; ORAHILLY S, 1991, DIABETES, V40, P777, DOI 10.2337/diabetes.40.6.777; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; RAFAELOFF R, 1991, BIOCHEM BIOPH RES CO, V179, P912, DOI 10.1016/0006-291X(91)91905-R; ROACH P, 1992, CLIN RES, V40, pA311; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SINHA MK, 1987, DIABETES, V36, P620, DOI 10.2337/diabetes.36.5.620; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Taylor Simeon I., 1993, P83; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WHITE MF, 1994, INSULIN RESISTANCE, P9; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; YAMAMOTOHONDA R, 1990, J BIOL CHEM, V265, P14777	64	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16034	16040						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206901				2022-12-27	WOS:A1994NQ72900016
J	DENHEZ, F; LAFYATIS, R				DENHEZ, F; LAFYATIS, R			CONSERVATION OF REGULATED ALTERNATIVE SPLICING AND IDENTIFICATION OF FUNCTIONAL DOMAINS IN VERTEBRATE HOMOLOGS TO THE DROSOPHILA SPLICING REGULATOR, SUPPRESSOR-OF-WHITE-APRICOT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEINS; MESSENGER-RNA; PREMESSENGER RNA; SR PROTEINS; U2 SNRNP; SITE SELECTION; GENE ENCODES; SEX-LETHAL; EXPRESSION; PRP9	Although several splicing regulatory proteins have been identified in Drosophila through characterization of various genetic mutations, including sex-lethal, transformer, transformer-2, suppressor-of-white-apricot (su(w(a))), and possibly suppressor-of-sable, none of these have been identified in vertebrates, We describe the cloning and characterization of human (HsSWAP) and mouse (MmSWAP) homologs of the su(w(a)) gene. Comparison of the Drosophila and mammalian proteins reveals five highly homologous regions, including an arginine/serine rich domain and two repeated modules that are homologous to regions in the constitutive splicing factor, SPP91/PRP21. These modules thus define a new motif likely important in the regulatory and constitutive splicing functions of these proteins. The Drosophila su(w(a)) gene autoregulates its expression by control of splicing of its first two introns. Comparison of mammalian and Drosophila SWAP mRNAs revealed that the splice junctions of these regulated introns are precisely conserved, showing definitively that these genes are ancestrally related. Moreover, mammalian SWAP mRNAs are also alternatively spliced at the same splice sites, showing that mammalian SWAP expression is regulated (presumably autogenously) by control of splicing of these two introns. These several structural features therefore strongly suggest that the mammalian SWAP gene functions as a vertebrate alternative splicing regulator.	INST PASTEUR, CTR IMMUNOL & BIOL PARASITAIRE,CNRS,U624,INSERM, U167, F-59019 LILLE, FRANCE; INST PASTEUR, CNRS, URA 1160, F-59019 LILLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Lafyatis, Robert/0000-0002-9398-5034				ABOVICH N, 1990, MOL CELL BIOL, V10, P6417, DOI 10.1128/MCB.10.12.6417; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; ARENAS JE, 1993, P NATL ACAD SCI USA, V90, P6771, DOI 10.1073/pnas.90.14.6771; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BENNETT M, 1993, SCIENCE, V262, P105, DOI 10.1126/science.8211113; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BROSI R, 1993, SCIENCE, V262, P102, DOI 10.1126/science.8211112; CHAPON C, 1992, EMBO J, V11, P3279, DOI 10.1002/j.1460-2075.1992.tb05406.x; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; KRAMER A, 1991, EMBO J, V10, P1503, DOI 10.1002/j.1460-2075.1991.tb07670.x; LEGRAIN P, 1990, EMBO J, V9, P2775, DOI 10.1002/j.1460-2075.1990.tb07465.x; LEGRAIN P, 1993, SCIENCE, V262, P108, DOI 10.1126/science.8211114; LEGRAIN P, 1993, GENE DEV, V7, P1390, DOI 10.1101/gad.7.7b.1390; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MING G, 1993, MOL CELL BIOL, V13, P1104, DOI 10.1128/MCB.13.2.1104; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sambrook J, 1989, MOL CLONING; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SPIKES D, 1992, NUCLEIC ACIDS RES, V20, P5719, DOI 10.1093/nar/20.21.5719; SUREAU A, 1992, P NATL ACAD SCI USA, V89, P11683, DOI 10.1073/pnas.89.24.11683; SWANSON MS, 1987, MOL CELL BIOL, V7, P1731, DOI 10.1128/MCB.7.5.1731; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; VOELKER RA, 1991, MOL CELL BIOL, V11, P894, DOI 10.1128/MCB.11.2.894; ZACHAR Z, 1993, J CELL BIOL, V121, P729, DOI 10.1083/jcb.121.4.729; ZACHAR ZZ, 1987, EMBO J, V6, P4105, DOI 10.1002/j.1460-2075.1987.tb02756.x; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	50	38	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16170	16179						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206918				2022-12-27	WOS:A1994NQ72900036
J	HUANG, TG; HACKNEY, DD				HUANG, TG; HACKNEY, DD			DROSOPHILA KINESIN MINIMAL MOTOR DOMAIN EXPRESSED IN ESCHERICHIA-COLI - PURIFICATION AND KINETIC CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN KINESIN; FAST AXONAL-TRANSPORT; HEAVY-CHAIN; CYTOPLASMIC MICROTUBULES; MUSCLE-CONTRACTION; BETA-TUBULIN; NCD PROTEIN; BINDING; ATPASE; MOTILITY	A truncated motor domain of the alpha subunit of Drosophila kinesin was obtained by expression in Escherichia coli and purified to homogeneity in the presence of MgATP. This domain (designated DKH340) extends from the N terminus to amino acid 340. The isolated protein contains a stoichiometric level of tightly bound ADP and has a low basal rate of ATP hydrolysis of 0.029 +/- 0.002 s(-1) in the absence of microtubules. The rate of release of bound ADP is 0.026 +/- 0.003 s(-1). The approximate equality of the ADP release rate and the steady state ATPase rate indicates that ADP release is the rate-limiting step in ATP hydrolysis in the absence of microtubules. The rate of ATP hydrolysis is stimulated 3000 fold by addition of microtubules (MT) (k(cat) = 80 s(-1); K-0.5,ATPase(MT) = 160 nM for half-saturation of the ATPase rate by microtubules at saturating ATP levels; K-0.5,ATPase(MT) = 43 mu M for half-saturation of the ATPase rate by ATP at saturating microtubule levels). Binding of DKH340 to MTs is biphasic in the presence of adenosine 5-(beta-gamma-imido)triphosphate. One DKH340 binds tightly per tubulin heterodimer, but greater than one DKH340/tubulin heterodimer can be bound at higher ratios of DKH340/ microtubules. In the presence of MgATP, K-0.5,Binding(MT) for physical binding of DKH340 to microtubules is weaker than K-0.5,ATPase(MT) for stimulation of hydrolysis. These re- sults are consistent with a model in which DKH340 cycles on and off the microtubule during hydrolysis of each ATP molecule. For this model, the kcat/K-0.5,ATPase(MT) ratio of 5 x 10(8) M(-1) s(-1) is at least as large as the bimolecular rate constant for association with microtubules, and this value approaches the diffusion controlled limit. Nucleotide-free DKH340 can be produced by gel filtration in the absence of Mg2+, but it reforms tightly bound ADP slowly in the presence of MgATP (t(1/2) greater than or equal to 10 min), and thus it is likely to be in a conformational state which is not produced during steady state ATP hydrolysis.	CARNEGIE MELLON UNIV, DEPT BIOL SCI, PITTSBURGH, PA 15213 USA	Carnegie Mellon University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028562] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28562] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; COHN SA, 1989, J BIOL CHEM, V264, P4290; EISENBERG E, 1985, SCIENCE, V227, P999, DOI 10.1126/science.3156404; ENDOW SA, 1991, P NATL ACAD SCI USA, V88, P4424, DOI 10.1073/pnas.88.10.4424; FERSHT A, 1984, ENZYME STRUCTURE MEC, P150; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; GOLDSMITH M, 1991, CELL MOTIL CYTOSKEL, V20, P249, DOI 10.1002/cm.970200308; GREENE LE, 1980, J BIOL CHEM, V255, P543; HACKNEY DD, 1990, BIOPHYS J, V57, pA348; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1984, P NATL ACAD SCI-BIOL, V81, P5345, DOI 10.1073/pnas.81.17.5345; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HACKNEY DD, 1985, J BIOL CHEM, V260, P5505; HACKNEY DD, 1989, J BIOL CHEM, V264, P15943; HACKNEY DD, 1991, METHOD ENZYMOL, V196, P175; HACKNEY DD, 1990, ENZYMES, V19, P1; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; HIBBERD MG, 1986, ANNU REV BIOPHYS BIO, V15, P119; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HISANAGA S, 1989, CELL MOTIL CYTOSKEL, V12, P264, DOI 10.1002/cm.970120407; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16502; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4589; KAMIMURA S, 1992, J CELL BIOL, V118, P865, DOI 10.1083/jcb.118.4.865; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; RODIONOV VI, 1990, J BIOL CHEM, V265, P5702; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; ROZDZIAL MM, 1990, EUR J CELL BIOL, V52, P27; SADHU A, 1992, J BIOL CHEM, V267, P11352; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SHIMIZU T, 1991, J CELL BIOL, V112, P1189, DOI 10.1083/jcb.112.6.1189; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; STEIN LA, 1984, BIOCHEMISTRY-US, V23, P1555, DOI 10.1021/bi00302a033; STEWART RJ, 1991, P NATL ACAD SCI USA, V88, P8470, DOI 10.1073/pnas.88.19.8470; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; Towbin H, 1979, 10 1073 PNAS 76 9 43, V76, P4350, DOI [10.1073/pnas.76.9.4350, DOI 10.1073/PNAS.76.9.4350]; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	64	178	183	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16493	16501						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206959				2022-12-27	WOS:A1994NQ72900080
J	RAJPUT, B; MUNIAPPA, N; VIJAY, IK				RAJPUT, B; MUNIAPPA, N; VIJAY, IK			DEVELOPMENTAL AND HORMONAL-REGULATION OF UDP-GLCNAC-DOLICHOL PHOSPHATE GLCNAC-1-P TRANSFERASE IN MOUSE MAMMARY-GLAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN GENE-EXPRESSION; ASPARAGINE-LINKED GLYCOPROTEINS; N-ACETYLGLUCOSAMINYLPYROPHOSPHORYL POLYPRENOLS; EPITHELIAL-CELL LINE; BETA-CASEIN; NUCLEAR FACTOR; OVIDUCT DIFFERENTIATION; PROTEIN GLYCOSYLATION; EXTRACELLULAR-MATRIX; ALPHA-LACTALBUMIN	The developmental and hormonal regulation of UDP-GlcNAc:dolichol phosphate N-acetylglucosamine-1-phosphate transferase (GPT), the enzyme which initiates the biosynthesis of asparagine-linked glycoproteins, was investigated in mouse mammary glands. An anti-peptide antibody raised against the carboxyl-terminal 11 amino acids of mouse GPT, immunoadsorbed GPT activity and recognized a protein of expected size (similar to 48 kDa) on Western blots. Mouse mammary glands at different stages of development were examined for GPT activity, immunoreactive protein, and GPT mRNA. All three parameters showed a similar trend, i.e. they were low in tissues from virgin and pregnant animals, increased steadily during lactation, reaching a peak around mid to late lactation, and declined thereafter in glands from post-lactating animals. At mid-lactation, the increase in GPT activity, immunoreactive protein, and GPT mRNA relative to the virgin stage was 9.5-, 3.3- and 5.4 fold respectively, on a per cell basis. These data suggest possible transcriptional and post-transcriptional modulation of GPT gene expression during development of mouse mammary gland. The results on hormonal regulation of GPT in mouse mammary explants and primary mouse mammary epithelial cells showed that all three parameters cited above were stimulated maximally by the combined presence of insulin, hydrocortisone, and prolactin, indicating that the hormonal regulation of GPT expression is also mediated at the level of RNA.	UNIV MARYLAND,DEPT ANIM SCI,COLL PK,MD 20742; UNIV MARYLAND,CTR AGR BIOTECHNOL,COLL PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park					NIDDK NIH HHS [DK-19682] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019682] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMANT DR, 1986, DEV BIOL, V113, P228, DOI 10.1016/0012-1606(86)90125-9; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BHATTACHARJEE M, 1984, ENDOCRINOLOGY, V115, P1070, DOI 10.1210/endo-115-3-1070; BRADSHAW JP, 1985, INT J BIOCHEM, V17, P175, DOI 10.1016/0020-711X(85)90112-0; CARSON DD, 1990, J BIOL CHEM, V265, P2947; CHEN LH, 1987, J BIOL CHEM, V262, P17247; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; EMERMAN JT, 1977, IN VITRO CELL DEV B, V13, P316, DOI 10.1007/BF02616178; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRIGOR MR, 1990, BIOCHEM J, V267, P815, DOI 10.1042/bj2670815; GUYETTE WA, 1979, CELL, V17, P1013, DOI 10.1016/0092-8674(79)90340-4; HARLOW E, 1988, ANTIBODIES LABORATOR, P78; HAYES GR, 1983, J BIOL CHEM, V258, P5095; HOUDEBINE LM, 1978, BIOCHIMIE, V60, P57, DOI 10.1016/S0300-9084(78)80198-9; KAUSHAL GP, 1985, J BIOL CHEM, V260, P6303; KEAN EL, 1985, J BIOL CHEM, V260, P2561; KEAN EL, 1980, J BIOL CHEM, V255, P1921; KEAN EL, 1982, J BIOL CHEM, V257, P7952; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEE CS, 1992, J BIOL CHEM, V267, P5797; LEE EYH, 1984, J CELL BIOL, V98, P146, DOI 10.1083/jcb.98.1.146; LEE EYHP, 1985, P NATL ACAD SCI USA, V82, P1419, DOI 10.1073/pnas.82.5.1419; LI ML, 1987, P NATL ACAD SCI USA, V84, P136, DOI 10.1073/pnas.84.1.136; LUCAS JJ, 1977, J BIOL CHEM, V252, P4330; NAKHASI HL, 1979, J BIOL CHEM, V254, P6016; ONO M, 1981, IN VITRO CELL DEV B, V17, P121, DOI 10.1007/BF02618068; QASBA PK, 1984, NATURE, V308, P377, DOI 10.1038/308377a0; RAJPUT B, 1992, BIOCHEM J, V285, P985, DOI 10.1042/bj2850985; RUSH J S, 1991, Glycobiology, V1, P229, DOI 10.1093/glycob/1.2.229; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SHAILUBHAI K, 1990, J BIOL CHEM, V265, P9701; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; STARR CM, 1985, ARCH BIOCHEM BIOPHYS, V237, P261, DOI 10.1016/0003-9861(85)90277-2; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; VIJAY IK, 1986, EUR J BIOCHEM, V154, P57, DOI 10.1111/j.1432-1033.1986.tb09358.x; WELPLY JK, 1985, DEV BIOL, V107, P252, DOI 10.1016/0012-1606(85)90393-8; YOSHIMURA M, 1990, P NATL ACAD SCI USA, V87, P3670, DOI 10.1073/pnas.87.10.3670; ZHU XY, 1992, J BIOL CHEM, V267, P8895	43	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16054	16061						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206904				2022-12-27	WOS:A1994NQ72900019
J	HUFF, S; MATSUKA, YV; MCGAVIN, MJ; INGHAM, KC				HUFF, S; MATSUKA, YV; MCGAVIN, MJ; INGHAM, KC			INTERACTION OF N-TERMINAL FRAGMENTS OF FIBRONECTIN WITH SYNTHETIC AND RECOMBINANT-D MOTIFS FROM ITS BINDING-PROTEIN ON STAPHYLOCOCCUS-AUREUS STUDIED USING FLUORESCENCE ANISOTROPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA FIBRONECTIN; RECEPTOR; CLONING; DOMAINS; HEPARIN; GENE; PURIFICATION; EXPRESSION; SEQUENCE; PEPTIDES	The N-terminal 29-kDa fragment of fibronectin (Fn29K) contains five type I ''finger'' modules. It binds to heparin, fibrin, and bacteria and is involved in fibronectin (Fn) matrix assembly. Binding to Staphylococcus aureus involves a cell wall-associated protein that contains similar to three repeats of a 38-residue D motif (Signas, C., Raucci, G., Jonsson, K., Lindgren, P.-E., Anantharamaiah, G. M., Hook, M., and Lindberg, M. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 699-703). Synthetic peptides representing D1, D2, and D3, when labeled with fluorescein isothiocyanate (FITC), exhibited increases in fluorescence anisotropy upon addition of Fn29K but not other Fn fragments. The response could be reversed by titration with unlabeled peptides to yield inhibition constants that agreed with the dissociation constants obtained by fitting the initial response. Values of K-d ranged between 2 and 12 mu M, with D3 having the highest affinity. Specificity of D3 for Fn29K was further illustrated by the fact that its C-terminal half (D3b, Lys(801) to Lys(821)), when immobilized, selectively adsorbed Fn29K from a thermolysin digest of fibronectin. The binding site in Fn was further localized within Fn29K by analyzing smaller proteolytic or recombinant subfragments. Those containing fingers, F3-5 and F4-5, were purified on D3b-Sepharose and bound FITC-D3b with K-d values of 4-6 mu M. Subfragments containing pairs of fingers 1-2, 2-3, or single fingers 1, 4, or 5 were inactive. Whole D1-3, expressed in Escherichia coli and labeled with fluorescein, bound 1.9 mol/mol of Fn29K with K-d = 1.5 nM. F4-5 and F2-3 bound with respective K-d values of 0.35 and 4.4 mu M. These and other results indicate that binding of the individual D region peptides is mediated through their C-terminal halves, primarily to fingers 4 and 5 of fibronectin. The possible basis of the much higher affinity of D1-3 is discussed.	AMER RED CROSS,JEROME H HOLLAND LAB,ROCKVILLE,MD 20855; UNIV MANITOBA,DEPT MED MICROBIOL,WINNIPEG R3E 0W3,MB,CANADA	American Red Cross; University of Manitoba				McGavin, Martin/0000-0001-5955-0689	NHLBI NIH HHS [HL21791] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021791] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BORSI L, 1986, ANAL BIOCHEM, V155, P335, DOI 10.1016/0003-2697(86)90443-4; BOZZINI S, 1992, EUR J BIOCHEM, V207, P327, DOI 10.1111/j.1432-1033.1992.tb17054.x; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ESPERSEN F, 1982, INFECT IMMUN, V37, P526, DOI 10.1128/IAI.37.2.526-531.1982; FLOCK JI, 1987, EMBO J, V6, P2351, DOI 10.1002/j.1460-2075.1987.tb02511.x; FROMAN G, 1987, J BIOL CHEM, V262, P6564; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GUAN C, 1987, GENE, V67, P21; HORMANN H, 1980, H-S Z PHYSIOL CHEM, V361, P1449; HOROVITZ A, 1987, P NATL ACAD SCI USA, V84, P6654, DOI 10.1073/pnas.84.19.6654; Hynes RO, 1990, FIBRONECTINS; INGHAM KC, 1993, BIOCHEMISTRY-US, V32, P12548, DOI 10.1021/bi00097a035; INGHAM KC, 1990, BIOCHEM J, V272, P605, DOI 10.1042/bj2720605; INGHAM KC, 1981, BIOCHIM BIOPHYS ACTA, V670, P181, DOI 10.1016/0005-2795(81)90007-6; ISAACS BS, 1989, BIOCHEMISTRY-US, V28, P842, DOI 10.1021/bi00428a065; LANTZ MS, 1991, J BACTERIOL, V173, P4263, DOI 10.1128/JB.173.14.4263-4270.1991; LINDGREN PE, 1992, J BIOL CHEM, V267, P1924; LOFDAHL S, 1983, P NATL ACAD SCI-BIOL, V80, P697, DOI 10.1073/pnas.80.3.697; MATSUKA YV, 1994, J BIOL CHEM, V269, P9539; MCGAVIN MJ, 1993, J BIOL CHEM, V268, P23946; MCGAVIN MJ, 1991, J BIOL CHEM, V266, P8343; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; MOSHER DF, 1980, SCIENCE, V209, P927, DOI 10.1126/science.7403857; NOVOKHATNY VV, 1994, J MOL BIOL, V238, P833, DOI 10.1006/jmbi.1994.1337; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; PRESS WH, 1986, NUMERICAL RECIPES, P146; PROCTOR RA, 1982, J BIOL CHEM, V257, P4788; RICHTER H, 1982, H-S Z PHYSIOL CHEM, V363, P351, DOI 10.1515/bchm2.1982.363.1.351; RYDEN C, 1983, J BIOL CHEM, V258, P3396; SEKIGUCHI K, 1980, P NATL ACAD SCI-BIOL, V77, P2661, DOI 10.1073/pnas.77.5.2661; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; WILLIAMS MJ, 1993, BIOCHEMISTRY-US, V32, P7388, DOI 10.1021/bi00080a008	36	55	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15563	15570						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195201				2022-12-27	WOS:A1994NP51300029
J	BUBB, MR; SENDEROWICZ, AMJ; SAUSVILLE, EA; DUNCAN, KLK; KORN, ED				BUBB, MR; SENDEROWICZ, AMJ; SAUSVILLE, EA; DUNCAN, KLK; KORN, ED			JASPLAKINOLIDE, A CYTOTOXIC NATURAL PRODUCT, INDUCES ACTIN POLYMERIZATION AND COMPETITIVELY INHIBITS THE BINDING OF PHALLOIDIN TO F-ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SPONGE	Jasplakinolide, a naturally occurring cyclic peptide from the marine sponge, Jaspis johnstoni, has both fungicidal and antiproliferative activity. We now report that this peptide is a potent inducer of actin polymerization in vitro. The peptide has a much greater effect on Mg2+-actin than on Ca2+-actin. Competitive binding studies using rhodamine-phalloidin suggest that jasplakinolide binds to F-actin competitively with phalloidin with a dissociation constant of approximately 15 nM. This compares favorably to the previously reported IC50 of 35 nn for the antiproliferative effect of jasplakinolide on PC3 prostate carcinoma cells. The binding curve suggests that nearest neighbor positive cooperativity influences the binding of jasplakinolide (and perhaps also phalloidin) to F actin. These results imply that jasplakinolide may exert its cytotoxic effect in vivo by inducing actin polymerization and/or stabilizing pre-existing actin filaments.	NHLBI, CELL BIOL LAB, BETHESDA, MD 20892 USA; NCI, DIV CANC TREATMENT, DEV THERAPEUT PROGRAM, BIOL CHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Duncan, Kimberly/C-3655-2013; Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				CARLIER MF, 1986, J BIOL CHEM, V261, P785; COLUCCIO LM, 1984, J CELL BIOL, V99, P529, DOI 10.1083/jcb.99.2.529; CREWS P, 1986, TETRAHEDRON LETT, V27, P2797, DOI 10.1016/S0040-4039(00)84645-6; DANCKER P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P197, DOI 10.1016/0304-4165(90)90116-E; ESTES JE, 1981, BIOCHEMISTRY-US, V20, P708, DOI 10.1021/bi00507a006; ESTES JE, 1981, BIOCHEMISTRY-US, V261, P10785; FAULSTICH H, 1982, CHEM PEPTIDES PROTEI, V1, P279; HILL TL, 1985, COOPERATIVITY THEORY, P327; HUANG ZJ, 1992, ANAL BIOCHEM, V200, P199, DOI 10.1016/0003-2697(92)90299-M; JOOS L, 1987, BIOCHEM CELL BIOL, V65, P261, DOI 10.1139/o87-034; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lynen F, 1938, LIEBIGS ANN CHEM, V533, P93; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MIYAMOTO Y, 1986, J BIOCHEM-TOKYO, V100, P1677, DOI 10.1093/oxfordjournals.jbchem.a121877; MUNEKATA E, 1978, LIEBIGS ANN CHEM, P776; Senderowicz A. M. J., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P409; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STINGL J, 1992, CANCER CHEMOTH PHARM, V30, P401, DOI 10.1007/BF00689969; WEHLAND J, 1980, EUR J CELL BIOL, V21, P188; WIELAND T, 1984, P NATL ACAD SCI-BIOL, V81, P5232, DOI 10.1073/pnas.81.16.5232; ZABRISKIE TM, 1986, J AM CHEM SOC, V108, P3123, DOI 10.1021/ja00271a062	22	679	690	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14869	14871						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195116				2022-12-27	WOS:A1994NP73800006
J	BURBACH, JPH; DASILVA, SL; COX, JJ; ADAN, RAH; COONEY, AJ; TSAI, MJ; TSAI, SY				BURBACH, JPH; DASILVA, SL; COX, JJ; ADAN, RAH; COONEY, AJ; TSAI, MJ; TSAI, SY			REPRESSION OF ESTROGEN-DEPENDENT STIMULATION OF THE OXYTOCIN GENE BY CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; THYROID-HORMONE RECEPTOR; FACTOR COUP-TF; RESPONSE ELEMENTS; ACID RECEPTORS; LACTOFERRIN GENE; ORPHAN RECEPTORS; VITAMIN-D; RXR-BETA; EXPRESSION	The orphan receptor chicken ovalbumin upstream promoter transcription factor I (COUP-TF I) fully prevented not only the activation of the oxytocin gene by retinoic acid and thyroid hormone but also completely repressed the estrogen dependent stimulation in transfected P19 EC cells. DNase I footprinting showed that the COUP-TF I protein bound to the 5'-flanking region of the oxytocin gene at the site of the distal composite hormone response element, which mediates the responses to estrogen, retinoic acid, and thyroid hormone. Electrophoretic mobility shift assay using this composite hormone response element as probe showed that COUP-TF I and the estrogen receptor competed for binding but did not form a heterodimer. The binding by COUP-TF I was stronger than the binding of the estrogen receptor. Thus, the mechanism of repression involves occupancy of integrated binding sites. By mutagenesis of the composite hormone response element, the COUP-TF I binding site and the estrogen response element could be separated, resulting in functional dissociation of the repressive action of COUP-TF I and the induction by estrogen. The results show that repression of gene expression by COUP-TF I is not limited to receptors that act through heterodimerization but also extends to the homodimer-forming estrogen receptor in a context-dependent manner. This interaction between COUP-TF I and the estrogen receptor may provide a physiological mechanism of selective antagonism of gene regulation by estrogens.	UNIV UTRECHT, RUDOLF MAGNUS INST PHARMACOL, DEPT MED PHARMACOL, 3584 CG UTRECHT, NETHERLANDS; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Utrecht University; Baylor College of Medicine					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045641, R01DK045641] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-45641] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAN RAH, 1993, MOL ENDOCRINOL, V7, P47, DOI 10.1210/me.7.1.47; ADAN RAH, 1991, BIOCHEM BIOPH RES CO, V175, P117, DOI 10.1016/S0006-291X(05)81208-2; ADAN RAH, 1992, J BIOL CHEM, V267, P3771; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BERRODIN TJ, 1992, MOL ENDOCRINOL, V6, P1468, DOI 10.1210/me.6.9.1468; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; BROWN M, 1990, J BIOL CHEM, V265, P11238; BURBACH JPH, 1992, ANN NY ACAD SCI, V652, P1, DOI 10.1111/j.1749-6632.1992.tb34341.x; CHANG C, IN PRESS P NATL ACAD; COONEY AJ, 1991, J VIROL, V65, P2853, DOI 10.1128/JVI.65.6.2853-2860.1991; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GEISER M, 1983, J BIOL CHEM, V258, P9024; IVELL R, 1984, P NATL ACAD SCI-BIOL, V81, P2006, DOI 10.1073/pnas.81.7.2006; JONK LJC, 1993, THESIS UTRECHT U; KADOWAKI Y, 1992, BIOCHEM BIOPH RES CO, V183, P492, DOI 10.1016/0006-291X(92)90509-J; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KURAMOCHI S, 1990, J MOL BIOL, V216, P567, DOI 10.1016/0022-2836(90)90384-X; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; LUTZ B, 1994, DEVELOPMENT, V120, P25, DOI 10.1242/dev.120.1.25; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MOHR E, 1991, MOL BRAIN RES, V9, P293, DOI 10.1016/0169-328X(91)90075-9; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; RICHARD S, 1991, J BIOL CHEM, V266, P21428; RICHARD S, 1990, J BIOL CHEM, V265, P6098; ROUET P, 1992, J BIOL CHEM, V267, P20765; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITZ E, 1991, DNA CELL BIOL, V10, P81, DOI 10.1089/dna.1991.10.81; SWANSON LW, 1992, PROG BRAIN RES, V92, P97, DOI 10.1016/S0079-6123(08)61167-X; TENG CT, 1992, MOL ENDOCRINOL, V6, P1969, DOI 10.1210/me.6.11.1969; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WEHRENBERG U, 1992, BIOCHEM BIOPH RES CO, V189, P496, DOI 10.1016/0006-291X(92)91585-E; WEHRENBERG U, 1994, J NEUROENDOCRINOL, V6, P1, DOI 10.1111/j.1365-2826.1994.tb00546.x; WEHRENBERG U, 1994, IN PRESS P NATL ACAD; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	53	64	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15046	15053						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195142				2022-12-27	WOS:A1994NP73800033
J	CHANDRA, S; FEWTRELL, C; MILLARD, PJ; SANDISON, DR; WEBB, WW; MORRISON, GH				CHANDRA, S; FEWTRELL, C; MILLARD, PJ; SANDISON, DR; WEBB, WW; MORRISON, GH			IMAGING OF TOTAL INTRACELLULAR CALCIUM AND CALCIUM INFLUX AND EFFLUX IN INDIVIDUAL RESTING AND STIMULATED TUMOR MAST-CELLS USING ION MICROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; GOLGI-APPARATUS; CULTURED-CELLS; ENDOPLASMIC-RETICULUM; ELEMENTAL DISTRIBUTION; CONFOCAL MICROSCOPY; HISTAMINE-RELEASE; IMMUNOGLOBULIN-E; 2H3 CELLS; RAT-LIVER	Ion microscopy was employed to investigate intracellular total calcium concentrations and calcium influx, and efflux in resting and antigen-stimulated tumor mast cells (RBL-2H3 cells). The nucleus, a perinuclear region which included the Golgi apparatus (Golgi region), and the remaining cytoplasm were spatially resolved with the Cameca IMS-3f ion microscope in cryogenically prepared cells. In resting cells the nucleus contained about 0.60 mM, the Golgi region about 1.2 mM, and the remaining cytoplasm about 1.0 mM total calcium. Antigen stimulation of rat basophilic leukemia cells resulted in a significant loading of calcium in all three cellular compartments. Antigen stimulation in the absence of extracellular calcium resulted in a significant loss of total calcium from all three intracellular compartments. Influx and efflux of calcium were measured simultaneously in resting and stimulated cells by using stable Ca-44 in the extracellular solution, and by imaging mass 40 to determine the native intracellular calcium (Ca-40) and mass 44 to localize the Ca-44 that entered the cell from extracellular solution. After a 10-min incubation, 0.240 fmol of the total calcium per cell had been replaced with Ca-44, which amounts to about 33% of the total cell calcium. If antigen was present during this incubation there was an additional loss of 0.229 fmol of Ca-40 and an added gain of 0.476 fmol of Ca-44 per cell, which corresponds to a net increase in total intracellular calcium of 0.247 fmol.	CORNELL UNIV, DEPT PHARMACOL, ITHACA, NY 14853 USA; CORNELL UNIV, SCH APPL & ENGN PHYS, ITHACA, NY 14853 USA	Cornell University; Cornell University	CHANDRA, S (corresponding author), CORNELL UNIV, DEPT CHEM, BAKER LAB, ITHACA, NY 14853 USA.		Webb, Watt W./B-5905-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024314] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 24314] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSSERER WA, 1989, J MICROSC-OXFORD, V154, P39, DOI 10.1111/j.1365-2818.1989.tb00566.x; AUSSERER WA, 1989, ANAL CHEM, V61, P2690, DOI 10.1021/ac00199a002; BACHS O, 1987, J BIOL CHEM, V262, P10786; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BEAVEN MA, 1984, J BIOL CHEM, V259, P7137; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BERLIN RD, 1993, CELL CALCIUM, V14, P379, DOI 10.1016/0143-4160(93)90042-5; BLACKMORE PF, 1978, J BIOL CHEM, V253, P4851; Castaing R., 1962, J MICROSC PARIS, V1, P395; CHANDRA S, 1991, J CELL SCI, V100, P747; CHANDRA S, 1987, J MICROSC-OXFORD, V148, P223, DOI 10.1111/j.1365-2818.1987.tb02869.x; CHANDRA S, 1985, SCIENCE, V228, P1543, DOI 10.1126/science.2990033; CHANDRA S, 1986, J MICROSC-OXFORD, V144, P15, DOI 10.1111/j.1365-2818.1986.tb04670.x; CHANDRA S, 1992, J CELL SCI, V102, P417; CHANDRA S, 1988, METHOD ENZYMOL, V158, P157, DOI 10.1016/0076-6879(88)58054-0; CHANDRA S, 1992, BIOL CELL, V74, P31, DOI 10.1016/0248-4900(92)90006-M; DOUGLAS WW, 1975, CALCIUM TRANSPORT CO, P167; EISEN HN, 1959, J EXP MED, V110, P187, DOI 10.1084/jem.110.2.187; FEWTRELL C, 1989, CIBA F SYMP, V147, P114; FEWTRELL C, 1987, BIOCHEMISTRY-US, V26, P6995, DOI 10.1021/bi00396a021; FEWTRELL C, 1981, BIOCH ACUTE ALLERGIC, P295; GOMPERTS BD, 1983, NATURE, V306, P64, DOI 10.1038/306064a0; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HODSON S, 1978, J CELL SCI, V30, P117; HOLOWKA D, 1982, MOL IMMUNOL, V19, P219, DOI 10.1016/0161-5890(82)90334-0; KANNER BI, 1984, J BIOL CHEM, V26, P6995; LING YC, 1987, J CHEM INF COMP SCI, V27, P86, DOI 10.1021/ci00054a009; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; LIU FT, 1980, J IMMUNOL, V124, P2728; MANTUS DS, 1990, ANAL CHEM, V62, P1148, DOI 10.1021/ac00210a011; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; MCCORMACK JG, 1992, BIOCHEM SOC T, V20, P153, DOI 10.1042/bst0200153; MILLARD PJ, 1989, J BIOL CHEM, V264, P19730; MILLARD PJ, 1988, P NATL ACAD SCI USA, V85, P1854, DOI 10.1073/pnas.85.6.1854; MOHR FC, 1987, J CELL BIOL, V104, P783, DOI 10.1083/jcb.104.3.783; MOHR FC, 1990, AM J PHYSIOL, V258, pC217, DOI 10.1152/ajpcell.1990.258.2.C217; NARASIMHAN V, 1988, J BIOL CHEM, V263, P19626; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SCHIBECI A, 1980, EUR J BIOCHEM, V113, P5; SELDIN DC, 1985, P NATL ACAD SCI USA, V82, P3871, DOI 10.1073/pnas.82.11.3871; SNEDECOR GW, 1989, STATISTICAL METHODS, P255; SOMLYO AP, 1985, NATURE, V314, P622, DOI 10.1038/314622a0; TAUROG JD, 1979, J IMMUNOL, V122, P2150; WEST DW, 1981, BIOCHIM BIOPHYS ACTA, V673, P374, DOI 10.1016/0304-4165(81)90469-4; [No title captured]	51	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15186	15194						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195154				2022-12-27	WOS:A1994NP73800051
J	NGUYEN, HHT; SHIEMKE, AK; JACOBS, SJ; HALES, BJ; LIDSTROM, ME; CHAN, SI				NGUYEN, HHT; SHIEMKE, AK; JACOBS, SJ; HALES, BJ; LIDSTROM, ME; CHAN, SI			THE NATURE OF THE COPPER IONS IN THE MEMBRANES CONTAINING THE PARTICULATE METHANE MONOOXYGENASE FROM METHYLOCOCCUS-CAPSULATUS (BATH)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOSINUS-TRICHOSPORIUM OB3B; HYDROXYLASE COMPONENT; MONO-OXYGENASE; METHANOTROPHS; PURIFICATION; OXIDATION	It is shown that the particulate methane monooxygenase (pMMO) has an obligate requirement for copper. The MMO activity in the particulate fractions obtained from Methylococcus capsulatus (Bath) cells is found to increase with increasing copper content of the membranes. The enzyme activity from membranes obtained from cells grown at low copper levels can be stimulated further by the addition of Cu(II) ions to the assay medium. The membrane-bound copper ions can exist in both Cu(II) and Cu(I) forms. EPR and magnetic susceptibility characterizations of the membranes indicate the presence of an exchange-coupled trinuclear Cu(II) cluster when the bulk of the copper ions is oxidized. However, the functional form of the enzyme is the reduced or partially reduced form. The copper ions in the membrane fractions as isolated often exhibit a high level of reduction. An EPR spectrum with one unpaired electron spin delocalized over three copper nuclei has been observed for the two-electron reduced trinuclear copper cluster. The high correlation between the copper level in the membranes and enzymatic activity as well as the high reactivity of the reduced copper clusters toward dioxygen strongly indicate that the membrane-bound copper ions constitute the active sites of the pMMO.	CALTECH, ARTHUR AMOS NOYES LAB CHEM PHYS, PASADENA, CA 91125 USA; CALTECH, WM KECK ENVIRONM ENGN SCI LAB, PASADENA, CA 91125 USA; LOUISIANA STATE UNIV, DEPT CHEM, BATON ROUGE, LA 70803 USA	California Institute of Technology; California Institute of Technology; Louisiana State University System; Louisiana State University					NIGMS NIH HHS [GM 22432, GM 40859] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022432, R01GM022432, R01GM040859] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKENT'EVA N P, 1988, Biokhimiya, V53, P91; ALLENDORF MD, 1985, P NATL ACAD SCI USA, V82, P3063, DOI 10.1073/pnas.82.10.3063; ANTHONY C, 1982, BIOCH METHYLOTROPHS, P1; BEDARD C, 1989, MICROBIOL REV, V53, P68; BURROWS KJ, 1984, J GEN MICROBIOL, V130, P3327; Carlin R. L, 1986, MAGNETOCHEMISTRY, P1; Chan S.I., 1993, BIOINORGANIC CHEM CO, P184; CORNISH A, 1985, BIOTECHNOL LETT, V5, P319; Dalton H, 1984, MICROBIAL GROWTH C C, P1; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; DRUMMOND D, 1989, EUR J BIOCHEM, V182, P667; FOX BG, 1990, METHOD ENZYMOL, V188, P191; FROLAND WA, 1992, J BIOL CHEM, V267, P17588; GERLOCK M, 1983, MAGNETISM LIGAND FIE, P250; KOH SC, 1993, APPL ENVIRON MICROB, V59, P960, DOI 10.1128/AEM.59.4.960-967.1993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAK DJ, 1983, J GEN MICROBIOL, V129, P3487; LIDSTROM ME, 1988, A VAN LEEUW J MICROB, V54, P189, DOI 10.1007/BF00443577; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARATHE VR, 1974, CHEM PHYS LETT, V27, P103, DOI 10.1016/0009-2614(74)80454-9; MESSERSCHMIDT A, 1989, J MOL BIOL, V206, P13; MUHOBERAC BB, 1988, BIOCHEMISTRY-US, V27, P746, DOI 10.1021/bi00402a038; Murrell J. C., 1993, P109; NAKAJIMA T, 1992, BIOSCI BIOTECH BIOCH, V56, P736, DOI 10.1271/bbb.56.736; ORBACH R, 1961, PROC R SOC LON SER-A, V264, P458, DOI 10.1098/rspa.1961.0211; PRIOR SD, 1985, J GEN MICROBIOL, V131, P155; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; STAINTHORPE AC, 1990, GENE, V91, P27, DOI 10.1016/0378-1119(90)90158-N; STAINTHORPE AC, 1991, FEMS MICROBIOL LETT, V70, P211; TONGE GM, 1977, BIOCHEM J, V161, P333, DOI 10.1042/bj1610333; Van Vleck J. H., 1932, THEORY ELECTRIC MAGN, P89; VERMAAS A, 1974, CHEM PHYS LETT, V27, P583, DOI 10.1016/0009-2614(74)80310-6; WHITTENBURY R, 1981, PROKARYOTES, V1, P894	33	173	173	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14995	15005						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195135				2022-12-27	WOS:A1994NP73800026
J	SHIMOMURA, Y; MURAKAMI, T; FUJITSUKA, N; NAKAI, N; SATO, Y; SUGIYAMA, S; SHIMOMURA, N; IRWIN, J; HAWES, JW; HARRIS, RA				SHIMOMURA, Y; MURAKAMI, T; FUJITSUKA, N; NAKAI, N; SATO, Y; SUGIYAMA, S; SHIMOMURA, N; IRWIN, J; HAWES, JW; HARRIS, RA			PURIFICATION AND PARTIAL CHARACTERIZATION OF 3-HYDROXYISOBUTYRYL-COENZYME-A HYDROLASE OF RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLMALONATE-SEMIALDEHYDE DEHYDROGENASE; VALINE METABOLISM; ACID; HINDQUARTER	An unusual feature of valine catabolism is a reaction in which an intermediate of its catabolic pathway, (S)- 3-hydroxyisobutyryl-CoA, is hydrolyzed to give the free acid and CoA-SH. The enzyme responsible for this reaction, 3-hydroxyisobutyryl-CoA hydrolase (EC 3.1.2.4), was purified 7200-fold from rat liver in this study. The purified enzyme consists of a single polypeptide with an M(r) of 36,000 in the native and denatured forms. The hydrolase is highly specific for (S)-3-hydroxyisobutyryl-CoA and 3 hydroxypropionyl-CoA (K-m, 6 and 25 mu M, respectively) with optimal activity around pH 8. The turnover rate of the enzyme for (S)-3-hydroxyisobutyryl-CoA is 270 s(-1), which is high relative to other enzymes of the valine pathway. Likewise, activity of the enzyme expressed on a wet weight basis is also very high in the major tissues of the rat. These findings suggest that rapid destruction of (S)-3-hydroxyisobutyryl-CoA produced during valine catabolism is physiologically important. We propose that the need for a mechanism to protect cells against the toxic effects of methacrylyl-CoA which is maintained in equilibrium with (S)-3-hydroxyisobutyryl-CoA by crotonase, explains why valine catabolism involves this enzyme and why its tissue activity is so high.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	SHIMOMURA, Y (corresponding author), NAGOYA INST TECHNOL, DEPT BIOSCI, SHOWA KU, GOKISO CHO, NAGOYA, AICHI 466, JAPAN.			Murakami, Taro/0000-0002-5367-2658	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040441] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40441] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABELES RH, 1992, BIOCHEMISTRY-US, P52; BROWN GK, 1982, PEDIATRICS, V70, P532; CORKEY BE, 1982, J BIOL CHEM, V257, P9668; DEARFIELD KL, 1991, MUTAGENESIS, V6, P519, DOI 10.1093/mutage/6.6.519; DIXON M, 1979, ENZYMES, P350; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GOODWIN GW, 1989, J BIOL CHEM, V264, P14965; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; KEDISHVILI NY, 1992, J BIOL CHEM, V267, P19724; KOVACHY RJ, 1983, J BIOL CHEM, V258, P1415; KOVACHY RJ, 1988, METHOD ENZYMOL, V166, P393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDAAS S, 1975, CLIN CHIM ACTA, V64, P143, DOI 10.1016/0009-8981(75)90196-5; LAU EP, 1977, BIOCHEMISTRY-US, V16, P2581, DOI 10.1021/bi00631a001; LEE SHC, 1986, BIOCHEM J, V233, P621, DOI 10.1042/bj2330621; LETTO J, 1986, BIOCHEM J, V240, P909, DOI 10.1042/bj2400909; RENDINA G, 1957, J BIOL CHEM, V225, P523; ROUGRAFF PM, 1988, J BIOL CHEM, V263, P327; ROUGRAFF PM, 1990, ANAL BIOCHEM, V184, P317, DOI 10.1016/0003-2697(90)90687-5; SHIMOMURA Y, 1987, ANAL BIOCHEM, V163, P74, DOI 10.1016/0003-2697(87)90094-7; SINGH AR, 1972, J DENT RES, V51, P1632, DOI 10.1177/00220345720510062201; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPEIR TW, 1971, BIOCHEM J, V125, P267, DOI 10.1042/bj1250267; SPYDEVOLD O, 1979, EUR J BIOCHEM, V97, P389, DOI 10.1111/j.1432-1033.1979.tb13125.x; STERN JR, 1956, J BIOL CHEM, V218, P971; STERN JR, 1956, J BIOL CHEM, V218, P985; WAGENMAKERS AJM, 1985, INT J BIOCHEM, V17, P957, DOI 10.1016/0020-711X(85)90240-X; WIELAND T, 1953, ANGEW CHEM-GER EDIT, V65, P186, DOI 10.1002/ange.19530650706; ZHANG B, 1987, BIOCHEM J, V246, P625, DOI 10.1042/bj2460625; 1986, NIH872570 US PHS PUB	30	50	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14248	14253						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188708				2022-12-27	WOS:A1994NL60600079
J	ALBLAS, J; VANCORVEN, EJ; HORDIJK, PL; MILLIGAN, G; MOOLENAAR, WH				ALBLAS, J; VANCORVEN, EJ; HORDIJK, PL; MILLIGAN, G; MOOLENAAR, WH			G(I)-MEDIATED ACTIVATION OF THE P21(RAS)-MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY BY ALPHA(2)-ADRENERGIC RECEPTORS EXPRESSED IN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALPHA-2-ADRENERGIC RECEPTOR; RAT-1 FIBROBLASTS; LYSOPHOSPHATIDIC-ACID; ADRENERGIC-RECEPTORS; CELL-PROLIFERATION; PHOSPHOLIPASE-D; STIMULATION; P21RAS; GENE; RAS	The alpha2-adrenergic receptors are linked to inhibition of adenylylcyclase and, under certain circumstances, to stimulation of phospholipid hydrolysis via pertussis toxin-sensitive G proteins. Here we show that alpha2-adrenergic receptors can couple to an alternative signaling pathway. When expressed in Rat-1 cells, stimulation of the alpha2A receptor, which couples to G(i2) and G(i3), causes rapid, transient activation of the protooncogene product p21ras as measured by an increase in the amount of bound GTP. Furthermore, alpha2A receptor stimulation causes rapid phosphorylation of the p42 mitogen-activated protein (MAP) kinase. Pertussis toxin completely inhibits both p21ras activation and MAP kinase phosphorylation, but both responses appear to be independent of adenylylcyclase inhibition or phospholipase stimulation. Thus, alpha2-adrenergic receptors can couple to the p21ras-MAP kinase pathway via G(i), which may explain the mitogenic potential of alpha2 agonists in certain cell types; together with previous results, these findings further suggest that activation of this pivotal signaling pathway may be a common event in the action of G(i)-coupled receptors.	NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS; UNIV GLASGOW,DEPT BIOCHEM,GLASGOW G12 8QQ,SCOTLAND	Netherlands Cancer Institute; University of Glasgow			Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519; Alblas, Jacqueline/0000-0002-2996-9697; Hordijk, Peter/0000-0002-3348-078X				BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BYLUND DB, 1988, TRENDS PHARMACOL SCI, V9, P356, DOI 10.1016/0165-6147(88)90254-4; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; KENNEDY MFG, 1983, CLIN EXP PHARMACOL P, V10, P577, DOI 10.1111/j.1440-1681.1983.tb00226.x; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIMBIRD LE, 1988, ALPHA 2 ADRENERGIC R; LOMASNEY JW, 1991, BIOCHIM BIOPHYS ACTA, V1095, P127, DOI 10.1016/0167-4889(91)90075-9; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; MCCLUE SJ, 1992, BIOCHEM J, V284, P565, DOI 10.1042/bj2840565; MICHEL MC, 1989, J BIOL CHEM, V264, P4986; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PLEVIN R, 1991, BIOCHEM J, V280, P609, DOI 10.1042/bj2800609; ROMAURY A, 1993, BIOCHEM J, V292, P283; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEUWEN K, 1990, CELL REGUL, V1, P445, DOI 10.1091/mbc.1.6.445; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SURPRENANT A, 1992, SCIENCE, V257, P977, DOI 10.1126/science.1354394; THOMAS G, 1992, CELL, V68, P1; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TUTTON PJM, 1987, ANTICANCER RES, V7, P1; ULLRICH S, 1988, J BIOL CHEM, V263, P8615; VALET P, 1993, J CLIN INVEST, V91, P2049, DOI 10.1172/JCI116427; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	34	218	221	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22235	22238						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226727				2022-12-27	WOS:A1993MD34800006
J	MENDOZAALVAREZ, H; ALVAREZGONZALEZ, R				MENDOZAALVAREZ, H; ALVAREZGONZALEZ, R			POLY(ADP-RIBOSE) POLYMERASE IS A CATALYTIC DIMER AND THE AUTOMODIFICATION REACTION IS INTERMOLECULAR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION; REACTION-MECHANISM; CDNA SEQUENCE; PROTEIN; SYNTHETASE; CHROMATIN; HISTONES; CELLS; ELONGATION; ACCEPTOR	We have determined the molecular mechanism of the automodification reaction of poly(ADP-ribose) polymerase (PARP) (EC 2.4.2.30). While PARP-mono(ADP-ribose) conjugates were the predominant products of automodification at 200 nM NAD, enzyme-bound branched polymers were preferentially synthesized at 200 muM NAD. Thus, the initiation, elongation, and branching reactions catalyzed by PARP appear to be [NAD]-dependent. Initial rates of automodification increased with second order kinetics as a function of [PARP] at both 200 nM and 200 muM NAD. Therefore, 2 molecules of PARP, i.e. a catalytic dimer, are required for the auto-mono(ADP-ribosyl)ation and the auto-poly(ADP-ribosyl)ation reactions. Initial rates of automodification also increased with second order kinetics at low NAD concentrations. Therefore, the catalytic dimer also requires 2 molecules of NAD. These results are consistent with the conclusion that the automodification reaction of PARP is intermolecular and that the 2 monomeric units of PARP may simultaneously function as catalyst and acceptor molecules in the automodification reaction. Confirmatory evidence for the catalytic role of protein-protein interactions in the automodification reaction was manifested by a marked inhibition of auto-poly(ADP-ribosyl)ation at 40 nM or higher [PARP].			MENDOZAALVAREZ, H (corresponding author), UNIV N TEXAS,TEXAS COLL OSTEOPATH MED,DEPT MICROBIOL & IMMUNOL,FT WORTH,TX 76107, USA.		Gonzalez, Rafael Alvarez/I-4560-2019	Alvarez-Gonzalez, Rafael/0000-0003-1038-7512				ADAMIETZ P, 1987, EUR J BIOCHEM, V169, P365, DOI 10.1111/j.1432-1033.1987.tb13621.x; ALVAREZGONZALEZ R, 1988, J BIOL CHEM, V263, P17690; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; ALVAREZGONZALEZ R, 1983, ANAL BIOCHEM, V135, P69, DOI 10.1016/0003-2697(83)90732-7; ALVAREZGONZALEZ R, 1993, FASEB J, V7, pA1094; BAUER PI, 1986, FEBS LETT, V195, P331, DOI 10.1016/0014-5793(86)80188-0; BAUER PI, 1990, BIOCHEM J, V270, P17, DOI 10.1042/bj2700017; BOULIKAS T, 1988, EMBO J, V7, P57, DOI 10.1002/j.1460-2075.1988.tb02783.x; BOULIKAS T, 1990, J BIOL CHEM, V265, P14638; BUTT TR, 1980, BIOCHEMISTRY-US, V19, P5235, DOI 10.1021/bi00564a013; BUTT TR, 1980, BIOCHEMISTRY-US, V19, P5243, DOI 10.1021/bi00564a014; CAPLAN AI, 1979, ARCH BIOCHEM BIOPHYS, V198, P60, DOI 10.1016/0003-9861(79)90395-3; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; DEMURCIA G, 1988, BIOCHEM CELL BIOL, V66, P626, DOI 10.1139/o88-072; DESMARAIS Y, 1991, BIOCHIM BIOPHYS ACTA, V1078, P179, DOI 10.1016/0167-4838(91)99007-F; FERRO AM, 1983, J BIOL CHEM, V258, P6000; HOLTLUND J, 1983, EUR J BIOCHEM, V130, P309, DOI 10.1111/j.1432-1033.1983.tb07153.x; HULETSKY A, 1985, EUR J BIOCHEM, V146, P277, DOI 10.1111/j.1432-1033.1985.tb08650.x; IKEJIMA M, 1987, J BIOL CHEM, V262, P17641; JUMP DB, 1980, BIOCHEMISTRY-US, V19, P1024, DOI 10.1021/bi00546a030; KAMESHITA I, 1986, J BIOL CHEM, V261, P3863; KAWAICHI M, 1981, J BIOL CHEM, V256, P9483; KIEHLBAUCH CC, 1993, ANAL BIOCHEM, V208, P26, DOI 10.1006/abio.1993.1004; KUROSAKI T, 1987, J BIOL CHEM, V262, P15990; LOETSCHER P, 1987, P NATL ACAD SCI USA, V84, P1286, DOI 10.1073/pnas.84.5.1286; MARTINEZ M, 1991, BIOCHEM BIOPH RES CO, V181, P1412, DOI 10.1016/0006-291X(91)92096-3; NAEGELI H, 1989, J BIOL CHEM, V264, P14382; OGATA N, 1980, BIOCHEM INT, V1, P229; PAINE A J, 1980, Biochemical Society Transactions, V8, P183; TANIGUCHI T, 1987, BIOCHEM BIOPH RES CO, V147, P1008, DOI 10.1016/S0006-291X(87)80170-5; UCHIDA K, 1987, BIOCHEM BIOPH RES CO, V148, P617, DOI 10.1016/0006-291X(87)90921-1; UCHIDA K, 1992, OJI INT SEMINAR ADP; YOSHIHARA K, 1977, BIOCHEM BIOPH RES CO, V78, P1281, DOI 10.1016/0006-291X(77)91431-0; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4; ZAHRADKA P, 1984, EUR J BIOCHEM, V142, P503, DOI 10.1111/j.1432-1033.1984.tb08314.x; ZAHRADKA P, 1982, EUR J BIOCHEM, V127, P579	36	192	201	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22575	22580						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226768				2022-12-27	WOS:A1993MD34800060
J	MORICE, WG; WIEDERRECHT, G; BRUNN, GJ; SIEKIERKA, JJ; ABRAHAM, RT				MORICE, WG; WIEDERRECHT, G; BRUNN, GJ; SIEKIERKA, JJ; ABRAHAM, RT			RAPAMYCIN INHIBITION OF INTERLEUKIN-2-DEPENDENT P33CDK2 AND P34CDC2 KINASE ACTIVATION IN T-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CELL-CYCLE; CDC2 PROTEIN-KINASE; P70 S6 KINASE; CYCLOSPORINE-A; IMMUNOSUPPRESSANT RAPAMYCIN; SIGNAL TRANSDUCTION; POSITIVE FEEDBACK; GENE-EXPRESSION; G1 CYCLINS; PHOSPHORYLATION	The immunosuppressant rapamycin (RAP) is a potent inhibitor of the entry of interleukin (IL)-2-stimulated T cells into S-phase. Earlier results indicated that RAP treatment arrested the growth of the murine IL-2-dependent T cell line CTLL-2 in late G1-phase. To explore further the interactions of RAP with the cell cycle control machinery in T cells, we examined the effects of RAP treatment on the activation of the cyclin-dependent kinases p34cdc2 and p33cdk2 in G1-phase CTLL-2 cells. Stimulation of factor-deprived cells with IL-2 led to the assembly of high molecular weight complexes containing active p34cdc2 and p33cdk2. The appearance of these complexes was explained, at least in part, by the association of both cyclin-dependent kinases with IL-2-induced cyclin A. RAP treatment profoundly inhibited both cyclin A expression and the appearance of active cyclin A-cyclin-dependent kinase complexes in IL-2-stimulated, late G1-phase CTLL-2 cells. Although p34cdc2 activation was largely dependent on association with cyclin A, a significant proportion of the active p33cdk2 pool was complexed with cyclin E. In contrast to cyclin A, the IL-2-induced accumulation of cyclin E in G1-phase cells was only partially suppressed by RAP, and cyclin E-p33cdk2 complexes were readily detected in drug-treated cells. These cyclin E-cyclin-dependent kinase complexes were nonetheless devoid of histone H1 kinase activity. The inhibitory effects of RAP on the activation of cyclin E- and cyclin A-associated cyclin-dependent kinases suggest that one or both events participate in the regulation of T cell entry into S-phase.	MAYO CLIN & MAYO FDN,DEPT IMMUNOL,RM 342B,GUGGENHEIM BLDG,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905; MERCK SHARP & DOHME LTD,DEPT IMMUNOL RES,RAHWAY,NJ 07065; IMMUNOBIOL RES INST,DEPT MOLEC IMMUNOL,ANNANDALE,NJ 08801	Mayo Clinic; Mayo Clinic; Merck & Company								ABRAHAM RT, 1986, J TISSUE CULTURE MET, V10, P93; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CROSS F, 1991, CELL, V66, P1217; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HEITMAN J, 1992, NEW BIOL, V4, P448; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Kirschner M W, 1992, Important Adv Oncol, P3; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MORICE WG, 1993, J BIOL CHEM, V268, P3734; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1992, Current Opinion in Cell Biology, V4, P144, DOI 10.1016/0955-0674(92)90024-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RUEGEMER JJ, 1990, J IMMUNOL, V144, P1767; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SIGAL NH, 1991, TRANSPLANT P, V23, P1; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WILKINSON M, 1991, NUCLEIC ACIDS RES, V19, P679, DOI 10.1093/nar/19.3.679	52	140	142	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22737	22745						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226784				2022-12-27	WOS:A1993MD34800081
J	ZLOTNICK, A; MITCHELL, RS; STEED, RK; BRENNER, SL				ZLOTNICK, A; MITCHELL, RS; STEED, RK; BRENNER, SL			ANALYSIS OF 2 DISTINCT SINGLE-STRANDED-DNA BINDING-SITES ON THE RECA NUCLEOPROTEIN FILAMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENETIC-RECOMBINATION; HELICAL FILAMENTS; DUPLEX DNA; PROTEIN; COMPLEXES; EXCHANGE; POLYNUCLEOTIDE; VISUALIZATION; MECHANISM	The binding stoichiometry of Escherichia coli recA protein to single-stranded DNA (ssDNA) determined by two separate assays differs by a factor of 2.2-2.4. Using the fluorescence of etheno-DNA (epsilonDNA), a chemically modified ssDNA, the stoichiometry was found to be 7.0 +/- 0.6 bases/recA protein monomer in a nucleoprotein filament. Using a competition assay, a similar stoichiometry, 7.5 bases/recA, is found for unmodified poly(dT). Using the DNA-dependent ATPase of recA, which monitors bound protein rather than bound DNA, we find that each recA monomer needs to bind only 3.1 +/- 0.5 bases to fully activate the ATPase. The difference in site size determined by the two assays indicates that there are two DNA binding sites with differential effects on ATPase activation. When recA protein is mixed with ssDNA at a ratio of 7 bases/recA or greater, the complex that forms contains 7 bases/recA and acts as a kinetic trap for the ssDNA. Upon further addition of recA protein, no additional ATPase activity is observed. If, on the other hand, the ssDNA is initially mixed with excess recA (at a ratio of 3-3.5 bases/recA or less) the ATPase activity is twice as high. Analysis of the binding curves suggests that the first DNA strand binds recA to form a filament with a stoichiometry of 3-3.5 bases/protein monomer. The ATPase activity of recA is completely active in this complex. A second strand of DNA can then be bound to this filament yielding a final stoichiometry of -7 bases/protein monomer. The presence of this second strand neither enhances nor inhibits ATP hydrolysis. This ternary complex may mimic the structures formed by recA in searching for homologous DNA sequences and/or in the strand exchange reaction.	DUPONT MERCK PHARMACEUT CO,EXPTL STN,WILMINGTON,DE 19880	DuPont				Zlotnick, Adam/0000-0001-9945-6267				BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BRENNER SL, 1987, J BIOL CHEM, V262, P4011; BRYANT FR, 1985, J BIOL CHEM, V260, P1196; BUJOLOWSKI W, 1987, BIOCHEMISTRY-US, V26, P3099; CHOW SA, 1986, J BIOL CHEM, V261, P6961; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DICAPUA E, 1982, J MOL BIOL, V157, P83; DOMBROSKI DF, 1983, NUCLEIC ACIDS RES, V11, P7487, DOI 10.1093/nar/11.21.7487; EGELMAN EH, 1989, SCIENCE, V245, P404, DOI 10.1126/science.2667137; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; GRIFFITH JD, 1988, CRC CR REV BIOCH MOL, V23, pS43, DOI 10.3109/10409238809083375; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LAUDER SD, 1991, J BIOL CHEM, V266, P5450; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MENETSKI JP, 1989, BIOCHEMISTRY-US, V28, P5871, DOI 10.1021/bi00440a025; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1987, J BIOL CHEM, V262, P2085; MITCHELL RS, 1988, BIOPHYS J, V53, pS220; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; MULLER B, 1990, J MOL BIOL, V212, P97, DOI 10.1016/0022-2836(90)90307-8; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; PUGH BF, 1987, J BIOL CHEM, V262, P1326; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; REGISTER JC, 1987, J BIOL CHEM, V262, P12812; REGISTER JC, 1988, J BIOL CHEM, V263, P11029; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; TSO PO, 1966, BIOCHEMISTRY-US, V5, P4153, DOI 10.1021/bi00876a052; ZLOTNICK A, 1990, J BIOL CHEM, V265, P17050	33	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22525	22530						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226762				2022-12-27	WOS:A1993MD34800053
J	ALMENOFF, JS; JURKA, J; SCHOOLNIK, GK				ALMENOFF, JS; JURKA, J; SCHOOLNIK, GK			INDUCTION OF HEAT-STABLE ENTEROTOXIN RECEPTOR ACTIVITY BY A HUMAN ALU REPEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTORS; ESCHERICHIA-COLI; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; GUANYLYL CYCLASE; SURFACE ANTIGEN; GENE; SEQUENCES; RNA; RAT	The heat-stable enterotoxins (ST) elaborated by enterotoxigenic Escherichia coli are a family of small cysteine-rich peptides that bind to specific epithelial receptors in the mammalian intestine, causing a secretory diarrhea. The expression of ST receptors is tightly regulated; they are found primarily in intestine, and their expression is developmentally modulated. One receptor for ST has been cloned, and its cDNA encodes a similar to 120-kDa particulate guanylyl cyclase (guanylyl cyclase-C). Recent studies suggest that there are additional ST receptors that are not homologous to guanylyl cyclase-C. We used an expression cloning strategy to identify intestinal mRNAs that lead to expression of ST receptor activity in transfected cells. Using an ST-specific affinity panning system, we identified a novel 1891-base pair cDNA that does not encode a receptor protein, but instead, consists primarily of untranslated sequence. This cDNA induced receptor activity in both COS and 293 embryonic kidney cells. Northern analysis of the T84 human intestinal cell line, from which this cDNA was cloned, suggests that it is part of a 7.8 kilobase mRNA transcript. This transcript was also identified in human small intestine and colon, as well. as in several extraintestinal tissues. Functional analysis of subcloned fragments reveals that ST binding activity is induced by a 457-base pair human Alu repetitive sequence within the cDNA and that the phenoytpe is independent of orientation. These findings suggest that a human Alu element induces expression of a unique ST receptor by a transacting mechanism. An unrelated Alu-rich genomic clone did not confer ST binding, suggesting that there may be structural and functional specificity within individual Alu sequences.	STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,STANFORD,CA 94305; LINUS PAULING INST SCI & MED,PALO ALTO,CA 94304	Howard Hughes Medical Institute; Stanford University								ADENIYIJONES S, 1985, NATURE, V317, P81, DOI 10.1038/317081a0; ALMENOFF JS, 1993, MOL MICROBIOL, V8, P865, DOI 10.1111/j.1365-2958.1993.tb01633.x; ARMITAGE RJ, 1992, BLOOD, V79, P1738; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BRINI AT, 1993, J BIOL CHEM, V268, P1355; CHAMBERLAIN JW, 1986, NUCLEIC ACIDS RES, V14, P3409, DOI 10.1093/nar/14.8.3409; CHANG DY, 1993, J BIOL CHEM, V268, P6423; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; COHEN MB, 1992, BIOCHEM BIOPH RES CO, V186, P483, DOI 10.1016/S0006-291X(05)80833-2; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DESAUVAGE FJ, 1992, P NATL ACAD SCI USA, V89, P9089, DOI 10.1073/pnas.89.19.9089; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; DESAUVAGE FJ, 1992, J BIOL CHEM, V267, P6479; FORTE LR, 1993, J CLIN INVEST, V91, P2423, DOI 10.1172/JCI116476; FRANTZ JC, 1984, INFECT IMMUN, V43, P622, DOI 10.1128/IAI.43.2.622-630.1984; FULLER F, 1988, J BIOL CHEM, V263, P9395; GARRET M, 1992, GENE, V111, P215, DOI 10.1016/0378-1119(92)90689-M; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HIRAYAMA T, 1992, INFECT IMMUN, V60, P4213, DOI 10.1128/IAI.60.10.4213-4220.1992; HOWARD B H, 1990, New Biologist, V2, P759; HUGUES M, 1992, BIOCHEMISTRY-US, V31, P12, DOI 10.1021/bi00116a003; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KOGA Y, 1988, P NATL ACAD SCI USA, V85, P4521, DOI 10.1073/pnas.85.12.4521; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANEY DW, 1992, AM J PHYSIOL, V263, pG816, DOI 10.1152/ajpgi.1992.263.5.G816; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; MANN EA, 1993, AM J PHYSIOL, V264, pG172, DOI 10.1152/ajpgi.1993.264.1.G172; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; SAKAMOTO K, 1991, J BIOL CHEM, V266, P3031; Schlager T A, 1988, Infect Dis Clin North Am, V2, P607; SCHMID CW, 1990, CHROMOSOMES EUKARYOT, P3; SCHULZ S, 1992, J BIOL CHEM, V267, P16019; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; STANNERS CP, 1981, CELL, V27, P211, DOI 10.1016/0092-8674(81)90375-5; STRUB K, 1990, MOL CELL BIOL, V10, P777, DOI 10.1128/MCB.10.2.777; THOMPSON MR, 1985, ANAL BIOCHEM, V148, P26, DOI 10.1016/0003-2697(85)90623-2; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; VIDAL F, 1993, P NATL ACAD SCI USA, V90, P208, DOI 10.1073/pnas.90.1.208; WICKENS M, 1994, NATURE, V367, P17, DOI 10.1038/367017a0; WU J, 1990, MOL CELL BIOL, V10, P1209, DOI 10.1128/MCB.10.3.1209	46	21	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16610	16617						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206979				2022-12-27	WOS:A1994NR29600017
J	BLANER, WS; OBUNIKE, JC; KURLANDSKY, SB; ALHAIDERI, M; PIANTEDOSI, R; DECKELBAUM, RJ; GOLDBERG, IJ				BLANER, WS; OBUNIKE, JC; KURLANDSKY, SB; ALHAIDERI, M; PIANTEDOSI, R; DECKELBAUM, RJ; GOLDBERG, IJ			LIPOPROTEIN-LIPASE HYDROLYSIS OF RETINYL ESTER - POSSIBLE IMPLICATIONS FOR RETINOID UPTAKE BY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; PROTEIN MESSENGER-RNA; BINDING PROTEIN; RAT-LIVER; STELLATE CELLS; ACID-BINDING; VITAMIN-A; DIFFERENTIATION; TRIGLYCERIDE	Adipose tissue contains substantial stores of retinoid (retinol + retinyl ester) that, quantitatively, are second only to retinoid stores in the liver. Our studies show that retinoid levels in adipose tissue are markedly influenced by dietary retinoid intake. Because lipoprotein lipase (LPL) increases the uptake of lipoproteins and lipid emulsion particles by many cell types including adipocytes, we investigated whether LPL also increases retinoid uptake by adipocytes from lipid-containing particles. Addition of LPL (10 mu g/ml) to BFC-1 beta adipocytes produced a a fold increase in cellular uptake of [H-3]retinoid from a lipid emulsion containing [H-3]retinyl ester. Heparin, which displaces LPL from binding sites on cell surface proteoglycans, increased [H-3]retinoid uptake by an additional a fold. High performance liquid chromatography analyses showed that greater than 75% of the media and 85% of the cellular radioactivity was present as retinol. The conversion of retinyl ester to retinol by LPL was then assessed using model retinyl ester containing lipid emulsions. Although triglyceride appears to be the preferred substrate for LPL, after greater than 25% of the triglyceride was hydrolyzed, significant amounts of retinyl ester were hydrolyzed by LPL. Retinyl ester hydrolysis was increased approximately 20-fold in the presence of a source of apolipoprotein C-II. The physiologically significant palmitate, stearate, oleate, and linoleate esters of retinol were all hydrolyzed by LPL. When LPL was incubated with [H-3]retinyl ester containing rabbit mesenteric chylomicrons and in the presence of heparin and apolipoprotein C-II, the LPL was able to completely hydrolyze the retinyl ester to retinol. Thus, LPL is able to catalyze the hydrolysis of retinyl esters and, through the process of hydrolysis, may facilitate uptake of retinoid by adipocytes.	COLUMBIA UNIV,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT PEDIAT,NEW YORK,NY 10032	Columbia University; Columbia University	BLANER, WS (corresponding author), COLUMBIA UNIV,INST HUMAN NUTR,630 W 168TH ST,NEW YORK,NY 10032, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043097, R01DK047389] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21006] Funding Source: Medline; NIDDK NIH HHS [DK47389, DK43097] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1991, P NATL ACAD SCI USA, V88, P6008, DOI 10.1073/pnas.88.14.6008; BLACKBERG L, 1980, FEBS LETT, V112, P51, DOI 10.1016/0014-5793(80)80125-6; Blaner William S., 1994, P229; BLANER WS, 1989, ENDOCR REV, V10, P308, DOI 10.1210/edrv-10-3-308; BLANER WS, 1987, J BIOL CHEM, V262, P53; BLANER WS, 1985, J NUTR, V115, P856, DOI 10.1093/jn/115.7.856; BLANER WS, 1986, J LIPID RES, V27, P1084; BLANER WS, 1990, METHOD ENZYMOL, V189, P193; BLANER WS, 1987, EUR J BIOCHEM, V164, P301, DOI 10.1111/j.1432-1033.1987.tb11058.x; BLANER WS, 1985, J LIPID RES, V26, P1241; BLOMHOFF R, 1982, P NATL ACAD SCI USA, V79, P7926; BOSNER MS, 1988, P NATL ACAD SCI USA, V85, P7438, DOI 10.1073/pnas.85.20.7438; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; DE LUCA LM, 1991, FASEB J, V5, P2924; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; EISENBERG S, 1992, J CLIN INVEST, V90, P1504; FOREST C, 1987, EXP CELL RES, V168, P218, DOI 10.1016/0014-4827(87)90430-7; FOREST C, 1987, EXP CELL RES, V168, P233, DOI 10.1016/0014-4827(87)90431-9; GOLDBERG IJ, 1986, ARCH BIOCHEM BIOPHYS, V244, P580, DOI 10.1016/0003-9861(86)90626-0; GOLDBERG IJ, 1986, BIOCHIM BIOPHYS ACTA, V878, P168, DOI 10.1016/0005-2760(86)90143-8; GOLDBERG IJ, 1988, BIOCHIM BIOPHYS ACTA, V959, P220, DOI 10.1016/0005-2760(88)90194-4; GOODMAN DS, 1965, J LIPID RES, V6, P390; GOODMAN DS, 1984, RETINOIDS, V2, P1; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; KATO M, 1985, J BIOL CHEM, V260, P4832; KHOO JC, 1981, J BIOL CHEM, V256, P7105; MAKOVER A, 1989, J LIPID RES, V30, P171; MILLER M, 1993, ARTERIOSCLER THROMB, V13, P385, DOI 10.1161/01.ATV.13.3.385; MORIWAKI H, 1988, J LIPID RES, V29, P1523; MULDER M, 1993, J BIOL CHEM, V268, P9369; NYKAER A, 1993, J BIOL CHEM, V268, P15048; PATSCH JR, 1992, ARTERIOSCLER THROMB, V12, P1336, DOI 10.1161/01.ATV.12.11.1336; QUARFORDT SH, 1967, J LIPID RES, V8, P264; RAJAN N, 1990, J LIPID RES, V31, P821; ROBERTS AB, 1984, RETINOIDS, V2, P209; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SOCORRO L, 1985, PREP BIOCHEM, V15, P133, DOI 10.1080/10826068508062267; Soprano Dianne Robert, 1994, P257; STEIN O, 1983, BIOCHIM BIOPHYS ACTA, V750, P306, DOI 10.1016/0005-2760(83)90033-4; TRABER MG, 1990, GASTROENTEROLOGY, V98, P96, DOI 10.1016/0016-5085(90)91296-I; TRABER MG, 1985, J CLIN INVEST, V75, P1729, DOI 10.1172/JCI111883; TSUTSUMI C, 1992, J BIOL CHEM, V267, P1805; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; ZOVICH DC, 1992, J BIOL CHEM, V267, P13884	45	102	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16559	16565						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206972				2022-12-27	WOS:A1994NR29600009
J	HANEY, SA; BROACH, JR				HANEY, SA; BROACH, JR			CDC25P, THE GUANINE-NUCLEOTIDE EXCHANGE FACTOR FOR THE RAS PROTEINS OF SACCHAROMYCES-CEREVISIAE, PROMOTES EXCHANGE BY STABILIZING RAS IN A NUCLEOTIDE-FREE STATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GENE-PRODUCT; MOLECULAR MECHANISM; ESCHERICHIA-COLI; CYCLASE PATHWAY; BINDING; MUTANTS; DOMAIN; YEAST; GAP	In Saccharomyces cerevisiae, adenylate cyclase activity is controlled by Ras1p and Ras2p. Activation of the Pas proteins is in turn controlled by the GTPase-activating proteins (GAPs), Ira1p and Ira2p, and the guanine nucleotide exchange factor (GNEF), Cdc25p. We have characterized Cdc25p enzymologically in order to gain information about the mechanism of Cdc25p-mediated guanine nucleotide exchange and to appreciate how the activity of a GNEF is integrated as a part of a basic molecular switch module consisting of Ras, GNEF, and GAP. Using Ras2p and a catalytic fragment of Cdc25p, both expressed in and purified from Escherichia coli, we determined that Cdc25p has a K-m for Ras2p.GDP of 160 nM and a maximal rate of 0.20 s(-1). The K-m of Cdc25p for Ras2p complexed to GTP is 3-fold greater than that for Ras2p complexed to GDP. The K-m of free GDP is about 2-fold higher than the K-m of free GTP. This suggests that Cdc25p activates Ras2p primarily by equilibrating Ras2p with the pool of free guanine nucleotides in the cell rather than by driving Ras2p inexorably into the activated state. This renders Ras activation potentially subject to energy charge fluctuations in the cell. The free guanine nucleotide affects K-cat, indicating that the rate-limiting step is nucleotide association. Finally, we demonstrated that dominant negative alleles of Ras2p are potent competitive inhibitors of Cdc25p. These data, in conjunction with the kinetic data, are consistent with the hypothesis that Cdc25p catalyzes guanine nucleotide exchange by stabilizing a nucleotide-free intermediate of Ras.	PRINCETON UNIV,LEWIS THOMAS LAB,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University				Broach, James/0000-0003-1197-0312				BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CRECHET JB, 1990, J BIOL CHEM, V265, P1563; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DE S, 1990, BIOCHEM PHARMACOL, V39, P1399; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERMI G, 1992, J MOL BIOL, V226, P883, DOI 10.1016/0022-2836(92)90638-Z; FERSHT AR, 1984, ENZYME STRUCTURE MEC, P102; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HEIDBUCHEL H, 1990, PFLUG ARCH EUR J PHY, V416, P213, DOI 10.1007/BF00370246; HUCUL JA, 1985, J BIOL CHEM, V260, P5585; HWANG YW, 1985, J BIOL CHEM, V260, P1498; HWANG YW, 1993, J BIOL CHEM, V268, P24692; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LEATHERBAARROW RJ, 1992, GRAFIT VERSION 3 0; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; ROBINSON LC, 1987, SCIENCE, V248, P866; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKLONIK EY, 1993, SCIENCE, V260, P1953; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WU G, 1990, CELL, V63, P835	52	61	64	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16541	16548						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206969				2022-12-27	WOS:A1994NR29600006
J	JI, H; LEUNG, M; ZHANG, Y; CATT, KJ; SANDBERG, K				JI, H; LEUNG, M; ZHANG, Y; CATT, KJ; SANDBERG, K			DIFFERENTIAL STRUCTURAL REQUIREMENTS FOR SPECIFIC BINDING OF NONPEPTIDE AND PEPTIDE ANTAGONISTS TO THE AT(1) ANGIOTENSIN RECEPTOR - IDENTIFICATION OF AMINO-ACID-RESIDUES THAT DETERMINE BINDING OF THE ANTIHYPERTENSIVE DRUG LOSARTAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-COUPLED RECEPTORS; BETA-ADRENERGIC-RECEPTOR; II TYPE-1 RECEPTOR; MOLECULAR-CLONING; SUBSTANCE-P; EXPRESSION; SUBTYPE; MUTAGENESIS; DISTINCT	The biphenylimidazole derivative losartan exemplifies a novel class of nonpeptide antagonists that selectively inhibit angiotensin II binding to the mammalian AT(1) receptor and have potentially wide application as anti-hypertensive agents. In contrast to mammalian AT(1) receptors, which have high affinity for both peptide antagonists and losartan, amphibian and avian angiotensin II receptors are pharmacologically distinct and recognize peptide but not nonpeptide antagonists. Mutant rat AT(1) receptors in which non conserved amino acids were replaced by the corresponding amphibian residues were constructed to identify specific sites in the AT(1) receptor that determine losartan binding. Only minor changes in binding affinity for peptide antagonists were observed in COS-7 cells transiently expressing mutant receptors, indicating that the structural integrity of the receptor was maintained. However, analysis of receptors with single point and combined mutations revealed that specific residues in transmembrane domains III, IV, V, VI, and VII are involved in binding of the nonpeptide antagonist to the mammalian AT(1) receptor. The most marked attenuation of losartan binding (IC50 > 50 mu M) was observed in a mutant receptor containing amino acid substitutions at Val(108), Ala(163), Thr(198), Ser(252), Leu(300), and Phe(301). These results have demonstrated that the inding site of a potent nonpeptide antagonist of the AT(1) receptor is defined by epitopes located within the membrane-spanning regions of the receptor and is distinct from the site at which peptide antagonists bind to the AT(1) receptor.	NICHHD,ENDOCRINOL & REPROD RES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BERGSMA DJ, 1992, BIOCHEM BIOPH RES CO, V183, P989, DOI 10.1016/S0006-291X(05)80288-8; BERGSMA DJ, 1993, MOL PHARMACOL, V44, P77; BURNS KD, 1993, AM J PHYSIOL, V264, pF645, DOI 10.1152/ajprenal.1993.264.4.F645; Catt KJ, 1993, CELLULAR MOL BIOL RE, P307; CHIU AT, 1993, BIOCHEM BIOPH RES CO, V197, P440, DOI 10.1006/bbrc.1993.2499; FONG TM, 1993, NATURE, V362, P350; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; ITAZAKI K, 1993, EUR J PHARM-MOLEC PH, V245, P147, DOI 10.1016/0922-4106(93)90122-P; JI H, 1993, BIOCHEM BIOPH RES CO, V194, P756, DOI 10.1006/bbrc.1993.1886; MURPHY TJ, 1993, MOL PHARMACOL, V44, P1; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SANDBERG K, 1994, TRENDS ENDOCRIN MET, V5, P28, DOI 10.1016/1043-2760(94)90118-X; SANDBERG K, 1992, J BIOL CHEM, V267, P9455; SANDBERG K, 1991, FEBS LETT, V284, P281, DOI 10.1016/0014-5793(91)80704-7; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SASAMURA H, 1992, BIOCHEM BIOPH RES CO, V185, P253, DOI 10.1016/S0006-291X(05)80983-0; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHAMBYE HT, 1994, IN PRESS P NATL ACAD; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SMITH RD, 1992, ANNU REV PHARMACOL, V32, P135; STRADER CD, 1988, J BIOL CHEM, V263, P10267; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; TSUNODA K, 1993, AM J HYPERTENS, V6, P28, DOI 10.1093/ajh/6.1.28; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x	30	132	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16533	16536						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206967				2022-12-27	WOS:A1994NR29600004
J	SCHMITTGEN, TD; DANENBERG, KD; HORIKOSHI, T; LENZ, HJ; DANENBERG, PV				SCHMITTGEN, TD; DANENBERG, KD; HORIKOSHI, T; LENZ, HJ; DANENBERG, PV			EFFECT OF 5-FLUOROURACIL AND 5-BROMOURACIL SUBSTITUTION ON THE TRANSLATION OF HUMAN THYMIDYLATE SYNTHASE MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CELLS; DNA	The synthesis of thymidylate synthase (TS) from 5-fluorouracil (FUra)- and 5-bromouracil (BrUra)-substituted mRNAs was examined to investigate the effect of incorporation of uracil (Ura) analogs on translation. Human TS cDNA was transcribed in the presence of Ura-, FUra-, or BrUTP to obtain 100% substituted mRNA The mRNAs were translated in a rabbit reticulocyte lysate system. The TS protein that was formed from each of the templates reacted identically with TS antibody in Western blots. Time courses of TS formation revealed a characteristic peak which occurred at 45 min for the Ura- and FUra-RNAs and at 2 h for the BrUra-RNA. Substitution of Ura with FUra did not alter the rate of translation, while substitution of BrU for Ura decreased the rate of translation. Substitution of Ura with FUra or BrUra enhanced the stability of the mRNAs in the rabbit reticulocyte lysate by 3- and 10-fold, respectively. Incor poration of BrUra influenced the binding and catalysis on the ribosome, resulting in a 3.5-fold greater rate of activation (K-act) and 6-fold lower V-max than the equivalent values for the Ura- and FUra-substituted mRNAs. Nondenaturing gel electrophoresis revealed that different conformations exist among the mRNAs. These data show that translation can be influenced by the incorporation of fraudulent bases into mRNA and those bases that stabilize RNA secondary structure will have the greatest inhibitory effect on translation.	UNIV SO CALIF,SCH MED,DEPT BIOCHEM,LOS ANGELES,CA 90033; UNIV SO CALIF,KENNETH NORRIS JR COMPREHENS CANC CTR,SCH MED,LOS ANGELES,CA 90033	University of Southern California; University of Southern California								CARRICO CK, 1979, CANCER RES, V39, P3694; CHU E, 1990, CANCER RES, V50, P5834; CHU E, 1993, MOL PHARMACOL, V43, P527; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; DANENBERG PV, 1992, NUCLEIC ACIDS RES, V20, P573, DOI 10.1093/nar/20.3.573; DOLNICK BJ, 1985, J BIOL CHEM, V260, P3006; GLAZER RI, 1983, MOL PHARMACOL, V23, P540; GLAZER RI, 1981, MOL PHARMACOL, V19, P117; HARLOWE E, 1988, ANTIBODIES LABORATOR; HEIDELBERGER C, 1983, ADV ENZYMOL RAMB, V54, P57; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KOZAK M, 1980, CELL, V19, P79, DOI 10.1016/0092-8674(80)90390-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASSOULIE J, 1966, BIOCHIM BIOPHYS ACTA, V114, P16, DOI 10.1016/0005-2787(66)90249-8; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PARKER WB, 1990, PHARMACOL THERAPEUT, V48, P381, DOI 10.1016/0163-7258(90)90056-8; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; SIERAKOWSKA H, 1989, J BIOL CHEM, V264, P19185; TAKEISHI K, 1985, NUCLEIC ACIDS RES, V13, P2035, DOI 10.1093/nar/13.6.2035; WASHTIEN WL, 1984, MOL PHARMACOL, V25, P171	20	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16269	16275						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206932				2022-12-27	WOS:A1994NQ72900050
J	DAIGNANFORNIER, B; VALENS, M; LEMIRE, BD; BOLOTINFUKUHARA, M				DAIGNANFORNIER, B; VALENS, M; LEMIRE, BD; BOLOTINFUKUHARA, M			STRUCTURE AND REGULATION OF SDH3, THE YEAST GENE ENCODING THE CYTOCHROME-B(560) SUBUNIT OF RESPIRATORY COMPLEX-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCCINATE-DEHYDROGENASE FLAVOPROTEIN; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; CLONING; CONSTRUCTION; SELECTION; SITE; DNA	Using an expression library, we have isolated yeast genes activated in the presence of the yeast CCAAT box-binding protein HAP2. One of these genes, SDH3, encodes the cytochrome b(560) subunit of respiratory complex II. The SDH3 protein contains three potential transmembrane domains and is more than 30% identical to bovine cytochrome b(560) and to a mitochondrially encoded protein from Marchantia polymorpha. Disruption of SDH3 shows that this gene is required for growth on non-fermentable carbon sources. Expression of SDH1, SDH3, and SDH4 is activated in the presence of the HAP2 transcriptional activator.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,AB,CANADA	University of Alberta	DAIGNANFORNIER, B (corresponding author), UNIV PARIS 11,GENET MOLEC LAB,BAT 400,F-91405 ORSAY,FRANCE.			Bolotin-Fukuhara, Monique/0000-0002-5285-5006				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BULLIS BL, 1994, J BIOL CHEM, V269, P6543; CHAPMAN KB, 1992, GENE, V118, P131, DOI 10.1016/0378-1119(92)90260-V; DAIGNANFORNIER B, 1988, GENE, V62, P45, DOI 10.1016/0378-1119(88)90578-1; DEWINDE JH, 1993, PROG NUCLEIC ACID RE, V46, P51, DOI 10.1016/S0079-6603(08)61018-1; FORSBURG SL, 1988, MOL CELL BIOL, V8, P647, DOI 10.1128/MCB.8.2.647; FORSBURG SL, 1989, GENE DEV, V3, P166; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOMBARDO A, 1990, J BIOL CHEM, V265, P10419; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; PON L, 1991, MOL CELLULAR BIOL YE, P333; ROBINSON KM, 1992, J BIOL CHEM, V267, P10101; RUBY SW, 1983, METHOD ENZYMOL, V101, P253; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULKE N, 1992, P NATL ACAD SCI USA, V89, P8011, DOI 10.1073/pnas.89.17.8011; YU L, 1992, J BIOL CHEM, V267, P24508	19	59	61	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15469	15472						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195189				2022-12-27	WOS:A1994NP51300014
J	RIENDEAU, D; GUAY, J; WEECH, PK; LALIBERTE, F; YERGEY, J; LI, C; DESMARAIS, S; PERRIER, H; LIU, S; NICOLLGRIFFITH, D; STREET, IP				RIENDEAU, D; GUAY, J; WEECH, PK; LALIBERTE, F; YERGEY, J; LI, C; DESMARAIS, S; PERRIER, H; LIU, S; NICOLLGRIFFITH, D; STREET, IP			ARACHIDONYL TRIFLUOROMETHYL KETONE, A POTENT INHIBITOR OF 85-KDA PHOSPHOLIPASE A(2), BLOCKS PRODUCTION OF ARACHIDONATE AND 12-HYDROXYEICOSATETRAENOIC ACID BY CALCIUM IONOPHORE-CHALLENGED PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE-A2; INDEPENDENT PHOSPHOLIPASE-A2; PREFERENTIALLY HYDROLYZES; CONTAINING VESICLES; SUICIDE INHIBITION; U937 CELLS; RELEASE; PURIFICATION; RAT; ENZYME	Arachidonyl trifluoromethyl ketone (AACOCF(3)) is a potent and selective slow binding inhibitor of the 85-kDa cytosolic phospholipase A(2) (cPLA(2)) (Street, I. P., Lin, H.-K., Laliberte, F., Ghomashchi, F., Wang, Z., Perrier; H., Tremblay, N. M., Huang, Z., Weech, P.K., and Gelb, M. H. (1993) Biochemistry 32, 5935-5940). AACOCF(3) and a number of its structural analogues have been used to investigate the role of cPLA(2) in the cellular generation of free arachidonic acid (AA) and in eicosanoid biosynthesis. AACOCF(3) inhibited the release of AA from calcium ionophore-challenged U937 cells (IC50 = 8 mu M, 2 x 10(6) cells ml(-1)) and from platelets (IC50 = 2 mu M, 4 x 10(7) cells ml(-1)). Arachidonyl methyl ketone (AACOCH(3)) and AACH(OH)CF3, both of which are noninhibitory to the purified cPLA(2), did not inhibit the production of AA in the ionophore-challenged cells. In addition 60 the release of AA, AA-COCF3 also inhibited the production of 12-hydroxyeicosatetraenoic acid (12-HETE) and thromboxane B-2, two of the major metabolites of AA produced by platelets. The inhibition of 12-HETE biosynthesis showed a dose dependence similar to that of AA release in ionophore-challenged platelets; however, when platelet 12-HETE production was stimulated with 10 mu M AA to circumvent the PLA(2)-dependent step, AACOCF(3) no longer inhibited the production of 12-HETE. In contrast, AACOCF(3) blocked thromboxane B-2 formation by both calcium ionophore- and AA-challenged platelets, indicating that the compound affects the cyclooxygenase pathway in addition to AA release. The crude cytosol and membrane fractions from platelets were assayed for calcium-dependent and calcium-independent PLA(2) activities and for the susceptibility of each to inhibition by AACOCF(3). At AACOCF(3) concentrations as high as 10 mol %, only one of the observed PLA(2) activities was inhibited by more than 25%. The AACOCF(3)-susceptible PLA(2) (77% inhibition at 1.6 mol %) was found in the cytosolic platelet fraction and showed the functional characteristics of the cPLA(2). These results suggest that the cPLA(2) plays an important role in the generation of free AA for 12-HETE biosynthesis in platelets.	MERCK FROSST CTR THERAPEUT RES, DEPT MOLEC BIOL & BIOCHEM, POINTE CLAIRE H9R 4P8, PQ, CANADA; MERCK FROSST CTR THERAPEUT RES, DEPT MED CHEM, POINTE CLAIRE H9R 4P8, PQ, CANADA	Merck & Company; Merck & Company								APITZCASTRO RJ, 1979, BIOCHEM BIOPH RES CO, V91, P63, DOI 10.1016/0006-291X(79)90583-7; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; CHAU LY, 1983, BIOCHEM BIOPH RES CO, V113, P241, DOI 10.1016/0006-291X(83)90457-6; CHEVY F, 1991, LIPIDS, V26, P1080, DOI 10.1007/BF02536506; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1991, BIOCHEM J, V280, P581, DOI 10.1042/bj2800581; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; IMAI A, 1982, JPN J EXP MED, V52, P99; KANNAGI R, 1979, ARCH BIOCHEM BIOPHYS, V196, P534, DOI 10.1016/0003-9861(79)90305-9; KIM DK, 1988, J BIOCHEM-TOKYO, V104, P492, DOI 10.1093/oxfordjournals.jbchem.a122496; Kramer R M, 1990, Adv Exp Med Biol, V275, P35; KRAMER RM, 1993, J LIPID MEDIATOR, V6, P209; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LEHR M, 1992, PHARM PHARM LETT, V2, P176; LI C, 1991, 39TH P ASMS C MASS S; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LU AYH, 1972, BIOCHEM BIOPH RES CO, V46, P1334, DOI 10.1016/S0006-291X(72)80121-9; MEADE CJ, 1986, BIOCHEM J, V238, P425, DOI 10.1042/bj2380425; MIZUSHIMA H, 1989, J BIOCHEM-TOKYO, V105, P520, DOI 10.1093/oxfordjournals.jbchem.a122699; MOUNIER C, 1993, EUR J BIOCHEM, V216, P169, DOI 10.1111/j.1432-1033.1993.tb18129.x; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1990, BIOCHIM BIOPHYS ACTA, V1043, P34, DOI 10.1016/0005-2760(90)90107-9; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; RAMANADHAM S, 1992, BIOCHEM BIOPH RES CO, V184, P647, DOI 10.1016/0006-291X(92)90638-2; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V210, P169, DOI 10.1111/j.1432-1033.1992.tb17405.x; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; TREMBLAY NM, 1993, PROTEIN EXPRES PURIF, V4, P490, DOI 10.1006/prep.1993.1064; TREMBLAY NM, 1992, BIOCHEM BIOPH RES CO, V183, P121, DOI 10.1016/0006-291X(92)91617-Y; WINKLER JD, 1991, BIOCHIM BIOPHYS ACTA, V1081, P339, DOI 10.1016/0005-2760(91)90291-O; ZUPAN LA, 1993, J MED CHEM, V36, P95, DOI 10.1021/jm00053a012	39	248	252	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15619	15624						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195210				2022-12-27	WOS:A1994NP51300038
J	SCHURMANN, A; BREINER, M; BECKER, W; HUPPERTZ, C; KAINULAINEN, H; KENTRUP, H; JOOST, HG				SCHURMANN, A; BREINER, M; BECKER, W; HUPPERTZ, C; KAINULAINEN, H; KENTRUP, H; JOOST, HG			CLONING OF 2 NOVEL ADP-RIBOSYLATION FACTOR-LIKE PROTEINS AND CHARACTERIZATION OF THEIR DIFFERENTIAL EXPRESSION IN 3T3-L1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT ACTIVITY; GTP-BINDING PROTEINS; CHOLERA-TOXIN; SUBCELLULAR-DISTRIBUTION; SELECTIVE AMPLIFICATION; MESSENGER-RNA; FACTOR ARF; INSULIN; ADIPOCYTES; NUCLEOTIDE	A polymerase chain reaction-based cloning approach was employed in order to identify ADP-ribosylation factors (ARF) in-murine 3T3-L1 cells and to study their expression before and after differentiation of cells to the adipocyte-like phenotype. Partial sequences comprising the effector domains of ARF were amplified with degenerate primers and cloned. Five of these sequences were identified as murine homologues of known human ADP-ribosylation factors (ARF 1, 2, 4, 5, and 6). In addition, partial sequences of two previously unknown isoforms were found, and complete cDNA clones were isolated from a rat fat cell library and were sequenced. Both sequences harbor a putative myristoylation site in position 2, the known consensus sequences presumably involved in GTP binding and hydrolysis, and lack cysteine residues in the C terminus. Their amino acid sequences share a 56 and 41% identity, respectively, with human ARF 1. Based on a comparison with the known ARF isoforms, the first clone appears to represent the mammalian homologue of a known sequence from Drosophila (dARL 1, 79% identity) and was therefore designated rARL 1. The second clone resembled none of the known ARF-like proteins and was designated rARL 4. mRNA of ARL 4 was undetectable in the fibroblasts but abundant in the adipocyte-like phenotype, its expression starting on day 6 of the differentiation. In contrast, ARF 1, 2, and 5 were unaltered by differentiation of the 3T3-L1 cells; mRNA levels of ARF 6, and also of ARL 1 and ARF 4, were reduced after differentiation. It is suggested that the function of ARL 4 is related to the adipocyte-like phenotype of 3T3-L1 cells.	RHEIN WESTFAL TH AACHEN,FAK MED,INST PHARMAKOL & TOXIKOL,D-52057 AACHEN,GERMANY; UNIV TAMPERE,DEPT CLIN MED,SF-33100 TAMPERE,FINLAND	RWTH Aachen University; Tampere University			Joost, Hans-Georg/J-4462-2013; Becker, Walter/B-8889-2008	Joost, Hans-Georg/0000-0002-5860-606X; Becker, Walter/0000-0002-0347-4768; Schurmann, Annette/0000-0002-4113-4377; Kainulainen, Heikki/0000-0001-5102-4350				BALDINI G, 1991, J BIOL CHEM, V266, P4037; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROST SC, 1985, J BIOL CHEM, V260, P2646; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GUERREMILLO M, 1993, DIABETES, V42, pA167; HUPPERTZ C, 1993, EUR J BIOCHEM, V215, P611, DOI 10.1111/j.1432-1033.1993.tb18072.x; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1992, J BIOL CHEM, V267, P13039; LACHAAL M, 1993, DIABETES, V42, pA170; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; ROSEN OM, 1978, J BIOL CHEM, V253, P7579; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WEILAND M, 1991, J CELL PHYSIOL, V149, P428, DOI 10.1002/jcp.1041490311; WEILAND M, 1990, BIOCHEM J, V270, P331, DOI 10.1042/bj2700331; ZIEHM D, 1993, HORM METAB RES, V25, P71, DOI 10.1055/s-2007-1002046	26	60	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15683	15688						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195219				2022-12-27	WOS:A1994NP51300047
J	LEE, SL; YU, ASL; LYTTON, J				LEE, SL; YU, ASL; LYTTON, J			TISSUE-SPECIFIC EXPRESSION OF NA+-CA2+ EXCHANGER ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SODIUM-CALCIUM EXCHANGER; FUNCTIONAL EXPRESSION; NA+/CA2+ EXCHANGER; MOLECULAR-CLONING; RABBIT KIDNEY; HELA-CELLS; GENE; RAT; LOCALIZATION; TRANSCRIPTS	The sodium-calcium exchanger (NCE) plays a critical role in diverse processes in many different tissues including heart, nerve, and kidney. Surprisingly, the NCE is encoded by a single gene. We have isolated and sequenced a rat renal NCE clone, denoted F1, that was identical to previous rat NCEs, except for two unique sequences: one in the 5'-untranslated region and the other at a site of alternative splicing in the coding sequence. To explore these regions further, we examined NCE transcripts in several tissues using- ''rapid amplification of cDNA 5'-ends'' and polymerase chain reaction amplification. Three species were identified each with a different 5'-end exon spliced to a common NCE core at nucleotide -34 in the 5'-untranslated region. Based on Northern analysis, each of these species had a unique tissue distribution. Whereas the F1 5'-end variant was abundantly expressed only in kidney, a second variant was expressed mostly in heart, and the third variant was expressed ubiquitously elsewhere. Investigation of the region of alternative splicing in the coding sequence also revealed tissue-specific expression of five major species. These findings indicate that the NCE expression is controlled and regulated under the influence of different promoters in a tissue-specific fashion. Therefore, we propose that the structural complexity of the single NCE gene allows it to respond independently to the unique demands of different environments.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Yu, Alan/AID-7467-2022	Yu, Alan/0000-0002-1776-2533; Lytton, Jonathan/0000-0003-4770-2512	NIDDK NIH HHS [T32 DK07527] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007527] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACETO JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P553, DOI 10.1016/0003-9861(92)90449-7; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BINDELS RJM, 1992, PFLUG ARCH EUR J PHY, V420, P566, DOI 10.1007/BF00374634; BLAUSTEIN MP, 1991, ANN NY ACAD SCI, V639, P254, DOI 10.1111/j.1749-6632.1991.tb17315.x; BLAUSTEIN MP, 1991, ANN NY ACAD SCI, V639; BOURDEAU JE, 1993, J AM SOC NEPHROL, V4, P105; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FURMAN I, 1993, FEBS LETT, V319, P105, DOI 10.1016/0014-5793(93)80046-W; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAHN SL, 1993, J NEUROCHEM, V60, P1058, DOI 10.1111/j.1471-4159.1993.tb03254.x; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; KILPATRICK DL, 1990, MOL CELL BIOL, V10, P3717, DOI 10.1128/MCB.10.7.3717; KOFUJI P, 1993, AM J PHYSIOL, V265, pF598, DOI 10.1152/ajprenal.1993.265.4.F598; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; LAUGHON A, 1986, MOL CELL BIOL, V6, P4676, DOI 10.1128/MCB.6.12.4676; LEE SL, 1994, BIOPHYS J, V66, pA330; LI ZP, 1993, J BIOL CHEM, V268, P11489; LI ZP, 1992, J BIOL CHEM, V267, P7828; LOW W, 1993, FEBS LETT, V316, P63, DOI 10.1016/0014-5793(93)81737-K; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; MCDANIEL LD, 1993, CYTOGENET CELL GENET, V63, P192, DOI 10.1159/000133532; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PIJUAN V, 1993, AM J PHYSIOL, V264, pC1066, DOI 10.1152/ajpcell.1993.264.4.C1066; REILLY RF, 1993, AM J PHYSIOL, V265, pF327, DOI 10.1152/ajprenal.1993.265.2.F327; REILLY RF, 1992, AM J PHYSIOL, V262, pF1105, DOI 10.1152/ajprenal.1992.262.6.F1105; SAMBROOK J, 1989, MOL CLONIN LABORATOR; TAYLOR Z, 1985, J BIOL CHEM, V260, P15473; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; YU ASL, 1992, AM J PHYSIOL, V263, pF680, DOI 10.1152/ajprenal.1992.263.4.F680; [No title captured]	34	220	223	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14849	14852						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195112				2022-12-27	WOS:A1994NP73800001
J	LAND, M; ISLASTREJO, A; RUBIN, CS				LAND, M; ISLASTREJO, A; RUBIN, CS			ORIGIN, PROPERTIES, AND REGULATED EXPRESSION OF MULTIPLE MESSENGER-RNAS ENCODED BY THE PROTEIN-KINASE C1 GENE OF CAENORHABDITIS-ELEGANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICED LEADER RNA; RAT-BRAIN; IMMUNOCYTOCHEMICAL LOCALIZATION; DEVELOPMENTAL REGULATION; CATALYTIC SUBUNIT; MESSENGER-RNA; SINGLE GENE; BETA-GENE; SEQUENCE; CLONING	Recently, we cloned and characterized cDNA encoding a novel, protein kinase C (designated PKC1B) from Caenorhabditis elegans. PKC1B (707 amino acid residues) is a developmentally regulated, calcium-independent kinase that is expressed exclusively in sensory neurons and related interneurons. We have now discovered a mechanism by which a second, distinct mRNA (PKC1A mRNA) with increased protein coding potential is generated from the C. elegans PKC1 gene. PKC1A mRNA is produced in a process that involves the utilization of an alternative, distal promoter, the incorporation of two unique exons into the mRNA, and alternative cis/trans splicing. Diversity among PKC1 gene transcripts is increased substantially by trans-splicing. The 5' end of PKC1A mRNA contains an acceptor site that is modified by the addition of either a classical spliced leader sequence 2 or one of four novel spliced leaders. PKC1A mRNA encodes a predicted kinase that contains the entire sequence of PKC1B as well as an N-terminal extension of 56 residues. The extension contains a preponderance of basic amino acids. The levels of transcripts arising from the distal (1A) and proximal (1B) promoters for the PKC1 gene are differentially regulated during C. elegans development. The ratio of 1B mRNA:1A mRNA varies from 40:1 to unity as the nematodes progress from early larval stages to mature adults. The novel exons in the PKC1A structural gene are not contiguous with the PKC1A promoter but are instead positioned downstream from a second gene, kinase upstream gene-1, in the context of a multicistronic operon. PKC1A and kinase upstream gene-1 mRNAs are coordinately expressed in a fixed ratio throughout C. elegans post-embryonic development, suggesting that a shared upstream promoter regulates transcription of both genes. Finally, PKC1A and PKC1B mRNA levels are differentially regulated by phorbol esters in a process that may involve the participation of another PKC isoform that is analogous to mammalian PKC delta.			LAND, M (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,ATRAN LABS,DEPT MOLEC PHARMACOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044957, T32DK007513] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07513, DK44957] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BAIER G, 1993, J BIOL CHEM, V268, P4997; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BLOBE GC, 1993, J BIOL CHEM, V268, P10627; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CHEN KH, 1990, J BIOL CHEM, V265, P19961; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CUMMINS C, 1988, MOL CELL BIOL, V8, P5339, DOI 10.1128/MCB.8.12.5339; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FIRE A, 1991, DEVELOPMENT, V113, P503; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FREEDMAN JH, 1993, J BIOL CHEM, V268, P2554; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GROSS RE, 1990, J BIOL CHEM, V265, P6896; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HOSODA K, 1989, P NATL ACAD SCI USA, V86, P1393, DOI 10.1073/pnas.86.4.1393; HU E, 1991, J BIOL CHEM, V266, P19796; HU ED, 1990, J BIOL CHEM, V265, P5072; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; Jaken S, 1990, CURR OPIN CELL BIOL, V2, P192, DOI 10.1016/0955-0674(90)90006-Z; KENYON C, 1988, SCIENCE, V240, P1448, DOI 10.1126/science.3287621; KHAN WA, 1993, J BIOL CHEM, V268, P5063; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KRUGER KE, 1991, J NEUROSCI, V11, P2303; KUWABARA PE, 1992, MOL BIOL CELL, V3, P461, DOI 10.1091/mbc.3.4.461; LAND M, 1994, J BIOL CHEM, V269, P9234; LU X, 1990, J BIOL CHEM, V265, P3292; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NIINO YS, 1992, J BIOL CHEM, V267, P6158; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBEID LM, 1992, J BIOL CHEM, V267, P20804; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1990, J BIOL CHEM, V265, P22434; OZAWA K, 1993, J BIOL CHEM, V268, P2280; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SAITO N, 1989, P NATL ACAD SCI USA, V86, P3409, DOI 10.1073/pnas.86.9.3409; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; SULSTON J, 1988, NEMATODE CAENORHABDI, P123; TABUSE Y, 1983, CARCINOGENESIS, V4, P783, DOI 10.1093/carcin/4.6.783; TABUSE Y, 1989, SCIENCE, V243, P1713, DOI 10.1126/science.2538925; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X; VANDOREN K, 1988, NATURE, V335, P556; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WOOTEN MW, 1992, FEBS LETT, V298, P74, DOI 10.1016/0014-5793(92)80025-C; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431; [No title captured]	63	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14820	14827						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182089				2022-12-27	WOS:A1994NM06500079
J	CARRAWAY, KL; SLIWKOWSKI, MX; AKITA, R; PLATKO, JV; GUY, PM; NUIJENS, A; DIAMONTI, AJ; VANDLEN, RL; CANTLEY, LC; CERIONE, RA				CARRAWAY, KL; SLIWKOWSKI, MX; AKITA, R; PLATKO, JV; GUY, PM; NUIJENS, A; DIAMONTI, AJ; VANDLEN, RL; CANTLEY, LC; CERIONE, RA			THE ERBB3 GENE-PRODUCT IS A RECEPTOR FOR HEREGULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-ACTIVITY; HUMAN-BREAST; EXPRESSION; ONCOGENE; CANCER; LIGAND; CELLS	ErbB3 is a member of the epidermal growth factor (EGF) receptor subfamily of receptor tyrosine kinases and is believed to be a receptor for an unknown ligand. We have tested the possibility that heregulin, a growth factor possessing an EGF-like domain, is a ligand for ErbB3. We have found that the iodinated recombinant EGF-like domain of heregulin-beta 1 (I-125-rHRG beta 1(177-244)) bound specifically to insect cell-expressed bovine ErbB3 with a dissociation constant of 0.85 nM. Moreover, I-125-rHRG beta 1(177-244) bound to NIH3T3 fibroblasts stably transfected with bovine erbB3 with a dissociation constant of 60 pM, but did not bind to parental cells. I-125-rHRG beta 1(177-244) could be chemically cross-linked to a 170-180 kDa protein in erbB3-transfected fibroblasts, and the cross-linked product could be immunoprecipitated with antibodies specific for ErbB3. Finally, rHRG beta 1 stimulated the tyrosine phosphorylation of both ErbB3 and endogenous p185(erbB2/neu) in, transfectants but not in parental cells. We conclude that ErbB3 is a receptor for HRG and is capable of mediating HRG-stimulated tyrosine phosphorylation of itself and pl85(erbB2/neu) in cells that express both receptors.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; BETH ISRAEL HOSP,DIV SIGNAL TRANSDUCT,BOSTON,MA 02115; GENENTECH INC,S SAN FRANCISCO,CA 94080; CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Roche Holding; Genentech; Cornell University			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NIGMS NIH HHS [R01 GM041890, GM40654, GM41890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654, R01GM041890, R37GM041890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GREENFIELD C, 1988, EMBO J, V7, P139, DOI 10.1002/j.1460-2075.1988.tb02793.x; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	18	361	393	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14303	14306						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188716				2022-12-27	WOS:A1994NL60600087
J	KASLIN, E; HEYER, WD				KASLIN, E; HEYER, WD			A MULTIFUNCTIONAL EXONUCLEASE FROM VEGETATIVE SCHIZOSACCHAROMYCES-POMBE CELLS EXHIBITING IN-VITRO STRAND EXCHANGE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER PROTEIN-ALPHA; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; DNA EXONUCLEASE; MEIOTIC CELLS; RECA PROTEIN; PURIFICATION; BINDING	A 140-kDa polypeptide (p140) has been purified over 2000-fold from vegetative Schizosaccharomyces pombe cells using an assay of homologous pairing and strand exchange between linear double-stranded DNA (dsDNA) and circular single-stranded DNA (ssDNA) in vitro. Electron microscopic analysis of the reaction products showed displacement of one strand of the linear duplex DNA by the circular ssDNA molecule. In addition, the protein contained 5' to 3' exonuclease activity on ssDNA and dsDNA (with a 50-fold preference on the single-stranded substrate) as well as on single stranded RNA. Furthermore, p140 was capable of renaturing complementary ssDNA as shown by S1 nuclease assays. p140 behaved like a monomer in solution under reaction conditions. Direct comparison of the biochemical properties, sequence analysis, and cross-reactivity to a monoclonal antibody suggests that p140 is probably identical with ExoII, purified from S. pombe meiotic cells as a ssDNA exonuclease (Szankasi, P., and Smith, G. R. (1992) Biochemistry 31, 6769-6773). Given the diverse activities of p140, the protein might be involved in DNA and/or RNA metabolism in vivo.	UNIV BERN,INST GEN MICROBIOL,CH-3012 BERN,SWITZERLAND	University of Bern								ARAI N, 1992, J BIOL CHEM, V267, P3514; BAHLER J, 1994, IN PRESS CHROMOSOMA; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASSUTO E, 1971, NATURE-NEW BIOL, V229, P13, DOI 10.1038/newbio229013a0; CLARK AB, 1991, MOL CELL BIOL, V11, P2576, DOI 10.1128/MCB.11.5.2576; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; Davis R.W., 1971, METHODS ENZYMOL, V21, P413; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYKSTRA CC, 1991, MOL CELL BIOL, V11, P2583, DOI 10.1128/MCB.11.5.2583; DYKSTRA CC, 1990, J BIOL CHEM, V265, P10968; EGGLESTON AK, 1991, BIOCHIMIE, V73, P163, DOI 10.1016/0300-9084(91)90199-B; FISHEL RA, 1981, NATURE, V294, P184, DOI 10.1038/294184a0; HALBROOK J, 1989, J BIOL CHEM, V264, P21403; HALL SD, 1993, J BACTERIOL, V175, P277, DOI 10.1128/JB.175.1.277-287.1993; HEYER WD, 1988, J BIOL CHEM, V263, P15189; HEYER WD, 1993, PROG NUCLEIC ACID RE, V46, P221, DOI 10.1016/S0079-6603(08)61023-5; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; JOSEPH JW, 1983, J BIOL CHEM, V258, P418; KASLIN E, 1994, J BIOL CHEM, V269, P14103; KERR C, 1972, J BIOL CHEM, V247, P305; KIM JM, 1990, GENETICS, V126, P799; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVERY PE, 1992, J BIOL CHEM, V267, P9307; LLOYD RG, 1988, MOL GEN GENET, V212, P317, DOI 10.1007/BF00334702; LOVETT ST, 1988, GENETICS, V120, P37; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; LOVETT ST, 1984, J BACTERIOL, V157, P190, DOI 10.1128/JB.157.1.190-196.1984; LOWENHAUPT K, 1989, J BIOL CHEM, V264, P20568; MELIN L, 1992, EMBO J, V11, P691, DOI 10.1002/j.1460-2075.1992.tb05101.x; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MOORE SP, 1990, J BIOL CHEM, V265, P11108; MUNIYAPPA K, 1986, J BIOL CHEM, V261, P7472; NORRIS D, 1990, BIOCHEMISTRY-US, V29, P7903, DOI 10.1021/bi00486a018; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RICHARDSON CC, 1966, J MOL BIOL, V15, P49, DOI 10.1016/S0022-2836(66)80208-5; SADOWSKI PD, 1985, NUCLEASES, P23; SANDER M, 1991, P NATL ACAD SCI USA, V88, P6780, DOI 10.1073/pnas.88.15.6780; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SIKORAV JL, 1991, J MOL BIOL, V222, P1085, DOI 10.1016/0022-2836(91)90595-W; Sipiczki M, 1989, MOL BIOL FISSION YEA, P431; SMITH GR, 1988, MICROBIOL REV, V52, P1; STEVENS A, 1978, BIOCHEM BIOPH RES CO, V81, P656, DOI 10.1016/0006-291X(78)91586-3; STEVENS A, 1991, J BACTERIOL, V173, P7024, DOI 10.1128/jb.173.21.7024-7028.1991; STEVENS A, 1980, J BIOL CHEM, V255, P3080; STEVENS A, 1987, ARCH BIOCHEM BIOPHYS, V252, P339, DOI 10.1016/0003-9861(87)90040-3; SUGINO A, 1988, P NATL ACAD SCI USA, V85, P3683, DOI 10.1073/pnas.85.11.3683; SZANKASI P, 1992, J BIOL CHEM, V267, P3014; SZANKASI P, 1992, BIOCHEMISTRY-US, V31, P6769, DOI 10.1021/bi00144a017; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; [No title captured]	54	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14094	14102						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188690				2022-12-27	WOS:A1994NL60600057
J	RAO, GHR; FIELDS, CG; WHITE, JG; FIELDS, GB				RAO, GHR; FIELDS, CG; WHITE, JG; FIELDS, GB			PROMOTION OF HUMAN PLATELET-ADHESION AND AGGREGATION BY A SYNTHETIC, TRIPLE-HELICAL MINI-COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM MOBILIZATION; BASEMENT-MEMBRANE; IV COLLAGEN; ACTIVATION; IDENTIFICATION; REQUIREMENT; SEQUENCES; ALPHA-2-BETA-1-INTEGRIN; SUBENDOTHELIUM; ALPHA-1(IV)	Platelet activation and aggregation by fibrillar collagens are based on substrate primary, secondary, tertiary, and quaternary structure. Although several peptides incorporating sequences from the triple-helical domains of types I and III collagen inhibit collagen-mediated platelet aggregation, none independently promote platelet activation and aggregation. It is believed that the absence of these platelet activities is due to the lack of proper substrate tertiary and quaternary structures. We have utilized a synthetic, triple-helical ''mini-collagen'' that incorporates a known cell adhesion site (alpha 1(IV)1263-1277) to better understand the relationship between substrate primary, secondary, tertiary, and quaternary structure and platelet activation and aggregation. The promotion of platelet adhesion, activation, and aggregation was compared for this triple helical polypeptide (THP), fibrillar and type TV collagens, and a single-stranded peptide (SSP) incorporating the alpha 1(TV)1263-1277 sequence. Glass coated fibrillar and type IV collagens and the THP supported platelet adhesion at substrate concentrations of 0.33 nM, 0.20 an, and 0.89 mu M, respectively. When platelets were stirred with 10 mu g/ml of fibrillar (0.33 nn) and type TV (0.20 nM) collagen, SSP (2.1 mu M), and THP (0.89 mu M), only the fibrillar collagen caused H-3-labeled arachidonic acid release, elevation of cytosolic calcium, irreversible aggregation, and secretion of granule contents. The THP (0.45-1.8 mu M) effectively inhibited fibrillar collagen-mediated platelet aggregation, while the SSP did not. At a substrate concentration of 40 mu g/ml, the THP (3.6 mu M) was as effective as fibrillar collagen (1.3 nM) at inducing H-3-labeled oleic acid-labeled platelet activation and microaggregate formation, while the SSP and type IV collagen were relatively ineffective. Rotary shadowing images indicated that aggregates of the THP could form distinct quaternary structures, while the type TV collagen used here could not. These results are the first demonstrations of a synthetic peptide promoting platelet adhesion, activation, and aggregation and suggest that the combination of THP primary, secondary, tertiary, and quaternary structural features are required for platelet aggregation.			RAO, GHR (corresponding author), UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,BOX 198 UMHC,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.			Rao, Gundu H.R./0000-0002-2692-7950	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL011880, R01HL049556, R37HL011880] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL11880, HL49556] Funding Source: Medline; PHS HHS [KD44494] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BABEL W, 1984, EUR J BIOCHEM, V143, P545, DOI 10.1111/j.1432-1033.1984.tb08404.x; BALLEISEN L, 1976, HAEMOSTASIS, V5, P155; BARNES MJ, 1980, THROMB RES, V18, P375, DOI 10.1016/0049-3848(80)90333-3; BAUMGARTNER HR, 1977, THROMB HAEMOSTASIS, V37, P1; BRASS LF, 1974, J CLIN INVEST, V54, P1480, DOI 10.1172/JCI107896; CHELBERG MK, 1990, J CELL BIOL, V111, P262; CHIANG TM, 1980, J LAB CLIN MED, V95, P99; CHIANG TM, 1990, THROMB RES, V59, P509, DOI 10.1016/0049-3848(90)90411-5; CHIANG TM, 1977, J CLIN INVEST, V59, P405, DOI 10.1172/JCI108653; CHIANG TM, 1975, J BIOL CHEM, V250, P6919; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; ERICKSON PR, 1992, J BIOL CHEM, V267, P10018; FIELDS CG, 1993, J BIOL CHEM, V268, P14153; FIELDS CG, 1993, BIOPOLYMERS, V33, P1695, DOI 10.1002/bip.360331107; GRYKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUGUES J, 1976, THROMB RES, V9, P223, DOI 10.1016/0049-3848(76)90211-5; JAFFE R, 1974, J CLIN INVEST, V53, P875, DOI 10.1172/JCI107628; KARNIGUIAN A, 1983, THROMB RES, V32, P593, DOI 10.1016/0049-3848(83)90061-0; KOLIAKOS GG, 1989, J BIOL CHEM, V264, P2313; LEGRAND YJ, 1980, BIOCHEM BIOPH RES CO, V96, P1579, DOI 10.1016/0006-291X(80)91354-6; MAZUROV AV, 1989, MATRIX, V9, P214, DOI 10.1016/S0934-8832(89)80053-8; MISELWITZ F, 1970, BIOCHIM BIOPHYS ACTA, V923, P436; MONBOISSE JC, 1990, BIOCHEM J, V270, P459, DOI 10.1042/bj2700459; MORIYAMA T, 1988, J BIOCHEM-TOKYO, V103, P901, DOI 10.1093/oxfordjournals.jbchem.a122383; MORTON L F, 1991, Biochemical Society Transactions, V19, p439S; MORTON LF, 1985, COLLAGEN REL RES, V5, P493; MORTON LF, 1993, THROMB RES, V72, P367, DOI 10.1016/0049-3848(93)90148-H; MUGGLI R, 1973, Thrombosis Research, V3, P715, DOI 10.1016/0049-3848(73)90018-2; PERRIS R, 1993, J CELL SCI, V106, P1357; RAO GHR, 1987, BIOCHEM BIOPH RES CO, V148, P768, DOI 10.1016/0006-291X(87)90942-9; SANTORO SA, 1991, CELL REGUL, V2, P905, DOI 10.1091/mbc.2.11.905; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1988, PLATELET MEMBRANE RE, P291; SCHARFFETTERKOCHANEK K, 1992, J INVEST DERMATOL, V98, P3, DOI 10.1111/1523-1747.ep12493266; SMITH CM, 1992, BLOOD, V80, P2774; SMITH JB, 1990, ANAL BIOCHEM, V187, P173, DOI 10.1016/0003-2697(90)90437-E; SMITH JB, 1992, BIOCHEM J, V288, P925, DOI 10.1042/bj2880925; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; TRELSTAD RL, 1979, J LAB CLIN MED, V93, P499; WEISS HJ, 1978, J LAB CLIN MED, V92, P750; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; ZIJENAH LS, 1990, THROMB RES, V59, P553, DOI 10.1016/0049-3848(90)90415-9	42	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13899	13903						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188668				2022-12-27	WOS:A1994NL60600030
J	SAWA, H; SOBEL, BE; FUJII, S				SAWA, H; SOBEL, BE; FUJII, S			INHIBITION OF TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR PRODUCTION BY ANTISENSE OLIGONUCLEOTIDES IN HUMAN VASCULAR ENDOTHELIAL AND SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CULTURE; SURFACE; GROWTH	We have hypothesized that type-1 plasminogen activator inhibitor (PAI-1) may exacerbate accumulation of extracellular matrix in atheroma by inhibiting local generation of plasmin and intramural proteolysis. Thus, suppression of PAI-1 expression would decrease atherogenesis. To inhibit expression of PAI-1 in cultured human umbilical vein endothelial and aortic smooth muscle cells, a 20-base antisense phosphorothioate oligonucleotide targeting specific sequences in the 3'-untranslated region of the PAI-1 gene was used. Studies with P-32-labeled oligomers verified stability in media. Secretion of PAI-1 protein assayed by enzyme-linked immunosorbent assay declined specifically and dose-dependently in cells exposed to the antisense oligonucleotide treated under basal conditions and after stimulation of PAI-1 expression with transforming growth factor beta (0.5 ng/ml for endothelial cell, 5 ng/ml for smooth muscle cell). Inhibition of expression was confirmed by immunoprecipitation of S-35-labeled PAI-1 and was paralleled by decreased steady-state levels of PAI-1 mRNA (Northern blots). Decreased PAI-1 synthesis was accompanied by augmentation of cell-associated plasmin activity. Thus, the antisense oligonucleotide down-regulated PAI-1 elaboration, an approach that may be useful in limiting obstructive vascular lesions.	WASHINGTON UNIV, SCH MED, DIV CARDIOVASC, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Sawa, Hirofumi/AAW-8816-2021; Sawa, Hirofumi/F-6954-2012	Sawa, Hirofumi/0000-0003-2569-2755	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL017646, P50HL017646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-17646] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOSMA PJ, 1988, J BIOL CHEM, V263, P9129; EPSTEIN SE, 1993, CIRCULATION, V88, P1351, DOI 10.1161/01.CIR.88.3.1351; FUJII S, 1991, CIRCULATION, V83, P645, DOI 10.1161/01.CIR.83.2.645; FUUJI S, CIRCULATION, V86, P2000; GE M, 1992, J CLIN INVEST, V90, P2508, DOI 10.1172/JCI116144; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KESSLER SW, 1975, J IMMUNOL, V115, P1617; LOSKUTOFF DJ, 1989, PROG HEMOSTASIS THRO, V9; LUCORE CL, 1988, J BIOL CHEM, V263, P15845; LUPU F, 1993, ARTERIOSCLER THROMB, V13, P1090, DOI 10.1161/01.ATV.13.7.1090; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; NODAHEINY H, 1993, CIRC RES, V72, P36, DOI 10.1161/01.RES.72.1.36; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; Sambrook J, 1989, MOL CLONING LABORATO; SAWA H, 1992, ARTERIOSCLER THROMB, V12, P1507, DOI 10.1161/01.ATV.12.12.1507; SAWA H, 1993, CIRC RES, V73, P671, DOI 10.1161/01.RES.73.4.671; TIPPING PG, 1993, AM J PATHOL, V143, P875	20	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14149	14152						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188696				2022-12-27	WOS:A1994NL60600064
J	HUNG, AY; HAASS, C; NITSCH, RM; QIU, WQ; CITRON, M; WURTMAN, RJ; GROWDON, JH; SELKOE, DJ				HUNG, AY; HAASS, C; NITSCH, RM; QIU, WQ; CITRON, M; WURTMAN, RJ; GROWDON, JH; SELKOE, DJ			ACTIVATION OF PROTEIN-KINASE-C INHIBITS CELLULAR PRODUCTION OF THE AMYLOID BETA-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FAMILIAL ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; IDENTIFICATION; DERIVATIVES; SECRETION; MUTATION; CLEAVAGE; PEPTIDE; CELLS; LOCALIZATION	The 39-43-amino acid amyloid beta-protein (Abeta), which is progressively deposited in cerebral plaques and blood vessels in Alzheimer's disease (AD), is released by cultured human cells during normal metabolism. Here we show that agents which activate protein kinase C or otherwise enhance protein phosphorylation caused a substantial decrease in Abeta production in vitro. Protein kinase C activation also markedly decreased Abeta release from cells that express mutant forms of the beta-amyloid precursor protein genetically linked to familial AD. Inhibition of Abeta secretion could also be effected by direct stimulation of m1 muscarinic acetylcholine receptors with carbachol. These results demonstrate that activation of the protein kinase C signal transduction pathways down-regulates the generation of the amyloidogenic Abeta peptide. Pharmacologic agents that activate this system, including a variety of first messengers, could potentially slow the development or growth of some Abeta plaques during the early stages of AD.	HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115; MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital	HUNG, AY (corresponding author), HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115, USA.			Qiu, Wei Qiao (Wendy)/0000-0002-2082-2410				BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P355; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GILLESPIE SL, 1992, BIOCHEM BIOPH RES CO, V187, P1285, DOI 10.1016/0006-291X(92)90442-N; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HUNG AY, 1992, P NATL ACAD SCI USA, V89, P9439, DOI 10.1073/pnas.89.20.9439; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; NITSCH RM, 1993, P NATL ACAD SCI USA, V90, P5191, DOI 10.1073/pnas.90.11.5191; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SUZUKI T, 1992, NEUROSCIENCE, V48, P755, DOI 10.1016/0306-4522(92)90264-3; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WANG R, 1991, J BIOL CHEM, V266, P16960; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	33	373	391	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					22959	22962						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226807				2022-12-27	WOS:A1993MF51500002
J	NUREKAMAL, MSA; VARGA, M; MARUTA, H				NUREKAMAL, MSA; VARGA, M; MARUTA, H			THE GTPASE-ACTIVATING NF1 FRAGMENT OF 91 AMINO-ACIDS REVERSES V-HA-RAS-INDUCED MALIGNANT PHENOTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; GAP; EXPRESSION; PROTEIN; DOMAIN; TRANSFORMATION; INHIBITION; CLONING; RAS-P21; ENCODES	The human neurofibromatosis type 1 gene encodes a Ras GAP (GTPase-activating protein) of 2818 amino acids called NF1. This GAP contains a domain of 338 amino acids (residues 1194-1531) called NF1-GRD, which shares 26% sequence identity with the C-terminal domain (GAP1C, residues 709-1044) of another Ras GAP called GAP1. Both NF1-GRD and GAP1C activate normal Ras GTPases but not oncogenic mutants such as v-Ha-Ras. Any attempt to reverse the v-Ha-Ras-induced malignant transformation by the GAP1C has, so far, been unsuccessful. However, we have found that when the NF1-GRD is overexpressed in v-Ha-Ras-transformed NIH/3T3 cells, it greatly reduces their ability to form colonies in a soft agar, the property tightly associated with their malignancy. This is, so far, the first demonstration that a Ras-binding protein can act as a potent antagonist of the oncogenic Ras mutants in mammalian cells. In an attempt to further screen the smallest anti-oncogenic fragment derived from the NF1-GRD, we have prepared a series of its deletion mutants and examined their interaction with Ras first by monitoring their GAP activity (ability to activate the normal Ras GTPase). The deletion analysis has revealed that the N-terminal 247 amino acids (residues 1194-1440) of NF1-GRD are not required for its GAP activity, suggesting that its remaining domain of 91 amino acids (NF91, residues 1441-1531) is sufficient to bind the v-Ha-Ras, although its GAP activity is 20 times lower than the NF1-GRD. The NF91 is indeed able to reverse the v-Ha-Ras-induced malignant transformation as the NF1-GRD. The NF91 is, so far, the smallest among the tumor suppressor proteins that show the anti-v-Ha-Ras action in vivo. Thus, the NF91 appears to be a good starting material from which a smaller and more potent v-Ha-Ras antagonist could be devised to be used as a potential cure for the human cancers caused by the Ras mutants.			NUREKAMAL, MSA (corresponding author), LUDWIG INST CANC RES, PO ROYAL MELBOURNE HOSP, MELBOURNE, VIC 3050, AUSTRALIA.							ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; BUETTNER R, 1991, MOL CELL BIOL, V11, P3573, DOI 10.1128/MCB.11.7.3573; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; HATA Y, 1990, J BIOL CHEM, V265, P7104; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KYRITSIS AP, 1992, INT J ONCOL, V1, P149; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Maniatis T., 1982, MOL CLONING; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MARUTA H, 1991, J BIOL CHEM, V266, P11661; NISHI T, 1991, ONCOGENE, V6, P1555; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; NUREKAMAL MSA, 1992, MOL BIOL CELL, V3, P1437, DOI 10.1091/mbc.3.12.1437; RESAR LMS, 1993, MOL CELL BIOL, V13, P1130, DOI 10.1128/MCB.13.2.1130; STRAHEY M, 1987, SCIENCE, V238, P542; SUGIMOTO Y, 1991, CANCER RES, V51, P99; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	31	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22331	22337						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226742				2022-12-27	WOS:A1993MD34800024
J	REYES, AM; IRIARTE, A; MARTINEZCARRION, M				REYES, AM; IRIARTE, A; MARTINEZCARRION, M			REFOLDING OF THE PRECURSOR AND MATURE FORMS OF MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE AFTER GUANIDINE-HYDROCHLORIDE DENATURATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; MOLTEN GLOBULE STATE; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; CONFORMATIONAL CHANGES; FOLDING INTERMEDIATE; PROTEIN-STRUCTURE; COENZYME BINDING; KINETIC ASPECTS; PIG-HEART	The mitochondrial isozyme of aspartate aminotransferase (mAspAT), a dimeric pyridoxal phosphate (PLP)-dependent enzyme, is encoded by the nuclear genome and synthesized in the cytoplasm as a precursor protein (pmAspAT) containing a 29-residue amino-terminal signal peptide which is essential for its targeting and import into mitochondria. In the cytosolic-like environment of rabbit reticulocyte lysate, newly synthesized rat liver pmAspAT has been found to slowly fold and bind PLP (Mattingly, J. R., Jr., Youssef, J., Iriarte, A. and Martinez-Carrion, M. (1993) J. Biol. Chem. 268, 3925-3937). On the other hand, isolated mammalian (pig) mAspAT, when denatured with guanidine hydrochloride, seems unable to refold to a catalytically active state (West, S. M., and Price, N. C. (1990) Biochem. J. 265, 45-50). With the availability of rat liver recombinant precursor and mature forms of mAspAT as homogeneous, stable preparations, an assessment of the influence of the signal peptide on the in vitro refolding of this protein can be made. Following unfolding induced by guanidine hydrochloride, we have investigated the refolding process of this complex, dimeric coenzyme-dependent protein system by activity, fluorescence, and circular dichroism. Both mAspAT and pmAspAT can be efficiently renatured after rapid dilution of the denaturing agent at low protein concentrations. The equilibrium unfolding/refolding transitions and the kinetics of folding are protein concentration-independent and identical for both protein forms. Binding of coenzyme into the active site pocket seems to occur at a late step in the folding process of both mAspAT and pmAspAT, suggesting that in these proteins the coenzyme does not direct the folding of the polypeptide chain. These results indicate that the in vitro refolding of mAspAT is not regulated or influenced by the presence of the amino-terminal signal peptide. On the other hand, in vitro refolding in buffer is significantly faster than the folding of newly synthesized precursor protein in reticulocyte lysate examined in our previous report (reference above), pointing at the likely influence of cytosolic factors in modulating folding in the cell.	UNIV MISSOURI,SCH BIOL SCI,DIV MOLEC BIOL & BIOCHEM,109 BIOL SCI BLDG,KANSAS CITY,MO 64110	University of Missouri System; University of Missouri Kansas City					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038184] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38412] Funding Source: Medline; NIGMS NIH HHS [GM-38184] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI F, 1989, J BIOL CHEM, V264, P4782; ARNONE A, 1982, MOL STRUCTURE BIOL A, P57; ARRIODUPONT M, 1979, BIOCHEM BIOPH RES CO, V89, P345, DOI 10.1016/0006-291X(79)90636-3; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BERTLAND LH, 1970, BIOCHEMISTRY-US, V9, P2653, DOI 10.1021/bi00815a014; BOETTCHER B, 1975, BIOCHEMISTRY-US, V14, P4528, DOI 10.1021/bi00691a030; BURNS DL, 1982, J BIOL CHEM, V257, P8638; CHAFFOTTE AF, 1983, BIOCHEMISTRY-US, V22, P2708, DOI 10.1021/bi00280a019; CHEN WJ, 1987, J BIOL CHEM, V262, P15598; CHENG S, 1972, J BIOL CHEM, V247, P6597; CHIEN JY, 1948, J AM CHEM SOC, V70, P2256, DOI 10.1021/ja01186a078; CHOI SY, 1986, EUR J BIOCHEM, V161, P289, DOI 10.1111/j.1432-1033.1986.tb10445.x; CHRISTEN P, 1985, TRANSAMINASES, P173; EICHELE G, 1979, J MOL BIOL, V133, P161, DOI 10.1016/0022-2836(79)90255-9; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FELIPO V, 1983, EUR J BIOCHEM, V133, P641, DOI 10.1111/j.1432-1033.1983.tb07511.x; FORD GC, 1980, P NATL ACAD SCI-BIOL, V77, P2559, DOI 10.1073/pnas.77.5.2559; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIARTOSI.A, 1973, FEBS LETT, V31, P339, DOI 10.1016/0014-5793(73)80136-X; GOLDBERG ME, 1990, FEBS LETT, V263, P51, DOI 10.1016/0014-5793(90)80703-L; GROHA C, 1978, EUR J BIOCHEM, V92, P437, DOI 10.1111/j.1432-1033.1978.tb12764.x; GUTFREUND H, 1972, ENZYMES PHYSICAL PRI, P159; HERMANN R, 1983, NATURWISSENSCHAFTEN, V70, P517, DOI 10.1007/BF00394060; HERMANN R, 1983, J BIOL CHEM, V258, P1014; HEROLD M, 1992, FEBS LETT, V308, P26, DOI 10.1016/0014-5793(92)81042-K; HEROLD M, 1990, BIOCHEMISTRY-US, V29, P1907, DOI 10.1021/bi00459a035; HEROLD M, 1991, BIOCHEMISTRY-US, V30, P3612, DOI 10.1021/bi00229a004; IRIARTE A, 1985, J BIOL CHEM, V260, P7457; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JAENICKE R, 1979, BIOCHEMISTRY-US, V18, P1217, DOI 10.1021/bi00574a016; Jaenicke R, 1986, Methods Enzymol, V131, P218; JAENICKE R, 1982, BIOCHEMISTRY-US, V21, P3378, DOI 10.1021/bi00257a020; JAENICKE R, 1980, P NATL ACAD SCI-BIOL, V77, P1966, DOI 10.1073/pnas.77.4.1966; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; JANSONIUS JN, 1984, CHEM BIOL ASPECTS B, P195; JANSONIUS JN, 1985, TRANSAMINASES, P109; JAUSSI R, 1987, J BIOL CHEM, V262, P12434; JENG JJ, 1991, ARCH BIOCHEM BIOPHYS, V289, P214, DOI 10.1016/0003-9861(91)90464-T; KALOUSEK F, 1984, J BIOL CHEM, V259, P5392; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; LEISTLER B, 1992, EUR J BIOCHEM, V205, P603, DOI 10.1111/j.1432-1033.1992.tb16818.x; LIU G, 1988, J BIOL CHEM, V263, P14790; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; MARTINEZ-CARRION M, 1970, Journal of Biological Chemistry, V245, P799; MARTINEZCARRION M, 1967, J BIOL CHEM, V242, P2397; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; METZLER DE, 1982, FED PROC, V41, P2432; MURAKAMI K, 1988, J BIOL CHEM, V263, P18437; MURAKAMI K, 1990, J BIOCHEM-TOKYO, V108, P207, DOI 10.1093/oxfordjournals.jbchem.a123182; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; ONO H, 1985, J BIOL CHEM, V260, P3402; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; Pace C N, 1986, Methods Enzymol, V131, P266; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RELIMPIO A, 1981, J BIOL CHEM, V256, P4478; RUDOLPH R, 1977, EUR J BIOCHEM, V81, P563, DOI 10.1111/j.1432-1033.1977.tb11983.x; RUDOLPH R, 1986, BIOCHEMISTRY-US, V25, P1662, DOI 10.1021/bi00355a033; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHMID D, 1992, EUR J BIOCHEM, V208, P699, DOI 10.1111/j.1432-1033.1992.tb17237.x; TEIPEL JW, 1971, BIOCHEMISTRY-US, V10, P792, DOI 10.1021/bi00781a011; TEIPEL JW, 1971, BIOCHEMISTRY-US, V10, P798, DOI 10.1021/bi00781a012; WEST SM, 1989, BIOCHEM J, V261, P189, DOI 10.1042/bj2610189; WEST SM, 1990, BIOCHEM J, V265, P45, DOI 10.1042/bj2650045	74	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22281	22291						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226737				2022-12-27	WOS:A1993MD34800018
J	SUGIMOTO, S; LECHLEIDER, RJ; SHOELSON, SE; NEEL, BG; WALSH, CT				SUGIMOTO, S; LECHLEIDER, RJ; SHOELSON, SE; NEEL, BG; WALSH, CT			EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF SH2-CONTAINING PROTEIN-TYROSINE-PHOSPHATASE, SH-PTP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; BINDING-SITE; SH2 DOMAINS; PHOSPHATIDYLINOSITOL-3 KINASE; SEQUENCE SIMILARITY; HUMAN-PLACENTA; EGF RECEPTOR; BETA-SUBUNIT; DROSOPHILA; TORSO	A human protein tyrosine phosphatase containing two src homology 2 (SH2) domains (SH-PTP2) was expressed in Escherichia coli under T7 promoter control and purified to near homogeneity. The purified protein, with molecular mass of 68 kDa on SDS-polyacrylamide gel electrophoresis, was identified as SH-PTP2 by its protein tyrosine phosphatase activity and N-terminal amino acid sequence analysis. Its protein tyrosine phosphatase activity was sensitive to pH and salt concentration. Whereas its optimum pH for the low molecular weight substrate para-nitrophenyl phosphate is 5.6, the pH optima for peptide substrates were shifted toward neutral. With the artificial protein substrate reduced, carboxy-amidomethylated, and maleylated lysozyme, it displays 2000-fold lower K(m) (1.7 muM) and 2.4-fold higher k(cat) (0.11 s-1) than with para-nitrophenyl phosphate. Among the phosphopeptides from autophosphorylation sites of receptors for epidermal growth factor and platelet-derived growth factor, SH-PTP2 displayed high activity toward phosphopeptides corresponding to pY992 of the epidermal growth factor receptor and pY1009 and pY1021 of the platelet-derived growth factor receptor. In further enzymatic studies with phosphopeptides corresponding to pY1009, SH-PTP2 showed nonlinear Line-weaver-Burk double-reciprocal plots, suggesting that the phosphopeptide corresponding to pY1009 may have a substrate and allosteric effect.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, 240 LONGWOOD AVE, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, JOSLIN DIABET CTR, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, MOLEC MED UNIT, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, DIV PULM MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020011, R01GM020011] Funding Source: NIH RePORTER; NIDCR NIH HHS [DERC 36836] Funding Source: Medline; NIGMS NIH HHS [GM20011] Funding Source: Medline; PHS HHS [49152] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIRAGA A, 1992, EUR J BIOCHEM, V209, P195, DOI 10.1111/j.1432-1033.1992.tb17277.x; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; HUNTER T, 1986, ENZYMES, V17, P191; KAHISHIAN A, 1992, EMBO J, V11, P1373; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARTIN B, 1985, J BIOL CHEM, V260, P4932; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; PLUTZKY J, 1992, GENOMICS, V13, P869, DOI 10.1016/0888-7543(92)90172-O; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; POT DA, 1991, J BIOL CHEM, V266, P19688; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	58	81	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22771	22776						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226787				2022-12-27	WOS:A1993MD34800085
J	YANG, XJ; MILES, EW				YANG, XJ; MILES, EW			A NOVEL INTERSUBUNIT REPAIR MECHANISM IN THE TRYPTOPHAN SYNTHASE ALPHA(2)BETA(2)-COMPLEX - CRITICAL ROLE OF THE BETA-SUBUNIT LYSINE-167 IN INTERSUBUNIT COMMUNICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SITE-SPECIFIC MUTAGENESIS; ESCHERICHIA-COLI; ALPHA-SUBUNIT; BIENZYME COMPLEX; SALMONELLA-TYPHIMURIUM; ALLOSTERIC INTERACTIONS; CONFORMATIONAL-CHANGES; CATALYTIC ACTIVITY; BINDING; ALPHA-2-BETA-2-COMPLEX	This study explores intersubunit communication in the tryptophan synthase alpha2beta2 complex from Salmonella typhimurium. We find that an engineered mutation in the contact region between the alpha and beta subunits remarkably alters the catalytic and spectroscopic properties of the beta subunit in the alpha2beta2 complex. Ligands that bind to the alpha subunit largely repair the deleterious effects of the beta subunit mutation in the alpha2beta2 complex. The conserved residue chosen for mutation, beta subunit lysine 167, appears to form an ion pair with alpha subunit aspartate 56 in the crystal structure of the wild type alpha2beta2 complex. Although replacement of beta subunit lysine 167 by threonine does not prevent formation of the alpha2beta2 complex, this mutation reduces the rate of synthesis of L-tryptophan from L-serine and indole (beta reaction) 25-fold. Ligands that bind to the alpha subunit (indole-3-glycerol phosphate, indole-3-propanol phosphate, alpha-glycerol 3-phosphate, or potassium phosphate) largely restore the activity of the mutant alpha2beta2 complex in the beta reaction. We conclude that beta subunit lysine 167 plays an important role in intersubunit communication in the alpha2beta2 complex. The striking allosteric effects of alpha subunit ligands on the mutant beta subunit in the alpha2beta2 complex may result from ligand-induced conformational changes in the alpha subunit that are transmitted to the beta subunit and repair the mutational defect in the beta subunit.	NIDDKD, BIOCHEM PHARMACOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								AHMED SA, 1991, J BIOL CHEM, V266, P21548; BERGER FG, 1975, J BACTERIOL, V124, P800, DOI 10.1128/JB.124.2.800-809.1975; BRZOVIC PS, 1992, J BIOL CHEM, V267, P13028; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P1180, DOI 10.1021/bi00119a030; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; BURNS DM, 1989, J BIOL CHEM, V264, P3840; CRAWFORD IP, 1989, BIOCHIMIE, V71, P521, DOI 10.1016/0300-9084(89)90183-1; CRAWFORD IP, 1964, P NATL ACAD SCI USA, V51, P390, DOI 10.1073/pnas.51.3.390; CREIGHTON TE, 1966, J BIOL CHEM, V241, P980; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNN MF, 1987, INDIAN J BIOCHEM BIO, V24, P44; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; DUNN MF, 1991, INT UNION B, V199, P257; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KIRSCHNER K, 1975, EUR J BIOCHEM, V60, P513, DOI 10.1111/j.1432-1033.1975.tb21030.x; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1984, EMBO J, V3, P279, DOI 10.1002/j.1460-2075.1984.tb01797.x; LIM WK, 1991, J BACTERIOL, V173, P1886, DOI 10.1128/jb.173.6.1886-1893.1991; LIM WK, 1992, ARCH BIOCHEM BIOPHYS, V292, P34, DOI 10.1016/0003-9861(92)90047-Z; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1980, BIOCH MED ASPECTS TR, P137; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; MOZZARELLI A, 1991, INT UNION B, V199, P273; NAGATA S, 1989, J BIOL CHEM, V264, P6288; OGASAHARA K, 1992, J BIOL CHEM, V267, P5222; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; STRAMBINI GB, 1992, BIOCHEMISTRY-US, V31, P7535, DOI 10.1021/bi00148a014; Swift S, 1991, Biotechnol Genet Eng Rev, V9, P229; YANG XJ, 1992, PROTEIN EXPRES PURIF, V3, P347, DOI 10.1016/1046-5928(92)90011-K; YANG XJ, 1992, J BIOL CHEM, V267, P7520; Yanofsky C., 1972, ENZYMES, P1, DOI [10.1016/s1874-6047(08)60445-x, DOI 10.1016/S1874-6047(08)60445-X]; YUTANI K, 1987, J BIOL CHEM, V262, P13429	41	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22269	22272						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226734				2022-12-27	WOS:A1993MD34800015
J	BIANCHI, V; FERRARO, P; BORELLA, S; BONVINI, P; REICHARD, P				BIANCHI, V; FERRARO, P; BORELLA, S; BONVINI, P; REICHARD, P			EFFECTS OF MUTATIONAL LOSS OF NUCLEOSIDE KINASES ON DEOXYADENOSINE 5'-PHOSPHATE DEOXYADENOSINE SUBSTRATE CYCLE IN CULTURED CEM AND V79 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEOSIDE-TRIPHOSPHATE POOLS; HAMSTER-CELLS; PICOMOLE AMOUNTS; MAMMALIAN-CELLS; DNA-SYNTHESIS; DEOXYCYTIDINE; LYMPHOBLASTS; METABOLISM; TOXICITY; DATP	The functions of a deoxynucleoside kinase and a deoxynucleotidase can give rise to substrate cycles in which the two enzymes catalyze in opposite directions the irreversible interconversion of a deoxynucleoside 5'-monophosphate (dNMP) and its deoxynucleoside. Earlier evidence showed that pyrimidine dNMP cycles occur in cultured cells and participate in the regulation of the size of dNMP pools there by affecting the transport of deoxyribonucleosides across the cell membrane. Here, we apply an isotope flow method using labeled adenine as precursor of dAMP and DNA to quantify deoxyadenosine excretion as a measure of the catabolic activity of a putative dAMP/deoxyadenosine cycle. A comparison of human CEM lymphoblasts and hamster V79 fibroblasts, including mutant cells lacking kinases for the phosphorylation of deoxyadenosine, shows a much lower deoxyadenosine excretion in CEM cells (0.05% of dATP synthesized by reduction of ADP) as compared with V79 cells (4% of dATP). Mutational loss of deoxycytidine kinase increases these values to 0.3% in CEM cells and to 10% in V79 cells. This strongly suggests the presence of a dAMP/deoxyadenosine cycle in both CEM and V79 cells. Additional loss of adenosine kinase only marginally affects deoxyadenosine excretion in CEM cells. The small excretion of deoxyadenosine (also in the absence of both kinases) demonstrates that in CEM cells the in situ activity of the deoxynucleotidase affecting the dAMP/deoxyadenosine substrate cycle is very low and that the cycle has mainly an anabolic function there.			BIANCHI, V (corresponding author), UNIV PADUA,DEPT BIOL,VIA TRIESTE 75,I-35121 PADUA,ITALY.		Bonvini, Paolo/J-9877-2018	Bonvini, Paolo/0000-0003-2889-108X				BIANCHI V, 1986, P NATL ACAD SCI USA, V83, P986, DOI 10.1073/pnas.83.4.986; BIANCHI V, 1992, EXP CELL RES, V199, P120, DOI 10.1016/0014-4827(92)90469-O; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; CARRERA CJ, 1987, MOL BASIS BLOOD DISE, P407; CARSON DA, 1981, J IMMUNOL, V126, P348; CARSON DA, 1991, BIOCHIM BIOPHYS ACTA, V1091, P22, DOI 10.1016/0167-4889(91)90216-K; De Serres F. S., 1985, GENETIC CONSEQUENCES; DURHAM JP, 1969, MOL PHARMACOL, V5, P358; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; HELLGREN D, 1979, BIOCHEM BIOPH RES CO, V88, P16, DOI 10.1016/0006-291X(79)91690-5; HERSHFIELD MS, 1982, J BIOL CHEM, V257, P6380; HOGLUND L, 1991, EUR J BIOCHEM, V196, P239, DOI 10.1111/j.1432-1033.1991.tb15810.x; HOGLUND L, 1988, CANCER RES, V48, P3681; IIZASA T, 1983, J IMMUNOL, V131, P1776; LINDBERG U, 1970, ANAL BIOCHEM, V34, P152, DOI 10.1016/0003-2697(70)90096-5; MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6; NICANDER B, 1985, J BIOL CHEM, V260, P9216; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SKOOG KL, 1973, EUR J BIOCHEM, V33, P428, DOI 10.1111/j.1432-1033.1973.tb02699.x; SKOOG L, 1970, EUR J BIOCHEM, V17, P202, DOI 10.1111/j.1432-1033.1970.tb01154.x	21	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16677	16683						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206987				2022-12-27	WOS:A1994NR29600027
J	WANG, DJ; HUANG, NN; HELLER, EJ; HEPPEL, LA				WANG, DJ; HUANG, NN; HELLER, EJ; HEPPEL, LA			A NOVEL SYNERGISTIC STIMULATION OF SWISS 3T3 CELLS BY EXTRACELLULAR ATP AND MITOGENS WITH OPPOSITE EFFECTS ON CAMP LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP ACCUMULATION; PROTEIN-KINASE-C; TRANSDUCTION PATHWAYS LEAD; HUMAN-LUNG FIBROBLASTS; BETA-GAMMA-SUBUNITS; PROSTAGLANDIN SYNTHESIS; ADENYLYL CYCLASE; SIGNALING PATHWAYS; MAMMALIAN-CELLS; GROWTH-FACTORS	In Swiss 3T3 mouse fibroblasts, the mitogenic effect of extracellular ATP depends on stimulation of adenylyl cyclase. Lysophosphatidic acid (LPA) and phosphatidic acid (PA) inhibited adenylyl cyclase but synergized with ATP in mitogenic stimulation. This unusual synergism of two mitogens with opposite effects on cAMP levels was further investigated. LPA and PA inhibited the elevation of cAMP caused by cholera toxin, prostaglandin E(2), or forskolin, but not the rise induced by ATP. In fact, ATP overcame the inhibitory effects of LPA or PA on cAMP levels. Indeed, in the presence of ATP and either cholera toxin or prostaglandin E(2), LPA became a stimulator of adenylyl cyclase. Stimulation of DNA synthesis and inhibition of cAMP accumulation by LPA were inhibited by pertussis toxin, but with different dose-response characteristics. In addition, a normal mitogenic response to LPA was obtained in transfected mutant cells with a defective regulatory subunit for protein kinase A and in cells whose regulation of cAMP levels was abnormal because of overproduction of cAMP phosphodiesterase. The data support the hypothesis that the mitogenic effect of LPA involves a PTX-sensitive G(i) protein but not inhibition of adenylyl cyclase.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University					NCI NIH HHS [5 RO1 CA58518] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058518] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURCH RM, 1989, J CELL PHYSIOL, V139, P29, DOI 10.1002/jcp.1041390106; DIAZLAVIADA I, 1991, J BIOL CHEM, V266, P1170; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GOLDSTEIN RH, 1984, PROSTAGLANDINS, V28, P717, DOI 10.1016/0090-6980(84)90180-1; HELDIN NE, 1989, J CELL PHYSIOL, V138, P17, DOI 10.1002/jcp.1041380104; HORIBATA K, 1970, EXP CELL RES, V60, P61, DOI 10.1016/0014-4827(70)90489-1; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HSIE AW, 1971, P NATL ACAD SCI USA, V68, P358, DOI 10.1073/pnas.68.2.358; HUANG N, 1994, J BIOL CHEM, V269, P548; HUANG NN, 1993, J BIOL CHEM, V268, P10789; HUANG NN, 1991, J CELL PHYSIOL, V146, P483, DOI 10.1002/jcp.1041460320; HUANG NN, 1989, P NATL ACAD SCI USA, V86, P7904, DOI 10.1073/pnas.86.20.7904; KELVIN DJ, 1989, J CELL BIOL, V108, P159, DOI 10.1083/jcb.108.1.159; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; KUMAGAI N, 1993, FEBS LETT, V311, P195; MASUI H, 1971, P NATL ACAD SCI USA, V68, P3206, DOI 10.1073/pnas.68.12.3206; MILLAR JBA, 1988, J CELL PHYSIOL, V137, P214, DOI 10.1002/jcp.1041370203; MOOLENAAR WH, 1992, REV PHYSIOL BIOCH P, V119, P47; MURAYAMA T, 1987, J BIOL CHEM, V262, P12463; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RALPH RK, 1983, FEBS LETT, V161, P1, DOI 10.1016/0014-5793(83)80719-4; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WANG D, 1990, BIOCHEM BIOPH RES CO, V166, P251, DOI 10.1016/0006-291X(90)91938-O; WANG DJ, 1991, J CELL PHYSIOL, V146, P473, DOI 10.1002/jcp.1041460319; WANG DJ, 1992, J CELL PHYSIOL, V153, P221, DOI 10.1002/jcp.1041530202; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; ZHANG H, 1990, J BIOL CHEM, V265, P76	34	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16648	16655						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206984				2022-12-27	WOS:A1994NR29600023
J	ANDERSEN, JP; VILSEN, B				ANDERSEN, JP; VILSEN, B			AMINO-ACIDS ASN(796) AND THR(799) OF THE CA2+-ATPASE OF SARCOPLASMIC-RETICULUM BIND CA2+ AT DIFFERENT SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; CALCIUM-PUMP; RECONSTITUTED PROTEOLIPOSOMES; TRANSMEMBRANE DOMAIN; ATPASE; CA-2+-ATPASE; MECHANISM; TRANSPORT; CA-2+; PHOSPHORYLATION	The Ca2+-binding properties of mutants Asn(798) --> Ala, Thr(799) --> Ala, and Glu(908) -->) Ala of the sarcoplasmic reticulum Ca2+-ATPase were analyzed in studies of CrATP-induced Ca2+ occlusion and of the Ca2+ dependencies of phosphorylation from ATP and P-i. The Asn(796) --> Ala and Thr(799) --> Ala mutants were unable to occlude Ca2+, whereas the Glu(908) --> Ala mutant was fully capable of occluding Ca2+. Mutant Asn(796) --> Ala was unable to form a phosphoenzyme from ATP, whereas mutants Thr(799), Ala and Glu(908) --> Ala phosphorylated from ATP with K-0.5 values for Ca2+ activation of 3 and 0.4 mM, respectively. In the Asn(796) --> Ala mutant, Ca2+ inhibited phosphorylation from P-i with a K-0.5 value of less than 10 mu M, whereas in mutants Thr(799) --> Ala and Glu(908) --> Ala, the K-0.5 values for Ca2+ inhibition of phosphorylation from P-i were much higher and similar to the K-0.5 values observed for Ca2+ activation of phosphorylation from ATP. These data are consistent with a model in which the respective side chains of Asn(796) and Thr(799) are assigned to two different Ca2+ sites being involved in Ca2+ occlusion, while the side chain of Glu(908) is excluded as a direct Ca2+ ligand in the Ca2+ occluded complex. The dephosphorylation of the ADP-insensitive E(2)P phosphoenzyme intermediate was blocked in the Asn(796) --> Ala mutant, suggesting the possibility that Asn(796) participates in the countertransport of protons.			ANDERSEN, JP (corresponding author), AARHUS UNIV,DANISH BIOMEMBRANE RES CTR,INST PHYSIOL,OLE WORMS ALLE 160,UNIV PARKEN,DK-8000 AARHUS C,DENMARK.			Andersen, Jens Peter/0000-0003-0654-4300; Vilsen, Bente/0000-0002-4727-9382				ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; ANDERSEN JP, 1992, ACTA PHYSIOL SCAND, V146, P151; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; CLARKE DM, 1993, J BIOL CHEM, V268, P18359; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1981, TRANSPORT LIFE SCI, V2; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; Forbush B 3rd, 1988, Prog Clin Biol Res, V268A, P229; FORGE V, 1993, J BIOL CHEM, V268, P10953; FUJIMORI T, 1992, J BIOL CHEM, V267, P18475; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; JENCKS WP, 1993, BIOCHEMISTRY-US, V32, P7030, DOI 10.1021/bi00078a031; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KLEMENS MR, 1988, BIOCHEM BIOPH RES CO, V155, P236, DOI 10.1016/S0006-291X(88)81074-X; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVY D, 1990, J BIOL CHEM, V265, P19524; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MCINTOSH DB, 1991, P NATL ACAD SCI USA, V88, P6437, DOI 10.1073/pnas.88.15.6437; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P11331, DOI 10.1021/bi00111a020; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANFORD C, 1987, P NATL ACAD SCI USA, V84, P7094, DOI 10.1073/pnas.84.20.7094; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1992, J BIOL CHEM, V267, P3539; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1992, FEBS LETT, V306, P247, DOI 10.1016/0014-5793(92)81010-J; VILSEN B, 1987, BIOCHIM BIOPHYS ACTA, V898, P313, DOI 10.1016/0005-2736(87)90072-1; VILSEN B, 1989, J BIOL CHEM, V264, P21024; YU X, 1993, BIOPHYS J, V64, P1232, DOI 10.1016/S0006-3495(93)81489-9	43	80	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15931	15936						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195248				2022-12-27	WOS:A1994NP51300082
J	GOLDMAN, PS; NATHANSON, NM				GOLDMAN, PS; NATHANSON, NM			DIFFERENTIAL ROLE OF THE CARBOXYL-TERMINAL TYROSINE IN DOWN-REGULATION AND SEQUESTRATION OF THE M2 MUSCARINIC ACETYLCHOLINE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; DENSITY-LIPOPROTEIN RECEPTOR; NEURO-BLASTOMA CELLS; CULTURED HEART-CELLS; CHOLINERGIC RECEPTORS; CYTOPLASMIC DOMAIN; BINDING PROTEIN; INTERNALIZATION; ENDOCYTOSIS; AGONIST	Muscarinic acetylcholine receptor (mAChR) number can be altered in response to sustained agonist exposure. Short term agonist exposure (seconds to minutes) causes a rapid removal of mAChR from the cell surface (sequestration) while agonist exposure for longer periods of time (hours) causes a decrease in total receptor number (down-regulation). Tyrosine residues located in the cytoplasmic tails of a number of membrane receptors have been demonstrated to be important in the regulation by either sequestration, as is the case with the mannose 6-phosphate receptor and other receptors endocytosed via clathrin coated vesicles, or down-regulation, as is the case with the beta(2)-adrenergic receptor. Mutation of the lone cytoplasmic tail tyrosine residue (Tyr-459) of the mammalian m2 mAChR to Phe, Trp, or Ala did not affect agonist-induced sequestration, although it significantly attenuated agonist-induced down-regulation. Conversion of m2 Tyr-459 to lie did not affect the rate or extent of agonist-induced sequestration or down-regulation, but the sensitivity of this mutant receptor to agonist-induced down-regulation was slightly decreased. Agonist and antagonist binding as well as functional coupling to the inhibition of cAMP accumulation was unaffected by any of the mutations to Tyr-459. These results are the first to identify a site in a mAChR involved in the down-regulation of receptor in response to agonist.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL44948] Funding Source: Medline; NIGMS NIH HHS [GM07750] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FEIGENBAUM P, 1985, J PHARMACOL EXP THER, V233, P134; GALPER JB, 1982, J BIOL CHEM, V257, P344; GALPER JB, 1980, J BIOL CHEM, V255, P9571; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDMAN PS, 1992, SOC NEUR ABSTR, V18, P387; HALVORSEN SW, 1981, J BIOL CHEM, V256, P7941; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HERTEL C, 1990, J BIOL CHEM, V265, P17988; HUNTER DD, 1984, P NATL ACAD SCI-BIOL, V81, P3582, DOI 10.1073/pnas.81.11.3582; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JONES DT, 1987, J BIOL CHEM, V262, P14241; KLEIN WL, 1979, BIOCHEM BIOPH RES CO, V90, P506, DOI 10.1016/0006-291X(79)91264-6; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LILES WC, 1986, J BIOL CHEM, V261, P5307; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MALOTEAUX JM, 1983, FEBS LETT, V156, P103, DOI 10.1016/0014-5793(83)80257-9; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MIGEON JC, 1994, IN PRESS J BIOL CHEM, V269; MORO O, 1993, J BIOL CHEM, V268, P6862; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; NATHANSON NM, 1989, MUSCARINIC RECEPTORS, P419; NATHANSON NM, 1992, METHODS NEUROSCI, V9, P116; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; Sambrook J, 1989, MOL CLONING LABORATO; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; TAYLOR JE, 1979, LIFE SCI, V25, P2181, DOI 10.1016/0024-3205(79)90090-0; VALIQUETTE M, 1993, BIOCHEMISTRY-US, V32, P4979, DOI 10.1021/bi00070a002; VALIQUETTE M, 1990, P NATL ACD SCI US, V87, P5989; WANG SZ, 1990, FEBS LETT, V276, P185, DOI 10.1016/0014-5793(90)80538-T; YU SS, 1993, J BIOL CHEM, V268, P337	42	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15640	15645						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195213				2022-12-27	WOS:A1994NP51300041
J	VOZNESENSKY, AI; SCHENKMAN, JB				VOZNESENSKY, AI; SCHENKMAN, JB			QUANTITATIVE-ANALYSES OF ELECTROSTATIC INTERACTIONS BETWEEN NADPH-CYTOCHROME P450 REDUCTASE AND CYTOCHROME-P450 ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; NADPH-CYTOCHROME-P-450 REDUCTASE; P-450 REDUCTASE; RAT-LIVER; BETA-NAPHTHOFLAVONE; HEPATIC MICROSOMES; INDUCIBLE FORMS; PURIFICATION; MECHANISM; COMPLEX	A decline in the ionic interactions in the medium with increasing ionic strength (decrease in the ionic activity coefficients) was accompanied by an increase in the fast phase rate constants of CYP2B4 and CYP1A2 reduction. The stimulations were observed both in reconstituted P450 systems and in microsomes. An increase in the ionic strength from 10 to 100 mM sodium phosphate resulted in a 7-fold decrease in the K-m of CYP1A2 for NADPH-cytochrome P450 reductase, while the V-max was unchanged. When ionic interactions were neutralized without changing the ionic strength by addition of charged oligopeptides (polylysine and polyglutamic acid), stimulations of CYP1A2 and CYP2B4 reduction were observed. Increase in the ionic strength also enhanced the rate of cytochrome P450 reduction in control and phenobarbital-induced rat liver microsomes and in reconstituted systems containing purified rat liver CYP2C6, CYP2C12, CYP2C13, and CYP2E1, and rat reductase. A method was devised for the quantification of the number of charges involved in protein-protein interactions based on the estimation of the ionic activity coefficients. Different numbers of charged residues are involved in the repulsion between different P450 forms and the reductase. The product of the number of charges involved in the interaction between rabbit reductase and CYP2B4 is 10.84 compared with the value of 6.64 for the reductase-CYP1A2 interaction.	UNIV CONNECTICUT,CTR HLTH,DEPT PHARMACOL,FARMINGTON,CT 06030	University of Connecticut					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026114] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26114] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTERMAN MA, 1990, BIOMED CHROMATOGR, V4, P221, DOI 10.1002/bmc.1130040510; BACKES WL, 1989, J BIOL CHEM, V264, P6252; BACKES WL, 1985, BIOCHEMISTRY-US, V24, P5139; BERNHARDT R, 1983, BIOCHIM BIOPHYS ACTA, V745, P140, DOI 10.1016/0167-4838(83)90042-0; BERNHARDT R, 1988, BIOMED BIOCHIM ACTA, V47, P581; BLANCK J, 1984, EUR J BIOCHEM, V144, P509, DOI 10.1111/j.1432-1033.1984.tb08495.x; CHEDDAR G, 1990, ARCH BIOCHEM BIOPHYS, V278, P265, DOI 10.1016/0003-9861(90)90257-Y; CHENG KC, 1982, J BIOL CHEM, V257, P2378; COGHLAN VM, 1992, J BIOL CHEM, V267, P8932; DAILEY HA, 1980, J BIOL CHEM, V255, P5184; DAILEY HA, 1979, J BIOL CHEM, V254, P5388; DIGNAM JD, 1975, BIOCHEM BIOPH RES CO, V63, P845, DOI 10.1016/0006-291X(75)90644-0; FAVREAU LV, 1987, J BIOL CHEM, V262, P14319; FOUTS JR, 1971, J PHARMACOL EXP THER, V179, P91; GASSER R, 1988, MOL PHARMACOL, V32, P22; GUENGERICH FP, 1982, BIOCHEMISTRY-US, V21, P6019, DOI 10.1021/bi00266a045; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; JANSSON I, 1985, DRUG METAB DISPOS, V13, P453; KAGAWA N, 1987, J BIOCHEM-TOKYO, V101, P1471, DOI 10.1093/oxfordjournals.jbchem.a122017; KATAGIRI M, 1986, J BIOCHEM-TOKYO, V100, P945, DOI 10.1093/oxfordjournals.jbchem.a121807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIDLER KJ, 1978, PHYSICAL CHEM BIOL A; MIWA GT, 1979, J BIOL CHEM, V254, P5695; MOCHAN E, 1970, BIOCHIM BIOPHYS ACTA, V216, P80, DOI 10.1016/0005-2728(70)90161-1; MOORE W, 1965, PHYSICAL CHEM; MULLERENOCH D, 1984, J BIOL CHEM, V259, P8174; NADLER SG, 1988, ARCH BIOCHEM BIOPHYS, V261, P418, DOI 10.1016/0003-9861(88)90358-X; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NG S, 1977, BIOCHEMISTRY-US, V16, P4975, DOI 10.1021/bi00642a006; OMURA T, 1964, J BIOL CHEM, V239, P2379; PERNECKY SJ, 1993, P NATL ACAD SCI USA, V90, P2651, DOI 10.1073/pnas.90.7.2651; SCHENK H, 1986, ENDOCYT CELL RES, V3, P107; SCHENKMAN JB, 1987, ARCH TOXICOL, V60, P43, DOI 10.1007/BF00296945; SCHWARZE W, 1985, CHEM-BIOL INTERACT, V54, P127, DOI 10.1016/S0009-2797(85)80158-7; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; SOGARA Y, 1993, ARCH BIOCHEM BIOPHYS, V304, P272; STRITTMATTER P, 1990, J BIOL CHEM, V265, P21709; TAMBURINI PP, 1986, ARCH BIOCHEM BIOPHYS, V245, P512, DOI 10.1016/0003-9861(86)90244-4; TAMBURINI PP, 1986, MOL PHARMACOL, V30, P178; TAMBURINI PP, 1985, J BIOL CHEM, V260, P4007; TAMBURINI PP, 1986, BIOCHEM BIOPH RES CO, V134, P519, DOI 10.1016/S0006-291X(86)80451-X; TAMURA M, 1990, ARCH BIOCHEM BIOPHYS, V280, P313, DOI 10.1016/0003-9861(90)90335-V; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; VOZNESENSKY AI, 1992, J BIOL CHEM, V267, P14669; VOZNESENSKY AI, 1992, EUR J BIOCHEM, V210, P741, DOI 10.1111/j.1432-1033.1992.tb17475.x; VOZNESENSKY AI, 1989, PHOSPHATIDYLCHOLINE, P147; WAGNER SL, 1987, BIOCHEMISTRY-US, V26, P2343, DOI 10.1021/bi00382a040; WU ES, 1984, BIOCHEMISTRY-US, V23, P28, DOI 10.1021/bi00296a005; ZHOU JS, 1991, J AM CHEM SOC, V113, P6067, DOI 10.1021/ja00016a021	50	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15724	15731						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195225				2022-12-27	WOS:A1994NP51300053
J	BAENZIGER, NL; MACK, P; JONG, YJI; DALEMAR, LR; PEREZ, N; LINDBERG, C; WILHELM, B; HADDOCK, RC				BAENZIGER, NL; MACK, P; JONG, YJI; DALEMAR, LR; PEREZ, N; LINDBERG, C; WILHELM, B; HADDOCK, RC			AN ENVIRONMENTALLY REGULATED RECEPTOR FOR DIAMINE OXIDASE MODULATES HUMAN ENDOTHELIAL CELL/FIBROBLAST HISTAMINE DEGRADATIVE UPTAKE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FIBROBLAST GROWTH-FACTOR; GAMMA-AMINOBUTYRIC ACID; LIPOPROTEIN-LIPASE; HEPARAN-SULFATE; PHORBOL ESTERS; PROSTACYCLIN SYNTHESIS; MEDIATED ENDOCYTOSIS; SKIN FIBROBLASTS; PHOSPHOLIPASE-C	Human vascular endothelial cells and fibroblasts express a cell-surface degradative pathway for the multifunctional mediator histamine, which employs a receptor for the metabolic enzyme diamine oxidase (DAO) and results in cellular accumulation of the final metabolite methylimidazoleacetic acid. We demonstrate recognition and regulatory properties of DAO receptors as a function of cellular environmental conditions. Fast and slow ligand binding receptor populations bind DAO at 4 degrees C maximally in 1 and 7 h, respectively; upon warming cells to 37 degrees C both populations participate in degradative uptake of histamine accumulated as methylimidazoleacetic acid. Bound DAO is displaced by heparin with 24-fold greater potency than dextran sulfate, implicating structural specificity of heparin-like glycosaminoglycan moieties as a critical factor in initial receptor/ enzyme interaction at fast and slow sites. Receptor-bound DAO is retained under mildly acidic conditions characteristic of early to mid endocytic intracellular compartments and thus could recycle to the plasma membrane intact after internalization. DAO initially bound to receptors in whole cells is retained through cell disruption/membrane fractionation procedures, but DAO binds poorly to isolated membrane fractions or presolubilized receptors, suggesting that the geometry of DAO binding components is not readily maintained upon cell disruption unless DAO is already bound. Cells down-regulate their complement of DAO receptors upon prolonged exposure to DAO. In cells plated at high density, half of the bound DAO becomes nondisplaceable by heparin within 15 min at 37 degrees C, a time consistent with receptor internalization, whereas cells plated at low density retain all bound DAO in a heparin-sensitive state. The protein kinase C activator phorbol 12-myristate 13-acetate modulates DAO receptor number by 35% and total histamine degradative uptake by >2 fold. Thus this pathway is subject to regulation at the levels of DAO receptor numbers, their state of cell-surface display, and additional cellular elements of the degradative pathway with which the DAO receptors interface.			BAENZIGER, NL (corresponding author), WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,660 S EUCLID AVE,BOX 8108,ST LOUIS,MO 63110, USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [T32AM007296] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007071] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 33699] Funding Source: Medline; NIADDK NIH HHS [2T32 AMO7296] Funding Source: Medline; NINDS NIH HHS [5T32 NS07071] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAENZIGER N L, 1990, Journal of Cell Biology, V111, p184A; BAENZIGER NL, 1981, CELL, V24, P915, DOI 10.1016/0092-8674(81)90117-3; BAENZIGER NL, 1980, BIOCHEM BIOPH RES CO, V92, P1435, DOI 10.1016/0006-291X(80)90447-7; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BAYLIN SB, 1973, J CLIN INVEST, V52, P1985, DOI 10.1172/JCI107383; BAYLIN SB, 1975, BIOCHIM BIOPHYS ACTA, V397, P294, DOI 10.1016/0005-2744(75)90119-9; BEAVEN MA, 1982, PHARM HISTAMINE RECE, P103; BERGERON JJM, 1985, ANNU REV PHYSIOL, V47, P383; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BOSNER MS, 1988, P NATL ACAD SCI USA, V85, P7438, DOI 10.1073/pnas.85.20.7438; BROCK TA, 1988, J CELL PHYSIOL, V136, P54, DOI 10.1002/jcp.1041360107; CARTER TD, 1989, BIOCHEM J, V262, P431, DOI 10.1042/bj2620431; CASTELLOT JJ, 1986, J CELL BIOL, V102, P1979, DOI 10.1083/jcb.102.5.1979; CHENG CF, 1981, J BIOL CHEM, V256, P2893; CHERIFI Y, 1992, J BIOL CHEM, V267, P25315; DAGOSTINO L, 1989, BIOCHIM BIOPHYS ACTA, V993, P228, DOI 10.1016/0304-4165(89)90169-4; DANIELE B, 1990, GASTROENTEROLOGY, V99, P1675, DOI 10.1016/0016-5085(90)90474-F; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; ERDMAN SH, 1989, GASTROENTEROLOGY, V96, P1533, DOI 10.1016/0016-5085(89)90523-4; FERREIRA SH, 1973, BRIT J PHARMACOL, V49, P543, DOI 10.1111/j.1476-5381.1973.tb17265.x; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; GRANERUS G, 1982, AGENTS ACTIONS, V12, P29, DOI 10.1007/BF01965102; GREEN JP, 1987, AGENTS ACTIONS, V22, P1, DOI 10.1007/BF01968810; HACHIYA HL, 1987, J BIOL CHEM, V262, P6417; HADDOCK RC, 1987, J BIOL CHEM, V262, P10220; HADDOCK RC, 1990, J BIOL CHEM, V265, P14395; HARDING C, 1983, BIOCHEM BIOPH RES CO, V113, P650, DOI 10.1016/0006-291X(83)91776-X; HARDING C, 1983, J CELL BIOL, V97, P329, DOI 10.1083/jcb.97.2.329; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HOUGH LB, 1979, J PHARMACOL EXP THER, V208, P422; IACOPETTA B, 1986, J CELL BIOL, V103, P851, DOI 10.1083/jcb.103.3.851; JONG YJI, 1993, P NATL ACAD SCI USA, V90, P10994, DOI 10.1073/pnas.90.23.10994; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P1207, DOI 10.1021/bi00600a011; KARLSSON K, 1988, BIOCHIM BIOPHYS ACTA, V967, P110, DOI 10.1016/0304-4165(88)90195-X; KEATING MT, 1988, J BIOL CHEM, V263, P12805; KHANDELWAL JK, 1989, J NEUROCHEM, V52, P1107, DOI 10.1111/j.1471-4159.1989.tb01854.x; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KOSHI S, 1991, BIOCHIM BIOPHYS ACTA, V1075, P231, DOI 10.1016/0304-4165(91)90271-H; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESSOF MH, 1990, CLIN EXP ALLERGY, V20, P373, DOI 10.1111/j.1365-2222.1990.tb02796.x; LUK GD, 1980, J CLIN INVEST, V66, P66, DOI 10.1172/JCI109836; MILLER LP, 1986, J NEUROCHEM, V46, P1412, DOI 10.1111/j.1471-4159.1986.tb01756.x; MONDOVI B, 1981, ADV POLYAMINE RES, V3, P75; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; OHRUI T, 1992, J PHARMACOL EXP THER, V261, P1268; OOSTING E, 1987, AGENTS ACTIONS, V21, P54, DOI 10.1007/BF01974921; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; REILLY MA, 1971, BRIT J PHARMACOL, V43, P349; ROBINSONWHITE A, 1985, J CLIN INVEST, V76, P93, DOI 10.1172/JCI111983; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SESSA A, 1982, BIOCHIM BIOPHYS ACTA, V698, P11, DOI 10.1016/0167-4781(82)90177-4; SHAKIR KMM, 1977, BIOCHEM PHARMACOL, V26, P2343, DOI 10.1016/0006-2952(77)90438-5; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; SICZKOWSKI M, 1992, BLOOD, V80, P912; SUNKARA PS, 1981, LIFE SCI, V28, P1497, DOI 10.1016/0024-3205(81)90382-9; SWANSON JA, 1985, J CELL BIOL, V100, P851, DOI 10.1083/jcb.100.3.851; TAKEDA T, 1992, J CELL SCI, V101, P745; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; VIHINEN T, 1993, J BIOL CHEM, V268, P17261; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	63	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14892	14898						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195119				2022-12-27	WOS:A1994NP73800010
J	EKRYLANDER, B; FLORES, M; WENDEL, M; HEINEGARD, D; ANDERSSON, G				EKRYLANDER, B; FLORES, M; WENDEL, M; HEINEGARD, D; ANDERSSON, G			DEPHOSPHORYLATION OF OSTEOPONTIN AND BONE SIALOPROTEIN BY OSTEOCLASTIC TARTRATE-RESISTANT ACID-PHOSPHATASE - MODULATION OF OSTEOCLAST ADHESION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							JB6 EPIDERMAL-CELLS; RAT-KIDNEY CELLS; SECRETED PHOSPHOPROTEIN-1; DEVELOPMENTAL EXPRESSION; PHYSIOLOGICAL-PROPERTIES; NONPHOSPHORYLATED FORMS; BINDING-PROPERTIES; PROTEINS; INTEGRIN; MATRIX	The tartrate-resistant acid phosphatase (TRAP) of skeletal osteoclasts was found to partially dephosphorylate the bone matrix phosphoproteins osteopontin (OPN) and bone sialoprotein (BSP). TRAP also partially dephosphorylated metabolically [P-32]PO4-labeled OPN as well as BSP, whereas comparable amounts of either alkaline phosphatase or prostatic acid phosphatase, at their respective pH optima, were ineffective, indicating a certain preference of TRAP for these phosphoprotein substrates. It has previously (Flores, M., Norgard, M., Heinegard, D., Reinholt, F. P., and Andersson, G. (1992) Exp. Cell Res. 201, 526-530) been shown that osteoclasts bind to OPN as well as to BSP coated onto glass. We can now show that the partially dephosphorylated proteins no longer support osteoclast binding. These results indicate that the secretion of TRAP from osteoclasts into the resorption area could exert a regulatory influence on the attachment of the cells to the bone surface. This could imply roles in the development of ruffled borders and/or in the regulation of osteoclast motility on the bone surface.	KAROLINSKA INST, HUDDINGE HOSP, DEPT IMMUNOL MICROBIOL PATHOL & INFECT DIS, DIV PATHOL, S-14186 HUDDINGE, SWEDEN; LUND UNIV, DEPT MED & PHYSIOL CHEM, S-22100 LUND, SWEDEN	Karolinska Institutet; Lund University								ANDERSON TR, 1986, ARCH BIOCHEM BIOPHYS, V247, P131, DOI 10.1016/0003-9861(86)90541-2; ANDERSSON G, 1984, ARCH BIOCHEM BIOPHYS, V228, P431, DOI 10.1016/0003-9861(84)90007-9; ANDERSSON G, 1991, BIOL PHYSL OSTEOCLAS, P55; BOSKEY AL, 1993, BONE MINER, V22, P147, DOI 10.1016/S0169-6009(08)80225-5; CHANG PL, 1991, CANCER RES, V51, P2144; CHANG PL, 1993, CANCER RES, V53, P2217; CHEN JK, 1992, J BONE MINER RES, V7, P987; CHEN Y, 1992, J BIOL CHEM, V267, P24871; DEBRUYNE I, 1983, ANAL BIOCHEM, V133, P110, DOI 10.1016/0003-2697(83)90229-4; EKRYLANDER B, 1991, J BIOL CHEM, V266, P24684; FLORES ME, 1992, EXP CELL RES, V201, P526, DOI 10.1016/0014-4827(92)90305-R; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; HEINEGARD D, 1989, CONNECT TISSUE RES, V21, P333; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HORTON MA, 1988, ISI ATLAS-IMMUNOL, V1, P35; HULTENBY K, 1991, MATRIX, V11, P206, DOI 10.1016/S0934-8832(11)80160-5; HULTENBY K, 1993, EUR J CELL BIOL, V62, P86; HULTENBY K, 1994, EUR J CELL BIOL, V63, P230; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; KASUGAI S, 1991, BONE MINER, V13, P235, DOI 10.1016/0169-6009(91)90071-7; KASUGAI S, 1991, J CELL PHYSIOL, V147, P111, DOI 10.1002/jcp.1041470115; MIDURA RJ, 1990, J BIOL CHEM, V265, P5285; NEMIR M, 1989, J BIOL CHEM, V264, P18202; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; REINHOLT FP, 1990, J BONE MINER RES, V5, P1055; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SINGH K, 1990, J BIOL CHEM, V265, P18696; SINGH K, 1993, J BIOCHEM-TOKYO, V114, P702, DOI 10.1093/oxfordjournals.jbchem.a124240; ZHANG R, 1990, J BIOL CHEM, V265, P15375	33	251	255	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14853	14856						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195113				2022-12-27	WOS:A1994NP73800002
J	HULETT, MD; WITORT, E; BRINKWORTH, RI; MCKENZIE, IFC; HOGARTH, PM				HULETT, MD; WITORT, E; BRINKWORTH, RI; MCKENZIE, IFC; HOGARTH, PM			IDENTIFICATION OF THE IGG BINDING-SITE OF THE HUMAN LOW-AFFINITY RECEPTOR FOR IGG FC-GAMMA-RII - ENHANCEMENT AND ABLATION OF BINDING BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER CELLS; MONOCLONAL-ANTIBODIES; EPSILON-RI; IMMUNOGLOBULIN SUPERFAMILY; MOLECULAR-CLONING; EXPRESSION; ANTIGEN; DOMAINS; DNA; POLYMORPHISM	Fc receptor-antibody interactions are key mechanisms through which antibody effector functions are mediated. The low affinity receptor for IgG, Fc gamma RII, is expressed on most hematopoietic cells, and through the binding of immune complexes mediates a large spectrum of biological responses vital for resistance to infection and the regulation of immunity. In this study the key residues of human Fc gamma RII involved in the interaction with IgG1 have been identified. Chimeric receptors composed of extracellular regions of Fc gamma RII and the Fc epsilon RI alpha chain have been used to localize the IgG1 binding site of Fc gamma RII to an 8-residue stretch in the second extracellular domain, Asn(154) to Ser(161). Site-directed mutagenesis of this region revealed that substitution of Ile(155) or Gly(156) With alanine ablated the binding of human and mouse IgG1, whereas replacement of Leu(159), Phe(160), or Ser(161) with alanine enhanced binding. Molecular modeling has been used to generate a putative 3-dimensional model structure of the second extracellular domain of Fc gamma RII, suggesting that the binding site lies in an exposed loop region at the interface of domains 1 and 2.	AUSTIN HOSP, AUSTIN RES INST, HEIDELBERG, VIC 3084, AUSTRALIA; UNIV QUEENSLAND, CTR DRUG DESIGN & DEV, BRISBANE, QLD 4072, AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Queensland			Hulett, Mark D/C-4160-2012	Hogarth, Mark/0000-0002-0360-7890; Hulett, Mark/0000-0003-2072-5968				ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; GRAZIANO RF, 1987, J IMMUNOL, V139, P3536; HARLOW E, 1988, ANTIBODIES LABORATOR; HIBBS ML, 1988, P NATL ACAD SCI USA, V85, P2240, DOI 10.1073/pnas.85.7.2240; HIBBS ML, 1985, IMMUNOGENETICS, V22, P335, DOI 10.1007/BF00430917; HIBBS ML, 1988, J IMMUNOL, V140, P544; HOGARTH PM, 1982, IMMUNOLOGY, V46, P135; HOGARTH PM, 1992, IMMUNOL REV, V125, P21, DOI 10.1111/j.1600-065X.1992.tb00623.x; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HULETT MD, 1993, EUR J IMMUNOL, V23, P640, DOI 10.1002/eji.1830230310; IERINO FL, 1993, J IMMUNOL, V150, P1794; IERINO FL, 1993, J EXP MED, V178, P1617, DOI 10.1084/jem.178.5.1617; LAH M, 1990, IMMUNOGENETICS, V31, P202, DOI 10.1007/BF00211557; LOPEZ AF, 1983, IMMUNOLOGY, V48, P503; LUND J, 1991, J IMMUNOL, V147, P2657; PARISH CR, 1974, PROC R SOC SER B-BIO, V187, P47, DOI 10.1098/rspb.1974.0060; PIETERSZ GA, 1988, CANCER RES, V48, P4469; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; RIGLEY KP, 1989, EUR J IMMUNOL, V19, P481, DOI 10.1002/eji.1830190311; RISKE F, 1991, J BIOL CHEM, V266, P11245; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; STENGELIN S, 1988, EMBO J, V7, P1053, DOI 10.1002/j.1460-2075.1988.tb02913.x; STUART SG, 1987, J EXP MED, V166, P1668, DOI 10.1084/jem.166.6.1668; STUART SG, 1989, EMBO J, V8, P3657, DOI 10.1002/j.1460-2075.1989.tb08540.x; TATE BJ, 1992, IMMUNOL CELL BIOL, V70, P79, DOI 10.1038/icb.1992.12; TAX WJM, 1983, NATURE, V304, P445, DOI 10.1038/304445a0; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; VANDEWINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511, DOI 10.1002/jlb.49.5.511; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WARMERDAM PAM, 1991, J IMMUNOL, V147, P1338; WILLIAMS AF, 1989, COLD SPRING HARB SYM, V54, P637; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	42	63	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15287	15293						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195166				2022-12-27	WOS:A1994NP73800065
J	MALLARDO, M; GIORDANO, V; DRAGONETTI, E; SCALA, G; QUINTO, I				MALLARDO, M; GIORDANO, V; DRAGONETTI, E; SCALA, G; QUINTO, I			DNA-DAMAGING AGENTS INCREASE THE STABILITY OF INTERLEUKIN-1-ALPHA, INTERLEUKIN-1-BETA, AND INTERLEUKIN-6 TRANSCRIPTS AND THE PRODUCTION OF THE RELATIVE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IMMUNODEFICIENCY-VIRUS TYPE-1; HEPATOCYTE-STIMULATING FACTOR; MESSENGER-RNA DEGRADATION; AUTOCRINE GROWTH-FACTOR; 3' UNTRANSLATED REGION; ALKYLATING-AGENTS; KINASE-C; CARCINOGENIC POTENCY; GENOTOXIC POTENCY	In this study, we addressed the question of whether carcinogens affected the expression of interleukin-1 alpha (IL1 alpha), interleukin-1 beta (IL1 beta), and interleukin-6 (IL6) genes and the production of the relative proteins. Primary cultures of human monocytes were exposed to the alkylating agents mitomycin C (Mit C), methylmethane sulfonate (MMS), and ethylmethane sulfonate (EMS) and tested for the production of IL1 alpha, IL1 beta, and IL6 proteins, as well as for the expression of IL1 alpha, IL1 beta, and IL6 transcripts. The production of IL1 beta and IL6 was significantly augmented by all the three chemicals after 24-48 h of treatment. IL1 alpha was also increased by Mit C and MMS. By Northern blotting analysis, the increased expression of IL1 alpha, IL1 beta, and IL6 genes was shown to occur at 30 min of Mit C and MMS treatment and to decline after 8 h. Similarly, EMS up-regulated the expression of IL1 beta and IL6 genes. The mutagen-mediated increase in interleukin transcripts did not require de novo protein synthesis, and it was due to the enhanced half-life of IL1 alpha, IL1 beta, and IL6 mRNAs rather than to the increased rate of gene transcription. These results suggest that carcinogens, in addition to causing DNA mutations and rearrangements, may also affect cell growth and differentiation by enhancing the expression of cytokine genes.	UNIV NAPLES FEDERICO II, DIPARTIMENTO BIOCHIM & BIOTECNOL MED, I-80131 NAPLES, ITALY; UNIV REGGIO CALABRIA, DIPARTIMENTO MED SPERIMENTALE & CLIN, I-88100 CATANZARO, ITALY	University of Naples Federico II; Universita Mediterranea di Reggio Calabria			SCALA, GIUSEPPE/A-3280-2009	QUINTO, Ileana/0000-0001-8212-8515; MALLARDO, Massimo/0000-0002-4001-3856				[Anonymous], 1985, DNA REPAIR; BENDTZEN K, 1986, SCIENCE, V232, P1545, DOI 10.1126/science.3086977; BODEL P, 1980, J CLIN INVEST, V65, P514, DOI 10.1172/JCI109695; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COZZOLINO F, 1989, P NATL ACAD SCI USA, V86, P2369, DOI 10.1073/pnas.86.7.2369; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DINARELLO CA, 1993, IMMUNOL TODAY, V14, P260, DOI 10.1016/0167-5699(93)90042-J; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1987, J IMMUNOL, V139, P1902; FENTON MJ, 1987, J IMMUNOL, V138, P3972; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOROSPE M, 1993, J BIOL CHEM, V268, P6214; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KODAKA T, 1989, JPN J CANCER RES, V80, P531, DOI 10.1111/j.1349-7006.1989.tb01672.x; KRAMER M, 1993, J BIOL CHEM, V268, P6734; KRIPKE ML, 1990, PHOTOCHEM PHOTOBIOL, V52, P919, DOI 10.1111/j.1751-1097.1990.tb08703.x; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MACCHIA G, 1990, MOL CELL BIOL, V10, P2731, DOI 10.1128/MCB.10.6.2731; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MIKI S, 1989, FEBS LETT, V250, P607, DOI 10.1016/0014-5793(89)80805-1; NOONAN FP, 1990, PHOTOCHEM PHOTOBIOL, V52, P801, DOI 10.1111/j.1751-1097.1990.tb08685.x; NORDAN RP, 1986, SCIENCE, V233, P566, DOI 10.1126/science.3726549; PISTOIA V, 1986, J IMMUNOL, V136, P1688; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; QUINTO I, 1993, J BIOL CHEM, V268, P26719; QUINTO I, 1990, MUTAT RES, V228, P177, DOI 10.1016/0027-5107(90)90074-E; QUINTO I, 1987, MUTAT RES, V181, P235, DOI 10.1016/0027-5107(87)90101-1; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROSS HJ, 1991, BLOOD, V77, P1787; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCALA G, 1984, J EXP MED, V159, P1637, DOI 10.1084/jem.159.6.1637; SCALA G, 1990, J EXP MED, V172, P61, DOI 10.1084/jem.172.1.61; SCALA G, 1984, NATURE, V309, P56, DOI 10.1038/309056a0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIMIZU S, 1988, BLOOD, V72, P1826; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SUNG SSJ, 1988, J EXP MED, V167, P937, DOI 10.1084/jem.167.3.937; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; WAAGE A, 1989, CLIN IMMUNOL IMMUNOP, V50, P394, DOI 10.1016/0090-1229(89)90146-3	55	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14899	14904						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195120				2022-12-27	WOS:A1994NP73800011
J	FLACK, MR; FROEHLICH, J; BENNET, AP; ANASTI, J; NISULA, BC				FLACK, MR; FROEHLICH, J; BENNET, AP; ANASTI, J; NISULA, BC			SITE-DIRECTED MUTAGENESIS DEFINES THE INDIVIDUAL ROLES OF THE GLYCOSYLATION SITES ON FOLLICLE-STIMULATING-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIO-GONADOTROPIN; ASPARAGINE-LINKED OLIGOSACCHARIDES; PITUITARY GLYCOPROTEIN HORMONES; CELL AROMATASE BIOASSAY; BETA-SUBUNIT; RECEPTOR-BINDING; SIALYLATED OLIGOSACCHARIDES; SIGNAL TRANSDUCTION; ALPHA-SUBUNIT; FOLLITROPIN	To determine the specific role of each follicle stimulating hormone (FSH) oligosaccharide, we mutated Asn to Gln at each glycosylation site (alpha Gln(52), alpha Gln(78), alpha Gln(52-78), beta Gln(7), beta Gln(24), and beta Gln(7-24)) to selectively inhibit oligosaccharide attachment. For wild-type and mutant FSH, we determined the binding affinity to homogenized rat Sertoli cells and the signal-transducing activity in cultured rat granulosa cells. The binding affinity of FSH lacking any one of the oligosaccharides was increased over wild-type FSH, while the signal-transducing activity of FSH lacking the oligosaccharide at alpha Asn(52) (alpha Gln(52) FSH) was markedly reduced, and that of FSH lacking either beta oligosaccharide (beta Gln(7) and beta Gln(24) FSH) was slightly reduced. At each FSH beta glycosylation site, we made a second amino acid substitution to inhibit glycosylation (beta Tyr(9) and beta Tyr(26)) and an amino acid substitution that preserved glycosylation (beta Ser(9) and beta Ser(26)). The amino acid sequence of the second p subunit glycosylation site was important for signal transduction, regardless of the presense or absence of the oligosaccharide. Thus, while each FSH oligosaccharide has a similar impact on binding affinity, the alpha(52) oligosaccharide has a disproportionate role in signal transduction, and the amino acid sequence at beta Asn(24) functions in both binding and signal transduction.			FLACK, MR (corresponding author), NICHHD, DEV ENDOCRINOL BRANCH, BLDG 10, RM 10N262, 9000 ROCKVILLE PK, BETHESDA, MD 20892 USA.							AMR S, 1984, ARCH BIOCHEM BIOPHYS, V229, P170, DOI 10.1016/0003-9861(84)90141-3; CALVO FO, 1986, BIOCHEMISTRY-US, V25, P3938, DOI 10.1021/bi00361a030; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; DAHL KD, 1989, METHOD ENZYMOL, V168, P414; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; GOODMAN AL, 1977, P SOC EXP BIOL MED, V155, P479; GOVERMAN JM, 1982, J BIOL CHEM, V257, P5059; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; HAGEVANNOORT M, 1992, P NATL ACAD SCI USA, V89, P3922, DOI 10.1073/pnas.89.9.3922; HARTREE AS, 1992, BIOCHEM J, V287, P665, DOI 10.1042/bj2870665; HATTORI M, 1988, MOL CELL ENDOCRINOL, V57, P17; HAYASHIZAKI Y, 1989, EMBO J, V8, P2291, DOI 10.1002/j.1460-2075.1989.tb08355.x; JIA XC, 1986, ENDOCRINOLOGY, V119, P1570, DOI 10.1210/endo-119-4-1570; KALYAN NK, 1983, J BIOL CHEM, V258, P67; KEUTMANN HT, 1992, MOL CELL ENDOCRINOL, V86, pC1, DOI 10.1016/0303-7207(92)90168-6; LASH RW, 1992, J ENDOCRINOL INVEST, V15, P255, DOI 10.1007/BF03348723; LIU L, 1988, J ANDROL, V9, P62; LUSTBADER JW, 1993, ENDOCR REV, V14, P291, DOI 10.1210/er.14.3.291; MANJUNATH P, 1982, MOL CELL ENDOCRINOL, V28, P125, DOI 10.1016/0303-7207(82)90026-0; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; PADMANABHAN V, 1991, MOL CELL ENDOCRINOL, V79, P119, DOI 10.1016/0303-7207(91)90102-X; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RICHARDSON MC, 1984, J ENDOCRINOL, V101, P327, DOI 10.1677/joe.0.1010327; SAIRAM MR, 1982, MOL CELL ENDOCRINOL, V28, P139, DOI 10.1016/0303-7207(82)90027-2; SAIRAM MR, 1983, J BIOL CHEM, V258, P445; SAIRAM MR, 1985, SCIENCE, V229, P65, DOI 10.1126/science.2990039; SAIRAM MR, 1985, RECEPTORS, V2, P307; SANTACOLOMA TA, 1991, MOL CELL ENDOCRINOL, V78, P197, DOI 10.1016/0303-7207(91)90123-A; STRICKLAND TW, 1982, ENDOCRINOLOGY, V111, P95, DOI 10.1210/endo-111-1-95	30	90	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14015	14020						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188681				2022-12-27	WOS:A1994NL60600046
J	LINGUEGLIA, E; RENARD, S; WALDMANN, R; VOILLEY, N; CHAMPIGNY, G; PLASS, H; LAZDUNSKI, M; BARBRY, P				LINGUEGLIA, E; RENARD, S; WALDMANN, R; VOILLEY, N; CHAMPIGNY, G; PLASS, H; LAZDUNSKI, M; BARBRY, P			DIFFERENT HOMOLOGOUS SUBUNITS OF THE AMILORIDE-SENSITIVE NA+ CHANNEL ARE DIFFERENTLY REGULATED BY ALDOSTERONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACETYLCHOLINE-RECEPTOR	Long term regulation of the amiloride-sensitive Na+ channel activity by steroid hormones occurs via de novo protein synthesis. The messenger level of RCNaCh1, previously shown by expression cloning to be a component of this channel, was measured in colons from rats fed with a low sodium diet. After 1 week of this diet, the channel activity was increased in an all-or-none fashion, whereas the level of RCNaCh1 messenger remained constant. A cDNA coding for another subunit of the Na+ channel was obtained by polymerase chain reaction. The 650-amino acid protein, entitled RCNaCh2, is 58% homologous to RCNaCh1 and displays a similar structure. It had no intrinsic activity when expressed alone in Xenopus oocytes, but its co-expression with RCNaCh1 increased the channel activity 18 +/- B-fold. The increase in messenger level for RCNaCh2 during the time course of the diet is likely to explain the positive regulation of the rat colon Na+ channel by steroids. Immunocytochemical localization of the RC-NaCh1 subunit revealed an apical labeling in colon from sodium-depleted rats. No labeling was observed in colon from control animals. These results suggest that oligomerization is needed for the proper expression of RCNaCh1 at the cell surface.	INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE				Barbry, Pascal/O-5021-2016; Waldmann, Rainer/Q-2108-2016; LINGUEGLIA, Eric/F-5509-2013	Barbry, Pascal/0000-0001-9632-6483; Waldmann, Rainer/0000-0002-4599-2926; LINGUEGLIA, Eric/0000-0003-3902-3405; Renard, Stephane/0000-0002-1374-4960				BETZ H, 1990, BIOCHEMISTRY-US, V29, P3591, DOI 10.1021/bi00467a001; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1993, J NEUROBIOL, V24, P1433, DOI 10.1002/neu.480241013; CRABBE J, 1961, J CLIN INVEST, V40, P2103, DOI 10.1172/JCI104436; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; RENARD S, 1994, J BIOL CHEM, V269, P12981; Rossier BC, 1992, KIDNEY PHYSL PATHOPH, P1373; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; WILL PC, 1980, AM J PHYSIOL, V238, pF261, DOI 10.1152/ajprenal.1980.238.4.F261; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N	21	174	176	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13736	13739						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188647				2022-12-27	WOS:A1994NL60600004
J	PERSSON, E; HOGG, PJ; STENFLO, J				PERSSON, E; HOGG, PJ; STENFLO, J			EFFECTS OF CA2+ BINDING ON THE PROTEASE MODULE OF FACTOR-XA AND ITS INTERACTION WITH FACTOR-VA - EVIDENCE FOR 2 GLA-INDEPENDENT CA2+-BINDING SITES IN FACTOR-XA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; BOVINE FACTOR-X; COAGULATION FACTOR-XA; FACTOR-LIKE DOMAINS; HUMAN FACTOR-VIIA; HUMAN FACTOR-IX; PROTHROMBINASE COMPLEX; CALCIUM-BINDING; TISSUE FACTOR; BLOOD-COAGULATION	The assembly of macromolecular complexes containing factors Xa and Va on suitable phospholipid surfaces is crucial for rapid activation of prothrombin. We have used quantitative affinity chromatography to characterize the interaction between factor Va and intact factor Xa on the one hand and between factor Va and factor Xa lacking the gamma-carboxyglutamic acid (Gla)-containing module on the other. The dissociation constants were found to be 1.0 +/- 0.1 and 9.5 +/- 1.8 muM, respectively. There was good agreement between these dissociation constants and the concentrations of active site-inhibited factor Xa and Gla-domainless factor Xa that caused half-maximal inhibition of prothrombin activation. To investigate whether the noncatalytic modules of factor Xa interacted directly with factor Va, intact modules were isolated from proteolytic digests of factor X and used as inhibitors of prothrombin activation. The inhibitory effect observed with the isolated Gla module in the absence of phospholipid was due to inhibition of the amidolytic activity of factor Xa rather than to an interaction with factor Va. The epidermal growth factor-like modules did not inhibit prothrombin activation. Using antibodies specific for calcium-dependent epitopes in the serine protease module of factor Xa we demonstrated that Ca2+ binding to the Gla module alters the conformation of the catalytic module. Half-maximal binding was observed at almost-equal-to 0.8 mM Ca2+. Evidence was also obtained for the presence of two Gla-independent Ca2+-binding sites in factor Xa. One of these sites, located in the NH-2-terminal epidermal growth factor-like module, was half-saturated at almost-equal-to 60 muM Ca2+ in intact factor Xa and at almost-equal-to 1.2 mM Ca2+ in Gla-domainless factor Xa. This site appeared not to influence the conformation of the protease module. The second site, which was half-saturated at almost-equal-to 0.16 mM Ca2+, appeared to reside in the serine protease module and to alter its conformation as judged by binding of antibodies specific for calcium-dependent epitopes.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN	Lund University				Hogg, Philip/0000-0001-6486-2863; Persson, Egon/0000-0003-3005-4926				ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BAJAJ SP, 1985, J BIOL CHEM, V260, P1574; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1975, FEBS LETT, V56, P139, DOI 10.1016/0014-5793(75)80128-1; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; DAHLBACK B, 1978, BIOCHEMISTRY-US, V17, P4938, DOI 10.1021/bi00616a013; DAHLBACK B, 1986, J BIOL CHEM, V261, P9495; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P2285; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GIESEN PLA, 1991, J BIOL CHEM, V266, P18720; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; HOGG PJ, 1987, ANAL BIOCHEM, V163, P331, DOI 10.1016/0003-2697(87)90232-6; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JACKSON CM, 1972, BIOCHEMISTRY-US, V11, P4873, DOI 10.1021/bi00776a001; Jesty J, 1976, Methods Enzymol, V45, P95; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; KANE WH, 1980, J BIOL CHEM, V255, P1170; KEYT B, 1982, J BIOL CHEM, V257, P8687; KISIEL W, 1981, METHOD ENZYMOL, V80, P275; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KUMAR A, 1991, J BIOL CHEM, V266, P915; LIN SW, 1990, J BIOL CHEM, V265, P144; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MORITA T, 1991, J BIOCHEM, V110, P990, DOI 10.1093/oxfordjournals.jbchem.a123701; MORITA T, 1986, J BIOL CHEM, V261, P4015; MORITA T, 1984, J BIOL CHEM, V259, P5698; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; OLSEN PH, 1992, BIOCHEMISTRY-US, V31, P746, DOI 10.1021/bi00118a016; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; OWEN WG, 1974, J BIOL CHEM, V249, P594; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PERSSON E, 1991, J BIOL CHEM, V266, P2453; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; REZAIE AR, 1992, J BIOL CHEM, V267, P11701; ROSING J, 1980, J BIOL CHEM, V255, P274; RUF W, 1991, J BIOL CHEM, V266, P15719; SAKAI T, 1990, J BIOL CHEM, V265, P1890; SKOGEN WF, 1984, J BIOL CHEM, V259, P2306; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; STENFLO J, 1991, BLOOD, V78, P1637; STENFLO J, 1976, J BIOL CHEM, V251, P355; STENFLO J, 1977, ANNU REV BIOCHEM, V46, P157, DOI 10.1146/annurev.bi.46.070177.001105; SUGO T, 1984, J BIOL CHEM, V259, P5705; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; VALCARCE C, 1993, METHOD ENZYMOL, V222, P416; VISOTCHIN A, 1992, FASEB J, V6, P329; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290; WILDGOOSE P, 1992, THROMB HAEMOSTASIS, V67, P679; WINZOR DJ, 1982, J THEOR BIOL, V98, P171, DOI 10.1016/0022-5193(82)90257-0; ZHANG L, 1991, BIOCHEMISTRY-US, V30, P6696, DOI 10.1021/bi00241a009	65	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22531	22539						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226763				2022-12-27	WOS:A1993MD34800054
J	KAWABE, J; IWAMI, G; EBINA, T; OHNO, S; KATADA, T; UEDA, Y; HOMCY, CJ; ISHIKAWA, Y				KAWABE, J; IWAMI, G; EBINA, T; OHNO, S; KATADA, T; UEDA, Y; HOMCY, CJ; ISHIKAWA, Y			DIFFERENTIAL ACTIVATION OF ADENYLYL-CYCLASE BY PROTEIN-KINASE-C ISOENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER TREATMENT; SIGNAL-TRANSDUCTION; ZETA-ISOFORM; EXPRESSION; INHIBITION; PHOSPHORYLATION; PURIFICATION; STIMULATION; PATHWAYS; ISOTYPES	Cyclic AMP production within cells is altered upon protein kinase C (PKC) activation; however, whether PKC directly modulates adenylyl cyclase (AC) catalytic activity has been controversial. Molecular studies have elucidated the existence of multiple PKC isoenzymes although the functional role of this diversity is not clear. Using purified PKC and AC isoenzymes, we demonstrate that PKC zeta directly phosphorylates type VAC, leading to an approximate 20-fold increase in its catalytic activity, a significantly larger enhancement than that achieved with forskolin (similar to 5-fold), the most potent activator of AC. When forskolin and PKC phosphorylation are combined, type V AC catalytic activity is increased 100-fold over basal levels. The two PKC isoenzymes (alpha and zeta) are additive in their capacity to activate AC, although PKC alpha is less potent than PKC zeta. Our data indicate that PKC can directly and potently regulate AC activity in an isoenzyme-specific manner, suggesting that direct cross-talk plays a major role in coordinating the activity of these two principal signal transduction pathways.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT PHARMACOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; YOKOHAMA CITY UNIV, SCH MED, DEPT MOLEC BIOL, YOKOHAMA 236, JAPAN; TOKYO INST TECHNOL, DEPT LIFE SCI, YOKOHAMA 227, JAPAN; AMER CYANAMID CO, LEDERLE LABS, DIV MED RES, PEARL RIVER, NY 10965 USA	Columbia University; Columbia University; Yokohama City University; Tokyo Institute of Technology			Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL038070] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38070] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BREDT DS, 1992, J BIOL CHEM, V267, P10976; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; DIVIRGILIO F, 1986, J BIOL CHEM, V261, P32; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; GOODE N, 1992, J BIOL CHEM, V267, P16878; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; ISHIKAWA F, 1987, ONCOGENE RES, V1, P243; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; Kitano T, 1986, Methods Enzymol, V124, P349; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STABEL S, 1991, METHOD ENZYMOL, V200, P670; STRANGE PG, 1991, TRENDS PHARMACOL SCI, V12, P48, DOI 10.1016/0165-6147(91)90494-D; STRASSER RH, 1992, CIRC RES, V70, P1304, DOI 10.1161/01.RES.70.6.1304; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604	41	210	212	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16554	16558						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206971				2022-12-27	WOS:A1994NR29600008
J	NATSUKA, S; GERSTEN, KM; ZENITA, K; KANNAGI, R; LOWE, JB				NATSUKA, S; GERSTEN, KM; ZENITA, K; KANNAGI, R; LOWE, JB			MOLECULAR-CLONING OF A CDNA-ENCODING A NOVEL HUMAN-LEUKOCYTE ALPHA-1,3-FUCOSYL-TRANSFERASE CAPABLE OF SYNTHESIZING THE SIALYL-LEWIS-X DETERMINANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; ELAM-1-DEPENDENT CELL-ADHESION; E-SELECTIN; CARBOHYDRATE LIGAND; EXPRESSION; ELAM-1; RECOGNITION; ANTIGEN; SPECIFICITIES; EPITOPES	The sialyl Lewis x determinant (NeuAc alpha 2,3Gal beta 1, 4[Fuc alpha 1,3]GlcNAc) is an essential component of leukocyte counterreceptors for E-selectin and P-selectin. The final step in sialyl Lewis x synthesis is catalyzed by alpha-1,3-fucosyltransferases acting on sialylated glycoconjugate precursors. Cultured human leukocytic cell lines express an alpha-1,3-fucosyltransferase gene termed Fuc-TIV or ELFT but do not express the other three cloned human alpha-1,3-fucosyltransferase genes to any significant degree. The physiological role of Fuc-TIV/ELFT in sialyl Lewis x biosynthesis is uncertain, however, since it can catalyze the synthesis of this determinant in some, but not all, transfected cell lines in a manner that is dependent upon the glycosylation phenotype of the host cell. We report here the molecular cloning of a cDNA encoding a new human leukocyte alpha-1,3-fucosyltransferase, termed Fuc-TVII, capable of synthesizing the sialyl Lewis x moiety. The cDNA sequence predicts a 341-amino acid-long type II transmembrane protein typical of mammalian glycosyltransferases. When expressed in mammalian cells, the Fuc-TVII cDNA directs the synthesis of cell surface sialyl Lewis x moieties but not the Lewis x, Lewis a, sialyl Lewis a, or VIM-2 determinants. Fuc-TVII can efficiently utilize alpha-2,3-sialyllactosamine in vitro to form the sialyl Lewis x tetrasaccharide but does not utilize lactosamine to form the Lewis x moiety. Northern blot analyses show that the Fuc-TVII gene is transcribed in HL-60 cells, a human promyelocytic cell line, and in YT cells, a natural killer-like cell line. Fuc-TVII represents a leukocytic alpha-1,3-fucosyltransferase that can participate in selectin ligand synthesis via its ability to catalyze the synthesis of sialyl Lewis x determinants.	UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; AICHI CANC CTR,EXPTL PATHOL LAB,NAGOYA,AICHI 464,JAPAN	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Aichi Cancer Center			Kannagi, Reiji/Q-6459-2018; Natsuka, Shunji/L-9330-2018	Kannagi, Reiji/0000-0003-4202-2921; Natsuka, Shunji/0000-0003-1726-8946	NIGMS NIH HHS [GM47455] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047455] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ESTON EW, 1993, BLOOD, V81, P2978; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P149; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lowe J B, 1991, Semin Cell Biol, V2, P289; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; Maniatis T, 1989, DECONTAMINATION DILU; MOLLICONE R, 1992, CARBOHYD RES, V228, P265, DOI 10.1016/S0008-6215(00)90564-0; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; OHMORI K, 1989, BLOOD, V74, P255; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; SMITH PL, 1994, J BIOL CHEM, V269, P15162; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YAGO K, 1993, CANCER RES, V53, P5559; YAN SB, 1993, GLYCOBIOLOGY, V3, P597, DOI 10.1093/glycob/3.6.597; YODOI J, 1985, J IMMUNOL, V134, P1623; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003	29	295	322	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16789	16794						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207002				2022-12-27	WOS:A1994NR29600045
J	BRUNHUBER, NMW; BANERJEE, A; JACOBS, WR; BLANCHARD, JS				BRUNHUBER, NMW; BANERJEE, A; JACOBS, WR; BLANCHARD, JS			CLONING, SEQUENCING, AND EXPRESSION OF RHODOCOCCUS L-PHENYLALANINE DEHYDROGENASE - SEQUENCE COMPARISONS TO AMINO-ACID DEHYDROGENASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; DEPENDENT GLUTAMATE-DEHYDROGENASE; ESCHERICHIA-COLI; NAD(P)+-DEPENDENT DEHYDROGENASES; BACILLUS-STEAROTHERMOPHILUS; CLOSTRIDIUM-SYMBIOSUM; LACTATE-DEHYDROGENASE; ASPERGILLUS-NIDULANS; MALATE-DEHYDROGENASE; NITRILE HYDRATASE	L-Phenylalanine dehydrogenase catalyzes the NAD(+)-dependent, reversible, oxidative deamination of L-phenylalanine to form ammonia, phenyl pyruvate, and NADH. The enzyme has been purified to homogeneity from Rhodococcus sp. M4, and a partial amino acid sequence was obtained. A cosmid library of Rhodococcus sp. M4 genomic DNA was prepared and used to isolate a 2.5-kilobase PstI fragment that contained the pdh gene. The open reading frame of 1068 nucleotides encodes a polypeptide of 356 amino acids, portions of which match the amino acid sequence determined for the purified enzyme. Expression of the Rhodococcus pdh gene in Escherichia coli, which does not contain a phenylalanine dehydrogenase activity, yields a soluble enzyme exhibiting phenylalanine dehydrogenase activity. Both the enzyme purified from Rhodococcus and the enzyme expressed in E. coli are post-translationally modified by removal of the amino terminal methionine. The overall amino acid sequence is homologous to previously reported sequences of leucine and phenylalanine dehydrogenases as well as several glutamate dehydrogenases. The amino-terminal portion of the enzyme contains resi dues involved in L-amino acid binding and catalysis, while the carboxyl-terminal portion contains the presumptive dinucleotide-binding domain. A detailed sequence comparison of Rhodococcus phenylalanine dehydrogenase with leucine, phenylalanine, and glutamate dehydrogenases suggests residues involved in general amino acid binding and others that provide for amino acid discrimination.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				Jacobs, William/0000-0003-3321-3080	NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033449, T32GM007260] Funding Source: NIH RePORTER; NCI NIH HHS [5P30CA13330] Funding Source: Medline; NIGMS NIH HHS [5T32 GM 07260, GM 33449] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIZADE MA, 1975, BIOCHIM BIOPHYS ACTA, V397, P5, DOI 10.1016/0005-2744(75)90173-4; BAKER PJ, 1992, PROTEINS, V12, P75, DOI 10.1002/prot.340120109; BANSAL A, 1989, J BIOL CHEM, V264, P9827; BARSTOW DA, 1986, GENE, V46, P47, DOI 10.1016/0378-1119(86)90165-4; Ben-Bassat A., 1987, NATURE, V326, P315; BRIDGEN J, 1987, FEBS LETT, V33, P1; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; BRUNHUBER NMW, 1993, FASEB J, V7, pA1069; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FINNERTY WR, 1992, ANNU REV MICROBIOL, V46, P193, DOI 10.1146/annurev.mi.46.100192.001205; GUTHEIL WG, 1992, BIOCHEMISTRY-US, V31, P475, DOI 10.1021/bi00117a025; GWYNNE DI, 1987, GENE, V51, P205, DOI 10.1016/0378-1119(87)90309-X; HABERLAND ME, 1980, J BIOL CHEM, V255, P7984; HASHIMOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1088, P225, DOI 10.1016/0167-4781(91)90058-T; HATFULL GF, 1993, MOL MICROBIOL, V7, P395, DOI 10.1111/j.1365-2958.1993.tb01131.x; HAWKINS AR, 1989, MOL GEN GENET, V218, P105, DOI 10.1007/BF00330572; HEDIGER MA, 1986, BIOL CHEM H-S, V367, P891, DOI 10.1515/bchm3.1986.367.2.891; HIBINO Y, 1990, Patent No. 4970157; HUMMEL W, 1987, APPL MICROBIOL BIOT, V26, P409; HUMMEL W, 1984, ARCH MICROBIOL, V137, P47, DOI 10.1007/BF00425806; KINNAIRD JH, 1983, GENE, V26, P253, DOI 10.1016/0378-1119(83)90195-6; KOBAYASHI M, 1991, BIOCHIM BIOPHYS ACTA, V1129, P23, DOI 10.1016/0167-4781(91)90208-4; KURODA SI, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00456a025; LILLEY KS, 1991, BIOCHIM BIOPHYS ACTA, V1080, P191, DOI 10.1016/0167-4838(91)90001-G; Liszewski M K, 1989, Biotechniques, V7, P1079; Maniatis T., 1982, MOL CLONING; MAYAUX JF, 1991, J BACTERIOL, V173, P6694, DOI 10.1128/jb.173.21.6694-6704.1991; MCALISTERHENN L, 1987, NUCLEIC ACIDS RES, V15, P4993, DOI 10.1093/nar/15.12.4993; NAGATA S, 1988, BIOCHEMISTRY-US, V27, P9056, DOI 10.1021/bi00425a026; NISHIYAMA M, 1986, J BIOL CHEM, V261, P14178; OHSHIMA T, 1991, J BACTERIOL, V173, P3943, DOI 10.1128/jb.173.13.3943-3948.1991; OKAZAKI N, 1988, GENE, V63, P337, DOI 10.1016/0378-1119(88)90537-9; OND M, 1990, J BIOCHEM-TOKYO, V107, P21; SERGHINI MA, 1989, NUCLEIC ACIDS RES, V17, P3604, DOI 10.1093/nar/17.9.3604; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; TAKADA H, 1991, J BIOCHEM-TOKYO, V109, P371, DOI 10.1093/oxfordjournals.jbchem.a123388; TELLER JK, 1992, EUR J BIOCHEM, V206, P151, DOI 10.1111/j.1432-1033.1992.tb16912.x; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	39	24	27	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16203	16211						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206922				2022-12-27	WOS:A1994NQ72900040
J	DEMENDEZ, I; GARRETT, MC; ADAMS, AG; LETO, TL				DEMENDEZ, I; GARRETT, MC; ADAMS, AG; LETO, TL			ROLE OF P67-PHOX SH3 DOMAINS IN ASSEMBLY OF THE NADPH OXIDASE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; GTP-BINDING PROTEIN; RESPIRATORY BURST OXIDASE; PHOSPHATIDYLINOSITOL 3-KINASE; CRYSTAL-STRUCTURE; TYROSINE KINASES; NEUTROPHIL; COMPONENTS; REGION; GRB2	Src homology 3 (SH3) domains direct cellular localization and signal transduction through specific protein-protein interactions with proline-rich target sequences. The two SH3 domain in p67-phox, a cytosolic component of the phagocyte NADPH oxidase system, may mediate interactions within the oxidase complex and direct its translocation to membranes. The requirement for SH3 domains in p67-phox was studied both in cell-free and whole cell oxidase assay systems. The amino-terminal domain of p67-phox (amino acids 1-246) that lacks both SH3 domains was active in vitro. Various forms of p67-phox lacking one or both SH3 domains were produced in whole cells using episomal expression vectors to stably transfect p67-phox-deficient Epstein-Barr virus-B cells derived from chronic granulomatous disease patients. Complete restoration of NADPH oxidase activity was achieved with full-length p67-phox cDNA expression. Deletion of either SH3 domain resulted in dramatic reductions of NADPH oxidase activity relative to corrected transfected cells, which correlated with decreases in membrane binding. Deletion of both SH3 domains completely abolished p67-phox membrane binding and oxidase activity. Thus, in contrast to oxidase reconstitution in a cell-free system, we observed a requirement for both SH3 motifs for restoration of oxidase activity and binding of p67-phox to membranes.	NIAID,HOST DEF LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; BRISTOL A, 1988, COLD SPRING HARB SYM, V53, P915, DOI 10.1101/SQB.1988.053.01.105; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; VOLKMAN DJ, 1984, J IMMUNOL, V133, P3006; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	36	101	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16326	16332						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206939				2022-12-27	WOS:A1994NQ72900058
J	MUNDSCHAU, LJ; FORMAN, LW; WENG, HQ; FALLER, DV				MUNDSCHAU, LJ; FORMAN, LW; WENG, HQ; FALLER, DV			PLATELET-DERIVED GROWTH-FACTOR (PDGF) INDUCTION OF EGR-1 IS INDEPENDENT OF PDGF RECEPTOR AUTOPHOSPHORYLATION ON TYROSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS EXPRESSION; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; KINASE-ACTIVITY; DNA-SYNTHESIS; 3T3 CELLS; TRANSFORMING PROTEIN; PATHWAYS; ACTIVATION; BINDING	Autophosphorylation of the platelet-derived growth factor (PDGF) receptor on tyrosine, which is dependent upon and occurs immediately after ligand binding, has been linked to the activation of second messenger pathways thought to be necessary for the induction of gene expression, DNA synthesis, and mitogenesis. We have investigated PDGF signal transduction in Balb/c-3T3 and NIH-3T3 cells at the level of immediate early gene induction under three conditions in which PDGF receptor autophosphorylation in response 60 PDGF binding is blocked: cells transformed by v-ras(Ki), cells transformed by v-mos, and cells treated with genistein, a specific inhibitor of tyrosine kinases. PDGF induction of immediate-early genes c-myc, c-fos, and JE is blocked in these systems. Induction of another immediate-early gene, egr-1, occurs normally despite the absence of measurable tyrosine kinase activity. The same results were obtained when cells were stimulated with PDGF-AA or PDGF-BB. It is not yet clear if this receptor tyrosine kinase-independent signal utilizes known PDGF second messengers, but these results demonstrate a new arm of the PDGF signal transduction pathway which operates in the absence of, and independently from, autophosphorylation of the receptor on tyrosine.	BOSTON UNIV, SCH MED, CANC RES CTR, BOSTON, MA 02118 USA	Boston University				Kasman, Laura/0000-0002-8661-2918				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FALLER DV, 1994, J BIOL CHEM, V269, P5022; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; JAMIESON GA, 1989, J CELL PHYSIOL, V139, P262, DOI 10.1002/jcp.1041390207; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LEE BA, 1991, J CELL BIOL, V113, P361, DOI 10.1083/jcb.113.2.361; LIM RW, 1987, ONCOGENE, V1, P263; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; QUINONES MA, 1991, J BIOL CHEM, V266, P14055; RAKE JB, 1991, J BIOL CHEM, V266, P5348; SALHANY KE, 1992, J CELL PHYSIOL, V150, P386, DOI 10.1002/jcp.1041500223; SCHALASTA G, 1990, MOL CELL BIOL, V10, P5558, DOI 10.1128/MCB.10.10.5558; SEYFERT VL, 1990, J IMMUNOL, V145, P3647; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATERS CM, 1990, ONCOGENE, V5, P669; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080; ZWILLER J, 1991, ONCOGENE, V6, P219	42	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16137	16142						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206913				2022-12-27	WOS:A1994NQ72900030
J	BHAUMIK, D; YANG, BL; TRANGAS, T; BARTLETT, JS; COLEMAN, MS; SORSCHER, DH				BHAUMIK, D; YANG, BL; TRANGAS, T; BARTLETT, JS; COLEMAN, MS; SORSCHER, DH			IDENTIFICATION OF A TRIPARTITE BASAL PROMOTER WHICH REGULATES HUMAN TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; N-REGIONS; TRANSCRIPTION; ELEMENT; CELLS; INITIATOR; LYMPHOCYTES; CONTAINS; COMPLEX; SITE	In order to locate the promoter region of the human terminal deoxynucleotidyl transferase gene, serially truncated segments of the 5'-flanking region of the gene were cloned into a chloramphenicol acetyltransferase reporter vector. Transient transfection analyses of the terminal transferase-reporter gene constructs identified the basal promoter region within -34 to +40 base pairs relative to the transcription start site. Three promoter elements were defined in this region. The primary element is within 34 base pairs upstream of the transcription start site. The CAP site is 62 base pairs upstream of the translation start site. The secondary element involves sequences around the transcription start site. The third is located 25 base pairs downstream from the initiation site (+25 to +40). This tripartite basal promoter was not tissue specific; similar patterns of promoter activity were observed in terminal transferase expressing and non-expressing cells. Transfection analyses also indicated the presence of negative regulatory elements upstream of the basal promoter region, and these elements were preferentially active in cells expressing terminal transferase.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [R01CA019492] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA19492] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS JM, 1989, MOL CELL BIOL, V9, P620, DOI 10.1128/MCB.9.2.620; AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; Bollum F.J., 1974, ENZYMES, P145; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; DEIBEL MR, 1983, J IMMUNOL, V131, P195; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; DREXLER HG, 1985, LEUKEMIA RES, V9, P209, DOI 10.1016/0145-2126(85)90084-0; ERNST P, 1993, MOL CELL BIOL, V13, P2982, DOI 10.1128/MCB.13.5.2982; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; IKUTA K, 1992, ANNU REV IMMUNOL, V10, P759; KOIWAI O, 1988, BIOCHEM BIOPH RES CO, V154, P91, DOI 10.1016/0006-291X(88)90654-7; KOLLMAR R, 1993, P SOC EXP BIOL MED, V203, P127; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; MATSUSHIMA GK, 1992, MOL CELL BIOL, V12, P5610, DOI 10.1128/MCB.12.12.5610; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PUGH BF, 1992, J BIOL CHEM, V267, P679; RILEY LK, 1988, P NATL ACAD SCI USA, V85, P2489, DOI 10.1073/pnas.85.8.2489; RINCONLIMAS DE, 1991, MOL CELL BIOL, V11, P4157, DOI 10.1128/MCB.11.8.4157; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; Sambrook J, 1989, MOL CLONING LABORATO; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHATZ DG, 1988, CELL, V53, P107, DOI 10.1016/0092-8674(88)90492-8; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TRANGAS T, 1989, BIOCHEM BIOPH RES CO, V164, P750, DOI 10.1016/0006-291X(89)91523-4; WANG TC, 1990, J BIOL CHEM, V265, P8908; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; ZENZIEGREGORY B, 1993, J BIOL CHEM, V268, P15823; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2828	31	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15861	15867						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195241				2022-12-27	WOS:A1994NP51300072
J	CALLAWAY, C; SERYSHEV, A; WANG, JP; SLAVIK, KJ; NEEDLEMAN, DH; CANTU, C; WU, YL; JAYARAMAN, T; MARKS, AR; HAMILTON, SL				CALLAWAY, C; SERYSHEV, A; WANG, JP; SLAVIK, KJ; NEEDLEMAN, DH; CANTU, C; WU, YL; JAYARAMAN, T; MARKS, AR; HAMILTON, SL			LOCALIZATION OF THE HIGH AND LOW-AFFINITY [H-3] RYANODINE BINDING-SITES ON THE SKELETAL-MUSCLE CA2+ RELEASE CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL SARCOPLASMIC-RETICULUM; PURIFIED RYANODINE RECEPTOR; CALCIUM-RELEASE; CA-2+ RELEASE; ACETYLCHOLINE-RECEPTOR; ION CHANNEL; PROTEIN; RECONSTITUTION; PURIFICATION; DIGESTION	The Ca2+ release channel of skeletal muscle sarcoplasmic reticulum is modulated in a biphasic manner by the plant allialoid ryanodine and there are two distinct binding sites on this channel for ryanodine. The Ca2+ release channel is a homotetramer with a subunit of 5037 amino acids. The ability of sarcoplasmic reticulum membranes to bind [H-3]ryanodine to the high affinity site is lost upon proteolysis with trypsin. [H-3]Ryanodine, however, bound before proteolysis remains bound after trypsin digestion. If the high affinity site is first occupied with [H-3]ryanodine and then 100 mu M ryanodine is added to occupy the low affinity sites, almost all of [H-3]ryanodine bound to the high affinity site remains bound after proteolysis. Proteolysis causes the solubilized Ca2+ release channel containing bound [H-3]ryanodine to undergo four discrete shifts in sedimentation (30 S --> 28 S --> 26 S --> 19 S --> 14 S). Polypeptides having apparent molecular masses of 76, 66, 56, 45, 37, and 27 kDa can be identified in the 14 S complex. The 76-, 56-, 45-, and 27-kDa polypeptides have been partially sequenced from the NH2 terminus. In addition, the 76-, 66-, and 27-kDa fragments are recognized by an antibody to the last 9 amino acids at the carboxyl terminus of the skeletal muscle ryanodine receptor and the 76-, 66-, and 37-kDa fragments are recognized by an antibody to a peptide matching the sequence 4670-4685. The 56-kDa and the 45-kDa fragments are not Ca2+ release channel fragments. Both high and low affinity ryanodine binding sites are found in the 14 S complex and are, therefore, most likely located between Arg-4475 and the carboxyl terminus.	BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030; MT SINAI HOSP,MT SINAI SCH MED,PROGRAM MOLEC MED,NEW YORK,NY 10029	Baylor College of Medicine; Icahn School of Medicine at Mount Sinai				Hamilton, Susan/0000-0003-0241-9369	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037028, P01HL037044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R55AR041729, R01AR041729] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37044, HL37028] Funding Source: Medline; NIAMS NIH HHS [AR41729] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CARROLL S, 1991, ARCH BIOCHEM BIOPHYS, V290, P239, DOI 10.1016/0003-9861(91)90615-P; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; CHEN SRW, 1993, J BIOL CHEM, V268, P22642; CHU A, 1988, BIOCHEMISTRY-US, V27, P2827, DOI 10.1021/bi00408a025; CHU A, 1990, MOL PHARMACOL, V37, P735; COLLINS JH, 1991, BIOCHEM BIOPH RES CO, V178, P1288, DOI 10.1016/0006-291X(91)91033-9; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20857; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GRUNWALD R, 1993, BIOPHYS J, V64, pA152; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HAMILTON SL, 1989, ANAL BIOCHEM, V183, P31, DOI 10.1016/0003-2697(89)90167-X; HAMILTON SL, 1991, CELLULAR CALCIUM, P313; HAWKES MJ, 1989, MEMBRANE BIOCHEM, V8, P133, DOI 10.3109/09687688909025827; HUDSON L, 1980, PRACTICAL IMMUNOLOGY, P224; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; INUI M, 1987, J BIOL CHEM, V262, P1740; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KNUDSON CM, 1990, J BIOL CHEM, V265, P2421; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEGENDRE N, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P49; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; MEISSNER G, 1989, J BIOL CHEM, V264, P1715; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; RARDON DP, 1990, CIRC RES, V67, P84, DOI 10.1161/01.RES.67.1.84; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; ROSEMBLATT M, 1981, J BIOL CHEM, V256, P8140; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHOSHANBARMATZ V, 1988, J BIOL CHEM, V263, P16772; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1993, FEBS LETT, V322, P105, DOI 10.1016/0014-5793(93)81547-D; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; WANG JP, 1993, J BIOL CHEM, V268, P20974; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	43	116	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15876	15884						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195243				2022-12-27	WOS:A1994NP51300074
J	SOLEIMANI, M; BOOKSTEIN, C; MCATEER, JA; HATTABAUGH, YJ; BIZAL, GL; MUSCH, MW; VILLEREAL, M; RAO, MC; HOWARD, RL; CHANG, EB				SOLEIMANI, M; BOOKSTEIN, C; MCATEER, JA; HATTABAUGH, YJ; BIZAL, GL; MUSCH, MW; VILLEREAL, M; RAO, MC; HOWARD, RL; CHANG, EB			EFFECT OF HIGH-OSMOLALITY ON NA+/H+ EXCHANGE IN RENAL PROXIMAL TUBULE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL MEMBRANE-VESICLES; SMOOTH-MUSCLE CELLS; RAT NA/H EXCHANGER; VOLUME REGULATION; H+ EXCHANGER; NA+-HCO3 COTRANSPORT; MOLECULAR-CLONING; EPITHELIAL-CELLS; PROTEIN-KINASE; RABBIT KIDNEY	Na+/H+ exchanger isoform and the effect of high osmolality on its function was studied in cultured renal epithelial cells (LLC-PK, and OK). Using NHE-3-specific antibody, immunoblots of luminal membranes from LLC-PK1 and OK cells specifically labeled proteins with molecular masses 90 and 95 kDa, indicating that NHE-3 is the isoform expressed on the luminal membranes of these epithelia. Proximal tubular suspensions from rabbit kidney cortex were incubated in control (310 mosm/ liter) or high osmolality (510 mosm/liter) medium for 45 min and utilized for brush border membrane vesicle preparation. Influx of amiloride-sensitive Na-22(+) at 10 s (pH(o) 7.5, pH(i) 6.0) into brush border membrane vesicles was 37% lower in the high osmolality group (p < 0.03). LLC-PK, or OK cells were grown to confluence and examined for Na+/H+ exchange activity. An increase in medium osmolality to 510 mosm following acid loading decreased the 5-min uptake of the amiloride-sensitive Na-22(+) in LLC-PK1 and OK cells (p < 0.04 and <0.03 for LLC-PK1 cell OK cells, respectively). An increase in medium osmolality to 510 mosm in vascular smooth muscle cells, which express NHE-1, produced 45 and 64% stimulation of the amiloride-sensitive Na-22(+) influx at base-line pH(i) and acid-loaded condition, respectively (p < 0.03 and < 0.01). Down-regulation of protein kinase C by preincubation with phorbol 12-myristate 13-acetate or inhibition of Ca2+-calmodulin-dependent protein kinase (calmodulin-kinase II) by N-6-aminohexyl-5-chloro-1-naphthalenesulfonamide (W-7) in LLC-PK1 cells did not block the inhibitory effect of high osmolality on Na+/H+ exchange activity. We conclude that renal proximal tubule epithelial cells express Na+/H+ exchange isoform NHE-3 on their luminal membranes and that hyperosmolality decreases transporter activity during cell acidification. This inhibitory effect might be unique to the NHE-3 isoform, since vascular smooth muscle cells which express NHE-1 exhibit an increase in Na+/H+ exchange activity in response to high osmolality.	INDIANA UNIV,DEPT ANAT,INDIANAPOLIS,IN 46202; VET AFFAIRS MED CTR,INDIANAPOLIS,IN 46202; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612	Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	SOLEIMANI, M (corresponding author), INDIANA UNIV,SCH MED,DEPT MED,NEPHROL SECT,FESLER HALL 108,1120 S DR,INDIANAPOLIS,IN 46202, USA.			soleimani, m/0000-0002-3446-8870	NIDDK NIH HHS [DK 42086, DK 38510] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038510, P30DK042086] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF833, DOI 10.1152/ajprenal.1992.263.5.F833; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; BROWN CDA, 1984, BIOCHIM BIOPHYS ACTA, V769, P471, DOI 10.1016/0005-2736(84)90332-8; BURNS KD, 1991, AM J PHYSIOL, V261, pF607, DOI 10.1152/ajprenal.1991.261.4.F607; CHAMLEY JH, 1977, CELL TISSUE RES, V177, P503; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; DASCALU A, 1992, J PHYSIOL-LONDON, V456, P503, DOI 10.1113/jphysiol.1992.sp019349; ESCOBALES N, 1990, AM J PHYSIOL, V259, pC640, DOI 10.1152/ajpcell.1990.259.4.C640; EVERS C, 1978, MEMBRANE BIOCHEM, V1, P202; GRASSL SM, 1986, J BIOL CHEM, V261, P8778; GRINSTEIN S, 1986, CURR TOP MEMBR TRANS, V26, P115; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; HEBERT SC, 1986, AM J PHYSIOL, V250, pC920, DOI 10.1152/ajpcell.1986.250.6.C920; KRAPF R, 1993, J MEMBRANE BIOL, V131, P1, DOI 10.1007/BF02258529; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MONTROSE MH, 1988, AM J PHYSIOL, V255, pC76, DOI 10.1152/ajpcell.1988.255.1.C76; MONTROSERAFIZADEH C, 1990, ANNU REV PHYSIOL, V52, P761; MORAN A, 1987, AM J PHYSIOL, V252, pC63, DOI 10.1152/ajpcell.1987.252.1.C63; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; POUYSSEGUR J, 1985, TRENDS BIOCHEM SCI, V10, P453, DOI 10.1016/0968-0004(85)90030-1; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; RAO GN, 1990, J BIOL CHEM, V265, P19393; REILLY RF, 1991, AM J PHYSIOL, V261, pF1088, DOI 10.1152/ajprenal.1991.261.6.F1088; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SERGEANT S, 1989, J MEMBRANE BIOL, V109, P209, DOI 10.1007/BF01870278; SOLEIMANI M, 1989, J BIOL CHEM, V264, P18302; SOLEIMANI M, 1994, CIRC RES, V74, P48, DOI 10.1161/01.RES.74.1.48; SOLEIMANI M, 1992, J CLIN INVEST, V90, P211, DOI 10.1172/JCI115838; SOLEIMANI M, 1990, J CLIN INVEST, V86, P1076, DOI 10.1172/JCI114810; SOLEIMANI M, 1993, J AM SOC NEPHROL, V4, pA847; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, P NATL ACAD SCI USA, V90, P9110, DOI 10.1073/pnas.90.19.9110; TSE CM, 1993, J BIOL CHEM, V268, P11917; WANG Z, 1993, J BIOL CHEM, V268, P11925; WHALLEY DW, 1991, J PHYSIOL-LONDON, V444, P193, DOI 10.1113/jphysiol.1991.sp018873	36	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15613	15618						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195209				2022-12-27	WOS:A1994NP51300037
J	SUZUKI, H; MURAKOSHI, I; SAITO, K				SUZUKI, H; MURAKOSHI, I; SAITO, K			A NOVEL O-TIGLOYLTRANSFERASE FOR ALKALOID BIOSYNTHESIS IN PLANTS - PURIFICATION, CHARACTERIZATION AND DISTRIBUTION IN LUPINUS PLANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOLIZIDINE ALKALOIDS; ESTERS; SEEDLINGS; HIRSUTUS; PROTEINS; SOPHORA; LUTEUS; ALBUS	A novel acyltransferase for alkaloid metabolism, tigloyl-CoA: (-)-13 alpha-hydroxymultiflorine/(+)-13 alpha-hydrox- ylupanine O-tigloyltransferase (HMT/HLTase), a monomeric 50-kDa protein, was purified to homogeneity from 10-day-old Lupinus termis seedlings. There were two isoforms of this acyltransferase with the same molecular mass (50 kDa) but slightly different isoelectric points (pI 7.8 and 7.6). These two isoforms showed the same catalytic activity of tigloyl transfer from tigloyl-CoA to (-)-13 alpha-hydroxymultiflorine and (+)-13 alpha-hydroxylupanine, which belong to the same (75, 9S) enantiomeric series of tetracyclic quinolizidine alkaloids; whereas no activity was detected toward an antipodal(7R, 9R) alkaloid, (-)-baptifoline, or to bicyclic quinolizidine alkaloids, (+)-epilupinine and (-)-lupinine. The K-m values for HMTase activity were determined to be 21 mu M and 46 mu M for (-)-13 alpha-hydroxymultiflorine and tigloyl-CoA, respectively; and for HLTase activity, 27 mu M and 52 mu M for (+)-13 alpha-hydroxylupanine and tigloyl-CoA, respectively. The activity was inhibited by CoASH in a competitive manner, and by (+)-lupanine and (+)-epilupinine in a partially noncompetitive manner. The enzyme showed the highest activity around pH 8.0 and was inactivated by heat treatment and by the addition of sulfhydryl blocking reagents, Such tigloyltransferases for quinolizidine alkaloid metabolism are distributed in some Lupinus species and Cytisus scoparius, in which tigloyl alkaloids are accumulated in addition to non-ester-type alkaloids, but not in other lupin plants, in which only non-ester-type alkaloids are present.	CHIBA UNIV,FAC PHARMACEUT SCI,INAGE KU,CHIBA 263,JAPAN	Chiba University			Saito, Kazuki/D-2670-2009; Suzuki, Hideyuki/J-7571-2016	Saito, Kazuki/0000-0001-6310-5342; 				[Anonymous], 1992, CHIN DRUGS PLANT ORI; [Anonymous], DICT ALKALOIDS; ASRES K, 1986, PHYTOCHEMISTRY, V25, P1443, DOI 10.1016/S0031-9422(00)81306-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONN EE, 1980, SECONDARY PLANT PROD, V7; CROW WD, 1959, AUST J CHEM, V12, P474, DOI 10.1071/CH9590474; HUSSAIN RA, 1988, J NAT PROD, V51, P809, DOI 10.1021/np50058a033; KRAUS W, 1987, TETRAHEDRON, V43, P2817, DOI 10.1016/S0040-4020(01)86887-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEETE E, 1973, PHYTOCHEMISTRY, V12, P2203, DOI 10.1016/0031-9422(73)85120-9; LOUNASMAA M, 1988, ALKALOIDS, V33, P2; Luckner M., 1990, SECONDARY METABOLISM; MCGAW BA, 1977, PHYTOCHEMISTRY, V16, P1711, DOI 10.1016/0031-9422(71)85076-8; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MURAKOSHI I, 1978, CHEM PHARM BULL, V26, P809; NEIDLE S, 1972, J CHEM SOC CHEM COMM, V3, P140; POLZ L, 1987, Z NATURFORSCH C, V42, P333; SAITO K, 1993, PHYTOCHEMISTRY, V32, P87, DOI 10.1016/0031-9422(92)80112-R; SAITO K, 1993, PHYTOCHEMISTRY, V34, P1041, DOI 10.1016/S0031-9422(00)90709-X; SAITO K, 1989, J CHROMATOGR, V462, P333, DOI 10.1016/S0021-9673(00)91359-1; SAITO K, 1994, IN PRESS STUDIES NAT; STOCKIGT J, 1975, Z NATURFORSCH C, V30, P352; STRACK D, 1991, PHYTOCHEMISTRY, V30, P1493, DOI 10.1016/0031-9422(91)84195-X; TAKAMATSU S, 1991, J NAT PROD, V54, P477, DOI 10.1021/np50074a020; VERDOORN GH, 1990, PHYTOCHEMISTRY, V29, P1297, DOI 10.1016/0031-9422(90)85446-M; Waterman PG, 1993, METHODS PLANT BIOCH; WINK M, 1987, PLANTA MED, V53, P509, DOI 10.1055/s-2006-962797; WINK M, 1982, PLANTA, V156, P560, DOI 10.1007/BF00392781; WINK M, 1983, PLANTA MED, V48, P253, DOI 10.1055/s-2007-969928; YAMAZAKI M, 1993, BIOL PHARM BULL, V16, P1182; YOSHIKAWA K, 1992, CHEM PHARM BULL, V40, P1779, DOI 10.1248/cpb.40.1779; ZENK MH, 1985, J NAT PROD, V48, P725, DOI 10.1021/np50041a003	32	23	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15853	15860						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195240				2022-12-27	WOS:A1994NP51300071
J	VOSSMCCOWAN, ME; XU, B; EPSTEIN, PN				VOSSMCCOWAN, ME; XU, B; EPSTEIN, PN			INSULIN SYNTHESIS, SECRETORY COMPETENCE, AND GLUCOSE-UTILIZATION ARE SENSITIZED BY TRANSGENIC YEAST HEXOKINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; GENE-EXPRESSION; GLUCOKINASE; ISLETS; RELEASE; ASSAY; MICE; LINE	Glucokinase regulates insulin secretion by controlling the rate of glucose phosphorylation. In this report we utilize islets transgenic for high affinity yeast hexokinase to examine the role of glucose phosphorylation on other beta cell functions. Normal pancreatic islets responded to culture in low glucose by lowering insulin synthetic rates, becoming depleted of insulin and insulin mRNA, losing competence to respond to glucose with increased insulin secretion, and lowering glucokinase levels by one half. In transgenic islets, increased high affinity hexokinase activity provided significant protection against reductions in all parameters of insulin synthesis and helped preserve the competence of beta cells to secrete insulin. The transgenic hexokinase also increased the rate of glucose utilization. These results demonstrate that glucose phosphorylation and presumably glucokinase mediate these glucose regulated responses. Of the parameters measured, only the change in glucokinase activity did not show an effect of the yeast hexokinase transgene. We also found that yeast hexokinase transgene expression was regulated 10-fold by glucose. This is the first demonstration of glucose inducibility of the insulin promoter in transgenic mice.	UNIV N DAKOTA, SCH MED, DEPT PHARMACOL & TOXICOL, GRAND FORKS, ND 58202 USA	University of North Dakota Grand Forks				Epstein, Paul/0000-0002-7006-8954	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044519] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29DK44519] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMOROSO S, 1990, SCIENCE, V247, P852, DOI 10.1126/science.2305257; ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; BEDOYA FJ, 1985, ANAL BIOCHEM, V144, P504, DOI 10.1016/0003-2697(85)90147-2; BRUN T, 1993, J BIOL CHEM, V268, P18905; CAGIERO E, 1988, J CLIN INVEST, V82, P735; CARROLL RJ, 1988, P NATL ACAD SCI USA, V85, P8943, DOI 10.1073/pnas.85.23.8943; EPSTEIN PN, 1992, P NATL ACAD SCI USA, V89, P12038, DOI 10.1073/pnas.89.24.12038; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; HALBAN PA, 1980, BIOCHEM PHARMACOL, V29, P2625, DOI 10.1016/0006-2952(80)90077-5; KIM YJ, 1988, ANAL BIOCHEM, V174, P168, DOI 10.1016/0003-2697(88)90532-5; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; MACDONALD MJ, 1991, J BIOL CHEM, V266, P1335; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; PURRELLO F, 1993, DIABETES, V42, P199, DOI 10.2337/diabetes.42.1.199; SHIMANO H, 1991, BIOCHIM BIOPHYS ACTA, V1090, P91, DOI 10.1016/0167-4781(91)90041-J; VELHO G, 1992, LANCET, V340, P444, DOI 10.1016/0140-6736(92)91768-4; VOSSMCCOWAN ME, 1993, TRANSGENE, V1, P103; WELSH M, 1985, J BIOL CHEM, V260, P3590; YIN L, 1992, DIABETES, V41, P792	20	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15814	15818						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195237				2022-12-27	WOS:A1994NP51300065
J	WELSH, CF; MOSS, J; VAUGHAN, M				WELSH, CF; MOSS, J; VAUGHAN, M			ISOLATION OF RECOMBINANT ADP-RIBOSYLATION FACTOR-6, A SIMILAR-TO-20-KDA GUANINE-NUCLEOTIDE-BINDING PROTEIN, IN AN ACTIVATED GTP-BOUND STATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLERA-TOXIN; ESCHERICHIA-COLI; GOLGI MEMBRANES; BREFELDIN-A; BOVINE BRAIN; HUMAN GENE; FACTOR-III; FACTOR-I; ARF; EXCHANGE	ADP-ribosylation factors (ARFs) are similar to 20-kDa guanine nucleotide-binding proteins, which, like other members of the ras superfamily, are activated by exchanging bound GDP for GTP and inactivated through hydrolysis of the gamma-phosphate of bound GTP to form GDP in a highly regulated cycle. ARF 6, a class III ARF, was expressed in Escherichia coli with its amino terminus fused to maltose-binding protein. Following release from maltose-binding protein, recombinant ARF 6 (rARF 6) exhibited maximal activity with or without GTP. Such constitutive activation was due to the predominance of ARF-GTP over ARF-GDP, as demonstrated by nucleotide analysis. rARF 6 expressed in E. coli without amino-terminal extension was bound primarily to GDP and exhibited typical GTP-dependent activity. After release from maltose-binding protein, rARF 6-GTP was stable; only a fraction of the nucleotide was removed using EDTA, whereas urea denaturation restored complete GTP dependence. [alpha-P-32]GTP bound to rARF 6 was in part protected from hydrolysis by alkaline phosphatase and resulted in the formation of [alpha-P-32]GTP, -GDP, and -GMP, whereas unbound nucleotide was completely hydrolyzed to guanosine. Thus, amino-terminal extension of rARF 6, by maltose-binding protein, promoted the formation of a constitutively activated GTP-bound species. By analysis of this species, we confirmed that rARF 6 lacks the intrinsic ability to hydrolyze bound GTP and speculate that maltose-binding protein may inhibit hydrolysis by extrinsic factors.	NHLBI,CELLULAR METAB LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BAGNARA AS, 1973, EUR J BIOCHEM, V36, P422, DOI 10.1111/j.1432-1033.1973.tb02927.x; BAGNARA AS, 1972, ANAL BIOCHEM, V45, P24, DOI 10.1016/0003-2697(72)90004-8; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FRECH M, 1990, J BIOL CHEM, V265, P6353; HALL A, 1986, J BIOL CHEM, V261, P963; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1986, J BIOL CHEM, V261, P7906; LEE CM, 1992, J BIOL CHEM, V267, P9028; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; NODA M, 1990, BIOCHIM BIOPHYS ACTA, V1034, P195, DOI 10.1016/0304-4165(90)90076-9; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1992, J BIOL CHEM, V267, P17766; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; REGAZZI R, 1991, BIOCHEM J, V275, P639, DOI 10.1042/bj2750639; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERVENTI IM, 1993, J BIOL CHEM, V268, P4863; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1991, J BIOL CHEM, V266, P23053; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WALKER MW, 1992, J BIOL CHEM, V267, P3230; WEISS O, 1989, J BIOL CHEM, V264, P21066	30	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15583	15587						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195204				2022-12-27	WOS:A1994NP51300032
J	CLARET, FX; CHAPEL, S; GARCES, J; TSAIPFLUGFELDER, M; BERTHOLET, C; SHAPIRO, DJ; WITTEK, R; WAHLI, W				CLARET, FX; CHAPEL, S; GARCES, J; TSAIPFLUGFELDER, M; BERTHOLET, C; SHAPIRO, DJ; WITTEK, R; WAHLI, W			2 FUNCTIONAL FORMS OF THE XENOPUS-LAEVIS ESTROGEN-RECEPTOR TRANSLATED FROM A SINGLE MESSENGER-RNA SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACIDS; 5' FLANKING SEQUENCE; MAMMARY-TUMOR VIRUS; CELL-FREE SYSTEM; INVITRO TRANSCRIPTION; GLUCOCORTICOID RECEPTOR; VACCINIA VIRUS; PROGESTERONE-RECEPTOR; RESPONSIVE ELEMENT; LATE GENE	Steroid receptors are nuclear proteins that regulate gene transcription in a ligand-dependent manner. Overexpression of the Xenopus estrogen receptor in a vaccinia virus derived expression system revealed that the receptor localized exclusively in the nucleus of the infected cells, irrespective of the presence or absence of the ligand. Furthermore, two forms of the receptor were produced, a full-length and a N-terminal truncated version, which are translated from a single mRNA species by the use of two AUG within the same reading frame. These 66- and 61-kDa receptors were also observed after in vitro translation of the mRNA as well as in primary Xenopus hepatocytes. Both forms are potent estrogen dependent transcriptional activators in transient transfection experiments, as well as in in vitro transcription assays.	UNIV LAUSANNE,INST BIOL ANIM,CH-1015 LAUSANNE,SWITZERLAND; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Lausanne; University of Illinois System; University of Illinois Urbana-Champaign			Wahli, Walter/B-1398-2009; Claret, Francois X/R-2104-2016; Wahli, Walter/I-3194-2019	Wahli, Walter/0000-0002-5966-9089; Claret, Francois X/0000-0003-4629-6495; 				ALNEMRI ES, 1991, J BIOL CHEM, V266, P3925; BAGCHI MK, 1990, NATURE, V345, P547, DOI 10.1038/345547a0; BAGCHI MK, 1990, J BIOL CHEM, V265, P5129; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERTHOLET C, 1986, EMBO J, V5, P1951, DOI 10.1002/j.1460-2075.1986.tb04449.x; BERTHOLET C, 1985, P NATL ACAD SCI USA, V82, P2096, DOI 10.1073/pnas.82.7.2096; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN M, 1990, J BIOL CHEM, V265, P11238; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CORTHESY B, 1989, MOL CELL BIOL, V9, P5548, DOI 10.1128/MCB.9.12.5548; CORTHESY B, 1990, P NATL ACAD SCI USA, V87, P7878, DOI 10.1073/pnas.87.20.7878; CORTHESY B, 1988, SCIENCE, V239, P1137, DOI 10.1126/science.2830672; DEBOER W, 1982, ENDOCRINOLOGY, V110, P1217, DOI 10.1210/endo-110-4-1217; DENTON RR, 1992, J BIOL CHEM, V267, P7263; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; ELLISTON JF, 1992, J BIOL CHEM, V267, P5193; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FREEDMAN LP, 1989, SCIENCE, V245, P298, DOI 10.1126/science.2473529; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HAYWARD MA, 1982, AM J PHYSIOL, V243, pC1, DOI 10.1152/ajpcell.1982.243.1.C1; HAYWARD MA, 1980, J BIOL CHEM, V255, P1308; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; KALFF M, 1990, NATURE, V344, P360, DOI 10.1038/344360a0; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; MARILLEY D, 1994, IN PRESS MOL CELL EN; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; MAY FEB, 1980, DEV BIOL, V77, P419, DOI 10.1016/0012-1606(80)90485-6; MOSS B, 1991, J BIOL CHEM, V266, P1355; NARDULLI AM, 1993, MOL ENDOCRINOL, V7, P331, DOI 10.1210/me.7.3.331; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PAKDEL F, 1989, MOL ENDOCRINOL, V3, P44, DOI 10.1210/mend-3-1-44; PATEL DD, 1987, EMBO J, V6, P3787, DOI 10.1002/j.1460-2075.1987.tb02714.x; PATEL DD, 1988, P NATL ACAD SCI USA, V85, P9431, DOI 10.1073/pnas.85.24.9431; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PRATT WB, 1992, J STEROID BIOCHEM, V41, P223, DOI 10.1016/0960-0760(92)90348-M; REESE JC, 1991, NUCLEIC ACIDS RES, V19, P6595, DOI 10.1093/nar/19.23.6595; ROSEL JL, 1986, J VIROL, V60, P436, DOI 10.1128/JVI.60.2.436-449.1986; Sambrook J, 1989, MOL CLONING LABORATO; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHEMSHEDINI L, 1992, J BIOL CHEM, V267, P1834; SLUYSER M, 1990, CANCER RES, V50, P451; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SRINIVASAN G, 1992, MOL ENDOCRINOL, V6, P857, DOI 10.1210/me.6.6.857; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; TOULAS C, 1992, HORM RES, V38, P73, DOI 10.1159/000182493; TSAI SY, 1990, J BIOL CHEM, V265, P17055; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; WEBB P, 1992, MOL ENDOCRINOL, V6, P157, DOI 10.1210/me.6.2.157; WEILER IJ, 1987, MOL ENDOCRINOL, V1, P355, DOI 10.1210/mend-1-5-355; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WESTLEY B, 1979, BIOCHEM BIOPH RES CO, V88, P1167, DOI 10.1016/0006-291X(79)91531-6; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WRIGHT CVE, 1983, EMBO J, V2, P973, DOI 10.1002/j.1460-2075.1983.tb01530.x	73	23	25	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14047	14055						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188685				2022-12-27	WOS:A1994NL60600051
J	MA, TH; FRIGERI, A; TSAI, ST; VERBAVATZ, JM; VERKMAN, AS				MA, TH; FRIGERI, A; TSAI, ST; VERBAVATZ, JM; VERKMAN, AS			LOCALIZATION AND FUNCTIONAL-ANALYSIS OF CHIP28K WATER CHANNELS IN STABLY TRANSFECTED CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; KIDNEY PROXIMAL TUBULE; BRUSH-BORDER; ENDOSOMES; TRANSPORT; RECONSTITUTION; EXPRESSION; VESICLES; PERMEABILITY; PURIFICATION	CHIP28 is a major water transporting protein in erythrocytes and plasma membranes in kidney proximal tubule and thin descending limb of Henle. Chinese hamster ovary cells were stably transfected with the coding sequence of cloned rat kidney CHIP28k using expression vectors containing cytomegalovirus or Rous sarcoma virus promoters. Clonal cell populations expressed a 1.3-kilobase mRNA on Northern blot probed by CHIP28k cDNA and a 28-kDa protein on immunoblot probed by a polyclonal CHIP28 antibody. The clone with greatest expression produced approximately 8 x 10(6) copies of CHIP28k protein/cell. Plasma membrane osmotic water permeability (P(f)), measured by stopped-flow light scattering, was 0.004 cm/s in control (vector-transfected) cells (10-degrees-C) and 0.014 cm/s in the CHIP28k-transfected cells. P(f) in CHIP28k-transfected cells had an activation energy of 4.9 kcal/mol and was reversibly inhibited by HgCl2. CHIP28k expression did not affect the transport of protons and the small polar non-electrolytes urea and formamide. CHIP28k immunoreactivity and function was then determined in subcellular fractions. P(f) in 6-carboxyfluorescein-labeled endocytic vesicles, measured by a stopped-flow fluorescence quenching assay, was 0.002 cm/s (control cells) and 0.011 cm/s (CHIP28k-transfected cells); P(f) in transfected cells was inhibited by HgCl2. Immunoblotting of fractionated endoplasmic reticulum, Golgi, and plasma membranes revealed high densities of CHIP28k (approximately 5000 monomers/mum2 in plasma membrane) with different glycosylation patterns; functional water transport activity was present only in Golgi and plasma membrane vesicles. Antibody detection of CHIP28k by confocal fluorescence microscopy and immunogold electron microscopy revealed localization to plasma membrane and intracellular vesicles. These studies establish a stably transfected somatic cell line that strongly expresses functional CHIP28k water channels. As in the original proximal tubule cells, the expressed CHIP28k protein is a selective water channel that is functional in endocytic vesicles and the cell plasma membrane.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT MED & PHYSIOL, 1065 HLTH SCI E TOWER, SAN FRANCISCO, CA 94143 USA; MASSACHUSETTS GEN HOSP, DEPT MED & PHYSIOL, RENAL UNIT, BOSTON, MA 02114 USA	University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital				Frigeri, Antonio/0000-0002-5284-2934; Ma, Tonghui/0000-0001-9338-1030; Verbavatz, Jean-Marc/0000-0002-4654-1174	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42368] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BROWN D, 1989, AM J PHYSIOL, V256, pF1, DOI 10.1152/ajprenal.1989.256.1.F1; DENKER BM, 1988, J BIOL CHEM, V263, P15634; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P203; ECHEVARRIA M, 1992, J GEN PHYSIOL, V99, P573, DOI 10.1085/jgp.99.4.573; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; Finkelstein A., 1987, WATER MOVEMENT LIPID; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HASEGAWA H, 1993, AM J PHYSIOL, V264, pC237, DOI 10.1152/ajpcell.1993.264.1.C237; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KOTLIAR N, 1992, MOL ENDOCRINOL, V6, P337, DOI 10.1210/me.6.3.337; LUCY JA, 1989, BIOCHEM SOC T, V17, P623, DOI 10.1042/bst0170623; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195; MEYER MM, 1987, J MEMBRANE BIOL, V96, P107, DOI 10.1007/BF01869237; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RODMAN JS, 1986, J CELL BIOL, V102, P77, DOI 10.1083/jcb.102.1.77; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SHI LB, 1990, J GEN PHYSIOL, V95, P941, DOI 10.1085/jgp.95.5.941; SHI LB, 1989, J GEN PHYSIOL, V94, P1101, DOI 10.1085/jgp.94.6.1101; SMITH BL, 1991, J BIOL CHEM, V266, P6407; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; VANHEESWIJK MPE, 1986, J MEMBRANE BIOL, V92, P183, DOI 10.1007/BF01870707; VANHOEK AN, 1991, J BIOL CHEM, V266, P16633; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; VERBAVATZ JM, 1993, IN PRESS J CELL BIOL; VERKMAN AS, 1987, J BIOENERG BIOMEMBR, V19, P481; VERKMAN AS, 1992, ANNU REV PHYSIOL, V54, P97, DOI 10.1146/annurev.physiol.54.1.97; VERKMAN AS, 1988, NATURE, V333, P268, DOI 10.1038/333268a0; VERKMAN AS, 1989, J BIOL CHEM, V264, P20608; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4; YE R, 1989, J GEN PHYSIOL, V93, P885, DOI 10.1085/jgp.93.5.885; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZEN K, 1992, J CELL BIOL, V119, P99, DOI 10.1083/jcb.119.1.99; ZHANG R, 1990, J MEMBRANE BIOL, V117, P253, DOI 10.1007/BF01868455; ZHANG RB, 1993, BIOCHEMISTRY-US, V32, P2938, DOI 10.1021/bi00063a002; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359	43	84	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22756	22764						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226786				2022-12-27	WOS:A1993MD34800083
J	PETERSEN, CCH; PETERSEN, OH; BERRIDGE, MJ				PETERSEN, CCH; PETERSEN, OH; BERRIDGE, MJ			THE ROLE OF ENDOPLASMIC-RETICULUM CALCIUM PUMPS DURING CYTOSOLIC CALCIUM SPIKING IN PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INOSITOL TRISPHOSPHATE; POTENTIAL OSCILLATIONS; CA-2+ OSCILLATIONS; DIFFERENT PATTERNS; TUMOR PROMOTER; THAPSIGARGIN; RELEASE; MEMBRANE; DEPENDENCE; ACTIVATION	Many cell types show repetitive short lasting cytosolic calcium spikes with long interspike periods when stimulated with submaximal concentrations of agonists linked to the phosphoinositide signaling pathway. In pancreatic acinar cells these spikes have been shown to be evoked by constant levels of inositol trisphosphate through a mechanism of calcium-induced calcium release and do not depend acutely on the presence of external calcium. However, the processes involved in the interspike period have remained unclear. Here we report that the endoplasmic reticulum Ca2+-ATPases play a significant role, not only in resequestering calcium after a spike, but also in regulating the long interspike period. Decreasing the activity of the endoplasmic reticulum calcium pumps leads to shorter interspike intervals and thus higher spiking frequencies, while the duration of each spike increases. The endoplasmic reticulum Ca2+-ATPases are able to entirely suppress a response that can subsequently be evoked by partial inhibition of the pumps. This suggests that during the interspike period there is a considerable amount of calcium released from intracellular stores, which is rapidly buffered by the endoplasmic reticulum calcium pumps and the cytosolic calcium-binding proteins. A calcium spike will be initiated by calcium-induced calcium release only when the buffering is saturated.	UNIV LIVERPOOL, PHYSIOL LAB, MRC, SECRETORY CONTROL GRP, LIVERPOOL L69 3BX, ENGLAND	University of Liverpool	PETERSEN, CCH (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, AFRC, MOLEC SIGNALING LAB, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.		Petersen, Carl/M-5123-2017; Petersen, Ole H/E-8708-2010	Petersen, Carl/0000-0003-3344-4495; Petersen, Ole/0000-0002-6998-0380	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1988, J PHYSIOL-LONDON, V403, P589, DOI 10.1113/jphysiol.1988.sp017266; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KLINE D, 1992, J BIOL CHEM, V267, P17624; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEVY S, 1993, J GEN PHYSIOL, V101, P67, DOI 10.1085/jgp.101.1.67; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PARKER I, 1993, J PHYSIOL-LONDON, V461, P133, DOI 10.1113/jphysiol.1993.sp019506; PETERSEN CCH, 1991, EMBO J, V10, P527, DOI 10.1002/j.1460-2075.1991.tb07979.x; PETERSEN CCH, 1991, FEBS LETT, V293, P179, DOI 10.1016/0014-5793(91)81181-7; RAPP PE, 1981, J EXP BIOL, V93, P119; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	27	73	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22262	22264						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226732				2022-12-27	WOS:A1993MD34800013
J	MCINTOSH, JM; YOSHIKAMI, D; MAHE, E; NIELSEN, DB; RIVIER, JE; GRAY, WR; OLIVERA, BM				MCINTOSH, JM; YOSHIKAMI, D; MAHE, E; NIELSEN, DB; RIVIER, JE; GRAY, WR; OLIVERA, BM			A NICOTINIC ACETYLCHOLINE-RECEPTOR LIGAND OF UNIQUE SPECIFICITY, ALPHA-CONOTOXIN-IMI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OMEGA-CONOTOXIN; CONUS-GEOGRAPHUS; GAMMA-CARBOXYGLUTAMATE; CALCIUM CHANNELS; PEPTIDE; VENOM; TOXIN; PROBES	We report the isolation, characterization, and total synthesis of a small peptide ligand for nicotinic acetylcholine receptors (nAChRs). It is highly active against the neuromuscular receptor in frog but not in mice. In contrast, it induces seizures when injected centrally in mice and rats, suggesting that it may target neuronal nAChRs in mammals. Although such receptors may be important in both normal cognition and the pathophysiology of several neuropsychiatric disorders, there are few ligands to discriminate between the multiple receptor subtypes. The new peptide is a highly divergent alpha-conotoxin from the snail Conus imperialis, which preys on polychaete worms, In this article, the purification, structural analysis, synthesis, and preliminary physiological characterization of alpha-conotoxin ImI (alpha-CTx-ImI) are reported. The sequence of the peptide is: Gly-Cys-Cys-Ser-Asp-Pro-Arg-Cys-Ala-Trp-Arg-Cys-NH2. The peptide shows striking sequence differences from all alpha-conotoxins of fish-hunting Conus, but its disulfide -bridging is similar: [2-8; 3-12]. We suggest that cone venoms may provide an array of ligands with selectivity for various neuronal nAChR subtypes.	UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112; SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037	Utah System of Higher Education; University of Utah; Salk Institute	MCINTOSH, JM (corresponding author), UNIV UTAH,DEPT PSYCHIAT,201 S BIOL,SALT LAKE CITY,UT 84112, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K20MH000929] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48677] Funding Source: Medline; NIMH NIH HHS [K20 MH00929] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADLER LE, 1993, AM J PSYCHIAT, V150, P1856; BURNS JA, 1991, J ORG CHEM, V56, P2648, DOI 10.1021/jo00008a014; CHIAPPINELLI VA, 1993, NATURAL SYNTHETIC NE, P66; CLARK C, 1981, TOXICON, V19, P691, DOI 10.1016/0041-0101(81)90106-9; CRUZ LJ, 1985, J TOXICOL-TOXIN REV, V4, P107, DOI 10.3109/15569548509014416; CRUZ LJ, 1986, J BIOL CHEM, V261, P6230; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FELDMAN DH, 1987, FEBS LETT, V214, P295, DOI 10.1016/0014-5793(87)80073-X; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; GRAY WR, 1983, J BIOL CHEM, V258, P2247; GRAY WR, 1984, BIOCHEMISTRY-US, V23, P2796, DOI 10.1021/bi00307a040; GRAY WR, 1981, J BIOL CHEM, V256, P4734; HAACK JA, 1990, J BIOL CHEM, V265, P6025; HAACK JA, 1993, NEUROSCI LETT, V163, P63, DOI 10.1016/0304-3940(93)90229-E; HAMMERLAND LG, 1992, EUR J PHARM-MOLEC PH, V226, P239, DOI 10.1016/0922-4106(92)90067-6; HARTZELL HC, 1975, J PHYSIOL-LONDON, V251, P427, DOI 10.1113/jphysiol.1975.sp011102; JANSON AM, 1988, ACTA PHYSIOL SCAND, V132, P589, DOI 10.1111/j.1748-1716.1988.tb08372.x; KERR LM, 1984, NATURE, V308, P282, DOI 10.1038/308282a0; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KUFFLER SW, 1975, J PHYSIOL-LONDON, V244, P703, DOI 10.1113/jphysiol.1975.sp010821; LIEBERMAN JA, 1984, LANCET, V1, P1066; LUETJE CW, 1990, J NEUROCHEM, V55, P632, DOI 10.1111/j.1471-4159.1990.tb04180.x; MARSHALL IG, 1990, TOXICON, V28, P231, DOI 10.1016/0041-0101(90)90417-6; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; MCINTOSH JM, 1993, TOXICON, V31, P1561, DOI 10.1016/0041-0101(93)90340-O; MCINTOSH M, 1982, ARCH BIOCHEM BIOPHYS, V218, P329, DOI 10.1016/0003-9861(82)90351-4; MOCZYDLOWSKI E, 1986, P NATL ACAD SCI USA, V93, P5321; MYERS RA, 1991, BIOCHEMISTRY-US, V30, P9370, DOI 10.1021/bi00102a034; MYERS RA, 1993, CHEM REV, V93, P1923, DOI 10.1021/cr00021a013; NIELSEN D, 1994, IN PRESS TOXICON; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PARDI A, 1989, BIOCHEMISTRY-US, V28, P5494, DOI 10.1021/bi00439a026; RAMILO CA, 1992, BIOCHEMISTRY-US, V31, P9919, DOI 10.1021/bi00156a009; REAVILL C, 1990, NICOTINE PSYCHOPHARM, P307; REYNOLDS IJ, 1986, P NATL ACAD SCI USA, V83, P8804, DOI 10.1073/pnas.83.22.8804; SANBERG PR, 1989, BIOMED PHARMACOTHER, V43, P19, DOI 10.1016/0753-3322(89)90186-8; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SEGUELA P, 1993, J NEUROSCI, V13, P596; WARBURTON DM, 1992, PROG NEURO-PSYCHOPH, V16, P181, DOI 10.1016/0278-5846(92)90069-Q; YOSHIKAMI D, 1989, ANN NY ACAD SCI, V560, P230, DOI 10.1111/j.1749-6632.1989.tb24100.x; ZAFARALLA GC, 1988, BIOCHEMISTRY-US, V27, P7102, DOI 10.1021/bi00418a065	44	182	191	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16733	16739						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206995				2022-12-27	WOS:A1994NR29600036
J	MINASSIAN, C; AJZANNAY, A; RIOU, JP; MITHIEUX, G				MINASSIAN, C; AJZANNAY, A; RIOU, JP; MITHIEUX, G			INVESTIGATION OF THE MECHANISM OF GLYCOGEN REBOUND IN THE LIVER OF 72-HOUR FASTED RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTES; GLUCOSE-6-PHOSPHATASE; GLUCOSE; STIMULATION; INHIBITION; GLUTAMINE; KINETICS	We have investigated the mechanism of the rebound of glycogen stores in the liver of 72-h fasted rats. The liver of 72- and 96-h fasted rats contains significant amounts of glycogen (about 5 mg/g, wet weight) as compared to the liver of 24- and 48-h fasted rats, which contains less than 2 mg of glycogen/g of liver, wet weight. Rebound of glycogen does not involve glycogen synthase activation or glycogen phosphorylase inhibition. It could be dependent on the concentration of the precursor substrate of glycogenesis, i.e. glucose 6-phosphate (Glc-6-P), which is higher by about 45% in the liver of 72- and 96-h fasted rats than in the liver of 48-h fasted rats. The 72-h increase of Glc-6-P compared with the 48-h values could not be explained either by late modifications of the total activities of glucokinase, hexokinases, Glc-6-P dehydrogenase, and glucose-6-phosphatase (Glc-6-Pase) or by changes in plasma glucose and insulin/glucagon ratio. In agreement with the fact that total glucose output tends to decrease upon prolonged fasting, the increase of Glc-6-P concentration in the liver of 72-h fasted rats suggests the involvement of a metabolite inhibition of Glc-6-Pase. The increase of the cy-ketoglutarate concentration in the 72- and 96-h fasted liver with regard to the 48-h fasted liver (about three times) might account for such an inhibition since we show here that Glc-6-Pase is inhibited in vitro in the presence of relevant concentrations of alpha-ketoglutarate, Glc-6-P, and Mg2+ ions.	FAC MED ALEXIS CARREL,INSERM,U197,F-69372 LYON 08,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)				Gilles, Mithieux/0000-0003-3579-8529				AJZANNAY A, 1993, EUR J BIOCHEM, V212, P335, DOI 10.1111/j.1432-1033.1993.tb17666.x; ARION WJ, 1965, BIOCHEM BIOPH RES CO, V20, P606, DOI 10.1016/0006-291X(65)90442-0; Baginski ES, 1974, METH ENZYMOL; BAQUET A, 1990, J BIOL CHEM, V265, P955; Bergmeyer H. U., 1974, METHOD ENZYMAT AN, V3, P1196; Bergmeyer H. U., 1974, METHOD ENZYMAT AN, P1577; BODE AM, 1992, J BIOL CHEM, V267, P2860; BOISJOYEUX B, 1987, DIABETES METAB, V13, P543; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; BOYD ME, 1981, J CLIN INVEST, V68, P142, DOI 10.1172/JCI110230; HALES CN, 1963, BIOCHEM J, V88, P137, DOI 10.1042/bj0880137; HARRIS V, 1979, METHOD HORM RADIOIMM, P643; HEMS DA, 1972, BIOCHEM J, V129, P529, DOI 10.1042/bj1290529; HUE L, 1975, BIOCHEM J, V152, P105, DOI 10.1042/bj1520105; KATZ J, 1976, P NATL ACAD SCI USA, V73, P3433, DOI 10.1073/pnas.73.10.3433; KATZ J, 1979, BIOCHEM J, V180, P389, DOI 10.1042/bj1800389; Keppler D., 1974, METHODS ENZYM ANALYS, V3, P1127; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG G, 1974, METHOD ENZYMAT AN, V3, P1238; LAVOINNE A, 1987, BIOCHEM J, V248, P429, DOI 10.1042/bj2480429; Lohr G. W., 1974, METHODS ENZYMATIC AN, V2, P636, DOI [DOI 10.1016/B978-0-12-091302-2.50026-8, 10.1016/B978-0-12-091302-2.50026-8]; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEIJER AJ, 1992, J BIOL CHEM, V267, P5823; MEISTER A, 1984, GLUTAMINE METABOLISM, P3; MITHIEUX G, 1993, EUR J BIOCHEM, V213, P461, DOI 10.1111/j.1432-1033.1993.tb17782.x; MITHIEUX G, 1990, J BIOL CHEM, V265, P20364; MOUTERDE O, 1992, BIOCHEM J, V288, P795, DOI 10.1042/bj2880795; NORDLIE RC, 1968, J BIOL CHEM, V243, P1140; NORDLIE RC, 1976, GLUCONEOGENESIS ITS, P93; OWEN OE, 1969, J CLIN INVEST, V48, P574, DOI 10.1172/JCI106016; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; SASSE D, 1975, HISTOCHEMISTRY, V45, P237, DOI 10.1007/BF00507698; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V110, P1	34	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16585	16588						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206976				2022-12-27	WOS:A1994NR29600013
J	NISHIMORI, I; JOHNSON, NR; SANDERSON, SD; PERINI, F; MOUNTJOY, K; CERNY, RL; GROSS, ML; HOLLINGSWORTH, MA				NISHIMORI, I; JOHNSON, NR; SANDERSON, SD; PERINI, F; MOUNTJOY, K; CERNY, RL; GROSS, ML; HOLLINGSWORTH, MA			INFLUENCE OF ACCEPTOR SUBSTRATE PRIMARY AMINO-ACID-SEQUENCE ON THE ACTIVITY OF HUMAN UDP-N-ACETYLGALACTOSAMINE-POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE - STUDIES WITH THE MUC1 TANDEM REPEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC EPITHELIAL MUCIN; O-GLYCOSYLATION; EXPRESSION; GALNAC; CELLS; CORE; SPECIFICITY; CLONING; INVITRO; PROTEIN	Synthetic peptides (30 and 20 residues long) corresponding to the native MUC1 tandem repeat sequence (20 residues long) were glycosylated in vitro using UDP-[H-3]GalNAc and lysates from the human breast tumor cell line MCF7. Purified glycopeptides were sequenced on a gas-phase sequenator, and glycosylated positions were determined by measuring the incorporated radio activity in fractions collected following each round of Edman degradation. The results showed that 2 of 3 threonines on the MUC1 tandem repeat peptides were glycosylated at the following positions: GVTSAPDTRP-APGSTAPPAH (underlined Thr residues indicate positions of GalNAc attachment); no glycosylation of serine residues was detected. Determination of the mass of the glycopeptides by mass spectrometry showed that a maximum of two molecules of GalNAc were covalently linked to each 20-residue repeat unit in the peptides. The influence of substrate primary amino acid sequence in determining the substrate specificity of UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase activity was evaluated using as acceptor substrates a series of overlapping 9-residue peptides that represent a moving set through the tandem repeat of the MUC1 mucin. In addition, the influence of primary amino acid sequence on acceptor substrate activity was evaluated using several peptides that contained single or double amino acid substitutions (relative to the native human MUC1 sequence). These included substitutions in the residues that were glycosylated and substitutions in the surrounding primary amino acid sequence. This study demonstrates that primary amino acid sequence, length, and relative position of the residue to be glycosylated dramatically affect the ability of peptides to serve as acceptor substrates for UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase.	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC & ALLIED DIS, OMAHA, NE 68198 USA; KOCHI MED SCH, DEPT INTERNAL MED 1, KOCHI 783, JAPAN; UNIV NEBRASKA, DEPT CHEM, LINCOLN, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; Kochi University; University of Nebraska System; University of Nebraska Lincoln					NATIONAL CANCER INSTITUTE [R01CA057362, P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044762] Funding Source: NIH RePORTER; NCI NIH HHS [CA36727, CA57362] Funding Source: Medline; NIDDK NIH HHS [DK44762] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABERNATHY JL, 1992, TECHNIQUES PROTEIN C, P277; BARND DL, 1989, P NATL ACAD SCI USA, V86, P7159, DOI 10.1073/pnas.86.18.7159; BURCHELL J, 1983, J IMMUNOL, V131, P508; BURCHELL J, 1987, CANCER RES, V47, P5476; Damme E.J.V., 1991, EUR J BIOCHEM, V202, P23; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; EMBER JA, 1992, J IMMUNOL, V148, P3165; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; HOMA FL, 1993, J BIOL CHEM, V268, P12609; JEROME KR, 1991, CANCER RES, V51, P2908; LAN MS, 1990, CANCER RES, V50, P2997; LAN MS, 1990, J BIOL CHEM, V265, P15294; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; SCANLON MJ, 1992, BIOCHEM J, V284, P137, DOI 10.1042/bj2840137; WANG Y, 1993, J BIOL CHEM, V268, P22979; WANG YC, 1992, J BIOL CHEM, V267, P2728; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529	19	72	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16123	16130						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206912				2022-12-27	WOS:A1994NQ72900028
J	YAMAGATA, K; SANDERS, LK; KAUFMANN, WE; YEE, W; BARNES, CA; NATHANS, D; WORLEY, PF				YAMAGATA, K; SANDERS, LK; KAUFMANN, WE; YEE, W; BARNES, CA; NATHANS, D; WORLEY, PF			RHEB, A GROWTH FACTOR-REGULATED AND SYNAPTIC ACTIVITY-REGULATED GENE, ENCODES A NOVEL RAS-RELATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; LONG-TERM POTENTIATION; IMMEDIATE-EARLY GENE; FACTOR MESSENGER-RNAS; POSTTRANSLATIONAL MODIFICATION; C-FOS; INDUCED SEIZURES; NERVOUS-SYSTEM; DENTATE GYRUS; EXPRESSION	Neuronal activity results in long term cellular changes that underlie normal brain development and synaptic plasticity. To examine the molecular basis of activity-dependent plasticity, we have used differential cloning techniques to identify genes that are rapidly induced in brain neurons by synaptic activity. Here we describe an inducible novel member of the Ras family of small GTP-binding proteins we have termed Rheb. rheb mRNA is rapidly and transiently induced in hippocampal granule cells by seizures and by NMDA-dependent synaptic activity in the long term potentiation paradigm. The predicted amino acid sequence of Rheb is most closely homologous to yeast Ras1 and human Rap2. The putative GTP binding regions are highly conserved. A bacterial fusion protein of Rheb binds GTP and exhibits intrinsic GTPase activity. Like Ha-Ras, the carboxyl-terminal sequence encodes a CAAX box that is predicted to signal post-translational farnesylation and to target Rheb to specific membranes. rheb mRNA is expressed at comparatively high levels in normal adult cortex as well as a number of peripheral tissues, including lung and intestine. In the developing brain, rheb mRNA is expressed at relatively high levels in embryonic day 19 cortical plate, and expression remains at stable levels throughout the remainder of prenatal and postnatal development. Its close homology with ras and its rapid inducibility by receptor-dependent synaptic activity suggest that rheb may play an important role in long term activity-dependent neuronal responses.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA; UNIV ARIZONA, DEPT PSYCHOL, TUCSON, AZ USA; UNIV ARIZONA, DEPT NEUROL, TUCSON, AZ USA; UNIV ARIZONA, DIV NEURAL SYST, TUCSON, AZ USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; University of Arizona; University of Arizona; University of Arizona	YAMAGATA, K (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA.		Snyder, Luann/E-8566-2013		NEI NIH HHS [EY09374, EY08900] Funding Source: Medline; NIA NIH HHS [AG09219] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008900, R01EY009374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009219] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABRAHAM WC, 1988, BRAIN RES, V462, P40, DOI 10.1016/0006-8993(88)90582-3; BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; COLE AJ, 1990, J NEUROCHEM, V55, P1920, DOI 10.1111/j.1471-4159.1990.tb05777.x; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; Foulkes, 1991, HORMONAL CONTROL REG, P257; GALL C, 1991, MOL BRAIN RES, V9, P113, DOI 10.1016/0169-328X(91)90136-L; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JEFFERY KJ, 1990, MOL BRAIN RES, V8, P267, DOI 10.1016/0169-328X(90)90039-G; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MCNAUGHTON BL, 1986, J NEUROSCI, V6, P563; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MULLER R, 1983, MOL CELL BIOL, V3, P1062; NEAL SE, 1988, J BIOL CHEM, V263, P19718; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OHMSTEDE CA, 1990, P NATL ACAD SCI USA, V87, P6527, DOI 10.1073/pnas.87.17.6527; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PIZON V, 1988, ONCOGENE, V3, P201; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; REED GD, 1991, ANN NY ACAD SCI, V627, P381; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; WORLEY PF, 1993, J NEUROSCI, V13, P4776; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	59	245	254	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16333	16339						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206940				2022-12-27	WOS:A1994NQ72900059
J	HOMMA, K; KURATA, S; NATORI, S				HOMMA, K; KURATA, S; NATORI, S			PURIFICATION, CHARACTERIZATION, AND CDNA CLONING OF PROCATHEPSIN-L FROM THE CULTURE-MEDIUM OF NIH-SAPE-4, AN EMBRYONIC-CELL LINE OF SARCOPHAGA-PEREGRINA (FLESH FLY), AND ITS INVOLVEMENT IN THE DIFFERENTIATION OF IMAGINAL DISKS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; LYSOSOMAL-ENZYMES; GROWTH-FACTOR; MURINE FIBROBLASTS; MOLECULAR-CLONING; CATHEPSIN-L; PROTEIN; TRANSFORMATION; SEQUENCE; SECRETION	A cysteine proteinase that preferentially hydrolyzes carbobenzyloxy-Phe-Arg-RICA (MCA, methylcoumaryl-7-amide) was purified from the culture medium of NIH-Sape-4 cells. The molecular mass of this enzyme was easily changed from 50 to 35 kDa, without appreciable loss of enzyme activity. From the analysis of its cDNA, this enzyme was concluded to be a procathepsin L of Sarcophaga. Only procathepsin L was found in the medium, while the mature 35-kDa cathepsin L was found exclusively in the cells, indicating that the cells have a mechanism to secrete procathepsin L selectively. An antibody against procathepsin L was found to inhibit the differentiation of imaginal discs cultured in vitro in the presence of 20-hydroxyecdysone. In fact imaginal discs were shown to secrete procathepsin L into the culture medium. These results suggest that procathepsin L is an essential proteinase for differentiation of imaginal discs. Northern blotting analysis revealed that unfertilized eggs contain a significant amount of mRNA for the procathepsin L as a maternal mRNA.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								APPEL LF, 1993, P NATL ACAD SCI USA, V90, P4937, DOI 10.1073/pnas.90.11.4937; Barrett A. J., 1977, PROTEINASES MAMMALIA, P181; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BROWN WJ, 1984, CELL, V36, P295, DOI 10.1016/0092-8674(84)90223-X; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHIANG CP, 1986, J BIOL CHEM, V261, P478; DOHERTY PJ, 1985, MOL CELL BIOL, V5, P466, DOI 10.1128/MCB.5.3.466; DONG JM, 1989, J BIOL CHEM, V264, P7377; DONG JM, 1990, J BIOL CHEM, V265, P4210; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FEKETE E, 1975, W ROUXS ARCH DEV BIO, V173, P123; FESSLER LI, 1993, DEVELOPMENT, V117, P1061; FRICK KK, 1985, MOL CELL BIOL, V5, P2582, DOI 10.1128/MCB.5.10.2582; GAL S, 1985, J CELL BIOL, V100, P535, DOI 10.1083/jcb.100.2.535; GAL S, 1988, BIOCHEM J, V253, P303, DOI 10.1042/bj2530303; GOTTESMAN MM, 1978, P NATL ACAD SCI USA, V75, P2767, DOI 10.1073/pnas.75.6.2767; HANADA K, 1978, AGR BIOL CHEM TOKYO, V42, P523, DOI 10.1080/00021369.1978.10863014; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; ISHIDOH K, 1987, FEBS LETT, V223, P69, DOI 10.1016/0014-5793(87)80511-2; KAWAGUCHI N, 1991, DEV BIOL, V144, P86, DOI 10.1016/0012-1606(91)90481-H; KOMANO H, 1987, BIOCHEM J, V248, P217, DOI 10.1042/bj2480217; KOMANO H, 1980, J BIOL CHEM, V255, P2919; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYCOCK MV, 1991, FEBS LETT, V292, P115, DOI 10.1016/0014-5793(91)80847-V; LAZZARINO D, 1990, J BIOL CHEM, V265, P11864; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCAULEY R, 1973, MOL CELL BIOCHEM, V1, P73, DOI 10.1007/BF01659940; MITSUHAS.J, 1964, CONTRIB BOYCE THOMPS, V22, P435; MORITA T, 1977, J BIOCHEM-TOKYO, V82, P1495, DOI 10.1093/oxfordjournals.jbchem.a131840; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PINOHEISS S, 1989, DEV BIOL, V132, P282, DOI 10.1016/0012-1606(89)90225-X; POODRY CA, 1971, ROUX ARCH DEV BIOL, V168, P1, DOI 10.1007/BF00582000; SAHAGIAN GG, 1982, J BIOL CHEM, V257, P1145; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADA H, 1983, EXPERIENTIA, V39, P377, DOI 10.1007/BF01963132; SCHER CD, 1983, MOL CELL BIOL, V3, P70, DOI 10.1128/MCB.3.1.70; SGARAMELLA V, 1972, J MOL BIOL, V72, P427, DOI 10.1016/0022-2836(72)90155-6; TROEN BR, 1987, BIOCHEM J, V246, P731, DOI 10.1042/bj2460731; UMEZAWA H, 1970, J ANTIBIOT, V23, P259, DOI 10.7164/antibiotics.23.259; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167	44	77	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15258	15264						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195162				2022-12-27	WOS:A1994NP73800061
J	OVERVOORDE, PJ; GRIMES, HD				OVERVOORDE, PJ; GRIMES, HD			TOPOGRAPHICAL ANALYSIS OF THE PLASMA MEMBRANE-ASSOCIATED SUCROSE BINDING-PROTEIN FROM SOYBEAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE-SEPARATION; TRITON X-114; HETEROLOGOUS EXPRESSION; SUGAR-TRANSPORT; COTTON FIBER; IDENTIFICATION; PROTOPLASTS; SPINACH; YEAST; CELLS	Plasma membranes of soybean cells actively engaged in sucrose transport have a sucrose binding protein (SBP) that does not appear to be an integral membrane protein. Experiments were undertaken to analyze the topographical association of this protein with the membrane. Treatment of purified plasma membrane vesicles with either 1 M KCl or KI released less than 35% of the sucrose binding protein from the membrane whereas treatment with either 4 M urea or 0.1 M Na2CO3, pH 11.5, disassociated between 50 and 70%, respectively, of this protein from the membrane. SDS, at either 0.5x, 1x, or 10x of its critical micelle concentration, effectively solubilized the sucrose binding protein. The nonionic detergents Triton X-100 and CHAPS, at either 0.5x, 1x, or 10x of their critical micelle concentration, solubilized between 65 and 75% of this protein. When either native plasma membrane-associated or in vitro-transcribed and -translated SBP were subjected to Triton X-114 phase separation, 80% partitioned into the detergent-poor aqueous phase. These results indicate that the SBP is a peripheral membrane protein but also suggest that there is a population of this protein that is tethered to the membrane.	WASHINGTON STATE UNIV,DEPT BOT,PULLMAN,WA 99164	Washington State University			Grimes, Howard D/C-6490-2017	Grimes, Howard D/0000-0002-8956-8609				ALCARAZ G, 1984, J BIOL CHEM, V259, P4922; BLATT MR, 1993, ANNU REV PLANT PHYS, V44, P543, DOI 10.1146/annurev.pp.44.060193.002551; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUSH DR, 1993, ANNU REV PLANT PHYS, V44, P513, DOI 10.1146/annurev.pp.44.060193.002501; DELMER DP, 1991, PLANT PHYSIOL, V95, P556, DOI 10.1104/pp.95.2.556; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2602; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GALLAGHER SR, 1982, PLANT PHYSIOL, V70, P1335, DOI 10.1104/pp.70.5.1335; GIAQUINTA RT, 1983, ANNU REV PLANT PHYS, V34, P347, DOI 10.1146/annurev.pp.34.060183.002023; GRIMES HD, 1992, PLANT CELL, V4, P1561, DOI 10.1105/tpc.4.12.1561; GRIMES HD, 1988, PLANT PHYSIOL, V88, P444, DOI 10.1104/pp.88.2.444; GRIMES HD, 1991, J PLANT PHYSIOL, V139, P45, DOI 10.1016/S0176-1617(11)80163-X; GRIMES HD, 1986, BIOCHIM BIOPHYS ACTA, V862, P165, DOI 10.1016/0005-2736(86)90480-3; Hatefi Y, 1974, Methods Enzymol, V31, P770; HITZ WD, 1985, PLANT PHYSIOL, V77, P291, DOI 10.1104/pp.77.2.291; Hodges T K, 1974, Methods Enzymol, V32, P392; HOOGEVEEN JT, 1970, J MEMBRANE BIOL, V3, P156, DOI 10.1007/BF01868013; KJELLBOM P, 1984, PHYSIOL PLANTARUM, V62, P501, DOI 10.1111/j.1399-3054.1984.tb02791.x; KJELLBOM P, 1989, PLANT PHYSIOL BIOCH, V27, P169; KUMAR BV, 1985, BIOCHEM BIOPH RES CO, V131, P883, DOI 10.1016/0006-291X(85)91322-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON C, 1984, FEBS LETT, V171, P271, DOI 10.1016/0014-5793(84)80502-5; LI LK, 1993, PLANT PHYSIOL, V101, P1149, DOI 10.1104/pp.101.4.1149; LI LK, 1993, PLANT PHYSIOL, V101, P1143, DOI 10.1104/pp.101.4.1143; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; OKUDA K, 1993, PLANT PHYSIOL, V101, P1131, DOI 10.1104/pp.101.4.1131; PATE JS, 1972, ANN REV PLANT PHYSIO, V23, P173, DOI 10.1146/annurev.pp.23.060172.001133; PRYDE JG, 1986, BIOCHEM J, V233, P525, DOI 10.1042/bj2330525; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RIESMEIER JW, 1992, EMBO J, V11, P4705, DOI 10.1002/j.1460-2075.1992.tb05575.x; RIPP KG, 1988, PLANT PHYSIOL, V88, P1435, DOI 10.1104/pp.88.4.1435; RUCK A, 1993, PLANT J, V4, P41, DOI 10.1046/j.1365-313X.1993.04010041.x; SANDELIUS AS, 1986, PLANT SCI, V48, P1; SANDSTROM RP, 1987, PLANT PHYSIOL, V85, P693, DOI 10.1104/pp.85.3.693; SAUER N, 1993, PLANT J, V4, P601, DOI 10.1046/j.1365-313X.1993.04040601.x; SAUER N, 1990, EMBO J, V9, P3045, DOI 10.1002/j.1460-2075.1990.tb07500.x; SCHMITT MR, 1984, PLANT PHYSIOL, V75, P941, DOI 10.1104/pp.75.4.941; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; TANNER MJA, 1971, BIOCHEM J, V125, P1109, DOI 10.1042/bj1251109; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONSCHAEWEN A, 1990, EMBO J, V9, P3033, DOI 10.1002/j.1460-2075.1990.tb07499.x	42	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15154	15161						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195152				2022-12-27	WOS:A1994NP73800047
J	SCHWARZ, MA; LAZO, JS; YALOWICH, JC; REYNOLDS, I; KAGAN, VE; TYURIN, V; KIM, YM; WATKINS, SC; PITT, BR				SCHWARZ, MA; LAZO, JS; YALOWICH, JC; REYNOLDS, I; KAGAN, VE; TYURIN, V; KIM, YM; WATKINS, SC; PITT, BR			CYTOPLASMIC METALLOTHIONEIN OVEREXPRESSION PROTECTS NIH 3T3 CELLS FROM TERT-BUTYL HYDROPEROXIDE TOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED-MAMMALIAN-CELLS; SINGLE-STRAND BREAKS; OXIDATIVE STRESS; GLUTATHIONE DEPLETION; RAT HEPATOCYTES; FREE-RADICALS; DNA; CADMIUM; SUPEROXIDE; INHIBITION	Metallothioneins (MT) are ubiquitous low molecular weight metal-binding proteins that may act as antioxidants. We examined the sensitivity of NIH 3T3 cells transfected with a plasmid containing mouse metallothionein-I gene (NIH3T3/MT) to the membrane permeant oxidant, tert-butyl hydroperoxide (tBH). NIH3T3/MT cells had a 4-fold increase in intracellular metallothionein as compared to cells transfected with a plasmid containing an inverted gene (NIH3T3/TM). Newly expressed metallothionein appeared to be localized to the cytoplasm as determined by immunofluorescence and confocal microscopy. NIH3T3/MT cells were 6 times more resistant than NIH3T3/TM cells to the cytotoxic effects of tBH. The antioxidant activity of NIH3T3/MT cells was greater than NIH3T3/TM cells, since exposure to tBH resulted in significantly less: (a) thiobarbituric acid-reactive substances and (b) fluorescence after loading cells with the oxidant-sensitive dye, 2'7'-dichlorodihydrofluorescein diacetate. Furthermore, homogenates of NIH3T3/MT cells were more capable of scavenging in vitro generated phenoxyl radicals as quantified by electron spin resonance detection. In contrast, overexpression of cytoplasmic MT did not protect against tBH-induced DNA damage, suggesting that subcellular location of MT is important for its function and that DNA damage is not a key determinant of cytotoxicity. These data provide direct support for an antioxidant role for MT, since physiologically relevant elevations in cytoplasmic MT interfere with tBH-induced cytotoxic peroxidation.	UNIV PITTSBURGH,SCH MED,DEPT ANESTHESIOL & CRIT CARE MED,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT ENVIRONM & OCCUPAT HLTH,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT SURG,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT CELL BIOL & PHYSIOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	SCHWARZ, MA (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15261, USA.		Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552; Yalowich, Jack/0000-0001-5414-573X; Reynolds, Ian/0000-0003-3028-5070; Tyurin, Vladimir/0000-0002-3474-1697	NATIONAL CANCER INSTITUTE [R01CA061299] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032154] Funding Source: NIH RePORTER; NCI NIH HHS [CA 61299] Funding Source: Medline; NHLBI NIH HHS [HL32154] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEL J, 1989, TOXICOL LETT, V47, P191, DOI 10.1016/0378-4274(89)90075-1; BAKKA A, 1982, EXPERIENTIA, V38, P381, DOI 10.1007/BF01949406; BASS DA, 1983, J IMMUNOL, V130, P1910; BAUMAN JW, 1991, TOXICOL APPL PHARM, V110, P347, DOI 10.1016/S0041-008X(05)80017-1; BEUGE JA, 1978, METHOD ENZYMOL, V52, P302; CHUBATSU LS, 1992, CHEM-BIOL INTERACT, V82, P99, DOI 10.1016/0009-2797(92)90017-F; CHUBATSU LS, 1993, BIOCHEM J, V291, P193, DOI 10.1042/bj2910193; COLEMAN JB, 1989, MOL PHARMACOL, V36, P193; COPPEN DE, 1988, P SOC EXP BIOL MED, V189, P100; EATON DL, 1982, TOXICOL APPL PHARM, V66, P134, DOI 10.1016/0041-008X(82)90068-0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FORNACE AJ, 1988, MOL CELL BIOL, V88, P4716; GUTTERIDGE JMC, 1982, INT J BIOCHEM, V14, P649, DOI 10.1016/0020-711X(82)90050-7; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HART BA, 1990, TOXICOL APPL PHARM, V103, P255, DOI 10.1016/0041-008X(90)90228-M; KAINA B, 1990, P NATL ACAD SCI USA, V87, P2710, DOI 10.1073/pnas.87.7.2710; KARIN M, 1985, CELL, V41, P9, DOI 10.1016/0092-8674(85)90051-0; KOHN KW, 1976, BIOCHEMISTRY-US, V15, P4629, DOI 10.1021/bi00666a013; KUO SM, 1994, TOXICOL APPL PHARM, V125, P104, DOI 10.1006/taap.1994.1054; MASAKI N, 1989, ARCH BIOCHEM BIOPHYS, V269, P390, DOI 10.1016/0003-9861(89)90122-7; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MELLOFILHO AC, 1988, BIOCHEM J, V266, P475; MORTON KA, 1992, J BIOL CHEM, V267, P2880; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; MULLER T, 1991, ARCH TOXICOL, V65, P20; OCHI T, 1989, CHEM-BIOL INTERACT, V72, P335, DOI 10.1016/0009-2797(89)90008-2; OCHI T, 1988, TOXICOLOGY, V50, P257, DOI 10.1016/0300-483X(88)90043-1; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; SCHROEDER JJ, 1990, P NATL ACAD SCI USA, V87, P3137, DOI 10.1073/pnas.87.8.3137; SHOEMAKER RH, 1985, CANCER RES, V45, P2145; STOYANOVSKY D, 1993, FREE RADICAL RES COM, V19, P371, DOI 10.3109/10715769309056527; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; THOMAS JP, 1986, BIOCHIM BIOPHYS ACTA, V884, P448, DOI 10.1016/0304-4165(86)90195-9; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; TSUJIKAWA K, 1991, FEBS LETT, V283, P239, DOI 10.1016/0014-5793(91)80597-V; Zar JH., 1999, BIOSTAT ANAL	36	165	166	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15238	15243						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195159				2022-12-27	WOS:A1994NP73800058
J	FANG, KS; BARKER, K; SUDOL, M; HANAFUSA, H				FANG, KS; BARKER, K; SUDOL, M; HANAFUSA, H			A TRANSMEMBRANE PROTEIN-TYROSINE-PHOSPHATASE CONTAINS SPECTRIN-LIKE REPEATS IN ITS EXTRACELLULAR DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELLS; V-MYB; CDNA; RECEPTOR; SEQUENCE; EXPRESSION; CLONING; HOMOLOGY; FAMILY; SRC	We report the first chicken transmembrane protein-tyrosine phosphatase, ChPTP lambda, isolated from a brain cDNA library and preB cells. ChPTP lambda has transcripts of about 5.6 kilobases and is abundant in spleen, intestine, and fibroblasts transformed by oncogenic ras or erbA/B. It has five alternative splicing products varying near their amino termini, and the largest one contains 1237 amino acids. The extracellular domain of ChPTP lambda has several features including a Ser/Thr/Pro-rich region, one fibronectin type III module, and spectrin-like repeats (the first case that spectrin-like repeats were found in the non-cytoplasmic compartment). These repeats were also found in other phosphatases, including CD45 and yeast acid phosphatases PHO5 and PHO3. Antibodies to ChPTP lambda recognized several protein species whose M(r) range from 170,000 to 210,000. ChPTP lambda exhibited phosphotyrosine-specific phosphatase activity. Since CD45 also has these features in the extracellular domain and the two protein-tyrosine phosphatases share 70% similarity in the intracellular domains, we propose that ChPTP lambda and CD45 belong to the same gene family.	ROCKEFELLER UNIV,MOLEC BIOL LAB,NEW YORK,NY 10021	Rockefeller University					NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NCI NIH HHS [CA44356, CA01605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABA TW, 1985, VIROLOGY, V144, P139, DOI 10.1016/0042-6822(85)90312-5; BAJWA W, 1984, NUCLEIC ACIDS RES, V12, P7721, DOI 10.1093/nar/12.20.7721; BARON MD, 1987, J BIOL CHEM, V262, P17623; BARTHELS D, 1987, EMBO J, V6, P907, DOI 10.1002/j.1460-2075.1987.tb04837.x; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1982, J CELL PHYSL S, V1, P195; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOPER JA, 1990, SRC FAMILY PROTEIN T; DARNELL JE, 1986, MOL CELL BIOL, P947; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FUKUI Y, 1991, ONCOGENE, V6, P407; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARCHESI VT, 1985, ANNU REV CELL BIOL, V1, P531, DOI 10.1146/annurev.cellbio.1.1.531; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAMBROOK J, 1989, MOL CLONING LABORATO, P197; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAITKAMRADT AG, 1986, MOL CELL BIOL, V6, P1855, DOI 10.1128/MCB.6.6.1855; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P336; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	52	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14056	14063						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188686				2022-12-27	WOS:A1994NL60600052
J	HENGSTSCHLAGER, M; KNOFLER, M; MULLNER, EW; OGRIS, E; WINTERSBERGER, E; WAWRA, E				HENGSTSCHLAGER, M; KNOFLER, M; MULLNER, EW; OGRIS, E; WINTERSBERGER, E; WAWRA, E			DIFFERENT REGULATION OF THYMIDINE KINASE DURING THE CELL-CYCLE OF NORMAL VERSUS DNA TUMOR VIRUS-TRANSFORMED COILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-STIMULATED CELLS; MESSENGER-RNA; GENE; EXPRESSION; INDUCTION; ENZYME; FIBROBLASTS; PROTEIN; LEVEL	We compared the cell cycle regulation of thymidine kinase (TK) after centrifugal elutriation in normal human and mouse cells (primary cells, diploid fibroblasts) with its expression in cells transformed with different DNA tumor viruses. Normal cells showed a rise of TK enzyme activity near the G(1)/S boundary, which peaked in S phase, and in G(2) returned approximately to the level of G(1). Conversely, in cells derived from viral transformation, TK activity remained high throughout S and G(2) phases, although it was induced to a comparable extent at the onset of DNA replication. In addition, transformed cells exhibited much more enzyme activity during all phases of the cell cycle. The observed differences in expression were due neither to different rates of protein turnover nor to differences in enzyme stability. Enzyme activity was always totally paralleled by the protein level. In all normal cells, the pattern of TK mRNA variation during the cell cycle was similar to that of enzyme activity. In all transformed lines, however, mRNA levels were higher and did not fluctuate throughout the cell cycle. Recently we showed (Ogris et al., 1993) that the E2F binding site present in the TK promoter is a target for transactivation of the TK gene by polyoma virus large T antigen. Using cells expressing this antigen under the control of a hormone-inducible promoter, we were able to switch TK cell cycle expression from the normal to the transformed status. Obviously, DNA tumor viruses suppress transcriptional down-regulation of the endogenous DNA precursor pathway enzyme TK during the eukaryotic cell cycle, maybe to improve conditions for their own replication.	UNIV VIENNA, VIENNA BIOCTR, INST MOLEC BIOL, A-1030 VIENNA, AUSTRIA	University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)				Ogris, Egon/0000-0001-5950-9264				ADLER R, 1974, CELL, V2, P113, DOI 10.1016/0092-8674(74)90100-7; BELLO LJ, 1974, EXP CELL RES, V89, P263, DOI 10.1016/0014-4827(74)90790-3; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; CHIBA P, 1989, BRIT J HAEMATOL, V72, P145; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; Favaloro J, 1980, Methods Enzymol, V65, P718; GROSS MK, 1988, NUCLEIC ACIDS RES, V16, P11625, DOI 10.1093/nar/16.24.11625; GROSS MK, 1989, P NATL ACAD SCI USA, V86, P4987, DOI 10.1073/pnas.86.13.4987; GROUDINE M, 1984, NUCLEIC ACIDS RES, V12, P1427, DOI 10.1093/nar/12.3.1427; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HENGSTSCHLAGER M, 1993, FEBS LETT, V321, P237, DOI 10.1016/0014-5793(93)80116-C; HENGSTSCHLAGER M, 1993, CYTOMETRY, V14, P39, DOI 10.1002/cyto.990140108; HORWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775; ITO M, 1990, J BIOL CHEM, V265, P6954; JOHNSON LF, 1982, EXP CELL RES, V138, P79, DOI 10.1016/0014-4827(82)90093-3; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; KNOFLER M, 1993, J BIOL CHEM, V268, P11409; LIEBERMAN HB, 1988, MOL CELL BIOL, V8, P5280, DOI 10.1128/MCB.8.12.5280; LITTLEFIELD JW, 1966, BIOCHIM BIOPHYS ACTA, V114, P398, DOI 10.1016/0005-2787(66)90319-4; MCKENNA PG, 1982, GENET RES, V40, P207, DOI 10.1017/S0016672300019078; MUDRAK I, 1994, MOL CELL BIOL, V14, P1886, DOI 10.1128/MCB.14.3.1886; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; OGRIS E, 1992, J VIROL, V66, P53, DOI 10.1128/JVI.66.1.53-61.1992; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PIPER AA, 1980, BIOCHIM BIOPHYS ACTA, V633, P400, DOI 10.1016/0304-4165(80)90198-1; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SHOWS TB, 1979, CYTOGENET CELL GENET, V25, P96, DOI 10.1159/000131404; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; STUART P, 1985, MOL CELL BIOL, V5, P1490, DOI 10.1128/MCB.5.6.1490; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; WAWRA E, 1981, J VIROL, V38, P973, DOI 10.1128/JVI.38.3.973-981.1981; [No title captured]	34	119	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13836	13842						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188661				2022-12-27	WOS:A1994NL60600021
J	LILLY, PJ; DEVREOTES, PN				LILLY, PJ; DEVREOTES, PN			IDENTIFICATION OF CRAC, A CYTOSOLIC REGULATOR REQUIRED FOR GUANINE-NUCLEOTIDE STIMULATION OF ADENYLYL-CYCLASE IN DICTYOSTELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP RECEPTOR; SACCHAROMYCES-CEREVISIAE; ALPHA-SUBUNITS; PROTEIN; DISCOIDEUM; GENE; SEQUENCE; TRANSDUCTION; PURIFICATION; EXPRESSION	As previously reported, guanine nucleotide regulation of adenylyl cyclase activity in the Dictyostelium mutant synag 7 can be restored in vitro by addition of a high speed supernatant prepared from wild-type cells (Theibert, A., and Devreotes, P. N. (1986) J. Biol. Chem. 261, 15121-15125). We have designated this activity CRAC, for cytosolic regulator of adenylyl cyclase. Trypsinization of partially purified material demonstrated that this activity contains a protein. We report here a 50,000-fold purification of this protein using Q and S Sepharose fast flow and P11 cellulose chromatography, followed by sucrose gradient centrifugation and separation on SDS-polyacrylamide gel electrophoresis. Purification of wild-type and mutant supernatants in parallel allowed identification of an 88-kDa protein required for reconstituting activity. A polyclonal antibody was raised against this protein; it stains a band in unfractionated wild-type, but not mutant, supernatants. Immunoblots of fractions from each purification step show that activity and the immunostaining band cochromatograph. We have determined a short N-terminal sequence of the 88-kDa CRAC polypeptide, which matches a portion of the deduced N terminus of a gene, dagA, isolated from a mutant similar to synag 7. Expression of the dagA cDNA in synag 7 cells restores both the 88 kDa band and CRAC activity.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028007, R37GM028007] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28007] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HARLOW E, 1988, ANTIBODIES LABORATOR; HUNKAPILLER MW, 1986, METHODS PROTEIN MICR; JOHNSON RL, 1993, GENE DEV, V7, P273, DOI 10.1101/gad.7.2.273; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; KLEIN P, 1987, J BIOL CHEM, V262, P352; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OKAICHI K, 1992, MOL BIOL CELL, V3, P725; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PUPILLO M, 1989, P NATL ACAD SCI USA, V86, P4892, DOI 10.1073/pnas.86.13.4892; PUPILLO M, 1988, COLD SPRING HARB SYM, V53, P657, DOI 10.1101/SQB.1988.053.01.075; PUPILLO M, 1992, MOL BIOL CELL, V3, P1229, DOI 10.1091/mbc.3.11.1229; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SAXE CL, 1991, GENE DEV, V5, P1, DOI 10.1101/gad.5.1.1; SNAARJAGALSKA BE, 1988, J CELL SCI, V91, P287; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANHAASTERT PJM, 1991, EUR J BIOCHEM, V195, P289; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WIGLER M, 1988, COLD SPRING HARB SYM, V53, P649, DOI 10.1101/SQB.1988.053.01.074; WU LJ, 1991, BIOCHEM BIOPH RES CO, V179, P1141, DOI 10.1016/0006-291X(91)91690-E	38	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14123	14129						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188693				2022-12-27	WOS:A1994NL60600061
J	BOJANOWSKI, K; FILHOL, O; COCHET, C; CHAMBAZ, EM; LARSEN, AK				BOJANOWSKI, K; FILHOL, O; COCHET, C; CHAMBAZ, EM; LARSEN, AK			DNA TOPOISOMERASE-II AND CASEIN KINASE-II ASSOCIATE IN A MOLECULAR-COMPLEX THAT IS CATALYTICALLY ACTIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSOR PROTEIN; EPIDERMAL GROWTH-FACTOR; SACCHAROMYCES-CEREVISIAE; MITOTIC CHROMOSOMES; ATTACHMENT SITE; CLEAVAGE SITES; PHORBOL ESTER; FISSION YEAST; CELL-GROWTH; PHOSPHORYLATION	Immunoprecipitation of DNA topoisomerase II from yeast results in a preparation that contains casein kinase II; this suggests that the two proteins may associate in the intact cell. Purified recombinant topoisomerase II and casein kinase II associate to form a complex in vitro which is stable after topoisomerase II becomes phosphorylated by the kinase. Studies with isolated recombinant casein kinase II subunits disclosed that although the alpha (catalytic) subunit alone can efficiently phosphorylate topoisomerase II, the formation of a stable topoisomerase II-casein kinase II association requires the presence of the beta subunit of the kinase. Both proteins engaged in this complex retain their catalytic activities. Naturally occurring polyamines and polyanionic compounds appear to be crucial factors governing the interaction between the two proteins. Although the biological significance of a stable catalytically active topoisomerase II-casein kinase II molecular complex remains to be defined, these observations suggest the possibility of a novel mechanism regulating topoisomerase II and casein kinase II activities.	INST GUSTAVE ROUSSY,CNRS,UNITE RECH ASSOCIEE 147,INSERM,UNITE 140,F-94805 VILLEJUIF,FRANCE; CEN,INSERM,UNITE 244,F-38041 GRENOBLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm)			Filhol-Cochet, Odile/I-3962-2016	Cochet, Claude/0000-0002-1772-4270; Filhol, Odile/0000-0003-1964-7958				ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BOJANOWSKI K, 1992, P NATL ACAD SCI USA, V89, P3025, DOI 10.1073/pnas.89.7.3025; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; BRILL SJ, 1987, NATURE, V326, P812, DOI 10.1038/326812a0; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; CAPRANICO G, 1990, BIOCHEMISTRY-US, V29, P562, DOI 10.1021/bi00454a033; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARDENAS ME, 1993, J CELL SCI, V104, P533; CARROLL D, 1989, J BIOL CHEM, V264, P7345; COCHET C, 1983, MOL CELL ENDOCRINOL, V30, P247, DOI 10.1016/0303-7207(83)90062-X; COCHET C, 1983, J BIOL CHEM, V258, P1403; CONSTANTINOU A, 1989, CANCER RES, V49, P1110; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; DEVORE RF, 1992, CANCER RES, V52, P2156; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DOWNES CS, 1991, P NATL ACAD SCI USA, V88, P8895, DOI 10.1073/pnas.88.20.8895; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P945, DOI 10.1016/S0006-291X(05)81157-X; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HSIEH TS, 1980, CELL, V21, P115, DOI 10.1016/0092-8674(80)90119-1; HU ED, 1990, J BIOL CHEM, V265, P5072; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; MARKOVITS J, 1989, CANCER RES, V49, P5111; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; POMMIER Y, 1990, J VIROL, V64, P419, DOI 10.1128/JVI.64.1.419-423.1990; POMMIER Y, 1989, BIOCHEMISTRY-US, V28, P995, DOI 10.1021/bi00429a012; POMMIER Y, 1991, J MOL BIOL, V222, P909, DOI 10.1016/0022-2836(91)90585-T; RAZIN SV, 1991, P NATL ACAD SCI USA, V88, P8515, DOI 10.1073/pnas.88.19.8515; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; ROSS W, 1984, CANCER RES, V44, P5857; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; SANDER M, 1984, P NATL ACAD SCI-BIOL, V81, P6938, DOI 10.1073/pnas.81.22.6938; SCHNEIDER HR, 1986, EUR J BIOCHEM, V161, P733, DOI 10.1111/j.1432-1033.1986.tb10501.x; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P124; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WOOD ER, 1990, J CELL BIOL, V111, P2389; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	73	91	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22920	22926						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226802				2022-12-27	WOS:A1993MD34800106
J	RAMALINGAM, R; SHAW, DR; ENNIS, HL				RAMALINGAM, R; SHAW, DR; ENNIS, HL			CLONING AND FUNCTIONAL EXPRESSION OF A DICTYOSTELIUM-DISCOIDEUM PROTEIN-TYROSINE-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLACENTA; RECEPTOR; PHOSPHORYLATION; SEQUENCE; FAMILY; CELLS; KINASES; ANTIGEN; SYSTEM; GENES	Using polymerase chain reaction methods, we cloned a 1.7-kilobase cDNA, denoted DdPTPa, that has high homology with other known eukaryotic protein tyrosine phosphatases. DdPTPa possess a 241-amino acid protein tyrosine phosphatase domain located in the C terminus, which exhibits a 39-43% amino acid sequence identity with published protein tyrosine phosphatases. Absence of a characteristic signal sequence and transmembrane domain suggests that DdPTPa is a nonreceptor type cytoplasmic protein tyrosine phosphatase. Southern blot analysis of genomic DNA indicates the presence of a multigene protein tyrosine phosphatase family in Dictyostelium. Northern blot analysis reveals four species of mRNA that hybridize to the DdPTPa probe, at least three of which are developmentally regulated. The entire coding sequence of DdPTPa was subcloned into the pET15-b vector and expressed in Escherichia coli. Affinity-purified DdPTPa protein efficiently dephosphorylates both p-nitrophenyl phosphate and tyrosine-phosphorylated reduced, carboxyamidomethylated, and maleylated lysozyme. A Dictyostelium transformant overexpressing DdPTPa does not develop normally. The overexpresser fails to aggregate, in contrast to the control transformant containing vector alone, and after 24 h gives rise to only a few abnormal slugs and small fruiting bodies.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110	Roche Holding								CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DASILVA AM, 1990, DEV BIOL, V140, P139, DOI 10.1016/0012-1606(90)90061-M; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GERISCH G, 1987, ANNU REV BIOCHEM, V56, P853, DOI 10.1146/annurev.biochem.56.1.853; GIORDA R, 1987, MOL CELL BIOL, V6, P2097; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HOWARD PK, 1993, SCIENCE, V259, P241, DOI 10.1126/science.7678470; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; SCHWEIGER A, 1992, J CELL SCI, V102, P601; SCHWEIGER A, 1990, FEBS LETT, V268, P199, DOI 10.1016/0014-5793(90)81007-B; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; TAN JL, 1990, MOL CELL BIOL, V10, P3578, DOI 10.1128/MCB.10.7.3578; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; ULRICH A, 1990, CELL, V61, P203; YAMAUCHI K, 1991, NUCLEIC ACIDS RES, V19, P2715, DOI 10.1093/nar/19.10.2715	33	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22680	22685						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226777				2022-12-27	WOS:A1993MD34800073
J	SHEPHERD, PR; GNUDI, L; TOZZO, E; YANG, HM; LEACH, F; KAHN, BB				SHEPHERD, PR; GNUDI, L; TOZZO, E; YANG, HM; LEACH, F; KAHN, BB			ADIPOSE CELL HYPERPLASIA AND ENHANCED GLUCOSE DISPOSAL IN TRANSGENIC MICE OVEREXPRESSING GLUT4 SELECTIVELY IN ADIPOSE-TISSUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DEPENDENT DIABETES-MELLITUS; INSULIN RESISTANCE; SKELETAL-MUSCLE; MESSENGER-RNA; TRANSPORTER; ADIPOCYTES; OBESITY; RAT; EXPRESSION; CLONING	To gain insight into the molecular pathogenesis of obesity and specifically the role of nutrient partitioning in the development of obesity, we overexpressed the insulin-responsive glucose transporter (GLUT4) in transgenic mice under the control of the fat-specific aP2 fatty acid-binding protein promoter/enhancer. Two lines of transgenic mice were generated, which overexpressed GLUT4 6-9-fold in white fat and 3-5-fold in brown fat with no overexpression in other tissues. In vivo glucose tolerance was enhanced in transgenic mice. In isolated epididymal, parametrial, and subcutaneous adipose cells from transgenic mice, basal glucose transport was 20-34-fold greater than in nontransgenic littermates. Insulin-stimulated glucose transport was 2-4-fold greater in cells from transgenic mice. Total body lipid was increased 2-3-fold in transgenic mice overexpressing GLUT4 in fat. Surprisingly, fat cell size was unaltered and fat cell number was increased >2-fold. This is the first animal model in which increased fat mass results solely from adipocyte hyperplasia and it will be a valuable model for understanding the mechanisms responsible for fat cell replication and/or differentiation in vivo.	BETH ISRAEL HOSP, DEPT MED, DIABET UNIT, 330 BROOKLINE AVE, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, THORNDIKE LAB, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, CHARLES A DANA RES INST, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center				gnudi, luigi/0000-0002-6353-630X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043051] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK43051, R01 DK043051] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; BUSE JB, 1992, DIABETES, V41, P1436, DOI 10.2337/diabetes.41.11.1436; COUSIN B, 1992, EUR J BIOCHEM, V207, P377, DOI 10.1111/j.1432-1033.1992.tb17060.x; CUSHMAN SW, 1978, J LIPID RES, V19, P269; CUSHMAN SW, 1970, J CELL BIOL, V46, P326, DOI 10.1083/jcb.46.2.326; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DOLE VP, 1956, J CLIN INVEST, V19, P269; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GLIEMANN J, 1984, BIOCHIM BIOPHYS ACTA, V804, P68, DOI 10.1016/0167-4889(84)90100-9; HIRSCH J, 1976, CLIN ENDOCRINOL META, V5, P299, DOI 10.1016/S0300-595X(76)80023-0; HIRSCH J, 1968, J LIPID RES, V9, P110; JAMES DE, 1985, DIABETES, V34, P1049, DOI 10.2337/diabetes.34.10.1049; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; KASHIWAGI A, 1983, J CLIN INVEST, V72, P1246, DOI 10.1172/JCI111080; KORANYI L, 1990, J CLIN INVEST, V85, P962, DOI 10.1172/JCI114526; MARIN P, 1987, METABOLISM, V36, P1154, DOI 10.1016/0026-0495(87)90242-3; PEDERSEN O, 1992, J CLIN INVEST, V89, P1964, DOI 10.1172/JCI115804; PEDERSEN O, 1990, DIABETES, V39, P865, DOI 10.2337/diabetes.39.7.865; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SALMON DMW, 1985, INT J OBESITY, V9, P443; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; York D. A., 1979, Animal models of obesity., P39	25	430	444	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22243	22246						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226728				2022-12-27	WOS:A1993MD34800008
J	SRINIVAS, SK; SRINIVAS, RV; ANANTHARAMAIAH, GM; COMPANS, RW; SEGREST, JP				SRINIVAS, SK; SRINIVAS, RV; ANANTHARAMAIAH, GM; COMPANS, RW; SEGREST, JP			CYTOSOLIC DOMAIN OF THE HUMAN-IMMUNODEFICIENCY-VIRUS ENVELOPE GLYCOPROTEINS BINDS TO CALMODULIN AND INHIBITS CALMODULIN-REGULATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; LYMPHOCYTES-T; TAT PROTEIN; HTLV-III; TYPE-1; CYTOPATHOGENICITY; ASSOCIATION; REPLICATION; ACTIVATION; SEGMENTS	Calmodulin (CaM), the major intracellular receptor for calcium, is involved in regulation of diverse cellular functions. Positively charged amphipathic helical segments have been identified as an important structural motif in the recognition of CaM by different CaM-activated enzymes and peptides. The carboxyl-terminal domain of the envelope glycoproteins of human and simian immunodeficiency viruses (HIV-1, HIV-2, and SIV) contain regions that can fold into amphipathic helical segments, which closely resemble the amphipathic segments found in CaM-activated enzymes. We show here that synthetic peptide analogs corresponding to the two putative amphipathic helical regions of HIV-1/WMJ gp160 bind to CaM with high affinity (K(d) 31-41 nM) in the presence of calcium. They also bind CaM in the absence of calcium, although with much lower affinity. The peptides inhibit CaM-regulated activation of bovine brain phosphodiesterase in vitro. The peptides also inhibit mitogen-induced lymphocyte activation, a property shared by CaM antagonists. Purified HIV-1 gp160 binds to CaM, while gp120, which lacks the putative amphipathic helical segments, does not bind CaM. In HIV-infected cells, the putative CaM-binding regions of gp160 are located intracellularly and may therefore interact with the cytosolic CaM. We postulate that CaM binding by HIV envelope proteins is likely to exert diverse modulatory effects, and the mechanism for HIV-induced cytotoxicity may involve, in part, inhibition of CaM-regulated cellular functions.	UNIV ALABAMA, DEPT MED, 630 BDB UAB MED CTR, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT BIOCHEM, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, ATHEROSCLEROSIS RES UNIT, BIRMINGHAM, AL 35294 USA; EMORY UNIV, DEPT MICROBIOL & IMMUNOL, ATLANTA, GA 30322 USA; ST JUDE CHILDRENS RES HOSP, DEPT INFECT DIS, MEMPHIS, TN 38105 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Emory University; St Jude Children's Research Hospital			Compans, Richard W/I-4087-2013	Compans, Richard W/0000-0003-2360-335X	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025784, R01AI028928] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIAID NIH HHS [AI 28928, AI 25784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANANTHARAMAIAH GM, 1986, METHOD ENZYMOL, V128, P627; ANDERSON SR, 1986, CALCIUM CELL FUNCTIO, V6, P2; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; COLOMBANI PM, 1985, SCIENCE, V228, P337, DOI 10.1126/science.3885394; COX JA, 1985, J BIOL CHEM, V260, P2527; EISENBERG D, 1990, BIOPOLYMERS, V29, P171, DOI 10.1002/bip.360290122; FISHER AG, 1986, SCIENCE, V233, P655, DOI 10.1126/science.3014663; FRANKEL AD, 1989, P NATL ACAD SCI USA, V86, P7397, DOI 10.1073/pnas.86.19.7397; GARRY RF, 1989, AIDS, V3, P683, DOI 10.1097/00002030-198911000-00001; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; HOFMANN B, 1990, J IMMUNOL, V145, P3699; JOHNSON JD, 1987, ANAL BIOCHEM, V162, P291, DOI 10.1016/0003-2697(87)90039-X; KINCAID RL, 1982, J BIOL CHEM, V257, P638; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KODAMA T, 1989, J VIROL, V63, P4709, DOI 10.1128/JVI.63.11.4709-4714.1989; KONG LI, 1988, SCIENCE, V240, P1525, DOI 10.1126/science.3375832; KOWALSKI M, 1991, J VIROL, V65, P281, DOI 10.1128/JVI.65.1.281-291.1991; LEE SJ, 1989, AIDS RES HUM RETROV, V5, P441, DOI 10.1089/aid.1989.5.441; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MCKEATING JA, 1989, AIDS, V3, pS35, DOI 10.1097/00002030-198901001-00005; MEREISH K A, 1990, Peptide Research, V3, P233; NELSON TY, 1987, MOL CELL BIOCHEM, V74, P83; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RIENZO AMD, 1992, J ACQ IMMUN DEF SYND, V5, P921; SAKAI K, 1988, J VIROL, V62, P4078, DOI 10.1128/JVI.62.11.4078-4085.1988; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SLAUGHTER GR, 1987, METHOD ENZYMOL, V139, P433; SRINIVAS SK, 1992, J BIOL CHEM, V267, P7121; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; VENABLE RM, 1989, AIDS RES HUM RETROV, V5, P7, DOI 10.1089/aid.1989.5.7; WEISLOW OS, 1989, JNCI-J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZAMECNIK PC, 1986, P NATL ACAD SCI USA, V83, P4143, DOI 10.1073/pnas.83.12.4143	34	88	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22895	22899						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226798				2022-12-27	WOS:A1993MD34800102
J	CESBRONDELAUW, MF; TOMAVO, S; BEAUCHAMPS, P; FOURMAUX, MP; CAMUS, D; CAPRON, A; DUBREMETZ, JF				CESBRONDELAUW, MF; TOMAVO, S; BEAUCHAMPS, P; FOURMAUX, MP; CAMUS, D; CAPRON, A; DUBREMETZ, JF			SIMILARITIES BETWEEN THE PRIMARY STRUCTURES OF 2 DISTINCT MAJOR SURFACE-PROTEINS OF TOXOPLASMA-GONDII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; MONOCLONAL-ANTIBODY; P-30 ANTIGEN; INFECTION; MICE; IDENTIFICATION; PURIFICATION; PROTECTION; IMMUNITY; CLEAVAGE	Toxoplasma gondii possesses a 43-kDa surface protein (SAG3) that is expressed by all invasive stages. We have cloned and sequenced cDNAs encoding SAG3, with the longest one encoding a primary product of 385 amino acid residues. The deduced amino acid sequence contains a putative NH2-terminal signal sequence, as well as a glycosylphosphatidylinositol anchor attachment site. It is characterized by 12 cysteine residues whose distribution suggests a tandem duplication of a single ancestral motif containing 6 cysteine residues. Although no DNA sequence analogies were found, comparative amino acid sequence analysis detected a resemblance to SAG1, which is the major surface antigen specifically expressed by the proliferative tachyzoite stage. Despite a low degree of identity between the two amino acid sequences (24%), the conservative distribution of the cysteine and tryptophan residues, as well as of repeated motifs, together with oligopeptide identities suggest similar folding and;possibly similar function for both proteins.	INSERM, U42, F-59650 VILLENEUVE DASCQ, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	CESBRONDELAUW, MF (corresponding author), INST PASTEUR, CTR IMMUNOL & BIOL PARASITAIRE,CNRS 624,INSERM, U167,UNITE MIXTE, 1 RUE PROF CALMETTE, F-59019 LILLE, FRANCE.		cesbron delauw, marie france/M-6076-2014					BULOW R, 1991, J IMMUNOL, V147, P3496; BURG JL, 1988, J IMMUNOL, V141, P3584; CESBRONDELAUW MF, 1989, P NATL ACAD SCI USA, V86, P7537, DOI 10.1073/pnas.86.19.7537; COUVREUR G, 1988, PARASITOLOGY, V97, P1, DOI 10.1017/S0031182000066695; DARCY F, 1992, J IMMUNOL, V149, P3636; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GRIMWOOD BG, 1979, EXP PARASITOL, V48, P282, DOI 10.1016/0014-4894(79)90110-3; GRIMWOOD J, 1992, EXP PARASITOL, V74, P106, DOI 10.1016/0014-4894(92)90144-Y; HANDMAN E, 1980, J IMMUNOL, V124, P2578; KASPER LH, 1984, J IMMUNOL, V132, P443; KASPER LH, 1983, J IMMUNOL, V130, P2407; KASPER LH, 1985, J IMMUNOL, V134, P3426; KASPER LH, 1982, J IMMUNOL, V129, P1694; KASPER LH, 1989, INFECT IMMUN, V57, P668, DOI 10.1128/IAI.57.3.668-672.1989; KASPER LH, 1993, RES IMMUNOL, V144, P45, DOI 10.1016/S0923-2494(05)80097-5; KHAN IA, 1991, J IMMUNOL, V147, P3501; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI DOI 10.1083/JCB.108.2.229; Krahenbuhl J. L., 1982, Immunology of parasitic infections.  2nd edition., P356; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANIATIS T, 1990, MOL CLONING; MARCHALONIS JJ, 1971, J BIOCHEM-TOKYO, V127, P921; MERCIER C, 1993, MOL BIOCHEM PARASIT, V58, P71, DOI 10.1016/0166-6851(93)90092-C; MINEO JR, 1993, J IMMUNOL, V150, P3951; NAGEL SD, 1989, J BIOL CHEM, V264, P5569; PRINCE JB, 1990, MOL BIOCHEM PARASIT, V43, P97, DOI 10.1016/0166-6851(90)90134-8; RODRIGUEZ C, 1985, EUR J IMMUNOL, V15, P747, DOI 10.1002/eji.1830150721; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIBLEY LD, 1991, PARASITOL TODAY, V7, P327, DOI 10.1016/0169-4758(91)90210-F; TOMAVO S, 1989, MOL CELL BIOL, V9, P4576, DOI 10.1128/MCB.9.10.4576; TOMAVO S, 1992, PARASITOL RES, V78, P541, DOI 10.1007/BF00936449; TOMAVO S, 1991, INFECT IMMUN, V59, P3750, DOI 10.1128/IAI.59.10.3750-3753.1991; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	33	62	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16217	16222						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206924				2022-12-27	WOS:A1994NQ72900042
J	DIMRI, GP; HARA, E; CAMPISI, J				DIMRI, GP; HARA, E; CAMPISI, J			REGULATION OF 2 E2F-RELATED GENES IN PRESENESCENT AND SENESCENT HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F; DIHYDROFOLATE-REDUCTASE PROMOTER; CYCLE-DEPENDENT GENES; CELL-CYCLE; BINDING PROTEIN; RETINOBLASTOMA PROTEIN; DIPLOID FIBROBLASTS; MURINE FIBROBLASTS; COMPLEX-FORMATION; GROWTH-FACTOR	Several mammalian genes expressed in late G, are positively regulated by E2F, a heterodimeric transcription factor, Genes encoding two E2F proteins, E2F-1 and DP-1, were regulated differently during the cell cycle and replicative senescence of normal human fibroblasts. In presenescent cells, E2F-1 mRNA was cell-cycle regulated, appearing a few hours before S phase. Ey contrast, DP-1 mRNA was constitutively expressed, independent of position in the cell cycle. After a finite number of divisions, normal cells enter a state of irreversible growth arrest termed senescence. Many genes remain mitogen-inducible in senescent cells; there are, however, exceptions, including several late G(1) genes potentially regulated by E2F. Senescent cells expressed DP-1 at the presenescent level, but did not express E2F-1 mRNA. Senescent cells were also markedly deficient in E2F binding activity associated with the dihydrofolate reductase promoter. E2F-1 and DP-1 expression vectors only weakly induced DNA synthesis in quiescent or senescent human cells and immortal murine NIH3T3 cells, although the E2F-1 vector stimulated DNA synthesis in immortal murine A31 cells, and transactivated E2F-responsive promoters in NIH3T3 cells. The results suggest that senescent cells may fail to express late G, genes due to repression of E2F-1, leading to a deficiency of E2F activity. Furthermore, although E2F-1 stimulates DNA synthesis in some cells, other cells, including normal human fibroblasts, require additional factors.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DEPT CELL & MOLEC BIOL,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley					NATIONAL INSTITUTE ON AGING [R37AG009909, R56AG009909, R01AG009909] Funding Source: NIH RePORTER; NIA NIH HHS [AG09909] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHANG ZF, 1988, J BIOL CHEM, V263, P11431; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HARA E, 1994, J BIOL CHEM, V269, P2139; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOFBAUER R, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P247; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; LIM K, 1989, BIOTECHNIQUES, V7, P576; LU KH, 1992, P NATL ACAD SCI USA, V89, P3889, DOI 10.1073/pnas.89.9.3889; LU KH, 1989, MOL CELL BIOL, V9, P3411, DOI 10.1128/MCB.9.8.3411; Naeve GS, 1991, CURR OPIN CELL BIOL, V3, P261, DOI 10.1016/0955-0674(91)90150-W; NEVINS JR, 1992, SCIENCE, V258, P424; PANG JH, 1993, J BIOL CHEM, V268, P2909; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; Sambrook J, 1989, MOL CLONING LABORATO; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SESHADRI T, 1993, J BIOL CHEM, V268, P18474; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014	44	103	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16180	16186						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206919				2022-12-27	WOS:A1994NQ72900037
J	LIEBERMAN, KR; DAHLBERG, AE				LIEBERMAN, KR; DAHLBERG, AE			THE IMPORTANCE OF CONSERVED NUCLEOTIDES OF 23-S RIBOSOMAL-RNA AND TRANSFER-RNA IN RIBOSOME CATALYZED PEPTIDE-BOND FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; RESISTANCE MUTATIONS; DOMAIN-V; A-SITES; P-SITES; CHLORAMPHENICOL; MUTAGENESIS; RECOGNITION; EFFICIENT; GENES	We have constructed the double mutant G2252C/ G2253C in Escherichia coli 23 S rRNA by site directed mutagenesis. These phylogenetically conserved residues are protected from chemical modification by the 3' CCA terminus of the peptidyl-tRNA site (P site)-bound tRNA. Expression of C2252/C2253 23 S rRNA in E. coli severely compromises cell growth. Mutant rRNA is assembled into 50 S subunits and 70 S ribosomes but is discriminated against in polysomes. Mutant ribosomes function at lower rates in peptidyltransferase assays than wild type ribosomes. To test whether this defect derives from disruption of base pairing with the 2 cytidines of the invariant 3' CCA terminus of tRNA, a mutant E. coli tRNA(Phe) gene was constructed, with the CCA sequence changed to GGA. As deacylated species, mutant and wild type tRNA(Phe) inhibit peptidyl transfer identically. Mutant tRNA(Phe) was aminoacylated in vitro but failed to react as a P site substrate, with either mutant or wild type ribosomes. These results support a role for G2252 and G2253 of 23 S rRNA in peptidyltransferase function and a role for the 3' residues of peptidyl-tRNA in catalytically productive P site interaction; but they fail to provide evidence supporting canonical base pairing between these 23 S residues and the 3' end of peptidyl-tRNA.	BROWN UNIV, DIV BIOL & MED, PROVIDENCE, RI 02912 USA	Brown University					NIGMS NIH HHS [GM19756] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bjork GR, 1992, TRANSFER RNA PROTEIN, P23; CHLADEK S, 1974, BIOCHEMISTRY-US, V13, P2727, DOI 10.1021/bi00710a011; DAHLBERG AE, 1989, CELL, V57, P525, DOI 10.1016/0092-8674(89)90122-0; GOURSE RL, 1985, P NATL ACAD SCI USA, V82, P1069, DOI 10.1073/pnas.82.4.1069; GREGORY ST, 1994, NUCLEIC ACIDS RES, V22, P279, DOI 10.1093/nar/22.3.279; GUTELL RR, 1990, NUCLEIC ACIDS RES, V18, P2319, DOI 10.1093/nar/18.suppl.2319; HAENNI AL, 1966, BIOCHIM BIOPHYS ACTA, V114, P135, DOI 10.1016/0005-2787(66)90261-9; HALL CC, 1988, BIOCHEMISTRY-US, V27, P3983, DOI 10.1021/bi00411a014; HARRINGTON KM, 1993, BIOCHEMISTRY-US, V32, P7617, DOI 10.1021/bi00081a003; HUMMEL H, 1987, NUCLEIC ACIDS RES, V15, P2431, DOI 10.1093/nar/15.6.2431; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEDER P, 1966, BIOCHEM BIOPH RES CO, V25, P233, DOI 10.1016/0006-291X(66)90586-9; LILL R, 1986, BIOCHEMISTRY-US, V25, P3245, DOI 10.1021/bi00359a025; LILL R, 1988, J MOL BIOL, V203, P699, DOI 10.1016/0022-2836(88)90203-3; MANKIN AS, 1991, J BACTERIOL, V173, P3559, DOI 10.1128/jb.173.11.3559-3563.1991; MOAZED D, 1991, P NATL ACAD SCI USA, V88, P3725, DOI 10.1073/pnas.88.9.3725; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MONRO RE, 1967, J MOL BIOL, V26, P147, DOI 10.1016/0022-2836(67)90271-9; MONRO RE, 1968, P NATL ACAD SCI USA, V61, P1042, DOI 10.1073/pnas.61.3.1042; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; OCONNOR M, 1993, EMBO J, V12, P2559, DOI 10.1002/j.1460-2075.1993.tb05911.x; PETERSON ET, 1992, BIOCHEMISTRY-US, V31, P10380, DOI 10.1021/bi00157a028; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHILLINGBARTETZKO S, 1992, J BIOL CHEM, V267, P4693; SIGMUND CD, 1988, METHOD ENZYMOL, V164, P673; STEINER G, 1988, EMBO J, V7, P3949, DOI 10.1002/j.1460-2075.1988.tb03281.x; SUNDARI RM, 1977, J BIOL CHEM, V252, P3941; VESTER B, 1988, EMBO J, V7, P3577, DOI 10.1002/j.1460-2075.1988.tb03235.x; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	31	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16163	16169						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206917				2022-12-27	WOS:A1994NQ72900035
J	NOUWEN, N; TOMMASSEN, J; DEKRUIJFF, B				NOUWEN, N; TOMMASSEN, J; DEKRUIJFF, B			REQUIREMENT FOR CONFORMATIONAL FLEXIBILITY IN THE SIGNAL SEQUENCE OF PRECURSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; ESCHERICHIA-COLI K-12; PHOE PROTEIN; TRANSLOCATION; SECA; ATP; PHOSPHOLIPIDS; EXPRESSION; PEPTIDE; PHOSPHATIDYLGLYCEROL	According to the ''unlooping'' model (de Vrije, T., Batenburg, A. M., Killian, J. A., and de Kruijff, B. (1990) Mel. Microbiol. 4, 143-150), proposed to explain how signal sequences serve to target proteins into the secretory pathway, the initial interaction of the signal sequence with the membrane in a helix-turn-helix conformation (spanning half of the bilayer) plays an important role in the initiation of the translocation reaction. To test this model we have introduced 2 cysteines (at positions -5 and -19) in the signal sequence of the Escherichia coli outer membrane protein PhoE. The mutations did not influence the translocation of precursor PhoE in vivo or in vitro. The 2 cysteines were oxidized to form a disulfide bridge. In vitro translocation of the looped precursor into inner membrane vesicles was disturbed. The looped precursor competed with translocation of wild type precursor PhoE, and looped precursor that was first bound to inner membrane vesicles could be translocated after the addition of dithiothreitol. Apparently, the mutant precursor with a disulfide bridge in the signal sequence is arrested as a very early intermediate in the translocation process. All of these results are consistent with the proposed unlooping model and show that, besides the primary structure characteristics of a signal sequence, conformational flexibility is needed to initiate the translocation reaction.	UNIV UTRECHT, DEPT MOLEC CELL BIOL, 3584 CH UTRECHT, NETHERLANDS; UNIV UTRECHT, DEPT MEMBRANE BIOCHEM, 3584 CH UTRECHT, NETHERLANDS	Utrecht University; Utrecht University	NOUWEN, N (corresponding author), UNIV UTRECHT, BIOMEMBRANE INST, PADUALAAN 8, 3584 CH UTRECHT, NETHERLANDS.		Tommassen, Jan/I-1690-2016	Tommassen, Jan/0000-0001-7633-4945				AGTERBERG M, 1988, FEMS MICROBIOL LETT, V50, P295; AKITA M, 1990, J BIOL CHEM, V265, P8164; BATENBURG AM, 1988, J BIOL CHEM, V263, P4202; BATENBURG AM, 1988, BIOCHEMISTRY-US, V27, P5678, DOI 10.1021/bi00415a043; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOSCH D, 1986, J MOL BIOL, V189, P449, DOI 10.1016/0022-2836(86)90316-5; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; DECOCK H, 1992, J MOL BIOL, V224, P369, DOI 10.1016/0022-2836(92)91001-6; DEVRIJE GJ, 1990, MOL MICROBIOL, V4, P143; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GELLER BL, 1985, J BIOL CHEM, V260, P3281; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; KUSTERS R, 1989, J BIOL CHEM, V264, P20827; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; PHOENIX DA, 1993, J BIOL CHEM, V268, P17069; RIZO J, 1993, BIOCHEMISTRY-US, V32, P4881, DOI 10.1021/bi00069a025; Sambrook J, 1989, MOL CLONING LABORATO; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHINDE UP, 1989, BIOSCIENCE REP, V9, P737, DOI 10.1007/BF01114812; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; TOMMASSEN J, 1987, J MOL BIOL, V198, P633, DOI 10.1016/0022-2836(87)90206-3; TOMMASSEN J, 1983, EMBO J, V2, P1275, DOI 10.1002/j.1460-2075.1983.tb01581.x; WANG ZL, 1993, BIOCHEMISTRY-US, V32, P13991, DOI 10.1021/bi00213a032; YAMANE K, 1987, J BIOL CHEM, V262, P2358	33	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16029	16033						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206900				2022-12-27	WOS:A1994NQ72900015
J	HAWES, BE; LUTTRELL, LM; EXUM, ST; LEFKOWITZ, RJ				HAWES, BE; LUTTRELL, LM; EXUM, ST; LEFKOWITZ, RJ			INHIBITION OF G-PROTEIN-COUPLED RECEPTOR SIGNALING BY EXPRESSION OF CYTOPLASMIC DOMAINS OF THE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; ALPHA-1-ADRENERGIC RECEPTOR; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; PHOSPHATIDYLINOSITOL HYDROLYSIS; BETA-2-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; ADENYLYL CYCLASE; ACTIVATION; BINDING	The third intracellular domain (3i) of G protein-coupled receptors plays a major role in the activation of G proteins. Alterations in this region of the receptor can affect receptor/G protein coupling efficiency and specificity. We recently reported (Luttrell, L. M., Cotecchia, S., Ostrowski, J., Kendall, H., Lefkowitz, R. J. (1993) Science 259, 1453-1457) that coexpression of the 3i domain of the alpha(1B) adrenergic receptor (AR) (alpha(1B)3i) specifically inhibited alpha(1B)AR-mediated inositol phosphate production, with no effect on D-1A dopamine receptor (D(1A)DR)-mediated cAMP production. Similarly, expression of the 3i domain of D(1A)DR (D(1A)3i) inhibited D(1A)DR-mediated cAMP production but did not affect alpha(1B)AR-mediated inositol phosphate accumulation. This suggests that peptides derived from a G protein-coupled receptor might serve as antagonists of receptor/G protein interactions. The present studies were performed to test the generality as well as the specificity of this phenomenon. The effect of expression of the second intracellular domain (2i), the 3i domain, and the fourth intracellular domain (4i) of alpha(1B)AR on second messenger generation mediated by the alpha(1B)AR, the M(1) muscarinic cholinergic receptor (M(1)AChR), and the D(1A)DR was examined. Although the alpha(1B)2i domain had no effect on receptor/G protein coupling for any receptor tested, the alpha(1B)3i domain inhibited signaling mediated by alpha(1B)AR and M(1)AChR but not by D(1A)DR, while the alpha(1B)4i domain inhibited signaling mediated by each of the receptors. To investigate the generality of 3i domain-induced inhibition of receptor activity further, the 3i domains of two G(q)-coupled receptors (alpha(1B)AR and M(1)AChR) and two G(i)-coupled receptors (alpha(2A)AR and M(2)AChR) were tested for effects on the second messenger generation mediated by each of the four receptors. In each case, the homologous 3i domain caused significant inhibition (40-60%), while the 3i domain of the receptor coupled to the same G protein also decreased receptor/G protein coupling. In contrast, receptor/G protein coupling appeared unaffected by expression of 3i domains derived from receptors coupled to different G proteins. The alpha(1B)3i domain-provoked inhibition of homologous receptor signaling was surmountable at high receptor density, and assays using a phorbol response element/reporter gene construct detected a weak enhancement of basal second messenger generation in cells expressing the alpha(1B)3i domain alone. These data demonstrate that disruption of receptor/G protein coupling by 3i domain peptides 1) can be generalized to both G(q)- and G(i)-coupled receptors and 2) Likely results from the ability of these peptides to act as competitive weak partial agonists at the receptor/G protein interface.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; DOHLMAN HG, 1988, BIOCHEMISTRY-US, V27, P1813, DOI 10.1021/bi00406a002; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUROSE H, 1993, MOL PHARMACOL, V43, P444; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MUKAI H, 1992, J BIOL CHEM, V267, P16237; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PEI G, 1994, IN PRESS P NATL ACAD; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; TAYLOR S, 1990, NATURE, V350, P516; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	39	89	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15776	15785						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195232				2022-12-27	WOS:A1994NP51300060
J	LAIN, B; IRIARTE, A; MARTINEZCARRION, M				LAIN, B; IRIARTE, A; MARTINEZCARRION, M			DEPENDENCE OF THE FOLDING AND IMPORT OF THE PRECURSOR TO MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE ON THE NATURE OF THE CELL-FREE TRANSLATION SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; HIGHER MOLECULAR-WEIGHT; CYTOSOLIC FACTOR; STRESS PROTEINS; ESCHERICHIA-COLI; BINDING; TRANSLOCATION; PRESEQUENCE; MEMBRANE; POLYPEPTIDES	The precursor to mitochondrial aspartate aminotransferase (pmAspAT), when newly synthesized in vitro using either rabbit reticulocyte lysate (RRL) or wheat germ extract (WGE), is highly susceptible to proteolysis. Treatment of these translation products with trypsin generates a characteristic pattern of proteolytic fragments which differs between WGE and RRL. pmAspAT synthesized in RRL acquires over time the trypsin resistance characteristic of purified recombinant pmAspAT in a process that reflects folding of the nascent protein in a cytosolic-like environment and results in the loss of its ability to be imported into mitochondria (Mattingly, J. R., Jr., Youssef, J., Iriarte, A., and Martinez-Carrion, M. (1993) J. Biol. Chem. 268, 3925-3937). Folding in RRL is temperature-dependent. By contrast, pmAspAT synthesized in WGE does not acquire trypsin resistance at any temperature and is unable to be imported into isolated mitochondria. Yet, addition of RRL to the protein synthesized in WGE restores both the folding and import processes. This effect is temperature and N-ethylmaleimide-sensitive and requires ATP. We have also detected that newly synthesized pmAspAT, in both the mammalian (RRL) and plant (WGE) environments, associates at an early stage, possibly cotranslationally, with cytosolic hsp70. This complex is transient and short-lived in RRL but is stable for protein synthesized in WGE. The mature form of the protein is also found associated with hsp70 early on during its synthesis. Yet, in RRL, it dissociates from the complex more easily than its precursor form. This suggests that the interaction between the precursor and hsp70 is at least partially dependent on the signal peptide. The dissociation of the precursor/hsp70 complex seems to precede ATP-requiring subsequent folding steps. Furthermore, release of precursor from this complex, either to be imported into mitochondria or to resume folding when in the absence of mitochondria, appears to be influenced by other factor(s) present in RRL but absent or inhibited in WGE.	UNIV MISSOURI, SCH BIOL SCI, DIV MOLEC BIOL & BIOCHEM, KANSAS CITY, MO 64110 USA	University of Missouri System; University of Missouri Kansas City					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038184, R01GM038341] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38184, GM-38341] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI F, 1989, J BIOL CHEM, V264, P4782; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHEN WJ, 1987, J BIOL CHEM, V262, P15598; CHIRICO WJ, 1992, BIOCHEM BIOPH RES CO, V189, P1150, DOI 10.1016/0006-291X(92)92324-Q; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; JOH T, 1985, P NATL ACAD SCI USA, V82, P6065, DOI 10.1073/pnas.82.18.6065; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTINEZCARRION M, 1990, ANN NY ACAD SCI, V585, P346, DOI 10.1111/j.1749-6632.1990.tb28067.x; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; MATTINGLY JR, 1993, J BIOL CHEM, V268, P26320; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; MURAKAMI K, 1992, J BIOL CHEM, V267, P13119; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; ONO H, 1990, ARCH BIOCHEM BIOPHYS, V280, P299, DOI 10.1016/0003-9861(90)90333-T; ONO H, 1990, ARCH BIOCHEM BIOPHYS, V277, P368, DOI 10.1016/0003-9861(90)90592-M; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PARSONS DF, 1966, ANN NY ACAD SCI, V137, P643, DOI 10.1111/j.1749-6632.1966.tb50188.x; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; REYES AM, 1993, J BIOL CHEM, V268, P22281; SAKAKIBARA R, 1980, BIOCHEM BIOPH RES CO, V95, P1781, DOI 10.1016/S0006-291X(80)80105-7; SCHMID D, 1992, EUR J BIOCHEM, V208, P699, DOI 10.1111/j.1432-1033.1992.tb17237.x; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SONDEREGGER P, 1980, BIOCHEM BIOPH RES CO, V94, P1256, DOI 10.1016/0006-291X(80)90554-9; SONDEREGGER P, 1982, J BIOL CHEM, V257, P3339; TSUGEKI R, 1993, FEBS LETT, V320, P198, DOI 10.1016/0014-5793(93)80585-I; VERNER K, 1987, EMBO J, V6, P2449, DOI 10.1002/j.1460-2075.1987.tb02524.x; VERNER K, 1993, TRENDS BIOCHEM SCI, V18, P366, DOI 10.1016/0968-0004(93)90090-A; WATERS MG, 1986, J CELL BIOL, V103, P2629, DOI 10.1083/jcb.103.6.2629; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; ZIMMERMANN R, 1988, EMBO J, V7, P2875, DOI 10.1002/j.1460-2075.1988.tb03144.x	47	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15588	15596						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195205				2022-12-27	WOS:A1994NP51300033
J	LAVOIE, BD; CHACONAS, G				LAVOIE, BD; CHACONAS, G			A 2ND HIGH-AFFINITY HU BINDING-SITE IN THE PHAGE-MU TRANSPOSOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; STRAND TRANSFER-REACTION; HISTONE-LIKE PROTEINS; ESCHERICHIA-COLI; DNA-BINDING; TRANSPOSITIONAL ENHANCER; BACTERIOPHAGE-LAMBDA; ATTACHMENT-SITE; COMPLEXES; INVITRO	The bacteriophage Mu in vitro transposition reaction proceeds through several higher order nucleoprotein intermediates (transpososomes). One of the requirements for complex assembly is the Escherichia coli sequence-independent DNA-binding protein, HU. This protein has an affinity for Mu transpososomes, which is at least 100 times greater than for supercolied DNA (Lavoie and Chaconas, 1990). We have recently identified one such high affinity binding site at the Mu left end by converting HU into a chemical nuclease (Lavoie and Chaconas, 1993). Using immunoelectron microscopy, we now report high affinity HU binding to a region(s) distinct from the previously characterized left end site. HU can be removed from this region by a 0.5 M NaCl wash and subsequently reassembled into the complex with high efficiency. Furthermore, chemical modification of the Mu A protein in the Type 1 complex does not block HU reassembly into the transpososome; the high affinity HU binding observed is therefore unlikely to result from A-HU interactions. These findings are corroborated by the ability of eukaryotic HMG-1 to functionally replace HU in transpososome formation and to efficiently assemble into HU-depleted complexes. We propose that HU recognition of an altered DNA structure, rather than protein-protein interactions, mediates high affinity HU binding to Mu transpososomes.			LAVOIE, BD (corresponding author), UNIV WESTERN ONTARIO, DEPT BIOCHEM, LONDON N6A 5C1, ON, CANADA.							ADZUMA K, 1988, STRUCTURE EXPRESSION, V3, P97; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BHATTACHARYYA A, 1991, J MOL BIOL, V221, P1191, DOI 10.1016/0022-2836(91)90928-Y; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BOOCOCK MR, 1992, TRENDS GENET, V8, P151, DOI 10.1016/0168-9525(92)90206-J; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DING ZM, 1993, NUCLEIC ACIDS RES, V21, P4281, DOI 10.1093/nar/21.18.4281; DRLICA K, 1987, MICROBIOL REV, V51, P310; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GOODMAN SD, 1992, P NATL ACAD SCI USA, V89, P11910, DOI 10.1073/pnas.89.24.11910; Haniford DB, 1992, CURR OPIN GENET DEV, V2, P698, DOI 10.1016/S0959-437X(05)80129-7; HAYKINSON MJ, 1993, EMBO J, V12, P2503, DOI 10.1002/j.1460-2075.1993.tb05905.x; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; HWANG DS, 1992, J BIOL CHEM, V267, P23083; Kleinschmidt A.K.=, 1968, METHODS ENZYMOL, V12, P361; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PETTIJOHN DE, 1988, J BIOL CHEM, V263, P12793; PONTIGGIA A, 1993, MOL MICROBIOL, V7, P343, DOI 10.1111/j.1365-2958.1993.tb01126.x; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; SERRANO M, 1993, TRENDS BIOCHEM SCI, V18, P202, DOI 10.1016/0968-0004(93)90187-R; SULLIVAN KM, 1987, J MOL BIOL, V193, P397, DOI 10.1016/0022-2836(87)90227-0; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; WESTMORELAND BC, 1969, SCIENCE, V163, P1343, DOI 10.1126/science.163.3873.1343; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; WU ZG, 1992, J BIOL CHEM, V267, P9552; ZHONG M, 1993, J MOL BIOL, V230, P766, DOI 10.1006/jmbi.1993.1199; ZOU A, 1991, J BIOL CHEM, V266, P20476	48	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15571	15576						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195202				2022-12-27	WOS:A1994NP51300030
J	RALSTON, E; BEUSHAUSEN, S; PLOUG, T				RALSTON, E; BEUSHAUSEN, S; PLOUG, T			EXPRESSION OF THE SYNAPTIC VESICLE PROTEINS VAMPS/SYNAPTOBREVIN-1 AND VAMPS/SYNAPTOBREVIN-2 IN NONNEURAL TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTEGRAL MEMBRANE-PROTEIN; RAT SKELETAL-MUSCLE; GLUCOSE TRANSPORTER; SYSTEMIC DELIVERY; FUSION PROTEIN; INSULIN; GENES; IDENTIFICATION; SYNAPTOBREVIN; LOCALIZATION	The VAMPs/synaptobrevins (Vp/Sybs) are small integral membrane proteins. Two isoforms, Vp/Syb 1 and Vp/Syb 2, are considered to be specific to neural tissue. They are associated with synaptic vesicles and are believed to play an important role in neurotransmitter release. A third isoform, cellubrevin, has recently been found in non-neural tissues. We now report that the distribution of Vp/Syb 1 and Vp/Syb 2 is wider than previously thought. RNA transcripts for both Vp/Syb 1 and Vp/Syb 2 were found in rat skeletal muscle and in several other rat non-neural tissues, and antibodies specific for Vp/Syb 2 detected a protein in the endoplasmic reticulum-Golgi area of skeletal muscle. Thus Vp/Sybs 1 and 2 are not restricted to the nervous system but appear to be co-expressed with cellubrevin in many different tissues. This redundancy of Vp/Sybs in a single cell may be required to control the specificity of vesicle-target interaction in the several pathways of intracellular vesicle traffic that are operative within each cell.	NIDDK,EXPTL DIABET METAB & NUTR SECT,DIABET BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	RALSTON, E (corresponding author), NINCDS,NEUROBIOL LAB,BETHESDA,MD 20892, USA.			Ploug, Thorkil/0000-0002-5375-6595				ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BARR E, 1991, SCIENCE, V254, P1507, DOI 10.1126/science.1962212; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BORNEMANN A, 1992, DIABETES, V41, P215, DOI 10.2337/diabetes.41.2.215; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; DAN Y, 1992, NATURE, V359, P733, DOI 10.1038/359733a0; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAHN R, 1993, J NEUROCHEM, V61, P12, DOI 10.1111/j.1471-4159.1993.tb03533.x; KELLY AM, 1969, J CELL BIOL, V42, P154, DOI 10.1083/jcb.42.1.154; LEUBE RE, 1987, EMBO J, V6, P3261, DOI 10.1002/j.1460-2075.1987.tb02644.x; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PLOUG T, 1992, AM J PHYSIOL, V262, pE700, DOI 10.1152/ajpendo.1992.262.5.E700; PLOUG T, 1990, AM J PHYSIOL, V259, pE778, DOI 10.1152/ajpendo.1990.259.6.E778; Ploug T., 1993, Molecular Biology of the Cell, V4, p429A; RALSTON E, 1993, J CELL BIOL, V120, P399, DOI 10.1083/jcb.120.2.399; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8	33	60	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15403	15406						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195178				2022-12-27	WOS:A1994NP51300002
J	EXLEY, M; VARTICOVSKI, L; PETER, M; SANCHO, J; TERHORST, C				EXLEY, M; VARTICOVSKI, L; PETER, M; SANCHO, J; TERHORST, C			ASSOCIATION OF PHOSPHATIDYLINOSITOL 3-KINASE WITH A SPECIFIC SEQUENCE OF THE T-CELL RECEPTOR XI-CHAIN IS DEPENDENT ON T-CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; MEDIATED SIGNAL TRANSDUCTION; TCR ZETA-CHAIN; ANTIGEN RECEPTOR; MICE LACKING; CD3 COMPLEX; DOMAIN; PHOSPHORYLATION; BINDING; STIMULATION	The T cell antigen receptor (TCR) CDS complex contains several distinct but related signal transduction modules termed ''Reth motifs'': one each in the cytoplasmic domains of CD3-gamma, -delta, and -epsilon chains and three in the CD3-zeta polypeptide (zeta(A), zeta(B), and zeta(C)). Cross-linking of individual motifs expressed in chimeric molecules leads to early and late T cell activation events. Although the activated T cell receptor associates with nonreceptor tyrosine kinases, the sites of interaction with kinases and other potential effector molecules have not been fully mapped. Here we show that phosphatidylinositol 3-kinase (PI 3-kinase) preferentially associated with the zeta chain membrane proximal motif zeta(A). Maximal PI 3-kinase/zeta(A) association occurred following TCR.CD3 activation and was dependent upon phosphorylation of both tyrosine residues in zeta(A). The association of PI 3-kinase was specific for zeta(A) and could be ranked zeta(A) >> zeta(C) > zeta(B). Phosphorylation of the zeta(A) motif on tyrosine residues occurred in response to TCR.CD3 cross-linking in vivo. These results indicate that T cell activation leads to assembly of an intracellular signaling complex: recruitment of a tyrosine kinase, phosphorylation of zeta(A), and association of PI 3-kinase. These data also support a model in which different Reth motifs of the TCR.CD3 complex recruit distinct signal transduction molecules. Thus, the subdomains of the T cell antigen receptor zeta chain may serve different roles during T cell maturation and antigen-driven activation.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV IMMUNOL, BOSTON, MA 02215 USA; TUFTS UNIV, ST ELIZABETHS HOSP, SCH MED, DEPT BIOMED RES, BOSTON, MA 02135 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Tufts University			Sancho, Jaime/O-3228-2013; Sancho, Jaime/K-5989-2019	Sancho, Jaime/0000-0003-3852-7951; Sancho, Jaime/0000-0003-3852-7951; Exley, Mark/0000-0002-5088-1032; Varticovski, Lyuba/0000-0002-5105-9008; Peter, Marcus Ernst/0000-0003-3216-036X	NATIONAL CANCER INSTITUTE [R29CA053094, R01CA053094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015066, R56AI015066] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA53094] Funding Source: Medline; NIAID NIH HHS [AI15066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EXLEY M, 1991, SEMIN IMMUNOL, V3, P287; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; HE TC, 1993, BLOOD, V82, P3530; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KANAGAWA O, 1991, J IMMUNOL, V147, P1307; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; PANAYOTU G, 1992, NATURE, V358, P684; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PETER ME, 1992, EMBO J, V11, P933, DOI 10.1002/j.1460-2075.1992.tb05132.x; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SANCHO J, 1993, J IMMUNOL, V150, P3230; SANCHO J, 1993, EUR J IMMUNOL, V23, P1636, DOI 10.1002/eji.1830230736; SANCHO J, 1992, J BIOL CHEM, V267, P7871; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMPSON PA, 1992, ONCOGENE, V7, P719; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VEILLETTE A, 1992, IMMUNOL TODAY, V8, P61; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	115	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15140	15146						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195151				2022-12-27	WOS:A1994NP73800045
J	TEZUKA, K; NEMOTO, K; TEZUKA, Y; SATO, T; IKEDA, Y; KOBORI, M; KAWASHIMA, H; EGUCHI, H; HAKEDA, Y; KUMEGAWA, M				TEZUKA, K; NEMOTO, K; TEZUKA, Y; SATO, T; IKEDA, Y; KOBORI, M; KAWASHIMA, H; EGUCHI, H; HAKEDA, Y; KUMEGAWA, M			IDENTIFICATION OF MATRIX METALLOPROTEINASE-9 IN RABBIT OSTEOCLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-RESORPTION; CATHEPSIN-L; CYSTEINE-PROTEINASES; POLYMORPHONUCLEAR LEUKOCYTES; COLLAGENOLYTIC CATHEPSIN; IV COLLAGENASE; RAT-LIVER; DEGRADATION; GELATINASE; TISSUE	Osteoclasts are multinucleate giant cells that play key roles in bone resorption. To identify genes predominantly expressed in osteoclasts, we screened a cDNA library of osteoclasts with cDNA probes of osteoclasts and alveolar macrophages. Clones specifically hybridizing to the osteoclast probe were isolated and sequenced. The nucleotide sequence of one such clone, F17, was found to share significant similarity with the sequences of human and mouse matrix metalloproteinase 9 (MMP-9) cDNA By isolation and sequencing of the full-length cDNA, F17 was revealed to encode the rabbit counterpart of MMP-9. By Northern blotting, messenger RNA for MMP-9 was found to be highly and predominantly expressed in isolated osteoclasts when compared with its level in alveolar macrophages and other tissues. By gelatin zymography, gelatinase activity was detected in conditioned medium of isolated osteoclasts, suggesting that MMP-9 is secreted by isolated osteoclasts. Expression of MMP-9 was also observed in in vivo osteoclasts in metacarpal bones of newborn rabbits by in situ hybridization. These facts suggest that MMP-9 is one of the major proteases produced by osteoclasts and possibly plays a role in osteoclastic bone resorption.	MEIKAI UNIV,SCH DENT,DEPT ORAL ANAT,SAKADO,SAITAMA 35002,JAPAN; ST MARIANNA UNIV,SCH MED,DEPT INTERNAL MED 3,KAWASAKI,KANAGAWA 216,JAPAN; YAMANOUCHI PHARMACEUT CO LTD,MOLEC MED RES LABS,TSUKUBA,IBARAKI 305,JAPAN; TEIJIN LTD,INST BIOMED RES,HINO,TOKYO 191,JAPAN	Meikai University; Saint Marianna University; Astellas Pharmaceuticals; Teijin Limited			Tezuka, Ken-ichi/B-3836-2012					BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BLAIR HC, 1993, BIOCHEM J, V290, P873, DOI 10.1042/bj2900873; BURLEIGH MC, 1974, BIOCHEM J, V137, P387, DOI 10.1042/bj1370387; DELAISSE JM, 1987, BONE, V8, P305, DOI 10.1016/8756-3282(87)90007-X; DELAISSE JM, 1991, BIOCHEM J, V279, P167, DOI 10.1042/bj2790167; ETHERINGTON DJ, 1972, BIOCHEM J, V127, P685, DOI 10.1042/bj1270685; ETHERINGTON DJ, 1987, COLLAGEN REL RES, V7, P185; EVANS P, 1978, EUR J BIOCHEM, V83, P87, DOI 10.1111/j.1432-1033.1978.tb12071.x; EVERTS V, 1988, CALCIFIED TISSUE INT, V43, P172, DOI 10.1007/BF02571316; EVERTS V, 1992, J CELL PHYSIOL, V150, P221, DOI 10.1002/jcp.1041500202; HIBBS MS, 1987, J CLIN INVEST, V80, P1644, DOI 10.1172/JCI113253; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HILL PA, 1993, BIOCHIM BIOPHYS ACTA, V1177, P71, DOI 10.1016/0167-4889(93)90159-M; KAKEGAWA H, 1993, FEBS LETT, V321, P247, DOI 10.1016/0014-5793(93)80118-E; KIRSCHKE H, 1989, BIOCHEM J, V264, P467, DOI 10.1042/bj2640467; KIRSCHKE H, 1982, BIOCHEM J, V201, P367, DOI 10.1042/bj2010367; MACIEWICZ RA, 1987, COLLAGEN REL RES, V7, P295; MACIEWICZ RA, 1988, BIOCHEM J, V256, P433, DOI 10.1042/bj2560433; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; MURPHY G, 1982, BIOCHEM J, V203, P209, DOI 10.1042/bj2030209; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; OKAMURA T, 1993, CALCIFIED TISSUE INT, V52, P325, DOI 10.1007/BF00296659; RIFKIN BR, 1991, BIOCHEM BIOPH RES CO, V179, P63, DOI 10.1016/0006-291X(91)91334-9; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SHIMIZU H, 1990, J BONE MINER RES, V5, P411, DOI 10.1002/jbmr.5650050415; SOPATA I, 1974, BIOCHIM BIOPHYS ACTA, V370, P510, DOI 10.1016/0005-2744(74)90112-0; TANAKA H, 1993, BIOCHEM BIOPH RES CO, V190, P732, DOI 10.1006/bbrc.1993.1110; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	32	142	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15006	15009						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195136				2022-12-27	WOS:A1994NP73800027
J	COHENSOLAL, L; ZYLBERBERG, L; SANGALLI, A; LIRA, MG; MOTTES, M				COHENSOLAL, L; ZYLBERBERG, L; SANGALLI, A; LIRA, MG; MOTTES, M			SUBSTITUTION OF AN ASPARTIC-ACID FOR GLYCINE-700 IN THE ALPHA-2(I) CHAIN OF TYPE-I COLLAGEN IN A RECURRENT LETHAL TYPE-II OSTEOGENESIS IMPERFECTA DRAMATICALLY AFFECTS THE MINERALIZATION OF BONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENGTH CDNA CLONE; ALPHA-1(I) CHAIN; TRIPLE HELIX; N-PROTEINASE; PROCOLLAGEN-I; CYSTEINE; GENE; MUTATIONS; TENDON; FIBRILS	We describe a new dominant mutation of type I collagen responsible for a recurrent lethal osteogenesis imperfecta. Dermal cultured fibroblasts of the proband produced both normal and overmodified type I collagen chains. Previous results (Cohen-Solal, L., Bonaventure, J., and Maroteaux, P. (1991) Hum. Genet. 87, 297-301) and cyanogen bromide peptide mapping after non-equilibrium pH gradient gel electrophoresis indicated that the anomaly was a charge mutation localized in the alpha 2CB3-5(A). The mutation was identified as a G to A transition in the COL1A2 gene, which converts glycine 700 to aspartic acid in the alpha 2I chain. This mutation caused the abolition of a ScrFI site, which was also absent in the suspected mosaic father. Pulse-chase experiment showed intracellular retention and increase of the degradation of the synthesized collagen. To understand more directly the tissue defect in osteogenesis imperfecta, skin and especially bone were studied with biochemical and transmission electron microscopy techniques. Collagen matrix of both tissues was dramatically decreased and presented a retarded migration, showing that abnormal molecules were incorporated during the fibrillogenesis. The abnormal collagen mostly remained within the fibroblasts and osteoblasts, which presented typical features of intracellular retention. We observed the presence of spheritic aggregates of mineral, unrelated to the scarse and thin collagen fibrils, in bone. Such abnormal mineralization could be the consequence not only of the decrease of the collagen content but more importantly of the inability of the abnormal molecules to form an organized network necessary to the deposition of apatite crystallites.	UNIV PARIS 07,CNRS,URA 1137,EQUIPE FORMAT SQUELETT,F-75251 PARIS,FRANCE; IST SCI BIOL,I-37134 VERONA,ITALY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	COHENSOLAL, L (corresponding author), HOP NECKER ENFANTS MALAD,PHYSIOPATHOL TISSUS CONJONCTIFS LAB,CNRS,URA 584,149 RUE SEVRES,F-75743 PARIS 15,FRANCE.		GOMEZ, MACARENA/AAP-3153-2021	GOMEZ LIRA, MACARENA/0000-0003-4119-2267; sangalli, antonella/0000-0001-6359-0149	Telethon [E.0013] Funding Source: Medline	Telethon(Fondazione Telethon)		BACHINGER HP, 1993, AM J MED GENET, V45, P152, DOI 10.1002/ajmg.1320450204; BATEMAN JF, 1986, BIOCHEM J, V240, P699, DOI 10.1042/bj2400699; BERNARD GW, 1972, J ULTRA MOL STRUCT R, V41, P1, DOI 10.1016/S0022-5320(72)90034-2; BONAVENTURE J, 1989, AM J MED GENET, V33, P299, DOI 10.1002/ajmg.1320330304; BONAVENTURE J, 1992, HUM GENET, V89, P640; BONAVENTURE J, 1986, BIOCHIM BIOPHYS ACTA, V889, P23, DOI 10.1016/0167-4889(86)90005-4; BRENNER RE, 1993, EUR J PEDIATR, V152, P505, DOI 10.1007/BF01955060; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; CHIPMAN SD, 1993, P NATL ACAD SCI USA, V90, P1701, DOI 10.1073/pnas.90.5.1701; CHRISTOFFERSEN J, 1991, ANAT RECORD, V230, P435, DOI 10.1002/ar.1092300402; COHENSOLAL L, 1991, HUM GENET, V87, P297; COHN DH, 1992, HUM GENET, V87, P167; COLE WG, 1981, BIOCHEM J, V197, P377, DOI 10.1042/bj1970377; Edwards Matthew J., 1992, Human Mutation, V1, P47, DOI 10.1002/humu.1380010108; FERTALA A, 1993, BIOCHEM J, V289, P195, DOI 10.1042/bj2890195; GLIMCHER MJ, 1990, BIOMATERIALS, V11, P7; KADLER KE, 1991, BIOCHEMISTRY-US, V30, P5081, DOI 10.1021/bi00234a035; KUIVANIEMI H, 1988, BIOCHEM J, V252, P633, DOI 10.1042/bj2520633; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LANDIS WJ, 1993, J STRUCT BIOL, V110, P39, DOI 10.1006/jsbi.1993.1003; LANDIS WJ, 1993, 23 EUR S CALC TISS H; LIGHTFOOT SJ, 1992, J BIOL CHEM, V267, P25521; MAITLAND ME, 1991, CALCIFIED TISSUE INT, V48, P341, DOI 10.1007/BF02556154; MOTTES M, 1992, HUM GENET, V89, P480; Neville D M Jr, 1974, Methods Enzymol, V32, P92; NIYIBIZI C, 1992, J BIOL CHEM, V267, P23108; ORVIG T, 1968, NOBEL S, V4, P373; PROCKOP DJ, 1990, J BIOL CHEM, V265, P15349; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; STEGEMAN H, 1958, Z PHYS CHEM, V318, P41; TENNI R, 1993, AM J MED GENET, V45, P252, DOI 10.1002/ajmg.1320450219; TORREBLANCO A, 1992, J BIOL CHEM, V267, P2650; TORREBLANCO A, 1992, J BIOL CHEM, V267, P4968; TRAUB W, 1992, CONNECT TISSUE RES, V28, P99, DOI 10.3109/03008209209014230; TRAUB W, 1992, MATRIX, V12, P251, DOI 10.1016/S0934-8832(11)80076-4; TRAUB W, 1989, P NATL ACAD SCI USA, V86, P9822, DOI 10.1073/pnas.86.24.9822; TRAUB W, 1992, 13TH M FED EUR CONN; TROMP G, 1988, BIOCHEM J, V253, P919, DOI 10.1042/bj2530919; TSUNEYOSHI T, 1991, J BIOL CHEM, V266, P15608; VALLI M, 1993, MATRIX, V13, P275, DOI 10.1016/S0934-8832(11)80022-3; VETTER U, 1991, CALCIFIED TISSUE INT, V49, P248, DOI 10.1007/BF02556213; VETTER U, 1993, J BONE MINER RES, V8, P133; VOGEL BE, 1988, J BIOL CHEM, V263, P19249; WAGNER HD, 1992, J BIOMECH, V25, P1311, DOI 10.1016/0021-9290(92)90286-A; WEINER S, 1992, FASEB J, V6, P879, DOI 10.1096/fasebj.6.3.1740237; WHITE SW, 1977, NATURE, V266, P421, DOI 10.1038/266421a0; Zylberberg L., 1992, BONE BONE METAB MINE, V4, P171	47	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14751	14758						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182080				2022-12-27	WOS:A1994NM06500070
J	MACHLEIDT, T; WIEGMANN, K; HENKEL, T; SCHUTZE, S; BAEUERLE, P; KRONKE, M				MACHLEIDT, T; WIEGMANN, K; HENKEL, T; SCHUTZE, S; BAEUERLE, P; KRONKE, M			SPHINGOMYELINASE ACTIVATES PROTEOLYTIC I-KAPPA-B-ALPHA DEGRADATION IN A CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DORSAL-VENTRAL PATTERN; SERINE-PROTEASE; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; CYTO-TOXICITY; NF-KB; DROSOPHILA; RECEPTORS; INHIBITOR	Tumor necrosis factor (TNF) is one of the most potent physiological inducers of the nuclear transcription factor kappa B (NF-kappa B). A key event in the activation of NF-kappa B is the rapid release of the inhibitory subunit I kappa B-alpha. Various inhibitors of serine-like proteases are shown to block TNF-mediated NF-kappa B activation as well as the disappearance of I kappa B-alpha immunoreactivity in primary murine T lymphocytes and in various human leukemic cell lines. The protease inhibitors did not block TNF induced activation of either phosphatidylcholine specific phospholipase C or acidic sphingomyelinase (SMase), indicating that the putative protease operates rather downstream of TNF signal transduction processes. I kappa B-alpha degradation could be directly induced by addition of sphingomyelinase or synthetic ceramide to a cell free system, indicating a stringent coupling of SMase to the NF-kappa B activation pathway. SMase-induced I kappa B-alpha degradation was suppressed by the protease inhibitor dichloroisocoumarin. Together, the data suggest that a TNF-responsive sphingomyelinase triggers the rapid degradation of I kappa B-alpha through a serine-like protease, which appears to be crucial to the control of NF-kappa B activation.	TECH UNIV MUNICH, INST MIKROBIOL & HYG, D-81675 MUNICH, GERMANY; UNIV FREIBURG, INST BIOCHEM, D-79014 FREIBURG, GERMANY	Technical University of Munich; University of Freiburg			Schütze, Stefan/C-8596-2011					BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; DJABALLAH H, 1992, EUR J BIOCHEM, V209, P629, DOI 10.1111/j.1432-1033.1992.tb17329.x; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; GERVAIX A, 1991, J IMMUNOL, V147, P1912; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HECHT P M, 1992, Trends in Cell Biology, V2, P197, DOI 10.1016/0962-8924(92)90246-J; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KRONKE M, 1982, J EXP MED, V156, P41, DOI 10.1084/jem.156.1.41; KRONKE M, 1991, TUMOR NECROSIS FACTO, P189; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MACHLEIDT T, 1993, PATHOPHYSIOLOGY PHAR, P89; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; OLD LJ, 1987, NATURE, V326, P330, DOI 10.1038/326330a0; ONG EB, 1965, J BIOL CHEM, V240, P694; QUINTERN LE, 1991, METHOD ENZYMOL, V197, P536; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; RUGGIERO V, 1987, CELL IMMUNOL, V107, P317, DOI 10.1016/0008-8749(87)90240-1; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SUFFYS P, 1988, EUR J BIOCHEM, V178, P257, DOI 10.1111/j.1432-1033.1988.tb14451.x; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997	41	100	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13760	13765						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188652				2022-12-27	WOS:A1994NL60600010
J	NISHIMURA, N; NAKAMURA, H; TAKAI, Y; SANO, K				NISHIMURA, N; NAKAMURA, H; TAKAI, Y; SANO, K			MOLECULAR-CLONING AND CHARACTERIZATION OF 2 RAB GDI SPECIES FROM RAT-BRAIN - BRAIN-SPECIFIC AND UBIQUITOUS TYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; NUCLEOTIDE-RELEASING FACTOR; GDP/GTP EXCHANGE PROTEIN; SMG P25A; DISSOCIATION INHIBITOR; GERANYLGERANYL TRANSFERASE; ACTIVATING PROTEIN; REGULATORY PROTEIN; CELLS; PURIFICATION	Rab GDP dissociation inhibitor (GDI) is a regulatory protein for Rab proteins that controls not only the GDP/GTP exchange reaction of Rab proteins but also their translocation between the cytosol and cell membranes. Recently, rab GDI cDNAs have been isolated from human, bovine, rat, and Drosophila, and these Rab GDI proteins indicated an important role in the regulation of intracellular vesicle traffic. In this study, we have isolated two different rab GDI cDNAs, designated rat rab GDI alpha and beta, from a rat brain cDNA library using bovine rab GDI cDNA as a probe. Rat rab GDI alpha and beta show 99 and 86% amino acid identity with bovine rab GDI, respectively, indicating that rat rab GDI alpha is a rat counterpart of bovine rab GDI. Both rat Rab GDI alpha and beta proteins expressed in Escherichia coli showed a similar degree of activity of regulating the GDP/GTP exchange reaction to that of bovine Rab GDI using Rab3A and Rab11 as substrates. Northern blot analysis revealed that rab GDI alpha mRNA was expressed abundantly in brain but much less in other tissues, whereas rat rab GDI beta mRNA was ubiquitously expressed. Reverse transcription-polymerase chain reaction analysis revealed that astrocytes expressed rat rab GDI beta gene but not rat rab GDI alpha gene. These results indicate that Rab GDI alpha is involved in sorting of highly specialized vesicles in brain such as neurosecretory vesicles, whereas Rab GDI beta plays a general role in vesicular trafficking in diverse types of cells.	KOBE UNIV,SCH MED,DEPT PEDIAT,CHUO KU,KOBE 650,JAPAN; KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University; Kobe University								ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ANTONY C, 1992, J CELL SCI, V103, P785; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; Goedbloed J., 1942, OPHTHALMOLOGICA, V104, P308; GROEBE DR, 1990, NUCLEIC ACIDS RES, V18, P4033, DOI 10.1093/nar/18.13.4033; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HUBNER LA, 1993, J CELLBIOL, V123, P34; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MOTOIKE T, 1993, NEUROSCI LETT, V156, P87, DOI 10.1016/0304-3940(93)90446-R; MOTOIKE T, 1991, NEUROSCI LETT, V134, P109, DOI 10.1016/0304-3940(91)90519-Y; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PLUNTER H, 1991, J CELL BIOL, V115, P31; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Sambrook J, 1989, MOL CLONING LABORATO; SANO K, 1989, BIOCHEM BIOPH RES CO, V158, P377, DOI 10.1016/S0006-291X(89)80058-0; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; UEDA T, 1991, BIOCHEMISTRY-US, V30, P909, DOI 10.1021/bi00218a005; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; ZAHNER JE, 1993, MOL CELL BIOL, V13, P217, DOI 10.1128/MCB.13.1.217; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	51	80	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14191	14198						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188702				2022-12-27	WOS:A1994NL60600071
J	OHSAKO, S; HAYASHI, Y; BUNICK, D				OHSAKO, S; HAYASHI, Y; BUNICK, D			MOLECULAR-CLONING AND SEQUENCING OF CALNEXIN-T - AN ABUNDANT MALE GERM CELL-SPECIFIC CALCIUM-BINDING PROTEIN OF THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; AMINO-ACID-SEQUENCE; MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; RECEPTOR-ALPHA; SPERMIOGENESIS; MEMBRANE; RAT; CALRETICULIN; GLYCOPROTEIN	A mouse testis cDNA expression library was screened using a monoclonal antibody (1C9) that recognized an abundant testis-specific 101-kDa endoplasmic reticulum-associated protein. The screening resulted in the isolation of a 2.3-kilobase cDNA clone (A2/6). The sequence encoded 611 amino acids with a calculated mass of 69,454 Da, that was 60% similar to mouse calnexin. A high affinity calcium binding domain, present in both calnexin and calreticulin, and one transmembrane domain similar to that of calnexin were found in the A2/6 protein domain. Northern blot analysis of total RNA from seven different tissues showed hybridization only to testis RNA. Southern blot analysis indicated that A2/6 was a single copy gene. The calculated molecular mass for A2/6 was unexpectedly lower than the 101-kDa protein recognized by 1C9 on Western blot analysis of total testis protein. However, Escherichia coli and in vitro translation products of A2/6 cDNA yielded a similar 100-kDa protein. Finally, using the recombinant protein, calcium binding activity was detected by a Ca-45(2+) overlay assay. These results suggest that spermatogenic cell endoplasmic reticulum has a unique calcium binding protein, calnexin-t, which appears to be a calnexin variant.	UNIV ILLINOIS, DEPT VET BIOSCI, URBANA, IL 61801 USA; UNIV TOKYO, DEPT VET ANAT, BUNKYO KU, TOKYO 113, JAPAN	University of Illinois System; University of Illinois Urbana-Champaign; University of Tokyo								AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; ANDREADIS A, 1987, ANNU REV CELL BIOL, V3, P207, DOI 10.1146/annurev.cellbio.3.1.207; BAKSH S, 1991, J BIOL CHEM, V266, P21458; CALA SE, 1993, J BIOL CHEM, V268, P2969; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLERMONT Y, 1978, AM J ANAT, V151, P191, DOI 10.1002/aja.1001510204; CLERMONT Y, 1985, ANAT REC, V213, P33, DOI 10.1002/ar.1092130106; Cohen P, 1988, CALMODULIN MOL ASPEC, V5; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; DODEMONT H, 1990, EMBO J, V9, P4083, DOI 10.1002/j.1460-2075.1990.tb07630.x; FAWCETT DW, 1971, DEV BIOL, V26, P220, DOI 10.1016/0012-1606(71)90124-2; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; GILCHRIST JSC, 1993, J BIOL CHEM, V268, P4291; HAKE LE, 1993, J BIOL CHEM, V268, P4788; HARRISON RAP, 1988, J REPROD FERTIL, V82, P777, DOI 10.1530/jrf.0.0820777; HAWN TR, 1993, J BIOL CHEM, V268, P7692; HEIZMANN CW, 1987, CELL CALCIUM, V8, P1, DOI 10.1016/0143-4160(87)90034-0; HESS RA, 1990, BIOL REPROD, V43, P525, DOI 10.1095/biolreprod43.3.525; HOFMANN SL, 1989, J BIOL CHEM, V264, P18083; HUANG LQ, 1993, J BIOL CHEM, V268, P6560; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1989, P NATL ACAD SCI USA, V86, P6047, DOI 10.1073/pnas.86.16.6047; LEBLOND CP, 1952, AM J ANAT, V90, P167, DOI 10.1002/aja.1000900202; LIU DY, 1993, BIOL REPROD, V48, P340, DOI 10.1095/biolreprod48.2.340; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; MORI H, 1980, J CELL BIOL, V84, P340, DOI 10.1083/jcb.84.2.340; NAKAMOTO T, 1989, CELL TISSUE RES, V257, P279, DOI 10.1007/BF00261831; OHSAKO S, 1991, J VET MED SCI, V53, P969, DOI 10.1292/jvms.53.969; OHSAKO S, 1994, ANAT REC, V238, P335, DOI 10.1002/ar.1092380308; OU WJ, 1992, J BIOL CHEM, V267, P23789; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; RUSSELL LD, 1991, AM J ANAT, V192, P97, DOI 10.1002/aja.1001920202; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WADA I, 1991, J BIOL CHEM, V266, P19599; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429; WANG ZY, 1992, P NATL ACAD SCI USA, V89, P11814, DOI 10.1073/pnas.89.24.11814; WHITE FH, 1992, INT J PEPT PROT RES, V39, P265; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	53	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14140	14148						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188695				2022-12-27	WOS:A1994NL60600063
J	REIF, K; BUDAY, L; DOWNWARD, J; CANTRELL, DA				REIF, K; BUDAY, L; DOWNWARD, J; CANTRELL, DA			SH3 DOMAINS OF THE ADAPTER MOLECULE GRB2 COMPLEX WITH 2 PROTEINS IN T-CELLS - THE GUANINE-NUCLEOTIDE EXCHANGE PROTEIN SOS AND A 75-KDA PROTEIN THAT IS A SUBSTRATE FOR T-CELL ANTIGEN RECEPTOR-ACTIVATED TYROSINE KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHWAYS; P21RAS	In T lymphocytes activated via the T cell antigen receptor (TCR), the SH2- and SH3-containing adapter molecule Grb2 forms a complex with the Ras guanine nucleotide exchange protein Sos and tyrosine phosphoproteins. The interaction of Sos with Grb2 is mediated via the Grb2 SH3 domains. In this study, it is shown that a 75-kDa protein is also complexed with the Grb2 SH3 domains in T cells, but not in Rat-1 fibroblasts. The identity of the p75 protein is not known, but immunoblot analysis with phosphotyrosine antibodies indicated that it is rapidly tyrosine-phosphorylated in TCR-activated T cells. This characteristic clearly distinguishes p75 from Sos since Sos is not a phosphotyrosine protein. In vitro binding studies indicated that the p75 phosphotyrosine protein binds to a glutathione S-transferase fusion protein of intact Grb2, but not to a Grb2 fusion protein mutated in its SH3 domains. p75 can also bind to the single COOH-terminal Grb2 SH3 domain, whereas Sos has an in vitro binding preference for the NH2-terminal Grb2 SH3 domain. Collectively, these data indicate that in T cells, two proteins can complex with the Grb2 SH3 domains: Sos and a p75 molecule that is tyrosine-phosphorylated in TCR-activated cells. The significance of p75 association with Grb2 is not clear, but by analogy with Sos, p75 is a potential candidate for a Grb2 effector protein. Data are presented showing that the interaction of the Grb2 SH2 domains with tyrosine phosphoproteins may be regulated by conformational restraints imposed by different molecules complexing with the Grb2 SH3 domains. It is thus possible to speculate that the interaction of either p75 or Sos with the Grb2 SH3 domain may influence the interaction of the Grb2 SH2 domain with tyrosine phosphoproteins.	IMPERIAL CANC RES FUND,LYMPHOCYTE ACTIVAT LABS,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,SIGNAL TRANSDUCT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; Cancer Research UK				Reif, Karin/0000-0001-5490-8389; Downward, Julian/0000-0002-2331-4729				BEVERLEY PCL, 1981, EUR J IMMUNOL, V11, P329, DOI 10.1002/eji.1830110412; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCOLNIK EY, 1993, EMBO J, V12, P1929; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	18	87	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14081	14087						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188688				2022-12-27	WOS:A1994NL60600055
J	WANG, Y; AGRWAL, N; ECKHARDT, AE; STEVENS, RD; HILL, RL				WANG, Y; AGRWAL, N; ECKHARDT, AE; STEVENS, RD; HILL, RL			THE ACCEPTOR SUBSTRATE-SPECIFICITY OF PORCINE SUBMAXILLARY UDP-GALNAC-POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE IS DEPENDENT ON THE AMINO-ACID-SEQUENCES ADJACENT TO SERINE AND THREONINE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED GLYCOSYLATION; TRANSFERASE; MUCIN	The acceptor substrate specificity of a pure polypeptide N-acetylgalactosaminyltransferase has been examined with synthetic polypeptides with sequences identical, or similar to those found in porcine mucin or human erythropoietin. The sequences adjacent to either threonine or serine markedly influence the formation of GalNAc-O-Thr and GalNAc-O-Ser. Examination of the mucin-like peptide VLGXXAV, where X is Thr, Ser, or Ala, shows only Thr-containing peptides to be acceptors. The best substrate is formed when XX is TT. Peptides with XX as either AT or TA are less effective and those with XX as either ST or TS are much less effective acceptors. The amino acids adjacent to serine in the peptide formed by residues 121-131 in human erythropoietin, PPDAASAAPLR, also markedly influence the formation of GalNAc-O-Ser. Thus, PPDASSSAPLR and PPDVVSVVPLR are about 5- and 30-fold, respectively, less active than the erythropoietin peptide. The peptide PPDGGSGGPLR is inactive. The shorter peptide DAASAAPL is also about 5-fold less active than the full-length peptide, but the peptide AASAA is inactive. These studies indicate that one transferase can form both GalNAc-O-Ser and GalNAc-O-Thr residues when the sequences adjacent to the glycosylated residue are of the proper kind. Thus, in contrast to earlier suggestions, there is no evidence that different transferases form GalNAc-O-Ser and GalNAc-O-Thr. Examination of tissue homogenates from various tissues confirms this conclusion.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PEDIAT, DURHAM, NC 27710 USA	Duke University; Duke University					NIGMS NIH HHS [GM 25766] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025766, R01GM025766] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERNATHY JL, 1992, TECHNIQUES PROTEIN C, V3, P277; AUBERT JP, 1976, ARCH BIOCHEM BIOPHYS, V175, P410, DOI 10.1016/0003-9861(76)90528-2; BRIAND JP, 1981, J BIOL CHEM, V256, P2205; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; HILL HD, 1977, J BIOL CHEM, V252, P3799; HUGHES RC, 1988, CARBOHYD RES, V178, P259, DOI 10.1016/0008-6215(88)80117-4; KILLEEN N, 1987, EMBO J, V6, P4029, DOI 10.1002/j.1460-2075.1987.tb02747.x; LAI PH, 1986, J BIOL CHEM, V261, P3116; NAKADA H, 1993, P NATL ACAD SCI USA, V90, P2495, DOI 10.1073/pnas.90.6.2495; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SIEBERT PD, 1986, P NATL ACAD SCI USA, V83, P1665, DOI 10.1073/pnas.83.6.1665; WANG YC, 1992, J BIOL CHEM, V267, P2728; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529	17	54	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					22979	22983						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226812				2022-12-27	WOS:A1993MF51500007
J	ALBERS, MW; WILLIAMS, RT; BROWN, EJ; TANAKA, A; HALL, FL; SCHREIBER, SL				ALBERS, MW; WILLIAMS, RT; BROWN, EJ; TANAKA, A; HALL, FL; SCHREIBER, SL			FKBP-RAPAMYCIN INHIBITS A CYCLIN-DEPENDENT KINASE-ACTIVITY AND A CYCLIN D1-CDK ASSOCIATION IN EARLY G1 OF AN OSTEOSARCOMA CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; PROTEIN-KINASE; IMMUNOSUPPRESSANT RAPAMYCIN; SACCHAROMYCES-CEREVISIAE; IMMUNOPHILIN; ACTIVATION; ENCODES	Upon entering a cell the natural product rapamycin, like the structurally related immunosuppressant FK506, associates with members of the FKBP family of proteins. One or more of the resulting FKBP-rapamycin complexes blocks signaling pathways emanating from some growth factor receptors. Recently, the addition of rapamycin was shown to inhibit the phosphorylation and activation of a 70-kDa ribosomal S6 protein kinase, which normally occurs minutes after the activation of certain cytokine and growth factor receptors. We now report that rapamycin can be added 4 to 6 h after the addition of serum growth factors to quiescent human osteosarcoma cells and still arrest these cells in G1. This window of action correlates with the inducible appearance of a cyclin-dependent kinase (cdk) activity, and the induction of this activity is inhibited by the addition of rapamycin. Furthermore, p36cyclin D1 associates with this cdk protein complex in lysates of untreated cells, but does not associate with this cdk protein complex in lysates of rapamycin-treated cells. Together, these studies demonstrate that FKBP-rapamycin can modulate a cyclin-dependent kinase activity and a cyclin D1-cdk association during early G1 in MG-63 human osteosarcoma cells.	HARVARD UNIV, DEPT CHEM, CAMBRIDGE, MA 02138 USA; UNIV SO CALIF, CHILDRENS HOSP LOS ANGELES, SCH MED, DIV ORTHOPED SURG, LOS ANGELES, CA 90089 USA; UNIV SO CALIF, SCH PHARM, DEPT MOLEC PHARMACOL & TOXICOL, LOS ANGELES, CA 90054 USA	Harvard University; Children's Hospital Los Angeles; University of Southern California; University of Southern California					NIGMS NIH HHS [GM-38627] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038627, R37GM038627] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRANCAVILLA A, 1992, HEPATOLOGY, V15, P871, DOI 10.1002/hep.1840150520; HALL FL, 1991, J BIOL CHEM, V266, P17430; HALL FL, 1993, ONCOGENE, V8, P1377; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1992, EMBO J, V11, P2902; MORICE WG, 1993, J BIOL CHEM, V268, P3734; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SHERR CJ, 1992, CIBA F SYMP, V170, P209; WIEDERRECHT G, 1991, P NATL ACAD SCI USA, V88, P1029, DOI 10.1073/pnas.88.3.1029; WILLIAMS RT, 1993, J BIOL CHEM, V268, P8871; WILLIAMS RT, 1992, ONCOGENE, V7, P423; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	28	140	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22825	22829						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226793				2022-12-27	WOS:A1993MD34800094
J	GARFINKEL, MS; KATZE, MG				GARFINKEL, MS; KATZE, MG			TRANSLATIONAL CONTROL BY INFLUENZA-VIRUS - SELECTIVE TRANSLATION IS MEDIATED BY SEQUENCES WITHIN THE VIRAL MESSENGER-RNA 5'-UNTRANSLATED REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADENOVIRUS TRIPARTITE LEADER; INFECTED-CELLS; CELLULAR INHIBITOR; PROTEIN-KINASE; POLIOVIRUS RNA; EXPRESSION; INITIATION; METABOLISM; POLYMERASE; ELEMENTS	In cells infected by influenza virus type A, host cell protein synthesis declines rapidly and dramatically, while influenza viral protein synthesis occurs efficiently throughout infection. Previously, we had shown that the selective translation of influenza viral mRNAs in infected cells occurred in a cap-dependent manner and was due at least in part to structures inherent in the mRNAs. Using chimeras containing the noncoding and coding regions of cellular and viral mRNAs, we can now report that the selective translation is mediated by sequences within the 5'-untranslated regions (UTR) of the viral mRNAs. Polysome analysis confirmed that a 45-nucleotide sequence contained in the 5'-UTR of the influenza viral nucleocapsid protein was necessary and sufficient to allow the host cell translational machinery to discriminate between viral and cellular mRNAs. In reciprocal experiments in which the 5'-UTR of the cellular mRNA-secreted embryonic alkaline phosphatase replaced the nucleocapsid protein 5'-UTR, viral protein synthesis was inhibited in virus-infected cells, resembling host protein synthesis. Finally, we demonstrated that the 5'-UTR of another influenza viral mRNA, that encoding the nonstructural protein, also conferred resistance to the shutoff of protein synthesis in influenza virus-infected cells.	UNIV WASHINGTON, SCH MED, DEPT MICROBIOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00166] Funding Source: Medline; NIAID NIH HHS [AI-22646] Funding Source: Medline; NIGMS NIH HHS [T32-GM07270] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSOCAPLEN FV, 1988, J VIROL, V62, P1606, DOI 10.1128/JVI.62.5.1606-1616.1988; Ausubel FM, 1988, MOL REPROD DEV; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DOLPH PJ, 1990, J VIROL, V64, P2669, DOI 10.1128/JVI.64.6.2669-2677.1990; ETKIND PR, 1975, J VIROL, V16, P1464, DOI 10.1128/JVI.16.6.1464-1475.1975; FEIGENBLUM D, 1993, J VIROL, V67, P3027, DOI 10.1128/JVI.67.6.3027-3035.1993; GARFINKEL MS, 1992, J BIOL CHEM, V267, P9383; GARFINKEL MS, 1993, IN PRESS GENE EXPRES; KATZE MG, 1990, ENZYME, V44, P265, DOI 10.1159/000468764; KATZE MG, 1984, MOL CELL BIOL, V4, P2198, DOI 10.1128/MCB.4.10.2198; KATZE MG, 1986, J VIROL, V60, P1027, DOI 10.1128/JVI.60.3.1027-1039.1986; KATZE MG, 1984, CELL, V37, P483, DOI 10.1016/0092-8674(84)90378-7; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAZAROWITZ SG, 1971, VIROLOGY, V46, P830, DOI 10.1016/0042-6822(71)90084-5; LEE TG, 1992, J BIOL CHEM, V267, P14238; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LENK R, 1979, CELL, V16, P289, DOI 10.1016/0092-8674(79)90006-0; LINDQUIST S, 1990, ENZYME, V44, P147, DOI 10.1159/000468754; LUYTJES W, 1989, CELL, V59, P1107, DOI 10.1016/0092-8674(89)90766-6; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; SEONG BL, 1992, VIROLOGY, V186, P247, DOI 10.1016/0042-6822(92)90079-5; SKEHEL JJ, 1972, VIROLOGY, V49, P23, DOI 10.1016/S0042-6822(72)80004-7; Strauss E.G., 1990, VIROLOGY, P167; ZHANG Y, 1989, J BIOL CHEM, V264, P10679	31	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22223	22226						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226725				2022-12-27	WOS:A1993MD34800003
J	MA, CP; WILLY, PJ; SLAUGHTER, CA; DEMARTINO, GN				MA, CP; WILLY, PJ; SLAUGHTER, CA; DEMARTINO, GN			PA28, AN ACTIVATOR OF THE 20-S PROTEASOME, IS INACTIVATED BY PROTEOLYTIC MODIFICATION AT ITS CARBOXYL-TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE; CATHEPSIN B2; PURIFICATION; INHIBITOR; COMPLEX; MACROPAIN; UBIQUITIN; COMPONENT; B1	PA28, a protein activator of the 20 S proteasome, was previously identified in soluble extracts of bovine red blood cells (Ma, C.-P., Slaughter, C. A., and De-Martino, G. N. (1992) J. Biol. Chem. 267, 10515-10523). To determine whether this regulatory protein is as widely distributed as the proteasome, PA28 content and activity were examined in various eukaryotic tissues by immunoblot analysis and by functional assays of tissue extracts. PA28 protein was present in all sources examined. PA28 activity, however, was not detected in many of these sources, including those with the highest level of PA28 protein. To determine the biochemical basis of this result, PA28 was purified from extracts of rat liver, which had high levels of PA28 protein but no PA28 activity. The resulting purified PA28 had no detectable activity but had native and subunit molecular weights indistinguishable from the active PA28 of bovine red blood cells. Using the inactivation of purified PA28 as an assay, a protein that inactivated PA28 without altering its apparent molecular weight on SDS-polyacrylamide gel electrophoresis was identified, purified, and characterized from bovine liver. It had biochemical and catalytic characteristics similar to those of lysosomal carboxypeptidase B. When leupeptin, an inhibitor of lysosomal carboxypeptidase B, was included in the buffers used for the preparation of PA28, PA28 activity was detected in tissues which otherwise failed to demonstrate this activity. A similar result was obtained when extracts were prepared in a manner that minimized disruption of lysosomes. Other carboxypeptidases such as carboxypeptidase Y and pancreatic carboxypeptidase B also inactivated PA28 without altering its apparent molecular weight. Active PA28 binds to the proteasome to form a protease-activator complex that can be isolated after velocity sedimentation centrifugation through glycerol density gradients. Carboxypeptidase-inactivated PA28 failed to form such a complex, suggesting that the carboxyl terminus of PA28 is required for binding to the proteasome. These results indicate the importance of the carboxyl terminus of PA28 for proteasome activation.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NHLBI NIH HHS [HL-06296] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AFROZ H, 1976, BIOCHIM BIOPHYS ACTA, V452, P503, DOI 10.1016/0005-2744(76)90201-1; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; DEMARTINO GN, 1977, J BIOL CHEM, V252, P7511; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V205, P9; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOUGH R, 1987, J BIOL CHEM, V262, P8303; LI XC, 1991, BIOCHEMISTRY-US, V30, P9709, DOI 10.1021/bi00104a020; LI XCS, 1992, BIOCHEMISTRY-US, V31, P11963, DOI 10.1021/bi00163a001; LIPPERHEIDE C, 1986, BIOCHIM BIOPHYS ACTA, V880, P171, DOI 10.1016/0304-4165(86)90077-2; LONES M, 1983, ARCH BIOCHEM BIOPHYS, V221, P64, DOI 10.1016/0003-9861(83)90122-4; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; MCDONALD JK, 1975, LIFE SCI, V17, P1269; MCDONALD JK, 1977, PROTEINASES MAMMALIA, P311; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; NINJOOR V, 1974, BIOCHIM BIOPHYS ACTA, V370, P308, DOI 10.1016/0005-2744(74)90055-2; OTTO K, 1975, BIOCHIM BIOPHYS ACTA, V379, P462, DOI 10.1016/0005-2795(75)90153-1; TANAKA K, 1992, NEW BIOL, V4, P173; TAYLOR S, 1973, ANAL BIOCHEM, V56, P140, DOI 10.1016/0003-2697(73)90178-4	23	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22514	22519						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226760				2022-12-27	WOS:A1993MD34800051
J	NAKANO, T; RAINES, EW; ABRAHAM, JA; WENZEL, FG; HIGASHIYAMA, S; KLAGSBRUN, M; ROSS, R				NAKANO, T; RAINES, EW; ABRAHAM, JA; WENZEL, FG; HIGASHIYAMA, S; KLAGSBRUN, M; ROSS, R			GLUCOCORTICOID INHIBITS THROMBIN-INDUCED EXPRESSION OF PLATELET-DERIVED GROWTH-FACTOR A-CHAIN AND HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH-FACTOR IN HUMAN AORTIC SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; HUMAN-ENDOTHELIAL-CELLS; 3' UNTRANSLATED REGION; FACTOR MESSENGER-RNA; GENE-EXPRESSION; MULTIPLE FORMS; ANGIOTENSIN-II; B-CHAIN; C-JUN; PDGF	Proliferation of smooth muscle cells (SMCs) in atherosclerosis may be modulated by several growth regulatory molecules. At least two mitogens for SMCs, platelet-derived growth factor (PDGF) A-chain and heparin-binding epidermal growth factor-like growth factor (HB-EGF), can be produced by SMCs themselves and may stimulate smooth muscle proliferation in an autocrine or paracrine fashion. We examined the effects of thrombin, which may be generated at the site of vascular injury during atherogenesis, and the potent anti-inflammatory glucocorticoid, dexamethasone (DEX), on the expression of the genes encoding these two growth factors. Since both PDGF A-chain and HB-EGF have affinity for heparin, we also examined the effect of thrombin and DEX on the release of heparin binding mitogenic activity from SMCs. Treatment of SMCs with thrombin resulted in increases both in the level of the PDGF-A and HB-EGF transcripts in the cells, as well as in released heparin-binding growth factor activity. DEX inhibits the thrombin-stimulated release of mitogenic activity in a dose-dependent manner. An enzyme-linked immunoadsorbent assay showed that DEX inhibits both constitutive and thrombin-stimulated release of PDGF-AA. DEX also decreases both constitutive and thrombin-stimulated mRNA levels for PDGF A-chain and HB-EGF and destabilizes the transcripts for both growth factors. A nuclear run-on assay revealed that DEX acts, in addition, to inhibit constitutive and thrombin-stimulated transcription of the PDGF A-chain and HB-EGF genes. Thus, these findings indicate that expression of PDGF A-chain and HB-EGF may be regulated by thrombin and glucocorticoid at the transcription level. Our results are consistent with the involvement of thrombin-induced growth factor expression in neointimal SMC proliferation and suggest the possibility that intimal proliferation may be attenuated by glucocorticoids.	UNIV WASHINGTON, SCH MED, DEPT PATHOL, SM-30, SEATTLE, WA 98195 USA; SCIOS NOVA INC, Mountain View, CA 94043 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT SURG RES & BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	University of Washington; University of Washington Seattle; Scios; Harvard University; Boston Children's Hospital; Harvard Medical School					NHLBI NIH HHS [HL18645, HL47151] Funding Source: Medline; NIGMS NIH HHS [GM47397] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047151, P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; BAIRD A, 1990, HDB EXPT PHARM, V95, P369; BARRETT TB, 1988, P NATL ACAD SCI USA, V85, P2810, DOI 10.1073/pnas.85.8.2810; BARSHAVIT R, 1992, AM J RESP CELL MOL, V6, P123, DOI 10.1165/ajrcmb/6.2.123; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BETSHOLTZ C, 1986, NATURE, V323, P226; BURNSTEIN KL, 1989, ANNU REV PHYSIOL, V51, P683, DOI 10.1146/annurev.ph.51.030189.003343; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; CHARRON J, 1986, P NATL ACAD SCI USA, V83, P8903, DOI 10.1073/pnas.83.23.8903; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORJAY MH, 1990, J CELL PHYSIOL, V145, P391, DOI 10.1002/jcp.1041450302; DLUZ SM, 1993, J BIOL CHEM, V268, P18330; DROUIN J, 1987, J CELL BIOCHEM, V35, P293, DOI 10.1002/jcb.240350404; EHRLICH HP, 1971, P SOC EXP BIOL MED, V137, P936, DOI 10.3181/00379727-137-35698; EMILIE D, 1988, EUR J IMMUNOL, V18, P2043, DOI 10.1002/eji.1830181226; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FU JY, 1990, J BIOL CHEM, V265, P16737; GAY CG, 1990, J BIOL CHEM, V265, P3284; GESSANI S, 1988, J BIOL CHEM, V263, P7454; GUYRE PM, 1988, J STEROID BIOCHEM, V30, P89, DOI 10.1016/0022-4731(88)90080-5; HARAGUCHI T, 1991, J BIOL CHEM, V266, P18299; HARLAN JM, 1986, J CELL BIOL, V103, P1129, DOI 10.1083/jcb.103.3.1129; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MAJESKY MW, 1988, P NATL ACAD SCI USA, V85, P1524, DOI 10.1073/pnas.85.5.1524; MURRAY MJ, 1988, BIOTECHNIQUES, V6, P196; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAKANO T, 1990, J BIOL CHEM, V265, P12745; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; RAGHOW R, 1986, J BIOL CHEM, V261, P4677; RAINES EW, 1985, METHOD ENZYMOL, V109, P749; RAINES EW, 1982, J BIOL CHEM, V257, P5154; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; Ross R., 1980, HDB PHYSL CARDIOVA 2, P69; SAREMBOCK IJ, 1991, CIRCULATION, V84, P232, DOI 10.1161/01.CIR.84.1.232; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEJERSEN T, 1986, P NATL ACAD SCI USA, V83, P6844, DOI 10.1073/pnas.83.18.6844; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHIRAISHI T, 1989, CLIN CHIM ACTA, V184, P65, DOI 10.1016/0009-8981(89)90257-X; TEMIZER DH, 1992, J BIOL CHEM, V267, P24892; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	63	63	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22941	22947						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226804				2022-12-27	WOS:A1993MD34800109
J	BAMBERG, K; SACHS, G				BAMBERG, K; SACHS, G			TOPOLOGICAL ANALYSIS OF H+,K+-ATPASE USING IN-VITRO TRANSLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NA,K-ATPASE ALPHA-SUBUNIT; SITE-DIRECTED MUTAGENESIS; GASTRIC H+/K+-ATPASE; SARCOPLASMIC-RETICULUM; MEMBRANE TOPOLOGY; COMPLEMENTARY-DNA; PROTEIN; EPITOPE; SURFACE	The membrane topology of the alpha subunit of the H+,K+-ATPase was investigated by using in vitro transcription/ translation of DNA sequences encoding fusion proteins that contained possible membrane-spanning segments. The vectors consisted of DNA sequences encoding (a) either the first 101 (M0 vectors) or the first 139 (M1 vectors) amino acids of the N-terminal region of the alpha subunit of the ATPase, (b) a variable region, and then (c) the C-terminal 177 amino acids of the C-terminal region of the beta subunit, with five N-linked glycosylation sites. The variable region of the fusion protein contained the cDNA sequences representing the possible eight or 10 membrane-spanning segments either alone or in various combinations. Transcription/translation was performed in the presence of [S-35]methionine using a coupled reticulocyte lysate in the absence and presence of microsomes. The fusion protein was identified by autoradiography following separation using SDS-polyacrylamide gel electrophoresis. Glycosylation of a translated sequence corresponded to membrane insertion and translocation of the C-terminal beta sequence. This method allowed analysis of signal anchor sequences using the M0 vector. The presence of a stop transfer sequence in the variable segment of the M1 vector resulted in inhibition of translocation of the C-terminal beta sequence. The sequences for the first four membrane segments could act as either signal anchor or stop transfer sequences. Therefore, this region of the a subunit has four membrane-spanning segments that are co-inserted with translation. The sequence corresponding to membrane segment M8 acted as a stop transfer sequence. The sequence corresponding to membrane segment M9 acted as a signal anchor sequence, and that corresponding to membrane segment M10 acted as a stop transfer sequence. The sequences representing the fifth, sixth, and seventh (M5, M6, and M7) membrane segments were unable to co-insert into the membrane. These data verify the first four and the eighth membrane-spanning segments of the alpha subunit of the gastric H+,K+-ATPase and provide evidence for translational insertion of an additional pair of membrane spanning segments, M9 and M10. It appears that insertion of membrane segments M5, M6, and M7 is determined differently from the other membrane-spanning segments. In combination with other methods, this in vitro transcription/translation method is useful for defining the membrane topology of the P type ATPases.	VET ADM WADSWORTH MED CTR,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90073	University of California System; University of California Los Angeles					NIDDK NIH HHS [R01 DK 40165, R01 DK 41301] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; CANESSA CM, 1993, J BIOL CHEM, V268, P17722; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; HALL K, 1990, BIOCHEMISTRY-US, V29, P701, DOI 10.1021/bi00455a016; HOLLAND EC, 1986, J BIOL CHEM, V261, P1286; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MATTHEWS I, 1990, J BIOL CHEM, V265, P1837; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; SACHS G, 1993, ALIMENT PHARM THER, V7, P4; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT DR, 1992, BIOCHIM BIOPHYS ACTA, V1112, P246, DOI 10.1016/0005-2736(92)90398-6; SHIN JM, 1994, J BIOL CHEM, V269, P8642; SHIN JM, 1993, BIOCHIM BIOPHYS ACTA, V1148, P223, DOI 10.1016/0005-2736(93)90133-K; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SMITH DL, 1993, J BIOL CHEM, V268, P22469; SUBRAHMANYESWARA-RAO U, 1991, Journal of Biological Chemistry, V266, P14740; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0	33	97	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16909	16919						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207013				2022-12-27	WOS:A1994NR29600060
J	FUJIWARA, K; OKAMURAIKEDA, K; MOTOKAWA, Y				FUJIWARA, K; OKAMURAIKEDA, K; MOTOKAWA, Y			PURIFICATION AND CHARACTERIZATION OF LIPOYL-AMP-N-EPSILON-LYSINE LIPOYLTRANSFERASE FROM BOVINE LIVER-MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE CLEAVAGE SYSTEM; H-PROTEIN; ESCHERICHIA-COLI; ACID; MUTAGENESIS; SEQUENCE	Lipoyl-AMP:N-epsilon-lysine lipoyltransferase (lipoyltransferase) catalyzes the transfer of the lipoyl group from lipoyl AMP to a lysine residue of the specific enzyme proteins. We have shown previously that the lipoyltransferase activities locate in mitochondria using apoH-protein of the glycine cleavage system as an acceptor of the lipoyl group (Fujiwara, K., Okamura-Ikeda, K., and Motokawa, Y. (1990) J. Biol. Chem. 265, 17463-17467). Here we describe the purification and the characterization of two isoforms of lipoyltransferase termed lipoyltransferase I and lipoyltransferase II from bovine liver mitochondria. Lipoyltransferase II was purified to apparent homogeneity, whereas the final product of lipoyltransferase I still contained a minor contaminant. Although the two forms could be resolved on a hydroxylapatite column chromatography, they were indistinguishable, as judged by: (a) behavior during purification on ion exchange, hydrophobic, or affinity columns; (b) molecular mass determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and gel exclusion chromatography (40 kDa); and (c) catalytic properties (substrate specificity, kinetic constants, and optimal pH), Both lipoyltransferase I and II could not use lipoic acid plus MgATP as a substrate in place of lipoyl-AMP. Surprisingly, the lipoyltransferases transferred not only the lipoyl group but also the acyl groups from hexanoyl-, octanoyl-, and decanoyl-AMP to apoH-protein to a similar extent.	UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN	Tokushima University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKFIELD DE, 1991, FEBS LETT, V295, P13, DOI 10.1016/0014-5793(91)81373-G; FUJIWARA K, 1992, J BIOL CHEM, V267, P20011; FUJIWARA K, 1979, ARCH BIOCHEM BIOPHYS, V197, P454, DOI 10.1016/0003-9861(79)90267-4; FUJIWARA K, 1991, FEBS LETT, V293, P115, DOI 10.1016/0014-5793(91)81164-4; FUJIWARA K, 1990, J BIOL CHEM, V265, P17463; KOCHI H, 1979, ARCH BIOCHEM BIOPHYS, V198, P589, DOI 10.1016/0003-9861(79)90535-6; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OHNUMA S, 1991, J BIOL CHEM, V266, P23706; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1958, J BIOL CHEM, V232, P123; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; TSUMODA JN, 1967, ARCH BIOCHEM BIOPHYS, V118, P395	16	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16605	16609						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206978				2022-12-27	WOS:A1994NR29600016
J	OMKUMAR, RV; RODWELL, VW				OMKUMAR, RV; RODWELL, VW			PHOSPHORYLATION OF SER(871) IMPAIRS THE FUNCTION OF HIS(865) OF SYRIAN-HAMSTER 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; HMG-COA REDUCTASE; RAT-LIVER; PROTEIN-KINASE; ISOCITRATE DEHYDROGENASE; INVITRO; ENZYME; SITE; DEPHOSPHORYLATION; INACTIVATION	The attenuation of catalytic activity that accompanies phosphorylation of Ser(871) of Syrian hamster 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (EC 1.1.1.34) reflects primarily the introduction of negative charge (Omkumar, R.V., Darnay, B. G., and Rodwell, V. W. (1994) J. Biol. Chem. 269, 6810-6814). To investigate how a negative charge at position 871 attenuates activity we phosphorylated wild-type and mutant HMG-CoA reductases and assayed reduction of the putative intermediate mevaldehyde to mevalonate. We observed attenuated activity when the phosphorylated wild-type enzyme was assayed in the presence or absence of coenzyme A, but not when assayed in the presence of desthio-CoA. These observations recall the behavior of mutant enzyme H865Q, for which coenzyme A inhibits, whereas desthio-CoA stimulates mevaldehyde reduction (Frimpong, K. F., and Rodwell, V. W. (1994) J. Biol. Chem. 269, 11478-11483). Catalysis of mevaldehyde reduction by mutant enzyme H865Q was unaffected by phosphorylation. By contrast, mutant enzymes H860Q and H868Y, in which nearby, but noncatalytic, histidines had been mutated, exhibited wild-type behavior upon phosphorylation. We conclude that the introduction of negative charge at position 871 impairs the function of His(865), presumably by a specific electrostatic interaction. We propose a novel mechanism by which phosphorylation regulates activity. Phosphorylation of the terminal serine of the consensus AGxLV(K/R)S (H) under bar MxxNR (S) under bar motif of eukaryotic HMG-CoA reductases attenuates activity by impairing the ability of the catalytic histidine to protonate the CoAS- anion formed during the reductive deacylation of HMG-CoA to mevaldehyde.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047113] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47113] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BARFORD D, 1991, BIOCHIM BIOPHYS ACTA, V1133, P55, DOI 10.1016/0167-4889(91)90241-O; BEG ZH, 1980, J BIOL CHEM, V255, P8541; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; DARNAY BG, 1993, J BIOL CHEM, V268, P8429; DEAN AM, 1989, J BIOL CHEM, V264, P20482; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRIMPONG K, 1994, J BIOL CHEM, V269, P11478; FRIMPONG K, 1994, J BIOL CHEM, V269, P1217; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HUNTER CF, 1980, J LIPID RES, V21, P399; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; KEITH ML, 1983, J PROTEIN CHEM, V2, P209, DOI 10.1007/BF01025355; KEITH ML, 1979, BIOCHEM BIOPH RES CO, V90, P969, DOI 10.1016/0006-291X(79)91922-3; KENNELLY PJ, 1983, BIOCHEMISTRY-US, V22, P2784, DOI 10.1021/bi00281a002; KENNELLY PJ, 1985, J LIPID RES, V26, P903; LAWRENCE CM, 1994, IN PRESS SCIENCE; MACKINTOSH RW, 1992, EUR J BIOCHEM, V209, P923, DOI 10.1111/j.1432-1033.1992.tb17364.x; OMKUMAR RV, 1994, J BIOL CHEM, V269, P6810; PARKER RA, 1989, J BIOL CHEM, V264, P4877; Sambrook J, 1989, MOL CLONING LABORATO; SHERBAN DG, 1985, J BIOL CHEM, V260, P2579; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422	26	40	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16862	16866						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207009				2022-12-27	WOS:A1994NR29600054
J	SU, ZH; FAN, DJ; GEORGE, SE				SU, ZH; FAN, DJ; GEORGE, SE			ROLE OF DOMAIN-3 OF CALMODULIN IN ACTIVATION OF CALMODULIN-STIMULATED PHOSPHODIESTERASE AND SMOOTH-MUSCLE MYOSIN LIGHT-CHAIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL HELIX; TARGET ENZYMES; TROPONIN-C; PEPTIDE COMPLEX; CALCIUM-BINDING; PROTEINS; PHOSPHORYLATION; CRYSTAL; GENE; NMR	CaM[3 TnC] is a calmodulin-cardiac troponin C chimeric protein containing the first, second, and fourth calcium-binding domains of calmodulin (CaM) and the third calcium-binding domain of cardiac troponin C (cTnC) (George, S. E., Su, Z., Fan, D., and Means, A. R. (1993) J. Biol. Chem. 268, 25213-25220). CaM[3 TnC] shows altered activation of phosphodiesterase (PDE) and is a potent competitive inhibitor of smooth muscle myosin light chain kinase (smMLCK) activation by CaM. To determine why CaM[3 TnC] exhibits altered target enzyme interactions, we constructed a series of domain 3 CaM mutants. We began with subdomain substitutions, replacing most of CaM's helix 5, Ca2+ binding loop 3, and helix 6 with the corresponding subdomains of cTnC. Only CaM[helix 6-TnC] exhibited significant impairment of smMLCK and PDE activation. We then individually substituted the residues in the region of CaM's helix 6 with the corresponding cTnC residue. This revealed that CaM residues Thr-110, Leu-112, and Lys-115 were critical for full smMLCK activation and could not be substituted by the corresponding cTnC residue (Gln, Thr, and Thr, respectively), In contrast, only the L112T substitution significantly affected PDE activation. The CaM-smMLCK peptide structure (Meader, W. E., Means, A. R., and Quiocho, F.A. (1992) Science 257, 1251-1255) suggests a relationship between the proposed helix 6 smMLCK-activating residues and those previously described in helix 2 (VanBerkum, M. F.A., and Means, A. R. (1991) J. Biol. Chem. 266, 21488-21495).	DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOVASC,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Duke University; Duke University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017670, R29HL048662, K08HL002433] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02433, HL17670, HL48662] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; COX JA, 1985, J BIOL CHEM, V260, P2527; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; GEORGE SE, 1990, J BIOL CHEM, V265, P9228; GEORGE SE, 1993, J BIOL CHEM, V268, P25213; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; KRETSINGER RH, 1992, SCIENCE, V258, P50, DOI 10.1126/science.1439768; Lakowicz J.R., 1983, PRINC FLUORESC SPECT, P341, DOI [10.1007/978-1-4615-7658-7_11, DOI 10.1007/978-1-4615-7658-7_11]; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; PUTKEY JA, 1986, J BIOL CHEM, V261, P9896; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488; WALSH MP, 1980, J BIOL CHEM, V255, P335; ZHANG MJ, 1994, J BIOL CHEM, V269, P981	26	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16761	16765						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206999				2022-12-27	WOS:A1994NR29600040
J	BRUCE, LJ; ANSTEE, DJ; SPRING, FA; TANNER, MJA				BRUCE, LJ; ANSTEE, DJ; SPRING, FA; TANNER, MJA			BAND-3 MEMPHIS VARIANT-II - ALTERED STILBENE DISULFONATE BINDING AND THE DIEGO (DI(A)) BLOOD-GROUP ANTIGEN ARE ASSOCIATED WITH THE HUMAN ERYTHROCYTE-BAND 3 MUTATION PRO(854)-]LEU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-TRANSPORT PROTEIN; MEMBRANE; PHOSPHOENOLPYRUVATE; POLYMORPHISM; SEQUENCE; SITES; CELLS	Band 3 Memphis is a commonly occurring polymorphic form of the human red cell anion transporter (band 3, AE1). Band 3 Memphis migrates more slowly on an SDS-polyacrylamide gel than normal band 3 and results from a point mutation Lys(56) --> Glu. TWO types of band 3 Memphis, variants I and II, can be distinguished by their susceptibility to covalent labeling with H2DIDS (4,4'-diisothiocyanato-2,2'-dihydrostilbene disulfonate). Memphis variant II is more readily labeled than Memphis variant I or normal band 3. The Memphis variant II is also associated with the presence of the Diego (Di(a)) blood group antigen on the red cells. We have shown that Memphis variant II carries the polymorphism Pro(854) --> Leu as well as Lys(56) --> Glu. The blood group antigen (Di(a)) present at the surface of Memphis variant II type red cells suggests the mutation Pro(854) --> Leu causes a change in the structure of an extracellular loop of Memphis variant II band 3. We discuss possible ways in which the mutation Pro(854) --> Leu affects the reactivity of Lys(539) to covalent reaction with H2DIDS.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,ENGLAND; INT BLOOD GRP REFERENCE LAB,BRISTOL BS10 5ND,AVON,ENGLAND	University of Bristol			Anstee, David/AAE-9231-2020	Bruce, Lesley/0000-0001-5922-7072				BOODHOO A, 1984, J BIOL CHEM, V259, P785; BRUCE LJ, 1993, BIOCHEM J, V293, P317, DOI 10.1042/bj2930317; CABANTCHIK IZ, 1975, J BIOL CHEM, V250, P5130; CABANTCHIK ZI, 1972, J MEMBRANE BIOL, V10, P311, DOI 10.1007/BF01867863; HAMASAKI N, 1983, EUR J BIOCHEM, V132, P531, DOI 10.1111/j.1432-1033.1983.tb07394.x; HSU L, 1985, BIOCHEMISTRY-US, V24, P3086, DOI 10.1021/bi00334a003; IDEGUCHI H, 1992, BRIT J HAEMATOL, V82, P122, DOI 10.1111/j.1365-2141.1992.tb04603.x; JANAS T, 1989, AM J PHYSIOL, V257, pC601, DOI 10.1152/ajpcell.1989.257.4.C601; JAROLIM P, 1992, BLOOD, V80, P1592; JENKINS RE, 1975, BIOCHEM J, V147, P393, DOI 10.1042/bj1470393; KAWANO Y, 1988, J BIOL CHEM, V263, P8232; KUSNIERZALEJSKA G, 1992, VOX SANG, V62, P124; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOURANT AE, 1976, DISTRIBUTION HUMAN B, P20; MUELLER TJ, 1977, J BIOL CHEM, V252, P6573; OKUBO K, 1994, J BIOL CHEM, V269, P1918; OKUBO K, 1991, J BIOL CHEM, V266, P16420; PIMPLIKAR SW, 1986, J BIOL CHEM, V261, P9770; RACE RR, 1975, BLOOD GROUPS MAN, P372; RANNEY HM, 1990, BRIT J HAEMATOL, V76, P262; Sambrook J, 1989, MOL CLONING LABORATO; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; SPRING FA, 1992, BIOCHEM J, V288, P713, DOI 10.1042/bj2880713; TANNER MJA, 1988, CARBOHYD RES, V178, P203, DOI 10.1016/0008-6215(88)80112-5; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; WOOD PG, 1992, J MEMBRANE BIOL, V127, P139; YANNOUKAKOS D, 1991, BLOOD, V78, P1117	27	72	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16155	16158						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206915				2022-12-27	WOS:A1994NQ72900033
J	ODONOVAN, A; SCHERLY, D; CLARKSON, SG; WOOD, RD				ODONOVAN, A; SCHERLY, D; CLARKSON, SG; WOOD, RD			ISOLATION OF ACTIVE RECOMBINANT XPG PROTEIN, A HUMAN DNA-REPAIR ENDONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COMPLEMENTATION GROUP-G; PIGMENTOSUM GROUP-F; XERODERMA-PIGMENTOSUM; DAMAGED DNA; EXCISION-REPAIR; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; (A)BC EXCINUCLEASE; 5' INCISION; BINDING	Complementation group G of xeroderma pigmentosum (XP-G) is one of the most rare and phenotypically heterogeneous forms of this inherited disorder. XP-G patients vary from having a very mild defect in DNA repair to being severely affected, and a few cases are also associated with the neurological complications of Cockayne's syndrome. The XPG gene encodes an acidic protein with a predicted molecular mass of 133 kDa that confers normal UV resistance when expressed in XP-G cells. Here we report the isolation of full-length XPG as a soluble protein expressed from a recombinant baculovirus. The purified polypeptide corrects the DNA nucleotide excision repair defect of XP-G cell extracts in vitro, and it acts as a magnesium-dependent single-stranded DNA endonuclease. This is the first direct evidence for a human protein with properties that implicate it in the incision step of nucleotide excision repair.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; CTR MED UNIV GENEVA,DEPT GENET & MICROBIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva			Wood, Richard/M-6319-2018	Wood, Richard/0000-0002-9495-6892				ARLETT CF, 1980, CARCINOGENESIS, V1, P745, DOI 10.1093/carcin/1.9.745; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; CLEAVER JE, 1991, PHOTOCHEM PHOTOBIOL, V54, P393, DOI 10.1111/j.1751-1097.1991.tb02033.x; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HANAWALT PC, 1991, MUTAT RES, V247, P203, DOI 10.1016/0027-5107(91)90016-H; HANSSON J, 1989, J BIOL CHEM, V264, P21788; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; ICHIHASHI M, 1985, J INVEST DERMATOL, V85, P284, DOI 10.1111/1523-1747.ep12276776; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KEIJZER W, 1979, MUTAT RES, V62, P183, DOI 10.1016/0027-5107(79)90231-8; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LIN JJ, 1992, J BIOL CHEM, V267, P17688; MACINNES MA, 1993, MOL CELL BIOL, V13, P6393, DOI 10.1128/MCB.13.10.6393; MALITSCHEK B, 1991, BIOTECHNIQUES, V11, P177; NORRIS PG, 1987, BRIT J DERMATOL, V116, P861, DOI 10.1111/j.1365-2133.1987.tb04906.x; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P185; REARDON JT, 1993, J BIOL CHEM, V268, P21301; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; TAKAO M, 1993, NUCLEIC ACIDS RES, V21, P4111, DOI 10.1093/nar/21.17.4111; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; TREIBER DK, 1992, NUCLEIC ACIDS RES, V20, P5805, DOI 10.1093/nar/20.21.5805; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; VERMEULEN W, 1993, AM J HUM GENET, V53, P185; WEEDA G, 1993, SEMIN CANCER BIOL, V4, P105	31	77	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15965	15968						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206890				2022-12-27	WOS:A1994NQ72900003
J	PERRINO, FW; MILLER, H; EALEY, KA				PERRINO, FW; MILLER, H; EALEY, KA			IDENTIFICATION OF A 3'-]5'-EXONUCLEASE THAT REMOVES CYTOSINE-ARABINOSIDE MONOPHOSPHATE FROM 3' TERMINI OF DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-ALPHA; EXONUCLEASE; BETA; ARABINOSYLCYTOSINE; PURIFICATION; INHIBITORS; ELONGATION; MECHANISM	Cytosine arabinoside monophosphate (araCMP) at the 3' terminus of DNA constitutes a lesion that impedes further synthesis by DNA polymerase alpha (DNA pol alpha). A biochemical assay has been designed to detect 3'-->5'-exonucleases in cell extracts that remove the 3'-araCMP lesion in an oligonucleotide template primer and permit subsequent extension by DNA pol alpha. The major 3'-->5'-exonuclease activity in human myeloblast extracts has been purified, and gel filtration chromatography of the purified enzyme indicates that the exonuclease has an apparent native molecular mass of 52 kDa. Incubation of the enzyme with a 5'-P-32-labeled araCMP template-primer results in exonucleolytic degradation of the primer exclusively in the 3'-->5' direction, demonstrating that the enzyme is a 3'-->5'-exonuclease. The products of the 3'-->5'-exonuclease reaction are 5'-mononucleotides. The apparent rate of araCMP removal by the exonuclease is approximately the same as the rate of deoxynucleoside monophosphate (dNMP) removal. Furthermore, the apparent rates of 3'-terminal excision are approximately the same whether the oligomer is hybridized to a complementary oligonucleotide, or not, indicating that the enzyme has both single- and double-stranded 3'-->5' exonuclease activity. The enzyme does not possess 5'-->3'-exonuclease activity, nor is it associated with DNA polymerase activity. In addition, the enzyme does not cleave 3'-phosphoryl-terminated DNA, and it does not cleave RNA. The enzymatic characteristics of the isolated 3'-->5'-exonuclease indicate that it is distinct from previously identified mammalian deoxyribonucleases.	WAKE FOREST UNIV,MED CTR,CTR COMPREHENS CANC,WINSTON SALEM,NC 27157	Wake Forest University	PERRINO, FW (corresponding author), WAKE FOREST UNIV,MED CTR,DEPT BIOCHEM,WINSTON SALEM,NC 27157, USA.		Miller, Holly/I-6942-2015	Miller, Holly/0000-0002-9076-5335	NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NCI NIH HHS [CA-12197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEARDSLEY GP, 1988, NUCLEIC ACIDS RES, V16, P9165, DOI 10.1093/nar/16.19.9165; CAPIZZI RL, 1991, SEMIN HEMATOL, V28, P54; COZZARELLI NR, 1977, ANNU REV BIOCHEM, V46, P641, DOI 10.1146/annurev.bi.46.070177.003233; GAO YG, 1991, BIOCHEMISTRY-US, V30, P9922, DOI 10.1021/bi00105a016; HOLLIS GF, 1981, J BIOL CHEM, V256, P8074; KEATING MJ, 1982, JAMA-J AM MED ASSOC, V248, P2481, DOI 10.1001/jama.248.19.2481; Kornberg A., 1992, DNA REPLICATION; KUFE DW, 1980, J BIOL CHEM, V255, P8997; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE MYWT, 1980, BIOCHEMISTRY-US, V19, P215, DOI 10.1021/bi00542a032; LINDAHL T, 1969, J BIOL CHEM, V244, P5014; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; MIKITA T, 1988, BIOCHEMISTRY-US, V27, P4698, DOI 10.1021/bi00413a018; MOSBAUGH DW, 1980, J BIOL CHEM, V255, P239; OHNO Y, 1988, CANCER RES, V48, P1494; PERRINO FW, 1992, J BIOL CHEM, V267, P23043; REID R, 1988, J BIOL CHEM, V263, P3898; REIN DC, 1990, EUKARYOTIC NUCLEUS M, P95; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SKARNES W, 1986, J BIOL CHEM, V261, P6629; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WRIGHT GE, 1990, PHARMACOL THERAPEUT, V47, P447, DOI 10.1016/0163-7258(90)90066-B	24	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16357	16363						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206943				2022-12-27	WOS:A1994NQ72900062
J	OSAWA, Y; FELLOWS, CS; MEYER, CA; WOODS, A; CASTORO, JA; COTTER, RJ; WILKINS, CL; HIGHET, RJ				OSAWA, Y; FELLOWS, CS; MEYER, CA; WOODS, A; CASTORO, JA; COTTER, RJ; WILKINS, CL; HIGHET, RJ			STRUCTURE OF THE NOVEL HEME ADDUCT FORMED DURING THE REACTION OF HUMAN HEMOGLOBIN WITH BRCCL3 IN RED-CELL LYSATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; PROSTHETIC HEME; MYOGLOBIN; METABOLISM; BENZO<A>PYRENE; MECHANISM; BINDING; OXIDASE; MOUSE; RATS	It was previously shown that the reductive debromination of BrCCl3 to trichloromethyl radical by human hemoglobin leads to formation of dissociable altered heme products, two of which are identical to those formed from myoglobin and one which is novel. In this study, we have elucidated the structure of this novel adduct with the use of mass spectrometry, as well as H-1 and C-13 NMR as a substitution product of a -C(Cl)=CCl2 moiety for a beta-hydrogen atom on the prosthetic heme's ring I vinyl group. From studies with the use of C-13-enriched BrCCl3, it was determined that the added carbon atoms were derived from 2 eq of BrCCl3. A mechanism that involves multiple reductive events and a radical cation heme intermediate is proposed. Consistent with this mechanism, cellular reductants were found to selectively enhance the amount of this novel dissociable heme adduct. These studies reveal fine differences between myoglobin and hemoglobin in the accessibility of reactive intermediates to the ring I vinyl group, as well as the potential importance of cellular reductants on the course of heme alteration.	NHLBI,BIOPHYS CHEM LAB,BETHESDA,MD 20892; UNIV CALIF RIVERSIDE,DEPT CHEM,RIVERSIDE,CA 92521; JOHNS HOPKINS UNIV,SCH MED,MIDDLE ATLANTIC MASS SPECT LAB,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of California System; University of California Riverside; Johns Hopkins University	OSAWA, Y (corresponding author), NHLBI,CHEM PHARMACOL LAB,BETHESDA,MD 20892, USA.		Fellows, Christine/C-1433-2008; Wilkins, Charles L/H-8274-2014	Wilkins, Charles L/0000-0001-6471-6313	NIGMS NIH HHS [GM-44606] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044606] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anders MW, 1985, BIOACTIVATION FOREIG, P283; AXWORTHY DB, 1988, CHEM-BIOL INTERACT, V68, P99, DOI 10.1016/0009-2797(88)90009-9; BRYANT MS, 1987, CANCER RES, V47, P602; CASTRO JA, 1992, RAPID COMMUN MASS SP, V6, P239, DOI 10.1002/rcm.1290060403; FALK JE, 1964, PORPHYRINS METALLOPO, P72; FARMER PB, 1987, ARCH TOXICOL, V60, P251, DOI 10.1007/BF01234663; GORELICK NJ, 1989, CARCINOGENESIS, V10, P1579, DOI 10.1093/carcin/10.9.1579; HAUGEN DA, 1989, CHEM RES TOXICOL, V2, P379, DOI 10.1021/tx00012a005; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kalinowski H.-O., 1988, CARBON 13 NMR SPECTR, P131; KAUR S, 1989, J BIOL CHEM, V264, P16981; KINDT JT, 1992, J BIOL CHEM, V267, P8739; KOSTER C, 1992, J AM CHEM SOC, V114, P7572, DOI 10.1021/ja00045a045; KUBIC VL, 1981, CHEM-BIOL INTERACT, V34, P201, DOI 10.1016/0009-2797(81)90131-9; NAYLOR S, 1990, CHEM RES TOXICOL, V3, P111, DOI 10.1021/tx00014a005; OSAWA Y, 1990, J BIOL CHEM, V265, P10340; OSAWA Y, 1991, P NATL ACAD SCI USA, V88, P7081, DOI 10.1073/pnas.88.16.7081; OSAWA Y, 1991, J BIOL CHEM, V266, P3208; OSAWA Y, 1993, BIOCHEM PHARMACOL, V46, P2299, DOI 10.1016/0006-2952(93)90621-3; OSAWA Y, 1989, CHEM RES TOXICOL, V2, P131, DOI 10.1021/tx00009a001; OSAWA Y, 1993, J BIOL CHEM, V268, P2953; OSAWA Y, 1989, J AM CHEM SOC, V111, P4462, DOI 10.1021/ja00194a048; OSAWA Y, 1992, SYNTHESIS AND APPLICATIONS OF ISOTOPICALLY LABELLED COMPOUNDS 1991, P415; REYNOLDS WF, 1989, MAGN RESON CHEM, V27, P162, DOI 10.1002/mrc.1260270214; SABBIONI G, 1990, ARCH TOXICOL, V64, P451, DOI 10.1007/BF01977626; SABBIONI G, 1990, CARCINOGENESIS, V11, P111, DOI 10.1093/carcin/11.1.111; SHELTON JB, 1984, J LIQ CHROMATOGR, V7, P1969, DOI 10.1080/01483918408068849; SKIPPER PL, 1989, CHEM RES TOXICOL, V2, P280, DOI 10.1021/tx00011a002; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUN JD, 1989, TOXICOL APPL PHARM, V100, P86, DOI 10.1016/0041-008X(89)90093-8; WATERMAN MR, 1978, METHOD ENZYMOL, V52, P460; Winslow R.M, 1992, HEMOGLOBIN BASED RED; WINSLOW RM, 1989, RED CELL, P305; WINTERBOURN CC, 1990, SEMIN HEMATOL, V27, P41	34	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15481	15487						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195191				2022-12-27	WOS:A1994NP51300016
J	TSAIMORRIS, CH; GENG, Y; XIE, XZ; BUCZKO, E; DUFAU, ML				TSAIMORRIS, CH; GENG, Y; XIE, XZ; BUCZKO, E; DUFAU, ML			TRANSCRIPTIONAL PROTEIN-BINDING DOMAINS GOVERNING BASAL EXPRESSION OF THE RAT LUTEINIZING-HORMONE RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; NUCLEAR FACTOR-I; PROMOTER SEQUENCES; SITE; INDUCTION; ELEMENTS; RECOGNITION; INITIATION; ENHANCER; ACTIVATE	The functional importance of specific protein binding domains on transcription within the CC-rich 173-base pair promoter of the luteinizing hormone receptor gene was studied by mutagenesis and gel retardation analysis. Transcription was dependent on the presence of two Sp1 elements in the promoter domain of transfected expressing mouse Leydig tumor cells (mLTC) and nonexpressing Chinese hamster ovary cells. Mutation of two protein binding domains located downstream of the Sp1 elements (M1 and C-box) revealed tissue-specific regulation of promoter activity by each domain. Also, gel retardation studies indicated the presence of multiple trans factors that bind to the C-box and M1 domains. Removal of the AP-2 element from the C-box resulted in mLTC-specific transcriptional activation that may involve an M1/C-box interaction. In addition, competition by overlapping NF-1 and AP-2 elements was demonstrable in both the C-box and upstream R domain for separate trans factors that exhibit neutral or inhibitory functions, respectively. Competition between the inhibitory and neutral DNA binding factors within both upstream and promoter domains may be responsible for a mechanism that controls the on/off state of luteinizing hormone receptor gene expression in gonadal cells. These studies reveal a complex pattern of transcriptional regulation that may reflect targeted mechanisms for the control of luteinizing hormone receptor gene expression.	NICHHD,ENDOCRINOL & REPROD RES BRANCH,MOLEC ENDOCRINOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Tsai Morris, Chon Hwa/0000-0002-8113-0979				ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COURTOIS SJ, 1992, J BIOL CHEM, V267, P19736; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUSSERRE Y, 1992, MOL CELL BIOL, V12, P5228, DOI 10.1128/MCB.12.11.5228; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PARK K, 1993, J BIOL CHEM, V268, P17811; REBOIS RV, 1982, J CELL BIOL, V94, P70, DOI 10.1083/jcb.94.1.70; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSALES R, 1987, EMBO J, V6, P3015, DOI 10.1002/j.1460-2075.1987.tb02607.x; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; TSAIMORRIS CH, 1993, J BIOL CHEM, V268, P4447	25	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15868	15875						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195242				2022-12-27	WOS:A1994NP51300073
J	ZHANG, MJ; LI, M; WANG, JH; VOGEL, HJ				ZHANG, MJ; LI, M; WANG, JH; VOGEL, HJ			The effect of Met-->Leu mutations on calmodulin's ability to activate cyclic nucleotide phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-INDEPENDENT RECOGNITION; ALPHA-HELICAL STRUCTURE; YEAST CALMODULIN; BINDING DOMAIN; CALCIUM-BINDING; AMINO-ACIDS; BETA-SHEET; TROPONIN-C; VERTEBRATE; PROTEINS	Calmodulin (CaM) has two hydrophobic surface patches that are particularly rich in Met residues, and these are the major contact areas where CaM interacts with its target enzymes. The amino acid Leu has been introduced by site directed mutagenesis to replace all the Met residues in CaM. All nine individual Met --> Leu mutants of CaM as well as some double and quadruple mutants were expressed in Escherichia coli. Ah mutants could be purified by calcium-dependent hydrophobic affinity chromatography, indicating that they still expose their hydrophobic surfaces upon binding calcium. Each single Met --> Leu mutation in the C-terminal domain of the protein had little effect on its ability to activate phosphodiesterase (PDE), while a quadruple mutant with four C-terminal Leu residues instead of Met has a significantly lower affinity for PDE. The M36L mutant is a poor activator compared with the other three N-terminal single Met --> Leu mutants, which have a slightly lower affinity for PDE than wild-type CaM. The introduction of a positively charged Arg for Met-145 resulted in an almost complete loss of CaM's ability to activate PDE. Nuclear magnetic resonance spectroscopy was used to show that most CaM mutants retain their overall three-dimensional structure. Thus, the altered activation properties appear to arise from differences in the flexibility and polarizability of the Met and Leu sidechains, rather than from structural perturbations.	UNIV CALGARY, DEPT BIOL SCI, CALGARY T2N 1N4, AB, CANADA; UNIV CALGARY, DEPT MED BIOCHEM, CALGARY T2N 1N4, AB, CANADA	University of Calgary; University of Calgary				Zhang, Mingjie/0000-0001-9404-0190				BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7931, DOI 10.1021/bi00246a009; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DAVIS TN, 1989, P NATL ACAD SCI USA, V86, P7909, DOI 10.1073/pnas.86.20.7909; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; EFTINK MR, 1989, J AM CHEM SOC, V111, P6765, DOI 10.1021/ja00199a041; FERSHT A, 1985, ENZYME STRUCTURE MEC, P294; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; GEORGE SE, 1990, J BIOL CHEM, V265, P9228; HIRAOKI T, 1987, J CARDIOVASC PHARM, V10, pS14, DOI 10.1097/00005344-198710001-00004; IKURA M, 1983, BIOCHEMISTRY-US, V22, P2568, DOI 10.1021/bi00279a038; IKURA M, 1985, BIOCHEMISTRY-US, V24, P4264, DOI 10.1021/bi00337a002; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; LUAN Y, 1987, J BIOCHEM-TOKYO, V102, P1531, DOI 10.1093/oxfordjournals.jbchem.a122201; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; OHYA Y, 1987, EUR J BIOCHEM, V168, P13, DOI 10.1111/j.1432-1033.1987.tb13380.x; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; RAO ST, 1993, PROTEIN SCI, V2, P436; Sambrook J, 1989, MOL CLONING LABORATO; Sharma R K, 1979, Adv Cyclic Nucleotide Res, V10, P187; SHARMA RK, 1983, METHOD ENZYMOL, V102, P210; STAROVASNIK MA, 1993, BIOCHEMISTRY-US, V32, P3261, DOI 10.1021/bi00064a008; VOGEL HJ, 1983, FEBS LETT, V157, P241, DOI 10.1016/0014-5793(83)80554-7; WALTERSSON Y, 1993, BIOCHEMISTRY-US, V32, P7866, DOI 10.1021/bi00082a005; YE RR, 1992, EUR J BIOCHEM, V204, P713, DOI 10.1111/j.1432-1033.1992.tb16686.x; ZHANG M, 1994, IN PRESS J MOL BIOL; ZHANG MJ, 1994, J BIOL CHEM, V269, P5099; ZHANG MJ, 1993, J BIOL CHEM, V268, P22420; ZHANG MJ, 1994, BIOCHEMISTRY-US, V33, P1163, DOI 10.1021/bi00171a016; ZHANG MJ, 1994, J BIOL CHEM, V269, P981; ZHANG MJ, 1993, PROTEIN SCI, V2, P1931, DOI 10.1002/pro.5560021114	46	88	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15546	15552						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195199				2022-12-27	WOS:A1994NP51300026
J	COREY, JL; DAVIDSON, N; LESTER, HA; BRECHA, N; QUICK, MW				COREY, JL; DAVIDSON, N; LESTER, HA; BRECHA, N; QUICK, MW			PROTEIN-KINASE-C MODULATES THE ACTIVITY OF A CLONED GAMMA-AMINOBUTYRIC-ACID TRANSPORTER EXPRESSED IN XENOPUS-OOCYTES VIA REGULATED SUBCELLULAR REDISTRIBUTION OF THE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE CELL; FREE FATTY-ACIDS; GLUCOSE TRANSPORTER; PLASMA-MEMBRANE; PHORBOL ESTERS; INDUCED TRANSLOCATION; INSULIN ACTION; 3T3-L1 CELLS; AFFINITY; PHOSPHORYLATION	We report that activators and inhibitors of protein kinase C (PKC) and protein phosphatases regulate the activity of a cloned rat brain gamma-aminobutyric acid (GABA) transporter (GAT1) expressed in Xenopus oocytes. Four compounds known to activate PKC increased GABA uptake 2-3.5-fold over basal control levels. Inhibition of PKC by bisindolylmaleimide reduced basal GABA uptake 80% and blocked the phorbol 12-myristate 13-acetate (PMA)-induced stimulation of transport. Okadaic acid, a protein phosphatase inhibitor, stimulated transport 2.5-fold; a 4-fold increase in GABA uptake occurred when oocytes were treated with cyclosporin A, a specific inhibitor of protein phosphatase 2B. Modulation resulted in changes to V-max but not to K-m and was influenced by the functional expression level of the transporter protein; as expression level increased, the ability to up-regulate transporter activity decreased. Down-regulation of transporter activity was independent of expression level. Modulation did not occur through phosphorylation of the three consensus PKC sites predicted by the primary protein sequence since their removal had no effect on the susceptibility of the transporter to modulation by PMA or bisindolylmaleimide. Subcellular fractionation of oocyte membranes demonstrated that under basal level conditions, the majority of GAT1 was targeted to a cytoplasmic compartment corresponding to the trans-Golgi or low density vesicles. Stimulation of PKC with PMA resulted in a translocation of transporters from this compartment to the plasma membrane. At higher expression levels of GAT1 protein, a larger portion of GAT1 was found on the plasma membrane during basal level conditions and treatment with bisindolylmaleimide resulted in removal of these transporters from the plasma membrane. At expression levels demonstrated to be resistant to modulation by PMA, PMA-treatment still resulted in translocation of transporters from the cytoplasm to the plasma membrane. Thus, the inability of PMA to increase uptake at high expression of the GAT1 protein is due to saturation at a step subsequent to translocation. These findings 1) demonstrate the presence of a novel regulated secretory pathway in oocytes and 2) suggest a modulatory mechanism for neurotransmitter transporters that could have significant effects upon synaptic function.	UNIV CALIF LOS ANGELES, SCH MED, DEPT ANAT & CELL BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, INST BRAIN RES, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, CTR ULCER RES, LOS ANGELES, CA 90024 USA; W LOS ANGELES VET AFFAIRS MED CTR, LOS ANGELES, CA 90073 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	COREY, JL (corresponding author), CALTECH, DIV BIOL, 156-29, PASADENA, CA 91125 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011756] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-11756] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; Alder J, 1993, Curr Opin Neurobiol, V3, P322, DOI 10.1016/0959-4388(93)90124-H; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ASANO T, 1992, J BIOL CHEM, V267, P19636; BLOK J, 1988, J CELL BIOL, V106, P69, DOI 10.1083/jcb.106.1.69; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CASADO M, 1991, J NEUROCHEM, V57, P1185, DOI 10.1111/j.1471-4159.1991.tb08278.x; COREY JL, 1992, MOL ENDOCRINOL, V6, P450, DOI 10.1210/me.6.3.450; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOMEZA J, 1991, BIOCHEM J, V275, P435, DOI 10.1042/bj2750435; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; HENSLEY CB, 1989, AM J PHYSIOL, V257, pC637, DOI 10.1152/ajpcell.1989.257.4.C637; KACZMAREK LK, 1988, ADV SEC MESS PHOSPH, V22, P113; KAIN KC, 1991, BIOTECHNIQUES, V10, P366; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KELLY RB, 1993, NEURON S, V10, P43; KLAUSNER RD, 1980, J BIOL CHEM, V255, P1286; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MUDD LM, 1990, BRAIN RES, V521, P192, DOI 10.1016/0006-8993(90)91542-O; NISHINO H, 1986, BIOCHIM BIOPHYS ACTA, V889, P236, DOI 10.1016/0167-4889(86)90109-6; QUICK MW, 1992, BIOTECHNIQUES, V13, P357; QUICK MW, 1994, METH NEUROSCI, V19, P261; SARANTIS M, 1993, NEURON, V11, P541, DOI 10.1016/0896-6273(93)90158-N; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SCHAEFFER BE, 1979, BIOCHIM BIOPHYS ACTA, V556, P131, DOI 10.1016/0005-2736(79)90425-5; SCHEUNER D, 1992, J CELL BIOL, V116, P359, DOI 10.1083/jcb.116.2.359; SHIBASAKI Y, 1992, BIOCHEM J, V281, P829, DOI 10.1042/bj2810829; SOLIS JM, 1992, J NEUROSCI, V12, P3466; SUGIMURA T, 1982, GANN, V73, P499; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; SWANN AC, 1984, ARCH BIOCHEM BIOPHYS, V233, P354, DOI 10.1016/0003-9861(84)90456-9; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WARDZALA LJ, 1978, J BIOL CHEM, V253, P8002; YANG J, 1992, BIOCHEM J, V281, P809, DOI 10.1042/bj2810809; [No title captured]	40	190	193	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14759	14767						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182081				2022-12-27	WOS:A1994NM06500071
J	LIU, AYC; BIAN, HJ; HUANG, LE; LEE, YK				LIU, AYC; BIAN, HJ; HUANG, LE; LEE, YK			TRANSIENT COLD SHOCK INDUCES THE HEAT-SHOCK RESPONSE UPON RECOVERY AT 37-DEGREES-C IN HUMAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; TRANSCRIPTIONAL ACTIVATION; CONFORMATIONAL DRIFT; PROMOTER ACTIVITY; BINDING-ACTIVITY; PROTEIN; STRESS; INDUCTION; GENES; EXPRESSION	We evaluated the effects of a transient cold shock followed by recovery and incubation at 37 degrees C on the regulation of heat shock gene expression in the IMR-90 human diploid fibroblasts and HeLa cells in tissue culture. We showed that preincubation of cells at 4 degrees C induced 6he synthesis and accumulation of the heat shock proteins (HSPs) upon recovery at 37 degrees C, and the degree of this induction was directly related to the time that the cells spent at 4 degrees C. Assays on the abundance of the hsp 70 transcript, the hsp 70 gene promoter activity, and the trimerization and activation of heat shock factor (HSF) to bind to its consensus heat shock element (HSE) provided evidence that this induction of the heat shock response in cells recovering from a transient cold shock is attributable to a transcriptional event mediated by the activation of HSF. Further, the induction was a response to the temperature upshift from 4 to 37 degrees C as opposed to the 4 degrees C treatment itself; quantitation of the HSE-binding activity of cells incubated at 4 degrees C without recovery and incubation at 37 degrees C gave no evidence of an activated response. Analysis of the effects of protein synthesis inhibitors demonstrated that neither cycloheximide nor puromycin was effective in blocking 6he induction of HSE-binding activity in cells recovering from a transient cold shock. Experiments on the time course and temperature dependence of this induction of HSE-binding activity showed that the onset, magnitude, and duration of this induction were directly proportional to the severity of the cold stress (measured by time and temperature). We discuss the possible mechanism(s) involved in this induction of the heat shock genes at 37 degrees C by a transient cold shock and the biological implications of this observation.			LIU, AYC (corresponding author), RUTGERS STATE UNIV,DEPT BIOL SCI,PISCATAWAY,NJ 08855, USA.			Liu, Alice Y./0000-0002-6984-1671; Huang, Eric/0000-0002-6444-1708				ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BECKMANN RP, 1992, J CELL BIOL, V117, P1137, DOI 10.1083/jcb.117.6.1137; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOCK PE, 1978, TRENDS BIOCHEM SCI, V3, P100, DOI 10.1016/S0968-0004(78)80013-9; BURTON V, 1988, MOL CELL BIOL, V8, P3550, DOI 10.1128/MCB.8.8.3550; CHANG NT, 1993, J BIOL CHEM, V268, P1436; CHOI HS, 1991, J BIOL CHEM, V266, P11858; CHOI HS, 1990, J BIOL CHEM, V265, P18005; CLOS J, 1993, NATURE, V364, P252, DOI 10.1038/364252a0; EDINGTON BV, 1989, J CELL PHYSIOL, V139, P219, DOI 10.1002/jcp.1041390202; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; KAUL SC, 1992, CELL MOL BIOL, V38, P133; KING L, 1986, BIOCHEMISTRY-US, V25, P3632, DOI 10.1021/bi00360a023; KONDO K, 1992, J BIOL CHEM, V267, P16259; KONDO K, 1991, J BIOL CHEM, V266, P17537; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LIU AYC, 1989, BIOCHEM BIOPH RES CO, V162, P1302, DOI 10.1016/0006-291X(89)90815-2; LIU AYC, 1989, J BIOL CHEM, V264, P12037; LIU AYC, 1991, J CELL PHYSIOL, V149, P560, DOI 10.1002/jcp.1041490327; LOVEN DP, 1988, MED HYPOTHESES, V26, P39, DOI 10.1016/0306-9877(88)90111-9; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; NAGLE WA, 1990, CRYOBIOLOGY, V27, P439, DOI 10.1016/0011-2240(90)90021-U; NOVER L, 1987, ENZYME MICROB TECH, V9, P130, DOI 10.1016/0141-0229(87)90066-4; NOVER L, 1990, HEAT SHOCK RESPONSE; NOVER L, 1984, HEAT SHOCK RESPONSE; OSTLUND RE, 1980, J CELL BIOL, V85, P386, DOI 10.1083/jcb.85.2.386; OURY TD, 1993, J BIOL CHEM, V268, P15394; PAIN RH, 1987, TEMPERATURE ANIMAL C, P21; PEPPEL K, 1990, BIOTECHNIQUES, V9, P711; PEROTTI M, 1990, FEBS LETT, V259, P331, DOI 10.1016/0014-5793(90)80040-P; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; Watson P, 1987, TEMPERATURE ANIMAL C, P311; WEBER G, 1986, BIOCHEMISTRY-US, V25, P3626, DOI 10.1021/bi00360a022; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752	49	88	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14768	14775						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182082				2022-12-27	WOS:A1994NM06500072
J	ESCRIOU, V; LAPORTE, F; GARIN, J; BRANDOLIN, G; VIGNAIS, PV				ESCRIOU, V; LAPORTE, F; GARIN, J; BRANDOLIN, G; VIGNAIS, PV			PURIFICATION AND PHYSICAL-PROPERTIES OF A NOVEL TYPE OF CYTOCHROME-B FROM RABBIT PERITONEAL NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; LEUKOTRIENE-B4 OMEGA-HYDROXYLASE; CHRONIC GRANULOMATOUS-DISEASE; GENERATING NADPH OXIDASE; RESPIRATORY BURST; MICROBICIDAL OXIDASE; PHAGOCYTIC-CELLS; REDUCTASE; PROTEIN; SYSTEM	The main redox component of the O-2(-) generating oxidase complex in neutrophils is believed to be a b-type cytochrome, named cytochrome b(558). In the course of purification of cytochrome b(558) from rabbit peritoneal neutrophils, another hemoprotein with an apparent molecular mass of 30 kDa, referred to as p-30, was isolated. Although the spectrum of p-30 was virtually identical to that of cytochrome b(558), its redox potential, E(m7) = -4 +/- 10 mV, was much less negative than that of cytochrome b(558) (-270 +/- 5 mV). The alkaline pyridine hemochrome from purified p-30 was typical of a b-type cytochrome. The 20 N-terminal amino acid residues and some tryptic peptides isolated from p-30 did not show any significant sequence homology to the human phagocyte cytochrome b(558) or to mitochondrial and microsomal cytochromes, except for the N-terminal region which displayed some homology to that of rat liver P-450. After subcellular fractionation, p-30 was found to be located in the plasma membrane and the granule fractions, similarly to cytochrome b(558). Upon neutrophil activation, part of p-30 was transferred from granules to the plasma membrane.	CEN, DEPT BIOL MOLEC & STRUCT, CHIM PROT LAB, F-38041 GRENOBLE, FRANCE		ESCRIOU, V (corresponding author), CEN, BIOCHIM LAB, CNRS, URA 1130, 85X, F-38041 GRENOBLE, FRANCE.			Escriou, Virginie/0000-0001-5686-9301				BABIOR BM, 1981, METHODS HEMATOLOGY, V3, P1; BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; BADWEY JA, 1983, BLOOD, V62, P152; BERTON G, 1985, BIOCHIM BIOPHYS ACTA, V810, P164, DOI 10.1016/0005-2728(85)90132-X; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BRANDOLIN G, 1974, FEBS LETT, V46, P149, DOI 10.1016/0014-5793(74)80356-X; DOUSSIERE J, 1993, BIOCHEMISTRY-US, V32, P8880, DOI 10.1021/bi00085a020; DUONG LT, 1982, J BIOL CHEM, V257, P8561; Fuhrhop J. H., 1975, PORPHYRINS METALLOPO, P804; HANSFORD RG, 1976, BILL HDB 1, P144; HARLOW E, 1988, ANTIBODIES LABORATOR; HOGEBOOM GH, 1955, METHOD ENZYMOL, V1, P16, DOI 10.1016/0076-6879(55)01007-0; ISOGAI Y, 1991, J BIOL CHEM, V266, P13481; KLEINBERG ME, 1989, J IMMUNOL, V143, P4152; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPORTE F, 1991, EUR J BIOCHEM, V196, P59, DOI 10.1111/j.1432-1033.1991.tb15785.x; LAUQIN JGM, 1976, FEBS LETT, V87, P306; LAUQUIN G, 1973, BIOCHIM BIOPHYS ACTA, V305, P534, DOI 10.1016/0005-2728(73)90074-1; LIGHT DR, 1981, BIOCHEMISTRY-US, V20, P1468, DOI 10.1021/bi00509a010; MEIER B, 1993, BIOCHEM J, V289, P481, DOI 10.1042/bj2890481; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; MOREL F, 1993, BIOCHIM BIOPHYS ACTA, V1182, P101, DOI 10.1016/0925-4439(93)90159-X; MOREL F, 1985, EUR J BIOCHEM, V152, P669, DOI 10.1111/j.1432-1033.1985.tb09247.x; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MOREL F, 1987, ADV BIOSCI, V66, P301; MUIRWOOD P, 1974, FEBS LETT, V44, P22, DOI 10.1016/0014-5793(74)80297-8; NICHOLLS DG, 1992, BIOENERGETICS, V2, P131; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PERIN MS, 1988, EMBO J, V7, P2697, DOI 10.1002/j.1460-2075.1988.tb03123.x; QUINN MT, 1992, J BIOL CHEM, V267, P7303; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SHAK S, 1985, J CLIN INVEST, V76, P1218, DOI 10.1172/JCI112077; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUMIMOTO H, 1988, EUR J BIOCHEM, V172, P315, DOI 10.1111/j.1432-1033.1988.tb13889.x; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	45	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14007	14014						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188680				2022-12-27	WOS:A1994NL60600045
J	SEIFERT, RA; COATS, SA; RAINES, EW; ROSS, R; BOWENPOPE, DF				SEIFERT, RA; COATS, SA; RAINES, EW; ROSS, R; BOWENPOPE, DF			PLATELET-DERIVED GROWTH-FACTOR (PDGF) RECEPTOR ALPHA-SUBUNIT MUTANT AND RECONSTITUTED CELL-LINES DEMONSTRATE THAT TRANSFORMING GROWTH-FACTOR-BETA CAN BE MITOGENIC THROUGH PDGF A-CHAIN-DEPENDENT AND A-CHAIN-INDEPENDENT PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; BIFUNCTIONAL REGULATOR; DNA-SYNTHESIS; FIBROBLASTS; EXPRESSION; CULTURES; ESTABLISHES; SECRETION; GENE	Mitogenic stimulation of connective tissue cells by transforming growth factor-beta (TGF-beta) has two unusual properties; entry into S-phase is delayed compared with that induced by other mitogens, and the dose response is biphasic, with low concentrations stimulating and high concentrations inhibiting or having no effect. A hypothesis that provides an explanation for both of these properties is that TGF-beta stimulates proliferation indirectly by inducing synthesis of platelet-derived growth factor (PDGF) A-chain, which in turn stimulates proliferation via autocrine activation of the PDGF receptor alpha-subunit (PHGFR alpha). High concentrations of TGF-beta reduce PDGFR alpha expression and break the autocrine loop. We tested this hypothesis by determining whether TGF-beta and interleukin-1 alpha can induce DNA synthesis in connective tissue (3T3) cells derived from the Patch mouse line in which the PDGFR alpha gene is deleted. We found that these cells do respond mitogenically to TGF-beta and interleukin-1 alpha, indicating that PDGF A-chain induction is not the sole mechanism of mitogenic stimulation. Reestablishing PDGFR alpha expression via transfection with a human PDGFR alpha construct enhanced the response to TGF-beta. Neutralizing anti-PDGF antiserum reduced TGF-beta stimulation of PDGFR alpha-expressing 3T3 cells by about 35%. We conclude that induction of PDGF A-chain/ PDGFR alpha autocrine stimulation does contribute to the ability of TGF-beta to stimulate connective tissue cells, but that there is, in addition, a PDGF-independent pathway.			SEIFERT, RA (corresponding author), UNIV WASHINGTON,DEPT PATHOL SJ60,SEATTLE,WA 98195, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18645] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BAZENET CE, 1994, ONCOGENE, V9, P517; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; CENTRELLA M, 1987, J BIOL CHEM, V262, P2869; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; GOLDSMITH KT, 1991, AM J PHYSIOL, V261, pL378, DOI 10.1152/ajplung.1991.261.6.L378; HARVEY AK, 1991, EXP CELL RES, V195, P376, DOI 10.1016/0014-4827(91)90387-A; HILL DJ, 1986, J CELL PHYSIOL, V128, P322, DOI 10.1002/jcp.1041280226; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; MAJACK RA, 1987, J CELL BIOL, V105, P465, DOI 10.1083/jcb.105.1.465; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MOSES HL, 1985, CANCER CELL, V3, P65; PAULSSON Y, 1993, J CELL PHYSIOL, V157, P97, DOI 10.1002/jcp.1041570113; Paulsson Y, 1988, GROWTH FACTORS, V1, P19, DOI 10.3109/08977198809000243; PERTOVAARA L, 1993, GROWTH FACTORS, V9, P81, DOI 10.3109/08977199308991584; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; REDINI F, 1993, ARTHRITIS RHEUM, V36, P44; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; SEIFERT RA, 1993, J BIOL CHEM, V268, P4473; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; SOMA Y, 1989, J CELL PHYSIOL, V140, P246, DOI 10.1002/jcp.1041400209; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; STORY MT, 1993, PROSTATE, V22, P183, DOI 10.1002/pros.2990220302; YOSHIDA K, 1992, BRAIN RES, V569, P14, DOI 10.1016/0006-8993(92)90364-F	28	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13951	13955						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188675				2022-12-27	WOS:A1994NL60600038
J	CHUCK, SL; LINGAPPA, VR				CHUCK, SL; LINGAPPA, VR			ANALYSIS OF A PAUSE TRANSFER SEQUENCE FROM APOLIPOPROTEIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; ENDOPLASMIC-RETICULUM; STRUCTURAL DOMAINS; PROTEIN; TRANSLOCATION; MEMBRANE; TRANSLATION; SECRETION; BINDING; CHAINS	In contrast to typical secretory proteins, apolipoprotein B pauses at distinct points along the nascent chain during its translocation into the lumen of the endoplasmic reticulum. Specific pause transfer sequences mediate such discrete pauses in the translocation of apolipoprotein B. These sequences have been shown to confer this translocational behavior to heterologous chimeric proteins. To investigate the function of pause transfer sequences, we: (i) examine whether the multiple pause transfer sequences of apolipoprotein B act independently or are dependent upon the action of upstream pause transfer sequences, (ii) identify residues of the prototypical B' pause transfer sequence that are involved in pausing, and (iii) determine whether the stopping step of a translocational pause is a consequence of translational pausing, as has been suggested by other investigators. We conclude that pause transfer sequences act independently of each other and of translation; translocational pausing occurs even in the absence of ongoing protein synthesis. Furthermore, like other topogenic sequences such as signal sequences, pause transfer sequences are degenerate in structure yet have distinctive features necessary for their action. This characterization of the B' pause transfer sequence may aid in the identification of such sequences elsewhere in apolipoprotein B and in other proteins and has implications for the mechanism of translocational pausing.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Lingappa, Vishwanath R./0000-0003-0962-6571	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045480] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45480] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS DW, 1988, J BIOL CHEM, V263, P15791; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHEN GC, 1989, J BIOL CHEM, V264, P14369; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1992, J CELL BIOL, V117, P1161, DOI 10.1083/jcb.117.6.1161; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PATERSON RG, 1987, CELL, V48, P441, DOI 10.1016/0092-8674(87)90195-4; PEASE R, 1992, NATURE, V356, P115, DOI 10.1038/356115c0; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; PESTKA S, 1971, ANNU REV MICROBIOL, V25, P487, DOI 10.1146/annurev.mi.25.100171.002415; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SIUTAMANGANO P, 1981, J BIOL CHEM, V256, P2094; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; VEGA GL, 1986, J CLIN INVEST, V78, P1410, DOI 10.1172/JCI112729; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1983, METHOD ENZYMOL, V96, P84; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	31	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22794	22801						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226789				2022-12-27	WOS:A1993MD34800089
J	CONSTANTINE, KL; MAPELLI, C; MEYERS, CA; FRIEDRICHS, MS; KRYSTEK, S; MUELLER, L				CONSTANTINE, KL; MAPELLI, C; MEYERS, CA; FRIEDRICHS, MS; KRYSTEK, S; MUELLER, L			MICELLE-BOUND CONFORMATIONAL PREFERENCES OF A PEPTIDE DERIVED FROM A MURINE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; COHERENCE-TRANSFER; COMPLETE SEQUENCE; CROSS-RELAXATION; NMR-SPECTROSCOPY; PROTEINS; MACROMOLECULES; ELUCIDATION; INITIATION; DYNAMICS	Models of the micelle-bound conformation of a 17-residue major histocompatibility complex-derived peptide, [Ala85]D(k)(69-85), have been determined by NMR spectroscopy and simulated annealing calculations. This peptide is a truncated, substituted version of D(k)(61-85), which is a fragment of the murine major histocompatibility complex class I molecule H-2D(k). D(k)(61-85) has been shown to adopt an ordered conformation required for augmentation of insulin-stimulated glucose uptake (Stagsted, J., Baase, W. A., Goldstein, A., and Olsson, L. (1991) J. Biol. Chem. 266, 12844-12847). [Ala85]D(k)(69-85) retains full biological activity. Thirty-eight converged NMR structures of [Ala85]D(k)(69-85) bound to dodecyl phosphocholine micelles have been generated. The NMR-derived models display a propensity for a type-I beta-bend involving residues 73-76 and an amphipathic helical region involving residues 77-84. CD spectra yield a helical content (8% at 20-25-degrees-C) consistent with transient, partial helix formation. The relative orientation of the beta-bend region with respect to the helical region is not well defined by the NMR data. This may reflect true heterogeneity of the micelle-bound conformation. The NMR structures were compared with a model of [Ala85]D(k)(69-85) derived from the x-ray coordinates of the human major histocompatibility complex class I allele HLA-Aw68 (Garrett, T. P. J., Saper, M. A., Bjorkmann, P. J., Strominger, T. L., and Wiley, D. C. (1989) Nature 342, 692-696). Structural features that are important for the bioactivity of [Ala85]D(k)(69-85) are discussed with reference to reported structure-activity relationships (Stagsted, J., Mapelli, C., Meyers, C., Matthews, B. W., Anfinsen, C. B., Goldstein, A., and Olsson, L. (1993) Proc. Natl. Acad. Sci. U. S. A., in press). A general description of the structural properties of the putative receptor site(s) that are likely to be required for binding [Ala85]D(k)(6985) is given.	BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT CARDIOVASC DIS & PEPTIDE CHEM,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MACROMOLEC MODELING,PRINCETON,NJ 08543	Bristol-Myers Squibb; Bristol-Myers Squibb	CONSTANTINE, KL (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MACROMOLEC NUCL MAGNET RESONANCE,POB 4000,PRINCETON,NJ 08543, USA.							BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; BORGIAS BA, 1990, PROG NUCL MAG RES SP, V22, P83, DOI 10.1016/0079-6565(90)80015-A; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BRUNGER AT, 1992, X PLOR VERSION 3 ZER, P311; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CONSTANTINE KL, 1992, J MOL BIOL, V223, P281, DOI 10.1016/0022-2836(92)90731-X; CONSTANTINE KL, 1990, BIOPOLYMERS, V30, P239, DOI 10.1002/bip.360300303; DUFOURC EJ, 1992, BIOPHYS J, V61, P42, DOI 10.1016/S0006-3495(92)81814-3; DYSON HJ, 1992, J MOL BIOL, V226, P819, DOI 10.1016/0022-2836(92)90634-V; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HANSEN T, 1989, P NATL ACAD SCI USA, V86, P3123, DOI 10.1073/pnas.86.9.3123; KESSLER H, 1988, J AM CHEM SOC, V110, P3393, DOI 10.1021/ja00219a008; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; NEUHAUS D, 1989, NUCLEAR OVERHAUSER E; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; ROBSON B, 1986, INTRO PROTEINS PROTE, P86; SHRIVER J, 1993, BIOCHEMISTRY-US, V32, P1610, DOI 10.1021/bi00057a027; STAGSTED J, 1990, CELL, V62, P297, DOI 10.1016/0092-8674(90)90367-N; STAGSTED J, 1991, J BIOL CHEM, V266, P12844; STAGSTED J, 1993, IN PRESS P NATL ACAD; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC	31	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22830	22837						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226794				2022-12-27	WOS:A1993MD34800095
J	FLINT, DH; TUMINELLO, JF; EMPTAGE, MH				FLINT, DH; TUMINELLO, JF; EMPTAGE, MH			THE INACTIVATION OF FE-S CLUSTER CONTAINING HYDRO-LYASES BY SUPEROXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; AMINO-ACID BIOSYNTHESIS; ESCHERICHIA-COLI; ACTIVATED ACONITASE; HYPERBARIC-OXYGEN; 4FE-4S CLUSTER; DEHYDRATASE; ENZYME; PURIFICATION; IRON	We report in this paper that highly purified Escherichia coli dihydroxy-acid dehydratase, fumarase A, fumarase B, and mammalian aconitase are inactivated by O2- with second order rate constants in the range of 10(6) to 10(7) M-1 s-1. Each of these enzymes belongs to the hydrolyase class and contains catalytically active [4Fe-4S] clusters. Simultaneous with inactivation by O2- is the release of iron from their clusters. Our working hypothesis is O2- inactivates these enzymes by oxidizing their clusterS to an unstable oxidation state, and cluster degradation follows. Consistent with this hypothesis is our observation that spinach dihydroxy-acid dehydratase, a member of the hydro-lyase class that has a catalytically active [2Fe-2S] cluster, is not inactivated and does not lose iron in the presence of O2-. Porcine fumarase, a member of the hydro-lyase class that does not contain an Fe-S cluster, is also not inactivated by O2-. We also report the rate constants for the inactivation of E. coli dihydroxy-acid dehydratase, fumarase A, fumarase B, and mammalian aconitase by O2 are close to 2 x 10(2) M-1 s-1, and the rate constants for the inactivation of E. coli dihydroxy-acid dehydratase and mammalian aconitase by H2O2 are about 10(3) M-1 s-1. E. coli dihydroxy-acid dehydratase has been reported previously to be inactivated in vivo when cells are grown in hyperbaric O2, presumably due to the increased O2- generated under these conditions. We report here that E. coli fumarase A, fumarase B, and aconitase are also inactivated in vivo by hyperbaric O2. Thermodynamic parameters for the oxidation of the cluster of aconitase by O2- and O2 are calculated.			FLINT, DH (corresponding author), DUPONT CO INC, CENT RES & DEV, EXPTL STN, WILMINGTON, DE 19880 USA.							BOEHME DE, 1976, NATURE, V262, P418, DOI 10.1038/262418a0; Bray RC., 1975, ENZYMES, V12, P299, DOI DOI 10.1016/S1874-6047(08)60229-2; BROWN OR, 1978, BIOCHEM BIOPH RES CO, V85, P1219, DOI 10.1016/0006-291X(78)90672-1; DREYER JL, 1985, EUR J BIOCHEM, V150, P145, DOI 10.1111/j.1432-1033.1985.tb09000.x; EMPTAGE M H, 1990, P315; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; Fee J.A., 1977, SUPEROXIDE SUPEROXID, P19; FEE JA, 1980, BIOCHEM INT, V1, P304; FEE JA, 1981, METAL ACTIVATION DIO, P209; FLINT D H, 1990, P285; FLINT DH, 1992, BIOCHEMISTRY-US, V31, P10331, DOI 10.1021/bi00157a022; FLINT DH, 1993, J BIOL CHEM, V268, P14732; FLINT DH, 1988, J BIOL CHEM, V263, P3558; FRIDOVICH I, 1972, ACCOUNTS CHEM RES, V5, P321, DOI 10.1021/ar50058a001; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; FRIDOVICH I, 1975, AM SCI, V63, P54; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GOTTLIEB SF, 1971, ANNU REV MICROBIOL, V25, P111, DOI 10.1146/annurev.mi.25.100171.000551; GRABOWSKI R, 1991, EUR J BIOCHEM, V199, P89, DOI 10.1111/j.1432-1033.1991.tb16095.x; HASSAN HM, 1979, J BIOL CHEM, V254, P846; HASSAN HM, 1978, J BIOL CHEM, V253, P8143; HAUGAARD N, 1968, PHYSIOL REV, V48, P311, DOI 10.1152/physrev.1968.48.2.311; KELLY JM, 1986, FEBS LETT, V202, P274, DOI 10.1016/0014-5793(86)80700-1; KENNEDY MC, 1987, P NATL ACAD SCI USA, V84, P8854, DOI 10.1073/pnas.84.24.8854; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Kiritani K., 1970, METHOD ENZYMOL, V17, P755; KLUG D, 1972, J BIOL CHEM, V247, P4839; KOPPENOL WH, 1976, BIOCHIM BIOPHYS ACTA, V449, P157, DOI 10.1016/0005-2728(76)90130-4; KUCHTA RD, 1985, J BIOL CHEM, V260, P3181; KUO CF, 1987, J BIOL CHEM, V262, P4724; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LIOCHEV SI, 1993, ARCH BIOCHEM BIOPHYS, V301, P379, DOI 10.1006/abbi.1993.1159; MAX B, 1992, TRENDS PHARMACOL SCI, V13, P272, DOI 10.1016/0165-6147(92)90084-J; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCCORD JM, 1971, P NATL ACAD SCI USA, V68, P1024, DOI 10.1073/pnas.68.5.1024; NIELSEN BE, 1969, ACTA CHEM SCAND, V23, P967, DOI 10.3891/acta.chem.scand.23-0967; POU S, 1992, J BIOL CHEM, V267, P24173; PRODROMOU C, 1991, J GEN MICROBIOL, V137, P2505, DOI 10.1099/00221287-137-11-2505; PRODROMOU C, 1992, EUR J BIOCHEM, V204, P599, DOI 10.1111/j.1432-1033.1992.tb16673.x; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROTILIO G, 1972, BIOCHEMISTRY-US, V11, P2182, DOI 10.1021/bi00761a027; SAWYER DT, 1981, ACCOUNTS CHEM RES, V14, P393, DOI 10.1021/ar00072a005; SCHWEIGER G, 1987, EUR J BIOCHEM, V169, P441, DOI 10.1111/j.1432-1033.1987.tb13631.x; SCOPES RK, 1984, ANAL BIOCHEM, V136, P530, DOI 10.1016/0003-2697(84)90257-4; SMYKRANDALL E, 1993, FREE RADICAL BIO MED, V14, P609, DOI 10.1016/0891-5849(93)90142-H; TELSER J, 1986, J BIOL CHEM, V261, P4840; WIMPENNY J W T, 1969, Symposium of the Society for General Microbiology, V19, P161; WOODS SA, 1988, BIOCHIM BIOPHYS ACTA, V954, P14, DOI 10.1016/0167-4838(88)90050-7	49	527	538	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22369	22376						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226748				2022-12-27	WOS:A1993MD34800030
J	GOTTESMAN, S; CLARK, WP; DECRECYLAGARD, V; MAURIZI, MR				GOTTESMAN, S; CLARK, WP; DECRECYLAGARD, V; MAURIZI, MR			CLPX, AN ALTERNATIVE SUBUNIT FOR THE ATP-DEPENDENT CLP PROTEASE OF ESCHERICHIA-COLI - SEQUENCE AND IN-VIVO ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA-O-PROTEIN; N-END RULE; REGULATORY SUBUNIT; ACTIVATED ATPASE; COLIPHAGE-LAMBDA; PHAGE-LAMBDA; CII PROTEIN; ION GENE; COMPONENT; PROTEOLYSIS	The ATP-dependent Clp protease of Escherichia coli consists of two subunits, the ClpP subunit, which has the proteolytic active site, and ClpA, which possesses ATPase activity and activates the proteolytic activity of ClpP in vitro. Recently, Zylicz and co-workers (Wojtkowiak, D., Georgopoulos, C., and Zylicz, M. (1993) J. Biol. Chem. 268, 22609-22617) identified another E. coli protein that activated ATP-dependent degradation of lambdaO protein in the presence of ClpP. The amino-terminal sequence of this protein corresponds to the translated amino-terminal sequence of a gene that we have named clpX. clpX encodes a protein with M(r) 46,300, similar to that observed for the protein purified by Wojtkowiak et al. clpX is in an operon with clpP; both genes are cotranscribed in a single heat-inducible 2200-base mRNA, with clpP the promoter proximal gene. The sequence of ClpX includes a single consensus ATP-binding site motif and has limited homology to regions of ClpA and other members of the ClpA/B/C family. A third group of proteins, ClpY, closely related to ClpX, has been identified by sequence homology. Mutations in either clpX or clpP abolish degradation of the highly unstable lambdaO protein in vivo. clpX mutants are not defective in degradation of previously identified ClpA/ClpP substrates such as a ClpA-beta-galactosidase fusion protein. It appears that selectivity of degradation by ClpP in vivo is determined by interaction of ClpP with different regulatory ATPase subunits.			GOTTESMAN, S (corresponding author), NCI,MOLEC BIOL & CELL BIOL LABS,BLDG 37,RM 4B03,BETHESDA,MD 20892, USA.		de Crecy-Lagard, Valerie/AAN-8995-2020					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANUETT F, 1986, J MOL BIOL, V187, P213, DOI 10.1016/0022-2836(86)90229-9; CHIN DT, 1988, J BIOL CHEM, V263, P11718; DAMERAU K, 1993, J BACTERIOL, V175, P53, DOI 10.1128/JB.175.1.53-63.1993; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GEUSKENS V, 1992, EMBO J, V11, P5121, DOI 10.1002/j.1460-2075.1992.tb05619.x; GOTTESMAN S, 1981, CELL, V24, P225, DOI 10.1016/0092-8674(81)90518-3; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; GOTTESMAN S, 1985, J BACTERIOL, V162, P1111, DOI 10.1128/JB.162.3.1111-1119.1985; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HAYES S, 1973, MOL GEN GENET, V126, P275, DOI 10.1007/BF00269438; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOYT MA, 1982, CELL, V31, P565, DOI 10.1016/0092-8674(82)90312-9; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG BJ, 1987, P NATL ACAD SCI USA, V84, P5550, DOI 10.1073/pnas.84.16.5550; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KITAGAWA M, 1991, J BACTERIOL, V173, P4247, DOI 10.1128/JB.173.14.4247-4253.1991; KROH HE, 1990, J BACTERIOL, V172, P6026, DOI 10.1128/jb.172.10.6026-6034.1990; MAURIZI MR, 1990, J BIOL CHEM, V265, P12546; MAURIZI MR, 1990, J BIOL CHEM, V265, P12536; MAURIZI MR, 1985, J BACTERIOL, V164, P1124, DOI 10.1128/JB.164.3.1124-1135.1985; MAURIZI MR, 1991, BIOCHEM SOC T, V19, P719, DOI 10.1042/bst0190719; MCMACKEN R, 1983, MECHANISMS DNA REPLI, P819; Miller JH., 1972, EXPT BACTERIAL GENET; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; RUDD KE, 1992, SHORT COURSE BACTERI; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOULAKERSCHWARZ R, 1991, P NATL ACAD SCI USA, V88, P4996, DOI 10.1073/pnas.88.11.4996; SHAPIRO JA, 1993, J BACTERIOL, V175, P2625, DOI 10.1128/JB.175.9.2625-2631.1993; Silhavy T. J., 1984, EXPT GENE FUSIONS; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WALKER GC, 1987, ESCHERICHIA COLI SAL, P1346; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEGRZYN G, 1992, J MOL BIOL, V226, P675; WEGRZYN G, 1992, J MOL BIOL, V226, P681; Weisberg RA, 1971, BACTERIOPHAGE LAMBDA, P489; WOJTKOWIAK S, 1993, J BIOL CHEM, V268, P22609; WOO KM, 1989, J BIOL CHEM, V264, P2088; WOO KM, 1992, J BIOL CHEM, V267, P20429; ZUBER M, 1987, P NATL ACAD SCI USA, V84, P4514, DOI 10.1073/pnas.84.13.4514	54	276	281	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22618	22626						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226770				2022-12-27	WOS:A1993MD34800065
J	ZHANG, J; KING, WG; DILLON, S; HALL, A; FEIG, L; RITTENHOUSE, SE				ZHANG, J; KING, WG; DILLON, S; HALL, A; FEIG, L; RITTENHOUSE, SE			ACTIVATION OF PLATELET PHOSPHATIDYLINOSITIDE 3-KINASE REQUIRES THE SMALL GTP-BINDING PROTEIN-RHO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							C3 ADP-RIBOSYLTRANSFERASE; HUMAN BLOOD-PLATELETS; ALPHA-THROMBIN; GENE-PRODUCT; RECEPTOR; KINASE; PHOSPHOINOSITIDES; ASSOCIATION	The small GTP-binding protein Rho regulates the assembly of actin stress fibers and focal adhesions in cells responding to growth factors. ADP-ribosylation of Rho by C3 transferase blocks this function; however, an enzymatic target for Rho has not yet been defined. We now report that Rho activates phosphatidylinositide 3-kinase in soluble preparations of platelets. Activation of phosphatidylinositide 3-kinase by GTPgammaS is blocked by ADP-ribosylation of endogenous Rho, and Rho shifts to the cytoskeleton in platelets exposed to thrombin. The inhibitory effects of ADP-ribosylation are overcome by exogenous recombinant Rho but not by recombinant Rac, another member of the Ras superfamily. Exposure of platelets to thrombin has been reported to lead to activation of phosphatidylinositide 3-kinase, a shift of this enzyme to the platelet membrane skeleton, and rapid cytoskeletal reorganization. In other studies, ADP-ribosylation of Rho has been found to inhibit thrombin-induced platelet aggregation, a cytoskeletally linked event. We suggest that Rho may exert its effects on cytoskeletal reorganization via phosphatidylinositide 3-kinase.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,CARDEZA FDN HEMATOL RES,PHILADELPHIA,PA 19107; ARIAD PHARMACEUT,CAMBRIDGE,MA 02139; TUFTS UNIV,DEPT BIOCHEM,BOSTON,MA 02111; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Jefferson University; Jefferson University; Takeda Pharmaceutical Company Ltd; Takeda Oncology; Tufts University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK					NATIONAL CANCER INSTITUTE [R29CA047391, R01CA047391] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038622] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47391] Funding Source: Medline; NHLBI NIH HHS [HL 38622] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARNEY DH, 1978, CELL, V15, P1341, DOI 10.1016/0092-8674(78)90059-4; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; EBERLE M, 1990, J BIOL CHEM, V265, P16725; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P36224; KING WG, 1991, BIOCHEM J, V278, P475, DOI 10.1042/bj2780475; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; MORII N, 1992, J BIOL CHEM, V267, P20921; NEMOTO Y, 1992, J BIOL CHEM, V267, P20916; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; VANOBBERGHENSCHILLING E, 1985, EMBO J, V4, P2927, DOI 10.1002/j.1460-2075.1985.tb04025.x; ZHANG J, 1992, J BIOL CHEM, V267, P4686	20	216	224	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22251	22254						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226730				2022-12-27	WOS:A1993MD34800010
J	DEGOLS, G; CLARENC, JP; LEBLEU, B; LEONETTI, JP				DEGOLS, G; CLARENC, JP; LEBLEU, B; LEONETTI, JP			REVERSIBLE INHIBITION OF GENE-EXPRESSION BY A PSORALEN FUNCTIONALIZED TRIPLE-HELIX FORMING OLIGONUCLEOTIDE IN INTACT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA DAMAGE; CROSS-LINKING; GROUP-F; REPAIR; RECOGNITION; EXTRACTS; REMOVAL; RANGE	Triple helix formation of nucleic acids is the most rational approach to designing site-specific transcription inhibitors. To increase their efficiency reactive moieties such as psoralen or ethenocytosine have been introduced on the third strand. In transfected cells, these compounds induce a site specific covalent binding of the third strand to the targeted sequence and efficiently block RNA polymerases. However, the stability of this transcription inhibition has never been checked. We have designed a plasmid containing a triple helix binding site in the coding region of the beta-galactosidase reporter gene and a polymerase chain reaction assay to follow quantitatively the cross-link of a psoralenderivatized third strand in transfected cells. This assay has revealed that the cross-link was removed within a few hours, leading only to a transitory inhibition of gene expression. Central experiments in DNA repair-deficient cells suggest the implication of repair enzymes in this process.	CNRS,INST MOLEC GENET,F-34033 MONTPELLIER,FRANCE; UNIV MONTPELLIER 2,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier								BOERRIGTER METI, 1991, MUTAT RES, V255, P49, DOI 10.1016/0921-8777(91)90017-J; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; CALSOU P, 1992, NUCLEIC ACIDS RES, V20, P6363, DOI 10.1093/nar/20.23.6363; DERVAN PB, 1992, NATURE, V359, P87, DOI 10.1038/359087a0; EVANS MK, 1993, J BIOL CHEM, V268, P4839; FRIEDBERG EC, 1985, DNA REPAIR, P213; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GOVAN HL, 1990, NUCLEIC ACIDS RES, V18, P3823, DOI 10.1093/nar/18.13.3823; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; HAVRE PA, 1993, P NATL ACAD SCI USA, V90, P7879, DOI 10.1073/pnas.90.16.7879; KALINOWSKI DP, 1992, NUCLEIC ACIDS RES, V20, P3485, DOI 10.1093/nar/20.13.3485; KRAWCZYK SH, 1992, P NATL ACAD SCI USA, V89, P3761, DOI 10.1073/pnas.89.9.3761; Maniatis T., 1982, MOL CLONING; MILLER PS, 1992, BIOCHEMISTRY-US, V31, P6788, DOI 10.1021/bi00144a020; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; NIELSEN PE, 1991, BIOCONJUGATE CHEM, V2, P1, DOI 10.1021/bc00007a001; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; REARDON JT, 1991, NUCLEIC ACIDS RES, V19, P4623, DOI 10.1093/nar/19.17.4623; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; TAKASUGI M, 1991, P NATL ACAD SCI USA, V88, P5602, DOI 10.1073/pnas.88.13.5602; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; ULRICH MJ, 1992, J BIOL CHEM, V267, P18649; VOS JMH, 1991, MOL CELL BIOL, V11, P2245, DOI 10.1128/MCB.11.4.2245; YAGI T, 1983, MUTAT RES, V112, P59, DOI 10.1016/0167-8817(83)90024-X; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023	26	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16933	16937						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207016				2022-12-27	WOS:A1994NR29600063
J	DITTMAN, WA; NELSON, SC; GREER, PK; HORTON, ET; PALOMBA, ML; MCCACHREN, SS				DITTMAN, WA; NELSON, SC; GREER, PK; HORTON, ET; PALOMBA, ML; MCCACHREN, SS			CHARACTERIZATION OF THROMBOMODULIN EXPRESSION IN RESPONSE TO RETINOIC ACID AND IDENTIFICATION OF A RETINOIC ACID RESPONSE ELEMENT IN THE HUMAN THROMBOMODULIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-CATALYZED ACTIVATION; ENDOTHELIAL-CELL COFACTOR; MOUSE HEMANGIOMA CELLS; TUMOR-NECROSIS-FACTOR; CYCLIC-AMP; PROTEIN-C; MESSENGER-RNA; NATURAL ANTICOAGULANT; FETAL DEVELOPMENT; REPORTER GENE	Thrombomodulin (TM) is an essential cofactor for the physiologic activation of the anticoagulant protein C by thrombin. We have observed that the expression of TM mRNA in response to retinoic acid was markedly increased in human U937 monoblast-like cells, and human MEG01 megakaryocyte-like cells, but not in human umbilical vein cells, murine hemangioma cells, human K562 erythroblast-like cells, and murine HSD fibroblast-like cells. TM activity in U937 cells and MEG01 cells was not detectable in untreated cells, but developed rapidly after treatment with retinoic acid. In endothelial cells there was minimal change in TM activity in response to retinoic acid treatment. We have isolated clones for the genes for murine and human TM and have identified potential retinoic acid response elements in the 5'-flanking region of the human gene. In U937 cells the increase in mRNA levels was associated with increased transcription, and transient transfection studies with reporter plasmids demonstrate functional retinoic acid response elements present in the 5'-flanking region of the gene. Deletion of, and mutations introduced into, the potential retinoic acid response element confirm the functional response in transient transfections.	VET ADM MED CTR,DEPT MED,DIV GERIATR,DURHAM,NC; VET ADM MED CTR,DEPT CELL BIOL,DIV GERIATR,DURHAM,NC; VET ADM MED CTR,DEPT GERIATR RES,DIV GERIATR,DURHAM,NC; VET ADM MED CTR,CTR EDUC & CLIN,DURHAM,NC; DUKE UNIV,SCH MED,DURHAM,NC 27710	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University	DITTMAN, WA (corresponding author), VET ADM MED CTR,DIV HEMATOL ONCOL,BOX 111-G,508 FULTON ST,DURHAM,NC 27705, USA.				NHLBI NIH HHS [P50-HL26309-11] Funding Source: Medline; NIAMS NIH HHS [P50-AR39162] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL026309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039162] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARSHAVIT R, 1983, J CELL BIOL, V96, P282, DOI 10.1083/jcb.96.1.282; BIZIOS R, 1986, J CELL PHYSIOL, V128, P485, DOI 10.1002/jcp.1041280318; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMUNK GAW, 1991, J CLIN INVEST, V88, P1680, DOI 10.1172/JCI115483; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DITTMAN WA, 1988, J BIOL CHEM, V263, P15815; DITTMAN WA, 1989, P NATL ACAD SCI USA, V86, P7179, DOI 10.1073/pnas.86.18.7179; DITTMAN WA, 1990, BLOOD, V75, P329; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; GLASS CK, 1991, DNA CELL BIOL, V10, P623, DOI 10.1089/dna.1991.10.623; HORIE S, 1992, BIOCHEM J, V281, P149, DOI 10.1042/bj2810149; IMADA M, 1987, DEV BIOL, V122, P483, DOI 10.1016/0012-1606(87)90312-5; IMADA S, 1990, DEV BIOL, V140, P113, DOI 10.1016/0012-1606(90)90058-Q; ISHII H, 1990, THROMB RES, V59, P841, DOI 10.1016/0049-3848(90)90397-U; ITO T, 1990, THROMB RES, V58, P615, DOI 10.1016/0049-3848(90)90307-X; JACKMAN RW, 1987, P NATL ACAD SCI USA, V84, P6425, DOI 10.1073/pnas.84.18.6425; KIZAKI M, 1990, LEUKEMIA RES, V14, P645, DOI 10.1016/0145-2126(90)90020-A; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MARUYAMA I, 1991, THROMB RES, V61, P301, DOI 10.1016/0049-3848(91)90107-8; MCCACHREN SS, 1991, BLOOD, V78, P3128; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; MOORE WT, 1984, J BIOL CHEM, V259, P2794; NARA K, 1989, J BIOL CHEM, V264, P19308; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; NIFORAS P, 1993, BIOCHIM BIOPHYS ACTA, V1193, P179; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; OWEN WG, 1981, J BIOL CHEM, V256, P5532; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SCHMIDT A, 1985, NATURE, V314, P286, DOI 10.1038/314286a0; SHIRAI T, 1988, J BIOCHEM-TOKYO, V103, P281, DOI 10.1093/oxfordjournals.jbchem.a122261; SOFF GA, 1991, BLOOD, V77, P515; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TREISMAN R, 1985, NATURE, V315, P72, DOI 10.1038/315072a0; VIVANCO RM, 1991, EMBO J, V10, P3829; WEILER GH, 1992, P NATL ACAD SCI USA, V89, P2155; WEN DZ, 1987, BIOCHEMISTRY-US, V26, P4350, DOI 10.1021/bi00388a025; YU K, 1992, J BIOL CHEM, V267, P23237; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	54	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16925	16932						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207015				2022-12-27	WOS:A1994NR29600062
J	NEUZIL, J; STOCKER, R				NEUZIL, J; STOCKER, R			FREE AND ALBUMIN-BOUND BILIRUBIN ARE EFFICIENT CO-ANTIOXIDANTS FOR ALPHA-TOCOPHEROL, INHIBITING PLASMA AND LOW-DENSITY-LIPOPROTEIN LIPID-PEROXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BLOOD-PLASMA; VITAMIN-E CONSUMPTION; AQUEOUS DISPERSIONS; SYNERGISTIC INHIBITION; HOMOGENEOUS SOLUTION; METHYL LINOLEATE; MODEL MEMBRANES; HEME OXYGENASE; HEART-DISEASE; BILE-PIGMENTS	Peroxidation of the lipid moieties of low density lipoproteins (LDL) is regarded as an early event in atherogenesis. Because bilirubin is a physiological reductant with antioxidant activities, we investigated its inhibitory action on the radical-mediated oxidation of LDL and plasma lipids. Exposing fresh human blood plasma to lipophilic peroxyl radicals generated from 2,2'-azobis(2,4-dimethylvaleronitrile) (AMVN) resulted in rapid oxidation of ubiquinol-10, followed by that of ascorbate and bilirubin. Plasma lipids were well protected from peroxidation as long as these three antioxidants were present, as assessed by the amounts of cholesterylester hydroperoxides formed during this period. Following consumption of these antioxidants, and in the presence of alpha-tocopherol, the rate of hydroperoxide formation increased sharply with roughly 2 molecules of cholesterylester hydroperoxides being formed for each peroxidation initiating event. Supplementation of AMVN-oxidizing plasma with exogenous bilirubin at the onset of rapid lipid peroxidation, i.e. after depletion of endogenous ubiquinol-10, ascorbate, and bilirubin, led to a halt in both hydroperoxide formation and consumption of alpha-tocopherol. When isolated LDL was incubated with AMVN, approximate to 9 molecules of cholesterylester hydroperoxides were formed per peroxidation initiating event and while alpha-tocopherol was consumed. Addition of free or albumin-bound bilirubin to isolated LDL at the onset of oxidation resulted in a strong inhibition of hydroperoxide formation and alpha-tocopherol consumption, the effect being more pronounced with the free pigment. Addition of the corresponding amounts of albumin alone was without effect. In the presence of albumin-bound bilirubin, some 30% of the pigment was initially converted into biliverdin, whereas formation of this oxidation product was not observed with the free pigment. Also, the presence of bilirubin oxidase partially reversed the inhibitory activity of bilirubin on AMVN-induced LDL oxidation in the absence but not presence of albumin. An attenuation of hydroperoxide formation and a temporary increase in LDL's alpha-tocopherol concentration were observed when free- or albumin-bound bilirubin were added to AMVN-oxidizing, alpha-tocopherol-containing LDL. In contrast, hydroperoxide formation was not inhibited significantly when the albumin-bound pigment was added to oxidizing LDL after complete consumption of its alpha-tocopherol. Our results show that bilirubin inhibits oxidation of LDL lipids initiated within the lipoprotein core and indicate that this activity is mediated by interaction of the pigment with LDL's alpha-tocopherol.	HEART RES INST,BIOCHEM GRP,CAMPERDOWN,NSW 2050,AUSTRALIA	University of Sydney; Heart Research Institute			Stocker, Roland/AAV-4489-2021; Neuzil, Jiri/H-7204-2014	Neuzil, Jiri/0000-0002-2478-2460				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; APPLEGATE LA, 1991, CANCER RES, V51, P974; BARCLAY LRC, 1984, J AM CHEM SOC, V106, P2479, DOI 10.1021/ja00320a066; BARCLAY LRC, 1987, CAN J CHEM, V65, P2541, DOI 10.1139/v87-423; BARCLAY LRC, 1990, BIOCHIM BIOPHYS ACTA, V1047, P255, DOI 10.1016/0005-2760(90)90524-2; BEHRENS WA, 1987, ANAL BIOCHEM, V165, P102, DOI 10.1016/0003-2697(87)90206-5; BOWRY VW, 1993, J AM CHEM SOC, V115, P6029, DOI 10.1021/ja00067a019; BOWRY VW, 1992, BIOCHEM J, V288, P341, DOI 10.1042/bj2880341; BOWRY VW, 1992, P NATL ACAD SCI USA, V89, P10316, DOI 10.1073/pnas.89.21.10316; BRODERSEN R, 1979, Critical Reviews in Clinical Laboratory Sciences, V11, P305; BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; BURTON GW, 1986, ACCOUNTS CHEM RES, V19, P194, DOI 10.1021/ar00127a001; CONSTANTINESCU A, 1993, J BIOL CHEM, V268, P10906; DAVIES MJ, 1988, BIOCHEM J, V255, P513; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; ESTERBAUER H, 1987, J LIPID RES, V28, P495; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FREI B, 1990, ADV EXP MED BIOL, V264, P155; FREI B, 1990, P NATL ACAD SCI USA, V87, P4879, DOI 10.1073/pnas.87.12.4879; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; GEY KF, 1991, AM J CLIN NUTR, V53, pS326, DOI 10.1093/ajcn/53.1.326S; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HOLLEY AE, 1991, FREE RADICAL RES COM, V15, P51, DOI 10.3109/10715769109049125; INGOLD KU, 1993, P NATL ACAD SCI USA, V90, P45, DOI 10.1073/pnas.90.1.45; KAGAN VE, 1992, J LIPID RES, V33, P385; KIMURA M, 1990, P SOC EXP BIOL MED, V195, P64; MOHR D, 1992, BIOCHIM BIOPHYS ACTA, V1126, P247, DOI 10.1016/0005-2760(92)90237-P; MOHR D, 1994, IN PRESS ARTERIOSCLE; MOTOYAMA T, 1989, ARCH BIOCHEM BIOPHYS, V270, P655, DOI 10.1016/0003-9861(89)90548-1; MUKAI K, 1990, BIOCHIM BIOPHYS ACTA, V1035, P77, DOI 10.1016/0304-4165(90)90176-W; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; NEWMAN TB, 1992, PEDIATRICS, V89, P809; NIKI E, 1986, B CHEM SOC JPN, V59, P471, DOI 10.1246/bcsj.59.471; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUBIN BY, 1988, J IMMUNOL, V141, P1180; SATO K, 1990, ARCH BIOCHEM BIOPHYS, V279, P402, DOI 10.1016/0003-9861(90)90508-V; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; SCHWERTNER HA, 1994, CLIN CHEM, V40, P18; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; STOCKER R, 1990, METHOD ENZYMOL, V186, P301; STOCKER R, 1989, BIOCHIM BIOPHYS ACTA, V1002, P238, DOI 10.1016/0005-2760(89)90293-2; STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; TSUCHIYA J, 1985, B CHEM SOC JPN, V58, P326, DOI 10.1246/bcsj.58.326; YAMAMOTO Y, 1984, B CHEM SOC JPN, V57, P1260, DOI 10.1246/bcsj.57.1260	56	403	417	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16712	16719						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206992				2022-12-27	WOS:A1994NR29600033
J	PHILLIPS, JE; COOPER, ST; POTTER, EE; CHURCH, FC				PHILLIPS, JE; COOPER, ST; POTTER, EE; CHURCH, FC			MUTAGENESIS OF RECOMBINANT PROTEIN-C INHIBITOR REACTIVE-SITE RESIDUES ALTERS TARGET PROTEINASE SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ANTITHROMBIN-III; HEPARIN COFACTOR-II; BLOOD-COAGULATION; SEMINAL PLASMA; THROMBIN; EXPRESSION; ALPHA-1-ANTITRYPSIN; BINDING; SERPINS; PURIFICATION	Protein C inhibitor (PCI) is a heparin-binding plasma serine proteinase inhibitor (serpin) which is thought to be a physiological regulator of activated protein C. We are using recombinant PCI (rPCI) to study structural determinants of target proteinase specificity. A cDNA encoding full-length PCI has been expressed as a fully active proteinase inhibitor using Autographa californica nuclear polyhedrosis virus (baculovirus). rPCI was expressed maximally 4 days after infection and could be expressed either in Sf9 or High-Five(TM) cells. rPCI bound heparin and was conveniently purified with heparin-Sepharose (eluting >0.5 M NaCl). The rPCI formed sodium dodecyl sulfate-polyacrylamide gel electrophoresis-stable complexes with thrombin and activated protein C (APC). The inhibitory properties of wild-type rPCI and plasma-derived PCI are essentially the same either in the absence or presence of heparin with thrombin, APC, trypsin, and urokinase. The residues Phe(353)-Arg(354)-Ser(355) (P2-P1-P1') constitute part of the reactive site loop of PCI with the Arg-Ser peptide bond being cleaved by the proteinase. Using site-directed mutagenesis we studied the contribution of the reactive site FRS for proteinase inhibition in rPCI. Changing the P1 residue Arg(-354) --> Met generated a reactive site similar to alpha(1)-proteinase inhibitor which was a much poorer inhibitor of thrombin, APC, trypsin, and urokinase. Changing the P2 residue Phe(353) --> Gly generated a mutant with a reactive site like antithrombin which was better at inhibiting thrombin or urokinase, but was much less active with APC or trypsin. Changing the P1' residue Ser(355) --> Met generated a reactive site like plasminogen activator inhibitor-1 and this protein inhibits all the proteinases essentially like wild-type rPCI. These results show the importance of PCI's Phe(353) (P2) and Arg(-354) (P1) in target proteinase specificity, and they further support the concept of reactive site sequences determining serpin function.	UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,SCH MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT MED,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NHLBI NIH HHS [HL-06530, F32-HL08413, 5T32-HL07149] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008413, T32HL007149] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLINDER MA, 1988, BIOCHEMISTRY-US, V27, P752, DOI 10.1021/bi00402a039; BODE W, 1992, PROTEIN SCI, V1, P426; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; CUNNINGHAM DD, 1992, ADV EXP MED BIOL, V313, P297; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; ECKE S, 1992, J BIOL CHEM, V267, P7048; ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; ESMON CT, 1991, THROMB HAEMOSTASIS, V66, P160; ESPANA F, 1991, BLOOD, V77, P1754; ESPANA F, 1991, THROMB RES, V64, P309, DOI 10.1016/0049-3848(91)90002-E; FURIE B, 1992, NEW ENGL J MED, V326, P800; GEIGER M, 1989, BLOOD, V74, P722; GEIGER M, 1991, J BIOL CHEM, V266, P11851; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; GILLESPIE LS, 1991, J BIOL CHEM, V266, P3995; HEEB MJ, 1990, J BIOL CHEM, V265, P2365; HEEB MJ, 1991, J BIOL CHEM, V266, P17606; HEEB MJ, 1988, J BIOL CHEM, V263, P11613; HEEB MJ, 1988, THROMB RES, V52, P33, DOI 10.1016/0049-3848(88)90038-2; HERMANS JM, 1993, BIOCHEM J, V295, P239, DOI 10.1042/bj2950239; HOOGENDOORN H, 1991, BLOOD, V78, P2283, DOI 10.1182/blood.V78.9.2283.bloodjournal7892283; HOOGENDOORN H, 1990, BLOOD, V75, P2164; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KUHN LA, 1990, P NATL ACAD SCI USA, V87, P8506, DOI 10.1073/pnas.87.21.8506; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURELL M, 1992, J CLIN INVEST, V89, P1094, DOI 10.1172/JCI115689; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; MEIJERS JCM, 1988, BIOCHEMISTRY-US, V27, P4231, DOI 10.1021/bi00412a005; OLSON ST, 1992, THROMBIN STRUCTURE F, P159; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PRATT CW, 1992, J BIOL CHEM, V267, P8795; PRATT CW, 1989, THROMB RES, V53, P595, DOI 10.1016/0049-3848(89)90149-7; PRATT CW, 1993, BLOOD COAGUL FIBRIN, V4, P479, DOI 10.1097/00001721-199306000-00013; PRATT CW, 1992, J BIOL CHEM, V267, P8789; RAGG H, 1988, J BIOL CHEM, V263, P12129; REZAIE AR, 1993, J BIOL CHEM, V268, P19943; ROBERTS HR, 1992, HOSP PRACT, V27, P97; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCULLY MF, 1993, THROMB HAEMOSTASIS, V69, P448; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SHIEH BH, 1987, J BIOL CHEM, V262, P6055; STEPHENS AW, 1988, J BIOL CHEM, V263, P15849; STEPHENS AW, 1987, P NATL ACAD SCI USA, V84, P3886, DOI 10.1073/pnas.84.11.3886; STONE SR, 1985, BIOCHEM J, V230, P497, DOI 10.1042/bj2300497; SUZUKI K, 1989, THROMB HAEMOSTASIS, V61, P337; SUZUKI K, 1987, J BIOL CHEM, V262, P611; SUZUKI K, 1983, J BIOL CHEM, V258, P163; TOLLEFSEN DM, 1992, ADV EXP MED BIOL, V313, P167; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WASLEY LC, 1987, J BIOL CHEM, V262, P14766; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; YORK JD, 1991, J BIOL CHEM, V266, P8495	60	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16696	16700						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206990				2022-12-27	WOS:A1994NR29600030
J	AHMED, SA; MILES, EW				AHMED, SA; MILES, EW			ALIPHATIC-ALCOHOLS STABILIZE AN ALTERNATIVE CONFORMATION OF THE TRYPTOPHAN SYNTHASE ALPHA(2)BETA(2) COMPLEX FROM SALMONELLA-TYPHIMURIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET FACTOR-IV; ESCHERICHIA-COLI; BETA-SUBUNIT; ORGANIC-SOLVENTS; ALPHA; IDENTIFICATION; ASSOCIATION; PROTEINS; CLEAVAGE; SITE	The conformational changes that accompany association of the tryptophan synthase alpha and beta(2) s are probed by investigating the effects of solvents on the catalytic and spectroscopic properties of tryptophan synthase. Low concentrations of ethanol, propanol, and butanol inhibit conversion of L-serine and indole to L-tryptophan by the alpha(2) beta(2) complex. Inhibition depends on the concentration, chain length, and hydrophobicity of the alcohol. In contrast, these alcohols increase the rates of conversion of beta-chloro-L-alanine and indole to L-tryptophan and of L-serine to pyruvate. Thus, alcohols alter the substrate specificity and reaction specificity of the alpha(2) beta(2) complex. These altered specificities are similar to those of the free beta(2) subunit in aqueous solution. The spectroscopic properties of enzyme-substrate intermediates formed by the alpha(2) beta(2) complex in 3 M ethanol and 0.5 M 1-butanol also resemble the intermediates formed by the free beta(2) subunit in aqueous solution. Experiments using gel-filtration, membrane ultrafiltration, and limited proteolysis show that the alpha(2) beta(2) complex does not dissociate at low concentrations of alcohols. Our results provide evidence that alcohols can stabilize an alternative conformation of the alpha(2) beta(2) complex which is similar to the open conformation of the free beta(2) aqueous solution.			AHMED, SA (corresponding author), NIDDK, BIOCHEM PHARMACOL LAB, BLDG 8, RM 2A-05, BETHESDA, MD 20892 USA.							AHMED SA, 1986, BIOCHEMISTRY-US, V25, P4233, DOI 10.1021/bi00363a010; AHMED SA, 1986, BIOCHEMISTRY-US, V25, P3118, DOI 10.1021/bi00359a008; AHMED SA, 1991, J BIOL CHEM, V266, P21548; AHMED SA, 1992, J BIOL CHEM, V267, P23309; CONIO G, 1970, J BIOL CHEM, V245, P3335; CRAWFORD IP, 1964, P NATL ACAD SCI USA, V51, P390, DOI 10.1073/pnas.51.3.390; DOUZOU P, 1984, ADV PROTEIN CHEM, V36, P245, DOI 10.1016/S0065-3233(08)60299-5; DREYFUS M, 1978, FEBS LETT, V95, P185, DOI 10.1016/0014-5793(78)80080-5; FINK AL, 1986, CRYOBIOLOGY, V23, P28, DOI 10.1016/0011-2240(86)90015-5; GILLILAND GL, 1984, METHOD ENZYMOL, V104, P370; GOLDBERG ME, 1967, BIOCHEMISTRY-US, V6, P2113, DOI 10.1021/bi00859a032; HIGGINS W, 1979, BIOCHEMISTRY-US, V18, P4827, DOI 10.1021/bi00589a010; HOGBERGRAIBAUD A, 1977, BIOCHEMISTRY-US, V16, P4014, DOI 10.1021/bi00637a012; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; LAANE C, 1987, BIOTECHNOL BIOENG, V30, P81, DOI 10.1002/bit.260300112; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1978, J BIOL CHEM, V253, P6266; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1968, BIOCHEMISTRY-US, V7, P2742, DOI 10.1021/bi00848a008; MILES EW, 1991, INT UNION B, V199, P249; PARODI RM, 1973, J BIOL CHEM, V248, P4047; SAKURAI T, 1988, J AM CHEM SOC, V110, P7236, DOI 10.1021/ja00229a061; SINGH TJ, 1979, J BIOL CHEM, V254, P8466; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; YANG XJ, 1992, PROTEIN EXPRES PURIF, V3, P347, DOI 10.1016/1046-5928(92)90011-K; YANG YQ, 1993, BIOCHEMISTRY-US, V32, P8661, DOI 10.1021/bi00084a038; YANG YQ, 1993, J BIOL CHEM, V268, P9223; Yanofsky C., 1972, ENZYMES, P1, DOI [10.1016/s1874-6047(08)60445-x, DOI 10.1016/S1874-6047(08)60445-X]	32	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16486	16492						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206958				2022-12-27	WOS:A1994NQ72900079
J	ANGLESON, JK; WENSEL, TG				ANGLESON, JK; WENSEL, TG			ENHANCEMENT OF ROD OUTER SEGMENT GTPASE ACCELERATING PROTEIN-ACTIVITY BY THE INHIBITORY SUBUNIT OF CGMP PHOSPHODIESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; PHOTORECEPTOR G-PROTEIN; BOVINE RETINAL RODS; BINDING-SITES; ALPHA-SUBUNIT; CONFORMATIONAL-CHANGES; ACTIVATION MECHANISM; VISUAL TRANSDUCTION; RHODOPSIN; MEMBRANES	The cGMP phosphodiesterase (PDE) of retinal rod outer segments (ROS) is activated by the GTP-bound form of the G protein, transducin (G(t alpha) ). This activation can be reversed by the inhibitory gamma subunit of PDE through two distinct mechanisms: acceleration of GTP hydrolysis and direct inactivation independent of GTP hydrolysis. We have found that acceleration of G(t alpha) GTPase by PDE(gamma) does not occur upon formation of a G(t alpha)-PDE(gamma) complex but rather reflects enhanced activity toward this complex of a membrane-bound GTPase accelerating protein. GTPase rate constants for G(t alpha) in the presence of 3.3 mu M PDE(gamma) were as high as 0.7 s(-1) with hypotonically washed ROS membranes at 40 mu M rhodop sin but were more than 10-fold lower when protein-free vesicles containing ROS lipids were substituted for ROS membranes. Acceleration of G(t alpha) GTPase by PDE(gamma) was also barely detectable at low ROS concentrations (e.g. 4 mu M rhodopsin) or if ROS treated with trypsin or urea were used. GTPase-independent inactivation by PDE(gamma) occurred efficiently at much lower membrane concentrations. Inhibition of G(t alpha)-activated PDE was much slower than inhibition of PDE(alpha beta) by PDE(gamma). Effects of PDE(gamma) upon successive additions of GTP suggested formation of a complex of PDE(gamma) and G(t alpha)-GDP that is refractory to reactivation.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine				Wensel, Theodore/0000-0003-3518-9352	NEI NIH HHS [EY07981, EY07001] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007981] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ANTONNY B, 1993, BIOCHEMISTRY-US, V32, P8646, DOI 10.1021/bi00084a036; ARSHAVSKY VY, 1989, FEBS LETT, V250, P353, DOI 10.1016/0014-5793(89)80754-9; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1993, INVEST OPHTH VIS SCI, V34, P1068; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CATTY P, 1992, J BIOL CHEM, V267, P19489; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CLERC A, 1992, J BIOL CHEM, V267, P6620; COTE RH, 1993, J BIOL CHEM, V268, P17190; DEGRIP WJ, 1979, BIOCHIM BIOPHYS ACTA, V558, P330, DOI 10.1016/0005-2736(79)90269-4; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; ERICKSON MA, 1992, SCIENCE, V257, P1255, DOI 10.1126/science.1519062; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GRAYKELLER MP, 1990, J BIOL CHEM, V265, P15323; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; HODGKIN AL, 1988, J PHYSIOL-LONDON, V403, P439, DOI 10.1113/jphysiol.1988.sp017258; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; KAHLERT M, 1991, BIOPHYS J, V59, P375, DOI 10.1016/S0006-3495(91)82231-7; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; KUHN H, 1981, P NATL ACAD SCI-BIOL, V78, P6873, DOI 10.1073/pnas.78.11.6873; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; PAGES F, 1992, J BIOL CHEM, V267, P22018; PAGES F, 1993, J BIOL CHEM, V268, P26358; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; STRYER L, 1991, J BIOL CHEM, V266, P10711; TYMINSKI PN, 1984, BIOCHEMISTRY-US, V23, P3986, DOI 10.1021/bi00312a028; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1993, J BIOL CHEM, V268, P8899; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; ZERA E, 1993, BIOPHYS J, V64, pA383	52	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16290	16296						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206935				2022-12-27	WOS:A1994NQ72900053
J	JAIN, RG; RUSCH, SL; KENDALL, DA				JAIN, RG; RUSCH, SL; KENDALL, DA			SIGNAL PEPTIDE CLEAVAGE REGIONS - FUNCTIONAL LIMITS ON LENGTH AND TOPOLOGICAL IMPLICATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LEADER PEPTIDASE; ESCHERICHIA-COLI; ALKALINE-PHOSPHATASE; PROTEIN EXPORT; NUCLEOTIDE-SEQUENCE; PLASMA-MEMBRANE; WILD-TYPE; SITE; CONFORMATION; SECRETION	As a first step toward understanding the topology of the signal peptide with respect to the membrane during the protein export process, we have examined the constraints on the length of the cleavage region needed to achieve signal peptidase recognition and cleavage. Using the signal peptide of Escherichia coli alkaline phosphatase, a series of cleavage region mutants has been constructed. Variations in length were brought about by replacing the wild type cleavage region of the signal peptide with polymers of increasingly more residues. In each case, alanine residues are used exclusively in the -1 and -3 positions to provide only one viable cleavage site. Glutamine residues are used in all other positions in order to vary the length from 3 to 13 total residues. Analysis of these mutants revealed that cleavage regions ranging from 3 to 9 residues are completely and efficiently processed. The extent of processing drops substantially thereafter, with no processing observed for signal peptides with 13-residue long cleavage regions. A second mutant with a 13-residue long cleavage region was designed and analyzed to ensure that the lack of processing reflected a cleavage problem and not a translocation defect. The results are consistent with the notion that the signal peptidase active site is in close proximity to the periplasmic surface of the inner membrane and that interaction of the cleavage region with the signal peptidase probably depends on, and is constrained by, other interactions involving the signal peptide.	UNIV CONNECTICUT,DEPT MOLEC & CELL BIOL,STORRS,CT 06269	University of Connecticut					NIGMS NIH HHS [GM37639] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037639] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BILGIN N, 1990, EMBO J, V9, P2717, DOI 10.1002/j.1460-2075.1990.tb07458.x; BLACK MT, 1993, J BACTERIOL, V175, P4957, DOI 10.1128/JB.175.16.4957-4961.1993; Boyd D, 1987, PHOSPHATE METABOLISM, P89; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; BRIGGS MS, 1984, BIOCHEMISTRY-US, V23, P3111, DOI 10.1021/bi00309a001; BRUCH MD, 1989, BIOCHEMISTRY-US, V28, P8554, DOI 10.1021/bi00447a043; CHOU MM, 1990, J BIOL CHEM, V265, P2873; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DUFFAUD G, 1988, J BIOL CHEM, V263, P10224; EBELING W, 1974, EUR J BIOCHEM, V47, P91, DOI 10.1111/j.1432-1033.1974.tb03671.x; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FIKES JD, 1990, J BIOL CHEM, V265, P3417; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; HALL MN, 1983, EMBO J, V2, P15, DOI 10.1002/j.1460-2075.1983.tb01373.x; INNIS MA, 1984, P NATL ACAD SCI-BIOL, V81, P3708, DOI 10.1073/pnas.81.12.3708; INOUYE S, 1982, P NATL ACAD SCI-BIOL, V79, P3438, DOI 10.1073/pnas.79.11.3438; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFORET GA, 1991, J BIOL CHEM, V266, P1326; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; LI SC, 1993, J BIOL CHEM, V268, P22975; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MICHAELIS S, 1986, J BACTERIOL, V167, P160, DOI 10.1128/jb.167.1.160-167.1986; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Miller J.H., 1972, EXPT MOL GENETICS; MOORE KE, 1987, J BIOL CHEM, V262, P8806; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NILSSON IM, 1991, J BIOL CHEM, V266, P3408; NOTHWEHR SF, 1990, J BIOL CHEM, V265, P17202; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; ROSENBLATT M, 1980, P NATL ACAD SCI-BIOL, V77, P3983, DOI 10.1073/pnas.77.7.3983; RUSCH SL, 1992, J MOL BIOL, V224, P77, DOI 10.1016/0022-2836(92)90577-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schneider Gisbert, 1993, Protein Sequences and Data Analysis, V5, P227; SHINNAR AE, 1984, J AM CHEM SOC, V106, P5006, DOI 10.1021/ja00329a063; SUNG M, 1992, J BIOL CHEM, V267, P13154; VLASUK GP, 1984, J BIOL CHEM, V259, P6195; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; YU F, 1984, FEBS LETT, V173, P264, DOI 10.1016/0014-5793(84)81060-1; ZWIZINSKI C, 1981, J BIOL CHEM, V256, P3593	53	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16305	16310						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206936				2022-12-27	WOS:A1994NQ72900055
J	MIFFLIN, LC; COHEN, RE				MIFFLIN, LC; COHEN, RE			CHARACTERIZATION OF DENATURED PROTEIN INDUCERS OF THE HEAT-SHOCK (STRESS) RESPONSE IN XENOPUS-LAEVIS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIC LIGHT-SCATTERING; MUTANT ACTIN GENES; ABNORMAL PROTEINS; DEPENDENT PROTEOLYSIS; ESCHERICHIA-COLI; UBIQUITIN; DEGRADATION; ATP; NUCLEAR; TRANSCRIPTION	In addition to thermal stress, a large variety of physical and chemical treatments are known to induce heat shock gene expression. Denatured protein, thought to result from the stress condition, has been postulated to act as the common signal. Accordingly, of three pairs of native and denatured proteins injected into Xenopus laevis oocytes, only the denatured derivatives induced expression of a reporter gene from a heat shock promoter (Ananthan, J., Goldberg, A. L., and Voellmy, R. (1986) Science 232, 522-525). These observations are extended here. Protein denaturation per se is shown to be insufficient for heat shock induction; although reduced and carboxymethylated bovine serum albumin (rcm-BSA) and alpha-crystallin elicited a stress response, many other denatured proteins had no effect. Methylation of protein lysines, done to prevent ubiquitination, suppressed heat shock induction by rcm-BSA, but enhanced induction by alpha-crystallin. Thus, the potential for a protein to be ubiquitinated is independent of its ability to induce the stress response. Instead, aggregation distinguished the proteins that were effective stress inducers, and the formation of large aggregates correlated with the magnitude of the response. This correlation may derive in part from decreased in vivo degradation rates of the inducer proteins. An apparent requirement for stress response induction that the inducer proteins be injected directly into the oocyte nucleus may relate to this issue of in vivo stability. The dependence of the stress response on the amount of injected protein is nonlinear and of a form consistent with the titration of a factor that otherwise suppresses heat shock gene expression.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of Iowa; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIGMS NIH HHS [R01 GM37666, GM07185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037666] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; BECKMANN RP, 1992, J CELL BIOL, V117, P1137, DOI 10.1083/jcb.117.6.1137; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; BOND U, 1985, MOL CELL BIOL, V5, P949, DOI 10.1128/MCB.5.5.949; BOND U, 1988, J BIOL CHEM, V263, P2384; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DUBOIS MF, 1991, J BIOL CHEM, V266, P9707; EVANS AC, 1985, BIOCHEMISTRY-US, V24, P2915, DOI 10.1021/bi00333a015; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FERBER S, 1986, J BIOL CHEM, V261, P3128; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HARRINGTON WF, 1959, BIOCHIM BIOPHYS ACTA, V31, P427, DOI 10.1016/0006-3002(59)90017-4; HAZRA AK, 1984, ANAL BIOCHEM, V137, P437, DOI 10.1016/0003-2697(84)90110-6; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HILL CP, 1993, P NATL ACAD SCI USA, V90, P4136, DOI 10.1073/pnas.90.9.4136; HIROMI Y, 1986, CELL, V44, P293, DOI 10.1016/0092-8674(86)90763-4; HIRS CHW, 1967, METHOD ENZYMOL, V11, P199; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; JONES BN, 1981, J LIQ CHROMATOGR, V4, P565, DOI 10.1080/01483918108059956; KING ML, 1987, DEV BIOL, V119, P532, DOI 10.1016/0012-1606(87)90056-X; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIS JT, 1988, UBIQUITIN SYSTEM, P56; MAYER A, 1989, SCIENCE, V244, P1480, DOI 10.1126/science.2544030; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MIFFLINLC, 1994, J BIOL CHEM, V269, P15718; Miller J. H, 1972, EXPT MOL GENETICS; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; NICOLI DF, 1991, AM LAB, V23, P32; NOVER L, 1989, MOL CELL BIOL, V9, P1298, DOI 10.1128/MCB.9.3.1298; NOVER L, 1984, HEAT SHOCK RESPONSE, P8; OKAMOTO H, 1986, EMBO J, V5, P589, DOI 10.1002/j.1460-2075.1986.tb04251.x; PARSELL DA, 1989, GENE DEV, V3, P1226, DOI 10.1101/gad.3.8.1226; PELHAM HRB, 1984, EMBO J, V3, P3095, DOI 10.1002/j.1460-2075.1984.tb02264.x; PINTO M, 1991, J BIOL CHEM, V266, P13941; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SEERY TAP, 1989, POLYMER, V30, P1197, DOI 10.1016/0032-3861(89)90036-0; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; TANAKA K, 1983, J CELL BIOL, V96, P1580, DOI 10.1083/jcb.96.6.1580; VOELLMY R, 1982, P NATL ACAD SCI-BIOL, V79, P1776, DOI 10.1073/pnas.79.6.1776; WILKINSON KD, 1981, J BIOL CHEM, V256, P9235	49	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15710	15717						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195223				2022-12-27	WOS:A1994NP51300051
J	XIANG, JL; LAHTI, JM; GRENET, J; EASTON, J; KIDD, VJ				XIANG, JL; LAHTI, JM; GRENET, J; EASTON, J; KIDD, VJ			MOLECULAR-CLONING AND EXPRESSION OF ALTERNATIVELY SPLICED PITSLRE PROTEIN-KINASE ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CELL-CYCLE; HUMAN NEUROBLASTOMAS; CATALYTIC SUBUNIT; CHROMOSOMAL GENE; SERINE KINASE; SHORT ARM; CENP-B; CDC2; PHOSPHORYLATION	Minimal ectopic expression of the p58(GTA) protein kinase results in a provocative phenotype involving cell cycle delay, mitotic catastrophe, and decreased cell viability. In addition, this kinase is well conserved evolutionarily, ubiquitously expressed, and its genes map to a position on human chromosome 1 frequently deleted in the late stages of tumorigenesis. Here we report that the p58(GTA) protein kinase is a member of a larger subfamily of proteins. The mRNAs encoding these proteins are generated by alternative splicing from multiple duplicated genes. These isoforms range in size from 50 to 110 kDa. Divergence between the alternatively spliced isoforms is localized to the amino terminal region of the molecule. The entire p58(GTA) Open reading frame is conserved in most of these p58(GTA) isoforms. The predicted sequences of the larger isoforms encode bipartite nuclear localization signal sequences and extensive polyglutamic acid domains. Antibodies to the p58(GTA) isoform were used to confirm the presence of the alternatively spliced isoforms in different cell types as well as identify two additional isoforms that appear to arise from a separate gene(s). Cellular fractionation studies indicate that one of the isoforms is found only in the nucleus, and the remainder are found in both the cytoplasm and the nucleus. Expression and localization of some p58(GTA) isoforms suggest that they may have specialized cellular functions. Because of the large number of isoforms generated from multiple genes we propose naming these kinases PITSLRE alpha 1, alpha 2-1, alpha 2-2, alpha 2-3 alpha 2-4, beta 1, beta 2-1, and beta 2-2 based on the conserved sequence of the PSTAIRE box unique to p34(cdc2) kinases and the gene from which they are transcribed.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; UNIV ALABAMA, DEPT CELL BIOL, BIRMINGHAM, AL 35294 USA	St Jude Children's Research Hospital; University of Alabama System; University of Alabama Birmingham				Easton, John/0000-0003-4503-6608	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044088] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 44088] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; ATKIN NB, 1986, CANCER GENET CYTOGEN, V21, P279, DOI 10.1016/0165-4608(86)90206-2; BALL LA, 1992, J VIROL, V66, P2326, DOI 10.1128/JVI.66.4.2326-2334.1992; BATES S, 1994, ONCOGENE, V9, P71; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRODEUR GM, 1981, CANCER RES, V41, P4678; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; EIPERS PG, 1991, GENOMICS, V11, P621, DOI 10.1016/0888-7543(91)90069-Q; EIPERS PG, 1992, GENOMICS, V13, P613, DOI 10.1016/0888-7543(92)90132-C; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARLOW E, 1988, ANTIBODIES, V8, P313; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; LEVINE H, 1987, EUR J BIOCHEM, V168, P481, DOI 10.1111/j.1432-1033.1987.tb13442.x; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOCK BA, 1994, MAMM GENOME, V5, P191, DOI 10.1007/BF00352357; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PLANASSILVA MD, 1992, EMBO J, V11, P507, DOI 10.1002/j.1460-2075.1992.tb05081.x; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SIMON D, 1991, ONCOGENE, V6, P765; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YODA K, 1992, J CELL BIOL, V119, P1413, DOI 10.1083/jcb.119.6.1413; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	56	86	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15786	15794						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195233				2022-12-27	WOS:A1994NP51300061
J	YU, HR; MUKHOPADHYAY, D; MISRA, TK				YU, HR; MUKHOPADHYAY, D; MISRA, TK			PURIFICATION AND CHARACTERIZATION OF A NOVEL ORGANOMETALLIC RECEPTOR PROTEIN REGULATING THE EXPRESSION OF THE BROAD-SPECTRUM MERCURY-RESISTANT OPERON OF PLASMID PDU1358	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEL-ELECTROPHORESIS; MER PROMOTER; DNA-SEQUENCE; GENE; BINDING; TRANSCRIPTION; ACTIVATION; BACTERIA; SYSTEM; TN501	The narrow spectrum mercury-resistant (mer) operons of transposons Tn21 and Tn501 are inducible by inorganic mercury salts. The major regulatory gene merR is transcribed divergently from the other mer genes, which are cotranscribed. The MerR protein represses its own expression, as well as the expression of the other mer genes in the absence of the inducers. The synthesis of the polycistronic ner message is stimulated by MerR in the presence of the inducers. The MerR(BS) protein encoded by the broad spectrum mer operon of plasmid pDU1358 was characterized as a novel organomercurial receptor, distinguishing it from the narrow spectrum MerR(NS) proteins, described above. Several organomercurial compounds directly effected cellular activation of the mer operon transcription via the receptor protein MerR(BS) but not by MerR(NS). The merR gene from pDU1358 was cloned under the tac promoter, and the overexpressed MerR(BS) protein was soluble in buffer solutions containing 0.5 M NaCl at pH 7.5, but precipitated when NaCl concentration was reduced to 0.1 M (MerR(BS) concentrations at or above 0.1 mg/ml). MerR(BS) was purified to near homogeneity by selective precipitation and solubilization by varying the salt concentration in buffer solutions, followed by Sephadex G-75 column chromatography. Both MerR(BS) and Tn21-encoded MerR(NS) bound with DNA fragments containing the pDU1358 mer operator sequence with comparable affinities. In vitro run-off transcription studies revealed that MerR(BS) activated mer operon expression in the presence of Hg2+ or phenylmercuric acetate. Phenylmercuric acetate did not induce mer operon expression when the MerR(NS) was used in the assay.	UNIV ILLINOIS, COLL MED, DEPT MICROBIOL & IMMUNOL, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NIGMS NIH HHS [GM-36722] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM036722] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; BARNES WM, 1983, NUCLEIC ACIDS RES, V11, P349, DOI 10.1093/nar/11.2.349; BHRIAIN NNN, 1983, J BACTERIOL, V155, P690, DOI 10.1128/JB.155.2.690-703.1983; FARINHA MA, 1990, J BACTERIOL, V172, P3496, DOI 10.1128/jb.172.6.3496-3499.1990; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GRIFFIN HG, 1987, P NATL ACAD SCI USA, V84, P3112, DOI 10.1073/pnas.84.10.3112; HELTZEL A, 1987, J BACTERIOL, V169, P3379, DOI 10.1128/jb.169.7.3379-3384.1987; HELTZEL A, 1990, BIOCHEMISTRY-US, V29, P9572, DOI 10.1021/bi00493a011; KLOTZ IM, 1986, INTRO BIOMOLECULAR E, P103; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUND PA, 1986, J GEN MICROBIOL, V132, P465; Miller J. H, 1972, EXPT MOL GENETICS; MISRA TK, 1992, PLASMID, V27, P4, DOI 10.1016/0147-619X(92)90002-R; MUKHOPADHYAY D, 1991, J BIOL CHEM, V266, P18538; NUCIFORA G, 1989, J BACTERIOL, V171, P4241, DOI 10.1128/JB.171.8.4241-4247.1989; OHALLORAN T, 1987, SCIENCE, V235, P211, DOI 10.1126/science.3798107; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PARKHILL J, 1990, NUCLEIC ACIDS RES, V18, P5157, DOI 10.1093/nar/18.17.5157; Ralston D M, 1990, Adv Inorg Biochem, V8, P1; Sambrook J, 1989, MOL CLONING LABORATO; SILVER S, 1992, MICROBIOL REV, V56, P195, DOI 10.1128/MMBR.56.1.195-228.1992; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; WALTS AE, 1988, J AM CHEM SOC, V110, P1950, DOI 10.1021/ja00214a047	26	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15697	15702						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195221				2022-12-27	WOS:A1994NP51300049
J	HIGMAN, MA; CHRISTEN, LA; NILES, EG				HIGMAN, MA; CHRISTEN, LA; NILES, EG			THE MESSENGER-RNA (GUANINE-7-)METHYLTRANSFERASE DOMAIN OF THE VACCINIA VIRUS MESSENGER-RNA CAPPING ENZYME - EXPRESSION IN ESCHERICHIA-COLI AND STRUCTURAL AND KINETIC COMPARISON TO THE INTACT CAPPING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA GUANYLYLTRANSFERASE; TRANSCRIPTION INITIATION-FACTOR; CAP STRUCTURES; EARLY GENES; VIRIONS; PURIFICATION; ASSOCIATION; POLYMERASE; SEQUENCE; COMPLEX	The mRNA (guanine-7-)methyltransferase active site of the heterodimeric vaccinia virus mRNA capping enzyme was previously localized to the carboxyl-terminal third of the large subunit, D1R, associated with the small subunit, D12L (Cong, P., and Shuman, S. (1992) J. Biol. Chem. 267, 16424-16429; Higman, M. A., Bourgeois, N., and Niles, E. G. (1992) J. Biol. Chem. 267, 16430-16437). A plasmid was constructed which directs the coexpression of the carboxyl terminus of the D1R subunit from amino acids 498 to 844 and the D12L subunit in Escherichia coli. The mRNA (guanine-7-)methyltransferase catalytic activity in the isolated domain was found to be kinetically equivalent to that present in the intact enzyme. Through mobility shift and ultraviolet photolinkage analyses, both domains were shown to bind RNA in a saturable fashion. RNA binding was localized predominantly to the large subunit, but a low level of linkage of RNA to D12L was also observed. A low, but reproducible, level of mRNA (guanine-7-)methyltransferase activity was detected in the isolated D1R(498-844) subunit demonstrating that the active site resides solely within the large subunit of the capping enzyme. This activity is enhanced 30- to 50-fold by the association of the D12L subunit.	SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT BIOCHEM, BUFFALO, NY 14214 USA; SUNY BUFFALO, SCH MED & BIOMED SCI, CTR ADV MOLEC BIOL & IMMUNOL, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIAID NIH HHS [AI28824] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028824] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBOSA E, 1978, J BIOL CHEM, V253, P7692; BAROUDY BM, 1980, J BIOL CHEM, V255, P4372; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CONG PJ, 1993, J BIOL CHEM, V268, P7256; CONG PJ, 1992, J BIOL CHEM, V267, P16424; Dawson R.M.C., 1986, DATA BIOCH RES, P399; FURUICHI Y, 1989, METHOD ENZYMOL, V180, P164; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GUO PX, 1990, P NATL ACAD SCI USA, V87, P4023, DOI 10.1073/pnas.87.11.4023; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HARRIS N, 1993, P NATL ACAD SCI USA, V90, P2860, DOI 10.1073/pnas.90.7.2860; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; HIGMAN MA, 1994, J BIOL CHEM, V269, P14982; KATES J, 1970, J MOL BIOL, V50, P19, DOI 10.1016/0022-2836(70)90101-4; KATES JR, 1967, P NATL ACAD SCI USA, V57, P314, DOI 10.1073/pnas.57.2.314; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUO Y, 1993, J BIOL CHEM, V268, P21253; MARTIN SA, 1975, J BIOL CHEM, V250, P9330; MARTIN SA, 1976, J BIOL CHEM, V251, P7313; MARTIN SA, 1975, J BIOL CHEM, V250, P9322; MORGAN JR, 1984, J VIROL, V51, P283, DOI 10.1128/JVI.51.2.283-297.1984; MOSS B, 1975, J BIOL CHEM, V250, P4722; NILES EG, 1993, J BIOL CHEM, V268, P24986; NILES EG, 1986, VIROLOGY, V153, P96, DOI 10.1016/0042-6822(86)90011-5; NILES EG, 1989, VIROLOGY, V172, P513, DOI 10.1016/0042-6822(89)90194-3; ROHRMANN G, 1986, CELL, V46, P1029, DOI 10.1016/0092-8674(86)90702-6; SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1989, J BIOL CHEM, V264, P21356; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; SHUMAN S, 1989, J BIOL CHEM, V264, P9690; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TUTAS DJ, 1977, J BIOL CHEM, V252, P3092; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6069, DOI 10.1073/pnas.84.17.6069; [No title captured]	41	58	92	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14974	14981						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195132				2022-12-27	WOS:A1994NP73800023
J	SCALONI, A; BARRA, D; JONES, WM; MANNING, JM				SCALONI, A; BARRA, D; JONES, WM; MANNING, JM			HUMAN ACYLPEPTIDE HYDROLASE - STUDIES ON ITS THIOL-GROUPS AND MECHANISM OF ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYLAMINOACYL-PEPTIDE HYDROLASE; ACID-RELEASING ENZYME; PROLYL OLIGOPEPTIDASE; PARA-NITROPHENYL; RAT-LIVER; SEQUENCE-ANALYSIS; SERINE PROTEASES; ENDOPEPTIDASE; PURIFICATION; SPECIFICITY	The presence of a cysteine residue(s) near the active site of acylpeptide hydrolase was suggested by inactivation of the enzyme with sulfhydryl-modifying agents and by the substantial protection against inactivation afforded by the competitive inhibitor acetylmethionine. 5,5'-dithiobis-(2-nitrobenzoate) titrations of the native and the denatured enzyme together with analysis for cysteic acid after performic acid oxidation showed that the enzyme contained 12 free SH groups and three disulfide bonds/monomer. Chemical modification with radiolabeled iodoacetamide led to the labeling of Cys-30 and Cys-64 suggesting that one or both of these Cys residues are close to the active site. Modification of one or both of them probably inhibits the enzyme either because of a distortion of the active site or because the adducts present a barrier to the efficient diffusion of substrates into and products out of the active site. Studies on the mechanism of action of acylpeptide hydrolase have employed p-nitrophenyl-N-propyl carbamate as a potent active site-directed inhibitor. Enzyme inactivation, which follows pseudo first-order kinetics, is diminished by the competitive inhibitor acetylmethionine. The inhibited enzyme slowly regains activity at a rate that is increased in the presence of the nucleophile hydroxylamine. A general mechanism involving an acyl enzyme intermediate is supported by evidence for the formation of acetyl-alanyl hydroxamate during hydrolysis of acetyl-alanine p-nitroanilide in the presence of hydroxylamine. The effects on V-max and K-m during this reaction indicate that hydrolysis of the acyl-enzyme intermediate is rate limiting.	ROCKEFELLER UNIV,NEW YORK,NY 10021; UNIV ROMA LA SAPIENZA,DIPARTIMENTO SCI BIOCHIM A ROSAI FANELLI,I-00185 ROME,ITALY; CNR,CTR BIOL MOLEC,I-00185 ROME,ITALY	Rockefeller University; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR)			Barra, Donatella/D-1236-2011	Scaloni, Andrea/0000-0001-9362-8515	NCRR NIH HHS [507-RR-07065] Funding Source: Medline; NHLBI NIH HHS [HL-18819] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL018819, R01HL018819] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDER ML, 1960, J AM CHEM SOC, V82, P3336, DOI 10.1021/ja01498a027; Cleland W W, 1979, Methods Enzymol, V63, P103; DAVID F, 1993, J BIOL CHEM, V268, P17247; ERLANDSSON R, 1991, ONCOGENE, V6, P1293; FEESE M, 1993, J MOL BIOL, V233, P546, DOI 10.1006/jmbi.1993.1531; FERSHT A, 1985, ENZYME STRUCTURE MEC, P195; HOSIE L, 1987, J BIOL CHEM, V262, P260; HUPEJENSEN B, 1987, LIPIDS, V22, P559; INWARD PW, 1965, J BIOL CHEM, V240, P1986; JONES WM, 1991, P NATL ACAD SCI USA, V88, P2194, DOI 10.1073/pnas.88.6.2194; JONES WM, 1988, BIOCHIM BIOPHYS ACTA, V953, P357, DOI 10.1016/0167-4838(88)90045-3; JONES WM, 1985, BIOCHEM BIOPH RES CO, V126, P933, DOI 10.1016/0006-291X(85)90275-X; KETTNER CA, 1984, J BIOL CHEM, V259, P5106; KOBAYASHI K, 1987, J BIOL CHEM, V262, P11435; KOBAYASHI K, 1989, J BIOL CHEM, V264, P8892; KRISHNA RG, 1992, PROTEIN SCI, V1, P582, DOI 10.1002/pro.5560010504; KRISHNA RG, 1991, ANAL BIOCHEM, V199, P45, DOI 10.1016/0003-2697(91)90267-W; KUHR RJ, 1976, CARBAMATE INSECTICID, P71; MITTA M, 1989, J BIOCHEM-TOKYO, V106, P548, DOI 10.1093/oxfordjournals.jbchem.a122891; NAYLOR SL, 1989, GENOMICS, V4, P355, DOI 10.1016/0888-7543(89)90342-X; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; POLGAR L, 1992, BIOCHEM J, V283, P647, DOI 10.1042/bj2830647; POLGAR L, 1991, EUR J BIOCHEM, V197, P441, DOI 10.1111/j.1432-1033.1991.tb15930.x; POLGAR L, 1992, BIOCHEMISTRY-US, V31, P10769, DOI 10.1021/bi00159a018; POLGAR L, 1992, BIOCHEMISTRY-US, V31, P7729, DOI 10.1021/bi00148a038; POLGAR L, 1989, MECHANISMS PROTEASE, P87; RADHAKRISHNA G, 1989, J BIOL CHEM, V264, P11076; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; SCALONI A, 1992, J BIOL CHEM, V267, P3811; SCALONI A, 1992, J LAB CLIN MED, V120, P546; SCOFIELD RE, 1977, BIOCHEMISTRY-US, V16, P2492, DOI 10.1021/bi00630a027; SHARMA KK, 1993, EUR J BIOCHEM, V216, P631, DOI 10.1111/j.1432-1033.1993.tb18183.x; SHIN HC, 1992, BIOCHEMISTRY-US, V31, P811, DOI 10.1021/bi00118a025; STONE SR, 1991, BIOCHEM J, V276, P837, DOI 10.1042/bj2760837; SUTTON LD, 1986, BIOCHEM BIOPH RES CO, V134, P386, DOI 10.1016/0006-291X(86)90575-9; TAN FL, 1993, J BIOL CHEM, V268, P16631; TSUNASAWA S, 1975, J BIOCHEM, V77, P89; UMEZAWA H, 1980, J ANTIBIOT, V33, P1594, DOI 10.7164/antibiotics.33.1594	39	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15076	15084						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195144				2022-12-27	WOS:A1994NP73800037
J	HOU, D; CENCIARELLI, C; JENSEN, JP; NGUYEN, HB; WEISSMAN, AM				HOU, D; CENCIARELLI, C; JENSEN, JP; NGUYEN, HB; WEISSMAN, AM			ACTIVATION-DEPENDENT UBIQUITINATION OF A T-CELL ANTIGEN RECEPTOR SUBUNIT ON MULTIPLE INTRACELLULAR LYSINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT-LIVED PROTEIN; ZETA-CHAIN; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; CYTOPLASMIC TAIL; DOMAIN; KINASE; POLYPEPTIDE; DEGRADATION	The T cell antigen receptor zeta chain and other T cell antigen receptor components are ubiquitinated on receptor occupancy. A systematic mutagenesis of the zeta subunit was undertaken to determine the sites of ubiquitination. Ubiquitination was found to occur in the cytoplasmic domain of zeta with multiple lysines serving as sites for mono- and polyubiquitination. The mutation of all potential sites of ubiquitination did not inhibit receptor tyrosine phosphorylation or the ubiquitination of other T cell antigen receptor subunits. Lysines introduced into nonnative positions in the zeta molecule were also able to serve as sites for ubiquitination. These findings demonstrate that once a T cell antigen receptor is targeted for ubiquitination, there is little specificity with regard to the lysine residues that are modified.	NCI, BIOL RESPONSE MODIFIERS PROGRAM, IMMUNE CELL BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; FRANK SJ, 1992, J BIOL CHEM, V267, P13656; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JABBEN M, 1989, J BIOL CHEM, V264, P4998; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1993, J BIOL CHEM, V268, P577; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKAMURA T, 1992, ONCOGENE, V7, P733; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; VANDERIJN M, 1990, J IMMUNOL, V145, P1477; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; WEISSMAN AM, 1994, IN PRESS CHEM IMMUNO; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	50	103	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14244	14247						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188707				2022-12-27	WOS:A1994NL60600078
J	SUNADA, Y; BERNIER, SM; KOZAK, CA; YAMADA, Y; CAMPBELL, KP				SUNADA, Y; BERNIER, SM; KOZAK, CA; YAMADA, Y; CAMPBELL, KP			DEFICIENCY OF MEROSIN IN DYSTROPHIC DY MICE AND GENETIC-LINKAGE OF LAMININ M-CHAIN GENE TO DY LOCUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCULAR-DYSTROPHY; GLYCOPROTEIN COMPLEX; SKELETAL-MUSCLE; MOUSE CHROMOSOME-10; SCHWANN-CELLS; PROTEINS; ACTIN; EXPRESSION; BINDING; DOMAIN	Merosin is the predominant laminin isoform in the basal lamina of striated muscle and peripheral nerve, and consists of M, B1 or S, and B2 chains. Here we have demonstrated that merosin is a native ligand for alpha-dystroglycan, an extracellular component of the dystrophin-glycoprotein complex. We have also mapped the mouse M chain gene, Lamm, to the same region of mouse chromosome 10 to which the dystrophia muscularis (dy) locus has been mapped; The dy mutation represents a severe neuromuscular disease resembling human muscular dystrophy. Analysis of merosin expression of dystrophic dy mice revealed a specific deficiency of merosin in skeletal muscle, cardiac muscle, and peripheral nerve. Our results indicate that merosin deficiency may be the primary defect in dy mice and suggest that a disruption of the link between alpha-dystroglycan and merosin may be involved in the pathogenesis of muscle degeneration and peripheral neuropathy in dy mice.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; NIDR,DEV BIOL LAB,BETHESDA,MD 20892; NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892	Howard Hughes Medical Institute; University of Iowa; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Campbell, Kevin/0000-0003-2066-5889				ADAMSON MC, 1991, VIROLOGY, V183, P778, DOI 10.1016/0042-6822(91)91010-E; BRADLEY WG, 1973, J NEUROL SCI, V18, P227, DOI 10.1016/0022-510X(73)90009-9; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ENGVALL E, 1992, EXP CELL RES, V198, P115, DOI 10.1016/0014-4827(92)90156-3; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FABBRIZIO E, 1993, BIOCHEMISTRY-US, V32, P10457, DOI 10.1021/bi00090a023; FARDEAU M, 1993, CR ACAD SCI III-VIE, V316, P799; Green EL, 1981, GENETICS PROBABILITY, P77; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; Hillyard A. L., 1993, Mouse Genome, V91, P15; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; LEVINE BA, 1992, FEBS LETT, V298, P44, DOI 10.1016/0014-5793(92)80019-D; MADRID RE, 1975, NATURE, V257, P319, DOI 10.1038/257319a0; MARDON G, 1990, MOL CELL BIOL, V10, P681, DOI 10.1128/MCB.10.2.681; MATSUMURA K, 1993, FEBS LETT, V334, P281, DOI 10.1016/0014-5793(93)80695-Q; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PASSOSBUENO MR, 1993, HUM MOL GENET, V2, P1945, DOI 10.1093/hmg/2.11.1945; PAULSSON M, 1991, J BIOL CHEM, V266, P17545; PETERSON AC, 1984, J CELL BIOL, V99, P1831, DOI 10.1083/jcb.99.5.1831; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; TAYLOR BA, 1993, MAMM GENOME, V4, pS154, DOI 10.1007/BF00360836; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G	36	285	288	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13729	13732						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188645				2022-12-27	WOS:A1994NL60600002
J	VANDERVORM, ER; KUIPERS, A; KIELKOPFRENNER, S; KRANS, HMJ; MOLLER, W; MAASSEN, JA				VANDERVORM, ER; KUIPERS, A; KIELKOPFRENNER, S; KRANS, HMJ; MOLLER, W; MAASSEN, JA			A MUTATION IN THE INSULIN-RECEPTOR THAT IMPAIRS PRORECEPTOR PROCESSING BUT NOT INSULIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; CELL-SURFACE; PROLINE MUTATION; TRANSPORT; GENE; SITE; SUBSTITUTION; RESISTANCE; AUTOPHOSPHORYLATION; CLEAVAGE	Here we report the identification of a new mutation in the alpha-chain of the insulin receptor, changing Trp(412) into Ser using DNA from consanguineous parents who gave birth to a child with leprechaunism. The mutant receptor was expressed stably in CHO and transiently in COS-1 cells. It was found that the Ser(412) mutant is not cleaved into alpha- and beta-subunits and remains as a 210-kDa proreceptor at an intracellular site. This property of the mutant receptor is in line with the observed decreased insulin binding to the parental fibroblasts. Cross-linkinging experiments show that the Ser(412) proreceptor is able to bind insulin with an affinity comparable to that of the wild-type alpha-chain. Despite its capacity to bind insulin, the mutant receptor is not autophosphorylated. We postulate that the patient was homozygous for the Trp(412)--> Ser mutation and that the mutation was responsible for the leprechaun phenotype. This is the first description of a transport defective receptor with the mutation outside the tetrabasic processing site and a functional insulin binding domain. The ability of the Ser(412) mutant to bind insulin in cross-linking experiments suggests that the impaired transport of the proreceptor to the cell surface is the primary cause for the binding defect to intact cells.	LEIDEN STATE UNIV,SYLVIUS LABS,DEPT BIOCHEM MED,2333 AL LEIDEN,NETHERLANDS; UNIV TUBINGEN,DEPT CLIN GENET,W-7400 TUBINGEN,GERMANY; ACAD HOSP LEIDEN,DEPT ENDOCRINOL & METAB DIS,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Eberhard Karls University of Tubingen; Leiden University; Leiden University Medical Center (LUMC)								ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BECKER AB, 1990, ANNU REV MED, V41, P99; COLLIER E, 1993, BIOCHEMISTRY-US, V32, P7818, DOI 10.1021/bi00081a029; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KADOWAKI T, 1991, J BIOL CHEM, V266, P21224; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KLINKHAMER MP, 1989, EMBO J, V8, P2503, DOI 10.1002/j.1460-2075.1989.tb08387.x; LANE MD, 1985, BIOCHIMIE, V67, P1069, DOI 10.1016/S0300-9084(85)80104-8; MAASSEN JA, 1988, DIABETOLOGIA, V31, P612, DOI 10.1007/BF00264769; MAASSEN JA, 1991, BIOCHEMISTRY-US, V30, P10778, DOI 10.1021/bi00108a024; QUON MJ, 1992, BIOCHEMISTRY-US, V31, P9947, DOI 10.1021/bi00156a013; SCHUMACHER MC, 1992, DIABETES, V41, P416, DOI 10.2337/diabetes.41.4.416; SUGIBAYASHI M, 1992, METABOLISM, V41, P820, DOI 10.1016/0026-0495(92)90161-3; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; VANDERVORM ER, 1992, J BIOL CHEM, V267, P66; WILLIAMS JF, 1990, J BIOL CHEM, V265, P8463; YIP CC, 1992, J CELL BIOCHEM, V48, P19, DOI 10.1002/jcb.240480105; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858	20	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14297	14302						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188715				2022-12-27	WOS:A1994NL60600086
J	MCALLISTERLUCAS, LM; SONNENBURG, WK; KADLECEK, A; SEGER, D; TRONG, HL; COLBRAN, JL; THOMAS, MK; WALSH, KA; FRANCIS, SH; CORBIN, JD; BEAVO, JA				MCALLISTERLUCAS, LM; SONNENBURG, WK; KADLECEK, A; SEGER, D; TRONG, HL; COLBRAN, JL; THOMAS, MK; WALSH, KA; FRANCIS, SH; CORBIN, JD; BEAVO, JA			THE STRUCTURE OF A BOVINE LUNG CGMP-BINDING, CGMP-SPECIFIC PHOSPHODIESTERASE DEDUCED FROM A CDNA CLONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; SELECTIVE-INHIBITION; ALPHA-SUBUNIT; BETA-SUBUNIT; STIMULATED PHOSPHODIESTERASE; MOLECULAR-CLONING; PROTEIN SEQUENCES; GMP BINDING; IDENTIFICATION; DOMAIN	Polymerase chain reaction (PCR) methodology and cDNA library screening were used to isolate a cDNA clone encoding a cGMP-binding, cGMP-specific phosphodiesterase (cGB-PDE) from bovine lung. Degenerate oligonucleotides based on cGB-PDE peptide sequences were used as primers for a PCR reaction with bovine lung cDNA as the template. An 824-base pair PCR product was recovered and used as a probe to screen a bovine lung cDNA library. A 4.5-kilobase pair cDNA clone encoding a full-length cGB-PDE was isolated. The open reading frame of this cDNA predicted an 875 amino acid (AA), 99,525-Da polypeptide. By Northern analysis, the cGB-PDE cDNA hybridized to a single lung 6.9-kilobase mRNA. The identity of the cGB-PDE cDNA was verified by comparison of the deduced AA sequence with several peptide sequences obtained from cGB-PDE. COS-7 cells transfected with cGB-PDE cDNA overexpressed cGMP-binding and cGMP-PDE activities characteristic of lung cGB-PDE. The sequence of cGB-PDE contained a segment (AA 578-812) that was homologous to the putative catalytic region conserved among all mammalian PDEs and a segment (AA 142-526) that was homologous to the putative cGMP binding region of the cGMP-stimulated PDE and the photoreceptor PDEs. As noted also for these PDEs, two internally homologous repeats were contained within the putative cGMP binding region of cGB-PDE. The amino-terminal 142 residues of cGB-PDE showed no significant homology to other PDEs and contained the serine (AA 92) which is phosphorylated by cGMP-dependent protein kinase.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA; UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	Vanderbilt University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029, R01DK021723] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK21723, DK40029] Funding Source: Medline; NIGMS NIH HHS [GM15731] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BAEHR W, 1991, FEBS LETT, V278, P107, DOI 10.1016/0014-5793(91)80095-K; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS F, 1992, BIOCHEM J, V283, P487, DOI 10.1042/bj2830487; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7931, DOI 10.1021/bi00246a009; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CHARONNEAU H, 1991, CYCLIC NUCLEOTIDE PH, P267; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; COLLINS C, 1992, GENOMICS, V13, P698, DOI 10.1016/0888-7543(92)90144-H; COQUIL JF, 1985, BIOCHEM BIOPH RES CO, V127, P226, DOI 10.1016/S0006-291X(85)80148-0; COQUIL JF, 1980, BIOCHIM BIOPHYS ACTA, V631, P148, DOI 10.1016/0304-4165(80)90063-X; DAVIS CW, 1977, J BIOL CHEM, V252, P4078; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FENG DF, 1990, METHOD ENZYMOL, V183, P375; FLOCKHART DA, 1984, BRAIN RECEPTOR MET A, P209; FRANCIS SH, 1980, J BIOL CHEM, V255, P620; FRANCIS SH, 1988, METHOD ENZYMOL, V159, P722; FRANCIS SH, 1991, CYCLIC NUCLEOTIDE PH, P117; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GILLESPIE PG, 1991, CYCLIC NUCLEOTIDE PH, P163; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HAMET P, 1984, ADV CYCLIC NUCL PROT, V16, P119; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAMER GL, 1977, BIOCHEMISTRY-US, V16, P3316, DOI 10.1021/bi00634a006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; LUGNIER C, 1986, BIOCHEM PHARMACOL, V35, P1743, DOI 10.1016/0006-2952(86)90333-3; MANGANIELLO VC, 1991, CYCLIC NUCLEOTIDE PH, P87; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PITTLER SJ, 1990, GENOMICS, V6, P272, DOI 10.1016/0888-7543(90)90567-E; REEVES ML, 1991, CYCLIC NUCLEOTIDE PH, P299; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SONNENBURG WK, 1991, J BIOL CHEM, V266, P17655; STRAUS NA, 1991, BIOTECHNIQUES, V10, P376; STROOP SD, 1991, J BIOL CHEM, V266, P23802; STROOP SD, 1989, J BIOL CHEM, V264, P13718; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; THOMAS MK, 1990, THESIS VANDERILT U; TRONG HL, 1990, BIOCHEMISTRY-US, V29, P10280, DOI 10.1021/bi00496a018; WANG JH, 1991, CYCLIC NUCLEOTIDE PH, P19; WELLS JN, 1981, J MED CHEM, V24, P954, DOI 10.1021/jm00140a008; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; YAMAMOTO T, 1984, BIOCHEMISTRY-US, V23, P670, DOI 10.1021/bi00299a013; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619	62	137	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22863	22873						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226796				2022-12-27	WOS:A1993MD34800099
J	MORO, O; LAMEH, J; HOGGER, P; SADEE, W				MORO, O; LAMEH, J; HOGGER, P; SADEE, W			HYDROPHOBIC AMINO-ACID IN THE I2-LOOP PLAYS A KEY ROLE IN RECEPTOR-G-PROTEIN COUPLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SITE-DIRECTED MUTAGENESIS; BETA-ADRENERGIC-RECEPTOR; MUSCARINIC ACETYLCHOLINE-RECEPTORS; HUMAN BETA-2-ADRENERGIC RECEPTOR; 3RD CYTOPLASMIC LOOP; RHODOPSIN; TRANSDUCIN; EXPRESSION; DOMAINS; ACTIVATION	Signal transduction of the heptahelical G protein-coupled receptors (GPCRs) involves multiple receptor domains, but a universal consensus domain for coupling has not yet been defined. Alanine mutagenesis scanning was performed on the intracellular loops and the COOH tail of the human muscarinic cholinergic receptor (Hm1) to identify coupling domains. Stimulation of phosphatidylinositol (PI) turnover was determined after transfection of the alanine mutants into U293 human embryonic kidney cells. Alanine substitutions in four regions (loops i1, i2, and NH2 and COOH junctions of i3) impaired coupling efficiency by approximately 50% or more, but the strongest reduction (>80%) resulted from alanine replacement of a single amino acid, leucine 131. This residue is located in the middle of the second intracellular loop (i2), within the highly conserved GPCR motif (DRYXXV(I)XXPL). The position equivalent to Leu-131 in Hm1 contains a bulky hydrophobic amino acid (L, I, V, M, or F) in nearly all cloned GPCRs. Substitution of Leu-131 with polar amino acids (aspartate and asparagine) also resulted in strongly defective coupling, whereas phenylalanine (found in the equivalent position in the beta2 adrenoceptor) can replace leucine without losing PI coupling ability of Hm1. Alanine substitution of the corresponding amino acid in the Hm3 receptor (L174A) also inhibited agonist-stimulated PI turnover, while replacing Phe-139 with alanine in the beta2 adrenoceptor suppressed stimulation of adenylyl cyclase. We propose that a bulky hydrophobic amino acid in the middle of the i2 loop serves as a general site relevant to G protein coupling, whereas coupling selectivity is governed by other receptor domains.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	MORO, O (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARM,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K21MH000996] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43102] Funding Source: Medline; NIMH NIH HHS [MH00996] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARDEN JR, 1992, BIOCHEM BIOPH RES CO, V188, P1111, DOI 10.1016/0006-291X(92)91346-R; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRASER CM, 1989, MOL PHARMACOL, V36, P840; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LAMEH J, 1990, PHARMACEUT RES, V7, P1213, DOI 10.1023/A:1015969301407; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MORO O, 1993, J BIOL CHEM, V268, P6862; MUNCH G, 1991, EUR J BIOCHEM, V198, P357, DOI 10.1111/j.1432-1033.1991.tb16023.x; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; WEISS ER, 1988, J BIOL CHEM, V263, P6150; WONG SKF, 1990, J BIOL CHEM, V265, P6219	26	195	199	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22273	22276						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226735				2022-12-27	WOS:A1993MD34800016
J	ZHANG, MJ; VOGEL, HJ				ZHANG, MJ; VOGEL, HJ			DETERMINATION OF THE SIDE-CHAIN PK(A) VALUES OF THE LYSINE RESIDUES IN CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR-SPECTROSCOPY; HETERONUCLEAR CORRELATION; MULTIDIMENSIONAL NMR; PEPTIDE COMPLEX; LYSYL RESIDUES; BINDING-SITES; TROPONIN-C; PROTEINS; REACTIVITIES; PROTON	The 7 Lys residues in mammalian calmodulin (CaM) were reductively methylated with C-17-enriched formaldehyde and studied by (H-1, C-13)-heteronuclear multiple quantum coherence (HMQC) NMR. The apo- and Ca2+-forms of CaM, as well as a complex with a 22-residue peptide which comprises the CaM binding region of myosin light chain kinase were studied. The complete assignment of the two-dimensional NMR spectra was obtained by site-directed mutagenesis (Lys-->Gln) of all the Lys. The pK(a) values for the individual Lys could be determined by pH titration experiments. In Ca2+-CaM, the pK(a) values range from 9.29 (Lys-75) to 10.23 (Lys-77). The Lys in apo-CaM have higher pK(a) values than those in Ca2+-CaM. The binding of the myosin light chain kinase peptide gives rise to an increase of the pK(a) values of Lys-148 and Lys-75 by 0.5 and 0.8 pH units, respectively; this results from the relocation of their side chains to a completely solvent accessible state. The changes in the pK(a) values upon binding Ca2+ or the myosin light chain kinase peptide show a remarkable correlation with earlier reported chemical reactivity changes. Thus, our results indicate that pK(a) values, rather than structural and steric effects, play the dominant role in determining the reactivity of Lys side chains towards small electrophilic chemical modification reagents. The methodology used here could prove useful for the determination of individual pK(a) values in other proteins.	UNIV CALGARY, DEPT BIOL SCI, 2500 UNIV DR NW, CALGARY T2N 1N4, ALBERTA, CANADA	University of Calgary				Zhang, Mingjie/0000-0001-9404-0190				ANDERSSON A, 1983, BIOCHEMISTRY-US, V22, P2039; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BASHFORD D, 1990, BIOCHEMISTRY-US, V29, P10219, DOI 10.1021/bi00496a010; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BRADBURY JH, 1973, EUR J BIOCHEM, V40, P565, DOI 10.1111/j.1432-1033.1973.tb03228.x; BRODIN P, 1989, PROTEIN ENG, V2, P353, DOI 10.1093/protein/2.5.353; BROWN LR, 1975, EUR J BIOCHEM, V54, P219, DOI 10.1111/j.1432-1033.1975.tb04131.x; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CACECI MS, 1984, BYTE, V9, P340; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; DWYER LD, 1992, J BIOL CHEM, V267, P22606; FAUST FM, 1987, J BIOL CHEM, V262, P1938; Fersht A., 1985, ENZYME STRUCTURE MEC; FORSEN S, 1986, CALCIUM CELL FUNCTIO, V6, P113; GERKEN TA, 1984, BIOCHEMISTRY-US, V23, P4688, DOI 10.1021/bi00315a026; GIEDROC DP, 1985, J BIOL CHEM, V260, P3406; GIEDROC DP, 1987, ARCH BIOCHEM BIOPHYS, V252, P136, DOI 10.1016/0003-9861(87)90017-8; GUERINI D, 1987, EUR J BIOCHEM, V170, P35, DOI 10.1111/j.1432-1033.1987.tb13664.x; HIRAOKI T, 1987, J CARDIOVASC PHARM, V10, pS14, DOI 10.1097/00005344-198710001-00004; HUQUE ME, 1993, IN PRESS J PROTEIN C; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1991, BIOCHEMISTRY-US, V30, P9216, DOI 10.1021/bi00102a013; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JACKSON AE, 1984, J BIOL CHEM, V259, P4985; JACKSON AE, 1986, J BIOL CHEM, V261, P2226; JARRETT HW, 1984, J BIOL CHEM, V259, P136; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; Lundblad R.L, 1984, CHEM REAGENTS PROTEI, VI; MANALAN AS, 1987, BIOCHEMISTRY-US, V26, P1382, DOI 10.1021/bi00379a026; MANN DM, 1988, J BIOL CHEM, V263, P11284; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; MONTELIONE GT, 1989, J AM CHEM SOC, V111, P3096, DOI 10.1021/ja00190a072; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NEWTON DL, 1989, BIOCHEMISTRY-US, V28, P3750, DOI 10.1021/bi00435a019; PITNER TP, 1974, NATURE, V250, P582, DOI 10.1038/250582a0; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; RAO ST, 1993, PROTEIN SCI, V2, P436; SANCHO J, 1992, BIOCHEMISTRY-US, V31, P2253, DOI 10.1021/bi00123a006; Schulz G. E., 1979, PRINCIPLES PROTEIN S; SPERA S, 1991, Journal of Biomolecular NMR, V1, P155, DOI 10.1007/BF01877227; STRYNADKA NCJ, 1988, PROTEINS, V3, P1, DOI 10.1002/prot.340030102; TANFORD C, 1972, BIOCHEMISTRY-US, V11, P2192, DOI 10.1021/bi00761a029; TYBURN JM, 1992, J MAGN RESON, V97, P305, DOI 10.1016/0022-2364(92)90315-X; UHLIN BE, 1983, GENE, V22, P255, DOI 10.1016/0378-1119(83)90110-5; VOGEL HJ, 1983, FEBS LETT, V157, P241, DOI 10.1016/0014-5793(83)80554-7; WANNER BL, 1977, J BACTERIOL, V130, P212, DOI 10.1128/JB.130.1.212-222.1977; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; WINKLER MA, 1987, J BIOL CHEM, V262, P15466; YANG AS, 1993, PROTEINS, V15, P252, DOI 10.1002/prot.340150304; ZHANG M, 1993, B MAGN RESON, V15, P95	57	92	95	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22420	22428						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226750				2022-12-27	WOS:A1993MD34800038
J	ALLAND, L; PESECKIS, SM; ATHERTON, RE; BERTHIAUME, L; RESH, MD				ALLAND, L; PESECKIS, SM; ATHERTON, RE; BERTHIAUME, L; RESH, MD			DUAL MYRISTYLATION AND PALMITYLATION OF SRC FAMILY MEMBER P59(FYN) AFFECTS SUBCELLULAR-LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNITS; PALMITIC ACID; PALMITOYLATION; PROTEINS; ACYLATION; RECEPTOR; MUTATION; DOMAIN; MOTIF	The Src family consists of nine related tyrosine protein kinases with a common domain structure, including a myristylated N-terminal glycine residue. In this report, we identify cysteine residues within the N-terminal region of the Src family member Fyn which serve as sites for palmitylation. To facilitate detection of protein fatty acylation, p59(fyn) was overexpressed in COS cells and incubated with radioiodinated fatty acid analogs of myristate (IC13) or palmitate (IC16), Incorporation of both fatty acids into p59(fyn) was readily observed. Acylation with the palmitate analog was prevented when Gly-2 was mutated to alanine, implying that N-myristylation is required for palmitylation, and when either Cys-3 or Cys-6 was mutated to serine. Palmitylation was shown to alter the distribution of p59(fyn) between mem brane-bound and soluble fractions. In contrast, no incorporation of the palmitate analog into pp60(v-src), which lacks N-terminal cysteine residues, was observed. Mutation of Ser-3 of Src to cysteine, but not Ser-6, resulted in incorporation of the palmitate analog. These results serve to delineate sequence elements important for dual acylation of proteins, and further illustrate the utility of radioiodinated fatty acid analogs for studies of protein fatty acid acylation.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center				Berthiaume, Luc/0000-0003-0926-059X; Resh, Marilyn/0000-0001-6118-9466	NATIONAL CANCER INSTITUTE [R01CA052405] Funding Source: NIH RePORTER; NCI NIH HHS [CA-52405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERTHIAUME L, 1994, J BIOL CHEM, V269, P6498; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DEICHAITE I, 1993, J BIOL CHEM, V268, P13738; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MACK D, 1988, BIOCHEM J, V256, P1021, DOI 10.1042/bj2561021; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PESECKIS SM, 1993, J BIOL CHEM, V268, P5107; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SILVERMAN L, 1993, CELL GROWTH DIFFER, V4, P475; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441	22	183	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16701	16705						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206991				2022-12-27	WOS:A1994NR29600031
J	CHEN, W; DIECKMANN, CL				CHEN, W; DIECKMANN, CL			CBP1P IS REQUIRED FOR MESSAGE STABILITY FOLLOWING 5'-PROCESSING OF COB MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL-MEMBRANE SYSTEM; YEAST NUCLEAR GENE; PRE-MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; CYTOCHROME-B; TRANSCRIPTS; TRANSFORMATION; IDENTIFICATION; RECOMBINATION; MUTAGENESIS	Cbp1p is a nuclear encoded protein required for the stabilization of mitochondrial COB mRNA, which codes for apocytochrome b in the yeast Saccharomyces cerevisiae. The COB gene is cotranscribed with the upstream tRNA(Glu) gene. Release of tRNA(Glu) from the initial transcript generates a precursor mRNA with a 5'-end at position -1098. The 5'-end of mature COB message is generated by cleavage of the pre-mRNA at nucleotide -955 or -954. Previous work indicated that Cbp1p acts through cis-elements near these cleavage sites. Here we have tested whether Cbp1p stabilizes COB mRNA solely by stimulating the processing of COB precursor RNA at nucleotide -955/-954. Yeast strain TG955 was constructed such that the -955 COB mRNA 5'-processing site coincides with the upstream tRNA 3'-endonuclease site at position -1098, allowing the 5-'end of COB mRNA to be formed by the tRNA 3'-processing enzyme. Respiratory growth and stability of COB mRNA in TG955 are Cbp1p-dependent. Therefore, we conclude that Cbp1p is important for the stabilization of COB mRNA after 5'-processing.	UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721	University of Arizona					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034893] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34893] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER NJ, 1980, CELL, V20, P199, DOI 10.1016/0092-8674(80)90247-0; BOLOTINFUKUHARA M, 1992, ANTON LEEUW INT J G, V62, P131, DOI 10.1007/BF00584467; BONITZ SG, 1982, J BIOL CHEM, V257, P6268; CAPONIGRO G, 1993, MOL CELL BIOL, V13, P5141, DOI 10.1128/MCB.13.9.5141; CHEN JY, 1988, J BIOL CHEM, V263, P13677; COHEN SN, 1972, P NATL ACAD SCI USA, V80, P5564; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DIECKMANN CL, 1994, INT REV CYTOL, V152, P145, DOI 10.1016/S0074-7696(08)62556-5; DIECKMANN CL, 1984, J BIOL CHEM, V259, P4722; FOURY F, 1978, J BIOL CHEM, V253, P3792; FOX TD, 1988, P NATL ACAD SCI USA, V85, P7288, DOI 10.1073/pnas.85.19.7288; HOLLINGSWORTH MJ, 1986, MOL CELL BIOL, V6, P1058, DOI 10.1128/MCB.6.4.1058; JOHNSTON SA, 1988, SCIENCE, V240, P1538, DOI 10.1126/science.2836954; KUCHKA MR, 1989, CELL, V58, P869, DOI 10.1016/0092-8674(89)90939-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARTIN NC, 1985, J BIOL CHEM, V260, P1479; MAYER SA, 1989, MOL CELL BIOL, V9, P4161, DOI 10.1128/MCB.9.10.4161; MCGRAW P, 1983, J BIOL CHEM, V258, P9459; MIN JJ, 1993, MOL CELL BIOL, V13, P4167, DOI 10.1128/MCB.13.7.4167; MITTELMEIER TM, 1990, CURR GENET, V18, P421, DOI 10.1007/BF00309911; MITTELMEIER TM, 1993, MOL CELL BIOL, V13, P4203, DOI 10.1128/MCB.13.7.4203; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; RODEL G, 1985, CURR GENET, V9, P641, DOI 10.1007/BF00449816; RODEL G, 1986, CURR GENET, V11, P41, DOI 10.1007/BF00389424; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LABORATO; SCHUSTER G, 1991, EMBO J, V10, P1493, DOI 10.1002/j.1460-2075.1991.tb07669.x; STAPLES RR, 1993, GENETICS, V135, P981; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; WEBER ER, 1990, J BIOL CHEM, V265, P1594; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P469	33	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16574	16578						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206974				2022-12-27	WOS:A1994NR29600011
J	DERETIC, D; AEBERSOLD, RH; MORRISON, HD; PAPERMASTER, DS				DERETIC, D; AEBERSOLD, RH; MORRISON, HD; PAPERMASTER, DS			ALPHA-A-CRYSTALLIN AND ALPHA-B-CRYSTALLIN IN THE RETINA - ASSOCIATION WITH THE POST-GOLGI COMPARTMENT OF FROG RETINAL PHOTORECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; LENS-SPECIFIC EXPRESSION; SEGMENT DISK FORMATION; AMINO-ACID SEQUENCE; NIH 3T3 FIBROBLASTS; TRANSGENIC MICE; QUATERNARY STRUCTURE; GEL-ELECTROPHORESIS; MOLECULAR CHAPERONE; CALF LENS	alpha A- and alpha B-Crystallins are significant contributors to maintaining the transparency of the vertebrate lens. We have found that both alpha A- and alpha B-crystallins are also present, at approximately equimolar concentrations, in frog retinal cells. They were identified by sequencing portions of each polypeptide, by immunochemical cross-reactivity with antibodies to bovine alpha-crystallins, and by their relative mobility in two-dimensional gel electrophoresis. Retinal alpha-crystallins form macromolecular multimeric complexes similar to those found in the lens, and they are abundant both in soluble and membrane-associated forms. A surprising finding is that alpha-crystallins bind specifically to the photoreceptor post-Golgi membranes that mediate transport of newly synthesized rhodopsin. Upon treatment of post-Golgi membranes with urea or Triton X-114, a portion of the bound alpha B-crystallin remains tightly associated, indicating that the alpha B-form may mediate membrane binding of an alpha-crystallin multimeric complex. Both subunits are synthesized in vitro by isolated frog retinas, but alpha B-crystallin appears to have a higher renewal rate. Newly synthesized alpha-crystallins become associated with the post-Golgi membranes concurrently with newly synthesized rhodopsin. Association of alpha-crystallins with newly synthesized rhodopsin suggests that they may participate in photoreceptor outer segment membrane renewal. Our findings implicate an important function for both alpha A- and alpha B-crystallins in the same, extralenticular, tissue.	UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC,CANADA	University of British Columbia	DERETIC, D (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284, USA.				NEI NIH HHS [EY-6891] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AEBERSOLD R, 1992, TECHNIQUES PROTEIN C, V3, P87; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; AUGUSTEYN RC, 1988, BIOCHIM BIOPHYS ACTA, V957, P192, DOI 10.1016/0167-4838(88)90272-5; AUGUSTEYN RC, 1987, FEBS LETT, V222, P1, DOI 10.1016/0014-5793(87)80180-1; BARBE MF, 1988, SCIENCE, V241, P1817, DOI 10.1126/science.3175623; BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BHAT SP, 1991, EUR J BIOCHEM, V102, P775; BINDELS JG, 1979, OPHTHALMIC RES, V11, P441, DOI 10.1159/000265048; BLOEMENDAL H, 1972, EUR J BIOCHEM, V24, P401, DOI 10.1111/j.1432-1033.1972.tb19699.x; BRAVO R, 1984, 2 DIMENSIONAL GEL EL, P3; CHAITIN MH, 1984, J CELL BIOL, V99, P239, DOI 10.1083/jcb.99.1.239; CHIESA R, 1987, J BIOL CHEM, V262, P1438; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; DELVECCHIO PJ, 1984, CURR EYE RES, V3, P1213; DERETIC D, 1993, J CELL SCI, V106, P803; DERETIC D, 1991, J CELL BIOL, V113, P1281, DOI 10.1083/jcb.113.6.1281; DERETIC D, 1993, METH NEUROSCI, V15, P108; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; DUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738, DOI 10.1073/pnas.85.15.5738; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HESS D, 1993, PROTEIN SCI, V2, P1342, DOI 10.1002/pro.5560020817; HOLT GD, 1987, J BIOL CHEM, V262, P14847; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; IFEANYI F, 1991, EXP EYE RES, V52, P535, DOI 10.1016/0014-4835(91)90054-I; INAGUMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P844, DOI 10.1016/0006-291X(92)91809-5; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KATO K, 1992, J BIOL CHEM, V267, P7718; KLEMENT JF, 1989, J BIOL CHEM, V264, P19837; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDEL CP, 1988, GENE DEV, V2, P1168, DOI 10.1101/gad.2.9.1168; LASSER A, 1972, EXP EYE RES, V13, P292, DOI 10.1016/0014-4835(72)90111-X; LEWIS GP, 1988, EXP EYE RES, V47, P839, DOI 10.1016/0014-4835(88)90067-X; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P121, DOI 10.1007/BF00221053; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MISKIN R, 1990, EUR J BIOCHEM, V190, P31, DOI 10.1111/j.1432-1033.1990.tb15541.x; NAKAMURA T, 1990, MOL CELL BIOL, V10, P3700, DOI 10.1128/MCB.10.7.3700; OVERBEEK PA, 1985, P NATL ACAD SCI USA, V82, P7815, DOI 10.1073/pnas.82.23.7815; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PATTERSON SD, 1992, ANAL BIOCHEM, V202, P193, DOI 10.1016/0003-2697(92)90227-X; QUAXJEUKEN Y, 1985, P NATL ACAD SCI USA, V82, P5819, DOI 10.1073/pnas.82.17.5819; RADLICK LW, 1992, BIOCHIM BIOPHYS ACTA, V1120, P193, DOI 10.1016/0167-4838(92)90269-J; RAMAEKERS FCS, 1980, BIOCHIM BIOPHYS ACTA, V596, P57, DOI 10.1016/0005-2736(80)90170-4; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; SCHURTENBERGER P, 1991, BIOPOLYMERS, V31, P1229, DOI 10.1002/bip.360311011; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; TAKEHANA M, 1987, INVEST OPHTH VIS SCI, V28, P780; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; TOMAREV SI, 1983, FEBS LETT, V162, P47, DOI 10.1016/0014-5793(83)81046-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; VANDEROU.FJ, 1974, EUR J BIOCHEM, V49, P157; WALSH MT, 1991, J BIOL CHEM, V266, P20079; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	67	89	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16853	16861						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207008				2022-12-27	WOS:A1994NR29600053
J	HOFFMAN, L; RECHSTEINER, M				HOFFMAN, L; RECHSTEINER, M			ACTIVATION OF THE MULTICATALYTIC PROTEASE - THE 11-S REGULATOR AND 20-S ATPASE COMPLEXES CONTAIN DISTINCT 30-KILODALTON SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOLYTIC COMPLEX; PROTEINASE COMPLEX; 26S COMPLEX; THERMOPLASMA-ACIDOPHILUM; 26-S PROTEASE; UBIQUITIN; PURIFICATION; MICROSCOPY; RESOLUTION; COMPONENTS	The multicatalytic protease (MCP) associates with a 20 S ATPase complex in the presence of ATP to form the 26 S ubiquitin/ATP dependent protease. This association results in a uniform 3-fold activation of peptide hydrolysis by MCP. In the absence of nucleotides, an 11 S regulator binds MCP and differentially stimulates its peptidase activities from 3-fold to 25-fold depending upon the peptide. When incubated separately with ATPase complex or regulator, ah MCP molecules are converted to 26 S protease or to an activated MCP, respectively. Competition between ATPase complex and regulator for limiting amounts of MCP results in the 26 S protease as the only assembled species. Rabbit reticulocyte regulator is composed of a single 30-kDa protein. Among the 15 subunits in the ATPase complex, there is also a 30-kDa protein. Three findings demonstrate that the 30-kDa subunits in each complex are distinct proteins. First, two-dimensional polyacrylamide gel revealed different isoelectric points for each 30-kDa protein. Second, anti-regulator antibodies did not cross-react with proteins in the ATPase complex or in the 26 S protease. Third, directly sequenced peptides from the 30-kDa subunit of the ATPase complex are not present in the deduced amino acid sequence of the regulator. Thus, the regulator and ATPase complex are independent activators of MCP.			HOFFMAN, L (corresponding author), UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132, USA.				NCI NIH HHS [CA-09602] Funding Source: Medline; NIGMS NIH HHS [GM-37009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMON T, 1990, J BIOL CHEM, V265, P20723; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DICOLA D, 1992, ITAL J BIOCHEM, V41, P213; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; IKAI A, 1991, FEBS LETT, V292, P21, DOI 10.1016/0014-5793(91)80824-M; KANAYAMA HO, 1992, EUR J BIOCHEM, V206, P567, DOI 10.1111/j.1432-1033.1992.tb16961.x; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P49; LINGRELL J, 1972, PROTEIN BIOSYNTHESIS, P234; MA CP, 1992, J BIOL CHEM, V267, P10515; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PETERS JM, 1991, EUR J CELL BIOL, V56, P422; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; REALINI C, 1994, IN PRESS J BIOL CHEM; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; TANAKA K, 1992, NEW BIOL, V4, P173; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YUKAWA M, 1991, BIOCHEM BIOPH RES CO, V178, P256, DOI 10.1016/0006-291X(91)91807-O; ZWICKL P, 1991, FEBS LETT, V278, P217, DOI 10.1016/0014-5793(91)80120-R; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	33	81	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16890	16895						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207011				2022-12-27	WOS:A1994NR29600057
J	MCBROOM, LDB; SADOWSKI, PD				MCBROOM, LDB; SADOWSKI, PD			DNA BENDING BY SACCHAROMYCES-CEREVISIAE ABF1 AND ITS PROTEOLYTIC FRAGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; TRANSCRIPTIONAL REPRESSION; NUCLEOPROTEIN STRUCTURES; YEAST SILENCER; BINDING-SITES; FACTOR-I; PROTEIN; REPLICATION; SEQUENCE; RAP1	The ABF1 protein of the yeast Saccharomyces cerevisiae has been found to bend the DNA containing the target site for DNA binding. A bend angle of about 120 degrees was measured and the bend center was 7 base pairs to the 5' end of the ABF1 consensus-containing sequence. Phasing analysis showed that intact ABF1 bends the DNA towards the minor groove. We have subjected ABF1 to partial proteolysis and have found that proteolytic fragments were able to bind to the DNA-binding site and induce partial bends in the DNA Interestingly, the locations of the bend centers, the bend angles, and the plane of the bends induced by the proteolytic peptides of ABF1 were different from those of the intact protein. We present a model for the mechanism of bending of DNA by ABF1.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA	University of Toronto								BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; HALFTER H, 1989, EMBO J, V8, P3029, DOI 10.1002/j.1460-2075.1989.tb08453.x; HALFTER H, 1989, EMBO J, V8, P4265, DOI 10.1002/j.1460-2075.1989.tb08612.x; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; MAHONEY DJ, 1991, GENE DEV, V5, P605, DOI 10.1101/gad.5.4.605; MCBROOM LDB, 1994, J BIOL CHEM, V269, P16455; MOEHLE CM, 1991, MOL CELL BIOL, V11, P2723, DOI 10.1128/MCB.11.5.2723; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; RHODE PR, 1992, MOL CELL BIOL, V12, P1064, DOI 10.1128/MCB.12.3.1064; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAWICK JD, 1992, MOL CELL BIOL, V12, P2302, DOI 10.1128/MCB.12.5.2302; VIGNAIS ML, 1989, J BIOL CHEM, V264, P8463; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0; ZWIEB C, 1989, GENE DEV, V3, P606, DOI 10.1101/gad.3.5.606	23	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16461	16468						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206955				2022-12-27	WOS:A1994NQ72900076
J	SCHWARZ, PM; HANSEN, JC				SCHWARZ, PM; HANSEN, JC			FORMATION AND STABILITY OF HIGHER-ORDER CHROMATIN STRUCTURES - CONTRIBUTIONS OF THE HISTONE OCTAMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWLY REPLICATED CHROMATIN; RNA POLYMERASE-II; ONE H2A.H2B DIMER; HYPERSENSITIVE SITES; ACTIVE CHROMATIN; MMTV PROMOTER; CORE HISTONES; BETA-GLOBIN; TRANSCRIPTION; NUCLEOSOME	Unique roles have been identified for the histone octamer in the formation and stabilization of higher order chromatin structures. Histone octamers were assembled onto 12 tandem repeats of Lytechinus 5 S rDNA, at either saturating or subsaturating ratios. The extent of oligonucleosome folding and intermolecular association in divalent salts was monitored using analytical and differential sedimentation techniques. Saturated oligonucleosomes (12 nucleosomes/DNA) sedimented at 29 S in very low salt buffer. In 1.0-2.0 mM MgCl2, saturated oligonucleosomes formed a maximally folded 55 S structure whose extent of compaction was equivalent to that of classical higher order 30-nm diameter chromatin structures. These results are in marked contrast to those obtained previously in NaCl, where the maximally folded oligonucleosome species sedimented at only similar to 40 S (Hansen, J.C., Ausio, J., Stanik, V.H., and van Holde, K.E. (1989) Biochemistry 28, 9129-9136). Mg2+-dependent formation of the 55 S conformation was inhibited by histone octamer depletion; the maximum sedimentation coefficient observed for rDNA molecules containing 10-11 nucleosomes in 2.0 mM MgCl2 was only 40 S. Above 2.0 mM MgCl2, the equilibrium was progressively shifted toward formation of large associated oligonucleosome species. The implications of these results to the mechanism of chromatin folding and its relationship to the biological activity of the chromatin fiber are discussed.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR008352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045916, R01GM045916] Funding Source: NIH RePORTER; NCRR NIH HHS [RR08352] Funding Source: Medline; NIGMS NIH HHS [GM45916] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1981, J CELL BIOL, V90, P279, DOI 10.1083/jcb.90.2.279; ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1981, DOI 10.1021/bi00356a022; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; BLOOMFIE.V, 1967, BIOPOLYMERS, V5, P135, DOI 10.1002/bip.1967.360050202; BOROCHOV N, 1984, NUCLEIC ACIDS RES, V12, P3089, DOI 10.1093/nar/12.7.3089; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; BUTLER PJG, 1980, J MOL BIOL, V140, P505, DOI 10.1016/0022-2836(80)90268-5; CARPENTER BG, 1976, NUCLEIC ACIDS RES, V3, P1739, DOI 10.1093/nar/3.7.1739; CHIPEV CC, 1992, MOL CELL BIOL, V12, P45, DOI 10.1128/MCB.12.1.45; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; CLARK DJ, 1986, J MOL BIOL, V140, P505; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; CUSICK ME, 1983, BIOCHEMISTRY-US, V22, P3873, DOI 10.1021/bi00285a024; DUBOCHET J, 1978, SCIENCE, V202, P280, DOI 10.1126/science.694532; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FEDOR M J, 1992, Current Opinion in Cell Biology, V4, P436, DOI 10.1016/0955-0674(92)90009-2; FELSENFELD G, 1986, CELL, V44, P375, DOI 10.1016/0092-8674(86)90456-3; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FISHER EA, 1986, BIOCHEMISTRY-US, V25, P8010, DOI 10.1021/bi00372a033; FLETCHER TM, 1994, BIOCHEMISTRY-US, V33, P2226, DOI 10.1021/bi00174a032; FREEMAN L A, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P165; GALE JM, 1988, BIOCHEMISTRY-US, V27, P7197, DOI 10.1021/bi00419a006; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GARRARD WT, 1991, BIOESSAYS, V13, P87, DOI 10.1002/bies.950130208; GEORGEL P, 1993, J BIOL CHEM, V268, P1947; GONZALEZ PJ, 1989, J BIOL CHEM, V264, P18457; GONZALEZ PJ, 1987, J BIOL CHEM, V262, P11280; GRAU LP, 1982, CHROMOSOMA, V87, P437; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; GUO XW, 1989, J BIOL CHEM, V264, P11653; GUO XW, 1989, J BIOL CHEM, V264, P16873; HANSEN JC, 1992, TRENDS BIOCHEM SCI, V17, P187, DOI 10.1016/0968-0004(92)90264-A; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HANSEN JC, 1993, J BIOL CHEM, V268, P5840; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; JIN YJ, 1986, J BIOL CHEM, V261, P5805; JORCANO JL, 1980, P NATL ACAD SCI-BIOL, V77, P6443, DOI 10.1073/pnas.77.11.6443; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KIMURA T, 1983, NATURE, V306, P709, DOI 10.1038/306709a0; KNOLL DA, 1988, STRUCTURE EXPRESSION, V2, P123; LEWIS EA, 1976, BIOCHEMISTRY-US, V15, P186, DOI 10.1021/bi00646a029; MORSE RH, 1992, TRENDS BIOCHEM SCI, V17, P23, DOI 10.1016/0968-0004(92)90422-6; POSTNIKOV YV, 1991, NUCLEIC ACIDS RES, V19, P717, DOI 10.1093/nar/19.4.717; RENZ M, 1977, P NATL ACAD SCI USA, V74, P1879, DOI 10.1073/pnas.74.5.1879; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RISDALE AJ, 1990, J BIOL CHEM, V265, P5150; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; SEN D, 1986, BIOCHEMISTRY-US, V25, P1495, DOI 10.1021/bi00355a004; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SMITH PA, 1984, BIOCHEMISTRY-US, V23, P1576, DOI 10.1021/bi00302a036; STRATLING WH, 1979, BIOCHEMISTRY-US, V18, P596, DOI 10.1021/bi00571a008; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; THOMA F, 1977, CELL, V12, P101, DOI 10.1016/0092-8674(77)90188-X; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS JO, 1980, EUR J BIOCHEM, V112, P501; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; VANHOLDE KE, 1978, BIOPOLYMERS, V25, P1981; VANHOLDE KE, 1988, CHROMATIN, P320; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; WIDOM J, 1986, J MOL BIOL, V190, P411, DOI 10.1016/0022-2836(86)90012-4; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; Wolffe A P, 1991, Trends Cell Biol, V1, P61, DOI 10.1016/0962-8924(91)90091-M; WOLFFE AP, 1992, FASEB J, V6, P3352; WOLFFE AP, 1993, CHROMATIN STRUCTURE, P31; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; YAO J, 1991, BIOCHEMISTRY-US, V30, P8408, DOI 10.1021/bi00098a019; ZLATANOVA J, 1990, TRENDS BIOCHEM SCI, V15, P273, DOI 10.1016/0968-0004(90)90053-E	75	147	150	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16284	16289						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206934				2022-12-27	WOS:A1994NQ72900052
J	OKAMOTO, CT; SONG, WX; BOMSEL, M; MOSTOV, KE				OKAMOTO, CT; SONG, WX; BOMSEL, M; MOSTOV, KE			RAPID INTERNALIZATION OF THE POLYMERIC IMMUNOGLOBULIN RECEPTOR REQUIRES PHOSPHORYLATED SERINE-726	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; IG RECEPTOR; MDCK CELLS; SIGNAL; PROTEIN; CD4; TRANSCYTOSIS; ENDOCYTOSIS; EXPRESSION; DELIVERY	S726 of the cytoplasmic domain of the polymeric immunoglobulin receptor (pIgR) resides within a consensus sequence for phosphorylation by protein kinases A, G, and C, and casein kinase II. Mutation of S726 to Ala and expression of this mutant pIgR in Madin-Darby canine kidney cells results in a receptor in which steady-state phosphorylation is reduced to 49% of wild-type levels. This mutant receptor is also significantly impaired in its internalization from the basolateral membrane. During the first minute, internalization of radioiodinated ligands (either dIgA or monovalent anti-pIgR Fabs) by this mutant pIgR is only 35% of that by wild-type pIgR. Internalization of unoccupied mutant receptors is similarly inhibited. Delivery of newly made mutant receptor from the trans-Golgi network to the basolateral surface is completely normal. The only other trafficking step inhibited by this mutation is the transcytosis of radioiodinated dIgA Within 2 h, the mutant pIgR will transcytose 58% of a preinternalized cohort of dIgA, while the wild-type transcytoses 76%. This inhibition of transcytosis may be an indirect consequence of impaired internalization. The correlation between the loss of phosphorylation and inhibition of internalization suggests that phosphorylation of S726 may represent a novel mechanism for regulation of internalization of the pIgR.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	OKAMOTO, CT (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.		Bomsel, Morgane/GSN-1948-2022	Bomsel, Morgane/0000-0002-9577-7474; mostov, keith/0000-0002-8123-6247	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025144] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI 25144] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APODACA G, 1993, J BIOL CHEM, V268, P20380; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BANTING G, 1989, FEBS LETT, V254, P177, DOI 10.1016/0014-5793(89)81034-8; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HURLEY TR, 1989, SCIENCE, V245, P407, DOI 10.1126/science.2787934; JADOT M, 1992, J BIOL CHEM, V267, P11069; KENNELLY PJ, 1991, J BIOL CHEM, V266, P1555; KRAJCI P, 1989, BIOCHEM BIOPH RES CO, V158, P783, DOI 10.1016/0006-291X(89)92790-3; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; OAKMOTO CT, 1992, J BIOL CHEM, V267, P9925; PELCHENMATTHEWS A, 1992, J CELL BIOL, V117, P279, DOI 10.1083/jcb.117.2.279; Sambrook J, 1989, MOL CLONING LABORATO; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SONG WX, 1994, P NATL ACAD SCI USA, V91, P163, DOI 10.1073/pnas.91.1.163; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C	31	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15676	15682						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195218				2022-12-27	WOS:A1994NP51300046
J	TSUBOI, S; MATSUMOTO, H; YAMAZAKI, A				TSUBOI, S; MATSUMOTO, H; YAMAZAKI, A			PHOSPHORYLATION OF AN INHIBITORY SUBUNIT OF CGMP PHOSPHODIESTERASE IN RANA-CATESBIANA ROD PHOTORECEPTORS .2. A POSSIBLE MECHANISM FOR THE TURNOFF OF CGMP PHOSPHODIESTERASE WITHOUT GTP HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; OUTER SEGMENTS; G-PROTEIN; BINDING PROTEIN; TRANSDUCIN; DEPHOSPHORYLATION; PHOSPHATASES; DEACTIVATION; ACTIVATION; KINETICS	In amphibian rod photoreceptor membranes, P gamma, an inhibitory subunit of cGMP phosphodiesterase, is phosphorylated by a protein kinase when P gamma is complexed with the guanosine 5'-O-(3-thiotriphosphate)-bound alpha subunit of transducin (GTP gamma S T alpha). Five different experiments support the conclusion that the phosphorylated P gamma loses its interaction with GTP gamma S.T alpha. These observations include 1) detection of the inhibitory effect of the GTP gamma S.T alpha.P gamma complex on cGMP phosphodiesterase activity after P gamma in the complex is phosphorylated in a system reconstituted from isolated components, 2) no stimulating effect of GTP gamma S.T alpha on the phosphorylated P gamma-inhibited cGMP phosphodiesterase in the reconstituted system, 3) physical release of phosphorylated P gamma from GTP gamma S.T alpha in the reconstituted system, 4) no inhibitory effect of phosphorylated P gamma on both GTP hydrolysis by T alpha and GTP gamma S/GDP exchange on T alpha in the reconstituted system, and 5) no enhanced activity of cGMP phosphodiesterase by GTP gamma S.T alpha in rod outer segment membranes after incubation of the membranes with the kinase preparation in the presence of ATP. Together with our data that P gamma released with GTP.T alpha is not phosphorylated, and that phosphorylated P gamma inhibits more effectively cGMP phosphodiesterase activity than nonphosphorylated Py (Tsuboi, S., Matsumoto, H., Jackson, K. W., Tsujimoto, K., Williams, T., and Yamazaki, A (1994) J. Biol. Chem. 269, 15016-15023), these observations suggest that, after P gamma is released with GTP.T alpha from catalytic subunits of cGMP phosphodiesterase, P gamma complexed with GTP.T alpha is phosphorylated by a kinase. Then, the phosphorylated P gamma is released from GTP.T alpha and binds to active cGMP phosphodiesterase to inhibit the cGMP hydrolysis. It is suggested that in some G-protein-dependent signal transduction systems G-protein-activated effector may be phosphorylated with a specific kinase and that phosphorylation of the effector results in the turnoff of signal transduction without GTP hydrolysis.	WAYNE STATE UNIV, SCH MED, KRESGE EYE INST, DEPT OPHTHALMOL, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, KRESGE EYE INST, DEPT PHARMACOL, DETROIT, MI 48201 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, OKLAHOMA CITY, OK 73190 USA	Wayne State University; Wayne State University; University of Oklahoma System; University of Oklahoma Health Sciences Center					NATIONAL EYE INSTITUTE [R01EY009631, R01EY007546] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06595, EY 07546, EY 09631] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1992, INVEST OPHTH VIS SCI, V33, P1103; ANTONNY B, 1993, BIOCHEMISTRY-US, V32, P8646, DOI 10.1021/bi00084a036; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLACK JW, 1983, NATURE, V305, P50, DOI 10.1038/305050a0; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; ERICKSON MA, 1992, SCIENCE, V257, P1255, DOI 10.1126/science.1519062; FOWLES C, 1989, BIOCHEMISTRY-US, V28, P9385, DOI 10.1021/bi00450a020; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4333, DOI 10.1073/pnas.88.10.4333; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; MILLER WH, 1990, INVEST OPHTH VIS SCI, V31, P1664; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; SITARAMAYYA A, 1988, BIOCHEMISTRY-US, V27, P4880, DOI 10.1021/bi00413a044; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TING TD, 1991, BIOCHEMISTRY-US, V30, P8996, DOI 10.1021/bi00101a013; TSUBOI S, 1994, J BIOL CHEM, V269, P15016; UMBARGER KO, 1992, J BIOL CHEM, V267, P19494; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1993, J BIOL CHEM, V268, P8899; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YAMAZAKI A, 1992, ADV SEC MESS PHOSPH, V25, P135; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445	29	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15024	15029						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195139				2022-12-27	WOS:A1994NP73800030
J	HERTZOG, PJ; HWANG, SY; HOLLAND, KA; TYMMS, MJ; IANNELLO, R; KOLA, I				HERTZOG, PJ; HWANG, SY; HOLLAND, KA; TYMMS, MJ; IANNELLO, R; KOLA, I			A GENE ON HUMAN-CHROMOSOME-21 LOCATED IN THE REGION 21Q22.2 TO 21Q22.3 ENCODES A FACTOR NECESSARY FOR SIGNAL-TRANSDUCTION AND ANTIVIRAL RESPONSE TO TYPE-I INTERFERONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA RECEPTOR GENE; TYROSINE KINASE; MESSENGER-RNA; HUMAN-CELLS; PROTEIN; BINDING; EXPRESSION; SUBTYPES; FAMILY; ASSAYS	The type I interferons (IFNs) are a family of multifunctional cytokines which includes the 15 IFN alpha subtypes and IFN beta. These IFNs compete for binding to cell surface receptors. However, murine cells transfected with a cDNA for a human IFN alpha receptor (IFNAR) developed an antiviral response only to human IFN alpha B, but not to human IFN alpha 2 nor -beta(1). In this study we show, using a panel of CHO human chromosome 21 hybrid cell lines which all express IFNAR, that only those containing the region 21q22.2 to 21q22.3 transduce signals for IFN responses. Two such hybrid cell lines responded to IFNs alpha 2, -alpha B and -beta by induction of 2'-5' oligoadenylate synthetase and resistance to viral infection. Other hybrid cell lines, that lacked the region 21q22.2-3, failed to transduce signals as above; even though they expressed IFNAR and bound human IFN alpha 2, -alpha B, and -beta. These data demonstrate that a gene(s) located in the region 21q22.2-3 encodes a factor(s) which is necessary for signaling but does not influence ligand binding. This factor is not the cofactor required for IFN gamma signaling which is located in the region 21p to 21q22.1(2).			HERTZOG, PJ (corresponding author), MONASH MED CTR,INST REPROD & DEV,MOLEC EMBRYOL & BIRTH DEFECTS LAB,CLAYTON,VIC 3168,AUSTRALIA.		Kola, Ismail/C-5254-2013; Hertzog, Paul/I-7053-2013	Hertzog, Paul/0000-0002-1373-8472				BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6931; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; DEHAAN JB, 1992, MOL BRAIN RES, V13, P179, DOI 10.1016/0169-328X(92)90025-7; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FISH EN, 1983, BIOCHEM BIOPH RES CO, V112, P537, DOI 10.1016/0006-291X(83)91498-5; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Hemmi S., 1993, Journal of Interferon Research, V13, pS55; HERTZOG PJ, 1988, CLIN IMMUNOL IMMUNOP, V48, P192, DOI 10.1016/0090-1229(88)90083-9; JUNG V, 1990, J BIOL CHEM, V265, P1827; LANGER JA, 1990, SOMAT CELL MOLEC GEN, V16, P231, DOI 10.1007/BF01233359; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LOVELAND BE, 1992, BIOCHEM INT, V27, P501; LUTFALLA G, 1990, J INTERFERON RES, V10, P515, DOI 10.1089/jir.1990.10.515; MOGENSEN KE, 1986, METHOD ENZYMOL, V119, P267; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; OROURKE EC, 1984, MOL CELL BIOL, V4, P2745, DOI 10.1128/MCB.4.12.2745; OVERALL ML, 1992, MOL IMMUNOL, V29, P391, DOI 10.1016/0161-5890(92)90027-U; PATTERSON D, 1993, GENOMICS, V15, P177, DOI 10.1006/geno.1993.1026; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PLATANIAS LC, 1993, J IMMUNOL, V150, P3382; PRITCHARD MA, 1992, MAMM GENOME, V3, P36, DOI 10.1007/BF00355839; ROBERTS RM, 1991, GROWTH FACTORS REPRO, P235; SHULMAN L, 1980, NATURE, V288, P98, DOI 10.1038/288098a0; Soh Jaemong, 1993, Journal of Interferon Research, V13, pS55; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WEIL J, 1980, J INTERFERON RES, V1, P111, DOI 10.1089/jir.1980.1.111; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4	37	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14088	14093						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188689				2022-12-27	WOS:A1994NL60600056
J	FUKUSHIMA, D; BUTZOW, R; HILDEBRAND, A; RUOSLAHTI, E				FUKUSHIMA, D; BUTZOW, R; HILDEBRAND, A; RUOSLAHTI, E			LOCALIZATION OF TRANSFORMING GROWTH-FACTOR-BETA BINDING-SITE IN BETAGLYCAN - COMPARISON WITH SMALL EXTRACELLULAR-MATRIX PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; MEMBRANE PROTEOGLYCAN; RECEPTOR SYSTEM; LIGAND-BINDING; III RECEPTOR; EXPRESSION; QUANTITATION; COMPONENT; PROTEINS; ENDOGLIN	The most abundant binding molecule for transforming growth factor beta (TGF-beta) on many cell types is betaglycan, a transmembrane proteoglycan. To localize the binding site for TGF-beta in betaglycan, parts of the betaglycan extracellular portion were expressed as recombinant fusion proteins in bacteria and tested for their ability to compete for the binding of TGF-beta1 to Hep G2 cells. One fragment encompassing 226 residues near the transmembrane domain (amino acids 543-769) (Lopez-Casillas, F., Cheifetz, S., Doody, J., Andres, J. L., Lane, W. S., and Massague, J. (1991) Cell 67, 785-795) was active, whereas fusion proteins representing the other parts of the betaglycan ectodomain were inactive. Affinity measurements revealed two classes of binding sites (K(d) = 3.9 nM and K(d) = 145 nm) for the active fusion protein. The binding of the betaglycan fusion protein to immobilized TGF-beta-1 was inhibited by fusion proteins representing the core proteins of the small interstitial proteoglycans decorin, biglycan and fibromodulin, each also known to bind TGF-beta. The effective concentrations of TGF-beta for binding to these other proteoglycans were similar to those required for binding to betaglycan, indicating similar affinities for the binding of proteoglycans and betaglycan. Affinity cross-linking showed that, at low concentrations, the betaglycan fragment enhanced the binding of TGF-beta to the type II receptor and to endogenous betaglycan but had no effect on the binding to type I receptor. At high concentrations, the TGF-beta binding fragment inhibited the binding of TGF-beta to all these receptors. The fragment enhanced the activity of TGF-beta in mink lung cell bioassay at all active concentrations. The results indicate that betaglycan and the decorin type proteoglycans all bind to the same or closely spaced sites in TGF-beta and compete with one another for the binding. In addition, betaglycan may cooperate with the type II receptor on TGF-beta binding.	LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA42507, CA30199] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA030199, R35CA042507] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; FISHER LW, 1991, J BIOL CHEM, V266, P14371; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; Matsudaira P, 1989, PRACTICAL GUIDE PROT; MOORADIAN DL, 1989, J CELL BIOCHEM, V41, P189, DOI 10.1002/jcb.240410404; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SCHULL MM, 1992, NATURE, V359, P693; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	31	65	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22710	22715						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226781				2022-12-27	WOS:A1993MD34800077
J	ISLAM, MR; GRUBB, JH; SLY, WS				ISLAM, MR; GRUBB, JH; SLY, WS			C-TERMINAL PROCESSING OF HUMAN BETA-GLUCURONIDASE - THE PROPEPTIDE IS REQUIRED FOR FULL EXPRESSION OF CATALYTIC ACTIVITY, INTRACELLULAR RETENTION, AND PROPER PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; HUMAN-FIBROBLASTS; MANNOSE 6-PHOSPHATE; LYSOSOMAL-ENZYMES; OLIGOSACCHARIDES; PINOCYTOSIS; EGASYN; CELLS; COMPARTMENTALIZATION; INVOLVEMENT	Beta-glucuronidase undergoes proteolytic C-terminal processing during or after its transport to lysosomes or endosomes. We determined the C-terminal processing site for human placental beta-glucuronidase to be the peptide bond between Thr633-Arg634. To evaluate the role of the 18-amino acid peptide removed in C-terminal processing, we changed the codon for Arg634 to a stop codon by site-directed mutagenesis and studied expression of the truncated mutant enzyme in COS-7 cells. An increased fraction of newly synthesized enzyme from R634Stop cDNA was secreted. Pulse-chase experiments provided no evidence for increased degradation of the intracellular R634Stop enzyme. The total amount of catalytic activity expressed from the R634Stop mutant cDNA was only half that seen with the wild type cDNA, and the K(cat) of the mutant enzyme was 52% that of wild type enzyme. These results indicate that the C-terminal propeptide in the precursor is important for beta-glucuronidase to achieve maximal activity. The truncated enzyme formed hybrid tetramers in cotransfection experiments with the cDNA for rat beta-glucuronidase. There appeared to be no decrease in stability of the R634Stop enzyme, since chaotropic agents, heat treatment, and pH had similar effects on the mutant and the wild type enzymes. The uptake rate of the truncated mutant (R634Stop) enzyme by beta-glucuronidase-deficient human fibroblast cells was only 55-60% that of the wild type enzyme. Binding to the immobilized cation-independent mannose-6-phosphate receptor and measurement of the P-32-labeled phosphorylated oligosaccharides revealed that the truncated mutant enzyme was 32-34% less phosphorylated and appeared to contain proportionately more covered phosphate groups than the wild type enzyme. These results suggest that the propeptide influences the accessibility to both processing enzymes that produce the mannose-6-phosphate recognition marker on beta-glucuronidase.	ST LOUIS UNIV,SCH MED,EDWARD A DOISY DEPT BIOCHEM & MOLEC BIOL,ST LOUIS,MO 63104	Saint Louis University					NIDDK NIH HHS [DK40163] Funding Source: Medline; NIGMS NIH HHS [GM34182] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034182, R01GM034182] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BROT FE, 1974, BIOCHEM BIOPH RES CO, V57, P1, DOI 10.1016/S0006-291X(74)80349-9; BROT FE, 1978, BIOCHEMISTRY-US, V17, P385, DOI 10.1021/bi00596a001; CREEK KE, 1982, J BIOL CHEM, V257, P9931; DONG J, 1989, J BIOL CHEM, V265, P4210; ERICKSON AH, 1979, BIOCHEMISTRY-US, V22, P5201; FISCHER HD, 1982, J BIOL CHEM, V257, P9938; FUNKENSTEIN B, 1988, MOL CELL BIOL, V8, P1160, DOI 10.1128/MCB.8.3.1160; GABEL CA, 1987, J CELL BIOL, V105, P1561, DOI 10.1083/jcb.105.4.1561; GABEL CA, 1984, J CELL BIOL, V99, P296, DOI 10.1083/jcb.99.1.296; GALLAGHER P M, 1988, Genomics, V2, P215, DOI 10.1016/0888-7543(88)90005-5; GANSCHOW R, 1967, P NATL ACAD SCI USA, V58, P939; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOLDBERG DE, 1981, J BIOL CHEM, V256, P3060; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HASILIK A, 1980, P NATL ACAD SCI-BIOL, V77, P7074, DOI 10.1073/pnas.77.12.7074; Ho K J, 1991, Protein Expr Purif, V2, P63, DOI 10.1016/1046-5928(91)90011-7; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; ISHII SI, 1983, METHOD ENZYMOL, V91, P378; KAPLAN A, 1977, P NATL ACAD SCI USA, V74, P2026, DOI 10.1073/pnas.74.5.2026; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KYLE JW, 1992, GUS PROTOCOLS USING, P189; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI H, 1990, J BIOL CHEM, V265, P14732; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEDDA S, 1986, BIOCHEM GENET, V24, P229, DOI 10.1007/BF00502791; MEDDA S, 1989, J BIOL CHEM, V264, P15824; MEDDA S, 1987, CELL, V50, P301, DOI 10.1016/0092-8674(87)90225-X; MERCOLINO TJ, 1980, J MOL BIOL, V139, P557, DOI 10.1016/0022-2836(80)90147-3; NATOWICZ MR, 1979, P NATL ACAD SCI USA, V76, P4322, DOI 10.1073/pnas.76.9.4322; NOVAK EK, 1991, J BIOL CHEM, V266, P6377; OSHIMA A, 1987, P NATL ACAD SCI USA, V84, P685, DOI 10.1073/pnas.84.3.685; OVNIC M, 1991, GENOMICS, V11, P956, DOI 10.1016/0888-7543(91)90020-F; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; POWELL PP, 1988, BIOCHEM J, V250, P547, DOI 10.1042/bj2500547; ROSENFELD MG, 1982, J CELL BIOL, V93, P135, DOI 10.1083/jcb.93.1.135; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKUDLAREK MD, 1979, J BIOL CHEM, V254, P9939; TABAS I, 1980, J BIOL CHEM, V255, P6633; TALKAD V, 1983, J BIOL CHEM, V258, P7345; TANAKA J, 1992, BIOL CHEM H-S, V373, P57, DOI 10.1515/bchm3.1992.373.1.57; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330	43	42	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22627	22633						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226771				2022-12-27	WOS:A1993MD34800066
J	JEOUNG, DI; ALLEN, DL; GULLER, S; YEN, V; SONENBERG, M				JEOUNG, DI; ALLEN, DL; GULLER, S; YEN, V; SONENBERG, M			MITOGENIC AND RECEPTOR ACTIVITIES OF HUMAN GROWTH HORMONE-108-129	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICALLY-ACTIVE FRAGMENTS; EXTRACELLULAR DOMAIN; TRANSGENIC MICE; ADIPOSE DIFFERENTIATION; H-1-NMR SPECTROSCOPY; ALPHA-HELIX; HORMONE GH; BOVINE; CELLS; ANALOG	We have selectively synthesized a number of peptides encompassing the region of helix 3 of growth hormone (GH). These peptides and native human (h) GH have been evaluated for mitogenic and receptor activities in 3T3-F442A preadipocytes. In this system, wild type hGH is anti-mitogenic. In contrast, hGH 108-129 stimulated DNA synthesis while other GH-derived peptides were ineffective. hGH (L) 108-129 had an EC50 of about 0.2 nM and was maximally effective at about 0.5 nm in stimulating [H-3]thymidine incorporation in 3T3-F442A cells. hGH (L) 108-129 was mitogenically as active as insulin-like growth factor-I and more active than insulin. It was less effective than transforming growth factor-beta. By cell cycle analysis, hGH (L) 108-129 increased the proportion of cells in S/G2/M phases to 28%. hGH, when coincubated with hGH (L) 108-129, blocked the mitogenic response of the peptide. A monoclonal antibody to the GH receptor significantly reduced binding of I-125-hGH to its receptor but had no effect on binding of I-125-hGH (L) 108-129. Affinity cross-linking of I-125-hGH to its receptor was not duplicated with I-125-hGH (L) 108-129. No other GH peptides or insulin competed for binding of I-125-hGH 108-129. Scatchard analysis indicated a K(d) of 5.2 nM with 5.6 x 10(5) binding sites/cell for hGH (L) 108-129. These studies indicate that hGH (L) 108-129, a sequence encompassing helix 3 of hGH, acts by binding to a site other than the GH receptor and evokes high mitogenic responses.	MEM SLOAN KETTERING CANC CTR,1275 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,DEPT MED,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041931] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 41931, DK 07313] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BREMS DN, 1987, BIOCHEMISTRY-US, V26, P7774, DOI 10.1021/bi00398a036; CHEN CH, 1977, BIOCHEMISTRY-US, V16, P2110, DOI 10.1021/bi00629a010; CHEN WY, 1991, J BIOL CHEM, V266, P2252; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; CHEN WY, 1990, P NATL ACAD SCI USA, V87, P5061, DOI 10.1073/pnas.87.13.5061; CHEN WY, 1991, ENDOCRINOLOGY, V129, P1402, DOI 10.1210/endo-129-3-1402; CORIN RE, 1990, P NATL ACAD SCI USA, V87, P7507, DOI 10.1073/pnas.87.19.7507; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAYHOFF MO, 1973, ATLAS PROTEIN SEQ S2, pS138; DAYHOFF MO, 1976, ATLAS PROTEIN SEQ S1, pS50; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EDMAN P, 1970, PROTEIN SEQUENCE DET, P211; FIDDES JC, 1979, P NATL ACAD SCI USA, V76, P4294, DOI 10.1073/pnas.76.9.4294; GOOLEY PR, 1988, BIOCHEMISTRY-US, V27, P802, DOI 10.1021/bi00402a047; GOOLEY PR, 1988, BIOCHEMISTRY-US, V27, P4032, DOI 10.1021/bi00411a020; GRAF L, 1974, BIOCHEMISTRY-US, V13, P5408, DOI 10.1021/bi00723a026; GRAF L, 1976, EUR J BIOCHEM, V64, P333, DOI 10.1111/j.1432-1033.1976.tb10306.x; GULLER S, 1988, ENDOCRINOLOGY, V122, P2084, DOI 10.1210/endo-122-5-2084; GULLER S, 1989, ENDOCRINOLOGY, V125, P2360, DOI 10.1210/endo-125-5-2360; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCANDREW SJ, 1991, J BIOL CHEM, V266, P15016; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; NIXON T, 1983, J CELL PHYSIOL, V115, P291, DOI 10.1002/jcp.1041150312; OKADA S, 1992, ENDOCRINOLOGY, V130, P2284, DOI 10.1210/en.130.4.2284; Roth J, 1975, Methods Enzymol, V37, P223; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEEBURG PH, 1983, DNA-J MOLEC CELL BIO, V2, P37, DOI 10.1089/dna.1.1983.2.37; SILVERMAN MS, 1989, ENDOCRINOLOGY, V125, P2600, DOI 10.1210/endo-125-5-2600; UCHIDA E, 1990, BIOCHEM BIOPH RES CO, V172, P357, DOI 10.1016/S0006-291X(05)80217-7; ULTSCH M, 1991, J MOL BIOL, V222, P865, DOI 10.1016/0022-2836(91)90578-T; YAMASAKI N, 1970, BIOCHEMISTRY-US, V9, P1107, DOI 10.1021/bi00807a009; YAMASAKI N, 1975, J BIOL CHEM, V250, P2510	36	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22520	22524						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226761				2022-12-27	WOS:A1993MD34800052
J	LI, CJ; AVERBOUKH, L; PARDEE, AB				LI, CJ; AVERBOUKH, L; PARDEE, AB			BETA-LAPACHONE, A NOVEL DNA TOPOISOMERASE-I INHIBITOR WITH A MODE OF ACTION DIFFERENT FROM CAMPTOTHECIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAKAGE-REUNION REACTION; CELL LUNG-CANCER; ANTITUMOR DRUGS; CLEAVAGE; MECHANISM; BINDING; COVALENT; PROTEIN; COMPLEX; DAMAGE	Beta-lapachone is a plant product that has been found to have many pharmacological effects. To date, very little is known about its biochemical target. In this study, we found that beta-lapachone inhibits the catalytic activity of topoisomerase I from calf thymus and human cells. But, unlike camptothecin, beta-lapachone does not stabilize the cleavable complex, indicating a different mechanism of action. Beta-lapachone inhibits topoisomerase I-mediated DNA cleavage induced by camptothecin. Incubation of topoisomerase I with beta-lapachone before adding DNA substrate dramatically increases this inhibition. Incubation of topoisomerase I with DNA prior to beta-lapachone makes the enzyme refractory, and treatment of DNA with beta-lapachone before topoisomerase has no effect. These results suggest a direct interaction of beta-lapachone with topoisomerase I rather than DNA substrate. Beta-lapachone does not inhibit binding of enzyme to DNA substrate. In cells, beta-lapachone itself does not induce a SDS-K+-precipitable complex, but it inhibits complex formation with camptothecin. We propose that the direct interaction of beta-lapachone with topoisomerase I does not affect the assembly of the enzyme-DNA complex but does inhibit the formation of cleavable complex.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	LI, CJ (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELL GROWTH & REGULAT,44 BINNEY ST,BOSTON,MA 02115, USA.				NCI NIH HHS [CA50608] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050608] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDOH T, 1987, P NATL ACAD SCI USA, V84, P5565, DOI 10.1073/pnas.84.16.5565; BOORSTEIN RJ, 1984, BIOCHEM BIOPH RES CO, V118, P828, DOI 10.1016/0006-291X(84)91469-4; BOOTHMAN DA, 1989, CANCER RES, V49, P605; BORITZKI TJ, 1988, BIOCHEM PHARMACOL, V37, P4063, DOI 10.1016/0006-2952(88)90096-2; CAMILLONI G, 1988, NUCLEIC ACIDS RES, V16, P7071, DOI 10.1093/nar/16.14.7071; CHAMPOUX JJ, 1977, P NATL ACAD SCI USA, V74, P3800, DOI 10.1073/pnas.74.9.3800; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHEN GL, 1984, J BIOL CHEM, V259, P3560; de Lima OG, 1962, REV I ANTIBIOT U REC, V4, P3; DRAKE FH, 1989, CANCER RES, V49, P2578; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; ENG WK, 1990, MOL PHARMACOL, V38, P471; GONCALVES AM, 1980, MOL BIOCHEM PARASIT, V1, P167, DOI 10.1016/0166-6851(80)90015-8; HERTZBERG RP, 1990, J BIOL CHEM, V265, P19287; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; Hooker SC, 1936, J AM CHEM SOC, V58, P1181, DOI 10.1021/ja01298a032; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; HSIEH TS, 1980, CELL, V21, P115, DOI 10.1016/0092-8674(80)90119-1; ISHII K, 1983, J BIOL CHEM, V258, P2728; JAVAHERIAN K, 1983, NUCLEIC ACIDS RES, V11, P461, DOI 10.1093/nar/11.2.461; JENSEN PB, 1990, CANCER RES, V50, P3311; KANZAWA F, 1990, CANCER RES, V50, P5919; LI CJ, 1993, P NATL ACAD SCI USA, V90, P1839, DOI 10.1073/pnas.90.5.1839; LIU LF, 1979, J BIOL CHEM, V254, P1082; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; MATTERN MR, 1991, CANCER RES, V51, P5813; MATTERN MR, 1982, BIOCHIM BIOPHYS ACTA, V697, P6, DOI 10.1016/0167-4781(82)90038-0; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; MULLER MT, 1985, BIOCHIM BIOPHYS ACTA, V824, P263, DOI 10.1016/0167-4781(85)90057-0; NELSON EM, 1984, P NATL ACAD SCI-BIOL, V81, P1361, DOI 10.1073/pnas.81.5.1361; OHNO R, 1991, J CLIN ONCOL, V10, P647; POMMIER Y, 1985, BIOCHEMISTRY-US, V24, P6410, DOI 10.1021/bi00344a015; RICHTER A, 1991, FEBS LETT, V294, P125, DOI 10.1016/0014-5793(91)81357-E; ROWE TC, 1986, CANCER RES, V46, P2021; ROWINSKY EK, 1992, J CLIN ONCOL, V10, P647, DOI 10.1200/JCO.1992.10.4.647; SCHAFFNERSABBA K, 1984, J MED CHEM, V27, P990, DOI 10.1021/jm00374a010; SCHUERCH AR, 1978, EUR J BIOCHEM, V84, P197, DOI 10.1111/j.1432-1033.1978.tb12157.x; SHAPIRO TA, 1990, P NATL ACAD SCI USA, V87, P950, DOI 10.1073/pnas.87.3.950; SHAPIRO TA, 1989, J BIOL CHEM, V264, P4173; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; TAMURA H, 1990, FEBS LETT, V261, P151, DOI 10.1016/0014-5793(90)80658-6; TANABE K, 1991, CANCER RES, V51, P4903; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; TEWEY KM, 1984, J BIOL CHEM, V259, P9182; THOMSEN B, 1987, EMBO J, V6, P1817, DOI 10.1002/j.1460-2075.1987.tb02436.x; TRASK DK, 1983, NUCLEIC ACIDS RES, V11, P2779, DOI 10.1093/nar/11.9.2779; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665	47	225	243	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22463	22468						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226754				2022-12-27	WOS:A1993MD34800044
J	KORNER, C; HERZOG, A; WEBER, B; ROSORIUS, O; HEMER, F; SCHMIDT, B; BRAULKE, T				KORNER, C; HERZOG, A; WEBER, B; ROSORIUS, O; HEMER, F; SCHMIDT, B; BRAULKE, T			IN-VITRO PHOSPHORYLATION OF THE 46-KDA MANNOSE 6-PHOSPHATE RECEPTOR BY CASEIN KINASE-II - STRUCTURAL REQUIREMENTS FOR EFFICIENT PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOPLASMIC DOMAIN; CARBOXYL-TERMINUS; LYSOSOMAL-ENZYMES; GOLGI; TAIL; INTERNALIZATION; SIGNALS; PROTEIN; BINDING	Some steps in the receptor-mediated transport of newly synthesized mannose 6-phosphate-containing lysosomal enzymes are assumed to be accompanied by changes in the phosphorylation state of receptors. In vitro, the metabolically phosphorylated 46-kDa mannose 6-phosphate receptor (MPR 46) was dephosphorylated by protein phosphatase 2A. The synthetic cytoplasmic domain of MPR 46 was phosphorylated in vitro by casein kinase II. Tryptic phosphopeptide mapping showed that casein kinase II phosphorylates MPR 46 in vitro at the same site that is phosphorylated in vivo. Inhibition studies using synthetic peptides corresponding to different amino acid sequences of the cytoplasmic tail of MPR 46 revealed that the sequence 26-32 (ADGCDFV) contribute to efficient phosphorylation of serine 56. Baby hamster kidney cells were transfected with wild type human MPR 46 cDNA or cDNAs containing mutations in the cytoplasmic tail and assayed for their phosphorylation state in vivo. The phosphorylation of mutant receptors with deleted residues 23-28 (NLVADG) was strongly reduced. These data indicate that residues on the N-terminal side of the phosphorylatable serine 56 may influence the efficiency with which a casein-kinase II-like kinase phosphorylates MPR 46.	UNIV GOTTINGEN,INST BIOCHEM 2,D-37073 GOTTINGEN,GERMANY	University of Gottingen			Braulke, Thomas/AAV-9121-2020	Braulke, Thomas/0000-0002-2336-8532				BRAULKE T, 1992, J BIOL CHEM, V267, P17347; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; HEMER F, 1993, J BIOL CHEM, V268, P17108; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; ROSORIUS O, 1993, BIOCHEM J, V292, P833, DOI 10.1042/bj2920833; ROSORIUS O, 1993, J BIOL CHEM, V268, P21470; SAYERS JR, 1989, PROTEIN FUNCTION PRA, P279; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; WENDLAND M, 1991, J BIOL CHEM, V266, P2917	22	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16529	16532						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206966				2022-12-27	WOS:A1994NR29600003
J	JOTTE, RM; KAMATA, N; HOLT, JT				JOTTE, RM; KAMATA, N; HOLT, JT			MYRISTYLATION-DEPENDENT TRANSACTIVATION BY FBR V-FOS IS REGULATED BY C/EBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; ALPHA-1(III) COLLAGEN PROMOTER; TRANSCRIPTION FACTOR AP-1; OSTEO-SARCOMA VIRUS; JUN PROTO-ONCOGENE; C-JUN; GENE-EXPRESSION; CELLULAR-TRANSFORMATION; 3T3-L1 PREADIPOCYTES; ADIPOSE CONVERSION	Viral oncogenes are generally believed to cause transformation through disregulated mimicry of their cellular homologues. However, here we show that FBR v-fos, unlike c-fos, transcriptionally activates unique genes in retrovirally induced chondro-osseous sarcomas. We show that FBR v-fos transactivates the collagen III and stromelysin promoters and that the unique transcriptional properties of transforming FBR depend upon its N-terminal myristylation and the differentiation state of the cell. Deletion or mutation of the myristylation site results in a loss of FBR v-fos transactivation in HeLa and undifferentiated 3T3-L1 preadipocyte cell lines. FBR v-fos transactivation of collagen III maps to a negative regulatory site which binds a key regulator of adipoctye differentiation, C/EBP alpha. Cotransfection of C/EBP alpha abolishes FBR v-fos transactivation of the alpha(1)(III) collagen promoter. Furthermore, FBR v-fos cannot transactivate collagen III subsequent to adipocyte differentiation. We also demonstrate that collagen III transcription is reduced during adipocyte differentiation as the transcriptional activity of C/EBP alpha is concomitantly induced. Our results indicate that FBR v-fos transactivation depends upon its cotranslational myristylation and maps to a negative regulatory region which binds C/EBP alpha.	VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232	Vanderbilt University					NCI NIH HHS [R01CA51735] Funding Source: Medline; NIGMS NIH HHS [5232GMO7347-14] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; DMITROVSKY E, 1986, CURR TOP MICROBIOL, V132, P327; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KAMATA N, 1992, MOL CELL BIOL, V12, P876, DOI 10.1128/MCB.12.2.876; KAMATA N, 1991, MOL CELL BIOL, V11, P765, DOI 10.1128/MCB.11.2.765; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MILLER AD, 1984, CELL, V36, P51; MUDRYJ M, 1988, NUCLEIC ACIDS RES, V16, P7513, DOI 10.1093/nar/16.15.7513; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RUTESHOUSER EC, 1989, J BIOL CHEM, V264, P13740; RUTESHOUSER EC, 1992, J BIOL CHEM, V267, P14398; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SALHANY KE, 1992, J CELL PHYSIOL, V150, P386, DOI 10.1002/jcp.1041500223; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SETOYAMA C, 1986, BIOCHEM BIOPH RES CO, V136, P1042, DOI 10.1016/0006-291X(86)90438-9; SIDHU RS, 1979, J BIOL CHEM, V254, P1111; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SPIEGELMAN BM, 1980, J BIOL CHEM, V255, P8811; SPOTTS GD, 1990, MOL CELL BIOL, V10, P2953; SU H, 1981, ONCOGENE, V66, P1759; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	59	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16383	16396						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206947				2022-12-27	WOS:A1994NQ72900066
J	BARTOLI, F; LIN, HK; GHOMASHCHI, F; GELB, MH; JAIN, MK; APITZCASTRO, R				BARTOLI, F; LIN, HK; GHOMASHCHI, F; GELB, MH; JAIN, MK; APITZCASTRO, R			TIGHT-BINDING INHIBITORS OF 85-KDA PHOSPHOLIPASE A(2) BUT NOT 14-KDA PHOSPHOLIPASE A(2) INHIBIT RELEASE OF FREE ARACHIDONATE IN THROMBIN-STIMULATED HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPETITIVE INHIBITORS; INTERFACIAL CATALYSIS; PHOSPHATIDIC-ACID; CYTOSOLIC PHOSPHOLIPASE-A2; SUBSTRATE SPECIFICITIES; RABBIT PLATELETS; PHOSPHORYLATION; PURIFICATION; METABOLISM; CELLS	An analogue of arachidonic acid in which the COOH group is replaced by a trifluoromethyl ketone group (COCF3) has recently been shown to be a tight binding inhibitor of the 85-kDa cytosolic phospholipase A, that is found in platelets and other cells (Street, I. P., Lin, H.-K., Laliberte, F., Ghomashchi, F. G., Wang, Z., Perrier, H., Tremblay, N. M., Huang, Z., Weech, P. K., and Gelb, M. H. (1993) Biochemistry 32, 5935-5940). This trifluoromethyl ketone inhibits most of the arachidonate release from the phospholipid pool in thrombin-stimulated human platelets at concentrations of 0-40 mu M with 4 x 10(8) platelets/ml. A structure-function analysis of related compounds reveals a good correlation between the inhibition of the purified phospholipase A(2) and the blockage of arachidonate release in platelets. A number of recently described potent inhibitors of the 14-bDa phospholipase A(2) that is secreted from activated platelets have no effect on the level of free arachidonate production. Furthermore, the addition of a large amount of recombinant 14-kDa phospholipase A(2) to platelets does not produce free arachidonate, and it does not alter the amount of arachidonate released following platelet activation with thrombin. These studies provide strong pharmacological evidence for the role of the cytosolic phospholipase A(2) in producing most, if not all, of the liberated arachidonate in thrombin stimulated human platelets, and they show that tight binding membrane-residing inhibitors of the cytosolic phospholipase A(2) can block the eicosanoid cascade in living cells.	UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; INST VENEZOLANO INVEST CIENT,TROMBOSIS EXPTL LAB,CARACAS,VENEZUELA; UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Venezuelan Institute Science Research; University of Delaware				gelb, michael/0000-0001-7000-5219	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036235, R37HL036235, R23HL036235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029703] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36235] Funding Source: Medline; NIGMS NIH HHS [GM562, GM29703] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARSMAN AJ, 1989, J LIPID MEDIATOR, V1, P49; ALMEHDI AB, 1993, BIOCHIM BIOPHYS ACTA, V1167, P56, DOI 10.1016/0005-2760(93)90217-W; APITZCASTRO R, 1991, BIOCHIM BIOPHYS ACTA, V1094, P269, DOI 10.1016/0167-4889(91)90086-D; APITZCASTRO R, 1983, THROMB RES, V32, P155, DOI 10.1016/0049-3848(83)90027-0; APITZCASTRO R, 1981, THROMB RES, V23, P347, DOI 10.1016/0049-3848(81)90195-X; APITZCASTRO RJ, 1979, BIOCHEM BIOPH RES CO, V91, P63, DOI 10.1016/0006-291X(79)90583-7; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; BENNION C, 1992, J MED CHEM, V35, P2939, DOI 10.1021/jm00094a003; BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; BILLAH MM, 1981, J BIOL CHEM, V256, P5399; BILLS TK, 1977, J CLIN INVEST, V60, P1, DOI 10.1172/JCI108745; BILLS TK, 1976, BIOCHIM BIOPHYS ACTA, V424, P303, DOI 10.1016/0005-2760(76)90198-3; BLACKWELL GJ, 1977, BRIT J PHARMACOL, V59, P353, DOI 10.1111/j.1476-5381.1977.tb07500.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROEKMAN MJ, 1981, J BIOL CHEM, V256, P8271; BROEKMAN MJ, 1986, J LIPID RES, V27, P884; BROEKMAN MJ, 1980, J CLIN INVEST, V66, P275, DOI 10.1172/JCI109854; CHAU LY, 1983, BIOCHEM BIOPH RES CO, V113, P241, DOI 10.1016/0006-291X(83)90457-6; CHAU LY, 1988, BIOCHIM BIOPHYS ACTA, V963, P436, DOI 10.1016/0005-2760(88)90312-8; CHILTON FH, 1989, BIOCHEM J, V258, P327, DOI 10.1042/bj2580327; CLAPHAM DE, 1990, BIOCHEM PHARMACOL, V39, P813, DOI 10.1016/0006-2952(90)90194-P; DIEZ E, 1992, J BIOL CHEM, V267, P18342; FISHER AB, 1992, BIOCHEM J, V288, P407, DOI 10.1042/bj2880407; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HULKOWER KI, 1992, BIOCHEM BIOPH RES CO, V184, P712, DOI 10.1016/0006-291X(92)90648-5; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; Jain M K, 1992, Mediators Inflamm, V1, P85, DOI 10.1155/S0962935192000164; JAIN MK, 1992, J MED CHEM, V35, P3584, DOI 10.1021/jm00097a018; KANNAGI R, 1979, ARCH BIOCHEM BIOPHYS, V196, P534, DOI 10.1016/0003-9861(79)90305-9; KARPATKI.S, 1969, J CLIN INVEST, V48, P1073, DOI 10.1172/JCI106063; KIM DK, 1991, BIOCHEM BIOPH RES CO, V174, P189, DOI 10.1016/0006-291X(91)90504-Z; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LEMAHIEU RA, 1993, J MED CHEM, V36, P3029, DOI 10.1021/jm00072a025; LIN HK, 1993, J AM CHEM SOC, V115, P3932, DOI 10.1021/ja00063a012; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAGOLDA RL, 1989, J CELL BIOCHEM, V40, P371, DOI 10.1002/jcb.240400313; MAUCO G, 1984, BIOCHEM J, V224, P933, DOI 10.1042/bj2240933; MCKEAN ML, 1981, J BIOL CHEM, V256, P1522; MOUNIER C, 1993, EUR J BIOCHEM, V216, P169, DOI 10.1111/j.1432-1033.1993.tb18129.x; MURAKAMI M, 1989, BIOCHIM BIOPHYS ACTA, V1005, P270; NEAGOS GR, 1993, AM J PHYSIOL, V264, pL261, DOI 10.1152/ajplung.1993.264.3.L261; PURDON AD, 1985, J BIOL CHEM, V260, P2700; QIU ZH, 1993, J BIOL CHEM, V268, P24506; RANSAC S, 1990, BIOCHIM BIOPHYS ACTA, V1043, P57, DOI 10.1016/0005-2760(90)90110-J; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; SHATTIL SJ, 1986, BLOOD, V68, P1224; SHOENE NW, 1975, FED PROC, V34, P257; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; VENABLE ME, 1993, J LIPID RES, V34, P691; WHEELERJONES CPD, 1992, BIOCHEM J, V281, P465, DOI 10.1042/bj2810465; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; WINKLER JD, 1991, BIOCHIM BIOPHYS ACTA, V1081, P339, DOI 10.1016/0005-2760(91)90291-O; XING MZ, 1992, J BIOL CHEM, V267, P25966; YU L, 1990, J BIOL CHEM, V265, P2657; ZWAAL RFA, 1982, SUBCELL BIOCH, V9, P299	62	190	193	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15625	15630						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195211				2022-12-27	WOS:A1994NP51300039
J	CHANDRA, M; DASILVA, EF; SORENSON, MM; FERRO, JA; PEARLSTONE, JR; NASH, BE; BORGFORD, T; KAY, CM; SMILLIE, LB				CHANDRA, M; DASILVA, EF; SORENSON, MM; FERRO, JA; PEARLSTONE, JR; NASH, BE; BORGFORD, T; KAY, CM; SMILLIE, LB			THE EFFECTS OF N-HELIX DELETION AND MUTANT F29W ON THE CA2+ BINDING AND FUNCTIONAL-PROPERTIES OF CHICKEN SKELETAL-MUSCLE TROPONIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIN FILAMENT; CONFORMATIONAL TRANSITION; CALCIUM-BINDING; DIRECTED MUTAGENESIS; MOLECULAR MECHANISM; VERTEBRATE MUSCLE; CA-2+ DEPENDENCE; TERMINAL HELIX; RABBIT PSOAS; CONTRACTION	To assess the structural and functional significance of the N helix (residues 3-13) of avian recombinant troponin C (rTnC), we have constructed NHdel, in which residues 1-11 have been deleted, both in rTnC and in the spectral probe mutant F29W (Pearlstone, J. R., Borgford, T., Chandra, M., Oikawa, K., Kay, C. M., Herzberg, O., Moult, J., Herklotz, A., Reinach, F. C., and Smillie, L.B. (1992) Biochemistry 31, 6545-6553). Comparison of the far- and near-UV CD spectra (+/-Ca2+) of F29W and F29W/ NHdel and titration of the Ca2+-induced ellipticity and fluorescence changes indicates that the deletion has little effect on the global fold of the molecule but reduces the Ca2+ affinity of the N domain, but not the C domain, by 1.6-1.8-fold. Comparisons of the mutants NHdel, F29W, and F29W/NHdel with rTnC have been made using several functional assays. In reconstituted troponin-tropomyosin actomyosin subfragment 1 and myofibrillar ATPase systems, both F29W and NHdel have significantly reduced Ca2+-activated enzymic activities. These effects are cumulative in the double mutant F29W/NHdel. On the other hand, maximal isometric tension development in Ca2+-activated reconstituted skinned fibers is not affected with F29W and NHdel, although the Ca2+ sensitivity of NHdel in this system is markedly reduced. We conclude that both mutations, NHdel and F29W, are functionally deleterious, possibly affecting interactions of the N domain with troponin I and/or T.	UNIV ALBERTA,DEPT BIOCHEM,MRC CANADA,PROT STRUCT & FUNCT GRP,EDMONTON T6G 2H7,AB,CANADA; FED UNIV RIO DE JANEIRO,CCS,ICB,DEPT BIOQUIM MED,BR-21941590 RIO JANEIRO,BRAZIL	University of Alberta; Universidade Federal do Rio de Janeiro			Ferro, Jesus Aparecido A/C-8251-2013	Ferro, Jesus Aparecido A/0000-0002-3966-1303; Fidalgo da Silva, Elizabeth/0000-0003-3540-9335				BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BRANDT PW, 1984, J MOL BIOL, V180, P379, DOI 10.1016/S0022-2836(84)80010-8; BRANDT PW, 1990, J MOL BIOL, V212, P473, DOI 10.1016/0022-2836(90)90326-H; CHANDRA M, 1994, BIOCHEMISTRY-US, V33, P2961, DOI 10.1021/bi00176a028; Cohen P, 1988, CALMODULIN; COOKE R, 1988, J PHYSIOL-LONDON, V395, P77, DOI 10.1113/jphysiol.1988.sp016909; COX JA, 1981, BIOCHEM J, V195, P205, DOI 10.1042/bj1950205; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; DASILVA EF, 1993, J BIOL CHEM, V268, P26220; DOBROWOLSKI Z, 1991, J BIOL CHEM, V266, P5703; DOBROWOLSKI Z, 1991, BIOCHEMISTRY-US, V30, P7089, DOI 10.1021/bi00243a008; EASTWOOD AB, 1979, TISSUE CELL, V11, P553, DOI 10.1016/0040-8166(79)90062-4; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; GEORGE SE, 1993, J BIOL CHEM, V268, P25213; GLYN H, 1985, J PHYSIOL-LONDON, V365, P259, DOI 10.1113/jphysiol.1985.sp015770; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P629; GOLOSINSKA K, 1991, J BIOL CHEM, V266, P15797; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; GRABAREK Z, 1992, J MUSCLE RES CELL M, V13, P383, DOI 10.1007/BF01738034; GULATI J, 1993, J BIOL CHEM, V268, P11685; GULATI J, 1992, J BIOL CHEM, V267, P25073; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1985, BIOCHEMISTRY-US, V24, P5298, DOI 10.1021/bi00341a004; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; JOHNSON JD, 1978, J BIOL CHEM, V253, P3775; KERRICK WGL, 1991, J MUSCLE RES CELL M, V12, P53, DOI 10.1007/BF01781174; KNIGHT PJ, 1982, METHOD ENZYMOL, V85, P9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUSHMERICK MJ, 1982, FED PROC, V41, P2232; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEVY RM, 1976, BIOCHIM BIOPHYS ACTA, V430, P352, DOI 10.1016/0005-2728(76)90091-8; LI MX, 1994, BIOCHEMISTRY-US, V33, P917, DOI 10.1021/bi00170a010; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCUBBIN WD, 1982, BIOCHEMISTRY-US, V21, P5948, DOI 10.1021/bi00266a034; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MORIMOTO S, 1987, J BIOCHEM-TOKYO, V101, P291, DOI 10.1093/oxfordjournals.jbchem.a121913; MOSS RL, 1992, CIRC RES, V70, P865, DOI 10.1161/01.RES.70.5.865; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; PARMACEK MS, 1991, CIRCULATION, V84, P991, DOI 10.1161/01.CIR.84.3.991; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P9703, DOI 10.1021/bi00155a025; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; PFERRER S, 1988, BIOPHYS J, V53, P127, DOI 10.1016/S0006-3495(88)83074-1; POTTER JD, 1982, CALCIUM CELL FUNCTIO, V2, P145; PUTKEY JA, 1991, J BIOL CHEM, V266, P14881; REINACH FC, 1988, J BIOL CHEM, V263, P2371; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SHENG Z, 1991, J BIOL CHEM, V266, P5711; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SMITH L, 1993, BIOPHYS J, V64, pA134; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; TOBACMAN LS, 1987, BIOCHEMISTRY-US, V26, P492, DOI 10.1021/bi00376a022; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; WANG ZY, 1992, P NATL ACAD SCI USA, V89, P11814, DOI 10.1073/pnas.89.24.11814; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; ZOT AS, 1987, J BIOL CHEM, V262, P1966; ZOT HG, 1982, J BIOL CHEM, V257, P7678; ZOT HG, 1986, J BIOL CHEM, V261, P5883	62	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14988	14994						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195134				2022-12-27	WOS:A1994NP73800025
J	CORTAY, JC; NEGRE, D; SCARABEL, M; RAMSEIER, TM; VARTAK, NB; REIZER, J; SAIER, MH; COZZONE, AJ				CORTAY, JC; NEGRE, D; SCARABEL, M; RAMSEIER, TM; VARTAK, NB; REIZER, J; SAIER, MH; COZZONE, AJ			IN-VITRO ASYMMETRIC BINDING OF THE PLEIOTROPIC REGULATORY PROTEIN, FRUR, TO THE ACE OPERATOR CONTROLLING GLYOXYLATE SHUNT ENZYME SYNTHESIZES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE PHOSPHOTRANSFERASE SYSTEM; LAC REPRESSOR PROTEIN; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; NUCLEOTIDE-SEQUENCE; AFFINITY-CHROMATOGRAPHY; GENETIC-REGULATION; OPERON EXPRESSION; DNA INTERACTIONS; ACETATE OPERON	The fruR gene of Escherichia coli, which encodes the regulatory protein FruR, was cloned in the pT7-5 expression vector so as to overproduce a protein tagged with 6 histidine residues. By using a one-step chromatographic procedure, FruR was purified to near homogeneity. Analysis of the protein under both denaturing and nondenaturing conditions indicated that it is a tetramer with a molecular mass of about 150 kilodaltons. The positions of interference between FruR and the operator of the acetate operon were examined. The number and nature of the nucleotides essential for FruR binding were determined by several different techniques: base methylation with dimethyl sulfate, base removal by formic acid and hydrazine, uracil interference, and hydroxyl radical footprinting. It was observed that FruR asymmetrically binds to a 16-base pair DNA sequence located 170 base pairs upstream from the transcriptional start point of the ace operon.	CNRS,INST BIOL & CHIM PROT,F-69367 LYON,FRANCE; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	Centre National de la Recherche Scientifique (CNRS); University of California System; University of California San Diego				Cortay, Jean-Claude/0000-0003-3676-8436; NEGRE, Didier/0000-0003-4769-0814	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014176, R01AI021702] Funding Source: NIH RePORTER; NIAID NIH HHS [NIAID 5R01AI 21702, NIAID 2R01AI 14176] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; ALLEN TD, 1991, J BIOL CHEM, V266, P6113; BLATTNER FR, 1977, SCIENCE, V196, P161, DOI 10.1126/science.847462; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; BYRNE C, 1988, NUCLEIC ACIDS RES, V19, P9342; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHIN AM, 1989, J BACTERIOL, V171, P2424, DOI 10.1128/jb.171.5.2424-2434.1989; CHIN AM, 1987, J BACTERIOL, V169, P897, DOI 10.1128/jb.169.2.897-899.1987; CHUNG T, 1988, J BACTERIOL, V170, P386, DOI 10.1128/jb.170.1.386-392.1988; CORTAY JC, 1989, BIOCHIMIE, V71, P1043, DOI 10.1016/0300-9084(89)90109-0; CORTAY JC, 1991, EMBO J, V10, P675, DOI 10.1002/j.1460-2075.1991.tb07996.x; DEVCHAND PR, 1993, NUCLEIC ACIDS RES, V21, P3437, DOI 10.1093/nar/21.15.3437; DICKSON RC, 1975, SCIENCE, V187, P27, DOI 10.1126/science.1088926; DUCLOS B, 1989, NUCLEIC ACIDS RES, V17, P2856, DOI 10.1093/nar/17.7.2856; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; FELDHEIM DA, 1990, J BACTERIOL, V172, P5459, DOI 10.1128/jb.172.9.5459-5469.1990; GARNAK M, 1978, SCIENCE, V203, P1111; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GEERSE RH, 1989, MOL GEN GENET, V216, P517, DOI 10.1007/BF00334399; GEERSE RH, 1989, MOL GEN GENET, V218, P348, DOI 10.1007/BF00331288; GOEDDEL DV, 1987, J MOL BIOL, V123, P661; HEMDAN ES, 1989, P NATL ACAD SCI USA, V86, P1811, DOI 10.1073/pnas.86.6.1811; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; JAHREIS K, 1991, MOL GEN GENET, V226, P332, DOI 10.1007/BF00273623; KAMMANN M, 1989, NUCLEIC ACIDS RES, V17, P5404, DOI 10.1093/nar/17.13.5404; LAPORTE DC, 1982, NATURE, V300, P458, DOI 10.1038/300458a0; LECLERC G, 1990, J BACTERIOL, V172, P4696, DOI 10.1128/jb.172.8.4696-4700.1990; MAHADEVAN S, 1987, CELL, V50, P485, DOI 10.1016/0092-8674(87)90502-2; MALOY SR, 1982, J BACTERIOL, V149, P173, DOI 10.1128/JB.149.1.173-180.1982; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; NEGRE D, 1992, J MOL BIOL, V228, P23, DOI 10.1016/0022-2836(92)90488-6; NIMMO GA, 1984, EUR J BIOCHEM, V141, P401, DOI 10.1111/j.1432-1033.1984.tb08205.x; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; PU WT, 1992, NUCLEIC ACIDS RES, V20, P771, DOI 10.1093/nar/20.4.771; RAMSEIER TM, 1993, J MOL BIOL, V234, P28, DOI 10.1006/jmbi.1993.1561; REZNIKOFF WS, 1992, J BACTERIOL, V174, P655, DOI 10.1128/jb.174.3.655-658.1992; ROLAND KL, 1985, J BACTERIOL, V163, P991, DOI 10.1128/JB.163.3.991-999.1985; SAIER MH, 1990, BACTERIAL ENERGETICS, P273; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUNNARBORG A, 1990, J BACTERIOL, V172, P2642, DOI 10.1128/jb.172.5.2642-2649.1990; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; WEICKERT MJ, 1993, J BACTERIOL, V175, P251, DOI 10.1128/JB.175.1.251-258.1993; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; WICK KL, 1991, J BIOL CHEM, V266, P6106	48	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14885	14891						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195118				2022-12-27	WOS:A1994NP73800009
J	TAUCHI, T; FENG, GS; SHEN, R; SONG, HY; DONNER, D; PAWSON, T; BROXMEYER, HE				TAUCHI, T; FENG, GS; SHEN, R; SONG, HY; DONNER, D; PAWSON, T; BROXMEYER, HE			SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE SYP IS A TARGET OF P210BCR-ABL TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; GUANINE-NUCLEOTIDE EXCHANGE; FACTOR RECEPTOR-BETA; P210 BCR-ABL; SIGNAL TRANSDUCTION; SH3 DOMAINS; PHOSPHOLIPASE-C; ADAPTER PROTEIN; GRB2; RAS	The phosphorylation of proteins at tyrosine residues is critical in cellular signal transduction and neoplastic transformation. These mechanisms are regulated by the activities of both protein-tyrosine kinases and protein-tyrosine phosphatases. Recent studies have identified a novel protein-tyrosine phosphatase, termed Syp, that is widely expressed in various tissues. Syp encodes a cytoplasmic phosphatase that contains two Src homology 2 (SH2) domains. Since SH2 domains have been shown to target the association of signal transducing molecules to activated tyrosine kinases, experiments were performed to determine whether Syp might form specific complexes with p210bcr-abl, a fusion protein believed to be involved in the pathogenesis of chronic myelogenous leukemia and, thus, possibly alter or mediate p210bcr-abl tyrosine kinase activity. We found that Syp was highly and constitutively tyrosine phosphorylated in three different murine cell lines transfected with a p210bcr-abl expression vector. Furthermore, p210bcr-abl, Syp, and Grb2 formed stable complexes in BCR-ABL expressing cells. Complex formation between p210bcr-abl and Syp was mediated in vitro by the NH2-terminal SH2 domain of Syp. Last, p210bcr-abl tyrosine kinase was effectively dephosphorylated by Syp in vitro. These results suggest an interaction between Syp and BCR-ABL protein, which might play a role in cellular transformation of BCR-ABL.	INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, DEPT MED HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, INDIANAPOLIS, IN 46202 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Pawson, Tony J/E-4578-2013		NATIONAL CANCER INSTITUTE [R37CA036464] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049202, R01HL046549] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA36464] Funding Source: Medline; NHLBI NIH HHS [R01 HL49202, R01 HL46549] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DRUKER B, 1992, BLOOD, V79, P2215; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FEEDMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FENG GS, 1994, IN PRESS ONCOGENE; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANDANAS RA, 1993, BLOOD, V82, P1838; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1988, ONCOGENE, V3, P491; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, IN PRESS EMBO J; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	92	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15381	15387						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195176				2022-12-27	WOS:A1994NP73800078
J	KRISANS, SK; ERICSSON, J; EDWARDS, PA; KELLER, GA				KRISANS, SK; ERICSSON, J; EDWARDS, PA; KELLER, GA			FARNESYL-DIPHOSPHATE SYNTHASE IS LOCALIZED IN PEROXISOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; STEROL CARRIER PROTEIN-2; IMMUNOELECTRON MICROSCOPY; CHOLESTEROL-SYNTHESIS; FIREFLY LUCIFERASE; ACETOACETYL-COA; ACETYL-COA; CELLS; PRENYLTRANSFERASE; METABOLISM	In this study, we have investigated the subcellular localization of farnesyl-diphosphate synthase (FPP synthase). FPP synthase produces FPP, which is utilized in the synthesis of squalene, cholesterol, farnesylated and geranylgeranylated proteins, dolichols, coenzyme Q, and the isoprenoid moiety of heme a. This enzyme is found in the 100,000 x g supernatant fraction of cells or tissues and has been considered to be a cytoplasmic protein. In this study, analysis of FPP synthase activity and protein in fractionated rat liver together with immunofluorescent and immunoelectron microscopy studies demonstrated unequivocally that FPP synthase is largely localized in peroxisomes. These data, in combination with the previous observation that mevalonate kinase is predominantly localized in peroxisomes, suggest that peroxisomes are the major site of synthesis of FPP from mevalonate. We also demonstrate that in liver tissue obtained from patients with peroxisomal deficiency diseases (Zellweger syndrome and neonatal adrenoleukodystrophy), the activities of five enzymes involved in isoprenoid synthesis, namely mevalonate kinase, phosphomevalonate kinase, mevalonate-diphosphate decarboxylase, isopentenyl-diphosphate isomerase, and FPP synthase, are significantly reduced, consistent with a peroxisomal localization of these enzymes.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DIV CARDIOL,LOS ANGELES,CA 90024; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Diego	KRISANS, SK (corresponding author), SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182, USA.		Ericsson, Johan/AAA-6664-2020	Ericsson, Johan/0000-0003-1186-6574	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044350, R01DK032852] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline; NIDDK NIH HHS [DK 44350, DK 32852] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHBY MN, 1989, J BIOL CHEM, V264, P635; BIARDI L, 1994, J BIOL CHEM, V269, P1197; BRUENGER E, 1986, ARCH BIOCHEM BIOPHYS, V248, P620, DOI 10.1016/0003-9861(86)90516-3; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; ERICSSON J, 1992, J BIOL CHEM, V267, P18708; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; HODGE VJ, 1991, BIOCHEM BIOPH RES CO, V181, P537, DOI 10.1016/0006-291X(91)91222-X; HOVIK R, 1991, J LIPID RES, V32, P993; JOLY A, 1993, J BIOL CHEM, V268, P26983; KELLER GA, 1987, P NATL ACAD SCI USA, V84, P3264, DOI 10.1073/pnas.84.10.3264; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER GA, 1984, P NATL ACAD SCI-BIOL, V81, P5744, DOI 10.1073/pnas.81.18.5744; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; KRISANS SK, 1992, AM J RESP CELL MOL, V7, P358, DOI 10.1165/ajrcmb/7.4.358; KRISANS SK, 1988, J CELL BIOL, V107, P122; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; NOLAND BJ, 1980, J BIOL CHEM, V255, P4282; RILLING HC, 1985, STEROLS BILE ACIDS, P17; SPURGEON SL, 1981, BIOSYNTHESIS ISOPREN, V1, P2; STAMELLOS KD, 1992, J BIOL CHEM, V267, P5560; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SUZUKI Y, 1990, CELL STRUCT FUNCT, V15, P301, DOI 10.1247/csf.15.301; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551	28	100	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14165	14169						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188698				2022-12-27	WOS:A1994NL60600067
J	SAKURAI, T; ABE, Y; KASUYA, Y; TAKUWA, N; SHIBA, R; YAMASHITA, T; ENDO, T; GOTO, K				SAKURAI, T; ABE, Y; KASUYA, Y; TAKUWA, N; SHIBA, R; YAMASHITA, T; ENDO, T; GOTO, K			ACTIVIN-A STIMULATES MITOGENESIS IN SWISS 3T3 FIBROBLASTS WITHOUT ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; FSH-RELEASING PROTEIN; C-MYC-GENE; GROWTH-FACTOR; MAP KINASE; EXPRESSION CLONING; MESSENGER-RNA; PHOSPHORYLATION; RECEPTOR; CELLS	Activin A stimulated DNA synthesis and transient c-fos expression in quiescent Swiss 3T3 fibroblasts. The activin A-induced DNA synthesis was dose dependent with a half-maximal effect obtained at 0.3 nM. The maximal response obtained at 10 nM was comparable with that induced by 5 ng/ml basic fibroblast growth factor. Swiss 3T3 fibroblasts expressed abundant high affinity binding sites for I-125-labeled activin A with a K-d value of 0.63 nM and the number of binding sites at 24,000/cell. Northern blot analysis revealed that Swiss 3T3 fibroblasts express a high level of type II activin receptor mRNA. In an attempt to elucidate the mechanism of mitogenic action of activin A, we examined the effect of activin A on mitogen-activated protein kinase activation. Unexpectedly, however, activin A did not induce kinase activation under conditions in which basic fibroblast growth factor and endothelin-1 at similar or even less potent mitogenic concentrations did. Furthermore, activin A did not induce phosphorylation of the Erk2 species of mitogen-activated protein kinase. These observations strongly suggest that the activation of mitogen-activated protein kinase is not a necessary step for activin A-induced DNA synthesis in Swiss 3T3 fibroblasts.	UNIV TOKYO,FAC MED,DEPT PHYSIOL,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,DEPT INTERNAL MED 4,BUNKYO KU,TOKYO 112,JAPAN; CHIBA UNIV,FAC SCI,DEPT BIOL,CHIBA 263,JAPAN	University of Tokyo; University of Tokyo; Chiba University	SAKURAI, T (corresponding author), UNIV TSUKUBA,INST BASIC MED SCI,DEPT PHARMACOL,TENNODAI 1-1-1,TSUKUBA,IBARAKI 305,JAPAN.		Shiba, Reiko/R-3091-2019; Abe, Yoichiro/J-5576-2013; Abe, Yoichiro/AAN-8801-2020	Abe, Yoichiro/0000-0001-6163-8794; Abe, Yoichiro/0000-0001-6163-8794; TAKUWA, Noriko/0000-0002-4278-2704; Kasuya, Yoshitoshi/0000-0003-0614-5836				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZMANCHON C, 1989, ENDOCRINOLOGY, V125, P1666, DOI 10.1210/endo-125-3-1666; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HEDGER MP, 1989, MOL CELL ENDOCRINOL, V61, P133, DOI 10.1016/0303-7207(89)90198-6; KAIBUCHI K, 1986, J BIOL CHEM, V261, P1187; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOHNO M, 1992, BIOCHEM J, V287, P917, DOI 10.1042/bj2870917; KOJIMA I, 1989, BIOCHEM BIOPH RES CO, V159, P1107, DOI 10.1016/0006-291X(89)92223-7; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; PALUMBO AP, 1986, EXP CELL RES, V167, P276, DOI 10.1016/0014-4827(86)90226-0; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SAKURAI T, 1992, BIOCHEM BIOPH RES CO, V186, P342, DOI 10.1016/S0006-291X(05)80813-7; SAWCHENKO PE, 1988, NATURE, V334, P868; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; STEH A, 1991, J BIOL CHEM, V266, P23521; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Vale W., 1990, HDB EXPT PHARM, P211; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	37	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14118	14122						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188692				2022-12-27	WOS:A1994NL60600060
J	SCRUTTON, NS; PACKMAN, LC; MATHEWS, FS; ROHLFS, RJ; HILLE, R				SCRUTTON, NS; PACKMAN, LC; MATHEWS, FS; ROHLFS, RJ; HILLE, R			ASSEMBLY OF REDOX CENTERS IN THE TRIMETHYLAMINE DEHYDROGENASE OF BACTERIUM W(3)A(1) - PROPERTIES OF THE WILD-TYPE ENZYME AND A C30A MUTANT EXPRESSED FROM A CLONED GENE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR FLAVOPROTEIN; COVALENTLY BOUND COENZYME; 6-HYDROXY-D-NICOTINE OXIDASE; SEQUENCE DETERMINATION; BACILLUS-SUBTILIS; FLAVIN; IDENTIFICATION; FLAVINYLATION; CLONING; CLUSTER	In trimethylamine dehydrogenase, the enzyme-bound FMN is covalently linked to Cys-30 by a 6-S cysteinyl FMN bond. The role played by this bond in catalysis has been investigated using a recombinant wild-type trimethylamine dehydrogenase and a Cys-30 to Ala-30 mutant, both expressed from a cloned gene (tmd) in the heterologous host Escherichia coli. The recombinant wild-type and C30A enzymes were found to be quantitatively associated with the 4Fe-4S center and ADP which are both present in the enzyme isolated from bacterium W(3)A(1). In contrast to the enzyme isolated from bacterium W(3)A(1), however, both recombinant proteins contained less than stoichiometric amounts of flavin and were refractory to reconstitution by FMN. The FMN in the recombinant wild-type enzyme was shown to be covalently linked to the protein, and the enzyme possessed catalytic properties similar to its counterpart isolated from bacterium W(3)A(1). It is envisaged that flavinylation proceeds via a nucleophilic attack by the thiolate of Cys-30 at C-6 of the isoalloxazine ring of enzyme-bound FMN. The C30A mutant was found to bind FMN noncovalently and to also catalyze the demethylation of trimethylamine. The major effect of removing the 6-S-cysteinyl FMN bond is to raise the apparent K-m for trimethylamine by 2 orders of magnitude and to diminish the apparent k(cat) for the reaction by only a factor of 2. Therefore, the 6-S-cysteinyl FMN bond is not essential for catalysis, but it is required for efficient functioning of the enzyme at micromolar concentrations of substrate.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM,ST LOUIS,MO 63110; OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210	Washington University (WUSTL); University System of Ohio; Ohio State University	SCRUTTON, NS (corresponding author), UNIV CAMBRIDGE,CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1QW,ENGLAND.							BARBER MJ, 1991, J BIOL CHEM, V267, P6611; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOYD G, 1992, FEBS LETT, V308, P271, DOI 10.1016/0014-5793(92)81291-S; BRANDSCH R, 1987, FEBS LETT, V224, P121, DOI 10.1016/0014-5793(87)80433-7; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; BROOKFIELD DE, 1991, FEBS LETT, V295, P13, DOI 10.1016/0014-5793(91)81373-G; CECCHINI G, 1988, FASEB J, V2, P354; CRICKMORE N, 1992, MOL MICROBIOL, V6, P1533, DOI 10.1111/j.1365-2958.1992.tb00874.x; DAWSON RMC, 1984, DATA BIOCH RES, P105; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GROSS NH, 1984, METHOD ENZYMOL, V106, P261; HILL CL, 1977, P NATL ACAD SCI USA, V74, P547, DOI 10.1073/pnas.74.2.547; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; KASPRZAK AA, 1983, J BACTERIOL, V156, P348, DOI 10.1128/JB.156.1.348-353.1983; KENNEY WC, 1978, FEBS LETT, V85, P137, DOI 10.1016/0014-5793(78)81265-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGRICE SFJ, 1986, MOL GEN GENET, V204, P229, DOI 10.1007/BF00425503; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; LIM LW, 1988, J BIOL CHEM, V263, P3075; LIM LW, 1986, J BIOL CHEM, V261, P5140; MASSEY V, 1966, J BIOL CHEM, V241, P3417; MAUCH L, 1989, FEBS LETT, V257, P86, DOI 10.1016/0014-5793(89)81792-2; MORAN CP, 1982, MOL GEN GENET, V186, P339, DOI 10.1007/BF00729452; PERRETT D, 1991, BIOMED CHROMATOGR, V5, P207, DOI 10.1002/bmc.1130050506; PHILLIPS DC, 1978, J MOL BIOL, V119, P329, DOI 10.1016/0022-2836(78)90440-0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SINGER TP, 1984, METHOD ENZYMOL, V106, P369; STEENKAMP DJ, 1978, BIOCHEM J, V169, P361, DOI 10.1042/bj1690361; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; STEVENSON RC, 1986, BIOCHIM BIOPHYS ACTA, V869, P81, DOI 10.1016/0167-4838(86)90313-4; VANONI MA, 1992, BIOCHEMISTRY-US, V31, P4613, DOI 10.1021/bi00134a011; VISCO C, 1985, J BIOL CHEM, V260, P6133	35	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13942	13950						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188674				2022-12-27	WOS:A1994NL60600037
J	SHIMONAKA, M; YAMAGUCHI, Y				SHIMONAKA, M; YAMAGUCHI, Y			PURIFICATION AND BIOLOGICAL CHARACTERIZATION OF EPITAXIN, A FIBROBLAST-DERIVED MOTILITY FACTOR FOR EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR; CARCINOMA CELLS; FACTOR-BETA; MIGRATION; EXPRESSION; RECEPTOR; IDENTIFICATION; CHEMOTAXIS; CYTOKINES	We have identified a motility factor in conditioned medium of human fibroblasts that stimulates the migration of HepG2 cells in the Boyden chamber assay. This factor, termed epitaxin, was purified to homogeneity by ammonium sulfate precipitation, hydrophobic interaction chromatography on phenyl-Sepharose, and a series of reverse phase high performance liquid chromatography. Under a nonreducing condition, purified epitaxin migrated as a 36-kDa band, and the biological activity was recovered from the area in the gel coinciding with this band. Purified epitaxin stimulates the motility of HepG2 cells in the concentrations above 1 ng/ml with half-maximal activity at 4.2 ng/ml, and its mode of action is mainly chemotactic. Epitaxin slightly stimulates DNA synthesis of HepG2 cells, while scatter factor/hepatocyte growth factor which also stimulates the motility of HepG2 cells showed a growth-inhibitory effect. Epitaxin increases the motility of a wide variety of epithelially derived tumor cell lines, but none of the tested fibroblast lines responded to epitaxin. These results define epitaxin as a novel fibroblast-derived factor that affects the migration, and possibly the invasion, of epithelially derived tumor cells.	LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA057366] Funding Source: NIH RePORTER; NCI NIH HHS [CA-57366] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATNIP KD, 1987, BIOCHEM BIOPH RES CO, V146, P996, DOI 10.1016/0006-291X(87)90746-7; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GREY AM, 1989, P NATL ACAD SCI USA, V86, P2438, DOI 10.1073/pnas.86.7.2438; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; KAKUNAGA T, 1978, P NATL ACAD SCI USA, V75, P1334, DOI 10.1073/pnas.75.3.1334; KOYAMA N, 1993, J BIOL CHEM, V268, P13301; LEAVITT J, 1982, CELL, V28, P259, DOI 10.1016/0092-8674(82)90344-0; LIOTTA LA, 1991, CANCER RES, V51, pS5054; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OTT MO, 1984, EMBO J, V3, P2505, DOI 10.1002/j.1460-2075.1984.tb02164.x; POSTLETHWAITE AE, 1987, J EXP MED, V165, P251, DOI 10.1084/jem.165.1.251; ROSEN EM, 1991, CANCER RES, V51, P5315; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SILLETTI S, 1991, CANCER RES, V51, P3507; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STONE KL, 1989, PRACTICAL GUIDE PROT; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; STRACKE ML, 1988, BIOCHEM BIOPH RES CO, V153, P1076, DOI 10.1016/S0006-291X(88)81338-X; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TAMM I, 1989, J EXP MED, V170, P1649, DOI 10.1084/jem.170.5.1649; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YOSHIDA K, 1970, INT J CANCER, V6, P123, DOI 10.1002/ijc.2910060116; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	34	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14284	14289						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188713				2022-12-27	WOS:A1994NL60600084
J	CHEN, HJ; REMMLER, J; DELANEY, JC; MESSNER, DJ; LOBEL, P				CHEN, HJ; REMMLER, J; DELANEY, JC; MESSNER, DJ; LOBEL, P			MUTATIONAL ANALYSIS OF THE CATION-INDEPENDENT MANNOSE 6-PHOSPHATE INSULIN-LIKE GROWTH FACTOR-II RECEPTOR - A CONSENSUS CASEIN KINASE-II SITE FOLLOWED BY 2 LEUCINES NEAR THE CARBOXYL-TERMINUS IS IMPORTANT FOR INTRACELLULAR TARGETING OF LYSOSOMAL-ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; RAPID INTERNALIZATION; SEQUENCE-ANALYSIS; EXONUCLEASE-III; LDL RECEPTOR; CATHEPSIN-D; ENDOCYTOSIS; BINDING; SIGNAL; CELLS	The cation-independent mannose 6-phosphate/insulin-like growth factor II receptor (CI-MPR) mediates intracellular sorting of lysosomal enzymes, binding lysosomal enzymes in the Golgi and delivering them to a lysosomal compartment. The receptor also mediates endocytosis of extracellular ligands. We have devised a new method that rigorously measures function of the CI-MPR in intracellular sorting and used it to identify a previously uncharacterized signal near the COOH terminus of the receptor that is required for sorting. We stably transfect mutant receptors into CI-MPR-deficient mouse L cells, isolate homogeneous clonal cell lines that express a range of receptor levels for each mutant, and assay each cell line for levels of receptor expression and secretion of total phosphorylated lysosomal enzymes. Examination of the secretion phenotype of the cells as a function of receptor levels provides a sensitive indicator of the intrinsic sorting efficiency of each mutant receptor. We find that chimeric CI-MPRs that contain the bovine extracytoplasmic domain and the human or mouse transmembrane and cytoplasmic domains function identically to the bovine receptor, thus demonstrating that sorting signals are conserved. Analysis of a series of truncation and alanine scanning mutants reveals that a consensus casein kinase II site followed by 2 leucines near the COOH terminus that has the sequence (-10)DDSDEDLL(-3) is important for receptor function in sorting of lysosomal enzymes.	CTR ADV BIOTECHNOL & MED,679 HOES LANE,PISCATAWAY,NJ 08854; RUTGERS UNIV,PROGRAM MICROBIOL & MOLEC GENET,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ 08854; UNIV ROCHESTER,SCH MED,DEPT PHARMACOL,ROCHESTER,NY 14627	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Rochester					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045992] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-45992] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1988, MOL REPROD DEV; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; FISHER HD, 1980, J BIOL CHEM, V255, P5069; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GALLATI H, 1985, J CLIN CHEM CLIN BIO, V23, P453; GALLATI VH, 1985, J CLIN CHEM CLIN BIO, V23, P231; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRUSBY MJ, 1990, NUCLEIC ACIDS RES, V18, P4008, DOI 10.1093/nar/18.13.4008; HARLOW E, 1988, ANTIBODIES LABORATOR; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; JADOT M, 1992, J BIOL CHEM, V267, P11069; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYLE JW, 1988, J BIOL CHEM, V263, P16230; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PUTNEY SD, 1981, P NATL ACAD SCI-BIOL, V78, P7350, DOI 10.1073/pnas.78.12.7350; ROME LH, 1979, P NATL ACAD SCI USA, V76, P2331, DOI 10.1073/pnas.76.5.2331; TAKAHASHI T, 1981, METHOD ENZYMOL, V80, P565; VALENZANO KJ, 1993, ANAL BIOCHEM, V209, P156, DOI 10.1006/abio.1993.1096; YANG YWH, 1991, ENDOCRINOLOGY, V128, P1177, DOI 10.1210/endo-128-2-1177	35	90	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22338	22346						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226743				2022-12-27	WOS:A1993MD34800025
J	CORCUFF, JB; GUERINEAU, NC; MARIOT, P; LUSSIER, BT; MOLLARD, P				CORCUFF, JB; GUERINEAU, NC; MARIOT, P; LUSSIER, BT; MOLLARD, P			MULTIPLE CYTOSOLIC CALCIUM SIGNALS AND MEMBRANE ELECTRICAL EVENTS EVOKED IN SINGLE ARGININE VASOPRESSIN-STIMULATED CORTICOTROPHS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTERIOR-PITUITARY-CELLS; THYROTROPIN-RELEASING-HORMONE; PROTEIN-KINASE-C; ACTIVATED POTASSIUM CURRENTS; RAT PITUITARY; ACTION-POTENTIALS; TUMOR-CELLS; ADRENOCORTICOTROPIN SECRETION; EXTRACELLULAR CALCIUM; INTRACELLULAR STORES	The action of arginine vasopressin (AVP) on cytosolic free Ca2+ concentration ([Ca2+]i) was investigated in single rat pituitary corticotrophs using indo-1 microfluorimetry, in part in combination with the monitoring of membrane electrical events with the perforated patch-clamp technique. In corticotrophs showing the series of short-lived [Ca2+]i rises (transient pattern) in response to corticotropin-releasing factor, 100 nM AVP evoked either the transient pattern or a [Ca2+]i spike followed by a sustained plateau (spike/plateau pattern). Not all corticotrophs responded to changes in AVP concentration in the same manner. Some cells exhibited a concentration-dependent increase in [Ca2+]i transient activity, whereas others showing the spike/plateau at high AVP concentrations responded to low agonist concentrations by two [Ca2+]i responses: a slow rising step or two to three sinusoidal-like oscillations. Combined [Ca2+]i and patch-clamp recordings as well as manipulation of extracellular Ca2+ showed that both transient pattern and the plateau of spike/plateau response depended on Ca2+ entry mainly through voltage-gated, dihydropyridine-sensitive Ca2+ channels. By contrast, step, oscillations, and spike were due to Ca2+ release from internal stores. These Ca2+-mobilizing responses caused the activation of Ca2+-activated, apamin-sensitive K+ channels, which led to a membrane hyperpolarization. These results reveal cell-specific [Ca2+]i signals and associated electrical events in individual AVP-stimulated corticotrophs.	UNIV BORDEAUX 2, CNRS, URA 1200, NEUROPHYSIOL LAB, F-33076 BORDEAUX, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux			Lussier, Benoit/B-9114-2012; Corcuff, jb/GWM-4201-2022	Lussier, Benoit/0000-0002-2152-6314; Guerineau, Nathalie/0000-0003-2517-4210; Mariot, Pascal/0000-0001-7226-9162				ABOUSAMRA AB, 1986, ENDOCRINOLOGY, V118, P212, DOI 10.1210/endo-118-1-212; ABOUSAMRA AB, 1987, J BIOL CHEM, V262, P1129; AGUILERA G, 1983, J BIOL CHEM, V258, P8039; ANTONI FA, 1984, NEUROENDOCRINOLOGY, V39, P186, DOI 10.1159/000123976; ARMSTRONG D, 1987, P NATL ACAD SCI USA, V84, P2518, DOI 10.1073/pnas.84.8.2518; ARMSTRONG DL, 1991, ANN NY ACAD SCI, V635, P26, DOI 10.1111/j.1749-6632.1991.tb36478.x; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BANDYOPADHYAY SK, 1989, J BIOL CHEM, V264, P14216; BILEZIKJIAN LM, 1987, MOL ENDOCRINOL, V1, P555, DOI 10.1210/mend-1-8-555; BROWN DA, 1988, J PHYSIOL-LONDON, V397, P149, DOI 10.1113/jphysiol.1988.sp016993; BRUHN TO, 1984, NEUROENDOCRINOLOGY, V39, P170, DOI 10.1159/000123974; CANNY BJ, 1992, J BIOL CHEM, V267, P8325; CARVALLO P, 1989, MOL ENDOCRINOL, V3, P1935, DOI 10.1210/mend-3-12-1935; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; DELIDOW BC, 1992, MOL ENDOCRINOL, V6, P1268, DOI 10.1210/me.6.8.1268; DOUGLAS WW, 1968, BRIT J PHARMACOL, V34, P451, DOI 10.1111/j.1476-5381.1968.tb08474.x; DUCHEMIN AM, 1992, MOL ENDOCRINOL, V6, P563, DOI 10.1210/me.6.4.563; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; GOLLASCH M, 1991, P NATL ACAD SCI USA, V88, P10262, DOI 10.1073/pnas.88.22.10262; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUERINEAU N, 1991, ENDOCRINOLOGY, V129, P409, DOI 10.1210/endo-129-1-409; GUERINEAU NC, 1992, CELL CALCIUM, V13, P521, DOI 10.1016/0143-4160(92)90020-S; GUILD S, 1987, J PHARMACOL EXP THER, V241, P125; GUILLON G, 1987, REGUL PEPTIDES, V18, P119, DOI 10.1016/0167-0115(87)90001-2; HESS P, 1984, NATURE, V311, P538, DOI 10.1038/311538a0; HOLMES MC, 1984, NEUROENDOCRINOLOGY, V39, P162, DOI 10.1159/000123973; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; JARD S, 1986, MOL PHARMACOL, V30, P171; KORN SJ, 1991, J PHYSIOL-LONDON, V439, P423, DOI 10.1113/jphysiol.1991.sp018674; LABRIE F, 1982, SCIENCE, V216, P1007, DOI 10.1126/science.6281886; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; LANG DG, 1990, PFLUG ARCH EUR J PHY, V416, P704, DOI 10.1007/BF00370618; LEONG DA, 1991, J BIOL CHEM, V266, P9016; LEONG DA, 1988, J EXP BIOL, V139, P151; LEREA LS, 1992, J NEUROSCI, V12, P2973, DOI 10.1523/JNEUROSCI.12-08-02973.1992; LINK H, 1992, ENDOCRINOLOGY, V130, P2183, DOI 10.1210/en.130.4.2183; LLEDO PM, 1991, J PHYSIOL-LONDON, V437, P477, DOI 10.1113/jphysiol.1991.sp018607; LUINI A, 1985, P NATL ACAD SCI USA, V82, P8034, DOI 10.1073/pnas.82.23.8034; LUSSIER BT, 1991, ENDOCRINOLOGY, V128, P570, DOI 10.1210/endo-128-1-570; MARCHETTI C, 1987, AM J PHYSIOL, V252, pE340, DOI 10.1152/ajpendo.1987.252.3.E340; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MITSUHASHI M, 1989, J BIOL CHEM, V264, P18356; MOLLARD P, 1991, EUR J PHARM-MOLEC PH, V206, P271, DOI 10.1016/0922-4106(91)90109-U; MOLLARD P, 1988, ENDOCRINOLOGY, V123, P721, DOI 10.1210/endo-123-2-721; MOLLARD P, 1988, J BIOL CHEM, V263, P19570; MOLLARD P, 1992, BIOCHEM J, V284, P637, DOI 10.1042/bj2840637; MOLLARD P, 1989, BIOCHEM BIOPH RES CO, V164, P1045, DOI 10.1016/0006-291X(89)91775-0; MOLLARD P, 1990, BIOCHEM J, V268, P345, DOI 10.1042/bj2680345; MOLLARD P, 1988, FASEB J, V2, P2907, DOI 10.1096/fasebj.2.13.2844618; MUALLEM S, 1988, BIOCHEM J, V255, P301; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; PRIBNOW D, 1992, MOL ENDOCRINOL, V6, P1003, DOI 10.1210/me.6.7.1003; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RAYMOND V, 1985, FEBS LETT, V182, P196, DOI 10.1016/0014-5793(85)81183-2; RITCHIE AK, 1987, J PHYSIOL-LONDON, V385, P611, DOI 10.1113/jphysiol.1987.sp016510; RITCHIE AK, 1987, J PHYSIOL-LONDON, V385, P591, DOI 10.1113/jphysiol.1987.sp016509; SCHERUBL H, 1991, P ROY SOC LOND B BIO, V245, P125; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SCHULMAN H, 1992, CELL CALCIUM, V13, P401, DOI 10.1016/0143-4160(92)90053-U; SHANGOLD GA, 1988, P NATL ACAD SCI USA, V85, P6566, DOI 10.1073/pnas.85.17.6566; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; STOJILKOVIC SS, 1991, J BIOL CHEM, V266, P10377; STOJILKOVIC SS, 1992, ENDOCR REV, V13, P256, DOI 10.1210/er.13.2.256; THELER JM, 1992, J BIOL CHEM, V267, P18110; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; VALE W, 1983, ENDOCRINOLOGY, V113, P1121, DOI 10.1210/endo-113-3-1121; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; WINIGER BP, 1988, BIOCHEM J, V255, P161, DOI 10.1042/bj2550161; WON JGS, 1990, ENDOCRINOLOGY, V126, P849, DOI 10.1210/endo-126-2-849; WON JGS, 1990, ENDOCRINOLOGY, V126, P858, DOI 10.1210/endo-126-2-858; ZIMMERMAN G, 1970, ENDOCRINOLOGY, V87, P426, DOI 10.1210/endo-87-2-426	77	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22313	22321						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226740				2022-12-27	WOS:A1993MD34800022
J	DEMARTIN, R; COWLED, PA; SMITH, SE; PAPAVASSILIOU, AG; SORRENTINO, V; PHILIPSON, L; BOHMANN, D				DEMARTIN, R; COWLED, PA; SMITH, SE; PAPAVASSILIOU, AG; SORRENTINO, V; PHILIPSON, L; BOHMANN, D			STRUCTURE AND REGULATION OF THE GROWTH ARREST-SPECIFIC (GAS-1) PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; MOUSE FIBROBLASTS; GENE; DNA; EXPRESSION; SEQUENCES; PROTEIN; UPSTREAM; ONCOGENE; SIGNAL	We have isolated recombinant genomic clones encompassing several kilobase pairs of the 5'-flanking regions of both the human and murine gas-1 gene (growth arrest-specific gene 1). Both species share a highly conserved region of approximately 550 base pairs upstream of the gas-1 transcription start site. Deletion analysis of the murine gas-1 promoter demonstrated that a fragment containing the first 665 base pairs is sufficient to drive the serum-regulated expression of a luciferase reporter gene in NIH3T3 cells, in a manner qualitatively reflecting the activity of the endogenous gene. Gel retardation assays indicated the presence of a number of DNA-binding proteins specific for sequences contained within the gas-1 transcription regulatory region. Comparative studies with extracts prepared from growing and resting cells revealed several growth state-specific binding activities. One promoter fragment that bound prominent growth- and arrest-specific complexes was further analyzed by copper-phenanthroline footprinting. It was found that the same DNA element is a target both for growth- and for arrest-specific activities. The factors characterized in this study are the first candidates for transcriptional regulators mediating cell growth-specific repression and/or growth arrest-specific activation of gene expression.	EUROPEAN MOLEC BIOL LAB,POB 102209,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Sorrentino, Vincenzo/A-4793-2014; Karamouzis, Michalis/AAD-2860-2020	Sorrentino, Vincenzo/0000-0002-8573-8631; 				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANSORGE W, 1987, NUCLEIC ACIDS RES, V15, P4593, DOI 10.1093/nar/15.11.4593; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; DAILEY L, 1986, P NATL ACAD SCI USA, V83, P7241, DOI 10.1073/pnas.83.19.7241; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DEMARTIN R, 1993, GENE, V124, P137, DOI 10.1016/0378-1119(93)90776-Y; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVELETH DD, 1986, NUCLEIC ACIDS RES, V14, P6169, DOI 10.1093/nar/14.15.6169; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; Howard A, 1953, HEREDITY           S, V6, P261; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LUMPKIN CK, 1986, SCIENCE, V232, P393, DOI 10.1126/science.2421407; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; PADMANABHAN R, 1987, MOL CELL BIOL, V7, P1894, DOI 10.1128/MCB.7.5.1894; PEPPERKOK R, 1988, P NATL ACAD SCI USA, V85, P6748, DOI 10.1073/pnas.85.18.6748; PEPPERKOK R, 1993, EXP CELL RES, V204, P278, DOI 10.1006/excr.1993.1034; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SHAUL Y, 1987, EMBO J, V6, P1913, DOI 10.1002/j.1460-2075.1987.tb02451.x; SMITH SE, 1993, NUCLEIC ACIDS RES, V21, P1581, DOI 10.1093/nar/21.7.1581; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; THOMAS MJ, 1990, MOL CELL BIOL, V10, P5378, DOI 10.1128/MCB.10.10.5378; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	28	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22788	22793						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226788				2022-12-27	WOS:A1993MD34800088
J	FISCHER, H; GLOCKSHUBER, R				FISCHER, H; GLOCKSHUBER, R			ATP HYDROLYSIS IS NOT STOICHIOMETRICALLY LINKED WITH PROTEOLYSIS IN THE ATP-DEPENDENT PROTEASE LA FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LON GENE-PRODUCT; HEAT-SHOCK; ION GENE; SUBSTRATES ACTIVATE; DEGRADATION; PROTEINS; MUTAGENESIS; BREAKDOWN; EXPRESSION; PEPTIDES	Protein degradation in Escherichia coli involves the ATP-dependent serine protease La. Protease La is a homotetramer with one proteolytic and one ATP binding site per monomer. Its proteolytic activity has been shown to be highly increased by simultaneous hydrolysis of ATP, which is essential for the degradation of protein substrates by this enzyme. We have cloned and purified a proteolytically inactive La mutant, in which the catalytically active serine residue at position 679 was replaced by alanine. Fluorescence and circular dichroism spectra of the purified wild type and mutant enzyme revealed identical conformations of the proteins. Based on this observation, the catalytic properties of the wild type enzyme and the S679A mutant were compared. Although the S679A mutant lacks proteolytic activity toward both peptide and protein substrates under all conditions investigated, its ATPase activity is completely unaffected by the removal of the protease activity. Since protein substrates stimulate the ATP-dependent hydrolysis of peptides by protease La, it has been argued that this stimulation is due to interactions with a regulatory binding site on the enzyme. In accordance with this model, protein substrates such as alpha-casein and denatured bovine serum albumin stimulate the ATPase activity of the S679A mutant to the same degree as in the active protease. Therefore, the intrinsic ATPase activity of protease La as well as its stimulation is not dependent on the simultaneous hydrolysis of the protein substrate.	UNIV REGENSBURG, INST BIOPHYS & PHYS BIOCHEM, UNIV STR 31, D-93053 REGENSBURG, GERMANY	University of Regensburg								AMERIK AY, 1991, FEBS LETT, V287, P211, DOI 10.1016/0014-5793(91)80053-6; AMERIK AY, 1988, BIOORG KHIM+, V14, P408; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GOFF SA, 1984, P NATL ACAD SCI-BIOL, V81, P6647, DOI 10.1073/pnas.81.21.6647; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOFF SA, 1987, J BIOL CHEM, V262, P4508; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; GOLDBERG AL, 1985, J BIOL CHEM, V260, P2029; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HERSHKO A, 1982, ANNU REV BIOCHEM, V51, P335, DOI 10.1146/annurev.bi.51.070182.002003; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MAURIZI MR, 1987, J BIOL CHEM, V262, P2696; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MENON AS, 1987, J BIOL CHEM, V262, P14921; MENON AS, 1987, J BIOL CHEM, V262, P14929; MENON AS, 1987, J BIOL CHEM, V262, P722; OLDEN K, 1978, BIOCHIM BIOPHYS ACTA, V542, P385, DOI 10.1016/0304-4165(78)90370-7; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PHILLIPS TA, 1984, J BACTERIOL, V159, P283, DOI 10.1128/JB.159.1.283-287.1984; ROTHMAN JE, 1986, NATURE, V322, P209, DOI 10.1038/322209a0; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN MY, 1992, EMBO J, V11, P71; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; SKERRA A, 1991, BIO-TECHNOL, V9, P273, DOI 10.1038/nbt0391-273; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TEALE FWJ, 1960, BIOCHEM J, V76, P381, DOI 10.1042/bj0760381; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WAXMAN L, 1982, P NATL ACAD SCI-BIOL, V79, P4883, DOI 10.1073/pnas.79.16.4883; WAXMAN L, 1985, J BIOL CHEM, V260, P2022; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22502	22507						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226758				2022-12-27	WOS:A1993MD34800049
J	JIA, ZC; QUAIL, JW; WAYGOOD, EB; DELBAERE, LTJ				JIA, ZC; QUAIL, JW; WAYGOOD, EB; DELBAERE, LTJ			THE 2.0-ANGSTROM RESOLUTION STRUCTURE OF ESCHERICHIA-COLI HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN HPR - A REDETERMINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; NUCLEAR-MAGNETIC-RESONANCE; BACILLUS-SUBTILIS; TERTIARY STRUCTURE; NMR-SPECTROSCOPY; ACTIVE-SITE; BACTERIAL PHOSPHOENOLPYRUVATE; SECONDARY STRUCTURE; TRANSPORT PROTEIN; FACTOR REFINEMENT	The x-ray structure of Escherichia coli HPr has been redetermined at 2.0-angstrom resolution. In contrast to the previous study (El-Kabbani, O. A. L., Waygood, E. B., and Delbaere, L. T. J. (1987) J. Biol. Chem. 262, 12926-12929), the overall structure is, in general, similar to other reported NMR and x-ray HPr structures, although there are some important differences in detail. The overall folding topology of HPr is a classical open-faced beta-sandwich, consisting of four antiparallel beta-strands and three alpha-helices. The least square refinement produced an R index of 0.135 for all measured unique data between 8.0 and 2.0 angstrom resolution. The active center consists of His15 which is hydrogen bonded to a sulfate anion, and Arg17 which has a fully open conformation. This corresponds to the first observed ''semi-closed'' conformation of the active center of HPr. The Streptococcus faecalis HPr structure (Jia, Z., Vandonselaar, M., Quail, J. W., and Delbaere, L. T. J. (1993) Nature 361, 94-97) has the ''open'' conformation in which the side chains of His15 and Arg17 are directed as far away from each other as possible. The Bacillus subtilis HPr (Herzberg, O., Reddy, P., Sutrina, S., Saier, M. H., Jr., Reizer, J., and Kapadia, G. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2499-2503) has the ''closed'' conformation in which the side chains of His15 and Arg17 are close together with a sulfate anion located in the active center. The open conformation represents the unphosphorylated form of HPr whereas the closed conformation likely resembles the phosphorylated form of HPr. The semi-closed conformation observed in the E. coli HPr structure could represent a structural intermediate on the phosphorylation/dephosphorylation pathway of HPr.	UNIV SASKATCHEWAN, DEPT CHEM, SASKATOON S7N 0W0, SASKATCHEWAN, CANADA; UNIV SASKATCHEWAN, DEPT BIOCHEM, SASKATOON S7N 0W0, SASKATCHEWAN, CANADA	University of Saskatchewan; University of Saskatchewan								ANDERSON B, 1971, J BIOL CHEM, V246, P7023; ANDERSON JW, 1991, BIOCHEMISTRY-US, V30, P9601, DOI 10.1021/bi00104a006; ANDERSON JW, 1993, J BIOL CHEM, V268, P12325; ANDERSON JW, 1992, BIOCHEM CELL BIOL, V70, P242, DOI 10.1139/o92-036; BENKOVIC SJ, 1971, J AM CHEM SOC, V93, P4009, DOI 10.1021/ja00745a032; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, XPLOR VERSION 30 MAN; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; CLARKE S, 1987, INT J PEPT PROT RES, V30, P808, DOI 10.1111/j.1399-3011.1987.tb03390.x; DEUTSCHER J, 1986, BIOCHEMISTRY-US, V25, P6543, DOI 10.1021/bi00369a031; DOOIJEWAARD G, 1979, BIOCHEMISTRY-US, V18, P2996, DOI 10.1021/bi00581a014; EISERMANN R, 1991, EUR J BIOCHEM, V197, P9, DOI 10.1111/j.1432-1033.1991.tb15875.x; ELKABBANI OAL, 1987, J BIOL CHEM, V262, P12926; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; HAMMEN PK, 1991, BIOCHEMISTRY-US, V30, P11842, DOI 10.1021/bi00115a014; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; JACOBSON BL, 1988, J MOL BIOL, V204, P783, DOI 10.1016/0022-2836(88)90369-5; JIA Z, 1992, THESIS U SASKATCHEWA; JIA ZC, 1993, NATURE, V361, P94, DOI 10.1038/361094a0; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KALBITZER HR, 1991, BIOCHEMISTRY-US, V30, P11186, DOI 10.1021/bi00110a024; KALBITZER HR, 1982, BIOCHEMISTRY-US, V21, P2879, DOI 10.1021/bi00541a012; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P7774, DOI 10.1021/bi00371a073; KONNERT JH, 1980, ACTA CRYSTALLOGR A, V36, P344, DOI 10.1107/S0567739480000794; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PAS HH, 1991, J BIOL CHEM, V266, P6690; POSTMA PW, 1985, MICROBIOL REV, V49, P232, DOI 10.1128/MMBR.49.3.232-269.1985; PRASAD L, 1993, J BIOL CHEM, V268, P10705; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; REIZER J, 1992, J BIOL CHEM, V267, P9158; RICHARDS FM, 1988, PROTEINS, V3, P71, DOI 10.1002/prot.340030202; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SANCHO J, 1992, BIOCHEMISTRY-US, V31, P2253, DOI 10.1021/bi00123a006; SHARMA S, 1991, P NATL ACAD SCI USA, V88, P4877, DOI 10.1073/pnas.88.11.4877; SHARMA S, 1993, J BIOL CHEM, V268, P17695; TITGEMEYER F, 1991, THESIS U OSNABRUK OS; VANDIJK AA, 1990, BIOCHEMISTRY-US, V29, P8164, DOI 10.1021/bi00487a026; VANDIJK AA, 1992, BIOCHEMISTRY-US, V31, P9063, DOI 10.1021/bi00152a050; VANNULAND NAJ, 1992, EUR J BIOCHEM, V203, P483; VERLINDE CLMJ, 1991, EUR J BIOCHEM, V198, P53, DOI 10.1111/j.1432-1033.1991.tb15985.x; WAYGOOD EB, 1985, BIOCHEMISTRY-US, V24, P6938, DOI 10.1021/bi00345a028; WAYGOOD EB, 1984, J CELL BIOCHEM, V25, P139, DOI 10.1002/jcb.240250304; WAYGOOD EB, 1989, FEMS MICROBIOL LETT, V63, P43, DOI 10.1016/0168-6445(89)90007-7; WAYGOOD EB, 1988, BIOCHEM CELL BIOL, V66, P76, DOI 10.1139/o88-010; WEARNE SJ, 1989, PROTEINS, V5, P8, DOI 10.1002/prot.340050103; WITTEKIND M, 1990, BIOCHEMISTRY-US, V29, P7191, DOI 10.1021/bi00483a006; WITTEKIND M, 1992, PROTEIN SCI, V1, P1363, DOI 10.1002/pro.5560011016; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532	59	114	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22490	22501						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226757				2022-12-27	WOS:A1993MD34800048
J	OTANI, H; ERDOS, M; LEONARD, WJ				OTANI, H; ERDOS, M; LEONARD, WJ			TYROSINE KINASE(S) REGULATE APOPTOSIS AND BCL-2 EXPRESSION IN A GROWTH FACTOR-DEPENDENT CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA FRAGMENTATION; C-MYC; CHROMOSOMAL BREAKPOINT; CLONAL DELETION; B-CELLS; DEATH; GENE; THYMOCYTES; ACTIVATION; SURVIVAL	Apoptosis (programmed cell death) plays a critical role in many physiological processes, but the mechanism(s) which regulate apoptosis are poorly understood. We demonstrate that in a hematopoietic cell line, which can grow in either interleukin (IL)-2 or IL-3, both of these growth factors can increase bcl-2 mRNA levels and prevent apoptosis normally seen following growth factor withdrawal. Herbimycin A, a protein tyrosine kinase inhibitor, blocks the ability of IL-2 and IL-3 to up-regulate bcl-2 mRNA levels and induces apoptosis. Transfection of a bcl-2 expression vector not only prolongs survival following growth factor withdrawal but also confers resistance to the effect of herbimycin A. We conclude that herbimycin A-sensitive protein tyrosine kinases are involved in the regulation of apoptosis and bcl-2 expression, but these protein tyrosine kinases appear not to be required for the action of Bcl-2 since Bcl-2 can exert its growth survival effect even in the presence of herbimycin A.	NHLBI,OFF DIRECTOR,INTRAMURAL RES PROGRAM,PULM & MOLEC IMMUNOL SECT,BETHESDA,MD 20892; NICHHD,MOLEC GENET LAB,BETHESDA,MD 20892; SHIMANE MED UNIV,DEPT ANAT,IZUMO,SHIMANE 693,JAPAN	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Shimane University			Leonard, Warren/AAA-1397-2022					BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CAO MV, 1992, NEURON, V9, P583; CHIBA T, 1993, NATURE, V362, P646, DOI 10.1038/362646a0; CHOW SC, 1989, ANAL BIOCHEM, V183, P42, DOI 10.1016/0003-2697(89)90168-1; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COHEN JJ, 1984, J IMMUNOL, V132, P38; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GURFINKEL N, 1987, EUR J IMMUNOL, V17, P567, DOI 10.1002/eji.1830170421; ISFORT R, 1988, J BIOL CHEM, V263, P19203; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KACZMAREK L, 1987, J CELL BIOL, V104, P183, DOI 10.1083/jcb.104.2.183; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MCCONKEY DJ, 1990, IMMUNOL TODAY, V11, P120, DOI 10.1016/0167-5699(90)90048-E; MIYASHITA T, 1992, CANCER RES, V52, P5407; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAKAYAMA K, 1992, SCIENCE, V257, P94, DOI 10.1126/science.1621101; NUNEZ G, 1990, J IMMUNOL, V144, P3602; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	38	101	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22733	22736						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226783				2022-12-27	WOS:A1993MD34800080
J	ALBONE, EF; HAGEN, FK; VANWUYCKHUYSE, BC; TABAK, LA				ALBONE, EF; HAGEN, FK; VANWUYCKHUYSE, BC; TABAK, LA			MOLECULAR-CLONING OF A RAT SUBMANDIBULAR-GLAND APOMUCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCIN-LIKE PROTEIN; INTESTINAL MUCIN; SALIVARY MUCIN; SUBMAXILLARY; EXPRESSION; SEQUENCE; CONSERVATION; CLEAVAGE; DOMAINS; GENES	Overlapping cDNA clones which encode the protein core of a rat submandibular gland mucin-glycoprotein have been isolated and characterized. Sequence analysis revealed a translated region of 966 nucleotides encoding a protein of 322 amino acid residues. The translational start site begins with a putative signal sequence comprising the initial 22 N-terminal residues. The predicted- secreted portion of the apomucin revealed three distinct domains: an N-terminal domain which is enriched in glutamine (14%), proline (13%), and tyrosine (10%); a central region which consisted of eleven, 39-base pair tandem repeats with the consensus sequence PTTDSTTPAPTTK; and a C-terminal domain which is enriched in threonine and serine residues (47%) which are not part of a repeat motif. The expression of apomucin transcript appears restricted to the rat submandibular and sublingual glands. Southern blot analysis of rat genomic DNAs suggested a low copy number (1, 2) for this apomucin gene and a limited polymorphism in the number of tandem repeats. Collectively, our sequence and expression data indicate that the cloned rat submandibular gland apomucin is distinct from any of the other salivary (bovine, porcine, or human) or rat apomucins reported thus far.	UNIV ROCHESTER,SCH MED & DENT,DEPT DENT RES,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NIDCR NIH HHS [DE-08108] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008108, R01DE008108] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER LF, 1991, J BIOL CHEM, V266, P3532; ECKHARDT AE, 1987, J BIOL CHEM, V262, P11339; EDGE ASB, 1981, J BIOL CHEM, V226, P9678; GERKEN TA, 1992, BIOCHEMISTRY-US, V31, P639, DOI 10.1021/bi00118a002; GOTTSCHALK A, 1969, NATURE, V222, P452, DOI 10.1038/222452a0; GUM JR, 1991, J BIOL CHEM, V266, P22733; HOFFMAN MP, 1993, INFECT IMMUN, V61, P1940, DOI 10.1128/IAI.61.5.1940-1949.1993; HUANG SH, 1992, METHOD MOL BIOL, V16, P357; JOHANSSON M, 1993, J HERED, V84, P259, DOI 10.1093/oxfordjournals.jhered.a111336; KHATRI IA, 1993, BIOCHEM J, V294, P391, DOI 10.1042/bj2940391; KOZAK M, 1983, MICROBIOL REV, V47, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIRELS L, 1987, J BIOL CHEM, V262, P7289; MOREIRA JE, 1989, J HISTOCHEM, V3, P515; NUGENT J, 1984, CIBA F S MUCUS MUCOS, V109, P1; ORSTAVIK TB, 1977, ACTA PHYSIOL SCAND, V100, P33, DOI 10.1111/j.1748-1716.1977.tb05919.x; QUISSELL DO, 1989, HDB PHYSL SALIVARY P, P79; Sambrook J, 1989, MOL CLONING LABORATO; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SHARIFI BG, 1985, J CHROMATOGR, V324, P173, DOI 10.1016/S0021-9673(01)81316-9; SPICER AP, 1991, J BIOL CHEM, V266, P15099; TABAK LA, 1982, J ORAL PATHOL MED, V11, P1, DOI 10.1111/j.1600-0714.1982.tb00138.x; TABAK LA, 1985, ARCH BIOCHEM BIOPHYS, V242, P383, DOI 10.1016/0003-9861(85)90222-X; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; TSUDA T, 1993, BIOCHEM BIOPH RES CO, V195, P363, DOI 10.1006/bbrc.1993.2052; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WARREN L, 1959, J BIOL CHEM, V234, P1971; XU GQ, 1992, BIOCHEM J, V286, P335, DOI 10.1042/bj2860335	33	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16845	16852						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207007				2022-12-27	WOS:A1994NR29600052
J	MENENDEZARIAS, L; WEBER, IT; SOSS, J; HARRISON, RW; GOTTE, D; OROSZLAN, S				MENENDEZARIAS, L; WEBER, IT; SOSS, J; HARRISON, RW; GOTTE, D; OROSZLAN, S			KINETIC AND MODELING STUDIES OF SUBSITES S-4-S-3' OF MOLONEY MURINE LEUKEMIA-VIRUS PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ROUS-SARCOMA VIRUS; MYELOBLASTOSIS-ASSOCIATED VIRUS; INFECTIOUS-ANEMIA VIRUS; MAMMARY-TUMOR VIRUS; HIV-1 PROTEINASE; ASPARTIC PROTEASE; CRYSTAL-STRUCTURE; CRYSTALLOGRAPHIC STRUCTURE; SUBSTRATE-SPECIFICITY	The substrate specificity of the Moloney murine leukemia virus protease (Mo-MuLV PR) was analyzed by using the oligopeptide substrate Val-Ser-Gln-Asn-Tyr down arrow Pro-Ile-Val-Gln-NH2 and a series of analogs containing single amino acid substitutions in the P-4-P-3' positions. Mo-MuLV PR appears to act similarly to the human immunodeficiency virus (HIV) PRs, except for peptides having substitutions at P-4 and P-2 positions. Mo-MuLV PR shows a strong preference for the analogs having hydrophobic residues, such as Val or Ile at P-4, and Ile and Leu at P-2, in contrast to HIV-1 and HIV-2 PRs, which prefer smaller or more polar residues at both positions. We built a molecular model of Mo-MuLV PR on the basis of the crystal structure of the related HIV PR. Although the overall structure of Mo-MuLV PR is predicted to be close to that of HIV-1 PR, almost all of the residues forming the subsites are different. The increased hydrophobicity due to the pro(12) insertion and the presence of more aromatic residues in the S-4 subsite of Mo-MuLV PR compared to HIV-1 and HIV-2 PRs can be correlated with the observed differences using P-4-substituted analogs of VSQNYPIVQ. The preference of Mo-MuLV PR for larger hydrophobic residues at the P-2 position can be correlated with the larger size of its S-2 subsite, due in part to the presence of Val(39) Ala(57), and His(84) in Mo-MuLV PR, instead of Ile(32), Ile(50), and Met(76), respectively, as occurs in HIV-2 PR.	THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA	Jefferson University	MENENDEZARIAS, L (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, MOLEC VIROL & CARCINOGENESIS LAB, FREDERICK, MD 21702 USA.		Arias, Luis Menendez/N-7447-2016; Menendez Arias, Luis/G-2436-2016	Arias, Luis Menendez/0000-0002-1251-6640; Harrison, Robert/0000-0003-2449-1214	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABOONIAN C, 1991, BIOCHEM BIOPH RES CO, V179, P17, DOI 10.1016/0006-291X(91)91327-9; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BILLICH A, 1991, ARCH BIOCHEM BIOPHYS, V290, P186, DOI 10.1016/0003-9861(91)90606-J; CAMERON CE, 1994, J BIOL CHEM, V269, P11170; CAMERON CE, 1993, J BIOL CHEM, V268, P11711; COPELAND TD, 1988, GENE ANAL TECH, V5, P109, DOI 10.1016/0735-0651(88)90010-6; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; ELFARRASH MA, 1994, J VIROL, V68, P233, DOI 10.1128/JVI.68.1.233-239.1994; GRIFFITHS JT, 1992, BIOCHEMISTRY-US, V31, P5193, DOI 10.1021/bi00137a015; GRINDE B, 1992, J BIOL CHEM, V267, P9491; GUSTCHINA A, 1994, PROTEIN ENG, V7, P309, DOI 10.1093/protein/7.3.309; GUSTCHINA A, 1991, PROTEINS, V10, P325, DOI 10.1002/prot.340100406; HARRISON RW, 1993, J COMPUT CHEM, V14, P1112, DOI 10.1002/jcc.540140912; HUI KY, 1993, FEBS LETT, V327, P355, DOI 10.1016/0014-5793(93)81020-Z; JASKOLSKI M, 1990, BIOCHEMISTRY-US, V29, P5889, DOI 10.1021/bi00477a002; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JUPP RA, 1991, FEBS LETT, V283, P180, DOI 10.1016/0014-5793(91)80583-O; KONVALINKA J, 1992, EMBO J, V11, P1141, DOI 10.1002/j.1460-2075.1992.tb05154.x; KONVALINKA J, 1990, FEBS LETT, V268, P35, DOI 10.1016/0014-5793(90)80966-M; MARGOLIN N, 1990, BIOCHEM BIOPH RES CO, V167, P554, DOI 10.1016/0006-291X(90)92060-D; MEAK TD, 1992, J ENZYM INHIB, V6, P65; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841; MENENDEZARIAS L, 1992, J BIOL CHEM, V267, P24134; MENENDEZARIAS L, 1992, J BIOL CHEM, V267, P11392; MENENDEZARIAS L, 1993, VIROLOGY, V196, P557, DOI 10.1006/viro.1993.1511; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; MULICHAK AM, 1993, J BIOL CHEM, V268, P13103; NAGY K, 1994, J VIROL, V68, P757, DOI 10.1128/JVI.68.2.757-765.1994; NAIDU YM, 1988, J VIROL, V62, P4691, DOI 10.1128/JVI.62.12.4691-4696.1988; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; OTTO MJ, 1993, P NATL ACAD SCI USA, V90, P7543, DOI 10.1073/pnas.90.16.7543; PARTIN K, 1990, J VIROL, V64, P3938, DOI 10.1128/JVI.64.8.3938-3947.1990; PAVLICKOVA L, 1992, ARCH BIOCHEM BIOPHYS, V298, P753, DOI 10.1016/0003-9861(92)90476-D; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; PHYLIP LH, 1990, BIOCHEM BIOPH RES CO, V171, P439, DOI 10.1016/0006-291X(90)91412-L; RICH DH, 1990, J MED CHEM, V33, P1285, DOI 10.1021/jm00167a003; RICHARDS AD, 1990, J BIOL CHEM, V265, P7733; ROBERTS MM, 1991, PROTEIN ENG, V4, P695, DOI 10.1093/protein/4.6.695; ROBERTS MM, 1989, BIOCHEM BIOPH RES CO, V160, P486, DOI 10.1016/0006-291X(89)92459-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805; TOH H, 1985, EMBO J, V4, P1267, DOI 10.1002/j.1460-2075.1985.tb03771.x; TONG L, 1993, P NATL ACAD SCI USA, V90, P8387, DOI 10.1073/pnas.90.18.8387; TOZSER J, 1992, BIOCHEMISTRY-US, V31, P4793, DOI 10.1021/bi00135a008; TOZSER J, 1991, FEBS LETT, V279, P356, DOI 10.1016/0014-5793(91)80186-7; TOZSER J, 1993, BIOCHEMISTRY-US, V32, P3347, DOI 10.1021/bi00064a018; WEBER IT, 1990, J BIOL CHEM, V265, P10492; WEBER IT, 1989, GENE, V85, P565, DOI 10.1016/0378-1119(89)90453-8; WEBERIT, 1993, BIOCHEMISTRY-US, V32, P3354; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; YOSHINAKA Y, 1985, P NATL ACAD SCI USA, V82, P1618, DOI 10.1073/pnas.82.6.1618	54	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16795	16801						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207003				2022-12-27	WOS:A1994NR29600046
J	WATANABE, M; CHEN, CY; LEVIN, DE				WATANABE, M; CHEN, CY; LEVIN, DE			SACCHAROMYCES-CEREVISIAE PKC1 ENCODES A PROTEIN-KINASE-C (PKC) HOMOLOG WITH A SUBSTRATE-SPECIFICITY SIMILAR TO THAT OF MAMMALIAN PKC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; SIGNAL-TRANSDUCTION; CELL-CYCLE; REGULATORY DOMAIN; 2ND MESSENGERS; PHORBOL ESTERS; GROWTH-FACTOR; MYC-GENE; ACTIVATION; YEAST	The PKC1 gene of the budding yeast Saccharomyces cerevisiae encodes a homolog of the alpha, beta, and gamma isoforms of mammalian protein kinase C (PKC) that is essential for cell growth. Loss of PKC1 function results in a cell lysis defect that is due to a deficiency in cell wall construction. In this study, Pkc1p was modified at its COOH terminus with the influenza virus hemagglutinin epitope and was detected by SDS-polyacrylamide gel electrophoresis as a 145- and 150-kDa doublet when overproduced in yeast cells. Pkc1p displayed intrinsic Ser/Thr protein kinase activity in vitro, possessing a substrate specificity similar to that described for mammalian PKC. Specifically, preferred substrates possess an arginine at position -3 and a basic residue at position +2 relative to the target site. A catalytically inactive missense mutant of Pkc1p failed to complement a pkc1 Delta mutant, suggesting that protein kinase activity is required for the biological function of Pkc1p. Both wild-type Pkc1p and the inactive form were isolated as phosphoproteins, indicating that Pkc1p is phosphorylated in vivo by another protein kinase. In vitro protein kinase activity of Pkc1p was not dependent on activating cofactors normally required for stimulation of mammalian PKC. However, mutational incapacitation of the pseudosubstrate site of Pkc1p resulted in constitutive activation of the enzyme, both in vivo and in vitro, suggesting that Pkc1p is normally regulated by a mechanism similar to that of its mammalian counterparts. The apparent molecular mass and substrate specificity of Pkc1p, together with its failure to respond to activating cofactors, suggest that this enzyme is distinct from an enzyme purified previously from budding yeast that has enzymatic properties similar to those of mammalian PKC.	JOHNS HOPKINS UNIV, SCH PUBL HLTH, DEPT BIOCHEM, BALTIMORE, MD 21205 USA	Johns Hopkins University				Levin, David/0000-0003-0696-2860	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048533] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM48533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANTONSSON B, 1994, J BIOL CHEM, V269, P16821; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FARLEY J, 1986, NATURE, V319, P220, DOI 10.1038/319220a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; HOUSE C, 1990, CELL SIGNAL, V2, P187, DOI 10.1016/0898-6568(90)90022-3; HOUSE C, 1987, J BIOL CHEM, V262, P772; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; HUANG KP, 1986, J BIOL CHEM, V261, P2134; HUBBARD SR, 1991, SCIENCE, V254, P1776; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IWAI T, 1992, J BIOCHEM, V112, P7, DOI 10.1093/oxfordjournals.jbchem.a123868; KAIBUCHI K, 1985, J BIOL CHEM, V260, P1366; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEVIN DE, 1987, P NATL ACAD SCI USA, V84, P6035, DOI 10.1073/pnas.84.17.6035; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LEVIN DE, 1993, J NIH RES, V5, P49; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MADISON DV, 1986, NATURE, V321, P695, DOI 10.1038/321695a0; Maniatis T., 1982, MOL CLONING; MURAMATSU M, 1992, FEBS LETT, V311, P75, DOI 10.1016/0014-5793(92)81371-R; NEGROVILAR A, 1985, ENDOCRINOLOGY, V117, P1559, DOI 10.1210/endo-117-4-1559; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; OGITA K, 1990, P NATL ACAD SCI USA, V87, P5011, DOI 10.1073/pnas.87.13.5011; OHMURA E, 1985, ENDOCRINOLOGY, V116, P728, DOI 10.1210/endo-116-2-728; OMURA S, 1977, J ANTIBIOT, V30, P275, DOI 10.7164/antibiotics.30.275; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; PEARS C, 1992, BIOCHEM J, V283, P515, DOI 10.1042/bj2830515; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; Sambrook J, 1989, MOL CLONING LABORATO; Sherman F., 1986, METHODS YEAST GENETI; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TORRES L, 1991, MOL MICROBIOL, V5, P2845, DOI 10.1111/j.1365-2958.1991.tb01993.x; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOODGETT JR, 1987, PROTEIN KINASE C ITS, P215	76	131	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16829	16836						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207005				2022-12-27	WOS:A1994NR29600050
J	CREEDON, KA; RATHOD, PK; WELLEMS, TE				CREEDON, KA; RATHOD, PK; WELLEMS, TE			PLASMODIUM-FALCIPARUM S-ADENOSYLHOMOCYSTEINE HYDROLASE - CDNA IDENTIFICATION, PREDICTED PROTEIN-SEQUENCE, AND EXPRESSION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-HOMOCYSTEINE HYDROLASE; ADENOSYL-L-HOMOCYSTEINE; AMINO-ACID SEQUENCE; RAT-LIVER; NEPLANOCIN-A; ANTIMALARIAL ACTIVITY; CHEMICAL MODIFICATION; GENOMIC ORGANIZATION; NUCLEOTIDE-SEQUENCE; MALARIA PARASITES	Compounds that specifically inhibit S-adenosylhomocysteine hydrolase (SAHH; EC 3.3.1.1) interfere with the proliferation of Plasmodium malarial parasites, but efforts to identify the enzyme directly in parasite extracts have been unsuccessful. Here we report genetic and biochemical evidence for the presence of a gene encoding P. falciparum SAHH. The gene is transcribed as a 2.8-kilobase mRNA in erythrocytic stage parasites. Analysis of the open reading frame predicts a 53.9-kDa protein having conserved regions thought to be involved in NAD binding. The cDNA sequence has been incorporated into an Escherichia coli expression construct to confirm the function of the sahh product. Transformed E. coli cells produce a protein with a relative molecular weight of 56,000 which possesses SAHH activity as evidenced by the conversion of 3-deazaadenosine to S-3-deazaadenosylhomocysteine. Several amino acid residues that have been suggested to be at the SAHH active site in other organisms show nonconserved replacements in P. falciparum, suggesting that some current proposals for the enzyme mechanism may need to be revised. The structural differences between the P. falciparum and mammalian SAHH enzymes may foster innovative strategies for drug development against malaria.	NIAID, MALARIA RES LAB, BETHESDA, MD 20892 USA; US FDA, CTR DRUG EVALUAT & RES, ROCKVILLE, MD 20857 USA; CATHOLIC UNIV AMER, INST BIOMOLEC STUDIES, DEPT BIOL, WASHINGTON, DC 20064 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); US Food & Drug Administration (FDA); Catholic University of America					NIAID NIH HHS [AI01112, NIAID AI26912] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI026912, K04AI001112, R01AI026912] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKSAMIT RR, 1994, J BIOL CHEM, V269, P4084; ALANO P, 1991, MOL BIOCHEM PARASIT, V46, P81, DOI 10.1016/0166-6851(91)90201-G; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASAWAMAHASAKDA W, 1993, PARASITOLOGY, V107, P1, DOI 10.1017/S0031182000079348; BHASIN VK, 1984, AM J TROP MED HYG, V33, P534, DOI 10.4269/ajtmh.1984.33.534; BITONTI AJ, 1990, BIOCHEM PHARMACOL, V40, P601, DOI 10.1016/0006-2952(90)90562-Y; BORCHARDT RT, 1984, J BIOL CHEM, V259, P4353; CANTONI GL, 1954, J AM CHEM SOC, V76, P4744, DOI 10.1021/ja01647a081; CHIANG PK, 1977, MOL PHARMACOL, V13, P939; COULTERKARIS DE, 1989, ANN HUM GENET, V53, P169, DOI 10.1111/j.1469-1809.1989.tb01781.x; CREEDON KA, 1992, MOL BIOCHEM PARASIT, V54, P113, DOI 10.1016/0166-6851(92)90102-P; DECLERCQ E, 1985, BIOCHEM BIOPH RES CO, V129, P306, DOI 10.1016/0006-291X(85)91438-X; DELAHABA G, 1959, J BIOL CHEM, V234, P603; DELVES CJ, 1990, MOL BIOCHEM PARASIT, V43, P271, DOI 10.1016/0166-6851(90)90151-B; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dolan S A, 1993, Methods Mol Biol, V21, P319; DUERRE JA, 1962, J BIOL CHEM, V237, P3737; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAJADHAR AA, 1991, MOL BIOCHEM PARASIT, V45, P147, DOI 10.1016/0166-6851(91)90036-6; GARDNER MJ, 1991, MOL BIOCHEM PARASIT, V44, P115, DOI 10.1016/0166-6851(91)90227-W; GOMI T, 1986, J BIOL CHEM, V261, P3422; GOMI T, 1989, BIOCHIM BIOPHYS ACTA, V994, P172, DOI 10.1016/0167-4838(89)90157-X; GOMI T, 1983, BIOCHEMISTRY-US, V22, P137, DOI 10.1021/bi00270a020; GOMI T, 1989, J BIOL CHEM, V264, P16138; GOMI T, 1990, J BIOL CHEM, V265, P16102; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; GURANOWSKI A, 1977, EUR J BIOCHEM, V80, P517, DOI 10.1111/j.1432-1033.1977.tb11907.x; HENDERSON DM, 1992, MOL BIOCHEM PARASIT, V53, P169, DOI 10.1016/0166-6851(92)90019-G; KASIR J, 1988, BIOCHEM BIOPH RES CO, V153, P359, DOI 10.1016/S0006-291X(88)81231-2; KAWALLECK P, 1992, P NATL ACAD SCI USA, V89, P4713, DOI 10.1073/pnas.89.10.4713; KNAPP B, 1990, MOL BIOCHEM PARASIT, V40, P1, DOI 10.1016/0166-6851(90)90074-V; KRUNGKRAI J, 1989, PARASITOL RES, V75, P512, DOI 10.1007/BF00931158; LAWRENCE F, 1981, BIOCH PROTOZOOLOGY, P436; OGAWA H, 1987, P NATL ACAD SCI USA, V84, P719, DOI 10.1073/pnas.84.3.719; PALMER JL, 1976, J BIOL CHEM, V251, P5817; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; POLLACK Y, 1991, EXP PARASITOL, V72, P339, DOI 10.1016/0014-4894(91)90079-C; PRASAD SS, 1991, M64306 GENB EMBL ACC; RAVETCH JV, 1984, NATURE, V312, P616, DOI 10.1038/312616a0; RAWLINGS DJ, 1992, J BIOL CHEM, V267, P3976; RICHARDS KD, 1993, L11872 GENB EMBL ACC; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHROEDER G, 1993, Z26881 GENB EMBL ACC; SGANGA MW, 1992, P NATL ACAD SCI USA, V89, P6328, DOI 10.1073/pnas.89.14.6328; SHAPIRO MB, 1986, NUCLEIC ACIDS RES, V14, P65, DOI 10.1093/nar/14.1.65; SHIMIZU S, 1984, EUR J BIOCHEM, V141, P385, DOI 10.1111/j.1432-1033.1984.tb08203.x; Siddiqui W A, 1979, Bull World Health Organ, V57 Suppl 1, P75; TAKATA Y, 1984, BIOCHEMISTRY-US, V23, P4357, DOI 10.1021/bi00314a017; TAKATA Y, 1983, J BIOL CHEM, V258, P7374; TAKATA Y, 1985, ARCH BIOCHEM BIOPHYS, V240, P827, DOI 10.1016/0003-9861(85)90092-X; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VIAL HJ, 1989, PARASITOLOGY, V98, P351, DOI 10.1017/S0031182000061424; WALKER RD, 1975, CAN J BIOCHEM CELL B, V53, P312, DOI 10.1139/o75-044; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; WEBER JL, 1987, GENE, V52, P103, DOI 10.1016/0378-1119(87)90399-4; WELLEMS TE, 1986, P NATL ACAD SCI USA, V83, P6065, DOI 10.1073/pnas.83.16.6065; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0; WESSELING JG, 1989, GENE, V83, P301, DOI 10.1016/0378-1119(89)90116-9; WESSELING JG, 1989, MOL BIOCHEM PARASIT, V35, P167, DOI 10.1016/0166-6851(89)90119-9; WHAUN JM, 1986, J PHARMACOL EXP THER, V236, P277; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YAGINUMA S, 1981, J ANTIBIOT, V34, P359, DOI 10.7164/antibiotics.34.359; YARLETT N, 1988, MOL BIOCHEM PARASIT, V27, P1, DOI 10.1016/0166-6851(88)90019-9; YEH JC, 1991, J COMPUT AID MOL DES, V5, P213, DOI 10.1007/BF00124340	66	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16364	16370						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206944				2022-12-27	WOS:A1994NQ72900063
J	CHACKO, S; JACOB, SS; HORIUCHI, KY				CHACKO, S; JACOB, SS; HORIUCHI, KY			MYOSIN-I FROM MAMMALIAN SMOOTH-MUSCLE IS REGULATED BY CALDESMON-CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER; BINDING PROTEIN; F-ACTIN; ACANTHAMOEBA-CASTELLANII; THIN-FILAMENTS; GIZZARD; PURIFICATION; TROPOMYOSIN; ATPASE; 110K-CALMODULIN	A single-headed monomeric myosin (myosin I) was isolated from pig urinary bladder smooth muscles and purified to homogeneity. Myosin I from smooth muscle is composed of a 110-kDa heavy chain and three 17-kDa light chains. The heavy chain from smooth muscle myosin I does not cross-react with the antibody against conventional myosin (myosin II) from smooth muscle, but it does show antigenic similarity to adrenal medulla myosin I heavy chain, The light chain from smooth muscle myosin I is similar to calmodulin in molecular weight, amino acid composition, and migration on SDS-polyacrylamide gel electrophoresis in the presence of Ca2+. The high salt ATPase activity of myosin I in the presence of CaCl2 is higher than that in K+-EDTA. Smooth muscle actin causes a 5-10-fold activation of the Mg-ATPase activity of myosin I. In the presence of Ca2+, exogenous calmodulin enhances the actin-activated ATPase activity of myosin I, and the increased activity is associated with the binding of exogenous calmodulin to myosin I heavy chain. A maximum of 4 mol of light chains/mol of myosin I heavy chain is observed in the presence of exogenous calmodulin. Caldesmon, a calmodulin/actin-binding protein, inhibits the actin-activated ATPase activity of myosin I. This inhibition is reversed by exogenous calmodulin in the presence of Ca2+. The actin activation of myosin I ATPase exhibits around 50% Ca2+ sensitivity in the presence of exogenous calmodulin. When caldesmon is bound to actin, Ca2+ sensitivity is increased to 80% in the presence of calmodulin. Therefore, smooth muscle caldesmon, which is thought to play a role in the regulation of actin activation of myosin II, also regulates the actin activation of myosin IATPase in smooth muscle.			CHACKO, S (corresponding author), UNIV PENN,DEPT PATHOBIOL,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044689, R01DK047514, R01DK039740] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39740, DK 44689, DK 47514] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; CHACKO S, 1977, P NATL ACAD SCI USA, V74, P129, DOI 10.1073/pnas.74.1.129; CHACKO S, 1990, J BIOL CHEM, V265, P2105; COLLINS JH, 1984, J BIOL CHEM, V259, P4128; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; COLUCCIO LM, 1993, CELL MOTIL CYTOSKEL, V24, P189, DOI 10.1002/cm.970240306; COLUCCIO LM, 1990, BIOCHEMISTRY-US, V29, P11089, DOI 10.1021/bi00502a011; COLUCCIO LM, 1987, J CELL BIOL, V106, P367; CONZELMAN KA, 1987, J CELL BIOL, V105, P313, DOI 10.1083/jcb.105.1.313; COTE GP, 1985, J BIOL CHEM, V260, P4543; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HEASLIP RJ, 1985, BIOCHEMISTRY-US, V24, P2731, DOI 10.1021/bi00332a020; HORIUCHI KY, 1988, BIOCHEMISTRY-US, V27, P8388, DOI 10.1021/bi00422a014; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; Korn ED, 1990, CURR OPIN CELL BIOL, V2, P57, DOI 10.1016/S0955-0674(05)80031-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN W, 1977, BIOCHEM J, V163, P291, DOI 10.1042/bj1630291; LEHMAN W, 1989, J MUSCLE RES CELL M, V10, P101, DOI 10.1007/BF01739966; LIN Y, 1989, P JPN ACAD B-PHYS, V65, P203, DOI 10.2183/pjab.65.203; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH WP, 1987, J BIOL CHEM, V262, P7429; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARUYAMA K, 1985, ANAL BIOCHEM, V151, P1, DOI 10.1016/0003-2697(85)90043-0; MOOSEKER MS, 1989, J CELL BIOL, V109, P1153, DOI 10.1083/jcb.109.3.1153; MOOSEKER MS, 1991, CURR TOP MEMBR, V38, P31; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOLENSKI JS, 1993, J CELL BIOL, V122, P613, DOI 10.1083/jcb.122.3.613	34	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15803	15807						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195235				2022-12-27	WOS:A1994NP51300063
J	CREWS, CM; COLLINS, JL; LANE, WS; SNAPPER, ML; SCHREIBER, SL				CREWS, CM; COLLINS, JL; LANE, WS; SNAPPER, ML; SCHREIBER, SL			GTP-DEPENDENT FINDING OF THE ANTIPROLIFERATIVE AGENT DIDEMNIN TO ELONGATION-FACTOR 1-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IMMUNOSUPPRESSIVE CYCLIC PEPTIDE; PROTEIN-PHOSPHORYLATION; BINDING-PROTEIN; CLINICAL-TRIAL; MOUSE SKIN; FACTOR-I; DEPSIPEPTIDE; PROLIFERATION; DYNAMICS; INVITRO	The marine natural product, didemnin B, is a 7-amino acid, cyclic depsipeptide that inhibits G(1) cell cycle progression at nanomolar concentrations by undefined mechanisms. It has been reported to exhibit immunosuppressive activities in animals and is undergoing clinical trials as a potential antineoplastic drug. In addition, at higher concentrations, didemnin B has been shown to inhibit in vivo and in vitro protein synthesis. However, the mechanisms by which inhibition is achieved are unknown. To investigate didemnin's various modes of action, an affinity column was synthesized and used to purify didemnin-binding proteins. The major retained protein was the 49-kDa guanine nucleotide-binding elongation factor, EF-1 alpha, which was identified by peptide sequence analysis, Moreover, didemnin binds EF-1 alpha only in the presence of GTP but does not inhibit the GTPase activity of EF-1 alpha. Therefore, EF-1 alpha is likely to be the intracellular target responsible for didemnin B's ability to inhibit protein synthesis. Furthermore, this specificity of didemnin affinity for the GTP-bound conformation of a guanine nucleotide-binding protein with homology to the Ras superfamily suggests a possible mode of action for didemnin's antiproliferative activity.	HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138; HARVARD UNIV,CHEM LABS,CAMBRIDGE,MA 02138	Harvard University; Harvard University			Crews, Craig M./ABH-9346-2020	Crews, Craig M./0000-0002-8456-2005				BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BRANDS JHGM, 1986, EUR J BIOCHEM, V155, P167, DOI 10.1111/j.1432-1033.1986.tb09472.x; CARVALHO MDD, 1984, ARCH BIOCHEM BIOPHYS, V234, P603, DOI 10.1016/0003-9861(84)90310-2; CRAMPTON SL, 1984, CANCER RES, V44, P1796; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIDSON BS, 1993, CHEM REV, V93, P1771, DOI 10.1021/cr00021a006; DESHPANDE BV, 1993, FASEB J, V7, pA1083; DORR FA, 1988, EUR J CANCER CLIN ON, V24, P1699; GSCHWENDT M, 1989, IMMUNOBIOLOGY, V179, P1; GSCHWENDT M, 1987, CANCER LETT, V34, P187, DOI 10.1016/0304-3835(87)90009-7; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; HAMADA Y, 1989, J AM CHEM SOC, V111, P669, DOI 10.1021/ja00184a041; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HOSHINO S, 1989, EMBO J, V8, P3807, DOI 10.1002/j.1460-2075.1989.tb08558.x; HOSSAIN MB, 1988, P NATL ACAD SCI USA, V85, P4118, DOI 10.1073/pnas.85.12.4118; JACOBS AJ, 1992, GYNECOL ONCOL, V44, P268, DOI 10.1016/0090-8258(92)90055-N; KESSLER H, 1989, HELV CHIM ACTA, V72, P530, DOI 10.1002/hlca.19890720316; KIKUCHI Y, 1988, EMBO J, V7, P1175, DOI 10.1002/j.1460-2075.1988.tb02928.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LEGRUE SJ, 1988, LYMPHOKINE RES, V7, P21; LI LH, 1984, CANCER LETT, V23, P279, DOI 10.1016/0304-3835(84)90095-8; LI WR, 1990, J AM CHEM SOC, V112, P7659, DOI 10.1021/ja00177a030; MALDONADO E, 1982, P R HLTH SCI J, V1, P22; MONTGOMERY DW, 1985, TRANSPLANTATION, V40, P49, DOI 10.1097/00007890-198507000-00011; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; RINEHART KL, 1990, PURE APPL CHEM, V62, P1277, DOI 10.1351/pac199062071277; RINEHART KL, 1987, J AM CHEM SOC, V109, P6846, DOI 10.1021/ja00256a046; RINEHART KL, 1981, SCIENCE, V212, P933, DOI 10.1126/science.7233187; SCHMIDT U, 1988, TETRAHEDRON LETT, V29, P4407, DOI 10.1016/S0040-4039(00)80507-9; SEARLE MS, 1989, INT J PEPT PROT RES, V34, P445; SHEN GK, 1992, INT J IMMUNOPHARMACO, V14, P63, DOI 10.1016/0192-0561(92)90106-U; SHIN DM, 1991, CANCER CHEMOTH PHARM, V29, P145, DOI 10.1007/BF00687325; STEVENS DW, 1989, TRANSPLANT P, V21, P1139; STEWART JA, 1991, CANCER, V68, P2550, DOI 10.1002/1097-0142(19911215)68:12<2550::AID-CNCR2820681203>3.0.CO;2-Q; WHITEHEART SW, 1989, J BIOL CHEM, V264, P14334; YUH DD, 1989, TRANSPLANT P, V21, P1141	37	121	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15411	15414						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195179				2022-12-27	WOS:A1994NP51300004
J	MIFFLIN, LC; COHEN, RE				MIFFLIN, LC; COHEN, RE			HSC70 MODERATES THE HEAT-SHOCK (STRESS) RESPONSE IN XENOPUS-LAEVIS OOCYTES AND BINDS TO DENATURED PROTEIN INDUCERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONES; HSP70; GENE; DROSOPHILA; ATP; TRANSCRIPTION; LOCALIZATION; POLYPEPTIDES	Injections of hsc70 protein into Xenopus oocytes lowered the stress response to both a thermal shock and to co-injected protein inducers. Binding of hsc70 to native and modified forms of bovine serum albumin (BSA) were tested by two assays. In one, nitrocellulose-bound proteins were incubated with hsc70, cross-linked with glutaraldehyde, and then bound hsc70 was probed with a monoclonal anti-hsc70 antibody. In the second, peroxidase-conjugated hsc70 was employed as a more direct probe for binding to proteins displayed on nitrocellulose membranes. hsc70 binding to the BSA derivatives correlated with their abilities to induce a stress response upon microinjection into oocytes. Reduced and carboxymethylated (rcm) BSA, the most potent stress inducer tested, was bound most tightly by hsc70, whereas hsc70 had moderate affinity for N-methylated rcm-BSA and very little affinity for the native protein. No binding was observed with iodinated BSA. The results suggest a mechanism whereby the cell employs hsc70 or other proteins of the hsp70 family both to trigger the response to an environmental stress and to provide a feedback mechanism to attenuate the response.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of Iowa; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM07185, R01 GM37666] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037666] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; ANGELIDIS CE, 1991, EUR J BIOCHEM, V199, P35, DOI 10.1111/j.1432-1033.1991.tb16088.x; ARRIGO AP, 1980, DEV BIOL, V78, P86, DOI 10.1016/0012-1606(80)90320-6; AVRAMEAS S, 1978, SCAND J IMMUNOL   S7, V8, P7; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BECKMANN RP, 1992, J CELL BIOL, V117, P1137, DOI 10.1083/jcb.117.6.1137; BOORSTEIN WR, 1990, MOL CELL BIOL, V10, P3262, DOI 10.1128/MCB.10.6.3262; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; CRAIG EA, 1984, CELL, V38, P841, DOI 10.1016/0092-8674(84)90279-4; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; DUBOIS MF, 1991, J BIOL CHEM, V266, P9707; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; JAKOB U, 1993, J BIOL CHEM, V268, P1517; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MIFFLIN LC, 1994, J BIOL CHEM, V269, P15710; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PELHAM HRB, 1984, EMBO J, V3, P3095, DOI 10.1002/j.1460-2075.1984.tb02264.x; PELHAM HRB, 1990, STRESS PROTEINS BIOL, P287; Penefsky H S, 1979, Methods Enzymol, V56, P527; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SHERMAN MY, 1992, EMBO J, V11, P71; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SOLOMON JM, 1991, NEW BIOL, V3, P1106; STONE DE, 1990, MOL CELL BIOL, V10, P1622, DOI 10.1128/MCB.10.4.1622; VALAZQUEZ JM, 1980, CELL, V20, P679; VOELLMY R, 1982, P NATL ACAD SCI-BIOL, V79, P1776, DOI 10.1073/pnas.79.6.1776; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; Welch WJ, 1990, STRESS PROTEINS BIOL, P223	41	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15718	15723						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195224				2022-12-27	WOS:A1994NP51300052
J	SAIDO, TC; YOKOTA, M; MARUYAMA, K; YAMAOHARIGAYA, W; TANI, E; IHARA, Y; KAWASHIMA, S				SAIDO, TC; YOKOTA, M; MARUYAMA, K; YAMAOHARIGAYA, W; TANI, E; IHARA, Y; KAWASHIMA, S			SPATIAL-RESOLUTION OF THE PRIMARY BETA-AMYLOIDOGENIC PROCESS-INDUCED IN POSTISCHEMIC HIPPOCAMPUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E POLYMORPHISM; ALZHEIMERS-DISEASE; PROTEIN-PRECURSOR; GERBIL HIPPOCAMPUS; MU-CALPAIN; ISCHEMIA; PEPTIDE; BRAIN; CELLS; PROTEOLYSIS	Proteolytic modifications of amyloid precursor protein (APP) play key roles in the development of Alzheimer's disease. However, each specific in vivo process has not yet been fully resolved in spatial terms because the orthodox approach employing electrophoretic analysis requires homogenization of samples and thus provides limited information on the localization of the process. To acquire such spatial information for the primary process involved in beta-amyloidogenesis, we have designed and developed a novel antibody exclusively specific to APP fragments possessing the exact amino terminus of the major beta-amyloid (A beta) peptide. Use of this antibody revealed that cleavage of APP at the amino terminal position of the A beta sequence is a normal steady-state process in gerbil hippocampus. Furthermore, nonfatal transient (10 min) forebrain ischemia followed by reperfusion enhanced the initial beta-amyloidogenic reaction mainly in pyramidal cells of CA1 sector and of dentate gyrus prior to and along with delayed neuronal degeneration. The APP fragments accumulated in cell bodies and dendrites of the neurons. These results suggest that beta-amyloidogenesis may involve a process that is also activated in postischemic brain and that ischemia-like conditions may contribute to pathogenic A beta accumulation.	HYOGO MED UNIV,DEPT NEUROSURG,NISHINOMIYA,HYOGO,JAPAN; UNIV TOKYO,SCH MED,INST BRAIN RES,BUNKYO KU,TOKYO 113,JAPAN	Hyogo College of Medicine; University of Hyogo; University of Tokyo	SAIDO, TC (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,BUNKYO KU,3-18-22 HONK OMAGOME,TOKYO 113,JAPAN.		Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903				ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CUMMING AM, 1984, CLIN GENET, V25, P310; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; KANEMARU K, 1990, AM J PATHOL, V137, P677; KANG J, 1987, NATURE, V197, P192; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; LANSBURY PT, 1992, BIOCHEMISTRY-US, V31, P6865, DOI 10.1021/bi00145a001; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; MORI H, 1992, J BIOL CHEM, V267, P17082; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHIN RW, 1991, LAB INVEST, V64, P693; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMAN R, 1990, FIDDIA RES F S SER, V4, P125; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; UTERMANN G, 1987, AM HEART J, V113, P433, DOI 10.1016/0002-8703(87)90610-7; YAMADA T, 1987, BIOCHEM BIOPH RES CO, V149, P665, DOI 10.1016/0006-291X(87)90419-0; YOKOTA M, 1992, BRAIN RES, V587, P123, DOI 10.1016/0006-8993(92)91436-I; YOSHIDA S, 1986, J NEUROCHEM, V47, P744	39	81	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15253	15257						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195161				2022-12-27	WOS:A1994NP73800060
J	BIZZARRI, C; SHIOI, A; TEITELBAUM, SL; OHARA, J; HARWALKAR, VA; ERDMANN, JM; LACEY, DL; CIVITELLI, R				BIZZARRI, C; SHIOI, A; TEITELBAUM, SL; OHARA, J; HARWALKAR, VA; ERDMANN, JM; LACEY, DL; CIVITELLI, R			INTERLEUKIN-1 INHIBITS BONE-RESORPTION AND ACUTELY INCREASES CYTOSOLIC CA2+ IN MURINE OSTEOCLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY STIMULATING FACTOR; EXTRACELLULAR CALCIUM; RAT OSTEOCLASTS; CELLS; CALCITONIN; PURIFICATION; MECHANISMS; ACTIVATION; RECEPTORS; CHANNELS	Interleukin-4 (IL-4) is an immune cytokine recently shown to inhibit bone resorption. To determine whether IL-4 directly acts on osteoclasts, we have analyzed its effect on cytosolic calcium concentration [Ca2+](i) and bone resorptive function of murine osteoclastic cells generated from bone marrow/stromal cell co-cultures. IL-4 exposure induced an immediate and sustained increase in [Ca2+](i) that remained elevated for at least 10 min. This IL-4 effect was dose-dependent, with the maximal effect (209 +/- 15% of baseline, n = 16) at 200 units/ml and an apparent ED(0.5) of 60 units/ml. The IL-4-induced [Ca2+](i). rise required extracellular Ca2+ influx, since the response was prevented by LaCl3, and voltage-gated Ca2+ channel blockers, although the IL-4 effect was more sensitive to nicardipine and nifedipine than to diltiazem. Depolarization by high extracellular K+ concentration also raised [Ca2+](i), and, under these conditions, osteoclasts failed to respond to IL-4. On the other hand, when intracellular Ca2+ stores were depleted by thapsigargin, IL-4 still induced an increase in [Ca2+](i), although smaller in amplitude and transient. Calcitonin also produced [Ca2+](i) increases in osteoclasts, yet it only slightly desensitized these cells to IL-4. Furthermore, IL-4 was much less effective on osteoclasts pretreated (5-10 min) with either forskolin or 8-bromo-cAMP. Both IL-4 and calcitonin were effective even when [Ca2+](i) had been increased by exposure to high extracellular Ca2+. Finally, IL-4 dose dependently inhibited the bone resorptive activity of mature osteoclasts. Therefore, IL-4 signal transduction in osteoclasts involves a rapid and sustained elevation of [Ca2+](i) mediated by a voltage dependent Ca2+ influx, in combination with Ca2+ release from intracellular stores. Modulation of osteoclast [Ca2+](i) represents a potential mechanism by which IL-4 inhibits bone resorption.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS, MED CTR, DIV ENDOCRINOL & BONE & MINERAL DIS, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, MED CTR, DEPT PATHOL, ST LOUIS, MO 63110 USA; UNIV COLORADO, HLTH SCI CTR, DIV GASTROENTEROL, DENVER, CO 80262 USA; CONSORZIO BIOLAQ LAQUILA, I-67100 LAQUILA, ITALY	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Civitelli, Roberto/AAA-8260-2019	Civitelli, Roberto/0000-0003-4076-4315; Teitelbaum, Steven/0000-0002-4054-6679	NIAMS NIH HHS [AR42356, AR32087, AR41255] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042356, P01AR032087, R01AR041255, R29AR041255] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BOULAY JL, 1992, J BIOL CHEM, V267, P20525; BRYAN J, 1985, J CELL BIOL, V101, P1236, DOI 10.1083/jcb.101.4.1236; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; CHAMBERS TJ, 1991, VITAM HORM, V46, P41; CHAMBERS TJ, 1985, J PATHOL, V145, P297, DOI 10.1002/path.1711450403; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; CIVITELLI R, 1990, ENDOCRINOLOGY, V127, P2253, DOI 10.1210/endo-127-5-2253; CIVITELLI R, 1991, J TISSUE CULTURE MET, V13, P217; EISNER DA, 1985, AM J PHYSIOL, V248, pC189, DOI 10.1152/ajpcell.1985.248.3.C189; FUJIMORI A, 1991, ENDOCRINOLOGY, V128, P3032, DOI 10.1210/endo-128-6-3032; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; KASONO K, 1993, BONE MINER, V21, P179, DOI 10.1016/S0169-6009(08)80229-2; KOJIMA I, 1985, J BIOL CHEM, V260, P9177; LACEY DL, 1987, J IMMUNOL, V138, P1680; LACEY DL, 1993, J CELL BIOCHEM, V53, P122, DOI 10.1002/jcb.240530205; LACEY DL, 1992, J BONE MINER RES, V7, pS95; MALGAROLI A, 1989, J BIOL CHEM, V264, P14342; MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696; MARCHISIO PC, 1987, EXP CELL RES, V169, P202, DOI 10.1016/0014-4827(87)90238-2; MIYAUCHI A, 1990, J CELL BIOL, V111, P2543, DOI 10.1083/jcb.111.6.2543; MOONGA BS, 1992, J ENDOCRINOL, V132, P241, DOI 10.1677/joe.0.1320241; MUNDY GR, 1984, NEW ENGL J MED, V310, P1718; OHARA J, 1987, J IMMUNOL, V139, P1127; OHARA J, 1989, YEAR IMMUNOLOGY IMMU, P126; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; RABIN EM, 1985, P NATL ACAD SCI USA, V82, P2935, DOI 10.1073/pnas.82.9.2935; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; REID IR, 1987, AM J PHYSIOL, V253, pE45, DOI 10.1152/ajpendo.1987.253.1.E45; SHANKAR VS, 1993, J CELL PHYSIOL, V155, P120, DOI 10.1002/jcp.1041550116; SHIOI A, 1991, J CELL BIOCHEM, V47, P272, DOI 10.1002/jcb.240470313; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P1504, DOI 10.1210/endo-123-3-1504; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TETI A, 1989, J CLIN INVEST, V84, P773, DOI 10.1172/JCI114235; THOMSON BM, 1987, J IMMUNOL, V138, P775; THOMSON BM, 1986, J EXP MED, V164, P104, DOI 10.1084/jem.164.1.104; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; WATANABE K, 1990, BIOCHEM BIOPH RES CO, V172, P1035, DOI 10.1016/0006-291X(90)91550-C; WATANABE K, 1991, J BONE MINER RES, V6, pS288; ZAIDI M, 1993, CELL CALCIUM, V14, P271, DOI 10.1016/0143-4160(93)90048-B; ZAIDI M, 1992, BIOCHEM BIOPH RES CO, V188, P1332, DOI 10.1016/0006-291X(92)91377-3; ZAMBONINZALLONE A, 1988, J BONE MINER RES, V3, P517	45	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13817	13824						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188659				2022-12-27	WOS:A1994NL60600019
J	MULLER, KM; EBENSPERGER, C; TAMPE, R				MULLER, KM; EBENSPERGER, C; TAMPE, R			NUCLEOTIDE-BINDING TO THE HYDROPHILIC C-TERMINAL DOMAIN OF THE TRANSPORTER ASSOCIATED WITH ANTIGEN-PROCESSING (TAP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-II REGION; TRANSMEMBRANE CONDUCTANCE REGULATOR; PUTATIVE PEPTIDE TRANSPORTER; MULTIDRUG-RESISTANCE; CYSTIC-FIBROSIS; ATP HYDROLYSIS; MALTOSE TRANSPORT; SALMONELLA-TYPHIMURIUM; STRUCTURAL MODEL	The gene products of tap1 and tap2 encoded in the major histocompatibility complex (MHC) class II:region belong to the ATP binding cassette superfamily of transporters. They are thought to form a heterodimer for the delivery of peptides into the lumen of the endoplasmic reticulum; peptides are required for correct assembly and presentation of the MHC class I molecule peptide complex at the cell surface. To elucidate the ATP binding properties of these proteins in vitro, we expressed the hydrophilic C terminal part of human transporter associated with antigen processing (TAP1) (nucleotide binding domain (NBD)-TAP1, amino acids 452-748) and TAP2 (NBD- TAP2, amino acids 399-686) fused to a His(6) tag in Escherichia coli. The recombinant proteins accumulated exclusively in inclusion bodies and were solubilized under denaturing conditions. After purification by immobilized metal ion affinity chromatography, we were able to refold the domains for functional studies. NBD-TAP1 bound to C-8-ATP-agarose and was specifically eluted with ATP or EDTA. Photoaffinity labeling of NBD-TAP1 with the ATP analogues 8-azido-[gamma-P-32]ATP and 3'-0-[(4-azido-3,5-[I-125]diiodo-2-hydroxybenzoyl)-beta-alanyl]-ATP was specific. The addition of 50 mu M ATP inhibited photoaffinity labeling by 8-azido-ATP down to 8% of controls. Efficiency of inhibition decreased as follows: ATP > GTP > ADP > CTP > AMP. Photolabeling of NBD-TAP2 was not observed. ATP hydrolysis by NBD-TAP1 was not detected. Until now strong but only indirect data of the TAP function existed. The described experiments demonstrate ATP binding to an isolated domain of the antigenic peptide transporter, TAP, and therefore support the theory of ATP-dependent peptide translocation.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY; TECH UNIV MUNICH, LEHRSTUHL BIOPHYS E22, D-85748 GARCHING, GERMANY	Max Planck Society; Technical University of Munich			Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AMES GFL, 1992, INT REV CYTOL, V137A, P1; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; DEAN DA, 1989, P NATL ACAD SCI USA, V86, P9134, DOI 10.1073/pnas.86.23.9134; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ECKERSKORN C, 1988, ELECTROPHORESIS, V9, P830, DOI 10.1002/elps.1150091208; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KOPPELMAN B, 1992, P NATL ACAD SCI USA, V89, P3908, DOI 10.1073/pnas.89.9.3908; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; KUCHLER K, 1993, J CELL BIOL, V120, P1203, DOI 10.1083/jcb.120.5.1203; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MORBACH S, 1993, J BIOL CHEM, V268, P18617; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; POWIS SH, 1992, P NATL ACAD SCI USA, V89, P1463, DOI 10.1073/pnas.89.4.1463; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHNEIDER E, 1991, MOL MICROBIOL, V5, P1375, DOI 10.1111/j.1365-2958.1991.tb00784.x; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALTER C, 1992, J BIOL CHEM, V267, P8863; YANG Y, 1992, J BIOL CHEM, V267, P11669; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5	46	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14032	14037						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188683				2022-12-27	WOS:A1994NL60600049
J	WAKITA, T; WANDS, JR				WAKITA, T; WANDS, JR			SPECIFIC-INHIBITION OF HEPATITIS-C VIRUS EXPRESSION BY ANTISENSE OLIGODEOXYNUCLEOTIDES - IN-VITRO MODEL FOR SELECTION OF TARGET SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NON-B-HEPATITIS; 5' UNTRANSLATED REGION; NON-A; TRANSLATION ARREST; VIRAL-RNA; OLIGONUCLEOTIDES; COMPLEMENTARY; REPLICATION; GENOME	The effect of sense and antisense oligodeoxynucleotides (ODNs) on hepatitis C virus (HCV) gene expression was studied to determine the role of the highly conserved 5'-untranslated region in the life cycle of the virus. It was found that antisense ODNs complementary to nucleotides (nt) 38-65, 134-175, and 312-339 in the 5' noncoding region and 341-377 in the core open reading frame efficiently blocked HCV RNA translation. Overlapping ODNs that differed by only several nucleotides showed substantially different inhibition of HCV RNA translation. Fine sequence specificity testing at nt positions 351-377 revealed that ODNs as small as a 12-mer (nt 351-363) retained a high degree (80%) of inhibitory activity compared to ODNs of longer sequences. These results suggest that there are three highly specific domains in the 5' noncoding region and a sequence immediately downstream of the HCV core initiation codon that may be critical for translation of HCV RNA. This study also provides an experimental approach for the selection of target HCV RNA sequences susceptible to antisense effects, as well as for definition of functional regions of the genome necessary for viral replication.	MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC HEPATOL LAB,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008169, R37AA002666, R01AA002666] Funding Source: NIH RePORTER; NCI NIH HHS [CA-357111] Funding Source: Medline; NIAAA NIH HHS [AA-08169, AA-02666] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALTMANN M, 1993, TRENDS BIOCHEM SCI, V18, P429, DOI 10.1016/0968-0004(93)90143-B; BLAKE KR, 1985, BIOCHEMISTRY-US, V24, P6132, DOI 10.1021/bi00343a015; BLUM HE, 1991, LANCET, V337, P1230, DOI 10.1016/0140-6736(91)92907-J; BROWN EA, 1992, NUCLEIC ACIDS RES, V20, P5041, DOI 10.1093/nar/20.19.5041; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; DELANGEL RM, 1989, P NATL ACAD SCI USA, V86, P8299; GOODARZI G, 1990, J GEN VIROL, V71, P3021, DOI 10.1099/0022-1317-71-12-3021; GUPTA KC, 1987, J BIOL CHEM, V262, P7492; HAEUPTLE MT, 1986, NUCLEIC ACIDS RES, V14, P1427, DOI 10.1093/nar/14.3.1427; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; ICHAUSPE G, 1991, P NATL ACAD SCI USA, V88, P10292; KABANOV AV, 1990, FEBS LETT, V259, P327, DOI 10.1016/0014-5793(90)80039-L; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LEMAITRE M, 1987, P NATL ACAD SCI USA, V84, P648, DOI 10.1073/pnas.84.3.648; LETSINGER RL, 1989, P NATL ACAD SCI USA, V86, P6553, DOI 10.1073/pnas.86.17.6553; LIEBHABER SA, 1984, J BIOL CHEM, V259, P5597; LISZIEWICZ J, 1992, P NATL ACAD SCI USA, V89, P11209, DOI 10.1073/pnas.89.23.11209; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; MIROSHNICHENKO NA, 1988, FEBS LETT, V234, P65, DOI 10.1016/0014-5793(88)81304-8; OFFENSPERGER WB, 1993, EMBO J, V12, P1257, DOI 10.1002/j.1460-2075.1993.tb05767.x; OKAMOTO H, 1992, VIROLOGY, V188, P331, DOI 10.1016/0042-6822(92)90762-E; OKAMOTO H, 1991, J GEN VIROL, V72, P2697, DOI 10.1099/0022-1317-72-11-2697; PATERSON BM, 1977, P NATL ACAD SCI USA, V74, P4370, DOI 10.1073/pnas.74.10.4370; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; SHIH DS, 1987, J VIROL, V61, P2033, DOI 10.1128/JVI.61.6.2033-2037.1987; SHIMIZU YK, 1993, P NATL ACAD SCI USA, V90, P6037, DOI 10.1073/pnas.90.13.6037; SMITH CC, 1986, P NATL ACAD SCI USA, V83, P2787, DOI 10.1073/pnas.83.9.2787; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203; ZAMECNIK PC, 1986, P NATL ACAD SCI USA, V83, P4143, DOI 10.1073/pnas.83.12.4143	41	123	132	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14205	14210						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188703				2022-12-27	WOS:A1994NL60600073
J	LEBORGNE, R; SCHMIDT, A; MAUXION, F; GRIFFITHS, G; HOFLACK, B				LEBORGNE, R; SCHMIDT, A; MAUXION, F; GRIFFITHS, G; HOFLACK, B			BINDING OF AP-1 GOLGI ADAPTERS TO MEMBRANES REQUIRES PHOSPHORYLATED CYTOPLASMIC DOMAINS OF THE MANNOSE 6-PHOSPHATE/INSULIN-LIKE GROWTH FACTOR-II RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREFELDIN-A; GUANINE-NUCLEOTIDE; CLATHRIN; PROTEIN; ENDOCYTOSIS; ENZYME; EXCHANGE; SIGNALS; ARF	In mammalian cells, clathrin-coated vesicles mediate transport of the lysosomal enzyme receptors from the trans-Golgi network to the endocytic pathway. A critical step of this process is the recruitment of Golgi-specific adaptors onto Golgi membranes for efficient clathrin polymerization. An in vitro assay was used here to quantitate this event in streptolysin-O-permeabilized NRK cells. At 37-degrees-C, these interactions are cytosol- and energy-dependent, sensitive to GTP(gamma)S (guanosine 5'-O-(thiotriphosphate)) and brefeldin A. We report that Golgi-specific adaptor binding is enhanced in mannose 6-phosphate/insulin-like growth factor II (IGF II) receptor-overexpressing cells and reduced in mannose 6-phosphate receptor-deficient cells. Furthermore, adaptor binding is partially inhibited after addition of soluble cytoplasmic domains of the mannose 6-phosphate/GF II receptor. Almost complete inhibition is only observed when this domain is phosphorylated on serines 2421 and 2492, a major modification acquired during exit of the receptor from the Golgi. These results show that the mannose 6-phosphate/IGF II receptor is part of the components that recruit the Golgi-specific adaptors and that its phosphorylation is an important feature for high affinity interactions with sorting components.	EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			MAUXION, Fabienne/ABE-3546-2021; HOFLACK, Bernard/AAZ-6668-2020	MAUXION, Fabienne/0000-0003-0554-8211; LE BORGNE, Roland/0000-0001-6892-278X; Schmidt, Anne/0000-0002-8326-0937				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Anderson R G, 1993, Trends Cell Biol, V3, P177, DOI 10.1016/0962-8924(93)90205-F; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GRAVOTTA D, 1990, J CELL BIOL, V111, P2983; Griffiths G., 1993, FINE STRUCTURE IMMUN, P459; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KOBAYASHI T, 1992, FEBS LETT, V300, P227, DOI 10.1016/0014-5793(92)80851-7; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; RODRIGUEZ JF, 1985, J VIROL, V56, P482, DOI 10.1128/JVI.56.2.482-488.1985; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SOSA MA, 1993, J BIOL CHEM, V268, P12537; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; von Figura K, 1991, Curr Opin Cell Biol, V3, P642, DOI 10.1016/0955-0674(91)90035-W	32	85	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22552	22556						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226766				2022-12-27	WOS:A1993MD34800057
J	LIU, QR; LOPEZCORCUERA, B; MANDIYAN, S; NELSON, H; NELSON, N				LIU, QR; LOPEZCORCUERA, B; MANDIYAN, S; NELSON, H; NELSON, N			CLONING AND EXPRESSION OF A SPINAL CORD-SPECIFIC AND BRAIN-SPECIFIC GLYCINE TRANSPORTER WITH NOVEL STRUCTURAL FEATURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; RAT-BRAIN; NMDA-RECEPTOR; MOUSE-BRAIN; GLUTAMATE TRANSPORTER; SEROTONIN TRANSPORTER; DOPAMINE TRANSPORTER; MOLECULAR-CLONING; PROTEIN-KINASE; STRYCHNINE	A novel glycine transporter (GLYT2) was cloned from a rat brain cDNA library. GLYT2 is about 48 and 50% homologous to the previously cloned mouse glycine transporter (GLYT1) and rat proline transporter (PROT), respectively. GLYT2 differs from GLYT1 in molecular structure, tissue specificity, and pharmacological properties. The cDNA of GLYT2 encodes for 799 amino acid residues with an extended amino-terminal peptide containing 200 amino acids before the first transmembrane domain. Potential phosphorylation sites for protein kinase C, cAMP-dependent kinase, and calmodulin-dependent kinase were identified in the amino-terminal region. GLYT2 mRNA was shown to be specifically localized in spinal cord, brain stem, and to a lesser extent in the cerebellum. In contrast, GLYT1 mRNA distribution in the brain has been found previously to be more ubiquitous. Xenopus oocytes injected with GLYT2 cRNA transport glycine with a K(m) of 17 muM, and the uptake of glycine is resistant to inhibition by sarcosine. The experimental data suggests GLYT2 might play a major role in the termination of the inhibitory effect of glycine in the brain stem and spinal cord of vertebrates. On the other hand, the main function of GLYT1 may be in the modulation of excitatory nerve terminals. Two types of GLYT1 cDNA, GLYT1a and GLYT1b, were cloned from the mouse brain library. They differ only at their amino-terminal sequences, and GLYT1b contains two additional potential phosphorylation sites for proline-dependent kinase. Cloning of the gene encoding the GLYT1 revealed that the two variants resulted from a differential splicing.	ROCHE RES CTR,ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110	Roche Holding			Liu, Qing-Rong/A-3059-2012; Corcuera, Beatriz López/D-5188-2009	Liu, Qing-Rong/0000-0001-8477-6452; Corcuera, Beatriz López/0000-0002-0383-4241				AMARA SG, 1991, CURR OPIN NEUROBIOL, V1, P184; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; CROUCHER MJ, 1991, BRAIN RES, V543, P91, DOI 10.1016/0006-8993(91)91051-2; DANGELO E, 1990, NATURE, V346, P467, DOI 10.1038/346467a0; DAVIDSON N, 1976, NEUROTRANSMITTER AMI; FLETCHER EJ, 1988, EUR J PHARMACOL, V151, P161, DOI 10.1016/0014-2999(88)90711-X; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; GAUSTELLA J, 1990, SCIENCE, V249, P1303; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; Johnson JW., 1989, ALLOSTERIC MODULATIO, P259; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kanner BI, 1989, CURR OPIN CELL BIOL, V1, P735, DOI 10.1016/0955-0674(89)90042-2; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KONTRO P, 1980, BRAIN RES, V184, P129, DOI 10.1016/0006-8993(80)90592-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIU QR, 1993, J BIOL CHEM, V268, P2106; LIU QR, 1992, P NATL ACAD SCI USA, V89, P12145, DOI 10.1073/pnas.89.24.12145; LIU QR, 1992, P NATL ACAD SCI USA, V89, P6639, DOI 10.1073/pnas.89.14.6639; LIU QR, 1993, FEBS LETT, V315, P114, DOI 10.1016/0014-5793(93)81145-P; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; LOPEZCORCUERA B, 1992, J BIOL CHEM, V267, P17491; LOPEZCORCUERA B, 1991, J BIOL CHEM, V266, P24809; LOPEZCORCUERA B, 1993, J BIOL CHEM, V268, P2239; MAYSER W, 1992, FEBS LETT, V305, P31, DOI 10.1016/0014-5793(92)80649-2; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NICOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462; Oja S.S., 1977, PROG PHARMACOL, V1, P1; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; PRIESTLEY T, 1990, BRAIN RES, V531, P183, DOI 10.1016/0006-8993(90)90772-4; PROBST A, 1986, NEUROSCIENCE, V17, P11, DOI 10.1016/0306-4522(86)90222-8; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SINGH L, 1990, P NATL ACAD SCI USA, V87, P347, DOI 10.1073/pnas.87.1.347; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; THOMSON AM, 1989, NATURE, V338, P422, DOI 10.1038/338422a0; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; YOUNG AB, 1973, P NATL ACAD SCI USA, V70, P2832, DOI 10.1073/pnas.70.10.2832; ZARBIN MA, 1981, J NEUROSCI, V1, P532	47	246	264	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22802	22808						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226790				2022-12-27	WOS:A1993MD34800090
J	OHTSUKA, T; NISHIJIMA, M; AKAMATSU, Y				OHTSUKA, T; NISHIJIMA, M; AKAMATSU, Y			A SOMATIC-CELL MUTANT DEFECTIVE IN PHOSPHATIDYLGLYCEROPHOSPHATE SYNTHASE, WITH IMPAIRED PHOSPHATIDYLGLYCEROL AND CARDIOLIPIN BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; RAT-LIVER; PHOSPHOLIPID-COMPOSITION; PHOSPHATIDYLSERINE BIOSYNTHESIS; CYTOCHROME-OXIDASE; CONTACT SITES; MITOCHONDRIA; PURIFICATION; PHOSPHATIDYLINOSITOL; REQUIREMENT	Phosphatidylglycerophosphate (PGP) synthase catalyzes a reaction involved in the synthesis of phosphatidylglycerol (PG), which serves as a metabolic precursor for cardiolipin (CL), found primarily in the mitochondrial membranes of eukaryotic cells. We isolated a Chinese hamster ovary cell mutant (designated PGS-S) with a specific lesion in PGP synthase by using an in situ enzymatic assay for the enzyme. This mutant was obtained by introducing a second mutation into mutant PGS-P that had been generated by first-step mutagenesis. The PGP synthase activities in cell extracts of mutant PGS-S grown at 33 and 40-degrees-C were 14 and 1% of those in the wild type cells, respectively; in addition, PGP synthase in cell extracts of mutant PGS-S exhibited higher sensitivity to heat than that of the wild type. Mutant PGS-S also showed a temperature-dependent defect in the synthesis of PG and CL in vivo, together with temperature sensitivity for cell growth. A temperature-resistant revertant of mutant PGS-S simultaneously restored PGP synthase activity and the ability to synthesize PG and CL in vivo to nearly the same levels as those of mutant PGS-P. These results constitute genetic evidence that PGP synthase is responsible for PG synthesis and is essential for cell growth.	NATL INST HLTH, DEPT BIOCHEM & CELL BIOL, TOYAMA 1-23-1, SHINJUKU KU, TOKYO 162, JAPAN									ARDAIL D, 1990, J BIOL CHEM, V265, P18797; AWASTHI YC, 1971, BIOCHIM BIOPHYS ACTA, V226, P42, DOI 10.1016/0005-2728(71)90176-9; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1978, P NATL ACAD SCI USA, V75, P1190, DOI 10.1073/pnas.75.3.1190; ESKO JD, 1980, J BIOL CHEM, V255, P4474; FRY M, 1980, BIOCHEM BIOPH RES CO, V93, P1238, DOI 10.1016/0006-291X(80)90622-1; HELMS JB, 1991, J BIOL CHEM, V266, P21368; Hostetler K. Y., 1982, PHOSPHOLIPIDS, V4, P215; HOSTETLER KY, 1972, BIOCHIM BIOPHYS ACTA, V260, P507, DOI 10.1016/0005-2760(72)90065-3; HOSTETLER KY, 1972, BIOCHIM BIOPHYS ACTA, V260, P380, DOI 10.1016/0005-2760(72)90052-5; KIYASU JY, 1963, J BIOL CHEM, V238, P2293; KREBS JJR, 1979, J BIOL CHEM, V254, P5308; KUGE O, 1986, J BIOL CHEM, V261, P5790; KUGE O, 1991, J BIOL CHEM, V266, P24184; KUGE O, 1985, P NATL ACAD SCI USA, V82, P1926, DOI 10.1073/pnas.82.7.1926; KUGE O, 1991, J BIOL CHEM, V266, P6370; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASON RJ, 1980, BIOCHIM BIOPHYS ACTA, V617, P36, DOI 10.1016/0005-2760(80)90222-2; NISHIJIMA M, 1984, J BIOL CHEM, V259, P7101; OU WJ, 1988, J BIOCHEM-TOKYO, V103, P589, DOI 10.1093/oxfordjournals.jbchem.a122312; RAETZ CRH, 1982, P NATL ACAD SCI-BIOL, V79, P3223, DOI 10.1073/pnas.79.10.3223; RAND RP, 1972, BIOCHIM BIOPHYS ACTA, V225, P484, DOI 10.1016/0005-2736(72)90152-6; RIETVELD A, 1983, EMBO J, V2, P907, DOI 10.1002/j.1460-2075.1983.tb01520.x; ROONEY SA, 1975, J LIPID RES, V16, P418; SANDERS RL, 1975, BIOCHEMISTRY-US, V14, P835, DOI 10.1021/bi00675a030; SCHLAME M, 1991, J BIOL CHEM, V266, P22398; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; TAKENAWA T, 1977, J BIOL CHEM, V252, P5419; VOELKER DR, 1986, J BIOL CHEM, V261, P1002; YAMASHITA S, 1972, EUR J BIOCHEM, V31, P565, DOI 10.1111/j.1432-1033.1972.tb02566.x	33	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22908	22913						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226800				2022-12-27	WOS:A1993MD34800104
J	HACKNEY, DD				HACKNEY, DD			THE RATE-LIMITING STEP IN MICROTUBULE-STIMULATED ATP HYDROLYSIS BY DIMERIC KINESIN HEAD DOMAINS OCCURS WHILE BOUND TO THE MICROTUBULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; MEROMYOSIN; MOVEMENT	DKH392 is a construct which contains the first 392 amino acids of the alpha-subunit of Drosophila kinesin and is dimeric in solution (Huang, T.-G., Suhan, J., and Hackney, D. D. (1994) J. Biol. Chem. 269, 16502-16507). The ATPase rate of DKH392 was 0.005 s(-1) in the absence of MTs. One ADP bound tightly to each subunit and the release of this ADP was the rate-limiting step in ATP hydrolysis. Microtubules accelerated the rate of ADP re- lease and increased the rate of steady state ATP hydrolysis by almost 10,000-fold (k(cat) = similar to 45 s(-1)). The K-0.5,ATPase(MT) value for saturation of the stimulation of the ATPase reaction by microtubules was 50 nM at 8 nM DKH392, but decreased at lower concentrations of DKH392. Physical binding of DKH392 to microtubules in the presence of 1 mm MgATP paralleled saturation of the stimulation of the ATPase activity by microtubules indicating that the rate limiting step in microtubule-stimulated ATP hydrolysis occurs while DKH392 is bound to the microtubule. These results suggest that microtubule-stimulated ATP hydrolysis by DKH392 may be processive with the hydrolysis of multiple ATP molecules during each diffusional encounter of DKH392 with a microtubule.			HACKNEY, DD (corresponding author), CARNEGIE MELLON UNIV, DEPT BIOL SCI, PITTSBURGH, PA 15213 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028562] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28562] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRUCK C, 1986, METHOD ENZYMOL, V121, P587; ELTIS LD, 1991, BIOCHEMISTRY-US, V30, P3663, DOI 10.1021/bi00229a011; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; Griffiths JR, 1978, BIOCHEM SOC T, V6, P258, DOI 10.1042/bst0060258; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1984, P NATL ACAD SCI-BIOL, V81, P5345, DOI 10.1073/pnas.81.17.5345; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HACKNEY DD, 1989, J BIOL CHEM, V264, P15943; HACKNEY DD, 1991, METHOD ENZYMOL, V196, P175; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; HUANG TG, 1994, J BIOL CHEM, V269, P16502; INGOLD AL, 1988, J CELL BIOL, V107, P2659; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; Towbin H, 1979, 10 1073 PNAS 76 9 43, V76, P4350, DOI [10.1073/pnas.76.9.4350, DOI 10.1073/PNAS.76.9.4350]; TRINICK J, 1979, J MOL BIOL, V133, P549, DOI 10.1016/0022-2836(79)90407-8; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	21	72	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16508	16511						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206961				2022-12-27	WOS:A1994NQ72900082
J	SEEDORF, K; KOSTKA, G; LAMMERS, R; BASHKIN, P; DALY, R; BURGESS, WH; VANDERBLIEK, AM; SCHLESSINGER, J; ULLRICH, A				SEEDORF, K; KOSTKA, G; LAMMERS, R; BASHKIN, P; DALY, R; BURGESS, WH; VANDERBLIEK, AM; SCHLESSINGER, J; ULLRICH, A			DYNAMIN BINDS TO SH3 DOMAINS OF PHOSPHOLIPASE C-GAMMA AND GRB-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; EGF-RECEPTOR; SIGNAL TRANSDUCTION; PROTEIN; RAS; PHOSPHORYLATION; SITE; IDENTIFICATION; GTPASE	Src homology 3 (SH3) domains are found in a variety of proteins that are involved in signal transduction or represent components of the cytoskeleton. These domains are thought to serve as modules that mediate specific protein-protein interactions that include prolinerich sequences on the target protein. We have identified proteins of 110, 80, 65, and 43 kDa in human embryonic fibroblasts that bind specifically to the SH3 domain of phospholipase C gamma, a primary substrate of receptor tyrosine kinases, and characterized the 110-kDa band as the microtubule-activated GTPase dynamin. In addition, dynamin binds the son of sevenless adaptor protein GRB-2 with even higher affinity. This interaction does not require the dynamin GTPase function and involves a proline-rich target sequence between residues 812 and 820 of dynamin.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY; AMER RED CROSS,DEPT MOLEC BIOL,ROCKVILLE,MD 20855; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Max Planck Society; American Red Cross; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; New York University			Daly, Roger J/C-8179-2009	Daly, Roger/0000-0002-5739-8027				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHARDIN P, 1993, SCIENCE, V260, P1138; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HIRAI J, 1990, MOL CELL BIOL, V10, P1307; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE J, 1989, EMBO J, V8, P1369; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARSHALL S, 1985, J BIOL CHEM, V260, P4136; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; RODAWAY ARF, 1989, NATURE, V342, P324; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALLEE RB, 1992, J MUSCLE RES CELL M, V13, P493, DOI 10.1007/BF01737991; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	52	146	150	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16009	16014						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206897				2022-12-27	WOS:A1994NQ72900012
J	IOBST, ST; WORMALD, MR; WEIS, WI; DWEK, RA; DRICKAMER, K				IOBST, ST; WORMALD, MR; WEIS, WI; DWEK, RA; DRICKAMER, K			BINDING OF SUGAR LIGANDS TO CA2+-DEPENDENT ANIMAL LECTINS .1. ANALYSIS OF MANNOSE-BINDING BY SITE-DIRECTED MUTAGENESIS AND NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; CARBOHYDRATE-RECOGNITION DOMAIN; PROTEIN; RAT; RESIDUES	The Ca2+-dependent carbohydrate-recognition domain (CRD) of rat serum mannose-binding protein has been subjected to site-directed mutagenesis to determine the importance of individual residues in ligation of mannose and related sugars. The effects of the mutations were assessed by direct binding assays, competition binding studies, partial proteolysis, and NMR analysis of sugar-CRD titrations. As suggested by the crystal structure of the mannose-binding CRD complexed with oligosaccharide ligand, asparagine and glutamic acid residues that interact with hydroxyl groups 3 and 4 of the sugar, as well as with one of the two bound Ca2+, are critical for ligand binding. In addition, the beta-carbon of His(189) contributes substantially to the binding affinity, apparently through a van der Waals contact with C-4 of the sugar ligand. van der Waals contacts between the imidazole ring of His(189) and the 2 hydroxyl group of mannose, and between Ile(207) and C-6 of mannose, observed in the crystal structure, contribute less to stability of the ligand complex. The effects of changes at positions 189 and 207 on the ability of the CRD to distinguish between alpha- and beta-methyl L-fucosides suggest that fucose may bind in an alternative orientation compared to the arrangement originally proposed based on the mannose-CRD complex.	COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; STANFORD UNIV,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305; UNIV OXFORD,DEPT BIOCHEM,INST GLYCOBIOL,OXFORD OX1 3QU,ENGLAND	Columbia University; Stanford University; University of Oxford			Weis, William I/G-1437-2011; Wormald, Mark R/G-2785-2011	Weis, William I/0000-0002-5583-6150; Wormald, Mark R/0000-0002-4853-2773	FOGARTY INTERNATIONAL CENTER [F06TW001925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042628] Funding Source: NIH RePORTER; FIC NIH HHS [TW01925] Funding Source: Medline; NIGMS NIH HHS [GM42628] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; DRICKAMER K, 1989, BIOCHEM SOC T, V17, P13, DOI 10.1042/bst0170013; DRICKAMER K, 1986, J BIOL CHEM, V261, P1034; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; IOBST ST, 1994, J BIOL CHEM, V269, P15512; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRONIS KA, 1982, BIOCHEMISTRY-US, V21, P3050, DOI 10.1021/bi00256a003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RT, 1991, J BIOL CHEM, V266, P4810; Maniatis T., 1982, MOL CLONING; MARKLEY JL, 1975, ACCOUNTS CHEM RES, V8, P70, DOI 10.1021/ar50086a004; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; SAUTER NK, 1989, BIOCHEMISTRY-US, V28, P8388, DOI 10.1021/bi00447a018; TAYLOR ME, 1989, BIOCHEM J, V262, P763, DOI 10.1042/bj2620763; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	20	103	111	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15505	15511						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195194				2022-12-27	WOS:A1994NP51300020
J	MINTHWORBY, CA				MINTHWORBY, CA			TRANSCRIPTIONAL REGULATION OF THE HUMAN NEUROPEPTIDE-Y GENE BY NERVE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR AP-2; CHLORAMPHENICOL ACETYLTRANSFERASE; PC12 CELLS; DEVELOPMENTAL REGULATION; EXPRESSION; BINDING; SEQUENCES; PROMOTER; DIFFERENTIATION; EMBRYOGENESIS	Neuropeptide Y (NPY) is the most ubiquitously expressed peptide in the mammalian nervous system. Transcription of the NPY gene in PC12 cells is regulated by a number of agents, including the neurotrophic peptide nerve growth factor (NGF). In this paper, we define the cis-acting promoter elements which respond to NGF and characterize the trans-acting factors which interact with these sequences. The NGF-responsive elements of the NPY gene lie between nucleotides -87 and -36. At least four proteins interact with this promoter region. One of these proteins interacts with a CT-rich sequence centered at position -51, which closely abuts a binding site for transcription factor AP-2 centered at position -63. Two newly characterized factors bind between positions -87 and -58. These proteins are expressed in a tissue-specific manner and, together with the other binding activities, modulate the transcriptional activity of the NPY gene. These results suggest that the concerted interplay of these proteins, in response to NGF, increases the transcriptional activity of the NPY gene.			MINTHWORBY, CA (corresponding author), UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS028496] Funding Source: NIH RePORTER; NINDS NIH HHS [NINDS NS28496] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN JM, 1987, MOL BRAIN RES, V3, P39, DOI 10.1016/0169-328X(87)90042-8; ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; CRABB DW, 1989, METHOD ENZYMOL, V168, P690; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P33; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAY TS, 1986, LIFE SCI, V38, P389, DOI 10.1016/0024-3205(86)90061-5; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KINGSLEY C, 1991, MOL CELL BIOL, V12, P4251; LEE SL, 1988, J BIOL CHEM, V263, P16604; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MINTH CD, 1990, J BIOL CHEM, V265, P12933; MINTH CD, 1986, J BIOL CHEM, V261, P1974; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; SABOL SL, 1990, MOL ENDOCRINOL, V4, P384, DOI 10.1210/mend-4-3-384; SILVA CM, 1987, P NATL ACAD SCI USA, V84, P1744, DOI 10.1073/pnas.84.7.1744; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709	32	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15460	15468						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195188				2022-12-27	WOS:A1994NP51300013
J	SASAKI, K; KURATA, K; KOJIMA, N; KUROSAWA, N; OHTA, S; HANAI, N; TSUJI, S; NISHI, T				SASAKI, K; KURATA, K; KOJIMA, N; KUROSAWA, N; OHTA, S; HANAI, N; TSUJI, S; NISHI, T			EXPRESSION CLONING OF A G(M3)-SPECIFIC ALPHA-2,8-SIALYLTRANSFERASE (G(D3) SYNTHASE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; GANGLIOSIDE-MEDIATED MODULATION; SIALYLTRANSFERASE GENE FAMILY; GROWTH-FACTOR RECEPTOR; MOLECULAR-CLONING; CELL-GROWTH; GAL-BETA-1,3(4)GLCNAC ALPHA-2,3-SIALYLTRANSFERASE; LIPID-COMPOSITION; MELANOMA-CELLS; GD3	A cDNA encoding a G(M3)-specific alpha-2,8-sialyltransferase (G(D3) synthase) was obtained from an expression cDNA library of human melanoma cell line WM266-4 by enrichment of Namalwa KJM-1 cells highly expressing G(D3) using an anti-G(D3) antibody and a fluorescence-activated cell sorter. Selection of B-cell line Namalwa cells expressing transfected cDNAs in the presence of anti-G(D3) monoclonal antibody KM641 gave a cDNA (pAMo-GD3) encoding a protein with a type II transmembrane topology as found for mammalian glycosyltransferases. The following evidence confirms that the cDNA encodes an alpha-2,8-sialyltransferase, which specifically converts G(D3) to G(D3). (i) Transfection of pAMo-GD3 into Namalwa KJM-1 cells leads to the appearance of G(D3) and a G(D3) synthase activity. (ii) Northern blot analysis revealed a correlation between the expression of this gene and G(D3) in several cell lines. (iii) The putative COOH-terminal active domain of this cloned enzyme fused with protein A has been purified with IgG-Sepharose beads and has been shown to possess G(D3)-synthesizing activity, excluding the possibility that the cloned cDNA encodes a transacting factor inducing a G(D3) synthase. The deduced primary sequence also contains the ''sialyl motif'' conserved among all the sialyltransferases cloned to date. The polymerase chain reaction analysis reveals that this gene is located on chromosome 12.	KYOWA HAKKO KOGYO CO LTD, TOKYO RES LABS, MACHIDA, TOKYO 194, JAPAN; INST PHYS & CHEM RES, FRONTIER RES PROGRAM, WAKO, SAITAMA 35101, JAPAN	Kyowa Kirin Ltd; RIKEN				Kurosawa, Nobuyuki/0000-0002-1548-4541				ANDO S, 1983, NEUROCHEM INT, V5, P507, DOI 10.1016/0197-0186(83)90043-8; BASU M, 1991, CARBOHYD RES, V209, P261, DOI 10.1016/0008-6215(91)80162-G; BREMER EG, 1984, J BIOL CHEM, V259, P6818; CHERESH DA, 1984, P NATL ACAD SCI-BIOL, V81, P5767, DOI 10.1073/pnas.81.18.5767; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; CONSOLAZIONE A, 1988, NEW TRENDS GANGLIOSI, V14, P523; DAWSON G, 1990, CANCER CELL-MON REV, V2, P327; DIXON SJ, 1987, J CELL BIOL, V105, P1153, DOI 10.1083/jcb.105.3.1153; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GOLDMAN JE, 1984, J NEUROIMMUNOL, V7, P179, DOI 10.1016/S0165-5728(84)80017-X; GRAVOTTA D, 1990, J NEUROSCI RES, V25, P214, DOI 10.1002/jnr.490250209; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; GU XB, 1990, BIOCHEM BIOPH RES CO, V166, P387, DOI 10.1016/0006-291X(90)91957-T; HAKOMORI S, 1985, CANCER RES, V45, P2405; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; Hamamoto T, 1993, Bioorg Med Chem, V1, P141, DOI 10.1016/S0968-0896(00)82111-2; HANAI N, 1990, ANTICANCER RES, V10, P1579; HANAI N, 1988, J BIOL CHEM, V263, P10915; HANAI N, 1988, J BIOL CHEM, V263, P6296; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOSOI S, 1991, CYTOTECHNOLOGY, V5, pS17, DOI 10.1007/BF00573878; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KOJIMA N, 1992, J BIOL CHEM, V267, P17264; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; KUROSAWA N, 1994, EUR J BIOCHEM, V219, P375, DOI 10.1111/j.1432-1033.1994.tb19949.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LADISCH S, 1987, J CLIN INVEST, V79, P1879, DOI 10.1172/JCI113031; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LEE YC, 1993, EUR J BIOCHEM, V216, P377, DOI 10.1111/j.1432-1033.1993.tb18155.x; LEE YC, 1994, J BIOL CHEM, V269, P10028; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MARCUS DM, 1984, MOL IMMUNOL, V21, P1083, DOI 10.1016/0161-5890(84)90118-4; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MARKWELL MAK, 1981, P NATL ACAD SCI-BIOL, V78, P5406, DOI 10.1073/pnas.78.9.5406; MIYAJI H, 1990, CYTOTECHNOLOGY, V3, P133, DOI 10.1007/BF00143675; NAGAI Y, 1988, FIDIA RES SERIES, V14, P329; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NOVIKOV AM, 1991, BIOCHEM GENET, V29, P627, DOI 10.1007/BF02426876; OHTA S, 1993, CANCER IMMUNOL IMMUN, V36, P260, DOI 10.1007/BF01740908; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; PORTOUKALIAN J, 1979, EUR J BIOCHEM, V94, P19, DOI 10.1111/j.1432-1033.1979.tb12866.x; PUSHKAREVA MY, 1992, J BIOL CHEM, V267, P15246; ROESNER H, 1985, Developmental Brain Research, V18, P85; ROSENBERG A, 1979, COMPLEX CARBOHYDRATE, P25; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1993, J BIOL CHEM, V268, P22782; Sato S, 1983, J TISSUE CULT METHOD, V8, P167; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEYFRIED TN, 1985, MOL CELL BIOCHEM, V68, P3; Sneath P.H.A., 1973, NUMERICAL TAXONOMY; SPIEGEL S, 1985, SCIENCE, V230, P1285, DOI 10.1126/science.2999979; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG XC, 1993, J BIOL CHEM, V268, P4355; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P21011; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YATES AJ, 1979, J LIPID RES, V20, P428	67	137	144	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15950	15956						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195250				2022-12-27	WOS:A1994NP51300085
J	COLOMBO, MI; MAYORGA, LS; NISHIMOTO, I; ROSS, EM; STAHL, PD				COLOMBO, MI; MAYORGA, LS; NISHIMOTO, I; ROSS, EM; STAHL, PD			G(S) REGULATION OF ENDOSOME FUSION SUGGESTS A ROLE FOR SIGNAL-TRANSDUCTION PATHWAYS IN ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; TRIMERIC-G-PROTEINS; MEDIATED ENDOCYTOSIS; ADRENERGIC-RECEPTORS; INVITRO; PHOSPHORYLATION; IDENTIFICATION; STIMULATION; TRANSPORT; KINASE	Work from several laboratories indicates that guanine nucleotide-binding proteins (GTP-binding proteins) are required for intracellular vesicular transport. In a previous report we presented evidence indicating that one or more heterotrimeric G proteins regulate fusion between endosomes (Colombo, M. I., Mayorga, L. S., Casey, P.J., and Stahl, P D. (1992) Science 255, 1695-1697). We now report on experiments showing that G(s) plays a role in endosome fusion. We have used several reagents known to modulate G(s) function including (i) peptides corresponding to the cytoplasmic domains of G protein-coupled receptors and peptides that mimic interaction of receptors with G proteins, (ii) anti-G protein antibodies, and (iii) cholera toxin. Synthetic peptides corresponding to the third cytoplasmic loop of the beta 2-adrenergic receptor which putatively interact with G(alpha s) inhibited endosomal fusion. The inhibitory effect of these peptides was prevented by a short preincubation of endosomes with guanosine-5'-3-O-(thio)triphosphate or by phosphorylating the peptide with cAMP-dependent protein kinase. The involvement of G(s) in endosome recognition and/or the fusion process was assessed by testing an antibody against the COOH terminus of G(alpha s). Anti-G(alpha s) IgG completely abolished fusion between endosomes. Lastly, preincubation of endosomal vesicles with cholera toxin abrogated fusion in the presence of NAD, whereas no effect was observed in the absence of the cofactor. Taken together these findings indicate a role for G(s) in either the mechanism or the regulation of fusion among endosomes. These results raise the possibility that signal transduction through cytoplasmic domains of receptors may participate in the regulation of endocytic trafficking.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63108; UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,TOKYO 112,JAPAN; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	Washington University (WUSTL); University of Tokyo; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Stahl, Philip/D-6315-2012	Mayorga, Luis S/0000-0002-5995-0671	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020015, R01AI020015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20015] Funding Source: Medline; NIGMS NIH HHS [GM42259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH W E, 1992, Current Biology, V2, P157, DOI 10.1016/0960-9822(92)90276-G; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1992, TRENDS BIOCHEM SCI, V17, P87; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; COLOMBO MI, 1992, METHOD ENZYMOL, V219, P32; COLOMBO MI, 1994, IN PRESS MOL MEMBR C; DIAZ R, 1988, J BIOL CHEM, V263, P6093; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; HARAGUCHI K, 1991, P NATL ACAD SCI USA, V88, P5964, DOI 10.1073/pnas.88.14.5964; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LENHARD JM, 1994, IN PRESS ARCH BIOH B; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MURAYAMA T, 1993, BIOCHEMISTRY-US, V32, P561, DOI 10.1021/bi00053a022; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; WESSLINGRESNICK M, 1990, J BIOL CHEM, V265, P16751; WONG SKF, 1990, J BIOL CHEM, V265, P6219	32	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14919	14923						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195123				2022-12-27	WOS:A1994NP73800014
J	GALLO, KA; MARK, MR; SCADDEN, DT; WANG, ZY; GU, QM; GODOWSKI, PJ				GALLO, KA; MARK, MR; SCADDEN, DT; WANG, ZY; GU, QM; GODOWSKI, PJ			IDENTIFICATION AND CHARACTERIZATION OF SPRK, A NOVEL SRC-HOMOLOGY-3 DOMAIN-CONTAINING PROLINE-RICH KINASE WITH SERINE/THREONINE KINASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; DEPENDENT PROTEIN-KINASE; LEUCINE ISOLEUCINE-ZIPPER; GROWTH-FACTOR RECEPTOR; LIGAND-BINDING SITE; SH3 DOMAINS; INSULIN-RECEPTOR; SECONDARY-STRUCTURE; SIGNALING PROTEINS	Protein kinases play important roles in the growth and differentiation of cells. We have isolated cDNA clones from the human megakaryocytic cell line CMK11-5 that encode a novel protein kinase, which we call SPRK (src-homology 3 (SH3) domain containing proline-rich kinase). The gene sequence predicts an 847-amino acid protein kinase with a unique domain arrangement. An amino-terminal glycine-rich region is followed by an SH3 domain and a kinase domain that is similar to both tyrosine and serine/threonine kinases. Adjacent to the kinase domain are two closely spaced leucine/isoleucine zipper motifs and a stretch of basic amino acids that resembles karyophilic nuclear localization signals. The COOH-terminal half of SPRK is basic, and proline accounts for 24% of the COOH-terminal 216 amino acids. The sprk gene is widely expressed as a 4-kilobase transcript in adult and fetal human tissues. Transfection of 293 cells with a vector encoding an epitope-tagged SPRK results in the expression of a 95-kDa protein. The epitope-tagged SPRK becomes phosphorylated on serine and threonine residues in an in vitro kinase assay, whereas SPRK variants with point mutations in the predicted ATP-binding site fail to become phosphorylated. These data indicate that SPRK has serine/threonine kinase activity. The SH3 domain of SPRK is interrupted by a unique 5-amino acid insert whose location in the SH3 consensus sequence is the same as that of the inserts found in the SH3 domains of neuronal SRC and of the p85 subunit of phosphatidylinositol 3-kinase.	GENENTECH INC, DEPT CELL GENET, San Francisco, CA 94080 USA; GENENTECH INC, DEPT MOLEC BIOL, San Francisco, CA 94080 USA; HARVARD UNIV, NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA	Roche Holding; Genentech; Roche Holding; Genentech; Harvard University; Harvard Medical School								ADACHI M, 1991, EXP HEMATOL, V19, P923; ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COZZONE AJ, 1993, J CELL BIOCHEM, V51, P7, DOI 10.1002/jcb.240510103; DEERY WJ, 1993, J CELL BIOL, V122, P21, DOI 10.1083/jcb.122.1.21; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; FENG DF, 1990, METHOD ENZYMOL, V183, P375; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GORMAN C, 1990, DNA CLONING PRACTICA, P143; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LANDGRAF W, 1990, BIOCHEMISTRY-US, V29, P9921, DOI 10.1021/bi00494a024; LEE J, 1994, GENE, V138, P247, DOI 10.1016/0378-1119(94)90817-6; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MARK MR, 1992, J BIOL CHEM, V267, P26166; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MOTOJIMA K, 1993, FEBS LETT, V319, P75, DOI 10.1016/0014-5793(93)80040-2; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PUGSLEY AP, 1989, PROTEIN TARGETING, P202; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WIELAND T, 1993, J BIOL CHEM, V268, P18111; YONEMOTO W, 1993, J BIOL CHEM, V268, P18626; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	59	112	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15092	15100						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195146				2022-12-27	WOS:A1994NP73800039
J	PRIGLINGER, U; GEIGER, M; BIELEK, E; VANYEK, E; BINDER, BR				PRIGLINGER, U; GEIGER, M; BIELEK, E; VANYEK, E; BINDER, BR			BINDING OF URINARY PROTEIN-C INHIBITOR TO CULTURED HUMAN EPITHELIAL KIDNEY TUMOR-CELLS (TCL-598) - THE ROLE OF GLYCOSAMINOGLYCANS PRESENT ON THE LUMINAL CELL-SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; SEMINAL PLASMA; UROKINASE; KALLIKREIN; ANTIGEN; HEPARIN	Binding of urinary protein C inhibitor (PCI) to cultured human epithelial kidney tumor cells (TCL-598) was studied. Binding was dose-dependent, time-dependent, and saturable. Heparin interfered in a dose-dependent way with PCI binding to TCL-598 as did heparan sulfate and to a lesser degree also dermatan sulfate. Pre- treatment of TCL-598 with protamine sulfate inhibited subsequent binding of PCI in a dose-dependent manner and >100 mu g/ml protamine sulfate reduced binding of PCI to <10% of the control. Binding of I-125-pCI was specific, and bound (125)-pCI was recovered from the cells by heparin treatment or detached together with intact cells by EDTA treatment, migrated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with the same mobility (M(r) = 57,000) as unbound I-125-pCI. Furthermore, cell-bound PCI was functionally active as judged from its ability to inhibit the amidolytic activity of urokinase, and its inhibitory activity was stimulated approximate to 3-4-fold as compared to fluid-phase PCI. Immunogold electron microscopy revealed that PCI-antigen presented to the cells from the luminal side bound exclusively to that surface in native as well as in prefixed cells. This binding of PCI was abolished in the presence of heparin (50 mu g/ml) and after pretreatment of the cells either with protamine sulfate (400 mu g/ml) or with heparinase III (0.5 unit/ml). A slight decrease in PCI binding was seen after pretreatment of the cells with chondroitinase ABC and chondroitinase AC. In contrast, binding of PCI to extracellular matrices of TCL-598 was decreased to approximate to 70% after chondroitinase ABC treatment of the extracellular matrices, whereas both heparinase III or chondroitinase AC treatment only reduced matrix-bound PCI to approximate to 95%. These data suggest that heparan sulfate-containing proteoglycans are predominantly involved in binding of PCI to the luminal side of TCL-598, while dermatan sulfate-containing proteoglycans, the overall predominant PCI-binding proteoglycans in TCL extracts, are responsible for PCI binding to the extracellular matrix. Heparan sulfate, however, exposed to an environment containing PCI under physiological conditions, might localize PCI and modulate its target enzyme specificity in vivo.	UNIV VIENNA,DEPT MED PHYSIOL,CLIN & EXPTL PHYSIOL LAB,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT HISTOL & EMBRYOL,A-1090 VIENNA,AUSTRIA	University of Vienna; University of Vienna				Geiger, Margarethe/0000-0003-2021-5319				ECKE S, 1992, J BIOL CHEM, V267, P7048; ECKE S, 1992, ANN NY ACAD SCI, V667, P84, DOI 10.1111/j.1749-6632.1992.tb51601.x; ECKE S, 1992, ANN HEMATOL S, V64, pA46; ESPANA F, 1991, THROMB RES, V64, P309, DOI 10.1016/0049-3848(91)90002-E; GEIGER M, 1988, Fibrinolysis, V2, P183, DOI 10.1016/0268-9499(88)90011-2; GEIGER M, 1989, BLOOD, V74, P722; GEIGER M, 1991, J BIOL CHEM, V266, P11851; Ishikawa E, 1980, J Immunoassay, V1, P385, DOI 10.1080/01971528008058479; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; KOHNO T, 1984, BIO-TECHNOL, V2, P628, DOI 10.1038/nbt0784-628; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURELL M, 1992, J CLIN INVEST, V89, P1094, DOI 10.1172/JCI115689; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; LITTLE JR, 1967, METHODS IMMUNOLOGY I, V2, P343; MARLAR RA, 1980, J CLIN INVEST, V66, P1186, DOI 10.1172/JCI109952; MEIJERS JCM, 1988, BIOCHEMISTRY-US, V27, P4231, DOI 10.1021/bi00412a005; MIMURO J, 1987, BLOOD, V70, P721; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1081; Patterson M K Jr, 1979, Methods Enzymol, V58, P141; PRATT CW, 1992, J BIOL CHEM, V267, P8789; PRIGLINGER U, 1992, FIBRINOLYSIS S2, V6, P6; RESCH I, 1991, NT C KININ 91 MUNICH, P199; STERN D, 1985, J CLIN INVEST, V75, P272, DOI 10.1172/JCI111685; SUZUKI K, 1989, THROMB HAEMOSTASIS, V61, P337; SUZUKI K, 1987, J BIOL CHEM, V262, P611; SUZUKI K, 1984, J BIOCHEM, V95, P187, DOI 10.1093/oxfordjournals.jbchem.a134583; SUZUKI K, 1983, J BIOL CHEM, V258, P163; WHINNA HC, 1993, J BIOL CHEM, V268, P3920	28	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14705	14710						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182078				2022-12-27	WOS:A1994NM06500063
J	SASAKI, K; KURATA, K; FUNAYAMA, K; NAGATA, M; WATANABE, E; OHTA, S; HANAI, N; NISHI, T				SASAKI, K; KURATA, K; FUNAYAMA, K; NAGATA, M; WATANABE, E; OHTA, S; HANAI, N; NISHI, T			EXPRESSION CLONING OF A NOVEL ALPHA-1,3-FUCOSYL-TRANSFERASE THAT IS INVOLVED IN BIOSYNTHESIS OF THE SIALYL-LEWIS-X CARBOHYDRATE DETERMINANTS IN LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; ELAM-1-DEPENDENT CELL-ADHESION; E-SELECTIN LIGAND; SERUM-FREE MEDIUM; MONOCLONAL-ANTIBODIES; FUCOSYL-TRANSFERASE; P-SELECTIN; GLYCOPROTEIN LIGAND; MOLECULAR-CLONING; BINDING-ACTIVITY	The sialyl Lewis x (NeuAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)Glc-NAc) determinants serve as ligands in the selectin-mediated adhesion of leukocytes to activated endothelium or platelets. In our efforts to identify glycosyltransferases involved in the biosynthesis of those ligands, we achieved expression cloning of a novel human alpha 1,3-fucosyltransferase termed Fuc-TVII from a THP-1 cDNA library by enrichment of the Namalwa cells highly expressing that determinant with a fluorescence-activated cell sorter. Expression of the COOH-terminal catalytic domain of Fuc-TVII showed an alpha 1,3-fucosyltransferase activity for a type II oligosaccharide with a terminal alpha 2,3-linked sialic acid among various accepters, consistent with that in vivo acceptor specificity. Alignment of the primary sequences of five alpha 1,3-fucosyltransferase and assignment of the chromosomal location of Fuc-TVII gene, together with that acceptor specificity, indicate that Fuc-TVII consists of a unique class of the alpha 1,3-fucosyltransferase family. Determination of the expression levels of these alpha 1,3-fucosyltransferases in various cells revealed that both Fuc-TVII and a myeloid fucosyltransferase Fuc-TIV were significantly expressed in myeloid Lineage cells. Fuc-TVII-transfected Namalwa cells exhibited significant binding to E-selectin in contrast to little binding of the Fuc-TIV-transfected cells. These results suggest that Fuc-TVII may participate in the biosynthesis of the selectin ligands.	KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,MACHIDA,TOKYO 194,JAPAN	Kyowa Kirin Ltd								BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BERG EL, 1991, J BIOL CHEM, V266, P14869; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; EASTON EW, 1993, BLOOD, V81, P2978; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Fukuda M., 1992, CELL SURFACE CARBOHY; FUKUSHI Y, 1984, J BIOL CHEM, V259, P511; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; FURUYA A, 1992, ANTICANCER RES, V12, P27; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GONWA TA, 1983, J IMMUNOL, V130, P706; HAKOMORI S, 1991, CURR OPIN IMMUNOL, V3, P646, DOI 10.1016/0952-7915(91)90091-E; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HANAI N, 1990, ANTICANCER RES, V10, P1579; HANDA K, 1991, BIOCHEM BIOPH RES CO, V181, P1223, DOI 10.1016/0006-291X(91)92069-V; HOLMES EH, 1993, ARCH BIOCHEM BIOPHYS, V301, P190, DOI 10.1006/abbi.1993.1132; HOSOI S, 1991, CYTOTECHNOLOGY, V5, pS17, DOI 10.1007/BF00573878; JOHNSON PH, 1987, BIOCHEM SOC T, V15, P396, DOI 10.1042/bst0150396; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LARKIN M, 1992, J BIOL CHEM, V267, P13661; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LOBB RR, 1991, J IMMUNOL, V147, P124; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MATSUSHITA Y, 1991, EXP CELL RES, V196, P20, DOI 10.1016/0014-4827(91)90451-Y; MEIER W, 1993, BIOCHEM J, V294, P25, DOI 10.1042/bj2940025; MIYAJI H, 1990, CYTOTECHNOLOGY, V4, P173, DOI 10.1007/BF00365098; MIYAJI H, 1990, CYTOTECHNOLOGY, V3, P133, DOI 10.1007/BF00143675; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MUROI K, 1992, BLOOD, V79, P713; NAKAMURA K, 1994, CANCER RES, V54, P1511; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1993, J BIOL CHEM, V268, P22782; Sato S, 1983, J TISSUE CULT METHOD, V8, P167; SHITARA K, 1987, CANCER RES, V47, P1267; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575	55	325	348	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14730	14737						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182079				2022-12-27	WOS:A1994NM06500067
J	JAMES, GL; GOLDSTEIN, JL; PATHAK, RK; ANDERSON, RGW; BROWN, MS				JAMES, GL; GOLDSTEIN, JL; PATHAK, RK; ANDERSON, RGW; BROWN, MS			PXF, A PRENYLATED PROTEIN OF PEROXISOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATION; HUMAN-FIBROBLASTS; RAT-BRAIN; FARNESYLTRANSFERASE; EXPRESSION; CLONING; P21RAS; ALPHA; ACID; ISOPRENYLATION	CAAX farnesyltransferase attaches a farnesyl group to proteins that terminate in the sequence CAAX, where C is cysteine, A is an aliphatic amino acid, and X is typically methionine or serine. A limited number of substrates for the CAAX farnesyltransferase have been identified in cultured cells. These include p21(ras) proteins and the nuclear lamins A and B. We describe here the use of a CAAX farnesyltransferase inhibitor, together with a hamster cell line that exhibits efficient uptake of [H-3]mevalonate, as a means of identifying novel farnesylated proteins. One candidate protein was purified and its attached prenyl group identified as farnesyl. The predicted amino acid sequence of this protein, deduced from a cloned cDNA, terminates with the tetrapeptide Cys-Leu-Ile-Met, which conforms to the consensus sequence for recognition by farnesyltransferase. This farnesylated protein, designated PxF, is localized to the outer surface of peroxisomes as determined by indirect immunofluorescence and electron microscopy.	UNIV TEXAS,SOUTHWESTERN MED CTR,DEPT CELL BIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	JAMES, GL (corresponding author), UNIV TEXAS,SOUTHWESTERN MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.				NHLBI NIH HHS [HL 20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BEISIEGEL U, 1981, J BIOL CHEM, V256, P4071; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; BROWN MS, 1978, J BIOL CHEM, V253, P1121; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; FARNSWORTH C C, 1990, Methods (Orlando), V1, P231, DOI 10.1016/S1046-2023(05)80322-6; FAUST J, 1987, J BIOL CHEM, V262, P1996; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; Glomset J. A., 1991, CURR OPIN LIPIDOL, V2, P118; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEILMEYER LMG, 1992, P NATL ACAD SCI USA, V89, P9554, DOI 10.1073/pnas.89.20.9554; INGLESE J, 1992, J BIOL CHEM, V267, P1422; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KIM CM, 1992, J BIOL CHEM, V267, P23113; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NOVIKOFF AB, 1969, J HISTOCHEM CYTOCHEM, V17, P675, DOI 10.1177/17.10.675; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PATHAK RK, 1989, J HISTOCHEM CYTOCHEM, V37, P69, DOI 10.1177/37.1.2491753; REESE JH, 1991, MOL CELL BIOCHEM, V104, P109; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; RILLING HC, 1993, ARCH BIOCHEM BIOPHYS, V301, P210, DOI 10.1006/abbi.1993.1135; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; THIERINGER R, 1993, J BIOL CHEM, V268, P12631; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872	44	94	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14182	14190						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188701				2022-12-27	WOS:A1994NL60600070
J	LEID, M				LEID, M			LIGAND-INDUCED ALTERATION OF THE PROTEASE SENSITIVITY OF RETINOID-X RECEPTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; CONFORMATIONAL-CHANGES; SIGNALING PATHWAYS; NUCLEAR RECEPTORS; RXR-ALPHA; ACID; BINDING; DIVERSITY; DOMAIN; GENES	Ligand-induced structural alterations of retinoid X receptor (RXR) appear to facilitate receptor homodimerization, to enhance DNA binding of RXR homodimeric complexes, and to dictate the transcriptional activation properties of RXR complexes bound to response elements located in the promoter region of 9-cis-retinoic acid responsive genes. The technique of limited proteolysis was used to address 9-cis-retinoic acid-induced RXR conformational change and to identify receptor region(s) which undergo structural alteration upon ligand binding. Proteolytic digestion of 9-cis-retinoic acid-liganded, but not unliganded, RXR gave rise to a fragment of 31 kilodaltons (PF31), which contained a large portion of the RXR ligand binding domain. The potency with which 9-cis-retinoic acid induced formation of PE31 was nearly identical to that with which the ligand enhanced DNA binding of a RXR homodimeric complex to a response element composed of the directly repeated hexanucleotide, PuGGTCA, separated by 1 base pair. The amino-terminal limit of PF31 mapped to Ser(229) of mouse RXR alpha, which lies roughly in the middle of the spacer region separating the DNA and ligand binding domains of the receptor. These results suggest that a fairly large region of the receptor protein undergoes a structural alteration upon ligand binding which may directly alter the multiple functions of the RXR ligand binding domain.	OREGON STATE UNIV, PROGRAM MOLEC & CELLULAR BIOL, CORVALLIS, OR 97331 USA	Oregon State University	LEID, M (corresponding author), OREGON STATE UNIV, COLL PHARM, CTR GENE RES & BIOTECHNOL, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA.							ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ALLAN GF, 1992, P NATL ACAD SCI USA, V89, P11750, DOI 10.1073/pnas.89.24.11750; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BHAT MK, 1993, BIOCHEM BIOPH RES CO, V195, P385, DOI 10.1006/bbrc.1993.2055; BOGENHAGEN DF, 1993, MOL CELL BIOL, V13, P5149, DOI 10.1128/MCB.13.9.5149; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; DE LUCA LM, 1991, FASEB J, V5, P2924; DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRITSCH M, 1992, BIOCHEMISTRY-US, V31, P5303, DOI 10.1021/bi00138a009; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HOROWITZ ZD, 1989, MOL ENDOCRINOL, V3, P148, DOI 10.1210/mend-3-1-148; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1993, ANN NY ACAD SCI, V684, P19, DOI 10.1111/j.1749-6632.1993.tb32268.x; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LU XP, 1993, MOL CELL BIOL, V13, P6509, DOI 10.1128/MCB.13.10.6509; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WEISSHART K, 1993, P NATL ACAD SCI USA, V90, P1028, DOI 10.1073/pnas.90.3.1028; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	39	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14175	14181						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188700				2022-12-27	WOS:A1994NL60600069
J	MORRISON, JR; SILVESTRE, MJ; PITTMAN, RC				MORRISON, JR; SILVESTRE, MJ; PITTMAN, RC			CHOLESTERYL ESTER TRANSFER BETWEEN HIGH-DENSITY-LIPOPROTEIN AND PHOSPHOLIPID-BILAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE UPTAKE; RAT-LIVER; PLASMA-MEMBRANES; PHOSPHATIDYLCHOLINE; MECHANISM; CELLS; EXCHANGE; VESICLES; SOLUBILIZATION; LOCALIZATION	High density lipoprotein associated cholesteryl esters (HDL CE) are taken up by many cells without parallel uptake of HDL apoproteins, a pathway we have termed ''selective uptake.'' The first step in this pathway, the reversible incorporation of HDL CE into the plasma membrane, is the subject of the present study. To examine the role of membrane proteins, the rate of HDL CE incorporation into isolated rat liver plasma membrane was compared with the rate of incorporation into synthetic membranes devoid of protein. Both membrane systems exhibited saturable uptake of CE, and at rates that were similar (t(1/2) approximate to 2 h, measured with 50 mu g of HDL protein). Addition of unlabeled HDL to ''chase'' CE tracer from the biological and synthetic membranes revealed two kinetically distinct CE pools (t(1/2) approximate to 0.5 h and t(1/2) approximate to 30 h). Both biological and synthetic membranes accepted similar amounts of CE into both pools, with a maximum incorporation of 2-4 mol % relative to membrane phospholipids. CE transfer between HDL and membranes was kinetically second order, in contrast to the first-order transfer of unesterified cholesterol. There was no evidence for direct participation of any apolipoprotein in CE uptake; CE in HDL or in protein-free microemulsions of similar particle size transferred to membranes at similar rates. To examine the possibility that CE transfer requires transient fusion of the HDL amphipathic coat with the membrane outer leaflet, radiolabeled cardiolipin was incorporated into either HDL particles or into synthetic membranes as an amphipathic coat marker that does not diffuse through the aqueous phase; transfer between HDL and membranes was not observed. Thus, CE are transferred between HDL and cell membranes in a collision mediated process that does not involve amphipathic coat fusion and is not dependent on either membrane protein or apolipoproteins.	UNIV CALIF SAN DIEGO,DEPT MED 0682,LA JOLLA,CA 92093	University of California System; University of California San Diego								BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Fleischer S, 1974, Methods Enzymol, V31, P6; GLASS C, 1985, J BIOL CHEM, V260, P744; GOORMAGHTIGH E, 1986, ANAL BIOCHEM, V159, P122, DOI 10.1016/0003-2697(86)90316-7; GREEN SR, 1991, J LIPID RES, V32, P457; HAMILTON JA, 1982, J BIOL CHEM, V257, P7318; HAMILTON JA, 1981, P NATL ACAD SCI-BIOL, V78, P6878, DOI 10.1073/pnas.78.11.6878; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HELLINGS JA, 1974, EUR J BIOCHEM, V47, P601, DOI 10.1111/j.1432-1033.1974.tb03731.x; HOMAN R, 1988, BIOCHIM BIOPHYS ACTA, V938, P155, DOI 10.1016/0005-2736(88)90155-1; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONES JD, 1989, BIOCHEMISTRY-US, V28, P129, DOI 10.1021/bi00427a019; JONES JD, 1990, BIOCHEMISTRY-US, V29, P1593, DOI 10.1021/bi00458a034; KADOWAKI H, 1992, J LIPID RES, V33, P1689; KADOWAKI H, 1993, J LIPID RES, V34, P180; KNECHT TP, 1989, BIOCHIM BIOPHYS ACTA, V1002, P365, DOI 10.1016/0005-2760(89)90351-2; LEBLOND L, 1993, J BIOL CHEM, V268, P1670; LETIZIA JY, 1991, BIOCHEMISTRY-US, V30, P866, DOI 10.1021/bi00217a041; LIS LJ, 1982, BIOPHYS J, V37, P657; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; MCPHERSON GA, 1985, KINETIC EBDA LIGAND; MILLER KW, 1983, BIOCHEMISTRY-US, V22, P443, DOI 10.1021/bi00271a030; MORRISON JR, 1992, J BIOL CHEM, V267, P13205; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; Pittman R C, 1986, Methods Enzymol, V129, P612; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; RAND RP, 1989, BIOCHIM BIOPHYS ACTA, V988, P351, DOI 10.1016/0304-4157(89)90010-5; RAY TK, 1970, BIOCHIM BIOPHYS ACTA, V196, P1, DOI 10.1016/0005-2736(70)90159-8; RINNINGER F, 1989, J BIOL CHEM, V264, P6111; RINNINGER F, 1988, J LIPID RES, V29, P1179; RINNINGER F, 1987, J LIPID RES, V28, P1313; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; TALL AR, 1986, METHOD ENZYMOL, V128, P647; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; VANHOEVEN RP, 1972, J MEMBRANE BIOL, V9, P105, DOI 10.1007/BF01868047; WALSH MT, 1986, METHOD ENZYMOL, V128, P582; WEDER HG, 1984, LIPOSOME TECHNOLOGY, V1; WETTERAU JR, 1984, J BIOL CHEM, V259, P863; [No title captured]	41	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13911	13918						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188670				2022-12-27	WOS:A1994NL60600032
J	ZHANG, ZJ; ZHAO, SM; BAI, G; LEE, EYC				ZHANG, ZJ; ZHAO, SM; BAI, G; LEE, EYC			CHARACTERIZATION OF DELETION MUTANTS OF THE CATALYTIC SUBUNIT OF PROTEIN PHOSPHATASE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PHOSPHORYLASE PHOSPHATASE; SERINE THREONINE PHOSPHATASES; RABBIT SKELETAL-MUSCLE; MOLECULAR-WEIGHT; MICROCYSTIN-LR; OKADAIC ACID; INHIBITOR; TYPE-1; PURIFICATION; FAMILY	Deletion mutagenesis was used to define the core region of the catalytic subunit of rabbit muscle protein phosphatase-1. Deletions in the N terminus were found to lead to loss of expression. Deletions of up to 33 residues from the C-terminal region were tolerated, and the truncated enzymes were fully active. Deletion of an additional 21 residues led to loss of expression. Mutants which had had 33 and 25 residues deleted maintained specific activities that were comparable to those of the wild type enzyme. The response of these two deletion mutants to okadaic acid, microcystin, and inhibitor-2 was determined, Only slightly lower IC50 values were observed in all cases, showing that the C terminus itself does not play a major role in the binding of these inhibitors. The deletion mutants formed stable complexes with inhibitor a as shown by gel filtration. These studies provide unambiguous evidence that the extreme C-terminal region of protein phosphatase-1 is not directly involved in catalytic function or in the binding of inhibitor-2, microcystin, or okadaic acid, and they also establish that the first similar to 300 residues of the sequence constitute a sufficient core for protein phosphatase-1 catalytic functions.	UNIV MIAMI, SCH MED, DEPT BIOCHEM & MOLEC BIOL R629, MIAMI, FL 33101 USA	University of Miami					NIDDK NIH HHS [DK18512] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018512] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; BAI G, 1990, J BIOL CHEM, V265, P7843; BAI G, 1988, FASEB J, V2, P3013; BALLOU LM, 1983, BIOCHEMISTRY-US, V22, P3393, DOI 10.1021/bi00283a014; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT H, 1975, BIOCHEM BIOPH RES CO, V63, P950, DOI 10.1016/0006-291X(75)90661-0; BRANDT H, 1974, BIOCHEM BIOPH RES CO, V61, P598, DOI 10.1016/0006-291X(74)90999-1; BRANDT H, 1975, J BIOL CHEM, V250, P8038; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; CHEN MX, 1992, FEBS LETT, V306, P54, DOI 10.1016/0014-5793(92)80836-6; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DOMBRADI V, 1990, EUR J BIOCHEM, V194, P739, DOI 10.1111/j.1432-1033.1990.tb19464.x; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; GRATECOS D, 1977, BIOCHEMISTRY-US, V16, P4812, DOI 10.1021/bi00641a009; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JOHANSEN JW, 1987, BIOCHIM BIOPHYS ACTA, V928, P63, DOI 10.1016/0167-4889(87)90086-3; KHANDELWAL RL, 1976, J BIOL CHEM, V251, P4850; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee E Y, 1976, Adv Enzyme Regul, V14, P467, DOI 10.1016/0065-2571(76)90026-1; Lee E Y, 1980, Adv Cyclic Nucleotide Res, V13, P95; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MACKINTOSH RW, 1990, FEBS LETT, V276, P156, DOI 10.1016/0014-5793(90)80531-M; MERLEVEDE W, 1984, CURR TOP CELL REGUL, V23, P177; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; RESINK TJ, 1983, EUR J BIOCHEM, V133, P455, DOI 10.1111/j.1432-1033.1983.tb07485.x; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; SCHLENDER KK, 1989, BIOCHEM BIOPH RES CO, V159, P72, DOI 10.1016/0006-291X(89)92406-6; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SILBERMAN SR, 1984, J BIOL CHEM, V259, P2913; SMITH RD, 1993, PLANT MOL BIOL, V21, P307, DOI 10.1007/BF00019946; VILLAMORUZZI E, 1991, FEBS LETT, V293, P67, DOI 10.1016/0014-5793(91)81154-Z; VILLAMORUZZI E, 1984, J BIOL CHEM, V259, P5857; ZHANG Z, 1993, ADV PROTEIN PHOSPHAT, V7, P183; ZHANG Z, 1994, IN PRESS ARCH BIOCH; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; ZHANG ZJ, 1993, ARCH BIOCHEM BIOPHYS, V303, P402, DOI 10.1006/abbi.1993.1301	43	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13766	13770						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188653				2022-12-27	WOS:A1994NL60600011
J	JI, IH; ZENG, HW; JI, TH				JI, IH; ZENG, HW; JI, TH			RECEPTOR ACTIVATION OF AND SIGNAL GENERATION BY THE LUTROPIN CHORIOGONADOTROPIN RECEPTOR - COOPERATION OF ASP(397) OF THE RECEPTOR AND ALPHA-LYS(91) OF THE HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HIGH-AFFINITY; CLONING; DOMAIN; BINDS; CDNA; GENE	We have developed a novel method of reciprocal substitution mutation to identify pairing of amino acids within a receptor and its ligand. Using this method, we demonstrate for the first time that a pair of counterionic amino acids, one from the lutropin/choriogonadotropin receptor and the other from the ligand (human choriogonadotropin), cooperate and perhaps interact with each other to activate the receptor and to generate hormonal signal. In this study, Asp397 of the receptor was converted to Lys while Lys91 of the alpha subunit of human choriogonadotropin was substituted with Asp, thus maintaining the counterionic nature of this pair of amino acids. Mutation at each of these positions does not affect the hormone-receptor interaction but results in the significant or complete loss of the bioactivity of both the receptor and the hormone. However, when the impotent mutant receptor and mutant hormone were paired to interact together, they induced cAMP synthesis, resulting in a potent receptor-hormone couple. Substitutions with other amino acids that eliminated the counterionic nature failed to induce cAMP synthesis. Our results shed light on the molecular mechanisms of receptor activation and will serve as a model for other G-protein-coupled peptide receptors, particularly glycoprotein hormone receptors.			JI, IH (corresponding author), UNIV WYOMING,DEPT MOLEC BIOL,LARAMIE,WY 82071, USA.				NHLBI NIH HHS [HL-18702] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; JI I, 1991, J BIOL CHEM, V266, P13076; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI I, 1990, GLYCOPROTEIN HORMONE, P355; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; JI J, 1993, J BIOL CHEM, V268, P20851; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MACFARLAND KC, 1989, SCIENCE, V245, P494; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; XIE YB, 1990, J BIOL CHEM, V265, P21411; YOO J, 1991, J BIOL CHEM, V266, P17741; YOO JK, 1993, J BIOL CHEM, V268, P13034	14	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					22971	22974						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226810				2022-12-27	WOS:A1993MF51500005
J	AOKI, M; HAMADA, F; SUGIMOTO, T; SUMIDA, S; AKIYAMA, T; TOYOSHIMA, K				AOKI, M; HAMADA, F; SUGIMOTO, T; SUMIDA, S; AKIYAMA, T; TOYOSHIMA, K			THE HUMAN COT PROTOONCOGENE ENCODES 2 PROTEIN-SERINE THREONINE KINASES WITH DIFFERENT TRANSFORMING ACTIVITIES BY ALTERNATIVE INITIATION OF TRANSLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE SARCOMA-VIRUS; N-END RULE; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; CELL-CYCLE; V-RAF; FAMILY; PHOSPHORYLATION; IDENTIFICATION; ACTIVATION	The cot gene is an oncogene encoding serine/threonine kinases isolated by DNA transfection assay. In this study, we isolated cDNA for the human cot proto-oncogene (proto-cot gene) and examined the structure and function of its gene products. The proto-cot gene has an open reading frame encoding 467 amino acids of which the first 397 amino acids are identical to those in the corresponding part of the cot gene. The protein products of the proto-cot gene were identified as 58- and 52-kDa proteins with intrinsic protein serine/threonine kinase activity. These two protein species were suggested to be generated by alternative initiation from two AUGs. The 58- and 52-kDa proteins are both localized predominantly in the cytosol, but the 58-kDa protein has a shorter half-life than the 52-kDa protein, suggesting the importance of the amino-terminal domain in regulating the stability of the proto-Cot protein. More interestingly, the 58-kDa protein showed stronger transforming activity than the 52-kDa protein, although this activity was much weaker than that of the Cot oncoprotein. Thus, the amino-terminal domain of the Cot protein may be necessary for cellular transformation, whereas the carboxyl-terminal domain may negatively regulate the transforming activity.	OSAKA UNIV,PHYS RES INST,DEPT ONCOGENE RES,3-1 YAMADA OKA,SUITA,OSAKA 565,JAPAN	Osaka University			Aoki, Masahiro/A-5149-2016	Aoki, Masahiro/0000-0003-4316-9490				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; AOKI M, 1991, ONCOGENE, V6, P1515; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLENIS J, 1991, CANCER CELLS, V3, P446; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN WS, 1987, NATURE, V328, P821; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU CK, 1987, J BIOL CHEM, V262, P1842; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FREEMAN RS, 1991, BIOCHEMISTRY-US, V30, P2293, DOI 10.1021/bi00223a001; FUKUI M, 1985, P NATL ACAD SCI USA, V82, P5954, DOI 10.1073/pnas.82.17.5954; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIGASHI T, 1990, P NATL ACAD SCI USA, V87, P2409, DOI 10.1073/pnas.87.7.2409; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; IKAWA S, 1990, MOL CELL BIOL, V10, P2503; JANSEN HW, 1983, EMBO J, V2, P1969, DOI 10.1002/j.1460-2075.1983.tb01686.x; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SARIS CJM, 1991, EMBO J; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078	50	52	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22723	22732						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226782				2022-12-27	WOS:A1993MD34800079
J	BROSE, N; GASIC, GP; VETTER, DE; SULLIVAN, JM; HEINEMANN, SF				BROSE, N; GASIC, GP; VETTER, DE; SULLIVAN, JM; HEINEMANN, SF			PROTEIN CHEMICAL CHARACTERIZATION AND IMMUNOCYTOCHEMICAL LOCALIZATION OF THE NMDA RECEPTOR SUBUNIT NMDA R1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GLUTAMATE RECEPTOR; RAT-BRAIN; MEMBRANE-PROTEINS; MOLECULAR-CLONING; CHANNEL; CLEAVAGE; CELLS	In the rat central nervous system, the mRNA encoding the N-methyl-D-aspartate receptor subunit R1 is the most ubiquitously distributed among the cloned subunit mRNAs of this glutamate receptor subtype. The N-methyl-D-aspartate R1 mRNA is very abundantly expressed and N-methyl-D-aspartate R1 coexpression is necessary for functional expression of all other cloned N-methyl-D-aspartate receptor subunits. Therefore, the R1 subunit is likely to be an essential component of all known N-methyl-D-aspartate receptors in rat brain. By employing sequence specific polyclonal antibodies, we demonstrate that rat brain N-methyl-D-aspartate R1, as well as recombinantly expressed receptor protein, has an apparent molecular mass of 116 kDa in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The receptor protein is heavily glycosylated. It is specifically localized to the central nervous system, and it coenriches with synaptic membranes upon subcellular fractionation of the cerebral cortex. Chemical cross-linking of synaptic membrane proteins shows that the N-methyl-D-aspartate R1 protein is part of a receptor protein complex with a molecular mass of 730 kDa. By using immunocytochemical methods, we demonstrate a widespread but distinct distribution of N-methyl-D-aspartate R1 in neurons of the rat brain, with prominent immunostaining in certain layers of the cerebral cortex, in the hippocampus and dentate gyrus, as well as in the cerebellum.			BROSE, N (corresponding author), SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB H,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Vetter, Douglas E./O-8150-2019		NINDS NIH HHS [NS 28706, NS 11549] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011549] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS JC, 1981, J HISTOCHEM CYTOCHEM, V29, P775, DOI 10.1177/29.6.7252134; ANANTHARAM V, 1992, FEBS LETT, V305, P27, DOI 10.1016/0014-5793(92)80648-Z; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROSE N, 1990, J BIOL CHEM, V265, P10604; CHANGEUX JP, 1987, TRENDS PHARMACOL SCI, V8, P459, DOI 10.1016/0165-6147(87)90039-3; CHAZOT PL, 1992, J NEUROCHEM, V59, P1176, DOI 10.1111/j.1471-4159.1992.tb08364.x; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; Friedrich Jr VL, 1981, NEUROANATOMICAL TRAC, P345; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARLOW E, 1988, ANTIBODIES LABORATOR; HUNTLEY GW, 1993, J NEUROSCI, V13, P2965; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MUGNAINI E, 1983, J HISTOCHEM CYTOCHEM, V31, P1435, DOI 10.1177/31.12.6355290; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; NAKANISHI S, 1992, SCIENCE, V258, P579; OLMSTEDT JB, 1987, METHOD ENZYMOL, V134, P467; ORDRONNEAU P, 1981, J HISTOCHEM CYTOCHEM, V29, P1397, DOI 10.1177/29.12.7033366; ROGERS SW, 1991, J NEUROSCI, V11, P2713; ROSEMUND C, 1992, J NEUROPHYSIOL, V68, P1901, DOI 10.1152/jn.1992.68.5.1901; Sambrook J, 1989, MOL CLONING LABORATO; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YAMAZAKI M, 1992, BIOCHEM BIOPH RES CO, V183, P886, DOI 10.1016/0006-291X(92)90566-4	37	153	153	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22663	22671						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226775				2022-12-27	WOS:A1993MD34800071
J	VILLAIN, P; CLABAULT, G; MACHE, R; ZHOU, DX				VILLAIN, P; CLABAULT, G; MACHE, R; ZHOU, DX			S1F BINDING-SITE IS RELATED TO BUT DIFFERENT FROM THE LIGHT-RESPONSIVE GT-1 BINDING-SITE AND DIFFERENTIALLY REPRESSES THE SPINACH RPS1 PROMOTER IN TRANSGENIC TOBACCO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-PLANTS; RBCS-3A GENE; REGULATORY ELEMENTS; RIBOSOMAL-PROTEIN; NUCLEAR FACTOR; PEA RBCS-3A; EXPRESSION; SEQUENCES; TRANSCRIPTION; ORGANIZATION	Nuclear genes encoding plastid ribosomal proteins are more highly expressed in leaves than in roots. This leaf-specific induction seems to be light-independent. We have previously characterized a spinach nuclear factor S1F binding to a cis-element within the rps1 promoter, which negatively regulates both the rps1 and the cauliflower mosaic virus 35S promoters in transient expression assays. Here, we show that the S1F binding site is related to but different from the light-responsive Box II of the pea rbcS-3A promoter, which is recognized by the nuclear factor GT-1. Transgenic plant analyses showed that the S1F site tissue-specifically represses the rps1 promoter in roots as well as in etiolated seedlings. We suggest that the GT-1-related S1F binding site is responsible, at least in part, for the transcriptional repression of rps1 in nonphotosynthetic tissues such as roots.	UNIV GRENOBLE 1,CNRS,URA 1178,BIOL MOLEC VEGETALE LAB,F-38041 GRENOBLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)				Zhou, Dao-Xiu/0000-0002-1540-0598				BISANZSEYER C, 1992, PLANT MOL BIOL, V18, P337, DOI 10.1007/BF00034960; DEAN C, 1989, ANNU REV PLANT PHYS, V40, P415, DOI 10.1146/annurev.pp.40.060189.002215; DEHESH K, 1990, SCIENCE, V250, P1397, DOI 10.1126/science.2255908; DEHESH K, 1992, EMBO J, V11, P4131, DOI 10.1002/j.1460-2075.1992.tb05506.x; DENG XW, 1988, EMBO J, V7, P3301, DOI 10.1002/j.1460-2075.1988.tb03200.x; ELLIOTT RC, 1989, PLANT CELL, V1, P681, DOI 10.1105/tpc.1.7.681; FRALEY RT, 1985, BIO-TECHNOL, V3, P629, DOI 10.1038/nbt0785-629; FRANZETTI B, 1992, NUCLEIC ACIDS RES, V20, P4153, DOI 10.1093/nar/20.16.4153; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GILMARTIN PM, 1992, PLANT CELL, V4, P839, DOI 10.1105/tpc.4.7.839; GILMARTIN PM, 1990, PLANT CELL, V2, P447, DOI 10.1105/tpc.2.5.447; GILMARTIN PM, 1990, MOL CELL BIOL, V10, P5565, DOI 10.1128/MCB.10.10.5565; GILMARTIN PM, 1990, PLANT CELL, V2, P369, DOI 10.1105/tpc.2.5.369; GREEN PJ, 1988, EMBO J, V7, P4035, DOI 10.1002/j.1460-2075.1988.tb03297.x; GREEN PJ, 1987, EMBO J, V6, P2543, DOI 10.1002/j.1460-2075.1987.tb02542.x; JEFFERSON RA, 1987, EMBO J, V6, P3901; KAY SA, 1989, PLANT CELL, V1, P351, DOI 10.1105/tpc.1.3.351; KUHLEMEIER C, 1987, GENE DEV, V1, P247, DOI 10.1101/gad.1.3.247; KUHLEMEIER C, 1988, P NATL ACAD SCI USA, V85, P4662, DOI 10.1073/pnas.85.13.4662; LAGRANGE T, 1993, MOL CELL BIOL, V13, P2614, DOI 10.1128/MCB.13.4.2614; LAM E, 1990, SCIENCE, V248, P471, DOI 10.1126/science.2330508; LAWTON MA, 1991, PLANT MOL BIOL, V16, P235, DOI 10.1007/BF00020555; MANZARA T, 1988, PHOTOSYNTH RES, V16, P117, DOI 10.1007/BF00039489; PERISIC O, 1992, PLANT CELL, V4, P831, DOI 10.1105/tpc.4.7.831; SCHINDLER U, 1990, EMBO J, V9, P3415, DOI 10.1002/j.1460-2075.1990.tb07549.x; STOCKHAUS J, 1987, P NATL ACAD SCI USA, V84, P7943, DOI 10.1073/pnas.84.22.7943; ZHOU DX, 1992, J BIOL CHEM, V267, P23515	27	29	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16626	16630						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206981				2022-12-27	WOS:A1994NR29600019
J	GETTS, RC; STAMATO, TD				GETTS, RC; STAMATO, TD			ABSENCE OF A KU-LIKE DNA END BINDING-ACTIVITY IN THE XRS DOUBLE-STRAND DNA REPAIR-DEFICIENT MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAY SENSITIVE MUTANTS; CHINESE-HAMSTER CELL; RNA POLYMERASE-II; IONIZING-RADIATION; BREAK REPAIR; TRANSCRIPTION FACTOR; AUTOANTIGEN-KU; PROTEIN-KINASE; SCID MUTATION; MECHANISM	Double-strand DNA break repair is important in maintaining the genetic integrity of the genome. Using a mobility shift assay, we find that a protein, or complex of proteins, that is present in mammalian and yeast cells binds to the ends of double-strand DNA and renders the ends resistant to exonuclease digestion. Additionally, a mammalian DNA double-strand repair-deficient mutant, xrs, has no observable DNA end binding activity, while a revertant cell has wild-type activity. In addition, mobility supershift assays using monoclonal antibodies to the human Ku antigen (M(r) 70,000 subunit) reveal that one of the proteins of this end binding activity may be the Ku antigen or a protein with similar antigenic determinants. These observations suggest that this DNA end-binding protein may function in DNA repair.	LANKENAU MED RES CTR,WYNNEWOOD,PA 19096	Lankenau Medical Center; Lankenau Institute for Medical Research								BADING H, 1988, NUCLEIC ACIDS RES, V16, P5241, DOI 10.1093/nar/16.12.5241; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FALZON M, 1993, J BIOL CHEM, V268, P10546; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GIACCIA A, 1985, SOMAT CELL MOLEC GEN, V11, P485, DOI 10.1007/BF01534842; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HANAWALT PC, 1979, ANNU REV BIOCHEM, V48, P483; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; MAY G, 1991, J BIOL CHEM, V266, P3052; MIMORI T, 1986, J BIOL CHEM, V261, P375; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; Sambrook J, 1989, MOL CLONING LABORATO; SASTRY SS, 1989, BIOCHEMISTRY-US, V28, P5670, DOI 10.1021/bi00439a050; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; STRICKLAND MS, 1988, BIOCHEMISTRY-US, V27, P5755, DOI 10.1021/bi00415a054; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; THACKER J, 1991, MUTAT RES, V254, P135, DOI 10.1016/0921-8777(91)90004-9; WHITMORE GF, 1989, INT J RADIAT BIOL, V56, P657, DOI 10.1080/09553008914551881; ZDZIENICKA MZ, 1992, RADIAT RES, V131, P309, DOI 10.2307/3578421; ZDZIENICKA MZ, 1988, MUTAT RES, V194, P239	24	220	222	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15981	15984						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206892				2022-12-27	WOS:A1994NQ72900007
J	JOHN, M; BRIAND, JP; GRANGERSCHNARR, M; SCHNARR, M				JOHN, M; BRIAND, JP; GRANGERSCHNARR, M; SCHNARR, M			2 PAIRS OF OPPOSITELY CHARGED AMINO-ACIDS FROM JUN AND FOS CONFER HETERODIMERIZATION TO GCN4 LEUCINE-ZIPPER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; COILED-COIL; BASIC REGION; SPECIFICITY; PROTEIN; DIMERIZATION; DOMAIN; TRANSFORMATION; REPRESSOR; RESIDUES	The preferential assembly of Jun and Fos into heterodimers has been shown to be mainly driven by 16 amino acids (8 from each protein) situated in positions e and g of the leucine zipper coiled-coil structures of the two proteins (O'Shea, E.K., Rutkowski, R., and Kim, P.S. (1992) Cell 68, 699-708). Using a similar approach, we show that among these residues two pairs of oppositely charged amino acids account in fact for most of the additional free energy of heterodimerization in this system. These residues are 2 glutamic acid side chains in positions g(1) and e(2) of the Pos leucine zipper and 2 lysine residues in the equivalent positions of the Jun zipper. These amino acids were placed in the context of a GCN4 leucine zipper using peptide synthesis. These peptides contain unique cysteine residues enabling the formation of covalent dimers. The gain in heterodimer free energy has been determined both by cysteine-linked dimer formation under redox conditions and by thermal melting experiments of covalent dimers using circular dichroism experiments. The two pairs of oppositely charged residues (Glu,Glu and Lys,Lys) in positions g(1) and e(2) contribute at least -1.9 kcal/mol of additional free energy, accounting for a 50-fold excess of the heterodimer with respect to one of the homodimers. Thermal denaturation studies as a function of pH and ionic strength suggest that electrostatic effects should indeed be a major driving force for heterodimerization. On the contrary, peptides harboring the 12 amino acids from Jun and Fos in the other e and g positions (i.e. in e(1), g(2), e(3), g(3), e(4), and g(4)) show only a moderate tendency to form heterodimers.	CNRS,UPR 9002,INST BIOL MOLEC & CELLULAIRE,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; COHEN DR, 1990, ONCOGENE, V5, P929; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HUDSON D, 1988, J ORG CHEM, V53, P617, DOI 10.1021/jo00238a026; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; NEIMARK J, 1991, 21ST P EUR PEPT S, P204; NICKLIN MJH, 1991, ONCOGENE, V6, P173; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; SCHMIDTDORR T, 1991, BIOCHEMISTRY-US, V30, P9657, DOI 10.1021/bi00104a013; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047	20	33	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16247	16253						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206929				2022-12-27	WOS:A1994NQ72900047
J	MURAKAMI, N; ELZINGA, M; SINGH, SS; CHAUHAN, VPS				MURAKAMI, N; ELZINGA, M; SINGH, SS; CHAUHAN, VPS			DIRECT BINDING OF MYOSIN-II TO PHOSPHOLIPID-VESICLES VIA TAIL REGIONS AND PHOSPHORYLATION OF THE HEAVY-CHAINS BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE NONMUSCLE MYOSIN; ACTIVATED MG-ATPASE; AMINO-ACID-SEQUENCE; BRUSH-BORDER MYOSIN; FILAMENT FORMATION; SMOOTH-MUSCLE; BRAIN MYOSIN; LIGHT CHAIN; CELLULAR MYOSIN; NERVOUS-SYSTEM	Recent cloning and sequencing studies suggest that heavy chains of all non-muscle myosins II have a protein kinase C (PKC) phosphorylation site within their tail regions. A fragment of human macrophage myosin heavy chain, encompassing its COOH-terminal 396 amino acids (MIIA(F46)), was expressed in Escherichia coli to provide a model system for study of PKC-mediated phosphorylation. PKC phosphorylated this fragment when phosphatidylserine (PS) liposomes were present, but not when liposomes made from PS/phosphatidylcholine (PC) were used. The reaction required Ca2+, but not other activators such as diacylglycerol (DG) or phosphatidylinositol 4,5-bisphosphate. Phosphorylation of MIIA(F46),as not observed in the presence of micelles of PS or PS/DG. Similar results were obtained using native myosin II purified from bovine brain and chicken intestine brush border. Phosphorylation of light chains, in contrast, occurred even with PS/PC liposomes if DG was present. Addition of the PS and PS/DG liposomes significantly increased the turbidities at 340 nm of MIIA(F46) and native myosin II, and the extent of increase depended upon the type of myosin used. Also, PS and PS/DG liposomes shifted the gel filtration elution positions of MIIA(F48) and myosin II. In contrast, liposomes of PS/PC and PS/PC/DG gave only a slight increase in turbidity with all myosins and fragments and did not noticeably shift their gel filtration elution positions. These results suggest that myosins II bind to PS liposomes via the COOH-terminal regions of their heavy chains with affinities specific to each myosin isoform, that the binding is dependent upon the PS composition, and that PKC phosphorylates the PS-bound heavy chains.	NEW YORK STATE INST BASIC RES DEV DISABIL, DEPT NEUROCHEM, STATEN ISL, NY 10314 USA	Institute for Basic Research in Developmental Disabilities	MURAKAMI, N (corresponding author), NEW YORK STATE INST BASIC RES DEV DISABIL, DEPT PHARMACOL, 1050 FOREST HILL RD, STATEN ISL, NY 10314 USA.							ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; BAZZI MD, 1992, J BIOL CHEM, V267, P22891; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BHATIADEY N, 1993, P NATL ACAD SCI USA, V90, P2856, DOI 10.1073/pnas.90.7.2856; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUHAN VPS, 1988, BIOCHEM BIOPH RES CO, V155, P18, DOI 10.1016/S0006-291X(88)81043-X; CHENG TPO, 1992, FEBS LETT, V311, P91, DOI 10.1016/0014-5793(92)81374-U; CITI S, 1986, J MOL BIOL, V188, P369, DOI 10.1016/0022-2836(86)90161-0; COLLINS JH, 1982, BIOCHEMISTRY-US, V21, P6910, DOI 10.1021/bi00269a045; CONTI MA, 1991, BIOCHEMISTRY-US, V30, P966, DOI 10.1021/bi00218a012; COTE GP, 1984, J BIOL CHEM, V259, P2781; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HAYDEN SM, 1990, J CELL BIOL, V111, P443, DOI 10.1083/jcb.111.2.443; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IKEDA N, 1990, BIOCHEM BIOPH RES CO, V169, P1191, DOI 10.1016/0006-291X(90)92022-R; KAWAMOTO S, 1989, J BIOL CHEM, V264, P2258; KELLEY CA, 1993, BIOPHYS J, V64, pA144; KELLY CA, 1991, J BIOL CHEM, V265, P17876; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; KUCZMARSKI ER, 1980, P NATL ACAD SCI-BIOL, V77, P7292, DOI 10.1073/pnas.77.12.7292; KUROO M, 1991, J BIOL CHEM, V266, P3768; KUZNICKI J, 1983, J BIOL CHEM, V258, P6011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI DQ, 1994, P NATL ACAD SCI USA, V91, P853, DOI 10.1073/pnas.91.3.853; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MCNALLY E, 1991, METHOD ENZYMOL, V196, P368; MILLER M, 1992, NEURON, V8, P25, DOI 10.1016/0896-6273(92)90106-N; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; MURAKAMI N, 1990, J BIOL CHEM, V265, P1041; MURAKAMI N, 1984, J BIOCHEM-TOKYO, V95, P651, DOI 10.1093/oxfordjournals.jbchem.a134654; MURAKAMI N, 1993, DEV BIOL, V157, P19, DOI 10.1006/dbio.1993.1108; MURAKAMI N, 1991, FEBS LETT, V278, P23, DOI 10.1016/0014-5793(91)80074-D; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8808; OGIHARA S, 1983, J BIOCHEM, V93, P205, DOI 10.1093/oxfordjournals.jbchem.a134155; PERRY SV, 1962, METHOD ENZYMOL, V5, P582; SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164; SAGARA J, 1983, BIOCHEM J, V214, P839, DOI 10.1042/bj2140839; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; Small J V, 1988, Electron Microsc Rev, V1, P155; SUN WD, 1992, J MOL BIOL, V224, P1185, DOI 10.1016/0022-2836(92)90482-Y; SWANLJUNGCOLLINS H, 1992, J BIOL CHEM, V267, P3445; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; TANAKA E, 1986, J NEUROCHEM, V47, P254; TRUONG T, 1992, J BIOL CHEM, V267, P9767; VAILLANCOURT JP, 1988, J BIOL CHEM, V263, P10082	51	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16082	16090						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206908				2022-12-27	WOS:A1994NQ72900023
J	NAH, HD; NIU, ZL; ADAMS, SL				NAH, HD; NIU, ZL; ADAMS, SL			AN ALTERNATIVE TRANSCRIPT OF THE CHICK TYPE-III COLLAGEN GENE THAT DOES NOT ENCODE TYPE-III COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2(I) COLLAGEN; MESSENGER-RNA; SPLICED TRANSCRIPTS; SEQUENCE-ANALYSIS; DNA-POLYMERASE; 5' END; EXPRESSION; CHONDROBLASTS; TRANSLATION; CHAIN	Type III collagen, a ubiquitous protein found in most connective tissues, is not present in hyaline cartilage. However, we have identified an alternative transcript of the type III collagen gene in cultured chondrocytes from several embryonic chick cartilages. This RNA contains exons 24-52, but exons 1-23 are replaced by 70 nucleotides of unique sequence, suggesting that transcription initiates at an alternative promoter. Two of the open reading frames in the alternative transcript are out of frame with the collagen coding sequence; a third open reading frame encodes the carboxyl-terminal two-thirds of the collagen sequence. Thus, this RNA cannot serve as a template for synthesis of normal type III collagen and may encode noncollagenous proteins and/or a truncated collagen. The alternative transcript has been detected as early as 2.5 days of embryogenesis and at later stages is present at low levels in many tissues, including limb mesenchyme and cartilage. These results, together with our previous identification of an alternative transcript of the chick alpha 2(I) collagen gene (Bennett, V. D., and Adams, S. L. (1990) J. Biol. Chem. 265, 2223-2230), suggest that some collagen genes may have alternative functions that are independent of their roles in collagen production.	UNIV PENN,SCH DENT MED,DEPT BIOCHEM,PHILADELPHIA,PA 19104	University of Pennsylvania					NIAMS NIH HHS [AR41042, AR41849] Funding Source: Medline; NIGMS NIH HHS [GM28840] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041849, R01AR041042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM128840] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SL, 1982, CELL, V30, P373, DOI 10.1016/0092-8674(82)90235-5; ADAMS SL, 1991, EXP CELL RES, V192, P190; AHO S, 1983, NUCLEIC ACIDS RES, V11, P5443, DOI 10.1093/nar/11.16.5443; BENNETT VD, 1989, J BIOL CHEM, V264, P8402; BENNETT VD, 1987, J BIOL CHEM, V262, P14806; BENNETT VD, 1990, J BIOL CHEM, V265, P2223; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1984, NATURE, V310, P337, DOI 10.1038/310337a0; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DROPCHO EJ, 1987, P NATL ACAD SCI USA, V84, P4552, DOI 10.1073/pnas.84.13.4552; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELLINI SA, 1978, AM J ANAT, V153, P451, DOI 10.1002/aja.1001530308; FINI ME, 1989, J CELL BIOL, V108, P2045, DOI 10.1083/jcb.108.6.2045; FOCHT RJ, 1984, MOL CELL BIOL, V4, P1843, DOI 10.1128/MCB.4.9.1843; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HENKEL W, 1982, EUR J BIOCHEM, V122, P205, DOI 10.1111/j.1432-1033.1982.tb05868.x; KEENE DR, 1987, J HISTOCHEM CYTOCHEM, V35, P311, DOI 10.1177/35.3.3546481; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P59, DOI 10.1177/39.1.1983874; KEENE DR, 1987, J CELL BIOL, V105, P2393, DOI 10.1083/jcb.105.5.2393; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MCMASTER K, 1977, P NATL ACAD SCI USA, V11, P4835; MURAGAKI Y, 1990, P NATL ACAD SCI USA, V87, P2400, DOI 10.1073/pnas.87.7.2400; MYERS JC, 1983, J BIOL CHEM, V258, P128; NAH HD, 1991, J BIOL CHEM, V266, P23446; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; PACIFICI M, 1985, EXP CELL RES, V161, P381, DOI 10.1016/0014-4827(85)90095-3; PACIFICI M, 1991, EXP CELL RES, V192, P266, DOI 10.1016/0014-4827(91)90185-W; PIHLAJANIEMI T, 1987, P NATL ACAD SCI USA, V84, P940, DOI 10.1073/pnas.84.4.940; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITTA B, 1990, J BIOL CHEM, V265, P6476; Sambrook J, 1989, MOL CLONING LABORATO; SANDBERG M, 1989, MATRIX, V9, P82, DOI 10.1016/S0934-8832(89)80025-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SU MW, 1991, J CELL BIOL, V115, P565, DOI 10.1083/jcb.115.2.565; SWASDISON S, 1992, MATRIX, V11, P56; TIKKA L, 1988, P NATL ACAD SCI USA, V85, P7491, DOI 10.1073/pnas.85.20.7491; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; YAMADA Y, 1983, J BIOL CHEM, V258, P4914; YAMADA Y, 1983, J BIOL CHEM, V258, P2758; YAMADA Y, 1984, NATURE, V310, P333, DOI 10.1038/310333a0; YAMADA Y, 1983, NUCLEIC ACIDS RES, V11, P2733, DOI 10.1093/nar/11.9.2733	46	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16443	16448						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206952				2022-12-27	WOS:A1994NQ72900073
J	SADEK, CM; ALLENHOFFMANN, BL				SADEK, CM; ALLENHOFFMANN, BL			CYTOCHROME P450IA1 IS RAPIDLY INDUCED IN NORMAL HUMAN KERATINOCYTES IN THE ABSENCE OF XENOBIOTICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE S-TRANSFERASES; HEAT-SHOCK PROTEIN; PLASMINOGEN-ACTIVATOR INHIBITOR-2; LIVER NAD(P)H-QUINONE REDUCTASE; ANTIOXIDANT RESPONSIVE ELEMENT; HUMAN EPIDERMAL-KERATINOCYTES; SUBUNIT GENE-EXPRESSION; AH-RECEPTOR; TERMINAL DIFFERENTIATION; SIGNAL-TRANSDUCTION	Cytochrome P450IA1 is a polycyclic aromatic hydrocarbon (PAH)-responsive monooxygenase enzyme with no known endogenous inducer or substrate. We investigated the effect of suspension on P450IA1 gene (CYP1A1) expression in cultured human keratinocytes without the addition of xenobiotics, To prohibit adhesion and trigger differentiation, human keratinocytes or dermal fibroblasts were suspended in medium made semisolid with methylcellulose. Following suspension, we observed dramatic increases (> 100-fold) in steady state P450IA1 mRNA in keratinocytes within 1 h; however, dermal fibroblasts were nonresponsive. This effect was not dependent on methylcellulose itself and could be achieved by suspension in medium alone or in Percoll solution. The induction of P450IA1 mRNA was independent of exogenous calcium or serum concentrations, agents commonly used to signal differentiation. Adherent keratinocytes overlaid with methylcellulose exhibited slight morphological changes accompanied by increased P450IA1 mRNA. The activity of the P450IA1 enzyme was found to parallel Northern analysis data. Changes in keratinocyte adhesion or shape also affect other PAH-responsive genes suggesting Ah receptor involvement. We report a novel mechanism for cell type-specific induction of CYP1A1 expression without the addition of xenobiotic inducers. These findings suggest a possible endogenous role for P450IA1 in stratified squamous epithelia.	UNIV WISCONSIN,CTR ENVIRONM TOXICOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	SADEK, CM (corresponding author), UNIV WISCONSIN,DEPT PATHOL,MADISON,WI 53706, USA.		Sadek, Christine/A-7356-2010		NIAMS NIH HHS [AR40284] Funding Source: Medline; NIEHS NIH HHS [T32 ES07015] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040284, R01AR040284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007015] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ALLENHOFFMANN BL, 1984, P NATL ACAD SCI-BIOL, V81, P7802, DOI 10.1073/pnas.81.24.7802; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BAYNEY RM, 1987, J BIOL CHEM, V262, P572; BERGHARD A, 1990, J BIOL CHEM, V265, P21086; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; BURKE MD, 1985, BIOCHEM PHARMACOL, V34, P3337, DOI 10.1016/0006-2952(85)90355-7; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; COOMES MW, 1983, J PHARMACOL EXP THER, V255, P770; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DIGIOVANNI J, 1989, CANCER RES, V49, P5567; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GRADIN K, 1993, J BIOL CHEM, V268, P4061; GREEN H, 1977, CELL, V11, P405, DOI 10.1016/0092-8674(77)90058-7; GUO JF, 1990, J INVEST DERMATOL, V94, P86, DOI 10.1111/1523-1747.ep12873939; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; JAISWAL AK, 1985, NUCLEIC ACIDS RES, V13, P4503, DOI 10.1093/nar/13.12.4503; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KRUITHOF EKO, 1988, BIOCHEM BIOPH RES CO, V156, P383, DOI 10.1016/S0006-291X(88)80852-0; KURPAKUS MA, 1991, J CELL BIOL, V115, P1737, DOI 10.1083/jcb.115.6.1737; LAI HCJ, 1984, J BIOL CHEM, V259, P5536; MANOHARAN TH, 1987, J BIOL CHEM, V262, P3739; MARCHISIO PC, 1991, J CELL BIOL, V112, P761, DOI 10.1083/jcb.112.4.761; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; MINTON AP, 1983, MOL CELL BIOCHEM, V55, P119, DOI 10.1007/BF00673707; MOREL F, 1993, CANCER RES, V53, P231; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEBERT DW, 1989, INT J BIOCHEM, V21, P243, DOI 10.1016/0020-711X(89)90182-1; NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; PAINE AJ, 1991, INT J EXP PATHOL, V72, P349; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1988, J BIOL CHEM, V263, P9848; PETERSEN DD, 1991, AM J HUM GENET, V48, P720; POHL RJ, 1984, DRUG METAB DISPOS, V12, P25; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; REINERS JJ, 1990, P NATL ACAD SCI USA, V87, P1825, DOI 10.1073/pnas.87.5.1825; REINERS JJ, 1992, DRUG METAB DISPOS, V20, P360; REINERS JJ, 1991, CHEM INDUCED CELL PR, P123; ROZEN F, 1992, ARCH BIOCHEM BIOPHYS, V292, P589, DOI 10.1016/0003-9861(92)90035-U; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; STAQUET MJ, 1990, EXP CELL RES, V187, P277, DOI 10.1016/0014-4827(90)90092-O; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; TU CPD, 1986, BIOCHEM BIOPH RES CO, V141, P229, DOI 10.1016/S0006-291X(86)80358-8; TU CPD, 1986, J BIOL CHEM, V261, P9540; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; WATT FM, 1982, NATURE, V295, P434, DOI 10.1038/295434a0; WATT FM, 1987, J CELL SCI S, V8, P313; WILLIAMS JB, 1986, J BIOL CHEM, V261, P5524; YE RD, 1987, J BIOL CHEM, V262, P3718	66	94	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16067	16074						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206906				2022-12-27	WOS:A1994NQ72900021
J	ALESHIN, AE; FIRSOV, LM; HONZATKO, RB				ALESHIN, AE; FIRSOV, LM; HONZATKO, RB			REFINED STRUCTURE FOR THE COMPLEX OF ACARBOSE WITH GLUCOAMYLASE FROM ASPERGILLUS-AWAMORI VAR. X100 TO 2.4-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STARCH-BINDING DOMAIN; RAW-STARCH; CONFORMATIONAL-ANALYSIS; 3-DIMENSIONAL STRUCTURE; AFFINITY SITE; I MOLECULE; NIGER; MUTAGENESIS; MALTOSE; CHAINS	The three-dimensional structure of the pseudotetrasaccharide acarbose complexed with glucoamylase II(471) from Aspergillus awamori var. X100 has been determined to 2.4-Angstrom resolution. The model includes residues corresponding to 1-471 of glucoamylase I from Aspergillus niger, a single molecule of bound acarbose, and 535 sites for water molecules. The crystallographic R factor from refinement is 0.124, and the root-mean-squared deviation in bond distances is 0.013 Angstrom. Electron density for a single molecule of bound acarbose defines what may be the first four subsites in the binding of extended maltooligosaccharides. Hydrogen bonds between acarbose and the enzyme involve Arg(54), Asp(55), Arg(305), carbonyl(177), main chain amide(121), Glu(179), Glu(180), and carbonyl(179). Glu(179) forms a salt link to the imino linkage between the first and second residues of acarbose. This buried salt link probably contributes significantly to the unusually tight association (K-d similar to 10(-12) M) of acarbose with glucoamylase. In addition, a significant hydrophobic contact between the third residue of acarbose and the side chain of Trp(120) distorts the three center angle of the glucosidic linkage between the second and third residues of acarbose. A water molecule (water(500)) hydrogen bonds to Glu(400) and the 6-hydroxyl of the valienamine moiety of acarbose and is at an approximate distance of 3.7 Angstrom from the ''anomeric'' carbon of the inhibitor. The relevance of the acarbose-glucoamylase complex to the mechanism of enzymic hydrolysis of oligosaccharides is discussed.	IOWA STATE UNIV SCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, AMES, IA 50011 USA; ST PETERSBURG NUCL PHYS INST, DEPT MOLEC BIOL, ST PETERSBURG 188350, RUSSIA	Iowa State University; National Research Centre - Kurchatov Institute; Petersburg Nuclear Physics Institute								ABDULLAH M, 1963, BIOCHEM J, V89, pP35; ALESHIN A, 1992, J BIOL CHEM, V267, P19291; ALESHIN AE, 1994, J MOL BIOL, V238, P575, DOI 10.1006/jmbi.1994.1316; ARNOTT S, 1972, J CHEM SOC PERK T 2, P324, DOI 10.1039/p29720000324; BELSHAW NJ, 1991, BIOCHIM BIOPHYS ACTA, V1078, P117, DOI 10.1016/0167-4838(91)90100-E; BELSHAW NJ, 1990, FEBS LETT, V269, P350, DOI 10.1016/0014-5793(90)81191-P; BENNET AJ, 1986, J AM CHEM SOC, V108, P7287, DOI 10.1021/ja00283a025; BOCK K, 1984, CARBOHYD RES, V132, P142, DOI 10.1016/0008-6215(84)85072-7; BOCK K, 1986, PROTEIN CARBOHYDRATE, P173; BOEL E, 1984, EMBO J, V3, P1097, DOI 10.1002/j.1460-2075.1984.tb01935.x; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; CHU SSC, 1968, ACTA CRYSTALL B-STRU, VB 24, P830, DOI 10.1107/S0567740868003250; CLARKE AJ, 1984, CARLSBERG RES COMMUN, V49, P559, DOI 10.1007/BF02908684; CLARKE AJ, 1984, CARLSBERG RES COMMUN, V49, P111, DOI 10.1007/BF02913970; DALMIA BK, 1991, ENZYME MICROB TECH, V13, P982, DOI 10.1016/0141-0229(91)90121-P; DOWD MK, 1992, CARBOHYD RES, V230, P223, DOI 10.1016/0008-6215(92)84035-Q; EINSPHAR HM, 1989, T AM CRYSTALLOGR ASS, V25, P1; GOLDSMITH EJ, 1987, J BIOL CHEM, V262, P1449; GOLUBEV AM, 1992, J MOL BIOL, V226, P271, DOI 10.1016/0022-2836(92)90139-B; GUNNARSSON A, 1984, EUR J BIOCHEM, V145, P463, DOI 10.1111/j.1432-1033.1984.tb08578.x; HAKANSSON K, 1989, CARLSBERG RES COMMUN, V54, P145, DOI 10.1007/BF02907184; HARRIS EMS, 1993, BIOCHEMISTRY-US, V32, P1618, DOI 10.1021/bi00057a028; HAYASHIDA S, 1989, AGR BIOL CHEM TOKYO, V53, P135, DOI 10.1080/00021369.1989.10869272; HAYASHIDA S, 1989, AGR BIOL CHEM TOKYO, V53, P143, DOI 10.1080/00021369.1989.10869246; HAYASHIDA S, 1975, AGR BIOL CHEM TOKYO, V39, P2093, DOI 10.1080/00021369.1975.10861931; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HIROMI K, 1982, BIOCHEMISTRY-US, V21, P102, DOI 10.1021/bi00530a018; HIROMI K, 1966, J BIOCHEM, V59, P469, DOI 10.1093/oxfordjournals.jbchem.a128329; HIROMI K, 1970, BIOCHEM BIOPH RES CO, V40, P1, DOI 10.1016/0006-291X(70)91037-5; HIROMI K, 1983, MOL CELL BIOCHEM, V51, P79, DOI 10.1007/BF00215589; ITOH T, 1989, AGR BIOL CHEM TOKYO, V53, P3159, DOI 10.1080/00021369.1989.10869825; JOHNSON LN, 1988, CURR TOP MICROBIOL, V139, P81; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KNOWLES JR, 1976, CRC CR REV BIOCH MOL, V4, P165, DOI 10.3109/10409237609105457; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEMIEUX RU, 1983, ARCH BIOCHEM BIOPHYS, V221, P125, DOI 10.1016/0003-9861(83)90128-5; LONGCHAMBON F, 1976, ACTA CRYSTALLOGR B, V32, P1822, DOI 10.1107/S0567740876006468; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Manjunath P, 1983, J Appl Biochem, V5, P235; MATTHEWS BW, 1975, ACTA CRYSTALLOGR A, V31, P480, DOI 10.1107/S0567739475001040; MEAGHER MM, 1989, BIOTECHNOL BIOENG, V34, P681, DOI 10.1002/bit.260340512; NEUSTROEV K N, 1990, Biokhimiya, V55, P776; OLSEN K, 1992, EUR J BIOCHEM, V209, P777, DOI 10.1111/j.1432-1033.1992.tb17348.x; PAZUR JH, 1960, J BIOL CHEM, V235, P297; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; SAHA BC, 1989, STARCH-STARKE, V41, P57, DOI 10.1002/star.19890410206; SAVEL'EV A N, 1983, Biokhimiya, V48, P1311; SAVEL'EV A N, 1982, Biokhimiya, V47, P1618; SERGEEV V R, 1985, Biokhimiya, V50, P416; SHASHKOV AS, 1986, CARBOHYD RES, V147, P175, DOI 10.1016/S0008-6215(00)90628-1; SIERKS MR, 1990, PROTEIN ENG, V3, P193, DOI 10.1093/protein/3.3.193; SIERKS MR, 1992, PROTEIN ENG, V5, P185, DOI 10.1093/protein/5.2.185; SIERKS MR, 1993, BIOCHEMISTRY-US, V32, P1113, DOI 10.1021/bi00055a017; SIERKS MR, 1989, PROTEIN ENG, V2, P621, DOI 10.1093/protein/2.8.621; SVENSSON B, 1986, EUR J BIOCHEM, V154, P497, DOI 10.1111/j.1432-1033.1986.tb09425.x; SVENSSON B, 1989, BIOCHEM J, V264, P309, DOI 10.1042/bj2640309; SVENSSON B, 1982, CARLSBERG RES COMMUN, V47, P55, DOI 10.1007/BF02907797; SVENSSON B, 1983, CARLSBERG RES COMMUN, V48, P529, DOI 10.1007/BF02907555; SVENSSON B, 1992, CARBOHYD RES, V227, P29, DOI 10.1016/0008-6215(92)85059-9; TAKAHASHI T, 1985, J BIOCHEM-TOKYO, V98, P663, DOI 10.1093/oxfordjournals.jbchem.a135323; TAKEGAWA K, 1988, BIOCHIM BIOPHYS ACTA, V955, P187, DOI 10.1016/0167-4838(88)90192-6; TANAKA A, 1982, J BIOCHEM-TOKYO, V91, P1; TANAKA A, 1982, BIOCHEMISTRY-US, V21, P107, DOI 10.1021/bi00530a019; TRUSCHEIT E, 1981, ANGEW CHEM INT EDIT, V20, P744, DOI 10.1002/anie.198107441; TVAROSKA I, 1986, CARBOHYD RES, V149, P389, DOI 10.1016/S0008-6215(00)90060-0; WEILL CE, 1954, CEREAL CHEM, V31, P150; WILLIAMSON G, 1992, BIOCHEM J, V282, P423, DOI 10.1042/bj2820423	67	150	153	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15631	15639						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195212				2022-12-27	WOS:A1994NP51300040
J	DIRACSVEJSTRUP, AB; SOLDATI, T; SHAPIRO, AD; PFEFFER, SR				DIRACSVEJSTRUP, AB; SOLDATI, T; SHAPIRO, AD; PFEFFER, SR			RAB-GDI PRESENTS FUNCTIONAL RAB9 TO THE INTRACELLULAR-TRANSPORT MACHINERY AND CONTRIBUTES SELECTIVITY TO RAB9 MEMBRANE RECRUITMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEINS; VESICULAR TRANSPORT; SACCHAROMYCES-CEREVISIAE; DISSOCIATION INHIBITOR; ENDOCYTIC PATHWAY; GOLGI NETWORK; BOVINE BRAIN; SEC4; ENDOSOMES; CYTOSOL	Rab proteins occur in the cytosol bound to Rab-GDP dissociation inhibitor (GDI). We demonstrate here that cytosolic complexes of Rab9 bound to GDI represent a functional pool of Rab9 protein that can be utilized for transport from late endosomes to the trans Golgi network in vitro. Immunodepletion of GDI and Rab proteins bound to GDI led to the loss of cytosol activity; readdition of pure Rab9-GDI complexes fully restored cytosol activity. Delipidated serum albumin could solubilize prenylated Rab9 protein, but unlike Rab9-GDI complexes, Rab9-serum albumin complexes led to indiscriminate membrane association of Rab9 protein. Rab9 delivered to membranes by serum albumin was functional, but GDI increased the efficiency of Rab9 utilization, presumably because it suppressed Rab9 protein mistargeting. Finally, GDI inhibited transport of proteins from late endosomes to the trans Golgi network, likely because of its capacity to inhibit the membrane recruitment of cytosolic Rab9. These experiments show that GDI contributes to the selectivity of Rab9 membrane recruitment and presents functional Rab9 to the endosome-trans Golgi network transport machinery.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University			SOLDATI, Thierry/A-2902-2009; SOLDATI, Thierry/U-6494-2019	SOLDATI, Thierry/0000-0002-2056-7931; SOLDATI, Thierry/0000-0002-2056-7931	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK037332, R01DK037332, R56DK037332] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37332] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; DUNN B, 1993, NATURE, V362, P533; ELZAR Z, 1994, J BIOL CHEM, V266, P794; GARRETT MD, 1993, FEBS LETT, V331, P233, DOI 10.1016/0014-5793(93)80343-S; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GODA Y, 1988, CELL, V55, P399; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	26	71	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15427	15430						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195183				2022-12-27	WOS:A1994NP51300008
J	LU, Q; WALLRATH, LL; EMANUEL, PA; ELGIN, SCR; GILMOUR, DS				LU, Q; WALLRATH, LL; EMANUEL, PA; ELGIN, SCR; GILMOUR, DS			INSENSITIVITY OF THE PRESET HSP26 CHROMATIN STRUCTURE TO A TATA BOX MUTATION IN DROSOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME-FREE REGIONS; I HYPERSENSITIVE SITES; RNA POLYMERASE-II; HEAT-SHOCK; BINDING PROTEIN; SEQUENCES DOWNSTREAM; CRYSTAL-STRUCTURE; TRANSCRIPTION; GENE; PROMOTER	The role of the TATA element in establishing the chromatin structure and inducible transcription of the Drosophila melanogaster hsp26 gene has been analyzed. An hsp26/lacZ fusion gene with a mutant promoter, in which the TATA box sequence TATAAA was changed to CCCAAA, was introduced into Drosophila by P-element transformation. The mutation had little effect on formation of the preset chromatin structure observed prior to induction. However, the mutation dramatically reduced transcription levels following heat shock. Northern analysis indicated that weak, inducible expression of the mutant promoter occurred within the same period of heat shock as for the normal promoter, suggesting that TFIID was associated with the mutant promoter prior to heat shock. Biochemical analysis showed that the mutant promoter still bound TFIID in vitro, but with 3-5-fold less affinity than the normal promoter. DNase I footprinting revealed that the conformation of the TFIID.DNA complex differed significantly from that of the normal promoter. These results indicate that alterations in the conformation or the stability of the TFIID.DNA complex drastically reduce the level of induction, but do not dramatically affect chromatin structure formation. Formation of the requisite chromatin structure is either independent of, or highly tolerant of, changes in the TFIID.DNA complex.	PENN STATE UNIV,CTR GENE REGULAT,DEPT BIOCHEM & MOLEC BIOL,UNIV PK,PA 16802; WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Washington University (WUSTL)				Elgin, Sarah C. R./0000-0002-5176-2510; Wallrath, Lori/0000-0002-4391-7199	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047477, F32GM014516, R01GM031532] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47477, GM14516, GM 31532] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATSON SC, 1993, NUCLEIC ACIDS RES, V21, P3459; BECKER PB, 1991, P NATL ACAD SCI USA, V88, P4109, DOI 10.1073/pnas.88.10.4109; CARTWRIGHT IL, 1986, MOL CELL BIOL, V6, P779, DOI 10.1128/MCB.6.3.779; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; EMANUEL PA, 1993, P NATL ACAD SCI USA, V90, P8449, DOI 10.1073/pnas.90.18.8449; FASCHER KD, 1993, J MOL BIOL, V231, P658, DOI 10.1006/jmbi.1993.1317; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GILMOUR DS, 1986, MOL CELL BIOL, V6, P3984, DOI 10.1128/MCB.6.11.3984; GILMOUR DS, 1988, MOL CELL BIOL, V8, P3204, DOI 10.1128/MCB.8.8.3204; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE H, 1992, GENE DEV, V60, P284; LEE MS, 1992, P NATL ACAD SCI USA, V89, P9166, DOI 10.1073/pnas.89.19.9166; LU Q, 1992, J MOL BIOL, V225, P985, DOI 10.1016/0022-2836(92)90099-6; LU Q, 1993, MOL CELL BIOL, V13, P2808; LU Q, 1993, J CELL BIOCHEM, V54, P1; Lu Qin, 1993, V1, P333; Maniatis T., 1982, MOL CLONING; OBRIEN T, 1993, MOL CELL BIOL, V13, P3456, DOI 10.1128/MCB.13.6.3456; PUGH BF, 1992, J BIOL CHEM, V267, P679; PURNELL BA, 1993, MOL CELL BIOL, V13, P2593, DOI 10.1128/MCB.13.4.2593; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SIMON JA, 1987, NUCLEIC ACIDS RES, V15; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; SYPES MA, 1994, NUCLEIC ACIDS RES, V22, P807, DOI 10.1093/nar/22.5.807; THOMAS GH, 1988, EMBO J, V7, P2191, DOI 10.1002/j.1460-2075.1988.tb03058.x; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VASLET CA, 1980, NATURE, V285, P674, DOI 10.1038/285674a0; VAZQUEZ J, 1993, CHROMOSOMA, V102, P233, DOI 10.1007/BF00352397; WALLRATH LL, 1990, MOL CELL BIOL, V10, P5114, DOI 10.1128/MCB.10.10.5114; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	46	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15906	15911						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195245				2022-12-27	WOS:A1994NP51300078
J	AMBROZIAK, J; HENRY, SA				AMBROZIAK, J; HENRY, SA			INO2 AND INO4 GENE-PRODUCTS, POSITIVE REGULATORS OF PHOSPHOLIPID BIOSYNTHESIS IN SACCHAROMYCES-CEREVISIAE, FORM A COMPLEX THAT BINDS TO THE INO1 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; DNA-BINDING; YEAST; MYC; MYOD; TRANSFORMATION; RECOGNITION; ACTIVATION; SEQUENCES; SYNTHASE	The INO4 gene encodes a protein required for derepression of a number of structural genes encoding enzymes involved in phospholipid biosynthesis in the yeast Saccharomyces cerevisiae. Ino4p shows structural similarity to the basic helix-loop-helix (bHLH) family of regulatory proteins (Hoshizaki, D. K., Hill, J. E., and Henry, S. A, (1990) J. Biol. Chem. 265, 4736-4745). In this report we demonstrate that Ino4p translated in vitro forms a complex with Ino2p, another positive regulator of phospholipid biosynthesis that contains a bHLH domain. The Ino2p.Ino4p complex binds to a fragment of the INO1 promoter containing two copies of the consensus binding site for the bHLH family of proteins. The complex formed when this DNA fragment is incubated with in vitro translated Ino2p and Ino4p is identical in mobility to the complex formed when this DNA fragment is incubated with whole cell extracts. The binding of DNA by the Ino2p.Ino4p complex is competed by an oligonucleotide containing the consensus binding sequence for bHLH proteins. Neither Ino2p nor Ino4p translated alone is capable of forming a complex with the INO1 promoter fragment. The two products, translated separately and mixed, show only reduced capability to form a complex compared with cotranslated proteins. Immunoprecipitation experiments demonstrate that Ino2p and Ino4p interact in the absence of DNA. Ino2p and Ino4p are, thus, both necessary and sufficient for formation of a complex with the INO1 promoter.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213	Carnegie Mellon University			Henry, Susan/K-5464-2014		NIGMS NIH HHS [GM-19629] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019629, R37GM019629] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1988, MOL REPROD DEV; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CULBERTSON MR, 1975, GENETICS, V80, P23; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DONAHUE TF, 1981, GENETICS, V98, P491; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER F, 1991, ONCOGENE, V6, P1099; HAMMOND C, 1994, IN PRESS CELL MOL BI; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOSHIZAKI DK, 1990, J BIOL CHEM, V265, P4736; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P3987, DOI 10.1093/nar/19.14.3987; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; NIKOLOFF DM, 1994, J BIOL CHEM, V269, P7402; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SERGHINI MA, 1989, NUCLEIC ACIDS RES, V17, P3604, DOI 10.1093/nar/17.9.3604; Sherman F., 1978, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722	35	162	164	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15344	15349						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195172				2022-12-27	WOS:A1994NP73800073
J	KAWAMOTO, S				KAWAMOTO, S			EVIDENCE FOR AN INTERNAL REGULATORY REGION IN A HUMAN NONMUSCLE MYOSIN HEAVY-CHAIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE PROMOTER; AMINO-ACID-SEQUENCES; SMOOTH-MUSCLE; MESSENGER-RNAS; TRANSCRIPTION INITIATION; DIFFERENTIAL EXPRESSION; CELLULAR MYOSIN; NERVOUS-SYSTEM; SV40 ENHANCER; DNA-SEQUENCE	We have isolated genomic clones which encode the promoter and flanking region of human nonmuscle myosin heavy chain (MHC)-A. The sequence of this region shows many features typical of a housekeeping gene; there is no TATA element and no functional CAAT box. The GC content is high, having an average GC content of 74% in the 600 base pairs (bp) surrounding the transcriptional start sites, and multiple GC boxes (putative Sp1 binding sites) are present. A number of nucleotide sites are utilized for the initiation of transcription. Promoter activity was monitored using luciferase as a reporter following transient transfection into NIH 3T3 cells. Analysis of 5' and 3' deletion mutants in the promoter region defines the core promoter as extending from nucleotide -112 to +61, where +1 is a major transcriptional start site. An essential sequence for core promoter activity resides in the 36-bp region from -77 to -112 which includes a single potential AP-2 binding site and a single potential Spl binding site. The region just downstream from the transcriptional start site (between +62 and +257) was found to be involved in cell type-specific activation of nonmuscle MHC-A gene expression. The increase in luciferase activity due to this proximal downstream region is approximately 15-fold in NIH 3T3 cells, but no increase was observed in C2C12 myotubes and neuroblastoma cells. This 196-bp region, which consists of 100 bp from exon 1 and 96 bp from intron 1, functions in a position- and orientation-dependent manner. Quantitation of luciferase mRNA content driven by the MHC-A promoter, using both competitive polymerase chain reaction and RNase protection assays, revealed that the increase seen in luciferase mRNA due to the 196-bp fragment is approximately 5-fold in NIH 3T3 cells. This only accounts for about one-third of the total increase seen in luciferase activity (protein amounts). Thus, this proximal downstream region appears to activate gene expression in MH 3T3 cells via both pretranslational (transcription and/or mRNA stability) and translational mechanisms.			KAWAMOTO, S (corresponding author), NHLBI,MOLEC CARDIOL LAB,BETHESDA,MD 20892, USA.							AUSUBEL FM, 1993, CURR PROTCOLS MOL BI, V1; BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; BABIJ P, 1991, P NATL ACAD SCI USA, V88, P10676, DOI 10.1073/pnas.88.23.10676; BHATIADEY N, 1993, P NATL ACAD SCI USA, V90, P2856, DOI 10.1073/pnas.90.7.2856; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOYER TG, 1989, J BIOL CHEM, V264, P5177; BURRIDGE K, 1975, J MOL BIOL, V99, P1, DOI 10.1016/S0022-2836(75)80154-9; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG S, 1989, MOL CELL BIOL, V9, P2075, DOI 10.1128/MCB.9.5.2075; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EMERSON CP, 1987, ANNU REV BIOCHEM, V56, P695, DOI 10.1146/annurev.bi.56.070187.003403; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P659, DOI 10.1073/pnas.90.2.659; HAMADA Y, 1990, BIOCHEM BIOPH RES CO, V170, P53, DOI 10.1016/0006-291X(90)91239-O; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; KETCHUM AS, 1990, P NATL ACAD SCI USA, V87, P6316, DOI 10.1073/pnas.87.16.6316; KIEHART DP, 1989, EMBO J, V8, P913, DOI 10.1002/j.1460-2075.1989.tb03452.x; KUROO M, 1989, J BIOL CHEM, V264, P18272; MAHDAVI V, 1986, MOL BIOL MUSCLE DEV, P345; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; SPUDICH JA, 1989, CELL REGUL, V1, P1; STREHLER EE, 1985, J BIOL CHEM, V260, P468; SUN WD, 1992, J MOL BIOL, V224, P1185, DOI 10.1016/0022-2836(92)90482-Y; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; TOOTHAKER LE, 1991, BLOOD, V78, P1826; WHALEN RG, 1986, MOL BIOL MUSCLE DEV, P237; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x	49	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15101	15110						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195147				2022-12-27	WOS:A1994NP73800040
J	TSUBOI, S; MATSUMOTO, H; JACKSON, KW; TSUJIMOTO, K; WILLIAMS, T; YAMAZAKI, A				TSUBOI, S; MATSUMOTO, H; JACKSON, KW; TSUJIMOTO, K; WILLIAMS, T; YAMAZAKI, A			PHOSPHORYLATION OF AN INHIBITORY SUBUNIT OF CGMP PHOSPHODIESTERASE IN RANA-CATESBIANA ROD PHOTORECEPTORS .1. CHARACTERIZATION OF THE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; PROTEIN-KINASE-C; LIGHT-INDUCED DEPHOSPHORYLATION; GTP-BINDING PROTEIN; OUTER SEGMENTS; GAMMA-SUBUNIT; DROSOPHILA PHOTORECEPTOR; ACTIVATION MECHANISM; AMINO-ACID; TRANSDUCIN	Interaction between the inhibitory subunit (P gamma) and catalytic subunits of cGMP phosphodiesterase is essential for the regulation of cGMP phosphodiesterase in vertebrate rod photoreceptors. P gamma phosphorylation in vitro has been studied using a kinase which is extracted from amphibian rod outer segments. Various chromatographies of the kinase preparation using ionic exchange, gel filtration, and heparin-Sepharose columns indicate that a kinase with M(r) 70,000 is responsible for the P gamma phosphorylation. The kinase does not require any of the known activators for protein kinases but is inhibited by cGMP in a concentration-dependent manner. Together with analysis by laser-desorption mass spectrometry, measurement of P-32 radioactivity in phosphorylated P gamma indicates that P gamma extracted with GTP-bound transducin alpha subunit is not phosphorylated and that a phosphate is incorporated into more than 80% of the P gamma by the kinase. Phosphoamino acid analysis, sequencing of phosphorylated peptides derived from phosphorylated P gamma, and phosphorylation of synthetic peptides indicate threonine 22 in P gamma is phosphorylated by the kinase. Phosphorylated P gamma has a higher inhibitory activity for active cGMP phosphodiesterase than nonphosphorylated P gamma. These data suggest that threonine 22 in P gamma is phosphorylated by a specific kinase and that the P gamma phosphorylation governs the interaction between P gamma and catalytic subunits of cGMP phosphodiesterase in vertebrate rod photoreceptors.	WAYNE STATE UNIV, SCH MED, KRESGE EYE INST, DEPT OPHTHALMOL, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, KRESGE EYE INST, DEPT PHARMACOL, DETROIT, MI 48201 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, OKLAHOMA CITY, OK 73190 USA; UNIV OKLAHOMA, HLTH SCI CTR, WILLIAM K WARREN MED RES INST, OKLAHOMA CITY, OK 73190 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT MED, OKLAHOMA CITY, OK 73190 USA; UNIV ELECTROCOMMUN, DEPT APPL PHYS & CHEM, CHOFU, TOKYO 182, JAPAN; JASCO INT CO LTD, HACHIOJI, TOKYO 193, JAPAN	Wayne State University; Wayne State University; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Electro-Communications - Japan					NEI NIH HHS [EY 07546, EY 09631, EY 06596] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009631, R01EY007546] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; BINDER BM, 1989, J BIOL CHEM, V264, P8857; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CUNNICK JM, 1990, BIOCHEM J, V271, P721, DOI 10.1042/bj2710721; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; HAMILTON SE, 1990, J BIOL CHEM, V265, P11259; HAMM H, 1990, J GEN PHYSIOL, V95, P545, DOI 10.1085/jgp.95.3.545; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4333, DOI 10.1073/pnas.88.10.4333; HAYASHI F, 1987, BIOCHEM BIOPH RES CO, V148, P54, DOI 10.1016/0006-291X(87)91075-8; HAYASHI F, 1988, MOL PHYSL RETINAL PR, P405; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; LEE RH, 1990, J BIOL CHEM, V265, P15867; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LEE RH, 1992, J BIOL CHEM, V267, P25104; LIEBMAN PA, 1980, NATURE, V287, P734, DOI 10.1038/287734a0; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; MATSUMOTO H, 1991, BIOCHEM BIOPH RES CO, V177, P1306, DOI 10.1016/0006-291X(91)90683-X; MILLER WH, 1990, INVEST OPHTH VIS SCI, V31, P1664; MORRISON DF, 1987, FEBS LETT, V222, P266, DOI 10.1016/0014-5793(87)80383-6; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; POLANS AS, 1979, J GEN PHYSIOL, V74, P595, DOI 10.1085/jgp.74.5.595; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P1205; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TSUBOI S, 1994, J BIOL CHEM, V269, P15024; TUTEJA N, 1990, GENE, V88, P227, DOI 10.1016/0378-1119(90)90035-P; TUTEJA N, 1988, FEBS LETT, V232, P182, DOI 10.1016/0014-5793(88)80413-7; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; YAN KW, 1989, ANNU REV NEUROSCI, V12, P289	44	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15016	15023						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195138				2022-12-27	WOS:A1994NP73800029
J	OKAMOTO, T; MURAYAMA, Y; STRITTMATTER, SM; KATADA, T; ASANO, S; OGATA, E; NISHIMOTO, I				OKAMOTO, T; MURAYAMA, Y; STRITTMATTER, SM; KATADA, T; ASANO, S; OGATA, E; NISHIMOTO, I			AN INTRINSIC GUANINE-NUCLEOTIDE EXCHANGE INHIBITOR IN G(I2)ALPHA - SIGNIFICANCE OF G-PROTEIN SELF-SUPPRESSION WHICH ANTAGONIZES RECEPTOR SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEIN; FACTOR-II RECEPTOR; ALPHA-SUBUNIT; PERTUSSIS-TOXIN; IDENTIFICATION; PURIFICATION; PEPTIDE; REGION; CELLS; BRAIN	The alpha subunit of G(i2) (G(i2)alpha) is a member of the heterotrimeric G protein family, which transduces receptor signals as a proto-oncogene product. We have found a novel self-suppressive region in G(i2)alpha near its C terminus. A polypeptide consisting of residues 338-352 of G(i2)alpha (G(i2)alpha-338-352) antagonizes receptor- and receptor peptide stimulated G(i2)alpha activation, without affecting basal activity. Antagonism by G(i2)alpha-338-352 is attributable to an interaction with activated G(i2)alpha, which is not competitive with receptor polypeptides. Combined with the reports suggesting the presence of self-suppressive domains in a juxta-C-terminal portion of G(i2)alpha and G(o) alpha, this study sup ports the hypothesis that G(i2)alpha-338-352 constitutes an intrinsic guanine nucleotide exchange inhibitor, which in turn antagonizes receptor stimulation, suggesting that G proteins are activated by receptors through relaxation of a self suppressive conformation.	MASSACHUSETTS GEN HOSP, CARDIOVASC RES CTR, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP, DEV BIOL LAB, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02129 USA; UNIV TOKYO, SCH MED, DEPT INTERNAL MED 4, BUNKYO KU, TOKYO 112, JAPAN; TOKYO INST TECHNOL, DEPT LIFE SCI, MIDORI KU, YOKOHAMA, KANAGAWA 227, JAPAN; CANC RES INST, TOSHIMA KU, TOKYO 170, JAPAN	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Tokyo; Tokyo Institute of Technology			Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092				ASANO T, 1989, BIOCHEMISTRY-US, V28, P4749, DOI 10.1021/bi00437a035; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; CHEE WW, 1989, J BIOL CHEM, V264, P5687; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DITTMAN AH, 1994, BIOCHEMISTRY-US, V33, P943, DOI 10.1021/bi00170a013; HAGA K, 1985, J BIOL CHEM, V260, P7927; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HEIDEMAN W, 1990, G PROTEINS, P17; JOHNSON GL, 1991, J CELL BIOCHEM, V47, P136, DOI 10.1002/jcb.240470207; KATADA T, 1987, FEBS LETT, V213, P353, DOI 10.1016/0014-5793(87)81521-1; KOTANI K, 1992, ONCOGENE, V7, P1699; LARIVIERE G, 1988, CANCER RES, V48, P3405; LESTER BR, 1989, CANCER RES, V49, P5940; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MORISHITA R, 1989, BIOCHEM BIOPH RES CO, V161, P1280, DOI 10.1016/0006-291X(89)91381-8; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; MUKAI H, 1992, J BIOL CHEM, V267, P16237; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMOTO I, 1991, J BIOL CHEM, V266, P12747; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; OKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P8020, DOI 10.1073/pnas.88.18.8020; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; TAKAHASHI K, 1993, P NATL ACAD SCI USA, V90, P11772, DOI 10.1073/pnas.90.24.11772; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234	28	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13756	13759						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188651				2022-12-27	WOS:A1994NL60600009
J	TAVERNA, FA; WANG, LY; MACDONALD, JF; HAMPSON, DR				TAVERNA, FA; WANG, LY; MACDONALD, JF; HAMPSON, DR			A TRANSMEMBRANE MODEL FOR AN IONOTROPIC GLUTAMATE-RECEPTOR PREDICTED ON THE BASIS OF THE LOCATION OF ASPARAGINE-LINKED OLIGOSACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; FUNCTIONAL EXPRESSION; HIPPOCAMPAL-NEURONS; KAINATE; AMPA; CHANNEL; DESENSITIZATION; PROTEINS; CLONING; SUBUNIT	Several different models have been proposed for the transmembrane structure of receptors for the neurotransmitter L-glutamate. In this study, the sites of N-linked oligosaccharides on GluR6, a member of the kainate class of ionotropic glutamate receptors, were examined. Site directed mutagenesis was utilized to alter the consensus sequence at three potential sites for N-linked glycosylation in the carboxyl-terminal half of the molecule. The presence of a carbohydrate substitution was monitored by shifts in the relative molecular weight of the mutant receptors on immunoblots. Molecular weight shifts were observed for the mutants N515Q and N720Q and for two companion mutants, T517A and T722A, which also eliminate the consensus sequence for N-linked glycosylation. No shift in molecular weight was observed in the the mutant N574Q. These results indicate that asparagines 515 and 720 are glycosylated and thus are likely located extracellularly. In immunocytochemical analyses of GluR6 expressed in baculovirus-infected cells, permeabilization with detergents was required for immunostaining with a carboxyl-terminal antibody, indicating that the carboxyl terminus is located intracellularly. Electrophysiological recordings of the mutant receptors expressed in human embryonic kidney cells demonstrated that the amplitudes of the kainate-activated currents mediated by the N574Q, N720Q, and the T722A mutants were not significantly different from currents mediated by wild type GluR6 receptors, while the currents mediated by the N515Q and T517A mutants were significantly depressed. Based on these findings, we propose a model for the transmembrane topology of GluR6.	UNIV TORONTO,FAC PHARM,TORONTO M5S 2S2,ON,CANADA; UNIV TORONTO,MRC,NERVE CELLS & SYNAPSES GRP,TORONTO M5S 2S2,ON,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 2S2,ON,CANADA; UNIV TORONTO,DEPT PHARMACOL,TORONTO M5S 2S2,ON,CANADA	University of Toronto; University of Toronto; University of Toronto; University of Toronto								BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; DINGLEDINE R, 1992, J NEUROSCI, V12, P4080; EGEBJERG J, 1993, P NATL ACAD SCI USA, V90, P755, DOI 10.1073/pnas.90.2.755; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; ESHHAR N, 1993, NEUROSCIENCE, V57, P943, DOI 10.1016/0306-4522(93)90040-M; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; GEHLE VM, 1991, MOL BRAIN RES, V11, P17, DOI 10.1016/0169-328X(91)90016-Q; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; HULLEBROECK MF, 1992, BRAIN RES, V590, P187, DOI 10.1016/0006-8993(92)91094-U; JAKOI ER, 1992, BRAIN RES, V582, P282, DOI 10.1016/0006-8993(92)90145-Y; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; LODISH HF, 1988, TRENDS BIOCHEM SCI, V13, P332, DOI 10.1016/0968-0004(88)90101-6; MAYER ML, 1989, P NATL ACAD SCI USA, V86, P1411, DOI 10.1073/pnas.86.4.1411; MOLNAR E, 1993, NEUROSCIENCE, V53, P307, DOI 10.1016/0306-4522(93)90198-O; MORI H, 1993, NEUROREPORT, V4, P519, DOI 10.1097/00001756-199305000-00014; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; PICKERING DS, 1993, J NEUROCHEM, V61, P85, DOI 10.1111/j.1471-4159.1993.tb03540.x; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROSS SM, 1994, IN PRESS NEUROSCI LE; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; TAVERNA FA, 1994, EUR J PHARM-MOLEC PH, V266, P181, DOI 10.1016/0922-4106(94)90108-2; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; UCHINO S, 1992, FEBS LETT, V308, P253, DOI 10.1016/0014-5793(92)81286-U; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WENTHOLD RJ, 1994, J BIOL CHEM, V269, P1332; WONG LA, 1993, MOL PHARMACOL, V44, P504; YAMADA KA, 1992, J PHYSIOL-LONDON, V458, P409, DOI 10.1113/jphysiol.1992.sp019424; ZORUMSKICF, 1992, PROG NEUROBIOL NY, V39, P295	40	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14159	14164						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188697				2022-12-27	WOS:A1994NL60600066
J	UENO, H; ESCOBEDO, JA; WILLIAMS, LT				UENO, H; ESCOBEDO, JA; WILLIAMS, LT			DOMINANT-NEGATIVE MUTATIONS OF PLATELET-DERIVED GROWTH-FACTOR (PDGF) RECEPTORS - INHIBITION OF RECEPTOR FUNCTION BY LIGAND-DEPENDENT FORMATION OF HETERODIMERS BETWEEN PDGF ALPHA-RECEPTORS AND BETA-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CHAIN; SIGNAL TRANSDUCTION; KINASE ACTIVATION; EXPRESSION; PHOSPHORYLATION; DIMERIZATION; DEGRADATION; ESTABLISHES; CLONING; BINDING	We showed previously that a truncated form of the platelet-derived growth factor (PDGF) beta-receptor lacking its kinase region can form a nonfunctional heterodimer with the wild-type beta-receptor and thereby inhibit its signal transduction. In this paper we investigated whether the truncated form of either alpha- or beta-receptor could block the function of the other type of wild-type PDGF receptor. When the truncated alpha-receptor was expressed in Xenopus oocytes in excess over either the wild-type alpha- or beta-receptor, the Ca2+ mobilization signal elicited by either the wild-type alpha- or beta-receptor was completely blocked. The truncated beta-receptor abolished signaling by the wild-type alpha-receptor in response to PDGF-AB or -BB. However signal transduction by the alpha-receptor in response to PDGF-AA was not affected by the truncated beta-receptor. In the presence of PDGF-AB or -BB, both the wild-type and truncated beta-receptors formed a heterologous complex with the alpha-receptor in intact cells. A kinase-inactive beta-receptor (an ATP-binding site mutation) became cross-phosphorylated on tyrosine residues by the co-expressed wild-type alpha-receptor in response to PDGF-AB or -BB but not in response to PDGF-AA. These findings indicate that the alpha- and beta-receptors interact in response to PDGF-AB or -BB and are consistent with the hypothesis that the truncated alpha-receptor inhibits function of the wild-type beta-receptor through formation of a ligand-dependent nonfunctional alphabeta-heterodimer. A similar heterodimer can form between the truncated beta-receptor and the wild-type alpha-receptor. These observations provide useful information for future studies using dominant-negative mutations of PDGF receptors to selectively inhibit the actions of specific PDGFs in animals.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco					NHLBI NIH HHS [R0-1 HL-32898] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; DUAN DSR, 1991, J BIOL CHEM, V266, P413; ESCOBEDO JA, 1988, SCIENCE, V240, P1532, DOI 10.1126/science.2836953; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HART CE, 1987, J BIOL CHEM, V262, P10780; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; JOSEPHS SF, 1984, SCIENCE, V223, P487, DOI 10.1126/science.6318322; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KEATING MT, 1987, J BIOL CHEM, V262, P7932; KELLY JD, 1991, J BIOL CHEM, V266, P8987; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; OLASHAW NE, 1991, J BIOL CHEM, V266, P10234; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; STROOBANT P, 1984, EMBO J, V12, P2963; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1470; WERNER S, 1993, IN PRESS EMBO; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	30	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22814	22819						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226792				2022-12-27	WOS:A1993MD34800092
J	WATERS, SB; YAMAUCHI, K; PESSIN, JE				WATERS, SB; YAMAUCHI, K; PESSIN, JE			FUNCTIONAL EXPRESSION OF INSULIN-RECEPTOR SUBSTRATE-1 IS REQUIRED FOR INSULIN-STIMULATED MITOGENIC SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHATIDYLINOSITOL 3'-KINASE; IRS-1; ASSOCIATION; 3-KINASE; PROTEIN; KINASE	To examine the role of the insulin receptor substrate-1 (IRS-1) in mediating insulin biological responsiveness, we generated Chinese hamster ovary cell lines expressing antisense IRS-1 RNA. These cells displayed morphological alterations as well as markedly reduced growth rates compared to the parental cells. Furthermore, the antisense IRS-1 cell lines had decreased insulin-stimulated IRS-1 tyrosine phosphorylation, reduced phosphatidylinositol 3-kinase activation, and decreased thymidine incorporation relative to the parental cell line. Insulin-dependent transcriptional regulation of a serum response element/luciferase reporter construct (SRE-Luc) was also reduced in the antisense IRS-1-expressing cell lines. However, co-transfection with a plasmid directing the expression of rat IRS-1 fully restored insulin-stimulated SRE-Luc activity in the IRS-1 antisense cell lines. Thus, the inhibition in insulin signaling was a specific effect of decreased IRS-1 tyrosine phosphorylation. Taken together, these data demonstrate that insulin regulation of mitogenic signaling requires the functional expression of IRS-1 and documents its central importance in the insulin intracellular signaling pathway.	UNIV IOWA HOSP & CLIN, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, R37DK033823, R01DK033823] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33823, DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; FOLLI F, 1992, J BIOL CHEM, V267, P22171; HADARI YR, 1993, J BIOL CHEM, V268, P9156; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TOBE K, 1993, J BIOL CHEM, V268, P11167; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1991, METHOD ENZYMOL, V201, P65; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	114	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22231	22234						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226726				2022-12-27	WOS:A1993MD34800005
J	XU, YZ; PLUNKETT, W				XU, YZ; PLUNKETT, W			REGULATION OF THYMIDINE KINASE AND THYMIDYLATE SYNTHASE IN INTACT HUMAN LYMPHOBLAST CCRF-CEM CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DNA-POLYMERASES; LEUKEMIA-CELLS; MESSENGER-RNA; DEOXYCYTIDYLATE DEAMINASE; ALLOSTERIC INTERACTION; BIOSYNTHETIC-ENZYMES; REPLITASE COMPLEX; 3T6 FIBROBLASTS; MAMMALIAN-CELLS; L1210 CELLS	It has been reported that thymidylate synthase (TS) is a component of a multienzyme complex associated with DNA replication based on observations that enzyme activity was decreased when cells were treated with various DNA synthesis inhibitors (Plucinski, T. M., Fager, R. S., and Reddy, G. P. V. (1990) MoL Pharmacol. 38, 114-120). The veracity of the TS assay (known as the tritium release assay) employed in these experiments may be compromised, however, because it requires the S phase-specific enzyme thymidine kinase (TK) to phosphorylate the substrate [5-H-3]dUrd. In our study, this problem was further illustrated as the phosphorylated products of [C-14]dCyd and [6-H-3]dUrd were simultaneously quantitated to determine the activities of TS, TK, and dCyd kinase in intact CCRF-CEM cells. TS and dCyd kinase were unaffected by aphidicolin, hydroxyurea, and 1-beta-D-arabinofuranosylcytosine, whereas TK was strongly inhibited by these agents. Elevation of the cellular dTTP pool that accompanied drug treatment was not the primary mechanism affecting TK activity because incubation of cells with dCyd elevated the dTTP pool to similar levels, but did not inhibit TK to the same extent as did the drugs. Furthermore, after cells were washed from aphidicolin, [6-H-3]dCyd incorporation, which primarily labels dTMP in DNA, proceeded at a linear rate, whereas a lag period of 15 min was observed before [H-3]dThd was incorporated at a linear rate. These results suggest that TK activity is affected by more than one mechanism in intact cells. Because the activities of dCyd kinase and dCMP deaminase do not fluctuate as much as that of TK in response to changes in DNA synthesis activity and cell cycle, dCyd incorporation appears to be a more reliable assay of TS in intact cells than does dUrd incorporation. Our findings also imply that [H-3]dThd incorporation assays may overestimate inhibition of DNA synthesis.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN INVEST,BOX 52,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA28596] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG RD, 1982, J BIOCHEM BIOPH METH, V6, P141, DOI 10.1016/0165-022X(82)90060-4; ARNER ESJ, 1988, EXP CELL RES, V178, P335, DOI 10.1016/0014-4827(88)90403-X; BALZARINI J, 1984, BIOCHIM BIOPHYS ACTA, V785, P36, DOI 10.1016/0167-4838(84)90231-0; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; BLACK ME, 1992, J BIOL CHEM, V267, P9743; BODYCOTE J, 1986, P NATL ACAD SCI USA, V83, P4749, DOI 10.1073/pnas.83.13.4749; BRESNICK E, 1964, CANCER RES, V24, P841; CHIBA P, 1984, BIOCHEM BIOPH RES CO, V123, P656, DOI 10.1016/0006-291X(84)90279-1; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; COPPOCK DL, 1985, J CELL PHYSIOL, V124, P269, DOI 10.1002/jcp.1041240215; DESAINTVINCENT BR, 1980, J BIOL CHEM, V255, P162; DUNLAP RB, 1971, BIOCHEMISTRY-US, V10, P88, DOI 10.1021/bi00777a014; ERIKSSON S, 1987, EXP CELL RES, V168, P79, DOI 10.1016/0014-4827(87)90417-4; FEDER JN, 1990, J CELL BIOL, V111, P2693, DOI 10.1083/jcb.111.6.2693; FITZGERALD GB, 1987, ANTI-CANCER DRUG DES, V1, P281; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FRIDLAND A, 1987, SEMIN ONCOL, V14, P262; FRIEDKIN M, 1973, ADV ENZYMOL RAMB, V38, P235; HARVEY G, 1988, J CELL PHYSIOL, V134, P25, DOI 10.1002/jcp.1041340104; HASHIMOTO Y, 1988, CANCER BIOCHEM BIOPH, V10, P1; HEINEMANN V, 1989, BIOCHEM PHARMACOL, V38, P4115, DOI 10.1016/0006-2952(89)90693-X; HEINEMANN V, 1990, MOL PHARMACOL, V38, P567; HUANG P, 1991, CANCER RES, V51, P6110; HUANG P, 1990, J BIOL CHEM, V265, P16617; ITO M, 1990, J BIOL CHEM, V265, P6954; JACKSON RC, 1978, J BIOL CHEM, V253, P7440; JENH CH, 1985, MOL CELL BIOL, V5, P2527, DOI 10.1128/MCB.5.10.2527; JOHNSON LF, 1982, EXP CELL RES, V138, P79, DOI 10.1016/0014-4827(82)90093-3; KARLE JM, 1983, CANCER LETT, V19, P147, DOI 10.1016/0304-3835(83)90148-9; KUCERA R, 1986, EXP CELL RES, V167, P417, DOI 10.1016/0014-4827(86)90182-5; LEEDS JM, 1987, MOL CELL BIOL, V7, P532, DOI 10.1128/MCB.7.1.532; MATHERLY LH, 1989, ANAL BIOCHEM, V182, P338, DOI 10.1016/0003-2697(89)90605-2; MATHEWS CK, 1992, BIOESSAYS, V14, P295, DOI 10.1002/bies.950140502; MATHEWS CK, 1988, TRENDS BIOCHEM SCI, V13, P394, DOI 10.1016/0968-0004(88)90182-X; MAURER HR, 1981, CELL TISSUE KINET, V14, P111, DOI 10.1111/j.1365-2184.1981.tb00516.x; MCINTOSH EM, 1986, MOL CELL BIOL, V6, P1711, DOI 10.1128/MCB.6.5.1711; NEWMAN CN, 1988, MUTAT RES, V200, P201, DOI 10.1016/0027-5107(88)90083-8; NICANDER B, 1985, J BIOL CHEM, V260, P5376; NOGUCHI H, 1983, CELL, V32, P443, DOI 10.1016/0092-8674(83)90464-6; NYGAARD P, 1987, LEUKEMIA RES, V11, P681, DOI 10.1016/0145-2126(87)90002-6; OHNO Y, 1988, CANCER RES, V48, P1494; PEDRALINOY G, 1979, BIOCHEM BIOPH RES CO, V88, P1194, DOI 10.1016/0006-291X(79)91106-9; PELLINIEMI TT, 1980, J CLIN INVEST, V65, P449, DOI 10.1172/JCI109688; PLUCINSKI TM, 1990, MOL PHARMACOL, V38, P114; REDDY GPV, 1982, BIOCHEM BIOPH RES CO, V109, P908, DOI 10.1016/0006-291X(82)92026-5; REDDY GPV, 1980, P NATL ACAD SCI-BIOL, V77, P3312; REDDY GPV, 1983, NATURE, V303, P86; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; ROBERTS D, 1966, BIOCHEMISTRY-US, V5, P3546, DOI 10.1021/bi00875a022; RODE W, 1985, BIOCHEM BIOPH RES CO, V128, P345, DOI 10.1016/0006-291X(85)91685-7; RODE W, 1980, J BIOL CHEM, V255, P1305; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; SPASOKUKOTSKAJA T, 1992, FEBS LETT, V297, P151, DOI 10.1016/0014-5793(92)80348-K; SPYROU G, 1987, J BIOL CHEM, V262, P16425; SPYROU G, 1989, J BIOL CHEM, V264, P960; TANAKA M, 1987, JPN J CANCER RES, V78, P851; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; WANG LM, 1990, CANCER CHEMOTH PHARM, V25, P418, DOI 10.1007/BF00686052; WICKREMASINGHE RG, 1983, FEBS LETT, V159, P175, DOI 10.1016/0014-5793(83)80441-4; XU Y-Z, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P416; XU YZ, 1992, BIOCHEM PHARMACOL, V44, P1819; YALOWICH JC, 1985, BIOCHEM PHARMACOL, V34, P2319, DOI 10.1016/0006-2952(85)90788-9; YOUDALE T, 1975, J CELL PHYSIOL, V86, P495, DOI 10.1002/jcp.1040860306	65	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22363	22368						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226747				2022-12-27	WOS:A1993MD34800029
J	LIU, ZJ; JACOB, ST				LIU, ZJ; JACOB, ST			CHARACTERIZATION OF A PROTEIN THAT INTERACTS WITH THE RAT RIBOSOMAL GENE PROMOTER AND MODULATES RNA-POLYMERASE-I TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-TIF-IA; FRACTIONATED NUCLEAR EXTRACT; UPSTREAM SPACER REGION; ENHANCER ELEMENT; FACTOR E1BF; INITIATION; RDNA; HEPATOMA; BINDING; LIVER	An RNA polymerase I core promoter binding factor (CPBF) was purified to apparent homogeneity from rat adenocarcinoma ascites cells by chromatographic fractionation on a series of columns including an oligodeoxynucleotide affinity column. The final preparation contained two polypeptides with molecular masses of 44,000 and 39,000 daltons. The binding of the factor to the promoter was demonstrated by Southwestern blotting, UV cross-linking and electrophoretic mobility shift assay. The specificity of its binding to the core promoter was confirmed by competitive electrophoretic mobility shift assay using several unlabeled oligo probes in the assay. The addition of increasing amounts of purified CPBF to the in vitro transcription reaction that contains a limiting quantity of the factor resulted in dramatic stimulation of RNA polymerase I (pol I) transcription of rat ribosomal RNA gene. The transcription stimulatory activity associated with the purified CPBF fractions copurified with the core promoter binding activity in an electrophoretic mobility shift assay. Finally, in a reconstitution transcription system which is devoid of the factor and is incapable of ribosomal gene transcription, purified CPBF could trans-activate the pol I promoter. These data indicate that CPBF is a novel pol I promoter binding factor required for ribosomal gene transcription.	CHICAGO MED SCH, DEPT MOLEC BIOL & PHARMACOL, N CHICAGO, IL 60064 USA	Chicago Medical School					NCI NIH HHS [CA 31894] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031894] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BUTTGEREIT D, 1985, NUCLEIC ACIDS RES, V13, P8165, DOI 10.1093/nar/13.22.8165; CAVANAUGH AH, 1984, P NATL ACAD SCI-BIOL, V81, P718, DOI 10.1073/pnas.81.3.718; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DIXIT A, 1987, J BIOL CHEM, V262, P11616; DUCEMAN BW, 1980, BIOCHEM J, V190, P781, DOI 10.1042/bj1900781; GARG LC, 1989, J BIOL CHEM, V264, P220; GHOSH AK, 1993, GENE, V125, P217, DOI 10.1016/0378-1119(93)90332-W; GOKAL PK, 1986, J BIOL CHEM, V261, P2536; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; HOFF CM, 1994, P NATL ACAD SCI USA, V91, P762, DOI 10.1073/pnas.91.2.762; HOFF CM, 1993, BIOCHEM BIOPH RES CO, V190, P747, DOI 10.1006/bbrc.1993.1112; JACOB ST, 1986, MOL CELL BIOCHEM, V70, P11; JACOB ST, 1969, EUR J BIOCHEM, V7, P449; JI Z, 1990, MOL CELL BIOL, V10, P5177, DOI 10.1128/MCB.10.10.5177; KANADOGA JT, 1986, P NATL ACAD SCI USA, V82, P6672; KURL RN, 1985, NUCLEIC ACIDS RES, V13, P89, DOI 10.1093/nar/13.1.89; KURL RN, 1985, P NATL ACAD SCI USA, V82, P1059, DOI 10.1073/pnas.82.4.1059; KURL RN, 1984, P NATL ACAD SCI-BIOL, V81, P6672, DOI 10.1073/pnas.81.21.6672; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; MAGUIRE KA, 1987, J BIOL CHEM, V262, P3932; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16225; MURAMATSU M, 1970, J MOL BIOL, V53, P91; Paule Marvin R., 1993, Gene Expression, V3, P1; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; RUBINSTEIN SJ, 1989, J VIROL, V63, P4689, DOI 10.1128/JVI.63.11.4689-4696.1989; SCHNAPP A, 1990, NUCLEIC ACIDS RES, V18, P1385, DOI 10.1093/nar/18.6.1385; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SCHNAPP A, 1993, MOL CELL BIOL, V13, P6723, DOI 10.1128/MCB.13.11.6723; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; SOLLNERWEBB B, 1991, TRENDS BIOCHEM SCI, V16, P58, DOI 10.1016/0968-0004(91)90025-Q; TANAKA N, 1990, J BIOL CHEM, V265, P13836; TOWER J, 1987, CELL, V50, P873, DOI 10.1016/0092-8674(87)90514-9; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WEBB ML, 1989, MOL ENDOCRINOL, V3, P1861, DOI 10.1210/mend-3-11-1861; WENDLER I, 1988, ANAL BIOCHEM, V172, P29, DOI 10.1016/0003-2697(88)90407-1; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235	38	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16618	16625						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206980				2022-12-27	WOS:A1994NR29600018
J	MAI, XH; ADAMS, MWW				MAI, XH; ADAMS, MWW			INDOLEPYRUVATE FERREDOXIN OXIDOREDUCTASE FROM THE HYPERTHERMOPHILIC ARCHAEON PYROCOCCUS-FURIOSUS - A NEW ENZYME INVOLVED IN PEPTIDE FERMENTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOSTABLE GLUTAMATE-DEHYDROGENASE; IRON-SULFUR PROTEIN; DENITRIFYING PSEUDOMONAS SP; THERMOCOCCUS-LITORALIS; ENTEROBACTER-CLOACAE; PROTEOLYTIC ACTIVITY; LABILE SULFIDE; COENZYME-A; SP-NOV; ARCHAEBACTERIUM	Pyrococcus furiosus is a strictly anaerobic archaeon that grows optimally at 100 degrees C by a fermentative-type metabolism in which complex peptide mixtures such as yeast extract and Tryptone, and also certain sugars, are oxidized to organic acids, H-2 and CO2. Enzymes involved in the utilization of peptides such as proteases, aromatic amino transferases, and glutamate dehydrogenase have been previously purified from this organism. It is shown here that P. furiosus also contains significant cytoplasmic concentrations of a new enzyme termed indolepyruvate ferredoxin oxidoreductase (IOR). This catalyzes the oxidative decarboxylation of aryl pyruvates, which are generated by the transamination of aromatic amino acids, to the corresponding aryl acetyl-CoA. IOR is a tetramer (alpha(2) beta(2)) of two identical subunits (66,000 and 23,000 Da) with a molecular weight of 180,000. The enzyme contains one molecule of thiamine pyrophosphate and four [4Fe-4S](2+,1+) and one [3Fe-4S](0,1+) cluster as determined by iron analyses and EPR spectroscopy. Significant amounts of other metals such as copper and zinc were not detected. IOR was virtually inactive at 25 degrees C and exhibited optimal activity above 90 degrees C (at pH 8.0) and at pH 8.5-10.5 (at 80 degrees C). The enzyme was sensitive to inactivation by O-2, losing 50% of its activity after exposure to air for 20 min at 23 degrees C, and was quite thermostable, with a half-life of activity at 80 degrees C (under anaerobic conditions) of about 80 min. The K-m values (in mu M) for indolepyruvate, p-hydroxyphenylpyruvate, phenylpyruvate, CoASH, and P. furiosus ferredoxin, the physiological electron carrier, were 250, 110, 90, 17, and 48, respectively. IOR was inhibited by KCN (apparent K-i = 7.5 mM), but not by CO (1 atm). An enzyme analogous to IOR has not been reported previously. Curiously, it has few properties in common with the pyruvate ferredoxin oxidoreductase of P. furiosus, even though the two enzymes catalyze virtually identical reactions. In fact, of known ketoacid oxidoreductases, the catalytic mechanism of IOR appears to be most similar to that of the pyruvate ferrodoxin oxidoreductase from the hyperthermophilic bacterium Thermotoga maritima.	UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; UNIV GEORGIA,CTR METALLOENZYME STUDIES,ATHENS,GA 30602	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia				Adams, Michael/0000-0002-9796-5014				ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; ADAMS MWW, 1990, FEMS MICROBIOL LETT, V75, P219, DOI 10.1016/0378-1097(90)90533-V; ADAMS MWW, 1994, IN PRESS FEMS MICROB; ADAMS MWW, 1992, AM CHEM SOC SERIES, V498; ANDREOTTI G, 1994, EUR J BIOCHEM, V220, P543, DOI 10.1111/j.1432-1033.1994.tb18654.x; AONO S, 1989, J BACTERIOL, V171, P3433, DOI 10.1128/jb.171.6.3433-3439.1989; BARKER HA, 1981, ANNU REV BIOCHEM, V50, P23, DOI 10.1146/annurev.bi.50.070181.000323; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; BLAMEY JM, 1993, BIOCHIM BIOPHYS ACTA, V1161, P19, DOI 10.1016/0167-4838(93)90190-3; BLAMEY JM, 1994, BIOCHEMISTRY-US, V33, P1000, DOI 10.1021/bi00170a019; BLUMENTALS II, 1990, APPL ENVIRON MICROB, V56, P1992, DOI 10.1128/AEM.56.7.1992-1998.1990; BRYANT FO, 1989, J BIOL CHEM, V264, P5070; CHEN JS, 1977, ANAL BIOCHEM, V79, P157, DOI 10.1016/0003-2697(77)90390-6; CONNARIS H, 1991, J GEN MICROBIOL, V137, P1193, DOI 10.1099/00221287-137-5-1193; CONSALVI V, 1991, EUR J BIOCHEM, V202, P1189, DOI 10.1111/j.1432-1033.1991.tb16489.x; Dagley S., 1986, BACTERIA, V10, P527; DIRUGGIERO J, 1993, J BIOL CHEM, V268, P17767; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EGGEN R, 1990, FEMS MICROBIOL LETT, V71, P17; ELSDEN SR, 1976, ARCH MICROBIOL, V107, P283, DOI 10.1007/BF00425340; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; Fujioka M, 1970, METHODS ENZYMOLOGY A, V17, P585; KELLY RM, 1988, BIOTECHNOL PROGR, V4, P47, DOI 10.1002/btpr.5420040202; KOGA J, 1992, J BIOL CHEM, V267, P15823; KOGA J, 1991, MOL GEN GENET, V226, P10, DOI 10.1007/BF00273581; LOVENBERG W, 1963, J BIOL CHEM, V238, P3899; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA K, 1994, APPL ENVIRON MICROB, V60, P562, DOI 10.1128/AEM.60.2.562-568.1994; MAYHEW SG, 1978, EUR J BIOCHEM, V85, P535, DOI 10.1111/j.1432-1033.1978.tb12269.x; MOHAMED MES, 1993, ARCH MICROBIOL, V159, P563, DOI 10.1007/BF00249036; MOHAMED MES, 1993, ARCH MICROBIOL, V159, P554, DOI 10.1007/BF00249035; MUKUND S, 1991, J BIOL CHEM, V266, P14208; MUKUND S, 1990, J BIOL CHEM, V265, P11508; MUKUND S, 1993, J BIOL CHEM, V268, P13592; NEUNER A, 1990, ARCH MICROBIOL, V153, P205, DOI 10.1007/BF00247822; OHSHIMA T, 1993, BIOSCI BIOTECH BIOCH, V57, P945, DOI 10.1271/bbb.57.945; Penttinen H K, 1979, Methods Enzymol, V62, P58, DOI 10.1016/0076-6879(79)62190-0; PLAGA W, 1992, EUR J BIOCHEM, V205, P391, DOI 10.1111/j.1432-1033.1992.tb16792.x; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; ROBB FT, 1992, BIOCHIM BIOPHYS ACTA, V1120, P267, DOI 10.1016/0167-4838(92)90247-B; SCHAFER T, 1992, ARCH MICROBIOL, V158, P188, DOI 10.1007/BF00290815; SMITH ET, 1994, BIOCHEMISTRY-US, V33, P1008, DOI 10.1021/bi00170a020; SNOWDEN LJ, 1992, APPL ENVIRON MICROB, V58, P1134, DOI 10.1128/AEM.58.4.1134-1141.1992; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; STETTER KO, 1982, NATURE, V300, P258, DOI 10.1038/300258a0; STETTER KO, 1986, THERMOPHILES GENERAL, P39; WEBER K, 1972, METHOD ENZYMOL, V26, P2; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	49	108	108	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16726	16732						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206994				2022-12-27	WOS:A1994NR29600035
J	VARRAULT, A; LENGUYEN, D; MCCLUE, S; HARRIS, B; JOUIN, P; BOCKAERT, J				VARRAULT, A; LENGUYEN, D; MCCLUE, S; HARRIS, B; JOUIN, P; BOCKAERT, J			5-HYDROXYTRYPTAMINE(1A) RECEPTOR SYNTHETIC PEPTIDES - MECHANISMS OF ADENYLYL-CYCLASE INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; PHOSPHOLIPID-VESICLES; CYTOPLASMIC DOMAINS; REGULATORY PROTEINS; LIGAND-BINDING; ALPHA; SITE; GI; MASTOPARAN; ACTIVATION	The 5-hydroxytryptamine(1A) receptor (5-HT(1A)R) is a G-protein-coupled receptor negatively coupled to adenylyl cyclase (AC). We have studied the functional domains of 5-HT(1A)R using synthetic peptides to block or mimic receptor function. The entire second intracellular loop (5-HT(1A)R-i(2)) and the carboxyl end of the third intracellular loop (5-HT(1A)R-i(3)-C) strongly inhibited forskolin-stimulated AC activity. These effects were not additive with those of 5-HT. Like 5-HT, the peptides 5-HT(1A)R-i(3)-C and -i(2) weakly inhibited AlF4- and Mn2+ stimulated AC activity. 5-HT(1A)R binding assays indicated that peptides could interact with the same G-protein pool as the 5-HT(1A)R. 5-HT(1A)R-i(3)-C- and -i(2)-stimulated [S-35]guanosine 5'-O-(thiotriphosphate) binding on G(o)/G(i) proteins. Only 5-HT(1A)R-i(3)-C partially adopted an alpha-helical conformation in solution. These data show that different domains in the 5-HT(1A)R second and third intracellular loops can couple to and activate G(i) proteins in order to mediate AC inhibition. Peptide-induced AC inhibition was not sensitive to pertussis toxin as opposed to the 5-HT(1A)R-mediated effect. Our data show that the 5-HT(1A)R and the 5-HT(1A)R peptides activate G(i) proteins in a slightly different manner.	CNRS,UPR 9023,F-34094 MONTPELLIER 05,FRANCE; MARION MERRELL DOW RES INST,STRASBOURG RES CTR,F-67046 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS)								ASANO T, 1984, J BIOL CHEM, V259, P9351; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BOCKAERT J, 1987, N-S ARCH PHARMACOL, V335, P588; BUSHFIELD M, 1990, MOL PHARMACOL, V38, P848; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; COTE TE, 1984, J BIOL CHEM, V259, P8693; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DEVIVO M, 1986, J PHARMACOL EXP THER, V238, P248; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; KISS Z, 1990, J BIOL CHEM, V265, P7345; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LENGUYEN D, 1987, J CHEM SOC PERK T 1, P1915, DOI 10.1039/p19870001915; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MALEK D, 1993, FEBS LETT, V325, P215; MARGALIT H, 1987, J IMMUNOL, V138, P2213; MUNCH G, 1991, EUR J BIOCHEM, V198, P357, DOI 10.1111/j.1432-1033.1991.tb16023.x; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1991, BIOCHEM BIOPH RES CO, V179, P10, DOI 10.1016/0006-291X(91)91326-8; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; OPPI C, 1992, P NATL ACAD SCI USA, V89, P8268, DOI 10.1073/pnas.89.17.8268; ROSS EM, 1977, J BIOL CHEM, V252, P5761; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; SMIGEL M, 1984, ADV CYCLIC NUCL PROT, V17, P1; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; VARRAULT A, 1992, MOL BIOL CELL, V3, P961, DOI 10.1091/mbc.3.9.961; VARRAULT A, 1991, J PHARMACOL EXP THER, V257, P433; VOSS T, 1993, J BIOL CHEM, V268, P4637; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WONG SKF, 1990, J BIOL CHEM, V265, P6219	40	56	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16720	16725						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206993				2022-12-27	WOS:A1994NR29600034
J	BHARADWAJ, D; ROY, MS; BOSE, D; HATI, RN				BHARADWAJ, D; ROY, MS; BOSE, D; HATI, RN			A NEW BLOOD-COAGULATING PROTEASE IN MITOCHONDRIAL-MEMBRANES OF RAT SUBMAXILLARY-GLANDS - PURIFICATION AND CHARACTERIZATION OF PROTEASE AND ITS BLOOD-COAGULATING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR; SUBMANDIBULAR-GLAND; BOVINE PROTHROMBIN; ACTIVATION; KININOGENASE; MECHANISM; THROMBIN; ENZYMES; THROMBOPLASTIN; KALLIKREINS	An integral membrane protease was solubilized and purified to homogeneity from rat submaxillary mitochondria. The purified enzyme could coagulate rabbit plasma. The molecular mass of the enzyme is 22 kDa on SDS-polyacrylamide gel electrophoresis under reducing conditions and 24 kDa on gel filtration on a Sephadex G-100 column. Its isoelectric point is 4.2-4.25. Enzyme activity is strongly inhibited by diisopropyl fluorophosphate, soybean trypsin inhibitor, benzamidine, aprotinin, and antipain, suggesting the enzyme as a serine protease. Its pH optimum for activity is 8.5. Zn2+ is strongly inhibitory; at 1 mM concentration it produced 72% inhibition. The enzyme is active toward different synthetic substrates (p-nitroanilide derivatives) containing Arg at the P, position with blocked NH, terminus. K-cat/K-m was highest with the substrate N-Bz-Pro-Arg-pNa (where Bz is benzoyl and pNA is paranitroanilide). The purified enzyme coagulates rabbit plasma in a dose-dependent manner. Plasma coagulation by the enzyme is completely blocked in the presence of aprotinin or soybean trypsin inhibitor, suggesting that protease activity is required for this coagulation reaction. Antibody raised against the purified enzyme inhibits the plasma coagulation initiated by the enzyme. The enzyme can correct the prolonged clotting time of factor X deficient human plasma but is unable to convert purified fibrinogen to fibrin clots, indicating factor X(a)-like activity of the enzyme. The enzyme has the ability to activate prothrombin. Several properties of the enzyme distinguish it from other reported submaxillary proteases.	INDIAN INST CHEM BIOL,CALCUTTA 700032,W BENGAL,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)				Bharadwaj, Dwaipayan/0000-0001-5268-8482				ARONSON DL, 1966, BIOCHEMISTRY-US, V5, P2635, DOI 10.1021/bi00872a022; BARLAS A, 1987, FEBS LETT, V218, P266, DOI 10.1016/0014-5793(87)81059-1; BARRETT AJ, 1990, BIOCHEM J, V271, P701, DOI 10.1042/bj2710701; Beynon R.J., 1989, PROTEOLYTIC ENZYMES, P241; BJORKLID E, 1973, BIOCHEM BIOPH RES CO, V55, P969, DOI 10.1016/0006-291X(73)91237-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDTZAEG P, 1976, BRIT J PHARMACOL, V56, P153; CAPORALE LH, 1981, J IMMUNOL, V126, P1963; COHEN S, 1960, P NATL ACAD SCI USA, V46, P302, DOI 10.1073/pnas.46.3.302; ERLANGER BF, 1961, ARCH BIOCHEM BIOPHYS, V95, P271, DOI 10.1016/0003-9861(61)90145-X; ESNOUF MP, 1968, ADV ENZYMOL RAMB, V30, P255; ESNOUF MP, 1984, HUMAN BLOOD COAGULAT, P46; GREENE LA, 1969, BIOCHEMISTRY-US, V8, P3735, DOI 10.1021/bi00837a037; IKEDA M, 1984, HYPERTENSION, V6, P222, DOI 10.1161/01.HYP.6.2_Pt_1.222; IKENO K, 1986, J BIOCHEM, V99, P1219, DOI 10.1093/oxfordjournals.jbchem.a135585; JOBIN F, 1966, NATURE, V211, P873, DOI 10.1038/211873b0; KAMIGUTI AS, 1985, TOXICON, V23, P383, DOI 10.1016/0041-0101(85)90022-4; KAMIIKE W, 1989, CLIN CHIM ACTA, V185, P265, DOI 10.1016/0009-8981(89)90216-7; KATO H, 1987, J BIOCHEM, V102, P1389, DOI 10.1093/oxfordjournals.jbchem.a122185; KHULLAR M, 1986, BIOCHEMISTRY-US, V25, P1851, DOI 10.1021/bi00356a002; KUROSAWA N, 1989, ELECTROPHORESIS, V10, P189, DOI 10.1002/elps.1150100307; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTTENBERG R, 1981, METHOD ENZYMOL, V80, P341; MANN KG, 1971, J BIOL CHEM, V246, P6106; MANN KG, 1976, METHOD ENZYMOL, V45, P127; MORITA T, 1977, J BIOCHEM-TOKYO, V82, P1495, DOI 10.1093/oxfordjournals.jbchem.a131840; MORITA T, 1976, J BIOCHEM, V79, P1089, DOI 10.1093/oxfordjournals.jbchem.a131150; NEMERSON Y, 1973, P NATL ACAD SCI USA, V70, P310, DOI 10.1073/pnas.70.2.310; ORLOWSKI M, 1987, ARCH BIOCHEM BIOPHYS, V254, P156, DOI 10.1016/0003-9861(87)90091-9; OWEN WG, 1974, J BIOL CHEM, V249, P594; PITLICK FA, 1975, J CLIN INVEST, V55, P175, DOI 10.1172/JCI107908; POWERS CA, 1982, J BIOL CHEM, V257, P5594; Rickwood D, 1987, MITOCHONDRIA PRACTIC, P3; RIEKKINEN PJ, 1967, ENZYMOLOGIA, V32, P97; RIEKKINEN PJ, 1966, BIOCHIM BIOPHYS ACTA, V118, P604, DOI 10.1016/S0926-6593(66)80101-7; ROY MS, 1991, CURR SCI INDIA, V60, P325; ROY MS, 1991, BIOCH INT, V25, P1035; SCHACHTER M, 1979, PHARMACOL REV, V31, P1; SCHACHTER M, 1969, PHYSIOL REV, V49, P509, DOI 10.1152/physrev.1969.49.3.509; SCHACHTER M, 1980, PHARMACOL REV, V31, P1; SCHILLER PW, 1976, CIRC RES, V39, P629, DOI 10.1161/01.RES.39.5.629; SCHMIDT FW, 1989, CLIN CHIM ACTA, V185, P253, DOI 10.1016/0009-8981(89)90215-5; SCHWERT GW, 1955, BIOCHIM BIOPHYS ACTA, V16, P570, DOI 10.1016/0006-3002(55)90280-8; SERVER AC, 1976, J BIOL CHEM, V251, P165; SINGER T P, 1957, Methods Biochem Anal, V4, P307, DOI 10.1002/9780470110201.ch9; TURKINGTON RW, 1971, CANCER RES, V31, P252; ZELDIS SM, 1972, SCIENCE, V175, P766, DOI 10.1126/science.175.4023.766	47	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16229	16235						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206926				2022-12-27	WOS:A1994NQ72900044
J	YAO, M; HATAHET, Z; MELAMEDE, RJ; KOW, YW				YAO, M; HATAHET, Z; MELAMEDE, RJ; KOW, YW			PURIFICATION AND CHARACTERIZATION OF A NOVEL DEOXYINOSINE-SPECIFIC ENZYME, DEOXYINOSINE 3' ENDONUCLEASE, FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-DNA GLYCOSYLASE; BASE-PAIRS; CRYSTAL-STRUCTURE; DAMAGE; URACIL; RESIDUES; EXCISION; PROTEINS; RELEASE; INVITRO	We have purified a novel endonuclease from Escherichia coli that recognizes deoxyinosine, a deamination product of deoxyadenosine in DNA. This activity, which we named deoxyinosine 3' endonuclease, is different from the known hypoxanthine DNA N-glycosylases which have been partially characterized in E. coli and other organisms. The enzyme was purified 24,800-fold to apparent homogeneity. SDS- and activity PAGE analyses indicate that the enzyme has an apparent molecular mass of 25 kDa. Deoxyinosine 3' endonuclease recognized deoxyinosine in both single- and double-stranded DNA but exhibited a 4-fold preference for double stranded over single-stranded DNA In addition to deoxyinosine, the enzyme recognized urea residues and AP sites. Deoxyinosine 3' endonuclease has an obligatory requirement for Mg2+, but other cations such as Co(2+)and Mn2+ could partially replace Mg2+. The optimal pH for deoxyinosine 3' endonuclease was around 7.5. In contrast to most of the known repair enzymes, deoxyinosine 3' endonuclease makes an incision at the second phosphodiester bond 3' to a deoxyinosine or AP site, leaving behind the intact lesion on the nicked DNA. Therefore, deoxyinosine 3' endonuclease recognizes, but does not remove, the lesion from the DNA molecule. The biological significance of this novel activity is discussed with reference to other repair activities in E. coli.	UNIV VERMONT,MARKEY CTR MOLEC GENET,DEPT MICROBIOL & MOLEC GENET,BURLINGTON,VT 05405	University of Vermont					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037216] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 37216] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1985, DNA REPAIR; ASHARA H, 1989, BIOCHEMISTRY-US, V28, P4444; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; CORFIELD PWR, 1987, NUCLEIC ACIDS RES, V15, P7935, DOI 10.1093/nar/15.19.7935; CRUSE WBT, 1989, NUCLEIC ACIDS RES, V17, P55, DOI 10.1093/nar/17.1.55; DEHAZYA P, 1986, CANCER RES, V46, P3756; DIANOV G, 1991, NUCLEIC ACIDS RES, V19, P3829, DOI 10.1093/nar/19.14.3829; DUNCAN BK, 1984, GENE, V28, P211, DOI 10.1016/0378-1119(84)90258-0; EFTEDAL I, 1993, NUCLEIC ACIDS RES, V21, P2095, DOI 10.1093/nar/21.9.2095; HARADA K, 1993, NUCLEIC ACIDS RES, V21, P2287, DOI 10.1093/nar/21.10.2287; HAROSH I, 1988, J BIOL CHEM, V263, P3328; HATAHET Z, 1989, BIOCHEM CELL BIOL, V67, P632, DOI 10.1139/o89-095; HILLPERKINS M, 1986, MUTAT RES, V162, P153, DOI 10.1016/0027-5107(86)90081-3; KARRAN P, 1980, BIOCHEMISTRY-US, V19, P6005, DOI 10.1021/bi00567a010; KARRAN P, 1978, J BIOL CHEM, V253, P5877; KLAND MJ, 1957, J AM CHEM SOC, V79, P6187, DOI 10.1021/ja01580a022; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; KOWALSKI D, 1979, ANAL BIOCHEM, V93, P346, DOI 10.1016/S0003-2697(79)80090-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; LONGLEY MJ, 1993, METHOD ENZYMOL, V218, P587; MYRNES B, 1982, NUCLEIC ACIDS RES, V10, P3693, DOI 10.1093/nar/10.12.3693; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; POEHLING HM, 1981, ELECTROPHORESIS, V2, P141, DOI 10.1002/elps.1150020304; PONNAMPERUMA C, 1961, SCIENCE, V134, P113, DOI 10.1126/science.134.3472.113; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SCHUSTER H., 1959, BIOCHEM AND BIOPHYS RES COMMUNICATIONS, V2, P320; Shapiro R, 1981, CHROMOSOME DAMAGE RE, P3; SNOWDEN A, 1990, BIOCHEMISTRY-US, V29, P7251, DOI 10.1021/bi00483a013; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WALLACE SS, 1981, DNA REPAIR LABORATOR, V1, P113; WEISS B, 1981, ENZYMES, V14, P203; XUAN JC, 1992, NUCLEIC ACIDS RES, V20, P5457, DOI 10.1093/nar/20.20.5457	36	104	115	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16260	16268						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206931				2022-12-27	WOS:A1994NQ72900049
J	AXELROD, A; GIBBS, VC; GOEDDEL, DV				AXELROD, A; GIBBS, VC; GOEDDEL, DV			THE INTERFERON-GAMMA RECEPTOR EXTRACELLULAR DOMAIN - NONIDENTICAL REQUIREMENTS FOR LIGAND-BINDING AND SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-GAMMA; EXPRESSION; CELLS; CHROMOSOME-21; CLONING; CDNA; IDENTIFICATION; SENSITIVITY; TRANSDUCER; AFFINITY	The human interferon-gamma receptor (hIFN-gamma R) extracellular domain interacts in a species-specific manner with both its ligand and an accessory factor encoded on human chromosome 21. Mutant interferon-gamma receptors were constructed by homolog-scanning mutagenesis, replacing segments of the human extracellular domain with the corresponding murine sequence. Replacement of hIFN-gamma R amino acids 1-100, 100-132, 134-183, or 183-245 abolished binding to human interferon-gamma (hIFN-gamma). However, replacement of hIFN-gamma R amino acids 134-209, 183-209, 134-153, 153-167, or 167-183 or deletion of residues 156-165 affected hIFN-gamma binding only partially or not at all. Receptors that bound hIFN-gamma were tested for their ability to signal a functional response, induction of major histocompatibility complex class I antigen expression. Replacement of residues 134-209 greatly reduced the ability of the receptor to signal. This signaling defect could not be attributed solely to a reduction in affinity for ligand and could not be localized to any subregion.	GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; UNIV CALIF SAN FRANCISCO,VET ADM MED CTR,DEPT SURG,SAN FRANCISCO,CA 94121	Roche Holding; Genentech; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)								AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CAO Y, 1990, Technique (Philadelphia), V2, P109; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DEVOS AM, 1992, SCIENCE, V248, P739; DIGHE AS, 1993, J BIOL CHEM, V268, P10645; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P13268; FOUNTOULAKIS M, 1991, J BIOL CHEM, V266, P14970; FOUNTOULAKIS M, 1992, EUR J BIOCHEM, V208, P7811; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; GRIGGS ND, 1992, J IMMUNOL, V149, P517; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HIBINO Y, 1991, J BIOL CHEM, V266, P6948; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; IMLER JL, 1992, EMBO J, V11, P2047, DOI 10.1002/j.1460-2075.1992.tb05262.x; JANSSEN JWG, 1986, CYTOMETRY, V7, P411, DOI 10.1002/cyto.990070504; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KUMAR CS, 1989, J BIOL CHEM, V264, P17939; LUTFALLA G, 1993, GENOMICS, V16, P366, DOI 10.1006/geno.1993.1199; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P8248; RAZIUDDIN A, 1984, P NATL ACAD SCI-BIOL, V81, P5504, DOI 10.1073/pnas.81.17.5504; SHEEHAN KCF, 1988, J IMMUNOL, V140, P4231; STUBER D, 1993, BIOCHEMISTRY-US, V32, P2423; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; WANG HM, 1992, J BIOL CHEM, V267, P979; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	39	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15533	15539						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195198				2022-12-27	WOS:A1994NP51300024
J	IOBST, ST; DRICKAMER, K				IOBST, ST; DRICKAMER, K			BINDING OF SUGAR LIGANDS TO CA2+-DEPENDENT ANIMAL LECTINS .2.. GENERATION OF HIGH-AFFINITY GALACTOSE BINDLNG BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CDNA SEQUENCE; CRYSTAL-STRUCTURE; PROTEIN; CARBOHYDRATE; ACETYLGALACTOSAMINE; CONSERVATION; HOMOLOGY; COMPLEX; LACTOSE; DOMAIN	Changes have been introduced into the Ca2+-dependent carbohydrate-recognition domain (CRD) of rat serum mannose-binding protein by site-directed mutagenesis to model the binding sites of homologous galactose-binding CRDs. Binding assays reveal that galactose-binding activity nearly identical to that of the CRD from the asialoglycoprotein receptor can be introduced into the mannose-binding site by 3 single amino acid changes and insertion of a segment of 5 amino acids. Separate changes are required to establish high-affinity binding to galactose and create high selectivity by exclusion of mannose from the binding site. The mutagenesis studies and NMR analysis of sugar CRD titrations demonstrate that an important component of high-affinity galactose binding is interaction between the B face of the sugar and tryptophan. The binding properties of the C-type CRD from the cartilage proteoglycan, aggrecan, can also be modeled based on the mannose-binding CRD framework. This lower affinity binding site involves stacking of a phenylalanine residue against the sugar ligand.	COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA	Columbia University					FOGARTY INTERNATIONAL CENTER [F06TW001925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042628] Funding Source: NIH RePORTER; FIC NIH HHS [TW01925] Funding Source: Medline; NIGMS NIH HHS [GM42628] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; CONNOLLY DT, 1982, J BIOL CHEM, V257, P939; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1993, PROG NUCLEIC ACID RE, V45, P207, DOI 10.1016/S0079-6603(08)60870-3; DWEK RA, 1973, NUCLEAR MAGNETIC RES; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HOLMSKOV U, 1993, J BIOL CHEM, V268, P10120; IOBST ST, 1994, J BIOL CHEM, V269, P15505; KAWASAKI T, 1986, CARBOHYD RES, V151, P197, DOI 10.1016/S0008-6215(00)90340-9; LEE RT, 1991, J BIOL CHEM, V266, P4810; LEE RT, 1982, BIOCHEMISTRY-US, V21, P1045, DOI 10.1021/bi00534a034; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; PEKINS SJ, 1980, BIOCHEMISTRY-US, V19, P245; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; RAUCH U, 1992, J BIOL CHEM, V267, P19536; SALEQUE S, 1993, GLYCOBIOLOGY, V3, P185, DOI 10.1093/glycob/3.2.185; SANFORD JP, 1990, BIOCHIM BIOPHYS ACTA, V1087, P259, DOI 10.1016/0167-4781(90)90216-O; SASTRY K, 1991, J IMMUNOL, V147, P692; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; TAKEZAWA R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P220, DOI 10.1016/0167-4781(93)90300-3; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	27	135	142	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15512	15519						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195195				2022-12-27	WOS:A1994NP51300021
J	ANDERSON, PM; KORTE, JJ; HOLCOMB, TA; CHO, YG; SON, CM; SUNG, YC				ANDERSON, PM; KORTE, JJ; HOLCOMB, TA; CHO, YG; SON, CM; SUNG, YC			FORMATION OF INTERSUBUNIT DISULFIDE BONDS AND PROPERTIES OF THE SINGLE HISTIDINE AND CYSTEINE RESIDUES IN EACH SUBUNIT RELATIVE TO THE DECAMERIC STRUCTURE OF CYANASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CARBONIC-ANHYDRASE	Reaction of the single cysteine residue in each subunit of cyanase with certain SH reagents gives an active decameric derivative that dissociates reversibly to an inactive dimer derivative (Anderson, P. M., Johnson, W. V., Korte, J. J., Xiong, X., Sung, Y.-c., and Fuchs, J. A. (1988) J. Biol. Chem. 263, 5674-5680). Reaction of mixed disulfide dimer derivatives of cyanase with dithiothreitol at 0 degrees C results in formation of a disulfide bond between the subunits in the dimer. The disulfide dimer was inactive and did not associate to a decamer; the intersubunit disulfide bond could not be formed when the dimers were associated as a decamer. The two SH groups apparently are in close proximity to each other in the dissociated dimer but not when the dimer is associated to a decamer. Substitution of glycine for the cysteine residue or of tyrosine, asparagine, glycine, valine, or leucine for the single histidine residue in each subunit gave mutant enzymes that were active. However, H113N, H113Y, and C83G were unstable at low temperature and/or ionic strength, dissociating reversibly to an inactive dimer. Efficient reassociation required the presence of bicarbonate or cyanate analog. The results are consistent with a proposed single site per subunit model explaining apparent half site binding of substrates and the requirement of decameric structure for activity.	POHANG INST SCI & TECHNOL,DEPT LIFE SCI,POHANG 790600,SOUTH KOREA	Pohang University of Science & Technology (POSTECH)	ANDERSON, PM (corresponding author), UNIV MINNESOTA,DEPT BIOCHEM & MOLEC BIOL,10 UNIV DR,DULUTH,MN 55812, USA.				NIGMS NIH HHS [GM33842] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033842] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1987, BIOCHEMISTRY-US, V26, P3938, DOI 10.1021/bi00387a029; ANDERSON PM, 1988, J BIOL CHEM, V263, P5674; ANDERSON PM, 1980, BIOCHEMISTRY-US, V19, P2882, DOI 10.1021/bi00554a010; ANDERSON PM, 1986, BIOCHEMISTRY-US, V25, P1621, DOI 10.1021/bi00355a026; CHIN CCQ, 1983, J BIOL CHEM, V258, P276; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; GUILLOTON MB, 1992, J BIOL CHEM, V267, P3731; GUILLOTON MB, 1993, J BACTERIOL, V175, P1443, DOI 10.1128/JB.175.5.1443-1451.1993; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; IYER KS, 1973, J BIOL CHEM, V248, P707; JOHNSON WV, 1987, J BIOL CHEM, V262, P9021; KUNKEL TA, 1985, P NATL ACAD SCI USA, V80, P3963; KYUNG HK, 1987, J MOL BIOL, V198, P137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTLE RM, 1987, J BIOL CHEM, V262, P10120; OTWINOWSKI Z, 1991, 4 P INT M CRYST BIOL, P54; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUNG YC, 1987, J BACTERIOL, V169, P5224, DOI 10.1128/jb.169.11.5224-5230.1987; TAUSSIG A, 1965, CAN J BIOCHEM CELL B, V43, P1063, DOI 10.1139/o65-119	20	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15036	15045						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195141				2022-12-27	WOS:A1994NP73800032
J	ONO, S; MINAMI, N; ABE, H; OBINATA, T				ONO, S; MINAMI, N; ABE, H; OBINATA, T			CHARACTERIZATION OF A NOVEL COFILIN ISOFORM THAT IS PREDOMINANTLY EXPRESSED IN MAMMALIAN SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN DEPOLYMERIZING FACTOR; BINDING PROTEINS; PORCINE BRAIN; NUCLEOTIDE-SEQUENCE; NUCLEAR TRANSPORT; HUMAN VILLIN; CHICKEN; CDNA; NITROCELLULOSE; POLYMERIZATION	Cofilin is an actin-modulating protein of 20 kDa, which is widely distributed throughout muscle and nonmuscle cells. By means of immunoblotting combined with two-dimensional gel electrophoresis, we found that two cofilin variants, muscle type (M-type) and nonmuscle type (NM-type), exist in mammals, while a single isoform exists in chickens. During in vitro myogenesis of mouse C2 cells, expression of the M-type cofilin was upregulated. To better understand the nature of the M-type cofilin, we cloned cDNAs encoding M-type cofilin from the cDNA library of C2 myotubes and determined the entire sequence. The deduced peptide sequence contained a nuclear localization signal and a putative actin-binding sequence as reported in NM-type cofilin. The sequence showed 81% identity in the amino acid residues with the mouse NM-type cofilin sequence and, interestingly, higher homology (96% identity) with that of chicken cofilin. The mRNA encoding M-type cofilin, though it contains two variants that differ in the size of their 3'-non coding sequences, was detected predominantly in heart, skeletal muscle, C2 myotubes, and testis by Northern blotting, while the mRNA for NM-type cofilin was seen in a variety of non-muscle tissues. The presence of the muscle type isoform of cofilin strongly suggests that cofilin is deeply involved in the regulation of actin function not only in non-muscle cells but also in muscle cells.	CHIBA UNIV, FAC SCI, GRAD SCH SCI & TECHNOL, INAGE KU, CHIBA 263, JAPAN; CHIBA UNIV, FAC SCI, DEPT BIOL, INAGE KU, CHIBA 263, JAPAN	Chiba University; Chiba University			Ono, Shoichiro/A-6475-2015	Ono, Shoichiro/0000-0002-4763-0398				ABE H, 1990, BIOCHEMISTRY-US, V29, P7420, DOI 10.1021/bi00484a010; ABE H, 1989, J BIOCHEM-TOKYO, V106, P696, DOI 10.1093/oxfordjournals.jbchem.a122919; ABE H, 1993, EXP CELL RES, V206, P1, DOI 10.1006/excr.1993.1113; ABE H, 1989, J BIOCHEM-TOKYO, V106, P172, DOI 10.1093/oxfordjournals.jbchem.a122810; ADAMS ME, 1990, BIOCHEMISTRY-US, V29, P7414, DOI 10.1021/bi00484a009; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; BAMBURG JR, 1987, J CELL BIOL, V105, P2817, DOI 10.1083/jcb.105.6.2817; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2302; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEBLAS AL, 1983, ANAL BIOCHEM, V133, P214, DOI 10.1016/0003-2697(83)90245-2; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HAYAKAWA K, 1993, J BIOCHEM-TOKYO, V114, P582, DOI 10.1093/oxfordjournals.jbchem.a124220; IIDA K, 1992, CELL STRUCT FUNCT, V17, P39, DOI 10.1247/csf.17.39; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEKAWA S, 1984, J BIOCHEM-TOKYO, V95, P377, DOI 10.1093/oxfordjournals.jbchem.a134618; MATSUZAKI F, 1988, J BIOL CHEM, V263, P11564; MIKAWA T, 1981, J BIOCHEM-TOKYO, V89, P1951, DOI 10.1093/oxfordjournals.jbchem.a133397; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; MORIYAMA K, 1992, J BIOL CHEM, V267, P7240; MORIYAMA K, 1990, NUCLEIC ACIDS RES, V18, P3053, DOI 10.1093/nar/18.10.3053; MORIYAMA K, 1990, J BIOL CHEM, V265, P5771; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P6624, DOI 10.1021/bi00344a049; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; OBINATA T, 1993, INT REV CYTOL, V143, P153; OBINATA T, 1991, INT CONGR SER, P235; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OGAWA K, 1990, NUCLEIC ACIDS RES, V18, P7169, DOI 10.1093/nar/18.23.7169; OHSHIMA S, 1989, J BIOCHEM-TOKYO, V105, P855, DOI 10.1093/oxfordjournals.jbchem.a122765; OHTA Y, 1989, J BIOL CHEM, V264, P16143; ONO S, 1993, J MUSCLE RES CELL M, V14, P195, DOI 10.1007/BF00115454; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; PRINGAULT E, 1991, P NATL ACAD SCI USA, V88, P10811, DOI 10.1073/pnas.88.23.10811; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINAGAWA Y, 1993, ZOOL SCI, V10, P611; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAY M, 1990, NATURE, V344, P292, DOI 10.1038/344292a0; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YONEZAWA N, 1989, EUR J BIOCHEM, V183, P235, DOI 10.1111/j.1432-1033.1989.tb14918.x; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YONEZAWA N, 1987, CELL STRUCT FUNCT, V12, P443, DOI 10.1247/csf.12.443; YONEZAWA N, 1991, J BIOL CHEM, V266, P10485	45	93	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15280	15286						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195165				2022-12-27	WOS:A1994NP73800064
J	OSSORIO, PN; DUBREMETZ, JF; JOINER, KA				OSSORIO, PN; DUBREMETZ, JF; JOINER, KA			A SOLUBLE SECRETORY PROTEIN OF THE INTRACELLULAR PARASITE TOXOPLASMA-GONDII ASSOCIATES WITH THE PARASITOPHOROUS VACUOLE MEMBRANE THROUGH HYDROPHOBIC INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE SURFACE-ANTIGEN; INDUCED PHASE-SEPARATION; HOST-CELL INVASION; PLASMODIUM-FALCIPARUM; MONOCLONAL-ANTIBODIES; DENSE GRANULES; TRITON X-114; INFECTED ERYTHROCYTES; LOCALIZATION; RHOPTRIES	The obligate intracellular parasite Toxoplasma gondii resides within a specialized, nonfusogenic vacuole termed the parasitophorous vacuole. We are exploring the hypothesis that parasite proteins contained in dense core granules and secreted into the vacuole after cell invasion contribute to the modification of the parasitophorous vacuole membrane (PVM). The dense granule protein GRA3 associates preferentially with the PVM. Here we show that GRA3 liberated from dense granules is a soluble protein. Following secretion, one-third or more of GRA3 in the parasitophorous vacuole becomes stably associated with the vacuole membrane as judged by sucrose flotation gradients and Triton X-114 phase partitioning experiments. GRA3 cannot be removed from the membrane by extraction with sodium carbonate at pH 11.0, nor can it be labeled in infected cells with [1-C-14]acetate. In sucrose velocity sedimentation gradients, GRA3 from vacuolar membranes solubilized in Triton X-100 sediments as an oligomer. Membrane-associated GRA3 cross-links to itself, migrating as a ladder of bands in SDS-polyacrylamide gel electrophoresis. No other parasite or cell proteins co-precipitate with cross-linked GRA3. We conclude that a portion of GRA3 secreted from the parasite as a soluble protein directly inserts into the vacuole membrane in an oligomeric form. This is the first report in Toxoplasma or related parasites of a protein which inserts into the vacuole membrane for some purpose other than to lyse that membrane.	INSERM, U42, F-59650 VILLENEUVE DASCQ, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	OSSORIO, PN (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, INFECT DIS SECT, NEW HAVEN, CT 06510 USA.		Joiner, Keith/AAH-1059-2021	Joiner, Keith/0000-0003-3062-823X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030060] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 30060] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHBAROU A, 1991, PARASITOLOGY, V103, P321, DOI 10.1017/S0031182000059837; ALEY SB, 1984, J EXP MED, V160, P1585, DOI 10.1084/jem.160.5.1585; ANDREWS NW, 1990, CELL, V61, P1277, DOI 10.1016/0092-8674(90)90692-8; ANDREWS NW, 1991, PARASITOL TODAY, V7, P335, DOI 10.1016/0169-4758(91)90212-7; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BERNHEIMER AW, 1986, BIOCHIM BIOPHYS ACTA, V864, P123, DOI 10.1016/0304-4157(86)90018-3; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROWN GV, 1985, J EXP MED, V162, P774, DOI 10.1084/jem.162.2.774; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; COPPEL RL, 1988, MOL BIOCHEM PARASIT, V31, P223, DOI 10.1016/0166-6851(88)90152-1; COUVREUR G, 1988, PARASITOLOGY, V97, P1, DOI 10.1017/S0031182000066695; CULVENOR JG, 1991, INFECT IMMUN, V59, P1183, DOI 10.1128/IAI.59.3.1183-1187.1991; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DUBREMETZ JF, 1993, PARASITOL RES, V79, P402, DOI 10.1007/BF00931830; ETZION Z, 1989, EUR J CELL BIOL, V48, P174; FOLEY M, 1990, MOL BIOCHEM PARASIT, V38, P69, DOI 10.1016/0166-6851(90)90206-2; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FURTADO GC, 1992, INFECT IMMUN, V60, P2337, DOI 10.1128/IAI.60.6.2337-2342.1992; GORMLEY JA, 1992, J CELL BIOL, V119, P1481, DOI 10.1083/jcb.119.6.1481; GUNTHER K, 1991, MOL BIOCHEM PARASIT, V46, P149, DOI 10.1016/0166-6851(91)90208-N; HIGH N, 1992, EMBO J, V11, P1991, DOI 10.1002/j.1460-2075.1992.tb05253.x; HOOPER NM, 1991, BIOCHEM J, V280, P745, DOI 10.1042/bj2800745; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; JONES TC, 1972, J EXP MED, V136, P1173, DOI 10.1084/jem.136.5.1173; KARA UAK, 1988, INFECT IMMUN, V56, P903, DOI 10.1128/IAI.56.4.903-909.1988; KIMATA I, 1987, J CELL SCI, V88, P231; LAKEY JH, 1992, FEBS LETT, V307, P26, DOI 10.1016/0014-5793(92)80895-N; LECORDIER L, 1993, MOL BIOCHEM PARASIT, V59, P143, DOI 10.1016/0166-6851(93)90015-P; LERICHE MA, 1991, MOL BIOCHEM PARASIT, V45, P249, DOI 10.1016/0166-6851(91)90092-K; LERICHE MA, 1990, PARASITOL RES, V76, P559, DOI 10.1007/BF00932560; LI WL, 1991, MOL BIOCHEM PARASIT, V49, P157, DOI 10.1016/0166-6851(91)90138-V; LINDER E, 1992, PARASITOL RES, V78, P175, DOI 10.1007/BF00931663; LUSTIGMAN S, 1990, MOL BIOCHEM PARASIT, V38, P261, DOI 10.1016/0166-6851(90)90029-L; LYCKE E, 1968, J BACTERIOL, V96, P785, DOI 10.1128/JB.96.3.785-788.1968; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P958, DOI 10.1073/pnas.82.4.958; MERCIER C, 1993, MOL BIOCHEM PARASIT, V58, P71, DOI 10.1016/0166-6851(93)90092-C; NAGEL SD, 1989, J BIOL CHEM, V264, P5569; NICHOLS BA, 1983, J ULTRA MOL STRUCT R, V83, P85, DOI 10.1016/S0022-5320(83)90067-9; NIEHRS C, 1992, EUR J CELL BIOL, V58, P35; OJCIUS DM, 1991, TRENDS BIOCHEM SCI, V16, P225, DOI 10.1016/0968-0004(91)90090-I; OSSORIO PN, 1992, MOL BIOCHEM PARASIT, V50, P1, DOI 10.1016/0166-6851(92)90239-G; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; PEITSCH M C, 1991, Current Opinion in Cell Biology, V3, P710, DOI 10.1016/0955-0674(91)90045-Z; PEITSCH MC, 1990, MOL IMMUNOL, V27, P589, DOI 10.1016/0161-5890(90)90001-G; POISNER AM, 1982, SECRETORY GRANULE; PORCHETHENNERE E, 1983, PROTISTOLOGICA, V19, P357; PORTNOY DA, 1992, INFECT IMMUN, V60, P1263, DOI 10.1128/IAI.60.4.1263-1267.1992; PRYDE JG, 1986, BIOCHEM J, V233, P525, DOI 10.1042/bj2330525; PRYDE JG, 1986, TRENDS BIOCHEM SCI, V11, P160, DOI 10.1016/0968-0004(86)90132-5; SAMYELLOWE TY, 1990, MOL BIOCHEM PARASIT, V39, P91, DOI 10.1016/0166-6851(90)90011-A; SCHWAB JC, 1994, P NATL ACAD SCI USA, V91, P509, DOI 10.1073/pnas.91.2.509; SCHWARTZMAN JD, 1986, INFECT IMMUN, V51, P760, DOI 10.1128/IAI.51.3.760-764.1986; SCHWARTZMAN JD, 1989, EXP PARASITOL, V68, P74, DOI 10.1016/0014-4894(89)90010-6; Sibley L. D., 1989, Intracellular parasitism., P245; SIBLEY LD, 1985, NATURE, V315, P416, DOI 10.1038/315416a0; SIBLEY LD, 1988, EUR J CELL BIOL, V47, P81; SIBLEY LD, 1986, J CELL BIOL, V103, P867, DOI 10.1083/jcb.103.3.867; SIMMONS D, 1987, EMBO J, V6, P485, DOI 10.1002/j.1460-2075.1987.tb04779.x; SUETTERLIN BW, 1991, MOL BIOCHEM PARASIT, V46, P113, DOI 10.1016/0166-6851(91)90205-K; TOKUNAGA H, 1992, BIOCHIM BIOPHYS ACTA, V1105, P125, DOI 10.1016/0005-2736(92)90170-Q; TOOZE SA, 1991, FEBS LETT, V285, P220, DOI 10.1016/0014-5793(91)80805-D; WALLACE BA, 1986, P NATL ACAD SCI USA, V83, P9423, DOI 10.1073/pnas.83.24.9423	62	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15350	15357						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195173				2022-12-27	WOS:A1994NP73800074
J	MCMASTER, CR; BELL, RM				MCMASTER, CR; BELL, RM			PHOSPHATIDYLCHOLINE BIOSYNTHESIS VIA THE CDP-CHOLINE PATHWAY IN SACCHAROMYCES-CEREVISIAE - MULTIPLE MECHANISMS OF REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING CHOLINEPHOSPHATE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLSERINE SYNTHASE ACTIVITY; DEPENDENT PROTEIN-KINASE; EPT1 GENE-PRODUCTS; PHOSPHOLIPID BIOSYNTHESIS; COORDINATE REGULATION; YEAST MUTANT; SN-1,2-DIACYLGLYCEROL CHOLINEPHOSPHOTRANSFERASE; PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE; PHOSPHATIDATE PHOSPHATASE	Multiple mechanisms of regulation in the CDP-choline pathway for phosphatidylcholine (PC) synthesis were revealed by exploring the effects of choline and inositol on this pathway in Saccharomyces cerevisiae. At exogenous choline concentrations below 100 mu M, phosphocholine cytidylyltransferase was rate-limiting; at higher choline concentrations the conversion of choline to phosphocholine by choline kinase became rate-limiting. Choline and inositol were found to regulate choline uptake; this established another regulatory mechanism by which PC synthesis is regulated in yeast. Inositol addition did not immediately affect labeled choline uptake or its incorporation into PC in actively dividing cells; however, preculturing the cells in the presence of choline decreased the rate of choline uptake, and this effect was amplified by the concomitant addition of inositol and choline. Additionally, a growth phase dependent effect of inositol supplementation was observed. Inositol addition to stationary phase cells resulted in an increase in choline uptake and subsequent PC production in these cells. This increase was shown to be due to an increase in the rate of choline transport into the cell. In the presence of inositol, choline transport is the main regulatory mechanism controlling flux through the CDP-choline pathway in S. cerevisiae. Inositol supplementation resulted in changes in the levels of enzyme activity detected in vitro. However, the effects observed in vivo correlated exclusively with changes in choline uptake. Choline transporter assays were consistent with these results. Since both the CPT1 and EPT1 gene products catalyze the cholinephosphotransferase reaction in vitro (Hjelmstad, R. H., and Bell, R. M. (1991) J. Biol. Chem. 266, 4357-4365), the effect of inositol on these two separate routes for PC biosynthesis was investigated. The data revealed that only cells harboring a functional CPT1 gene synthesized PC in vivo. These cells (ept1-Delta 1::URA3) also displayed an identical mode of regulation in response to inositol as did cells containing an intact EPT1 gene (wild type) indicating there is no requirement for an alternate functional CDP-aminoalcohol pathway for inositol to regulate PC synthesis via the CDP-choline pathway.	DUKE UNIV, MED CTR, DEPT MOLEC CANC BIOL, DURHAM, NC 27710 USA	Duke University				McMaster, Christopher/0000-0003-0822-5776	NIGMS NIH HHS [GM20015] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BAILIS AM, 1992, NUCLEIC ACIDS RES, V20, P1411, DOI 10.1093/nar/20.6.1411; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARSON MA, 1984, J BIOL CHEM, V259, P6267; CARSON MA, 1982, J BIOL CHEM, V257, P8115; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; EXTON JH, 1990, J BIOL CHEM, V265, P1; GAYNOR PM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P326, DOI 10.1016/0167-4781(91)90197-T; GREENBERG ML, 1988, MOL CELL BIOL, V8, P4773, DOI 10.1128/MCB.8.11.4773; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; HJELMSTAD RH, 1988, J BIOL CHEM, V263, P19748; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P5094; HJELMSTAD RH, 1990, J BIOL CHEM, V265, P1755; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; HOMANN MJ, 1985, J BACTERIOL, V163, P1265, DOI 10.1128/JB.163.3.1265-1266.1985; HOMANN MJ, 1987, J BACTERIOL, V169, P3276, DOI 10.1128/jb.169.7.3276-3280.1987; HOSAKA K, 1981, EUR J BIOCHEM, V116, P1, DOI 10.1111/j.1432-1033.1981.tb05292.x; HOSAKA K, 1990, J BACTERIOL, V172, P2005, DOI 10.1128/jb.172.4.2005-2012.1990; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HOSAKA K, 1992, J BIOCHEM-TOKYO, V111, P352, DOI 10.1093/oxfordjournals.jbchem.a123761; HOSAKA K, 1987, EUR J BIOCHEM, V162, P7, DOI 10.1111/j.1432-1033.1987.tb10533.x; HOSAKA K, 1980, J BACTERIOL, V143, P176, DOI 10.1128/JB.143.1.176-181.1980; HOSHIZAKI DK, 1990, J BIOL CHEM, V265, P4736; HOUTS GE, 1979, J VIROL, V29, P517, DOI 10.1128/JVI.29.2.517-522.1979; JOHNSON JE, 1992, BIOCHEM J, V285, P815, DOI 10.1042/bj2850815; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KINNEY AJ, 1990, J BACTERIOL, V172, P1133, DOI 10.1128/jb.172.2.1133-1136.1990; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KOVAC L, 1980, EUR J BIOCHEM, V111, P491, DOI 10.1111/j.1432-1033.1980.tb04965.x; LAMPING E, 1991, J BACTERIOL, V173, P6432, DOI 10.1128/jb.173.20.6432-6437.1991; LESTER RL, 1968, J BIOL CHEM, V243, P4889; LETTS VA, 1985, J BACTERIOL, V163, P560, DOI 10.1128/JB.163.2.560-567.1985; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGRAW P, 1989, GENETICS, V122, P317; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; NIKAWA J, 1983, EUR J BIOCHEM, V131, P223, DOI 10.1111/j.1432-1033.1983.tb07253.x; NIKAWA J, 1982, J BACTERIOL, V150, P441, DOI 10.1128/JB.150.2.441-446.1982; NIKAWA J, 1981, BIOCHIM BIOPHYS ACTA, V665, P420, DOI 10.1016/0005-2760(81)90254-X; NIKAWA J, 1991, J BIOL CHEM, V266, P11184; NIKAWA JI, 1986, J BACTERIOL, V166, P328, DOI 10.1128/jb.166.1.328-330.1986; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; POOLE MA, 1986, J BACTERIOL, V168, P668, DOI 10.1128/jb.168.2.668-672.1986; QUINLAN JJ, 1992, J BIOL CHEM, V267, P18013; Rose M. D., 1990, METHODS YEAST GENETI, P140; STEINER MR, 1970, BIOCHEMISTRY-US, V9, P63, DOI 10.1021/bi00803a009; SUMMERS EF, 1988, GENETICS, V120, P909; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; TSUKAGOSHI Y, 1991, J BACTERIOL, V173, P2134, DOI 10.1128/jb.173.6.2134-2136.1991; VANCE DE, 1984, TRENDS BIOCHEM SCI, V9, P17, DOI 10.1016/0968-0004(84)90041-0; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P33; WAECHTER CJ, 1969, J BIOL CHEM, V244, P3419; White DA, 1973, FORM FUNCTION PHOSPH, P441; WHITE MJ, 1991, ADV MICROB PHYSIOL, V32, P1, DOI 10.1016/S0065-2911(08)60004-1; WHITE MJ, 1991, J BIOL CHEM, V266, P863; YAMASHITA S, 1980, EUR J BIOCHEM, V104, P611, DOI 10.1111/j.1432-1033.1980.tb04465.x; YAMASHITA S, 1982, EUR J BIOCHEM, V128, P589; ZELINSKI TA, 1980, J BIOL CHEM, V255, P1423; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	70	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14776	14783						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182083				2022-12-27	WOS:A1994NM06500073
J	SIMONEN, M; JAMSA, E; MAKAROW, M				SIMONEN, M; JAMSA, E; MAKAROW, M			THE ROLE OF THE CARRIER PROTEIN AND DISULFIDE FORMATION IN THE FOLDING OF BETA-LACTAMASE FUSION PROTEINS IN THE ENDOPLASMIC-RETICULUM OF YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPRO-ALPHA-FACTOR; SACCHAROMYCES-CEREVISIAE; GROWTH-FACTOR; S-CEREVISIAE; SECRETION; GENE; EXPRESSION; SEQUENCE; INVITRO; ENCODES	We have studied the relationship between folding and secretion competence of hsp150-beta-lactamase fusion proteins in Saccharomyces cerevisiae. hsp150 is a secretory protein of yeast, and beta-lactamase was chosen, since its folding can be monitored by assaying its enzymatic activity. The hsp150 pre-pro-protein consists of a signal peptide, subunit I, a repetitive region, and a unique C terminus. Fusion of beta-lactamase to the C terminus of hsp150 produced Cla-bla protein, which was secretion-competent but inactive. The Pst-bla protein, where p-lactamase was fused to subunit I, was also inactive and mostly secreted, but part of it remained in the pre-Golgi compartment. When beta-lactamase was fused to the C terminus of the repetitive region, the fusion protein (Kpn-bla) was translocated to the endoplasmic reticulum, acquired disulfide bonds, and adopted an enzymatically active conformation. Kpn-bla was secreted to the medium without decrease of specific activity or retention in the cell. Folding of Kpn-bla to an active and transport competent form required co-translational disulfide for formation, since treatment of cells with dithiothreitol resulted in endoplasmic reticulum-retained inactive Kpn-bla. When dithiothreitol was removed, Kpn-bla resumed transport competence but remained inactive. Reduction of prefolded Kpn-bla did not inhibit enzymatic activity or transport. The repetitive hsp150 carrier may have use in heterologous protein production by conferring secretion competence to foreign proteins in yeast.			SIMONEN, M (corresponding author), UNIV HELSINKI, INST BIOTECHNOL, VALIMOTIE 7, SF-00380 HELSINKI, FINLAND.		Jokitalo, Eija/C-8375-2009	Jokitalo, Eija/0000-0002-4159-6934				ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; AMMERER G, 1983, METHOD ENZYMOL, V101, P192; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BIELEFELD M, 1992, CURR GENET, V21, P265, DOI 10.1007/BF00351680; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRAKE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P4642, DOI 10.1073/pnas.81.15.4642; CHANG A, 1993, P NATL ACAD SCI USA, V90, P5808, DOI 10.1073/pnas.90.12.5808; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; FILHO SA, 1986, BIOTECHNOLOGY, V4, P311; GELLERFORS P, 1989, J BIOL CHEM, V264, P11444; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUNTHER R, 1991, J BIOL CHEM, V266, P24557; HOLLENBERG CP, 1983, GENE EXPRESSION YEAS, P73; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; JAMSA E, 1994, YEAST, V10, P355, DOI 10.1002/yea.320100308; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LOISON G, 1988, BIO-TECHNOL, V6, P72, DOI 10.1038/nbt0188-72; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; RIEDERER MA, 1991, J BACTERIOL, V173, P3539, DOI 10.1128/jb.173.11.3539-3546.1991; ROGGENKAMP R, 1985, J BIOL CHEM, V260, P1508; ROMANOS MA, 1992, YEAST, V8, P423, DOI 10.1002/yea.320080602; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1987, EMBO J, V6, P3455, DOI 10.1002/j.1460-2075.1987.tb02669.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUSSO P, 1992, P NATL ACAD SCI USA, V89, P3671, DOI 10.1073/pnas.89.9.3671; RUSSO P, 1993, MOL GEN GENET, V239, P273, DOI 10.1007/BF00281628; RUSSO P, 1992, P NATL ACAD SCI USA, V89, P8857, DOI 10.1073/pnas.89.18.8857; SAKAI A, 1991, BIO-TECHNOL, V9, P1382, DOI 10.1038/nbt1291-1382; Sambrook J, 1989, MOL CLONING LABORATO; SATO T, 1989, GENE, V83, P355, DOI 10.1016/0378-1119(89)90122-4; SCHERENS B, 1991, YEAST, V7, P185, DOI 10.1002/yea.320070212; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; THIM L, 1986, P NATL ACAD SCI USA, V83, P6766, DOI 10.1073/pnas.83.18.6766; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885	39	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13887	13892						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188666				2022-12-27	WOS:A1994NL60600028
J	SAKATA, N; WU, XJ; DIXON, JL; GINSBERG, HN				SAKATA, N; WU, XJ; DIXON, JL; GINSBERG, HN			PROTEOLYSIS AND LIPID-FACILITATED TRANSLOCATION ARE DISTINCT BUT COMPETITIVE PROCESSES THAT REGULATE SECRETION OF APOLIPOPROTEIN-B IN HEP-G2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MESSENGER-RNA LEVELS; LOW-DENSITY LIPOPROTEINS; ENDOPLASMIC-RETICULUM; G2 CELLS; APO-B; HEPG2 CELLS; INTRACELLULAR DEGRADATION; COMBINED HYPERLIPIDEMIA; RABBIT LIVER; OLEIC-ACID	Under lipid-poor conditions, most newly synthesized apolipoprotein B100 (apoB) undergoes rapid degradation in Hep G2 cells such that only a small fraction of newly synthesized apoB is actually secreted. Addition of oleate to Hep G2 culture medium stimulates apoB secretion by a post-translational mechanism. In the current studies we have explored oleate-stimulation of apoB secretion by using calpain inhibitor I, N-acetyl-leucyl-leucyl-norleucinal (ALLN), a compound that inhibits the intracellular degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and the T cell receptor alpha subunit. Preincubation of Hep G2 cells with ALLN (40 mug/ml) for 1 h markedly inhibited degradation of newly synthesized apoB. Whereas only 32% of newly labeled apoB remained intact (cells + medium) in control cells after a 10-min pulse with [H-3]leucine followed by a 60-min chase, 84% of labeled apoB was intact in ALLN-treated cells. However, most of the ALLN-protected apoB remained intracellular, as ALLN did not stimulate the rate of apoB secretion over the control rate (12 versus 9.2%). Although secretion of apoB was not accelerated, the protection afforded by ALLN continued for several hours, and labeled apoB continued to be secreted over 3 h of chase after which secretion ceased. The protection afforded by ALLN resulted in 37% of labeled apoB secreted by 3 h compared to 15% in control cells. In contrast, simultaneous treatment of cells with ALLN and oleate both accelerated and increased total apoB secretion, such that 36% of initially labeled apoB was recovered in the medium by 60 min and 71% of labeled apoB was secreted by 180 min of chase. These data show that ALLN and oleate affect apoB metabolism by different mechanisms. Although ALLN can protect nascent apoB from rapid early intracellular degradation, it does not accelerate apoB secretion. In contrast, although our results can not rule out the possibility that oleate may directly inhibit proteolysis of apoB, oleate appears to protect apoB mainly by facilitating transport of apoB out of a protease-containing compartment associated with the endoplasmic reticulum.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,630 W 168TH ST,NEW YORK,NY 10032; UNIV MISSOURI,DEPT FOOD SCI & HUMAN NUTR,COLUMBIA,MO 65211	Columbia University; University of Missouri System; University of Missouri Columbia			Sakata, Nobuhiro/ACN-9770-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL047586, R01HL036000, R01HL047586, P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-21006, HL-36000, HL-47586] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBERGER MJ, 1988, J BIOL CHEM, V263, P11868; ARAD Y, 1990, J LIPID RES, V31, P567; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; DASHTI N, 1989, J LIPID RES, V30, P1365; DASHTI N, 1992, J BIOL CHEM, V267, P7160; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON J L, 1989, Journal of Cell Biology, V109, p148A; DIXON JL, 1992, J CELL BIOL, V117, P1161, DOI 10.1083/jcb.117.6.1161; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; HENNESSY LK, 1992, J LIPID RES, V33, P351; INOUE S, 1992, J BIOL CHEM, V267, P9080; JANUS ED, 1980, EUR J CLIN INVEST, V10, P161, DOI 10.1111/j.1365-2362.1980.tb02076.x; KISSEBAH AH, 1981, METABOLISM, V30, P856, DOI 10.1016/0026-0495(81)90064-0; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KROON PA, 1986, P NATL ACAD SCI USA, V83, P5071, DOI 10.1073/pnas.83.14.5071; KUSHWAHA RS, 1991, J LIPID RES, V32, P1929; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; PULLINGER CR, 1989, J LIPID RES, V30, P1065; SATO R, 1990, J BIOL CHEM, V265, P11880; SORCITHOMAS M, 1989, J BIOL CHEM, V264, P9039; SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731; TAM SP, 1991, ATHEROSCLEROSIS, V91, P51, DOI 10.1016/0021-9150(91)90186-7; TENG B, 1986, J CLIN INVEST, V77, P663, DOI 10.1172/JCI112360; THERIAULT A, 1992, BIOCHEM BIOPH RES CO, V186, P617, DOI 10.1016/0006-291X(92)90791-I; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WILKINSON J, 1992, BIOCHEM J, V288, P413, DOI 10.1042/bj2880413; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0	39	130	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					22967	22970						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226809				2022-12-27	WOS:A1993MF51500004
J	OHTSUKA, T; NISHIJIMA, M; SUZUKI, K; AKAMATSU, Y				OHTSUKA, T; NISHIJIMA, M; SUZUKI, K; AKAMATSU, Y			MITOCHONDRIAL DYSFUNCTION OF A CULTURED CHINESE-HAMSTER OVARY CELL MUTANT DEFICIENT IN CARDIOLIPIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-OXIDASE; RESPIRATORY-CHAIN; ETHIDIUM BROMIDE; COMPLEX; BIOSYNTHESIS; REQUIREMENT; HELA	In our preceding paper, we reported that a temperature-sensitive Chinese hamster ovary cell mutant, PGS-S, with thermolabile phosphatidylglycerophosphate synthase was defective in the biogenesis of both phosphatidylglycerol and cardiolipin (CL) at a nonpermissive temperature (Ohtsuka, T., Nishijima, M., and Akamatsu, Y. (1993) J. Biol. Chem. 268, 22908-22913). To investigate the biological role of cardiolipin, we examined the structure and function of mitochondria in mutant PGS-S cells, since CL is primarily found in the mitochondrial membranes of eukaryotic cells. Under conditions where the formation of CL was impaired, this mutant had both morphological and functional mitochondrial abnormalities, manifested by more stringent temperature sensitivity for cell growth in glucose-deficient medium and by reduced ATP production, increased glycolysis, and reduced oxygen consumption in intact cells. Rotenone-sensitive NADH oxidase activity in cell extracts was also reduced in the mutant cultivated at a nonpermissive temperature, showing a defect(s) in the respiratory electron transport chain of mitochondria. Of the respiratory chain complexes, rotenone-sensitive NADH-ubiquinone reductase (Complex I) was most severely impaired in the mutant, whereas its activity was restored in a revertant of the mutant that had regained the ability to synthesize CL. These results suggest that CL plays a critical role in mitochondrial functions, at least in the respiratory electron transport chain.	NATL INST HLTH, DEPT BIOCHEM & CELL BIOL, TOYAMA 1-23-1, SHINJUKU KU, TOKYO 162, JAPAN									AWASTHI YC, 1971, BIOCHIM BIOPHYS ACTA, V226, P42, DOI 10.1016/0005-2728(71)90176-9; CHU EHY, 1972, P NATL ACAD SCI USA, V69, P3459, DOI 10.1073/pnas.69.11.3459; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; DITTA G, 1976, SOMAT CELL GENET, V2, P331, DOI 10.1007/BF01538838; ESKO JD, 1980, J BIOL CHEM, V255, P4474; FRY M, 1980, BIOCHEM BIOPH RES CO, V93, P1238, DOI 10.1016/0006-291X(80)90622-1; FRY M, 1981, J BIOL CHEM, V256, P1874; HANADA K, 1990, J BIOL CHEM, V265, P22137; Hostetler K. Y., 1982, PHOSPHOLIPIDS, V4, P215; KING ME, 1972, J CELL BIOL, V53, P127, DOI 10.1083/jcb.53.1.127; KUGE O, 1985, P NATL ACAD SCI USA, V82, P1926, DOI 10.1073/pnas.82.7.1926; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORAIS R, 1980, J CELL PHYSIOL, V103, P455, DOI 10.1002/jcp.1041030311; OHTSUKA T, 1993, J BIOL CHEM, V268, P22908; RAGAN CI, 1978, BIOCHEM J, V172, P539, DOI 10.1042/bj1720539; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; Robinson B.H., 1989, METABOLIC BASIS INHE, P869; SCHEFFLER IE, 1974, J CELL PHYSIOL, V83, P219, DOI 10.1002/jcp.1040830208; SCHLAME M, 1990, BIOCHEM J, V265, P79, DOI 10.1042/bj2650079; SEGALBENDIRDJIAN E, 1988, CANCER RES, V48, P4982; SINGER TP, 1971, ADV ENZYMOL RAMB, V34, P79; SOSLAU G, 1971, J CELL BIOL, V51, P514, DOI 10.1083/jcb.51.2.514; STANLEY PE, 1969, ANAL BIOCHEM, V29, P381, DOI 10.1016/0003-2697(69)90323-6; SUN NC, 1975, P NATL ACAD SCI USA, V72, P469, DOI 10.1073/pnas.72.2.469; Tisdale HD, 1967, METHODS ENZYMOL, V10, P213, DOI DOI 10.1016/0076-6879(67)10042-6; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; Whitfield C. D., 1985, MOL CELL GENETICS, P545; YU CA, 1979, ARCH BIOCHEM BIOPHYS, V198, P314, DOI 10.1016/0003-9861(79)90424-7	29	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22914	22919						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226801				2022-12-27	WOS:A1993MD34800105
J	TANG, DG; CHEN, YQ; NEWMAN, PJ; SHI, L; GAO, X; DIGLIO, CA; HONN, KV				TANG, DG; CHEN, YQ; NEWMAN, PJ; SHI, L; GAO, X; DIGLIO, CA; HONN, KV			IDENTIFICATION OF PECAM-1 IN SOLID TUMOR-CELLS AND ITS POTENTIAL INVOLVEMENT IN TUMOR-CELL ADHESION TO ENDOTHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOEMBRYONIC ANTIGEN; ALPHA-IIB-BETA-3 INTEGRIN; MELANOMA-CELLS; MOLECULE; EXPRESSION; CARCINOMA; LINE; METASTASIS; MEMBRANE; PLATELET	PECAM-1 (CD31/EndoCAM) is an adhesion molecule in the immunoglobulin supergene family that is expressed on endothelial cells, platelets, and some hematopoietic lineage cells. In this paper, using several polyclonal and monoclonal antibodies against PECAM-1, we identified PECAM-1 molecules on human, rat, and murine solid tumor cell lines. Immunocytochemical labeling and flow cytometric analysis using either polyclonal, monoclonal, or Fab portion of the antibodies against PECAM-1 detected a distinct distribution on tumor cell surface. Immunoblotting revealed proteins ranging from 120 to 130 kDa in tumor cells derived from different species. Immunoprecipitation and subcellular fractionation studies indicated that PECAM-1 is constitutively expressed on the surface of human tumor cells (i.e. colon adenocarcinoma). The specificity of a major polyclonal anti-PECAM-1 used in the current study (i.e. SEW-3) was confirmed by the preabsorption studies. PECAM-1 molecules on tumor cells appear to bear terminal carbohydrate moieties (i.e. sialic acid residues) different from those on platelets, since neuraminidase treatment of tumor cells, unlike platelets, did not result in a mobility shift. Polymerase chain reaction (PCR) analysis of genomic DNA derived from tumor cell lines of different species revealed the presence of PECAM-1 gene in the genome. The mRNAs of PECAM-1 in tumor cells were detected by reverse transcription-PCR followed by Southern hybridization. Screening of more than 20 human, rat, and murine solid tumor cell lines indicated that PECAM-1 is widely expressed, although the level of expression varies considerably among different cell lines. The expression of PECAM-1 message in tumor cells was confirmed by Northern blotting. DNA sequencing of the PCR fragment revealed that human tumor cell PECAM-1 matches 100% to the human endothelial cell counterpart. Finally, it was demonstrated that tumor cell PECAM-1 is involved in mediating tumor cell adhesion to endothelium, as evidenced by the ability of anti-PECAM-1 antibodies to decrease the adhesion of unstimulated tumor cells to microvascular endothelial cells.	WAYNE STATE UNIV,DEPT RADIAT ONCOL,431 CHEM,DETROIT,MI 48202; WAYNE STATE UNIV,DEPT CHEM,DETROIT,MI 48202; WAYNE STATE UNIV,DEPT PATHOL,DETROIT,MI 48202; HARPER GRACE HOSP,GERSHENSON RADIAT ONCOL CTR,DETROIT,MI 48201; BLD CTR SE WISCONSIN,BLOOD RES INST,MILWAUKEE,WI 53233; MED COLL WISCONSIN,DEPT CELL BIOL & ANAT,MILWAUKEE,WI 53207	Wayne State University; Wayne State University; Wayne State University; Versiti Blood Center of Wisconsin; Medical College of Wisconsin			Chen, Yong Q/AAI-9864-2021; Tang, Dean/AAI-3457-2020	Chen, Yong Q/0000-0003-4747-4708; Tang, Dean/0000-0001-5029-1174	NATIONAL CANCER INSTITUTE [R01CA047115, R01CA029997] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040926] Funding Source: NIH RePORTER; NCI NIH HHS [CA 29997, CA 47115] Funding Source: Medline; NHLBI NIH HHS [HL-40926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BRACKENBURY R, 1985, CANCER METAST REV, V4, P41, DOI 10.1007/BF00047736; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROTHMAN AR, 1989, INT J CANCER, V44, P898, DOI 10.1002/ijc.2910440525; CHANG YS, 1992, INT J CANCER, V51, P445, DOI 10.1002/ijc.2910510318; CHEN YQ, 1992, J BIOL CHEM, V267, P17314; CHOPRA H, 1990, CANCER RES, V50, P7686; CHOPRA H, 1988, CANCER RES, V48, P3787; DIGLIO CA, 1989, LAB INVEST, V60, P523; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; GROSSI IM, 1989, CANCER RES, V49, P1029; GROSSI IM, 1988, FASEB J, V2, P2385, DOI 10.1096/fasebj.2.8.2452113; HONN KV, 1992, CANCER METAST REV, V11, P353, DOI 10.1007/BF01307187; HONN KV, 1992, SEMIN THROMB HEMOST, V18, P390; JOHNSON JP, 1989, P NATL ACAD SCI USA, V86, P641, DOI 10.1073/pnas.86.2.641; KNAPP W, 1989, BLOOD, V74, P1448; LAURI D, 1991, JNCI-J NATL CANCER I, V83, P1321, DOI 10.1093/jnci/83.18.1321; LEE KH, 1992, J INVEST DERMATOL, V98, P79, DOI 10.1111/1523-1747.ep12495643; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LIU B, 1991, CELL REGUL, V2, P1045, DOI 10.1091/mbc.2.12.1045; MAJURI ML, 1992, BIOCHEM BIOPH RES CO, V182, P1376, DOI 10.1016/0006-291X(92)91885-T; MARTINPADURA I, 1991, CANCER RES, V51, P2239; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; NAYAK SK, 1977, BRIT J CANCER, V35, P142, DOI 10.1038/bjc.1977.21; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; NICHOLSON GL, 1988, CANCER METAST REV, V7, P143; PAULI BU, 1990, CANCER METAST REV, V9, P175, DOI 10.1007/BF00046359; SAMBROOK J, 1987, MOL CLONING LABORATO; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SIMMONS DL, 1990, J EXP MED, V171, P2147, DOI 10.1084/jem.171.6.2147; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TANG DG, 1993, INT J CANCER, V54, P102, DOI 10.1002/ijc.2910540117; TANG DG, 1993, J CELL BIOL, V121, P689, DOI 10.1083/jcb.121.3.689; TIBBETTS LM, 1977, CANCER, V40, P2651, DOI 10.1002/1097-0142(197711)40:5+<2651::AID-CNCR2820400939>3.0.CO;2-V; TURBIDE C, 1991, J BIOL CHEM, V266, P309; WEISS L, 1988, FASEB J, V2, P12, DOI 10.1096/fasebj.2.1.3275560; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZEHNDER JL, 1992, J BIOL CHEM, V267, P5243	45	64	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22883	22894						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226797				2022-12-27	WOS:A1993MD34800101
J	TONISSEN, K; WELLS, J; COCK, I; PERKINS, A; OROZCO, C; CLARKE, F				TONISSEN, K; WELLS, J; COCK, I; PERKINS, A; OROZCO, C; CLARKE, F			SITE-DIRECTED MUTAGENESIS OF HUMAN THIOREDOXIN - IDENTIFICATION OF CYSTEINE-74 AS CRITICAL TO ITS FUNCTION IN THE EARLY-PREGNANCY FACTOR SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; MUTANT THIOREDOXINS; REDUCTION; EXPRESSION; COMPONENTS; POLYMERASE; RESOLUTION; MOLECULES; SERUM	Thioredoxin has been identified as a key component of the ''early pregnancy factor'' system, a system of components present in pregnancy sera which expresses a lymphocyte modifying activity in an assay known as the rosette inhibition assay. Although thioredoxin alone is inactive, addition of thioredoxin to lymphocytes in combination with nonpregnancy sera or platelet-activating factor results in a positive response. We have changed several amino acids of human thioredoxin by site-directed mutagenesis to investigate the residues required for this cooperative function. Conversion of the two active site residues (cysteines 32 and 35) to serines results in a protein devoid of classical redox activity; however, this protein retained its ability to cooperate with non-pregnancy sera or platelet-activating factor in the rosette inhibition assay. Vertebrate thioredoxins contain an additional conserved pair of cysteine residues in the C-terminal portion of the protein. Changing both to serines resulted in no change in redox activity but completely abolished function in the rosette inhibition assay. Further study revealed this function was solely dependent on cysteine 74 as conversion of only cysteine 74 to serine abolished function, whereas replacement of only cysteine 70 with serine had no effect. The nonfunctional mutants counteracted the action of pregnancy serum in the assay stongly supporting the hypothesis that thioredoxin is an intergral part of the early pregnancy factor system with residue cysteine 74 having an important role.	GRIFFITH UNIV, FAC SCI & TECHNOL, NATHAN, QLD 4111, AUSTRALIA; UNIV ADELAIDE, DEPT BIOCHEM, ADELAIDE, SA 5001, AUSTRALIA	Griffith University; University of Adelaide			Perkins, Tony/K-6648-2019; Tonissen, Kathryn F/E-9424-2010	Perkins, Tony/0000-0002-9829-6772; Tonissen, Kathryn F/0000-0002-1018-2798; Cock, Ian/0000-0002-8732-8513				CLARKE FM, 1990, J REPROD FERTIL, V88, P459; CLARKE FM, 1991, J REPROD FERTIL, V93, P525, DOI 10.1530/jrf.0.0930525; CLARKE FM, 1992, REPROD FERT DEVELOP, V4, P423, DOI 10.1071/RD9920423; CRAWFORD NA, 1988, METHOD ENZYMOL, V167, P415; DITRAPANI G, 1991, HUM REPROD, V6, P450, DOI 10.1093/oxfordjournals.humrep.a137357; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ERICSON ML, 1992, LYMPHOKINE CYTOK RES, V11, P201; FORMANKAY JD, 1991, BIOCHEMISTRY-US, V30, P2685, DOI 10.1021/bi00224a017; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1977, J BIOL CHEM, V252, P4600; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HUBER HE, 1986, J BIOL CHEM, V261, P5006; KAMINSKY SM, 1992, PROTEIN SCI, V1, P22; KAMINSKY SM, 1992, PROTEIN SCI, V1, P10; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; MORTON H, 1977, LANCET, V1, P394; MORTON H, 1987, CURR TOP DEV BIOL, V23, P73; OROZCO C, 1990, J REPROD FERTIL, V88, P447, DOI 10.1530/jrf.0.0880447; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; SCHALLREUTER KU, 1989, FREE RADICAL BIO MED, V6, P519, DOI 10.1016/0891-5849(89)90045-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	29	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22485	22489						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226756				2022-12-27	WOS:A1993MD34800047
J	SHASHIDHARAN, P; MICHAELIDIS, TM; ROBAKIS, NK; KRESOVALI, A; PAPAMATHEAKIS, J; PLAITAKIS, A				SHASHIDHARAN, P; MICHAELIDIS, TM; ROBAKIS, NK; KRESOVALI, A; PAPAMATHEAKIS, J; PLAITAKIS, A			NOVEL HUMAN GLUTAMATE-DEHYDROGENASE EXPRESSED IN NEURAL AND TESTICULAR TISSUES AND ENCODED BY AN X-LINKED INTRONLESS GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROLOGICAL DISORDERS; RAT-BRAIN; LOCALIZATION; RETROPOSONS; CEREBELLUM; RECEPTORS; EVOLUTION; SEQUENCE; BINDING; CDNA	Glutamate dehydrogenase, an enzyme central to glutamate metabolism, is deficient in patients with heterogeneous neurological disorders characterized by multiple system atrophy. There is evidence for multiplicity of human glutamate dehydrogenase, which may account for the heterogeneity of the above disorders. However, only one mRNA that is encoded by an intron-containing gene (GLUD1) is presently known. Because blindness due to neuroretinal degeneration can occur in rare forms of multiple system atrophy, we searched for retina specific GLUD mRNA(s) by screening a lambda gt10 library derived from human retina. A novel cDNA encoded by an X chromosome-linked intronless gene, designated GLUD2, was isolated and characterized. Reverse transcription-polymerase chain reaction analysis of human tissues revealed that the novel cDNA is expressed in human retina, testis, and, at lower levels, brain. In vitro translation of mRNAs derived from GLUD1 and GLUD2 genes generated proteins with distinct electrophoretic characteristics. The retinal cDNA was expressed in the baculovirus heterologous system, producing a protein capable of catalyzing the oxidative deamination of glutamate. The mobility of the expressed protein on SDS-polyacrylamide gel electrophoresis and its catalytic properties were very similar to those of the naturally occurring human brain glutamate dehydrogenases. The novel gene will be useful for understanding the biology of human neural and testicular tissues and in the study of X-linked neurodegenerative disorders.	CUNY MT SINAI SCH MED, DEPT NEUROL, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT PSYCHIAT, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, FISHBERG RES CTR NEUROBIOL, NEW YORK, NY 10029 USA; UNIV CRETE, RES CTR CRETE, INST MOLEC BIOL & BIOTECHNOL, GR-71110 IRAKLION, GREECE; UNIV CRETE, DEPT BIOL, GR-71110 IRAKLION, GREECE; UNIV CRETE, SCH MED SCI, GR-71110 IRAKLION, GREECE	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Crete; University of Crete; University of Crete			Robakis, Nikolaos/AAA-1838-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016871] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-16871] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE T, 1992, INVEST OPHTH VIS SCI, V33, P447; ALBIN RL, 1990, BRAIN RES, V522, P37, DOI 10.1016/0006-8993(90)91574-Z; AMURO N, 1988, BIOCHEM BIOPH RES CO, V152, P1395, DOI 10.1016/S0006-291X(88)80440-6; ANAGNOU NP, 1993, HUM HERED, V43, P351, DOI 10.1159/000154158; AOKI C, 1987, J NEUROSCI, V7, P2214; BANNER C, 1987, J NEUROCHEM, V49, P246, DOI 10.1111/j.1471-4159.1987.tb03422.x; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; COLON AD, 1986, J NEUROCHEM, V46, P1811; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; EHINGER B, 1988, P NATL ACAD SCI USA, V85, P8321, DOI 10.1073/pnas.85.21.8321; HANAUER A, 1987, NUCLEIC ACIDS RES, V15, P6308, DOI 10.1093/nar/15.15.6308; HARLOW E, 1986, ANTIBODIES LABORATOR; Huang Y P, 1984, Adv Neurol, V41, P39; HUSSAIN MM, 1989, J BIOL CHEM, V264, P20730; LAI JCK, 1986, NEUROCHEM RES, V11, P733, DOI 10.1007/BF00965341; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAVROTHALASSITIS G, 1988, P NATL ACAD SCI USA, V85, P3494, DOI 10.1073/pnas.85.10.3494; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; MICHAELIDIS TM, 1993, GENOMICS, V16, P150, DOI 10.1006/geno.1993.1152; NAKATANI Y, 1988, NUCLEIC ACIDS RES, V16, P6237, DOI 10.1093/nar/16.13.6237; Plaitakis A, 1993, Can J Neurol Sci, V20 Suppl 3, pS109; PLAITAKIS A, 1984, ANN NEUROL, V15, P144, DOI 10.1002/ana.410150206; PLAITAKIS A, 1982, SCIENCE, V216, P193, DOI 10.1126/science.6121377; PLAITAKIS A, 1991, HDB CLIN NEUROLOGY, V16, P551; PLAITAKIS A, 1986, HDB CLIN NEUROL, V17, P218; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; Sambrook J, 1989, MOL CLONING LABORATO; Smith E.L., 1975, ENZYMES, P293, DOI DOI 10.1016/S1874-6047(08)60213-9; TSIOTOS P, 1989, BRAIN RES, V481, P87, DOI 10.1016/0006-8993(89)90487-3; YOUNG AB, 1990, TRENDS PHARMACOL SCI, V11, P126, DOI 10.1016/0165-6147(90)90199-I; YU ACH, 1984, J NEUROSCI RES, V11, P351, DOI 10.1002/jnr.490110403	32	136	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16971	16976						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207021				2022-12-27	WOS:A1994NR29600068
J	BUSCH, SJ; BARNHART, RL; MARTIN, GA; FITZGERALD, MC; YATES, MT; MAO, SJT; THOMAS, CE; JACKSON, RL				BUSCH, SJ; BARNHART, RL; MARTIN, GA; FITZGERALD, MC; YATES, MT; MAO, SJT; THOMAS, CE; JACKSON, RL			HUMAN HEPATIC TRIGLYCERIDE LIPASE EXPRESSION REDUCES HIGH-DENSITY-LIPOPROTEIN AND AORTIC CHOLESTEROL IN CHOLESTEROL-FED TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIC HEART-DISEASE; GEL-ELECTROPHORESIS; METABOLISM; ATHEROSCLEROSIS; DEFICIENCY; ESTER; GENE; MEN; RNA	We have produced a line of transgenic mice expressing human hepatic triglyceride lipase (hH-TGL) to examine the in vivo effects of hepatic lipase expression on high density lipoprotein catabolism. Activation of a metallothionine I promoter-hH-TGL cDNA transgene produced high levels of lipase mRNA in liver, heart, and kidney and elevated enzyme activity as assayed in post-heparin plasma. In a series of hyperlipidemic diet studies in which zinc was included in the diet to induce the transgene, hH-TGL expression was associated with a 34% lowering of plasma HDL-cholesterol levels (p < 0.01) when compared with animals on the same hyperlipidemic diet without zinc. This lowering of HDL cholesterol was paralleled by a decrease in total cholesterol and a decrease in HDL particle size. SDS-polyacrylamide gel electrophoresis analysis of the smaller HDL particles revealed that apolipoprotein AI was still the major apoprotein associated with the HDL. Quantitative analysis of abdominal aortic cholesterol content from the same animals suggests that the observed changes in plasma HDL by hH-TGL over-expression correlated with a decrease in the accumulation of aortic cholesterol (42%, p < 0.01). These data support the hypothesis that hH-TGL mediates a non-receptor pathway for the clearance of cholesterol from the plasma compartment.			BUSCH, SJ (corresponding author), MARION MERRELL DOW RES INST,2110 E GALBRAITH RD,CINCINNATI,OH 45267, USA.							AGELLON LB, 1991, J BIOL CHEM, V266, P10796; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHANG SF, 1991, FEBS LETT, V289, P69, DOI 10.1016/0014-5793(91)80910-U; ENGER SC, 1979, ARTERY, V5, P170; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GOLDBOURT U, 1979, AM J EPIDEMIOL, V109, P296, DOI 10.1093/oxfordjournals.aje.a112683; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; HEGELE RA, 1991, BIOCHEM BIOPH RES CO, V179, P78, DOI 10.1016/0006-291X(91)91336-B; HEGELE RA, 1991, J CLIN ENDOCR METAB, V72, P730, DOI 10.1210/jcem-72-3-730; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JACKSON RL, 1983, ENZYMES, V16, P141; KADOWAKI H, 1992, J LIPID RES, V33, P1689; KATZEL LI, 1992, ARTERIOSCLER THROMB, V12, P814, DOI 10.1161/01.ATV.12.7.814; KUUSI T, 1980, ATHEROSCLEROSIS, V36, P589, DOI 10.1016/0021-9150(80)90251-8; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; MARTIN GA, 1988, J BIOL CHEM, V263, P10907; MILLER GJ, 1975, LANCET, V1, P16; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NOZAKI S, 1986, METABOLISM, V35, P53, DOI 10.1016/0026-0495(86)90095-8; PETERSON J, 1986, BIOCHIM BIOPHYS ACTA, V878, P65, DOI 10.1016/0005-2760(86)90344-9; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; SAMMETT D, 1985, J BIOL CHEM, V260, P6687; SHIRAI K, 1981, BIOCHEM BIOPH RES CO, V100, P591, DOI 10.1016/S0006-291X(81)80217-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TIKKANEN MJ, 1982, J CLIN ENDOCR METAB, V54, P1113, DOI 10.1210/jcem-54-6-1113	28	139	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16376	16382						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206946				2022-12-27	WOS:A1994NQ72900065
J	DEPALO, D; KINLAW, WB; ZHAO, CQ; ENGELBERGKULKA, H; STGERMAIN, DL				DEPALO, D; KINLAW, WB; ZHAO, CQ; ENGELBERGKULKA, H; STGERMAIN, DL			EFFECT OF SELENIUM DEFICIENCY ON TYPE-I 5'-DEIODINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE GENE; 3' UNTRANSLATED REGION; XENOPUS-LAEVIS-OOCYTES; RAT-LIVER; IODOTHYRONINE 5'-DEIODINASE; MESSENGER-RNA; THYROID-HORMONE; UGA CODON; SELENOCYSTEINE; SEQUENCES	The type I iodothyronine 5' deiodinase (5'-DI) present in rat liver and kidney has recently been demonstrated to be a selenoprotein. The goal of the present study was to examine in detail the effect of selenium (Se) deficiency on 5'-DI at the protein and mRNA levels. In weanling rats fed a selenium-deficient (Se(-)) diet for 6 weeks, 5'-DI activity was decreased 91 and 69% relative to control activities in liver and kidney, respectively. Administration of 3,5,3'-triiodothyronine resulted in a a-fold increase in 5'-DI activity in control animals, but had little or no effect on 5'-DI activity in Se(-) animals. Western analysis using a specific antiserum directed against a bacterial fusion protein containing the carboxyl-terminal half of the 5'-DI protein demonstrated that this decrease in 5'-DI activity in Se(-) animals was explained by a marked decrease in 5'-DI protein. Administration of Se to Se(-) animals resulted in parallel increases in 5'-DI protein and activity over a 72-h time period. It was also shown that selenium deficiency was accompanied by a 40% decrease in 5'-DI mRNA levels in the kidney, but not in the liver. In both tissues, the administration of 3,5,3'-triiodothyronine resulted in increased 5'-DI mRNA levels which were not altered by selenium status. These studies indicate that selenium deficiency decreases 5'-DI activity by decreasing the amount of 5'-DI protein. The mechanism of this impairment in enzyme synthesis appears to be a defect in translation, presumably due to a block in the UGA-directed selenocysteine incorporation in selenium deficiency.	DARTMOUTH COLL,SCH MED,DEPT MED,LEBANON,NH 03756; DARTMOUTH COLL,SCH MED,DEPT PHYSIOL,LEBANON,NH 03756; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MOLEC BIOL,IL-91010 JERUSALEM,ISRAEL	Dartmouth College; Dartmouth College; Hebrew University of Jerusalem					NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042271, R01DK043142] Funding Source: NIH RePORTER; NCI NIH HHS [CA 23108] Funding Source: Medline; NIDDK NIH HHS [DK-42271, DK-43142] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKETT GJ, 1987, BIOCHEM J, V248, P443, DOI 10.1042/bj2480443; BECKETT GJ, 1991, J TRACE ELEM ELECT H, V5, P265; BEHNE D, 1990, BIOCHEM BIOPH RES CO, V173, P1143, DOI 10.1016/S0006-291X(05)80905-2; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; CHANG M, 1991, BIOCHEM BIOPH RES CO, V181, P1431, DOI 10.1016/0006-291X(91)92099-6; CHRISTENSEN MJ, 1992, J NUTR, V122, P1620, DOI 10.1093/jn/122.8.1620; Cochran W.G, 1957, STAT METHODS, V6th ed; GODFREY K, 1985, NEW ENGL J MED, V313, P1450, DOI 10.1056/NEJM198512053132305; GROSS M, 1992, ACTA ENDOCRINOL-COP, V126, P175; HARLOWE E, 1988, ANTIBODIES LABORATOR; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; HILL KE, 1992, BIOCHEM BIOPH RES CO, V185, P260, DOI 10.1016/S0006-291X(05)80984-2; HILL KE, 1993, P NATL ACAD SCI USA, V90, P537, DOI 10.1073/pnas.90.2.537; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; OMARA BA, 1993, ENDOCRINOLOGY, V133, P1715, DOI 10.1210/en.133.4.1715; SHEN QC, 1993, J BIOL CHEM, V268, P11463; STGERMAIN DL, 1989, J BIOL CHEM, V264, P3054; STGERMAIN DL, 1988, J CLIN INVEST, V81, P1476, DOI 10.1172/JCI113479; STGERMAIN DL, 1990, J BIOL CHEM, V265, P20087; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VISSER TJ, 1988, J CLIN ENDOCR METAB, V67, P17, DOI 10.1210/jcem-67-1-17; VISSER TJ, 1976, BIOCHEM J, V157, P479, DOI 10.1042/bj1570479; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660	26	40	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16223	16228						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206925				2022-12-27	WOS:A1994NQ72900043
J	KRUKLITIS, R; NAKAI, H				KRUKLITIS, R; NAKAI, H			PARTICIPATION OF THE BACTERIOPHAGE-MU-A PROTEIN AND HOST FACTORS IN THE INITIATION OF MU-DNA-SYNTHESIS IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI MUTANTS; NUCLEOPROTEIN STRUCTURES; REPLICATION PROTEIN; GENE-PRODUCT; INVITRO TRANSPOSITION; ENZYMATIC REPLICATION; DEOXYRIBONUCLEIC-ACID; PHYSICAL-PROPERTIES; NALIDIXIC-ACID	During bacteriophage Mu transposition, strand transfer is catalyzed in the presence of phage-encoded A and B proteins and Escherichia coli HU protein, attaching Mu ends to target DNA and creating an intermediate in transposition. Bacteriophage Mu A protein, which remains tightly bound to the Mu ends in the native strand-transfer intermediate, blocked initiation of Mu DNA replication by a system of 8 host proteins (DnaB helicase, DnaC protein, DnaG primase, DNA polymerase III holoenzyme, DNA polymerase I, DNA gyrase, DNA ligase, and single-strand binding protein). This 8-protein system had all enzymatic activities to convert the deproteinized intermediate to a cointegrate; however, additional host factor(s) were required to replicate the native intermediate. While replication of the native intermediate absolutely required DnaB helicase, DnaC protein, and DNA polymerase III holoenzyme, the specific requirements were relaxed for the deproteinized intermediate. Other host factors were able to replace these specific factors. These results indicate that Mu A protein, in conjunction with additional host factor(s), acts to promote assembly of specific host replication proteins at the Mn replication fork. This process may alter the stable interaction of Mu A protein with the ends to allow initiation of Mu DNA synthesis.	GEORGETOWN UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WASHINGTON, DC 20007 USA	Georgetown University								ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; ARAI K, 1981, J BIOL CHEM, V256, P5247; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; CAMPBELL JL, 1972, P NATL ACAD SCI USA, V69, P2090, DOI 10.1073/pnas.69.8.2090; CARL PL, 1970, MOL GEN GENET, V109, P107, DOI 10.1007/BF00269647; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CHACONAS G, 1981, J MOL BIOL, V150, P341, DOI 10.1016/0022-2836(81)90551-9; CHACONAS G, 1983, VIROLOGY, V128, P48, DOI 10.1016/0042-6822(83)90317-3; CRAIGIE R, 1985, J BIOL CHEM, V260, P1832; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; DODSON M, 1989, J BIOL CHEM, V264, P10719; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; GEFTER ML, 1971, P NATL ACAD SCI USA, V68, P3150, DOI 10.1073/pnas.68.12.3150; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P4474, DOI 10.1073/pnas.73.12.4474; HARSHEY RM, 1984, NATURE, V311, P580, DOI 10.1038/311580a0; HIGGINS NP, 1983, J BIOL CHEM, V258, P4293; HIGGINS NP, 1983, CELL, V33, P623, DOI 10.1016/0092-8674(83)90443-9; HUBSCHER U, 1980, J BIOL CHEM, V255, P1698; JOHANSON KO, 1980, J BIOL CHEM, V255, P984; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; KOBORI JA, 1982, J BIOL CHEM, V257, P13763; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LANKA E, 1983, NUCLEIC ACIDS RES, V11, P987, DOI 10.1093/nar/11.4.987; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6547; MASAI H, 1990, J BIOL CHEM, V265, P15134; MATSON SW, 1981, J BACTERIOL, V146, P275, DOI 10.1128/JB.146.1.275-284.1981; MCBETH DL, 1983, J VIROL, V48, P149, DOI 10.1128/JVI.48.1.149-156.1983; MCBETH DL, 1982, J VIROL, V44, P555, DOI 10.1128/JVI.44.2.555-564.1982; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MOSES RE, 1970, P NATL ACAD SCI USA, V67, P674, DOI 10.1073/pnas.67.2.674; NAKAI H, 1993, J BIOL CHEM, V268, P23997; NAKAI H, 1988, J BIOL CHEM, V263, P9831; PATO M, 1987, J BACTERIOL, V169, P5504, DOI 10.1128/jb.169.12.5504-5509.1987; RESIBOIS A, 1984, PROTEINS INVOLVED DN, P69; ROSS W, 1986, J BACTERIOL, V167, P905, DOI 10.1128/jb.167.3.905-919.1986; ROWEN L, 1978, J BIOL CHEM, V253, P758; Sambrook J, 1989, MOL CLONING LABORATO; SCHALLER H, 1972, J MOL BIOL, V63, P183, DOI 10.1016/0022-2836(72)90369-5; SCHUBACH WH, 1973, J MOL BIOL, V74, P205, DOI 10.1016/0022-2836(73)90107-1; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; TOUSSAINT A, 1974, MOL GEN GENET, V131, P209, DOI 10.1007/BF00267960; TOUSSAINT A, 1983, MOBILE GENETIC ELEME, P105; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WECHSLER JA, 1975, J BACTERIOL, V121, P594, DOI 10.1128/JB.121.2.594-599.1975; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; WEINER JH, 1975, J BIOL CHEM, V250, P1972; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; WICKNER W, 1973, P NATL ACAD SCI USA, V70, P1764, DOI 10.1073/pnas.70.6.1764	66	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16469	16477						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206956				2022-12-27	WOS:A1994NQ72900077
J	SINGER, KL; STEVENSON, BR; WOO, PL; FIRESTONE, GL				SINGER, KL; STEVENSON, BR; WOO, PL; FIRESTONE, GL			RELATIONSHIP OF SERINE/THREONINE PHOSPHORYLATION/DEPHOSPHORYLATION SIGNALING TO GLUCOCORTICOID REGULATION OF TIGHT JUNCTION PERMEABILITY AND ZO-1 DISTRIBUTION IN NONTRANSFORMED MAMMARY EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; NUCLEAR RECEPTORS; ZONULA-OCCLUDENS; GENE-EXPRESSION; PROTEIN ZO-1; 2 STRAINS; IDENTIFICATION; RESISTANCE; CINGULIN; GROWTH	The synthetic glucocorticoid dexamethasone regulates tight junction permeability resulting in an increased transepithelial electrical resistance (TER) of cultured 31EG4 mammary epithelial cells. Inhibition of cellular type 1 and type 2A protein phosphatase activity by okadaic acid reduced the TER of dexamethasone-treated monolayers of 31EG4 cells to basal levels within 24 h. Coincident with the increase in tight junction permeability, immunofluorescence revealed that okadaic acid caused a partial cellular redistribution of the ZO-1 tight junction-associated protein. The potent glucocorticoid antagonist RU486 had no effect on TER or ZO-1 distribution, indicating that the effects of okadaic acid are not a result of disrupting glucocorticoid receptor function. Immunoprecipitation of P-32-labeled cells and V8 protease peptide mapping demonstrated that dexamethasone did not alter ZO-1 phosphorylation. However, consistent with the changes in TER, dexamethasone induced a 2.3-fold stimulation in ZO-1 protein levels which was reduced to 73% of basal levels by okadaic acid. No effects on ZO-1 transcript levels were observed. Monolayers grown in the presence of glucocorticoids had only 28% less junction density and 16.5% more Linear junction/cell, which cannot account for the observed increases of TER and ZO-1 protein levels. Taken together, our results have shown that a disruption of phosphorylation/dephosphorylation activity overrides the glucocorticoid regulation of tight junction permeability in 31EG4 mammary cells.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720; UNIV ALBERTA,DEPT ANAT & CELL BIOL,EDMONTON T6G 2H7,AB,CANADA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Alberta					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK042799, R01DK042799] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-42799] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; ANDERSON JM, 1989, J CELL BIOL, V109, P1047, DOI 10.1083/jcb.109.3.1047; BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; CEREIJIDO M, 1981, AM J PHYSIOL, V240, pC96, DOI 10.1152/ajpcell.1981.240.3.C96; CEREIJIDO M, 1991, TIGHT JUNCTIONS, P1; CITI S, 1993, J CELL BIOL, V121, P485, DOI 10.1083/jcb.121.3.485; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; CITI S, 1992, J CELL BIOL, V117, P169, DOI 10.1083/jcb.117.1.169; CLAUDE P, 1978, J MEMBRANE BIOL, V39, P219, DOI 10.1007/BF01870332; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; FULLER PJ, 1991, FASEB J, V5, P3092, DOI 10.1096/fasebj.5.15.1743440; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; GONZALEZMARISCAL L, 1985, J MEMBRANE BIOL, V86, P113, DOI 10.1007/BF01870778; GONZALEZMARISCAL L, 1990, AM J PHYSIOL, V259, pC978, DOI 10.1152/ajpcell.1990.259.6.C978; GOODMAN LJ, 1993, MOL ENDOCRINOL, V7, P94, DOI 10.1210/me.7.1.94; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; HARAGUCHI T, 1991, J BIOL CHEM, V266, P18299; HARLOW E, 1988, ANTIBODIES LABORATOR, P641; HOWARTH AG, 1994, J MEMBRANE BIOL, V137, P261; HOWARTH AG, 1992, AM J PHYSIOL, V262, P461; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINZELL JL, 1971, J PHYSIOL-LONDON, V216, P701, DOI 10.1113/jphysiol.1971.sp009548; MADARA JL, 1988, CELL, V53, P497, DOI 10.1016/0092-8674(88)90562-4; MADARA JL, 1985, J CELL BIOL, V101, P2124, DOI 10.1083/jcb.101.6.2124; MADARA JL, 1987, J MEMBRANE BIOL, V100, P49; MANDEL LJ, 1993, NATURE, V361, P552, DOI 10.1038/361552a0; MCROBERTS JA, 1992, AM J PHYSIOL, V262, pC207, DOI 10.1152/ajpcell.1992.262.1.C207; MCROBERTS JA, 1990, J CLIN INVEST, V85, P1127, DOI 10.1172/JCI114544; MOGUILEWSKY M, 1984, J STEROID BIOCHEM, V20, P271, DOI 10.1016/0022-4731(84)90216-4; NIGAM SK, 1991, BIOCHEM BIOPH RES CO, V181, P548, DOI 10.1016/0006-291X(91)91224-Z; OJAKIAN GK, 1981, CELL, V23, P95, DOI 10.1016/0092-8674(81)90274-9; PITELKA DR, 1973, J CELL BIOL, V56, P797, DOI 10.1083/jcb.56.3.797; PITELKA DR, 1978, LACTATION COMPREHENS, P141; RABITO CA, 1991, TIGHT JUNCTIONS, P203; REICHEL RR, 1993, FASEB J, V7, P427, DOI 10.1096/fasebj.7.5.8385039; SANCHEZ I, 1993, CELL GROWTH DIFFER, V4, P215; SHORE EM, 1991, J BIOL CHEM, V266, P19672; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; STEVENSON BR, 1989, AM J PHYSIOL, V257, pC621, DOI 10.1152/ajpcell.1989.257.4.C621; STEVENSON BR, 1989, BIOCHEM J, V263, P597, DOI 10.1042/bj2630597; STEVENSON BR, 1988, J CELL BIOL, V107, P2401, DOI 10.1083/jcb.107.6.2401; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101; ZETTL KS, 1992, P NATL ACAD SCI USA, V89, P9069, DOI 10.1073/pnas.89.19.9069; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	52	97	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16108	16115						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206910				2022-12-27	WOS:A1994NQ72900026
J	TAYEH, MA; OLSON, ST; SHORE, JD				TAYEH, MA; OLSON, ST; SHORE, JD			SURFACE-INDUCED ALTERATIONS IN THE KINETIC PATHWAY FOR CLEAVAGE OF HUMAN HIGH-MOLECULAR-WEIGHT KININOGEN BY PLASMA KALLIKREIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; COAGULATION FACTOR-XII; LIGHT CHAIN; BLOOD-COAGULATION; CONTACT ACTIVATION; HAGEMAN-FACTOR; HMW KININOGEN; HEAVY-CHAIN; FUNCTIONAL-PROPERTIES; PROCOAGULANT ACTIVITY	We have studied the cleavage of human high molecular weight kininogen (HK) by plasma kallikrein in the absence and presence of the surfaces, dextran sulfate (DxSO(4)) and sulfatides. Using a combination of SDS-polyacrylamide gel electrophoresis, Western blotting with polyclonal antibodies that specifically recognize the COOH terminus of the bradykinin moiety, and high pressure liquid chromatography analyses of the cleavage reaction, we have identified two intermediates in the formation of bradykinin from intact kininogen and demonstrated that alternative cleavage pathways are followed in the absence and presence of surfaces. The COOH-terminal bradykinin cleavage occurred first both in the absence and presence of DxSO(4), producing a 103-kDa HK intermediate consisting of disulfide-linked heavy and light chains that retained the kinin moiety. In the presence of DxSO(4), this was followed exclusively by the NH2-terminal bradykinin cleavage and release of kinin with no apparent change in molecular mass. Subsequently, a slower cleavage of an 8-kDa peptide from the amino terminus of the HK light chain occurred to form a 95-kDa end product. In contrast to this sequential cleavage pattern, NH2-terminal bradykinin and light chain cleavages occurred randomly in the absence of DxSO(4), resulting in the production of an additional 95-kDa intermediate that retained bradykinin but had lost the 8-kDa peptide from the HK light chain. Comparison of the relative rates of the three kallikrein cleavages in the absence and presence of DxSO(4) indicated that the surface enhanced the rates of both bradykinin cleavages 2-4-fold, but inhibited the light chain cleavage rate similar to 10-fold, thereby accounting for the change from a partially random to a sequential cleavage pattern in the presence of the surface. Steady-state kinetic analysis revealed that DxSO(4) enhanced the K-cat/K-M for bradykinin release by the rate-limiting NH2-terminal bradykinin cleavage by similar to 2-fold due exclusively to an increase in K-cat. Sulfatides appeared to produce the same effects on the pattern of HK cleavages as DxSO(4). Blocking of the nonactive site, i.e. exosite, interaction between kallikrein and HK with excess prekallikrein or a synthetic peptide containing the region of HK that interacts with the kallikrein exosite significantly reduced the rate of bradykinin release as well as HK cleavages detected by SDS-polyacrylamide gel electrophoresis either in the absence or presence of DxSO(4), indicating that the exosite interaction facilitates bradykinin cleavage.	HENRY FORD HOSP,DIV BIOCHEM RES,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital					NHLBI NIH HHS [HL 25670] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025670] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BOCK PE, 1983, J BIOL CHEM, V258, P5079; BOCK PE, 1985, J BIOL CHEM, V260, P2434; BOUMA BN, 1983, BLOOD, V62, P1123; CHAO J, 1988, BIOCHIM BIOPHYS ACTA, V964, P329, DOI 10.1016/0304-4165(88)90033-5; COLMAN RW, 1985, BLOOD, V65, P311; GREENGARD JS, 1984, BIOCHEMISTRY-US, V23, P6863, DOI 10.1021/bi00321a090; Griffin J H, 1976, Methods Enzymol, V45, P56; HAN YN, 1975, J BIOCHEM-TOKYO, V77, P55; HEIMARK RL, 1981, METHOD ENZYMOL, V80, P157; HIGASHIYAMA S, 1987, BIOCHEMISTRY-US, V26, P7450, DOI 10.1021/bi00397a038; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; IKARI N, 1981, J BIOCHEM, V89, P1699, DOI 10.1093/oxfordjournals.jbchem.a133370; KATO H, 1981, METHOD ENZYMOL, V80, P172; KERBIRIOU DM, 1980, J BIOL CHEM, V255, P3952; KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS SD, 1985, J BIOL CHEM, V260, P192; MAIER M, 1983, P NATL ACAD SCI-BIOL, V80, P3928, DOI 10.1073/pnas.80.13.3928; MANDLE RJ, 1976, P NATL ACAD SCI USA, V73, P4179, DOI 10.1073/pnas.73.11.4179; MEIER HL, 1977, J CLIN INVEST, V60, P18, DOI 10.1172/JCI108754; MELHADO LL, 1982, J AM CHEM SOC, V104, P7299, DOI 10.1021/ja00389a065; MORI K, 1981, J BIOCHEM-TOKYO, V89, P1465, DOI 10.1093/oxfordjournals.jbchem.a133339; MULLERESTERL W, 1985, FEBS LETT, V182, P310, DOI 10.1016/0014-5793(85)80322-7; MULLERESTERL W, 1986, TRENDS BIOCHEM SCI, V11, P336, DOI 10.1016/0968-0004(86)90293-8; NAKAYASU T, 1979, J BIOCHEM, V85, P249, DOI 10.1093/oxfordjournals.jbchem.a132318; NARAYANAN TK, 1984, J CHROMATOGR, V306, P109, DOI 10.1016/S0378-4347(00)80874-9; OHKUBO I, 1984, BIOCHEMISTRY-US, V23, P5691, DOI 10.1021/bi00319a005; OLSON ST, 1993, BIOCHEMISTRY-US, V32, P12148, DOI 10.1021/bi00096a027; OLSON ST, 1993, BIOCHEMISTRY-US, V32, P12136, DOI 10.1021/bi00096a026; REDDIGARI S, 1988, BLOOD, V71, P1334; RETZIOS AD, 1987, J BIOL CHEM, V262, P3074; SCHIFFMAN S, 1980, J BIOL CHEM, V255, P6433; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SCICLI AG, 1982, J LAB CLIN MED, V100, P81; SCOTT CF, 1984, J CLIN INVEST, V73, P954, DOI 10.1172/JCI111319; SHIMADA T, 1985, J BIOCHEM-TOKYO, V97, P1637, DOI 10.1093/oxfordjournals.jbchem.a135221; SHORE JD, 1987, BIOCHEMISTRY-US, V26, P2250, DOI 10.1021/bi00382a027; SINHA D, 1987, BIOCHEMISTRY-US, V26, P3768, DOI 10.1021/bi00387a005; SUEYOSHI T, 1985, FEBS LETT, V182, P193, DOI 10.1016/0014-5793(85)81182-0; SUGO T, 1980, BIOCHEMISTRY-US, V19, P3215, DOI 10.1021/bi00555a018; TAIT JF, 1986, J BIOL CHEM, V261, P5396; TAIT JF, 1987, J BIOL CHEM, V262, P11651; TANS G, 1987, J BIOL CHEM, V262, P11308; TANS G, 1983, J BIOL CHEM, V258, P8215; THOMPSON RE, 1979, P NATL ACAD SCI USA, V76, P4862, DOI 10.1073/pnas.76.10.4862; THOMPSON RE, 1978, J EXP MED, V147, P488, DOI 10.1084/jem.147.2.488; VANDERGRAAF F, 1982, J BIOL CHEM, V257, P4300; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; WIGGINS RC, 1977, P NATL ACAD SCI USA, V74, P4636, DOI 10.1073/pnas.74.10.4636	51	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16318	16325						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206938				2022-12-27	WOS:A1994NQ72900057
J	FRENCH, AR; SUDLOW, GP; WILEY, HS; LAUFFENBURGER, DA				FRENCH, AR; SUDLOW, GP; WILEY, HS; LAUFFENBURGER, DA			POSTENDOCYTIC TRAFFICKING OF EPIDERMAL GROWTH FACTOR-RECEPTOR COMPLEXES IS MEDIATED THROUGH SATURABLE AND SPECIFIC ENDOSOMAL INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; LIGAND-INDUCED INTERNALIZATION; FACTOR-ALPHA; QUANTITATIVE-ANALYSIS; ENDOCYTIC PATHWAY; HUMAN-FIBROBLASTS; DOWN-REGULATION; EGF RECEPTOR; DEGRADATION; PROTEIN	Intracellular trafficking of the epidermal growth factor receptor (EGF-R) is regulated by receptor occupancy. To investigate this, we developed an assay to study endosomal sorting under steady-state conditions. Using a cell line transfected with EGF-R variants, we found that the fraction of internalized EGF.EGF-R complexes sorted to lysosomes was a function of the number of intracellular complexes and required sequences in the cytoplasmic domain of the receptor. As the number of intracellular occupied wild-type receptors increased from 3 x 10(2) to 2 x 10(5)/cell, the fraction of internalized EGF that was degraded dropped from 70 to 20%. Transforming growth factor-alpha, which dissociates from the EGF-R at endosomal pH, was degraded to a uniform extent of approximately 50% at all intracellular ligand concentrations. EGF internalized by receptors lacking a cytoplasmic domain (c'647) was degraded to an extent of only 5-10% independent of the number of intracellular complexes. Mutant receptors truncated either at residues 1022 or 973 displayed sorting patterns intermediate between wild-type and c'647 receptors. Despite large differences in their internalization rates, the fractional sorting patterns of c'1022 and c'973 receptors were indistinguishable, Receptor tyrosine kinase activity appeared to have a small effect on sorting pattern, but only in the context of full-length receptors. Our results indicate that the default pathway of internalized receptors is rapidly recycling and that lysosomal targeting of occupied EGF-R is due to endosomal retention that is both specific and saturable. In addition, internalization and endosomal retention of EGF-R appear to be mediated by distinct structural elements.	UNIV ILLINOIS, DEPT CELL & STRUCT BIOL, URBANA, IL 61801 USA; UNIV UTAH, MED CTR, DEPT PATHOL, DIV CELL BIOL & IMMUNOL, SALT LAKE CITY, UT 84132 USA	University of Illinois System; University of Illinois Urbana-Champaign; Utah System of Higher Education; University of Utah	FRENCH, AR (corresponding author), UNIV ILLINOIS, DEPT CHEM ENGN, URBANA, IL 61801 USA.			Wiley, Steven/0000-0003-0232-6867				BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BURGERT HG, 1983, EXP CELL RES, V144, P127, DOI 10.1016/0014-4827(83)90447-0; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DUNN KW, 1992, J CELL BIOL, V117, P301, DOI 10.1083/jcb.117.2.301; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; HELIN K, 1991, J BIOL CHEM, V266, P8363; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; KAMPS MP, 1988, ONCOGENE, V2, P305; KORC M, 1989, J BIOL CHEM, V264, P14990; LAUFFENBURGER DA, 1993, RECEPTORS MODELS BIN, P73; LINDERMAN JJ, 1988, J THEOR BIOL, V132, P203, DOI 10.1016/S0022-5193(88)80157-7; LINDERMAN JJ, 1986, BIOPHYS J, V50, P295, DOI 10.1016/S0006-3495(86)83463-4; LUND KA, 1990, J BIOL CHEM, V265, P15713; MARSH M, 1986, P NATL ACAD SCI USA, V83, P2899, DOI 10.1073/pnas.83.9.2899; MASUI H, 1991, CANCER RES, V51, P6170; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; Segel IH, 1976, BIOCH CALCULATIONS, P214; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; SORKIN A, 1991, J CELL BIOL, V112, P55, DOI 10.1083/jcb.112.1.55; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; THEROUX SJ, 1992, J BIOL CHEM, V267, P16620; WARD DM, 1989, J BIOL CHEM, V264, P8164; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; ZIGMOND SH, 1982, J CELL BIOL, V92, P34, DOI 10.1083/jcb.92.1.34	43	128	132	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15749	15755						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195228				2022-12-27	WOS:A1994NP51300056
J	ROSEN, GD; BARKS, JL; IADEMARCO, MF; FISHER, RJ; DEAN, DC				ROSEN, GD; BARKS, JL; IADEMARCO, MF; FISHER, RJ; DEAN, DC			AN INTRICATE ARRANGEMENT OF BINDING-SITES FOR THE ETS FAMILY OF TRANSCRIPTION FACTORS REGULATES ACTIVITY OF THE ALPHA-4 INTEGRIN GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR SUPERFAMILY; ECDYSONE-INDUCIBLE GENE; LONG TERMINAL REPEAT; DNA-BINDING; C-ETS; LYMPHOID-CELLS; DROSOPHILA-MELANOGASTER; MONOCLONAL-ANTIBODY; ADHESION MOLECULE; LEUKEMIA-VIRUS	alpha 4 integrins mediate cell-cell and cell-extracellular matrix interactions that are critical for maturation and function of the immune system as well as differentiation of skeletal muscle. Here we examine molecular mechanisms controlling the pattern of alpha 4 expression. The activity of constructs containing 5' deletion mutants of the alpha 4 gene promoter was compared in transfection assays into cell lines that express alpha 4 and cell lines that do not. The sequence between position -42 and -76 base pairs (bp) was required for efficient transcription in cells that express alpha 4, but it showed no activity in HeLa cells, which do not express alpha 4. Three binding sites for the Ets family of transcription factors are found in this region: two adjacent sites at positions -50 and -54 bp and a more 5' site at position -67 bp. Using a series of constructs containing deletions and mutations in this region, we found that the 3'-most site alone was sufficient for binding GA-binding protein alpha (GABP alpha)/GABP beta and for a low level of transcriptional activation. When all three sites were present, a second complex ''a'' was detected, which contains an unknown member of the Ets family. Formation of complex a was cell-type specific and correlated with a high level of transcription. Deletion of the 5'-most Ets site had no effect on binding to GABP alpha/GABP beta, but it eliminated a. Concomitant with this loss of a, a new Ets-1-containing complex ''c'' appeared. Complex c substituted efficiently for complex a in transcriptional activation. We conclude that although neither of the two 5'-most Ets sites alone binds nuclear protein, they appear to act as modulators which control the pattern of Ets proteins that bind the alpha 4 gene promoter. This arrangement of Ets sites, coupled with the tissue- and developmental-specific expression of Ets members, likely play a key role in defining the pattern of alpha 4 integrin.	WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; PROGRAM RESOURCES INC,DYNCORP,FREDERICK,MD 21701	Washington University (WUSTL); Washington University (WUSTL)			Fisher, Robert/B-1431-2009		NHLBI NIH HHS [HL 02558, HL 43418] Funding Source: Medline; NIAMS NIH HHS [AR41908] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041908] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BHAT NK, 1992, HYBRIDOMA, V11, P277, DOI 10.1089/hyb.1992.11.277; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DEAN DC, 1989, MOL CELL BIOL, V9, P1498, DOI 10.1128/MCB.9.4.1498; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FEIGL G, 1989, NUCLEIC ACIDS RES, V17, P7167, DOI 10.1093/nar/17.18.7167; FUJIWARA S, 1990, HYBRIDOMA, V9, P559, DOI 10.1089/hyb.1990.9.559; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; KANG YH, 1991, J HISTOCHEM CYTOCHEM, V39, P413, DOI 10.1177/39.4.2005371; KANG YH, 1991, ANAT REC, V229, P86, DOI 10.1002/ar.1092290110; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOISUMI S, 1990, ONCOGENE, V5, P675; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAZENBY AJ, 1990, AM REV RESPIR DIS, V142, P206, DOI 10.1164/ajrccm/142.1.206; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LEUNG S, 1993, ONCOGENE, V8, P989; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MACARAK EJ, 1989, J CELL PHYSIOL, V139, P517, DOI 10.1002/jcp.1041390310; MOULD AP, 1990, J BIOL CHEM, V265, P4020; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; PETTERSSON M, 1987, GENE DEV, V1, P962, DOI 10.1101/gad.1.9.962; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SETH A, 1993, ONCOGENE, V8, P1783; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VIRVASIUS JV, 1993, GENE DEV, V7, P380; WALLE TK, 1990, SCAND J IMMUNOL, V31, P535, DOI 10.1111/j.1365-3083.1990.tb02802.x; WALSH GM, 1991, J IMMUNOL, V146, P3419; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0; YUAN Q, 1991, BIOCHEM BIOPH RES CO, V176, P1443, DOI 10.1016/0006-291X(91)90448-G	72	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15652	15660						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195215				2022-12-27	WOS:A1994NP51300043
J	WEBER, C; LEE, VD; CHAZIN, WJ; HUANG, B				WEBER, C; LEE, VD; CHAZIN, WJ; HUANG, B			HIGH-LEVEL EXPRESSION IN ESCHERICHIA-COLI AND CHARACTERIZATION OF THE EF-HAND CALCIUM-BINDING PROTEIN CALTRACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; MYOSIN LIGHT CHAIN; SPINDLE POLE BODY; MODULATED PROTEINS; CA-2+-BINDING PROTEIN; MOLECULAR-CLONING; FLAGELLAR ROOTS; CA2+ BINDING; TROPONIN-C; 3D NMR	Caltractin is a member of the calmodulin superfamily of Ca2+-binding proteins that was originally cloned at the DNA level from the unicellular green alga Chlamydomonas reinhardtii. Human and mouse homologs to algal caltractin have been recently characterized. In the studies reported here, recombinant Chlamydomonas caltractin was expressed at high levels in Escherichia coli and purified to homogeneity. The use of the ompT- host BL21 proved critical for obtaining high yields of homogeneous full-length protein. Growth and purification protocols were optimized to allow reproducible and efficient production of tens of milligrams of pure protein from 1-liter cultures. Caltractin has a distinct UV spectrum which is largely dominated by the fine structure due to the 9 Phe residues. Unlike other members of the same protein family, the UV and the CD spectra do not change upon addition of Ca2+ to the apoprotein. However, the H-1 NMR spectrum shows distinct changes upon Ca2+ binding, which are indicative of structural and/or dynamic changes largely reminiscent of other members of the calmodulin superfamily. Ca2+ binding measurements demonstrated the binding of four Ca2+ ions to caltractin with two higher affinity (K-d = 1.2 x 10(-6) M) and two lower affinity (K-d = 1.6 x 10(-4) M) sites. Caltractin is highly stable in both the apo- and the Ca2+-loaded states. The unusual stability of apocaltractin makes this protein highly suited for structural studies by multidimensional NMR aimed at understanding the structural and dynamic consequences of Ca2+ binding, and the molecular basis of Ca2+ signal transduction.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NIGMS NIH HHS [GM 40120, GM 38113] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040120, R29GM040120] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; BHATTACHARYA D, 1993, PLANT MOL BIOL, V23, P1243, DOI 10.1007/BF00042357; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BURGESS WH, 1982, J BIOL CHEM, V257, P1800; CARLSTROM G, 1993, J MOL BIOL, V231, P415, DOI 10.1006/jmbi.1993.1291; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; DASILVA ACR, 1991, TRENDS BIOCHEM SCI, V16, P53, DOI 10.1016/0968-0004(91)90024-P; ERRABOLU R, 1994, J CELL SCI, V107, P9; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; GARBAREK Z, 1990, NATURE, V345, P132; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HAIECH J, 1991, J BIOL CHEM, V266, P3427; HAIECH J, 1988, CALCIUM BINDING PROT, V1, P11; HUANG B, 1988, J CELL BIOL, V107, P133, DOI 10.1083/jcb.107.1.133; HUANG B, 1988, J CELL BIOL, V107, P121, DOI 10.1083/jcb.107.1.121; IIDA S, 1986, J BIOCHEM-TOKYO, V99, P1765, DOI 10.1093/oxfordjournals.jbchem.a135654; IKURA M, 1990, BIOCHEM PHARMACOL, V40, P153; IKURA M, 1985, BIOCHEMISTRY-US, V24, P4264, DOI 10.1021/bi00337a002; KILHOFFER MC, 1992, BIOCHEMISTRY-US, V31, P8098, DOI 10.1021/bi00149a046; KIM HW, 1990, FEBS LETT, V272, P34, DOI 10.1016/0014-5793(90)80442-L; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; LEE VD, 1993, P NATL ACAD SCI USA, V90, P11039, DOI 10.1073/pnas.90.23.11039; LEE VD, 1990, CALCIUM INTRACELLULA, P245; LINSE S, 1987, BIOCHEMISTRY-US, V26, P6723, DOI 10.1021/bi00395a023; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; MARTIN EA, 1984, MENCKENIANA, P1; MAUNE JF, 1992, J BIOL CHEM, V267, P52866; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MELKONIAN M, 1988, PROTOPLASMA, V144, P56, DOI 10.1007/BF01320280; MESSERLE BA, 1989, J MAGN RESON, V85, P608, DOI 10.1016/0022-2364(89)90252-7; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; NAKAYAMA S, 1992, J MOL EVOL, V34, P416, DOI 10.1007/BF00162998; OGAWA K, 1993, BIOCHIM BIOPHYS ACTA, V1216, P126, DOI 10.1016/0167-4781(93)90048-I; OLWIN BB, 1984, J BIOL CHEM, V259, P949; POTTER JD, 1983, METHOD ENZYMOL, V102, P135; ROBERTS DM, 1985, BIOCHEMISTRY-US, V24, P5090, DOI 10.1021/bi00340a020; SALISBURY JL, 1984, J CELL BIOL, V99, P962, DOI 10.1083/jcb.99.3.962; SPANG A, 1993, J CELL BIOL, V123, P405, DOI 10.1083/jcb.123.2.405; STAROVASNIK MA, 1992, PROTEIN SCI, V1, P245; Strynadka NCJ, 1991, CURR OPIN STRUC BIOL, V1, P905, DOI 10.1016/0959-440X(91)90085-8; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TAILLON BE, 1992, J CELL BIOL, V119, P1613, DOI 10.1083/jcb.119.6.1613; TSUDA S, 1988, BIOCHEMISTRY-US, V27, P4120, DOI 10.1021/bi00411a032; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; WALTERSSON Y, 1993, BIOCHEMISTRY-US, V32, P7866, DOI 10.1021/bi00082a005; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	51	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15795	15802						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195234				2022-12-27	WOS:A1994NP51300062
J	MATTAR, S; SCHARF, B; KENT, SBH; RODEWALD, K; OESTERHELT, D; ENGELHARD, M				MATTAR, S; SCHARF, B; KENT, SBH; RODEWALD, K; OESTERHELT, D; ENGELHARD, M			THE PRIMARY STRUCTURE OF HALOCYANIN, AN ARCHAEAL BLUE COPPER PROTEIN, PREDICTS A LIPID ANCHOR FOR MEMBRANE FIXATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; SIGNAL PEPTIDE; NATRONOBACTERIUM-PHARAONIS; OUTER-MEMBRANE; GENE STRUCTURE; CLEAVAGE SITE; OPSIN GENE; LIPOPROTEIN; ARCHAEBACTERIUM	Halocyanin, a small blue copper protein, was isolated from the haloalkaliphilic archaeon Natronobacterium pharaonis. The NH2 terminus was not accessible to Edman degradation. About 70% of the amino acid sequence was determined by protein sequence analysis. The sequence information of two peptides was used for cloning and sequencing the halocyanin gene (hcy). The open reading frame codes for 489 base pairs, which account for a protein with 163 amino acids and a molecular mass of 17,223 Da. The discrepancy between this value and the molecular mass of 15,456 +/- 1.5 Da for the copper-free protein determined by electrospray mass spectrometry can be explained by a post-translational processing of the gene product. The NH2-terminal sequence of the open reading frame contains a motif that is characteristic for prokaryotic lipoproteins. Assuming a similar processing for halocyanin, Cys at position 25 of the primary transcript would be modified by a diphytanyl (glycerol)diether. Subsequently, the precursor is cleaved by a signal peptidase II-like protease and then acetylated at its NH2-terminal alpha-amino group. These modifications would yield a protein with a calculated molecular mass of 15,456 Ha. A comparison of the primary structure of halocyanin with a number of other blue copper proteins places it into the plastocyanin-related group.	MAX PLANCK INST MOLEK PHYSIOL, D-44139 DORTMUND, GERMANY; MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY; SCRIPPS RES INST, LA JOLLA, CA 92037 USA	Max Planck Society; Max Planck Society; Scripps Research Institute								ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; BERGMAN C, 1977, BIOCHEM BIOPH RES CO, V77, P1052, DOI 10.1016/S0006-291X(77)80084-3; BETLACH M, 1984, NUCLEIC ACIDS RES, V12, P7949, DOI 10.1093/nar/12.20.7949; BLANCK A, 1987, EMBO J, V6, P265, DOI 10.1002/j.1460-2075.1987.tb04749.x; BOUVIER J, 1991, J BACTERIOL, V173, P5523, DOI 10.1128/jb.173.17.5523-5531.1991; BRISCHWEIN M, 1993, BIOCHEMISTRY-US, V32, P13710, DOI 10.1021/bi00212a041; BROWN JW, 1989, CRIT REV MICROBIOL, V16, P287, DOI 10.3109/10408418909105479; BULUWELA L, 1989, NUCLEIC ACIDS RES, V17, P452, DOI 10.1093/nar/17.1.452; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COLMAN PM, 1978, NATURE, V272, P319, DOI 10.1038/272319a0; DASSARMA S, 1984, P NATL ACAD SCI-BIOL, V81, P125, DOI 10.1073/pnas.81.1.125; DEROSA M, 1986, MICROBIOL REV, V50, P70, DOI 10.1128/MMBR.50.1.70-80.1986; DUFFAUD GD, 1985, CURR TOP MEMBR TRANS, V24, P65; FUJITA VS, 1984, P NATL ACAD SCI-BIOL, V81, P4260, DOI 10.1073/pnas.81.14.4260; GIAM CZ, 1984, EUR J BIOCHEM, V141, P331, DOI 10.1111/j.1432-1033.1984.tb08196.x; GOTSCHLICH EC, 1987, FEMS MICROBIOL LETT, V43, P253; HANTKE K, 1973, EUR J BIOCHEM, V34, P284, DOI 10.1111/j.1432-1033.1973.tb02757.x; HASE T, 1977, FEBS LETT, V77, P308, DOI 10.1016/0014-5793(77)80257-3; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HOLTKE HJ, 1992, BIOTECHNIQUES, V12, P104; INOUYE S, 1983, EMBO J, V2, P87, DOI 10.1002/j.1460-2075.1983.tb01386.x; LANYI JK, 1990, J BIOL CHEM, V265, P1253; LANYI JK, 1974, BACTERIOL REV, V38, P272, DOI 10.1128/MMBR.38.3.272-290.1974; LODWICK D, 1991, SYST APPL MICROBIOL, V14, P352, DOI 10.1016/S0723-2020(11)80309-7; MATTAR S, 1993, THESIS RUHR U BOCHUM; MCMANUS JD, 1992, J BIOL CHEM, V267, P6531; POLLITT S, 1986, J BIOL CHEM, V261, P1835; REITER WD, 1988, NUCLEIC ACIDS RES, V16, P1, DOI 10.1093/nar/16.1.1; RYDEN L, 1984, COPPER PROTEINS COPP, V1, P157; RYDEN L, 1988, OXIDASES RELATED RED, P349; RYDEN LG, 1993, J MOL EVOL, V36, P41, DOI 10.1007/BF02407305; Sambrook J, 1989, MOL CLONING LABORATO; SCHARF B, 1993, BIOCHEMISTRY-US, V32, P12894, DOI 10.1021/bi00210a043; SCHARF B, 1992, THESIS RUHR U BOCHUM; SOLIMAN GSH, 1982, ZBL BAKT MIK HYG I C, V3, P318, DOI 10.1016/S0721-9571(82)80045-8; SOPPA J, 1994, SYST APPL MICROBIOL, V16, P725; STEINER M, 1983, THESIS LUDWIG MAXIMI; STRITTMATTER W, 1986, J EXP MED, V164, P2038, DOI 10.1084/jem.164.6.2038; SYKES AG, 1991, ADV INORG CHEM, V36, P377, DOI 10.1016/S0898-8838(08)60044-6; THOMM M, 1988, NUCLEIC ACIDS RES, V16, P151, DOI 10.1093/nar/16.1.151; TINDALL BJ, 1984, SYST APPL MICROBIOL, V5, P41; TOBARI J, 1981, BIOCHEM BIOPH RES CO, V101, P502, DOI 10.1016/0006-291X(81)91288-2; TOKUNAGA M, 1982, P NATL ACAD SCI-BIOL, V79, P2255, DOI 10.1073/pnas.79.7.2255; VOGELSANG H, 1983, METHOD ENZYMOL, V97, P226; WEYER KA, 1987, BIOCHEMISTRY-US, V26, P2909, DOI 10.1021/bi00384a036; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Zillig W., 1992, ORIGIN EVOLUTION CEL, P163	48	79	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14939	14945						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195126				2022-12-27	WOS:A1994NP73800017
J	VILLALBA, M; BATANERO, E; MONSALVE, RI; DELAPENA, MAG; LAHOZ, C; RODRIGUEZ, R				VILLALBA, M; BATANERO, E; MONSALVE, RI; DELAPENA, MAG; LAHOZ, C; RODRIGUEZ, R			CLONING AND EXPRESSION OF OLE-E-I, THE MAJOR ALLERGEN FROM OLIVE TREE POLLEN - POLYMORPHISM ANALYSIS AND TISSUE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Ole e I, the major allergen from the olive tree (Olea europaea), is one of the main causes of allergy in Mediterranean countries and some areas of North America. The cloning and sequencing of several cDNAs coding for the olive allergen have been achieved. cDNA has been synthesized from total pollen RNA and amplified by using the polymerase chain reaction. The nucleotide sequence data demonstrate the existence of microheterogeneities in at least 37 positions out of the 145 amino acids of Ole e I, thus explaining the high degree of polymorphism exhibited by the natural protein. One of the sequenced cDNAs encoding a full-length isoform was inserted into the plasmid vector pGEX-2T and overexpressed. The recombinant Ole e I has been produced in Escherichia coli as a fusion protein with glutathione S-transferase of Schistosoma japonicum. This chimeric protein was purified by affinity chromatography on a glutathione-Sepharose 4B column and digested with thrombin to release the recombinant allergen. Both the fusion protein and the recombinant Ole e I were recognized in Western blot analysis by rabbit polyclonal and mouse monoclonal antisera raised against native Ole e I as well as by the IgE of olive pollen-sensitive human sera. This indicates that the recombinant production of individual isoforms may be useful for the improvement of reagents to be used in diagnosis and therapy of IgE-mediated disorders. In addition, Ole e I mRNA has been observed to be pollen-specific as shown in a Northern blot analysis.	UNIV COMPLUTENSE MADRID,FAC QUIM,DEPT BIOQUIM & BIOL MOLEC,E-28040 MADRID,SPAIN; FDN JIMENEZ DIAZ,DEPT IMMUNOL,E-28040 MADRID,SPAIN	Complutense University of Madrid			Gonzalez, Manuel A/A-3404-2013; RODRIGUEZ, ROSALIA/K-4993-2014; Villalba, Mayte/K-5365-2014	RODRIGUEZ, ROSALIA/0000-0002-4280-3691; VILLALBA, MAYTE/0000-0002-0042-9953; Monsalve, Rafael/0000-0002-6838-4472					0	119	125	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15217	15222						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195158				2022-12-27	WOS:A1994NP73800055
J	INAGAKI, Y; TRUTER, S; RAMIREZ, F				INAGAKI, Y; TRUTER, S; RAMIREZ, F			TRANSFORMING GROWTH-FACTOR-BETA STIMULATES ALPHA-2(I) COLLAGEN GENE-EXPRESSION THROUGH A CIS-ACTING ELEMENT THAT CONTAINS AN SP1-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; TRANSCRIPTIONAL ACTIVATION; EXTRACELLULAR-MATRIX; FUNCTIONAL-ANALYSIS; DNA-SEQUENCES; REPORTER GENE; PROMOTER; FACTOR-BETA-1; INHIBITION; SP1	Transforming growth factor-beta 1 (TGF-beta) is a strong and rapid inducer of several genes coding for extracellular matrix components, such as type I collagen. Fire report here that TGF-beta stimulates transcription of the human alpha 2(I) collagen gene (COL1A2) promoter by increasing the affinity of an Sp1-containing protein complex for its cognate DNA-binding site. Cell transfection experiments mapped the TGF-beta-responsive element (TbRE) of the COL1A2 promoter to a 131 bp region that contains at least two cis-acting elements. Insertion of the TbRE upstream of the thymidine kinase promoter conferred TGF-beta inducibility to the otherwise unresponsive thymidine kinase promoter. Footprinting assays revealed that the TbRE contains two neighboring protein-bound sequences, termed Box 3A and Box B. Within Box 3A is an Sp1 recognition sequence whose structural integrity is required for nuclear protein binding in vitro, and for promoter inducibility in vivo. Gel mobility shift assays documented increased binding to the TbRE of nuclear proteins hom TGF-beta-treated cells compared with those from TGF-beta-untreated fibroblasts. There was, however, no binding increase with Box 3A alone or with an Sp1 oligonucleotide. Thus, the results strongly suggest a functional interaction between Sp1 and other components of the TbRE complex in mediating TGF-beta stimulation of COL1A2 gene expression.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038648, R37AR038648] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-38648] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BOAST S, 1990, J BIOL CHEM, V265, P13351; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DICKSON LA, 1985, NUCLEIC ACIDS RES, V13, P3427, DOI 10.1093/nar/13.10.3427; DIEGELMANN RF, 1988, COLLAGEN BIOCH BIOME, P113; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hay E.D., 1991, CELL BIOL EXTRACELLU, P419; HIGUCHI RB, 1988, NUCLEIC ACIDS RES, V10, P7351; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIM SJ, 1989, J BIOL CHEM, V264, P19373; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS GF, 1986, P NATL ACAD SCI USA, V83, P1; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NIEDERREITHER K, 1992, J CELL BIOL, V119, P1361, DOI 10.1083/jcb.119.5.1361; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; RIZZINO A, 1988, DEV BIOL, V130, P411, DOI 10.1016/0012-1606(88)90337-5; ROBERTS AB, 1990, ANN NY ACAD SCI, V580, P225, DOI 10.1111/j.1749-6632.1990.tb17931.x; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; Sambrook J, 1989, MOL CLONING LABORATO; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; TRUTER S, 1992, J BIOL CHEM, V267, P25389; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105	39	273	282	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14828	14834						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182090				2022-12-27	WOS:A1994NM06500080
J	KIM, JH; JOHANSEN, FE; ROBERTSON, N; CATINO, JJ; PRYWES, R; KUMAR, CC				KIM, JH; JOHANSEN, FE; ROBERTSON, N; CATINO, JJ; PRYWES, R; KUMAR, CC			SUPPRESSION OF RAS TRANSFORMATION BY SERUM RESPONSE FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							C-FOS PROMOTER; ALPHA-ACTIN PROMOTER; PROTEIN KINASE-C; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; FIBROBLAST CELLS; ELEMENT PATHWAY; CASEIN KINASE; CDNA; PHOSPHORYLATION	Serum response factor (SRF) is a nuclear transcription factor that binds to the serum response element (SRE) found in the promoter regions of a number of growth factor-inducible genes, as well as muscle-specific genes. The smooth muscle alpha-actin promoter contains two SRE sequences that can bind to SRF. Its expression is repressed in Ras-transformed fibroblast cells and derepressed in revertant cells. In this study, we demonstrate that SRF can activate alpha-actin expression in Ras-transformed cells and that overexpression of SRF in Res-transformed cells can revert their transformed phenotype. The ability of SRF to bind to the SRE was required for this effect, since mutations that inhibit DNA binding abolish SRF's ability to activate alpha-actin expression and suppress transformation by the ras oncogene. These results show that SRF, thought to be involved in stimulation of cell growth through activation of growth factor-inducible genes, can actually have the opposite effect and suggest a novel mechanism for suppression of transformation by Ras.	SCHERING PLOUGH CORP,RES INST,DEPT TUMOR BIOL,KENILWORTH,NJ 07033; COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Merck & Company; Schering Plough Corporation; Columbia University			Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208				BRAVO R, 1980, EXP CELL RES, V127, P249, DOI 10.1016/0014-4827(80)90430-9; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; Franza BR, 1984, CANC CELLS, V1, P137; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KIM JH, 1993, BIOCHEM BIOPH RES CO, V190, P1115, DOI 10.1006/bbrc.1993.1165; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KUMAR CC, 1992, CANCER RES, V52, P6877; KUMAR CC, 1992, CELL GROWTH DIFFER, V3, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVITT J, 1978, J BIOL CHEM, V253, P2497; LEAVITT J, 1986, MOL CELL BIOL, V6, P2721, DOI 10.1128/MCB.6.7.2721; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MANAK JR, 1993, ONCOGENE, V8, P703; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; POLLACK R, 1984, ADV VIRAL ONCOL, V4, P3; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Treisman R, 1990, Semin Cancer Biol, V1, P47; VARDROMME M, 1992, J CELL BIOL, V118, P1489	40	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13740	13743						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188648				2022-12-27	WOS:A1994NL60600005
J	SANDBRINK, R; MASTERS, CL; BEYREUTHER, K				SANDBRINK, R; MASTERS, CL; BEYREUTHER, K			SIMILAR ALTERNATIVE SPLICING OF A NONHOMOLOGOUS DOMAIN IN BETA-A4-AMYLOID PROTEIN PRECURSOR-LIKE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PROTEIN; ALZHEIMERS-DISEASE; MESSENGER-RNA; HUMAN-BRAIN; CDNA; EXPRESSION; PEPTIDE; CELLS; GENE; IDENTIFICATION	The beta A4 amyloid protein precursor (APP) is a transmembrane glycoprotein that is the source of the characteristic beta A4-amyloid deposits found in Alzheimer brains. It is expressed in several isoforms generated by alternative splicing of exons 7, 8, and 15, of which the leukocyte derived APP mRNAs lacking exon 15 are significantly expressed in non-neuronal tissues, but not in neurons. The recent finding of APP-like proteins prompted us to analyze alternative splicing of the nearest relative of APP, the amyloid protein precursor homologue (APPH) or amyloid precursor-like protein 2 (APLP2). We were able to show that there are two alternatively spliced inserts, i.e. the Kunitz protease inhibitor domain and a 12-amino-acid-encoding region on the NH2-terminal side of the transmembrane domain, which is part of the region of highest divergence between APP and APLP2/ APPH. Analysis of the tissue specific differential expression of the resulting four APLP2/APPH mRNA isoforms revealed that isoforms lacking the latter, non-homologous insert are highly expressed in non-neuronal tissues, but only weakly in neurons. While this resembles the tissue-specific alternative splicing of exon 15 of APP, expression of the Kunitz protease inhibitor-encoding exon of APLP2/APPH is abundant in both neuronal and non-neuronal tissues and thus differs from APP. Because of the similar regulation of alternative splicing of exon 15 of APP and the described APLP2/APPH insert, and because of structural similarities of the sequences and the predicted secondary structures, a functional homology of alternatively spliced isoforms of APP and APLP2/ APPH is suggested.	UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA	University of Melbourne	SANDBRINK, R (corresponding author), UNIV HEIDELBERG,CTR MOLEC BIOL HEIDELBERG,NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.							CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK MJ, 1985, EMBO J, V4, P113, DOI 10.1002/j.1460-2075.1985.tb02324.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; KANG J, 1990, BIOCHEM BIOPH RES CO, V166, P1192, DOI 10.1016/0006-291X(90)90992-V; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KONIG G, 1992, J BIOL CHEM, V267, P10804; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MONNING U, 1992, J BIOL CHEM, V267, P23950; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANDBRINK R, 1994, J BIOL CHEM, V269, P1510; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VIDAL F, 1992, BIOCHEM BIOPH RES CO, V189, P1336, DOI 10.1016/0006-291X(92)90220-F; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; YAN YC, 1990, P NATL ACAD SCI USA, V87, P2405, DOI 10.1073/pnas.87.7.2405; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	28	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14227	14234						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188705				2022-12-27	WOS:A1994NL60600076
